k
dunsmor
b
n
n
n
r
j
n
b
k
p
e
n
w
clinic
pediatr
roanok
usa
minnesota
research
institut
pediatr
hematologyoncolog
minneapoli
usa
florida
biostatist
gainesvil
usa
washington
seattl
hematopatholog
seattl
usa
univers
radiat
oncolog
atlanta
usa
new
mexico
pediatr
hematologyoncolog
albuquerqu
usa
margaret
hospit
children
pharmaci
subiaco
australia
univers
school
medicin
pediatr
hematologyoncolog
st
lou
usa
children
hospit
patholog
colombu
usa
alabama
birmingham
genet
birmingham
usa
ohio
state
univers
patholog
colombu
usa
rochest
medic
center
pediatr
oncolog
rochest
usa
colleg
medicin
pediatr
hematologyoncolog
houston
usa
inc
hematolog
malign
waltham
usa
york
univers
medic
center
pediatr
hematologyoncolog
new
york
usa
san
franciso
pediatr
hematologyoncolog
san
francisco
usa
texa
southwestern
medic
center
pediatr
hematologyoncolog
dalla
usa
york
univers
medic
center
pediatr
new
york
usa
hospit
pennsylvania
pediatr
oncolog
philadelphia
usa
backgroundobject
nelarabin
nel
specif
agent
fda
approv
patient
fail
least
two
regimen
cog
evalu
safeti
efficaci
nel
incorpor
cog
augment
bfm
abfm
chemotherapi
newli
diagnos
patient
designmethod
enrol
patient
includ
x
random
use
abfm
regimen
patient
random
receiv
escal
dose
methotrex
pegaspargas
cmtx
high
dose
mtx
hdmtx
intermedi
patient
random
six
cours
nel
consolid
delay
intensif
mainten
intermedi
high
risk
patient
receiv
prophylact
cgi
therapeut
cgi
cranial
irradi
patient
induct
failur
assign
hdmtxnel
result
random
patient
surviv
df
overal
surviv
os
rate
df
rate
patient
random
nel
vs
nel
vs
among
patient
random
cmtx
df
nel
vs
nel
vs
random
hdmtx
df
nel
vs
without
nel
differ
df
comparison
highli
signific
p
signific
interact
mtx
nel
random
patient
induct
failur
assign
hdmtxnel
df
overal
toxic
neurotox
accept
significantli
differ
four
arm
conclus
cog
show
outstand
overal
outcom
patient
malign
nel
improv
df
children
young
adult
b
vaarwerk
gl
de
n
j
c
h
k
g
r
van
h
children
hospitalacadem
medic
centr
depart
paediatr
oncolog
amsterdam
netherland
univers
hospit
pediatr
hematolog
oncolog
depart
woman
child
health
padova
itali
istituto
oncologico
veneto
clinic
trial
biostatist
unit
padova
itali
depart
pediatr
oncolog
lyon
franc
hospit
wale
depart
pediatr
oncolog
cardiff
unit
kingdom
curi
siredo
oncolog
psl
univers
pari
franc
marsden
hospit
children
young
peopl
depart
sutton
unit
kingdom
ircc
istituto
nazional
tumori
milano
pediatr
oncolog
unit
milano
itali
ircc
istituto
nazional
tumori
milano
depart
radiolog
milano
itali
curi
imag
depart
pari
franc
ormond
street
hospit
children
depart
radiolog
london
unit
kingdom
children
hospitalacadem
medic
center
pediatr
radiolog
amsterdam
netherland
center
pediatr
oncolog
solid
tumor
depart
utrecht
netherland
backgroundobject
find
indetermin
pulmonari
nodul
patient
newli
diagnos
rhabdomyosarcoma
pose
diagnost
dilemma
sinc
differenti
malign
benign
nodul
difficult
aim
assess
clinic
signific
indetermin
pulmonari
nodul
defin
less
nodul
mm
nodul
mm
diagnosi
patient
pediatr
rhabdomyosarcoma
rm
designmethod
select
patient
suppos
rm
treat
larg
oncolog
center
unit
kingdom
franc
itali
netherland
enrol
studi
patient
diagnos
septemb
decemb
chest
ct
diagnosi
avail
review
includ
local
radiologist
ask
review
chest
ct
presenc
pulmonari
nodul
use
standard
case
report
form
studi
patient
indetermin
pulmonari
nodul
treat
ident
patient
without
pulmonari
nodul
enabl
compar
surviv
ef
overal
surviv
os
test
group
result
total
patient
includ
patient
show
indetermin
pulmonari
nodul
patient
show
pulmonari
nodul
diagnosi
median
survivor
month
ef
os
rate
ci
patient
indetermin
nodul
patient
without
nodul
diagnosi
respect
group
patient
indetermin
pulmonari
nodul
develop
lung
metastas
compar
patient
group
without
nodul
conclus
analys
indic
indetermin
pulmonari
nodul
diagnosi
affect
outcom
patient
local
rm
need
biopsi
upstag
patient
indetermin
pulmonari
nodul
diagnosi
futur
rhabdomyosarcoma
protocol
c
sullivan
l
w
alabama
birmingham
school
nurs
birmingham
usa
baselin
nurs
standard
taskforc
podc
nurs
geneva
switzerland
jude
children
research
hospit
dept
global
pediatr
medicin
memphi
usa
children
hospit
hematologyoncolog
boston
usa
tennesse
health
scienc
center
colleg
nurs
memphi
usa
backgroundobject
nurs
care
children
adolesc
cancer
set
face
barrier
deliv
qualiti
care
better
understand
barrier
across
survey
conduct
evalu
abil
hospit
meet
intern
societi
pediatr
oncolog
siop
recommend
baselin
nurs
standard
analysi
siop
baselin
nurs
standard
survey
data
conduct
determin
proport
hospit
met
partial
met
meet
baselin
nurs
standard
determin
predictor
baselin
nurs
standard
designmethod
august
januari
nurs
center
countri
survey
via
redcap
english
mandarin
french
spanish
criteria
met
partial
met
met
standard
determin
expert
consensu
descript
statist
calcul
multivari
logist
regress
analys
conduct
determin
predictor
standard
result
proport
hospit
met
partial
met
meet
standard
respect
standard
staf
plan
standard
orient
standard
continu
educ
standard
multidisciplinari
teamwork
standard
resourc
safe
care
standard
oncolog
nurs
polici
multivari
analysi
compar
hospit
bone
marrow
transplant
bmt
unit
hospit
without
bmt
unit
increas
risk
achiev
standard
odd
ratio
confid
interv
ci
standard
ci
standard
ci
conclus
hospit
without
bmt
unit
increas
risk
siop
baselin
nurs
standard
like
requir
greater
support
much
work
need
toward
rais
standard
pediatr
oncolog
nurs
practic
global
k
ribeiro
bivanco
de
c
de
da
santa
casa
de
paulo
depart
collect
health
paulo
brazil
oncocentro
de
paulo
depart
epidemiolog
paulo
brazil
backgroundobject
treatment
osteosarcoma
os
complex
requir
multidisciplinari
approach
optim
result
studi
analyz
effect
hospit
special
volum
prognosi
patient
os
countri
designmethod
conduct
retrospect
cohort
studi
includ
patient
os
age
year
diagnos
submit
chemotherapi
period
case
retriev
cancer
registri
state
paulo
brazil
studi
variabl
includ
age
gender
stage
socioeconom
statu
se
tumor
site
diagnost
delay
hospit
volum
special
overal
surviv
calcul
use
method
curv
compar
use
test
cox
regress
model
employ
estim
adjust
hazard
ratio
plu
confid
interv
ci
result
total
patient
male
femal
evalu
median
age
diagnosi
year
approxim
individu
live
area
high
se
present
metastat
diseas
vast
major
treat
hospit
manag
new
pediatr
cancer
casesyear
overal
surviv
ci
univari
analysi
surviv
affect
surgeri
p
radiat
therapi
hospit
special
stage
p
tumor
site
p
hospit
volum
multipl
analysi
adjust
se
hospit
special
tumor
site
axial
vs
extrem
ci
stage
ii
ci
iii
ci
iv
ci
hospit
volum
casesyear
ci
ci
ci
identifi
independ
prognost
factor
conclus
result
support
effect
hospit
volum
outcom
patient
os
brazil
possibl
reflect
associ
physician
experi
adher
guidelin
higher
enrol
clinic
trial
isoda
c
medic
dental
univers
depart
development
biolog
tokyo
japan
san
diego
divis
biolog
scienc
la
jolla
usa
backgroundobject
well
establish
transcript
regul
specifi
cell
fate
howev
remain
enigma
distal
locat
enhanc
separ
vast
genom
distanc
select
target
cognat
promot
explor
mechan
underpin
target
examin
nuclear
architectur
regul
express
designmethod
identifi
posit
transcrib
long
rna
commit
use
publish
rnaseq
data
gener
thymod
p
p
mous
hgh
sequenc
insert
target
region
promot
locat
locu
control
region
locu
reposit
employ
doubl
neg
stage
cell
whole
genom
bisulfit
sequenc
use
determin
enhanc
activ
result
found
cell
commit
reposit
lamina
transcript
permiss
compart
search
candid
factor
reposit
control
region
identifi
long
rna
thymod
thymocyt
differenti
factor
thymod
express
pattern
cell
progenitor
immedi
preced
mice
display
block
cell
develop
leaki
scid
phenotyp
rapidli
develop
malign
found
thymod
transcript
act
ci
promot
demethyl
ctcf
bound
site
activ
loop
reposit
enhanc
lamina
nuclear
interior
juxtapos
enhanc
promot
domain
chang
nuclear
architectur
associ
deposit
activ
epigenet
mark
across
loop
domain
plausibl
facilit
phase
separ
conclus
data
indic
development
progress
tumor
suppress
transcript
orchestr
chromatin
fold
compartment
direct
high
precis
commun
barenboim
b
dtw
recht
der
isar
technic
univers
munich
pediatr
oncolog
center
depart
pediatr
munich
germani
hospit
basel
univers
basel
bone
tumour
refer
centr
institut
patholog
basel
switzerland
heidelberg
kitz
hopp
children
cancer
center
heidelberg
germani
hospit
heidelberg
hematolog
immunolog
depart
pediatr
oncolog
heidelberg
germani
stuttgart
centr
child
youth
women
medicin
depart
pediatr
stuttgart
germani
kassel
depart
pediatr
oncolog
kassel
germani
backgroundobject
osteosarcoma
os
common
primari
malign
bone
tumour
show
complex
pattern
genom
variat
includ
structur
singl
nucleotid
variat
brcaness
phenotyp
trait
resembl
tumor
mutat
character
homolog
recombin
hr
defici
shown
occur
major
os
might
render
tumor
suscept
inhibitor
poli
adp
ribos
polymeras
parp
analyz
dna
methyl
data
os
sampl
search
pattern
correl
brcaness
designmethod
methyl
data
patient
relaps
os
obtain
within
scope
inform
project
illumina
human
epic
array
use
determin
dna
methyl
sampl
profil
select
sampl
base
myriad
genet
mychoic
score
system
train
classifi
algorithm
random
forest
rf
probe
rank
accord
minimum
variabl
within
group
maximum
variabl
group
top
probe
select
rf
train
import
predictor
assess
mean
decreas
accuraci
mda
probe
zero
mda
remov
train
set
iter
result
sampl
cluster
unambigu
group
unsupervis
hierarch
cluster
valid
sampl
accur
classifi
independ
os
set
sampl
exhibit
brcaness
differenti
express
analysi
sampl
result
differenti
express
gene
gene
sampl
show
highli
signific
homolog
recombin
nucleotid
excis
mismatch
repair
signatur
conclus
establish
valid
dna
classifi
differenti
os
sampl
high
accuraci
differenti
express
enrich
analys
identifi
genom
instabl
signatur
methyl
classifi
gene
express
signatur
could
provid
use
aid
clinic
decis
make
administ
parp
inhibitor
gupta
j
c
c
n
p
sick
children
divis
haematologyoncolog
toronto
canada
oncolog
group
ontario
scientif
research
offic
toronto
canada
clinic
evalu
scienc
cancer
research
program
toronto
canada
michael
hospit
depart
gener
surgeri
toronto
canada
backgroundobject
retrospect
studi
shown
adolesc
young
adult
aya
acut
lymphoblast
leukemia
superior
surviv
treat
pediatr
versu
adult
center
locu
care
loc
clinic
studi
show
superior
surviv
aya
treat
pediatr
protocol
led
adopt
adult
center
whether
narrow
loc
dispar
real
world
set
unknown
designmethod
impact
cohort
ontario
cohort
captur
demograph
diseas
treatment
treatment
protocol
chemotherapi
dose
data
year
old
diagnos
cancer
outcom
determin
chart
abstract
linkag
provinci
administr
health
care
databas
treatment
protocol
classifi
either
examin
predictor
outcom
includ
diseas
biolog
loc
protocol
type
time
period
result
patient
receiv
therapi
adult
center
surviv
ef
standard
error
among
aya
treat
pediatr
vs
adult
center
vs
overal
surviv
os
vs
p
recent
time
period
aya
treat
adult
center
receiv
pediatr
protocol
aya
superior
outcom
aya
treat
adult
protocol
inferior
aya
treat
pediatr
center
ef
vs
vs
os
vs
vs
induct
death
mortal
dose
reduct
vari
loc
conclus
surviv
dispar
aya
treat
pediatr
vs
center
persist
time
partial
attribut
incomplet
adopt
pediatr
protocol
adult
center
although
use
pediatr
protocol
improv
surviv
residu
dispar
remain
seem
due
excess
toxic
dose
reduct
j
mcneer
e
k
l
k
n
j
b
n
w
e
chicago
comprehens
cancer
center
pediatr
hematologyoncolog
chicago
usa
children
cancer
program
pediatr
hematologyoncolog
scarborough
usa
hospit
colorado
pediatr
hematologyoncolog
aurora
usa
pharma
consult
hematologyoncolog
mystic
usa
columbia
children
hospit
pediatr
hematologyoncolog
vancouv
canada
hospit
alabama
genet
birmingham
usa
ohio
state
univers
patholog
columbu
usa
children
hospit
patholog
laboratori
medicin
columbu
usa
hopkin
universitysidney
kimmel
cancer
center
patholog
baltimor
usa
children
hospit
laboratori
medicin
seattl
usa
southwesternsimmon
cancer
pediatr
hematologyoncolog
dalla
usa
isaac
perlmutt
cancer
center
nyu
langon
pediatr
hematologyoncolog
new
york
usa
public
health
health
univers
florida
biostatist
gainesvil
usa
hospit
philadelphia
oncolog
philadelphia
usa
children
helen
diller
comprehens
cancer
univers
california
pediatr
san
francisco
usa
backgroundobject
due
poor
outcom
hypodiploid
often
consid
indic
hematopoiet
stem
cell
transplant
hsct
first
remiss
describ
ef
overal
surviv
os
rate
patient
impact
hsct
designmethod
outcom
patient
hypodiploid
chromosom
di
enrol
estim
use
standard
error
calcul
per
peto
curv
compar
use
test
result
hypodiploid
identifi
patient
patient
remov
studi
induct
ef
os
transplant
statu
avail
underw
hsct
ef
hsct
vs
without
os
hsct
vs
without
p
correct
median
time
hsct
day
signific
differ
ef
os
rate
without
hsct
vs
respect
nci
risk
group
mrd
subset
benefit
significantli
hsct
patient
ef
os
hsct
vs
without
patient
ef
os
hsct
vs
without
patient
mrd
ef
os
hsct
vs
without
mrd
patient
fare
poorli
ef
os
hsct
vs
without
multivari
regress
analysi
show
mrd
neg
significantli
associ
ef
hr
p
os
hr
p
conclus
patient
hypodiploid
fare
poorli
particularli
mrd
hsct
confer
signific
benefit
new
strategi
urgent
need
patient
p
brown
g
l
ca
von
hopkin
univers
depart
oncolog
baltimor
usa
research
munich
gmbh
clinic
develop
munich
germani
colorado
anschutz
medic
campu
divis
medic
oncolog
hematolog
aurora
usa
inc
clinic
develop
thousand
oak
usa
poh
depart
pediatr
oncologyhematolog
berlin
germani
backgroundobject
blinatumomab
establish
treatment
relapsedrefractori
base
pivot
trial
eudract
earli
predict
biomark
respons
would
allow
person
effect
therapi
designmethod
patient
phase
studi
von
stackelberg
et
al
jco
treat
recommend
blinatumomab
dose
step
respons
assess
best
respons
within
cycl
complet
mrd
respons
complet
remiss
cr
previous
defin
von
stackelberg
et
al
jco
cr
aplasia
responseprogress
diseaseparti
respons
defin
success
complet
mrd
respons
cr
failur
anyth
success
blood
morpholog
day
bone
marrow
morpholog
molecular
mrd
day
day
analyz
potenti
earli
predict
biomark
complet
mrd
respons
result
total
patient
day
bone
marrow
mrd
result
categor
day
bone
marrow
posit
neg
mrd
patient
mrd
posit
mrd
neg
patient
success
rate
complet
mrd
respons
cr
accur
predict
failur
patient
patient
success
rate
accur
predict
success
patient
overal
day
mrd
result
predict
best
respons
cycl
accuraci
correctli
patient
paramet
analyz
less
accur
predictor
accuraci
rang
conclus
day
bone
marrow
mrd
predict
best
respons
blinatumomab
cycl
patient
day
could
potenti
pursu
altern
therapi
dose
escal
combin
therapi
day
mrd
result
may
allow
person
treatment
improv
outcom
pediatr
patient
relapsedrefractori
c
ogawa
h
j
h
k
k
n
moriya
h
cancer
center
hospit
depart
pediatr
oncolog
tokyo
japan
children
cancer
group
relaps
committe
nagoya
japan
univers
hospit
depart
pediatr
tsu
japan
research
institut
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
medic
univers
school
medicin
depart
pediatr
nagakut
japan
medic
center
clinic
research
center
nagoya
japan
gakuin
univers
depart
nutrit
faculti
psycholog
physic
scienc
nisshin
japan
backgroundobject
classif
lead
indic
prognosi
children
first
relaps
acut
lymphoblast
leukemia
plan
prospect
observ
studi
assess
treatment
prognosi
japan
japanes
pediatr
leukemialymphoma
studi
group
jplsg
pediatr
patient
intermedi
group
conduct
multicent
phase
ii
clinic
trial
estim
efficaci
safeti
modifi
bfm
japan
designmethod
compris
ii
patient
posit
minim
residu
diseas
mrd
induct
therapi
underw
allogen
hematopoiet
stem
cell
transplant
hct
primari
endpoint
surviv
secondari
endpoint
surviv
remiss
rate
risk
group
incid
rate
advers
effect
assess
surviv
use
method
result
total
patient
enrol
pt
four
patient
inelig
enrol
respect
group
respect
differ
statist
signific
second
complet
remiss
rate
respect
notabl
one
patient
die
progress
cn
infiltr
trial
although
advers
event
report
patient
appreci
advers
event
present
conclus
classif
good
predictor
prognosi
children
initi
treat
per
japanes
protocol
accord
stratif
base
mrd
patient
patient
underw
hct
prognosi
similar
patient
c
depart
pediatr
hematologyoncologybmt
berlin
germani
backgroundobject
childhood
acut
lymphoblast
leukemia
patient
suffer
relaps
frontlin
therapi
extramedullari
relaps
oem
besid
cn
testi
rare
heterogen
subgroup
retrospect
analyz
data
children
first
oem
relaps
respect
clinic
prognost
featur
designmethod
patient
oem
relaps
treat
accord
relaps
bfm
studi
march
decemb
analyz
outcom
diagnos
imag
mri
ct
scan
scintigraphi
andor
histolog
result
among
patient
treat
within
bfm
studi
patient
oem
relaps
combin
oembon
marrow
bm
relaps
isol
oem
relaps
withwithout
cn
testi
involv
oem
relaps
associ
unfavour
factor
immunophenotyp
age
year
relaps
earli
earli
patient
late
lymphat
organ
frequent
site
oem
relaps
follow
mediastinumthymu
skingland
bone
organ
eyeorbita
kidney
colon
serosa
pancrea
lung
infrequ
involv
probabl
surviv
pef
year
oem
patient
significantli
wors
patient
relaps
p
similar
isol
bm
relaps
pef
patient
mediastinalthym
involv
poorest
follow
involv
bone
patient
involv
skingland
p
lymphat
organ
p
organ
p
better
pef
subsequ
relaps
occur
patient
oem
conclus
prognosi
patient
oem
relaps
poor
patient
combin
especi
isol
oem
might
need
intens
therapi
includ
allogen
hematopoet
stem
cell
transplant
hsct
prevent
relaps
l
c
h
ch
karol
jude
children
research
hospit
patholog
memphi
usa
jude
children
research
hospit
pharmaceut
scienc
memphi
usa
jude
children
research
hospit
biostatist
memphi
usa
jude
children
research
hospit
oncolog
memphi
usa
jude
children
research
hospit
diagnost
imag
memphi
usa
backgroundobject
osteonecrosi
signific
toxic
associ
modern
therapi
acut
lymphoblast
leukemia
children
age
year
older
diagnosi
greatest
risk
develop
osteonecrosi
develop
symptom
glucocorticoid
asparaginas
key
driver
osteonecrosi
arteriopathi
preced
patholog
develop
therefor
test
abil
quinapril
prevent
arteriopathi
osteonecrosi
murin
model
system
designmethod
male
balbcj
mice
age
day
treat
week
dexamethason
drink
water
weekli
inject
intraperiton
mice
random
receiv
quinapril
drink
water
control
osteonecrosi
arteriopathi
evalu
histolog
distal
femur
week
therapi
blood
pressur
measur
use
coda
tail
cuff
system
result
mice
receiv
quinapril
lower
rate
osteonecrosi
vs
arteriopathi
vs
knee
control
mice
chemotherapi
result
systol
hypertens
median
mmhg
vs
mmhg
mice
attenu
mice
treat
quinapril
addit
chemotherapi
median
mmhg
vs
chemotherapi
treat
mice
antihypertens
therapi
decreas
osteonecrosi
mice
evalu
associ
hypertens
osteonecrosi
children
treat
st
jude
total
xv
studi
children
year
older
diagnosi
hypertens
either
induct
reinduct
like
osteonecrosi
normotens
children
conclus
quinapril
decreas
osteonecrosi
murin
model
prospect
clinic
trial
evalu
util
older
children
warrant
l
desjardin
k
w
c
de
p
hospit
sick
children
psycholog
toronto
canada
backgroundobject
children
recent
diagnos
cancer
caregiv
high
risk
emot
distress
compa
et
al
psychosoci
screen
practic
establish
core
standard
psychosoci
care
pediatr
oncolog
kazak
et
al
howev
limit
inform
avail
pathway
care
base
psychosoci
screen
result
studi
aim
evalu
feasibl
pilot
intervent
studi
map
comprehens
screen
psychosoci
risk
mental
health
psychosoci
resourc
time
designmethod
particip
includ
parent
child
age
dyad
enrol
within
first
week
cancer
diagnosi
larg
oncolog
center
canada
parent
complet
psychosoci
assess
tool
parent
children
complet
distress
thermomet
promi
measur
anxieti
depress
enrol
year
later
dyad
randomli
assign
intervent
treatment
usual
control
group
intervent
group
complet
monthli
psychosoci
distress
screen
psychosoci
navig
provid
treat
team
famili
initi
monthli
screen
result
summari
recommend
resourc
tailor
screen
result
date
particip
famili
approach
famili
enrol
n
intervent
n
control
eight
famili
declin
particip
famili
withdrew
enrol
retent
monthli
screen
experiment
group
reason
predominantli
famili
feel
overwhelm
emot
logist
aspect
new
diagnosi
treatment
demand
conclus
feasibl
result
similar
intervent
studi
recruit
pediatr
oncolog
patient
near
diagnosi
kazak
et
al
retent
rate
indic
good
accept
result
studi
offer
novel
insight
avenu
toward
implement
psychosoci
screen
practic
link
famili
psychosoci
servic
earli
throughout
child
cancer
journey
r
daruvala
ss
melavarig
l
chandershekhar
p
p
v
shaw
medic
center
depart
paediatr
haematolog
oncolog
bangalor
india
medic
center
depart
palli
care
kolkata
india
backgroundobject
treatment
paediatr
haematolog
oncolog
condit
progress
howev
prolong
life
ill
continu
associ
death
incur
loss
suffer
malta
schall
modena
review
satapathi
etal
show
cultur
specif
intervent
research
necessari
provid
better
psycholog
care
paediatr
patient
cancer
designmethod
retrospect
data
analysi
two
centr
analys
understand
psycholog
relationship
variou
haematolog
oncolog
condit
data
diseas
relat
data
psycholog
diagnosi
analys
paediatr
patient
refer
result
children
refer
paediatr
servic
adjust
disord
promin
follow
mood
disord
anxieti
disord
percent
refer
children
acut
lymphoblast
leukaemia
found
adjust
disord
anxieti
disord
mood
disord
thu
major
children
seen
mental
health
profession
diagnos
leukaemia
reflect
proport
patient
seen
paediatr
team
acut
myeloid
leukaemia
aml
constitut
referr
refer
aml
diagnos
adjust
disord
children
refer
solid
tumour
commonli
diagnos
adjust
disord
mood
disord
anxieti
disord
could
explain
psycholog
impact
solid
tumour
concern
bodi
imag
possibl
disabl
benign
condit
thalassemia
aplast
anaemia
etc
found
least
psycholog
comorbid
refer
sampl
major
refer
assess
minor
children
refer
present
behaviour
problem
specif
particular
diseas
condit
besid
psycholog
support
children
sever
famili
irrespect
diagnosi
requir
support
child
treatment
conclus
understand
diseas
specif
psycholog
manifest
help
tailor
intervent
may
provid
better
psycholog
servic
paediatr
patient
scheper
k
k
f
h
jude
children
research
hospit
psycholog
memphi
usa
memphi
psycholog
memphi
usa
jude
children
research
hospit
biostatist
memphi
usa
backgroundobject
daili
chang
individu
mood
across
time
play
key
role
mental
health
new
cancer
diagnosi
lead
mani
daili
chang
live
youth
aim
identifi
daili
mood
profil
treatment
childhood
cancer
understand
predict
overal
psychosoci
adjust
time
designmethod
youth
cancer
week
sinc
diagnosi
control
age
year
report
posit
neg
mood
seven
consecut
day
two
four
month
later
youth
report
psychosoci
adjust
complet
measur
perceiv
parent
care
overprotect
anxieti
physic
psychosoci
qualiti
life
qol
primari
caregiv
complet
measur
parent
distress
child
extern
intern
problem
latent
profil
analysi
lpa
conduct
identifi
individu
profil
daili
mood
profil
use
predict
overal
psychosoci
adjust
control
sociodemograph
factor
age
gender
se
health
statu
cancer
vs
control
result
lpa
reveal
four
daili
mood
profil
label
stabl
posit
mood
spm
stabl
neg
mood
snm
intermedi
mood
im
fluctuat
neg
mood
fnm
sociodemograph
health
statu
differ
found
across
mood
profil
result
show
sever
relat
mood
profil
across
week
adjust
outcom
overal
spm
profil
treatment
relat
favor
adjust
outcom
wherea
snm
fnm
profil
relat
least
favor
adjust
compar
fnm
snm
relat
less
perceiv
parent
care
higher
youth
anxieti
conclus
children
show
healthi
mood
pattern
treatment
cancer
close
monitor
qol
mood
treatment
import
identifi
youth
risk
wors
psychosoci
adjust
outcom
time
n
ouyang
k
x
r
univers
school
nurs
guangzhou
china
univers
cancer
center
pediatr
oncolog
depart
guangzhou
china
backgroundobject
physic
activ
pa
becom
import
part
childhood
cancer
care
howev
scarc
evid
avail
regard
effect
physic
activ
intervent
china
purpos
studi
examin
effect
physic
activ
intervent
mitig
symptom
distress
improv
qualiti
life
qol
designmethod
studi
conduct
base
conveni
sampl
childhood
cancer
patient
year
old
admit
cancer
center
includ
intervent
group
ig
childhood
cancer
patient
two
hospit
match
ig
age
gender
diagnosi
includ
control
group
cg
pa
intervent
includ
one
pa
health
educ
session
pa
intervent
session
implement
children
ig
wherea
children
cg
receiv
standard
care
symptom
distress
qol
measur
use
memori
symptom
assess
scale
msa
pediatr
qualiti
life
inventori
gener
core
scale
baselin
result
signific
differ
ig
cg
identifi
chang
score
msa
vs
p
physic
symptom
vs
p
psycholog
symptom
vs
p
global
distress
index
vs
p
social
psycholog
qol
vs
p
physic
function
qol
vs
p
physiolog
function
qol
vs
p
social
function
qol
vs
p
baselin
howev
chang
number
symptom
role
function
qualiti
life
group
signific
conclus
find
suggest
pa
intervent
releas
symptom
distress
improv
qualiti
life
childhood
cancer
patient
hospit
hcw
li
hong
kong
school
nurs
hong
kong
china
backgroundobject
evid
suggest
survivor
paediatr
brain
tumour
neg
psycholog
sequela
survivor
childhood
cancer
previou
studi
indic
damag
neural
cell
result
brain
tumour
treatment
potenti
interact
psycholog
adjust
lead
last
neuropsychiatr
condit
survivor
increas
evid
suggest
use
music
train
improv
psychosoci
children
autism
nevertheless
effect
enhanc
psycholog
qualiti
life
among
childhood
brain
tumour
survivor
remain
rel
unknown
studi
aim
examin
effect
music
train
promot
psycholog
qualiti
life
survivor
paediatr
brain
tumour
designmethod
pilot
random
control
trial
conduct
children
surviv
brain
tumour
medic
outpati
clinic
hospit
invit
particip
studi
randomli
alloc
experiment
control
group
subject
experiment
group
receiv
weekli
lesson
music
train
week
wherea
control
group
receiv
usual
care
subject
depress
symptom
level
qualiti
life
assess
time
recruit
start
intervent
result
subject
experiment
group
report
statist
signific
fewer
depress
symptom
higher
level
qualiti
life
children
control
group
receiv
usual
care
follow
conclus
music
train
investig
effect
reduc
depress
symptom
improv
qualiti
life
childhood
brain
tumour
survivor
addit
demonstr
feasibl
implement
music
train
hong
kong
chines
context
content
natur
shown
accept
children
surviv
brain
tumour
parent
elli
u
r
l
p
c
children
hospit
kid
cancer
centr
sydney
australia
univers
sydney
school
psycholog
sydney
australia
new
south
wale
school
women
children
unsw
medicin
sydney
australia
backgroundobject
parent
children
hospit
cancer
treatment
increas
risk
poor
sleep
outcom
impair
sleep
may
neg
impact
parent
physic
psycholog
health
qualiti
life
capac
care
unwel
child
aim
studi
qualit
assess
barrier
facilit
parent
sleep
unmet
needsprefer
intervent
develop
evalu
ecolog
valid
sleep
intervent
hospit
set
designmethod
conduct
interview
parent
healthcar
profession
hcp
recruit
sydney
children
hospit
interview
transcrib
verbatim
analyz
use
induct
themat
approach
qualit
find
conjunct
systemat
review
literatur
expert
advisori
panel
inform
develop
cat
nap
intervent
base
cognit
behavior
therapi
also
conduct
pilot
feasibilityaccept
trial
cat
nap
intervent
result
parent
hcp
identifi
signific
difficulti
parent
sleep
hospit
ward
cite
need
person
intervent
barrier
sleep
categor
five
theme
environment
psycholog
unhelp
thoughtsbelief
unhelp
behavior
particip
also
identifi
parent
guilt
need
constant
alert
child
difficulti
priorit
contribut
poor
sleep
overal
wellb
ten
parent
age
year
mother
particip
pilot
respons
rate
withdraw
qualit
parent
identifi
differ
intervent
compon
help
highlight
import
multimod
framework
parent
report
benefit
intervent
state
would
recommend
other
conclus
parent
hcp
identifi
complex
combin
factor
impact
sleep
outcom
hospit
set
cat
nap
intervent
design
target
aspect
sleep
amen
chang
appear
feasibl
accept
parent
risk
poor
sleep
r
ladenstein
u
v
g
g
k
w
h
c
v
r
g
p
anna
kinderkrebsforschung
ev
studi
statist
integr
research
project
vienna
austria
anna
children
hospit
vienna
depart
medic
univers
vienna
austria
cancer
research
institut
studi
statist
integr
research
project
vienna
austria
roussi
paediatr
oncolog
haematolog
pari
franc
universitari
politecn
la
fe
paediatr
oncolog
unit
valencia
spain
teach
hospit
nh
trust
paediatr
oncolog
haematolog
leed
unit
kingdom
children
medic
center
israel
paediatr
oncolog
haematolog
petach
tikvah
israel
hong
kong
queen
maryhospit
paediatr
oncolog
haematolog
hong
kong
hong
kong
sar
hospit
ghent
paediatr
oncolog
haematolog
ghent
belgium
hospit
lausann
paediatr
oncolog
haematolog
lausann
switzerland
helsinki
dept
pediatr
helsinki
finland
univers
medic
colleg
paediatr
oncolog
haematolog
krakow
poland
hospit
aarhu
depart
paediatr
aarhu
denmark
dublin
paediatr
oncolog
haematolog
dublin
ireland
clinic
paediatr
oncolog
haematolog
ljubljana
slovenia
sofia
children
hospit
athen
paediatr
oncolog
haematolog
athen
greec
children
hospit
paediatr
oncolog
haematolog
randwick
australia
ircc
istituto
nazional
dei
tumori
paediatr
oncolog
haematolog
milan
itali
curi
paediatr
oncolog
haematolog
pari
franc
anna
kinderkrebsforschung
ev
tumour
biolog
vienna
austria
giannina
gaslini
paediatr
oncolog
haematolog
genoa
itali
backgroundobject
trial
test
hypothesi
induct
regimen
kushner
jco
increas
metastat
complet
respons
mcr
surviv
ef
compar
cojec
ladenstein
jco
designmethod
elig
patient
stage
mycn
amplif
mna
age
year
without
mna
age
month
segment
chromosom
alter
month
genom
profil
patient
stratifi
nation
group
metastat
site
treatment
includ
addit
tvd
amoroso
cancer
re
treat
mcr
primari
tumour
resect
bumel
megatherapi
primari
site
irradi
antibodi
plu
primari
endpoint
aim
increas
mcr
rate
cojec
ef
increas
result
patient
randomis
cojec
femal
stage
median
age
year
infant
age
mo
median
year
primari
endpoint
show
differ
ef
cojec
vs
mcr
rate
induct
cojec
vs
secondari
endpoint
neither
show
differ
overal
surviv
cojec
vs
mortal
nrm
cojec
vs
cumul
incid
relapseprogress
cojec
vs
comparison
ctc
grade
toxic
show
signific
differ
favour
cojec
compromis
gener
condit
neutropenia
low
platelet
count
infect
stomat
nauseavomit
diarrhoea
hypertens
central
neurotox
conclus
cojec
less
toxic
maintain
induct
standard
siopen
studi
patel
albertacross
cancer
institut
depart
oncolog
edmonton
canada
albertastolleri
children
hospit
depart
oncolog
edmonton
canada
backgroundobject
radiotherapi
rt
qualiti
assur
qa
program
aim
standard
rt
deliv
multicent
clinic
trial
minim
variabl
may
confound
valid
result
object
review
avail
evid
report
correl
rt
qualiti
clinic
outcom
within
pediatr
multicent
clinic
trial
designmethod
literatur
search
encompass
medlin
embas
cochran
central
regist
control
trial
qualiti
assur
review
center
bibliographi
perform
restrict
english
date
limit
candid
studi
accru
children
age
year
median
age
led
cooper
group
publish
full
describ
central
subject
andor
object
assess
rt
protocol
complianc
qualiti
data
abstract
includ
assign
violat
relat
clinic
outcom
andor
distant
failur
surviv
pf
overal
surviv
os
advers
event
result
multicent
clinic
trial
report
rhabdomyosarcoma
rm
trial
medulloblastoma
mbl
ewe
sarcoma
ew
classic
hodgkin
lymphoma
chl
supratentori
primit
neuroectoderm
tumor
spnet
acut
lymphocyt
leukemia
deviat
found
rt
plan
review
variou
primari
site
report
rt
protocol
deviat
eg
dose
field
placement
significantli
affect
clinic
outcom
form
inferior
os
trial
pf
local
control
recurr
one
studi
suggest
improv
pf
local
field
rt
deviat
versu
without
conclus
suboptim
rt
neg
impact
clinic
outcom
pediatr
multicent
cooper
group
trial
c
rd
j
b
timmermann
hospit
essen
west
german
proton
therapi
center
depart
particl
therapi
essen
germani
medic
center
depart
pediatr
haematolog
oncolog
hamburg
germani
leipzig
medic
center
depart
radiat
therapi
leipzig
germani
children
hospit
depart
pediatr
oncolog
calgari
canada
backgroundobject
choroid
plexu
tumor
rare
pediatr
brain
tumor
diagnos
mainli
infant
littl
known
role
radiotherapi
rt
aim
retrospect
studi
evalu
impact
rt
patient
choroid
plexu
carcinoma
cpc
designmethod
analyz
data
studi
patient
cpc
patient
f
median
age
year
rang
evalu
complet
resect
achiev
case
subtot
extent
resect
specifi
patient
patient
chemotherapi
appli
rt
patient
receiv
rt
rt
group
receiv
local
median
dose
rang
craniospin
irradi
local
boost
median
dose
rang
case
detail
rt
miss
patient
rt
appli
group
median
age
diagnosi
rang
rang
surviv
data
estim
use
kaplan
meier
method
cox
model
result
median
rang
surviv
os
vs
rt
vs
group
surviv
pf
vs
rt
vs
group
rt
appli
rel
risk
failur
death
time
higher
respect
conclus
analysi
indic
rt
play
import
role
cure
cpc
os
und
pf
rate
significantli
higher
patient
receiv
rt
role
rt
cpc
need
consid
futur
concept
knowledg
still
need
optim
concept
time
rt
fonseca
ch
f
j
df
c
l
f
hospit
sick
children
haematolog
oncolog
toronto
canada
oncolog
group
statist
data
center
monrovia
usa
hospit
sick
children
urolog
toronto
canada
southern
california
prevent
medicin
lo
angel
usa
healthcar
atlanta
aflac
cancer
blood
disord
center
atlanta
usa
univers
school
medicin
hematolog
oncolog
new
usa
california
davi
comprehens
cancer
center
sacramento
usa
texa
southwestern
medic
center
children
medic
center
hematolog
oncolog
dalla
usa
hospit
children
surgeri
indianapoli
usa
jude
children
research
hospit
global
pediatr
medicin
memphi
usa
cancer
harvard
medic
school
haematolog
oncolog
boston
usa
backgroundobject
investig
relaps
detect
method
among
children
adolesc
malign
germ
cell
tumor
mgct
determin
tumor
marker
alon
suffici
surveil
designmethod
retrospect
review
patient
enrol
phase
iii
singl
arm
trial
lr
ir
mgct
detect
method
relaps
assess
base
case
report
form
tumor
marker
imag
patholog
report
relaps
classifi
one
three
categori
base
whether
associ
elev
tumor
marker
alon
elev
tumor
marker
imag
find
imag
find
alon
first
two
categori
consid
detect
tumor
marker
elev
determin
proport
relaps
detect
tumor
marker
elev
result
three
hundr
two
patient
enrol
patient
complet
data
review
six
patient
normal
tumor
marker
initi
diagnosi
none
experienc
relaps
median
year
patient
experienc
relaps
male
testicular
tumor
less
year
age
institut
report
relaps
detect
tumor
marker
alon
relaps
tumor
marker
imag
relaps
imag
alon
howev
upon
central
review
patient
report
detect
imag
alon
concurr
tumor
marker
elev
fifth
patient
tumor
marker
inform
avail
conclus
overal
relaps
children
mgct
detect
tumor
marker
elev
last
patient
unknown
tumor
marker
level
relaps
result
suggest
tumor
marker
elev
may
highli
sensit
method
relaps
surveil
least
among
children
adolesc
tumor
marker
elev
initi
diagnosi
avoid
exposur
imag
studi
ioniz
radiat
dunn
g
e
c
b
f
c
j
h
r
alfr
dupont
hospit
children
pediatr
surgeri
solid
organtransplant
wilmington
delawar
usa
children
hospit
medic
center
pediatr
surgeri
solid
organ
transplant
cincinnati
ohio
usa
bonheur
children
univers
tennesse
pediatr
surgeri
memphi
tn
usa
virginia
children
hospit
pediatr
surgeri
charlottesvil
va
usa
children
hospit
pediatr
surgeri
boston
massachusett
usa
childrenshospit
medic
center
pediatr
radiolog
cincinnati
oh
usa
jude
children
research
hospit
pediatr
radiolog
memphi
tn
usa
radiat
oncolog
core
depart
radiat
oncolog
univ
massachusett
lincoln
ri
usa
colleg
texa
children
hospit
patholog
houston
tx
usa
oncolog
group
cog
statist
data
center
monrovia
ca
usa
center
childhood
cancer
research
pediatr
hematolog
oncolog
jacksonvil
fl
usa
children
univers
utah
pediatr
surgeri
salt
lake
citi
usa
backgroundobject
stratum
children
oncolog
group
includ
children
unresect
diagnosi
hepatoblastoma
preoper
chemotherapi
combin
review
patient
underw
liver
transplant
prospect
multicent
trial
designmethod
surgic
guidelin
recommend
earli
referr
surgic
team
second
fourth
cours
chemotherapi
iii
concomit
v
venou
p
portal
andor
f
multifoc
iv
radiograph
imag
pretext
patholog
central
review
liver
transplant
procedur
detail
complic
obtain
particip
institut
patient
graft
surviv
determin
cohort
accord
versu
graft
result
children
receiv
liver
transplant
stratum
studi
aliv
time
last
mean
month
rang
patient
age
diagnosi
oper
detail
avail
patient
patient
donor
graft
type
caval
reconstruct
bicav
piggyback
left
lobe
bicav
segment
piggyback
two
patient
underw
rescu
liver
transplant
one
relaps
two
year
left
one
follow
fail
convent
resect
two
week
transplant
earli
complic
includ
hepat
arteri
thrombosi
requir
retransplant
portal
vein
thrombosi
major
postop
bleed
biliari
strictur
late
complic
includ
lung
relaps
two
year
success
treat
resect
retransplant
six
year
chronic
cholang
secondari
malign
askin
tumor
five
year
conclus
outcom
patient
receiv
liver
transplant
arm
trial
excel
thrombot
complic
uncommon
children
underw
cadaver
transplant
type
graft
approach
reconstruct
inferior
vena
cava
impact
outcom
v
radhakrishnan
j
p
institut
wia
medic
oncolog
pediatr
oncolog
chennai
india
backgroundobject
fosaprepit
receptor
antagonist
approv
adult
prevent
vomit
associ
administr
moder
highli
emetogen
chemotherapi
drug
efficaci
safeti
fosaprepit
children
known
therefor
conduct
phase
random
trial
assess
safeti
efficaci
fosaprepit
children
designmethod
studi
phase
singl
centr
doubl
blind
random
placebo
control
trial
children
age
year
document
malign
schedul
receiv
moder
highli
emetogen
chemotherapi
randomli
assign
arm
fosaprepit
arm
b
placebo
arm
receiv
intraven
ondansetron
mgkg
plu
dexamethason
mgkg
follow
fosaprepit
mgkg
short
infus
arm
b
receiv
intraven
ondansetron
mgkg
plu
dexamethason
mgkg
follow
normal
salin
placebo
ondansetron
dexamethason
continu
hour
complet
chemotherapi
primari
studi
proport
patient
achiev
complet
respons
defin
vomit
retch
hour
delay
phase
administr
fosaprepit
secondari
proport
patient
achiev
complet
respons
acut
hour
overal
phase
administr
fosaprepit
result
patient
analyz
fosaprepit
arm
placebo
arm
complet
respons
rate
significantli
higher
fosaprepit
arm
compar
placebo
arm
acut
phase
vs
p
delay
phase
vs
p
overal
phase
vs
three
patient
fosaprepit
arm
fourteen
patient
placebo
arm
requir
rescu
fosaprepit
relat
grade
advers
event
observ
conclus
addit
fosaprepit
ondansetron
dexamethason
safe
effect
prevent
chemotherapi
induc
vomit
children
treat
moder
highli
emetogen
chemotherapi
totadri
ak
r
r
graduat
institut
medic
educ
research
pediatr
hematolog
oncolog
depart
pediatr
chandigarh
india
graduat
institut
medic
educ
research
depart
radiodiagnosi
imag
chandigarh
india
graduat
institut
medic
educ
research
depart
radiotherapi
chandigarh
india
graduat
institut
medic
educ
research
depart
pediatr
surgeri
chandigarh
india
backgroundobject
studi
evalu
outcom
patient
ewe
sarcoma
es
therapi
low
countri
lmic
designmethod
retrospect
case
review
children
es
januari
till
decemb
neoadjuv
chemotherapi
vdc
vincristin
doxorubicin
cyclophosphamid
ie
ifosfamid
etoposid
administ
week
reassess
plan
week
follow
local
therapi
surgeryradiotherapi
result
patient
mean
age
year
receiv
therapi
primari
site
axial
appendicular
patient
median
time
start
chemotherapi
till
local
therapi
surgeryradiotherapi
week
iqr
local
therapi
includ
surgeri
radiotherapi
modal
patient
two
patient
abandon
therapi
two
succumb
neutropen
sepsi
prior
local
therapi
median
durat
follow
month
iqr
surviv
ef
surviv
thirteen
patient
relapseprogress
delay
local
therapi
beyond
week
emerg
independ
predictor
relapseprogress
multivari
analysi
ci
median
time
radiolog
reassess
surgeri
radiotherapi
week
patient
delay
local
therapi
patient
greater
median
interv
start
chemotherapi
radiolog
reassess
vs
week
surgeri
vs
week
p
radiotherapi
vs
week
p
pauciti
bed
contribut
delay
neoadjuv
chemotherapi
interv
first
cycl
prior
local
therapi
greater
patient
delay
local
therapi
vs
week
p
conclus
coordin
effort
ensur
admiss
chemotherapi
radiolog
reassess
local
therapi
essenti
improv
outcom
tumour
lmic
g
seitz
ic
c
b
j
e
hospit
marburg
depart
pediatr
surgeri
marburg
germani
children
hospit
depart
pediatr
surgeri
tuebingen
germani
stuttgart
olgahospit
pediatr
immunolog
stuttgart
germani
hospit
depart
radiat
therapi
germani
hospit
depart
paidopatholog
kiel
germani
hospit
depart
pediatr
hematolog
oncolog
frankfurt
main
germani
backgroundobject
soft
tissu
ewe
tumor
stet
includ
primit
neuroectoderm
tumor
pnet
extraoss
ewe
sarcoma
frequent
malign
tumor
chest
wall
children
young
adult
surgic
manag
tumor
challeng
aim
studi
analyz
patient
treat
within
five
differ
cooper
weichteilsarkom
studiengrupp
cw
trial
suffer
intrathorac
chest
wall
stet
regard
treatment
outcom
surgic
procedur
designmethod
patient
year
suffer
chest
wall
stet
enrol
five
differ
cw
trial
male
femal
retrospect
chart
analysi
carri
institut
review
board
approv
obtain
trial
result
median
age
patient
year
overal
os
event
free
es
surviv
rate
patient
tumor
local
wors
outcom
es
compar
chest
wall
tumor
es
patient
year
better
surviv
compar
year
es
vs
tumor
size
cm
associ
significantli
better
surviv
compar
size
vs
primari
resect
carri
patient
incomplet
result
inferior
es
incomplet
secondari
resect
perform
impact
es
radiotherapi
improv
surviv
patient
conclus
thorac
stet
rare
aggress
tumor
inferior
outcom
posit
predict
factor
outcom
age
year
size
local
thorac
wall
baumhoer
w
hospit
basel
bone
tumour
refer
centr
institut
patholog
basel
switzerland
histopatholog
depart
stanmor
unit
kingdom
hospit
patholog
germani
backgroundobject
fibroma
nof
consid
common
benign
lesion
bone
estim
children
develop
one
lesion
skelet
growth
true
incid
howev
unknown
seem
like
mani
lesion
stay
undetect
due
lack
symptom
spontan
resolut
due
high
frequenc
clinic
cours
nof
regard
mani
author
repres
development
abnorm
rather
actual
neoplasm
molecular
pathogenesi
elucid
far
designmethod
analys
tumour
sampl
patient
histolog
confirm
nof
use
whole
exom
sequenc
custom
illumina
gene
panel
result
detect
pathogen
hotspot
mutat
kra
individu
mutat
account
two
third
case
identifi
mutat
individu
mutat
two
patient
clinic
diagnos
neurofibromatosi
type
mutat
mutual
exclus
affect
germ
line
except
mutat
mutat
record
caus
activ
signal
taken
togeth
kra
mutat
found
patient
conclus
pathogen
kra
mutat
identifi
studi
establish
varieti
carcinoma
sarcoma
haematolog
cancer
recent
describ
also
vascular
malform
benign
endometriosi
find
therefor
add
anoth
clearli
benign
tumour
spectrum
lesion
although
activ
signal
seem
repres
drive
forc
major
nof
uniformali
benign
clinic
cours
suggest
alter
signal
either
diminish
time
least
suffici
prevent
autonom
regress
resolut
g
ahm
n
medicin
helwan
univers
children
cancer
hospit
egypt
surgeri
cairo
egypt
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
cairo
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
cairo
children
cancer
hospit
egypt
patholog
cairo
egypt
cancer
cairo
children
cancer
hospit
egypt
radiolog
cairo
egypt
cancer
hospit
egypt
research
cairo
egypt
cancer
cairo
children
cancer
hospit
egypt
surgic
oncolog
cairo
egypt
backgroundobject
complet
metastasectomi
best
predictor
surviv
osteosarcoma
patient
pulmonari
metastas
controversi
exist
literatur
prognost
signific
time
occurr
lung
metastasi
designmethod
studi
includ
osteosarcoma
patient
pulmonari
metastas
treat
metastasectomi
hospit
jan
end
dec
patient
metastasectomi
categor
group
group
patient
lung
metastas
initi
present
group
patient
lung
metastas
develop
chemotherapi
group
patient
lung
metastas
develop
complet
chemotherapi
data
obtain
retrospect
obtain
end
june
result
studi
includ
patient
identifi
pulmonari
nodul
patient
metastasectomi
thoracotomi
eleven
patient
pulmonari
nodul
exclud
patient
group
group
group
mean
durat
month
rang
month
post
metastasi
year
overal
surviv
os
surviv
ef
respect
post
metastasi
os
ef
group
group
group
group
p
time
lung
metastasi
number
lung
nodul
signific
factor
associ
surviv
univari
analysi
conclus
time
occurr
lung
metastasi
import
prognost
factor
among
osteosarcoma
patient
elig
metastasectomi
patient
metastasi
chemotherapi
worst
surviv
id
fabian
p
r
school
hygien
tropic
medicin
intern
centr
eye
health
london
unit
kingdom
washington
depart
ophthalmolog
washington
usa
backgroundobject
retinoblastoma
rb
outcom
improv
recent
year
countri
howev
improv
seen
countri
lmic
main
reason
late
present
limit
special
treatment
servic
aim
investig
global
rb
present
mode
singl
year
accord
nation
incom
level
designmethod
analysi
present
rb
patient
present
particip
center
associ
clinic
paramet
present
nation
incom
level
investig
result
cohort
includ
children
countri
contin
countri
mean
present
age
month
signific
correl
found
higher
nation
incom
level
associ
younger
present
age
p
famili
rb
report
children
signific
trend
higher
proport
patient
famili
diseas
higher
incom
nation
p
ophthalm
examin
children
present
extraocular
rb
lmic
children
lmic
present
intraocular
rb
advanc
form
distant
metastas
detect
present
children
lmic
die
present
lmic
conclus
accord
studi
repres
approxim
estim
global
incid
rb
calendar
year
children
lmic
cohort
present
later
age
advanc
diseas
higher
risk
death
metastat
diseas
significantli
less
famili
diseas
lmic
probabl
due
late
present
result
death
given
rb
curabl
diseas
data
alarm
necessit
immedi
intervent
local
global
level
c
virgon
f
de
r
l
f
g
p
padua
pediatr
depart
women
child
health
padua
itali
pediatr
hospit
pediatr
surgeri
rome
itali
hospit
pittsburgh
depart
patholog
pittsburgh
usa
civili
di
brescia
pediatr
surgeri
brescia
itali
nazional
tumori
pediatr
oncolog
milan
itali
buzzi
children
hospit
pediatr
surgeri
milan
itali
padua
pediatr
oncolog
depart
women
child
health
padua
itali
backgroundobject
neuroendocrin
tumour
net
rare
tumor
aris
chromaffin
cell
pancrea
bronchi
common
site
onset
prognosi
may
vari
wide
depend
mainli
site
stage
present
complet
surgic
resect
still
cornerston
treatment
designmethod
total
patient
younger
year
diagnosi
net
prospect
regist
januari
march
within
trep
project
rare
tumor
pediatr
age
complet
data
tumor
featur
diagnosi
treatment
avail
patient
result
among
patient
male
femal
age
rang
month
mean
mo
local
net
bronchi
case
pancrea
liver
meckel
diverticulum
thymu
patient
primari
site
remain
undetermin
mediastinum
gastrointestin
tract
metastasi
diagnosi
pancreat
bronchi
thymu
liver
undetermin
origin
die
diseas
lost
stableprogress
diseas
among
local
tumor
none
experienc
relaps
complet
remiss
miss
data
surgic
treatment
conclus
report
data
experi
show
wide
heterogen
present
outcom
affect
group
tumor
complet
surgic
resect
avail
main
prognost
factor
good
outcom
therapi
may
role
prolong
surviv
metastat
diseas
intern
cooper
network
necessari
better
defin
epidemiolog
prognost
factor
overal
surviv
p
b
j
j
j
j
c
c
c
e
e
e
j
l
scheurer
colleg
medicin
pediatr
houston
usa
hutchinson
cancer
research
center
public
health
scienc
seattl
usa
nation
registri
childhood
cancer
pari
franc
otago
depart
prevent
social
medicin
dunedin
new
zealand
univers
epidemiolog
prevent
medicin
cairo
egypt
cancer
societi
research
center
copenhagen
denmark
lo
angel
epidemiolog
lo
angel
usa
univers
biostatist
occup
health
montreal
canada
del
piemont
oriental
medicina
traslazional
novara
itali
berkeley
epidemiolog
berkeley
usa
kid
institut
cancer
epidemiolog
perth
australia
nacion
central
american
institut
studi
toxic
substanc
heredia
costa
rica
kapodistrian
univers
athen
prevent
medicin
epidemiolog
athen
greec
nacion
de
programa
de
rio
de
janeiro
brazil
york
health
scienc
york
unit
kingdom
agenc
research
cancer
section
environ
radiat
lyon
franc
modena
reggio
emilia
biomed
metabol
scienc
neurosci
modena
itali
minnesota
pediatr
minneapoli
usa
backgroundobject
associ
syndrom
childhood
leukemia
well
establish
less
known
possibl
relationship
chromosom
anomali
childhood
leukemia
risk
due
rariti
condit
difficult
assess
associ
pool
data
multipl
studi
investig
associ
differ
congenit
anomali
categori
childhood
leukemia
subtyp
designmethod
pool
data
childhood
leukemia
intern
consortium
studi
includ
studi
conduct
countri
anomali
categor
syndrom
chromosom
anomali
anomali
use
multivari
logist
regress
estim
adjust
odd
ratio
aor
confid
interv
ci
anomali
categori
risk
acut
lymphoblast
leukemia
acut
myeloid
leukemia
aml
adjust
infant
sex
gestat
age
birthweight
matern
age
patern
age
studi
center
result
analys
includ
childhood
leukemia
case
control
presenc
syndrom
associ
increas
risk
ci
aml
ci
associ
observ
among
children
chromosom
anomali
ci
aml
ci
slightli
increas
risk
associ
presenc
anomali
ci
stronger
analys
restrict
data
studi
ci
associ
aml
anomali
observ
studi
ci
conclus
result
suggest
children
anomali
increas
risk
addit
work
need
identifi
specif
anomali
underli
associ
inform
could
util
improv
cancer
surveil
affect
children
provid
insight
suscept
p
roger
c
b
p
r
children
hospit
pediatr
vancouv
canada
univers
pediatr
hamilton
canada
univers
health
evid
impact
hamilton
canada
manitoba
oncolog
winnipeg
canada
alberta
pediatr
edmonton
canada
backgroundobject
adolesc
young
adult
aya
age
year
age
uniqu
need
met
dichotom
healthcar
system
canada
designmethod
canadian
aya
task
forc
cancer
form
address
gap
care
three
work
group
form
final
year
mandat
task
forc
address
metric
oncofertil
sustain
variou
method
undertaken
work
group
includ
intern
workshop
literatur
review
administr
data
analysi
last
two
decad
survey
group
task
produc
final
report
area
result
metric
incid
increas
cancer
case
year
old
surviv
year
surviv
rate
increas
year
age
group
respect
palliat
aya
cancer
death
occur
hospit
psychosoci
issu
emot
support
rate
neg
aya
male
femal
survivorship
cancer
survivor
similar
achiev
educ
higher
unemploy
compar
gener
popul
research
cancer
research
repres
cancer
research
canada
avail
clinic
trial
trial
cancer
preval
among
aya
oncofertil
toolkit
knowledg
action
plan
developedto
support
clinic
fertil
discuss
sustain
task
forc
fund
end
favour
approach
new
aya
nation
network
consist
repres
provinci
cancer
agenc
health
ministri
interdisciplinari
healthcar
provid
aya
survivor
charg
remedi
system
gap
care
focu
initi
educ
capac
build
qualiti
care
metric
oncofertil
conclus
canada
taken
cancer
control
perspect
establish
need
barrier
cancer
aya
health
care
metric
necessari
implement
chang
w
l
w
z
hematolog
blood
diseas
chines
academi
medic
scienc
peke
union
medic
colleg
pediatr
blood
diseas
center
tianjin
china
backgroundobject
myelodysplast
syndrom
md
uncommon
children
limit
known
gene
mutat
landscap
pediatr
patient
md
designmethod
perform
whole
exom
sequenc
target
sequenc
pediatr
md
patient
target
sequenc
pediatr
case
diagnosi
accord
revis
criteria
childhood
md
dna
obtain
bone
marrow
germlin
statu
analyz
oral
epitheli
cell
result
found
germlin
mutat
distinct
gene
somat
mutat
distinct
gene
mutat
load
vari
patient
least
gene
mutat
nine
gene
mutat
greater
patient
includ
nra
germlin
mutat
detect
patient
mutat
rare
gene
associ
chromatin
modif
ra
transcript
regul
respect
multivari
analysi
show
isol
delet
chromosom
significantli
enrich
mutat
subject
nra
significantli
associ
subject
respect
p
use
copi
vaf
reconstruct
clonal
architectur
explor
ancestr
subclon
mutat
like
ancestr
mutat
overal
surviv
os
patient
without
hsct
os
p
patient
delet
chromosom
mutat
wors
os
howev
patient
accept
hsct
signific
associ
genet
mutat
os
conclus
collect
result
help
defin
mutat
landscap
md
children
g
yamato
n
k
n
h
k
k
children
medic
center
hematolog
oncolog
shibukawa
japan
biolog
depart
biolog
tokyo
japan
citi
univers
hospit
depart
pediatr
kanagawa
japan
research
institut
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
univers
graduat
school
medicin
depart
pediatr
gunma
japan
center
child
health
develop
children
cancer
center
tokyo
japan
univers
depart
pediatr
okayama
japan
depart
human
health
graduat
school
medicin
kyoto
japan
univers
medic
scienc
depart
pediatr
shiga
japan
hospit
organ
nagoya
medic
center
clinic
research
center
aichi
japan
research
institut
child
health
develop
depart
biolog
tokyo
japan
univers
institut
physiolog
medicin
gunma
japan
backgroundobject
acut
myeloid
leukemia
aml
complic
diseas
character
variou
genet
alter
reportedli
dna
methyl
pattern
associ
molecular
featur
clinic
outcom
impli
definit
dna
methyl
pattern
aml
expect
reveal
clinic
molecular
featur
surviv
patient
aml
howev
report
dna
methyl
pediatr
patient
aml
thu
analyz
dna
methyl
pediatr
patient
aml
designmethod
perform
comprehens
dna
methyl
analysi
use
infinium
methylationep
beadchip
illumina
inc
san
diego
ca
usa
pediatr
patient
de
novo
aml
year
particip
japanes
trial
conduct
japanes
pediatr
leukemialymphoma
studi
group
result
unsupervis
hierarch
cluster
base
methyl
valu
cpg
site
show
variabl
methyl
valu
individu
gener
four
cluster
cluster
four
cluster
harbor
molecular
featur
follow
cluster
rearrang
cluster
high
express
cluster
cebpa
biallel
mutat
addit
focus
cpg
site
signific
differ
methyl
valu
patient
without
consequ
patient
divid
patient
group
b
remark
posit
patient
classifi
group
show
signific
wors
overal
surviv
os
surviv
ef
compar
patient
classifi
group
b
os
vs
p
ef
vs
p
conclus
investig
dna
methyl
pattern
pediatr
aml
patient
prognosi
patient
predict
dna
methyl
pattern
find
impli
dna
methyl
pattern
use
risk
stratif
pediatr
aml
yoshimura
c
k
k
center
child
health
develop
divis
leukemia
lymphomasolid
children
cancer
center
tokyo
japan
research
institut
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
center
child
health
develop
divis
children
cancer
center
tokyo
japan
center
child
health
develop
divis
stem
cell
transplant
cellular
children
cancer
center
tokyo
japan
backgroundobject
diseas
vod
complic
hematopoiet
stem
cell
transplant
hsct
defibrotid
unavail
japan
recombin
thrombomodulin
rtm
often
use
treatment
vod
although
sever
report
effect
exist
adult
report
children
limit
report
experi
preemptiv
therapi
rtm
children
vod
hsct
designmethod
case
record
consecut
patient
receiv
hsct
institut
review
result
eighteen
patient
clinic
diagnos
vod
treat
rtm
eleven
male
median
age
diagnosi
year
thirteen
receiv
myeloabl
condit
regimen
receiv
regimen
receiv
total
bodi
regimen
among
underw
allogen
hsct
patient
receiv
danaparoid
ursodeoxychol
acid
vod
prophylaxi
median
day
hsct
rtm
initi
median
administr
period
day
two
patient
met
modifi
seattl
baltimor
diagnost
criteria
rtm
administr
patient
includ
two
sever
vod
eventu
met
criteria
reason
earli
rtm
administr
meet
criteria
patient
coagulopathi
thromobocytopenia
elev
level
mild
elev
total
bilirubin
liver
enzym
abnorm
abdomin
ultrasonograph
find
hepatomegali
mild
weight
gain
two
patient
sever
vod
requir
addit
therapi
corticosteroid
hemorrhag
event
respiratori
failur
death
due
vod
conclus
preemptiv
treatment
rtm
earli
phase
vod
develop
take
notic
laboratori
abnorm
abdomin
ultrasonograph
find
addit
coagulopathi
children
feasibl
may
prevent
progress
vod
haavisto
p
k
k
k
helsinki
depart
psycholog
logoped
helsinki
finland
univers
helsinki
helsinki
univers
central
hospit
divis
stem
cell
transplant
helsinki
finland
univers
copenhagen
depart
pediatr
adolesc
medicin
copenhagen
denmark
univers
central
hospit
depart
pediatr
turku
finland
univers
copenhagen
depart
growth
reproduct
copenhagen
denmark
institutet
univers
hospit
pediatr
endocrinolog
depart
women
children
health
stockholm
sweden
backgroundobject
grow
number
pediatr
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
surviv
research
focus
qualiti
life
retrospect
multicent
studi
focus
sexual
function
adult
age
designmethod
total
adult
male
treat
allogen
hsct
denmark
finland
age
complet
derogati
interview
sexual
function
averag
rang
year
time
assess
mean
time
rang
year
control
group
recruit
men
without
histori
hsct
result
significantli
fewer
hsct
recipi
live
relationship
compar
healthi
control
p
hsct
recipi
report
significantli
poorer
sexual
function
compar
healthi
control
group
f
wilk
signific
interact
group
relationship
statu
indic
hsct
recipi
live
relationship
compar
sexual
function
healthi
peer
f
wilk
howev
hsct
recipi
relationship
significantli
poorer
qualiti
orgasm
p
less
sexual
behaviour
p
sexual
fantasi
sexual
drive
compar
control
group
regress
analys
cancer
treatment
total
bodi
irradi
smaller
testicular
size
relat
poorer
sexual
function
significantli
variat
outcom
explain
depress
symptom
older
age
hsct
recipi
current
sexual
activ
conclus
among
men
undergon
childhood
allogen
hsct
problem
orgasm
drive
sexual
fantasi
experi
common
patient
live
relationship
adult
age
caus
seem
multifactori
increas
age
absenc
sexual
experi
depress
symptom
well
cancer
treatment
total
bodi
irradi
gonad
damag
risk
factor
e
rahiman
r
p
n
r
k
r
graduat
institut
medic
educ
research
pediatr
unit
chandigarh
india
graduat
institut
medic
educ
research
pediatr
surgeri
chandigarh
india
graduat
institut
medic
educ
research
histopatholog
chandigarh
india
graduat
institut
medic
educ
research
cytolog
chandigarh
india
graduat
institut
medic
educ
research
radiodiagnosi
imag
chandigarh
india
graduat
institut
medic
educ
research
radiotherapi
chandigarh
india
backgroundobject
prognost
factor
affect
outcom
children
wilm
tumor
wt
develop
countri
infrequ
report
designmethod
design
retrospect
analysi
set
univers
period
diagnosi
calcul
v
length
x
width
x
thick
x
ml
dimens
obtain
diagnosi
deriv
criteria
util
assess
nutrit
statu
result
children
diagnos
wt
month
iqr
distribut
stage
ii
iii
iv
v
patient
respect
categori
observ
major
protocol
administ
major
radiotherapi
administ
treatment
refusalabandon
observ
therapi
complet
mortal
mean
durat
month
diagnosi
patient
sever
diagnosi
ml
iqr
reduc
ml
iqr
follow
chemotherapi
observ
p
reduct
compar
among
patient
across
histolog
stage
patient
relaps
os
ef
patient
complet
therapi
respect
os
patient
stage
diseas
respect
os
patient
low
intermedi
histolog
respect
larger
ci
lower
ci
predict
deathrelaps
conclus
larger
diagnosi
advers
affect
surviv
patient
wt
treatment
refusalabandon
observ
patient
concern
necessit
improv
support
infrastructur
jackson
r
j
j
k
g
colleg
london
great
ormond
street
institut
child
health
cancer
section
london
unit
kingdom
depart
paediatr
oncolog
haematolog
copenhagen
denmark
ormond
street
hospit
nh
foundat
trust
oncolog
depart
london
unit
kingdom
royal
hospit
sick
children
oncolog
depart
glasgow
unit
kingdom
hospit
wale
depart
cellular
patholog
cardiff
unit
kingdom
medicin
depart
patholog
doha
qatar
backgroundobject
intern
societi
paediatr
oncolog
siop
protocol
recommend
chemotherapi
appropri
wilm
tumour
wt
children
renal
tumour
age
month
reserv
biopsi
atyp
case
children
cancer
leukaemia
group
cclg
join
siop
wt
studi
continu
nation
practic
biopsi
present
designmethod
retrospect
studi
concord
local
report
renal
tumour
biopsi
patholog
panel
nephrectomi
diagnos
children
enrol
cclg
centr
siop
wt
studi
result
biopsi
report
avail
children
unilater
tumour
normal
tissu
necrot
insuffici
sampl
indetermin
result
disproportion
sensit
specif
biopsi
identifi
tumour
requir
siop
empir
chemotherapi
respect
biopsi
result
discord
nephrectomi
renal
cell
carcinoma
clear
cell
sarcoma
ccsk
poorli
recognis
children
age
month
wt
nephroblastomatosi
benign
tumour
one
diagnos
biopsi
biopsi
result
correctli
chang
clinic
manag
includ
identifi
ccsk
would
led
overtreat
undertreat
children
age
year
biopsi
correctli
chang
manag
case
discord
conclus
biopsi
less
effect
identifi
wt
rare
chang
manag
younger
children
biopsi
reserv
children
year
younger
children
clinic
radiolog
featur
inconsist
wt
l
pio
n
h
e
e
e
c
j
f
f
kremlin
pediatr
surgeri
pari
franc
kremlin
pari
xi
pediatr
surgeri
pari
franc
necker
depart
cardiovascular
surgeri
pari
franc
mari
depart
pediatr
cardiolog
congenit
heart
diseas
le
franc
universitair
necker
enfant
pari
descart
depart
pediatr
surgeri
pari
franc
backgroundobject
nephroblastoma
complic
thrombosi
renal
vein
vena
cava
sometim
extend
right
atrium
oncolog
prognosi
seem
compromis
complic
surgic
manag
complex
standard
aim
work
tri
identifi
key
element
surgic
manag
analysi
seri
patient
designmethod
retrospect
studi
perform
patient
nephroblastoma
oper
two
pediatr
surgeri
depart
januari
june
inclus
criteria
presenc
renal
vein
andor
vena
cava
thrombu
time
diagnosi
tumor
stage
treatment
preoper
imag
oper
report
patholog
per
postop
complic
collect
result
patient
inclus
criteria
patient
right
atrial
extens
one
patient
budd
chiari
syndrom
diagnosi
patient
receiv
neoadjuv
chemotherapi
accord
siop
siop
protocol
regress
tumor
thrombu
observ
case
sixteen
patient
persist
auricular
thrombu
oper
cardiopulmonari
bypass
thrombu
could
remov
one
piec
nephrectomi
case
fragment
case
two
massiv
bleed
occur
surgic
intervent
eight
cava
vein
thrombosi
azygo
drainag
observ
except
death
diagnosi
pulmonari
embol
surviv
mean
year
year
conclus
extens
surgeri
feasibl
low
complic
rate
neoadjuv
chemotherapi
join
proper
combin
surgic
strategi
pediatr
cardiosurgeon
pediatr
surgic
oncologist
prove
effect
term
surgic
outcom
result
compar
surviv
children
nephroblastoma
without
intravascular
extens
r
furtwaengl
n
l
p
c
j
g
c
univers
hospit
pediatr
hematolog
oncolog
homburgsaar
germani
anna
children
hospit
pediatr
hematolog
oncolog
vienna
austria
univers
hospit
radiationoncolog
homburgsaar
germani
univers
pediatr
surgeri
germani
haunersch
kinderspit
der
lmu
pediatr
surgeri
munich
germani
hospit
paidopatholog
doha
qatar
albrecht
section
paidopatholog
kiel
germani
backgroundobject
siop
work
classif
includ
number
reason
stage
iii
includ
necrot
lymph
node
ln
chang
cic
resect
margin
rm
howev
cic
ignor
certain
case
classif
thu
hypothes
cic
rm
reason
stage
iii
risk
denomin
local
failur
local
combin
relaps
designmethod
retrospect
analysi
unilater
nephroblastoma
patient
regist
nephroblastoma
studi
austria
switzerland
germani
respect
reason
stage
iii
viabil
type
relaps
median
follow
year
result
local
stage
distribut
unilater
tumour
stage
stage
ii
stage
iii
rf
os
stage
iii
respect
reason
stage
iii
cic
rm
nln
nln
cic
rm
viabl
v
rm
vln
ruptur
biopsi
rb
combin
cic
rm
compar
local
stage
iii
vs
p
relaps
vs
local
failur
similarli
cic
rm
andor
nln
vs
local
stage
iii
vs
relaps
vs
p
local
relaps
comparison
cic
rmnln
patient
show
similar
result
vs
conclus
result
indic
current
stage
iii
criteria
modifi
cic
rm
lesser
extent
nln
could
ignor
sinc
local
relaps
extrem
rare
despit
lack
irradi
patient
contrast
patient
viabl
ln
metastasi
combin
significantli
increas
risk
local
relaps
chintagumpala
e
f
j
r
shamberg
g
k
e
e
j
p
c
j
p
colleg
medicin
pediatr
houston
usa
robert
h
luri
children
hospit
patholog
chicago
usa
data
center
gainesvil
usa
diagnost
imag
rhode
island
usa
robert
h
luri
children
hospit
chicago
radiat
oncolog
chicago
usa
reed
nation
militari
medic
center
hematologyoncolog
bethesda
usa
children
dana
farber
cancer
institut
surgeri
boston
usa
univers
school
medicin
pediatr
radiolog
st
loui
usa
children
hospit
surgeri
boston
usa
children
hospit
surgeri
seattl
usa
anderson
cancer
center
radiat
oncolog
houston
usa
oncolog
group
pediatr
oncolog
philadelphia
usa
children
blood
disord
cancer
center
pediatr
oncolog
boston
usa
children
hospit
hematologyoncolog
cincinnati
usa
alberta
children
hospit
hematologyoncolog
edmonton
canada
univers
iwk
health
centr
depart
pediatr
bioethic
halifax
canada
children
hospit
divis
urolog
phoenix
usa
nation
medic
center
divis
oncolog
dc
usa
mott
children
hospit
dept
ped
surgeri
ann
arbor
usa
backgroundobject
surviv
ef
estim
patient
bilater
wilm
tumor
bwt
favor
histolog
diffus
anaplast
histolog
object
improv
outcom
use
preoper
chemotherapi
limit
durat
modifi
postop
chemotherapi
base
histopatholog
respons
designmethod
enrol
children
treat
vincristin
v
dactinomycin
doxorubicin
week
follow
surgeri
postop
therapi
prescrib
accord
histopatholog
respons
stage
use
siop
system
patient
treat
either
regimen
va
regimen
vda
regimen
vincristin
doxorubicin
cyclophosphamid
c
etoposid
e
regimen
vdce
carboplatin
base
risk
highest
risk
kidney
classif
determin
treatment
group
appropri
radiat
therapi
prescrib
result
bwt
underw
chemotherapi
evalu
ef
overal
surviv
os
respect
percent
patient
definit
surgeri
week
week
patient
complet
necrot
tumor
patient
post
induct
histolog
anaplasia
one
hundr
intermedi
risk
histolog
includ
focal
anaplasia
common
histopatholog
within
group
mix
follow
predominantli
epitheli
subtyp
ef
os
estim
respect
complet
necrot
tumor
intermedi
risk
diffus
anaplasia
conclus
treatment
approach
bwt
base
prenephrectomi
chemotherapi
postop
histopatholog
result
excel
outcom
patient
bwt
diffus
anaplasia
worst
prognosi
among
histolog
subgroup
verschuur
r
c
h
van
l
g
c
f
b
de
j
g
c
j
c
van
den
n
timon
children
pediatr
marseil
franc
univers
hospit
pediatr
oncolog
homburg
germani
roussi
pediatr
oncolog
villejuif
franc
cancer
institut
biostatist
amsterdam
netherland
hospit
pediatr
oncolog
liverpool
unit
kingdom
virgen
del
pediatr
oncolog
sevilla
spain
pediatr
oncolog
lyon
franc
tumori
pediatr
oncolog
milan
itali
de
paulo
depart
pediatr
sao
paolo
brazil
hospit
copenhagen
pediatr
oncolog
copenhagen
denmark
medisch
centrum
radiolog
amsterdam
netherland
medicin
depart
patholog
doha
qatar
hospit
kiel
patholog
kiel
germani
patholog
pari
franc
univers
hospit
pediatr
surgeri
wroclaw
poland
univers
hospit
radiotherapi
homburg
germani
maxima
centrum
pediatr
oncolog
utrecht
netherland
backgroundobject
determin
outcom
children
metastat
wilm
tumor
mwt
treat
accord
siop
protocol
identifi
advers
prognost
factor
designmethod
patient
treat
preoper
vincristin
dactinomycin
doxorubicin
patient
complet
remiss
cr
remain
vad
patient
remain
metastasi
andor
high
risk
hr
histolog
cyclophosphamidedoxorubicin
rt
persist
andor
hr
metastas
central
patholog
review
includ
calcul
blastem
residu
volum
renal
tumor
surviv
curv
log
rank
test
perform
well
univariablemultivari
analys
result
patient
mwt
treat
patient
mwt
older
vs
month
p
larger
tumor
volum
vs
ml
p
compar
patient
local
wt
local
stage
distribut
mwt
stage
iiiiii
respect
low
intermedi
high
risk
histolog
percent
cr
postop
metastasectomi
patient
cr
chemotherapi
metastasectomi
better
outcom
patient
multipl
unresect
metastas
os
resp
p
median
month
patient
aliv
combin
metastas
vs
either
pulmonari
metastas
boy
significantli
better
girl
vs
residu
blastem
volum
ml
vs
p
ml
tumour
volum
surgeri
vs
p
influenc
advers
multivari
analysi
histolog
blastem
residu
volum
correl
inferior
ef
conclus
patient
mwt
rel
good
outcom
although
subgroup
inferior
outcom
identifi
h
j
k
von
rd
b
timmermann
hospit
essen
depart
particl
therapi
essen
germani
german
proton
therapi
centr
essen
west
german
cancer
center
essen
germani
institut
biostatist
clinic
research
germani
berlin
depart
paediatr
oncolog
hematolog
berlin
germani
leipzig
medic
center
depart
radiat
therapi
leipzig
germani
augsburg
children
hospit
augsburg
germani
backgroundobject
atyp
teratoidrhabdoid
tumour
atrt
rare
malign
childhood
origin
central
nervou
system
aim
analysi
evalu
role
radiotherapi
rt
patient
atrt
designmethod
retrospect
analyz
data
patient
regist
registri
precursor
rhabdoid
surviv
data
analyz
use
kaplan
meier
method
multivari
cox
regress
rt
use
covari
result
data
patient
f
median
age
year
rang
evalu
patient
underw
gross
total
resect
subtot
biopsi
chemotherapi
appli
patient
patient
receiv
rt
rt
group
group
median
total
local
spinal
dose
gy
rang
gy
gy
rang
gy
respect
median
time
rang
use
rt
independ
prognost
factor
overal
surviv
os
surviv
ef
hazard
ratio
os
rate
rt
group
vs
group
p
ef
rate
rt
group
vs
group
p
advantag
rt
observ
independ
age
os
ef
superior
treatment
compar
protocol
deviat
regardless
craniospin
rt
could
prove
posit
impact
os
ef
compar
local
rt
conclus
analysi
reveal
rt
independ
posit
prognost
factor
os
ef
children
atrt
howev
optim
combin
treatment
strategi
aim
reduct
late
effect
futur
l
g
v
p
c
c
c
c
l
e
children
hospit
pediatr
oncolog
calgari
canada
jude
research
hospit
pediatr
oncolog
memphi
usa
jude
research
hospit
development
neurobiolog
depart
memphi
usa
jude
children
research
hospit
development
neurobiolog
depart
memphi
usa
jude
children
research
hospit
biostatist
memphi
usa
sick
children
neuropatholog
toronto
canada
hopkin
medecin
neuropatholog
baltimor
usa
medicin
patholog
chicago
usa
cornel
medic
colleg
radiolog
new
york
usa
sloan
ketter
cancer
center
neurolog
surgeri
new
york
usa
children
hospit
pediatr
oncolog
cincinnati
usa
sick
children
pediatr
brain
tumor
program
toronto
canada
jude
children
research
hospit
pediatr
oncolog
memphi
usa
backgroundobject
multicent
trial
convent
chemotherapi
children
local
nodular
desmoplast
medulloblastoma
medulloblastoma
extens
nodular
ndmben
base
modifi
hit
regimen
exclud
intraventricular
methotrex
trial
close
prematur
excess
relaps
report
describ
methyl
profil
final
surviv
outcom
enrol
cohort
designmethod
dna
methyl
perform
prospect
collect
tumor
sampl
use
infinium
methylationep
beadchip
profil
dkfz
molecular
neuropatholog
classifi
dna
variant
infer
dna
methyl
array
use
conume
methyl
profil
ad
founder
cohort
infant
analyz
stochast
neighbor
embed
delin
subtyp
result
cohort
includ
elig
patient
nd
mben
median
age
month
diagnosi
tumor
cluster
within
shh
group
separ
subtyp
patient
significantli
older
diagnosi
patient
vs
month
mben
signific
associ
found
histolog
subgroup
chromosom
gain
exclus
describ
tumor
twelv
patient
relaps
median
time
month
rang
pf
entir
cohort
pf
accord
molecular
subgroup
versu
age
mo
mben
histolog
femal
sex
also
associ
better
pf
conclus
cohort
prospect
valid
exist
shh
subgroup
young
children
patient
fare
significantli
wors
compar
patient
regimen
convent
system
chemotherapi
without
serial
intraventricular
methotrex
inject
l
szalontay
j
j
j
glade
j
univers
irv
medic
center
depart
pediatr
new
york
usa
univers
irv
medic
center
depart
patholog
cell
biolog
new
york
usa
york
univers
langon
medic
center
pediatr
new
york
usa
york
univers
langon
medic
center
neurolog
new
york
usa
backgroundobject
tumor
whole
exom
sequenc
we
transcriptom
analysi
pediatr
central
nervou
system
cn
tumor
increasingli
use
clinic
practic
guid
medic
manag
review
combin
experi
pediatr
oncolog
center
designmethod
obtain
inform
consent
cn
tumor
sampl
peripher
blood
subject
whole
exom
sequenc
transcriptom
analysi
laboratori
person
genom
medicin
columbia
univers
irv
medic
center
result
classifi
tier
action
somat
mutat
associ
specif
tumor
type
tier
somat
mutat
target
pathway
well
establish
cancer
gene
action
tumor
tier
somat
cancer
gene
mutat
tier
somat
mutat
unknown
signific
result
access
brain
tumor
sampl
fulli
evalu
partial
evalu
tier
mutat
found
patient
respect
patient
tier
mutat
found
variant
detect
patient
copi
number
chang
detect
patient
transcriptom
analysi
patient
significantli
gene
fusion
detect
patient
found
potenti
action
mutat
half
case
initi
target
therapi
patient
best
respons
low
glioma
harbor
braf
mutat
fusion
mean
treatment
durat
month
month
complet
clinic
respons
partial
respons
stabl
diseas
ongo
pseudo
progressionprogress
progress
diseas
conclus
routin
applic
tumor
whole
exom
sequenc
transcriptom
analysi
provid
clinic
impact
result
major
pediatr
cn
tumor
patient
includ
confirm
diagnosi
refin
prognosi
identif
clinic
relev
target
mutat
k
fukuoka
r
guerreiro
j
b
j
ln
n
j
j
p
u
k
e
v
c
u
hospit
sick
children
divis
haematologyoncolog
toronto
canada
health
network
princess
margaret
cancer
centr
centr
research
toronto
canada
jude
children
research
hospit
divis
patholog
memphi
usa
toronto
depart
laboratori
medicin
pathobiolog
toronto
canada
sonia
labatt
brain
tumour
research
hospit
sick
children
program
development
stem
cell
biolog
toronto
canada
hospit
sick
children
divis
patholog
toronto
canada
margaret
hospit
depart
radiat
oncolog
toronto
canada
hospit
sick
children
divis
neurosurgeri
toronto
canada
backgroundobject
methyl
analysi
provid
insight
diagnosi
prognosi
pediatr
brain
tumor
howev
role
methylom
pediatr
low
grade
glioma
plgg
still
unclear
designmethod
perform
methylom
analysi
use
illumina
epic
array
combin
patholog
molecular
outcom
data
well
annot
plgg
sickkid
glioma
high
grade
glioma
also
includ
result
hierarch
cluster
stochast
neighbor
embed
tsne
plot
uncov
multipl
factor
influenc
cluster
plgg
importantli
tumor
locat
lymphocyt
infiltr
influenc
cluster
molecular
statu
patholog
methyl
data
result
help
inform
chang
clinic
manag
tumor
classifi
tumor
incorrectli
glioma
tumor
delet
includ
pxa
cluster
regardless
patholog
analysi
show
gene
highli
methyl
promot
region
pxa
cluster
relev
central
nervou
systemcelltissu
differentiationdevelop
tumor
cluster
pxa
dkfz
classifi
overal
surviv
os
howev
group
could
stratifi
os
low
grade
histolog
versu
hgg
p
conclus
plgg
methylom
affect
multipl
factor
provid
inform
rare
subtyp
combin
molecular
patholog
methyl
classif
requir
implement
analysi
clinic
set
chicard
v
n
j
masliah
c
f
g
f
curi
siric
rtop
recherch
translationel
en
oncologi
translat
research
research
psl
research
univers
pari
franc
laboratoir
de
recherch
translationnel
lyon
franc
curi
de
servic
de
hospit
group
pari
franc
curi
institut
curi
genom
excel
icgex
research
center
pari
franc
curi
cnr
umr
inserm
pari
sud
univers
pari
franc
et
doncologi
depart
pediatr
clinic
trial
depart
pediatr
lyob
franc
curi
depart
pediatr
hospit
group
pari
franc
curi
inserm
laboratoir
de
et
biologi
de
research
psl
research
univers
pari
franc
backgroundobject
liquid
biopsi
revolutionari
tool
detect
genet
alter
bodi
fluid
assess
whether
circul
tumor
dna
ctdna
cerebr
spinal
fluid
csf
could
use
tumor
genet
profil
medulloblastoma
mb
designmethod
extract
ctdna
csf
droplet
lumbar
punctur
patient
medulloblastoma
etmr
ctdna
quantiti
mean
rang
match
genom
dna
primari
tumor
sequenc
whole
exom
sequenc
we
illumina
use
nimblegen
medexom
captur
snvsmutat
call
use
samtool
filter
constitut
dna
public
databas
copi
number
profil
gener
cnvkit
result
cfdna
we
yield
satisfactori
depth
mean
rang
snv
detect
primari
tumor
rang
csf
mean
rang
common
snv
observ
cfdna
primari
tumor
compris
classic
medulloblastoma
gene
smo
interestingli
sever
snv
observ
either
tumor
mean
rang
csf
mean
rang
suggest
clonal
heterogen
case
copi
number
profil
also
avail
allow
detect
mycn
amplif
mb
mirna
cluster
amplif
etmr
conclus
altogeth
demonstr
feasibl
we
csf
low
input
ctdna
result
allow
innov
diagnost
method
may
pave
way
new
tumor
monitor
tool
l
c
k
c
e
f
f
k
v
p
j
l
roussi
children
adolesc
oncolog
depart
villejuif
franc
institut
genet
depart
pari
franc
univers
divis
human
genet
innsbruck
austria
universitair
rein
fabiola
depart
bruxel
belgium
ospedaliera
di
padova
pediatr
oncolog
hematolog
padova
itali
institut
adolesc
young
adult
cancer
center
pari
franc
hospitali
depart
neuropatholog
pari
franc
de
pathologi
et
de
centr
de
humain
bruxel
belgium
policlinico
universitario
gemelli
instituto
di
medicina
genomica
roma
itali
medic
center
genet
institut
petah
tikvah
israel
children
hospit
depart
pediatr
hematolog
clinic
immunolog
duesseldorf
germani
de
octubr
hospit
madrid
spain
univers
hospit
dept
pediatr
adolesc
medicin
copenhagen
denmark
univers
vienna
depart
pediatr
adolesc
medicin
vienna
austria
lausann
servic
genet
medicin
lausann
sweden
hospitali
saint
ann
neuropatholog
pari
franc
roussi
children
adolesc
oncolog
dept
villejuif
franc
backgroundobject
constitut
mismatch
repair
defici
cmmrd
rare
childhood
cancer
predisposit
syndrom
omim
due
biallel
germlin
mutat
mmr
gene
lead
broad
spectrum
childhood
malign
includ
brain
hematolog
colorect
cancer
associ
macul
calm
designmethod
malign
brain
tumor
report
patient
countri
regist
databas
result
overal
malign
brain
tumor
glioma
hgg
embryon
tumor
diagnos
patient
median
age
first
brain
tumor
patient
patient
develop
multipl
malign
includ
brain
tumor
famili
consanguin
patient
biallel
germlin
mutat
mmr
gene
patient
avail
cutan
data
one
calm
addit
sever
patient
present
development
brain
anomali
patient
receiv
standard
treatment
immunotherapi
era
without
unusu
toxic
median
surviv
first
brain
tumor
ci
ci
hgg
embryon
tumor
respect
ten
patient
aliv
hgg
medulloblastoma
last
among
death
patient
die
brain
tumor
first
brain
tumor
second
brain
tumor
cancer
conclus
despit
high
risk
multipl
malign
seri
suggest
patient
may
survivor
prognosi
could
improv
earli
recognit
rare
condit
lead
specif
treatment
includ
immunotherapi
screen
second
malign
h
lukolyo
e
c
p
j
n
p
l
j
bcm
pediatr
malign
tch
baylor
intern
pediatr
aid
colleg
medicin
pediatr
houston
usa
utah
pediatr
emerg
medicin
salt
lake
citi
usa
children
hospit
emerg
medicin
boston
usa
colleg
medicin
children
na
kampala
uganda
colleg
medicin
children
na
lilongw
malawi
children
clinic
centr
excel
na
gaboron
botswana
colleg
medicin
children
na
mbeya
tanzania
intern
pediatr
aid
initi
texa
children
hospit
na
houston
usa
backgroundobject
current
children
live
hiv
worldwid
receiv
antiretrovir
therapi
art
among
adult
art
shown
decreas
risk
malign
howev
studi
describ
associ
among
children
live
hiv
especi
set
object
determineth
associ
age
art
initi
incid
malign
children
hiv
infect
designmethod
conduct
multicent
studi
five
pediatr
hiv
center
botswana
malawi
tanzania
uganda
case
defin
children
live
hiv
age
year
cancer
diagnosi
control
defin
children
hiv
cancer
match
base
sex
countri
age
enrol
hiv
care
conduct
longitudin
cohort
analysi
subset
incid
cancer
case
defin
malign
diagnosi
month
enrol
care
result
total
case
malign
incid
case
among
children
live
hiv
control
case
femal
median
age
year
iqr
time
hiv
diagnosi
cancer
diagnos
kaposi
sarcoma
lymphoma
hodgkin
lymphoma
malign
histopatholog
diagnosi
obtain
incid
case
signific
increas
cancer
risk
male
compar
children
initi
art
year
age
increas
odd
develop
incid
cancer
children
began
art
age
year
year
conclus
earli
diagnosi
hiv
prompt
initi
art
may
decreas
incid
malign
effort
improv
earli
infant
diagnosi
prompt
initi
art
may
reduc
malign
among
children
live
hiv
n
ahm
h
el
h
el
h
r
cancer
hospit
egypt
clinic
pharmaci
cairo
egypt
univers
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
univers
children
cancer
hospit
egypt
clinic
patholog
cairo
egypt
univers
pharmacolog
toxicolog
cairo
egypt
backgroundobject
bacteria
suscept
colistin
co
emerg
caus
complic
infect
especi
immunocompromis
patient
reviv
interest
use
colistin
purpos
studi
test
renal
toxic
colistin
cohort
pediatr
cancer
patient
blood
stream
infect
designmethod
prospect
observ
cohort
studi
perform
may
octob
children
cancer
hospit
egypt
patient
blood
stream
infect
due
co
bacteria
receiv
intraven
colistin
prospect
enrol
standard
case
form
use
record
patient
characterist
includ
age
sex
weight
underli
comorbid
type
infect
caus
organ
vitro
suscept
daili
dose
durat
colistin
therapi
cumul
dose
colistin
antibiot
nephrotox
agent
aminoglycosid
vancomycin
clinic
microbiolog
respons
therapi
dose
schedul
base
load
dose
mu
divid
mainten
dose
titrat
renal
function
colistin
cours
clinic
cure
bacteriolog
clearanc
daili
serum
creatinin
clearanc
estim
creatinin
clearanc
record
result
blood
stream
infecti
episod
detect
patient
klebsiella
ecoli
strain
suscept
colistin
mic
mgl
patient
predominantli
femal
mean
age
year
employ
combin
therapi
carbapenem
aminoglycosid
acut
kidney
injuri
develop
treatment
cours
use
combin
amikacin
renal
replac
therapi
requir
subsid
within
day
colistin
discontinu
correl
found
variat
serum
creatinin
level
line
peak
daili
cumul
dose
cm
conclus
studi
show
sever
infect
due
co
bacteria
colistin
high
efficaci
without
signific
renal
toxic
j
geel
k
v
j
van
e
b
van
l
du
g
f
univers
charlott
maxek
johannesburg
academ
hospit
johannesburg
south
africa
cape
town
red
cross
war
memori
children
hospit
cape
town
south
africa
cape
town
depart
econom
cape
town
south
africa
kwazulu
natal
inkosi
albert
luthuli
hospit
durban
south
africa
free
state
universita
hospit
bloemfontein
south
africa
limpopo
pietersburg
provinci
hospit
polokwan
south
africa
sisulu
univers
port
elizabeth
provinci
hospit
port
elizabeth
south
africa
stellenbosch
tygerberg
hospit
tygerberg
south
africa
makgatho
health
scienc
univers
georg
mukhari
hospit
garankuwa
south
africa
sisulu
univers
frere
hospit
east
london
south
africa
free
state
kimberley
hospit
kimberley
south
africa
univers
chri
hani
baragwanath
academ
hospit
soweto
south
africa
pretoria
steve
biko
academ
hospit
pretoria
south
africa
jude
children
research
hospit
st
jude
global
memphi
usa
backgroundobject
children
adolesc
young
adult
caya
hodgkin
lymphoma
hl
south
africa
treat
varieti
manag
regimen
base
larg
institut
prefer
multicentr
retrospect
analysi
children
adolesc
treat
hl
ten
year
period
demonstr
uneven
surviv
rate
across
countri
rang
set
establish
centr
harmonis
manag
protocol
research
set
identifi
strategi
improv
surviv
rate
caya
cancer
designmethod
email
audit
conduct
exist
servic
centr
complet
spreadsheet
paramet
includ
number
patient
hl
number
oncologist
teach
hour
access
specif
servic
radiat
chemotherapi
intens
care
fund
sourc
run
nation
meet
meet
conduct
onlin
potenti
solut
explor
discuss
result
clinician
ten
paediatr
oncolog
unit
respond
question
answer
identifi
challeng
includ
inequit
access
resourc
inadequ
radiat
servic
lack
research
infrastructur
compet
demand
time
supervis
degre
extern
research
identifi
potenti
motiv
mechan
facilit
harmonis
protocol
onlin
tool
use
redcap
suggest
mean
offer
clinic
support
research
framework
specif
featur
new
context
includ
bodi
surfac
area
calcul
intern
classif
diseas
code
morpholog
code
chemotherapi
dose
calcul
conclus
harmonisationof
hl
treatment
feasibl
south
africa
well
identifi
group
treat
clinician
common
purpos
enthusiasm
improv
research
infrastructur
collabor
work
anticip
surviv
rate
caya
hl
improv
strategi
approach
success
appli
childhood
malign
c
garrido
l
j
w
v
c
nacion
de
guatemala
guatemala
children
cancer
blood
disord
center
oncolog
usa
denver
hematolog
oncolog
sct
denver
usa
infantil
benjamin
bloom
oncolog
san
salvador
el
salvador
infantil
robert
reid
cabral
oncolog
santo
domingo
dominican
republ
infantil
la
mascota
oncolog
managua
nicaragua
jude
children
research
hospit
depart
global
pediatr
medicin
tn
usa
backgroundobject
evalu
approach
treat
pediatr
germ
cell
tumor
incom
countri
designmethod
patient
age
diagnos
germ
cell
tumor
gct
treat
one
particip
ahopca
center
central
america
elig
low
risk
patient
matureimmatur
teratoma
stage
gonad
malign
gct
treat
surgeri
activ
surveil
intermedi
risk
patient
stage
ii
gonad
tumor
stage
ii
extragonad
tumor
stage
gonad
age
treat
jeb
x
cycl
carboplatin
etoposid
bleomycin
high
risk
patient
stage
iiiiv
gonad
age
stage
extragonad
tumor
treat
peb
x
cycl
cisplatin
etoposid
bleomycin
patient
cr
cycl
could
receiv
addit
cycl
event
defin
progress
diseas
relaps
andor
abandon
ef
os
calcul
result
protocol
open
central
american
countri
enrol
elig
patient
guatemala
san
salvador
dominican
republ
nicaragua
patient
due
inelig
histolog
type
age
diagnosi
miss
data
patient
exclud
overal
ef
os
year
ef
os
risk
group
low
risk
intermedi
risk
high
risk
abandon
low
intermedi
high
risk
group
respect
conclus
high
rate
ef
os
possibl
children
gct
set
upfront
risk
assess
therapi
alloc
low
rate
abandon
trehan
e
r
univers
divis
pediatr
hematologyoncologystem
cell
transplant
new
york
usa
hematolog
oncolog
depart
post
graduat
institut
medic
educ
chandigarh
india
memori
hospit
depart
pediatr
oncolog
mumbai
india
health
mcmaster
univers
pediatr
hamilton
canada
backgroundobject
surviv
rate
pediatr
oncolog
approach
high
incom
countri
low
middl
incom
ountri
lmic
effort
improv
treatment
outcom
includ
nutrit
intervent
lmic
malnutrit
strikingli
high
use
framework
develop
siop
podc
nutrit
work
group
wg
level
nutrit
care
among
pediatr
cancer
unit
pcu
designmethod
onlin
survey
base
upon
wg
framework
employ
evalu
nutrit
care
india
sent
survey
monkey
assess
medic
set
access
nutrit
product
capac
personnel
train
nutrit
assess
intervent
institut
identifi
nation
list
pcu
respons
score
level
zero
littl
resourc
four
resourc
reflect
set
result
teach
hospit
particip
state
union
territori
capit
percent
particip
pcu
south
north
central
west
east
respect
overal
score
level
level
level
level
access
nutrit
product
overal
score
level
pcu
north
south
central
west
show
need
capac
personnel
train
overal
score
less
level
central
north
score
less
level
nutrit
assess
intervent
overal
score
less
level
pcu
north
central
score
less
level
conclus
vari
level
care
exist
across
india
exhibit
unmet
need
nutrit
assess
intervent
human
capac
mostli
central
northern
state
assess
import
address
region
gap
direct
educ
programmat
develop
nutrit
care
p
g
van
av
k
p
cm
e
v
rand
institut
cancer
research
wolfson
childhood
cancer
research
centr
newcastl
upon
tyne
unit
kingdom
medicin
queen
elizabeth
central
hospit
depart
paediatr
blantyr
malawi
middlesex
univers
hospit
depart
histopatholog
isleworth
unit
kingdom
colleg
london
depart
histopatholog
london
unit
kingdom
upon
tyne
hospit
nh
foundat
trust
depart
cellular
patholog
newcastl
upon
tyne
unit
kingdom
upon
tyne
hospit
nh
foundat
trust
depart
haematolog
newcastl
upon
tyne
unit
kingdom
backgroundobject
despit
excel
outcom
burkitt
lymphoma
bl
set
deliveri
intens
prevent
countri
high
cost
insuffici
access
support
care
facil
consequ
patient
outcom
remain
unsatisfactori
new
therapeut
approach
urgent
need
improv
surviv
use
genom
profil
aim
identifi
abnorm
stratifi
patient
base
respons
current
protocol
defin
potenti
therapeut
target
designmethod
collect
diagnost
sampl
queen
elizabeth
central
hospit
malawi
children
cancer
leukaemia
group
cclg
uk
copi
number
profil
data
gener
use
affymetrix
oncoscan
cytoscan
array
surviv
analysi
examin
associ
factor
risk
relaps
multivari
cox
regress
model
appli
develop
risk
stratif
model
result
thirti
recurr
focal
copi
number
abnorm
detect
endem
bl
case
use
region
gain
contain
known
gene
larg
genom
alter
includ
gain
surviv
analysi
identifi
abnorm
involv
chromosom
associ
increas
risk
relaps
gain
either
abnorm
identifi
one
third
patient
relaps
compar
group
hazard
ratio
ci
despit
differ
treatment
intens
differ
outcom
endem
sporad
patient
identifi
model
howev
outcom
patient
significantli
differ
relaps
risk
versu
endem
sporad
bl
respect
conclus
develop
first
risk
stratif
model
endem
bl
identifi
patient
relaps
may
benefit
stratifi
increas
treatment
intens
contrast
patient
may
candid
treatment
reduc
healthcar
set
j
j
j
k
kulkarni
univers
depart
microbiolog
halifax
canada
health
centr
divis
depart
pediatr
halifax
canada
health
centr
divis
pediatr
hematolog
depart
pediatr
halifax
canada
univers
depart
pharmacolog
halifax
canada
backgroundobject
associ
gut
microbiom
infecti
complic
children
acut
lymphoblast
leukemia
clear
studi
aim
assess
relationship
designmethod
ethic
approv
prospect
studi
examin
gut
microbiom
pediatr
patient
manag
iwk
health
centr
stool
sampl
collect
prior
chemotherapi
throughout
first
month
treatment
sequenc
use
rrna
gene
whole
metagenom
approach
virul
factor
determin
within
assembl
metagenom
read
patient
infecti
complic
ic
clinic
defin
infect
microbi
defin
infect
febril
neutropenia
studi
period
patient
classifi
complic
nic
patient
result
seventeen
patient
recruit
mean
age
month
sex
ratio
f
patient
face
ic
significantli
lower
microbi
alpha
divers
significantli
differ
microbi
commun
structur
total
genera
found
signific
differ
greater
rel
abund
patient
ic
without
notabl
genera
increas
nic
patient
includ
bacteroid
parabacteroid
clostridium
notabl
genera
increas
ic
patient
includ
streptococcu
enterococcu
enterobact
metagenom
data
reveal
signific
differ
gene
pathway
pathway
includ
feed
product
vitamin
k
fatti
acid
oxid
heme
biosynthesi
furthermor
metagenom
data
show
increas
abund
microbi
gene
annot
virul
factor
ic
patient
compar
nic
patient
conclus
studi
indic
gut
microbiom
pediatr
patient
experi
infecti
complic
composit
function
alter
investig
warrant
determin
gut
microbiom
featur
contribut
risk
infecti
complic
pediatr
patient
lion
k
h
g
r
u
cancer
research
institut
austria
molecular
microbiolog
vienna
austria
children
austria
stem
cell
transplant
vienna
austria
cancer
research
institut
austria
fac
core
unit
vienna
austria
cancer
research
institut
austria
sirp
vienna
austria
backgroundobject
human
adenovirus
hadv
major
caus
morbid
mortal
pediatr
stem
cell
transplant
hsct
recipi
mostli
result
reactiv
persist
virus
lion
clin
microbiol
rev
previou
studi
identifi
gastrointestin
tract
main
site
hadv
persist
reactiv
children
kosulin
et
al
clin
microbiol
infect
sinc
hadv
expans
gastrointestin
tract
almost
invari
preced
invas
infect
frequent
molecular
hadv
monitor
serial
stool
sampl
least
day
becom
standard
diagnost
surveil
pediatr
transplant
set
designmethod
recent
analyz
allogen
hsct
recipi
treat
stanna
children
hospit
vienna
austria
serial
molecular
test
stool
peripher
blood
specimen
presenc
quantiti
adenovirus
assess
occurr
invas
infect
relat
current
known
risk
factor
result
analysi
reveal
significantli
common
occurr
invas
infect
patient
hadv
persist
intestin
shed
hsct
vs
p
therebi
unveil
novel
risk
factor
ensu
invas
infect
dissemin
diseas
kosulin
et
al
ebiomedicin
observ
highlight
need
time
hadv
monitor
therapeut
consider
hsct
recipi
conclus
import
insight
gain
past
year
diagnosi
treatment
invas
adenovir
infect
provid
new
paradigm
monitor
clinic
manag
complic
advanc
understand
etiologypathogenesi
futur
treatment
option
result
novel
recommend
diagnost
approach
therapi
reflect
present
state
knowledg
hiwarkar
et
al
rev
med
virol
press
recent
emerg
diagnost
therapeut
option
expectedli
facilit
effect
control
prevent
diseas
pediatr
hsct
set
aoki
h
n
k
h
h
k
h
moriya
k
school
chiba
univers
depart
pediatr
chiba
japan
univers
depart
pediatr
tokyo
japan
school
kyoto
univers
depart
clinic
biostatisticsclin
biostatist
cours
kyoto
japan
citi
univers
hospit
depart
pediatr
yokohama
japan
prefectur
kobe
children
hospit
depart
hematologyoncolog
kobe
japan
univers
depart
pediatr
tsu
japan
univers
depart
pediatr
hirosaki
japan
univers
depart
pediatr
miyazaki
japan
hospit
kyushu
cancer
center
depart
pediatr
fukuoka
japan
univers
hospit
depart
pediatr
hematologyoncolog
okayama
japan
children
medic
center
depart
hematologyoncolog
saitama
japan
children
medic
center
depart
hematologyoncolog
yokohama
japan
hospit
nagoya
medic
center
clinic
research
center
nagoya
japan
marianna
school
medicin
depart
pediatr
kawasaki
japan
center
child
health
develop
divis
leukemia
children
cancer
center
tokyo
japan
hospit
osaka
nation
hospit
depart
pediatr
osaka
japan
medic
univers
depart
pediatr
otsu
japan
univers
depart
human
health
scienc
kyoto
japan
backgroundobject
intensifi
chemotherapi
acut
myeloid
leukemia
aml
accompani
profound
myelosuppress
howev
degre
myelosuppress
equal
among
patient
children
oncolog
group
reveal
longer
durat
neutropenia
associ
reduc
risk
relaps
studi
may
differ
among
protocol
race
herein
analyz
prognost
impact
prolong
neutropenia
studi
designmethod
analysi
conduct
use
prospect
collect
data
jplsg
studi
recruit
elig
children
age
year
de
novo
aml
novemb
decemb
analysi
focus
patient
complet
protocol
treatment
without
recurr
withdraw
among
patient
low
risk
lr
intermedi
risk
ir
high
risk
hr
exclud
patient
complet
protocol
treatment
reason
violat
protocol
receiv
transplant
first
complet
remiss
whose
averag
rel
dose
intens
alin
receiv
treatment
prolong
neutropenia
defin
longer
median
neutropenia
period
second
third
cours
risk
group
result
median
end
treatment
month
longer
durat
neutropenia
associ
better
overal
surviv
rate
os
vs
risk
group
hr
patient
prolong
neutropenia
show
significantli
better
os
influenc
relaps
risk
differ
among
risk
group
proport
hazard
model
hazard
ratio
cumul
incid
relaps
prolong
neutropenia
lr
ir
hr
respect
conclus
higher
risk
patient
prolong
neutropenia
second
third
cours
associ
better
outcom
ahmad
fs
childrenhospit
institut
child
health
lahor
paediatr
haematologyoncolog
lahor
pakistan
children
hospit
institut
child
health
lahor
pakistan
paediatr
haematolog
lahor
pakistan
children
hospit
institut
child
health
lahor
pakistan
dean
lahor
pakistan
backgroundobject
febril
neutropenia
fn
one
common
potenti
lethal
complic
patient
cancer
chemotherapi
inadequ
manag
countri
object
studi
evalu
burden
fn
role
resourc
limit
set
like
public
sector
hospit
pakistan
designmethod
prospect
review
data
patient
treat
febril
neutropenia
octob
decemb
haematologyoncolog
depart
children
hospit
lahor
irb
approv
result
patient
treat
fn
three
month
male
acut
lymphoblast
leukaemia
sarcoma
lymphoma
solid
malign
differ
chemotherapi
regimen
receiv
chemo
last
day
last
week
prior
fn
admiss
receiv
either
induct
intens
phase
respiratori
tract
infect
follow
age
fever
alon
case
mucos
case
symptom
hour
seek
treatment
fn
anc
platelet
case
case
stay
hour
drive
hospit
parent
adequ
awar
fn
manag
discharg
home
expir
mainli
fn
progress
diseas
abandon
treatment
use
rx
cost
hospit
stay
blood
product
inotrop
mean
estim
cost
rupe
patient
total
million
rs
stay
hr
cultur
show
g
posit
organ
among
posit
cultur
conclus
studi
show
fn
profound
burden
childhood
cancer
care
public
sector
hospit
resourc
limit
set
use
help
earli
discharg
solid
tumor
j
styczynski
k
j
j
j
p
j
j
p
k
l
univers
hospit
collegium
medicum
umk
depart
pediatr
hematolog
oncolog
bydgoszcz
poland
center
institut
oncolog
hematolog
gliwic
poland
univers
depart
pediatr
hematolog
oncolog
wroclaw
poland
univers
depart
hematolog
gdansk
poland
univers
depart
hematolog
katowic
poland
univers
depart
pediatr
hematolog
oncolog
transplantolog
poznan
poland
univers
depart
pediatr
oncolog
transplantolog
lublin
poland
univers
hematolog
warszawa
poland
univers
hematolog
lublin
poland
univers
hematolog
lodz
poland
univers
hematolog
krakow
poland
univers
collegium
medicum
krakow
poland
univers
hematolog
wroclaw
poland
institut
medicin
hematolog
warszawa
poland
hematolog
transfus
medicin
hematolog
warszawa
poland
univers
hematolog
poznan
poland
backgroundobject
comparison
incid
outcom
infect
pediatr
adult
hsct
center
poland
studi
period
designmethod
consecut
patient
transplant
pediatr
adult
tc
includ
retrospect
studi
report
known
etiolog
infect
analyz
studi
result
data
pediatr
adult
hsct
recipi
analyz
bacteri
infect
incid
children
adult
patient
p
includ
vs
ns
vs
p
incid
compar
patient
amlmd
nhlhd
saa
mortal
irm
bacteri
infect
lower
pediatr
patient
vs
invas
fungal
diseas
ifd
incid
children
adult
p
includ
vs
p
vs
p
patient
vs
p
amlmd
vs
p
irm
ifd
lower
pediatr
patient
vs
p
viral
infect
incid
children
adult
p
vs
p
incid
higher
cmv
vs
p
bkv
vs
p
ebv
vs
p
adv
vs
p
influenza
vs
viral
infect
contribut
mortal
usual
coexist
infect
irm
viral
infect
similar
children
adult
viral
infect
vs
ns
specif
infect
cmv
vs
ns
bkv
vs
ns
ebv
vs
ns
adv
vs
ns
influenza
vs
ns
conclus
pediatr
patient
hsct
higher
incid
better
outcom
infect
adult
rheingold
k
e
e
l
w
n
hospit
philadelphia
pediatr
oncolog
philadelphia
usa
hosptial
colorado
pediatr
oncolog
denver
usa
oncolog
group
biotatist
gainesvil
usa
california
san
francisco
pediatr
oncolog
san
francisco
usa
children
cancer
center
pediatr
oncolog
portland
usa
langon
pediatr
oncolog
new
york
usa
sick
kid
pediatr
oncolog
toronto
canada
southwestern
pediatr
oncolog
dalla
usa
backgroundobject
random
patient
acut
lymphoblast
leukemia
dexamethason
prednison
induct
start
patient
year
receiv
prednison
due
osteonecrosi
enhanc
infect
report
institut
examin
risk
factor
associ
infecti
morbid
mortal
induct
designmethod
review
grade
toxic
report
steril
site
list
specif
organ
bacteremia
includ
virus
exclud
grade
toxic
deem
infecti
primari
studi
team
includ
result
grade
infect
occur
patient
induct
grade
infect
account
induct
death
univari
analysi
among
patient
mortal
significantli
higher
patient
year
vs
despit
significantli
less
infect
overal
vs
p
caucasian
infect
black
patient
vs
patient
random
dexamethason
infect
random
prednison
vs
increas
infecti
mortal
infecti
toxic
note
patient
bacteremia
follow
distantli
lung
soft
tissu
gastrointestin
staphylococcu
speci
account
bacteremia
follow
pseudomona
speci
viridan
group
streptococci
ecoli
except
clostridium
bacillu
organ
rare
fatal
fungi
account
infect
mold
prevel
yeast
fungi
caus
death
patient
year
conclus
older
patient
higher
risk
infecti
mortal
induct
although
patient
year
caucasian
random
dexamethason
infect
overal
bacteremia
common
report
infect
organ
frequent
least
morbid
fungal
invas
clostridi
cn
polymicrobi
infect
trend
higher
mortal
rate
dupui
l
g
k
hospit
sick
children
child
health
evalu
scienc
toronto
canada
toronto
lesli
dan
faculti
pharmaci
toronto
canada
hospit
sick
children
depart
pharmaci
toronto
canada
toronto
institut
health
manag
evalu
toronto
canada
hospit
sick
children
divis
haematologyoncolog
toronto
canada
health
networkmt
sinai
hospit
depart
medicin
toronto
canada
inc
clinic
develop
kenilworth
usa
inc
oncolog
kenilworth
usa
backgroundobject
data
larg
pediatr
drug
develop
program
use
identifi
factor
associ
civ
pediatr
patient
receiv
emetogen
chemotherapi
designmethod
individu
pool
analysi
perform
use
data
prospect
clinic
trial
aprepitantfosaprepit
subject
year
age
receiv
emetogen
chemotherapi
primari
end
point
analysi
absenc
vomit
children
receiv
highli
emetogen
chemotherapi
hec
acut
phase
period
initi
first
chemotherapi
dose
hour
administr
last
chemotherapi
dose
logist
regress
use
identifi
factor
patient
age
sex
race
puberti
statu
cancer
type
durat
acut
phase
antiemet
regimen
influenc
civ
rel
risk
rr
confid
interv
ci
calcul
result
total
subject
mean
age
year
rang
year
receiv
least
dose
studi
medic
hec
median
acut
phase
durat
day
rang
day
absenc
vomit
less
like
increas
year
age
rr
ci
day
acut
phase
durat
rr
ci
subject
receiv
antiemet
regimen
ondansetron
alon
n
ondansetron
dexamethason
n
ondansetron
aprepitantfosaprepit
n
ondansetron
aprepitantfosaprepit
dexamethason
n
seven
patient
miss
efficaci
data
antiemet
regimen
significantli
influenc
civ
absenc
vomit
frequent
receiv
ondansetron
aprepitantfosaprepit
compar
ondansetron
alon
vs
rr
ci
conclus
younger
age
shorter
acut
phase
durat
antiemet
regimen
significantli
associ
higher
likelihood
acut
phase
vomit
children
receiv
hec
jain
g
g
gandhi
cancer
institut
research
centr
pediatr
delhi
india
gandhi
cancer
institut
research
centr
research
delhi
india
backgroundobject
chemotherapi
induc
vomit
civ
common
distress
advers
effect
cancer
treatment
emerg
second
gener
receptor
antagonist
greater
receptor
select
longer
half
life
compar
efficaci
cost
palonosetron
ondansetron
designmethod
singl
centr
open
label
random
studi
children
receiv
moder
high
emetogen
chemotherapi
assign
get
either
ondansetron
palonosetron
addit
prophylaxi
primari
efficaci
endpoint
proport
children
complet
respons
acut
phase
first
chemotherapi
cycl
palonosetron
ondansetron
assess
use
statist
tool
risk
factor
suboptim
respons
cost
administr
two
drug
also
analys
result
children
analys
variou
factor
like
influenc
civ
equal
distribut
two
arm
patient
receiv
block
chemotherapi
sixti
nine
patient
receiv
hec
first
cycl
hec
compris
chemotherapi
block
administ
singl
day
chemotherapi
acut
phase
complet
respons
record
receiv
ondansetron
palonosetron
respect
p
valu
lower
limit
confid
interv
greater
palonosetron
arm
statist
signific
risk
factor
predispos
respons
use
dexamethason
p
cost
associ
palonosaetron
administr
significantli
lower
compar
ondansetron
indian
rupe
respect
p
conclus
singl
dose
palonosetron
equal
efficaci
ondansetron
prevent
acut
civ
children
receiv
moder
high
emetogen
chemotherapi
pharmacoeconom
implic
reduc
nurs
line
handl
crucial
secondari
gain
resourc
limit
set
kashyap
india
institut
medic
scienc
medic
oncolog
new
delhi
india
backgroundobject
children
cancer
vulner
malnutrit
increas
catabol
due
diseas
andor
treatment
limit
data
regard
impact
treatment
studi
aim
assess
nutrit
statu
children
cancer
effect
treatment
designmethod
prospect
observ
studi
data
regard
heightlength
weight
mid
upper
arm
circumfer
muac
collect
patient
baselin
month
inform
regard
literaci
statu
caretak
place
resid
ruralurban
collect
children
age
year
defin
undernourish
muac
age
weight
age
age
year
year
classifi
undernourish
weight
age
bmi
age
respect
nutrit
intervent
form
counsel
provis
high
protein
supplement
baselin
two
dedic
nutritionist
result
includ
patient
whose
data
avail
endpoint
hematolog
malign
solid
tumor
baselin
patient
undernourish
decreas
month
respect
subgroup
hematolog
malign
undernourish
children
baselin
month
respect
subgroup
solid
tumor
undernourish
children
baselin
month
respect
interv
haematolog
p
solid
malign
p
show
signific
reduct
proport
malnutrit
malnutrit
interv
significantli
associ
illiteraci
p
rural
background
conclus
nutrit
statu
children
cancer
improv
adequ
dietri
intervent
even
chemotherapi
literaci
statu
place
resid
effect
nutrit
patient
l
cheng
h
n
univers
school
nurs
shanghai
china
children
medic
center
affili
shanghai
jiao
tong
univers
school
medicin
pediatr
intens
care
unit
shanghai
china
children
medic
center
affili
shanghai
jiao
tong
univers
school
medicin
nurs
depart
hematolog
oncolog
shanghai
china
backgroundobject
aim
studi
describ
nutrit
statu
determin
impact
pediatr
oncolog
patient
admiss
pediatr
intens
care
unit
picu
designmethod
secondari
data
analysi
pediatr
oncolog
patient
prospect
cohort
studi
subset
databas
record
demograph
clinic
characterist
nutrit
statu
children
age
month
year
cancer
admit
picu
data
obtain
medic
record
patient
follow
hospit
discharg
anthropometr
paramet
use
evalu
nutrit
statu
malnutrit
consid
anthropometr
paramet
adjust
cox
regress
adjust
sex
age
pediatr
critic
ill
score
cross
tabul
use
examin
associ
nutrit
statu
outcom
result
preval
malnutrit
accord
accord
accord
bodi
mass
accord
accord
arm
serum
albumin
level
normal
rang
major
cohort
respect
anthropometr
paramet
predict
durat
mechan
ventil
hazard
ratio
hr
confid
interv
ci
hr
ci
hr
ci
upper
arm
muscl
hr
ci
length
picu
stay
predict
hr
ci
low
level
serum
albumin
associ
mortal
risk
ratio
rr
ci
conclus
malnutrit
preval
among
pediatr
oncolog
patient
admit
picu
malnutrit
admiss
picu
associ
length
picu
stay
durat
mechan
ventil
nutrit
statu
assess
follow
target
intervent
perform
children
agulnik
l
c
jude
children
research
hospit
global
pediatr
medicin
memphi
usa
infantil
teleton
de
oncologia
critic
care
queretaro
mexico
backgroundobject
hospit
pediatr
oncolog
patient
clinic
deterior
requir
pediatr
intens
care
unit
picu
transfer
result
high
inpati
mortal
rate
particularli
set
studi
describ
frequenc
clinic
characterist
outcom
clinic
deterior
event
among
pediatr
oncolog
patient
hospit
center
across
latin
america
designmethod
april
implement
uniform
prospect
system
track
clinic
deterior
event
defin
unplan
picu
transfer
vasopressor
mechan
ventil
cpr
death
floor
collabor
center
latin
america
qualiti
improv
measur
monthli
hospit
admiss
also
report
site
preliminari
analysi
data
collect
novemb
result
three
hundr
twenti
five
deterior
event
report
hospit
pediatr
oncolog
patient
among
hospit
admiss
time
preliminari
analysi
event
complet
case
report
form
major
patient
clinic
deterior
event
aml
solid
tumor
clinic
deterior
event
patient
requir
intens
intervent
floor
transfer
higher
level
care
intens
care
unit
similar
die
prior
hospit
discharg
patient
requir
mechan
ventil
vasopressor
cpr
significantli
higher
mortal
p
sixti
seven
patient
experienc
delay
identif
clinic
deterior
picu
transfer
result
higher
mortal
conclus
hospit
pediatr
oncolog
patient
clinic
deterior
set
high
mortal
critic
intervent
set
frequent
initi
hospit
floor
patient
access
picu
admiss
delay
identif
deterior
picu
transfer
may
contribut
poor
outcom
k
hardi
j
n
r
l
nation
medic
center
neuropsycholog
washington
usa
nation
medic
center
neurolog
washington
usa
florida
gainesvil
biostatist
gainesvil
usa
texa
southwestern
dalla
usa
pittsburgh
medic
center
pediatr
psychiatri
psycholog
pittsburgh
usa
hope
popul
scienc
support
care
medicin
duart
usa
sloan
ketter
pediatr
neuropsycholog
new
york
usa
texa
health
scienc
center
san
antonio
pediatr
san
antonio
usa
backgroundobject
survivor
childhood
may
experi
cognit
difficulti
includ
attent
execut
function
ef
problem
ef
collect
interrel
capac
respons
purpos
behavior
impact
school
occup
perform
aim
identifi
demograph
factor
associ
risk
execut
dysfunct
popul
designmethod
children
treat
protocol
enter
two
random
either
methotrex
capizzi
dexamethason
prednison
neuropsycholog
function
evalu
via
protocol
particip
femal
white
month
follow
treatment
complet
mean
age
diagnosi
year
ef
evalu
assess
measur
result
mean
score
measur
within
averag
rang
virtual
signific
differ
outcom
function
mtx
deliveri
steroid
treatment
howev
multivari
model
particip
us
public
insur
exhibit
significantli
greater
ef
difficulti
us
privat
insur
brief
metacognit
behavior
regul
p
addit
particip
diagnos
year
age
perform
poorli
measur
attent
cpt
commiss
omiss
respons
variabl
p
ef
dkef
categori
fluenci
letter
fluenci
tol
total
move
conclus
consist
publish
data
intellectu
outcom
sampl
attent
ef
differ
base
methotrex
deliveri
type
corticosteroid
receiv
howev
sever
outcom
vari
demograph
characterist
exampl
outcom
significantli
wors
children
age
diagnosi
compar
older
children
addit
ef
wors
children
us
public
insur
indic
econom
hardship
futur
research
continu
investig
contribut
socioeconom
statu
demograph
cognit
outcom
survivor
pediatr
cancer
j
wang
z
l
g
hospit
zhejiang
univers
school
medicin
surgic
oncolog
depart
hangzhou
china
backgroundobject
last
year
minim
invas
surgeri
mi
surgic
approach
pediatr
surgeri
howev
mi
popular
children
adren
area
tumor
studi
aim
evalu
safeti
effect
mi
resect
seri
children
adren
area
tumor
without
risk
factor
idrf
designmethod
sinc
institut
protocol
mi
resect
adren
area
tumor
pediatr
patient
without
idrf
appli
absenc
idrf
consid
main
indic
mi
approach
regardless
tumor
size
case
underw
preoper
chemotherapi
exclud
protocol
patient
underw
mi
adren
area
tumor
septemb
decemb
includ
specif
technic
consider
demograph
data
dada
record
result
patient
underw
mi
resect
adren
area
tumor
median
age
rang
median
diamet
mass
rang
mm
median
oper
time
min
rang
median
hospit
stay
day
neuroblast
tumor
main
postop
patholog
diagnosi
includ
case
neuroblastoma
case
ganglioneuroma
diagnosi
includ
case
adren
cortic
tumor
case
pheochromocytoma
case
adren
hematoma
five
patient
convert
open
surgeri
case
caus
intraop
hemorrhag
case
found
extrem
easi
ruptur
case
pheochromocytoma
ventricular
fibril
occur
mi
approach
success
patient
patient
treat
success
seriou
postop
complic
includ
periton
metastas
experienc
conclus
studi
demonstr
safeti
effect
mi
resect
adren
area
tumor
without
idrf
children
open
surgeri
consid
altern
approach
seriou
complic
occur
blood
pressur
control
intens
perform
case
pheochromocytoma
r
ladenstein
u
g
j
j
jm
r
v
v
j
w
c
h
ad
k
anna
kinderkrebsforschung
ev
studi
statist
integr
research
project
vienna
austria
anna
children
hospit
depart
medic
univers
vienna
austria
anna
children
cancer
research
institut
studi
statist
integr
research
project
vienna
austria
enfant
malad
pari
descart
univers
depart
pediatr
surgeri
pari
franc
univers
hospit
paediatr
surgeri
olso
norway
hospit
padua
paediatr
surgeri
padua
itali
universitario
la
fe
paediatr
oncolog
valencia
spain
astrid
lindgren
children
hospit
paediatr
oncolog
stockholm
sweden
hospit
lausann
paediatr
oncolog
lausann
switzerland
isituto
nazional
dei
tumori
paediatr
oncolog
milan
itali
children
medic
center
israel
paediatr
oncolog
haematolog
tikvah
israel
sofia
children
hospit
depart
paediatr
oncolog
haematolog
athen
greec
hospit
motol
depart
paediatr
oncolog
haematolog
pragu
czech
republ
univers
medic
colleg
depart
paediatr
oncolog
haematolog
krakow
poland
dublin
depart
paediatr
oncolog
haematolog
dublin
ireland
greifswald
depart
paediatr
oncolog
haematolog
greifswald
germani
hospit
ghent
depart
paediatr
oncolog
haematolog
ghent
belgium
gustav
roussi
depart
paediatr
oncolog
haematolog
pari
franc
cancer
research
royal
marsden
nh
trust
depart
paediatr
oncolog
haematolog
sutton
unit
kingdom
georg
hospit
paediatr
surgeri
london
unit
kingdom
backgroundobject
trial
influenc
complet
macroscop
excis
cme
post
immunotherapi
era
designmethod
elig
criteria
enrol
stage
diseas
complet
rapid
cojec
induct
cours
tvd
progressionrelapsedeath
prior
attempt
resect
complet
oper
data
intend
therapi
follow
oper
compris
hdtsct
bumel
cem
bumel
radiotherapi
primari
site
follow
ra
antibodi
short
term
infus
patient
fulfil
criteria
treat
prior
avail
immunotherapi
era
median
observ
time
year
year
result
cme
achiev
incomplet
macroscop
excis
ime
inoper
surgic
mortal
five
year
surviv
standard
error
follow
cme
vs
follow
ime
cumul
incid
local
relaps
cilr
cme
ime
p
radiotherapi
cme
ime
young
patient
patient
larg
primari
tumour
radiotherapi
omit
patient
cme
radiotherapi
compar
without
less
cme
compar
without
radiotherapi
ns
cilr
patient
cme
radiotherapi
vs
without
radiotherapi
significantli
higher
patient
enrol
compar
ef
patient
achiev
cme
vs
ime
respect
compar
vs
ime
prior
conclus
immunotherapi
era
cme
stage
patient
receiv
local
radiotherapi
result
improv
k
burnand
g
k
k
ormond
street
hospit
specialist
paediatr
neonat
surgeri
london
unit
kingdom
ormond
street
hospit
paediatr
oncolog
london
unit
kingdom
ormond
street
hospit
paediatr
radiolog
london
unit
kingdom
backgroundobject
imag
requir
assess
diseas
prior
surgeri
neuroblastoma
nbl
european
protocol
howev
mri
ct
scan
accept
routin
util
mri
diagnosi
nbl
concern
regard
mri
underestim
extent
diseas
chang
practic
sinc
use
mri
ct
abdomin
neuroblastoma
resect
aim
retrospect
studi
establish
imag
modal
superior
term
preoper
plan
designmethod
abdomin
mri
ct
scan
abdominalpelv
nbl
refer
surgeri
januari
februari
retrospect
review
evalu
extent
diseas
presenc
risk
factor
idrf
result
patient
elig
consider
surgeri
post
mrimibg
mdt
meet
seven
patient
exclud
two
adher
siopen
treatment
protocol
two
ct
three
patient
exclud
preoper
ct
mri
differ
treatment
stage
patient
underw
surgeri
ct
perform
mean
rang
day
mri
mri
unrepres
idrf
patient
notabl
fundament
chang
manag
post
ct
patient
three
patient
decis
went
surgeri
surgeri
due
newli
recognis
unresect
diseas
one
postpon
surgeri
high
dose
therapi
previous
consid
minim
invas
surgeri
two
alter
surgic
approach
bilater
diseas
note
need
extens
approach
chang
lead
surgeon
ct
underestim
diseas
compar
mri
patient
conclus
due
tumor
fibrosi
calcif
mri
underestim
extent
diseas
half
patient
consid
neuroblastoma
resect
preoper
ct
scan
necessari
identifi
idrf
ensur
safe
surgeri
futur
protocol
take
limit
mri
consider
avoid
underestim
tumor
extent
irtan
h
ducou
le
c
h
c
l
j
j
f
j
l
n
k
k
k
tousseau
assist
publiqu
de
pari
pediatr
surgeri
pari
franc
trousseau
assist
publiqu
de
pari
pediatr
radiolog
pari
franc
institut
pediatr
radiolog
pari
franc
newcastl
upon
tyne
hospit
nh
foundat
trust
pediatr
surgeri
newcastl
unit
kingdom
gaslini
institut
pediatr
radiolog
genoa
itali
gaslini
institut
pediatr
surgeri
genoa
itali
la
fe
pediatr
surgeri
valencia
spain
manchest
children
hospit
pediatr
surgeri
manchest
unit
kingdom
univers
hospit
pediatr
surgeri
urolog
stockholm
sweden
univers
hospit
pediatr
radiolog
stockholm
sweden
grenobl
servic
grenobl
franc
elisabeth
children
hospit
neonat
paediatr
surgeri
ghent
belgium
lausann
servic
de
chirurgi
lausann
switzerland
univers
hospit
pediatr
surgeri
oslo
norway
univers
hospit
pediatr
radiolog
oslo
norway
ormond
street
children
pediatr
surgeri
london
unit
kingdom
ormond
street
hospit
children
pediatr
radiolog
london
unit
kingdom
necker
assist
publiqu
de
pari
pediatr
surgeri
pari
franc
backgroundobject
controversi
issu
regard
impact
residu
neuroblastoma
hrnbl
still
remain
partli
tumor
residu
base
surgeon
report
view
futur
european
hrnbl
protocol
radiotherapi
plan
residu
volum
residu
patient
oper
hrnbl
analys
associ
risk
factor
outcom
designmethod
retrospectivereviewof
imag
diagnosi
preoper
postop
time
children
year
diagnos
hrnbl
treat
accord
protocol
oper
primari
locat
particip
countri
centr
conduct
result
total
patient
median
age
diagnosi
month
analys
metastat
mycn
amplif
local
ms
mycn
amplif
tumour
origin
adren
gland
sympathet
chain
paravertebr
thorax
abdomen
one
perivascular
one
abdomin
unknown
residu
note
patient
review
postop
imag
median
delay
surgeri
day
link
presenc
idrf
patient
median
volum
residu
ml
ml
patient
residu
restrict
micro
calcif
omit
residu
volum
ml
patient
presenc
residu
associ
number
preoper
idrf
diagnosi
preoper
tumour
volum
number
idrf
diagnosi
locat
morbid
seem
impact
overal
surviv
conclus
volum
postop
residu
hrnbl
surgeri
low
expert
centr
impact
outcom
studi
base
radiotherapi
control
data
l
van
zogchel
b
de
e
van
j
l
van
r
j
h
e
van
der
b
f
g
center
pediatr
oncolog
research
utrecht
netherland
hospit
univers
cologn
depart
pediatr
hematolog
oncolog
cologn
germani
research
landstein
laboratori
univers
amsterdam
depart
experiment
immunohematolog
amsterdam
netherland
research
landstein
laboratori
univers
amsterdam
depart
immunocytolog
amsterdam
netherland
children
academ
medic
center
depart
pediatr
oncolog
amsterdam
netherland
univers
mathemat
institut
leiden
netherland
backgroundobject
rel
small
retrospect
studi
previous
describ
mrd
detect
quantit
pcr
qpcr
correl
surviv
prospect
studi
neuroblastoma
nb
patient
treat
gpoh
dcog
prognost
valu
diagnost
level
mrna
clinic
signific
bm
clearanc
cours
end
designmethod
serial
bm
sampl
nb
patient
diagnosi
set
time
point
treatment
prospect
collect
gpoh
dcog
qpcr
perform
use
five
homeobox
tyrosin
hydroxylas
th
dopa
decarboxylas
ddc
cholinerg
receptor
alpha
protein
bm
infiltr
defin
describ
previous
stutterheim
van
wezel
compar
ic
surviv
ef
overal
surviv
os
studi
multivari
cox
regress
model
includ
age
mna
infiltr
level
result
diagnosi
level
correl
ef
p
os
p
adjust
hazard
ratio
patient
bm
infiltr
diagnosi
ef
os
respect
bm
infiltr
vs
cours
differ
significantli
ef
signific
poorer
outcom
seen
bm
posit
year
ef
os
neg
respect
qpcr
overal
sensit
better
predictor
outcom
ic
especi
end
induct
vs
patient
poorer
outcom
conclus
high
bm
infiltr
level
diagnosi
correl
poor
outcom
bm
clearancelow
infiltr
cycl
induct
therapi
associ
better
ef
qpcr
bm
clearanc
end
induct
therapi
significantli
associ
better
ef
os
j
molenaar
w
j
vd
p
f
b
e
maxima
center
pediatr
oncolog
translat
reserach
utrecht
netherland
medic
center
amsterdam
oncogenom
amsterdam
netherland
backgroundobject
attempt
improv
treatment
relaps
neuroblastoma
pediatr
cancer
precis
medicin
program
aim
identifi
genom
andor
epigenet
aberr
could
serv
biomark
target
therapi
howev
sever
studi
shown
averag
action
event
identifi
patient
identifi
potenti
treatment
option
remain
patient
develop
person
model
use
autom
compound
screen
designmethod
use
serum
free
cultur
condit
gener
neuroblastoma
organoid
use
bioinformat
platform
identifi
addit
growth
factor
improv
growth
rate
singl
cell
tumor
take
genom
profil
singl
cell
rna
sequenc
use
studi
mainten
tumor
heterogen
model
identifi
potenti
new
intervent
develop
robot
platform
systemat
screen
librari
compound
refer
compound
librari
addit
test
organoid
tissu
includ
colon
duodenum
kidney
liver
result
use
optim
cultur
protocol
could
grow
neuroblastoma
organoid
primari
tumor
materi
failur
growth
mainli
relat
low
tumor
content
biopsi
materi
genom
profil
confirm
mainten
genom
aberr
primari
tumor
materi
heterogen
retain
shown
singl
cell
rnaseq
analysi
compound
screen
identifi
target
compound
interf
dna
damag
signal
epigenet
modifi
increas
sensit
neuroblastoma
organoid
compound
screen
data
correl
genom
profil
sampl
identifi
potenti
new
biomark
conclus
conclud
neuroblastoma
organoid
valid
system
develop
person
tumor
model
sato
h
c
iowa
stead
famili
children
hospit
pediatr
hematolog
oncolog
iowa
citi
usa
iowa
carver
colleg
medicin
iowa
citi
usa
iowa
stead
famili
children
hospit
center
disabl
develop
iowa
citi
usa
iowa
biostatist
iowa
citi
usa
iowa
colleg
public
health
epidemiolog
iowa
citi
usa
iowa
colleg
educ
depart
psycholog
quantit
iowa
citi
usa
backgroundobject
academ
achiev
children
brain
tumor
address
cohort
creat
via
linkag
involv
iowa
cancer
registri
icr
iowa
test
program
itp
icr
record
patient
brain
tumor
diagnosi
sinc
itp
set
standard
academ
achiev
measur
obtain
student
kindergarten
high
school
last
year
measur
domain
includ
vocabulari
read
languag
math
social
studi
scienc
purpos
studi
identifi
pattern
academ
achiev
children
diagnosi
brain
tumor
diagnosi
treatment
designmethod
academ
achiev
data
analyz
form
nation
percentil
rank
score
grade
content
domain
trajectori
academ
achiev
prior
post
diagnosi
statist
analys
benign
malign
tumor
male
femal
right
left
tumor
analyz
result
children
median
age
brain
tumor
diagnos
identifi
total
academ
achiev
test
result
analyz
children
malign
children
benign
tumor
signific
differ
academ
achiev
diagnosi
benign
malign
group
compar
gender
femal
group
show
better
trajectori
scienc
prior
diagnosi
male
group
diagnosi
signific
declin
academ
achiev
domain
benign
malign
group
suggest
surgeri
intervent
impact
academ
achiev
later
comparison
show
signific
declin
math
math
comput
tumor
group
conclus
academ
achiev
test
help
measur
degre
brain
function
declin
brain
tumor
diagnosi
academ
achiev
test
school
util
evelop
intervent
patient
neurocognit
declin
g
calaminu
c
u
je
rd
children
hospit
depart
paediatr
oncolog
bonn
germani
univers
duesseldorf
depart
paediatr
oncolog
duesseldorf
germani
leipzig
depart
radiat
therapi
leipzig
germani
vienna
depart
neurosurgeri
vienna
austria
backgroundobject
cn
germinoma
achiev
five
year
ef
craniospin
irradi
alon
combin
chemo
radiotherapi
occur
suprasellar
pineal
bifoc
radiotherapi
rt
pituitari
area
caus
total
panhypopituitar
pan
partial
anterior
pituitari
failur
apf
vmh
damag
vmh
damag
also
result
bodi
mass
index
bmi
elev
thu
examin
effect
treatment
anterior
pituitari
function
cut
designmethod
evalu
patient
treat
aliv
without
recurr
male
femal
median
age
year
median
observ
time
year
apf
pan
bmi
examin
treatment
least
year
result
patient
bifocalsuprasellar
primari
tumor
suprasellarbifoc
show
pan
partial
apf
therapi
patient
show
apf
treatment
show
pan
treatment
patient
develop
new
pan
caus
oper
irradi
unclear
pineal
germinoma
develop
partial
apf
treatment
patient
suprasellarbifoc
tumor
receiv
gy
radiotherapi
rt
dose
pituitari
area
patient
pineal
tumor
receiv
less
rt
dose
pituitari
area
patient
develop
riskfactor
develop
suprasellarbifoc
localis
apf
radiat
dose
gy
pa
also
includ
vmh
conclus
patient
rt
dose
pituitari
area
signific
higher
risk
develop
partial
apf
pan
result
show
lower
rt
dose
pituitari
area
need
prevent
apf
vmh
damag
develop
addit
health
risk
ehrhardt
c
k
c
c
r
z
j
l
k
jude
children
research
hospit
oncolog
memphi
usa
jude
children
research
hospit
epidemiolog
cancer
control
memphi
usa
hospit
univers
medic
center
oncolog
saida
lebanon
state
univers
obstetr
gynecolog
detroit
usa
tennesse
radiolog
memphi
usa
anderson
cancer
center
radiat
physic
houston
usa
jude
children
research
hospit
comput
biolog
memphi
usa
backgroundobject
femal
childhood
cancer
survivor
risk
subsequ
breast
cancer
character
breast
cancer
risk
screen
outcom
femal
sjlife
particip
designmethod
femal
sjlife
particip
age
year
underw
clinic
assess
valid
prior
health
event
screen
chest
radiat
dosimetri
estim
whole
genom
sequenc
biopsi
report
suspect
breast
cancer
review
subgroup
women
underw
breast
magnet
reson
imag
mri
mammographi
pair
imag
retrospect
interpret
radiologist
blind
clinic
outcom
proport
hazard
model
use
investig
associ
hazard
ratio
hr
confid
interv
ci
patient
characterist
childhood
cancer
treatment
breast
cancer
occurr
result
women
develop
breast
cancer
situ
carcinoma
invas
ductal
carcinoma
age
year
cumul
incid
age
year
chest
radiat
cgi
chest
radiat
respect
multivari
model
breast
cancer
associ
increas
age
diagnosi
per
year
chest
radiat
dose
cgi
cumul
anthracyclin
dose
pathogeniclik
pathogen
mutat
one
nine
autosom
domin
gene
atm
pten
high
penetr
link
breast
cancer
women
pair
imag
age
year
mean
chest
radiat
dose
cgi
sensit
specif
mammographi
mri
either
imag
posit
imag
neg
parallel
dual
imag
conclus
treatment
genet
risk
factor
identifi
survivor
highest
risk
breast
cancer
may
benefit
parallel
mammographymri
screen
hodgson
h
r
lansdorp
margaret
cancer
centr
radiat
oncolog
toronto
canada
mc
depart
public
health
rotterdam
netherland
backgroundobject
childhood
cancer
survivor
cc
high
risk
colorect
cancer
crc
compar
gener
popul
potenti
benefit
cost
earli
crc
screen
unclear
howev
consequ
recommend
guidelin
vari
respect
screen
initi
designmethod
modifi
establish
model
crc
screen
microsimul
screen
reflect
crc
risk
mortal
among
cc
crc
risk
compet
caus
death
base
epidemiolog
studi
crc
cc
data
surveil
epidemiolog
end
result
seer
evalu
colonoscopi
screen
strategi
vari
screen
interv
age
start
age
stop
cc
comput
risk
crc
death
crc
death
prevent
increment
ratio
icer
assum
threshold
per
gain
lyg
result
among
cc
survivor
per
risk
predict
die
crc
without
screen
number
per
among
treat
abdominalpelv
radiat
therapi
aprt
screen
colonoscopi
everi
year
age
optim
among
cc
icer
per
lyg
avoid
crc
death
treat
aprt
optim
strategi
colonoscopi
start
age
icer
per
lyg
prevent
crc
mortal
repeat
colonoscopi
screen
everi
year
optim
respect
among
wt
age
lower
crc
mortal
hl
survivor
age
reduct
crc
mortal
age
primari
cancer
diagnosi
addit
mortal
data
affect
optim
age
start
screen
conclus
knowledg
first
quantit
evid
indic
earli
initi
crc
screen
would
cost
effect
among
cc
particularli
treat
aprt
tolkkinen
l
n
f
j
cancer
registri
finnish
cancer
registri
helsinki
finland
hospit
univers
helsinki
helsinki
univers
hospit
helsinki
finland
univers
hospit
divis
pediatr
oncolog
stem
cell
transplant
helsinki
finland
tamper
faculti
social
scienc
tamper
finland
cancer
research
group
danish
cancer
societi
research
center
copenhagen
denmark
helsinki
depart
public
health
helsinki
finland
backgroundobject
survivor
childhood
cancer
may
face
broad
spectrum
somat
follow
cancer
diagnosi
addit
increas
risk
somat
morbid
survivor
may
face
socioeconom
difficulti
adulthood
salicc
socioeconom
consequ
adult
life
childhood
cancer
scandinavia
research
program
uniqu
three
popul
base
cohort
childhood
cancer
survivor
denmark
finland
sweden
aim
studi
find
childhood
cancer
diagnosi
affect
incom
survivor
adult
life
preliminari
result
present
describ
finnish
designmethod
survivor
diagnos
cancer
age
year
age
older
aliv
identifi
finnish
cancer
registri
annual
dispos
incom
retriev
statist
finland
survivor
median
dispos
incom
compar
match
popul
comparison
match
sex
birth
year
test
signific
use
wilcoxon
test
median
dispos
incom
also
calcul
specif
diagnost
group
result
median
dispos
incom
eur
childhood
cancer
survivor
versu
eur
popul
comparison
differ
dispos
incom
cancer
survivor
popul
comparison
statist
signific
p
survivor
median
dispos
incom
eur
survivor
cn
tumor
eur
survivor
leukemia
eur
survivor
lymphoma
eur
survivor
malign
neoplasm
conclus
preliminari
result
indic
survivor
childhood
cancer
lower
averag
median
dispos
incom
compar
gener
popul
survivor
cn
tumor
lowest
incom
cancer
survivor
somat
morbid
psychosoci
challeng
barrier
employ
may
contribut
low
incom
observ
among
survivor
p
lupo
v
j
k
w
f
l
l
g
k
k
colleg
medicin
pediatr
houston
usa
colleg
medicin
molecular
human
genet
houston
usa
colleg
medicin
medicin
pediatr
houston
usa
hutchinson
cancer
research
center
clinic
research
seattl
usa
jude
children
research
hospit
epidemiolog
cancer
control
memphi
usa
cancer
institut
divis
cancer
epidemiolog
genet
bethesda
usa
alabama
birmingham
pediatr
birmingham
usa
univers
medicin
durham
usa
backgroundobject
obes
import
late
effect
among
survivor
childhood
although
numer
bodi
mass
index
bmi
suscept
variant
identifi
gener
popul
genet
predisposit
obes
survivor
remain
poorli
understood
conduct
gwa
bmi
among
survivor
ccss
texa
children
cancer
center
tccc
designmethod
discoveri
gwa
includ
adult
survivor
particip
ccss
genotyp
array
imput
use
genom
project
independ
replic
set
tccc
genotyp
illumina
omniexpress
array
includ
adult
survivor
survivor
year
age
bmi
calcul
growth
chart
separ
model
popul
bmi
bmi
regress
age
diagnosi
age
cranial
radiotherapi
crt
sex
age
interact
result
residu
includ
depend
variabl
linear
regress
model
estim
beta
snp
adjust
princip
compon
snp
associ
bmi
p
discoveri
set
conduct
across
three
popul
use
approach
result
first
evalu
snp
identifi
gwa
gener
popul
none
associ
bmi
among
survivor
correct
multipl
comparison
identifi
put
locu
reach
signific
consist
beta
estim
across
three
popul
ccss
tccc
tccc
gtex
snp
locu
associ
express
across
multipl
tissu
implic
lipoprotein
metabol
conclus
identifi
potenti
novel
locu
chromosom
survivor
addit
analys
underway
includ
replic
estim
polygen
risk
score
investig
treatment
group
l
mascarenha
j
j
l
r
hospit
lo
keck
school
univers
southern
california
oncolog
blood
marrow
transplant
lo
angel
usa
hospit
lo
angel
oncolog
blood
marrow
transplant
lo
angel
usa
hospit
lo
keck
school
univers
southern
california
gener
pediatr
surgeri
lo
angel
usa
hospit
lo
keck
school
univers
southern
california
pediatr
surgic
lo
angel
usa
hospit
lo
keck
school
univers
southern
california
transplant
surgeri
lo
angel
usa
backgroundobject
chic
group
recent
develop
new
intern
risk
stratif
system
hepatoblastoma
hb
risk
stratif
includ
age
pretext
stage
pretext
annot
factor
metastas
serum
level
tumor
resect
categor
patient
four
risk
group
low
low
intermedi
high
howev
perform
evalu
independ
group
patient
designmethod
analyz
retrospect
collect
data
newli
diagnos
patient
hb
treat
children
hospit
lo
angel
use
chic
risk
stratif
tree
patient
assign
risk
group
result
consecut
patient
male
age
rang
month
year
diagnos
hb
time
period
patient
fell
low
low
intermedi
high
risk
group
respect
median
year
total
cancer
specif
death
estim
overal
surviv
rate
chic
risk
classif
tree
patient
low
low
intermedi
high
risk
group
respect
compar
lowlow
risk
group
hazard
ratio
hr
death
patient
high
risk
intermedi
hepatoblastoma
ci
ci
respect
kaplan
meier
surviv
curv
cohort
follow
predict
trend
show
signific
differ
surviv
p
overal
surviv
p
conclus
chic
risk
stratif
hb
perform
well
cohort
first
independ
valid
chic
risk
stratif
hb
j
j
l
r
l
mascarenha
hospit
lo
keck
school
univers
southern
california
pediatr
surgic
lo
angel
usa
hospit
lo
angel
oncolog
blood
marrow
transplant
lo
angel
usa
hospit
lo
keck
school
univers
southern
california
gener
pediatr
lo
angel
usa
hospit
lo
keck
school
univers
southern
california
transplant
lo
angel
usa
hospit
lo
keck
school
univers
southern
california
prevent
medicin
oncolog
blood
marrow
transplant
lo
angel
usa
hospit
lo
keck
school
univers
southern
california
oncolog
blood
marrow
transplant
lo
angel
usa
backgroundobject
chic
risk
stratif
hepatoblastoma
hb
categor
patient
risk
group
base
sever
prognost
factor
omit
histolog
designmethod
retrospect
analyz
data
hb
patient
diagnos
institut
use
chic
risk
stratif
patient
assign
risk
group
next
base
intern
pediatr
liver
tumor
consensu
classif
tumor
first
assign
broadli
either
epitheli
mix
type
one
follow
subtyp
fetal
embryon
embryon
fetal
hepat
malign
neoplasm
otherwis
specifi
hemno
other
includ
small
cell
undifferenti
scu
result
hb
patient
male
age
year
categor
low
low
intermedi
high
risk
pretext
stage
iiiiv
tumor
patient
metastas
year
patient
afp
level
ngml
tumor
epitheli
type
histolog
subtyp
classif
embryon
fetal
epitheli
subtyp
predomin
follow
embryon
epitheli
subtyp
scu
retain
group
separ
sinc
group
insuffici
event
patient
hemno
surviv
median
year
total
cancer
specif
death
os
rate
chic
risk
group
patient
low
low
intermedi
diseas
respect
multivari
analysi
chic
risk
group
histolog
subtyp
independ
signific
os
p
p
respect
patient
embryon
epitheli
subtyp
highest
risk
death
similar
result
observ
ef
conclus
histolog
subtyp
prognost
may
add
chic
risk
stratif
hb
e
hiyama
k
k
j
k
k
k
univers
hospit
pediatr
surgeri
hiroshima
japan
children
caner
group
liver
tumor
commite
tokyo
japan
backgroundobject
aim
clarifi
whether
afp
concentr
declin
afp
concentr
tumor
resect
repres
prognost
factor
patient
hepatoblastoma
hbl
treat
studi
designmethod
studi
except
initi
resect
case
cours
patient
hbl
underw
preoper
chemotherapi
ctx
elig
patient
underw
three
differ
treatment
strata
cours
main
frame
cita
cisplatin
pirarubicin
regimen
accord
pretext
classif
serum
concentr
afp
diagnosi
tumor
resect
assess
associ
surviv
ef
overal
surviv
os
result
distribut
pretext
classif
follow
patient
pretext
tumor
ii
iii
iv
includ
metastat
hbl
afp
level
ngml
diagnosi
ngml
resect
decreas
afp
level
diagnosi
resect
resect
pretext
ii
iii
iv
patient
significantli
correl
declin
afp
efso
cours
cours
cours
hbl
respect
among
patient
receiv
cur
surgeri
due
refractori
progress
die
diseas
afp
level
diagnosi
show
signific
associ
surgeri
ef
os
case
hand
log
declin
afp
level
signific
ef
p
os
p
differ
signific
cours
patient
conclus
declin
serum
afp
level
use
prognosi
hbl
monitor
afp
level
might
aid
determin
optim
surgic
time
patient
hbl
especi
local
hbl
oneil
md
c
p
rl
hm
cancer
institut
pediatr
oncolog
boston
usa
davi
pediatr
oncolog
davi
usa
school
medicin
univers
southern
california
prevent
medicin
monrovia
usa
oncolog
group
statist
data
center
monrovia
usa
heart
children
hospit
pediatr
oncolog
spokan
usa
north
carolina
pediatr
oncolog
chapel
hill
usa
utah
pediatr
surgeri
salt
lake
citi
usa
health
nemour
children
specialti
care
pediatr
oncolog
jacksonvil
usa
backgroundobject
hepatoblastoma
hb
common
pediatr
liver
neoplasm
major
newli
diagnos
patient
present
elev
serum
alpha
afp
level
exact
relationship
afp
declin
treatment
outcom
well
establish
designmethod
children
oncolog
group
cog
protocol
children
newli
diagnos
hb
includ
stratum
patient
unresect
diseas
resect
diseas
small
cell
undifferenti
scu
histolog
anticip
receiv
cycl
cisplatin
vincristin
doxorubicin
resect
convent
surgeri
transplant
intend
occur
prior
cycl
afp
level
obtain
diagnosi
therapi
visit
analyz
afp
level
respons
therapi
normal
per
institut
standard
result
one
hundr
four
elig
subject
enrol
stratum
mean
afp
diagnosi
ngml
median
rang
ngml
afp
valu
normal
subject
follow
patient
conclus
protocol
therapi
patient
six
twelv
eighteen
greater
month
eleven
subject
fail
normal
relaps
patient
normal
afp
conclus
therapi
none
relaps
patient
relaps
progress
increas
afp
howev
addit
patient
rise
afp
either
therapi
median
rang
ngml
median
rang
normal
without
diseas
recurr
conclus
combin
local
control
effect
promot
normal
afp
rate
afp
declin
declin
associ
relaps
increas
afp
necessarili
indic
relaps
pire
c
de
r
univers
clinic
pediatr
surgeri
transplant
unit
bruxel
belgium
backgroundobject
chemotherapi
associ
cur
surgeri
potenti
cur
treatment
hepatoblastoma
hb
total
hepatectomi
indic
children
unresect
hb
present
studi
aim
review
singl
center
experi
live
donor
liver
transplant
ldlt
hb
children
designmethod
children
receiv
live
donor
liver
graft
unresect
hb
pretext
iv
hb
requir
extrem
resect
pretext
ii
iii
major
vascular
involv
siopel
chemotherapi
protocol
result
median
age
ldlt
year
rang
donor
underw
major
left
lobectomi
without
mortal
donor
procedur
pretext
iv
observ
children
pretext
iii
pretext
ii
rescu
hb
tumor
recurr
remain
liver
partial
hepat
resect
median
delay
year
ldlt
caval
replac
perform
case
prognost
factor
surviv
associ
decreas
hb
recurr
risk
p
postop
sever
morbid
includ
biliari
leak
hemorrhag
sushepat
thrombosi
hematoma
peripher
venou
thrombosi
among
case
tumor
recurr
children
die
includ
rescu
hb
tumor
recurr
ldlt
ldlt
rescu
hb
associ
prognost
factor
poor
surviv
p
respect
tumor
recurr
occur
first
year
ldlt
surviv
year
ldlt
reach
children
survivor
conclus
prognosi
patient
ldlt
hb
better
children
undergo
previou
hepat
resect
good
overal
surviv
year
caval
replac
ldlt
associ
improv
surviv
pietsch
v
c
bonn
depart
neuropatholog
bonn
germani
medic
center
campu
kiel
depart
patholog
kiel
germani
backgroundobject
hepatocellular
carcinoma
hcc
childhood
rare
neoplam
pathogenesi
believ
differ
hcc
adulthood
differenti
diagnosi
hepatoblastoma
hbl
import
wors
prognosi
pediatr
hcc
phcc
differ
treatment
approach
aim
studi
identifi
recurr
chromosom
aberr
mrna
express
epigenet
signatur
larger
cohort
phcc
compar
hbl
identifi
characterist
epi
genom
alter
signatur
phcc
designmethod
genom
dna
extract
ffpe
sampl
cohort
phcc
identifi
archiv
german
pediatr
tumor
registri
univers
kiel
sampl
patient
hcc
age
rang
year
year
median
year
collect
copi
analysi
perform
molecular
invers
profil
gistic
analysi
done
identifi
signific
larg
focal
aberr
fresh
frozen
hcc
sampl
hbl
use
rna
express
methyl
studi
result
frequent
copi
number
alter
gain
chromosom
loss
chromosom
region
alter
signaificantli
frequent
phcc
compar
hbl
phcc
lack
larger
chromosom
imbal
note
genom
stabl
tumor
show
fibrolamellar
differenti
carri
fusion
cluster
analysi
mrna
express
methyl
data
separ
phcc
hbl
gsea
analysi
show
enrich
signatur
pedhcc
compar
fetal
liver
conclus
copi
number
analysi
mrna
express
methyl
analysi
larg
cohort
pediatr
hcc
identifi
characterist
genet
alter
signatur
indic
possibl
specif
pathogenesi
neoplasm
may
help
subclassifi
phcc
differenti
tumor
hbl
ds
gerhard
c
j
p
e
j
j
cancer
institut
offic
cancer
genom
md
usa
hospit
philadelphia
pediatr
philadelphia
usa
children
medic
center
pediatr
hartford
usa
cancer
institut
center
cancer
research
bethesda
usa
hutchinson
cancer
research
center
pediatr
hematologyoncolog
seattl
usa
robert
h
luri
children
hospit
chicago
patholog
chicago
usa
jude
children
research
hospit
comput
biolog
memphi
usa
cancer
institut
cancer
therapi
evalu
program
md
usa
backgroundobject
new
therapeut
target
prognost
marker
need
pediatr
cancer
designmethod
target
project
perform
comprehens
molecular
character
whole
genom
whole
exom
transcriptom
sequenc
tumornorm
pair
six
histotyp
determin
genet
chang
drive
initi
progress
pediatr
cancer
result
median
somat
mutat
rate
pediatr
cancer
fold
lower
observ
common
adult
cancer
case
germlin
variant
associ
cancer
predisposit
somat
copi
number
altern
structur
variat
compris
major
observ
event
singl
nucleotid
mutat
small
indel
less
frequent
mani
patient
genom
alter
driver
event
total
gene
popul
mutat
frequenc
high
enough
declar
driver
match
potenti
cancer
driver
found
adult
tumor
provid
strong
support
pediatr
cancer
differ
initi
progress
process
adult
cancer
larg
number
low
frequenc
driver
present
within
among
diseas
cohort
biolog
pathway
disrupt
driver
alter
eg
cell
cycl
epigenet
regul
may
target
exist
treatment
certain
signal
pathway
show
distinct
somat
alter
solid
tumor
leukemia
half
observ
pediatr
driver
gene
specif
singl
histotyp
eg
alk
neuroblastoma
analys
found
known
novel
statist
signific
eg
aml
crebbp
wilm
tumor
mutual
exclus
eg
mycn
atrx
neuroblastoma
among
conclus
pediatr
cancer
differ
initi
progress
process
adult
cancer
highlight
need
new
therapi
target
pediatr
cancer
target
data
avail
research
commun
http
wwwocgcancergov
gisselsson
j
univers
depart
clinic
genet
patholog
lund
sweden
univers
clinic
genet
patholog
lund
sweden
backgroundobject
recent
studi
childhood
cancer
reveal
genet
divers
among
cell
inhabit
differ
part
tumor
caus
problem
consist
detect
genet
biomark
aim
toassess
extent
dna
sequenc
copi
number
analysi
multipl
sampl
singl
tumour
multipl
cell
singl
biopsi
reveal
distinct
pattern
intratumor
variat
designmethod
total
sampl
tumour
consist
neuroblastoma
wilm
tumor
rhabdomyosarcoma
subject
whole
exom
sequenc
copi
number
analys
tumour
follow
singl
cell
low
pass
whole
genom
sequenc
cell
per
sampl
result
phylogenet
analys
base
multiregion
sampl
indic
neuroblastoma
rhabdomyosarcoma
p
truncal
mutat
mean
allel
imbal
wilm
tumor
mean
branch
length
show
overal
differ
among
three
tumour
type
mean
wilm
tumour
diffus
anaplasia
mutat
show
branch
anomali
mean
intermedi
risk
wilm
tumour
mean
truncal
aberr
neuroblastoma
rhabdomyosarcoma
primarili
encompass
structur
chromosom
rearrang
contrast
anomali
favor
subtyp
singl
cell
whole
genom
sequenc
reveal
stagger
divers
tumour
accumul
subclon
fractal
characterist
specif
case
singl
cell
profil
reveal
signific
migrat
cell
clonal
territori
conclus
data
suggest
neuroblastoma
rhabdomyosarcoma
alreadi
latest
clonal
expans
endow
genom
profil
contrast
complex
genom
anaplast
wilm
tumour
typic
develop
latest
clonal
expans
intratumor
migrat
distanc
cancer
cell
belong
differ
genet
lineag
may
occur
tumour
complic
clonal
geographi
childhood
cancer
potter
j
r
f
h
h
n
k
sen
sf
dc
id
r
nm
dw
children
cancer
centerbaylor
colleg
medicin
pediatr
hematologyoncolog
houston
usa
colleg
medicinetexa
children
hospit
depart
patholog
immunolog
houston
usa
colleg
medicin
depart
molecular
human
genet
houston
usa
colleg
medicinetexa
children
hospit
depart
surgeri
houston
usa
colleg
medicinetexa
children
hospit
depart
otolaryngolog
houston
usa
colleg
medicinetexa
children
hospit
pediatr
endocrinolog
houston
usa
backgroundobject
pediatr
papillari
thyroid
carcinoma
ptc
clinic
biolog
differ
adult
ptc
perform
integr
dna
sequenc
cohort
tumor
identifi
genet
alter
might
inform
improv
diagnost
therapeut
approach
designmethod
case
identifi
tch
patholog
archiv
tumor
dna
captur
use
mutat
panel
includ
entir
code
region
select
region
gene
implic
pediatr
solid
tumor
tumor
rna
analyz
use
commerci
avail
multiplex
gene
fusion
panel
archer
oncolog
research
panel
target
pediatr
solid
tumor
gene
result
total
pediatr
ptc
case
featur
priorit
analysi
major
patient
metastat
cervic
lymph
node
one
third
also
found
pulmonari
metastas
relapsedrefractori
diseas
occur
patient
dna
sequenc
success
perform
case
reveal
potenti
target
mutat
tumor
braf
x
rna
sequenc
accomplish
case
identifi
potenti
target
fusion
tumor
ret
x
x
braf
total
case
dna
rna
analyz
alter
discov
conclus
frequent
alter
identifi
known
cancer
gene
pediatr
ptc
case
mani
current
target
investig
inclus
rna
sequenc
detect
fusion
gene
critic
evalu
tumor
p
k
cj
cm
v
rand
institut
cancer
research
wolfson
childhood
cancer
research
centr
newcastl
upon
tyne
unit
kingdom
upon
tyne
hospit
nh
foundat
trust
depart
cellular
patholog
newcastl
upon
tyne
unit
kingdom
backgroundobject
current
frontlin
therapi
paediatr
lymphoma
effect
achiev
surviv
howev
children
relaps
treatment
option
limit
outcom
remain
poor
littl
current
known
biolog
relaps
diseas
marker
identifi
children
relaps
perform
copi
number
analysi
identifi
abnorm
associ
relaps
diseas
designmethod
includ
paediatr
case
studi
diagnost
sampl
obtain
children
cancer
leukaemia
group
cclg
tumour
bank
case
identifi
literatur
match
relaps
sampl
obtain
relaps
case
copi
number
data
gener
use
affymetrix
cytoscan
hd
oncoscan
array
mutat
detect
use
sanger
sequenc
univari
multivari
analys
examin
associ
abnorm
risk
relaps
overal
surviv
result
recurr
copi
number
abnorm
cna
region
copi
number
neutral
loss
heterozygos
detect
recurr
cna
involv
known
cancer
gene
includ
rel
identifi
case
biallel
inactiv
multivari
analysi
identifi
biallel
inactiv
independ
prognost
factor
identifi
children
increas
risk
relaps
hazard
ratio
ci
shorter
surviv
hazard
ratio
ci
match
relaps
sampl
case
biallel
inactiv
relaps
maintain
abnorm
diagnosi
one
acquir
inactiv
relaps
conclus
analysi
reveal
biallel
inactiv
associ
increas
risk
relaps
shorter
surviv
paediatr
work
essenti
understand
biolog
exploit
genom
abnorm
improv
surviv
relaps
n
timchenko
l
k
l
r
kd
l
j
children
hospit
medic
center
surgeri
cincinnati
usa
children
hospit
medic
center
oncolog
cincinnati
usa
children
hospit
medic
center
patholog
cincinnati
usa
jude
children
hospit
scienc
memphi
usa
children
hospit
medic
center
gastroenterolog
cincinnati
usa
colleg
medicin
cell
biolog
houston
usa
children
hospit
medic
center
biomed
informat
cincinnati
usa
children
hospit
medic
center
neurolog
cincinnati
usa
backgroundobject
hepatoblastoma
hbl
common
type
liver
cancer
children
unfortun
mechan
behind
develop
hbl
well
understood
goal
work
determin
mechan
hbl
develop
new
therapeut
approach
designmethod
analyz
larg
biobank
hbl
sampl
cchmc
investig
four
anim
model
recapitul
differ
molecular
featur
hbl
global
transcriptom
profil
epigenet
regul
complex
modif
tumor
suppressor
protein
tsp
oncogen
examin
use
art
techniqu
result
found
classic
hbl
character
reduct
tsp
reduct
mediat
tsp
mrna
degrad
protein
system
surprisingli
found
subset
patient
hbl
elev
tsp
undergon
modif
ptm
specif
modif
cebpalpha
convert
protein
oncogen
search
mechan
behind
elev
level
newfound
oncogen
hbl
identifi
uniqu
aggress
liver
cancer
domain
alcd
activ
chromatin
remodel
activ
alcd
increas
express
oncogen
form
tsp
also
activ
mani
pathway
includ
wnt
signal
inhibit
liver
cancer
cell
block
activ
alcd
normal
express
oncogen
result
inhibit
prolifer
cancer
cell
conclus
studi
identifi
two
type
hbl
classic
hbl
degrad
tsp
aggress
hbl
elev
oncogen
form
tsp
addit
cancer
relat
pathway
current
work
develop
target
therapi
use
inhibitor
gankyrin
treatment
patient
classic
aggress
hbl
respect
p
tem
hospit
essen
depart
pediatr
iii
essen
germani
hospit
essen
institut
human
genet
essen
germani
backgroundobject
survivor
herit
retinoblastoma
carri
high
risk
develop
second
primari
malign
spm
incid
spm
significantli
rais
extern
beam
radiotherapi
ebrt
aim
analyz
impact
type
constitut
mutat
incid
spm
without
previou
irradi
designmethod
nation
patient
treat
herit
retinoblastoma
german
referr
center
complet
inform
second
primari
malign
data
constitut
mutat
avail
patient
result
spm
occur
survivor
herit
retinoblastoma
irradi
cumul
incid
ratio
per
person
year
spm
confid
interv
influenc
type
constitut
mutat
retinoblastoma
survivor
cumul
incid
ratio
spm
lower
compar
irradi
patient
ir
p
without
previou
irradi
spm
observ
patient
heterozyg
nonsens
mutat
ir
spm
report
survivor
somat
mosaicm
gene
ir
survivor
heterozyg
constitut
missens
mutat
larg
delet
promotor
mutat
ir
type
tumor
herit
retinoblastoma
survivor
divers
compris
three
soft
tissu
sarcoma
one
hematolog
malign
three
mamma
carcinoma
one
bronchial
carcinoma
one
melanoma
one
brain
tumor
conclus
influenc
type
constitut
mutat
incid
spm
cohort
evid
without
previou
radiotherapi
treatment
extern
beam
radiotherapi
survivor
herit
retinoblastoma
risk
second
cancer
regardless
constitut
genotyp
mansouri
univ
cancer
radiat
gustav
franc
inserm
team
cancer
radiat
villejuif
franc
backgroundobject
childhood
cancer
survivor
cc
develop
heart
failur
hf
within
year
primari
cancer
diagnosi
role
irradi
heart
volum
hf
occurr
popul
remain
unclear
consequ
irradi
larg
part
heart
lower
dose
versu
irradi
smaller
part
heart
high
dose
investig
aim
studi
determin
dose
irradi
volum
heart
left
ventricl
lv
relat
risk
hf
cc
investig
impact
anthracyclin
exposur
risk
designmethod
studi
nest
french
childhood
cancer
survivor
studi
cohort
mean
heart
lv
dose
volum
indic
estim
reconstruct
individu
treatment
result
total
hf
case
match
control
includ
median
age
hf
diagnosi
year
interact
anthracyclin
administr
mean
heart
dose
mean
lv
dose
signific
patient
receiv
anthracyclin
risk
hf
increas
less
lv
receiv
least
gy
compar
patient
expos
cardiac
radiat
anthracyclin
risk
much
higher
among
patient
treat
anthracyclin
increas
ci
patient
receiv
least
gy
heart
volum
conclus
small
irradi
volum
heart
lv
significantli
associ
hf
risk
author
knowledg
first
studi
report
relationship
base
indic
cc
translat
effici
current
clinic
practic
c
van
g
l
l
k
marcu
cancer
radiat
oncolog
vancouv
canada
medisch
centrum
universiteit
van
amsterdam
pediatr
oncolog
amsterdam
netherland
medisch
centrum
universiteit
van
amsterdam
radiat
oncolog
amsterdam
netherland
ircc
istituto
nazional
dei
tumori
di
milano
prostat
cancer
program
milan
itali
di
riferimento
oncologico
aviano
ircc
divis
medic
physic
aviano
itali
univers
hospit
stockholm
sweden
medisch
centrum
universiteit
van
amsterdam
pediatr
amsterdam
netherland
rochest
medic
center
radiat
oncolog
rochest
usa
children
cancer
blood
disord
harvard
medic
school
radiat
oncolog
boston
usa
backgroundobject
breast
hypoplasia
impair
lactat
poorli
studi
morbid
consequ
chest
rt
children
pentec
femal
breast
task
forc
aim
quantit
radiat
effect
endpoint
designmethod
pubm
search
conduct
manuscript
evalu
breast
hypoplasia
lactat
chest
rt
children
yield
abstract
two
studi
children
irradi
year
age
angioma
provid
dosimetr
data
correl
breast
hypoplasia
calcul
rel
risk
rr
confid
interv
ci
base
data
one
studi
patient
given
rt
hodgkin
lymphoma
age
year
relev
lactat
endpoint
result
three
studi
involv
subject
total
risk
breast
hypoplasia
rr
ci
rr
ci
rr
ci
breast
anlag
singl
rt
fraction
simpl
linear
regress
model
p
show
irradi
breast
smaller
unirradi
breast
suggest
lesser
sever
breast
hypoplasia
total
dose
given
multipl
versu
singl
fraction
patient
receiv
gy
patient
receiv
gy
multipl
fraction
experienc
breast
volum
reduct
respect
risk
unsuccess
breastfeed
median
mediastin
dose
compar
sibl
control
group
rt
dose
associ
less
breastfeed
success
conclus
young
adult
expos
thorac
rt
children
signific
risk
breast
hypoplasia
impair
lactat
preval
sever
breast
hypoplasia
increas
increas
dose
breast
bud
f
de
vathair
r
c
g
h
n
g
c
el
b
f
e
p
n
unit
cancer
radiat
team
villejuif
franc
cancer
radiat
team
villejuif
franc
curi
depart
radiotherapi
pari
franc
curi
depart
pediatri
pari
franc
roussi
depart
radiotherapi
villejuif
franc
roussi
depart
pediatri
villejuif
franc
backgroundobject
although
breast
cancer
risk
highest
secondari
cancer
risk
women
cancer
childhood
intern
late
effect
childhood
cancer
guidelin
harmon
group
recommend
screen
less
gy
radiat
deliv
region
chest
evid
increas
breast
cancer
risk
gy
consid
moder
low
even
low
radiat
dose
gy
designmethod
studi
women
treat
childhood
cancer
franc
radiat
dose
receiv
region
breast
other
organ
estim
patient
result
one
hundr
sixteen
women
year
less
childhood
cancer
diagnosi
develop
least
one
breast
cancer
breast
cancer
occur
age
risk
breast
cancer
increas
linearli
increas
radiat
dose
breast
region
women
receiv
gy
least
one
breast
nippl
develop
breast
cancer
cumul
incid
age
ci
lower
radiat
dose
also
increas
breast
cancer
risk
adjust
risk
factor
includ
chemotherapi
women
receiv
gy
gy
maxim
dose
one
breast
nippl
rel
risk
ci
compar
receiv
radiat
respect
ovari
pituitari
gland
irradi
significantli
reduc
breast
cancer
risk
conclus
radiat
dose
lower
gy
receiv
childhood
cancer
treatment
strongli
increas
breast
cancer
risk
guidelin
survivor
adapt
take
account
result
j
yeh
zj
q
wm
kc
mm
kr
tm
r
gt
l
children
hospitalharvard
medic
school
gener
pediatr
boston
usa
th
chan
school
public
health
center
health
decis
scienc
boston
usa
alberta
public
health
servic
edmonton
canada
jude
children
research
hospit
epidemiolog
cancer
control
memphi
usa
children
hospit
gener
pediatr
boston
usa
hutchinson
cancer
research
center
clinic
research
seattl
usa
univers
school
medicin
medicin
durham
usa
jude
children
research
hospit
oncolog
epidemiolog
cancer
control
memphi
usa
anderson
cancer
center
radiat
physic
houston
usa
children
cancer
blood
disord
center
pediatr
oncolog
boston
usa
backgroundobject
late
mortal
among
survivor
childhood
cancer
recent
era
declin
yet
translat
improv
life
expect
unclear
estim
life
expect
among
survivor
diagnos
assess
whether
reduc
therapeut
exposur
led
improv
time
designmethod
develop
microsimul
model
lifetim
cours
survivor
childhood
cancer
compet
risk
includ
mortal
late
recurr
secondari
cancer
cardiac
pulmonari
caus
base
data
ccss
particip
us
background
mortal
rate
model
outcom
includ
condit
life
expect
le
defin
number
year
survivor
expect
live
loss
le
defin
differ
le
survivor
individu
without
cancer
histori
result
condit
le
survivor
diagnos
mean
age
year
year
compar
individu
without
cancer
histori
repres
loss
le
year
respect
loss
le
vari
treatment
subgroup
highest
among
treat
radiat
alon
radiat
chemotherapi
loss
le
remain
larg
unchang
survivor
treat
radiat
alon
year
year
moder
improv
receiv
radiat
chemotherapi
year
year
contrast
loss
le
among
survivor
treat
chemotherapi
alon
declin
year
year
conclus
evolv
treatment
approach
project
lead
improv
le
treatment
pediatr
cancer
among
survivor
radiat
therapi
exposur
remain
associ
consider
loss
project
le
even
recent
decad
j
van
kooten
h
van
b
c
de
r
van
univers
medic
center
depart
pediatr
amsterdam
netherland
children
hospitalacadem
medic
center
amc
psychosoci
depart
amsterdam
netherland
children
hospitalacadem
medic
center
amc
depart
pediatr
oncolog
amsterdam
netherland
univers
medic
center
depart
pediatr
maastricht
netherland
univers
medic
center
depart
pediatr
oncologyhematolog
nijmegen
netherland
maxima
center
pediatr
oncolog
psychosoci
depart
utrecht
netherland
backgroundobject
sleep
problem
common
survivor
brain
tumor
sleep
neg
affect
neurocognit
function
qualiti
life
qol
import
better
understand
sleep
problem
vulner
group
studi
aim
determin
preval
sleep
problem
risk
factor
sleep
problem
survivor
brain
tumor
neurocognit
complaint
designmethod
baselin
data
rct
effect
neurofeedback
report
survivor
year
year
brain
tumor
treatment
without
adhd
elig
parent
complet
sleep
disturb
scale
children
sdsc
sdsc
score
norm
consid
clinic
relev
sleep
problem
sdsc
score
survivor
compar
norm
use
risk
factor
sleep
problem
assess
multipl
linear
regress
analys
predict
sdsc
score
sociodemograph
characterist
tumor
locat
time
sinc
treatment
emot
problem
hyperactivityinattent
strength
difficulti
questionnair
result
total
survivor
particip
year
treatment
age
year
male
survivor
high
preval
sleep
problem
total
scale
disord
initi
maintain
sleep
dim
transit
disord
disord
excess
somnol
mean
score
survivor
significantli
higher
norm
p
effect
size
scale
differ
found
sleep
breath
disord
sbd
sleep
hyperhidrosi
shi
emot
symptom
andor
hyperactivityinattent
associ
higher
scale
score
beta
except
sbd
shi
higher
age
associ
higher
score
dim
beta
conclus
survivor
brain
tumor
subject
cognit
problem
high
preval
sleep
problem
differ
domain
emot
problem
hyperactivityinattent
import
risk
factor
address
sleep
problem
import
sinc
could
improv
cognit
function
qol
sato
h
n
k
h
h
center
child
health
develop
depart
data
manag
tokyo
japan
univers
school
medicin
depart
pediatr
tokyo
japan
lddyslexia
center
depart
lddyslexia
chiba
japan
backgroundobject
surviv
rate
children
osteosarcoma
improv
due
advanc
treatment
includ
intraven
methotrex
although
associ
neurotox
effect
among
survivor
childhood
acut
lymphoblast
leukemia
osteosarcoma
survivor
receiv
cumul
dosag
greater
children
impact
osteosarcoma
treatment
neurocognit
function
japan
designmethod
evalu
neurocognit
statu
children
median
age
diagnosi
year
median
age
baselin
year
use
wechsler
intellig
scale
children
edit
baselin
annual
period
children
underw
first
test
one
month
diagnosi
remain
children
complet
therapi
median
year
year
rang
present
preliminari
result
includ
data
baselin
test
cognit
function
attent
memori
medic
demograph
inform
obtain
three
children
receiv
cycl
dose
baselin
test
addit
median
total
dose
rang
second
test
nine
children
complet
treatment
prior
baselin
median
total
dose
rang
result
result
cognit
measur
convert
use
norm
data
baselin
children
perform
within
averag
rang
across
cognit
domain
median
fsiq
rang
child
averag
fsiq
second
test
result
similar
baselin
data
median
fsiq
rang
one
child
averag
conclus
final
studi
expect
confirm
cognit
function
remain
stabl
time
jongman
j
f
van
h
r
van
der
h
j
geurt
van
r
n
r
de
genet
nijmegen
netherland
center
pediatr
oncolog
genet
utrecht
netherland
groningen
genet
groningen
netherland
utrecht
genet
utrecht
netherland
center
pediatr
oncolog
molecular
biolog
utrecht
netherland
carl
gustav
caru
depart
surgic
research
dresden
germani
patholog
nijmegen
netherland
oncolog
institut
porto
genet
porto
portug
institut
gastroenterolog
sixth
affili
hospit
guangdong
provinci
key
laboratori
colorect
pelvic
floor
diseas
guangzhou
china
backgroundobject
colorect
cancer
crc
rare
condit
children
adolesc
crc
syndrom
caus
earli
onset
famili
adenomat
polyposi
lynch
syndrom
constitut
defici
cmmrd
howev
major
crc
patient
year
associ
polyposi
show
often
mucin
histolog
wors
prognosi
compar
crc
differ
suggest
crc
year
repres
distinct
clinic
crc
entiti
object
unravel
underli
genet
crc
children
adolesc
designmethod
perform
sequenc
germlin
dna
patient
crc
year
age
pair
tumour
sampl
includ
patient
patient
child
parent
sequenc
perform
enabl
us
specif
search
de
novo
mutat
mutat
follow
recess
inherit
result
six
patient
carri
pathogen
mutat
known
cancer
predispos
gene
one
year
old
boy
carri
de
novo
mutat
gene
vitro
express
mutant
reveal
increas
erk
phosphoryl
suggest
effect
addit
three
patient
present
potenti
pathogen
mutat
gene
involv
extracellular
matrix
conclus
sequenc
tumour
pair
germlin
sampl
select
screen
de
novo
mutat
provid
power
strategi
investig
known
novel
gene
predispos
earli
onset
crc
find
indic
genet
predisposit
frequent
heterogen
patient
kazubskaya
v
e
v
v
n
blokhin
scienc
medic
research
center
oncolog
oncogenet
moscow
russia
pediatr
oncolog
hematolog
n
n
blokhin
scienc
medic
research
center
oncolog
scientif
advisori
moscow
russia
pediatr
oncolog
hematolog
n
n
blokhin
scienc
medic
research
center
oncolog
head
neck
tumor
moscow
russia
medic
academi
postgradu
educ
pediatr
oncolog
moscow
russia
centr
medic
genet
epigenet
moscow
russia
backgroundobject
aim
analyz
associ
germlin
mutat
differ
clinic
present
rb
patient
designmethod
genet
test
mutat
perform
peripher
blood
sampl
patient
rel
analysi
gene
conduct
first
use
next
gener
sequenc
ng
multiplex
probe
amplif
mlpa
perform
patient
mutat
found
sequenc
result
germlin
mutat
point
mutat
gross
delet
identifi
children
includ
patient
bilater
rb
unilater
rb
exon
harbor
point
mutat
five
case
mosaic
mutat
detect
children
unilater
rb
relationship
differ
type
germlin
mutat
clinic
present
analyz
mainli
hereditari
rb
carrier
nonsens
frameshift
mutat
develop
sever
clinic
form
high
penetr
five
famili
harbor
mutat
splice
site
intron
exon
g
exon
missens
mutat
p
g
c
exon
c
exon
detect
asymptomat
famili
member
carri
low
penetr
mutat
interestingli
germlin
mutat
inherit
affect
father
besid
patient
hereditari
rb
detect
second
cancer
case
germlin
mutat
inherit
affect
father
besid
patient
hereditari
rb
detect
develop
second
cancer
case
conclus
patient
germlin
mutat
show
correl
specif
mutat
associ
incomplet
penetr
depend
upon
sex
transmit
parent
molecular
method
genet
diagnost
rb
import
support
individu
diseas
manag
plan
patient
kruger
l
g
j
van
j
van
j
c
k
j
univers
paediatr
child
faculti
medicin
health
tygergerg
hospit
tygerberg
south
africa
witwatersrand
depart
paediatr
child
chri
hani
baragwanath
academ
hospit
johannesburg
south
africa
cape
town
servic
depart
paediatr
child
health
red
cross
children
hospit
cape
town
south
africa
free
sate
depart
paediatr
child
health
paediatr
haematolog
oncolog
bloemfontein
south
africa
witwatersrand
paediatr
haematolog
charlott
maxek
johannesburg
academ
hospit
johannesburg
south
africa
cape
town
divis
radiat
oncolog
cape
town
south
africa
cape
town
divis
opthalmolog
cape
town
south
africa
backgroundobject
introduct
collabor
treatment
protocol
improv
overal
surviv
children
cancer
aim
determin
outcom
children
treat
standard
nation
treatment
protocol
retinoblastoma
south
africa
designmethod
specialist
involv
retinoblastoma
care
particip
develop
nation
treatment
protocol
base
retinoblastoma
guidelin
high
incom
countri
hic
treatment
involv
local
therapi
intraocular
diseas
chemotherapi
andor
surgeri
andor
radiotherapi
extens
diseas
five
nine
exist
pediatr
oncolog
unit
pou
initi
treatment
januari
result
one
hundr
patient
includ
interim
data
analys
median
age
month
rang
month
iqr
malefemal
ratio
patient
bilater
diseas
nearli
half
patient
advanc
diseas
interim
analysi
year
post
treatment
surviv
data
overal
surviv
exclud
abscond
patient
children
limit
diseas
overal
surviv
os
versu
advanc
diseas
conclus
comparison
previou
publish
singl
south
african
unit
studi
mean
age
younger
month
versu
month
os
improv
nation
retinoblastoma
treatment
protocol
feasibl
south
africa
improv
overal
surviv
gajdo
b
sm
c
lg
llr
curi
oncolog
center
care
innov
research
adolesc
young
adult
cancer
pari
franc
rothschild
intervent
neuroradiolog
depart
pari
franc
curi
biostatist
depart
pari
franc
curi
ocular
oncolog
depart
pari
franc
backgroundobject
past
year
introduct
system
chemotherapi
combin
local
treatment
enabl
dramat
increas
globe
retent
retinoblastoma
patient
without
use
extern
beam
radiat
ebr
ophthalm
arteri
chemosurgeri
recent
emerg
primari
conserv
treatment
retinoblastoma
conduct
prospect
phase
ii
non
random
studi
determin
efficaci
melphalan
ophthalm
arteri
chemosurgeri
term
globe
salvag
rate
without
ebr
month
inclus
ii
patient
surviv
iii
advers
event
designmethod
patient
unilater
retinoblastoma
group
b
c
without
diffus
vitreou
seed
asymetr
bilater
retinoblastoma
includ
one
group
eye
elig
patient
nation
refer
institut
curi
treat
ophthalm
arteri
chemosurgeri
intervent
neuroradiolog
depart
fondat
rothschild
result
februari
decemb
patient
unilater
retinoblastoma
classifi
irc
classif
group
b
group
c
group
includ
two
patient
receiv
ophthalm
arteri
chemosurgeri
one
due
initi
catheter
failur
second
prolong
gener
anesthesia
median
age
ophthalm
arteri
chemosurgeri
month
median
number
ophthalm
arteri
chemosurgeri
cycl
rang
patient
ophthalm
arteri
chemosurgeri
associ
ophthalmolog
local
treatment
start
second
cycl
diod
laser
cryotherapi
patient
aliv
median
month
inclus
twelv
seriou
advers
event
declar
includ
vascular
retin
occlus
eight
patient
present
leucopenia
extraocular
retinoblastoma
second
cancer
complic
occur
last
patient
actual
month
enucl
rate
yet
assess
conclus
advanc
rb
focal
oac
feasibl
gener
well
toler
may
expos
system
retin
vascular
toxic
r
oostveen
r
j
r
k
g
great
ormond
street
institut
child
health
development
biolog
cancer
london
unit
kingdom
great
ormond
street
institut
child
heatlh
development
biolog
cancer
london
unit
kingdom
copenhagen
univers
hospit
depart
paediatr
haematolog
oncolog
copenhagen
denmark
servic
de
chirurgi
pari
franc
ormond
street
hospit
children
nh
foundat
trust
depart
haematolog
oncolog
london
unit
kingdom
medic
research
center
depart
patholog
doha
qatar
teach
hospit
nh
trust
depart
paediatr
surgeri
leed
unit
kingdom
ormond
street
hospit
children
nh
foundat
trust
depart
radiolog
london
unit
kingdom
backgroundobject
aim
retrospect
determin
diagnost
signific
ct
mri
assess
presum
tumour
ruptur
children
renal
tumour
diagnosi
ruptur
result
stage
diseas
may
lead
intensif
treatment
suspicion
ruptur
may
case
influenc
surgic
plan
designmethod
review
patient
regist
import
improv
popul
outcom
renal
tumour
childhood
studi
uk
republ
ireland
novemb
novemb
patient
suspect
tumour
ruptur
central
review
expert
radiologist
select
surgic
patholog
form
review
confirm
diagnosi
patient
ruptur
seen
surgeri
also
select
see
correl
find
central
radiolog
review
result
case
central
radiolog
review
possibl
ruptur
diagnost
andor
scan
mri
use
evalu
abdomin
diseas
statu
patient
imag
qualiti
variabl
adequ
suboptim
inadequ
unknown
qualiti
scan
surgic
form
avail
case
case
patholog
form
ruptur
confirm
surgeri
patient
patholog
review
patient
surgic
inform
avail
patient
patient
ruptur
found
surgeri
major
ruptur
fissur
occur
twenti
four
patient
surgic
ruptur
also
correspond
radiolog
form
ruptur
previous
identifi
central
radiolog
review
patient
conclus
conclud
featur
ruptur
found
radiolog
review
alway
confirm
surgeri
andor
patholog
review
suggest
ruptur
radiolog
therefor
use
definit
stage
treatment
saltzman
j
r
k
r
p
n
colorado
divis
urolog
aurora
usa
colorado
biostatist
informat
aurora
usa
colorado
radiat
oncolog
aurora
usa
children
hospit
pediatr
surgeri
colombu
usa
children
hospit
pediatr
surgeri
cincinnati
usa
children
hospit
pediatr
surgeri
seattl
usa
alexandra
cohen
medic
center
new
york
pediatr
surgeri
new
york
usa
mott
children
hospit
pediatr
surgeri
ann
arbor
usa
backgroundobject
current
investig
prioriti
treatment
favor
histolog
wilm
tumor
fhwt
center
accur
stage
extent
lymphadenectomi
clearli
defin
howev
import
accur
lymph
node
ln
stage
overst
guid
adjuv
therapi
identif
minimum
ln
yield
sampl
ensur
accur
stage
could
help
direct
develop
surgic
guidelin
present
statist
model
describ
risk
occult
metastat
diseas
patient
fhwt
function
number
ln
examin
designmethod
nation
cancer
databas
queri
patient
unilater
fhwt
demograph
clinic
data
abstract
underw
surgic
resect
least
one
posit
ln
ln
examin
given
number
ln
sampl
probabl
fals
neg
ln
sampl
estim
use
model
empir
result
identifi
patient
meet
studi
criteria
median
age
yr
rang
median
number
ln
sampl
rang
median
number
ln
posit
rang
achiev
probabl
ln
sampl
model
estim
ln
need
sampl
empir
estim
ln
would
need
sampl
conclus
use
separ
approach
appear
desir
ln
yield
reduc
risk
ln
sampl
object
attempt
determin
desir
ln
yield
accur
stage
patient
fhwt
data
may
use
standard
surgic
guidelin
qualiti
metric
measur
surgeon
perform
r
ladenstein
u
j
r
v
g
c
gcf
e
h
h
g
p
h
anna
kinderkrebsforschung
ev
studi
statist
integr
research
project
vienna
austria
anna
children
hospit
depart
medic
depart
paediatr
vienna
austria
roussi
children
adolesc
oncolog
depart
franc
hospit
southampton
nh
foundat
trust
univers
southampton
paediatr
oncolog
haematolog
southampton
unit
kingdom
ircc
istituto
nazional
dei
tumori
paediatr
oncolog
haematolog
milan
itali
universitario
politecnico
la
fe
paediatr
oncolog
haematolog
valencia
spain
children
medic
center
sackler
faculti
medicin
tel
aviv
univers
paediatr
oncolog
haematolog
petach
tikvah
israel
hospit
ghent
paediatr
oncolog
haematolog
ghent
belgium
ladi
children
hospit
paediatr
haematologyoncolog
dublin
ireland
children
hospit
paediatr
oncolog
haematolog
randwick
australia
mari
hospit
depart
paediatr
adolesc
medicin
hong
kong
hong
kong
sar
paediatr
oncolog
haematolog
oslo
norway
hospit
aarhu
paediatr
oncolog
haematolog
aarhu
denmark
hospit
lausann
paediatr
oncolog
haematolog
lausann
switzerland
biolog
ag
chief
execut
offic
vienna
austria
austrian
institut
technolog
gmbh
center
health
bioresourc
graz
austria
anna
kinderkrebsforschung
ev
tumour
biolog
vienna
austria
enfant
malad
pari
descart
univers
depart
pediatr
surgeri
pari
franc
medicin
greifswald
paediatr
oncolog
haematolog
greifswald
germani
backgroundobject
random
immunotherapi
versu
standard
possibl
trial
order
explor
impact
immunotherapi
outcom
use
trial
patient
prior
avail
intern
control
designmethod
trial
patient
receiv
rapid
cojec
two
cours
tvd
need
surgeri
hdtsct
bumel
cem
radiotherapi
mrd
treatment
mrdt
consist
isoretinoin
alon
control
popul
cp
cycl
immunotherapi
popul
ip
patient
month
diagnosi
hdtsct
pr
better
prior
hdtsct
progress
hdtsct
start
mrdt
median
time
day
cp
ip
sex
age
group
stage
mycn
amplifi
mna
respons
prior
hdtsct
balanc
cohort
median
follow
result
ip
cp
p
univari
risk
factor
analysi
show
signific
impact
age
stage
metastat
compart
mc
delay
surgeri
respons
pre
hdtsct
type
hdt
analysi
identifi
independ
higher
risk
patient
without
immunotherapi
hr
treat
cem
hr
respons
cr
prior
mrd
hr
diagnosi
hr
adjust
age
stage
mc
tvd
respons
benefit
immunotherapi
confirm
hr
vs
ip
vs
cp
patient
hr
vs
ip
vs
cp
conclus
introduct
immunotherapi
achiev
major
improv
outcom
patient
trial
nakajima
h
ss
h
nk
cancer
center
hospit
pediatr
oncolog
tokyo
japan
sloan
ketter
cancer
center
pediatr
new
york
usa
backgroundobject
ex
vivo
polyclon
cell
arm
use
chimer
antigen
receptor
bispecif
antibodi
bsab
infusion
cytotherapi
use
igg
l
format
scfv
link
carboxyl
end
naxitamab
light
chain
shown
promis
properti
tumor
phase
studi
cell
arm
chemic
conjug
naxitamab
x
biab
safe
suggest
clinic
respons
report
safeti
efficaci
cell
arm
recombin
preclin
model
designmethod
cell
normal
volunt
expand
activ
use
bead
form
atc
day
later
atc
harvest
gmp
grade
room
temperatur
minut
arm
atc
test
cytotox
vitro
vivo
human
cell
line
pdx
xenograft
dko
mice
result
arm
atc
show
robust
tumor
cytotox
tumor
vitro
rang
antibodi
dose
cell
optim
arm
occur
zeptomol
mole
molecul
bsab
per
cell
without
evid
activ
induc
cell
death
confront
target
cell
vivo
arm
atc
show
potent
effect
neuroblastoma
melanoma
rang
cell
dose
x
per
inject
twice
week
week
without
signific
side
effect
dko
mice
immunohistochemistri
frequenc
tumor
infiltr
cell
strongli
correl
tumor
respons
conclus
arm
atc
may
provid
viabl
immunotherapi
platform
tumor
adult
pediatr
compar
gene
modif
bsab
use
standard
manufactur
method
distribut
network
potenti
much
higher
cell
dose
without
cytokin
storm
v
pillai
k
j
g
children
hospit
philadelphia
patholog
laboratori
medicin
philadelphia
usa
pennsylvania
perelman
school
medicin
philadelphia
usa
children
hospit
philadelphia
oncolog
philadelphia
usa
backgroundobject
chimer
antigen
receptor
cell
target
tisagenlecleucel
shown
excel
respons
patient
relapsedrefractori
recent
approv
fda
relationship
express
respons
clear
assess
whether
baselin
blast
express
level
prior
target
therapi
impact
respons
therapi
designmethod
case
leukemia
treat
children
hospit
philadelphia
assess
flow
cytometr
express
blast
classifi
dim
normal
bright
compar
normal
b
cell
express
immunophenotyp
blast
pre
therapi
correl
respons
therapi
failur
reach
remiss
consid
presenc
aberr
blast
time
point
remiss
consid
relaps
diseas
result
one
hundr
fifti
case
identifi
classifi
relaps
relaps
immunophenotyp
relaps
ident
diseas
case
consist
loss
car
cell
etiolog
relaps
relaps
like
relat
diseas
paramet
rate
respons
relaps
significantli
differ
group
fifteen
patient
receiv
prior
therapi
blinatumomab
andor
differ
cart
cell
therapi
prior
therapi
associ
significantli
higher
rate
relaps
compar
patient
receiv
prior
target
therapi
conclus
cell
therapi
effect
across
level
express
howev
prior
target
therapi
associ
increas
relaps
henc
use
blinatumomab
car
cell
therapi
may
impact
cur
treatment
fda
approv
car
cell
therapi
l
f
h
cd
tj
tasian
cancer
institut
pediatr
oncolog
branch
bethesda
usa
hospit
philadelphia
divis
oncolog
center
childhood
cancer
research
philadelphia
usa
colorado
denver
pediatr
hematolog
immunolog
aurora
usa
backgroundobject
cellular
immunotherapi
major
potenti
overcom
chemoresist
acut
myeloid
leukemia
aml
express
pediatr
aml
improv
efficaci
gemtuzumab
ozogamicin
addit
chemotherapi
demonstr
children
aml
gami
jco
hypothes
chimer
antigen
receptor
would
potent
activ
sought
studi
identifi
optim
product
clinic
develop
designmethod
creat
six
use
gemtuzumab
lintuzumab
variabl
fragment
domain
describ
tarun
blood
cytokin
product
cytox
incub
aml
cell
line
quantifi
immunoabsorb
incucyt
assay
respect
administ
immunocompromis
mice
engraft
human
aml
cell
line
primari
childhood
aml
cell
xenograft
pdx
model
inhibit
leukemia
prolifer
expans
measur
via
bioluminesc
imag
flow
cytometr
quantif
human
aml
murin
blood
spleen
bone
marrow
studi
termin
result
vitro
incub
aml
cell
line
induc
similarli
high
level
robust
leukemia
cell
kill
six
inhibit
vivo
leukemia
proliferationin
luciferas
xenograft
model
mice
treat
demonstr
signific
respons
eventu
die
progress
diseas
convers
mice
given
evid
diseas
month
similarli
markedli
inhibit
leukemia
prolifer
childhood
aml
pdx
model
versu
salin
control
complet
leukemia
erad
superior
expans
observ
pdx
anim
p
anovatukey
conclus
base
preclin
result
pediatr
bone
marrow
transplant
phase
trial
evalu
safeti
children
relapsedrefractori
aml
b
campbel
n
c
e
u
arthur
sonia
labatt
brain
tumour
research
hospit
sick
canada
depart
haematologyoncolog
toronto
canada
hospit
sick
children
depart
hematologyoncolog
toronto
canada
hospit
sick
children
genet
genom
biolog
toronto
canada
medicin
inc
depart
cancer
immunotherapi
boston
usa
hospit
sick
children
depart
genet
genom
biolog
toronto
canada
hospit
sick
children
depart
patholog
toronto
canada
backgroundobject
hypermut
constitut
import
subgroup
cancer
confer
sensit
immun
checkpoint
inhibit
ici
hypermut
tumor
aris
either
due
therapi
germlin
mutat
replic
repair
gene
rrd
object
quantifi
frequenc
hypermut
tumor
children
determin
whether
mutat
signatur
predict
germlin
mutat
treat
hypermut
tumor
ici
designmethod
deep
panel
sequenc
pediatr
tumor
adult
tumor
perform
algorithm
devis
determin
mutat
burden
mutat
signatur
driver
alter
uncov
treatment
germlin
induc
hypermut
data
patient
hypermut
tumor
identifi
sequenc
enrol
ici
registri
trial
result
hypermut
tumor
mutmb
compris
pediatr
tumor
highli
enrich
rrd
mutat
p
mutat
load
correl
hypermut
adult
tumor
shown
demonstr
clinic
respons
ici
analysi
tumor
mutat
burden
signatur
paramet
abl
uncov
germlin
mutat
replic
repair
gene
past
histori
treatment
caus
hypermut
patient
children
hypermut
cancer
treat
ici
tumor
object
respons
includ
metastat
recurr
tumor
overal
surviv
year
respect
surviv
brain
tumor
respect
conclus
high
mutat
burden
sensit
predictor
germlin
mutat
replic
repair
gene
lead
cancer
predisposit
hypermut
tumor
common
pediatr
set
previous
appreci
induc
prior
chemotherapi
germlin
mutat
necessit
novel
therapeut
avenu
encourag
respons
ici
observ
especi
recurrentprogress
metastat
hypermut
cancer
prospect
clinic
trial
requir
hypermut
cancer
l
singh
mk
millia
islamia
bioscienc
new
delhi
india
india
institut
medic
scienc
ocular
patholog
new
delhi
india
backgroundobject
interact
malign
cell
creat
tumor
microenviron
tme
cell
tme
dynam
function
stage
carcinogenesi
cytotox
lymphocyt
associ
antigen
program
program
key
compon
immun
checkpoint
pathway
play
role
regul
activ
express
tme
constitut
predict
biomark
cancer
recent
shown
chemotherapeut
agent
could
modifi
tumor
microenviron
therefor
investig
express
primari
chemoreduc
retinoblastoma
defin
signific
tumor
microenviron
patient
prognosi
designmethod
express
immun
marker
protein
evalu
prospect
case
primari
group
case
chemoreduc
group
ii
retinoblastoma
specimen
immunohistochemistri
mrna
express
gene
interest
investig
quantit
real
time
pcr
qpcr
result
correl
clinicopatholog
paramet
patient
outcom
statist
analysi
result
differenti
express
pattern
protein
found
group
primari
retinoblastoma
group
ii
chemoreduc
retinoblastoma
case
immunohistochemistri
show
cytoplasmicmembran
stain
immun
marker
use
respect
antibodi
increas
express
found
stromalimmun
cell
group
ii
compar
group
express
immun
marker
show
signific
correl
poor
tumor
differenti
tumor
invas
patient
outcom
p
conclus
first
kind
studi
investig
role
immun
marker
primari
retinoblastoma
alter
express
chemotherapi
tumor
microenviron
retinoblastoma
show
express
primari
patient
increas
express
chemotherapi
pave
way
develop
immunotherapi
new
strategi
treatment
chemoreduc
retinoblastoma
k
p
w
c
l
p
pg
f
mj
c
hernand
n
k
r
hospit
swabian
children
cancer
center
augsburg
germani
scientif
practic
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
hemeonc
moscow
russia
children
hosptal
cologn
pediatr
hemonc
cologn
germani
children
hospit
budapest
pediatr
hemeonc
budapest
hungari
children
hospit
essen
pediatr
hemeonc
essen
germani
children
hospit
giessen
pediatr
hemeonc
giessen
germani
children
hospit
freiburg
pediatr
hemeonc
freiburg
germani
hannov
pediatr
hemeonc
hannov
germani
children
hospit
berlin
charit
pediatr
hemeonc
berlin
germani
children
hospit
pediatr
hemeonc
germani
medisch
centrum
oncolooghematoloog
amsterdam
netherland
hospit
hematolog
oncolog
porto
portug
hospit
bristol
pediatr
hemeonc
bristol
unit
kingdom
infantil
universitario
pediatr
hemeonc
madrid
spain
univers
hospit
depart
pediatr
oncolog
hematolog
augsburg
germani
copenhagen
sect
paeditr
haematolog
dept
paediatr
adolesc
medicin
copenhagen
denmark
ulm
univers
hospit
ulm
institut
human
ulm
germani
augsburg
klinik
diagnostisch
und
interventionel
radiologi
augsburg
germani
univers
hospit
depart
pediatr
oncolog
hematolog
homburg
germani
augsburg
children
hospit
swabian
children
cancer
center
augsburg
germani
backgroundobject
malign
rhabdoid
tumor
mrt
highli
aggress
malign
affect
young
children
year
per
million
registri
prospect
collect
data
uniformli
treat
patient
rhabdoid
tumor
lay
foundat
clinic
trial
across
europ
designmethod
clinic
data
patient
extracrani
mrt
regist
evalu
tumor
tissu
investig
mutat
fish
mlpa
sequenc
blood
examin
germlin
mutat
result
patient
present
extracrani
extraren
rhabdoid
tumor
emrt
renal
mrt
nine
demonstr
synchron
tumor
median
age
diagnosi
month
rang
distant
metastas
diagnosi
present
region
lymph
node
involv
emrt
synchron
tumor
renal
mrt
stage
iiiiii
germlin
mutat
glm
detect
gross
total
resect
gtr
obtain
radiotherapi
rtx
appli
complet
remiss
cr
achiev
rate
age
vs
month
vs
distant
metastas
vs
synchron
tumor
vs
presenc
glm
vs
achiev
gtr
vs
rtx
vs
cr
vs
signific
prognost
factor
os
p
multivari
analysi
gtr
presenc
glm
distant
metastas
diagnosi
independ
prognost
lower
os
conclus
data
suggest
link
outcom
clinic
also
genet
factor
propos
stratif
scheme
defin
standard
sr
high
risk
hr
group
patient
glm
distant
metastas
stage
iiiiv
andor
lack
gtr
high
risk
progress
need
novel
therapi
support
deutsch
kinderkrebsstiftung
dkk
schneider
f
f
ib
b
g
u
dortmund
clinic
pediatr
dortmund
germani
hospit
clinic
pediatr
hematolog
oncolog
germani
hospit
bonn
clinic
pediatr
bonn
germani
hospit
esp
research
group
germani
backgroundobject
juvenil
granulosa
cell
tumor
juvgct
rare
sex
cord
stromal
tumor
previou
analys
shown
associ
spontan
preoper
tumor
ruptur
malign
ascit
periton
metastas
poor
outcom
approx
group
designmethod
patient
median
age
year
regist
prospect
largest
pediatr
seri
collect
date
therapeut
risk
stratif
base
tumor
stage
evalu
standard
recommend
includ
pei
chemotherapi
patient
malign
ascit
preoper
ruptur
andor
metastas
patient
watch
wait
recommend
result
symptom
includ
abdomin
pain
distens
endocrinolog
symptom
isosexu
precoc
median
tumor
diamet
cm
cm
stage
accord
figo
ia
pt
ic
pt
iia
pt
incomplet
data
pt
patient
underw
ovarectomi
adnectomi
stage
ia
patient
follow
expectantli
pt
intraop
spillag
pt
preoper
spontan
ruptur
malign
ascit
well
stage
ii
pt
receiv
chemotherapi
median
year
two
event
report
patient
initi
present
stage
ia
tumor
one
patient
develop
metachron
contralater
juvgct
sever
subsequ
ultim
fatal
relaps
present
highli
anaplast
histolog
mitot
count
hpf
vascular
invas
intens
salvag
treatment
includ
chemotherapi
irradi
second
continu
remiss
achiev
interim
analysi
estim
surviv
overal
surviv
conclus
compar
histor
cohort
central
registr
patient
includ
access
refer
patholog
evalu
introduct
chemotherapi
stage
ic
patient
preoper
ruptur
malign
ascit
result
improv
prognosi
patient
juvenil
granulosa
cell
tumor
support
german
childhood
cancer
foundat
foundat
j
wang
l
c
j
q
hospit
zhejiang
univers
school
medicin
surgic
oncolog
depart
hangzhou
china
hospit
zhejiang
univers
school
medicin
depart
pag
hangzhou
china
hospit
zhejiang
univers
school
medicin
depart
radiolog
hangzhou
china
backgroundobject
minim
invas
surgeri
mi
surgic
approach
pediatr
surgeri
howev
mi
popular
children
ovarian
neoplasm
studi
aim
evalu
safeti
effect
mi
resect
seri
children
ovarian
neoplasm
designmethod
sinc
institut
protocol
mi
resect
ovarian
neoplasm
appli
neoplasm
clear
border
line
mr
ct
scan
consid
main
indic
mi
approach
ovari
conserv
neoplasm
resect
standard
method
patient
underw
mi
ovarian
neoplasm
januari
decemb
includ
specif
technic
consider
demograph
data
dada
record
result
two
hundr
patient
underw
mi
resect
ovarian
neoplasm
age
left
median
ovarian
neoplasm
case
right
side
case
bilater
neoplasm
case
mi
perform
success
case
case
convert
open
surgeri
seriou
adhes
median
hospit
stay
day
case
prenat
diagnos
case
underw
mi
ovari
conserv
success
case
case
underw
mi
older
ovari
conserv
success
case
case
malign
tumor
found
patient
case
grade
ii
immatur
teratoma
postop
chemotherapi
case
endoderm
sinu
tumor
chemotherapi
adnexectomi
case
juvenil
granulosa
cell
tumor
case
gonadoblastoma
case
mix
germ
cell
tumor
redo
mi
adnexectomi
seriou
complic
observ
conclus
studi
demonstr
safeti
effect
laparoscop
ovari
conserv
neoplasm
resect
pediatr
popul
earli
laparoscop
surgeri
consid
prenat
diagnos
patient
improv
ovari
conserv
rate
hol
de
b
j
h
j
l
medic
center
depart
oral
maxillofaci
surgeri
amsterdam
netherland
ormond
street
hospit
depart
pediatr
oncolog
london
unit
kingdom
medic
center
depart
radiolog
amsterdam
netherland
medic
center
depart
radiat
oncolog
amsterdam
netherland
medic
center
depart
plastic
surgeri
amsterdam
netherland
colleg
hospit
depart
radiat
oncolog
london
unit
kingdom
marsden
hospit
depart
pediatr
oncolog
sutton
unit
kingdom
marsden
hospit
depart
radiotherapi
sutton
unit
kingdom
depart
maxillofaci
surgeri
nijmegen
netherland
medic
center
depart
pediatr
oncolog
amsterdam
netherland
backgroundobject
facial
growth
deform
follow
treatment
head
neck
cancer
pediatr
patient
common
sever
late
advers
effect
occur
patient
popul
howev
differ
growth
deform
differ
treatment
modal
head
neck
rhabdomyosarcoma
hnrm
analyz
yet
purpos
studi
quantifi
compar
facial
growth
deform
children
hnrm
follow
differ
treatment
modal
inher
differ
radiat
dose
distribut
designmethod
studi
consist
children
treat
hnrm
least
year
ago
either
extern
beam
radiat
therapi
photon
ebrt
multidisciplinari
approach
consist
abl
surgeri
mold
techniqu
afterload
brachytherapi
reconstruct
surgeri
amor
survivor
taken
analyz
curvatur
surfac
area
volum
deplet
use
healthi
averag
match
face
match
base
age
sex
ethnic
final
quantifi
growth
deform
indic
found
two
treatment
group
compar
result
mean
year
therefor
patient
post
growth
spurt
growth
deform
radiat
side
present
howev
significantli
less
curvatur
significantli
volum
deplet
found
p
furthermor
signific
growth
deform
comparison
healthi
popul
found
side
clinic
signific
hypoplasia
present
ebrt
treatment
group
result
esthet
function
problem
conclus
found
signific
differ
facial
growth
deform
two
treatment
modal
favor
patient
treat
amor
especi
lack
curvatur
surfac
area
healthi
side
face
well
clinic
signific
hypoplasia
profound
futur
potenti
advers
effect
consid
therapi
plan
l
cui
q
hh
ty
zg
r
children
capit
medic
nation
center
children
health
hematolog
oncolog
beij
pediatr
research
institut
beij
china
children
capit
medic
nation
center
children
health
hematolog
oncolog
center
beij
china
backgroundobject
langerhan
cell
histiocytosi
lch
common
histiocytosi
lch
case
report
harbour
mutat
aim
studi
investig
clinic
valu
mutat
detect
circul
ccf
dna
paediatr
lch
cohort
designmethod
pcr
assay
appli
quantit
detect
ccf
diagnosi
plasma
children
lch
eight
braf
lch
patient
also
includ
neg
control
result
diagnosi
ccf
detect
lch
patient
ccf
posit
patient
posit
multisystem
ro
ms
lch
patient
ms
lch
patient
ss
lch
posit
ccf
load
significantli
higher
ro
children
median
rang
children
median
rang
ss
patient
median
rang
clinic
characterist
children
posit
ccf
detect
compar
children
neg
ccf
detect
accord
threshold
patient
posit
ccf
ro
ms
lch
lch
ss
lch
age
patient
posit
ccf
significantli
lower
neg
detect
median
age
year
year
respect
liver
spleen
involv
also
associ
posit
ccf
liver
spleen
p
conclus
result
indic
ccf
associ
clinic
classif
characterist
patient
lch
could
serv
promis
biomark
childhood
lch
ishii
n
r
univers
depart
pediatr
faculti
medic
scienc
fukuoka
japan
univers
r
laboratori
innov
graduat
school
pharmaceut
scienc
fukuoka
japan
cancer
center
depart
pediatr
surgic
oncolog
tokyo
japan
univers
school
medicin
depart
pediatr
surgeri
niigata
japan
backgroundobject
advanc
neuroblastoma
poor
surviv
despit
intens
multimod
treatment
includ
antibodi
thu
establish
novel
modal
new
class
natur
killer
nk
cell
high
cytotox
neuroblastoma
variou
tumor
cell
line
show
low
phenotyp
indic
new
nk
cell
might
exhaust
addit
also
character
high
express
adhes
molecul
chemokin
receptor
similar
express
pattern
lymphocyt
unlik
seen
circul
primari
activ
nk
cell
herein
investig
kill
invas
activ
assay
vivo
studi
designmethod
gener
previous
describ
laboratori
saito
et
al
neuroblastoma
cell
line
spheroid
fluoresc
label
imag
invas
effector
cell
spheroid
perform
spheroid
subject
count
number
livedead
tumor
cell
flow
cytometri
murin
periton
metastasi
model
cellshead
inject
tumor
bear
nog
mous
intraperiton
inject
peritonea
excis
examin
use
fluoresc
microscopi
result
cytotox
assay
effici
kill
spheroid
compar
primari
nk
cell
antibodi
combin
surprisingli
cytotox
alon
nearli
equal
seen
combin
antibodi
imag
demonstr
migrat
infiltr
destroy
via
effici
tumor
cell
kill
even
spheroid
contrast
primari
nk
cell
could
infiltr
spheroid
furthermor
intraperiton
infus
nog
mice
dramat
reduc
tumor
progress
conclus
exhibit
high
cytotox
invas
activ
human
neuroblastoma
spheroid
offer
highli
promis
modal
treatment
solid
bulki
lesion
advanc
neuroblastoma
l
linder
j
k
cf
ys
utah
colleg
nurs
salt
lake
citi
usa
wisconsin
milwauke
colleg
nurs
milwauke
usa
merci
hospit
pediatr
hematologyoncolog
kansa
citi
usa
children
hospit
nurs
seattl
usa
commonwealth
univers
school
nurs
richmond
usa
backgroundobject
adolesc
young
adult
aya
cancer
experi
multipl
symptom
due
diseas
treatment
howev
littl
known
symptom
identifi
prioriti
symptom
studi
describ
occurr
sever
associ
distress
prioriti
symptom
identifi
ayasand
relationship
sever
distress
design
prioriti
statu
designmethod
aya
use
computer
symptom
captur
tool
report
symptom
symptom
heurist
app
allow
user
identifi
perspect
symptom
relationship
symptom
symptom
cluster
prioriti
symptom
within
cluster
prioriti
cluster
result
particip
aya
median
year
rang
year
male
white
receiv
chemotherapi
site
unit
state
particip
report
median
symptom
two
timepoint
immedi
prior
cours
chemotherapi
rang
symptom
symptom
number
symptom
report
differ
base
age
adolesc
vs
young
adult
gender
sever
p
distress
p
greater
among
prioriti
symptom
versu
identifi
prioriti
preval
prioriti
symptom
lack
energi
nausea
difficulti
sleep
pain
symptom
sever
distress
differ
base
prioriti
design
regardless
prioriti
design
mean
sever
distress
rate
four
symptom
greater
symptom
across
studi
sampl
conclus
fatigu
nausea
difficulti
sleep
pain
among
sever
distress
symptom
regardless
whether
identifi
prioriti
symptom
identif
prioriti
symptom
provid
clinician
start
point
develop
plan
symptom
manag
intervent
fund
univers
utah
st
baldrick
foundat
clinic
translat
scienc
institut
southeast
wisconsin
h
salem
e
wreford
k
j
falck
wg
c
pe
survivorship
danish
cancer
societi
research
center
danish
cancer
societi
copenhagen
denmark
hospit
rigshospitalet
institut
clinic
medicin
medic
faculti
univers
copenhagen
copenhagen
denmark
psychiatri
behavior
scienc
memori
sloan
ketter
cancer
center
new
york
usa
oncolog
finsen
centr
univers
hospit
rigshospitalet
denmark
backgroundobject
investig
risk
first
prescript
psychotrop
medicin
among
parent
children
cancer
compar
parent
children
designmethod
conduct
registri
studi
parent
children
cancer
diagnos
age
cohort
parent
children
match
individu
birth
year
sex
cox
proport
hazard
model
estim
hazard
ratio
hr
first
prescript
psychotrop
medic
antidepress
anxiolyt
hypnot
accord
exposur
child
cancer
statu
adjust
age
calendar
period
examin
effect
modif
accord
parent
sex
famili
type
size
parent
educ
incom
result
identifi
parent
father
mother
children
cancer
parent
father
mother
children
parent
children
cancer
increas
risk
first
prescript
psychotrop
medic
first
three
year
diagnosi
risk
highest
first
year
hr
ci
increas
risk
seen
particularli
anxiolyt
hr
ci
hypnot
hr
ci
signific
increas
seen
antidepress
hr
ci
conclus
registri
studi
document
parent
children
cancer
greater
risk
psychiatr
morbid
sever
requir
medic
treatment
parent
children
pediatr
oncologist
nurs
identifi
potenti
vulner
famili
monitor
earli
symptom
anxieti
sleep
problem
schwartz
atia
children
medic
center
israel
hematolog
oncolog
tikva
israel
aviv
univers
gershon
gordon
faculti
social
scienc
tel
aviv
israel
aviv
univers
steyer
school
health
profess
tel
aviv
israel
backgroundobject
current
studi
investig
aspect
posit
psycholog
involv
cope
pediatr
cancer
patient
parent
order
explor
resourc
util
cope
popul
concept
ill
percept
social
support
hope
subject
chosen
designmethod
particip
recruit
studi
consist
respond
parent
child
pediatr
patient
six
month
diagnosi
one
year
complet
intens
treatment
research
tool
includ
two
type
questionnair
parent
children
reliabl
found
good
data
analyz
use
spss
amo
program
examin
research
hypothes
result
find
reveal
cope
ill
pediatr
cancer
patient
parent
experi
twice
mani
posit
emot
neg
one
parent
group
signific
correl
found
parent
percept
child
ill
subject
less
parent
emot
control
children
ill
posit
emot
display
regard
cope
resourc
children
group
direct
correl
found
hope
posit
attitud
hope
life
satisfact
direct
correl
found
social
support
hope
hope
posit
attitud
similar
find
found
parent
group
conclus
studi
present
signific
hope
social
support
variabl
affect
subject
practition
must
familiar
factor
contribut
help
famili
construct
treatment
plan
guid
factor
found
posit
influenc
cope
life
threaten
ill
c
phillip
j
unives
school
nurs
indianapoli
usa
univers
school
nurs
indianapoli
usa
backgroundobject
adolescentsyoung
adult
cancer
aya
experi
poorer
qualiti
life
qol
outcom
healthi
peer
older
cancer
survivor
haas
resili
ill
model
identifi
two
risk
factor
neg
influenc
aya
qol
five
protect
factor
may
minim
risk
factor
use
aya
howev
systemat
approach
assess
address
aya
risk
protect
factor
team
develop
resili
enhanc
aya
cancer
healthcar
provid
reach
intervent
foster
aya
use
protect
factor
minim
risk
factor
present
describ
reach
intervent
develop
feasibl
accept
use
designmethod
develop
site
aya
complet
reliabl
valid
measur
rim
factor
factor
score
summar
aya
rim
profil
depict
aya
avatar
posit
soccer
field
relat
aya
age
gender
ayapar
advisori
board
dyad
provid
iter
feedback
layout
word
interpret
summar
factor
display
evalu
reach
feasibl
accept
use
use
motiv
interview
strategi
interven
foster
ayapar
convers
regard
rim
factor
dyad
provid
feedback
reach
profil
convers
result
approach
dyad
agre
particip
complet
measur
within
timefram
miss
data
aya
parent
activ
engag
focus
convers
highli
satisfi
reach
content
time
commit
requir
help
gain
insight
protect
strength
build
identifi
area
need
addit
support
conclus
high
feasibl
accept
use
next
step
conduct
pilot
studi
estim
effect
size
reach
qol
outcom
develop
feasibl
strategi
provid
use
reach
profil
routin
assess
care
plan
ce
wakefield
j
km
p
tn
jm
l
v
scienc
kid
cancer
centr
sydney
children
hospit
nsw
australia
women
children
health
unsw
sydney
sydney
australia
cancer
centr
princ
wale
hospit
sydney
australia
cancer
centr
sydney
children
hospit
nsw
australia
children
cancer
blood
disord
center
depart
pediatr
oncolog
usa
cancer
institut
unsw
sydney
nsw
australia
backgroundobject
prism
precis
medicin
trial
use
novel
technolog
eg
genom
drug
test
make
person
therapeut
recommend
children
cancer
despit
great
optim
surround
precis
medicin
possibl
find
cure
children
precis
medicin
trial
complex
mean
famili
even
healthcar
profession
understand
trial
might
limit
prospect
assess
parent
patient
healthcar
profession
hope
expect
regard
prism
designmethod
patient
age
year
cancer
anticip
chanc
surviv
elig
prism
parent
adolesc
patient
healthcar
profession
complet
survey
enrol
result
deliveri
annual
five
year
interview
healthcar
profession
annual
result
famili
healthcar
profession
opt
parent
adolesc
patient
parent
mother
child
mean
age
patient
mean
age
return
survey
interview
healthcar
profession
oncologist
enrol
parent
adolesc
expect
patient
chanc
cure
would
increas
particip
prism
parent
recogn
somewhatveri
unlik
adolesc
believ
veryextrem
like
mani
parent
adolesc
indic
understood
prism
involv
rank
group
peopl
would
benefit
healthcar
profession
rank
futur
patient
benefit
rank
current
patient
rank
scientist
would
benefit
conclus
enrol
famili
felt
understood
prism
howev
concurr
held
hope
person
benefit
patient
identifi
barrier
predictor
implement
precis
medicin
clinic
practic
result
import
futur
trial
across
ill
age
group
warbi
wale
hospit
powh
hereditari
cancer
clinic
new
south
wale
australia
backgroundobject
past
five
year
increas
number
children
refer
hereditari
cancer
centr
worldwid
prompt
identif
concern
emerg
counsel
need
better
servic
grow
popul
improv
understand
clinic
factor
relat
parent
concern
rais
counsel
facilit
provis
tailor
support
famili
designmethod
review
medic
record
paediatr
patient
refer
hereditari
cancer
clinic
sydney
australia
geneticist
genet
counsellor
involv
case
code
record
base
reason
referr
recommend
genet
test
type
test
result
primari
concern
emerg
counsel
theme
rais
genet
counsel
result
new
paediatr
referr
receiv
underw
genet
test
reason
referr
includ
child
affect
cancer
predict
test
asymptomat
child
predict
test
symptomat
child
referr
clinic
opinion
eight
key
concern
famili
rais
counsel
emerg
parent
distress
cope
uncertainti
plan
screen
cope
genet
diagnosi
consid
risk
offspr
consid
risk
famili
member
consid
risk
potenti
futur
cancer
child
child
distress
parent
children
cancer
diagnosi
like
concern
risk
famili
member
risk
offspr
famili
unaffect
children
children
test
parent
children
undergo
initi
genet
test
like
discuss
risk
famili
member
famili
undergo
predict
test
conclus
studi
identifi
concern
famili
wish
discuss
counsel
relat
clinic
factor
may
help
staff
identifi
area
psycholog
distress
promptli
l
k
h
j
lm
helsinki
helsinki
children
hospit
faculti
medicinedoctor
programm
clinic
research
helsinki
finland
helsinki
helsinki
children
hospit
depart
pediatr
helsinki
finland
cancer
registri
finnish
cancer
registri
helsinki
finland
cancer
registryunivers
helsinkihelsinki
children
hospit
depart
pediatr
helsinki
finland
backgroundobject
sever
studi
demonstr
associ
high
birth
weight
neonat
childhood
incid
matern
diabet
rise
fraction
mother
requir
pharmacolog
intervent
metformin
insulin
therapi
associ
matern
diabet
medic
earli
onset
cancer
previous
explor
set
designmethod
use
design
aim
explor
whether
matern
diabet
overal
insulin
andor
metformin
medic
matern
diabet
associ
increas
risk
earli
onset
cancer
combin
data
three
popul
base
registri
identifi
total
case
ie
person
diagnos
earli
onset
cancer
defin
malign
neoplasm
age
year
total
birth
match
popul
control
mother
diagnosi
diabet
mellitu
pregnanc
mother
use
insulin
metformin
pregnanc
identifi
drug
result
condit
logist
regress
model
use
analyz
risk
earli
onset
cancer
expos
vs
unexpos
dm
preval
data
earli
onset
cancer
expos
matern
diabet
ci
compar
unexpos
offspr
group
expos
matern
insulinmetformin
ci
statist
signific
compar
unexpos
offspr
conclus
matern
diabet
appear
associ
increas
risk
earli
onset
cancer
offspr
possibl
underli
mechan
could
involv
insulin
like
growth
factor
implic
promotor
cell
growth
possibl
associ
exposur
diabet
medic
risk
cancer
warrant
research
b
jone
j
j
c
health
queensland
depart
paediatr
surgeri
south
brisban
australia
queensland
depart
paediatr
child
health
brisban
australia
council
queensland
australian
childhood
cancer
registri
fortitud
valley
australia
univers
menzi
health
institut
gold
coast
australia
children
hospit
depart
paediatr
surgeri
adelaid
australia
adelaid
disciplin
surgeri
adelaid
australia
medic
centr
depart
urolog
adelaid
australia
research
institut
children
cancer
research
unit
sydney
australia
sydney
divis
child
adolesc
health
sydney
australia
hospit
westmead
depart
paediatr
surgeri
sydney
australia
backgroundobject
describ
incid
outcom
childhood
renal
malign
australia
use
popul
data
australian
childhood
cancer
registri
accr
describ
occurr
second
primari
malign
spm
children
treat
renal
cancer
designmethod
children
year
diagnos
renal
malign
inclus
identifi
accr
demograph
tumour
characterist
incid
mortal
treatment
data
extract
registri
cs
ef
surviv
year
diagnosi
estim
use
cohort
method
adjust
excess
mortal
hazard
ratio
hr
calcul
use
multivari
flexibl
parametr
surviv
model
cumul
incid
standardis
incid
ratio
sir
absolut
excess
risk
aer
mortal
relat
spm
calcul
result
children
diagnos
renal
malign
nephroblastoma
gener
annual
incid
rate
per
million
children
incid
chang
studi
period
surviv
year
respect
ef
cs
chang
studi
period
cs
highest
nephroblastoma
poorest
rhabdoid
renal
tumour
comparison
nephroblastoma
p
death
rhabdoid
tumour
occur
within
month
diagnosi
patient
achiev
remiss
relaps
subsequ
cs
ten
children
diagnos
spm
cumul
incid
year
give
sir
aer
half
spm
die
within
year
second
diagnosi
conclus
children
treat
renal
malign
australia
excel
surviv
unchang
sinc
spm
uncommon
follow
treatment
childhood
renal
cancer
carri
poor
prognosi
relaps
carri
similarli
poor
prognosi
data
compar
registri
outcom
similarli
develop
nation
mc
jd
k
uh
ca
j
lr
l
hospit
sick
children
depart
divis
haematologyoncolog
toronto
canada
oncolog
group
ontario
applic
toronto
canada
hospit
sick
children
program
child
health
evalu
toronto
canada
divis
depart
pediatr
halifax
canada
children
hospit
depart
divis
hematologyoncolog
hamilton
canada
univers
hospit
paediatr
saskatoon
canada
pediatr
depart
pediatr
mcgill
univers
canada
children
hospit
divis
hematolog
oncolog
bmt
vancouv
canada
backgroundobject
te
complic
cancer
lead
mortal
excess
morbid
conflict
inform
epidemiolog
te
pediatr
oncolog
object
describ
incid
risk
factor
te
children
cancer
designmethod
includ
children
cancer
less
year
age
diagnos
treat
one
canadian
pediatr
center
outsid
ontario
enter
cancer
young
databas
outcom
te
requir
medic
intervent
potenti
risk
factor
te
evalu
use
cox
proport
hazard
regress
stratifi
hematolog
malign
vs
solid
tumor
factor
associ
non
relat
te
compar
use
fisher
exact
test
result
children
includ
experienc
te
requir
medic
intervent
relat
cumul
incid
te
year
fatal
te
hematolog
malign
follow
factor
associ
te
multivari
regress
age
year
year
year
rel
age
year
hematopoiet
stem
cell
transplant
hsct
ci
anthracyclin
ci
asparaginas
ci
solid
tumor
obes
ci
surgeri
ci
radiat
ci
anthracyclin
ci
platinum
agent
ci
associ
te
fatal
te
common
among
access
te
vs
recent
surgeri
also
associ
access
relat
te
vs
conclus
cohort
children
cancer
develop
clinic
signific
te
accur
risk
stratif
tool
need
specif
malign
type
c
collin
j
linda
univers
school
medicin
pediatr
loma
ca
usa
linda
univers
research
consult
group
loma
ca
usa
hospit
lo
angel
pediatr
lo
ca
usa
backgroundobject
rate
improv
surviv
adolesc
young
adult
aya
cancer
lag
behind
younger
children
older
adult
reason
trend
appear
multifactori
aya
may
opportun
access
either
pediatr
adult
subspecialti
oncolog
care
explor
whether
provid
subspecialti
affect
surviv
outcom
aya
popul
designmethod
use
data
california
cancer
registri
collect
data
incid
case
cancer
state
perform
retrospect
cohort
studi
patient
age
diagnos
malign
period
januari
exclud
case
kaposi
sarcoma
melanoma
skin
thyroid
ovarian
endometri
cervic
carcinoma
relaps
secondari
malign
case
diagnos
autopsi
patient
assign
receiv
pediatr
care
treat
children
oncolog
center
treat
physician
pediatr
train
design
california
state
medic
licens
databas
multivari
model
built
diagnosi
use
cox
regress
provid
subspecialti
pediatr
adult
primari
variabl
interest
result
studi
includ
patient
pediatr
adult
patient
diagnosi
germ
cell
tumor
hodgkin
lymphoma
carcinoma
sarcoma
acut
lymphoblast
acut
myeloid
leukemia
signific
differ
surviv
treat
pediatr
versu
adult
provid
patient
cn
malign
significantli
better
surviv
treat
pediatr
provid
hr
adult
vs
pediatr
p
conclus
common
cancer
aya
popul
appear
signific
differ
surviv
patient
treat
pediatr
adult
provid
howev
aya
patient
cn
malign
may
benefit
target
referr
pediatr
oncolog
provid
j
van
warmerdam
c
j
p
r
p
hospit
sick
children
research
institut
child
health
evalu
scienc
toronto
canada
toronto
institut
medic
scienc
toronto
canada
clinic
evalu
scienc
ice
cancer
toronto
canada
oncolog
group
ontario
pogo
epidemiolog
toronto
canada
addict
mental
health
camh
mental
health
polici
research
toronto
canada
clinic
evalu
scienc
ice
mental
health
addict
toronto
canada
toronto
institut
health
evalu
toronto
canada
hospit
sick
children
hematologyoncolog
toronto
canada
backgroundobject
impact
child
cancer
diagnosi
mother
mental
health
unclear
health
servic
data
offer
object
measur
mental
health
outcom
designmethod
assembl
retrospect
cohort
ontario
mother
children
diagnos
cancer
use
provinci
pediatr
cancer
registri
birth
record
linkag
healthcar
data
captur
mental
outpati
visit
emerg
depart
ed
visit
hospit
suicid
primari
outcom
assess
rate
mental
health
outpati
visit
cancer
diagnosi
secondaryoutcom
includ
risk
sever
mental
health
event
ed
visit
hospit
suicid
risk
specif
sever
psychiatr
diagnos
recurr
event
time
event
regress
model
compar
cancer
mother
match
popul
control
assess
predictor
advers
outcom
result
median
year
rang
compar
control
childhood
cancer
mother
higher
rate
outpati
mental
health
visit
rate
ratio
rr
confid
interv
ci
p
higher
visit
rate
associ
prior
mental
healthcar
use
rr
per
addit
visityear
ci
p
low
incom
rr
lowest
versu
highest
incom
quintil
ci
larg
famili
size
rr
per
addit
child
ci
p
cancer
treatment
factor
signific
predictor
matern
outcom
though
risk
overal
sever
psychiatr
event
differ
cohort
cancer
mother
increas
risk
ed
visit
hospit
hazard
ratio
ci
p
predictor
sever
event
similar
outpati
visit
conclus
mother
children
cancer
experi
significantli
higher
rate
mental
health
outpati
visit
control
increas
risk
sever
event
matern
risk
predict
sociodemograph
factor
rather
factor
mother
children
cancer
requir
target
psychosoci
support
hargreav
k
cancer
societi
research
center
lifestyl
gene
copenhagen
denmark
depart
pediatr
adolesc
medicin
copenhagen
denmark
backgroundobject
fertil
treatment
suspect
link
increas
childhood
cancer
risk
designmethod
follow
nationwid
cohort
live
born
children
januari
decemb
individu
linkag
danish
infertil
cohort
order
identifi
children
born
women
fertil
problem
andor
conceiv
fertil
treatment
studi
popul
follow
date
birth
first
diagnosi
cancer
year
regist
danish
cancer
registri
date
birthday
date
emigr
date
death
end
decemb
whichev
occur
first
analys
data
use
cox
model
hazard
rate
hr
measur
associ
correspond
confid
interv
ci
result
children
diagnos
cancer
type
fertil
treatment
hr
ci
fertil
drug
use
hr
ci
assist
reproduct
technolog
hr
ci
vitro
fertil
hr
ci
intracytoplasm
sperm
inject
hr
ci
statist
significantli
affect
risk
type
cancer
children
affect
risk
specif
cancer
type
compar
children
born
fertil
women
contrast
frozen
embryo
transfer
markedli
increas
risk
type
cancer
hr
ci
mainli
due
increas
risk
leukaemia
hr
ci
sympathet
nervou
system
tumour
hr
ci
lymphoma
hr
ci
sensit
analys
use
children
born
women
fertil
problem
refer
instead
fertil
women
show
similar
result
conclus
use
frozen
embryo
transfer
fertil
treatment
may
increas
risk
cancer
children
especi
leukaemia
lymphoma
sympathet
nervou
system
tumour
z
gu
k
c
jude
children
research
hospit
patholog
memphi
usa
jude
children
research
hospit
immunolog
memphi
usa
backgroundobject
acut
lymphoblast
leukemia
remain
lead
caus
childhood
cancer
death
mani
chimer
gene
identifi
led
refin
classif
tailor
therapi
still
classifi
establish
subtyp
outcom
mani
poor
studi
aim
identifi
novel
subtyp
caus
recurr
genet
alter
commonli
disturb
pathway
designmethod
perform
transcriptom
sequenc
case
analyz
chromosom
rearrang
gene
express
profil
gep
somat
mutat
alter
case
lack
known
put
alter
subject
whole
genom
sequenc
screen
driver
lesion
effect
prolifer
transform
novel
lesion
assess
retrovir
express
cell
line
knockin
mice
use
genom
edit
result
use
integr
genet
alter
gene
express
profil
observ
subgroup
four
canon
subgroup
includ
case
similar
gep
altern
unknown
driver
eg
notabl
identifi
two
group
character
alter
one
compris
case
rearrang
divers
partner
second
group
case
missens
mutat
mutat
either
hemizyg
due
delet
second
allel
compound
heterozyg
frameshiftnonsens
mutat
indic
homozyg
driver
lesion
new
subtyp
consist
mice
heterozyg
homozyg
develop
median
latenc
day
respect
heterozyg
mice
acquir
alter
second
allel
contrast
mice
harbor
mutat
observ
famili
leukemia
spontan
develop
conclus
studi
demonstr
power
refin
classif
reinforc
central
role
checkpoint
leukemogenesi
kubota
k
k
k
k
n
k
k
e
j
univers
tokyo
depart
pediatr
tokyo
japan
univers
depart
pediatr
hirosaki
japan
research
institut
child
health
develop
depart
biolog
tokyo
japan
univers
depart
patholog
tumor
biolog
kyoto
japan
research
institut
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
univers
tokyo
laboratori
dna
inform
human
genom
institut
medic
scienc
tokyo
japan
children
medic
center
depart
hematolog
oncolog
takasaki
japan
children
hospit
depart
hematolog
oncolog
sendai
japan
backgroundobject
children
syndrom
ds
predispos
develop
acut
lymphoblast
leukemia
display
uniqu
genet
alter
howev
molecular
basi
still
incomplet
designmethod
cohort
includ
pediatr
precursor
sampl
perform
whole
transcriptom
sequenc
dna
methyl
array
analysi
mutat
analysi
copi
number
analysi
result
express
profil
stratifi
sampl
cluster
cluster
well
correl
biolog
subtyp
intriguingli
case
cluster
cluster
suggest
heterogen
one
classifi
cluster
character
inde
snp
array
analysi
reveal
case
focal
amplif
case
fusion
classifi
cluster
also
includ
fusion
case
cluster
also
includ
one
case
signatur
high
hyperdiploidi
heh
classifi
cluster
also
includ
heh
sampl
cluster
character
fusion
express
profil
cohort
case
signatur
show
mutat
identifi
similar
express
analysi
dna
methyl
analysi
reveal
sampl
cluster
correspond
subtyp
addit
dna
methyl
array
analysi
reveal
uniqu
hypermethyl
promot
region
hypermethyl
region
confirm
normal
ds
without
conclus
confirm
highli
heterogen
due
inclus
mani
subtyp
subtyp
similar
express
methyl
profil
hypermethyl
locat
chromosom
uniqu
characterist
ds
patient
may
associ
increas
incid
ds
patient
j
schraw
j
k
p
colleg
medicin
depart
section
epidemiolog
popul
scienc
houston
usa
colleg
medicin
depart
section
houston
usa
backgroundobject
minim
residu
diseas
mrd
import
predictor
relaps
pediatr
acut
lymphoblast
leukemia
howev
mani
relaps
occur
patient
hypothes
global
metabolom
profil
diagnost
bone
marrow
plasma
could
improv
predict
mrd
provid
insight
biolog
relaps
designmethod
retrospect
identifi
patient
diagnos
treat
texa
children
hospit
mrd
posit
end
induct
use
diagnost
bone
marrow
plasma
subject
metabolom
profil
via
use
nonparametr
test
comput
univari
compar
vs
neg
plasma
metabolit
set
enrich
analysi
msea
identifi
pathway
enrich
differenti
abund
metabolit
kegg
refer
metabolit
univari
evalu
logist
regress
model
mrd
best
predictor
obtain
backward
elimin
assess
perform
model
mrd
use
clinic
featur
alon
clinic
featur
metabolit
via
delong
test
correl
receiv
oper
characterist
curv
measur
vitro
cytotox
drug
target
pathway
cell
line
use
flow
cytometr
stain
iodid
result
msea
reveal
central
carbon
metabol
pathway
enrich
differenti
abund
metabolit
constitu
metabolit
pyruv
succin
fumar
malat
significantli
increas
mrd
posit
patient
predict
model
mrd
incorpor
metabolit
outperform
clinic
featur
alon
auc
vs
nampt
inhibitor
deplet
metabolit
demonstr
signific
cytotox
cell
line
nm
conclus
metabolom
profil
improv
predict
subsequ
mrd
identifi
potenti
druggabl
metabol
alter
valid
biomark
may
improv
risk
predict
understand
diseas
biolog
j
z
n
n
e
l
n
w
g
g
r
g
k
davi
center
childhood
cancer
stanford
univers
pediatr
stanford
usa
laboratori
stem
cell
stanford
univers
depart
microbiolog
immunolog
stanford
usa
laboratori
stem
cell
biolog
stanford
univers
depart
microbiolog
immunolog
stanford
usa
diller
famili
comprehens
cancer
univers
california
san
francisco
depart
neurolog
san
francisco
usa
stanford
univers
depart
pediatr
stanford
usa
univers
depart
obstetr
gynecolog
stanford
usa
tettamanti
research
univers
milano
bicocca
depart
pediatr
monza
itali
univers
depart
statist
stanford
usa
blood
stanford
univers
depart
patholog
stanford
usa
backgroundobject
despit
high
rate
initi
respons
frontlin
treatment
cancer
mortal
larg
result
relaps
metastasi
improv
insight
cancer
cell
popul
respons
relaps
diseas
lead
better
outcom
patient
resist
cell
rare
accur
repres
anim
model
henc
studi
requir
analys
primari
human
tissu
new
analyt
tool
align
rare
popul
clinic
outcom
report
studi
precursor
acut
lymphoblast
leukemia
diagnosisthat
reveal
hidden
development
depend
cell
signal
state
uniqu
associ
relaps
designmethod
mass
cytometri
simultan
quantifi
development
protein
primari
diagnost
sampl
known
outcom
healthi
donor
sampl
leukemia
cell
match
nearest
healthi
popul
development
classifi
oper
level
machin
learn
approach
use
identifi
featur
portend
relaps
time
diagnosi
result
identifi
six
featur
expand
leukem
popul
suffici
predict
patient
relaps
diagnosi
featur
implic
cell
activ
mtor
signal
cell
activ
unrespons
receptor
signal
associ
relaps
model
term
development
depend
predictor
relaps
ddpr
significantli
improv
current
establish
risk
stratif
method
furthermor
analysi
match
sampl
seven
patient
confirm
persist
enrich
ddpr
featur
time
relaps
conclus
leverag
approach
demonstr
predict
valu
omic
patient
stratif
broadli
studi
highlight
translat
valu
understand
cancer
level
appli
machin
learn
guid
treatment
paradigm
patient
cancer
b
schaefer
g
l
l
j
f
children
hospit
oncolog
zuerich
switzerland
backgroundobject
paradigm
cancer
therapi
current
shift
broadli
use
cytotox
drug
cocktail
patient
specif
precis
therapi
direct
toward
tumor
specif
driver
oncogen
identifi
mostli
genom
mutat
analysi
individu
tumor
case
tumor
low
mutat
burden
undrugg
target
howev
approach
less
suitabl
direct
drug
profil
vitro
cultur
tumor
cell
repres
promis
altern
condit
maintain
tumor
heterogen
cultur
howev
tumor
entiti
ill
defin
designmethod
establish
vitro
drug
profil
platform
rhabdomyosarcoma
rm
isol
cell
seven
alveolar
eight
embryon
rm
patient
deriv
xenograft
pdx
systemat
test
differ
cultur
condit
find
suitabl
condit
effici
vitro
propag
primari
rm
cell
without
overgrowth
normal
fibroblast
result
approach
reveal
cell
tumor
surviv
prolifer
medium
wherea
tumor
cell
serum
contain
medium
progress
lost
time
importantli
cell
preserv
clonal
composit
phenotyp
characterist
primari
pdx
assess
genom
copi
number
analysi
moreov
condit
also
allow
growth
organoid
drug
profil
establish
librari
drug
reveal
subgroup
individu
vulner
well
unrecogn
sensit
toward
akt
inhibitor
subgroup
patient
furthermor
screen
resensit
resist
relaps
sampl
identifi
famili
inhibitor
potent
resensit
toward
chemotherapi
detail
molecular
analysi
reveal
effect
base
blockad
axi
conclus
proof
concept
studi
highlight
feasibl
vitro
drug
profil
primari
rm
cell
treatment
select
altern
addit
molecular
profil
set
b
campbel
e
c
u
arthur
sonia
labatt
brain
tumour
research
hospit
sick
canada
depart
haematologyoncolog
toronto
canada
hospit
sick
children
depart
hematologyoncolog
toronto
canada
hospit
sick
children
genet
genom
biolog
toronto
canada
medicin
inc
depart
cancer
immunotherapi
boston
usa
hospit
sick
children
depart
patholog
toronto
canada
backgroundobject
hypermut
pediatr
high
grade
glioma
phgg
constitut
total
phgg
almost
invariantli
caus
replic
repair
defici
rrd
constitut
activ
rasmapk
pathway
via
oncogen
mutat
target
mek
inhibitor
meki
hypothes
hypermut
rrd
phgg
would
harbor
mutat
mapk
pathway
regul
make
tumor
suscept
target
meki
designmethod
tumor
sequenc
data
pediatr
tumor
extract
cohort
exom
sequenc
perform
tumor
intern
rrd
consortium
xenograft
patient
deriv
brain
gi
tumor
establish
mice
treat
mek
inhibitor
trametinib
selumetinib
function
experi
perform
demonstr
deregul
mapk
pathway
tumor
result
screen
childhood
cancer
reveal
mutat
rasmapk
second
common
mutat
pediatr
tumor
exom
data
patient
reveal
phgg
crc
gi
tumor
found
harbor
mutat
key
rasmapk
pathway
regul
subclon
analysi
reveal
mutat
pathway
subclon
enrich
mutat
time
treatment
patient
deriv
rrd
hypermut
phgg
colon
cancer
meki
reveal
signific
tumor
suppress
decreas
tumor
volum
improv
surviv
p
final
two
cmmrd
patient
progressiverecurr
phgg
treat
selumetinib
trametinib
exhibit
object
tumor
respons
prolong
surviv
conclus
preclin
clinic
observ
suggest
novel
therapeut
option
children
hypermut
rrd
phgg
base
possibl
oncogen
addict
rasmapk
alter
observ
basi
upcom
intern
clinic
trial
denburg
j
j
w
hospit
sick
children
haematologyoncolog
toronto
canada
hospit
sick
children
paediatr
toronto
canada
univers
health
research
evid
impact
hamilton
canada
hospit
sick
children
child
health
evalu
scienc
toronto
canada
backgroundobject
cancer
drug
consum
increas
proport
health
system
budget
need
priorit
scarc
health
system
resourc
come
acut
focu
mani
countri
import
societ
valu
set
health
system
prioriti
littl
knowledg
exist
public
prefer
regard
health
care
fund
children
assess
societ
prefer
health
resourc
alloc
children
gener
evid
inform
prioriti
set
cancer
drug
within
publicli
fund
health
system
designmethod
conduct
random
experiment
state
prefer
survey
societ
view
priorit
health
resourc
among
children
adult
particip
intervent
group
subject
moral
reason
exercis
prior
choic
task
construct
multipl
regress
mix
model
evalu
direct
strength
societ
prefer
health
resourc
alloc
children
adult
identifi
sociodemograph
factor
significantli
impact
express
societ
prefer
result
final
studi
sampl
compris
particip
intervent
control
repres
canadian
popul
multipl
regress
analys
demonstr
consist
aggreg
prefer
alloc
children
across
scenario
experiment
group
exposur
moral
reason
exercis
weaken
alloc
prefer
children
younger
respond
age
parenthood
associ
greater
prefer
children
three
moral
principl
influenc
particip
prefer
equal
treatment
relief
suffer
rule
rescu
conclus
studi
affirm
relev
age
public
prefer
alloc
scarc
health
care
resourc
involv
children
despit
fairli
consist
prioriti
attach
children
result
suggest
express
societ
valu
attach
children
differ
circumst
social
context
find
direct
relev
public
polici
decis
cancer
drug
fund
children
canada
intern
phipp
k
jude
children
research
hospit
psycholog
memphi
usa
backgroundobject
although
diagnost
interview
consid
gold
standard
diagnosi
ptsd
research
medic
set
reli
survey
measur
use
establish
cutoff
relationship
preval
estim
ptsd
base
survey
diagnost
interview
examin
pediatr
set
relianc
survey
absenc
appropri
comparison
group
may
lead
inflat
estim
ptsd
designmethod
children
adolesc
cancer
n
demograph
similar
children
without
histori
seriou
ill
n
along
one
parent
per
child
assess
ptsd
youth
complet
ucla
ptsd
inventori
ucla
clinician
administ
ptsd
scale
children
adolesc
parent
complet
impact
event
scale
cap
establish
approach
identifi
case
appli
questionnair
compar
diagnost
interview
result
ucla
youth
cancer
exceed
establish
cutoff
compar
healthi
comparison
ns
stringent
specif
symptom
approach
reduc
rate
cancer
group
comparison
ns
contrast
diagnost
interview
rate
meet
full
criteria
current
ptsd
less
group
rate
ptsd
survey
measur
significantli
higher
diagnost
interview
group
p
similar
find
obtain
parent
absenc
differ
rate
questionnair
significantli
higher
diagnost
interview
p
conclus
survey
measur
overestim
rate
ptsd
youth
parent
phenomenon
demonstr
militari
context
appear
medic
set
highlight
import
methodolog
consider
studi
medic
traumat
stress
k
howard
sharp
r
h
l
l
k
k
b
c
research
institut
nationwid
children
hospitalohio
state
univers
center
biobehavior
health
columbu
usa
research
institut
nationwid
children
hospit
center
biobehavior
health
columbu
usa
univers
psycholog
scienc
nashvil
usa
backgroundobject
object
commun
link
children
adjust
pediatr
cancer
parent
stress
one
famili
factor
found
influenc
commun
howev
research
gener
examin
interact
independ
mother
without
examin
overal
pattern
commun
across
mother
father
moreov
littl
research
examin
gener
commun
concurr
present
studi
identifi
pattern
mother
father
gener
commun
diagnosi
examin
stress
cancer
percept
predict
famili
membership
profil
designmethod
method
particip
famili
recruit
pediatr
hospit
unit
state
children
age
initi
diagnosisrelaps
mother
father
report
gener
stress
stress
children
stress
frequenc
commun
children
children
report
regard
open
problemat
commun
parent
profil
gener
commun
deriv
use
latent
profil
analysi
mplu
logist
regress
examin
whether
parent
stress
child
stress
predict
treatment
success
predict
famili
profil
membership
result
three
profil
emerg
blrt
p
open
commun
limitedproblemat
commun
mother
domin
commun
parent
stress
differenti
profil
membership
howev
mother
percept
children
stress
chanc
treatment
success
predict
famili
like
belong
mother
domin
profil
compar
limitedproblemat
profil
conclus
discuss
famili
gener
character
open
commun
particularli
mother
mother
percept
child
experi
stress
may
prompt
mother
initi
commun
confid
treatment
success
perhap
yield
comfort
commun
regard
cancer
topic
parent
stress
differenti
pattern
commun
instead
perhap
one
parent
may
compens
find
suggest
screen
parent
percept
children
cancer
stressor
treatment
experi
f
schult
c
dk
k
r
e
l
w
l
g
k
calgari
depart
divis
psychosoci
oncolog
calgari
canada
jude
children
research
hospit
epidemiologycanc
control
memphi
usa
jude
children
research
hospit
biostatist
memphi
usa
children
hospit
neuropsycholog
calgari
canada
univers
texa
md
anderson
cancer
centr
houston
usa
california
san
francisco
benioff
children
hospit
san
francisco
usa
nation
medic
center
neurolog
washington
usa
calgari
depart
pediatr
calgari
canada
hutchinson
cancer
research
center
clinic
research
divis
seattl
usa
backgroundobject
pediatr
cn
tumor
survivor
experi
problem
social
adjust
examin
tumor
treatment
demograph
factor
associ
social
adjust
deficit
adolesc
survivor
pediatr
cn
tumor
designmethod
survivor
cn
tumor
male
median
rang
year
old
year
diagnosi
treat
cranial
radiat
compar
solid
tumor
survivor
neuroblastoma
wilm
tumor
male
year
old
year
diagnosi
sibl
control
male
year
old
social
adjust
measur
item
examin
qualiti
quantiti
peer
interact
behavior
problem
inventori
latent
profil
analysi
identifi
social
adjust
class
multinomi
logist
regress
determin
predictor
class
membership
path
analysi
use
determin
whether
social
problem
mediat
sensori
physic
andor
cognit
limit
result
class
identifi
cn
tumor
survivor
solid
tumor
survivor
sibl
nearli
seven
time
mani
cn
tumor
survivor
report
zero
friend
compar
solid
tumor
survivor
sibl
cn
tumor
survivor
report
interact
friend
less
per
week
compar
solid
tumor
survivor
sibl
among
cn
survivor
cranial
radiat
dose
associ
poor
qualiti
per
ci
limit
interact
ci
adjust
age
sex
age
diagnosi
limit
cognit
function
stronger
mediat
number
friend
p
time
friend
p
compar
sensori
p
p
physic
p
p
limit
conclus
cranial
radiat
therapi
cognit
impair
associ
increas
risk
social
adjust
problem
among
cn
tumor
survivor
intervent
facilit
develop
cognit
social
skill
popul
need
e
j
c
de
dj
hospit
sick
children
psycholog
toronto
canada
oncolog
group
ontario
research
unit
toronto
canada
univers
toronto
psycholog
toronto
canada
hospit
sick
children
hematologyoncolog
toronto
canada
hospit
sick
children
diagnost
imag
toronto
canada
backgroundobject
paediatr
patient
treat
brain
tumour
previous
shown
display
deficit
facial
emot
recognit
monitor
might
help
explain
identifi
facial
emot
thought
reli
white
matter
wm
connect
posterior
limbic
frontal
brain
region
eg
inferior
fasciculu
ifof
thu
examin
wm
ifof
relat
emot
recognit
social
function
designmethod
children
treat
posterior
fossa
pf
brain
tumour
healthi
control
particip
hospit
sick
children
toronto
canada
particip
complet
diagnost
analysi
nonverb
accuraci
computer
task
measur
facial
emot
recognit
use
photograph
record
diffus
tensor
imag
dti
use
assess
fraction
anisotropi
fa
radial
diffus
rd
ifof
social
function
assess
child
behavior
checklist
cbcl
relat
wm
microstructur
ifof
emot
recognit
social
function
evalu
partial
least
squar
pl
path
model
result
patient
made
emot
recognit
error
control
howev
patient
control
differ
number
fixat
made
time
spent
look
photograph
patient
lower
social
function
control
treatment
pf
brain
tumour
predict
wm
microstructur
ifof
howev
wm
ifof
predict
emot
recognit
across
particip
social
function
predict
wm
ifof
emot
recognit
p
conclus
emot
recognit
deficit
experienc
children
treat
pf
brain
tumour
appear
result
inattent
photograph
differ
visual
process
photograph
ifof
appear
relat
emot
recognit
abil
across
particip
manner
uniqu
treatment
pf
brain
tumour
patel
albertacross
cancer
institut
depart
oncolog
edmonton
canada
albertastolleri
children
hospit
depart
oncolog
edmonton
canada
backgroundobject
radiotherapi
rt
qualiti
assur
qa
program
aim
standard
rt
deliv
multicent
clinic
trial
minim
variabl
may
confound
valid
result
object
review
avail
evid
report
correl
rt
qualiti
clinic
outcom
within
pediatr
multicent
clinic
trial
designmethod
literatur
search
encompass
medlin
embas
cochran
central
regist
control
trial
qualiti
assur
review
center
bibliographi
perform
restrict
english
date
limit
candid
studi
accru
children
age
year
median
age
led
cooper
group
publish
full
describ
central
subject
andor
object
assess
rt
protocol
complianc
qualiti
data
abstract
includ
assign
violat
relat
clinic
outcom
andor
distant
failur
surviv
pf
overal
surviv
os
advers
event
result
multicent
clinic
trial
report
rhabdomyosarcoma
rm
trial
medulloblastoma
mbl
ewe
sarcoma
ew
classic
hodgkin
lymphoma
chl
supratentori
primit
neuroectoderm
tumor
spnet
acut
lymphocyt
leukemia
deviat
found
rt
plan
review
variou
primari
site
report
rt
protocol
deviat
eg
dose
field
placement
significantli
affect
clinic
outcom
form
inferior
os
trial
pf
local
control
recurr
one
studi
suggest
improv
pf
local
field
rt
deviat
versu
without
conclus
suboptim
rt
neg
impact
clinic
outcom
pediatr
multicent
cooper
group
trial
c
rd
j
b
timmermann
hospit
essen
west
german
proton
therapi
center
depart
particl
therapi
essen
germani
medic
center
depart
pediatr
haematolog
oncolog
hamburg
germani
leipzig
medic
center
depart
radiat
therapi
leipzig
germani
children
hospit
depart
pediatr
oncolog
calgari
canada
backgroundobject
choroid
plexu
tumor
rare
pediatr
brain
tumor
diagnos
mainli
infant
littl
known
role
radiotherapi
rt
aim
retrospect
studi
evalu
impact
rt
patient
choroid
plexu
carcinoma
cpc
designmethod
analyz
data
studi
patient
cpc
patient
f
median
age
year
rang
evalu
complet
resect
achiev
case
subtot
extent
resect
specifi
patient
patient
chemotherapi
appli
rt
patient
receiv
rt
rt
group
receiv
local
median
dose
rang
craniospin
irradi
local
boost
median
dose
rang
case
detail
rt
miss
patient
rt
appli
group
median
age
diagnosi
rang
rang
surviv
data
estim
use
kaplan
meier
method
cox
model
result
median
rang
surviv
os
vs
rt
vs
group
surviv
pf
vs
rt
vs
group
rt
appli
rel
risk
failur
death
time
higher
respect
conclus
analysi
indic
rt
play
import
role
cure
cpc
os
und
pf
rate
significantli
higher
patient
receiv
rt
role
rt
cpc
need
consid
futur
concept
knowledg
still
need
optim
concept
time
rt
n
wahe
q
mf
e
z
k
r
colleg
medicin
radiat
oncolog
houston
usa
colleg
medicin
hematologyoncolog
houston
usa
colleg
medicin
biostatist
houston
usa
colleg
medicin
endocrinolog
houston
usa
anderson
cancer
center
radiat
oncolog
houston
usa
backgroundobject
compar
height
weight
indic
among
patient
acut
lymphoblast
leukemia
receiv
chemotherapi
without
gy
cranial
radiotherapi
rt
designmethod
record
children
treat
singl
institut
review
patient
height
weight
bodi
mass
index
bmi
convert
use
center
diseas
control
growth
chart
normal
valu
number
standard
deviat
mean
valu
measur
time
diagnosi
pretreat
follow
clinic
growth
indic
fit
gener
estim
equat
model
analyz
variou
clinic
factor
result
patient
boy
median
age
year
rang
year
initi
diagnosi
subject
studi
patient
categor
accord
gy
cranial
rt
group
rt
group
b
n
median
year
year
group
b
respect
statist
signific
differ
height
weight
bmi
initi
diagnosi
last
among
patient
group
b
multivari
analysi
femal
weight
p
bmi
p
differ
male
patient
similarli
patient
age
year
less
weight
p
less
bmi
p
differ
compar
age
year
conclus
differ
height
weight
bmi
initi
diagnosi
last
among
patient
receiv
gy
rt
chemotherapi
alon
suggest
impact
growth
hormon
gy
femal
patient
children
age
year
suscept
chang
weight
bmi
h
uezono
j
r
e
r
w
florida
depart
radiat
oncolog
jacksonvil
usa
children
specialti
clinic
divis
pediatr
oncolog
jacksonvil
usa
children
specialti
clinic
depart
pediatr
otolaryngolog
jacksonvil
usa
backgroundobject
proton
therapi
use
reduc
dose
radiat
develop
tissu
brain
skull
base
region
children
treat
nasopharyng
carcinoma
purpos
studi
report
outcom
children
treat
use
pediatr
regimen
induct
chemotherapi
follow
proton
therapi
designmethod
seventeen
patient
undifferentiatedpoorli
differenti
nasopharyng
carcinoma
treat
proton
therapi
singl
institut
februari
juli
median
age
year
rang
percent
patient
male
eleven
patient
ajcc
edit
tumor
respect
median
radiat
dose
primari
target
volum
posit
lymph
node
gy
rbe
rang
elect
neck
radiat
deliv
uninvolv
cervic
node
gy
rbe
rang
radiat
deliv
gy
rbe
fx
daili
use
sequenti
plan
imrt
use
elect
neck
irradi
phase
patient
optim
dose
homogen
improv
target
conform
patient
receiv
induct
chemotherapi
one
receiv
concurr
chemotherapi
three
patient
receiv
adjuv
therapi
result
median
year
rang
patient
lost
overal
surviv
surviv
local
control
rate
fifteen
patient
develop
mucos
requir
enter
feed
n
total
parenter
nutrit
n
radiat
therapi
seriou
late
toxic
includ
cataract
esophag
stenosi
requir
dilat
sensorineur
hear
loss
requir
aid
n
hormon
defici
n
includ
isol
hypothyroid
conclus
follow
induct
chemotherapi
proton
therapi
reduc
lowintermedi
radiat
exposur
develop
tissu
brain
skull
base
region
without
compromis
diseas
control
produc
unexpect
major
toxic
jl
habrand
j
c
j
r
bacless
radiat
oncolog
caen
franc
roussi
cancer
campu
radiat
oncolog
villejuif
franc
curi
radiat
oncolog
pari
franc
backgroundobject
evalu
place
particl
therapi
mainli
proton
childrenadolesc
extens
review
literatur
acut
toxicitysequela
endpoint
designmethod
perform
review
publish
articl
base
medlin
accord
follow
keyword
english
toxic
novel
technolog
compar
studi
technolog
taken
consider
dosimetr
studi
group
secondari
cancer
predict
model
group
clinic
seri
group
evalu
separ
best
author
recommend
quot
p
xr
particl
photon
respect
along
degre
signific
ps
result
articl
select
compar
p
vs
xr
studi
repres
core
project
anatom
site
toxic
concern
cn
pub
necrosi
cognit
vision
hear
pituitari
brain
hippocampu
head
neck
hn
pub
pituitari
auditori
eye
facial
bone
thorax
pub
cardiac
pulmonari
thyroid
breast
abdomenpelvi
pub
liver
stomach
bowel
pancrea
total
bodi
pub
mix
site
pub
cn
p
ps
hn
p
ps
thorax
p
abdomen
p
ps
x
pn
p
ps
cn
p
ps
hn
p
endocrin
p
ps
lung
xr
ps
acut
toxic
p
ps
p
conclus
vast
major
publish
seri
deal
dosimetri
model
favor
particl
therapi
preventionlimit
toxic
concern
although
ps
valu
systemat
mention
similar
find
concern
clinic
evalu
data
remain
scarc
mainli
relat
cn
particl
therapi
becom
popular
remain
essenti
base
dosimetr
cn
investig
extra
cranial
clinic
studi
warrant
mcgovern
mf
r
anderson
cancer
center
depart
radiat
oncolog
houston
usa
children
hospit
bone
marrow
transplantstem
cell
transplant
program
houston
usa
texa
houston
medic
school
houston
usa
clinic
depart
radiat
oncolog
rochest
usa
backgroundobject
histor
cranial
boost
includ
condit
regimen
total
bodi
irradi
tbi
patient
acut
lymphocyt
leukemia
undergo
bone
marrow
transplant
bmt
current
patient
central
nervou
system
cn
leukem
involv
prior
bmt
receiv
cranial
craniospin
boost
studi
undertaken
examin
contemporari
pattern
failur
tbi
without
cranial
craniospin
boost
prior
bmt
designmethod
medic
record
pediatr
patient
treat
tbi
bmt
singl
center
retrospect
review
result
median
follow
patient
month
patient
receiv
either
cranial
craniospin
boost
prior
tbi
patient
fail
bmt
bone
marrow
cerebrospin
fluid
csf
testicl
bone
bone
marrow
csf
patient
cn
involv
prior
bmt
receiv
cranial
craniospin
boost
tbi
patient
fail
bmt
bone
marrow
testicl
patient
receiv
boost
fail
cn
differ
crude
rate
failur
bmt
group
receiv
boost
group
vs
p
conclus
bone
marrow
remain
common
site
failur
bmt
tbi
condit
patient
cn
involv
prior
transplant
fail
cn
alon
cranial
craniospin
boost
suggest
boost
improv
likelihood
cn
control
patient
without
cn
involv
prior
transplant
none
fail
cn
suggest
cranial
craniospin
boost
requir
e
k
r
vatner
cincinnati
colleg
medicin
depart
radiat
oncolog
cincinnati
usa
cincinnati
cincinnati
children
hospit
medic
center
depart
radiat
oncolog
cincinnati
usa
backgroundobject
effect
spinal
radiat
childhood
depend
upon
patient
age
gender
radiat
dose
howev
radiat
dose
respons
spinal
growth
unknown
appli
deform
registr
tool
quantit
analysi
vertebr
bodi
growth
pediatr
patient
abdomin
radiotherapi
designmethod
retrospect
studi
pediatr
patient
treat
abdomin
radiotherapi
depart
perform
ct
imag
avail
analysi
dosimetr
data
obtain
treatment
plan
autom
deform
registr
perform
ct
imag
simul
patient
align
focus
spine
growth
vertebr
bodi
quantifi
use
displac
vector
deriv
map
rel
volumetr
axial
growth
use
softwar
compar
use
unpair
publish
expect
normal
growth
thorac
vertebr
bodi
valu
age
gender
result
analyz
patient
age
month
year
year
receiv
median
thorac
radiat
dose
gy
respect
observ
thorac
rel
growth
rate
per
year
mm
compar
age
match
expect
growth
rate
mm
respect
p
similar
result
demonstr
impair
growth
low
dose
radiat
obtain
analysi
lumbar
growth
impair
spinal
growth
observ
even
low
dose
radiotherapi
gy
conclus
present
novel
applic
deform
imag
registr
measur
axial
vertebr
bodi
growth
pediatr
patient
expos
low
dose
spinal
radiat
abdomin
radiotherapi
techniqu
allow
precis
growth
analysi
individu
vertebr
bodi
provid
unbias
quantit
rapid
method
determin
magnitud
spinal
growth
impair
function
radiat
dose
indelicato
j
r
h
e
p
n
c
n
florida
depart
radiat
oncolog
jacksonvil
usa
children
specialti
clinic
divis
pediatr
oncolog
jacksonvil
usa
florida
depart
neurosurgeri
jacksonvil
usa
backgroundobject
dosimetr
studi
show
proton
therapi
reduc
lowintermedi
radiat
dose
deliv
uninvolv
tissu
children
low
grade
glioma
lgg
base
rational
lgg
becom
common
pediatr
tumor
treat
proton
therapi
worldwid
yet
clinic
outcom
data
efficaci
toxic
limit
designmethod
march
june
children
year
old
lgg
treat
proton
therapi
singl
institut
median
age
year
rang
male
neurofibromatosi
percent
tumor
grade
ii
children
diagnos
base
imag
characterist
alon
common
histolog
pilocyt
astrocytoma
top
tumor
subsit
diencephalonopt
pathway
caudal
brainstem
cerebellum
percent
patient
receiv
chemotherapi
initi
treatment
result
median
year
four
patient
lost
actuari
rate
local
control
surviv
overal
surviv
ci
ci
ci
respect
univari
analysi
brainstemspin
cord
tumor
locat
vs
subsit
radiat
dose
gy
rbe
vs
gy
rbe
associ
inferior
progress
free
surviv
p
strong
sitedos
correl
prohibit
multivari
analysi
pseudoprogress
observ
patient
seriou
toxic
includ
vasculopathi
n
radiat
retinopathi
n
brainstem
toxic
requir
steroid
n
death
high
grade
glioma
n
conclus
studi
suggest
gy
rbe
may
associ
improv
diseas
control
lgg
limit
critic
adjac
cn
tissu
compar
modern
seri
use
xray
proton
therapi
may
reduc
radiat
dose
develop
brain
tissu
without
compromis
diseas
control
produc
unexpect
toxic
acharya
j
c
j
h
jude
children
research
hospit
depart
radiat
oncolog
memphi
usa
jude
children
research
hospit
depart
biostatist
memphi
usa
jude
children
research
hospit
depart
psycholog
memphi
usa
backgroundobject
hippocamp
avoid
suggest
strategi
reduc
memori
declin
adult
receiv
whole
brain
radiat
therapi
rt
purpos
studi
determin
whether
hippocamp
dose
pediatr
patient
undergo
focal
radiat
glioma
lgg
associ
memori
perform
designmethod
eighti
pediatr
patient
age
five
lgg
treat
conform
rt
gy
cm
clinic
target
volum
phase
ii
protocol
patient
administ
california
verbal
learn
test
cvlt
baselin
six
month
yearli
five
year
year
year
patient
particip
least
two
memori
assess
includ
analysi
linear
mix
model
use
estim
longitudin
trend
cognit
assess
score
estim
effect
clinic
variabl
trend
result
patient
least
two
cvlt
assess
median
age
rt
year
median
neurocognit
follow
year
multivari
analysi
declin
delay
sd
associ
hydrocephalu
greater
left
hippocamp
greater
right
hippocamp
treat
entir
left
hippocampu
gy
associ
reduct
five
year
standard
deviat
sd
sd
patient
without
hydrocephalu
respect
treat
entir
right
hippocampu
gy
associ
reduct
five
year
sd
sd
patient
without
hydrocephalu
respect
conclus
greater
hippocamp
dose
associ
greater
declin
memori
measur
find
might
inform
radiat
therapi
plan
children
brain
tumor
h
j
k
von
rd
b
timmermann
hospit
essen
depart
particl
therapi
essen
germani
german
proton
therapi
centr
essen
west
german
cancer
center
essen
germani
institut
biostatist
clinic
research
germani
berlin
depart
paediatr
oncolog
hematolog
berlin
germani
leipzig
medic
center
depart
radiat
therapi
leipzig
germani
augsburg
children
hospit
augsburg
germani
backgroundobject
atyp
teratoidrhabdoid
tumour
atrt
rare
malign
childhood
origin
central
nervou
system
aim
analysi
evalu
role
radiotherapi
rt
patient
atrt
designmethod
retrospect
analyz
data
patient
regist
registri
precursor
rhabdoid
surviv
data
analyz
use
kaplan
meier
method
multivari
cox
regress
rt
use
covari
result
data
patient
f
median
age
year
rang
evalu
patient
underw
gross
total
resect
subtot
biopsi
chemotherapi
appli
patient
patient
receiv
rt
rt
group
group
median
total
local
spinal
dose
gy
rang
gy
gy
rang
gy
respect
median
time
rang
use
rt
independ
prognost
factor
overal
surviv
os
surviv
ef
hazard
ratio
os
rate
rt
group
vs
group
p
ef
rate
rt
group
vs
group
p
advantag
rt
observ
independ
age
os
ef
superior
treatment
compar
protocol
deviat
regardless
craniospin
rt
could
prove
posit
impact
os
ef
compar
local
rt
conclus
analysi
reveal
rt
independ
posit
prognost
factor
os
ef
children
atrt
howev
optim
combin
treatment
strategi
aim
reduct
late
effect
futur
c
nantavithya
k
k
univers
texa
md
anderson
cancer
center
radiat
oncolog
houston
usa
chulalongkorn
memori
hospit
divis
radiat
depart
radiolog
bangkok
thailand
univers
texa
md
anderson
cancer
center
health
servic
research
houston
usa
univers
texa
md
anderson
cancer
center
pediatr
houston
usa
children
cancer
center
pediatr
houston
usa
colleg
medicin
pediatr
houston
usa
backgroundobject
analyz
incid
type
second
malign
neoplasm
smn
patient
treat
medulloblastoma
designmethod
use
multipl
incid
ratio
session
seer
registri
data
compar
incid
smn
patient
medulloblastoma
treat
radiotherapi
rt
gener
popul
incid
ratio
oe
ratio
ci
report
overal
cohort
classifi
diseas
site
accord
age
era
treat
use
chemotherapi
ct
report
statist
signific
result
patient
medulloblastoma
receiv
rt
develop
smn
total
smn
report
patient
smn
smn
oe
ratio
smn
ci
patient
diagnos
medulloblastoma
p
highest
risk
develop
smn
cn
oe
ci
follow
endocrin
oe
ci
bone
oe
ci
soft
tissu
oe
ci
digest
oe
ci
lymphatichematopoiet
oe
ci
system
patient
receiv
chemotherapi
higher
oe
compar
rt
alon
oe
ci
vs
ci
chemotherapi
patient
also
higher
oe
smn
cn
salivari
gland
acut
leukemia
compar
rt
alon
patient
account
differ
length
standard
incid
ratio
patient
treat
younger
age
diagnosi
associ
higher
oe
smn
conclus
medulloblastoma
patient
elev
risk
smn
compar
gener
popul
variat
organ
system
risk
observ
base
treatment
modal
age
diagnosi
time
period
cn
common
site
smn
seen
frequent
younger
patient
receiv
chemotherapi
mf
mcaleer
j
c
l
l
tm
univers
texa
md
anderson
cancer
center
radiat
oncolog
houston
usa
children
hospit
pediatr
oncolog
houston
usa
children
hospitalacadem
medic
center
univers
amsterdam
public
health
epidemiolog
amsterdam
netherland
children
hospitalacadem
medic
center
univers
amsterdam
pediatr
oncolog
amsterdam
netherland
rochest
medic
center
radiat
oncolog
rochest
usa
univers
texa
md
anderson
cancer
center
medic
physic
houston
usa
backgroundobject
aim
pentec
pulmonari
task
forc
quantifi
dosimetr
factor
develop
acut
late
pulmonari
toxic
among
children
treat
cancer
designmethod
comprehens
search
pubm
conduct
develop
predict
model
lung
injuri
follow
radiat
pediatr
cancer
popul
radiat
pneumon
rp
grade
base
common
terminolog
criteria
advers
event
ctcae
radiat
therapi
oncolog
group
rtog
european
organ
research
treatment
cancer
eortc
criteria
clinic
outcom
report
use
ctcae
questionnair
respons
lung
dose
use
rp
analysi
calcul
histogram
dvh
data
result
abstract
identifi
paper
detail
treatment
toxic
data
select
review
nine
paper
dvh
data
use
model
pool
acut
late
rp
cohort
treat
includ
patient
respect
age
grade
rp
patient
receiv
thorac
rt
acut
rang
late
rang
clinic
outcom
data
includ
patient
treat
age
although
patient
often
asymptomat
abnorm
pft
correl
dose
larg
studi
suggest
relationship
dose
gy
abnorm
lung
function
clinic
outcom
pulmonari
death
bleomycin
dose
use
contemporari
treatment
regimen
appear
contribut
advers
pulmonari
outcom
conclus
acut
late
pulmonari
toxic
pediatr
patient
treat
thorac
radiat
appear
low
frequenc
sever
contemporari
pediatr
popul
multivari
analysi
dvh
contribut
factor
would
greatli
improv
trial
registri
continu
pulmonari
function
late
adulthood
requir
vennarini
b
ip
gs
protontherapi
trento
itali
bambino
children
hospit
depart
pediatr
hematolog
oncolog
rome
itali
bambino
children
hospit
depart
neurosci
neurosurgeri
unit
rome
itali
bambino
children
hospit
neuroradiolog
imag
depart
rome
itali
backgroundobject
proton
therapi
pt
use
extens
treat
paediatr
cerebr
tumour
medulloblastoma
current
public
includ
limit
case
radionecrosi
use
pt
paediatr
patient
studi
compar
find
publish
data
median
insurg
equal
month
rang
state
see
sf
kralik
er
al
j
neuroradiol
aug
designmethod
retrospect
analysi
paediatr
patient
high
risk
medulloblastoma
treat
pt
axi
dose
gy
rbe
follow
higher
dose
posterior
cranial
fossa
gy
rbe
paediatr
patient
underw
post
surgeri
pt
primari
tumour
intens
myelobl
chemotherapi
potenti
risk
factor
prematur
radionecrosi
patient
high
risk
medulloblastoma
also
underw
brain
spine
mri
prior
post
pt
mri
imag
carri
rm
magnetom
skyra
siemen
healthcar
erlangen
germani
axial
sagitt
tse
axial
coron
tse
axial
flair
axial
dwi
adc
map
intraven
administ
paramagnet
contrast
result
studi
demonstr
via
median
follow
month
rang
record
case
radionecrosi
per
criteria
state
current
public
two
patient
demonstr
divers
area
constrast
enhanc
follow
consid
patholog
signific
conclus
paediatr
patient
high
risk
medulloblastoma
underw
pt
treatment
present
lower
risk
prematur
radionecrosi
respect
data
current
avail
offici
public
studi
ongo
object
continu
confirm
emerg
data
preliminari
analysi
p
khullar
hospit
research
institut
radiat
oncolog
new
delhi
india
hospit
radiat
oncolog
gurugram
india
backgroundobject
pediatr
nasopharyng
carcinoma
npc
account
pediatr
tumor
limit
data
clinic
featur
treatment
result
prognost
factor
outcom
late
toxic
pediatr
npc
india
designmethod
analysi
carri
consecut
patient
pediatr
npc
regist
center
may
april
year
patient
treat
neoadjuv
chemoradiotherapi
ctrt
cisplatin
follow
cisplatin
concurr
ctrt
cisplatin
result
median
age
year
rang
year
male
femal
ratio
median
durat
symptom
month
rang
year
ajcc
stage
distribut
stage
stage
stage
distant
metastasi
present
seen
patient
complet
respons
seen
overal
respons
observ
case
median
time
month
overal
surviv
os
rate
control
rate
distant
surviv
rate
respect
recurr
distant
metastas
multivari
analysi
p
stage
iv
p
independ
advers
prognost
factor
os
signific
reduct
trismu
vs
p
xerostomia
v
p
observ
patient
treat
intens
modul
radiotherapi
imrt
conclus
patient
pediatr
npc
present
advanc
stage
diseas
center
differ
respons
rate
outcom
seen
two
schedul
ctrt
neoadjuv
vs
concurr
local
control
could
achiev
major
patient
howev
distant
metastasi
common
reason
relaps
late
toxic
less
imrt
biswa
r
r
k
india
institut
medic
scienc
radiotherapi
oncolog
new
delhi
india
india
institut
medic
scienc
medic
oncolog
new
delhi
india
india
institut
medic
scienc
otorhinolaryngolog
new
delhi
india
backgroundobject
esthesioneuroblastoma
rare
cancer
aris
neuroendocrin
cell
olfactori
epithelium
constitut
sinonas
tumour
designmethod
data
pertain
paediatr
adolesc
patient
esthesioneuroblastoma
attend
institut
abstract
retrospect
chart
review
result
identifi
patient
esthesioneuroblastoma
median
age
present
year
rang
year
male
femal
ratio
common
symptom
includ
nasal
obstruct
epistaxi
proptosi
visual
symptom
headach
patient
clinicoradiolog
examin
patient
modifi
kadish
b
c
stage
chemotherapi
administ
patient
neoadjuv
chemotherapi
given
cisplatin
etoposid
regimen
neuroblastoma
protocol
cyclophosphamid
doxorubicin
cisplatin
etoposid
surgeri
done
rhinotomi
excis
tumour
craniofaci
resect
radiotherapi
rt
deliv
intent
cur
palli
patient
respect
median
rt
dose
week
weekli
concurr
cisplatin
ad
patient
mean
month
patient
diseas
progress
lead
death
common
pattern
failur
neck
brain
spinal
drop
metastas
last
patient
complet
partial
respons
patient
stabl
progress
diseas
median
overal
surviv
os
reach
estim
median
progress
free
surviv
pf
month
year
actuari
rate
os
pf
respect
conclus
major
paediatr
adolesc
patient
esthesioneuroblastoma
present
advanc
stage
develop
nation
multimod
manag
form
surgeri
follow
radiotherapi
recommend
kadish
b
tumour
chemotherapi
assum
import
role
kadish
c
tumour
hara
n
k
g
n
h
k
univers
graduat
school
medicin
pediatr
maebashi
japan
citi
univers
hospit
pediatr
yokohama
japan
research
institut
child
health
develop
pediatr
hematolog
oncolog
research
tokyo
japan
children
medic
center
hematolog
oncolog
shibukawa
japan
center
child
health
develop
children
cancer
tokyo
japan
prefectur
univers
medicin
molecular
diagnost
therapeut
kyoto
japan
marianna
univers
school
medicin
pediatr
kawasaki
japan
hospit
organ
osaka
nation
hospit
pediatr
osaka
japan
hospit
nagoya
medic
center
clinic
research
center
nagoya
japan
univers
medic
scienc
pediatr
otsu
japan
univers
graduat
school
medicin
human
health
scienc
kyoto
japan
backgroundobject
prognost
marker
pediatr
acut
myeloid
leukemia
aml
inv
identifi
yet
designmethod
analyz
molecular
clinic
characterist
pediatr
aml
patient
enrol
japanes
trial
surviv
analys
reveal
excel
overal
surviv
os
patient
howev
surviv
ef
remain
unsatisfactori
thu
compar
characterist
patient
without
event
treatment
n
respect
event
studi
includ
death
relaps
second
malign
result
median
age
frequenc
nra
mutat
significantli
differ
two
group
year
vs
year
p
vs
p
respect
consequ
perform
surviv
analys
patient
accord
age
nra
mutat
statu
defin
year
old
cutoff
patient
age
year
patient
age
surviv
analys
reveal
significantli
wors
ef
cumul
incid
relaps
cir
patient
age
year
age
year
vs
p
vs
p
respect
convers
patient
n
significantli
better
ef
cir
patient
n
vs
p
vs
respect
accordingli
patient
age
year
n
worst
outcom
ef
cir
conclus
age
statu
may
use
prognost
marker
pediatr
aml
util
marker
investig
prevent
relaps
stem
cell
transplant
liu
l
c
x
g
l
c
jiaotong
univers
shanghai
children
medic
center
shanghai
china
backgroundobject
leukemia
mll
multifari
partner
gene
lead
aggress
leukemia
dismal
outcom
designmethod
use
target
sequenc
examin
total
childhood
acut
leukemia
case
includ
patient
acut
lymphoblast
leukemia
patient
acut
myeloid
leukemia
aml
result
precis
mll
breakpoint
complet
rearrang
character
novel
mll
fusion
identifi
total
patient
display
singl
direct
mll
fusion
gene
carri
singl
reciproc
fusion
reciproc
mll
fusion
allel
remain
case
complex
transloc
homozyg
disrupt
chromosom
two
breakpoint
mll
allel
delet
function
region
total
patient
aml
receiv
chemotherapi
median
year
unexpectedli
found
children
reciproc
mll
fusion
exhibit
rel
favor
outcom
compar
children
complex
transloc
singl
direct
mll
fusion
allel
versu
p
function
featur
truncat
mll
fusion
protein
may
give
explan
favour
clinic
prognosi
reciproc
mll
transloc
conclus
conclus
comprehens
analysi
target
sequenc
ng
provid
detail
molecular
inform
help
precis
stratifi
treatment
clinic
prognosi
determin
shen
r
l
j
children
medic
center
pediatr
hematolog
oncolog
shanghai
china
children
medic
center
hematolog
oncolog
shanghai
china
backgroundobject
transcript
factor
modul
gene
express
target
scan
data
found
bind
bind
motif
promotor
region
explor
acut
myeloid
leukemia
aml
microarray
databas
confirm
express
consist
aml
patient
sampl
confirm
find
quantit
express
pediatr
aml
sampl
shanghai
children
medic
center
expect
case
higher
moreov
express
independ
poor
prognost
factor
overal
surviv
compar
patient
higher
lower
express
designmethod
understand
role
leukemogen
function
fusion
gene
knock
express
cell
shrna
growth
cell
vitro
significantli
inhibit
cell
cycl
exit
apoptosi
transform
fetal
liver
cell
condit
knockout
mice
leukemia
model
retroviru
conduct
express
induc
delet
delay
full
blown
leukemia
vivo
result
overal
surviv
prolong
day
median
vs
day
guanin
nucleotid
exchang
factor
rhoa
gtpase
delet
decreas
activ
express
phosphoryl
one
rock
kinas
substrat
spleen
cell
leukem
mice
cultur
vitro
rock
inhibitor
significantli
decreas
cell
prolifer
mimic
knockout
phenotyp
combin
tamoxifen
treat
cell
almost
erad
aliv
leukemia
cell
ninth
day
delay
leukemogenesi
vivo
conclus
find
suggest
transcript
target
fusion
protein
play
essenti
role
leukemogenesi
pathway
may
serv
new
therapeut
target
aml
kimura
k
h
k
k
r
n
k
j
univers
tokyo
depart
pediatr
tokyo
japan
univers
depart
pediatr
hiroshima
japan
school
kyoto
univers
depart
patholog
tumor
biolog
kyoto
japan
research
institut
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
children
medic
center
depart
hematologyoncolog
saitama
japan
hokuyu
hospit
depart
pediatr
sapporo
japan
univers
hospit
depart
pediatr
tsu
japan
univers
graduat
school
medicin
depart
pediatr
suita
japan
prefectur
univers
graduat
school
medic
scienc
depart
pediatr
kyoto
japan
hematolog
oncolog
miyagi
children
hospit
sendai
japan
luke
intern
hospit
depart
pediatr
tokyo
japan
hospit
organ
nagoya
medic
center
clinic
research
center
nagoya
japan
univers
depart
pediatr
tokyo
japan
medic
univers
tokyo
human
genom
center
tokyo
japan
backgroundobject
aberr
constitut
activ
signal
major
oncogen
event
acut
lymphoblast
leukemia
classifi
two
pattern
activ
lia
impair
degrad
id
sever
type
aberr
report
activ
pattern
far
studi
explor
clinicopatholog
relev
aberr
designmethod
reanalyz
previous
publish
data
sequenc
whole
transcriptom
sequenc
wt
defin
subclon
variant
allel
frequenc
result
total
detect
aberr
activ
signal
case
subclon
mutat
observ
singl
nucleotid
variat
heterodimer
domain
frequent
follow
pest
domain
mutat
lia
id
pattern
detect
mutat
mutual
exclus
within
lia
id
pattern
detect
three
case
snv
utr
four
intragen
delet
del
miss
exon
two
fusion
confirm
del
activ
signal
luciferas
report
assay
analysi
frequenc
cluster
etp
tlx
reveal
alter
frequent
detect
tlx
wherea
less
frequent
fusion
observ
despit
low
rate
importantli
case
harbor
subclon
mutat
show
significantli
wors
outcom
p
prognost
differ
case
without
mutat
conclus
observ
alter
detect
rare
intragen
delet
fusion
recurr
addit
subclon
aberr
might
relev
unfavor
outcom
result
might
use
develop
new
therapeut
strategi
pediatr
patient
c
liang
x
c
w
l
l
x
first
affili
hospit
sun
univers
pediatr
guangzhou
china
backgroundobject
signific
number
childhood
present
dismal
prognosi
studi
evalu
impact
microrna
outcom
childhood
context
clinic
molecular
prognost
explor
mechan
action
designmethod
microrna
express
profil
childhood
investig
geo
express
bone
marrow
pair
case
two
differ
time
point
initi
diagnosi
first
relaps
statu
detect
bioinformat
softwar
dual
luciferas
report
assay
appli
predict
verifi
target
furthermor
four
human
cell
line
transfect
mimic
inhibitor
correspond
control
cell
viabil
cell
apoptosi
analyz
use
flow
cytometri
assay
protein
express
analyz
use
western
blot
result
total
differenti
express
mirna
identifi
patient
compar
healthi
subject
patient
higher
express
shorter
overal
surviv
shorter
surviv
higher
cumul
incid
relaps
interestingli
statist
signific
overal
surviv
surviv
tradit
p
express
associ
gene
express
profil
enrich
gene
involv
cellular
mechan
deregul
eg
mtor
ampk
demonstr
higher
express
level
lower
express
level
significantli
promot
prolifer
inhibit
apoptosi
cell
line
jurket
dual
luciferas
report
system
confirm
potenti
target
conclus
express
may
well
contribut
improv
prognost
stratif
children
may
play
role
pathogenesi
disord
target
r
bakhshi
r
v
rajguru
colleg
appli
univers
delhi
biomed
scienc
new
delhi
india
india
institut
medic
scienc
medic
oncolog
new
delhi
india
india
institut
medic
scienc
biostatist
new
delhi
india
backgroundobject
role
variat
mitochondri
dna
particularli
region
acut
myeloid
leukemia
aml
remain
investig
studi
aim
assess
pattern
variat
mitochondri
region
aml
patient
evalu
associ
express
gene
designmethod
denovo
aml
patient
year
age
june
bone
marrow
sampl
buccal
swab
sampl
mother
blood
sampl
collect
baselin
dna
extract
pcr
loop
region
subsequ
sanger
sequenc
perform
rna
extract
patient
analyz
use
real
time
pcr
rel
gene
express
four
mitochondri
dna
encod
gene
viz
nicotinamid
adenin
dineucleotid
dehydrogenas
subunit
cytochrom
b
cytb
cytochrom
c
oxidas
atp
synthetas
subunit
result
patient
includ
gene
express
analyz
patient
total
variat
found
posit
variat
germlin
somat
posit
identifi
probabl
hotspot
region
variat
per
posit
chang
commonest
variat
germlin
well
somat
variat
g
base
appear
stabl
nucleotid
least
number
singl
base
substitut
wherea
appear
prone
variat
germlin
commonest
cytb
gene
express
significantli
higher
variat
posit
express
cytb
significantli
lower
variat
posit
variat
posit
significantli
decreas
express
posit
attenu
express
conclus
first
studi
evalu
type
overal
pattern
variat
region
segreg
somat
germlin
variat
effect
variat
mitochondri
encod
gene
novel
inform
aml
genom
g
narula
memori
center
pediatr
oncolog
mumbai
india
memori
center
impacct
pediatr
oncolog
mumbai
india
backgroundobject
sinc
group
put
place
comprehens
measur
includ
financi
accommod
transfus
nutrit
support
ensur
patient
deni
treatment
ground
measur
cover
new
registr
acut
lymphoblast
leukemia
minim
residu
diseas
mrd
base
protocol
implement
onward
retrospect
audit
impact
measur
outcom
designmethod
record
children
regist
centr
jan
dec
retrospect
review
patient
incomplet
data
prior
treatment
refer
treatment
institut
exclud
assess
impact
support
care
divid
period
two
incomplet
complet
also
protocol
financi
support
patient
categoris
complet
support
cs
nb
support
ns
result
patient
elig
analysi
cs
treatment
refus
abandon
tr
rate
fell
overal
surviv
os
patient
show
signific
improv
p
respect
os
entir
cohort
respect
outcom
base
support
need
patient
improv
across
categori
differ
also
narrow
os
conclus
holist
measur
could
address
need
regist
patient
improv
overal
outcom
equit
manner
diminish
impact
statu
adopt
improv
outcom
tertiari
cancer
centr
india
x
chen
x
b
w
x
blood
diseas
hospit
chines
academi
medic
scienc
cam
depart
paediatr
haematolog
tianjin
china
backgroundobject
china
children
leukemia
group
cclg
conduct
studi
acut
lymphoblast
leukemia
designmethod
analyz
outcom
patient
treat
accord
platform
center
result
complet
remiss
rate
patient
death
remiss
overal
surviv
os
rate
children
respect
os
rate
standard
risk
middl
risk
high
risk
group
respect
p
last
follow
develop
second
neoplasm
patient
relaps
high
risk
group
patient
receiv
stem
cell
transplant
first
complet
remiss
stage
protocol
tyrosin
kinas
inhibitor
tki
nt
regularli
combin
chemotherapi
patient
bcrabl
patient
treat
tki
os
conclus
surviv
rate
children
increas
approxim
substanti
progress
treatment
strategi
studi
group
seem
lower
surviv
rate
develop
countri
patient
bcrabl
poor
outcom
lower
rate
tki
use
increas
number
transplant
may
increas
cure
rate
reduc
relaps
high
risk
group
patient
p
de
alarcon
em
p
f
c
p
p
j
illinoi
colleg
medicin
st
jude
children
research
hospit
depart
pediatr
peoria
usa
oncolog
guatemala
guatemala
manuel
de
jesu
rivera
oncolog
managua
nicaragua
nacion
de
benjamin
bloom
oncolog
san
salvador
el
salvador
jude
children
research
hospit
oncolog
memphi
usa
backgroundobject
surviv
ef
overal
surviv
os
hl
middl
countri
lmic
improv
still
mani
fail
therapi
chemotherapi
follow
stem
cell
rescu
cure
patient
therapi
alway
avail
lmic
rescu
children
ahopca
design
rescu
regimen
ifosphamid
carboplatin
etoposid
ice
report
preliminari
result
one
ahopca
center
designmethod
children
refractoryresist
rr
relaps
hl
treat
defin
rr
subject
achiev
respons
present
relaps
within
three
month
complet
therapi
earli
relaps
er
three
month
complet
therapi
late
relaps
lr
recur
one
year
complet
therapi
ice
regimen
consist
etoposid
day
carboplatin
day
ifosfamid
day
involv
field
radiotherapi
cgi
without
cycl
repeat
everi
day
four
six
cycl
respons
achiev
result
ahopca
center
treat
hl
rr
relaps
rr
lr
diseas
time
analysi
children
aliv
dead
abandon
therapi
lost
ef
cohort
os
ef
os
er
lr
respect
ef
rr
relaps
hl
differ
conclus
limit
data
conclud
children
late
relaps
hl
rescu
ice
base
regimen
set
lmic
children
rr
less
like
rescu
prasad
g
g
r
b
memori
hospit
paediatr
oncolog
mumbai
india
enterpris
clinic
densitometri
mumbai
india
tilak
municip
medic
colleg
gener
hospit
paediatr
mumbai
india
memori
hospit
biostatist
mumbai
india
backgroundobject
half
children
malign
countri
lmic
malnourish
lead
poor
treatment
toler
higher
toxic
lower
surviv
earli
nutrit
intervent
may
obviat
effect
rutf
establish
medic
nutrit
therapi
howev
efficaci
data
children
malign
lack
designmethod
sever
moder
malnourish
sammam
children
cancer
age
year
underw
stratifi
random
receiv
either
rutf
standard
nutrit
therapi
snt
week
dietari
intak
nutrit
statu
weight
height
bodi
mass
index
age
bodi
composit
use
dual
energi
absorptiometri
dexa
scan
health
relat
qualiti
life
hrqol
health
util
treatment
toler
compar
baselin
clinic
monitor
done
weekli
week
monthli
month
result
children
arm
enrol
evalu
median
age
f
children
compar
greater
week
baselin
weight
vs
like
achiev
normal
nutrit
statu
week
month
respect
rutf
enabl
increas
protein
energi
consumpt
increas
hrqol
score
week
children
less
treatment
delay
intervent
period
vs
p
vs
p
well
fewer
episod
febril
neutropenia
vs
shorter
admiss
period
per
episod
vs
conclus
rutf
effect
well
toler
nutrit
intervent
sammam
children
malign
improv
nutrit
statu
qualiti
life
reduc
toxic
chemotherapi
compar
snt
benefit
maintain
time
rutf
immens
potenti
improv
treatment
outcom
supplement
strongli
consid
intens
phase
treatment
v
gota
v
r
kc
h
centr
research
educ
cancer
tata
memori
centr
clinic
pharmacolog
navi
mumbai
india
memori
centr
medic
oncolog
mumbai
india
memori
centr
medic
ondolog
mumbai
india
backgroundobject
essenti
medicin
qualiti
gener
brand
matter
concern
compar
qualiti
variou
brand
avail
india
designmethod
nine
commonli
use
gener
brand
identifi
qualiti
assess
test
formul
asparaginas
activ
use
micropl
base
colorimetr
method
ii
comparison
trough
asparaginas
activ
children
receiv
induct
chemotherapi
administ
dose
im
everi
day
per
protocol
hour
trough
blood
sampl
patient
drawn
next
dose
result
one
hundr
eighti
nine
patient
enrol
march
may
age
medianrang
year
standardintermediatehigh
risk
case
iu
two
hundr
thirti
four
blood
sampl
analyz
asparaginas
activ
number
sampl
analyz
brand
rang
median
averag
asparaginas
activ
brand
rang
ul
sampl
lowest
activ
brand
ul
highest
activ
brand
median
asparaginas
activ
correspond
ul
proport
patient
fail
achiev
predefin
threshold
activ
ul
rang
highest
activ
brand
lowest
activ
brand
median
direct
analysi
three
formul
comparison
medac
asparaginas
innov
show
asparaginas
activ
gener
rang
innov
conclus
wide
variat
asparaginas
activ
brand
six
nine
brand
test
markedli
inferior
patient
fail
achiev
trough
activ
ul
rais
seriou
concern
qualiti
gener
essenti
medicin
need
pharmacovigil
area
n
faruqui
b
c
r
r
sydney
school
public
health
sydney
australia
sydney
faculti
medicin
sydney
australia
univers
school
public
health
global
health
boston
usa
ngo
medic
project
delhi
india
research
independ
research
delhi
india
super
special
hospit
paediatr
oncolog
delhi
india
georg
institut
global
health
offic
chief
scientist
sydney
australia
backgroundobject
limit
access
essenti
medicin
em
treat
chronic
diseas
major
challeng
particularli
countri
although
india
largest
manufactur
gener
medicin
avail
afford
price
guarante
assess
avail
price
em
treat
childhood
cancer
delhi
india
designmethod
use
modifi
health
action
intern
methodolog
collect
data
avail
price
em
specif
dosag
em
studi
control
data
collect
pharmaci
survey
anchor
hospit
public
privat
treat
childhood
cancer
random
sampl
retail
pharmaci
locat
near
survey
anchor
median
price
ratio
mpr
calcul
compar
consum
price
intern
refer
price
irp
result
averag
survey
anchor
area
hospit
plu
retail
pharmaci
em
avail
least
one
dosag
form
avail
em
control
em
respect
inject
inject
unavail
mean
avail
facil
type
em
retail
pharmaci
public
privat
mpr
except
inject
line
target
consum
pay
time
irp
estim
chemotherapi
cost
base
consum
price
treat
child
leukaemia
inr
usd
hodgkin
diseas
inr
usd
india
incom
respect
conclus
em
found
survey
anchor
area
howev
mean
avail
less
control
medicin
meet
target
avail
across
facil
local
context
cost
chemotherapi
medicin
appear
afford
howev
greater
burden
cost
may
lie
elsewher
queudevil
u
hm
h
von
p
p
r
hospit
children
hospit
gener
hematologyoncolog
germani
stuttgart
olgahospit
pediatr
hematolog
immunolog
stuttgart
germani
hospit
frankfurt
depart
children
adolesc
frankfurt
germani
univers
medic
center
depart
pediatr
oncologyhematolog
berlin
germani
medic
center
kiel
depart
gener
pediatr
kiel
germani
von
hauner
univers
children
lmu
depart
pediatr
oncolog
stem
cell
transplant
munich
germani
backgroundobject
pediatr
patient
relaps
refractori
acut
lymphoblast
leukemia
extrem
poor
prognosi
blinatumomab
bispecif
engag
antibodi
construct
simultan
bind
cytotox
lead
lysi
normal
malign
designmethod
report
retrospect
analysi
experi
blinatumomab
patient
relaps
refractori
pediatr
precursor
result
median
age
onset
therapi
year
year
eighti
percent
patient
undergon
least
one
hematopoiet
stem
cell
transplant
hsct
prior
therapi
blinatumomab
patient
receiv
antibodi
therapi
state
open
relaps
despit
high
tumor
load
patient
start
immunotherapi
total
patient
show
primari
respons
blinatumomab
addit
patient
respond
second
cycl
predomin
side
effect
consist
febril
reaction
almost
patient
nearli
half
defin
cytokin
releas
syndrom
cr
major
cr
low
grade
easili
manag
neurotox
seen
patient
duringaft
first
patient
second
cycl
date
seven
patient
aliv
remiss
mean
surviv
month
month
blinatumomab
enabl
transit
hsct
three
survivor
one
patient
low
blast
count
start
blinatumomab
remiss
without
hsct
conclus
despit
heavi
pretreat
patient
sever
advers
event
rare
respons
rate
encourag
patient
signific
proport
patient
respond
second
treatment
cycl
blinatumomab
promis
new
agent
front
line
treatment
current
investig
pediatr
random
control
clinic
trial
z
zhen
j
j
f
j
x
univers
cancer
center
pediatr
oncolog
guangzhou
china
backgroundobject
data
regard
use
rituximab
children
adolesc
burkitt
lymphoma
bl
limit
studi
retrospect
analyz
effect
rituximab
children
adolesc
bl
designmethod
patient
underw
chemotherapi
accord
revis
protocol
rituximab
administ
dose
day
cycl
result
total
patient
includ
stratifi
number
dose
rituximab
patient
group
rituximab
group
dose
rituximab
group
dose
rituximab
respect
surviv
ef
rate
group
group
group
respect
patient
diseas
ef
rate
patient
treat
rituximab
treat
without
rituximab
patient
diseas
relaps
rate
group
group
group
respect
p
conclus
rituximab
highli
effect
children
adolesc
bl
optim
number
dose
patient
bl
anastasopoul
r
im
g
ah
institut
depart
women
children
health
stockholm
sweden
univers
depart
children
adolesc
oulu
finland
univers
hospit
depar
pediatr
hematologyoncolog
oslo
norway
hospit
rigshospitalet
depart
pediatr
adolesc
medicin
copenhagen
denmark
univers
hospit
depart
pediatr
vilniu
lithuania
tartu
depart
hematolog
oncolog
tartu
estonia
iceland
depart
pediatr
iceland
uppsala
depart
women
children
health
uppsala
sweden
backgroundobject
posterior
revers
encephalopathi
syndrom
pre
clinicoradiolog
entiti
increasingli
recogn
among
pediatr
patient
acut
lymphoblast
leukemia
hypothes
trigger
treatment
aim
explor
clinic
cours
pre
pediatr
patient
treat
accord
nordic
protocol
nopho
identifi
risk
factor
pre
designmethod
studi
group
includ
patient
year
age
diagnosi
b
bcp
five
nordic
two
baltic
countri
patient
treat
accord
nopho
patient
identifi
uniqu
registr
system
inform
regard
detail
phenotyp
pre
collect
questionnair
focus
central
nervou
system
toxic
treatment
result
pre
diagnos
patient
cumul
incid
pre
one
month
ci
ci
one
year
cox
regress
identifi
age
signific
predictor
pre
hr
increas
age
ci
risk
higher
bcp
hr
vs
ci
seizur
occur
patient
hypertens
present
patient
encephalopathi
third
common
symptom
patient
conclus
seizur
hypertens
encephalopathi
common
symptom
pre
patient
treat
nopho
protocol
includ
high
dose
methotrex
vincristin
steroid
first
year
treatment
incidens
pre
highest
studi
need
identifi
underli
mechan
pre
patient
well
neurocognit
outcom
tomizawa
k
h
n
k
h
center
child
health
develop
divis
leukemia
children
cancer
center
tokyo
japan
center
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
univers
depart
hematolog
oncolog
kyoto
japan
univers
graduat
school
medicin
depart
pediatr
osaka
japan
univers
medic
scienc
depart
pediatr
otsu
japan
univers
depart
human
health
scienc
kyoto
japan
children
medic
center
depart
hematologyoncolog
saitama
japan
kyushu
cancer
center
depart
pediatr
fukuoka
japan
children
hospit
depart
hematolog
oncolog
chiba
japan
citi
univers
hospit
depart
pediatr
tokyo
japan
children
hospit
depart
hematolog
oncolog
shizuoka
japan
women
children
hospit
depart
hematologyoncolog
osaka
japan
data
center
hematopoiet
cell
transplant
data
center
nagoya
japan
citi
hospit
depart
pediatr
kyoto
japan
backgroundobject
cytogenet
abnorm
signific
prognost
factor
acut
myeloid
leukemia
aml
standard
care
alloc
patient
aml
cytogenet
abnorm
allogen
hematopoiet
stem
cell
transplant
howev
controversi
whether
truli
improv
outcom
patient
designmethod
data
children
adolesc
age
year
receiv
first
first
second
remiss
extract
nationwid
hsct
registri
japan
societi
hematopoiet
cell
transplant
patient
congenit
abnorm
eg
syndrom
secondari
aml
andor
lack
cytogenet
data
exclud
defin
aml
complex
karyotyp
inv
andor
patient
inv
inelig
outcom
patient
retrospect
evalu
result
surviv
ef
overal
surviv
os
rate
ci
respect
patient
univari
analysi
cytogenet
subgroup
signific
impact
ef
os
p
rate
especi
fourteen
patient
show
extrem
poor
outcom
ef
os
addit
older
age
year
old
myeloabl
condit
irradi
grade
acut
diseas
gvhd
associ
inferior
os
donor
type
occurr
chronic
gvhd
affect
outcom
multivari
analysi
reveal
associ
increas
overal
mortal
hazard
p
conclus
heterogen
outcom
among
cytogenet
subgroup
outcom
patient
certain
subgroup
case
extrem
poor
even
remiss
develop
novel
therapi
urgent
requir
h
abdel
rahman
say
r
abdel
n
el
e
cancer
cairo
chidren
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
cairo
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
cairo
chidren
cancer
hospit
egypt
patholog
cairo
egypt
cancer
cairo
chidren
cancer
hospit
egypt
radiodiagnosi
cairo
egypt
cancer
hospit
egypt
research
cairo
egypt
backgroundobject
aim
studi
report
respons
rate
toxic
profil
line
chemotherapi
gemcitabin
vinorelbin
gemvin
primari
refractoryrelaps
hl
year
period
designmethod
retrospect
analysi
includ
patient
receiv
salvag
gemvin
follow
abvd
radiotherapi
line
follow
ice
line
chemotherapi
patient
diagnos
treat
children
cancer
hospit
egypt
result
patient
regist
relaps
progress
diseas
receiv
ice
second
line
chemotherapi
fail
second
line
receiv
third
line
four
patient
exclud
analysi
receiv
type
chemotherapi
patient
receiv
gemvin
includ
studi
male
femal
mean
age
year
common
patholog
subtyp
nodular
sclerosi
one
patient
stage
stage
ii
stage
iii
stage
iv
major
high
risk
patient
sixteen
patient
late
relaps
year
earli
relaps
year
progressiverefractori
less
month
chemotherapi
cycl
rang
mean
thirteen
patient
respond
gemvin
underw
autolog
hematopoiet
stem
cell
transplant
progress
continu
treatment
palli
basi
eight
patient
die
due
diseas
progress
chemotherapi
toxic
year
overal
surviv
respond
patient
multivari
analysi
includ
sex
stage
risk
stratif
type
relaps
show
statist
signific
conclus
gemcitabin
vinorelbin
safe
given
line
chemotherapi
relaps
primari
refractori
hl
finkbein
v
k
g
children
hospit
pediatr
hematologyoncologytranspl
calgari
canada
backgroundobject
epstein
barr
viru
ebv
infect
reactiv
common
occurr
allogen
hematopoiet
stem
cell
transplant
hsct
sought
determin
overal
incid
ebv
reactiv
lymphoprolif
diseas
ptld
children
designmethod
retrospect
chart
review
children
underw
allogen
hsct
alberta
children
hospit
calgari
alberta
januari
januari
result
period
allogen
hsct
patient
perform
malign
condit
overal
incid
ebv
level
overal
incid
ebv
greater
iuml
incid
ptld
use
globulin
atg
condit
significantli
associ
high
ebv
titr
ebv
reactiv
associ
presenc
ebv
posit
donor
neither
recipi
ebv
statu
presenc
mismatch
ebv
statu
donor
recipi
signific
patient
receiv
peripher
blood
stem
cell
pbsc
higher
risk
ebv
reactiv
compar
cord
blood
bone
marrow
use
cord
blood
protect
multivari
analysi
use
atg
presenc
ebv
posit
donor
remain
signific
factor
patient
receiv
treatment
ebv
level
greater
iuml
receiv
rituximab
part
therapi
associ
ebv
reactiv
develop
graft
versu
host
diseas
gvhd
graft
failur
death
conclus
ebv
reactiv
common
children
undergon
allogen
hsct
overal
incid
greater
iuml
statist
associ
use
atg
ebv
posit
donor
use
pbsc
develop
featur
ptld
uncommon
treatment
initi
onset
symptom
c
grosset
de
bordeaux
bordeaux
franc
backgroundobject
surgeri
treatment
hepatoblastoma
hb
current
guarante
surviv
patient
howev
import
challeng
remain
diagnos
high
risk
tumor
identifi
relev
target
pathway
offer
new
therapeut
avenu
previous
two
molecular
subclass
hepatoblastoma
tumor
describ
name
subgroup
poorest
prognosi
advanc
tumor
stage
worst
overal
surviv
rate
associ
signatur
discrimin
two
tumor
subgroup
propos
transfer
clinic
routin
designmethod
address
issu
perform
rna
sequenc
tumor
match
normal
liver
sampl
patient
result
transcript
profil
separ
hb
three
distinct
subgroup
name
identifi
concis
signatur
vim
characterist
prolif
tumor
differenti
express
gene
confirm
expand
cohort
immunohistochemistri
also
reveal
signific
overexpress
gene
involv
fanconi
anemia
fa
pathway
subgroup
investig
abil
sever
describ
fa
inhibitor
block
grow
hb
cell
vitro
vivo
demonstr
bortezomib
proteasom
inhibitor
strongli
impair
prolifer
surviv
hb
cell
line
vitro
block
fa
pathway
associ
dna
repair
significantli
imped
hb
growth
vivo
conclus
conclus
highli
prolifer
subtyp
character
gene
fa
pathway
activ
hb
therapeut
arsen
could
includ
bortezomib
treatment
patient
aggress
tumor
f
neumann
l
b
c
b
v
hospit
pediatr
oncolog
depart
franc
kremlin
hospit
pediatr
radiolog
depart
le
kremelin
franc
roussi
cancer
campu
depart
oncolog
children
villejuif
franc
necker
depart
patholog
pari
franc
kremlin
hospit
depart
patholog
le
kremelin
franc
kremlin
hospit
pediatr
surgeri
depart
le
kremelin
franc
backgroundobject
aim
studi
assess
prognost
radiolog
characterist
lung
nodul
children
metastat
hepatoblastoma
hb
designmethod
patient
treat
franc
includ
central
databas
hepatobio
elig
studi
pulmonari
tomographi
scan
central
review
diagnost
inform
number
size
later
evolut
treatment
collect
data
histopatholog
chemotherapi
regimen
record
overal
surviv
os
event
free
surviv
ef
analyz
univari
analysi
result
period
patient
metastat
hb
includ
patient
treat
studi
overal
surviv
os
event
free
surviv
ef
respect
patient
less
nodul
increas
ef
ci
os
ci
vs
ci
ci
patient
nodul
ef
os
respect
patient
nodul
ef
os
vs
ef
ci
os
ci
p
ef
os
respect
patient
bilater
nodul
ef
ci
os
wherea
patient
unilater
lesion
ef
os
conclus
children
metastat
hb
poor
prognosi
variou
present
diseas
seem
exist
among
patient
light
metastat
diseas
better
prognosi
treatment
intens
could
adapt
regard
burden
metastat
diseas
limit
toxiti
long
term
multivari
analysi
must
perform
confirm
result
author
thank
hepatobio
databas
scientif
committe
ackermann
b
c
c
f
f
r
r
r
f
j
f
j
hospit
cologn
experiment
pediatr
oncolog
cologn
germani
cologn
translat
genom
cologn
germani
hospit
cologn
pediatr
oncolog
hematolog
cologn
germani
pediatr
oncolog
hematolog
berlin
germani
univers
center
medic
genet
ghent
belgium
cologn
depart
patholog
cologn
germani
pittsburgh
cancer
institut
upci
pharmacolog
chemic
biolog
pittsburgh
usa
depart
medic
oncolog
essen
germani
cancer
research
center
neuroblastoma
genom
heidelberg
germani
backgroundobject
recent
genom
transcriptom
profil
studi
neuroblastoma
shed
light
cancer
gene
mutat
frequenc
structur
genom
rearrang
copi
number
alter
tumor
type
howev
none
abl
convert
data
coher
model
explain
pathogenesi
diverg
subtyp
separ
case
spontan
regress
occur
whose
diseas
progress
designmethod
determin
molecular
basi
favor
advers
diseas
cours
perform
massiv
parallel
sequenc
untreat
neuroblastoma
sequenc
target
sequenc
determin
telomer
mainten
mechan
case
addit
perform
target
sequenc
neuroblastoma
relaps
sampl
result
detect
genom
alter
gene
relat
ra
pathway
patient
presenc
mutat
strongli
associ
dismal
outcom
entir
cohort
well
subgroup
relaps
neuroblastoma
frequenc
mutat
increas
sampl
notic
howev
prognost
effect
pathway
mutat
strictli
depend
occurr
telomer
mainten
mechan
surviv
patient
whose
tumor
telomer
dramat
inferior
addit
pathway
mutat
present
compar
without
alter
contrast
patient
whose
tumor
lack
telomer
mainten
mechan
excel
outcom
spontan
regress
differenti
occur
presenc
absenc
pathway
mutat
conclus
togeth
data
suggest
precis
mechanist
definit
clinic
neuroblastoma
phenotyp
base
presenc
absenc
telomer
mainten
ra
pathway
mutat
provid
start
point
improv
diagnost
therapeut
manag
neuroblastoma
patient
v
v
b
r
v
di
g
k
j
sophia
children
hospit
depart
pediatr
athen
greec
gaslini
children
hospit
depart
genoa
itali
michallon
de
grenobl
franc
polytechn
la
fe
hospit
pediatr
oncolog
depart
valencia
spain
children
medic
center
depart
israel
universitair
saint
luc
et
oncologi
bruxel
belgium
cancer
research
institut
st
anna
children
hospit
unit
studi
statist
integr
research
project
vienna
austria
laboratoir
de
recherch
translationnel
lyon
cedex
franc
catania
pediatr
hematolog
oncolog
catania
itali
curi
laboratoir
de
et
biologi
de
cancer
pari
franc
children
hospit
depart
paediatr
haematolog
oncolog
oxford
unit
kingdom
valencia
depart
statist
valencia
spain
backgroundobject
differenti
diagnosi
neonat
supraren
mass
rang
benign
adren
haemorrhag
malign
neuroblastoma
adren
carcinoma
optim
manag
clearli
defin
neuroblastoma
age
intrigu
entiti
carri
good
prognosi
case
siopen
intern
societi
paediatr
oncolog
european
neuroblastoma
launch
studi
risk
neuroblastoma
studi
http
wwwclinicaltrialsorg
primari
aim
maintain
ef
initi
approach
infant
small
local
supraren
mass
designmethod
singl
multicent
prospect
studi
infant
day
mass
region
metastat
involv
undertaken
initi
work
includ
urinari
catecholamin
imag
us
andor
mri
migb
scintigraphi
mycn
analysi
sera
infant
monitor
first
year
mass
increas
volum
orand
catecholamin
excret
increas
observ
stop
surgeri
perform
mass
persist
month
excis
mass
recommend
result
cohort
infant
regist
median
age
day
rang
femal
mass
describ
cystic
solid
mix
antenat
diagnosi
made
case
patient
underw
resect
observ
end
observ
period
prove
neuroblastoma
two
surgic
complic
includ
hemorrhag
renal
ischemia
without
fatal
migb
done
patient
receiv
thyroid
protect
despit
protocol
guidelin
ef
respect
os
median
month
fifteen
event
observ
progress
ms
tumor
conclus
observ
approach
infant
local
supraren
mass
discov
antenat
neonat
suspect
neuroblastoma
prove
safe
patient
avoid
surgeri
close
monitor
effect
jeopard
overal
outcom
hl
j
j
j
oldenburg
medic
campu
univers
oldenburg
depart
pediatr
pediatr
hematolog
oncolog
oldenburg
germani
depart
neuroradiolog
germani
institut
biostatist
clinic
research
muenster
germani
southern
medic
univers
depart
neurosurgeri
guangzhou
china
hospit
uke
depart
neurosurgeri
hamburg
germani
backgroundobject
assess
presurg
hypothalam
involv
pshi
hypothalam
damag
trhd
relev
decis
treatment
rehabilit
strategi
craniopharyngioma
designmethod
surgic
report
craniopharyngioma
patient
recruit
kraniopharyngeom
analyz
data
pshi
avail
base
surgeon
refer
neuroradiologist
local
radiologist
assess
surgic
degre
resect
dor
assess
neurosurgeon
refer
neuroradiologist
local
radiologist
trhd
assess
neurosurgeon
refer
neuroradiologist
local
radiologist
neurosurg
center
size
categor
base
patient
load
result
surgic
assess
pshi
dor
trhd
document
surgic
report
could
compar
assess
respect
paramet
refer
neuroradiologist
differ
regard
dor
trhd
p
detect
surgeon
refer
neuroradiologist
assess
wherea
pshi
assess
similarli
concord
dor
trhd
observ
respect
surgeon
estim
higher
rate
complet
resect
lower
rate
trhd
neuroradiolog
refer
assess
trhd
higher
predict
valu
hypothalam
sequela
surgic
assess
observ
differ
relat
neurosurg
center
size
conclus
observ
differ
surgic
neuroradiolog
estim
risk
factor
craniopharyngioma
support
necess
neuroradiolog
refer
review
assur
standard
qualiti
could
establish
central
neuroradiolog
review
kraniopharyngeom
standard
surgic
report
includ
specif
assess
tumordamag
locat
recommend
g
michaiel
n
u
h
j
b
jr
ms
ka
g
l
np
na
kk
e
l
children
hospit
section
pediatr
bmt
ab
canada
margaret
hospit
children
pediatr
oncolog
hematolog
perth
australia
hospit
sick
children
divis
hematologyoncolog
canada
hospit
eastern
ontario
divis
hematologyoncolog
canada
columbia
children
hospit
divis
neurolog
oncolog
bc
canada
children
hospit
divis
oncolog
palli
care
ab
canada
health
scienc
centr
pediatr
oncolog
canada
children
murdoch
children
research
institut
solid
brain
tumour
divis
melbourn
australia
children
hospit
hematologyoncolog
bmt
oh
usa
hospit
philadelphia
pediatr
program
pa
usa
hospit
lo
angel
children
center
cancer
blood
diseas
lo
ca
usa
hospit
colorado
pediatr
co
usa
robert
h
luri
children
hospit
chicago
stem
cell
transplant
il
usa
palmer
hospit
children
pediatr
fl
usa
jude
children
research
hospit
depart
oncolog
tn
usa
children
hospit
divis
hematologyoncolog
wa
usa
packard
children
hospit
stanford
pediatr
hematolog
oncolog
ca
usa
hospit
lo
angel
children
center
cancer
blood
diseas
lo
ca
usa
backgroundobject
intracrani
grow
teratoma
syndrom
igt
rare
phenomenon
paradox
germ
cell
tumor
gct
growth
follow
treatment
despit
normal
tumor
marker
sought
evalu
frequenc
clinic
characterist
outcom
igt
patient
australian
institut
designmethod
patient
igt
diagnos
retrospect
evalu
result
gct
diagnos
igt
identifi
patient
igt
occur
gct
immatur
teratoma
germinomasgerminoma
matur
teratoma
secret
tumour
median
age
gct
diagnosi
year
rang
male
gender
pineal
locat
predomin
patient
elev
marker
median
serum
afp
ngml
rang
iul
rang
respect
igt
occur
median
time
month
rang
diagnosi
chemotherapi
radiat
treatment
complet
surgic
resect
attempt
lead
gross
total
resect
patient
resum
gct
chemotherapyradi
surgeri
median
year
rang
patient
aliv
succumb
progress
diseas
malign
transform
gct
conclus
igt
occur
less
patient
gct
commonli
initi
chemotherapi
igt
common
patient
biopsi
gct
surgic
resect
princip
treatment
modal
surviv
outcom
patient
develop
igt
favour
kaneko
rp
h
cancer
center
research
institut
clinic
oncolog
ina
japan
cancer
center
research
institut
cancer
genom
divis
tokyo
japan
univers
depart
patholog
tokyo
japan
children
medic
center
depart
patholog
yokohama
japan
center
child
health
develop
research
institut
tokyo
japan
colleg
medicin
depart
pediatr
surgeri
nishinomiya
japan
medic
univers
depart
radiolog
koshigaya
japan
univers
school
medicin
depart
pediatr
tokyo
japan
medic
center
research
institut
matern
child
health
depart
pediatr
surgeri
izumi
japan
univers
school
medicin
depart
pediatr
surgeri
tokyo
japan
backgroundobject
overal
surviv
os
rate
patient
wilm
tumor
wt
reach
biomark
predict
favor
unfavor
outcom
need
improv
os
rate
avoid
advers
late
effect
designmethod
analyz
array
cgh
acgh
pattern
mutat
gene
unilater
wt
patient
classifi
accord
acgh
genet
alter
alter
correl
surviv
rf
os
rate
express
microarray
analysi
perform
wt
upregul
gene
specif
chromosom
duplic
wt
downregul
gene
specif
chromosom
arm
lost
wt
determin
correl
overexpress
upregul
gene
downregul
gene
favor
unfavor
os
determin
use
databas
result
patient
alter
tumor
rf
type
acgh
aberr
rf
silent
type
acgh
chang
without
alter
type
patient
classifi
presenc
absenc
loss
rf
better
without
rf
wors
loss
without
rf
wt
examin
gene
chromosom
upregul
tumor
compar
tumor
gene
downregul
tumor
compar
tumor
overexpress
upregul
gene
downregul
gene
correl
better
wors
os
patient
wt
respect
conclus
prognost
signific
chromosom
abnorm
may
causal
relat
upregul
gene
extra
chromosom
downregul
gene
delet
chromosom
arm
region
r
shah
k
j
r
l
blood
marrow
children
center
cancer
blood
children
hospit
lo
angel
depart
keck
school
univers
southern
california
lo
angel
usa
blood
marrow
transplant
children
center
cancer
blood
children
hospit
lo
angel
lo
angel
usa
blood
marrow
children
center
cancer
blood
children
hospit
lo
angel
depart
prevent
medicin
keck
school
univers
southern
california
lo
angel
usa
hospit
lo
angel
depart
radiolog
lo
angel
usa
backgroundobject
standard
surveil
earli
detect
relaps
extracrani
solid
tumor
est
elev
tumor
marker
tm
diagnosi
includ
tm
monitor
serial
radiograph
imag
given
high
sensit
tm
detect
relaps
role
radiograph
imag
debat
patient
est
designmethod
retrospect
chart
review
newli
diagnos
patient
est
elev
tm
result
patient
male
age
rang
year
includ
median
year
hepatoblastoma
hb
hepatocellular
carcinoma
hcc
malign
germ
cell
tumor
gct
median
serum
afp
diagnosi
ngml
ngml
ngml
hb
hcc
gct
respect
median
chorion
gonadotropin
diagnosi
gct
fourteen
patient
experienc
confirm
relaps
patient
tm
elev
preced
radiograph
detect
relaps
one
patient
hcc
tm
never
normal
diseas
progress
detect
radiograph
imag
prior
rise
serum
afp
mean
time
tm
elev
radiograph
detect
relaps
day
total
number
radiograph
imag
studi
perform
chest
comput
tomographi
ct
chest
ct
abdomenpelvi
magnet
reson
imag
radionuclid
bone
total
number
afp
assay
perform
respect
base
medicar
fee
schedul
total
tm
cost
radiograph
imag
cost
thu
omiss
routin
radiograph
surveil
patient
cohort
could
potenti
result
mean
cost
save
conclus
tm
assess
without
radiograph
imag
adequ
diseas
surveil
patient
est
elev
tm
diagnosi
normal
end
primari
treatment
surveil
tm
alon
reduc
radiat
exposur
health
care
cost
treger
r
g
r
c
r
j
n
k
pritchard
w
great
ormond
street
institut
child
franci
crick
institut
development
biolog
bioinformat
comput
biolog
laboratori
london
unit
kingdom
great
ormond
street
institut
child
health
development
biolog
cancer
london
unit
kingdom
school
hygien
tropic
medicin
clinic
research
faculti
infecti
tropic
diseas
london
unit
kingdom
franci
crick
institut
bioinformat
comput
biolog
laboratori
london
unit
kingdom
great
ormond
street
institut
child
health
development
biolog
depart
paediatr
haematolog
oncolog
london
unit
kingdom
great
ormond
street
institut
child
health
development
biolog
depart
histopatholog
london
unit
kingdom
backgroundobject
diffus
anaplast
wilm
tumour
dawt
rare
subtyp
often
miss
needl
biopsi
somat
mutat
found
approxim
case
associ
poorer
surviv
particularli
advanc
stage
diseas
detect
circul
could
aid
earlier
diagnosi
anaplast
tumour
chemotherapi
commenc
without
histolog
confirm
standard
manag
childhood
renal
tumour
countri
follow
siop
guidelin
designmethod
patient
diagnosi
wt
enrol
import
studi
patient
treat
accord
siop
wt
normal
kidney
tumour
tissu
collect
surgeri
whilst
blood
urin
collect
five
treatment
time
point
assess
statu
frozen
tumour
match
germlin
dna
circul
tumour
dna
ctdna
plasma
serum
urin
patient
dawt
statu
determin
sanger
target
sequenc
droplet
digit
polymeras
chain
reaction
ddpcr
employ
evalu
ctdna
sampl
patient
dawt
variant
result
mutant
detect
ctdna
plasma
serum
patient
detect
variant
volum
urin
one
patient
display
heterogen
tumour
despit
section
display
anaplast
histolog
concentr
ctdna
plasmaserum
taken
vari
significantli
patient
rang
observ
variat
ctdna
throughout
treatment
one
patient
relaps
day
ctdna
level
fell
follow
nephrectomi
conclus
result
first
demonstr
ddpcr
effect
method
detect
mutant
ctdna
children
wt
even
somat
heterogen
low
burden
diseas
dh
jo
e
jh
yg
jh
nation
univers
hospit
depart
ophthalmolog
seoul
republ
korea
nation
univers
hospit
depart
ophthalmologyfight
blind
farb
clinic
research
institut
seoul
republ
korea
univers
colleg
pharmaci
seongnam
republ
korea
backgroundobject
known
highli
express
retinoblastoma
tumor
previous
report
inhibit
could
treatment
option
retinoblastoma
via
cluster
studi
investig
therapeut
potenti
inhibitor
librari
differ
deriv
michael
acceptor
treatment
retinoblastoma
designmethod
cell
differ
retinoblastoma
cell
line
treat
inhibitor
librari
deriv
screen
cellular
toxic
level
phosphoryl
estim
immunosorb
assay
express
level
target
gene
measur
quantit
polymeras
chain
reaction
upon
treatment
inhibitor
librari
inhibitor
potent
inhibitor
select
aforement
assay
use
mous
orthotop
transplant
model
vivo
therapeut
efficaci
evalu
toxic
inhibitor
normal
retin
tissu
estim
histolog
evalu
termin
deoxynucleotidyl
transferas
dutp
nick
end
label
assay
result
differ
deriv
demonstr
differenti
cellular
toxic
phosphoryl
express
target
gene
potent
inhibitor
effect
inhibit
format
retinoblastoma
tumor
mous
orthotop
transplant
model
despit
therapeut
efficaci
inhibitor
significantli
affect
cellular
viabil
histolog
integr
retina
even
time
therapeut
concentr
conclus
novel
inhibitor
identifi
screen
librari
chemic
demonstr
potent
vitro
vivo
therapeut
efficaci
without
definit
toxic
normal
tissu
expect
inhibitor
util
treatment
retinoblastoma
l
zhu
l
l
jude
children
research
hospit
pharmaceut
scienc
memphi
usa
children
hospit
patholog
houston
usa
backgroundobject
hepatoblastoma
hb
common
liver
cancer
cancer
children
prognosi
children
metastat
recurr
hb
remain
dismal
past
decad
previou
studi
demonstr
cell
often
hijack
normal
stem
cell
pathway
gain
surviv
growth
advantag
recent
advanc
stem
cell
cultur
provid
mean
rapidli
select
propag
cancer
cell
strong
stem
properti
biolog
analysi
therapeut
test
designmethod
hb
organoid
model
establish
mous
human
tumor
via
stem
cell
cultur
vivo
tumorigen
determin
via
liver
orthotop
transplant
mice
conduc
larg
compar
profil
identifi
gene
commonli
dysregul
metastat
hb
tumor
organoid
compar
counterpart
biolog
function
therapeut
valu
top
candid
gene
determin
via
impact
molecular
manipul
hb
cell
growth
invas
metastasi
drug
respons
vitro
vivo
result
multipl
hb
organoid
model
display
potent
vivo
tumorigen
drive
rapid
invas
metastasi
upon
orthotop
transplant
profil
identifi
small
number
gene
significantli
upregul
aggress
hb
tumor
organoid
among
enzym
catalyz
format
deoxyribonucleotid
ribonucleotid
essenti
dna
replic
repair
analysi
reveal
signific
associ
express
prognosi
hb
patient
make
promis
therapeut
target
high
risk
hb
studi
current
ongo
reveal
effect
biolog
pharmacolog
inhibit
hb
growth
metastasi
vitro
vivo
conclus
approach
repres
uniqu
strategi
model
high
risk
hb
power
research
platform
identif
novel
diseas
mechan
drug
target
j
akter
h
r
r
institut
clinic
saitama
cancer
center
clinic
oncolog
saitama
japan
backgroundobject
neuroblastoma
nb
common
pediatr
tumor
account
death
children
chromatin
remodel
factor
atrx
tumor
suppressor
gene
recurr
somat
mutat
associ
stage
nb
patient
precis
mechan
atrx
mutat
relat
nb
tumorigenesi
aggress
remain
elucid
demonstr
ko
induc
depend
dna
damag
respons
nb
cell
designmethod
atrx
ko
clone
establish
mycn
amplifi
ngp
singl
copi
nb
cell
use
technolog
cell
prolifer
detect
wst
assay
express
analysi
atrx
ko
clone
perform
agil
oligonucleotid
microarray
gene
set
enrich
analysi
gsea
use
analyz
data
inactiv
done
lentivir
mutant
transduct
atm
signal
pathway
studi
analysi
result
herein
sever
atrx
ko
clone
establish
nb
cell
line
interestingli
clone
prolifer
slowli
compar
control
becom
differenti
gsea
analysi
microarray
data
indic
relat
dna
break
repair
dna
damag
respons
neg
cell
cycl
regul
checkpoint
pathway
activ
induc
atrx
ko
cell
vitro
analysi
atrx
loss
result
increas
express
phosphoryl
histon
variant
canon
marker
break
indic
accumul
endogen
dna
damag
atrx
ko
cell
furthermor
accumul
dna
damag
result
activ
pathway
lead
cell
cycl
arrest
moreov
inactiv
rescu
decreas
cell
growth
level
atrx
ko
cell
also
studi
correl
pathway
inactiv
multiom
databas
analysi
conclus
taken
togeth
find
suggest
atrx
play
role
maintain
dna
integr
pathway
inactiv
requir
nb
tumorigenesi
byrjalsen
u
k
k
depart
clinic
genet
depart
paediatr
adolesc
medicin
copenhagen
denmark
depart
paediatr
adolesc
medicin
copenhagen
denmark
depart
clinic
genet
copenhagen
denmark
copenhagen
depart
anthropolog
copenhagen
denmark
backgroundobject
examin
parent
perspect
particip
whole
genom
sequenc
wg
research
week
follow
cancer
diagnosi
designmethod
embed
part
project
stage
sequenc
tumor
germlin
dna
implic
nation
guidelin
qualit
parent
perspect
studi
conduct
physician
anthropologist
document
pragmat
social
ethic
dilemma
face
famili
decid
particip
pediatr
wg
research
follow
genet
counsel
systemat
debrief
held
anthropologist
physician
anthropologist
subsequ
carri
parent
interview
parent
patient
interview
transcrib
verbatim
debrief
interview
read
themat
analyz
anthropologist
physician
separ
follow
meet
consensu
key
theme
result
parent
approach
day
diagnosi
major
report
earli
approach
accept
although
one
famili
state
earli
particip
stage
explain
term
altruism
desir
learn
child
develop
cancer
parent
request
full
feedback
genom
find
although
describ
torn
want
receiv
cancer
diseas
predisposit
find
worri
would
becom
small
minor
want
littl
inform
return
possibl
parent
openli
disagre
amount
inform
want
report
back
follow
famili
deliber
reach
consensu
precondit
particip
stage
conclus
parent
newli
diagnos
childhood
cancer
patient
articul
numer
dilemma
aris
particip
wg
research
enrol
diagnosi
feasibl
howev
flexibl
research
essenti
notwithstand
high
particip
rate
tendenc
choos
full
disclosur
caution
regard
parent
view
particip
wg
research
warrant
studi
famili
receiv
wg
find
necessari
n
phillip
c
l
k
k
jude
children
research
hospit
epidemiolog
cancer
control
memphi
usa
jude
children
research
hospit
oncolog
memphi
usa
backgroundobject
survivor
childhood
acut
lymphoblast
leukemia
risk
exercis
intoler
neurocognit
deficit
exercis
capac
associ
cognit
perform
intervent
improv
exercis
capac
associ
improv
cognit
perform
popul
thu
aim
analysi
determin
exercis
intoler
associ
neurocognit
impair
survivor
designmethod
submaxim
predict
heart
rate
cardiopulmonari
exercis
test
neurocognit
perform
compar
survivor
femal
mean
rang
age
diagnosi
year
age
evalu
year
control
femal
age
evalu
year
within
survivor
multivari
model
test
associ
peak
oxygen
uptak
neurocognit
domain
adjust
sex
age
diagnosi
cranial
radiat
anthracyclin
exposur
tobacco
smoke
statu
result
survivor
wors
peak
oxygen
uptak
vs
milliliterskilogramminut
mlkgmin
p
perform
verbal
intellig
vs
verbal
fluenci
vs
work
memori
vs
motor
speed
vs
vs
visual
speed
vs
memori
span
vs
read
vs
math
vs
measur
p
control
adjust
model
metabol
equival
increas
exercis
toler
associ
increas
standard
deviat
perform
verbal
intellig
verbal
fluenci
p
work
memori
domin
motor
speed
p
motor
speed
p
speed
p
memori
span
p
read
academ
p
math
academ
p
survivor
conclus
studi
demonstr
fit
level
significantli
lower
survivor
childhood
peer
clear
associ
fit
level
neurocognit
outcom
intellig
execut
function
process
speed
memori
academ
perform
graetz
k
j
jude
children
research
hospit
hematologyoncolog
memphi
usa
farber
cancer
institut
psycholog
boston
usa
farber
cancer
institut
psychiatri
boston
usa
farber
cancer
institut
oncolog
boston
usa
backgroundobject
adolesc
young
adult
aya
experi
cancer
midst
emerg
ident
life
goal
investig
aya
prioriti
cancer
treatment
balanc
psychosoci
concern
therapi
potenti
late
effect
designmethod
survey
aya
cancer
patient
respons
rate
age
treat
cancer
institut
boston
massachusett
oncologist
patient
approach
within
week
diagnosi
ask
rate
import
aspect
cancer
treatment
cancer
outcom
life
treatment
patient
complet
relev
question
attribut
respons
option
extrem
somewhat
littl
import
import
rate
extrem
import
use
indic
strong
prioriti
result
patient
frequent
prioriti
cure
good
peopl
care
support
peopl
around
also
priorit
famili
return
schoolwork
maintain
relationship
friend
feel
normal
still
import
mani
patient
fewer
priorit
minim
long
term
acut
side
effect
fertil
older
aya
like
priorit
cure
romant
relationship
p
around
support
patient
poorer
prognos
chanc
cure
report
oncologist
less
like
priorit
school
work
treatment
less
like
priorit
cure
compar
patient
favor
prognos
conclus
nearli
aya
cancer
patient
priorit
best
chanc
cure
maintain
relationship
sens
normalci
prioriti
may
influenc
decis
make
medic
aspect
treatment
provid
help
support
aya
patient
recogn
acknowledg
prioriti
diagnosi
k
maslak
c
r
f
g
la
l
lo
p
v
e
f
g
di
hospit
policlinico
depart
pediatr
hematolog
oncolog
catania
itali
catania
depart
medic
surgic
scienc
advanc
technolog
gf
ingrassia
catania
itali
hospit
policlinico
section
depart
gener
surgeri
medic
specialti
catania
itali
catania
depart
pediatr
hematolog
depart
clinic
experiment
medicin
catania
itali
backgroundobject
cancer
intrud
children
life
everyday
equilibrium
destroy
suddenli
find
total
new
world
adult
make
import
decis
children
undergo
diagnost
therapeut
treatment
experi
increas
level
anxieti
repeat
invas
procedur
adapt
discomfort
bone
marrow
aspir
lumbar
punctur
remain
one
vivid
memori
even
year
treatment
finish
profession
agre
children
must
receiv
development
appropri
preparatori
inform
invas
procedur
along
adequ
psycholog
support
literatur
describ
differ
support
modal
eg
pharmacolog
behaviour
sed
etc
howev
report
possibl
ask
children
prefer
medic
support
designmethod
day
procedur
child
offer
choos
type
medic
support
among
gener
anesthesia
ga
consciou
sedat
cs
noth
child
receiv
also
psycholog
support
ie
given
psychologist
procedur
ad
hoc
assess
tool
prepar
order
measur
child
discomfort
procedur
also
caregiv
adequaci
measur
base
evalu
form
fill
everi
procedur
attend
psychologist
result
monitor
consecut
invas
procedur
children
found
choic
type
medic
support
differ
variou
age
group
age
group
show
significantli
higher
distress
level
other
distress
level
diminish
succeed
procedur
caregiv
behaviour
influenc
children
experi
conclus
offer
children
opportun
choos
medic
support
invas
procedur
effect
modal
return
activ
control
way
truli
strengthen
children
capac
face
invas
procedur
limit
emot
traumat
content
mn
sitaresmi
bw
public
health
universita
gadjah
mada
dr
sardjito
hospit
paediatr
depart
yogyakarta
indonesia
backgroundobject
qualiti
life
hrqol
adolesc
cancer
may
affect
diseas
treatment
aim
studi
assess
profil
hrqol
adolesc
cancer
assess
influenc
demograph
medic
characterist
hrqol
score
designmethod
method
conduct
cross
section
studi
hrqol
dr
sardjito
gener
hospit
yogyakarta
indonesia
june
novemb
adolesc
cancer
patient
year
old
guardian
variou
phase
treatment
recruit
hrqol
assess
use
pedsql
gener
modul
cancer
modul
indonesian
valid
version
result
adolesc
guardian
recruit
intern
valid
scale
good
cronbach
alpha
coeffici
rang
well
intern
correl
report
icc
patient
guardian
report
low
score
school
function
subscal
compar
boy
femal
adolesc
patient
report
lower
score
emot
function
subscal
vs
p
late
adolesc
report
lower
score
earli
adolesc
especi
total
score
scale
emot
subscal
worri
subscal
guardian
malign
patient
report
lower
score
hematolog
malign
patient
physic
function
vs
p
social
function
vs
p
function
vs
p
conclus
late
adolesc
problem
gener
cancer
scale
psychosoci
support
provid
famili
peer
group
facilit
cope
diseas
treatment
school
substitut
offer
adolesc
treatment
n
jm
de
r
n
r
univers
hospit
pediatr
oncolog
hematolog
depart
barakaldo
spain
univers
hospit
pediatr
depart
spain
univers
hospit
pediatr
depart
barakaldo
spain
backgroundobject
countri
patient
acut
lymphoblast
leukemia
treat
accord
nation
protocol
consensu
support
manag
patient
first
phase
treatment
induct
object
studi
describ
conserv
manag
carri
first
month
unit
designmethod
retrospect
descript
studi
clinic
characterist
evolut
ia
induct
patient
year
diagnos
tertiari
hospit
result
patient
diagnos
averag
stay
admiss
day
present
complic
first
admiss
especi
due
treatment
toxic
discharg
neutropenia
neutropenia
plu
thrombocytopenia
discharg
infecti
prophylaxi
unrel
risk
absolut
neutrophil
count
anc
discharg
first
control
consult
made
day
averag
patient
induct
phase
although
one
within
first
hour
discharg
mean
admiss
day
febril
neutropenia
main
caus
admiss
obtain
microbiolog
confirm
case
cultur
isol
bacteria
second
admiss
caus
infect
relat
cathet
neg
coagulas
staphylococcu
frequent
microorgan
remain
patient
due
deep
vein
thrombosi
toxic
secondari
chemotherapi
patient
die
induct
conclus
half
patient
first
discharg
howev
nt
believ
extend
hospit
stay
could
prevent
caus
risk
associ
risk
anc
discharg
conserv
manag
nt
impli
higher
rate
complic
agarw
k
india
institut
medic
scienc
paediatr
delhi
india
india
institut
medic
scienc
paediatr
delhi
india
india
institut
medic
scienc
biostatist
delhi
india
backgroundobject
acut
lymphoblast
leukemia
commonest
leukemia
children
surviv
upto
higher
mortal
indian
children
found
associ
copi
number
alter
variou
coexist
gene
repres
vari
mechan
carcinogenesi
includ
gene
involv
progress
cell
divis
well
inhibit
cell
differenti
conduct
studi
object
find
copi
number
variat
gene
implic
prognosi
childhood
designmethod
newli
diagnos
confirm
children
age
year
includ
studi
children
investig
hematolog
cytogenet
prognost
factor
addit
children
also
monitor
respons
prednisolon
complet
morpholog
remiss
minim
residu
diseas
post
induct
children
follow
minimum
month
children
analyz
copi
number
alter
use
multiplex
probe
amplif
mlpa
assay
salsa
mlpa
holland
amsterdam
netherland
result
copi
number
alter
seen
individu
gene
delet
commonli
delet
alter
gene
locat
pseudo
autosom
region
also
frequent
delet
includ
delet
gene
duplic
gene
conclus
gene
significantli
associ
higher
age
leukocyt
count
present
higher
incid
advers
event
gene
associ
higher
mrd
gene
delet
associ
poor
cytogenet
children
p
aggarw
tb
v
medic
banara
hindu
univers
divis
pediatr
hematolog
depart
pediatr
varanasi
india
medic
banara
hindu
univers
divis
depart
commun
medicin
varanasi
india
backgroundobject
aim
studi
assess
effect
profil
along
nutrit
statu
patient
pediatr
durat
induct
phase
chemotherapi
designmethod
one
hundr
ten
patient
age
year
underw
induct
remiss
june
februari
includ
studi
weight
immun
statu
child
type
hous
sanitari
facil
sourc
drink
water
note
start
treatment
weight
age
percentil
child
determin
use
growth
chart
kuppuswami
scale
use
assess
socioeconom
statu
se
durat
induct
phase
chemotherapi
consid
delay
patient
receiv
chemotherapi
day
result
patient
belong
lower
middl
socioeconom
statu
signific
effect
durat
induct
phase
chemotherapi
p
among
paramet
durat
significantli
delay
patient
immun
p
resid
mud
hous
sanitari
facil
access
filter
drink
water
although
durat
delay
patient
weight
percentil
statist
signific
conclus
durat
induct
phase
chemotherapi
affect
significantli
immun
statu
child
type
hous
presenc
absenc
sanitari
facil
sourc
drink
water
v
aguilar
ap
j
c
region
train
teach
hospit
depart
pediatr
albay
philippin
philippin
philippin
gener
hospit
depart
pediatr
manila
philippin
children
medic
center
depart
pediatr
quezon
citi
philippin
philippin
philippin
gener
hospit
depart
clinic
epidemiolog
manila
philippin
backgroundobject
acut
lymphoblast
leukemia
surviv
philippin
remain
poor
due
low
detect
rate
late
referr
incomplet
treatment
financi
constraint
chemotherapi
drug
main
barrier
program
free
chemotherapi
implement
pediatr
cancer
unit
hospit
nationwid
review
program
impact
outcom
designmethod
retrospect
chart
review
newli
diagnos
patient
year
use
standard
data
sheet
januari
decemb
studi
decemb
result
patient
reach
program
evalu
diagnosi
base
immunophenotyp
patient
morpholog
mean
age
diagnosi
year
old
f
ratio
nci
risk
stratif
low
high
treatment
protocol
vari
across
center
end
studi
period
aliv
complet
treatment
die
abandon
treatment
common
caus
death
sepsi
bleed
relaps
includ
complet
treatment
site
bone
marrow
cn
combin
year
overal
surviv
os
os
respect
multivari
analysi
patient
characterist
show
mortal
strongli
correl
nci
high
risk
initi
level
hemoglobin
platelet
count
conclus
major
caus
treatment
failur
abandon
toxic
death
expand
wholist
nation
leukemia
program
urgent
need
includ
initi
patient
navig
infect
control
safe
blood
product
standard
clinic
practic
guidelin
creation
hospit
registri
eg
aguillen
jimenez
mm
ama
amf
nacion
de
pediatria
pediatr
oncolog
mexico
citi
mexico
backgroundobject
recent
acut
lymphoblast
leukemia
protocol
high
incom
countri
includ
peg
asparaginas
front
treatment
sinc
due
cost
low
countri
unlik
implement
systemat
object
review
frequenc
advers
event
associ
e
coli
ela
rate
ofth
central
nervou
system
relaps
institut
addit
elabor
systemat
review
search
inform
countri
order
element
discuss
ethic
issu
current
problem
designmethod
made
prospect
observ
studi
includ
pediatr
patient
regist
advers
event
associ
ela
time
treatment
phase
present
associ
nutrit
statu
review
rate
cn
relaps
cohort
patient
treat
st
jude
xiiib
result
includ
ela
administr
regist
thrombosi
pancreat
anaphylaxi
drug
induc
skin
disord
hypertriglyceridemia
patient
develop
first
applic
applic
induct
therapi
consolid
mainten
cn
relaps
rate
advers
event
bare
lower
ecoli
rate
cn
relaps
decreas
start
use
difficult
demonstr
decreas
due
use
one
drug
howev
safer
first
line
treatment
drug
ethic
use
ela
conclus
despit
advers
event
ela
higher
risk
cn
relaps
realiti
use
drug
still
choic
consid
correct
ethic
decis
df
akin
bali
aslar
ae
n
h
halisdemir
faculti
medicin
medic
biolog
turkey
univers
molecular
biolog
ankara
turkey
children
adult
hospit
pediatr
hematolog
ankara
turkey
hospit
pediatr
diseas
ankara
turkey
biotechnolog
institut
biotechnolog
ankara
turkey
backgroundobject
precursor
acut
lymphoblast
leukemia
character
recur
cytogenet
molecular
genet
abnorm
aim
investig
recent
identifi
genom
risk
factor
affect
pathogenesi
effect
molecular
mechan
prognost
signific
next
gener
sequenc
ng
gene
express
analys
childhood
secondari
aim
studi
correl
data
obtain
studi
biolog
clinic
featur
characterist
pediatr
patient
genet
aberr
prognosi
base
treatment
protocol
criteria
designmethod
blood
sampl
obtain
pediatr
patient
use
ng
method
studi
tslp
crebbp
erg
gene
known
mutat
hot
spot
region
gene
sequenc
gene
express
level
perform
use
result
among
gene
analys
pediatr
patient
identifi
gene
variant
includ
delet
insert
duplic
indel
singl
nucleotid
mutat
polymorph
ng
hot
spot
region
gene
identifi
mutat
novel
mutat
present
studi
among
commonli
mutat
gene
follow
crebbp
detect
erg
gene
express
associ
differ
pathophysiolog
clinic
featur
peripher
blood
cell
count
treatment
protocol
studi
group
conclus
detect
variant
like
lead
end
product
gene
differ
splice
possibl
transcript
transform
amino
acid
data
suggest
prognost
role
studi
gene
express
level
mutat
profil
pediatr
l
h
univers
school
medicin
depart
pediatr
nagano
japan
univers
graduat
school
medicin
center
advanc
medicin
clinic
research
nagoya
japan
welfar
teach
baghdad
colleg
medicin
depart
pediatr
baghdad
iraq
children
specialti
hospit
depart
basra
iraq
backgroundobject
molecular
diagnosi
acut
lymphoblast
leukemia
acut
myeloid
leukemia
aml
help
defin
prognosi
select
appropri
treatment
protocol
success
previou
genet
analysi
pediatr
iraqi
allaml
sampl
japan
use
flinder
technolog
associ
fta
card
implement
result
manag
enrol
patient
motiv
us
perform
comprehens
analysi
detect
genet
prognost
marker
allaml
use
sequenc
ng
technolog
designmethod
fta
filter
card
use
transfer
sampl
bone
marrow
aspir
day
therapi
children
acut
leukemia
age
main
center
iraq
sinc
octob
plan
patient
sampl
aml
acut
undifferenti
leukemia
ship
shinshu
universityjapan
dna
extract
ng
done
nagoya
universityjapan
perform
sequenc
wx
sampl
time
diagnosi
remiss
identifi
somaticgermlin
mutat
includ
copi
number
aberr
minim
residu
diseas
mrd
detect
also
perform
base
immunoglobulin
igh
result
wx
use
dna
satisfactori
term
sequenc
coverag
sensit
error
rate
spectrum
somat
mutat
among
iraqi
childhood
allaml
compar
countri
slightli
higher
frequenc
mrd
marker
detect
howev
sensit
limit
due
insuffici
amount
dna
deliv
fta
card
conclus
molecular
marker
iraqi
childhood
allaml
success
detect
use
dna
sampl
ng
mrd
detect
also
possibl
use
igh
studi
contribut
better
manag
patient
acut
leukemia
iraq
acknowledg
appreci
siop
accept
abstract
publish
offici
congress
public
alarcon
r
j
l
nacion
de
enfermedad
lima
peru
edgardo
rebagliati
martin
lima
peru
backgroundobject
acut
lymphoblast
leukemia
common
caus
pediatr
cancer
instituto
nacion
de
enfermedad
neoplasica
mayor
stratifi
high
risk
patient
age
year
white
blood
count
blast
marrow
day
induct
minim
residu
diseas
post
induct
involv
leptomening
testicular
aim
determin
patient
marrow
day
wors
outcom
high
risk
designmethod
retrospect
studi
januari
decemb
patient
less
year
age
diagnos
patient
met
high
risk
criteria
separ
group
classifi
white
blood
count
yo
age
year
patient
group
ii
marrow
day
induct
patient
without
criteria
surviv
analysi
perform
use
method
result
median
age
year
rang
year
mf
ratio
one
hundr
fifteen
patient
complet
remiss
relaps
patient
abandon
treatment
die
die
induct
patient
progress
diseas
median
time
follow
month
year
overal
surviv
os
abandon
includ
event
event
free
surviv
ef
group
complet
remiss
group
ii
conclus
amount
high
risk
exce
intern
report
complet
remiss
high
risk
patient
end
induct
intern
report
marrow
day
wors
outcom
group
alsaleh
h
n
b
v
faisal
specilaist
hospit
research
centr
pediatr
hematolog
oncolog
riyadh
saudi
arabia
faisal
specilaist
hospit
research
centr
pediatr
nurs
riyadh
saudi
arabia
backgroundobject
incid
venou
thromboembol
vte
patient
cancer
known
associ
solid
tumor
studi
suggest
similar
incid
rate
acut
leukemia
al
common
children
vte
may
neg
prognost
impact
pediatr
hematolog
section
king
faisal
specialist
hospit
research
centr
riyadh
manag
sever
case
childhood
al
vte
designmethod
retrospect
chart
review
newli
diagnos
patient
al
conduct
result
total
patient
identifi
aml
case
mean
period
year
vte
observ
patient
aml
repres
overal
incid
major
children
femal
develop
vte
within
month
diagnosi
occur
nervou
system
cn
defin
central
venou
cathet
cvc
associ
upper
lower
deep
venou
thrombosi
dvt
occur
cn
defin
dexamethson
asparginas
cerebr
venou
thrombosi
patient
thrombocytopen
secondari
bone
marrow
failur
vte
cours
upper
extrem
dvt
common
amongst
case
one
develop
cerebr
emboli
rest
experienc
cerebr
sinu
thrombosi
amongst
cn
case
overal
surviv
os
cohort
comparison
vte
leukemia
case
os
respect
observ
statist
conclus
vte
incid
compar
publish
thrombosi
risk
pediatr
case
risk
factor
remain
cvc
asparginas
therapi
higher
incid
upper
extrem
dvt
observ
due
practic
howev
region
pediatr
vte
registri
accur
estim
risk
thrombosi
treatment
delay
surviv
childhood
malign
warrant
anastasopoul
r
im
g
ah
institut
depart
women
children
health
stockholm
sweden
univers
depart
children
adolesc
oulu
finland
univers
hospit
depar
pediatr
hematologyoncolog
oslo
norway
hospit
rigshospitalet
depart
pediatr
adolesc
medicin
copenhagen
denmark
univers
hospit
depart
pediatr
vilniu
lithuania
tartu
depart
hematolog
oncolog
tartu
estonia
iceland
depart
pediatr
iceland
uppsala
depart
women
children
health
uppsala
sweden
backgroundobject
posterior
revers
encephalopathi
syndrom
pre
clinicoradiolog
entiti
increasingli
recogn
among
pediatr
patient
acut
lymphoblast
leukemia
hypothes
trigger
treatment
aim
explor
clinic
cours
pre
pediatr
patient
treat
accord
nordic
protocol
nopho
identifi
risk
factor
pre
designmethod
studi
group
includ
patient
year
age
diagnosi
b
bcp
five
nordic
two
baltic
countri
patient
treat
accord
nopho
patient
identifi
uniqu
registr
system
inform
regard
detail
phenotyp
pre
collect
questionnair
focus
central
nervou
system
toxic
treatment
result
pre
diagnos
patient
cumul
incid
pre
one
month
ci
ci
one
year
cox
regress
identifi
age
signific
predictor
pre
hr
increas
age
ci
risk
higher
bcp
hr
vs
ci
seizur
occur
patient
hypertens
present
patient
encephalopathi
third
common
symptom
patient
conclus
seizur
hypertens
encephalopathi
common
symptom
pre
patient
treat
nopho
protocol
includ
high
dose
methotrex
vincristin
steroid
first
year
treatment
incidens
pre
highest
studi
need
identifi
underli
mechan
pre
patient
well
neurocognit
outcom
espinosa
astigarraga
aguirr
n
larrinaga
r
lopez
j
de
pedro
r
adan
echebarria
garcia
mc
pinedo
j
sanchez
univers
hospit
pediatr
bilbao
spain
univers
hospit
pediatr
oncolog
hematolog
barakaldo
spain
univers
hospit
pediatr
vitoria
spain
univers
hospit
pediatr
domiciliari
hospit
unit
barakaldo
spain
backgroundobject
tradit
intraven
antimicrobi
treatment
administ
entir
inpati
set
pediatr
domiciliari
hospit
unit
becom
safe
altern
care
especi
patient
chronic
malign
diseas
object
studi
present
experi
outpati
parent
antimicrobi
therapi
pediatr
domiciliari
hospit
unit
patient
diagnos
cancer
designmethod
conduct
retrospectivedescript
studi
medic
record
review
pediatr
patient
diagnos
cancer
receiv
outpati
parenter
antimicrobi
therapi
octob
decemb
result
period
total
episod
treat
patient
male
femal
age
year
fifti
percent
patient
diagnos
acut
lymphoblast
leukemia
main
indic
antimicrobi
therapi
bacteremia
common
organ
isol
staphylococcu
epidermidi
teicoplanin
use
episod
treatment
given
central
venou
cathet
peripher
line
antibiot
administ
direct
infus
programm
infus
devic
use
episod
two
patient
treat
parent
antifung
agent
caspofungin
voriconazol
mean
durat
outpati
antimicrobi
treatment
day
regist
two
case
cathet
occlus
resolv
home
complic
patient
requir
inpati
treatment
analysi
health
cost
show
differ
daili
cost
inpati
outpati
manag
conclus
outpati
parenter
antimicrobi
therapi
provid
support
pediatr
domiciliari
hospit
unit
feasibl
safe
option
patient
cancer
strategi
reduc
health
care
cost
improv
qualiti
life
children
famili
atout
b
univers
faculti
nurs
amman
jordan
univers
nurs
amman
jordan
hill
univers
faculti
health
social
care
edg
hill
unit
kingdom
backgroundobject
littl
research
middl
east
regard
experi
commun
children
cancer
perspect
physician
famili
carer
nurs
studi
explor
experi
commun
regard
care
children
cancer
perspect
physician
nurs
mother
children
palestin
designmethod
studi
employ
ethnograph
collect
qualit
case
studi
approach
conduct
one
oncolog
unit
palestinian
hospit
two
data
collect
method
employ
particip
observ
interview
result
thirti
two
interview
collect
date
physician
nurs
children
age
mother
grandmoth
total
observ
hour
complet
find
reveal
parent
complet
hid
diagnosi
leukaemia
children
other
tri
reliev
situat
inform
children
differ
diagnos
blood
infect
term
cancer
taboo
term
arab
cultur
avoid
discuss
diseas
health
care
provid
parent
amelior
neg
effect
term
gener
children
involv
discuss
relat
diseas
commun
ill
parent
physician
conclus
studi
find
reveal
challeng
physician
nurs
mother
face
commun
children
cancer
also
report
need
improv
commun
skill
children
cancer
final
strategi
need
involv
children
commun
regard
diseas
prognosi
hospit
level
atout
univers
faculti
nurs
amman
jordan
backgroundobject
aim
studi
explor
experi
second
child
leukemia
perspect
palestinian
mother
designmethod
studi
employ
hermeneut
phenomenolog
approach
inform
philosophi
heidegg
studi
conduct
two
academ
paediatr
oncolog
center
palestin
data
collect
use
interview
result
thirteen
interview
collect
mother
children
leukemia
find
indic
mother
second
child
diseas
stronger
experi
increas
abil
adapt
second
situat
howev
mother
report
enorm
pain
experi
admit
room
previou
child
care
addit
second
child
often
treat
health
profession
treat
deceas
child
mother
one
child
ill
tendenc
dredg
unhappi
memori
refus
talk
student
expect
ask
review
famili
histori
mother
avoid
kind
discuss
pain
memori
also
mean
maintain
strength
face
current
situat
conclus
clinic
practic
could
benefit
find
avoid
stimul
pain
memori
parent
deceas
children
could
help
parent
adapt
children
ill
howev
import
assess
parent
prefer
intervent
account
individu
differ
among
parent
therefor
clear
discuss
parent
second
child
ill
order
understand
prefer
regard
medic
environ
medic
team
would
like
treat
second
child
could
significantli
improv
parent
satisfact
hospit
aydin
mm
b
r
th
rc
uz
children
hospit
depart
pediatr
hematolog
oncolog
izmir
turkey
uz
children
hospit
depart
pediatr
cardiolog
izmir
turkey
univers
school
medicin
depart
pediatr
oncolog
izmir
turkey
backgroundobject
although
anthracyclin
chronic
cardiotox
well
recogn
import
subclin
anthracyclin
acut
cardiotox
yet
unknown
aim
prospect
evalu
acut
cardiotox
effect
singl
dose
increas
cumul
anthracyclin
dose
cardiac
repolar
chang
electrocardiograp
ecg
children
cancer
designmethod
total
patient
cancer
treat
anthracyclin
enrol
studi
month
standard
electrocardiograp
perform
basal
first
fourth
hour
first
dose
anthracyclin
treatment
time
cumul
anthracyclin
dose
cumul
anthracyclin
dose
patient
p
wave
dispers
pwd
qt
dispers
qtd
correct
qt
dispers
qtcd
interv
qt
qtc
ratio
obtain
electrocardiograp
patient
classifi
three
group
accord
increas
cumul
anthracyclin
dose
group
first
dose
group
group
result
median
age
patient
month
rang
month
pwd
qtd
qtcd
interv
significantli
increas
first
hour
first
dose
anthracyclin
treatment
p
respect
qt
qtc
ratio
significantli
alter
first
hour
cumul
dose
anthracyclin
treatment
p
howev
chang
electrocardiograp
ecg
parametr
significantli
higher
cumul
dose
anthracyclin
treatment
therewith
result
show
increas
administr
anthracyclin
cumul
dose
associ
chang
ecg
paramet
especi
parametr
pwd
qt
qtc
ratio
good
correl
statist
among
group
group
group
conclus
ecg
parametr
use
detect
subclin
cardiac
abnorm
acut
anthracyclin
toxic
aydin
b
mm
r
th
rc
uz
children
hospit
depart
pediatr
hematolog
oncolog
izmir
turkey
uz
children
hospit
depart
pediatr
cardiolog
izmir
turkey
univers
school
medicin
depart
pediatr
oncolog
izmir
turkey
backgroundobject
anthracyclin
effect
group
chemotherapeut
drug
commonli
use
childhood
cancer
aim
prospect
evalu
heart
rate
variabl
increas
cumul
dose
holter
electrocardiographi
ecg
children
cancer
treat
anthracyclin
drug
designmethod
holter
electrocardiographi
ecg
perform
diagnosi
time
time
cumul
anthracyclin
dose
cumul
anthracyclin
dose
patient
cancer
treat
anthracyclin
respect
heart
rate
variabl
us
sdnn
sdann
sdnn
index
rmssd
lf
hf
vlf
total
power
lfhf
ration
heart
rate
parametr
mean
averag
heart
rate
mean
minimum
heart
rate
mean
maximum
heart
rate
mean
rr
obtain
holter
ecg
patient
classifi
three
group
accord
increas
cumul
anthracyclin
dose
group
diagnosi
group
group
group
taken
control
group
result
median
age
patient
month
rang
month
type
cancer
distribut
patient
acut
lymphoblast
leukemia
patient
lymphoblast
lymphoma
patient
childhood
cancer
treat
anthracyclin
chemotherapi
protocol
howev
heart
rate
variabl
parametr
decreas
increas
cumul
dose
especi
sdnn
index
rmssd
lf
hf
total
power
significantli
alter
among
group
group
lfhf
ration
also
increas
statist
signific
group
accord
heart
rate
paramet
mean
averag
heart
rate
mean
minimum
heart
rate
mean
rr
statist
significantli
prolong
especi
group
group
conclus
heart
rate
variabl
parametr
noninvas
techniqu
demonstr
cardiac
autonom
neural
dysfunct
earli
myocardi
injuri
g
bahoush
mehdiabadi
k
arjmandi
professor
pediatr
hematolog
children
iran
univers
medic
scienc
pediatr
tehran
iran
pediatr
tehran
iran
backgroundobject
stimul
factor
use
prevent
febril
neutropenia
support
intens
chemotherapi
howev
impact
outcom
oncolog
patient
includ
children
acut
lymphoblast
leukemia
determin
far
designmethod
current
studi
data
individu
patient
recruit
children
hospit
prospect
random
studi
pool
perform
joint
analysi
among
children
treat
protocol
patient
assign
receiv
prophylact
along
chemotherapi
patient
treat
without
support
result
median
year
tendenc
toward
increas
year
probabl
surviv
arm
compar
control
versu
p
despit
fact
number
patient
arm
almost
twice
high
control
earli
relaps
arm
two
case
control
two
case
late
relaps
arm
compar
four
case
control
conclus
prophylact
use
chemotherapi
childhood
associ
improv
outcom
recommend
especi
set
childhood
analysi
provid
direct
evid
come
prospect
studi
impact
primari
prophylaxi
surviv
oncolog
patient
j
barredo
g
b
miami
miller
school
medicin
medicin
biochmeistri
molecular
biolog
miami
usa
miami
miller
school
medicin
pediatr
miami
usa
miami
miller
school
medicin
pediatr
miami
usa
backgroundobject
cure
rate
relapsedrefractori
patient
poor
result
remain
common
caus
death
children
adolesc
cell
exhibit
signific
vulner
energymetabol
stress
strategi
target
pathway
viabl
therapeut
option
designmethod
treat
cell
aicar
amp
mimet
known
disrupt
cellular
ampatp
balanc
mimic
energi
stress
activ
amp
activ
protein
kinas
ampk
analyz
mrna
transcript
profil
use
rnaseq
quantit
chromatin
immunoprecipit
chip
assay
employ
valid
rnaseq
data
use
cell
model
result
found
aicar
treatment
mimic
energi
stress
trigger
rapid
epigenet
reprogram
within
hour
cell
model
bioinformat
profil
gene
signatur
relat
mitogen
activ
protein
kinas
mapk
immedi
earli
gene
ieg
identifi
overlap
known
integr
int
transcript
complex
signatur
top
hit
extens
analyz
valid
use
dedic
gene
express
assay
found
dosetim
depend
correl
aicar
treatment
ieg
repress
upregul
inhibitor
myc
transcript
activ
activ
consist
result
chip
assay
reveal
rna
occup
repress
gene
loci
also
diminishedabolish
follow
aicar
treatment
notabl
repress
ieg
revert
overtim
suggest
compensatori
signal
also
activ
ampk
experi
partial
revers
dual
specif
phosphatas
gene
reprogram
suggest
role
ampk
transcript
regul
conclus
conclud
aicar
treatment
trigger
transient
yet
signific
energi
stress
respons
led
shut
ieg
express
manner
like
respons
delin
aicar
jndepend
mechan
epigenet
reprogram
respons
molecular
pathway
allow
us
exploit
synthet
lethal
relapserefractori
mc
berton
ml
v
c
la
n
e
j
ms
nacion
de
prof
dr
juan
p
garrahan
hematolog
oncolog
bueno
air
argentina
backgroundobject
usual
receiv
similar
treatment
howev
total
clear
differ
biolog
characterist
behavior
outcom
aim
compar
biolog
characterist
respons
treatment
event
outcom
group
patient
designmethod
analyz
record
elig
patient
accru
studi
nhl
protocol
receiv
methotrex
treatment
characterist
compar
test
use
estim
compar
surviv
result
differ
median
age
sex
distribut
howev
infant
diagnos
group
detect
pleural
pericardi
involv
observ
respect
p
phenotyp
detect
case
distribut
patient
iii
patient
iiiiv
complet
remiss
cr
achiev
among
patient
achiev
cr
relaps
within
group
patient
die
cr
develop
second
malign
df
se
probabl
differ
mean
time
present
relaps
latenc
develop
second
malign
longer
relaps
conclus
compromis
occur
frequent
even
advanc
diseas
differ
surviv
mean
time
relaps
group
second
neoplasm
observ
longer
latenc
period
c
bohnstedt
l
k
h
baekgaard
l
eh
adolesc
medicin
julian
mari
univers
hospit
rigshospitalet
denmark
univers
hospit
rigshospitalet
pediatr
adolesc
medicin
copenhagen
denmark
hospit
rigshospitalet
pediatr
adolesc
medicin
copenhagen
denmark
ryhov
ungdommedicinska
klinik
sweden
julian
mari
univers
hospit
rigshospitalet
pediatr
adolesc
medicin
copenhagen
denmark
faculti
health
univers
copenhagen
institut
clinic
medicin
copenhagen
denmark
univers
hospit
rigshospitalet
pediatr
adolesc
julian
mari
centr
copenhagen
denmark
backgroundobject
purpos
purpos
studi
explor
experi
parent
patient
syndrom
ds
acut
lymphoblast
leukemia
relat
background
lower
treatment
intens
mainten
treatment
patient
designmethod
criterion
sampl
parent
patient
treat
nopho
sweden
denmark
select
captur
wide
rang
experi
interview
conduct
nativ
languag
interpret
use
one
case
structur
topic
parent
experi
child
symptom
adher
treatment
collabor
physician
regul
dose
abl
address
special
need
provid
suffici
treatment
care
popul
interview
parent
permiss
transcrib
verbatim
transcrib
text
analyz
research
group
use
qualit
content
analysi
result
main
theme
child
spokesperson
safeguard
child
specif
need
interpret
symptom
adher
treatment
commun
physician
balanc
suffici
treatment
sub
theme
vari
reaction
treatment
challeng
interpret
symptom
commun
import
adapt
child
behavior
deal
child
sensit
dosag
regul
conclus
parent
patient
experi
great
varieti
degre
parent
report
difficulti
adher
therapi
parent
experi
challeng
interact
interpret
children
ds
howev
parent
possess
valuabl
knowledg
children
health
condit
leav
great
respons
act
spokesperson
children
involv
parent
treatment
children
ds
enabl
accur
interpret
symptom
may
improv
outcom
c
bohnstedt
b
h
k
adolesc
medicin
julian
mari
univers
hospit
rigshospitalet
denmark
julian
mari
univers
hospit
rigshospitalet
pediatr
adolesc
medicin
copenhagen
denmark
copenhagen
depart
copenhagen
denmark
hospit
oslo
depart
oslo
norway
helsinki
univers
hospit
childeren
hospit
helsinki
finland
hospit
reykjavik
depart
reykjavik
iceland
childhood
cancer
research
unit
depart
women
children
health
stockholm
sweden
institut
childhood
cancer
research
unit
depart
women
children
stockholm
sweden
univers
hospit
rigshospitalet
pediatr
adolesc
julian
mari
centr
copenhagen
denmark
backgroundobject
children
syndrom
ds
acut
lymphoblast
leukemia
inferior
prognosi
compar
patient
methotrex
given
concurr
oral
frequent
follow
myelotox
caus
treatment
interrupt
may
enhanc
incorpor
cytotox
metabolit
dna
increas
dosag
chromosom
gene
may
increas
cellular
mtx
uptak
reduc
folat
carrier
designmethod
review
cours
white
blood
cell
wbc
absolut
neutrophil
count
anc
week
follow
mainten
therapi
children
nordic
countri
compar
diagnos
diagnos
result
total
blood
sampl
follow
cours
receiv
reduc
dose
hdm
treatment
wherea
receiv
reduc
dose
cours
p
model
describ
level
wbc
anc
follow
cours
significantli
differ
group
defin
dose
vs
p
p
respect
howev
differ
time
nadir
administr
similarli
differ
ds
patient
receiv
full
dose
absolut
reduct
anc
wbc
level
clearanc
measur
hour
infus
start
similar
reduc
dose
level
differ
nd
p
conclus
conclus
myelotox
similar
frequenc
intens
ds
vs
thu
dose
reduct
recommend
prospect
studi
need
determin
dose
reduct
necessari
avoid
myelotox
ds
borovova
associ
oncolog
patient
zdravstvuy
russian
associ
oncolog
patient
zdravstvuy
moscow
russia
associ
oncolog
patient
zdravstvuy
russian
associ
oncolog
patient
zdravstvuy
moscow
russia
backgroundobject
children
age
malign
neoplasm
diagnos
first
time
case
higher
case
case
malign
neoplasm
detect
children
age
year
diagnosi
cancer
chang
patient
life
also
live
love
one
cancer
occur
children
young
peopl
increasingli
child
cancer
great
impact
famili
psycholog
health
creativ
love
help
face
ailment
parent
whose
children
fight
cancer
need
assist
get
distract
heavi
thought
find
busi
hospit
stay
becom
happier
designmethod
confer
theme
advanc
cure
transform
care
submit
abstract
session
understand
impact
child
cancer
famili
dynam
result
skill
hand
weekli
free
sew
mom
children
treatment
particip
project
get
starter
kit
thread
needl
pattern
cloth
flap
cours
sew
skill
new
hobbi
thing
sewn
hand
shred
toy
born
new
charact
mother
courag
patient
creat
accord
idea
children
give
smile
warmth
joy
cute
littl
friend
help
children
recov
faster
particip
grant
certif
complet
cours
complet
product
three
toy
conclus
mother
support
children
way
recoveri
particip
receiv
certif
end
cours
mani
alreadi
step
outsid
wall
oncolog
center
even
open
small
sew
busi
disclosur
relev
conflict
interest
declar
j
cai
j
h
c
j
b
x
j
l
j
children
medic
shanghai
jiao
tong
univers
school
key
lab
pediatr
hematolog
oncolog
china
ministri
health
hematologyoncolog
shanghai
china
backgroundobject
retrospect
studi
conduct
shanghai
children
medic
center
china
scmc
investig
result
treatment
childhood
acut
lymphoblast
leukemia
order
improv
outcom
childhood
identifi
prognost
factor
designmethod
patient
age
year
old
enrol
treat
use
protocol
result
patient
age
year
old
enrol
treat
use
protocol
analysi
includ
evalu
patient
treatment
intens
base
patient
present
featur
genet
abnorm
earli
respons
treatment
level
minim
residu
diseas
mrd
complet
remiss
cr
achiev
patient
year
surviv
ef
rate
overal
surviv
rate
ef
rate
patient
lr
ir
hr
group
respect
induct
failur
confer
wors
prognosi
patient
younger
year
age
diagnosi
immunophenotyp
male
gender
associ
significantli
wors
prognosi
statu
day
associ
significantli
reduc
ef
ef
vs
especi
patient
achiev
cr
conclus
overal
outcom
lr
ir
patient
treat
protocol
scmc
reason
statu
day
induct
therapi
import
predict
therapeut
implic
jp
caneba
j
p
c
ap
gener
hospit
hematolog
oncolog
manila
philippin
jude
children
research
hospit
depart
global
pediatr
depart
oncolog
memphi
usa
backgroundobject
philippin
gener
hospit
adopt
intern
societi
pediatr
oncolog
siop
pediatr
oncolog
develop
countri
podc
graduat
intens
regimen
acut
lymphoblast
leukemia
improv
outcom
compar
baselin
report
overal
surviv
os
toxic
death
rate
treatment
abandon
rate
proceed
stepwis
protocol
intensif
regimen
report
outcom
designmethod
prospect
data
collect
retrospect
analysi
patient
yr
seen
januari
decemb
patient
stratifi
standard
risk
sr
high
risk
hr
high
risk
vhr
base
nci
criteria
cn
statu
immunophenotyp
day
prednison
respons
post
induct
bone
marrow
morpholog
treatment
outcom
analyz
endpoint
march
result
patient
evalu
risk
classif
vhr
remiss
induct
die
abandon
resist
death
first
remiss
relaps
occur
patient
achiev
second
remiss
median
month
rang
complet
respond
continu
complet
remiss
ef
overal
surviv
os
abandon
event
respect
efso
sr
hr
vhr
respect
conclus
stepwis
treatment
intensif
regimen
coupl
improv
support
care
associ
better
overal
surviv
although
abandon
relaps
major
caus
treatment
failur
role
institut
delay
protocol
evalu
particularli
sr
patient
treatment
stratif
hr
vhr
patient
regimen
could
improv
outcom
sh
chen
th
cp
ij
ty
yj
ly
chang
gung
memori
hospit
pediatr
hematologyoncolog
taoyuan
taiwan
roc
chang
gung
memori
hospit
hematologyoncolog
taoyuan
taiwan
roc
backgroundobject
adolesc
acut
lymphoblast
leukemia
report
poorer
prognosi
compar
younger
patient
recent
studi
demonstr
person
treatment
base
minim
residu
diseas
mrd
improv
outcom
identifi
patient
success
manag
regimen
well
requir
intensifi
treatment
avert
relaps
aim
studi
evalu
impact
therapi
treatment
outcom
adolesc
singl
center
taiwan
designmethod
pediatr
patient
includ
adolesc
age
year
complet
geneticcytogenet
analysi
diagnosi
treat
consecut
taiwan
pediatr
oncolog
group
tpog
protocol
linkou
chang
gung
memori
hospit
taiwan
earlier
protocol
risk
stratif
base
present
clinic
featur
leukem
cell
genet
latest
protocol
start
determin
mrd
multiparamet
flow
cytometri
pcr
analysi
mrd
level
use
guid
treatment
intens
result
adolesc
significantli
like
less
like
hyperdiploidi
compar
younger
patient
adolesc
patient
treat
earlier
protocol
fifteen
adolesc
patient
underw
chemotherapi
protocol
signific
differ
definit
risk
group
alloc
compar
earlier
protocol
three
patient
provision
hr
group
mrd
end
induct
assign
definit
vhr
group
overal
treatment
outcom
better
patient
treat
protocol
surviv
rate
vs
p
conclus
although
case
number
small
durat
short
adolesc
cure
intens
chemotherapi
x
chen
x
b
w
x
blood
diseas
hospit
chines
academi
medic
scienc
cam
depart
paediatr
haematolog
tianjin
china
backgroundobject
china
children
leukemia
group
cclg
conduct
studi
acut
lymphoblast
leukemia
designmethod
analyz
outcom
patient
treat
accord
platform
center
result
complet
remiss
rate
patient
death
remiss
overal
surviv
os
rate
children
respect
os
rate
standard
risk
middl
risk
high
risk
group
respect
p
last
follow
develop
second
neoplasm
patient
relaps
high
risk
group
patient
receiv
stem
cell
transplant
first
complet
remiss
stage
protocol
tyrosin
kinas
inhibitor
tki
nt
regularli
combin
chemotherapi
patient
bcrabl
patient
treat
tki
os
conclus
surviv
rate
children
increas
approxim
substanti
progress
treatment
strategi
studi
group
seem
lower
surviv
rate
develop
countri
patient
bcrabl
poor
outcom
lower
rate
tki
use
increas
number
transplant
may
increas
cure
rate
reduc
relaps
high
risk
group
patient
p
chitalkar
cd
v
r
n
p
r
saim
cancer
centr
depart
medic
pediatr
oncolog
indor
india
india
medic
oncolog
indor
india
medic
oncolog
indor
india
backgroundobject
methotrex
hdmtx
deliv
h
infus
leucovorin
lv
rescu
therapeut
strategi
acut
lymphoblast
leukemia
methotrex
level
estim
logist
issu
rural
underserv
area
report
experi
hdmtx
use
leucovorin
rescu
without
monitor
mtx
level
designmethod
retrospect
studi
patient
feb
treat
protocol
risk
stratif
hdmtx
given
hour
consecut
urin
ph
hydrat
sodium
bicarbon
urinari
alkalin
leucovorin
rescu
start
hour
complet
total
dose
everi
hourli
toxic
record
base
common
terminolog
criteria
advers
event
ctcae
version
result
patient
f
median
age
median
distanc
hospit
km
eight
support
teenag
young
adult
cancer
tyacan
foundat
thirteen
standard
risk
sr
intermedi
ir
high
risk
hr
four
cycl
hdmtx
given
sr
ir
wherea
hr
patient
receiv
cycl
hdmtx
cyle
hdmtx
administ
elev
alt
time
uln
occur
serum
bilirubin
elev
upto
nausea
vomit
occur
oral
mucos
transient
elev
serum
creatinin
note
hematolog
toxic
occur
subacut
encephalopathi
occur
morbilliform
rash
toxic
grade
manag
conserv
two
patient
relaps
one
ir
isol
testicular
relaps
one
hr
marrow
testicular
cn
relaps
conclus
unavail
mtx
level
delay
time
outsourc
sampl
maintain
cold
chain
challeng
use
hdmtx
care
pretreat
evalu
adequ
hydrat
alkalan
leucovorin
appear
feasibl
manag
toxic
even
patient
come
long
distanc
pemit
therapi
rural
patient
limit
resourc
chu
mc
mb
children
medic
center
cancer
hematolog
center
quezon
citi
philippin
backgroundobject
acut
lymphoblast
leukemia
repres
largest
group
pediatr
malign
high
cure
rate
childhood
repres
one
remark
success
stori
war
cancer
lower
middl
incom
countri
lmic
like
philippin
review
five
year
surviv
tertiari
referr
center
retrospect
cohort
studi
aim
determin
surviv
children
year
old
treat
tertiari
referr
center
childhood
cancer
januari
decemb
designmethod
research
design
employ
retrospect
cohort
studi
medic
chart
newli
diagnos
age
year
old
januari
decemb
review
result
total
subject
includ
studi
year
overal
surviv
os
event
free
surviv
ef
respect
year
os
standard
risk
high
risk
patient
year
os
patient
remiss
relaps
univari
multivari
cox
proport
hazard
regress
reveal
wbc
count
diagnosi
risk
classif
immunophenotyp
relaps
show
signific
prognost
impact
mortal
age
gender
report
prognost
signific
conclus
os
ef
lower
compar
develop
countri
compar
lmic
prognost
factor
identifi
compat
literatur
prognosi
relaps
poor
overal
adopt
treatment
protocol
childhood
institut
show
accept
result
c
chun
fei
h
c
h
ln
baon
shalu
taichung
citi
taiwan
roc
daytim
even
phone
number
master
depart
preceptor
hung
kuang
univers
taichung
citi
taiwan
roc
quemoy
univers
school
nurs
associ
professor
kinmen
counti
taiwan
roc
medicin
nation
taiwan
univers
phd
emeritu
school
nurs
taipei
taiwan
roc
kuang
univers
assist
kuang
director
hemotolg
section
attend
doctor
infecti
diseas
depart
taichung
veteran
gener
taichung
veteran
gener
hospit
taichung
citi
taiwan
roc
backgroundobject
mother
feel
shock
fear
anxieti
sad
upon
learn
child
diagnos
acut
lymphocyt
leukemia
follow
child
cancer
diagnosi
mother
must
assum
new
role
respons
especi
first
year
follow
diagnosi
studi
examin
desir
mother
care
children
within
year
initi
diagnosi
designmethod
research
adopt
qualit
model
involv
guid
interview
mother
age
year
children
age
year
month
year
diagnos
explor
matern
desir
care
children
cancer
interview
transcript
verbatim
data
analysi
perform
use
content
analysi
result
find
reveal
mother
desir
follow
want
feel
alon
term
avail
emot
support
understand
famili
health
profession
want
learn
appropri
knowledg
skill
health
profession
internet
parent
children
cancer
want
health
profession
take
time
discuss
children
condit
want
extra
support
care
healthi
children
want
god
protect
sick
children
danger
pose
cancer
treatment
want
spiritu
support
provid
famili
willpow
overcom
difficult
period
want
financi
secur
resign
job
pay
cancer
treatment
conclus
health
profession
provid
emot
inform
practic
support
also
use
variou
resourc
assist
mother
overcom
challeng
face
care
child
cancer
hold
famili
social
welfar
interdisciplinari
meet
enhanc
qualiti
care
provid
children
famili
l
e
f
gome
de
e
pereira
ms
nacion
de
pediatr
hematolog
oncolog
program
rio
de
janeiro
brazil
backgroundobject
acut
lymphoblast
leukemia
heterogen
diseas
regard
immunophenotyp
profil
molecular
alter
contrast
precursor
outcom
associ
complet
understood
designmethod
investig
somat
alter
nkra
mutat
gene
rearrang
copi
number
alter
cna
evalu
correl
clinic
laboratori
featur
matur
profil
immunophenotyp
evalu
case
year
old
mutat
fusion
gene
identifi
accord
standard
molecular
techniqu
pcr
direct
sequenc
multiplex
ligat
depend
probe
amplif
mlpa
kit
mc
holland
result
case
associ
alter
epigenet
regul
neg
correl
alter
signal
pathway
nkra
pten
regard
associ
alter
epigenet
regul
associ
p
rare
found
subtyp
p
analys
tcr
cellular
express
case
higher
frequenc
ptendel
p
respect
also
found
group
case
analys
surviv
probabl
overal
surviv
po
impact
po
regard
molecular
alter
case
lower
po
po
case
po
nkrasmut
case
po
higher
po
respect
conclus
associ
alter
gene
enrich
immatur
phenotyp
subtyp
epigenet
regul
signal
pathway
regul
nkra
genom
alter
associ
outcom
cohort
v
cr
r
india
institut
medic
scienc
paediatr
new
delhi
india
backgroundobject
improv
surviv
acut
lymphoblast
leukemia
focu
late
effect
therapi
among
neurocognit
deficit
worrisom
object
studi
determin
preval
spectrum
variou
factor
associ
neurocognit
deficit
survivor
age
year
designmethod
observ
studi
children
enrol
studi
neurocognit
function
assess
use
indian
adapt
wechsler
intellig
scale
full
scale
intellig
quotient
fsiq
primari
index
score
determin
result
preval
confid
interv
neurocognit
deficit
sampl
popul
preval
confid
interv
deficit
sampl
popul
verbal
comprehens
perceptu
reason
work
memori
process
speed
among
variou
risk
factor
assess
lower
socioeconom
statu
poorer
matern
patern
educ
higher
birth
order
associ
increas
preval
neurocognit
deficit
sampl
popul
factor
includ
gender
age
assess
age
initi
treatment
number
sibl
famili
type
presenc
cn
diseas
diagnosi
type
chemotherapi
protocol
use
statist
signific
children
neurocognit
deficit
poorer
nutrit
statu
time
initi
therapi
time
assess
conclus
preval
neurocognit
deficit
survivor
childhood
high
hypothes
children
normal
score
domain
preval
deficit
higher
perceptu
reason
compar
primari
index
score
mc
cruz
j
mf
children
medic
center
cancer
hematolog
center
quezon
citi
philippin
backgroundobject
dispar
surviv
outcom
pediatr
acut
lymphocyt
leukemia
larg
due
high
pocket
cost
low
incom
countri
like
philippin
philhealth
govern
insur
system
launch
z
benefit
packag
standard
risk
sr
treatment
naiv
childhood
determin
outcom
patient
enrol
z
benefit
philippin
children
medic
center
designmethod
patient
enrol
consecut
demograph
clinic
data
gather
includ
age
gender
initi
white
blood
cell
count
initi
csf
analysi
cytospin
testicular
involv
male
bone
marrow
morpholog
immunophenotyp
nation
cancer
institut
nci
clinic
criteria
risk
stratif
use
sr
patient
philhealth
elig
abl
avail
z
benefit
modifi
kong
protocol
use
treat
patient
result
total
patient
newli
diagnos
slightli
male
femal
sr
patient
compris
overal
patient
enrol
z
benefit
elig
avail
dramat
increas
trend
patient
abandon
treatment
among
z
benefit
compar
patient
avail
likewis
patient
relaps
without
z
benefit
versu
patient
z
benefit
ef
os
z
benefit
respect
without
z
benefit
ef
os
conclus
data
suggest
establish
financ
scheme
effect
dismantl
econom
barrier
care
translat
improv
outcom
children
h
davidson
j
n
univers
depart
clinic
experiment
crown
princess
victoria
children
univers
hospit
sweden
univers
depart
medic
health
divis
health
care
analysi
sweden
institutet
depart
women
children
divis
pediatr
oncolog
stockholm
sweden
academi
health
counti
council
depart
institut
clinic
sahlgrenska
univers
gothenburg
sweden
univers
depart
women
children
health
uppsala
sweden
backgroundobject
treatment
pegyl
asparaginas
childhood
acut
lymphoblast
leukaemia
crucial
part
paediatr
treatment
protocol
howev
inform
optim
treatment
intens
unclear
caus
uncertainti
regard
efficaci
toxic
treatment
well
impact
health
care
cost
current
paediatr
treatment
protocol
nordic
countri
nopho
randomis
patient
delay
intensif
earli
mainten
versu
interv
total
vs
dose
interv
dose
standard
treatment
purpos
studi
compar
resourc
use
cost
childhood
treatment
accord
nopho
randomis
group
designmethod
retrospect
studi
design
use
base
patient
file
two
consecut
year
two
swedish
univers
hospit
total
patient
treatment
accord
protocol
investig
cost
calcul
euro
base
health
care
consumpt
due
year
diagnosi
result
total
cost
patient
treat
administ
standard
arm
correspond
cost
patient
treat
experiment
arm
dose
interv
differ
cost
signific
patient
includ
random
cost
higher
patient
includ
studi
vs
conclus
found
total
treatment
cost
differ
patient
treat
administ
interv
sinc
higher
frequenc
total
dose
seem
influenc
surviv
clear
impact
toxic
et
al
blood
administ
interv
lower
total
dose
prefer
treatment
context
de
pietri
pt
tl
sw
k
k
christian
andersen
children
odens
univers
hospit
depart
pediatr
hematolog
oncolog
odens
denmark
univers
copenhagen
depart
pediatr
adolesc
medicin
copenhagen
denmark
copenhagen
depart
clinic
veterinari
anim
section
compar
pediatr
nutrit
copenhagen
denmark
copenhagen
institut
clinic
faculti
health
medicin
copenhagen
denmark
backgroundobject
gastrointestin
toxic
common
advers
effect
chemotherapi
childhood
acut
lymphoblast
leukemia
present
oral
mucos
diarrhea
abdomin
pain
increas
risk
infect
bovin
colostrum
bc
rich
trophic
factor
shown
protect
effect
gastrointestin
toxic
piglet
random
trial
establish
investig
bc
affect
gastrointestin
toxic
system
inflamm
infecti
morbid
chemotherapi
childhood
designmethod
total
children
year
treat
accord
protocol
odens
univers
hospit
univers
hospit
rigshospitalet
denmark
random
diagnosi
daili
nutrit
supplement
bc
placebo
product
induct
therapi
famili
regist
daili
complianc
bodi
temperatur
gastrointestin
toxic
pediatr
oral
mucos
daili
questionnair
omdq
gastrointestin
toxic
score
weekli
investig
use
criteria
plasma
crp
measur
weekli
blood
cultur
intraven
antibiot
regist
throughout
induct
treatment
outcom
investig
analysi
result
patient
random
placebo
bc
similar
overal
complianc
respect
two
group
differ
gender
age
phenotyp
risk
group
treat
center
overal
bc
influenc
incid
sever
mucos
four
week
induct
nevertheless
sever
oral
mucos
first
two
week
significantli
lower
bc
group
compar
placebo
group
ci
patient
receiv
placebo
bc
differ
number
day
fever
number
bacteremia
episod
day
intraven
antibiot
crp
level
conclus
despit
low
complianc
preliminari
result
show
protect
effect
bc
oral
mucos
h
dhingra
apollo
hospit
pediatr
hematolog
oncolog
delhi
india
backgroundobject
high
dose
methotrex
hdmtx
integr
part
manag
children
acut
lymphoblast
leukemia
non
hodgkin
lymphoma
nhl
hdmtx
caus
signific
toxic
henc
need
stringent
monitor
plasma
drug
level
studi
aim
investig
toxic
profil
hdmtx
correl
plasma
drug
level
toxic
also
share
experi
drug
level
monitor
cohort
designmethod
year
retrospect
analysi
perform
clinic
laboratori
data
patient
age
year
underw
cycl
hdmtx
base
experi
prior
time
inhous
methotrex
level
estim
avail
unit
polici
send
first
level
monitor
third
dose
leucovorin
hour
result
three
episod
develop
sever
toxic
form
sever
mucos
sever
myelosupress
requir
prolong
hospit
patient
renal
failur
life
threaten
toxic
monitor
drug
level
hour
seen
cycl
drug
level
rang
micromolland
cycl
level
micomol
howev
cycl
hdmtx
manag
monitor
singl
plasma
drug
level
hour
start
hour
infus
conclus
though
imper
dynam
monitor
plasma
drug
level
may
alway
predict
toxic
strategi
monitor
drug
concentr
hour
safe
cohort
n
dhingra
p
h
v
r
india
institut
medic
scienc
hematolog
new
delhi
india
super
special
patparganj
haematolog
bone
marrow
transplant
new
delhi
india
india
institut
medic
scienc
patholog
new
delhi
india
backgroundobject
traumat
lumbar
punctur
tlp
diagnosi
acut
lymphoblast
leukemia
advers
impact
surviv
especi
blast
also
present
platelet
count
recommend
diagnost
lp
scarciti
platelet
achiev
target
difficult
analyz
risk
factor
tlp
impact
central
nervou
system
cn
relaps
pediatr
designmethod
medic
record
children
treat
retrospect
analyz
put
risk
factor
tlp
age
sex
bodi
mass
index
total
leucocyt
count
platelet
count
day
protocol
lp
prior
chemotherapi
administ
patient
tlp
csf
receiv
addit
intrathec
therapi
induct
patient
achiev
remiss
diseas
relaps
note
result
children
median
age
year
rang
year
male
preponder
identifi
children
baselin
tlp
seen
case
median
day
lp
rang
none
risk
factor
analyz
tlp
found
signific
except
hyperleukocytosi
ci
median
platelet
count
patient
atraumat
lp
vs
tlp
median
durat
month
rang
month
patient
remiss
cn
relaps
occur
patient
use
surviv
estim
cn
surviv
rf
patient
tlp
ci
ci
ci
month
conclus
hyperleucocytosi
found
risk
tlp
insignific
trend
tlp
lower
platelet
count
cohort
tlp
found
cn
relaps
n
dhingra
n
h
r
india
institut
medic
scienc
hematolog
new
delhi
india
backgroundobject
surviv
rate
pediatr
acut
lymphoblast
leukemia
india
vari
treatment
abandon
infect
diseas
relaps
major
caus
inferior
outcom
compar
first
world
countri
identifi
therapi
interrupt
induct
chemotherapi
major
impedi
surviv
rf
designmethod
medic
record
children
underw
treatment
retrospect
review
children
plan
uniform
induct
follow
post
remiss
therapi
therapi
interrupt
defin
deviat
protocol
hepat
renal
dose
modif
detail
record
till
last
visit
result
children
median
age
year
rang
year
male
femal
ratio
underw
induct
studi
period
median
durat
case
went
remiss
month
rang
month
case
therapi
interrupt
induct
account
sever
infect
jaundic
induc
pancreat
seizur
hypersensit
reaction
case
amongst
infecti
caus
fungal
pneumonia
observ
case
end
induct
morpholog
remiss
attain
case
therapi
interrupt
case
relaps
medullari
extramedullari
combin
compar
relaps
group
without
therapi
interrupt
p
surviv
estim
month
rf
patient
therapi
interrupt
ci
vs
ci
patient
interrupt
conclus
infecti
complic
common
caus
treatment
interrupt
despit
achiev
morpholog
remiss
end
induct
patient
therapi
interrupt
advers
outcom
inferior
rf
cl
diez
aj
dv
bj
ga
j
c
mc
philippin
medic
center
depart
children
cancer
institut
davao
citi
philippin
jude
children
research
hospit
global
pediatr
medicin
depart
memphi
usa
backgroundobject
southern
philippin
medic
center
largest
tertiari
govern
referr
center
pediatr
cancer
mindanao
philippin
common
diagnosi
new
patient
seen
annual
baselin
data
show
event
free
time
week
abandon
modifi
bfm
protocol
treatment
regimen
shift
cog
backbon
report
outcom
designmethod
newli
diagnos
pediatr
patient
year
old
treatment
protocol
includ
studi
retrospect
review
demograph
data
treatment
outcom
conduct
hospit
medic
record
pediatr
oncolog
network
databas
studi
period
januari
result
elig
analysi
patient
diagnos
refus
treatment
upfront
regimen
die
prior
treatment
mean
age
diagnosi
year
old
male
femal
ratio
nci
risk
classif
show
sr
hr
n
immunophenotyp
b
cell
cell
remiss
induct
studi
endpoint
aliv
relaps
die
abandon
treatment
infect
bleed
major
caus
death
event
free
surviv
overal
surviv
consid
abandon
event
respect
conclus
decreas
treatment
abandon
reflect
better
complianc
current
treatment
regimen
allow
higher
chanc
cure
improv
support
care
address
infect
prevent
bleed
may
improv
surviv
well
strategi
promot
enhanc
access
care
z
dreyer
j
k
j
k
r
r
j
e
l
c
colleg
medicin
pediatr
houston
usa
backgroundobject
histor
diseas
wbc
blast
twice
within
four
week
met
definit
cn
relaps
cn
r
current
dx
cn
r
wbc
blast
assess
role
diseas
outcom
review
patient
diagnos
diseas
post
induct
januari
designmethod
twenti
eight
patient
csf
first
event
post
induct
includ
median
age
yr
diagnosi
first
event
occur
consolid
interim
mainten
delay
intensif
mainten
end
treatment
year
treatment
patient
treat
accord
cog
protocol
current
berlinfrankfort
munster
bfm
augment
bfm
schema
result
patient
categor
categori
x
subsequ
event
categori
x
subsequ
non
event
categori
x
two
event
fourteen
event
occur
marrow
relaps
combin
cnsbm
median
time
second
event
month
seven
event
occur
multipl
marrow
relaps
combin
cnsbm
median
time
second
event
month
patient
categori
remain
first
remiss
six
patient
categori
five
categori
aliv
diseas
control
treatment
ten
pt
die
diseas
infect
conclus
patient
singl
event
well
without
event
categori
categori
patient
remain
diseas
free
though
earli
recognitionintervent
remain
aliv
remiss
n
jm
de
r
e
n
r
univers
hospit
pediatr
oncolog
hematolog
depart
barakaldo
spain
backgroundobject
need
empir
antibiot
therapi
well
establish
febril
neutropenia
remain
unclear
ideal
manag
patient
fever
diagnosi
object
studi
describ
preval
manag
patient
fever
diagnosi
unit
designmethod
retrospect
descript
studi
children
year
diagnos
center
june
januari
analyz
fever
onset
axillari
day
fever
presenc
sever
neutropenia
absolut
neutrophil
count
x
blood
cultur
administr
durat
empir
antibiotherapi
result
children
diagnos
n
fever
diagnosi
half
case
sepsi
suspect
although
one
admit
picu
due
fulmin
hepat
failur
requir
emerg
liver
transplant
prior
diagnosi
three
confirm
infect
pneumonia
digit
cellul
blood
cultur
obtain
febril
patient
neg
one
contamin
scapiti
n
patient
fever
receiv
empir
antibiot
therapi
median
durat
fever
one
day
usual
disappear
within
first
hour
onset
prednison
nt
find
associ
neutrophil
count
diagnosi
risk
fever
vs
p
blast
count
peripher
blood
risk
fever
p
conclus
bacteremia
rare
children
fever
diagnosi
strengthen
theori
possibl
neoplas
origin
fever
believ
antibiot
therapi
discontinu
patient
neg
cultur
remain
afebril
clinic
stabl
although
remain
neutropenia
ehsani
h
e
univers
medic
scienc
pediatr
hemaiolog
oncolog
tehran
iran
univers
medic
scienc
faculti
pharmaci
khorramabad
iran
pharmaci
tehran
univers
medic
scienc
pharmacoeconom
pharmaceut
departart
tehran
iran
chariti
hospit
pediatr
oncolog
tehran
iran
backgroundobject
requir
assess
effect
resourc
use
two
protocol
unit
kingdom
commonli
use
treatment
patient
oncologist
iran
accordingli
analyz
cost
treatment
util
children
treat
two
protocol
iran
designmethod
entir
medic
direct
cost
patient
bfm
protocol
uk
protocol
calcul
apr
jun
calcul
util
qualiti
adjust
life
year
qali
patient
use
standard
questionnair
health
util
index
patient
parent
interview
data
analyz
use
softwar
excel
result
averag
direct
medic
cost
patient
usd
usd
show
signific
differ
total
cost
treatment
two
protocol
final
signific
differ
util
score
mainten
phase
two
method
conclus
domin
bfm
protocol
domin
side
total
cost
util
qali
mainli
hospit
stay
bfm
protocol
caus
rais
cost
protocol
consid
differ
qali
method
low
cost
uk
protocol
uk
protocol
prefer
ehsani
e
h
univers
medic
scienc
pediatr
hemaiolog
oncolog
tehran
iran
univers
medic
scienc
pharmaci
colleg
khorramabad
iran
univers
medic
scienc
pharmacoeconom
pharmaceut
administr
tehran
iran
chariti
hospit
pediatr
oncolog
tehran
iran
backgroundobject
among
pediatr
cancer
acut
lymphoblast
leukemia
highli
preval
overal
cost
manag
need
assess
bfm
protocol
commonli
use
manag
iran
aim
studi
estim
direct
indirect
cost
treatment
among
children
base
protocol
societ
perspect
iran
designmethod
retrospect
studi
conduct
pediatr
patient
newli
diagnos
manag
bfm
protocol
includ
final
total
cost
includ
direct
medic
cost
direct
cost
indirect
cost
calcul
result
total
direct
medic
cost
per
patient
complet
treatment
period
us
dollar
direct
cost
incur
usd
indirect
cost
due
product
loss
usd
conclus
treatment
pediatr
less
costli
iran
compar
countri
physician
polici
maker
health
care
system
administr
devis
appropri
strategi
reduc
direct
medic
cost
econom
burden
special
hospit
day
chemotherapi
cost
base
find
ehsani
h
univers
medic
scienc
pediatr
hemaiolog
oncolog
tehran
iran
univers
medic
scienc
pharmaci
faculti
khorramabad
iran
univers
medic
scienc
pharmacoeconom
pharmaceut
administr
tehran
iran
chariti
hospit
pediatr
oncolog
tehran
iran
backgroundobject
pediatr
acut
lymphoblast
leukemia
common
yet
curabl
childhood
malign
within
pediatr
cancer
develop
develop
countri
cost
cancer
treatment
children
high
specifi
rang
expens
treatment
pediatr
cancer
compar
result
develop
develop
countri
designmethod
evalu
treatment
cost
childhood
review
taken
place
publish
paper
year
search
multipl
well
known
databas
medlin
scopu
isi
web
scienc
googl
scholar
januari
cost
effect
cost
util
cost
minim
cost
analysi
econom
evalu
childhood
acut
lymphoblast
leukemia
keyword
result
regard
review
evid
essenti
result
total
cost
treatment
pediatr
develop
countri
asian
countri
consider
lower
cost
report
high
incom
countri
europ
north
america
differ
protocol
perform
treat
matter
signific
due
differ
durat
hospit
conclus
accord
result
total
cost
treatment
pediatr
develop
countri
consider
lower
cost
report
high
incom
countri
z
fadoo
f
khan
univers
oncolog
karachi
pakistan
khan
univers
medic
colleg
karachi
pakistan
khan
univers
pediatr
child
health
karachi
pakistan
backgroundobject
minim
residu
diseas
mrd
detect
presenc
leukem
cell
even
morpholog
evid
bone
marrow
convent
method
mrd
establish
prognost
marker
risk
relaps
gener
proport
level
mrd
major
center
world
treat
childhood
use
mrd
predictor
respons
adjust
treatment
accordingli
studi
aim
valid
mrd
result
establish
correl
post
induct
mrd
event
free
surviv
rate
children
acut
lymphoblast
leukemia
treat
aga
khan
univers
hospit
designmethod
retrospect
studi
done
aga
khan
univers
karachi
pakistan
patient
children
age
year
newli
diagnos
septemb
complet
therapi
flow
cytometri
base
mrd
valu
avail
day
obtain
patient
patient
care
inquiri
pci
system
medic
record
patient
come
akuh
result
total
patient
complet
entir
chemotherapi
patient
day
mrd
valu
avail
mean
age
year
patient
age
group
year
male
major
patient
diagnos
b
precursor
patient
year
ef
patient
year
ef
significantli
lower
mrd
lymphoblast
valu
ie
ci
versu
ci
mrd
conclus
studi
valid
mrd
result
techniqu
institut
show
mrd
posit
blast
associ
signific
lower
ef
rate
ol
fan
k
f
g
kt
ck
chines
univers
hong
kong
depart
paediatr
hong
kong
hong
kong
sar
backgroundobject
mercaptopurin
mp
essenti
treat
paediatr
acut
lymphoblast
leukaemia
thiopurin
methyltransferas
tpmt
mutat
associ
toxic
low
incid
asian
polymorph
nudix
hydrolas
inosin
triphosphatas
itpa
cassett
c
member
also
potenti
predictor
toxic
aim
explor
correl
dosag
incid
differ
variant
gene
includ
tpmt
itpa
etc
hk
patient
identifi
novel
gene
interact
snp
designmethod
patient
treat
princ
wale
hospit
recruit
clinic
data
includ
maxim
toler
mtx
dosag
mainten
phase
leukopenia
neutropenia
episod
retriev
blood
sampl
consent
patient
analyz
genotyp
result
clinic
data
survivor
retriev
recommend
dose
mean
toler
patient
poor
toler
dna
sampl
analys
gene
mutat
frequenc
follow
tmpt
c
delggagtc
g
c
itpa
c
c
c
genotyp
sampl
dosag
data
correl
dose
significantli
correl
intoler
mean
toler
patient
wild
type
wt
heterozyg
allel
respect
potenti
gene
interact
found
itpa
c
mean
toler
patient
wt
itpa
allel
doubl
heterozyg
genotyp
respect
signific
correl
toler
conclus
result
indic
associ
genet
polymorph
itpa
toxic
hk
patient
sampl
snp
analys
formul
comprehens
pharmacogenet
model
guid
treatment
x
x
n
l
fang
hospit
nanj
medic
univers
depat
hematolog
oncolog
nanj
china
medic
univers
key
laboratori
hematolog
nanj
china
backgroundobject
protein
encod
member
famili
gene
consist
cation
amino
acid
transport
system
yl
system
yl
transport
system
transport
cation
amino
acid
cell
arginin
lysin
arginin
critic
cell
activ
function
process
immun
respons
designmethod
studi
analys
cell
prolifer
apoptosi
rate
cell
cycl
abil
migrat
invas
explor
role
gene
jurkat
cell
result
studi
prolifer
abil
jurkat
cell
chang
significantli
transfect
vector
howev
percentag
apoptosi
jurkat
cell
decreas
significantli
p
proport
phase
cell
p
migrat
p
invas
p
abil
obvious
increas
cell
knockdown
cell
apoptosi
ratio
increas
p
phase
ratio
p
migrat
p
invas
p
abil
jurkat
cell
decreas
conclus
result
demonstr
signific
role
pathogenesi
acut
lymphoblast
leukemia
fernand
ft
nurs
universita
indonesia
pediatr
nurs
depart
depok
indonesia
backgroundobject
chemotherapi
impact
disrupt
sleep
pattern
fatigu
children
suffer
acut
lymphoblast
leukemia
fatigu
children
exacerb
sleep
problem
experienc
studi
aim
analyz
relationship
sleep
problem
fatigu
children
acut
lymphoblast
leukemia
undergo
one
cycl
induct
phase
chemotherapi
designmethod
use
descript
analyt
repeat
measur
children
age
year
data
taken
day
consist
one
day
chemotherapi
five
day
chemotherapi
one
day
chemotherapi
result
major
patient
characterist
male
children
acut
lymphoblast
leukemia
sleep
problem
preval
fatigu
preval
use
pearson
correl
test
signific
level
shown
signific
relationship
p
sleep
problem
fatigu
moreov
combin
chemotherapi
agent
contribut
sleep
problem
fatigu
methotrex
dexamethason
l
asparaginas
conclus
children
cancer
suffer
sleep
problem
would
experi
sever
fatigu
nurs
need
screen
sleep
problem
well
fatigu
regularli
chemotherapi
finkbein
v
f
children
hospit
pediatr
hematologyoncologytranspl
calgari
canada
calgari
cum
school
medicin
calgari
canada
calgari
depart
patholog
calgari
canada
backgroundobject
follow
therapi
acut
leukemia
increas
risk
secondari
leukemia
commonli
acut
myeloid
leukemia
aml
describ
patient
initi
diagnosi
aml
later
develop
acut
lymphoblast
leukemia
designmethod
case
report
exploratori
precis
therapeut
approach
result
boy
diagnos
fab
aml
normal
cytogeneticmolecular
assess
treatment
per
children
oncolog
group
studi
arm
includ
standard
induct
cytarabin
daunorubicin
etoposid
end
induct
mrd
neg
stratifi
low
risk
arm
receiv
cycl
remain
remiss
fifteen
month
complet
aml
therapi
diagnos
evid
aml
cytogenet
time
show
trisomi
previous
present
associ
de
novo
myeloid
malign
data
suggest
de
novo
leukemia
evid
lineag
transform
began
induct
per
ukal
protocol
vincristin
dexamethason
peg
asparaginas
daunorubicin
went
remiss
current
mainten
chemotherapi
remain
remiss
leukemia
cell
line
establish
screen
panel
approv
small
molecul
inhibitor
identifi
number
agent
signific
vitro
activ
includ
parp
inhibitor
veliparib
inhibitor
activ
metabolit
irinotecan
mapk
inhibitor
conclus
secondari
follow
aml
therapi
highli
unusu
describ
novel
case
de
novo
follow
aml
therapi
without
evid
lineag
transform
leukemia
continu
grow
cell
relaps
specimen
provid
opportun
studi
rare
leukemogen
event
well
gain
molecular
insight
action
pathway
c
fiori
hospit
pediatr
oncolog
cascavel
brazil
hospit
pediatr
cascavel
brazil
backgroundobject
introducion
brazil
accord
nation
cancer
institut
new
case
cancer
occur
children
adolesc
year
per
year
repres
new
case
cancer
leukemia
common
childhood
childhood
cancer
compris
object
evalu
epidemiolog
profil
leukemia
children
adolesc
western
region
brazil
designmethod
descript
statist
data
obtain
electron
medic
record
analysi
physic
record
provid
medic
archiv
servic
patient
younger
year
diagnosi
leukemia
attend
januari
decemb
result
medic
record
analyz
case
aml
one
case
chronic
myeloid
leukemia
cml
male
femal
age
group
highest
preval
school
age
patient
follow
preschool
age
patient
two
group
respons
case
white
subgroup
frequent
clinic
manifest
observ
time
diagnosi
fever
pallor
bone
pain
splenomegali
lymph
node
enlarg
hepatomegali
conclus
southern
brazil
epidemiolog
characterist
similar
found
develop
countri
howev
still
frequent
late
diagnosi
diseas
like
alert
health
profession
possibl
diagnos
leukemia
two
sign
symptom
go
away
within
first
week
persist
symptom
request
blood
count
help
earli
diagnosi
leukemia
countri
b
e
lopez
n
garcia
de
basqu
upvehu
depart
physic
anthropolog
anim
physiolog
leioa
spain
hospit
donostia
depart
pediatr
san
sebastian
spain
hospit
la
paz
depart
madrid
spain
hospit
cruce
depart
pediatr
barakaldo
spain
backgroundobject
hepat
toxic
one
common
toxic
treatment
childhood
acut
lymphoblast
leukemia
mani
gene
involv
signal
pathway
tightli
control
mirna
mirna
function
could
modul
snp
consequ
hypothes
variant
mirna
could
associ
hepatotox
designmethod
analyz
snp
mirna
cohort
children
homogen
treat
result
signific
snp
consolid
phase
fdr
correct
probabl
effect
target
gene
dhfr
mtr
mthfr
conclus
result
point
possibl
involv
snp
mirna
toxic
chemotherapi
children
e
lopez
b
n
de
basqu
upvehu
depart
physic
anthropolog
anim
physiolog
leioa
spain
hospit
donostia
depart
pediatr
san
sebastian
spain
hospit
la
paz
depart
oncohematolog
madrid
spain
hospit
cruce
depart
pediatr
barakaldo
spain
backgroundobject
mucos
one
debilit
frequent
side
effect
childhood
acut
lymphoblast
leukemia
therapi
character
breakdown
gastrointestin
mucosa
frequent
accompani
vomit
diarrhea
consequ
treatment
could
delay
even
discontinu
may
impair
surviv
mucos
link
sever
antileukem
agent
methotrex
mtx
daunorubicin
dnr
cyclophosphamid
cpa
nowaday
known
mirna
regul
express
gene
involv
pharmacokinet
pk
pharmacodynam
pd
pathway
drug
snp
mirna
could
affect
level
function
affect
target
gene
pathway
therefor
aim
studi
determin
associ
mirna
genet
variant
target
gene
risk
develop
toxic
designmethod
achiev
aim
analyz
snp
mirna
cohort
spanish
children
precursor
homogen
treat
lalshop
protocol
result
identifi
three
snp
associ
mucos
diarrhea
vomit
respect
could
explain
effect
gene
relat
drug
pk
pd
well
mucos
gene
conclus
result
point
possibl
involv
snp
mirna
digest
toxic
children
gutierrez
garcia
e
lopez
basqu
upvehu
depart
physic
anthropolog
anim
physiolog
leioa
spain
health
research
institut
pediatr
oncolog
group
barakaldo
spain
hospit
cruce
depart
pediatr
barakaldo
spain
backgroundobject
although
acut
lymphoblast
leukemia
defin
singl
diseas
etiolog
diagnosi
clinic
behavior
respons
treatment
heterogen
although
group
risk
defin
addit
marker
need
line
microrna
mirna
emerg
new
tool
diagnosi
classif
prognosi
predict
differ
malign
case
sever
studi
perform
mirna
signatur
defin
aim
perform
systemat
review
literatur
determin
mirna
involv
diagnosi
classif
prognosi
respons
designmethod
use
keyword
acut
lymphoblast
leukemia
microrna
noncod
pubm
result
obtain
record
identifi
analyz
mirna
express
pediatr
diagnosi
classif
prognosi
treatment
found
microrna
signific
least
studi
strongest
candid
signatur
conclus
mirna
could
use
tool
marker
diagnosi
classif
prognosi
respons
valid
publish
mirna
deep
search
new
mirna
need
order
establish
signatur
use
clinic
manag
children
diagnos
k
ghanem
n
c
h
h
r
n
r
h
univers
beirut
pediatr
beirut
lebanon
univers
beirut
pharmacolog
toxicolog
beirut
lebanon
univers
beirut
faculti
medicin
beirut
lebanon
univers
beirut
medicin
beirut
lebanon
backgroundobject
aim
studi
evalu
potenti
associ
candid
genet
polymorph
peripher
neuropathi
arab
children
acut
lymphoblast
leukemia
designmethod
retrospect
evalu
arab
children
treat
children
cancer
center
lebanon
protocol
adopt
st
jude
total
xv
therapi
incid
sever
well
time
week
grade
higher
peripher
neuropathi
occur
record
genotyp
perform
use
light
assay
lightcycl
result
sampl
includ
children
mean
sd
age
year
male
femal
fifteen
palestinian
syrian
iraqi
sixti
six
alloc
low
risk
treatment
protocol
arm
alloc
intermediatehigh
risk
arm
subject
develop
peripher
neuropathi
three
occur
induct
phase
statist
signific
associ
reveal
polymorph
neither
incid
toxic
toxic
sever
time
first
episod
grade
higher
peripher
neuropathi
conclus
studi
present
first
pharmacogenet
analysi
peripher
neuropathi
children
arab
countri
result
show
lack
associ
variant
two
us
cohort
children
treat
anoth
cohort
adult
treat
also
show
associ
candid
genet
variant
larger
genet
analys
may
warrant
evalu
variant
candid
gene
reveal
new
report
allel
may
peculiar
region
world
v
gota
v
r
kc
h
centr
research
educ
cancer
tata
memori
centr
clinic
pharmacolog
navi
mumbai
india
memori
centr
medic
oncolog
mumbai
india
memori
centr
medic
ondolog
mumbai
india
backgroundobject
essenti
medicin
qualiti
gener
brand
matter
concern
compar
qualiti
variou
brand
avail
india
designmethod
nine
commonli
use
gener
brand
identifi
qualiti
assess
test
formul
asparaginas
activ
use
micropl
base
colorimetr
method
ii
comparison
trough
asparaginas
activ
children
receiv
induct
chemotherapi
administ
dose
im
everi
day
per
protocol
hour
trough
blood
sampl
patient
drawn
next
dose
result
one
hundr
eighti
nine
patient
enrol
march
may
age
medianrang
year
standardintermediatehigh
risk
case
iu
two
hundr
thirti
four
blood
sampl
analyz
asparaginas
activ
number
sampl
analyz
brand
rang
median
averag
asparaginas
activ
brand
rang
ul
sampl
lowest
activ
brand
ul
highest
activ
brand
median
asparaginas
activ
correspond
ul
proport
patient
fail
achiev
predefin
threshold
activ
ul
rang
highest
activ
brand
lowest
activ
brand
median
direct
analysi
three
formul
comparison
medac
asparaginas
innov
show
asparaginas
activ
gener
rang
innov
conclus
wide
variat
asparaginas
activ
brand
six
nine
brand
test
markedli
inferior
patient
fail
achiev
trough
activ
ul
rais
seriou
concern
qualiti
gener
essenti
medicin
need
pharmacovigil
area
gottschalk
b
j
p
l
tram
g
k
g
k
b
klug
j
univers
hospit
depart
pediatr
adolesc
medicin
aarhu
denmark
univers
depart
women
children
health
uppsala
sweden
olav
hospit
depart
pediatr
trondheim
norway
univers
gothenburg
depart
paediatr
institut
clinic
scienc
gothenburg
sweden
univers
hospit
depart
pediatr
adolesc
medicin
turku
finland
univers
clinic
children
faculti
medicin
vilniu
lithuania
children
hospit
depart
oncolog
haematolog
tallinn
estonia
univers
hospit
children
hospit
reykjavik
iceland
univers
hospit
karolinska
institut
depart
women
children
childhood
cancer
research
unit
stockholm
sweden
hospit
rigshospitalet
depart
pediatr
adolesc
medicin
copenhagen
denmark
hospit
rigshospitalet
pediatr
oncolog
research
rigshospitalet
copenhagen
denmark
backgroundobject
repres
key
element
treatment
acut
lymphoblast
leukemia
howev
allerg
reaction
lack
asparaginas
enzym
activ
shortli
administr
silent
inactiv
constitut
signific
challeng
antibodi
form
prior
exposur
suggest
caus
latter
acceler
clearanc
phenomenon
investig
antibodi
respons
therapi
children
treat
accord
nopho
protocol
without
silent
inactiv
hypersensit
designmethod
enzym
activ
determin
patient
age
year
part
nopho
protocol
measur
use
categor
patient
without
enzym
activ
case
control
studi
recoveri
spike
activ
igg
complex
deplet
protein
g
affin
chromatographi
use
evalu
igg
antibodi
sampl
analyz
patient
advers
phenotyp
ii
silent
inactiv
iii
allergi
asparaginas
enzym
inactiv
iv
allergi
asparaginas
enzym
activ
result
patient
enzym
activ
develop
antibodi
treatment
thu
children
without
clinic
allergi
enzym
activ
could
distinguish
serolog
contrast
igg
antibodi
detect
children
without
enzym
activ
regardless
allergi
statu
lack
vivo
asparaginas
enzym
activ
alway
display
first
administr
antibodi
detect
sampl
patient
patient
miss
sampl
conclus
igg
respons
repeat
administr
primari
driver
inactiv
howev
antibodi
may
acceler
drug
clearanc
valid
investig
igm
antibodi
warrant
order
gain
knowledg
inactiv
gupta
v
india
institut
medic
scienc
new
delhi
lab
irch
new
delhi
india
india
institut
medic
scienc
new
delhi
medic
irch
new
delhi
india
institut
epidemiolog
divis
epidemiolog
biostatist
chennai
india
backgroundobject
delet
seen
pediatr
acut
lymphoblast
leukemia
associ
poor
outcom
recent
shown
type
delet
associ
advers
prognosi
adult
neg
kobitzsch
et
al
undertook
studi
assess
distribut
clinic
impact
function
subtyp
delet
neg
pediatr
designmethod
genom
dna
new
case
pediatr
enrol
month
analyz
delet
use
multiplex
ligat
depend
probe
amplif
delet
divid
function
whole
gene
delet
involv
b
domin
neg
delet
c
other
event
free
surviv
ef
overal
surviv
os
note
result
overal
pediatr
median
age
year
year
delet
nine
posit
case
delet
remain
neg
case
delet
analyz
delet
group
delet
neg
case
combin
delet
remiss
rate
case
delet
lower
compar
without
delet
case
delet
significantli
wors
ef
os
compar
case
without
delet
case
domin
neg
delet
statist
analysi
conclus
delet
seen
neg
pediatr
delet
patient
type
case
delet
lower
remiss
rate
significantli
wors
ef
os
compar
case
without
delet
may
investig
novel
altern
therapi
v
gupta
r
sk
medic
banara
hindu
univers
divis
hematolog
depart
pediatr
varanasi
india
medic
banara
hindu
univers
depart
endocrinolog
varanasi
india
backgroundobject
disturb
bone
metabol
frequent
occur
patient
acut
lymphoblast
leukemia
lead
increas
risk
osteopenia
osteoporosi
diagnosi
chemotherapi
telopeptid
human
type
collagen
ictp
one
resorpt
marker
indic
bone
turnov
present
studi
conduct
evalu
level
ictp
newli
diagnos
patient
chemotherapi
designmethod
forti
four
newli
diagnos
patient
age
group
year
admit
depart
pediatr
includ
relaps
refractori
case
exclud
risk
stratif
done
accord
nci
criteria
quantit
analysi
bone
resorpt
marker
telopeptid
human
type
collagen
ictp
evalu
baselin
month
chemotherapi
level
compar
relat
age
gender
bodi
mass
index
bmi
risk
stratif
cell
lineag
b
cell
result
mean
age
patient
year
median
age
male
femal
ratio
thirti
seven
patient
signific
increas
mean
serum
ictp
level
month
level
diagnosi
month
chemotherapi
ngml
ngml
respect
male
patient
cell
diseas
significantli
higher
mean
ictp
level
month
vs
vs
compar
femal
vs
b
cell
diseas
patient
vs
high
standard
risk
patient
bmi
age
year
year
significantli
increas
level
month
conclus
signific
increas
bone
resorpt
patient
diseas
intens
chemotherapi
harama
k
k
k
h
k
yamanashi
depart
pediatr
chuo
citi
japan
univers
school
medicin
depart
hematolog
oncolog
isehara
japan
medic
univers
depart
nanoparticl
translat
research
shinjuku
japan
backgroundobject
transcript
factor
primarili
involv
surviv
differenti
b
cell
precursor
bcp
alter
gene
shown
confer
poor
prognosi
bcp
acut
lymphoblast
leukemia
particularli
philadelphia
chromosom
posit
ph
report
treatment
lenalidomid
len
thalidomid
deriv
complet
abrog
activ
select
degrad
normal
isoform
phall
cell
commonli
express
domin
neg
isoform
effect
induc
apoptosi
synergi
tyrosin
kinas
inhibitor
tki
imatinib
im
present
studi
address
effect
tki
dasatinib
da
ponatinib
po
mechan
induct
apoptosi
effect
lentki
xenograft
mice
model
phall
final
addit
effect
dexamethason
dex
lentki
examin
designmethod
phall
cell
line
express
use
synerg
effect
len
tki
dex
also
examin
ex
vivo
studi
use
nog
mice
model
perform
result
dalen
effect
induc
apoptosi
phall
cell
polen
effect
induct
apoptosi
phall
cell
line
mutat
express
protein
bax
markedli
western
blot
analysi
lenim
treatment
gradual
increas
cleav
form
lenim
significantli
elong
surviv
nog
mice
transplant
phall
cell
addit
dex
lenim
effect
induct
apoptosi
almost
phall
cell
even
mutat
kill
drug
treatment
conclus
len
function
potent
apoptosi
phall
togeth
agent
thu
drug
treatment
lentkidex
clinic
effect
treatment
phall
even
case
mutat
hassan
u
el
n
univers
pediatr
zagazig
egypt
medic
biochemistri
zagazig
egypt
univers
medic
biochemistri
zagazig
egypt
backgroundobject
acut
lymphoblast
leukemia
common
malign
diagnos
children
repres
quarter
pediatr
cancer
past
decad
mark
extraordinari
advanc
genet
basi
leukemogenesi
treatment
respons
assert
may
genet
basi
long
pursu
associ
studi
base
candid
gene
folat
metabol
polymorph
folat
pathway
gene
may
influenc
suscept
acut
lymphoblast
leukemia
aim
evalu
contribut
mthfr
gene
polymorph
risk
acut
lymphoblast
leukemia
children
designmethod
dna
isol
children
divid
group
group
includ
pediatr
patient
group
ii
includ
healthi
donor
control
genotyp
mthfr
perform
polymeras
chain
fragment
length
polymorph
use
hinf
hhai
restrict
endonucleas
respect
result
mthfr
allel
carrier
significantli
lower
case
healthi
control
reduct
risk
observ
heterozyg
ct
homozyg
tt
carrier
mthfr
allel
ci
p
allel
carrier
increas
suscept
risk
increas
time
ci
p
carrier
conclus
mthfr
gene
variant
associ
decreas
rate
risk
reduc
risk
associ
mthfr
polymorph
may
result
chang
intracellular
folat
redistribut
result
studi
also
support
suggest
singl
nucleotid
polymorph
contribut
increas
suscept
develop
pediatr
c
hendrick
r
n
b
h
van
albert
luthuli
central
univers
kwazulu
natal
paediatr
haematolog
durban
south
africa
albert
luthuli
central
univers
kwazulu
natal
nation
health
laboratori
servic
durban
south
africa
backgroundobject
minim
residu
diseas
mrd
detect
shown
best
prognost
factor
lymphoblast
leukaemia
multicolour
flow
cytometri
fcm
specif
molecular
aberr
mol
classic
techniqu
use
assess
mrd
former
faster
less
costli
studi
compar
morpholog
flow
cytometri
molecular
method
detect
mrd
resourc
limit
set
designmethod
retrospect
review
children
manag
inkosi
albert
luthuli
central
hospit
ialch
januari
januari
fcm
perform
use
panel
mol
look
common
cytogenet
marker
present
morpholog
may
grunwald
giemsa
stain
fcm
mol
data
mrd
analys
result
eleven
patient
exclud
record
leav
analys
femal
median
age
year
bone
marrow
aspir
five
aspir
unsuit
hypocellulardilut
rest
morpholog
remiss
diagnosi
children
respect
fcm
perform
posit
mol
result
found
patient
diagnosi
assay
repeat
post
induct
mol
tat
averag
day
compar
fcm
averag
day
mrd
found
patient
fcm
patient
molecular
test
patient
good
correl
two
remain
patient
fcm
mrd
posit
molecular
compar
patient
neg
fcm
posit
mol
mrd
conclus
morpholog
insensit
unnecessari
mrd
assess
fcm
correl
well
molecular
mrd
set
shortest
time
fcm
major
benefit
patient
neg
mol
also
safe
use
guid
treatment
escal
patient
await
molecular
result
k
horib
j
c
h
c
hospit
organ
nagoya
medic
center
clinic
research
center
aichi
japan
inc
global
develop
thousand
oak
usa
inc
global
biostatist
scienc
thousand
oak
usa
inc
clinic
pharmacolog
thousand
oak
usa
children
medic
center
hematologyoncolog
regen
medicin
yokohama
japan
cancer
center
hospit
depart
pediatr
oncolog
tokyo
japan
backgroundobject
outcom
children
rr
poor
blinatumomab
bispecif
engag
antibodi
construct
demonstr
antileukem
activ
phase
studi
children
rr
von
stackelberg
jco
evalu
maximum
toler
dose
mtd
safeti
efficaci
pharmacokinet
blinatumomab
japanes
children
rr
designmethod
elig
patient
year
old
rr
bone
marrow
relaps
marrow
relaps
allohsct
refractori
treatment
bone
marrow
blast
karnofskylanski
perform
statu
patient
year
old
cn
patholog
primari
endpoint
incid
toxic
dlt
cohort
receiv
induct
blinatumomab
week
continu
intraven
infus
cycl
cycl
subsequ
cyclesweek
follow
interv
cycl
respond
bone
marrow
blast
within
induct
cycl
could
receiv
addit
consolid
cycl
inductionconsolid
result
nine
patient
femal
median
rang
age
prior
allohsct
receiv
blinatumomab
median
cycl
sinc
patient
experienc
dlt
mtd
five
patient
grade
cytokin
releas
syndrom
patient
grade
ae
commonli
febril
neutropenia
neutropenia
pyrexia
lymphopenia
one
patient
fatal
hemorrhag
shock
five
patient
remiss
within
first
cycl
full
hematolog
recoveri
one
achiev
complet
mrd
respons
mean
sd
blinatumomab
concentr
pgml
pgml
mean
sd
clearanc
vd
hour
antibodi
detect
conclus
safeti
pharmacokinet
blinatumomab
japanes
children
rr
consist
previou
global
studi
huang
state
univers
hershey
colleg
medicin
depart
pediatr
hershey
usa
backgroundobject
ctcf
insul
constrain
tempor
hox
gene
express
pattern
within
confin
chromatin
domain
normal
develop
howev
dysregul
hox
gene
also
common
featur
aml
molecular
mechan
aberr
hox
express
associ
aml
pathogenesi
remain
unclear
designmethod
systemat
investig
hox
gene
regul
aml
employ
pool
genet
knockout
librari
screen
interrog
intergen
regulatori
chromatin
boundari
element
hox
gene
loci
screen
identifi
chromatin
boundari
locat
gene
critic
maintain
aberr
express
posterior
hoxa
gene
aml
delin
role
carri
genom
wide
analysi
examin
chang
chromatin
domain
organ
correspond
gene
express
pattern
compar
ko
aml
cell
result
disrupt
result
spread
repress
domain
domain
subsequ
alter
enhancerpromot
chromatin
access
reduc
ectop
interact
among
posterior
hoxa
gene
impair
reduc
posterior
hoxa
gene
express
alter
myeloid
specif
transcriptom
profil
import
pathogenesi
myeloid
malign
furthermor
cb
boundari
delet
mll
rearrang
aml
cell
primari
patient
sampl
genom
edit
edit
cell
transplant
nsg
mice
develop
human
aml
mice
disrupt
hoxa
locu
reduc
human
leukem
blast
develop
invas
well
enhanc
surviv
transplant
aml
cell
xenograft
patient
deriv
xenograft
pdx
mous
model
conclus
thu
demonstr
ctcf
boundari
constrain
normal
gene
express
program
also
maintain
oncogen
transcript
program
leukem
transform
alter
ctcf
mediat
topolog
boundari
oncogen
loci
provid
therapeut
approach
target
aml
p
huong
nam
nation
cancer
hospit
pediatr
oncolog
ha
noi
vietnam
backgroundobject
acut
lymphoblast
leukemia
common
type
cancer
children
cholestat
jaundic
unusu
present
even
rarer
caus
involv
pancrea
result
obstruct
jaundic
purpos
describ
obstruct
jaundic
secondari
pancreat
involv
childhood
matur
b
cell
object
four
year
old
girl
diagnos
matur
b
cell
pediatr
oncolog
depart
viet
nam
nation
cancer
hospit
designmethod
describ
clinic
case
result
pancreat
involv
rare
obstruct
jaundic
secondari
pancreat
mass
primari
present
report
literatur
case
report
primari
result
treatment
fab
lmb
portocol
excel
conclus
rare
clinic
case
matur
b
cell
children
sever
condit
exact
diagnosi
result
success
treatment
j
hwee
r
jc
l
jd
toronto
dalla
lana
school
public
epidemiolog
toronto
canada
clinic
evalu
scienc
cancer
research
program
toronto
canada
clinic
evalu
scienc
primari
care
popul
health
research
program
toronto
canada
hospit
sick
children
depart
haematologyoncolog
toronto
canada
oncolog
group
ontario
research
toronto
canada
backgroundobject
infecti
trigger
etiolog
childhood
acut
lymphoblast
leukemia
hypothes
assess
whether
rate
infect
critic
exposur
period
type
sever
infect
associ
designmethod
conduct
match
studi
use
administr
databas
match
control
case
date
birth
sex
place
resid
use
valid
approach
infect
determin
rate
infect
examin
critic
exposur
period
infect
ye
age
year
develop
odd
ratio
estim
use
adjust
condit
logist
regress
model
mean
number
infect
time
calcul
use
mean
cumul
function
result
case
match
control
age
year
infectionsyear
increas
odd
childhood
ci
compar
children
infectionsyear
respiratori
infectionsyear
increas
odd
ci
compar
children
respiratori
infectionsyear
invas
infect
increas
odd
ci
infect
age
year
increas
odd
ci
cumul
incid
infect
slightli
higher
children
compar
control
conclus
rule
confound
children
physician
visit
infect
compar
control
may
due
dysregul
immun
function
earli
life
caus
greater
propens
need
clinic
care
contract
infect
howev
confirm
relationship
studi
also
provid
insight
time
type
infect
may
role
develop
u
imam
h
ul
f
f
g
cancer
centr
caa
institut
child
health
pediatr
oncolog
karachi
pakistan
institut
child
health
phrc
special
research
centr
child
health
karachi
pakistan
backgroundobject
one
signific
complic
pediatr
cancer
treatment
occurr
cardiotox
result
anthracyclin
base
chemotherapi
clinic
examin
screen
echocardiogram
therefor
mandatori
initi
chemotherapi
limit
data
avail
cardiac
statu
childhood
cancer
patient
countri
studi
aim
find
cardiac
abnorm
patient
help
establish
optim
use
tool
identif
risk
factor
patient
stabil
start
chemotherapi
designmethod
studi
conduct
januari
decemb
pediatr
oncolog
depart
nation
institut
child
health
karachi
pakistan
medic
record
includ
clinic
present
primari
diagnosi
cardiac
manifest
echocardiographi
result
note
children
relaps
diseas
exclud
cardiovascular
event
initi
chemotherapi
defin
heart
failur
left
ventricular
dysfunct
arrhythmia
hypertens
murmur
echocardiogram
abnorm
defin
eject
fraction
ef
valvular
lesion
left
ventricular
dysfunct
left
ventricular
hypertrophi
pericardi
effus
result
among
elig
patient
abnorm
cardiac
event
echocardiographi
result
observ
case
n
mean
age
children
year
f
ratio
congest
cardiac
failur
low
eject
fraction
echocardiographi
follow
hypertens
pericardi
effus
found
common
cardiac
manifest
baselin
low
eject
fraction
significantli
common
children
hematolog
malign
sever
anemia
mean
hemoglobin
risk
factor
left
ventricular
dysfunct
p
conclus
baselin
assess
cardiac
function
screen
echocardiographi
childhood
cancer
patient
prior
chemotherapi
unveil
abnorm
prompt
better
support
care
henc
better
treatment
outcom
n
jabbar
indu
hospit
pediatr
hematolog
oncolog
karachi
pakistan
backgroundobject
central
nervou
system
cn
involv
childhood
acut
lymphoblast
leukemia
associ
poor
outcom
develop
countri
delay
present
malnourish
patient
high
count
common
therefor
modifi
approach
term
one
week
prednisolon
prophas
delay
diagnost
lumbar
punctur
lp
day
follow
object
stabil
patient
less
intens
cours
minim
peripher
absolut
blast
count
intrathec
therapi
avoid
iatrogen
introduct
cn
diseas
designmethod
retrospect
observ
studi
done
pediatr
oncolog
depart
indu
hospit
total
case
age
year
analyz
day
lp
june
till
octob
result
compar
day
diagnost
lp
previou
data
patient
record
januari
decemb
patient
left
die
day
exclud
result
among
total
case
incid
cn
cn
tlp
respect
incid
cn
cn
significantli
higher
previou
institut
data
show
respect
howev
tlp
preval
cohort
less
previou
cn
posit
case
analyz
respect
age
white
cell
count
phenotyp
prophas
respons
conclus
although
incid
tlp
case
decreas
modifi
approach
day
higher
preval
cn
cohort
unusu
find
differ
hypothet
explan
includ
delay
present
high
burden
diseas
differ
diseas
biolog
delay
cn
direct
therapi
week
thu
continu
modifi
approach
protocol
incid
higher
cn
diseas
warrant
relev
studi
cy
jamal
sa
sheikh
mujib
medic
univers
pediatr
hematolog
oncolog
dhaka
bangladesh
backgroundobject
seizur
one
common
cn
complic
among
patient
receiv
chemotherapi
seizur
seen
patient
acut
lymphoblast
leukemia
seizur
occur
induct
consolid
phase
treatment
much
known
etiolog
risk
factor
natur
histori
seizur
data
regard
bangladeshi
popul
lack
designmethod
prospect
observ
studi
conduct
depart
pediatr
hematolog
oncolog
bangabandhu
sheikh
mujib
medic
univers
dhaka
children
age
neurolog
abnorm
develop
first
episod
seizur
period
induct
remiss
chemotherapi
includ
relev
clinic
treatment
relat
investig
data
collect
prospect
analyz
result
thirteen
patient
develop
seizur
patient
get
induct
remiss
chemotherapi
studi
period
major
seizur
occur
year
age
group
major
seizur
occur
immunophenotyp
signific
increas
risk
found
sex
initi
wbc
count
type
chemotherapi
regimen
receiv
underli
caus
identifi
includ
cn
leukem
infiltr
mening
brain
abscess
cn
infarct
tumor
lysi
syndrom
remain
patient
exact
caus
identifi
intracrani
hemorrhag
suspect
among
patient
develop
seizur
patient
die
conclus
studi
found
slightli
higher
frequenc
seizur
previou
studi
lower
age
group
immunophenotyp
found
signific
risk
factor
develop
seizur
etiolog
could
detect
seizur
episod
studi
outcom
found
poor
patient
develop
seizur
jurkov
mlakar
cr
v
p
l
aziz
h
ansari
research
univers
faculti
medicin
pediatr
oncolog
hematolog
unit
geneva
switzerland
cancer
chu
research
univers
montreal
depart
pediatr
pharmacolog
montreal
canada
univers
montreal
depart
pediatr
montreal
canada
universitair
de
genev
unit
oncologi
et
hematologi
depart
de
l
enfant
et
adolesc
geneva
switzerland
backgroundobject
busulfan
bu
bifunct
alkyl
agent
commonli
use
hematopoiet
transplant
howev
efficaci
vari
greatli
among
treat
patient
influenc
individu
genet
background
particularli
main
metabol
enzym
order
explor
potenti
associ
gene
chose
use
lymphoblast
cell
line
lcl
alreadi
fulli
sequenc
data
onlin
addit
neglig
express
allow
opportun
evalu
metabol
gene
involv
cellular
toxic
designmethod
explor
role
function
gene
variant
cth
delet
delet
determin
inhibitori
concentr
bu
differ
lcl
activ
cellular
apoptosi
necrosi
level
oxid
reduc
form
gsh
gshoxgshr
screen
lcl
stratifi
accord
presenc
signific
variant
involv
gsh
resist
bu
investig
inhibitor
gsh
synthesi
bso
result
observ
increas
valu
lcl
carri
allel
compar
null
signific
differ
genotyp
subgroup
observ
ratio
necrosi
earli
apoptosi
induct
bu
significantli
lower
lcl
p
suggest
slower
progress
rate
apoptosi
gstm
lcl
gshoxgshr
ratio
higher
lcl
p
suggest
deplet
reduc
form
gsh
might
main
mechan
decreas
cell
surviv
condit
conclus
result
indic
variant
associ
increas
lcl
treat
bu
possibl
cellular
surviv
result
provid
addit
mechanist
explan
previou
report
demonstr
signific
associ
gene
delet
surviv
among
patient
treat
bu
za
kanakkand
kandi
hospit
pediatr
oncolog
abu
dhabi
unit
arab
emir
backgroundobject
object
publish
literatur
gc
children
scant
comprehens
review
publish
literatur
conduct
understand
current
outcom
childhood
gc
designmethod
search
medlin
embas
use
keyword
leukemia
child
gulf
countri
carri
studi
report
outcom
surviv
relat
publish
includ
result
search
compar
merg
refer
list
includ
studi
search
identifi
elig
studi
result
number
studi
publish
scarc
studi
identifi
singl
centr
studi
multicentr
studi
gc
met
inclus
criteria
total
children
childrenstudi
median
age
present
year
major
studi
minimum
residu
diseas
mrd
use
major
case
treatment
consist
chemotherapi
consider
variat
chemotherapi
use
among
differ
canter
differ
chemotherapi
use
commonli
often
without
minim
residu
diseas
mrd
base
risk
stratif
one
multicent
studi
publish
yet
median
overal
surviv
os
rang
event
free
surviv
ef
rang
report
rate
abandon
limit
data
side
effect
also
limit
conclus
surviv
outcom
children
gc
encourag
lack
public
mani
center
make
difficult
understand
current
practic
outcom
mani
center
recommend
co
ordin
multicentr
approach
collabor
western
center
treat
analyz
experi
address
sever
question
role
children
cancer
registri
entir
gulf
countri
effect
use
highli
recommend
karaman
z
e
r
z
istanbul
faculti
medicin
pediatr
hematolog
oncolog
turkey
istanbul
faculti
medicin
radiolog
turkey
backgroundobject
sickl
cell
anemia
sca
hemoglobinopathi
result
hemolysi
life
threaten
acut
complic
chronic
damag
variou
organ
acut
vascular
occlus
common
caus
hospit
admiss
sickl
cell
anemia
carrier
clinic
usual
normal
report
case
acut
leukemia
dactil
known
carrier
sickl
cell
anemia
thought
deep
anemia
may
caus
sickl
cell
crisi
lead
tissu
hypoxia
leukem
blast
may
also
trigger
condit
designmethod
girl
present
swell
finger
toe
two
day
admiss
right
food
first
metatarsophalang
mtp
joint
day
right
hand
joint
develop
swell
red
pain
also
ad
drop
bike
month
ago
timemri
examin
reveal
fractur
right
distal
fibula
foot
plaster
learn
mother
grandmoth
grandfath
uncl
aunt
diagnos
sca
patient
month
diagnos
sca
carrier
physic
examin
normal
except
right
hand
joint
mkf
right
foot
mtf
joint
swell
pain
hyperem
laboratori
test
reveal
pancytopenia
bone
marrow
aspir
perform
acut
lymphoblast
leukemia
diagnos
medullari
infarct
observ
hand
mri
patient
given
red
blood
cell
transfus
effect
hydrat
signific
improv
symptom
observ
patient
remissionand
follow
depart
result
patient
sca
carrier
clinic
normal
howev
report
hypoxia
dehydr
exercis
travel
pressur
airplan
high
region
may
develop
infarct
literatur
case
clinic
normal
diagnosi
leukemia
pain
crisi
diagnosi
first
pain
crisi
due
profound
anemia
blastic
infiltr
conclus
clinic
sign
expect
carrier
sickl
cell
anemia
howev
kept
mind
accompani
diseas
infect
may
manifest
anemia
patient
hypoxia
may
trigger
pain
crisi
karaman
r
h
z
sezgin
z
n
u
b
yilmaz
e
meral
z
u
istanbul
faculti
medicin
pediatr
turkey
cerrahpasa
faculti
medicin
pediatr
turkey
univers
faculti
medicin
pediatr
bone
marrow
transplant
unit
bursa
turkey
univers
faculti
medicin
pediatr
bone
marrow
transplant
unit
ankara
turkey
health
scienc
ankara
educ
research
hospit
pediatr
bone
marrow
transplant
unit
ankara
turkey
univers
faculti
medicin
pediatr
konya
turkey
hospit
pediatr
bone
marrow
transplant
unit
adana
turkey
eylul
univers
faculti
medicin
pediatr
bone
marrow
transplant
unit
izmir
turkey
univers
faculti
medicin
pediatr
bone
marrow
transplant
unit
izmir
turkey
univers
faculti
medicin
pediatr
bone
marrow
transplant
unit
kayseri
turkey
backgroundobject
invas
fungal
infect
includ
central
nervou
system
cnsfi
caus
signific
morbid
mortal
children
leukemia
necessit
earli
diagnosi
treatment
limit
data
regard
cnsfi
children
designmethod
retrospect
studi
demograph
featur
diagnost
approach
treatment
outcom
cnsfi
children
leukemia
treat
center
turkey
evalu
result
twenti
three
children
femal
male
acut
lymphoblast
leukemia
cnsfi
evalu
reciev
antibiot
prolong
neutropen
fever
fourteen
seizur
four
patient
headac
radiolog
imag
perform
patient
febril
neutropenia
median
day
seventeen
multipl
singl
brain
lesion
magnet
reson
imag
concurr
cnsfi
pulmonari
andor
hepatosplen
fungal
infect
one
patient
geotrichum
capitatum
fungemia
one
candida
albican
fungemia
galactomannan
posit
patient
ten
patient
underw
surgeri
nine
microbiolog
evid
fungi
confirm
four
aspergillu
flavu
one
aspergillu
niger
one
mucormycosi
one
trichoderm
longibrachiatum
hemophagocytosi
observ
patient
nine
receiv
granulocyt
transfus
eleven
transfer
icu
seven
patient
die
due
cnsfi
median
day
begin
episod
survivor
six
perman
neurolog
sequela
cnsfi
diagnosi
antifung
prophylaxi
perform
patient
five
patient
receiv
singl
antifung
agent
treat
combin
antifung
liposom
voriconazol
two
mostli
use
agent
conclus
cnsfi
major
caus
mortal
morbid
children
leukemia
prolong
neutropen
fever
cranial
imag
recommend
children
even
absenc
local
sign
symptom
antifung
spectrum
cover
mucor
rare
fungi
karim
f
sheikh
mujib
medic
univers
pediatr
hematolog
oncolog
dhaka
bangladesh
backgroundobject
acut
lymphoblast
leukemia
common
malign
children
display
characterist
pattern
surfac
antigen
express
cd
antigen
detect
flowcytometri
facilit
identif
proper
classif
evalu
immunophenotyp
pattern
also
recogn
frequenc
differ
subtyp
treatment
outcom
induct
remiss
therapi
designmethod
prospect
cohort
studi
studi
done
juli
march
dept
pediatr
hematolog
oncolog
bangabandhu
sheikh
mujib
medic
univers
eighti
seven
newli
diagnos
admit
case
age
year
includ
bone
marrow
examin
morpholog
immunophenotyp
relev
investig
done
immunophenoytp
perform
cytom
flowcytomet
patient
stratifi
accord
risk
treat
modifi
protocol
b
accord
risk
stratif
outcom
determin
record
event
induct
period
determin
bone
marrow
statu
result
among
patient
patient
patient
rest
mix
phenotyp
complet
induct
remiss
patient
undergon
complet
remiss
b
cell
p
patient
die
b
cell
cell
common
caus
death
septicemia
b
cell
cell
p
complic
septicemia
bleed
dyselectrolytemia
tumor
lysi
syndrom
hyperglycemia
develop
patient
induct
therapi
complic
patient
receiv
regimen
b
reg
reg
b
p
valu
death
rate
also
higher
patient
regimen
b
reg
reg
p
valu
conclus
b
cell
phenotyp
commonest
pattern
observ
case
b
cell
cell
undergon
complet
remiss
kawamura
n
cancer
center
hematolog
saitama
japan
red
cross
hospit
survivor
hospit
pediatr
hiroshima
japan
institut
radiat
biolog
medicin
cellular
biolog
hiroshima
japan
backgroundobject
complex
karyotyp
relat
poor
prognosi
acut
leukemia
chromothripsi
catastroph
mechan
genom
instabl
identifi
whole
genom
sequenc
could
repres
drive
forc
develop
progress
acut
leukemia
well
cancer
tri
identifi
chromothripsi
use
practic
method
includ
singl
nucleotid
polymorph
snp
array
cgh
acgh
designmethod
perform
cytogenet
acgh
analys
childrenadolesc
young
adult
hematolog
malign
select
case
analysi
case
girl
normal
karyotyp
case
girl
secondari
aml
complex
karyotyp
year
diagnos
normal
karyotyp
case
girl
complex
karyotyp
perform
acgh
detect
genom
aberr
detect
dicentricr
chromosom
gene
analyz
acgh
sequenc
pcr
result
ccgh
show
snp
array
pattern
csap
fish
use
tel
probe
demonstr
copi
leukem
cell
respect
indic
intrachromosom
amplif
chromosom
case
cycl
typic
initi
event
chromothripsi
detect
acgh
chromothripsi
suggest
casp
confirm
whole
genom
rna
sequenc
case
case
also
show
fusion
complex
chromosom
abnorm
mutat
novel
fusion
complex
chromosom
abnorm
mutat
found
case
numer
dicentricr
chromosom
identifi
case
conclus
acgh
use
screen
chromothripsi
mechan
underli
chromothripsi
poorli
understood
establish
clinic
detect
method
develop
treatment
strategi
need
improv
outcom
patient
leukemia
v
khandelw
r
superspeci
hospit
haematooncolog
bmt
delhi
india
superspeci
hospit
haematolog
delhi
india
superspeci
hospit
transfus
medicin
delhi
india
backgroundobject
haploident
transplant
perform
cyclophosphamid
ptci
diseas
gvhd
prophylaxi
associ
favor
outcom
adult
patient
acut
leukemia
lymphoma
howev
remain
unclear
approach
effect
children
high
risk
acut
leukemia
aim
studi
analyz
retrospect
outcom
children
high
risk
leukemia
age
year
designmethod
retrospect
data
analyz
patient
underw
haploident
hsct
center
jan
feb
median
age
year
rang
diagnosi
acut
lymphoblast
leukemia
patient
acut
myeloid
leukemia
patient
first
remiss
second
third
condit
regimen
reduc
intens
condit
ric
flucytbi
patient
myeloabl
condit
mac
bufluci
gvhd
prophylaxi
ptci
tacrolimusmmf
result
patient
receiv
csf
mobil
peripher
blood
stem
cell
median
million
cellskg
infus
total
patient
engraft
median
time
neutrophil
platelet
engraft
day
day
respect
four
patient
develop
hemorrhag
cystiti
acut
graft
gvhd
gr
ii
iv
seen
chronic
gvhd
patient
cmv
reactiv
seen
patient
treat
gancyclovir
primari
reject
seen
patient
eight
patient
die
caus
relaps
leukemia
n
primari
reject
infect
n
grade
iv
gut
gvhd
n
median
follow
period
day
overal
surviv
os
whole
group
conclus
haploident
hsct
ptci
cheaper
suitabl
option
pediatr
high
risk
leukemia
encourag
result
mk
kim
mr
sm
jw
hs
cj
yonsei
univers
colleg
medicin
pediatr
seoul
republ
korea
cancer
center
divis
pediatr
hematolog
oncolog
seoul
republ
korea
inj
univers
colleg
medicin
pediatr
busan
republ
korea
backgroundobject
mutat
relat
poor
prognosi
ra
mutat
frequent
occur
subclon
high
chanc
relaps
small
molecul
therapi
open
new
window
cancer
treatment
bind
directli
rg
domain
axin
enhanc
destruct
complex
activ
result
degrad
ra
current
studi
effect
midostaurin
quizartinib
studi
leukem
cell
line
patient
bm
sampl
designmethod
cultur
variou
concentr
cell
prolifer
assay
immunoblot
check
downstream
target
wnt
pathway
studi
immunoblot
stimul
chang
wnt
pathway
observ
bm
patient
evalu
ra
two
went
mac
select
treat
result
midostaurin
quizartinib
higher
compar
show
downregul
cell
line
downregul
promin
downstream
target
evalu
downregul
concentr
activ
wnt
pathway
effect
downregul
bm
sampl
patient
show
variou
statu
ra
express
inhibit
patient
hyerleukocytosi
effect
weaker
patient
conclus
effect
midostaurin
quizartinib
show
effect
constant
narrow
rang
effect
destabil
ra
acut
leukemia
even
wnt
pathway
activ
vivo
studi
need
build
strategi
small
molecul
therapi
acut
leukemia
whether
target
ra
kimura
k
h
k
k
r
n
k
j
univers
tokyo
depart
pediatr
tokyo
japan
univers
depart
pediatr
hiroshima
japan
school
kyoto
univers
depart
patholog
tumor
biolog
kyoto
japan
research
institut
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
children
medic
center
depart
hematologyoncolog
saitama
japan
hokuyu
hospit
depart
pediatr
sapporo
japan
univers
hospit
depart
pediatr
tsu
japan
univers
graduat
school
medicin
depart
pediatr
suita
japan
prefectur
univers
graduat
school
medic
scienc
depart
pediatr
kyoto
japan
hematolog
oncolog
miyagi
children
hospit
sendai
japan
luke
intern
hospit
depart
pediatr
tokyo
japan
hospit
organ
nagoya
medic
center
clinic
research
center
nagoya
japan
univers
depart
pediatr
tokyo
japan
medic
univers
tokyo
human
genom
center
tokyo
japan
backgroundobject
aberr
constitut
activ
signal
major
oncogen
event
acut
lymphoblast
leukemia
classifi
two
pattern
activ
lia
impair
degrad
id
sever
type
aberr
report
activ
pattern
far
studi
explor
clinicopatholog
relev
aberr
designmethod
reanalyz
previous
publish
data
sequenc
whole
transcriptom
sequenc
wt
defin
subclon
variant
allel
frequenc
result
total
detect
aberr
activ
signal
case
subclon
mutat
observ
singl
nucleotid
variat
heterodimer
domain
frequent
follow
pest
domain
mutat
lia
id
pattern
detect
mutat
mutual
exclus
within
lia
id
pattern
detect
three
case
snv
utr
four
intragen
delet
del
miss
exon
two
fusion
confirm
del
activ
signal
luciferas
report
assay
analysi
frequenc
cluster
etp
tlx
reveal
alter
frequent
detect
tlx
wherea
less
frequent
fusion
observ
despit
low
rate
importantli
case
harbor
subclon
mutat
show
significantli
wors
outcom
p
prognost
differ
case
without
mutat
conclus
observ
alter
detect
rare
intragen
delet
fusion
recurr
addit
subclon
aberr
might
relev
unfavor
outcom
result
might
use
develop
new
therapeut
strategi
pediatr
patient
k
kobayashi
n
prefectur
amagasaki
gener
medic
center
depart
pediatr
hematolog
oncolog
amagasaki
japan
prefectur
amagasaki
gener
medic
center
depart
clinic
laboratori
amagasaki
japan
prefectur
amagasaki
gener
medic
center
depart
pediatr
amagasaki
japan
backgroundobject
hypereosinophilia
hematolog
malign
either
neoplast
reactiv
condit
neopslast
eosinophilia
well
document
myeloid
neoplasm
particular
chromosom
transloc
ie
pdgfr
invers
chromosom
chromosom
transloc
involv
igh
locu
hallmark
malign
compris
malign
young
adult
predomin
transloc
posit
acut
lymphoblast
leukemia
eosinopnilia
well
document
accompani
life
threaten
thromboembol
complic
lug
heart
brain
littl
known
exact
molecular
mechan
concurr
hypereosinophila
designmethod
encount
boy
posit
hypereosinophilia
develop
organ
damag
left
ventricular
thrombosi
cardioembol
brain
infarct
verifi
genom
signatur
includ
transloc
fraction
grow
eosinophil
respect
result
recurr
transloc
develop
fusion
gene
igh
enhanc
promot
region
drive
constitut
express
confirm
complet
concord
among
three
paramet
bone
marrow
mrna
express
fusion
genom
eosinophil
count
fusion
genom
identifi
cell
prolifer
eosinophil
confirm
absenc
driver
mutat
prolifer
eosinophil
sequenc
analysi
confirm
blast
cell
grow
eosinophil
express
receptor
express
indic
mediat
clonal
cell
account
type
hypereosinophilia
fact
show
refractori
convent
therapi
success
treat
allogen
bone
marrow
transplant
subsequ
clinic
cours
unev
complet
molecular
remiss
coincid
resolut
hypereosinophila
conclus
concurr
hypereosinophila
transloc
posit
paraneoplast
phenomenon
driven
leukem
cell
sg
kong
ej
km
jm
jo
sk
jk
jy
ks
j
es
jy
yj
hs
h
ej
ja
yt
univers
colleg
medicin
depart
pediatr
busan
republ
korea
nation
univers
children
hospit
depart
pediatr
yangsan
republ
korea
univers
colleg
medicin
depart
pediatr
daegu
republ
korea
fatima
hospit
depart
pediatr
daegu
republ
korea
univers
hospit
depart
pediatr
ulsan
republ
korea
univers
gil
medic
center
depart
pediatr
daegu
republ
korea
nation
univers
school
medicin
depart
pediatr
daegu
republ
korea
univers
busan
paik
hospit
depart
pediatr
busan
republ
korea
nation
univers
school
medicin
depart
pediatr
jinju
republ
korea
univers
school
medicin
depart
pediatr
daegu
republ
korea
univers
colleg
medicin
depart
pediatr
busan
republ
korea
cathol
univers
medic
center
depart
pediatr
daegu
republ
korea
univers
haeunda
paik
hospit
depart
pediatr
busan
republ
korea
sloan
ketter
cancer
center
depart
pediatr
new
york
usa
backgroundobject
gene
rearrang
pediatr
acut
lymphoblast
leukemia
known
good
prognost
factor
sever
studi
report
may
independ
prognost
factor
therefor
studi
evalu
clinic
characterist
prognosi
posit
childhood
yeungnam
south
korea
designmethod
studi
includ
patient
pediatr
diagnos
hospit
yeungnam
area
januari
decemb
posit
patient
patient
show
hyperdiploidi
result
mean
age
posit
group
year
neg
group
year
mean
leukocyt
count
posit
group
neg
group
platelet
versu
lactat
dehydrogenas
versu
iul
hemoglobin
versu
gdl
count
significantli
lower
posit
group
neg
group
complet
remiss
rate
recurr
rate
posit
neg
group
respect
recurr
central
nervou
system
cn
posit
group
recurr
cn
occur
neg
group
surviv
rate
posit
group
neg
group
overal
surviv
os
rate
posit
group
neg
group
statist
signific
account
patient
display
hyperdiploidi
os
rate
posit
group
hyperdiploidi
group
neg
group
without
hyperdiploidi
show
statist
signific
conclus
posit
show
higher
surviv
rate
neg
group
without
hyperdiploidi
hh
koo
yh
yt
medic
center
pediatr
seoul
republ
korea
univers
hospitap
pediatr
seoul
republ
korea
nation
univers
children
hospit
pdiatric
pusan
republ
korea
backgroundobject
human
mesenchym
stem
cell
includ
adipos
tissu
stem
cell
asc
potenti
support
supress
tumor
growth
howev
littl
known
relationship
asc
hematolog
malign
includ
leukemia
whether
asc
support
leukemia
cell
surviv
remain
unclear
studi
effect
asc
growth
acut
lymphoblast
leukemia
cell
examin
vivo
model
designmethod
establish
cell
line
express
firefli
luciferas
allfluc
lentivir
infect
inject
intraperiton
nodscid
mice
result
luciferas
activ
significantli
higher
mice
allfluc
cell
asc
inject
allfluc
cell
alon
allfluc
cell
asc
differ
ratio
mice
gradual
increas
bioluminesc
intens
group
mice
asc
show
higher
bioluminesc
intens
receiv
lower
number
interestingli
mice
inject
allfluc
cell
alon
format
tumor
mass
observ
least
five
week
moreov
allfluc
cell
asc
mice
increas
bioluminesc
intens
group
show
significantli
higher
bioluminesc
intens
compar
mice
human
normal
fibroblast
cell
conclus
overal
asc
promot
growth
cell
vivo
suggest
asc
neg
influenc
hematolog
malign
taken
account
develop
cell
therapi
product
base
asc
h
kook
hg
hs
sm
hj
tj
nation
univers
hwasun
hospit
pediatr
republ
korea
backgroundobject
acut
leukemia
ambigu
lineag
alau
leukemia
show
clear
evid
differenti
along
singl
lineag
includ
acut
undifferenti
leukemia
aul
mix
phenotyp
acut
leukemia
mpal
contain
acut
bilineag
leukemia
acut
biphenotyp
leukemia
terminolog
definit
confus
pose
mani
diagnost
therapeut
challeng
mpal
account
acut
leukemia
accord
egil
criteria
wherea
incid
criteria
clinic
characterist
therapeut
outcom
children
alau
describ
respect
egil
criteria
designmethod
studi
retrospect
review
medic
document
patient
diagnos
depart
pediatr
chonnam
nation
univers
hwasun
hospit
korea
result
among
acut
leukemia
patient
patient
found
alau
egil
criteria
aul
bmyeloid
tmyeloid
tbmyeloid
howev
patient
remain
alau
aul
bmyeloid
mpal
mpal
v
median
age
diagnosi
year
male
predomin
remiss
induct
achiev
patient
initi
induct
therapi
induct
therapi
result
remiss
wherea
therapi
p
two
patient
achiev
remiss
switch
therapi
hsct
done
patient
median
year
probabl
os
clinic
laboratori
variabl
associ
surviv
outcom
conclus
studi
demonstr
rariti
alau
children
outcom
seem
better
adult
counterpart
induct
chemotherapi
use
hsct
may
salvag
patient
alau
best
manag
plan
sought
multicent
collabor
studi
g
kuhlen
heinrich
hein
univers
depart
pediatr
hematolog
clin
univers
children
hospit
duesseldorf
germani
medic
center
clinic
pediatr
hematolog
oncolog
hamburg
germani
medic
center
campu
kiel
depart
pediatr
kiel
germani
backgroundobject
therapi
success
acut
lymphoblast
leukemia
counterbalanc
burden
sequela
includ
osteonecrosi
sever
impact
qualiti
life
howev
littl
known
ankl
designmethod
mri
adolesc
year
diagnos
enrol
prospect
multicent
opal
trial
analyz
result
patient
enrol
underw
standard
mri
screen
ankl
median
age
year
rang
median
time
evalu
day
femal
drop
screen
termin
accord
protocol
symptomat
involv
joint
initi
diagnosi
mri
show
osteoedema
oe
upper
ankl
patient
joint
surfac
involv
month
oe
month
oe
month
oe
month
month
neither
oe
patient
end
treatment
lower
ankl
oe
present
patient
time
point
detect
patient
month
respect
two
patient
present
ankl
noteworthi
patient
report
persist
symptom
ankl
last
conclus
oe
ankl
frequent
adolesc
find
confirm
larger
patient
cohort
longer
time
p
van
b
de
lammen
univers
hospit
depart
pediatr
stem
cell
transplant
ghent
belgium
univers
cancer
research
institut
ghent
ghent
belgium
univers
center
medic
genet
ghent
ghent
belgium
backgroundobject
genet
transloc
er
character
second
common
oncogen
subtyp
children
pediatr
precursor
acut
lymphoblast
leukemia
fioreto
blood
although
oncogen
subtyp
cure
rate
contemporari
treatment
protocol
pui
et
al
leukemia
patient
suffer
relaps
diseas
understand
molecular
biolog
group
necessari
develop
effect
target
therapi
increas
cure
rate
reduc
side
effect
designmethod
pclo
transcript
level
sampl
cell
line
pediatr
patient
process
analys
total
rna
sequenc
andor
furthermor
mrna
express
level
pclo
evalu
silico
leukemia
gene
atla
dataset
haferlach
et
al
result
total
rna
sequenc
cell
line
evidenc
pclo
transcript
highli
express
within
reh
cell
line
absent
molecular
group
valid
initi
find
silico
gene
express
analysi
perform
use
mrna
express
profil
pclo
patient
addit
mrna
express
level
pclo
pediatr
sampl
cell
line
evalu
result
silico
well
express
analysi
confirm
pclo
transcript
significantli
overexpress
group
patient
silico
dataset
well
pediatr
sampl
cell
line
carri
transloc
conclus
current
find
show
pclo
overexpress
function
studi
need
unveil
key
mechan
pclo
cell
carri
er
transloc
inhibitor
aberrantli
activ
pclo
pathway
may
repres
interest
target
therapi
patient
f
lanfranconi
f
l
e
w
univers
institut
health
sport
melbourn
australia
school
medicin
surgeri
milano
itali
brianza
foundat
children
mother
mbbm
depart
pediatr
san
gerardo
hospit
monza
itali
backgroundobject
hematolog
malign
hm
childhood
character
progress
loss
physic
function
along
treatment
lead
reduct
muscl
mass
strength
exercis
capac
although
sport
therapi
accept
mani
diseas
role
tailor
train
patient
hm
phm
still
debat
aim
studi
evalu
effect
combin
aerob
strength
balanc
flexibl
exercis
program
physic
function
qualiti
life
qol
pmh
designmethod
italian
base
prospect
longitudin
cohort
studi
recruit
phm
femal
elect
discontinu
treatment
mainten
therapi
divid
cohort
age
yr
exercis
train
took
place
time
week
week
insid
hospit
stair
test
tud
min
walk
test
well
repetit
maximum
leg
extens
evalu
week
child
parent
inventori
pedsql
use
measur
particip
qol
visual
analog
scale
va
method
evalu
satisfact
particip
parent
train
intervent
result
adher
train
tud
well
show
improv
perform
p
sec
kg
respect
signific
increas
qol
p
phm
parent
va
score
phm
parent
conclus
studi
show
phm
train
week
present
improv
physic
function
qol
tailor
exercis
program
perceiv
fulli
satisfactori
phm
famili
jm
lee
jo
ej
km
yt
sk
jk
jy
ks
j
es
jy
yj
hs
h
sg
ej
ja
univers
colleg
medicin
depart
pediatr
daegu
republ
korea
fatima
hospit
depart
pediatr
daegu
republ
korea
nation
univers
school
medicin
depart
pediatr
pusan
republ
korea
univers
hospit
depart
pediatr
ulsan
republ
korea
univers
gil
medic
center
depart
pediatr
incheon
republ
korea
nation
univers
school
medicin
depart
pediatr
daegu
republ
korea
univers
busan
paik
hospit
depart
pediatr
pusan
republ
korea
nation
univers
school
medicin
depart
pediatr
jinju
republ
korea
univers
school
medicin
depart
pediatr
daegu
republ
korea
univers
colleg
medicin
depart
pusan
republ
korea
univers
colleg
medicin
depart
pediatr
pusan
republ
korea
cathol
univers
medic
center
depart
pediatr
daegu
republ
korea
univers
haeunda
paik
hospit
depart
pediatr
pusan
republ
korea
sloan
ketter
cancer
center
depart
pediatr
new
york
usa
backgroundobject
recent
treatment
outcom
significantli
improv
children
acut
lymphoblast
leukemia
surviv
rate
howev
surviv
rate
adolesc
lower
younger
counterpart
designmethod
total
patient
age
year
newli
diagnos
enrol
studi
januari
decemb
yeungnam
region
korea
divid
patient
two
group
younger
children
group
age
year
adolesc
group
age
year
result
surviv
ef
overal
surviv
os
adolesc
group
respect
compar
younger
children
group
due
increas
cumul
incid
relaps
cir
cir
vs
p
due
increas
incid
death
cumul
incid
death
cid
vs
p
adolesc
like
present
phenotyp
p
less
like
fusion
hyperdiploid
karyotyp
respect
conclus
adolesc
like
present
diagnosi
biolog
higher
risk
diseas
like
experi
complic
younger
children
therefor
specif
age
group
may
need
particular
vigil
receiv
intens
chemotherapi
surviv
similar
younger
children
h
z
k
l
first
affili
sun
univers
pediatr
guangzhou
china
backgroundobject
current
treatment
strategi
result
remiss
children
acut
lymphoblast
leukemia
howev
protocol
recommend
quantit
minim
residu
disas
mrd
monitor
flow
cytometri
analysi
method
inaccess
especi
develop
countri
designmethod
studi
bone
marrow
sampl
collect
newli
diagnos
children
risk
agre
monitor
mrd
depart
ig
tcr
gene
rearrang
amplifi
multiplex
pcr
kind
qualit
pcr
clonal
pcr
product
analyz
autom
fragment
analysi
use
genemapperid
softwar
carri
monoclon
igtcr
diagnosi
arrang
monitor
mrd
end
vdld
induct
detect
clonal
igtcr
defin
mrd
posit
patient
treat
protocol
last
decemb
relaps
free
surviv
rf
estim
compar
use
test
result
august
decemb
case
children
risk
treat
depart
agre
receiv
mrd
monitor
patient
found
least
one
marker
posit
case
refus
test
case
mrd
analyz
significantli
differ
gender
age
initi
wbc
immunophenotyp
clinic
prognost
classif
rf
mrd
group
group
case
mrd
case
mrd
neg
case
mrd
posit
rf
respect
conclus
use
multiplex
pcr
autom
fragment
analysi
monoclon
igtcr
gene
rearrang
simpl
feasibl
method
monitor
mrd
non
high
risk
childhood
h
li
h
z
j
j
n
k
children
hospit
hematologyoncolog
shanghai
china
backgroundobject
studi
aim
assess
efficaci
prognosi
children
acut
lymphoblast
leukemia
improv
efficaci
childhood
designmethod
retrospect
studi
patient
newli
diagnos
hospit
januari
januari
case
treat
case
case
analyz
retrospect
clinic
biolog
characterist
ef
case
statist
softwar
use
analyz
data
result
accord
risk
stratif
divid
case
lr
group
case
ir
group
case
hr
group
complet
remiss
rate
patient
induct
therapi
ef
lr
group
ir
group
hr
group
compar
differ
treatment
protocol
ef
rate
p
result
cox
regress
multivari
analysi
show
risk
group
effect
prognost
factor
childhood
death
rate
relaps
differ
protocol
protocol
low
death
rate
relaps
compar
protocol
conclus
rate
induct
remiss
center
high
risk
group
effect
prognost
factor
case
childhood
prognosi
ir
hr
group
childhood
remain
improv
childhood
use
protocol
signific
differ
surviv
rate
protocol
lower
death
rate
relaps
compar
protocol
c
liang
x
c
w
l
l
x
first
affili
hospit
sun
univers
pediatr
guangzhou
china
backgroundobject
signific
number
childhood
present
dismal
prognosi
studi
evalu
impact
microrna
outcom
childhood
context
clinic
molecular
prognost
explor
mechan
action
designmethod
microrna
express
profil
childhood
investig
geo
express
bone
marrow
pair
case
two
differ
time
point
initi
diagnosi
first
relaps
statu
detect
bioinformat
softwar
dual
luciferas
report
assay
appli
predict
verifi
target
furthermor
four
human
cell
line
transfect
mimic
inhibitor
correspond
control
cell
viabil
cell
apoptosi
analyz
use
flow
cytometri
assay
protein
express
analyz
use
western
blot
result
total
differenti
express
mirna
identifi
patient
compar
healthi
subject
patient
higher
express
shorter
overal
surviv
shorter
surviv
higher
cumul
incid
relaps
interestingli
statist
signific
overal
surviv
surviv
tradit
p
express
associ
gene
express
profil
enrich
gene
involv
cellular
mechan
deregul
eg
mtor
ampk
demonstr
higher
express
level
lower
express
level
significantli
promot
prolifer
inhibit
apoptosi
cell
line
jurket
dual
luciferas
report
system
confirm
potenti
target
conclus
express
may
well
contribut
improv
prognost
stratif
children
may
play
role
pathogenesi
disord
target
f
liu
q
j
x
institut
hematolog
blood
diseas
chines
academi
medic
scienc
divis
depart
clinic
hematolog
tianjin
china
children
medic
center
hematolog
oncolog
shanghai
china
hospit
soochow
univers
hematolog
suzhou
china
china
second
univers
hospit
west
china
women
children
hospit
pediatr
hematolog
oncolog
chengdu
china
medic
tongji
hospit
depart
pediatr
wuhan
china
hospit
chongq
medic
univers
hematolog
oncolog
chongq
china
backgroundobject
fusion
gene
thought
common
rearrang
independ
good
prognost
factor
pediatr
acut
lymphoblast
leukemia
howev
situat
subgroup
chines
popul
thoroughli
studi
studi
go
investig
clinic
featur
efficaci
chines
children
larg
cohort
designmethod
children
adolesc
newli
diagnos
differ
pediatr
hematolog
center
china
januari
decemb
enrol
studi
patient
receiv
chemotherapi
includ
induct
consolid
reinduct
mainten
therapi
accompani
regular
intrathec
chemotherapi
clinic
characterist
collect
diagnosi
decemb
chosen
refer
date
end
data
collect
surviv
assess
result
case
rang
age
year
median
year
median
leukocyt
count
almost
case
show
precursor
phenotyp
abnorm
karyotyp
demonstr
children
children
note
cryptic
transloc
one
case
suffer
central
nervou
system
leukemia
diagnosi
case
good
respons
prednison
patient
achiev
hematolog
complet
remiss
cr
induct
patient
suffer
relaps
late
relaps
isol
bm
relaps
common
probabl
event
free
surviv
five
year
statist
signific
differ
among
differ
oncolog
center
conclus
lower
age
leukocyt
count
mostli
precursor
phenotyp
higher
cr
rate
surviv
show
basic
clinic
featur
outcom
chines
patient
countri
popul
hc
liu
k
aej
c
ck
tc
ekh
hj
dt
memori
hospit
mackay
medic
colleg
divis
pediatr
pediatr
taipei
taiwan
roc
children
medic
center
depart
hematologyoncolog
saitama
japan
prefectur
univers
medicin
graduat
school
medic
scienc
depart
pediatr
kyoto
japan
univers
singapor
depart
paediatr
singapor
singapor
univers
graduat
school
medic
dental
scienc
depart
pediatr
niigata
japan
univers
graduat
school
medic
dental
scienc
depart
pediatr
kagoshima
japan
wale
hospit
chines
univers
hong
kong
depart
paediatr
hong
kong
hong
kong
sar
veteran
gener
hospit
nation
univers
depart
pediatr
taipei
taiwan
roc
taiwan
univers
hospit
depart
pediatr
taipei
taiwan
roc
backgroundobject
sought
determin
clinic
featur
treatment
outcom
childhood
acut
lymphoblast
leukemia
asian
designmethod
collect
cooper
studi
group
enrol
patient
age
year
old
newli
diagnos
treat
asia
categor
major
group
japan
cclsg
jacl
kyccsg
tccsg
malaysiasingapor
hong
kong
hkphosg
taiwan
tpog
altogeth
patient
posit
aggreg
data
clinic
featur
treatment
regimen
surviv
outcom
could
obtain
patient
result
incid
genet
subtyp
rang
group
among
evalu
patient
treat
regimen
therapi
cranial
radiat
crrt
receiv
dose
intrathec
therapi
given
alon
hd
hd
mtx
administ
patient
whole
group
surviv
overal
surviv
os
cumul
risk
cn
relaps
respect
statist
differ
group
use
multivari
analysi
patient
age
year
cn
diseas
diagnosi
inferior
os
p
n
asian
group
tend
age
year
wbc
nci
compar
without
n
tpog
p
conclus
incid
higher
asian
report
caucasian
surviv
outcom
similar
asian
group
treat
arm
contemporari
protocol
crrt
impact
outcom
x
liu
x
w
x
blood
diseas
hospit
chines
academi
medic
scienc
cam
depart
paediatr
haematolog
tianjin
china
backgroundobject
evalu
clinic
efficaci
prognost
factor
childhood
lineag
acut
lymphocyt
leukemia
use
protocol
designmethod
retrospect
analyz
pediatr
patient
use
platform
collect
clinic
characterist
treatment
effect
prognost
factor
result
among
patient
case
boy
case
girl
median
age
median
wbc
count
diagnosi
point
three
percent
patient
normal
karyotyp
abnorm
karyotyp
number
abnorm
karyotyp
number
abnorm
karyotyp
number
complex
chromosom
proport
patient
percent
case
belong
group
case
belong
group
case
prednison
reaction
rate
remiss
rate
patient
relaps
overal
surviv
os
surviv
ef
respect
os
medium
risk
group
significantli
higher
high
risk
group
p
ef
medium
risk
group
significantli
higher
high
risk
group
p
cox
multivari
regress
analysi
show
partit
risk
group
accord
protocol
import
factor
patient
os
ef
p
conclus
childhood
phenotyp
often
high
wbc
count
wors
outcom
diseas
recurr
remain
main
caus
death
partit
risk
group
accord
protocol
import
factor
prognosi
liu
l
c
x
g
l
c
jiaotong
univers
shanghai
children
medic
center
shanghai
china
backgroundobject
leukemia
mll
multifari
partner
gene
lead
aggress
leukemia
dismal
outcom
designmethod
use
target
sequenc
examin
total
childhood
acut
leukemia
case
includ
patient
acut
lymphoblast
leukemia
patient
acut
myeloid
leukemia
aml
result
precis
mll
breakpoint
complet
rearrang
character
novel
mll
fusion
identifi
total
patient
display
singl
direct
mll
fusion
gene
carri
singl
reciproc
fusion
reciproc
mll
fusion
allel
remain
case
complex
transloc
homozyg
disrupt
chromosom
two
breakpoint
mll
allel
delet
function
region
total
patient
aml
receiv
chemotherapi
median
year
unexpectedli
found
children
reciproc
mll
fusion
exhibit
rel
favor
outcom
compar
children
complex
transloc
singl
direct
mll
fusion
allel
versu
p
function
featur
truncat
mll
fusion
protein
may
give
explan
favour
clinic
prognosi
reciproc
mll
transloc
conclus
conclus
comprehens
analysi
target
sequenc
ng
provid
detail
molecular
inform
help
precis
stratifi
treatment
clinic
prognosi
determin
b
lope
c
c
n
c
g
c
c
g
u
zur
n
r
ms
r
nacion
de
molecular
cancer
studi
divis
clinic
research
rio
de
janeiro
brazil
frankfurt
diagnost
center
acut
institut
pharmaceut
biolog
frankfurtmain
germani
lill
nord
de
franc
laboratori
hematolog
tumor
cancer
research
institut
lill
lill
franc
degli
studi
di
centro
ricerca
dipartimento
di
medicina
e
chirurgia
monza
itali
institut
cancer
newcastl
univers
leukaemia
research
cytogenet
wolfson
childhood
cancer
research
centr
newcastl
unit
kingdom
de
prof
dr
juan
p
garrahan
hematolog
oncolog
depart
bueno
air
argentina
institut
medic
cell
technolog
region
children
hospit
yekaterinburg
russia
india
institut
medic
scienc
laboratori
oncolog
dr
bra
irch
new
delhi
india
medic
center
hamburg
eppendorf
center
diagnost
hamburg
germani
new
south
wale
children
cancer
lowi
cancer
research
centr
sydney
australia
nacion
de
pediatr
program
rio
de
janeiro
brazil
backgroundobject
delet
predict
relaps
acut
lymphoblast
leukemia
previous
reveal
rearrang
could
promot
aim
character
genom
level
unravel
clinic
import
designmethod
first
cohort
patient
prescreen
either
microarray
salsa
mlpa
consid
cobl
locat
kb
downstream
encompass
region
therefor
group
defin
either
complet
delet
partial
delet
recurr
confirm
multiplex
remain
sampl
evalu
custom
mlpa
chromosom
could
identifi
potenti
order
confirm
alter
also
perform
ldi
character
breakpoint
rearrang
nucleotid
level
result
patient
enrol
studi
compris
two
group
associ
sever
chromosom
alter
includ
monosomi
loss
interstiti
delet
hand
recurr
delet
patient
present
larger
delet
overal
found
cohort
breakpoint
locat
close
cobl
promot
within
mainli
within
cobl
intron
intron
dnase
hypersensit
site
conclus
divers
alter
character
molecular
delet
within
gene
investig
cohort
patient
includ
subgroup
patient
carri
larger
delet
compris
cobl
gene
respect
r
f
v
l
l
e
n
oswaldo
cruz
foundat
fiocruz
depart
immunolog
recif
brazil
oswaldo
cruz
foundat
feder
univers
pernambuco
depart
immunolog
medicin
program
recif
brazil
oswaldo
cruz
foundat
feder
univers
pernambuco
depart
immunolog
recif
brazil
paulo
usp
depart
anim
biotechnolog
piracicaba
brazil
paulo
usp
divis
clinic
depart
medicin
preto
brazil
oswaldo
cruz
foundat
instituto
de
medicina
integr
professor
fernando
figueira
imip
hospit
depart
immunolog
pediatr
oncolog
servic
recif
brazil
backgroundobject
acut
lymphoblast
leukemia
aggress
diseas
frequent
cancer
children
immunolog
genet
factor
solubl
microrna
mirna
influenc
tumor
prolifer
dissemin
use
diseas
prognosi
studi
aim
investig
mirna
differenti
express
de
childhood
accord
level
low
versu
high
produc
designmethod
patient
attend
imip
hospit
recif
brazil
bone
marrow
aspir
use
total
rna
extract
trizol
mirna
librari
construct
truseq
small
rna
kit
sequenc
hiseq
platform
illumina
perform
data
analyz
use
fastqc
cutadapt
edger
fals
discoveri
rate
mirwalk
rnahybrid
de
analysi
conduct
base
level
determin
elisa
exbio
low
produc
uml
median
age
versu
high
produc
uml
median
age
patient
result
bioinformat
analysi
reveal
mirna
upregul
high
produc
group
previous
studi
group
focus
remain
mirna
mrna
exhibit
bind
site
nine
mirna
interact
present
minimum
free
energi
kcalmol
rnahybrid
analysi
reveal
put
interact
mirna
exon
mirna
target
exon
exon
target
one
mirna
exclus
interestingli
bind
site
map
within
exon
recogn
utr
overlap
ct
polymorph
site
conclus
data
suggest
mechan
action
name
translat
induct
mirna
mrna
find
must
replic
sampl
confirm
acknowledg
madney
w
h
e
pedeatr
oncolog
cche
lectur
pediatr
oncolog
cancer
institut
cairo
univers
pediatr
oncolog
cairo
egypt
cancer
institut
pediatr
oncolog
cairo
egypt
cancer
institut
clinic
microbiolog
cairo
egypt
backgroundobject
improv
overal
surviv
children
acut
lymphoblast
leukemia
last
decad
consider
around
surviv
long
term
despit
recent
advanc
support
care
infect
relat
morbid
mortal
compris
major
challeng
success
treatment
limit
number
studi
done
analyz
type
incid
infect
encount
differ
phase
treatment
type
frequenc
infect
vari
accord
phase
treatment
evalu
epidemiolog
outcom
infecti
complic
mainten
phase
chemotherapi
designmethod
retrospect
studi
pediatr
patient
treat
mainten
phase
month
st
jude
total
xv
protocol
nation
cancer
institut
egypt
period
accord
treatment
phase
mainten
chemotherapi
degre
neutropenia
febril
infecti
episod
record
analyz
categor
bacteremia
viral
fungal
clinic
document
infect
fuo
final
outcom
infecti
complic
infect
relat
mortal
analyz
result
total
infecti
episod
record
pediatr
patient
mainten
chemotherapi
low
risk
standard
risk
high
risk
group
infecti
episod
occur
earli
phase
mainten
chemotherapi
fuo
common
infecti
episod
follow
clinic
document
infect
viral
bacteri
fungal
infect
major
infect
episod
report
neutropenia
statist
signific
relat
relaps
number
patient
infect
cours
mainten
therapi
mortal
whole
cours
mainten
chemotherapi
death
infect
relat
conclus
incid
death
high
infecti
complic
still
major
morbid
mortal
challeng
children
acut
lymphoblast
leukemia
develop
countri
maher
ar
l
r
k
egypt
cancer
institut
cancer
biolog
depart
assiut
egypt
cancer
institut
cancer
biolog
depart
cairo
egypt
cancer
institut
pediatr
oncolog
depart
cairo
egypt
egypt
cancer
institut
clinic
patholog
depart
assiut
egypt
egypt
cancer
institut
pediatr
oncolog
depart
assiut
egypt
backgroundobject
human
cytomegaloviru
hcmv
one
caus
morbid
mortal
pediatr
cancer
patient
designmethod
patient
method
newli
diagnos
pediatr
cancer
patient
age
rang
year
treat
total
xiii
chemotherapi
protocol
seci
studi
hcmv
seroposit
igmigg
viremia
blood
plasma
via
pcr
diagnosi
day
end
chemotherapi
induct
phase
day
result
shown
diagnosi
day
igg
posit
equivoc
neg
patient
igm
plasma
pcr
neg
case
upon
repeat
panel
end
induct
phase
day
observ
complet
seroconvers
patient
neg
igg
igm
pcr
also
neg
review
bma
result
end
induct
found
patient
fail
reach
bone
marrow
remiss
hcmv
igg
posit
conclus
observ
acut
cmv
infect
either
recent
cancer
diagnosi
hospit
acquir
even
reactiv
chemotherapi
induct
phase
treatment
studi
made
assur
hcmv
impact
cancer
treatment
outcom
south
egypt
cancer
institut
maher
arn
mn
l
r
kf
egypt
cancer
institut
cancer
biolog
depart
assiut
egypt
cancer
institut
cancer
biolog
depart
cairo
egypt
cancer
institut
pediatr
oncolog
depart
cairo
egypt
egypt
cancer
institut
clinic
patholog
depart
assiut
egypt
egypt
cancer
institut
pediatr
oncolog
depart
assiut
egypt
backgroundobject
innat
host
defens
includ
mucocutan
barrier
phagocyt
cell
natur
killer
cell
nk
nonclon
b
cell
nk
cell
peripher
blood
mononuclear
cell
pbmc
rang
act
innat
effector
cell
play
import
role
defens
cancer
viral
infect
designmethod
peripher
blood
sampl
collect
newli
diagnos
pediatr
cancer
patient
age
rang
year
treat
total
xiii
chemotherapi
protocol
seci
studi
via
flowcytometri
use
antibodi
fitc
pe
design
enumer
matur
human
natur
killer
nk
use
flowcytometri
end
chemotherapi
induct
phase
day
result
nk
percent
diagnosi
day
rang
median
interquartil
rang
iqr
absolut
circul
nk
cell
rang
median
iqr
upon
repeat
panel
end
induct
phase
day
nk
percent
rang
median
interquartil
rang
iqr
absolut
circul
nk
cell
rang
median
iqr
conclus
follow
initi
leukemia
therapi
increas
percent
nk
cell
pbmc
note
decreas
absolut
number
circul
cell
pediatr
patient
south
egypt
cancer
institut
maher
arn
mn
l
rm
kf
egypt
cancer
institut
cancer
biolog
depart
assiut
egypt
cancer
institut
cancer
biolog
depart
cairo
egypt
cancer
institut
pediatr
oncolog
depart
cairo
egypt
egypt
cancer
institut
clinic
patholog
depart
assiut
egypt
egypt
cancer
institut
pediatr
oncolog
depart
assiut
egypt
backgroundobject
repertoir
nk
cell
differ
greatli
one
person
patient
anoth
cmv
infect
peculiar
situat
dramat
expans
clonal
nk
cell
could
bia
divers
repertoir
consequ
subvert
recognit
patholog
situat
neoplast
cell
designmethod
among
newli
diagnos
pediatr
cancer
patient
treat
total
xiii
chemotherapi
protocol
hcmv
seroposit
igmigg
viremia
blood
plasma
via
pcr
nk
cell
enumer
via
flowcytometri
use
antibodi
fitc
pe
studi
diagnosi
day
end
chemotherapi
induct
phase
day
result
patient
show
nk
percent
normal
rang
posit
hcmv
igg
diagnosi
neg
hcmv
igg
signific
relat
nk
percent
significantli
normal
rang
episod
hcmv
seroposit
patient
compar
seroneg
patient
conclus
diagnosi
seroposit
hcmv
patient
show
significantli
higher
nk
percent
normal
rang
compar
hcmv
seroneg
patient
seci
end
induct
speed
recoveri
nk
cell
less
hcmv
posit
patient
compar
hcmv
neg
one
h
mai
x
x
x
c
f
children
hospit
heamatolog
oncolog
shenzhen
china
backgroundobject
exam
outcom
children
acut
lymphoblast
leukemia
treat
bfm
intern
base
protocol
gd
protocol
designmethod
total
patient
newli
diagnos
age
year
enrol
onto
protocol
juli
june
overal
surviv
os
rate
surviv
ef
rate
examin
addit
analys
caus
relaps
death
result
probabl
os
ef
ef
sr
group
ir
group
hr
group
respect
patient
die
reason
mortal
includ
case
due
relaps
leukemia
seven
case
due
sever
infect
one
case
due
hepat
failur
one
case
due
intracrani
hemorrhag
accid
eight
case
abandon
relaps
case
relaps
includ
case
relaps
bone
marrow
alon
case
cn
relaps
alon
case
testicular
relaps
case
relaps
bone
marrow
extramedullari
eleven
patient
surviv
therapi
relaps
receiv
hsct
two
relaps
hsct
continu
cart
therapi
four
relaps
patient
receiv
relaps
protocol
treatment
patient
remain
remiss
statu
conclus
singl
institut
review
pediatr
treat
gd
protocol
toler
good
long
term
outcom
although
relaps
major
factor
affect
long
term
surviv
still
option
hsct
immunotherapi
avail
patient
e
makimbetov
center
oncolog
hematolog
pediatr
oncolog
hematolog
depart
bishkek
kyrgyzstanr
backgroundobject
background
acut
lymphoblast
leukemia
first
common
childhood
malign
develop
develop
countri
object
studi
childhood
incid
age
sex
geograph
ethnic
differ
kyrgyz
republ
designmethod
materi
method
incid
rate
count
hospit
base
statist
studi
cover
period
collect
form
submit
morpholog
cytolog
immunophenotyp
find
death
certif
popul
figur
incid
rate
provid
age
ethnic
sex
group
calendar
year
count
crude
rate
asr
per
also
estim
popul
rel
risk
urban
rural
area
result
regist
case
children
year
year
year
highest
incid
rate
regist
youngest
age
group
asr
per
popul
moder
incid
rate
age
group
asr
respect
total
crude
incid
rate
per
popul
male
femal
proport
case
boy
case
girl
asr
sex
male
femal
caus
death
diseas
risk
death
incid
rate
urban
area
slightli
higher
rural
region
p
incid
rate
significantli
higher
russian
asr
compar
nativ
kyrgyz
uzbek
conclus
incid
rate
among
children
kyrgyzstan
low
similar
report
asian
develop
countri
peak
incid
youngest
age
group
incid
rate
signific
high
european
nativ
asian
nation
makiya
dibar
j
c
g
g
f
p
e
italiano
de
bueno
air
pediatr
hematolog
oncolog
bmt
unit
caba
argentina
iturrasp
santa
fe
pediatr
hematolog
santa
fe
argentina
infantil
mar
del
plata
pediatr
hematolog
mar
delplata
argentina
notti
pediatr
hematolog
mendoza
argentina
italiano
de
bueno
air
pediatr
hematolog
bueno
air
argentina
p
elizald
pediatr
hematolog
bueno
air
argentina
de
de
rosario
pediatr
hematolog
rosario
argentina
san
luca
pediatr
hematolog
neuquen
argentina
sor
ludovica
pediatr
hematolog
la
plata
argentina
de
pediatr
hematolog
argentina
italiano
de
bueno
air
pediatr
hematolog
oncolog
bmt
unit
bueno
air
argentina
backgroundobject
associ
implement
therapeut
element
pattern
relaps
focus
designmethod
prospect
observ
pattern
relaps
analyz
three
decad
gatla
result
children
treat
evalu
five
consecut
trial
surviv
ef
overal
surviv
os
year
improv
studi
studi
cumul
incid
recurr
cir
first
studi
studi
complet
remiss
cr
increas
death
induct
decreas
studi
cir
high
cir
studi
introduc
methotrex
mtx
gr
decreas
despit
high
risk
hr
receiv
radiotherapi
cir
studi
hr
receiv
block
withdraw
hr
os
ef
unexpectedli
bad
despit
cumul
incid
event
group
death
cr
block
phase
studi
hr
reintroduc
improv
os
previou
studi
decreas
risk
special
hr
studi
implement
g
mtx
earli
relaps
decreas
risk
cir
similar
intern
protocol
conclus
gatla
standard
treatment
improv
result
cn
protect
compar
intern
studi
reduc
radiotherapi
even
elimin
intens
system
intrathec
chemotherapi
l
mathew
r
l
medic
colleg
paediatr
vellor
india
medic
colleg
biostatist
vellor
india
backgroundobject
assess
nutrit
statu
ns
children
treatment
acut
lymphoblast
leukaemia
essenti
appropri
nutrit
intervent
may
affect
overal
outcom
conduct
retrospect
studi
assess
chang
ns
cohort
children
treatment
designmethod
children
boy
girl
age
year
diagnosi
treat
includ
analysi
data
collect
medic
record
weight
height
record
everi
visit
purpos
analysi
ns
assess
use
bmi
centil
diagnosi
twice
treatment
begin
delay
intensif
di
mainten
phase
end
treatment
eot
result
undernourish
un
well
nourish
wn
diagnosi
three
time
point
ns
assess
preval
nutrit
decreas
respect
gradual
increas
preval
wn
children
un
diagnosi
continu
un
di
remain
malnourish
eot
group
move
un
wn
becam
complet
treatment
transit
nutrit
statu
wn
diagnosi
show
becam
un
di
remain
un
end
treatment
incid
obes
increas
begin
delay
intensif
end
treatment
owo
start
larg
remain
nutrit
group
throughout
treatment
conclus
nutrit
statu
children
treatment
dynam
period
assess
requir
appropri
intervent
jp
meena
r
india
institut
medic
scienc
pediatr
oncolog
new
delhi
india
backgroundobject
invas
fungal
infect
ifi
import
caus
morbid
mortal
children
haematolog
malign
use
combin
antifung
modal
treatment
infect
explor
much
designmethod
case
record
patient
admit
centr
januari
juli
diagnosi
hematolog
malign
receiv
antifung
combin
review
retrospect
result
total
children
ifi
fulfil
criteria
enrol
studi
median
age
patient
rang
year
proven
ifi
probabl
ifi
possibl
ifi
aspergillu
speci
commonest
organ
suspect
pneumonia
underli
diagnosi
children
thirteen
patient
treat
empir
monotherapi
one
patient
voriconazol
two
chang
caspofungin
view
improv
clinic
deterior
nine
patientsvoriconazol
ad
four
patient
caspofungin
ad
patient
complet
four
six
week
antifung
therapi
overal
mortal
attribut
ifi
cohort
conclus
ifi
import
caus
mortal
morbid
pediatr
leukemia
patient
aspergillu
speci
predomin
caus
invas
fungal
pneumonia
common
manifest
children
combin
antifung
drug
feasibl
effect
way
salvag
patient
case
non
antifung
monotherapi
trial
studi
need
determin
whether
drug
combin
could
use
upfront
ifi
mehrvar
aa
hedayati
v
fallah
h
hematolog
oncolog
research
center
shahid
beheshti
univers
medic
scienc
tehran
iran
backgroundobject
infant
malign
often
special
clinic
biolog
properti
distribut
type
malign
differ
cancer
patient
month
old
project
design
evalu
pediatr
patient
less
month
old
malign
mahak
pediatr
cancer
treatment
research
center
mpctrc
tehran
iran
designmethod
pediatr
patient
less
month
old
approv
diagnosi
malign
refer
mpctrc
apr
sep
enrol
studi
patient
characterist
gather
individu
document
data
analyz
spss
softwar
version
overal
surviv
os
rate
progress
free
surviv
pf
rate
calcul
accord
kaplan
meyer
result
total
child
enrol
studi
age
rang
patient
day
month
median
day
mf
ratio
diagnos
malign
respect
retinoblastoma
neuroblastoma
brain
tumor
leukemia
sarcoma
wilm
tumor
rare
cancer
rate
recurr
first
relaps
second
relaps
third
relaps
median
time
relaps
first
relaps
month
second
relaps
month
third
relaps
month
rate
recurr
retinoblastoma
neuroblastoma
brain
tumor
os
also
pf
os
categor
malign
neuroblastoma
retinoblastoma
brain
tumor
conclus
singl
center
studi
common
malign
patient
less
month
retinoblastoma
neuroblastoma
brain
tumor
low
pf
rate
mean
high
risk
factor
preced
recurr
multidisciplinari
decis
decreas
factor
p
mehta
hospit
pediatr
mumbai
india
backgroundobject
childhood
cancer
treatabl
curabl
provid
child
receiv
correct
treatment
cytogenet
techniqu
childhood
acut
lymphoblast
leukemia
help
risk
stratifi
children
differ
treatment
arm
among
high
risk
one
hypodiplod
chromosom
mll
gene
rearrang
rare
high
risk
chromosom
abnorm
intrachromosom
amplif
chromosom
amp
occur
approxim
pediatr
patient
precursor
designmethod
slraheja
hospit
privat
tertiari
care
hospit
treat
children
per
year
year
two
children
precursor
treat
bfm
standard
risk
arm
result
five
year
old
femal
child
case
precursor
b
high
risk
cytogenet
featur
treat
standard
risk
arm
bfm
protocol
mrd
neg
post
induct
relaps
month
post
complet
maintain
therapi
eleven
year
old
male
child
precursor
b
high
risk
cytogenet
featur
treat
standard
risk
arm
bfm
mrd
posit
post
induct
turn
amp
posit
amplif
allel
cytogenet
test
retreat
chromosom
abnorm
specif
ask
done
relaps
failur
remiss
respect
children
succumb
relaps
treatment
conclus
intrachromosom
amplif
chromosom
amp
includ
upfront
risk
stratifi
children
precursor
b
upstag
treatment
prevent
relaps
treatment
standard
protocol
lead
poor
outcom
children
e
e
km
g
te
lh
meyer
univers
medic
center
dept
pediatr
adolesc
medicin
ulm
germani
univers
dept
molecular
medicin
padova
itali
univers
dept
women
children
health
padova
itali
backgroundobject
microrna
mirna
short
rna
involv
regul
differ
cellular
process
address
mirna
pediatr
precursor
acut
lymphoblast
leukemia
analyz
impact
specif
mirna
leukemia
develop
patient
outcom
designmethod
investig
mirna
express
small
rna
sequenc
xenograft
pdx
sampl
correspond
clinic
outcom
data
mirna
stabli
overexpress
cell
line
pdx
sampl
compar
empti
vector
control
cell
prolifer
death
analyz
flow
cytometri
vivo
leukemia
growth
upon
transplant
onto
mice
result
identifi
signific
cluster
pdx
long
engraftmentgood
outcom
significantli
higher
level
also
identifi
good
outcom
larger
cohort
valid
find
moreov
increas
express
correl
significantli
longer
remiss
durat
point
associ
high
express
favor
outcom
analysi
put
target
function
identifi
cellular
prolifer
enrich
process
point
tumor
suppress
function
investig
function
impact
develop
growth
stabli
overexpress
cell
overexpress
effect
prolifer
cell
death
vitro
howev
upon
transplant
overexpress
cell
lower
splenic
load
observ
also
investig
primari
short
engraftmentpoor
outcomelow
express
vivo
importantli
overexpress
result
delay
leukemia
manifest
significantli
lower
leukemia
load
spleen
bone
marrow
experi
addit
address
surviv
observ
longer
surviv
week
mice
transplant
overexpress
cell
conclus
taken
togeth
high
express
associ
favor
outcom
delay
leukemia
develop
prolong
surviv
upon
overexpress
thu
neg
regul
leukemia
growth
act
mizuta
n
k
prefectur
amagasaki
gener
medic
center
clinic
laboratori
amagasaki
japan
prefectur
amagasaki
gener
medic
center
pediatr
hematolog
oncolog
amagasaki
japan
prefectur
amagasaki
gener
medic
center
pediatr
amagasaki
japan
backgroundobject
grow
concern
lineag
switch
associ
molecular
target
therapi
refractori
hematolog
diseas
nelarabin
prodrug
arabinosylguanin
nucleotid
triphosph
current
incorpor
frontlin
therapi
refractori
malign
earli
precursor
acut
lymphoblast
leukemia
littl
known
lineag
switch
phenomenon
designmethod
encount
boy
underw
lineag
switch
acut
monoblast
leukemia
follow
treatment
nelarabin
cord
blood
stem
cell
transplant
cbsct
serial
analyz
cell
surfac
antigen
express
cytogen
chang
receptor
tcr
rearrang
result
time
admiss
leukem
cell
posit
stain
cytoplasm
cyt
aberr
antigen
ie
achiev
complet
remiss
induct
therapi
develop
earli
relaps
first
round
intensif
therapi
second
complet
remiss
attain
nelarabin
cbsct
howev
week
transplant
found
emerg
monoblast
leukem
cell
peripher
blood
posit
stain
leukem
cell
neg
harbor
tcr
rearrang
chromosom
aberr
mostli
ident
initi
diagnost
specimen
second
nelarabin
relaps
effect
conclus
possibl
lineag
target
therapi
ie
nelarabin
associ
lineag
switch
etp
monocyt
leukem
cell
specul
epigenet
shuttl
might
earli
sign
treatment
refractori
suggest
import
serial
cell
surfac
analysi
pr
mogensen
bo
k
lr
ra
ge
bk
lt
b
og
k
tl
hospit
rigshospitalet
diabet
research
unit
paediatr
oncolog
laboratori
copenhagen
denmark
hospit
rigshospitalet
paediatr
oncolog
laboratori
copenhagen
denmark
copenhagen
section
depart
public
health
copenhagen
denmark
hospit
rigshospitalet
depart
pediatr
adolesc
medicin
copenhagen
denmark
univers
central
hospit
univers
helsinki
helsinki
finland
faculti
medicin
clinic
children
diseas
vilniu
lithuania
univers
hospit
skejbi
depart
paediatr
aarhu
denmark
univers
hospit
tartu
univers
hospit
tartu
estonia
olav
univers
hospit
depart
paediatr
trondheim
norway
univers
hospit
children
hospit
reykjavik
iceland
univers
uppsala
univers
uppsala
sweden
lindgren
hospit
depart
paediatr
stockholm
sweden
hospit
rigshospitalet
depart
paediatr
adolesc
medicin
copenhagen
denmark
backgroundobject
pancreat
frequent
sever
toxic
childhood
acut
lymphoblast
leukemia
treatment
asparaginas
exposur
older
age
known
risk
factor
pancreat
childhood
howev
recent
data
suggest
obes
elev
risk
pancreat
sinc
obes
increas
global
health
issu
hypertriglyceridemia
risk
factor
pancreat
adult
obes
correl
triglycerid
level
associ
seem
plausibl
accordingli
investig
associ
bodi
mass
index
bmi
pancreat
designmethod
children
year
diagnos
receiv
asparaginas
accord
protocol
juli
decemb
includ
studi
pancreat
defin
accord
pont
di
legno
criteria
patient
follow
day
pancreat
death
caus
relaps
day
diagnosi
whichev
came
first
bmi
calcul
time
diagnosi
reflect
individu
differ
median
match
refer
group
result
among
children
includ
pancreat
diagnos
patient
cumul
incid
ci
patient
identifi
relaps
death
cumul
ci
pancreat
incid
significantli
higher
adolesc
year
compar
children
year
vs
bmi
associ
risk
pancreat
per
increas
ci
signific
interact
age
group
bmi
group
obes
vs
adjust
age
group
chang
bmi
group
conclus
increas
bmi
obes
diagnosi
associ
risk
pancreat
futur
studi
need
clarifi
exact
mechan
bmi
hypertriglyceridemia
asparaginas
pancreat
children
adolesc
pr
mogensen
k
k
bo
ss
tl
hospit
rigshospitalet
diabet
research
unit
paediatr
oncolog
laboratori
copenhagen
denmark
hospit
rigshospitalet
depart
pediatr
adolesc
medicin
copenhagen
denmark
copenhagen
section
depart
public
health
copenhagen
denmark
hospit
rigshospitalet
paediatr
oncolog
laboratori
copenhagen
denmark
hospit
rigshospitalet
depart
paediatr
adolesc
medicin
copenhagen
denmark
backgroundobject
increas
lipid
level
childhood
therapi
associ
sever
toxic
thrombosi
osteonecrosi
hypertriglyceridemia
associ
pancreat
risk
adult
therapi
attribut
elev
lipid
level
childhood
howev
leukem
influenc
remain
unclear
accordingli
studi
lipid
diagnosi
children
explor
associ
hyperlipidaemia
thrombosi
osteonecrosi
pancreat
designmethod
children
year
diagnos
treat
accord
nopho
protocol
univers
hospit
rigshospitalet
copenhagen
denmark
includ
hyperlipidemia
hypertriglyceridemia
hypercholesterolemia
defin
accord
pont
di
legno
criteria
bmi
calcul
reflect
individu
differ
median
match
refer
group
patient
follow
diagnosi
thrombosisosteonecrosispancreat
death
caus
relaps
end
treatment
year
diagnosi
result
hypertriglyceridemia
triglycerid
mmoll
present
studi
patient
miss
data
diagnosi
children
hypertriglyceridemia
significantli
younger
children
without
hypertriglyceridemia
median
age
iqr
year
vs
borderlin
higher
tumour
burden
median
iqr
wbc
vs
low
platelet
vs
differ
bmi
two
group
triglycerid
correl
bmi
spearman
baselin
hypertriglyceridemia
bmi
associ
risk
thrombosi
osteonecrosi
pancreat
therapi
p
conclus
influenc
lipid
metabol
prior
therapi
larger
studi
need
clarifi
exact
biolog
link
lipid
level
bmi
toxic
childhood
je
montoya
vasquez
c
ugaz
r
moral
alarcon
nacion
de
enfermedad
lima
lima
peru
backgroundobject
malnutrit
caus
morbid
reduc
surviv
previou
background
countri
nutrit
statu
children
leukemia
unlik
countri
south
america
aim
studi
evalu
nutrit
statu
children
acut
lymphoblast
leukemia
diagnosi
designmethod
retrospect
descript
studi
infant
children
younger
year
acut
lymphoblast
leukemia
diagnos
instituto
nacion
de
enfermedad
inen
januari
decemb
includ
sampl
size
patient
stata
use
statist
analysi
result
total
children
identifi
patient
male
femal
median
age
year
rang
month
year
frequent
diagnos
patient
lima
capit
one
hundr
nineteen
patient
eutroph
malnourish
overweight
obes
patient
normal
hemoglobin
valu
diagnosi
mild
anemia
moder
anemia
sever
anemia
one
hundr
twelv
normal
albumin
valu
patient
parasit
giardia
lamblia
found
children
conclus
children
diagnos
acut
lymphoblast
leukemia
eutroph
age
group
normal
nutrit
statu
signific
percentag
overweight
malnourish
patient
studi
encourag
us
follow
patient
chemotherapi
treatment
determin
complic
associ
nutrit
state
mulatsih
ph
e
da
sardjito
gener
hospit
pediatr
subdivis
yogyakarta
special
provinc
indonesia
backgroundobject
background
base
yogyakarta
pediatr
cancer
registri
ypcr
signific
increas
pediatr
acut
lymphoblast
leukemia
case
handl
dr
sardjito
hospit
dsh
time
novel
protocol
develop
increas
outcom
said
protocol
object
compar
possibl
relaps
pediatr
patient
period
designmethod
method
retrospect
studi
data
taken
ypcr
patient
group
relaps
surviv
comparison
risk
posit
neg
regard
leukocyt
count
age
year
old
year
old
year
old
sex
male
femal
result
total
patient
includ
studi
regard
leukocyt
count
odd
ratio
relaps
ci
p
age
ci
p
sex
ci
p
conclus
posit
risk
leukocyt
count
age
increas
possibl
relaps
sex
give
appar
risk
hh
myint
kt
yy
pediatr
mandalay
myanmar
burma
backgroundobject
malign
one
lead
caus
death
childhood
studi
review
mortal
childhood
malign
analyz
caus
death
pediatr
oncolog
center
designmethod
retrospect
studi
review
record
mortal
case
newli
regist
case
year
includ
mortal
data
collect
analyz
regard
age
sex
diagnosi
caus
death
time
death
diagnosi
result
among
newli
diagnos
malign
overal
mortal
case
median
age
diagnosi
year
f
ratio
median
surviv
time
day
mortal
rate
higher
leukemia
solid
tumor
lymphoma
mortal
newli
diagnos
leukemia
solid
tumor
lymphoma
accord
diseas
acut
lymphoblast
leukemia
highest
mortal
follow
acut
myeloid
leukemia
lymphoma
brain
tumor
neuroblastoma
rhabdomyosarcoma
solid
tumor
hepatoblastoma
retinoblastoma
nephroblastoma
ewe
sarcoma
germ
cell
tumor
sinonas
squamou
cell
carcinoma
analyz
caus
death
infect
commonest
septicaemia
febril
neutropenia
sever
pneumonia
fungal
infect
infect
enceph
document
caus
infect
die
due
diseas
progress
advancedmetastat
diseas
time
diagnosi
bleed
lead
caus
organ
failur
respons
death
five
due
toxic
death
remain
death
due
choke
conclus
leukemia
higher
mortal
rate
solid
tumor
lymphoma
infect
major
caus
death
support
care
especi
infect
control
import
improv
surviv
center
key
word
mortal
leukemia
infect
g
narula
memori
center
pediatr
oncolog
mumbai
india
memori
center
impacct
pediatr
oncolog
mumbai
india
backgroundobject
sinc
group
put
place
comprehens
measur
includ
financi
accommod
transfus
nutrit
support
ensur
patient
deni
treatment
ground
measur
cover
new
registr
acut
lymphoblast
leukemia
minim
residu
diseas
mrd
base
protocol
implement
onward
retrospect
audit
impact
measur
outcom
designmethod
record
children
regist
centr
jan
dec
retrospect
review
patient
incomplet
data
prior
treatment
refer
treatment
institut
exclud
assess
impact
support
care
divid
period
two
incomplet
complet
also
protocol
financi
support
patient
categoris
complet
support
cs
nb
support
ns
result
patient
elig
analysi
cs
treatment
refus
abandon
tr
rate
fell
overal
surviv
os
patient
show
signific
improv
p
respect
os
entir
cohort
respect
outcom
base
support
need
patient
improv
across
categori
differ
also
narrow
os
conclus
holist
measur
could
address
need
regist
patient
improv
overal
outcom
equit
manner
diminish
impact
statu
adopt
improv
outcom
tertiari
cancer
centr
india
navai
r
colleg
medicin
pediatr
houston
usa
backgroundobject
incid
risk
factor
hepatotox
children
acut
lymphoblast
leukemia
well
understood
contribut
factor
may
includ
diseas
burden
chemotherapeut
exposur
underli
genet
risk
object
defin
incid
hepatotox
local
pediatr
cohort
identifi
characterist
suggest
need
closer
monitor
earli
phase
treatment
designmethod
perform
retrospect
chart
review
children
treat
diagnos
texa
children
hospit
patient
hepatotox
induct
consolid
treatment
phase
includ
ast
alt
upper
limit
normal
conjug
bilirubin
mgdl
base
recommend
threshold
dose
modif
differ
age
gender
ethnic
bmi
compar
chi
squar
analysi
appropri
result
elig
case
hepat
abnorm
median
age
year
compar
year
entir
cohort
hispan
ethnic
compar
larger
cohort
gender
distribut
equival
group
vs
femal
p
two
pattern
hepatotox
identifi
isol
elev
transaminas
transaminas
elev
combin
conjug
hyerbilirubinemia
patient
conjug
hyperbilirubinemia
present
induct
older
averag
year
vs
year
like
bmi
percentil
vs
conclus
hepatotox
side
effect
earli
therapi
pediatr
older
overweight
children
hispan
ethnic
may
higher
risk
hepatox
includ
conjug
hyperbilirubinemia
may
benefit
closer
monitor
liver
function
test
induct
consolid
phase
therapi
h
nguyen
kh
vh
w
central
hospit
hue
pediatr
center
hue
vietnam
children
care
leagu
founder
tokyo
japan
backgroundobject
outcom
acut
lymphoblast
leukaemia
children
shown
improv
howev
relaps
diseas
still
big
issu
develop
countri
studi
aim
analyz
incid
surviv
rate
relaps
patient
childhood
acut
lymphoblast
leukemia
treat
hue
central
hospit
vietnam
period
designmethod
retrospect
prospect
descript
studi
data
analyz
accord
age
gender
relaps
type
relaps
time
result
new
patient
admit
hospit
relaps
case
account
relaps
case
ratio
male
femal
high
risk
group
time
higher
standard
group
vs
patient
achiev
remiss
induct
phase
median
time
diagnosi
relaps
month
rate
earli
earli
late
relaps
respect
base
relaps
time
relaps
mainten
phase
relaps
finish
therapi
relaps
delay
intensif
phase
relaps
induct
phase
due
abandon
treatment
base
relaps
type
bone
marrow
relaps
occupi
follow
isol
cn
bone
marrow
combin
cn
relaps
respect
rest
relaps
test
combin
testi
bone
marrow
combin
bone
marrow
testi
cn
median
time
relaps
death
month
april
relaps
case
pass
away
case
aliv
conclus
relaps
case
occur
mainten
phase
finish
treatment
bone
marrow
cn
main
site
relaps
tackl
fact
modifi
protocol
use
escal
methotrex
dose
provid
new
therapi
stem
cell
transplant
need
appli
nodomi
k
central
hospit
pediatr
okayama
japan
school
medic
kyoto
prefectur
univers
medicin
pediatr
kyoto
japan
backgroundobject
subgroup
acut
lymphoblast
leukemia
call
recogn
associ
poor
prognosi
minim
residu
diseas
mrd
signific
prognost
factor
howev
discord
result
shown
sever
techniqu
mrd
recent
studi
pediatr
patient
patient
fusion
posit
subgroup
relaps
chemotherapi
despit
mrd
neg
designmethod
case
posit
monitor
mrd
transcript
level
sequenti
compar
mrd
receptor
tcr
gene
rearrang
result
male
precursor
bone
marrow
show
lymphoblast
leukem
cell
express
cd
cd
tdt
express
cytoplasm
chain
cytogenet
studi
show
normal
karyotyp
abnorm
signal
fish
probe
detect
fusion
transcript
exon
fuse
exon
sanger
sequenc
treat
accord
chemotherapi
childhood
base
japanes
pediatr
leukemialymphoma
studi
group
protocol
prednison
good
respond
complet
remiss
induct
therapi
treat
chemotherapi
without
relaps
although
transcript
level
bone
marrow
show
rna
initi
diagnosi
detect
transcript
induct
therapi
therapi
mrd
tcr
perform
follow
standard
euromrd
recommend
show
also
neg
therapi
conclus
observ
suggest
fusion
mrd
mrd
detect
patient
fusion
posit
furthermor
must
analyz
relationship
discord
mrd
two
method
relaps
oberoi
r
manitoba
paediatr
haematolog
oncolog
winnipeg
canada
scienc
centr
section
genet
metabol
winnipeg
canada
scienc
centr
depart
patholog
winnipeg
canada
scienc
centr
depart
radiolog
winnipeg
canada
backgroundobject
combin
rearrang
myc
seen
commonli
matur
lymphoma
refer
rare
precursor
acut
lymphoblast
leukemia
particularli
pediatr
patient
describ
present
outcom
adolesc
diagnos
designmethod
retrospect
review
patient
chart
done
retriev
clinic
laboratori
data
result
adolesc
boy
present
histori
pain
swell
right
knee
upper
eyelid
associ
fever
weight
loss
elev
ldh
femur
demonstr
destruct
lesion
associ
joint
effus
ct
imag
reveal
soft
enhanc
mass
involv
lacrim
gland
orbit
diffus
infiltr
parotid
gland
facial
neck
muscl
without
involv
lymph
node
liver
spleen
extens
epidur
diseas
demonstr
throughout
thorac
lumber
spine
mri
morpholog
knee
joint
aspir
show
numer
small
round
blue
cell
consist
biopsi
sub
mental
lymph
node
show
minim
involv
diseas
bone
marrow
aspir
confirm
diagnosi
bone
marrow
cytogenet
fish
identifi
karyotyp
rearrang
myc
consist
diagnosi
xy
xy
treatment
initi
use
cog
protocol
high
risk
earli
poor
respons
chang
cog
protocol
matur
b
cell
leukemia
includ
rituximab
transient
partial
respons
subsequ
treat
blinatumumab
clear
evid
respons
die
refractori
progress
diseas
three
month
diagnosi
conclus
rare
character
aggress
clinic
behavior
poor
respons
intens
therapi
case
remark
extent
extranod
diseas
young
age
patient
b
oh
univers
hospit
singapor
paediatr
singapor
singapor
backgroundobject
cure
rate
acut
lymphoblast
leukemia
increas
rapidli
recent
advanc
give
birth
new
gener
long
term
survivor
singapor
protocol
yeoh
al
jco
highli
success
achiev
cure
rate
teenag
adolesc
usual
treat
intens
protocol
uniqu
set
challeng
manag
henc
aim
studi
impact
diagnosi
adolesc
health
outcom
earli
adulthood
designmethod
retrospect
case
note
review
perform
nation
univers
hospit
singapor
patient
diagnos
age
januari
result
patient
evalu
studi
mean
durat
mean
age
time
analysi
studi
popul
treat
protocol
patient
requir
bone
marrow
transplant
obes
rate
increas
significantli
diagnosi
recent
specif
increas
diagnosi
recent
neurolog
complic
thrombosi
leukoencephalopathi
occur
commonli
septicemia
treatment
commonest
late
effect
psychosoci
issu
endocrinopathi
hypogonad
thyroid
problem
includ
case
secondari
thyroid
carcinoma
survivor
achiev
univers
degre
complet
least
tertiari
educ
diploma
gce
level
certif
unemploy
rate
studi
popul
compar
nation
rate
conclus
overal
outcom
excel
adolesc
survivor
despit
intens
treatment
obes
psychosoci
issu
endocrinopathi
major
issu
care
need
tailor
toward
effect
screen
earli
treatment
problem
young
adult
survivor
r
h
g
n
nacion
de
pediatria
hematopoiet
cell
trasplant
cell
therapi
depart
mexico
nacion
de
pediatria
director
hemoncolog
nation
institut
pediatr
program
director
pediatr
hemoncolog
medic
center
abc
mexico
citi
mexico
center
abc
bone
marrow
transplant
unit
mexico
backgroundobject
patient
relaps
refractori
convent
treatment
possibl
achiev
long
term
remiss
report
refer
therapeut
efficaci
advers
event
blinatumomab
achiev
molecular
remiss
patient
lead
haploident
transplant
consolid
designmethod
pilot
studi
conduct
children
refractori
strategi
achiev
remiss
blinatumomab
usedat
dose
contin
infus
hour
increas
dose
day
patient
mrd
log
cycl
receiv
haploident
bone
marrow
transplant
consolid
condit
regimen
total
bodi
irradi
scheme
day
cyclophosphamid
etoposid
receiv
prophylaxi
gvhd
cyclophosphamid
result
total
patient
includ
achiev
complet
remiss
cycl
blinatumomab
patient
receiv
haploident
transplant
achiev
graft
transplant
patient
two
patient
bone
marrow
relaps
first
month
patient
free
diseas
month
acut
complic
patient
present
cytokin
releas
syndrom
infus
blinatumumab
patient
present
tachycardia
patient
present
agvhd
grade
ii
grade
iv
conclus
allogen
bone
marrow
transplant
constitut
treatment
option
patient
relaps
becom
refractori
treatment
one
major
problem
basic
identifi
donor
altern
haploident
donor
import
factor
get
result
diseas
statu
transplant
use
blinatumomab
proven
effect
achiev
remiss
relaps
acut
linfoblast
leukemia
cd
refractori
treatment
olsen
serum
institut
centr
fetal
depart
epidemiolog
research
copenhagen
denmark
backgroundobject
retrospect
studi
suggest
dietari
intak
pregnanc
may
play
role
aetiolog
childhood
cancer
thu
high
matern
intak
phytoestrogen
may
increas
veget
may
reduc
offspr
risk
acut
lymphoblast
leukaemia
matern
intak
nitrosamid
cure
meat
may
increas
offspr
risk
brain
tumour
danish
norwegian
nation
birth
cohort
first
databas
hypothes
challeng
prospect
analys
two
databas
recent
brought
togeth
avail
us
data
open
yet
purpos
object
present
discuss
strategi
open
pool
data
cohort
purpos
examin
impact
specif
dietari
factor
offspr
cancer
risk
main
question
whether
might
earli
whether
wait
data
larg
cohort
avail
designmethod
pregnanc
recruit
danish
nation
birth
cohort
dnbc
pregnanc
recruit
norwegian
mother
child
cohort
studi
moba
cohort
diet
pregnanc
assess
use
similar
food
item
ffq
result
continu
dietari
variabl
categor
quintil
analysi
compar
highest
lowest
quintil
combin
dnbc
moba
databas
would
chanc
detect
rel
risk
rr
signific
level
achiev
condit
similar
power
leukaemia
rr
would
conclus
base
advanc
power
calcul
pro
con
discuss
two
possibl
data
combin
nordic
cohort
shall
open
specif
dietari
hypothes
address
shall
wait
data
larg
prospect
cohort
becom
avail
pool
n
oosterom
r
de
de
r
wj
bd
van
mm
van
den
sg
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
medic
center
depart
clinic
chemistri
amsterdam
netherland
children
univers
univers
medic
center
groningen
depart
pediatr
oncolog
groningen
netherland
medic
center
depart
clinic
chemistri
rotterdam
netherland
backgroundobject
methotrex
mtx
import
cytotox
agent
pediatr
acut
lymphoblast
leukemia
treatment
mtx
deplet
intracellular
folat
level
therebi
inhibit
rna
synthesi
mtx
infus
folat
rescu
therapi
leucovorin
administ
reduc
toxic
previou
studi
show
oral
mucos
predominantli
occur
first
four
mtx
cours
leucovorin
structur
analogu
mtx
possibl
compet
cellular
transport
mechan
lead
decreas
intracellular
mtx
level
neutral
effect
mtx
decreas
treatment
efficaci
aim
studi
determin
whether
intracellular
folat
level
increas
consecut
mtx
cours
therefor
overrescu
mtx
effect
designmethod
prospect
assess
erythrocyt
folat
vitam
thf
thf
serum
folat
level
children
start
stop
cours
interv
result
total
sum
erythrocyt
folat
vitam
increas
mean
nmoll
mean
nmoll
p
mainli
due
increas
erythrocyt
thf
level
mean
increas
nmoll
p
wherea
thf
level
chang
median
increas
nmoll
serum
folat
increas
therapi
median
increas
nmoll
p
chang
significantli
affect
age
gender
immunophenotyp
mthfr
genotyp
hospit
inclus
conclus
serum
intracellular
folat
level
accumul
cours
leucovorin
therapi
children
show
leucovorin
abl
restor
intracellular
folat
pool
futur
studi
determin
whether
result
decreas
intracellular
mtx
level
neutral
effect
mtx
necessari
prove
overrescu
patel
r
r
v
cancer
institut
depart
pediatr
blood
marrow
transplant
chennai
india
backgroundobject
mix
phenotyp
acut
leukemia
mpal
rare
subgroup
acut
leukemia
seen
less
pediatr
leukemia
case
data
regard
standard
therapi
regimen
outcom
children
scant
designmethod
perform
retrospect
analysi
children
diagnos
mpal
center
march
march
immunophenotyp
flow
cytometri
per
egil
criteria
children
assign
four
drug
induct
therapi
acut
lymphoblast
leukemia
standard
acut
myeloid
leukemia
aml
induct
initi
base
predomin
marker
respons
assess
end
induct
second
induct
aml
chemotherapi
administ
hsct
offer
patient
initi
therapi
mainten
chemotherapi
year
continu
declin
hsct
result
nineteen
children
includ
studi
median
age
diagnosi
eight
year
year
year
median
total
leukocyt
count
present
fifteen
two
bt
lymphoid
two
children
immunophenotyp
document
eleven
patient
receiv
aml
induct
therapi
patient
receiv
induct
therapi
eight
thirteen
children
underw
allogen
hematopoiet
stem
cell
transplant
best
avail
donor
two
five
patient
undergo
hsct
aliv
overal
surviv
cohort
common
caus
mortal
relaps
follow
regimen
relat
toxic
conclus
children
receiv
induct
follow
aml
induct
trend
toward
improv
surviv
seri
overal
surviv
relaps
common
caus
mortal
mrd
base
individu
therapi
would
help
optim
outcom
patel
k
p
z
n
b
jerbai
wadia
hospit
children
depart
pediatr
mumbai
india
backgroundobject
despit
vast
improv
outcom
pediatr
acut
lymphoblast
leukemia
relaps
remain
major
cancer
subgroup
studi
evalu
clinic
profil
patient
relaps
designmethod
retrospect
data
analysi
patient
relaps
regist
bj
wadia
children
hospit
mumbai
done
paramet
initi
diagnosi
evalu
patient
later
relaps
result
total
patient
precursor
patient
relaps
relaps
earli
relaps
earli
late
relaps
data
respect
common
site
relaps
medullari
cn
wherea
medullari
follow
combin
medullari
cn
initi
diagnosi
bulki
diseas
total
leukocyt
count
pre
b
cn
diseas
none
testicular
diseas
poor
prednison
respons
cytogenet
found
patient
patient
achiev
morpholog
remiss
howev
minim
residu
diseas
mrd
patient
patient
patient
major
break
treatment
mainten
chemotherapi
absolut
neutrophil
count
anc
maintain
visit
anc
visit
conclus
mrd
import
predictor
relaps
pediatr
major
break
upfront
treatment
complianc
mainten
assess
ad
risk
factor
relaps
n
pathak
r
india
institut
medic
scienc
pediatr
new
delhi
india
backgroundobject
dysregul
cell
cycl
promot
methyl
cell
cycl
control
gene
frequent
event
acut
lymphoblast
leukemia
recogn
critic
event
diseas
pathogenesi
progress
cell
cycl
neg
regul
cdk
interact
proteinkinas
inhibitori
protein
cipkip
famili
gene
epigenet
inactiv
gene
report
discrep
frequenc
aim
investig
methyl
statu
cdk
interact
proteinkinas
inhibitori
protein
famili
gene
pediatr
patient
find
correl
treatment
outcom
designmethod
bisulphit
modif
extract
total
genom
dna
bone
marrow
peripher
blood
mononuclear
cell
pediatr
patient
done
follow
amplif
modifi
dna
use
methyl
specif
pcr
result
total
pediatr
patient
median
age
yr
rang
yr
f
median
rang
studi
hypermethyl
gene
observ
patient
frequenc
hypermethyl
significantli
associ
higher
age
group
age
year
hypermethyl
cip
also
found
predictor
poorer
diseas
free
surviv
df
hazard
ratio
ci
conclus
frequenc
hypermethyl
cell
cycl
control
gene
found
higher
patient
correl
significantli
poorer
df
explor
indian
scenario
might
provid
insight
regard
poorer
outcom
patient
compar
west
k
k
w
pediatr
jagiellonian
univers
medic
colleg
depart
children
oncolog
hematolog
krakow
poland
pediatr
jagiellonian
univers
medic
colleg
depart
clinic
immunolog
transplantolog
krakow
poland
backgroundobject
blast
clearanc
strong
indic
outcom
childhood
acut
lymphoblast
leukemia
accord
mani
therapeut
protocol
achiev
minim
residu
diseas
mrd
day
induct
evalu
flow
cytometri
fc
use
risk
direct
therapi
children
assess
prognost
impact
mrd
measur
fc
day
induct
therapi
well
avail
mrd
detect
time
point
consid
therapi
relat
antigen
modul
bone
marrow
hypocellular
designmethod
sinc
novemb
march
bone
marrow
children
age
younger
year
newli
diagnos
treat
depart
children
oncolog
hematolog
institut
pediatr
jagiellonian
univers
krakow
poland
accord
protocol
taken
fc
mrd
analysi
day
induct
therapi
use
color
fc
detect
immunophenotyp
result
enrol
patient
assess
sampl
fc
mrd
day
children
time
point
immunophenotyp
recogn
studi
patient
accord
fc
mrd
day
three
risk
group
identifi
standard
blast
cell
total
intermedi
high
cumul
incid
relaps
se
se
se
respect
multivari
analysi
mrd
day
strongest
prognost
factor
among
other
age
leukocyt
number
blast
genet
rearrang
conclus
sinc
earli
blast
clearanc
kinet
still
strongest
prognost
valu
mrd
detect
earli
phase
induct
treatment
becom
mandatori
tool
childhood
therapi
fc
mrd
evalu
fast
highli
sensit
applic
becom
use
strategi
residu
cell
assess
e
petrid
f
n
j
c
csg
clic
studi
kapodistrian
univers
athen
medic
school
dept
epidemiolog
medic
statist
athen
greec
institut
clinic
epidemiolog
depart
medicin
stockholm
sweden
agenc
research
cancer
section
environ
radiat
lyon
franc
cancer
societi
research
center
childhood
cancer
survivorship
research
unit
survivorship
copenhagen
denmark
liver
menoufia
univers
depart
epidemiolog
prevent
collabor
research
center
cair
egypt
nacion
heredia
central
american
institut
studi
toxic
substanc
iret
heredia
costa
rica
univers
depart
biostatist
occup
health
faculti
medicin
canada
univers
depart
women
children
health
uppsala
sweden
john
david
r
johnni
julia
e
eleanor
alic
xiaomei
corrado
catherin
beth
maria
waffa
eve
michael
e
logan
g
rong
wang
clic
studi
group
athen
greec
backgroundobject
advanc
parent
age
associ
advers
health
effect
offspr
includ
childhood
year
acut
lymphoblast
leukemia
report
publish
studi
primari
data
studi
particip
childhood
leukemia
intern
consortium
provid
uniqu
methodolog
opportun
explor
associ
designmethod
data
cc
studi
case
interview
control
five
nest
ncc
studi
case
control
record
link
via
registri
enrol
period
rang
use
adjust
odd
ratio
deriv
studi
use
patern
matern
age
increment
introdud
two
cc
ncc
studi
design
result
advanc
patern
age
associ
statist
signific
higher
risk
offspr
advanc
matern
age
ncc
contrast
result
heterogen
cc
studi
heterogen
posit
associ
parent
age
risk
evid
age
group
among
year
remain
unchang
mutual
adjust
collinear
effect
patern
matern
age
variabl
perform
analys
rel
small
number
discord
patern
matern
age
pair
explor
collinear
effect
parent
age
result
fulli
enlighten
conclus
result
larger
ever
dataset
primari
data
allow
separ
analysi
studi
design
better
control
select
bia
cc
studi
strengthen
evid
advanc
parent
age
associ
increas
childhood
risk
observ
studi
design
ollinear
matern
patern
age
complic
causal
interpret
employ
dataset
cytogenet
inform
may
elucid
involv
parent
compon
clarifi
underli
mechan
pike
k
iwk
health
centr
depart
pediatr
halifax
canada
iwk
health
centr
depart
divis
pediatr
hematologyoncolog
halifax
canada
iwk
health
centr
depart
divis
pediatr
hematologyoncolog
halifax
canada
backgroundobject
asparaginas
therapeut
drug
monitor
tdm
detect
silent
inactiv
si
asparaginas
patient
acut
lymphoblast
leukemia
asparaginas
level
measur
surrog
asparagin
deplet
result
leukem
cell
death
pauciti
inform
clinic
implic
asparaginas
level
therapeut
minimum
studi
describ
asparaginas
tdm
experi
maritim
canada
designmethod
prospect
cohort
studi
includ
newli
diagnos
leukemialymphoma
patient
manag
iwk
health
centr
patient
treat
accord
children
oncolog
group
protocol
use
pegyl
asparaginas
research
ethic
board
approv
inform
consent
blood
sampl
taken
patient
approxim
day
dose
allow
switch
product
event
si
level
analyz
next
molecular
clinic
laboratori
improv
amend
clia
certifi
laboratori
level
iuml
consid
therapeut
result
level
measur
patient
mean
age
year
level
supratherapeut
mean
iuml
rang
mean
level
significantli
higher
standard
risk
iuml
patient
iuml
asparaginas
level
vari
significantli
base
age
sex
diseas
type
minim
residu
diseas
statu
three
patient
experienc
toxic
reaction
hive
pancreat
conclus
averag
asparaginas
level
approxim
time
higher
therapeut
minimum
patient
show
sign
si
standard
risk
patient
significantli
higher
asparaginas
level
perhap
receiv
lower
number
dose
previou
studi
demonstr
lower
dose
asparaginas
maintain
level
iuml
length
time
higher
dose
studi
consid
review
minimum
asparaginas
dose
requir
adequ
asparagin
deplet
lower
dose
may
reduc
toxic
cost
therapi
maintain
surviv
outcom
pogorzala
j
r
e
b
e
n
k
p
p
univers
hospit
collegium
medicum
umk
depart
pediatr
hematolog
oncolog
bydgoszcz
poland
univers
hospit
collegium
medicum
umk
depart
pediatr
surgeri
bydgoszcz
poland
backgroundobject
first
report
children
treat
acut
lymphoblast
leukemia
bydgoszcz
poland
come
eleven
children
treat
steroid
blood
transfus
object
studi
analysi
result
treatment
children
studi
poland
designmethod
total
number
children
includ
studi
children
treat
variou
drug
children
treat
total
therapi
protocol
st
jude
memphi
children
treat
accord
children
treat
accord
children
treat
new
york
iii
protocol
children
treat
children
treat
result
respect
period
follow
probabl
overal
surviv
po
obtain
p
b
adjust
time
period
univari
cox
analysi
comparison
hazard
risk
hr
death
patient
treat
respect
p
hazard
risk
leukem
relaps
patient
treat
respect
p
hazard
risk
event
patient
treat
respect
p
conclus
complex
manag
children
base
therapi
intern
strategi
multidrug
chemotherapi
multidirect
support
therapi
enabl
increas
surviv
popov
l
j
g
research
center
pediatr
oncolog
immunolog
laboratori
depart
moscow
russia
children
hospit
research
institut
medic
cell
technolog
pediatr
oncologyhematolog
depart
ekaterinburg
russia
research
center
pediatr
oncolog
immunolog
institut
oncolog
radiolog
nuclear
medicin
moscow
russia
pediatr
oncolog
hematolog
berlin
germani
backgroundobject
despit
signific
improv
childhood
acut
lymphoblast
leukemia
treatment
result
manag
still
challeng
addit
prognost
factor
type
requir
object
studi
investig
prognost
signific
tumor
blast
immunophenotyp
childhood
designmethod
total
consecut
children
boy
girl
median
age
year
prospect
studi
two
refer
flow
cytometr
laboratori
trial
accord
protocol
stratif
system
patient
distribut
risk
risk
risk
group
surviv
ef
standard
error
se
use
outcom
paramet
result
among
studi
singl
marker
receptor
tcr
express
found
influenc
treatment
outcom
patient
significantli
better
ef
se
compar
one
se
case
tcr
coexpress
outcom
patient
wors
oppos
tcr
ef
se
ef
se
respect
similarli
group
tcr
express
associ
poor
prognosi
tcr
children
ef
se
tcr
case
ef
se
taken
togeth
tcr
express
allow
distinguish
three
group
favor
tcr
ef
se
intermedi
tcr
tcr
ef
se
unfavor
tcr
ef
se
definit
patient
differ
outcom
retain
signific
also
group
analyz
separ
respect
conclus
result
present
studi
indic
signific
prognost
role
tcr
express
childhood
flow
cytometr
data
could
success
appli
patient
stratif
togeth
convent
risk
criteria
pushpam
n
v
r
india
institut
medic
scienc
medic
oncolog
delhi
india
india
institut
medic
scienc
laboratori
oncolog
delhi
india
india
institut
medic
scienc
depart
biostatist
delhi
india
backgroundobject
correl
absolut
lymphocyt
count
alc
minim
residu
diseas
mrd
whether
use
surrog
marker
mrd
resourc
limit
set
known
data
lack
regard
immunolog
differ
mrd
posit
neg
patient
b
studi
correl
alc
mrd
steroid
respons
complet
remiss
cr
designmethod
prospect
studi
done
juli
june
alc
done
baselin
day
day
end
induct
day
mrd
peripher
blood
lymphocyt
subset
assess
day
alc
calcul
percentag
lymphocyt
determin
manual
multipli
total
leucocyt
count
mrd
assess
done
flow
cytometri
mrd
posit
cut
peripher
blood
lymphocyt
analysi
done
flow
cytometri
associ
evalu
result
total
patient
de
novo
b
upto
year
enrol
median
age
year
rang
patient
achiev
cr
patient
mrd
posit
neg
evalu
peripher
lymphocyt
subset
avail
patient
mrd
posit
mrd
neg
alc
baselin
day
day
day
correl
mrd
alc
day
greater
poor
steroid
respond
good
steroid
respond
mdn
p
alc
baselin
day
day
correl
steroid
respons
alc
point
correl
cr
cell
higher
patient
mrd
posit
mdn
compar
mrd
neg
mdn
p
conclus
alc
use
surrog
marker
mrd
immunolog
mrd
posit
mrd
neg
patient
differ
cell
pushpam
v
r
india
institut
medic
scienc
medic
oncolog
delhi
india
india
institut
medic
scienc
laboratori
oncolog
delhi
india
india
institut
medic
scienc
biostatist
delhi
india
backgroundobject
absolut
lymphocyt
count
alc
readili
avail
prognost
marker
correl
minim
residu
diseas
mrd
cell
acut
lymphoblast
leukemia
tall
known
studi
evalu
correl
alc
mrd
explor
whether
use
surrog
marker
resourc
limit
set
alc
also
correl
induct
outcom
ie
steroid
respons
complet
remiss
cr
designmethod
prospect
studi
conduct
juli
june
newli
diagnos
patient
age
year
includ
alc
done
baselin
day
day
end
induct
day
calcul
percentag
lymphocyt
manual
examin
peripher
smear
multipli
total
leucocyt
count
mrd
assess
done
flow
cytometri
level
use
mrd
posit
associ
continu
categor
data
examin
result
total
patient
enrol
median
age
year
rang
patient
achiev
cr
mrd
avail
patient
analyz
alc
baselin
day
day
correl
mrd
alc
day
greater
mrd
neg
patient
mdn
mrd
posit
patient
mdn
p
alc
point
correl
steroid
respons
cr
conclus
alc
day
correl
mrd
higher
alc
favour
factor
possibl
alc
may
act
surrog
marker
mrd
end
induct
find
need
valid
studi
queudevil
u
hm
h
von
p
p
r
hospit
children
hospit
gener
hematologyoncolog
germani
stuttgart
olgahospit
pediatr
hematolog
immunolog
stuttgart
germani
hospit
frankfurt
depart
children
adolesc
frankfurt
germani
univers
medic
center
depart
pediatr
oncologyhematolog
berlin
germani
medic
center
kiel
depart
gener
pediatr
kiel
germani
von
hauner
univers
children
lmu
depart
pediatr
oncolog
stem
cell
transplant
munich
germani
backgroundobject
pediatr
patient
relaps
refractori
acut
lymphoblast
leukemia
extrem
poor
prognosi
blinatumomab
bispecif
engag
antibodi
construct
simultan
bind
cytotox
lead
lysi
normal
malign
designmethod
report
retrospect
analysi
experi
blinatumomab
patient
relaps
refractori
pediatr
precursor
result
median
age
onset
therapi
year
year
eighti
percent
patient
undergon
least
one
hematopoiet
stem
cell
transplant
hsct
prior
therapi
blinatumomab
patient
receiv
antibodi
therapi
state
open
relaps
despit
high
tumor
load
patient
start
immunotherapi
total
patient
show
primari
respons
blinatumomab
addit
patient
respond
second
cycl
predomin
side
effect
consist
febril
reaction
almost
patient
nearli
half
defin
cytokin
releas
syndrom
cr
major
cr
low
grade
easili
manag
neurotox
seen
patient
duringaft
first
patient
second
cycl
date
seven
patient
aliv
remiss
mean
surviv
month
month
blinatumomab
enabl
transit
hsct
three
survivor
one
patient
low
blast
count
start
blinatumomab
remiss
without
hsct
conclus
despit
heavi
pretreat
patient
sever
advers
event
rare
respons
rate
encourag
patient
signific
proport
patient
respond
second
treatment
cycl
blinatumomab
promis
new
agent
front
line
treatment
current
investig
pediatr
random
control
clinic
trial
v
radhakrishnan
j
p
institut
wia
medic
oncolog
pediatr
oncolog
chennai
india
backgroundobject
patient
nutrit
statu
shown
impact
outcom
acut
lymphoblast
leukemia
present
studi
conduct
analys
trend
chang
nutrit
statu
children
intens
phase
treatment
designmethod
studi
includ
newli
diagnos
patient
less
year
age
treat
uniform
protocol
januari
patient
height
weight
collect
prospect
diagnosi
end
induct
consolid
interim
mainten
delay
intensif
start
mainten
weight
age
wa
bodi
mass
index
bmi
refer
standard
use
classifi
nutrit
statu
valu
standard
deviat
sd
sd
consid
undernourish
obes
respect
result
studi
includ
patient
median
age
year
patient
male
undernutrit
normal
nutrit
obes
observ
patient
diagnosi
end
delay
intensif
respect
p
signific
weight
chang
patient
observ
induct
phase
treatment
phase
treatment
nci
categori
paramet
predict
undernutrit
present
patient
whose
bmiwa
diagnosi
risk
obes
undernutrit
later
respect
maximum
variat
nutrit
statu
occur
patient
wabmi
chang
bmiwa
induct
induct
start
mainten
significantli
associ
inferior
event
free
surviv
ef
respect
conclus
weight
chang
intens
phase
treatment
associ
inferior
ef
predictor
futur
obes
strategi
optim
nutrit
treatment
help
improv
outcom
patient
treat
develop
countri
v
radhakrishnan
j
p
institut
wia
medic
oncolog
pediatr
oncolog
chennai
india
institut
wia
patholog
chennai
india
backgroundobject
use
risk
respons
adapt
protocol
develop
countri
hamper
lack
access
cytogenet
minim
residu
diseas
mrd
test
share
experi
first
risk
respons
adapt
protocol
treat
pediatr
designmethod
studi
includ
newli
diagnos
patient
year
age
prospect
enrol
januari
group
patient
stratifi
standard
risk
sr
intermedi
risk
ir
high
risk
hr
base
nci
criteria
diseas
bulk
cytogenet
day
prednisolon
respons
post
induct
mrd
patient
treat
hr
event
free
surviv
ef
overal
surviv
os
analys
use
method
test
use
compar
variabl
result
total
consecut
patient
elig
analysi
median
age
year
patient
male
cell
phenotyp
observ
patient
baselin
group
sr
ir
hr
sr
ir
hr
respect
blast
clearanc
day
observ
patient
median
month
overal
ef
os
respect
ef
os
sr
ir
hr
cohort
respect
ef
os
respect
nci
risk
stratif
predict
ef
day
prednisolon
respons
immunophenotyp
mrd
significantli
predict
ef
os
conclus
contrast
data
develop
countri
major
patient
cohort
diseas
surviv
outcom
compar
similar
result
report
centr
india
better
histor
cohort
ranjani
r
p
c
care
global
depart
paediatr
haematolog
oncolog
bmt
bengaluru
india
children
hospit
depart
paediatr
oncolog
bengaluru
india
health
bengaluru
india
india
backgroundobject
background
leukemia
constitut
childhood
malign
acut
lymphoblast
leukemia
account
pediatr
leukemia
case
report
india
annual
surviv
rate
children
increas
last
year
worldwid
surviv
rate
pediatr
surviv
rate
india
still
report
object
studi
clinic
hematolog
cytogenet
profil
children
acut
lymphoblast
leukemia
designmethod
design
retrospect
studi
januari
decemb
tertiari
center
pediatr
oncolog
southern
india
sampl
size
children
method
children
year
diagnos
includ
children
relaps
exclud
risk
stratif
accord
uk
protocol
present
featur
record
case
file
flowcytometri
use
classifi
type
bone
marrow
evalu
mrd
flowcytometri
done
ascertain
remiss
result
mean
age
present
year
male
preponder
observ
major
year
children
present
splenomegali
present
hepatomegali
lymphadenopathi
mean
hb
children
hyper
leukocytosi
observ
children
karyotyp
done
children
normal
karyotyp
hyper
diploid
hypo
diploid
bcr
abl
posit
children
mll
diseas
free
surviv
studi
conclus
incid
childhood
leukemia
increas
data
requir
understand
clinic
profil
children
develop
countri
import
cytogenet
risk
classif
stress
help
risk
adopt
therapi
g
hospit
west
indi
depart
paediatr
kingston
jamaica
hospit
west
indi
depart
hematolog
kingston
jamaica
backgroundobject
current
treatment
acut
lymphoblast
leukaemia
produc
surviv
rate
greater
countri
regimen
also
associ
mortal
morbid
particularli
induct
initi
risk
stratif
gener
base
age
white
cell
count
diagnosi
presenc
absenc
diseas
due
limit
local
resourc
facilit
cytogenet
studi
evalu
minim
residu
diseas
risk
stratif
paediatr
patient
diagnos
treat
uwhi
augment
arm
protocol
reserv
patient
success
strategi
induct
evalu
designmethod
patient
retrospect
risk
stratifi
use
children
oncolog
group
cog
criteria
induct
phase
relat
morbid
mortal
assess
associ
use
protocol
popul
includ
paediatr
patient
year
diagnos
treat
uhwi
jamaica
result
seven
patient
elig
analysi
four
classifi
standard
risk
three
high
risk
receiv
combin
chemotherapi
includ
dose
doxorubicin
went
remiss
post
induct
death
case
tumor
lysi
syndrom
treatment
abandon
three
febril
neutropenia
one
chemotherapi
induc
hyperglycemia
conclus
augment
arm
ccg
protocol
abl
achiev
post
induct
remiss
rate
percent
mortal
low
morbid
addit
inform
properli
risk
stratifi
patient
would
allow
patient
known
standard
risk
treat
less
chemotherapi
regimen
prove
toler
low
middl
incom
set
effect
may
issu
popul
j
sarno
c
g
g
k
center
childhood
cancer
stanford
univers
pediatr
stanford
usa
univers
denmark
depart
bio
health
informat
kongen
lyngbi
denmark
laboratori
stem
cell
stanford
univers
depart
microbiolog
immunolog
stanford
usa
tettamanti
research
univers
milano
bicocca
depart
pediatr
monza
itali
curi
psl
research
univers
orsay
franc
backgroundobject
glucocorticoid
gc
crucial
role
treatment
acut
lymphoblast
leukemia
respons
glucocorticoid
consid
strong
prognost
marker
relaps
risk
despit
mechan
action
resist
still
poorli
understood
designmethod
rna
sequenc
analysi
healthi
development
popul
identifi
gene
relat
gc
pathway
upregul
togeth
receptor
bcr
signal
gene
transit
cell
cell
better
understand
impact
gc
leukem
perform
experi
primari
cell
treat
dexamethason
profil
use
mass
cytometri
proteom
data
also
confirm
evalu
bcr
glucocorticoid
receptor
gcr
pathway
gene
pcr
result
analyz
patient
found
gcr
highli
express
cell
gc
treatment
mostli
affect
cell
cell
cycl
cell
interestingli
although
observ
cell
death
also
identifi
phenotyp
chang
resist
cell
compat
matur
phenotyp
activ
signal
phenotyp
chang
could
revert
treatment
scrabl
inhibitor
dasatinib
result
also
increas
cell
death
combin
dexamethason
moreov
cell
present
also
upregul
gene
transcript
factor
associ
matur
statu
conclus
data
suggest
dual
role
glucocorticoid
apoptosi
preferenti
cycl
cell
well
differenti
process
stage
stage
furthermor
pressur
gc
treatment
cell
push
next
development
stage
becom
sensit
combin
treatment
dasatinib
open
new
insight
treatment
respond
patient
r
segura
pediatr
hematolog
oncolog
guadalajara
mexico
civil
guadalajara
anestesiolog
guadalajara
mexico
backgroundobject
studi
inhal
anesthet
vs
intraven
effect
earli
remiss
patient
acut
lymphoblast
leukemia
compar
anesthet
use
predispon
factor
late
remiss
minim
residu
diseas
mrd
day
designmethod
transvers
analyt
studi
june
februari
new
diagnosi
age
year
two
group
conform
inhal
anesthesia
vs
intraven
pediatr
servic
hospit
civil
nuevo
guadalajara
mexico
result
twenti
patient
inhal
anesthesia
intraven
twelv
gender
male
femal
averag
age
year
found
patient
inhal
anesthesia
group
older
averag
vs
weight
kilogram
durat
anesthesia
minut
anesthesia
longer
inhal
anesthesia
group
vs
minut
patient
got
remiss
day
mrd
vs
get
remiss
remiss
bigger
intraven
anesthesia
group
median
vs
eighteen
lineag
b
vs
lineag
blast
white
blood
cell
diagnosi
conclus
identifi
potenti
impression
variabl
determin
therapeut
difficulti
long
time
durat
inhal
anesthesia
could
fact
ca
nt
get
earli
remiss
mrd
day
factor
older
age
inhal
anesthesia
overweight
obes
inhal
anesthesia
inflat
anesthesia
mani
patient
could
wet
earli
remiss
day
comparison
intraven
anesthesia
aleatori
studi
realiz
confirm
find
p
k
n
sen
dhirubhai
ambani
hospit
depart
paediatr
oncolog
bmt
mumbai
india
backgroundobject
present
acut
lymphoblast
leukemia
acut
bone
pain
well
known
howev
rare
patient
present
osteoporosi
present
case
young
boy
present
sever
osteoporosi
precipit
leukemia
designmethod
year
old
boy
present
sever
back
pain
difficulti
walk
mri
show
small
linear
undisplac
fractur
along
superior
margin
vertebr
bodi
normal
blood
count
patient
advis
bed
rest
week
repeat
x
ray
week
show
multipl
compress
fractur
sever
osteoporot
chang
bone
patient
evalu
routin
blood
work
dexa
scan
cbc
stage
show
leukem
blast
found
b
cell
origin
investig
result
patient
bedridden
sever
osteoporosi
induct
therapi
start
along
bisphosphon
repeat
month
patient
follow
pinp
procollagen
intact
level
marker
osteoporosi
along
chemotherapi
subsequ
becam
mobil
month
therapi
rise
bone
densiti
seen
calcium
supplement
vitamin
given
complic
relat
respond
well
therapi
repeat
x
ray
pinp
level
significantli
improv
along
clinic
improv
conclus
one
third
leukem
patient
present
bone
pain
time
may
misdiagnos
rheumatoid
septic
arthriti
steroid
induc
osteoporosi
time
seen
initi
therapi
almost
unknown
diseas
present
sever
osteoporosi
clinician
need
awar
divers
present
g
sezgin
univers
medic
school
divis
pediatr
oncologysct
unit
adana
turkey
memori
hospit
divis
pediatr
hematologyoncolog
sct
unit
turkey
backgroundobject
one
reason
improv
cure
rate
pediatr
central
nervou
system
cn
consist
intrathec
methotrex
cytarabin
steroid
dexamethason
hydrocortison
prednisolon
intrathec
methylprednisolon
shown
effect
postherpet
neuralgia
use
cn
direct
treatment
leukemia
designmethod
total
patient
acut
lymphoblast
leukemia
diagnos
hospit
januari
novemb
includ
studi
patient
treat
base
bfm
chemotherapi
protocol
steroid
treatment
initi
daili
dose
mgkg
methylprednisolon
day
treatment
patient
divid
risk
group
standard
srg
moder
mrg
high
hrg
base
respons
methylprednisolon
treatment
patient
receiv
intrathec
methylprednisolon
methotrex
cytarabin
maintenac
phase
everi
week
result
fifti
boy
twenti
three
girl
group
mean
age
patient
month
median
rang
month
overal
surviv
rate
os
patient
evalu
use
test
variou
time
point
follow
year
year
two
five
year
surviv
rate
respect
relaps
devep
twenti
one
patient
ten
patient
isol
cn
relaps
seven
patient
cn
system
relaps
four
patient
system
relaps
patient
relaps
srg
mrg
hrg
risk
group
patient
cn
involv
rate
patient
toler
intrathec
methylprednisolon
well
complic
seen
conclus
intrathec
methylprednisolon
well
toler
complic
seen
cn
relaps
rate
correl
literatur
j
shao
h
h
j
l
children
hospit
hematologyoncolog
shanghai
china
backgroundobject
occurr
due
abnorm
chang
cell
precursor
cell
hedgehoggli
signal
pathway
play
import
role
tumor
develop
aim
studi
role
signal
pathway
pathogenesi
children
designmethod
detect
express
transcript
factor
bone
marrow
newli
diagnos
patient
human
cell
line
jurkat
cell
investig
chang
gene
express
knock
transcript
factor
jurkat
cell
analyz
differenti
gene
geo
databas
result
express
transcript
factor
significantli
higher
bone
marrow
newli
diagnos
control
group
express
transcript
factor
detect
human
cell
line
jurkat
cell
transcript
factor
knock
lentiviru
transfer
jurkat
cell
total
gene
signific
differ
obtain
analysi
whole
gene
express
profil
intersect
analysi
carri
differenti
gene
differenti
gene
express
data
set
geo
databas
data
set
includ
sampl
bone
marrow
cell
children
diagnos
sampl
surgic
excis
thymocyt
cell
result
show
common
differenti
express
gene
includ
gene
gene
analyz
common
differenti
express
gene
report
literatur
result
show
intersect
gene
includ
gene
regul
gene
detect
intersect
gene
bone
marrow
sampl
children
diagnos
express
level
significantli
decreas
conclus
pathway
activ
abnorm
increas
transcript
factor
particip
pathogenesi
l
sherief
e
abdel
r
k
h
univers
pediatr
zagazig
egypt
univers
medic
biochemistri
zagazig
egypt
univers
radiodiagnosi
zagazig
egypt
backgroundobject
osteonecrosi
one
major
complic
childhood
acut
lymphoblast
leukemia
treatment
advers
affect
qualiti
life
studi
conduct
assess
frequenc
consolid
therapi
children
detect
whether
polymorph
vitamin
receptor
gene
vdr
plasminogen
activ
gene
may
affect
risk
osteonecrosi
childhood
designmethod
includ
children
newli
diagnos
age
year
treat
st
jude
total
xv
protocol
investig
serum
calcium
phosphoru
magnesium
alkalin
phosphatas
addit
detect
polymorph
vitamin
receptor
foki
gene
restrict
fragment
length
polymorph
polymeras
chain
reaction
screen
done
diagnosi
consolid
therapi
mri
hip
knee
case
classifi
accord
modifi
ficat
alert
system
knee
arco
classif
system
hip
result
five
patient
develop
osteonecrosi
consolid
therapi
patient
older
year
male
femal
insuffici
level
oh
vitamin
polymorph
associ
case
total
ga
genotyp
develop
compar
gg
genotyp
group
genotyp
frequenc
vdr
gene
children
ct
cc
frequenc
vdr
polymorph
case
patient
cc
one
ct
genotyp
conclus
osteonecrosi
develop
earli
therapi
age
older
year
insuffici
vitamin
detect
import
risk
factor
inherit
variat
vdr
may
contribut
risk
l
sherief
e
abdel
w
el
univers
pediatr
zagazig
egypt
al
aini
school
univers
radiolog
cairo
egypt
children
special
hospit
pediatr
benha
egypt
backgroundobject
childhood
acut
lymphoblast
leukemia
survivor
receiv
multipl
pack
red
blood
transfus
prbc
may
risk
vital
organ
iron
deposit
caus
seriou
late
effect
studi
undertaken
assess
frequenc
anatom
pattern
sever
iron
overload
liver
heart
magnet
reson
imag
mri
designmethod
studi
conduct
childhood
survivor
age
year
appar
healthi
age
children
control
group
particip
subject
histori
take
physic
assess
laboratori
investig
includ
complet
blood
pictur
liver
function
kidney
function
test
protein
serum
ferritin
hepat
marker
addit
quantif
iron
content
liver
heart
mri
result
survivor
show
evid
increas
liver
iron
concentr
lic
mri
children
show
moder
cardiac
iron
overload
msec
statist
show
significantli
posit
correl
liver
serum
ferritin
total
volum
blood
transfus
frequenc
transfus
hcv
infect
signific
correl
myocardi
valu
serum
ferritin
transfus
therapi
conclus
liver
iron
overload
detect
children
adolesc
therapi
risk
iron
overload
relat
mainli
transfus
burden
therapi
shibl
h
n
n
egypt
cancer
assiut
univeristi
pediatr
oncolog
assiut
egypt
egypt
cancer
assiut
univeristi
clinic
patholog
assiut
egypt
cancer
institut
cancer
epidemiolog
cairo
egypt
backgroundobject
leukemia
common
caus
death
childhood
despit
signific
improv
surviv
modern
risk
stratif
prognost
signific
absolut
lymphocyt
count
alc
recoveri
studi
pediatr
patient
acut
lymphoblast
leukemia
designmethod
one
hundr
twenti
one
patient
newli
diagnos
year
enrol
age
sex
initi
total
leucocyt
count
immunophenotyp
cn
involv
mediastin
mass
bm
respons
day
fifteen
finish
induct
remiss
compar
alc
recoveri
day
day
induct
respons
also
prognost
impact
alc
recoveri
event
free
surviv
ef
overal
surviv
os
evalu
result
alc
nt
show
signific
relat
known
prognost
patient
factor
patient
low
alc
nt
show
signific
lower
respons
day
post
induct
evalu
high
alc
p
respect
cellsul
show
prognost
signific
patient
poorer
outcom
ef
patient
cellsul
carri
better
outcom
multivari
analysi
cellsul
still
poor
impact
outcom
ci
bm
respons
ci
age
ci
conclus
independ
prognost
impact
outcom
togeth
bm
respons
age
use
simpl
predictor
outcom
shibl
h
egypt
cancer
assiut
univeristi
pediatr
oncolog
assiut
egypt
egypt
cancer
assiut
univeristi
clinic
patholog
assiut
egypt
backgroundobject
acut
lymphoblast
leukemia
rare
report
avail
studi
fm
like
tyrosin
kinas
express
relat
patient
characterist
also
bare
inform
prognost
signific
express
aim
evalu
flowcytometr
cd
express
relat
patient
clinic
laboratori
featur
impact
patient
outcom
designmethod
prospect
studi
includ
newli
diagnos
pediatr
patient
cd
express
diagnosi
evalu
relat
patient
clinic
laboratori
featur
impact
surviv
outcom
follow
result
median
cd
express
mean
fluoresc
intens
mfi
statist
signific
differ
high
low
express
relat
age
sex
cn
involv
p
respect
high
preval
patient
precursor
mediastin
mass
lymphomat
featur
present
statist
signific
relat
express
myeloid
express
dna
index
signific
posit
correl
express
cd
hladr
express
r
valu
p
respect
signific
neg
correl
express
p
express
nt
show
impact
earli
respons
induct
respons
p
express
nt
show
prognost
impact
surviv
outcom
overal
surviv
diseas
free
surviv
event
free
surviv
p
respect
conclus
high
express
preval
patient
precursor
patient
favour
initi
featur
nt
prognost
impact
surviv
outcom
shibl
h
egypt
cancer
assiut
univeristi
pediatr
oncolog
assiut
egypt
egypt
cancer
assiut
univeristi
clinic
patholog
assiut
egypt
backgroundobject
surviv
children
acut
lymphoblast
leukemia
shown
remark
improv
past
decad
aim
evalu
prognost
factor
outcom
children
designmethod
retrospect
studi
includ
two
hundr
newli
diagnos
children
januari
januari
patient
treat
accord
modifi
total
therapi
studi
xiiib
higher
risk
adopt
st
jude
children
research
hospit
sjcrh
outcom
prognost
factor
analyz
result
patient
favor
age
occur
unfavour
intial
total
leucocyt
count
encount
hyperleukocytosi
repres
central
nervou
system
cn
involv
occur
accord
nci
rome
criteria
risk
classif
high
risk
patient
repres
induct
remiss
occur
slow
earli
respons
ser
occur
nt
achiev
induct
remiss
rapid
er
year
overal
surviv
diseas
free
surviv
event
free
surviv
respect
advers
event
includ
induct
death
refractori
leukemia
relaps
aml
occur
one
patient
patient
die
continu
complet
remiss
death
relaps
due
diseas
progress
multivari
analysi
found
unfavour
age
group
year
hyperleukocytosi
patient
ser
associ
unfavour
impact
outcom
high
risk
group
poor
prognost
factor
onlyin
univari
analysi
cn
leukemia
sex
nt
prognost
signific
statist
signific
differ
standard
high
risk
conclus
surviv
patient
improv
institut
previou
still
lower
develop
countri
risk
stratif
use
intensifi
treatment
higher
risk
patient
sill
l
colleg
dublin
ireland
school
ladi
children
hospit
dublin
haematolog
dublin
ireland
colleg
dublin
school
medicin
dublin
ireland
ladi
children
dublin
haematolog
dublin
ireland
colleg
ladi
children
hospit
dublin
haematolog
dublin
ireland
backgroundobject
intraven
iv
proven
similarli
efficaci
intramuscular
nativ
ecoli
without
long
term
increas
toxic
increas
frequenc
use
advers
reaction
iv
peg
asparaginas
hypersensit
associ
asparaginas
inactiv
report
designmethod
retrospect
patient
chart
review
perform
ascertain
spectrum
iv
hypersensit
reaction
occur
cohort
patient
precursor
acut
lymphoblast
leukaemia
result
event
iv
relat
hypersensit
patient
total
patient
receiv
iv
studi
period
reaction
per
cent
reaction
occur
consolid
phase
treatment
nine
patient
grade
reaction
two
patient
grade
reaction
respect
seven
patient
requir
treatment
corticosteroid
initi
period
eleven
patient
receiv
erwinia
asparaginas
altern
subsequ
cycl
therapi
toler
well
conclus
asparaginas
long
establish
integr
drug
paediatr
efficaci
howev
come
insignific
toxic
includ
develop
hypersensit
causat
believ
multifactori
g
univers
upper
silesia
children
care
heatlh
centr
depart
pediatr
haematolog
chemotherapi
katowic
poland
backgroundobject
cell
lymphocyt
nk
natur
killer
cell
immun
system
compon
defici
impair
function
might
result
develop
seriou
infect
promot
develop
malign
includ
acut
lymphoblast
leukaemia
purpos
research
assess
prognost
role
nkt
cell
percentag
bone
marrow
evalu
day
diagnosi
designmethod
procedur
children
male
mean
age
yr
newli
diagnos
enrol
nkt
percentag
assess
use
flow
cytometri
patient
divid
two
subset
group
l
nkt
patient
nk
cell
detect
bone
marrow
group
nkt
patient
nk
cell
undetect
bone
marrow
patient
surviv
wherea
patient
includ
nkt
subset
die
result
patient
nk
cell
detect
bone
marrow
upon
diagnosi
prednison
good
respons
observ
significantli
often
day
treatment
p
similarli
remiss
day
treatment
observ
significantli
often
group
p
analysi
demonstr
significantli
better
surviv
children
nkt
subset
compar
nkt
subset
p
hr
ci
conclus
presenc
nk
cell
bone
marrow
diagnosi
independ
prognost
factor
children
acut
lymphoblast
leukemia
c
sun
l
f
l
c
x
b
x
key
laboratori
experiment
institut
hematolog
blood
diseas
chines
academi
medic
peke
union
medic
colleg
center
pediatr
blood
ti
china
laboratori
genom
precis
collabor
innov
center
genet
ca
center
excel
molecular
cell
beij
institut
chines
academi
scienc
key
laboratori
genom
precis
medicin
beij
china
pediatr
blood
state
key
laboratori
experiment
institut
hematolog
blood
diseas
chines
academi
medic
peke
union
medic
colleg
center
pediatr
blood
state
key
laboratori
experiment
institut
hematolog
blood
diseas
chines
academi
medic
peke
union
medic
colleg
tianjin
china
pediatr
blood
state
key
laboratori
experiment
institut
hematolog
blood
diseas
chines
academi
medic
peke
union
medic
colleg
center
pediatr
blood
diseas
tianjin
china
backgroundobject
er
acut
lymphoblast
leukemia
one
common
childhood
malign
pathogenesi
mechan
remain
elucid
comprehens
designmethod
studi
investig
whole
bone
marrow
transcript
profil
patient
compar
transcript
profil
healthi
control
children
bioinformat
statist
method
includ
differenti
express
analysi
lncrna
analysi
altern
splice
analysi
metabol
network
analysi
use
result
found
thousand
differenti
express
gene
deg
patient
normal
control
function
enrich
analysi
indic
cell
prolifer
cell
divis
cell
cycl
especi
associ
transit
significantli
enrich
gene
inflammatori
respons
immun
respons
defens
respons
gene
addit
identifi
novel
lncrna
function
relat
regul
immun
cell
prolifer
differenti
apoptosi
sampl
furthermor
splice
analysi
indic
exon
skip
event
sampl
mani
gene
among
potenti
associ
conclus
thu
result
character
whole
transcriptom
chang
childhood
patient
elucid
gene
express
signal
pathway
novel
lncrna
transcript
rna
splice
alter
may
play
import
role
pathogenesi
e
n
g
h
b
h
l
celkan
faculti
medicin
pediatr
turkey
sultan
train
research
hospit
pediatr
turkey
faculti
medicin
pediatr
turkey
backgroundobject
acut
lymphoblast
leukemia
common
malign
children
today
patient
chanc
surviv
without
sequela
high
aim
determin
characterist
patient
designmethod
investig
file
patient
one
hundr
seventeen
patient
nt
meet
inclus
criteria
remain
newli
diagnos
patient
treat
bfm
protocol
includ
analysi
patient
divid
two
group
diagnos
first
second
year
result
mean
age
year
patient
age
year
male
common
complaint
weak
hepatomegali
splenomegali
lymphadenopathi
observ
case
respect
admiss
median
leukocyt
count
common
b
cell
pre
b
pro
b
undifferenti
patient
respect
diagnosi
patient
traumat
lumbar
punctur
extramedullari
involv
involv
cn
central
nervou
system
increas
transloc
hypodiploidi
hyperdiploidi
case
respect
patient
standard
medium
high
risk
group
relaps
rate
five
year
ef
surviv
standard
medium
high
risk
patient
os
overal
surviv
respect
cohort
year
os
ef
respect
conclus
ef
os
patient
satisfactori
compar
studi
decreas
death
rate
cn
relaps
promis
e
sunamak
n
g
h
b
h
l
faculti
medicin
pediatr
turkey
sultan
train
research
hospit
pediatr
turkey
faculti
medicin
pediatr
turkey
backgroundobject
surviv
children
complic
seen
treatment
increas
aim
studi
report
result
use
bfm
protocol
designmethod
patient
treat
bfm
protocol
hospit
includ
statist
analysi
patient
divid
group
diagnos
first
second
year
result
earli
complic
tumor
lysi
syndrom
hypercalcemia
central
airway
compress
syndrom
superior
vena
cava
syndrom
thrombosi
bleed
central
nervou
system
leukemia
isol
facial
nerv
palsi
brain
mass
optic
nerv
involv
case
complic
thrombosi
bleed
central
venou
cathet
complic
intussuscept
acut
append
postop
ileu
paralyt
ileu
sever
oral
mucos
typhliti
grade
hepat
toxic
venoocclus
diseas
pancreat
brain
abscess
seizur
spinal
cord
lipoma
epidur
hematoma
acut
flaccid
paralysi
osteonecrosi
hyperthyroid
hyperglycemia
hypoglycemia
case
death
rate
patient
first
year
second
year
respect
conclus
despit
rise
rate
high
risk
patient
treatment
intens
declin
complic
encount
satisfactori
except
hypoglycemia
frequent
patient
younger
year
treatment
complic
often
patient
older
year
e
sunamak
g
b
h
n
faculti
medicin
pediatr
turkey
faculti
medicin
pediatr
hematolog
oncolog
turkey
sultan
train
research
hospit
pediatr
hematolog
oncolog
turkey
faculti
medicin
radiolog
turkey
backgroundobject
incid
posterior
revers
encephalopathi
syndrom
pre
children
acut
lymphoblast
leukemia
report
syndrom
inappropri
antidiuret
hormon
secret
siadh
known
complic
chemotherapeut
aim
studi
detect
incid
pre
siadh
emphas
rare
report
two
syndrom
patient
designmethod
file
patient
treat
bfm
protocol
hospit
analyz
retrospect
determin
characterist
pre
siadh
coexist
patient
new
diagnosi
result
fourteen
n
patient
diagnosi
pre
patient
male
year
old
age
diagnosi
classifi
medium
risk
group
ten
patient
diagnos
protocol
phase
treatment
recurr
pre
observ
patient
two
patient
epilepsi
sequela
six
n
patient
diagnosi
siadh
patient
male
year
old
age
diagnosi
classifi
medium
risk
group
two
patient
central
nervou
system
involv
four
patient
diagnos
protocol
phase
treatment
serum
sodium
concentr
patient
meql
four
patient
seizur
hyponatremia
two
patient
treat
intens
care
unit
patient
underw
fluid
restrict
treatment
four
patient
siadh
also
diagnosi
pre
conclus
want
emphas
diagnosi
pre
ad
clinic
situat
patient
siadh
treatment
children
p
surapolchai
u
n
thammasat
univers
depart
pediatr
pathumthani
thailand
ramathibodi
mahidol
univers
depart
pediatr
bangkok
thailand
backgroundobject
aim
studi
outcom
prognost
featur
thai
children
acut
lymphoblast
leukemia
treat
modifi
st
jude
children
research
hospit
sjcrh
total
therapi
iiib
xv
protocol
designmethod
retrospect
cohort
studi
includ
patient
newli
diagnos
former
group
treat
modifi
total
xiiib
protocol
previou
protocol
latter
group
treat
modifi
total
xv
protocol
current
protocol
result
two
hundr
patient
male
femal
includ
studi
mean
age
diagnosi
year
rang
surviv
ef
rate
previou
protocol
ef
rate
current
protocol
year
respect
overal
surviv
os
rate
previou
protocol
os
rate
current
protocol
year
respect
relaps
rate
previou
protocol
patient
isol
hematolog
relaps
isol
combin
cn
relaps
relaps
rate
current
protocol
patient
isol
hematolog
relaps
isol
combin
cn
relaps
extramedullari
relaps
age
diagnosi
year
confer
inferior
ef
rate
patient
previou
protocol
mrd
posit
shown
prognost
factor
surviv
sinc
treatment
modifi
depend
level
mrd
conclus
demonstr
favor
outcom
childhood
thailand
use
adopt
protocol
sjcrh
might
due
multidisciplinari
support
care
team
parent
advocaci
regard
pediatr
cancer
treatment
lg
tago
la
ci
teach
hospit
child
health
accra
ghana
medicin
univers
ghana
child
health
accra
ghana
backgroundobject
treatment
outcom
childhood
acut
lymphoblast
leukaemia
remain
develop
countri
ghana
paediatr
oncolog
unit
korl
bu
teach
hospit
kbth
accra
serv
major
referr
centr
twin
programm
establish
royal
hospit
sick
children
edinburgh
object
includ
awar
creation
fund
subsid
treatment
cost
present
studi
determin
outcom
childhood
kbth
success
period
sinc
incept
twin
programm
designmethod
retrospect
review
patient
record
age
year
confirm
januari
decemb
compar
previous
publish
data
unit
segbefia
et
al
result
case
case
burkitt
leukaemia
inact
clinic
patient
incomplet
data
exclud
data
analysi
perform
patient
major
year
male
classifi
nci
rome
criteria
patient
complet
induct
mainli
treatment
abandon
mortal
compar
previou
studi
complet
induct
event
mainli
abandon
therapi
relaps
induct
failur
previou
studi
abandon
relaps
induct
failur
respect
overal
abandon
treatment
primari
event
follow
relaps
similar
previou
aliv
continu
remiss
last
median
month
rang
month
vs
previou
studi
conclus
abandon
rate
remain
high
childhood
kbth
despit
twin
programm
effort
must
direct
toward
identifi
address
caus
abandon
yl
tang
lb
first
affili
sun
univers
depart
pediatr
guangzhou
china
backgroundobject
leukemia
aggress
malign
associ
poor
outcom
refractori
convent
treatment
melatonin
proven
exert
activ
effect
melatonin
leukemia
underli
mechan
remain
poorli
understood
designmethod
firstli
cell
viabil
determin
assay
apoptosi
examin
fac
analysi
secondli
western
blot
use
examin
express
htert
furthermor
pulldown
assay
chip
assay
use
test
bind
htert
promot
subunit
bind
promot
moreov
investig
effect
melatonin
growth
xenograft
mous
model
result
studi
show
melatonin
inhibit
cell
prolifer
induc
apoptosi
activ
depend
apoptot
pathway
leukemia
cell
mechanist
investig
reveal
melatonin
suppress
express
htert
abrog
bind
activ
htert
promot
melatonin
also
block
nuclear
transloc
suppress
bind
promot
therebi
suppress
express
addit
clinic
sampl
reveal
melatonin
exert
activ
primari
leukemia
blast
ex
vivo
vivo
mice
treat
melatonin
experienc
larger
reduct
leukem
burden
control
group
leukemia
xenograft
mous
model
conclus
result
suggest
melatonin
inhibit
leukemia
suppress
signal
pathway
find
provid
new
insight
role
melatonin
leukemia
treatment
h
teranishi
w
k
k
k
medic
school
depart
pediatr
okayama
japan
backgroundobject
febril
neutropenia
episod
fne
one
common
advers
event
chemotherapi
fever
occur
neutropenia
patient
like
develop
seriou
infecti
diseas
variou
microb
administ
empir
antibiot
therapi
fn
patient
undertook
blood
cultur
howev
sensit
blood
cultur
remain
low
also
take
time
identifi
caus
microorgan
set
microb
detect
system
pcr
method
detect
bacteria
fungi
virus
blood
sampl
short
time
designmethod
june
march
blood
cultur
sampl
patient
fne
examin
presenc
bacteria
fungi
base
rrna
gene
rrna
combin
pcr
amplif
sequenc
furthermor
use
pcr
assay
detect
vzv
ebv
cmv
bkv
result
sampl
bacteria
identifi
fne
pcr
assay
blood
cultur
blood
sampl
pcr
assay
detect
type
bacteria
fungu
detect
pcr
assay
blood
cultur
virus
identifi
fne
blood
cultur
took
hour
min
identifi
caus
bacteria
pcr
assay
hour
conclus
conclud
pcr
assay
could
given
higher
microb
detect
rate
need
shorter
turnaround
time
smaller
blood
sampl
blood
cultur
may
choos
earli
optim
antibiot
patient
fne
pcr
assay
h
ueki
c
h
j
k
r
k
h
red
cross
narita
hospit
depart
pediatr
hematlologyoncolog
narita
japan
children
cancer
group
relaps
committe
nagoya
japan
medic
univers
school
medicin
depart
pediatr
nagakut
japan
medic
center
clinic
research
center
nagoya
japan
gakuin
univers
depart
nutrit
faculti
psycolog
physic
scienc
nisshin
japan
backgroundobject
children
relaps
acut
lymphoblast
leukemia
efficaci
cell
transplant
hct
per
minim
residu
diseas
mrd
recogn
hypothes
hct
condit
regimen
would
enhanc
surviv
children
reinduct
designmethod
japanes
pediatr
leukemialymphoma
studi
group
jplsg
studi
compris
patient
intermedi
risk
first
relaps
therapi
base
acut
lymphoblast
studi
group
bfm
patient
mrd
end
induct
n
assign
transplant
arm
condit
regimen
compris
total
bodi
irradi
tbi
gy
etoposid
etp
mgkg
patient
kg
patient
kg
maximum
dose
mgday
cyclophosphamid
cy
mgkg
day
patient
result
patient
includ
mrd
unevalu
mrd
assign
hct
arm
physician
discret
transplant
unrel
bone
marrow
unrel
cord
blood
use
patient
respect
engraft
confirm
patient
acut
chronic
diseas
observ
patient
respect
thrombot
microangiopathi
sinusoid
obstruct
syndrom
lung
diseas
report
patient
respect
grade
allergi
grade
mucos
observ
patient
respect
notabl
neither
grade
nonhematolog
toxic
mortal
observ
three
patient
develop
relaps
die
eventu
surviv
overal
surviv
respect
conclus
etpcytbi
regimen
feasibl
effect
patient
unsatisfactori
reduct
mrd
jplsg
cohort
l
wang
l
affili
hospit
qingdao
univers
pediatr
hematolog
qingdao
china
backgroundobject
memori
lymphocyt
capac
surviv
comparison
effector
lymphocyt
aim
explor
effect
new
immunomodulatori
compos
muramyl
dipeptid
mdp
monoclon
antibodi
mab
intend
treatment
leukemia
activ
specif
memori
lymphocyt
designmethod
pbmc
isol
cultur
indic
reagent
respect
supernat
collect
measur
level
time
point
hour
express
level
analyz
xenograft
leukemia
mous
model
establish
studi
whether
could
target
tumor
cell
could
stimul
immun
cell
activ
result
cell
group
bcg
group
show
aggreg
hour
time
went
number
cell
cluster
increas
obviou
bcg
group
level
group
bcg
group
significantli
higher
control
group
indic
time
point
hour
percentag
cell
cell
group
bcg
group
higher
compar
control
group
xenograft
leukemia
mous
model
establish
show
could
target
tumor
cell
especi
obvious
hour
inject
tumor
growth
curv
show
tumor
growth
group
lower
pb
group
flow
cytometri
cell
increas
group
level
also
higher
conclus
induc
express
lymphocyt
stimul
secret
indic
induc
specif
memori
lymphocyt
activ
vitro
vivo
provid
theoret
support
applic
leukemia
immunotherapi
watanab
k
j
l
van
der
h
k
n
k
k
g
k
k
k
k
yamanashi
depart
pediatr
yamanashi
japan
yamanashi
depart
health
scienc
yamanashi
japan
univers
depart
medic
molecular
medicin
scienc
life
laboratori
uppsala
sweden
trust
sanger
institut
experiment
cancer
wellcom
trust
genom
campu
cambridg
unit
kingdom
univers
depart
diseas
research
institut
radiat
biolog
medicin
hiroshima
japan
research
institut
child
health
develop
depart
social
medicin
tokyo
japan
research
institut
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
univers
school
medicin
depart
pediatr
tokyo
japan
univers
depart
pediatr
tokyo
japan
children
medic
center
hematologyoncolog
regen
medicin
kanagawa
japan
univers
school
medicin
depart
pediatr
shizuoka
japan
pediatr
mie
univers
mie
japan
red
cross
fukushima
blood
center
fukushima
japan
backgroundobject
karyotyp
import
risk
factor
treatment
stratif
current
chemotherapi
childhood
asparaginas
one
import
compon
chemotherapi
cell
unabl
synthes
adequ
amount
asparagin
normal
hematopoiet
cell
produc
asparagin
asparagin
synthetas
asn
sinc
asn
gene
cpg
island
comprehens
investig
associ
asn
gene
methyl
asparaginas
sensit
karyotyp
childhood
designmethod
asn
gene
methyl
cell
line
primari
sampl
well
normal
hematopoiet
cell
asn
gene
methyl
mice
leukemia
sampl
quantifi
ng
analysi
bisulfit
pcr
level
asn
gene
express
determin
use
alamar
blue
assay
real
time
respect
associ
karyotyp
asn
gene
methyl
analyz
nopho
ccc
tccsg
sampl
result
asn
gene
bcp
cell
line
frequent
methyl
allel
specif
manner
almost
unmethyl
normal
hematopoiet
cell
asn
gene
methyl
statu
significantli
associ
asn
gene
express
level
sensit
cell
line
primari
sampl
diagnosi
primari
sampl
relaps
nopho
cohort
hyperdiploidi
repres
higher
methyl
mllr
low
hypodiploidi
repres
lower
methyl
ident
pattern
valid
ccc
tccsg
cohort
similar
pattern
asn
gene
methyl
confirm
mous
leukemia
sampl
mice
transgen
mice
conclus
associ
asn
gene
methyl
statu
sensit
karyotyp
could
one
pharmacogenet
background
associ
karyotyp
chemosensit
asn
gene
methyl
statu
might
use
biomark
precis
medicin
childhood
ph
widjajanto
e
ajp
sardjito
hospit
pediatr
hematolog
oncolog
yogyakarta
indonesia
univers
medic
center
pediatr
oncolog
amsterdam
netherland
backgroundobject
childhood
acut
lymphoblast
leukemia
common
malign
clinic
last
year
protocol
appli
estella
clinic
children
cancer
hematolog
diseas
dr
sardjito
hospit
support
twin
program
vu
medic
center
amsterdam
cooper
indonesian
pediatrician
associ
studi
aim
measur
outcom
protocol
design
optim
version
meet
set
indonesia
countri
designmethod
observ
retrospect
studi
subject
children
diagnos
treat
dr
sardjito
hospit
inclus
criteria
age
year
previous
untreat
steroid
chemotherapi
morpholog
compar
outcom
patient
treat
use
protocol
surviv
analysi
method
surviv
ef
overal
surviv
os
conduct
use
spss
program
result
patient
studi
induct
phase
remiss
rate
subsequ
estim
ef
subsequ
os
abandon
death
induct
lower
protocol
other
conclus
indonesian
childhood
protocol
outcom
show
improv
last
year
better
support
govern
insur
ngo
experienc
medic
staff
play
import
role
outcom
howev
death
remain
import
event
relaps
rate
might
influenc
frequent
interrupt
therapi
often
unavail
essenti
drug
j
wiemel
r
de
l
ab
p
c
x
southern
california
prevent
medicin
lo
angel
usa
epidemiolog
san
francisco
usa
u
epidemiolog
new
usa
prevent
medicin
lo
angel
usa
neurosurgeri
san
francisco
usa
epidemiolog
berkeley
usa
epidemiolog
reno
usa
laboratori
medicin
san
francisco
usa
epidemiolog
san
francisco
usa
backgroundobject
immun
system
function
clearli
relat
risk
childhood
acut
lymphoblast
leukemia
given
establish
associ
childhood
contact
via
daycar
infecti
diseas
histori
studi
less
clear
whether
immun
develop
includ
prenat
period
impact
risk
designmethod
assess
whether
cytokin
level
birth
differ
case
childhood
acut
lymphoblast
leukemia
control
subject
match
case
month
year
birth
sex
raceethn
luminex
multiplex
cytokin
screen
perform
protein
extract
neonat
blood
spot
cytokin
includ
vegf
result
initi
evalu
three
cytokin
remov
analys
studi
subject
level
comparison
made
individu
cytokin
follow
categor
low
versu
high
control
tertil
significantli
higher
level
found
case
compar
control
remaind
cytokin
due
signific
collinear
mani
cytokin
use
principl
compon
approach
deriv
independ
compon
among
cytokin
first
compon
describ
cytokin
varianc
compon
domin
vegf
significantli
posit
associ
leukemia
risk
conclus
data
suggest
proinflammatori
vegf
type
pathway
birth
may
enhanc
risk
leukemia
whether
immun
phenotyp
influenc
leukemia
risk
directli
consequ
prenat
event
andor
set
stage
infant
react
differ
infecti
stimul
enhanc
leukemogenesi
requir
research
fund
nation
institut
health
epa
p
wongmast
p
kaen
univers
pediatr
khon
kaen
thailand
backgroundobject
thromboembot
event
tee
seriou
complic
childhood
cancer
asparaginas
standard
chemotherapi
success
agent
childhood
acut
lymphoblast
leukemia
lymphoblast
lymphoma
howev
asparaginas
increas
risk
thromboembol
studi
determin
describ
characterist
treatment
outcom
childhood
asparaginas
relat
thrombosi
srinagarind
hospit
thailand
designmethod
retrospect
studi
pediatr
lymphoblast
lymphoma
patient
age
year
age
treat
includ
studi
evalu
includ
basic
characterist
dosag
asparaginas
clinic
present
imag
prothrombot
studi
treatment
outcom
imag
modifi
rankin
scale
cn
thrombosi
result
patient
symptomat
tee
includ
median
follow
time
month
rang
month
median
age
patient
year
rang
year
patient
patient
lymphoma
patient
receiv
asparaginas
dosag
cn
thrombosi
pulmonari
embol
multipl
site
tee
cn
dvt
left
leg
venou
site
common
arteri
site
vs
one
patient
develop
central
line
relat
tee
common
present
seizur
median
time
onset
day
first
exposur
rang
day
common
thrombot
state
acquir
protein
defici
follow
acquir
antithrombin
acquir
protein
c
defici
patient
treat
weight
heparin
patient
outcom
assess
imag
complet
respons
partial
respons
patient
cn
tee
favor
outcom
modifi
rankin
scale
patient
aliv
patient
die
advanc
cancer
patient
die
brain
herniat
cerebr
infarct
conclus
asparaginas
relat
tee
increas
morbid
mortal
lymphoblast
lymphoma
patient
studi
tee
prophylaxi
asparaginas
use
done
improv
outcom
p
wongmast
p
kaen
univers
pediatr
khon
kaen
thailand
backgroundobject
kidney
involv
childhood
hematolog
malign
effect
clinic
outcom
treatment
wide
report
designmethod
report
case
acut
lymphoblast
leukemia
diffus
larg
b
cell
lymphoma
dlbcl
renal
involv
diagnosi
result
first
case
girl
present
prolong
fever
headach
fatiqu
hypertens
bilater
periorbit
edema
gener
lymphadenopathi
bilater
nephromegali
hepatosplenomegali
cbc
reveal
anemia
blast
cell
seen
serum
biochemistri
show
bun
mgdl
creatinin
mgdl
normal
electrolyt
urinalysi
normal
ultrasound
abdomen
reveal
bilater
kidney
enlarg
bone
marrow
aspir
compat
patient
commenc
standard
risk
protocol
rise
creatinin
induct
renal
function
kidney
size
normal
second
case
boy
present
hypertens
emerg
oligur
progress
renal
failur
high
uric
acid
level
proteinuria
hematuria
hematolog
data
show
mild
anemia
blast
cell
seen
initi
diagnos
rapid
progress
glomerulonephr
treat
puls
methylprednisolon
hemodialysi
clinic
statu
improv
kidney
biopsi
subsequ
perform
result
reveal
medium
larg
size
lymphoid
cell
infiltr
renal
tissu
compat
dlbcl
mri
whole
abdomen
reveal
diffus
infiltr
mass
kidney
multipl
bone
liver
metastas
treat
high
risk
matur
lymphoma
protocol
first
cycl
chemotherapi
creatinin
becam
normal
howev
develop
hematolog
toxic
grade
iv
chemotherapi
renal
scintigraphi
reveal
moder
impair
function
bilater
kidney
total
gfr
mlmin
chemotherapi
dosag
adjust
accord
gfr
clinic
statu
improv
less
toxic
chemotherapi
conclus
regard
sever
complic
chemotherapi
dosag
adjust
accord
renal
function
improv
outcom
decreas
toxic
lm
wu
medic
univers
nurs
kaohsiung
citi
taiwan
roc
backgroundobject
despit
dramat
improv
outcom
pediatr
cancer
patient
cancer
lead
caus
death
taiwan
account
death
pediatr
eof
care
extens
explor
pediatr
cancer
patient
studi
evalu
trend
pediatr
cancer
eof
care
medic
center
taiwan
designmethod
retrospect
chart
review
conduct
particip
diagnos
cancer
die
southern
medic
center
taiwan
particip
includ
result
averag
age
diagnosi
death
year
old
year
old
respect
patient
last
month
life
spent
greater
day
hospit
complet
dnr
die
intens
care
unit
receiv
relat
chemotherapi
underw
intub
receiv
cardiopulmonari
resuscit
patent
receiv
hospic
care
hospic
last
month
life
patent
stare
servic
within
last
day
care
pediatr
cancer
eof
chang
studi
period
except
significantli
increas
dnr
permit
relat
chemotherapi
last
month
life
conclus
overli
aggress
treatment
report
last
month
pediatr
cancer
patient
taiwan
qualiti
eof
care
pediatr
cancer
patient
develop
meet
individu
famili
need
prefer
lm
wu
medic
univers
nurs
kaohsiung
citi
taiwan
roc
backgroundobject
purpos
current
studi
describ
live
experi
parent
child
incur
cancer
end
life
eol
designmethod
qualit
studi
conduct
follow
phenomenolog
approach
ten
parent
children
incur
cancer
recruit
medic
center
southern
taiwan
may
june
data
collect
interview
analyz
use
giorgi
procedur
result
two
major
theme
emerg
keep
fight
accept
death
keep
fight
divid
three
tri
hope
aliv
hope
wait
miracl
accept
death
includ
four
end
suffer
live
moment
discuss
death
let
go
love
core
valu
use
make
decis
regardless
whether
aggress
treatment
palli
care
chosen
conclus
parent
difficulti
adapt
palli
care
perspect
due
misconcept
meant
give
child
critic
howev
parent
move
toward
accept
impend
death
religion
belief
system
play
vari
import
role
live
experi
parent
child
incur
cancer
x
xu
h
w
hospit
zhejiang
univers
school
medicin
depart
hematologyoncolog
hangzhou
china
backgroundobject
surviv
rate
children
acut
lymphoblast
leukemia
increas
significantli
recent
decad
designmethod
januari
octob
patient
newli
diagnos
treat
nation
protocol
childhood
china
result
male
femal
ratio
median
age
year
fusion
gene
found
patient
overal
surviv
os
surviv
ef
rate
cohort
respect
ef
rate
low
intermedi
high
risk
group
minim
residu
diseas
mrd
turn
neg
patient
induct
end
induct
patient
underw
diseas
relaps
includ
cn
relaps
patient
underw
relat
mortal
cumul
incid
relaps
cir
univari
analysi
age
initi
wbc
count
immunophenotyp
fusion
gene
risk
group
mrd
level
induct
end
induct
associ
ef
diseas
relaps
multivari
analysi
fusion
gene
mrd
level
end
induct
independ
prognost
factor
ci
ci
fold
relaps
patient
neg
mrd
equal
higher
compar
patient
posit
cir
mrd
less
cir
conclus
patient
treat
protocol
achiev
rel
high
rate
diseas
cure
quit
low
rate
cn
relaps
fusion
gene
mrd
level
end
induct
import
biomark
prognosi
evalu
xue
x
l
hospit
nanj
medic
univers
depat
hematolog
oncolog
nanj
china
backgroundobject
type
alpha
enzym
catalyz
phosphoryl
form
genom
studi
report
associ
genet
polymorph
pediatr
acut
lymphoblast
leukemia
howev
molecular
mechan
pathogenesi
reveal
designmethod
conduct
assay
cell
cycl
cell
apoptosi
detect
explor
role
jurkat
cell
block
effect
investig
whether
biolog
function
depend
result
found
proport
phase
cell
increas
significantli
leukemia
cell
p
jurkat
cell
p
cell
proport
decreas
jurkat
cell
treat
p
p
respect
furthermor
percentag
apoptosi
lymphocyt
leukemia
cell
decreas
significantli
p
jurkat
cell
p
cell
apoptosi
cell
notabl
increas
p
p
respect
subsequ
inhibit
biolog
function
found
effect
attenu
conclus
present
studi
demonstr
promot
factor
pathogenesi
biolog
function
may
mediat
zakaria
pediatr
hematolog
oncolog
pediatr
univers
zagazig
egypt
pediatr
hematolog
oncolog
pediatr
univers
zagazig
egypt
clinic
patholog
clinic
patholog
univers
zagazig
egypt
clinic
patholog
clinic
patholog
univers
zagazig
egypt
backgroundobject
novel
receptor
vascular
endotheli
growth
factor
vegf
express
endotheli
tumor
cell
promot
prolifer
chemotaxi
leukem
cell
respons
vegf
inhibit
function
may
provid
new
therapeut
strategi
treatment
aim
studi
express
profil
normal
b
lineag
leukem
lymphoblast
prognost
valu
role
minim
residu
diseas
detect
designmethod
prospect
conduct
forti
newli
diagnos
patient
acut
leukemia
femal
mean
age
year
forti
age
sex
match
subject
control
group
express
flow
cytometri
done
diagnosi
end
induct
therapi
result
fourti
five
case
express
fifti
five
statist
signific
differ
case
express
regard
clinic
present
morpholog
immunophenotyp
cn
infiltr
statist
signific
differ
regard
relaps
relaps
case
posit
prognosi
case
express
die
signific
correl
cd
age
bone
marrow
blast
cell
ldh
level
signific
correl
wbc
count
hb
level
signific
differ
posit
neg
case
regard
overal
surviv
rate
month
posit
case
neg
case
high
signific
differ
conclus
high
express
bone
marrow
blast
consid
marker
bad
prognosi
children
could
use
diseas
monitor
zakaria
pediatr
hematolog
oncolog
pediatr
univers
zagazig
egypt
professor
clinic
univers
clinic
patholog
zagazig
egypt
backgroundobject
febril
neutropenia
fn
often
observ
children
hematolog
malign
protein
procalcitonin
use
diagnost
marker
bacteri
infect
limit
recent
presepsin
glycoprotein
deriv
monocyt
macrophag
also
known
solubl
report
novel
promis
biomark
diagnosi
sepsi
howev
use
identifi
infect
patient
hematolog
malign
episod
fever
neutropenia
remain
unclear
aim
evalu
signific
presepsin
biomark
diagnosi
bacteremia
children
hematolog
malign
designmethod
sixti
pediatr
patient
hematolog
malign
acut
lymphoblast
leukemia
acut
myeloid
leukemia
lymphoma
hodgkin
diseas
thirti
age
sex
match
healthi
children
serv
control
enrol
studi
estim
presepsin
procalcitonin
c
reactiv
protein
episod
fn
addit
absolut
neutrophil
count
blood
cultur
perform
particip
result
signific
elev
presepsin
level
patient
control
high
increment
posit
blood
cultur
patient
steril
case
presepsin
concentr
significantli
higher
bacteremia
clinic
prove
infect
fever
unknown
origin
presepsin
also
superior
c
reactiv
protein
procalcitonin
identif
bacteri
infect
either
form
bacteremia
clinic
prove
infect
sensit
respect
specif
respect
statist
signific
posit
correl
persepsin
c
reactiv
protein
procalcitonin
level
neg
correl
absolut
neutrophil
count
observ
patient
subgroup
conclus
presepsin
use
marker
detect
bacteremia
high
sensit
specif
find
support
presepsin
superior
procalcitonin
c
reactiv
protein
identifi
bacteri
infect
patient
cancer
develop
fever
neutropenia
l
h
zhang
c
x
j
h
children
capit
medic
univers
hematolog
oncolog
center
beij
china
medic
chines
academi
medicin
scienc
peke
union
medic
colleg
institut
medic
biolog
kunm
china
genet
development
chines
academi
scienc
institut
genet
development
biolog
beij
china
life
leshan
normal
univers
colleg
life
scienc
leshan
china
backgroundobject
despit
improv
therapeut
respons
polychemotherapi
strategi
pediatr
acut
lymphoblast
leukemia
remain
fatal
case
splice
factor
also
term
link
variou
human
cancer
includ
pediatr
previou
studi
show
serv
factor
howev
modif
phosphoryl
pathogenesi
pediatr
remain
unclear
designmethod
leukem
cell
isol
primari
pediatr
bone
marrow
sampl
follow
ip
assay
mass
spectrum
analysi
specif
subcellular
local
protein
mutant
analyz
immunofluoresc
stain
cell
prolifer
coloni
format
cell
apoptosi
cell
cycl
also
investig
use
stabl
leukem
cell
line
gener
overexpress
mutant
plasmid
withwithout
treatment
kinas
inhibitor
result
phosphoryl
tyrosin
residu
identifi
newli
diagnos
sampl
complet
remiss
sampl
compar
type
cell
missens
mutant
phosphoryl
affect
subcellular
local
addit
phosphoryl
also
lead
increas
cell
prolifer
enhanc
properti
promot
cell
differenti
phase
predict
strong
possibl
phosphoryl
residu
use
onlin
tool
result
show
phosphoryl
markedli
increas
prolifer
cell
could
suppress
applic
kinas
inhibitor
conclus
identifi
phosphoryl
state
link
differ
phase
pediatr
phosphoryl
disrupt
subcellular
local
promot
prolifer
leukemia
cell
drive
progress
inhibitor
target
kinas
may
catalyz
phosphoryl
offer
promis
therapeut
target
treatment
pediatr
j
zhang
hematolog
blood
diseas
chines
academi
medic
scienc
peke
union
medic
colleg
depart
pediatr
tianjin
china
backgroundobject
pediatr
cell
acut
lymphoblast
leukemia
aggress
subtyp
pediatr
character
recur
genet
epigenet
alter
mutat
polycomb
repress
complex
core
compon
includ
eed
identifi
extens
associ
poor
prognosi
howev
detail
mechan
pediatr
tumorigenesi
driven
remain
clarifi
designmethod
patient
treat
blood
diseas
hospit
chines
academi
medic
scienc
cam
accord
protocol
patient
carrier
involv
studi
sign
inform
consent
form
approv
irb
camspumc
target
sequenc
eed
perform
bone
marrow
nucleic
cell
pediatr
patient
rna
sequenc
perform
sort
leukemia
cell
normal
cell
posit
bone
marrow
nucleic
cell
mutat
patient
pediatr
donor
transplant
respect
result
studi
analysi
primari
cell
mutat
eed
reveal
aberr
express
increas
express
activ
downstream
pathway
also
observ
jurkat
cell
assay
reveal
loss
modif
caus
disrupt
close
coupl
enhanc
transcript
furthermor
inhibitor
sorafenib
quzartinib
signific
prolong
surviv
recipi
nodscid
mice
transplant
mutat
cell
conclus
pediatr
patient
suffer
poor
outcom
partial
due
lack
prognost
marker
direct
risk
stratif
therapi
studi
found
aberr
express
defici
patient
cell
cell
line
xenograft
model
reveal
inhibit
significantli
prolong
surviv
defici
xenograft
suggest
aberr
pathway
potent
target
defici
patient
n
zhang
h
j
n
h
j
j
children
hospit
hematologyoncolog
shanghai
china
children
medic
center
hematologyoncolog
shanghai
china
medic
univers
second
affili
hospit
hematolog
shanghai
china
backgroundobject
analyz
clinic
characterist
outcom
multipl
center
protocol
acut
lymphoblast
leukemia
year
old
adolesc
designmethod
newli
diagnos
patient
age
year
old
three
hospit
includ
may
april
receiv
protocol
follow
decemb
clinic
characterist
outcom
prognost
analysi
evalu
compar
two
protocol
result
total
patient
involv
studi
case
treat
protocol
case
protocol
complet
remiss
cr
induct
therapi
patient
relaps
median
time
month
patient
pass
away
follow
time
surviv
ef
overal
surviv
os
patient
ef
os
ef
intermedi
risk
group
protocol
protocol
ef
high
risk
group
two
protocol
five
year
relaps
rate
two
protocol
mortal
separ
singl
prognosi
analysi
indic
age
male
risk
bcrabl
transloc
resist
induct
risk
prognost
factor
surviv
p
cox
multivari
analysi
show
male
risk
resist
induct
independ
risk
prognost
factor
p
conclus
protocol
enhanc
chemotherapi
intens
intermedi
risk
group
benefit
surviv
fusion
transloc
still
risk
factor
prognosi
tki
inhibitor
use
patient
could
improv
surviv
ef
rate
lift
littl
death
rate
push
protocol
signific
lower
relaps
rate
compar
protocol
f
zhou
q
h
j
hospit
huazhong
univers
scienc
technolog
depart
paediatr
wuhan
china
backgroundobject
philadelphia
consid
high
risk
acut
lymphoblast
leukemia
children
imatinib
tailor
drug
wherea
tradit
chines
medicin
huaier
extract
found
antitumor
activ
present
studi
aim
investig
potenti
benefit
combin
therapi
imatinib
huaier
extract
designmethod
cell
treat
huaier
extract
umol
imatinib
mgml
prolifer
apoptosi
cell
detect
fcm
respect
express
level
protein
bax
protein
detect
western
blot
activ
measur
elisa
cell
bone
marrow
liver
spleen
mous
model
detect
fcm
result
analysi
cell
prolifer
show
imatinib
huaier
extract
exert
synergist
effect
cell
cell
use
flow
cytometri
western
blot
synergist
effect
reveal
induct
cell
apoptosi
two
drug
also
exhibit
synergist
effect
decreas
proteinenzymat
activ
level
furthermor
result
western
blot
reveal
two
drug
synergist
inhibit
effect
express
consist
vitro
result
combin
huaier
extract
imatinib
exert
mark
inhibitori
effect
xenograft
tumor
growth
conclus
find
suggest
potenti
clinic
applic
imatinib
huaier
extract
combin
x
zou
x
w
b
x
blood
diseas
hospit
chines
academi
medic
scienc
cam
depart
paediatr
haematolog
tianjin
china
backgroundobject
data
adolesc
acut
lymphoblast
leukemia
china
know
outcom
age
group
patient
retrospect
analys
patient
treat
protocol
singl
center
designmethod
analyz
outcom
patient
newli
diagnos
adolesc
acut
lymphoblast
leukemia
treat
protocol
center
result
among
patient
patient
femal
patient
patient
twelev
patient
bcrabl
infus
gene
patient
infus
gene
respect
patient
known
gene
abnorm
surviv
ef
overal
surviv
os
rate
studi
respect
ef
os
rate
children
younger
year
respect
signific
differ
two
age
group
complet
remiss
rate
death
remiss
patient
relaps
older
age
patient
older
year
conclus
studi
indic
protocol
effect
newli
diagnos
adolesc
patient
treat
adult
studi
mostli
patient
known
gene
infus
mutat
rearrang
studi
gene
detect
group
patient
urgent
need
univers
scienc
technolog
pediatr
irbid
jordan
backgroundobject
intensifi
regimen
chemotherapi
risk
classif
attribut
improv
surviv
designmethod
medic
record
patient
aml
review
assess
outcom
result
boy
median
age
year
commonli
observ
fab
classif
follow
low
risk
intermedi
high
risk
receiv
hsct
rate
low
risk
intermedi
risk
high
risk
patient
requir
cycl
chemotherapi
treatment
failur
observ
relaps
rate
common
site
relaps
bone
marrow
pmlrar
bm
classif
aml
high
risk
found
significantli
associ
relaps
age
diagnosi
time
found
associ
relaps
relaps
went
hsct
median
month
five
year
overal
surviv
cohort
patient
significantli
poor
relaps
compar
result
five
year
event
free
surviv
among
relaps
group
five
year
overal
surviv
significantli
better
receiv
hsct
five
year
overal
surviv
also
significantli
better
group
compar
relaps
patient
hsct
administ
conclus
result
treatment
effort
conform
western
literatur
precis
risk
classif
vital
predictor
plan
first
line
salvag
therapi
includ
hsct
pediatr
patient
aml
r
ando
c
k
k
center
child
health
develop
children
cancer
center
tokyo
japan
backgroundobject
cytarabin
hdca
associ
profound
neutropenia
develop
sever
bacteri
infect
therefor
prophylact
antibiot
use
certain
occas
patient
undergo
hdca
controversi
exist
especi
concern
emerg
strain
designmethod
retrospect
analyz
relationship
prophylact
antibiot
blood
stream
infect
bsi
children
year
old
newli
diagnos
acut
myeloid
leukemia
aml
exclud
acut
promyelocyt
leukemia
syndrom
case
treat
nation
center
child
health
develop
januari
march
result
among
patient
aml
prophylact
antibiot
without
evalu
ampicillin
cefepim
piperacillin
tazobactam
cefazolin
levofloxacin
use
prophylact
antibiot
prophylaxi
group
seven
bsi
detect
case
rod
develop
sepsi
case
staphylococcu
prophylaxi
group
two
bsi
document
conclus
trend
lower
incid
bsi
prophylact
antibiot
use
hdca
treatment
develop
sever
rod
infect
staphylococcu
issu
investig
role
prophylact
antibiot
use
explor
f
andrad
fvd
ep
e
ms
brazilian
studi
group
childhood
acut
cancer
institut
pediatr
program
rio
de
janeiro
brazil
backgroundobject
acut
leukemia
aris
earli
age
assum
initi
fetal
life
accumul
addit
genom
lesion
first
year
life
possibl
hematopoiet
progenitor
sensit
genotox
event
describ
frequenc
recurr
molecular
abnorm
infant
toddler
young
children
year
age
acut
myeloid
leukemia
aml
investig
associ
demograph
molecular
featur
outcom
designmethod
two
hundr
patient
diagnos
de
novo
aml
assess
throughout
multicentr
network
studi
brazil
mutat
hotspot
region
ra
pathway
affect
gene
nra
kra
analyz
well
fusion
gene
rearrang
respect
associ
aml
patient
treat
accord
guidelin
formal
enrol
treatment
protocol
patient
acut
promyelocyt
leukemia
apl
exclud
surviv
analysi
result
phenotyp
associ
low
white
blood
cell
wbc
count
diagnosi
aml
associ
syndrom
repres
case
molecular
abnorm
found
repres
follow
mutat
gene
ra
pathway
observ
case
associ
high
wbc
count
diagnosi
cumul
probabl
overal
surviv
po
locat
treatment
associ
advers
outcom
apart
tumor
genet
abnorm
present
diagnosi
conclus
collabor
effort
allow
establish
network
diagnosi
character
molecular
subtyp
aml
differ
outcom
observ
brazilian
geograph
region
midwest
associ
low
po
ausa
j
p
ap
philippin
philippin
gener
hospit
depart
pediatr
manila
philippin
backgroundobject
philippin
gener
hospit
see
new
acut
myelog
leukemia
aml
per
year
palli
care
offer
due
limit
support
care
mean
patient
surviv
time
month
howev
open
dedic
pediatr
cancer
unit
aml
protocol
adapt
ahopca
regimen
implement
consist
cours
chemotherapi
reduc
anthracyclin
follow
month
oral
metronom
therapi
prednison
etoposid
mercaptopurin
antibiot
antifung
prophylaxi
given
chemotherapi
cours
report
patient
profil
outcom
designmethod
retrospect
chart
review
newli
diagnos
aml
except
apml
seen
januari
decemb
patient
outcom
evalu
end
studi
period
march
result
total
patient
diagnosi
immunophenotyp
mean
age
year
patient
start
aml
regimen
refus
treatment
chose
palliat
receiv
protocol
thirti
patient
went
remiss
studi
endpoint
patient
aliv
includ
activ
diseas
abandon
treatment
die
six
patient
bone
marrow
relaps
mean
month
diagnosi
caus
death
progress
diseas
patient
infect
bleed
patient
year
overal
surviv
event
free
surviv
respect
mean
patient
surviv
time
month
conclus
combin
low
intens
aml
regimen
combin
oral
metronom
therapi
associ
dismal
outcom
futur
plan
includ
identif
favor
aml
subgroup
routin
cytogenet
protocol
intensif
escal
anthracyclin
dose
r
bakhshi
r
v
rajguru
colleg
appli
univers
delhi
biomed
scienc
new
delhi
india
india
institut
medic
scienc
medic
oncolog
new
delhi
india
india
institut
medic
scienc
biostatist
new
delhi
india
backgroundobject
role
variat
mitochondri
dna
particularli
region
acut
myeloid
leukemia
aml
remain
investig
studi
aim
assess
pattern
variat
mitochondri
region
aml
patient
evalu
associ
express
gene
designmethod
denovo
aml
patient
year
age
june
bone
marrow
sampl
buccal
swab
sampl
mother
blood
sampl
collect
baselin
dna
extract
pcr
loop
region
subsequ
sanger
sequenc
perform
rna
extract
patient
analyz
use
real
time
pcr
rel
gene
express
four
mitochondri
dna
encod
gene
viz
nicotinamid
adenin
dineucleotid
dehydrogenas
subunit
cytochrom
b
cytb
cytochrom
c
oxidas
atp
synthetas
subunit
result
patient
includ
gene
express
analyz
patient
total
variat
found
posit
variat
germlin
somat
posit
identifi
probabl
hotspot
region
variat
per
posit
chang
commonest
variat
germlin
well
somat
variat
g
base
appear
stabl
nucleotid
least
number
singl
base
substitut
wherea
appear
prone
variat
germlin
commonest
cytb
gene
express
significantli
higher
variat
posit
express
cytb
significantli
lower
variat
posit
variat
posit
significantli
decreas
express
posit
attenu
express
conclus
first
studi
evalu
type
overal
pattern
variat
region
segreg
somat
germlin
variat
effect
variat
mitochondri
encod
gene
novel
inform
aml
genom
sv
r
p
n
bansal
institut
medic
educ
research
hematologyoncolog
dept
advanc
pediatr
center
chandigarh
india
institut
medic
educ
research
pediatr
dept
advanc
pediatr
center
chandigarh
india
institut
medic
educ
research
hematolog
chandigarh
india
institut
medic
educ
research
clinic
hematolog
chandigarh
india
backgroundobject
role
monitor
imatinib
children
cml
uncertain
trough
plasma
level
ngml
propos
adult
optim
respons
designmethod
design
observ
studi
set
patient
year
diagnosi
cml
receiv
imatinib
month
enrol
complianc
ensur
dispens
imatinib
exchang
empti
blister
pack
patient
exclud
blood
collect
prior
next
dose
imatinib
measur
imatinib
level
renalliv
biochemistri
assess
investig
perform
singl
result
enrol
median
age
enrol
year
iqr
median
durat
iqr
receiv
remain
receiv
median
dose
iqr
patient
evid
renalliv
dysfunct
qpcr
avail
patient
median
qpcr
iqr
rang
patient
major
molecular
remiss
deep
molecular
respons
dmr
median
trough
level
imatinib
ngml
iqr
rang
patient
ngml
dose
imatinib
correl
plasma
level
imatinib
p
median
imatinib
level
patient
lack
dmr
ngml
iqr
ngdl
iqr
respect
correl
age
sex
bodi
surfac
area
conclus
trough
level
imatinib
wide
rang
childrenadolesc
cml
correl
dose
imatinib
singl
assess
found
use
clinic
manag
cml
cezar
f
f
l
e
e
ms
cancer
institut
pediatr
program
rio
de
janeiro
brazil
backgroundobject
acut
megakaryoblast
leukemia
amkl
repres
de
novo
acut
myeloid
leukemia
aml
subtyp
divid
two
distinct
entiti
amkl
aris
context
syndrom
ii
de
novo
amkl
aim
compar
biolog
featur
pediatr
amkl
without
syndrom
ds
evalu
outcom
accord
leukemia
subtyp
designmethod
analyz
case
de
novo
aml
exclud
acut
promyelocyt
leukemia
age
frequent
genet
alter
amkl
rearrang
rearrang
identifi
fish
multiplex
mutat
identifi
sanger
sequenc
case
ds
overal
surviv
os
analyz
kaplan
meier
method
differ
group
compar
log
rank
test
result
amkl
subtyp
repres
aml
mostli
month
age
p
white
blood
cell
wbc
count
diagnosi
cellml
p
median
wbc
count
age
diagnosi
patient
month
respect
patient
median
wbc
count
age
month
respect
analyz
case
month
age
found
also
patient
patient
correspond
present
alter
associ
mutat
frequenc
case
mutat
gene
patient
present
higher
probabl
os
compar
patient
respect
conclus
fusion
gene
frequent
genet
heterogen
associ
poor
prognosi
w
chan
j
g
cw
ck
sy
mari
hospit
paediatr
adolesc
medicin
hong
kong
hong
kong
sar
elizabeth
hospit
paediatr
adolesc
medicin
hong
kong
hong
kong
sar
wale
hospit
paediatr
adolesc
medicin
hong
kong
hong
kong
sar
backgroundobject
bpdcn
uncommon
haematolog
malign
deriv
type
dendrit
cell
dc
first
classifi
distinct
entiti
acut
myeloid
leukemia
aml
relat
precursor
neoplasm
classif
neoplasm
typic
follow
highli
aggress
clinic
cours
adult
elderli
wherea
experi
children
diseas
limit
designmethod
retrospect
review
clinic
patholog
find
local
paediatr
case
bpdcn
present
age
year
past
year
januari
decemb
regist
hong
kong
paediatr
haematolog
oncolog
studi
group
hkphosg
addit
paediatr
bpdcn
case
literatur
use
pubm
search
keyword
bpdcn
incorpor
combin
statist
analys
use
statist
packag
social
scienc
version
spss
inc
chicago
il
probabl
overal
surviv
os
event
free
surviv
ef
calcul
use
estim
log
rank
test
use
compar
surviv
differ
group
deem
signific
result
total
case
identifi
local
case
identifi
literatur
median
durat
follow
month
rang
month
year
among
patient
avail
follow
nine
patient
aliv
year
diagnosi
os
ef
respect
statist
signific
better
os
ef
observ
patient
treat
vers
protocol
os
aml
other
p
ef
aml
other
p
result
concur
conclus
publish
literatur
conclus
bpdcn
children
clinic
less
aggress
compar
adult
high
index
suspicion
crucial
earli
diagnosi
treatment
chemotherapi
appear
superior
outcom
p
chhabra
n
sp
medic
pediatr
bmt
gurugram
india
backgroundobject
convent
treatment
acut
promyelocyt
leukemia
apml
chemotherapi
costli
high
morbid
mortal
arsen
trioxid
ato
alon
low
cost
therapi
apml
associ
signific
relaps
risk
combin
low
dose
chemotherapi
ato
might
effect
therapi
describ
experi
treat
children
apml
combin
therapi
designmethod
retrospect
analyz
data
five
children
diagnos
apml
unit
start
retino
acid
atra
soon
diagnosi
four
patient
receiv
cours
induct
chemotherapi
daunorubicin
x
day
cytarabin
x
day
children
idarubicin
alon
x
day
child
child
develop
steroid
resist
differenti
syndrom
day
induct
atra
ato
stop
daunorubicin
day
given
five
patient
subsequ
receiv
ato
day
consolid
therapi
mainten
ato
cycl
day
per
month
follow
mainten
oral
chemotherapi
methotrex
atra
day
everi
monthli
total
durat
year
result
children
achiev
morpholog
remiss
end
induct
chemotherapi
molecular
remiss
ato
consolid
one
child
develop
differenti
syndrom
induct
anoth
develop
gut
perfor
induct
requir
surgeri
third
develop
splenic
pulmonari
infarct
along
right
atrial
thrombosi
induct
requir
anticoagul
child
achiev
morpholog
molecular
remiss
receiv
ato
consolid
five
children
aliv
complet
molecular
remiss
median
month
month
conclus
feasibl
safe
treat
children
apml
combin
low
dose
chemotherapi
ato
svm
feliciano
mdo
ms
nacion
de
alencar
gome
da
silva
programa
de
phop
rio
de
janeiro
brazil
nacion
de
alencar
gome
da
silva
de
e
de
de
e
rio
de
janeiro
brazil
backgroundobject
leukemia
nll
heterogen
vari
pathogenesi
recent
brazilian
cancer
registri
pbcr
demonstr
differ
incid
rate
childhood
leukemia
brazil
object
studi
evalu
trend
incid
mortal
rate
nll
among
children
adolesc
young
adult
caya
brazil
designmethod
incid
data
extract
dataset
pbcr
citi
locat
five
geograph
region
mortal
databas
brazilian
health
mortal
inform
system
brazilian
citi
incid
asir
mortal
asmr
incid
aair
mortal
aamr
crude
incid
mortal
rate
calcul
accord
pbcr
age
strata
joinpoint
regress
analys
perform
trend
evalu
region
annual
percent
chang
apc
averag
annual
percent
chang
aapc
also
estim
result
median
aair
nll
per
million
highest
asir
observ
children
year
per
million
young
adult
year
old
per
million
lowest
asir
observ
children
age
strata
per
million
analysi
incid
trend
aapc
show
signific
declin
manau
paulo
increas
rate
observ
fortaleza
pessoa
grand
mortal
rate
demonstr
signific
declin
belo
horizont
campina
curitiba
fortaleza
grand
pessoa
porto
alegr
recif
salvador
paulo
conclus
data
analysi
demonstr
declin
incid
rate
compar
histor
seri
substanti
decreas
mortal
rate
observ
interpret
improv
nll
recognit
therapeut
approach
myeloid
malign
kg
gopakumar
n
r
cs
cancer
centr
pediatr
oncolog
trivandrum
india
cancer
centr
cancer
research
trivandrum
india
backgroundobject
children
core
bind
factor
cbf
acut
myeloid
leukemia
aml
high
surviv
current
standard
chemotherapi
protocol
howev
upcom
data
variou
part
world
point
ethnic
variat
surviv
children
transloc
designmethod
prospect
studi
assess
clinic
profil
children
year
age
aml
conduct
depart
pediatr
oncolog
region
cancer
centr
south
india
children
treat
two
cycl
standard
induct
chemotherapi
constitut
daunorubicin
cytosin
arabinosid
follow
consolid
cours
high
dose
cytosin
arabinosid
event
describ
induct
failur
two
induct
cours
diseas
recurr
treatment
complet
clinic
outcom
estim
use
kaplan
meier
analysi
result
total
children
de
novo
aml
enrol
period
year
children
transloc
constitut
studi
popul
complet
remiss
induct
achiev
two
children
attain
remiss
follow
cours
induct
chemotherapi
ef
patient
transloc
se
se
respect
inferior
compar
outcom
high
incom
countri
five
children
group
aberr
sex
chromosom
significantli
associ
inferior
surviv
compar
children
without
aberr
vs
conclus
data
consist
recent
emerg
literatur
indic
ethnic
heterogen
surviv
outcom
children
aml
transloc
multicent
trial
incorpor
cytogenet
molecular
analysi
would
help
identifi
addit
factor
associ
ethnic
variat
treatment
outcom
kg
gopakumar
rn
n
r
cs
cancer
centr
pediatr
oncolog
trivandrum
india
cancer
centr
microbiolog
trivandrum
india
backgroundobject
infect
import
caus
morbid
mortal
children
acut
myeloid
leukemia
aml
identif
character
infect
often
challeng
resourc
limit
set
impact
play
crucial
role
determin
surviv
vulner
group
designmethod
prospect
studi
conduct
depart
pediatr
oncolog
region
cancer
centr
south
india
assess
infect
infect
relat
mortal
induct
chemotherapi
children
de
novo
aml
treat
standard
induct
protocol
result
total
children
de
novo
aml
apml
exclud
enrol
period
year
total
induct
cours
analys
infecti
episod
per
induct
cours
document
infecti
episod
microbiolog
cultur
taken
posit
thirti
seven
gram
neg
gram
posit
fungal
organ
isol
multi
drug
resist
mdr
organ
constitut
posit
cultur
blood
cultur
taken
blood
stream
infect
detect
case
fever
without
focu
seen
instanc
case
proven
pneumon
case
skin
infect
septic
shock
develop
case
clinic
document
infect
seven
infect
relat
death
account
induct
mortal
three
cultur
proven
sepsi
four
case
mdr
infect
conclus
infect
induct
predominantli
gram
neg
mdr
organ
contribut
significantli
infect
relat
mortal
vigil
microbiolog
surveil
ration
antibiot
use
intens
support
care
possibl
limit
infect
relat
mortal
resourc
limit
set
low
level
achiev
high
incom
countri
k
green
ormond
street
hospit
paediatr
haematolog
london
unit
kingdom
backgroundobject
congenit
acut
myeloid
leukaemia
rare
leukaemia
present
within
first
month
life
clinic
biolog
distinct
leukaemia
infanc
childhood
overal
prognosi
poor
high
report
mortal
treatment
remain
challeng
balanc
diseas
remiss
morbid
mortal
present
first
uk
singl
centr
experi
patient
congenit
acut
myeloid
leukaemia
aid
overview
characterist
congenit
leukaemia
better
evalu
optim
treatment
strategi
designmethod
data
collect
infant
diagnos
congenit
leukaemia
uk
tertiari
paediatr
haematolog
centr
paramet
record
includ
demograph
antenat
histori
diseas
morpholog
karyotyp
treatment
overal
outcom
result
newborn
infant
diagnos
congenit
myeloid
leukaemia
femal
male
averag
gestat
age
week
newborn
famili
histori
paediatr
malign
antenat
postnat
torch
infect
congenit
malform
consanguin
averag
age
diagnosi
day
newborn
acut
myeloid
leukaemia
myeloid
sarcoma
newborn
display
typic
mll
rearrang
rearrang
transloc
present
newborn
display
cutan
blue
nodul
splenomegali
hepatomegali
lymphadenopathi
children
present
leukostasi
averag
white
cell
count
diagnosi
patient
present
dic
newborn
infant
receiv
chemotherapi
treatment
due
transloc
spontan
remit
diseas
newborn
die
surviv
conclus
newborn
congenit
acut
myeloid
leukaemia
overal
dismal
outcom
primarili
due
treatment
relat
toxic
increas
risk
relaps
larger
studi
intern
cohort
patient
need
aid
achiev
balanc
cure
minimis
treatment
relat
toxic
hara
n
k
g
n
h
k
univers
graduat
school
medicin
pediatr
maebashi
japan
citi
univers
hospit
pediatr
yokohama
japan
research
institut
child
health
develop
pediatr
hematolog
oncolog
research
tokyo
japan
children
medic
center
hematolog
oncolog
shibukawa
japan
center
child
health
develop
children
cancer
tokyo
japan
prefectur
univers
medicin
molecular
diagnost
therapeut
kyoto
japan
marianna
univers
school
medicin
pediatr
kawasaki
japan
hospit
organ
osaka
nation
hospit
pediatr
osaka
japan
hospit
nagoya
medic
center
clinic
research
center
nagoya
japan
univers
medic
scienc
pediatr
otsu
japan
univers
graduat
school
medicin
human
health
scienc
kyoto
japan
backgroundobject
prognost
marker
pediatr
acut
myeloid
leukemia
aml
inv
identifi
yet
designmethod
analyz
molecular
clinic
characterist
pediatr
aml
patient
enrol
japanes
trial
surviv
analys
reveal
excel
overal
surviv
os
patient
howev
surviv
ef
remain
unsatisfactori
thu
compar
characterist
patient
without
event
treatment
n
respect
event
studi
includ
death
relaps
second
malign
result
median
age
frequenc
nra
mutat
significantli
differ
two
group
year
vs
year
p
vs
p
respect
consequ
perform
surviv
analys
patient
accord
age
nra
mutat
statu
defin
year
old
cutoff
patient
age
year
patient
age
surviv
analys
reveal
significantli
wors
ef
cumul
incid
relaps
cir
patient
age
year
age
year
vs
p
vs
p
respect
convers
patient
n
significantli
better
ef
cir
patient
n
vs
p
vs
respect
accordingli
patient
age
year
n
worst
outcom
ef
cir
conclus
age
statu
may
use
prognost
marker
pediatr
aml
util
marker
investig
prevent
relaps
stem
cell
transplant
p
huong
nam
nation
cancer
hospit
pediatr
oncolog
ha
noi
vietnam
backgroundobject
background
myeloid
sarcoma
ms
tumor
compos
granulocyt
precursor
cell
occur
extramedullari
locat
ms
rare
neoplasm
whose
knowledg
larg
base
case
report
ms
often
initi
misdiagnos
common
altern
diagnos
lymphoma
undifferenti
cancer
malign
melanoma
extramedullari
hematopoiesi
inflamm
immunohistochemistri
immunophenoti
crucial
accur
diagnosi
ms
purpos
introduct
rare
clinic
case
ms
diagnosi
myelodysplast
syndrom
object
year
old
boy
ms
treat
pediatr
oncolog
depart
k
hospit
may
august
designmethod
retrospect
describ
clinic
case
result
patient
describ
smilar
case
literatur
treat
acut
myeloicyt
leukemia
convent
chemotherapeut
protocol
discharg
conclus
case
rare
clinic
practic
exact
diagnosi
made
immunohistochemistri
immunophenoti
treatment
system
chemotherapi
associ
primari
favor
surviv
outcom
ibragimova
n
f
k
research
institut
hematolog
blood
transfus
children
tashkent
uzbekistan
backgroundobject
evalu
effect
reproduc
modifi
protocol
uzbekistan
treatment
acut
myeloid
leukemia
children
designmethod
patient
acut
myeloid
leukemia
aml
receiv
treatment
children
depart
scientif
research
institut
hematolog
blood
transfus
period
mean
age
patient
median
year
among
patient
girl
boy
modifi
protocol
provid
stratif
patient
two
prognost
risk
group
standard
srg
n
includ
children
aml
fab
aml
fab
group
hrg
n
includ
patient
dose
cytarabin
reduc
perform
allogen
bone
marrow
transplant
patient
high
risk
first
remiss
absenc
therapi
uzbekistan
result
patient
treat
aml
patient
refer
srg
remain
hrg
patient
resist
therapi
remiss
achiev
death
induct
note
patient
death
remiss
one
reason
high
mortal
initi
period
treatment
increas
risk
sever
hemorrhag
complic
due
initi
thrombocytopenia
period
therapi
death
remiss
main
caus
mortal
infecti
complic
often
fungal
etiolog
patient
achiev
remiss
relaps
occur
surviv
rate
patient
conclus
despit
modif
aml
protocol
gener
aml
protocol
effect
treatment
program
reproduc
hematolog
clinic
uzbekistan
n
jabbar
indu
hospit
pediatr
hematolog
oncolog
karachi
pakistan
backgroundobject
factor
cbf
acut
myeloid
leukemia
aml
consid
favor
subgroup
accord
exist
classif
medic
research
council
mrc
criteria
two
major
subtyp
cbfa
invers
inv
cbfb
center
countri
offer
treatment
childhood
aml
due
limit
resourc
poor
outcom
therefor
ration
approach
adapt
institut
find
treat
cbf
aml
case
data
analyz
preval
treatment
outcom
favor
subgroup
may
help
make
strategi
treat
aml
nation
level
designmethod
retrospect
observ
studi
conduct
pediatr
oncolog
depart
indu
hospit
total
case
age
group
year
aml
exclud
acut
promyelocyt
leukemia
aml
syndrom
regist
period
juli
june
cytogenet
studi
fish
perform
cbf
posit
case
treat
cur
intend
analyz
outcom
result
cytogenet
perform
case
cbf
detect
includ
inv
case
mainli
seen
aml
wherea
inv
aml
subgroup
abandon
treatment
relat
mortal
seen
respect
diseas
relaps
case
wherea
event
free
surviv
without
abandon
note
patient
respect
median
follow
month
conclus
preval
cbf
aml
compar
intern
data
howev
set
anticip
outcom
influenc
variabl
abandon
high
treatment
relat
mortal
intern
data
advoc
high
likelihood
respons
surviv
suggest
broaden
ration
approach
treatment
strategi
negoti
limit
factor
especi
poor
support
care
kaburagi
g
n
k
h
n
k
hematologyoncolog
gunma
children
medic
center
gunma
japan
research
center
nation
hospit
organ
nagoya
medic
aichi
japan
pediatr
yokohama
citi
univers
hospit
kanagawa
japan
pediatr
gunma
univers
graduat
school
medicin
gunma
japan
pediatr
hematolog
oncolog
research
nation
research
institut
child
health
develop
tokyo
japan
leukemia
lymphoma
children
cancer
nation
center
child
health
develop
tokyo
japan
human
health
scienc
graduat
school
kyoto
univers
kyoto
japan
pediatr
shiga
univers
medic
scienc
shiga
japan
physiolog
medicin
jobu
univers
gunma
japan
backgroundobject
acut
myeloid
leukemia
aml
complex
diseas
caus
genet
heterogen
variou
driver
gene
mutat
aml
identifi
owe
massiv
parallel
sequenc
technolog
mutat
ra
pathway
gene
major
caus
aml
like
juvenil
myelomonocyt
leukemia
howev
characterist
pediatr
aml
mutat
ra
pathway
gene
remain
unclear
thu
reveal
signific
mutat
analyz
cbl
n
mutat
pediatr
aml
patient
designmethod
pediatr
patient
de
novo
aml
year
particip
japanes
trial
conduct
japanes
pediatr
leukemialymphoma
studi
group
sampl
avail
analyz
exon
cbl
exon
n
exon
mutat
use
sanger
sequenc
result
found
ra
pathway
mutat
follow
cbl
nra
kra
five
cbl
mutat
identifi
kra
mutat
associ
high
frequenc
mutat
p
nra
mutat
frequent
observ
inv
p
monosomi
p
mutual
exclus
mutat
also
frequent
observ
monosomi
p
remark
signific
differ
surviv
patient
without
mutat
ef
vs
p
overal
surviv
patient
without
nra
mutat
os
vs
p
interestingli
althoughcbl
mutat
associ
prognosi
pediatr
aml
patient
without
relaps
conclus
pediatr
aml
patient
cbl
nra
kra
mutat
harbor
molecular
featur
respect
would
like
discuss
data
annual
meet
k
kawaguchi
k
k
children
hospit
depart
hematolog
shizuoka
children
hospit
shizuoka
citi
japan
backgroundobject
allogen
hematopoiet
stem
cell
transplant
remain
cur
treatment
children
acut
myeloid
leukemia
aml
prognosi
patient
relaps
aml
dismal
second
potenti
cur
option
relaps
designmethod
children
relaps
aml
shizuoka
children
hospit
receiv
second
review
medic
record
retrospect
analyz
clinic
data
outcom
result
median
age
second
year
old
six
patient
femal
median
interv
transplant
day
day
graft
sourc
second
follow
bone
marrow
cord
blood
peripher
blood
stem
cell
time
second
three
patient
cr
six
condit
regimen
myeloabr
patient
median
month
month
cumul
incid
grade
acut
diseas
gvhd
chronic
gvhd
overal
surviv
rate
year
mortal
rate
year
two
three
patient
receiv
second
cr
still
aliv
one
die
infect
contrast
two
six
receiv
second
surviv
two
death
seven
receiv
myeloabl
condit
caus
complic
thrombot
microangiopathi
infect
conclus
result
suggest
second
promis
therapeut
approach
patient
especi
cr
mortal
observ
myeloabl
condit
studi
requir
identifi
optim
condit
regimensfor
second
bk
kim
kt
hj
hy
jy
hy
hs
kd
ds
nation
univers
colleg
medicin
pediatr
seoul
republ
korea
nation
univers
colleg
medicin
pediatr
cheongju
republ
korea
nation
univers
colleg
medicin
laboratori
medicin
seoul
republ
korea
backgroundobject
viru
ebv
aggress
natur
leukemia
ankl
rare
malign
matur
natur
killer
cell
poor
surviv
rate
patient
rapidli
declin
clinic
cours
poor
prognosi
median
surviv
month
less
ankl
case
report
literatur
date
pediatr
patient
report
first
case
pediatr
patient
ankl
success
treat
achiev
complet
remiss
designmethod
analyz
retrospect
boy
diagnos
ankl
success
treat
use
combin
chemotherapi
subsequ
allogen
hematopoiet
stem
cell
transplant
allohsct
result
boy
present
prolong
fever
night
sweat
diarrhea
anorexia
cough
sputum
week
hepatosplenomegali
observ
laboratori
find
show
thrombocytopenia
mild
leukopenia
mild
elev
alanin
aminotransferas
aspart
aminotransferas
ferritin
level
markedli
increas
pmoll
ngml
triglycerid
fibrinogen
level
mmoll
gl
respect
diagnos
ankl
bone
marrow
biopsi
immunohistocytochem
stain
success
treat
use
combin
chemotherapi
subsequ
allohsct
seriou
side
effect
treatment
year
month
allohsct
conclus
case
show
combin
chemotherapi
regimen
follow
allohsct
combin
chemotherapi
could
feasibl
strategi
treatment
pediatr
ankl
kim
jw
ps
ng
b
cathol
univers
korea
pediatr
seoul
republ
korea
backgroundobject
karyotyp
diagnosi
import
prognost
valu
pediatr
aml
studi
aim
determin
prognost
valu
complex
karyotyp
pediatr
de
novo
acut
myeloid
leukemia
aml
except
designmethod
present
studi
includ
patient
diagnos
treat
de
novo
aml
cathol
univers
korea
april
septemb
found
abnorm
karyotyp
patient
core
bind
factor
aml
mll
rearrang
normal
karyotyp
aml
exclud
median
age
diagnosi
patient
complex
karyotyp
ck
femal
defin
three
numer
structur
abnorm
remain
patient
abnorm
karyotyp
primari
endpoint
surviv
ef
overal
surviv
os
ck
patient
compar
patient
abnorm
karyotyp
result
ck
patient
two
primari
refractori
five
fail
achiev
remiss
first
cours
induct
chemotherapi
ef
patient
ck
abnorm
karyotyp
respect
os
ck
patient
significantli
inferior
patient
abnorm
karyotyp
vs
three
ck
patient
treat
chemotherapi
alon
first
complet
remiss
die
diseas
progress
relaps
os
ck
patient
inferior
patient
abnorm
karyotyp
even
allogen
hematopoiet
cell
transplant
first
cr
although
without
statist
signific
vs
overal
ck
relaps
die
patient
abnorm
karyotyp
relaps
die
conclus
patient
ck
show
poor
outcom
chemotherapi
treatment
strategi
relaps
respons
salvag
chemotherapi
inferior
ck
patient
compar
patient
abnorm
karyotyp
result
significantli
lower
os
ck
patient
koga
k
h
u
h
school
medic
kyushu
univers
depart
pediatr
fukuoka
japan
hospit
organ
kyushu
cancer
center
divis
pediatr
fukuoka
japan
backgroundobject
rare
occur
pediatr
leukemia
fusion
type
aml
stratifi
leukemia
need
hematopoiet
stem
cell
transplant
hsct
complet
remiss
cr
designmethod
four
case
myeloid
neoplasia
treat
hospit
result
case
seri
case
male
aml
show
x
dic
add
die
match
relat
bone
marrow
transplant
fluoresc
situ
hybrid
analysi
reveal
leukem
cell
case
male
aml
show
xy
idem
add
idem
dic
myeloid
antigen
die
complic
hsct
case
male
myeloid
sarcoma
mediastinum
show
xy
idem
add
myeloid
antigen
obtain
cr
chemotherapi
die
tumor
lysi
therapi
regrowth
case
infant
aml
show
xy
myelomonocyt
antigen
receiv
induct
failur
led
cr
continu
year
conclus
poor
outcom
report
pediatr
case
chemotherapi
howev
earli
hsct
might
inevit
control
aml
pediatr
adult
case
k
lappin
k
k
univers
belfast
centr
cancer
research
cell
biolog
belfast
unit
kingdom
backgroundobject
leukaemia
frequent
occur
type
paediatr
cancer
approxim
acut
lymphoblast
leukaemia
acut
myeloid
leukaemia
aml
case
make
remain
manag
improv
dramat
recent
year
unfortun
children
aml
promis
outlook
surviv
high
risk
respond
induct
therapi
accompani
high
rate
relaps
recent
data
bolouri
et
al
strongli
indic
need
therapi
children
aml
designmethod
silico
analysi
data
therapeut
applic
research
gener
effect
treatment
target
cohort
perform
gener
gene
express
chang
differ
patient
subgroup
compar
patient
surviv
without
relaps
follow
treatment
addit
high
throughput
compound
screen
perform
cell
line
repres
paediatr
aml
differ
cytogenet
mutat
background
identifi
effect
compound
across
differ
patient
group
result
analysi
identifi
number
key
pathway
includ
associ
dna
damag
respons
ddr
deregul
amongst
patient
die
within
year
compar
surviv
without
relaps
sever
ddr
gene
show
shown
interfer
patient
respons
chemotherapi
brousta
lieberman
due
sever
side
effect
standard
therapi
percentag
patient
respond
sought
identifi
possibl
altern
therapi
treatment
patient
screen
experiment
compound
fda
approv
therapi
identifi
sever
compound
repurpos
potenti
aml
treatment
venetoclax
conclus
improv
outcom
paediatr
patient
aml
imper
altern
therapi
identifi
combin
mean
identifi
lead
improv
outcom
k
lee
j
j
nation
univers
school
medicin
depart
pediatr
daegu
republ
korea
backgroundobject
chromosom
analysi
import
diagnost
tool
cancer
primarili
evalu
type
chromosom
abnorm
known
cancer
patient
singl
hospit
year
designmethod
chromosom
studi
done
specimen
peripher
blood
bone
marrow
cancer
tissu
cell
cultur
short
term
long
term
period
variou
medium
includ
rpmi
without
mitogen
band
trypsin
edta
done
result
mean
age
yo
yo
male
femal
ratio
year
among
total
sampl
success
cultur
cytogenet
studi
half
studi
recent
year
cancer
cytogenet
case
peripher
blood
bone
marrow
cell
tissu
evalu
other
peripher
blood
clinic
diagnosi
chromosom
abnorm
cancer
case
amniot
fluid
chorion
villi
prenat
diagnosi
chromosom
abnorm
case
includ
among
transloc
observ
peripher
blood
philadelphia
chromosom
detect
balanc
transloc
unbalanc
transloc
bone
marrow
cultur
numer
abnorm
observ
sampl
hypodiploidi
hyperdiploidi
hypotriploidi
hypertriploidi
hypotetraploidi
hypertetraploidi
trisomi
monosomi
xxi
structur
abnorm
observ
sampl
includ
philadelphia
chromosom
transloc
transloc
partial
abnorm
includ
inv
inv
inv
der
mar
frequent
aberr
aml
hyperploidi
cml
dup
dup
del
md
conclus
studi
type
cytogenet
abnorm
known
cancer
patient
review
c
liang
x
l
c
w
l
x
first
affili
hospit
sun
univers
pediatr
guangzhou
china
backgroundobject
previou
research
show
arsen
trioxid
ato
retino
acid
atra
select
target
posit
aml
cell
line
studi
investig
mechan
mediat
degrad
designmethod
studi
conduct
two
posit
aml
cell
line
two
neg
aml
cell
line
treat
interact
determin
western
blot
effect
regul
detect
cycloheximid
chx
proteasom
inhibitor
bortezomib
cell
viabil
cell
apoptosi
analyz
use
cell
count
flow
cytometri
assay
protein
express
analyz
use
western
blot
result
concurr
treatment
atra
ato
significantli
reduc
cell
viabil
induc
cell
apoptosi
cell
line
mechanist
found
oncoprotein
ubiquitin
degrad
cotreat
atra
ato
manner
moreov
proteasom
inhibitor
bortezomib
obvious
increas
abund
human
enzym
concern
potenti
mechan
involv
process
illustr
express
oncoprotein
mediat
up
system
conclus
data
support
combin
might
potenti
candid
therapi
aml
treatment
activ
apoptot
pathway
degrad
oncoprotein
via
mediat
up
r
min
q
l
l
l
c
g
z
z
c
z
blood
diseas
chines
academi
medic
peke
union
medic
colleg
pediatr
tianjin
china
backgroundobject
investig
efficaci
prognost
factor
pediatr
acut
myeloid
leukemia
accord
standard
diagnost
therapeut
regimen
designmethod
aml
patient
treat
regimen
april
decemb
enrol
studi
clinic
characterist
therapeut
effect
prognost
factor
retrospect
analyz
overal
surviv
os
event
free
surviv
ef
rate
estim
method
result
total
case
enrol
studi
includ
male
femal
median
age
diagnosi
year
introduct
therapi
patient
occur
patient
achiev
cr
achiev
cr
patient
accept
hematopoiet
stem
cell
transplant
hsct
patient
relaps
os
ef
patient
respect
os
ef
boy
girl
p
os
ef
patient
low
white
blood
cell
wbc
count
patient
high
wbc
count
p
os
ef
patient
accept
hsct
patient
achiev
cr
p
conclus
rate
cr
rate
relaps
rate
aml
patient
treat
respect
os
ef
respect
sex
wbc
count
may
import
factor
prognosi
hsct
may
improv
outcom
pediatr
aml
r
min
q
l
l
l
c
g
z
z
c
z
blood
diseas
chines
academi
medic
peke
union
medic
colleg
pediatr
tianjin
china
backgroundobject
discuss
relationship
molecular
biolog
characterist
prognosi
pediatr
acut
myeloid
leukemia
aml
designmethod
aml
patient
treat
regimen
august
decemb
enrol
studi
gene
analysi
perform
clinic
characterist
therapeut
effect
retrospect
analyz
overal
surviv
os
event
free
surviv
ef
rate
estim
method
prognost
factor
evalu
cox
regress
analysi
result
total
case
enrol
studi
includ
male
femal
median
age
diagnosi
year
patient
posit
posit
posit
cebpa
doubl
mutat
posit
mutat
posit
mll
rearrang
posit
abnorm
found
case
os
ef
patient
os
ef
patient
patient
patient
cebpa
doubl
mutat
patient
mutat
patient
mll
rearrang
patient
mutat
patient
cox
multivari
analysi
show
molecular
biolog
characterist
independ
prognost
factor
conclus
molecular
biolog
characterist
independ
factor
prognosi
pediatr
aml
e
nazarova
g
g
n
rogachev
nation
research
center
pediatr
oncolog
immunolog
radiolog
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
hematolog
moscow
russia
backgroundobject
patient
requir
regular
monitor
iron
content
bodi
due
iron
overload
syndrom
aim
introduc
method
map
instead
liver
biopsi
children
develop
score
system
valu
base
siderosi
grade
designmethod
mri
investig
perform
patient
age
liver
iron
overload
quantif
use
cartesian
breath
hold
techniqu
radial
free
breath
techniqu
valu
estim
special
relax
map
tool
correl
iron
concentr
measur
liver
biopsi
immedi
mri
scan
result
assess
lic
liver
iron
concentr
free
breath
breath
hold
techniqu
receiv
calibr
curv
biopsi
data
valu
correl
coeffici
confid
interv
cc
confid
interv
cc
respect
also
obtain
score
system
valu
base
siderosi
grade
ms
lic
dri
lic
dri
lic
dri
ms
lic
conclus
therefor
map
replac
liver
biopsi
phase
clinic
observ
patient
stage
iron
overload
start
chelat
therapi
evalu
efficaci
end
therapi
establish
free
breath
map
conveni
iron
quantif
children
need
patient
hold
breath
also
provid
much
higher
resolut
thinner
slice
whole
liver
coverag
oberoi
g
j
v
manitoba
paediatr
hematolog
oncolog
winnipeg
canada
scienc
centr
paediatr
radiolog
winnipeg
canada
scienc
centr
paediatr
critic
care
winnipeg
canada
backgroundobject
idiopath
hypereosinophil
syndrom
he
present
thrombosi
rare
children
report
adolesc
idiopath
he
present
pulmonari
embol
deep
venou
thrombosi
lower
limb
designmethod
retrospect
review
patient
electron
chart
conduct
retriev
clinic
laboratori
data
result
boy
present
fever
short
breath
chest
pain
swell
left
leg
doppler
ultrasound
lower
limb
reveal
thrombosi
left
femor
poplit
vein
ct
scan
chest
demonstr
segment
pulmonari
embol
along
pleural
effus
start
dalteparin
antibiot
complet
blood
count
show
absolut
eosinophil
count
aec
aec
persist
elev
subsequ
develop
extens
occlus
clot
right
femor
poplit
vein
mark
eosinophilia
detect
pleural
fluid
eosinophil
full
diagnost
work
infecti
immunolog
rheumatolog
caus
eosinophilia
neg
bone
marrow
aspir
biopsi
normocellular
mark
eosinophilia
bone
marrow
cytogenet
flow
cytometri
normal
bcrabl
mutat
neg
pdgfra
pdgfrb
gene
region
normal
pcr
evid
clonal
seen
start
methylprednisolon
work
diagnosi
idiopath
he
clinic
statu
improv
aec
normal
within
day
dalteparin
chang
apixaban
due
level
oral
prednisolon
start
follow
puls
dose
methylprednisolon
assess
done
three
month
treatment
show
resolv
pulmonari
emboli
normal
pulmonari
function
persist
old
thrombu
lower
limb
clinic
continu
well
apixaban
minimum
dose
prednisolon
conclus
he
present
multipl
thrombos
children
one
awar
thromboembol
complic
he
patel
b
g
bra
india
institut
medic
new
delhi
depart
medic
oncolog
new
delhi
india
council
medic
research
center
nutrit
research
train
icmr
new
delhi
india
india
institut
medic
new
delhi
depart
biochemistri
new
delhi
india
backgroundobject
data
institut
unpublish
micronutri
pediatr
malign
show
decreas
serum
zinc
zn
level
associ
trend
toward
decreas
overal
surviv
pediatr
aml
subject
view
lacuna
literatur
role
zn
aml
pilot
unpublish
data
plan
studi
explor
designmethod
singl
institut
prospect
studi
consecut
treat
pediatr
aml
patient
apr
morbid
data
durat
fever
use
second
line
antibiot
probabl
fungal
infect
presenc
bacteraemia
death
within
day
collect
serum
zn
sampl
collect
start
treatment
analys
induct
coupl
plasma
mass
spectrometri
method
pilot
unpublish
data
case
power
error
calcul
sampl
size
low
zn
predict
inferior
os
year
hazard
result
aml
patient
median
age
year
rang
zn
level
low
normal
normal
patient
mean
zn
ugl
cr
rate
median
follow
rang
os
ci
ef
ci
zn
defici
associ
increas
use
second
line
antibiot
increas
mortal
also
inferior
cr
rate
low
zn
level
predict
ef
os
exploratori
analysi
high
zn
level
ugl
predict
inferior
os
ef
conclus
low
zn
level
predict
outcom
howev
associ
increas
death
initi
day
use
second
line
antibiot
inferior
rate
cr
high
level
associ
inferior
outcom
therefor
whenev
supplement
zn
narrow
rang
need
maintain
patel
r
r
v
cancer
institut
depart
pediatr
blood
marrow
transplant
chennai
india
backgroundobject
juvenil
myelomonocyt
leukemia
jmml
rare
hematopoiet
malign
earli
childhood
repres
pediatr
leukemia
allogen
hematopoiet
stem
cell
transplant
cur
option
studi
analyz
outcom
patient
jmml
treat
center
designmethod
perform
retrospect
analysi
children
diagnos
juvenil
myelomonocyt
leukemia
per
criteria
centr
year
period
novemb
novemb
demograph
clinic
laboratori
treatment
characterist
record
medic
record
result
ten
children
jmml
includ
studi
male
femal
ratio
median
age
diagnosi
eight
month
month
year
median
total
leukocyt
count
present
common
present
featur
fever
splenomegali
two
children
clinic
evid
monosomi
seen
children
splenectomi
prior
transplant
perform
children
children
receiv
low
dose
chemotherapi
acid
prior
transplant
ten
children
two
children
progress
diseas
die
prior
hsct
treatment
abandon
one
child
seven
children
underw
allogen
hsct
two
need
second
transplant
graft
reject
myeloabl
condit
busulfan
cyclophosphamid
melphalan
result
sustain
chimer
three
children
match
sibl
donor
treosulfan
fludarabin
base
condit
result
sustain
chimer
two
children
altern
donor
hsct
result
overal
surviv
conclus
allogen
hsct
match
sibl
altern
donor
offer
surviv
rate
children
jmml
factor
determin
optim
outcom
includ
adequ
diseas
control
prior
hsct
myeloabl
condit
e
r
h
k
c
p
colleg
medicin
depart
section
houston
usa
backgroundobject
langerhan
cell
histiocytosi
lch
inflammatori
myeloid
neoplasia
character
lesion
includ
pathogen
dendrit
cell
among
inflammatori
infiltr
children
lch
experi
high
relaps
rate
near
recent
sequenc
studi
found
recurr
activ
mutat
mapk
pathway
gene
lch
lesion
includ
carrier
experi
increas
relaps
risk
howev
role
inherit
genet
effect
lch
relaps
remain
unknown
therefor
conduct
pilot
associ
studi
gwa
character
role
inherit
genet
variant
risk
lch
relaps
designmethod
patient
lch
recruit
texa
children
hospit
patient
experienc
relaps
event
genotyp
perform
illumina
quad
beadchip
evalu
role
common
variant
minor
allel
frequenc
lch
relaps
use
plink
appli
threshold
threshold
suggest
signific
result
identifi
variant
disequilibrium
cluster
loci
chromosom
associ
decreas
risk
lch
relaps
rna
gene
larg
uncharacter
rna
function
regul
gene
express
transcript
level
conclus
assess
inherit
genet
variat
lch
relaps
identifi
genom
region
may
associ
lch
relaps
genet
region
need
valid
independ
replic
set
result
provid
initi
evid
suggest
inherit
risk
factor
influenc
lch
diseas
sever
peyam
r
n
institut
medic
educ
research
pediatr
hematolog
oncolog
depart
pediatr
chandigarh
india
institut
medic
educ
research
pediatr
hematolog
oncolog
depart
pediatr
chandigarh
india
institut
medic
educ
research
depart
hematolog
chandigarh
india
backgroundobject
acut
myeloid
leukemia
aml
report
high
abandon
high
treatment
relat
mortal
trm
low
middl
incom
countri
previous
present
trm
analysi
perform
determin
improv
year
outcom
pediatr
aml
treat
tertiari
centr
india
designmethod
one
hundr
fourteen
children
treat
aml
non
aml
mrc
protocol
januari
decemb
analyz
patient
underw
transplant
result
mean
age
year
boy
girl
fab
subtyp
fourteen
patient
gum
hypertrophi
chloroma
four
patient
central
nervou
system
diseas
cytogenet
profil
molecular
respons
avail
complet
remiss
cr
base
morpholog
alon
eighti
six
patient
evalu
remiss
induct
cr
blast
eighti
cr
induct
refractori
therapi
overal
mortal
earli
death
six
die
induct
cours
cumul
mortal
decreas
infect
relat
death
ten
default
therapi
twenti
six
patient
relaps
earli
relaps
time
relaps
day
year
event
free
surviv
ef
ef
conclus
high
trm
preclud
satisfactori
outcom
aml
infect
respons
major
trm
howev
slow
improv
visibl
attribut
dedic
fellow
train
enhanc
support
care
facil
qualiti
improv
refin
infrastructur
educ
pivot
remedi
measur
requir
lmic
enabl
give
demand
intens
therapi
h
poparn
n
p
k
p
medicin
pediatr
bangkok
thailand
backgroundobject
facial
palsi
rare
manifest
central
nervou
system
cn
involv
pediatr
leukemia
characterist
infiltr
leukem
cell
peripher
nervou
system
present
clinic
present
treatment
outcom
two
case
relaps
aml
present
facial
palsi
designmethod
retrospect
studi
result
two
patient
girl
boy
present
facial
palsi
lower
motor
neuron
type
complet
acut
myeloid
leukemia
aml
treatment
initi
diagnos
aml
cn
involv
receiv
four
cours
intens
chemotherapi
without
bone
marrow
transplant
develop
facial
palsi
month
treatment
competit
isol
cn
relaps
reveal
csf
cytolog
brain
mri
show
csf
posit
blast
cell
high
signal
intens
lesion
left
globu
pallidu
mri
first
patient
blast
cell
csf
mri
show
abnorm
signal
intens
lesion
intracanalicular
segment
right
facial
nerv
second
patient
receiv
system
chemotherapi
intrathec
cytarabin
hydrocortison
methotrex
irradi
subsequ
bone
marrow
relaps
month
month
cn
relaps
die
diseas
conclus
facial
palsi
consid
rare
manifest
cn
aml
children
isol
cn
relaps
remain
dismal
prognosi
nd
pradhan
k
h
g
n
p
pg
memori
centr
medic
oncolog
pediatr
mumbai
india
memori
centr
hematopatholog
laboratori
mumbai
india
backgroundobject
mutat
confer
poor
prognosi
acut
myeloid
leukemia
aml
low
remiss
rate
earli
relaps
convent
chemotherapi
necessit
altern
treatment
approach
stem
cell
transplant
allosct
analyz
outcom
pediatr
mutat
aml
patient
centr
treat
combin
sorafenib
chemotherapi
designmethod
pediatr
aml
patient
regist
includ
patient
receiev
either
standard
hdac
chemotherapi
oral
metronom
therapi
etoposid
prednisolon
cladribin
cytarabin
sorafenib
given
dose
daili
found
posit
none
underw
sct
financi
logist
reason
result
pediatr
aml
patient
regist
period
median
age
rang
twenti
high
allel
ratio
six
patient
refus
treatment
remain
receiv
convent
chemotherapi
without
sorafenib
survivor
receiv
sorafenib
induct
mrd
neg
cr
phase
mrd
neg
cr
patient
receiv
cladribin
base
consolid
becam
wherea
patient
receiv
hdac
consolid
fail
becom
diseas
free
surviv
month
patient
receiv
upfront
sorafenib
oppos
patient
nt
receiv
upfront
sorafenib
conclus
though
allogen
sct
best
outcom
aml
mani
patient
achiev
cr
thu
transplant
upfront
addit
sorafenib
later
cladribin
base
consolid
help
us
produc
deep
remiss
patient
treat
thu
regimen
may
help
patient
cur
allogen
sct
ja
salina
sanz
cm
b
j
j
hospit
universitario
son
espas
pediatr
mallorca
spain
hospit
universitario
son
espas
pediatr
mallorca
spain
hospit
universitario
son
espas
hematolog
mallorca
spain
hospit
universitario
son
espas
inmunolog
mallorca
spain
hospit
universitario
son
espas
pediatr
mallorca
spain
backgroundobject
neonat
leukemoid
reaction
lr
rel
rare
condit
newborn
incid
infant
increas
defin
leukocyt
neutrophil
without
evid
malign
etiolog
unclear
relat
excess
inflammatori
cytokin
associ
prenat
corticosteroid
chorioamnion
infect
recent
bronchopulmonar
dysplasia
femal
gender
prematur
recent
grow
evid
suggest
poor
prognosi
designmethod
analyz
retrospect
newborn
lr
control
match
gender
gestat
age
relat
admit
center
exclud
case
trisomi
compar
matern
neonat
characterist
clinic
evolut
laboratori
find
group
result
lr
observ
newborn
incid
mean
gestat
age
birth
weight
case
control
group
vs
week
g
vs
g
group
women
sever
leucocytosi
relat
less
gestat
age
lower
weight
chorioamnion
increas
risk
lr
well
matern
steroid
lr
group
significantli
ventil
need
surfact
dose
less
hospit
durat
vs
day
mortal
rl
began
day
peak
time
day
last
day
higher
valu
pcr
mgdl
use
roc
curv
chosen
leukocyt
valu
maximum
sensit
specif
predict
exitu
studi
conclus
lr
frequent
newborn
whose
mother
clinic
chorioamnion
associ
ventil
support
surfact
mortal
number
leukocyt
increas
significantli
dose
betametasona
less
gestat
age
weight
n
mdr
jl
medico
imbanaco
pediatr
oncolog
unit
cali
colombia
infantil
lo
angel
pediatr
oncolog
unit
pasto
colombia
libr
pediatr
cali
colombia
backgroundobject
dendrit
cell
leukemia
dcl
childhood
acut
leukemia
cutan
lymphoma
express
absenc
myeloid
lymphoid
natur
killer
cell
marker
defin
diseas
inform
leukemia
children
scarc
therefor
consid
clinic
descript
case
valuabl
pediatr
oncologist
designmethod
direct
observ
author
medic
record
laboratori
patholog
report
use
obtain
demograph
clinic
data
includ
case
diagnos
third
level
pediatr
oncolog
unit
pasto
colombia
result
includ
three
patient
patient
older
case
year
age
patient
present
year
age
patient
skin
lesion
number
flat
plaqu
skin
sever
skin
nodul
patient
skin
lesion
patient
elev
plasma
lactat
dehydrogenas
liver
spleen
enlarg
none
cn
involv
report
case
common
find
hepatosplenomegali
lymph
node
enlarg
medullar
infiltr
patient
dcl
skin
lesion
cn
involv
pulmonari
renal
muscular
diseas
describ
none
case
show
infiltr
organ
patient
show
complet
remiss
myeloid
type
induct
low
minim
residu
diseas
patient
day
allogen
bmt
two
process
bmt
three
patient
aliv
conclus
suspicion
dcl
arous
patient
skin
lesion
plu
pancytopenia
nevertheless
also
occur
without
skin
lesion
identifi
blast
immunophenotyp
earli
allogen
bmt
consid
patient
remiss
cur
treatment
semari
n
beni
sweif
univers
children
cancer
hospit
egypt
cche
depart
pediatr
oncolog
cairo
egypt
cancer
institut
cche
pediatr
oncolog
cairo
egypt
canser
institut
cche
clinic
patholog
cairo
egypt
cancer
institut
cche
clinic
patholog
cairo
egypt
pharmaci
cairo
egypt
clinic
research
cairo
egypt
backgroundobject
presenc
flt
mutat
pediatr
aml
associ
high
rate
failur
induct
wors
surviv
consid
high
risk
group
aim
work
evalu
pediatr
aml
patient
mutant
treat
children
cancer
hospit
egypt
cche
year
period
designmethod
retrospect
studi
evalu
pediatr
aml
mutant
juli
till
juli
cche
result
total
patient
gene
mutat
patient
aml
sixti
five
patient
gene
mutat
allel
ratio
patient
achiev
cr
patient
refractori
die
bmt
done
patient
cr
aliv
cr
patient
relaps
die
seven
patient
aliv
cr
without
bmt
eight
patient
die
patient
lost
fu
patient
relaps
soon
patient
cr
aliv
rest
relaps
patient
receiv
salvag
chemotherapi
die
three
year
os
ef
patient
gene
mutat
allel
ratio
respect
three
year
os
ef
patient
treat
bmt
respect
versu
patient
treat
achiev
cr
without
bmt
respect
conclus
flt
mutat
pediatr
aml
associ
higher
rate
induct
failur
surviv
relaps
patient
extrem
poor
bmt
first
remiss
possibl
best
option
otherwis
significantli
wors
os
ef
trial
inhibitor
sorafenib
mandatori
improv
outcom
subset
patient
shen
r
l
j
children
medic
center
pediatr
hematolog
oncolog
shanghai
china
children
medic
center
hematolog
oncolog
shanghai
china
backgroundobject
transcript
factor
modul
gene
express
target
scan
data
found
bind
bind
motif
promotor
region
explor
acut
myeloid
leukemia
aml
microarray
databas
confirm
express
consist
aml
patient
sampl
confirm
find
quantit
express
pediatr
aml
sampl
shanghai
children
medic
center
expect
case
higher
moreov
express
independ
poor
prognost
factor
overal
surviv
compar
patient
higher
lower
express
designmethod
understand
role
leukemogen
function
fusion
gene
knock
express
cell
shrna
growth
cell
vitro
significantli
inhibit
cell
cycl
exit
apoptosi
transform
fetal
liver
cell
condit
knockout
mice
leukemia
model
retroviru
conduct
express
induc
delet
delay
full
blown
leukemia
vivo
result
overal
surviv
prolong
day
median
vs
day
guanin
nucleotid
exchang
factor
rhoa
gtpase
delet
decreas
activ
express
phosphoryl
one
rock
kinas
substrat
spleen
cell
leukem
mice
cultur
vitro
rock
inhibitor
significantli
decreas
cell
prolifer
mimic
knockout
phenotyp
combin
tamoxifen
treat
cell
almost
erad
aliv
leukemia
cell
ninth
day
delay
leukemogenesi
vivo
conclus
find
suggest
transcript
target
fusion
protein
play
essenti
role
leukemogenesi
pathway
may
serv
new
therapeut
target
aml
shimada
h
univers
hospit
pediatr
hematologyoncolog
okayama
japan
univers
pediatr
nagoya
japan
medic
jobu
univers
medic
physiolog
isezaki
japan
backgroundobject
pediatr
patient
myeloprolif
neoplasm
mpn
except
chronic
myeloid
leukemia
juvenil
myelomonocyt
leukemia
jmml
rare
report
compar
adult
includ
polycythemia
vera
pv
essenti
thromobocytosi
et
myelofibrosi
mf
etc
remain
unknown
precis
incid
disord
pediatr
popul
recent
calr
mpl
pivot
role
adult
pvetmf
especi
found
pv
et
mf
howev
previou
studi
show
pediatr
et
patient
sekiya
et
al
int
j
hematol
compar
detect
method
sanger
sequenc
allel
specif
pcr
specif
differ
furthermor
correl
haplotyp
found
pediatr
et
therefor
tri
detect
variant
next
gener
sequenc
ng
et
pediatr
patient
designmethod
establish
custerm
haloplex
target
sequenc
panel
equip
leukemia
relat
gene
agil
analyz
miseq
ilumina
inform
consent
obtain
parent
local
ethnic
committe
approv
project
result
found
variant
kit
etc
furthermor
patient
variant
exon
three
gene
calr
mpl
conclus
adult
ng
studi
et
heterogen
variant
includ
etc
lundberg
p
et
al
blood
howev
variant
frequenc
limit
pediatr
studi
karow
et
al
leukemia
therefor
larger
studi
need
confirm
biolog
differ
adult
pediatr
mpn
start
studi
pediatr
mpn
japan
jw
ps
ng
b
ke
j
shin
cathol
univers
korea
pediatr
seoul
republ
korea
backgroundobject
acut
myeloid
leukemia
aml
character
compris
pediatr
aml
studi
aim
determin
import
prognost
variabl
among
aggreg
clinic
genet
treatment
factor
pediatr
aml
designmethod
studi
cohort
includ
patient
femal
diagnos
treat
aml
depart
pediatr
cathol
univers
korea
april
januari
real
time
quantit
polymeras
chain
reaction
fusion
done
diagnosi
cours
chemotherapi
whole
bodi
magnet
reson
imag
mri
undertaken
diagnosi
patient
determin
presenc
extramedullari
involv
emi
patient
also
evalu
possibl
kit
mutat
result
median
age
diagnosi
year
rang
median
initi
white
blood
cell
wbc
count
rang
emi
diagnos
patient
kit
mutat
found
patient
surviv
ef
relaps
one
death
remiss
induct
median
time
relaps
month
rang
less
fusion
transcript
decrement
remiss
induct
emi
diagnosi
presenc
kit
mutat
higher
initi
wbc
count
significantli
predict
lower
ef
howev
multivari
studi
show
lower
fusion
transcript
decrement
remiss
induct
emi
diagnosi
signific
predictor
wors
outcom
overal
surviv
os
surviv
patient
remain
conclus
comprehens
studi
risk
factor
pediatr
aml
show
fusion
transcript
decrement
remiss
induct
presenc
emi
diagnosi
import
prognost
variabl
sr
siddaiahgari
b
children
banjara
hill
pediatr
hematolog
oncolog
hyderabad
india
children
banjara
hill
pediatr
hyderabad
india
backgroundobject
introduct
acut
leukemia
common
pediatr
malign
account
acut
myeloid
leukemia
aml
account
acut
leukemia
gap
surviv
rate
aml
develop
develop
countri
develop
countri
surviv
rate
develop
countri
apml
higher
surviv
rate
aim
look
outcom
aml
children
develop
countri
designmethod
period
year
januari
decemb
type
prospect
retrospect
observ
studi
rainbow
children
tertiari
care
center
method
data
patient
diagnos
aml
underw
treatment
rainbow
children
hospit
studi
period
collect
analys
result
total
number
case
femal
male
case
infantil
onset
case
year
age
unfavour
prognosi
common
aml
base
morpholog
immunophenotyp
case
apml
report
case
posit
present
symptom
fever
skin
mucos
bleed
case
case
firm
organomegali
time
present
cbp
sever
anemia
gdl
case
wbc
count
case
case
rest
case
wbc
count
platelet
count
case
case
blast
peripher
smear
except
treat
aml
protocol
conclus
surviv
rate
studi
par
develop
countri
risk
adopt
chemotherapi
good
support
care
improv
surviv
rate
even
develop
countri
ha
sjakti
depart
child
health
jakarta
indonesia
backgroundobject
pediatr
acut
myeloid
leukemia
aml
still
big
problem
limit
resourc
countri
report
overal
surviv
os
surviv
ef
sever
effort
done
includ
chemoterapi
protocol
revis
sinc
improv
support
care
nt
bone
marrow
transplant
bmt
patient
receiv
protocol
aim
studi
evalu
result
new
revis
protocol
designmethod
retrospect
studi
pediatr
patient
cipto
mangunkusumo
hospit
cmh
data
gather
medic
record
analys
use
statist
program
patient
diagnos
aml
treat
revis
indonesia
nation
protocol
consist
block
induct
day
daunorubicin
day
cytarabin
block
intensif
day
high
dose
cytarabin
etoposid
evalu
induct
chemoterapi
done
bone
marrow
examin
remiss
determin
blast
cell
less
result
treat
patient
age
year
diagnosi
establish
morpholog
stain
less
half
use
leukem
immunophenotyp
patient
receiv
chemotherapi
patient
got
remiss
induct
patient
nt
get
remiss
patient
loss
follow
relaps
rate
time
relaps
rang
week
remiss
total
patient
die
patient
die
receiv
chemoterapi
die
chemotherapi
caus
death
mainli
due
sever
infect
treatment
relat
death
overal
surviv
ef
conclus
result
still
poor
regardless
protocol
modif
improv
support
care
obviou
need
strong
chemotherapi
bmt
risk
stratif
detail
patient
profil
must
risk
base
treatment
reduc
treatment
relat
death
e
supriyadi
ph
g
hematolog
dr
sardjito
hospit
health
nurs
faculti
universita
gadjah
mada
pediatr
yogyakarta
indonesia
vu
univers
medic
amsterdam
pediatr
amsterdam
netherland
backgroundobject
surviv
gap
childhood
cancer
develop
develop
countri
wide
childhood
acut
myeloid
leukemia
aml
develop
countri
estim
develop
countri
achiev
develop
implement
nation
protocol
pediatr
aml
indonesia
start
aim
studi
evalu
result
protocol
designmethod
medic
record
children
year
age
newli
diagnos
aml
octob
retrospect
review
diagnosi
aml
confirm
base
morpholog
histochem
examin
marrow
sampl
peripher
blood
surviv
analysi
perform
patient
treat
nation
aml
protocol
doxorubicin
cytarabin
etoposid
plu
tripl
drug
intrathec
methotrex
hydrocortison
aml
protocol
maspor
calgb
result
patient
diagnos
aml
patient
receiv
chemotherapi
patient
exclud
analysi
one
hundr
five
patient
receiv
nation
aml
protocol
receiv
aml
protocol
death
first
event
occur
patient
receiv
nation
protocol
protocol
caus
death
nation
protocol
infect
bleed
aml
unknown
protocol
caus
infect
bleed
aml
unknown
probabl
overal
surviv
patient
treat
nation
aml
protocol
wherea
significantli
lower
aml
protocol
group
conclus
nation
protocol
infect
major
factor
caus
death
gener
treatment
nation
aml
protocol
result
higher
surviv
rate
compar
aml
protocol
howev
overal
outcom
still
poor
improv
support
care
includ
blood
transfus
prevent
treatment
infect
like
key
success
treatment
aml
tamura
n
n
k
children
hospit
depart
hematolog
oncolog
kobe
citi
japan
univers
hospit
depart
pediatr
suita
japan
univers
hospit
depart
pedictr
kobe
japan
backgroundobject
dismal
prognosi
pediatr
acut
myeloid
leukemia
aml
relaps
hematopoiet
stem
cell
transplant
hsct
requir
explor
novel
strategi
prevent
relaps
azacitidin
aza
mainten
therapi
could
potenti
reduc
recurr
rate
present
case
children
aml
treat
aza
mainten
therapi
designmethod
retrospect
review
medic
record
patient
treat
aza
april
april
kobe
children
hospit
aza
mainten
therapi
regimen
compris
consecut
day
cycl
begin
around
day
patient
aml
result
patient
girl
aml
time
relaps
underw
third
hsct
receiv
cycl
aza
without
major
advers
event
month
hsct
month
discontinu
aza
remain
complet
remiss
cr
patient
girl
aml
monosomi
relaps
underw
second
hsct
aza
administ
although
elev
astalt
observ
revers
receiv
cycl
aza
remain
cr
month
patient
boy
aml
fail
achiev
cr
despit
two
cycl
induct
chemotherapi
subsequ
underw
hsct
state
nine
cycl
aza
given
without
advers
effect
current
therapi
cr
month
conclus
aza
mainten
therapi
feasibl
current
three
patient
cr
despit
characterist
encourag
data
warrant
larger
prospect
studi
assess
efficaci
safeti
aza
mainten
therapi
pediatr
patient
aml
c
tang
w
x
f
j
hospit
zhejiang
univers
school
medicin
depart
hangzhou
china
backgroundobject
acut
myeloid
leukemia
aml
less
common
hematopoiet
malign
children
poorli
defin
term
fusion
gene
karyotyp
minim
residu
diseas
mrd
outcom
assess
china
designmethod
one
hundr
children
aml
januari
june
admit
children
hospit
zhejiang
univers
school
medicin
treat
karyotyp
fusion
gene
mrd
detect
flow
cytometri
outcom
analyz
result
fusion
gene
detect
patient
patient
posit
fusion
gene
respect
ef
rate
children
apl
one
hundr
six
patient
receiv
formal
protocol
ef
os
rate
respect
ef
rate
patient
significantli
better
without
vs
p
patient
mll
rearrang
significantli
wors
without
vs
p
patient
success
karyotyp
result
ef
rate
good
intermedi
bad
karyotyp
group
respect
p
ef
patient
mrd
first
cycl
induct
therapi
significantli
better
p
conclus
children
aml
china
much
higher
proport
apl
western
countri
survial
rate
patient
apl
type
aml
low
mrd
level
first
cycl
induct
significantli
higher
aml
type
posit
worst
survial
patietn
mll
rearrang
indic
signific
impact
genet
heterogen
mrd
level
first
cycl
induct
outcom
tomizawa
k
h
n
k
h
center
child
health
develop
divis
leukemia
children
cancer
center
tokyo
japan
center
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
univers
depart
hematolog
oncolog
kyoto
japan
univers
graduat
school
medicin
depart
pediatr
osaka
japan
univers
medic
scienc
depart
pediatr
otsu
japan
univers
depart
human
health
scienc
kyoto
japan
children
medic
center
depart
hematologyoncolog
saitama
japan
kyushu
cancer
center
depart
pediatr
fukuoka
japan
children
hospit
depart
hematolog
oncolog
chiba
japan
citi
univers
hospit
depart
pediatr
tokyo
japan
children
hospit
depart
hematolog
oncolog
shizuoka
japan
women
children
hospit
depart
hematologyoncolog
osaka
japan
data
center
hematopoiet
cell
transplant
data
center
nagoya
japan
citi
hospit
depart
pediatr
kyoto
japan
backgroundobject
cytogenet
abnorm
signific
prognost
factor
acut
myeloid
leukemia
aml
standard
care
alloc
patient
aml
cytogenet
abnorm
allogen
hematopoiet
stem
cell
transplant
howev
controversi
whether
truli
improv
outcom
patient
designmethod
data
children
adolesc
age
year
receiv
first
first
second
remiss
extract
nationwid
hsct
registri
japan
societi
hematopoiet
cell
transplant
patient
congenit
abnorm
eg
syndrom
secondari
aml
andor
lack
cytogenet
data
exclud
defin
aml
complex
karyotyp
inv
andor
patient
inv
inelig
outcom
patient
retrospect
evalu
result
surviv
ef
overal
surviv
os
rate
ci
respect
patient
univari
analysi
cytogenet
subgroup
signific
impact
ef
os
p
rate
especi
fourteen
patient
show
extrem
poor
outcom
ef
os
addit
older
age
year
old
myeloabl
condit
irradi
grade
acut
diseas
gvhd
associ
inferior
os
donor
type
occurr
chronic
gvhd
affect
outcom
multivari
analysi
reveal
associ
increas
overal
mortal
hazard
p
conclus
heterogen
outcom
among
cytogenet
subgroup
outcom
patient
certain
subgroup
case
extrem
poor
even
remiss
develop
novel
therapi
urgent
requir
wang
blood
diseas
hospit
chines
academi
medic
scienc
cam
pediatr
blood
diseas
dapart
tianjin
china
backgroundobject
improv
diagnosi
treatment
alveolar
hemorrhag
designmethod
retrospect
analyz
blood
diseas
patient
alveolar
hemorrhag
januari
march
hospit
pediatr
depart
result
ct
scan
show
pulmonari
infect
everi
patient
alveolar
hemorrhag
patient
show
diffus
ground
appear
alveolar
hemorrhag
happen
diagnos
alveolar
hemorrhag
ct
scan
two
patient
suffer
septicemia
bleed
happen
progress
multipl
organ
failur
one
patient
suffer
stenotrophomona
maltophilia
anoth
one
suffer
streptococcu
miti
patient
dyspnea
hyoxemia
two
patient
oxyhemoglobin
satur
recov
anoth
two
sever
oxyhemoglobin
satur
less
dead
hemoglobin
reduc
patient
alveolar
hemorrhag
happen
antibiot
use
patient
high
dose
methylprednisolon
use
three
patient
high
dose
methylprednisolon
use
two
patient
one
dead
multipl
organ
failur
one
recoveri
anoth
one
patient
receiv
oxyhemoglobin
satur
declin
cure
last
receiv
three
cours
chemic
treatment
patient
four
patient
cure
four
patient
dead
conclus
alveolar
hemorrhag
pay
high
attent
patient
suffer
pulmonari
infect
septicemia
especi
patient
suffer
hemoptysi
dyspea
continu
decreas
hemoglobin
ct
scan
abnorm
high
dose
methylprednisolon
effect
treatment
n
yupensuk
h
k
p
p
medicin
pediatr
bangkok
thailand
backgroundobject
surviv
rate
pediatr
aml
approxim
develop
countri
wherea
outcom
still
inferior
develop
middl
low
incom
countri
treatment
relat
toxic
diseas
relaps
major
caus
death
compar
treatment
outcom
toxic
novel
intens
less
intens
chemotherapi
regimen
designmethod
retrospect
cohort
studi
children
diagnos
aml
treat
chemotherapi
alon
hospit
result
patient
median
age
year
diagnos
aml
eighteen
patient
treat
less
intens
induct
protocol
consist
idarubicin
day
cytarabin
day
twenti
patient
treat
novel
intens
indict
consist
idarubicin
day
cytarabin
day
group
treat
subsequ
three
consolid
intens
chemotherapi
remiss
rate
induct
higher
vs
group
statist
signific
p
median
follow
month
overal
surviv
higher
vs
group
statist
signific
p
sever
bacteri
fungal
infect
induct
significantli
differ
among
group
vs
conclus
intens
chemotherapi
show
higher
remiss
rate
similar
toxic
affect
diseas
overal
surviv
bone
marrow
transplant
good
support
care
crucial
pediatr
aml
treatment
h
abdel
rahman
say
r
abdel
n
el
e
cancer
cairo
chidren
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
cairo
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
cairo
chidren
cancer
hospit
egypt
patholog
cairo
egypt
cancer
cairo
chidren
cancer
hospit
egypt
radiodiagnosi
cairo
egypt
cancer
hospit
egypt
research
cairo
egypt
backgroundobject
aim
studi
report
respons
rate
toxic
profil
line
chemotherapi
gemcitabin
vinorelbin
gemvin
primari
refractoryrelaps
hl
year
period
designmethod
retrospect
analysi
includ
patient
receiv
salvag
gemvin
follow
abvd
radiotherapi
line
follow
ice
line
chemotherapi
patient
diagnos
treat
children
cancer
hospit
egypt
result
patient
regist
relaps
progress
diseas
receiv
ice
second
line
chemotherapi
fail
second
line
receiv
third
line
four
patient
exclud
analysi
receiv
type
chemotherapi
patient
receiv
gemvin
includ
studi
male
femal
mean
age
year
common
patholog
subtyp
nodular
sclerosi
one
patient
stage
stage
ii
stage
iii
stage
iv
major
high
risk
patient
sixteen
patient
late
relaps
year
earli
relaps
year
progressiverefractori
less
month
chemotherapi
cycl
rang
mean
thirteen
patient
respond
gemvin
underw
autolog
hematopoiet
stem
cell
transplant
progress
continu
treatment
palli
basi
eight
patient
die
due
diseas
progress
chemotherapi
toxic
year
overal
surviv
respond
patient
multivari
analysi
includ
sex
stage
risk
stratif
type
relaps
show
statist
signific
conclus
gemcitabin
vinorelbin
safe
given
line
chemotherapi
relaps
primari
refractori
hl
h
abdel
rahman
say
el
n
el
el
r
cancer
cairo
univers
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
sweif
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
center
research
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
cairo
univers
children
cancer
hospit
egypt
patholog
cairo
egypt
cancer
cairo
univers
children
cancer
hospit
egypt
radiodiagnosi
cairo
egypt
cancer
hospit
egypt
research
cairo
egypt
backgroundobject
aim
current
studi
report
epidemiolog
data
respons
rate
treatment
outcom
overal
surviv
os
anaplast
larg
cell
lymphoma
alcl
patient
year
period
designmethod
retrospect
studi
includ
newli
diagnos
alcl
patient
juli
till
decemb
children
cancer
hospit
egypt
cche
result
total
patient
enrol
repres
nhl
patient
treat
cche
within
period
time
major
male
mean
age
year
rang
patient
low
stage
ii
advanc
stage
iii
iv
eighteen
patient
extranod
diseas
alk
posit
patient
neg
follow
induct
chemotherapi
patient
achiev
complet
remiss
cr
partial
remiss
pr
stabl
diseas
sd
two
patient
die
induct
chemotherapi
stage
iv
diseas
statu
last
follow
show
patient
cr
relaps
diseas
progress
dp
lost
follow
fu
median
time
relaps
month
rang
four
patient
salvag
high
dose
hd
chemotherapi
ice
follow
autolog
hematopoiet
stem
cell
transplant
ahsct
die
dp
treatment
relat
mortal
trm
year
os
year
ef
median
fu
period
month
rang
month
multivari
analysi
includ
age
sex
stage
respons
chemotherapi
show
statist
signific
conclus
treatment
alcl
accord
children
oncolog
group
anhl
protocol
well
toler
relaps
patient
could
salvag
hd
chemotherapi
ahsct
g
ahm
h
n
r
cancer
hospit
egypt
cche
nation
cancer
institut
surgic
oncolog
cairo
egypt
medicin
helwan
univers
children
cancer
hospit
egypt
surgeri
cairo
egypt
cancer
hospit
egypt
cche
nation
cancer
institut
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
cche
radiolog
cairo
egypt
cancer
hospit
egypt
cche
research
cairo
egypt
backgroundobject
perfor
common
surgic
complic
pediatr
intestin
lymphoma
oper
mani
surgic
decis
debat
includ
extent
resect
feasibl
primari
anastomosi
aim
assess
outcom
surgic
manag
perfor
pediatr
intestin
lymphoma
designmethod
retrospect
analysi
data
juli
end
june
case
intestin
lymphoma
patient
present
develop
perfor
treatment
analys
risk
factor
perfor
type
manag
outcom
patient
year
old
result
studi
includ
patient
intestin
lymphoma
perfor
develop
patient
patient
burkitt
lymphoma
median
age
year
ileum
common
site
perfor
time
perfor
present
induct
n
mainten
n
relaps
primari
resect
anastomosi
done
patient
patient
resect
stoma
patient
hade
stoma
resect
resect
specimen
show
viabl
tumor
patient
viabl
tumor
n
chronic
inflamm
patient
median
delay
restart
chemotherapi
day
day
wound
infect
dehisc
common
complic
os
ef
perfor
patient
respect
compar
patient
statist
signific
differ
os
ef
group
conclus
perfor
advers
prognost
factor
surviv
pediatr
intestin
lymphoma
patientss
primari
resect
anastomosi
safe
option
complet
tumor
resect
feasibl
ahm
h
abdel
h
el
e
sohag
univers
clinic
oncolog
depart
sohag
egypt
cancer
univers
pediatr
oncolog
depart
cairo
egypt
cancer
univers
patholog
depart
cairo
egypt
backgroundobject
hodgkin
lymphoma
constitut
approxim
childhood
cancer
children
adolesc
hodgkin
lymphoma
achiev
overal
surviv
rate
convent
chemotherapi
alon
combin
chemotherapi
radiotherapi
nevertheless
low
stage
children
advanc
stage
hl
relaps
primari
refractori
diseas
aim
assess
outcom
children
adolesc
relapsingrefractori
hodgkin
lymphoma
nation
cancer
univers
designmethod
retrospect
analysi
period
extend
januari
decemb
includ
patient
relaps
primari
refractori
hodgkin
lymphoma
result
patient
includ
studi
patient
relaps
hl
primari
refractori
diseas
overal
surviv
rate
wors
primari
refractori
relaps
patient
p
valu
diseas
stage
relaps
found
statist
signific
overal
surviv
rate
p
valu
extranod
involv
wors
outcom
nodal
diseas
p
valu
three
year
os
rate
os
rate
three
year
ef
signific
differ
patient
respond
salvag
chemotherapi
cycl
respond
later
regard
event
free
surviv
rate
p
valu
age
gender
patholog
subtyp
presenc
b
symptom
initi
diagnosi
relaps
found
statist
signific
conclus
patient
primari
refractori
diseas
advanc
diseas
stage
relaps
extranod
involv
wors
outcom
earli
respons
salvag
chemotherapi
associ
better
outcom
k
r
univers
scienc
technolog
pediatr
irbid
jordan
faisal
specialist
hospit
research
center
pediatr
hematologyoncolog
riyadh
saudi
arabia
backgroundobject
nlphl
distinct
rare
subtyp
hodgkin
lymphoma
associ
progress
transform
germin
center
concurr
post
diagnosi
conduct
review
understand
present
outcom
diseas
tertiari
care
hospit
designmethod
medic
record
consecut
patient
diagnos
review
research
databas
maintain
data
prospect
fashion
surviv
pattern
evalu
via
surviv
curv
result
male
preponder
observ
boy
median
age
diagnosi
year
rang
cervic
lymph
node
commonli
involv
serolog
viral
hepat
b
c
hiv
neg
posit
one
patient
anterior
mediastin
mass
less
one
third
thorac
diamet
almost
half
stage
ii
follow
stage
stage
iii
stage
iv
treatment
given
abvd
first
line
chemotherapi
median
cycl
radiat
therapi
given
patient
part
line
treatment
two
patient
achiev
remiss
end
line
treatment
median
time
first
remiss
record
month
median
month
patient
aliv
last
review
februari
relaps
rate
patient
treatment
failur
achiev
five
year
event
free
surviv
one
relaps
treatment
failur
success
salvag
three
relaps
case
refer
stem
cell
transplant
sct
aliv
cr
post
transplant
none
patient
experienc
transform
germin
center
conclus
therapi
choic
sct
salvag
reason
therapeut
option
cohort
patient
e
ataseven
b
z
b
b
h
tepecik
research
train
hospit
depart
pediatr
hematolog
oncolog
izmir
turkey
backgroundobject
nhl
account
pediatr
cancer
children
studi
aim
evalu
clinic
character
treatment
outcom
nhl
case
treat
institut
designmethod
evalu
record
patient
nhl
retrospect
institut
demograph
clinic
featur
treatment
result
overal
surviv
os
event
free
surviv
ef
rate
evalu
result
hundr
thirti
six
patient
male
femal
evalu
retrospect
median
age
patient
year
year
median
durat
complaint
month
month
common
complaint
abdomin
pain
patient
abdomin
involv
patholog
subtyp
burkitt
lymphoma
bl
lymphoblast
lymphoma
diffus
larg
b
cell
lymphoma
dlbl
anaplast
larg
cell
lymphoma
alcl
patient
advanc
stage
diagnosi
stage
iii
stage
iv
patient
bone
marrow
metastas
one
patient
one
ataxia
telangiectasia
patient
treat
pog
comp
protocol
patient
treat
accord
bfm
protocol
eight
patient
die
treatment
tumor
lysi
post
oper
period
dissemin
ill
median
time
month
year
year
ef
order
os
respect
earli
stage
stage
year
ef
os
advanc
stage
year
ef
os
signific
differ
year
ef
accord
sex
fm
os
fm
differ
detect
accord
initi
ldh
level
year
ef
os
signific
differ
bl
differ
ef
os
year
ef
os
alcl
patient
differ
surviv
rate
patient
treat
bfm
comp
pog
protocol
lower
protocol
conclus
patient
ef
os
similar
studi
ef
os
rate
earli
stage
significantli
higher
advanc
stage
also
initi
ldh
level
promin
effect
prognosi
differ
literatur
alcl
patient
excel
prognosi
fb
b
h
professor
bezmialem
vakif
univers
pediatr
hematolog
oncolog
istanbul
turkey
patholog
istanbul
turkey
pediatr
surgeri
istanbul
turkey
pediatr
istanbul
turkey
univers
medic
faculti
patholog
istanbul
turkey
backgroundobject
irf
novel
oncogen
situat
next
immunglobulin
loci
show
better
prognosi
among
diffus
larg
b
cell
lymphoma
yr
old
boy
diagnos
diffus
larg
b
cell
lymphoma
presenc
posit
present
designmethod
yr
old
boy
hospit
symptom
acut
abdomen
one
month
last
wax
wane
abdomin
pain
constip
invagin
colon
detect
magnet
reson
imag
right
hemicolectomi
ileal
resect
carri
differenti
diagnosi
patholog
diffus
larg
b
cell
lymphoma
follicular
lymphoma
exist
result
follicular
pattern
b
type
lymphoma
infiltr
cd
bcl
posit
identifi
rearrang
detect
atyp
lymphoid
cell
fish
method
confirm
diagnosi
diffus
larg
b
cell
lymphoma
patient
stage
accord
lymphoma
stage
found
tumor
free
two
cycl
bfm
base
chemotherapi
conclus
posit
new
diagnost
marker
diffus
larg
b
cell
lymphoma
also
report
good
prognost
marker
surviv
patient
rel
improv
type
diffus
larg
b
cell
lymphoma
jy
choi
hy
kt
hj
hy
hs
research
seoul
nation
univers
colleg
medicin
depart
pediatr
seoul
republ
korea
backgroundobject
treatment
outcom
pediatr
lymphoma
improv
substanti
past
two
decad
patient
high
risk
relaps
diseas
still
show
poor
prognosi
role
high
dose
chemotherapi
hdc
autolog
stem
cell
transplant
controversi
much
data
sct
pediatr
lymphoma
designmethod
retrospect
studi
design
evalu
outcom
hdc
pediatr
patient
high
risk
relaps
lymphoma
decemb
decemb
patient
receiv
nitrosourea
bcnu
acnu
etoposid
cyclophosphamid
bec
aec
condit
regimen
result
total
patient
male
femal
evalu
median
age
rang
year
forti
four
patient
underw
achiev
complet
remiss
induct
chemotherapi
eight
patient
treat
relaps
patient
nkt
cell
lymphoma
plan
median
number
infus
cell
rang
x
patient
achiev
neutrophil
platelet
engraft
except
patient
die
septic
shock
hepat
diseas
vod
develop
patient
pulmonari
vod
occur
patient
receiv
acnu
bcnu
pneumon
suspect
patient
recov
seven
patient
relaps
die
diseas
progress
mortal
trm
occur
patient
pulmonari
vod
acut
respiratori
distress
syndrom
septic
shock
patient
overal
surviv
surviv
patient
hd
nhl
hd
nhl
respect
conclus
hdc
bec
aec
regimen
pediatr
high
risk
lymphoma
patient
show
favor
outcom
howev
treatment
modif
warrant
reducetrm
toxic
p
de
alarcon
em
p
f
c
p
p
j
illinoi
colleg
medicin
st
jude
children
research
hospit
depart
pediatr
peoria
usa
oncolog
guatemala
guatemala
manuel
de
jesu
rivera
oncolog
managua
nicaragua
nacion
de
benjamin
bloom
oncolog
san
salvador
el
salvador
jude
children
research
hospit
oncolog
memphi
usa
backgroundobject
surviv
ef
overal
surviv
os
hl
middl
countri
lmic
improv
still
mani
fail
therapi
chemotherapi
follow
stem
cell
rescu
cure
patient
therapi
alway
avail
lmic
rescu
children
ahopca
design
rescu
regimen
ifosphamid
carboplatin
etoposid
ice
report
preliminari
result
one
ahopca
center
designmethod
children
refractoryresist
rr
relaps
hl
treat
defin
rr
subject
achiev
respons
present
relaps
within
three
month
complet
therapi
earli
relaps
er
three
month
complet
therapi
late
relaps
lr
recur
one
year
complet
therapi
ice
regimen
consist
etoposid
day
carboplatin
day
ifosfamid
day
involv
field
radiotherapi
cgi
without
cycl
repeat
everi
day
four
six
cycl
respons
achiev
result
ahopca
center
treat
hl
rr
relaps
rr
lr
diseas
time
analysi
children
aliv
dead
abandon
therapi
lost
ef
cohort
os
ef
os
er
lr
respect
ef
rr
relaps
hl
differ
conclus
limit
data
conclud
children
late
relaps
hl
rescu
ice
base
regimen
set
lmic
children
rr
less
like
rescu
j
elhoudzi
e
hospit
moham
pediatr
hematolog
oncolog
marrakesh
morocco
hospit
moham
vi
pediatr
hematolog
oncolog
marrakesh
morocco
backgroundobject
hodgkin
lymphoma
hl
highli
curabl
malign
rare
malign
pediatr
popul
howev
constitut
approxim
lymphoma
present
childhood
common
malign
adolesc
young
adult
age
group
hodgkin
lymphoma
highli
sensit
chemotherapi
irradi
object
carri
epidemiolog
analysi
studi
clinic
histolog
aspect
evalu
therapeut
respons
marrakesh
designmethod
patient
biopsi
proven
hl
retrospect
review
depart
result
averag
age
year
children
male
cervic
lymphadenopathi
major
sign
reach
case
averag
consult
time
month
case
stage
ii
accord
classif
hl
type
common
case
presenc
gener
b
sign
found
case
patient
treat
accord
protocol
patient
favor
group
treat
vamp
cours
administ
everi
day
patient
advers
group
treat
cours
oppa
follow
cours
copp
given
everi
day
follow
radiotherapi
complet
remiss
obtain
case
patient
lost
follow
conclus
percentag
cr
could
improv
reduc
delay
diagnosi
rais
adher
treatment
ergurhan
ilhan
z
yildirim
g
h
b
vural
ec
z
n
bilimleri
univers
ankara
oncolog
hospit
pediatr
hematologyoncolog
ankara
turkey
uivers
faculti
medicin
pediatr
hematologyocolog
erzurum
turkey
bilimleri
dr
sami
ulu
hastanesi
pediatr
hematologyoncolog
ankara
turkey
bilimleri
univers
tepecik
educ
train
hospit
pediatr
hematologyocolog
turkey
faculti
medicin
pediatr
hematologyoncolog
edirn
turkey
faculti
medicin
pediatr
ocolog
bursa
turkey
bilimleri
sisli
hamidiy
etfal
hospit
pediatr
hematologyocolog
istabul
turkey
faculti
medici
pediatr
hematologyoncolog
mersin
turkey
faculti
medicin
pediatr
hematologyoncolog
istanbul
turkey
mender
faculti
medicin
pediatr
hematologyoncolog
aydin
turkey
bilimleri
ankara
oncolog
hospit
pediatr
hematolog
oncolog
ankara
turkey
backgroundobject
primari
subdiaphramat
hodgkin
lymphoma
hl
rare
entiti
account
hl
case
childhood
experi
entiti
limit
retrospect
review
seri
fewer
patient
adult
designmethod
childhood
hl
diagnos
treat
pediatr
hematolog
oncolog
center
turkey
among
patient
histolog
confirm
clinic
stage
iii
pure
subdiaphragmat
hl
includ
studi
medic
record
patient
retrospect
review
result
median
age
year
histolog
subtyp
nodular
lymphocyt
predomin
hodgkin
lymphoma
nlphl
mix
cellular
nodular
sclerosi
lymphocyt
predomin
unclassifi
b
symptom
patient
seven
patient
three
site
nodal
involv
present
patient
bulki
diseas
stage
distribut
ii
iv
one
due
addit
hepat
involv
median
hemoglobin
level
gmdl
albumin
level
gmdl
patient
treat
chemotherapi
base
abvd
equival
regimen
cycl
addit
patient
receiv
radiotherapi
gy
abdomen
complet
respons
achiev
patient
except
one
develop
relap
eight
month
initi
treatment
median
time
patient
year
rang
year
patient
die
due
diseas
develop
secondari
neoplasia
conclus
even
largest
childhood
pure
subdiaphramat
hodgkin
lymphoma
seri
literatur
small
number
patient
hard
estim
prognost
factor
effect
surviv
studi
suggest
outcom
pure
infradiaphragmat
hl
wors
supradiapragmat
counterpart
fatima
rc
pediatr
oncolog
lahor
pakistan
medic
centr
lahor
pakistan
backgroundobject
studi
aim
assess
treatment
outcom
children
biopsi
proven
hodgkin
lymphoma
discuss
variou
factor
lead
poor
outcom
compar
develop
countri
designmethod
retrospect
studi
done
shaukat
khanum
research
hospit
lahor
decemb
decemb
data
regard
age
stage
histopatholog
treatment
outcom
impact
delay
present
collect
analyz
patient
treat
abvd
regimen
result
total
patient
analyz
age
rang
includ
f
ratio
patient
present
advanc
stage
stage
ii
present
histopatholog
examin
show
mix
cellular
nodular
sclerosi
lymphocyt
predomin
lymphocyt
deplet
case
wherea
report
specifi
subtyp
bone
marrow
involv
patient
total
complet
treatment
treatment
left
medic
advic
lama
expir
due
sepsi
progress
diseas
conclus
surviv
fair
expir
mortal
reduc
earli
diagnosi
aggress
control
strategi
combat
complic
develop
countri
late
referr
strongli
associ
metastat
diseas
prognosi
significantli
improv
public
awar
seek
earli
treatment
establish
safe
effect
share
care
oncolog
pathway
multidisciplinari
team
approach
provid
strong
social
support
intens
psychosoci
counsel
effici
run
day
care
oncolog
patient
complianc
improv
significantli
fedorova
v
n
research
center
pediatr
hematolog
immunolog
clinic
research
minsk
belaru
research
center
pediatr
hematolog
immunolog
research
minsk
belaru
research
center
pediatr
hematolog
immunolog
clinic
laboratori
minsk
belaru
backgroundobject
aim
studi
defin
epidemiolog
venou
thrombosi
vt
children
adolesc
young
adult
lymphoma
identifi
thrombot
risk
factor
vt
prognost
valu
designmethod
review
medic
record
lymphoma
patient
hodgkin
lymphoma
hl
lymphoma
nhl
age
year
median
year
diagnos
lymphoma
risk
thrombot
factor
assess
use
binari
cox
regress
univari
multivari
model
calcul
odd
ratio
ci
result
patient
ci
diagnos
vt
total
thrombot
event
incid
vt
nhl
patient
ci
higher
hl
patient
ci
p
age
older
year
ci
p
lymphoblast
lymphoma
subtyp
ci
p
independ
associ
occurr
vt
patient
nhl
hl
group
case
vt
detect
patient
older
year
risk
factor
predispos
patient
hl
vt
bulki
diseas
p
presenc
vt
influenc
os
nhl
patient
neg
impact
os
hl
patient
se
versu
se
p
conclus
cumul
incid
vt
nhl
patient
higher
hl
patient
age
older
year
independ
thrombot
risk
factor
nhl
patient
age
older
year
bulki
diseas
increas
risk
vt
hl
patient
vt
occurr
decreas
os
young
hl
patient
prophylact
anticoagul
high
thrombot
risk
patient
might
warrant
goga
r
bg
cl
albert
luthuli
central
nelson
r
mandela
school
univers
natal
paediatr
haematolog
oncolog
dept
paediatr
child
health
durban
south
africa
backgroundobject
anaplast
larg
cell
lymphoma
alcl
account
paediatr
lymphoma
area
high
tuberculosi
tb
burden
lymphoma
often
misdiagnos
tb
diagnosi
delay
sought
describ
patient
characterist
treatment
respons
surviv
patient
alcl
singl
centr
designmethod
retrospect
review
patient
alcl
januari
decemb
result
eighteen
patient
diagnos
fifteen
year
period
male
femal
distribut
eighteen
patient
black
patient
age
two
twelv
year
two
patient
human
immunodefici
viru
posit
two
patient
stage
diseas
patient
stage
diseas
half
patient
stage
diseas
aliv
half
lost
ltfu
patient
treat
nhl
bfm
protocol
ten
patient
stage
diseas
lost
die
within
month
diagnosi
progress
diseas
relaps
aliv
alk
statu
posit
patient
aliv
neg
patient
dead
ltfu
unknown
patient
dead
ltfu
six
patient
stage
diseas
treat
tb
month
prior
diagnosi
anoth
patient
delay
month
stage
diseas
present
wide
rang
sign
includ
pleural
effus
tender
lymphadenopathi
bone
lesion
gibbu
ascit
signific
abdomin
adenopathi
conclus
patient
stage
diseas
poor
outcom
due
delay
diagnosi
incorrectli
treat
tb
intens
public
awar
earli
warn
sign
clinician
educ
enabl
earlier
diagnosi
need
improv
surviv
e
guler
g
b
v
univers
medic
faculti
pediatr
hematolog
oncolog
antalya
turkey
univers
medic
faculti
patholog
antalya
turkey
univers
medic
park
hospit
pediatr
hematolog
oncolog
istanbul
turkey
backgroundobject
evalu
clinic
find
patholog
characterist
treatment
regimen
outcom
lymphoma
nhl
patient
treat
institut
designmethod
retrospect
analyz
demograph
characterist
clinic
featur
histopatholog
find
diseas
stage
chemotherapi
regimen
outcom
nhl
patient
treat
januari
decemb
result
male
femal
median
age
year
malefemal
ratio
common
present
symptom
abdomin
distens
common
histopatholog
subtyp
burkitt
lymphoma
follow
lymphoblast
lymphoma
n
dlbcl
alcl
n
malt
lymphoma
respect
seventeen
patient
earli
stage
stage
ii
patient
stage
iii
patient
stage
iv
diseas
sixteen
patient
bone
marrow
patient
cn
involv
initi
primari
tumor
locat
site
abdomen
head
neck
region
thorax
patient
lymphoblast
lymphoma
treat
bfm
regimen
patient
bldlbcl
treat
lmb
lmb
bfm
nhl
regimen
median
time
month
overal
surviv
os
surviv
ef
patient
respect
patient
progress
diseas
acut
infect
lost
ten
patient
relaps
median
relaps
time
month
surviv
rate
significantli
higher
patient
earli
stage
diseas
p
ef
stage
iii
iv
respect
signific
relationship
age
gender
histolog
type
chemotherapi
regimen
surviv
rate
conclus
surviv
rate
low
advanc
diseas
prognosi
improv
better
support
care
awar
earli
recognit
symptom
cancer
k
gyurina
c
debrecen
dept
pediatr
debrecen
hungari
backgroundobject
applic
contemporari
combin
chemotherapi
regimen
result
excel
treatment
outcom
measur
major
pediatr
lymphoma
nhl
relaps
rr
case
rel
rare
associ
poor
surviv
figur
rituximab
introduc
first
target
therapi
within
frame
clinic
trial
prove
benefici
pediatr
patient
hr
diffus
larg
lymphoma
dlbcl
designmethod
perform
retrospect
analysi
patient
nhl
admit
divis
pediatr
depart
pediatr
univers
debrecen
data
obtain
institut
electron
databas
nation
pediatr
oncolog
regist
treatment
regiment
hungarian
pediatr
oncolog
group
appli
product
use
obtain
approv
nation
pharmaceut
institut
result
patient
diagnos
lymphoma
hodgkin
lymphoma
nhl
mean
age
patient
yr
nine
patient
burkitt
lymphoma
bl
lymphoblast
lymphoma
dlbcl
case
anaplast
lymphoma
cutan
lymphoma
angioimmunoblast
lymphoma
al
margin
zone
lymphoma
cd
patient
treat
protocol
sinc
lmb
protocol
use
patient
dlbcl
treat
use
rituximab
r
patient
al
treat
chop
cycl
case
castleman
diseas
siltuximab
appli
two
patient
relaps
matur
nhl
receiv
obinutuzumab
eighteen
patient
aliv
first
remiss
patient
die
bl
dlbcl
conclus
treatment
result
approach
standard
industri
countri
target
treatment
modal
introduc
conjunct
combin
chemotherapi
regimen
appli
success
pediatr
cohort
larg
multicentr
clinic
trial
may
contribut
develop
optim
treatment
pediatr
nhl
hamoda
h
e
r
n
cancer
univers
children
cancer
hospit
egypi
pediatr
oncolog
cairo
egypt
univers
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
nation
cancer
cairo
univers
children
cancer
hospit
egypt
patholog
cairo
egypt
nation
cancer
cairo
univers
children
cancer
hospit
egypt
radiodiagnosi
cairo
egypt
cancer
hospit
egypt
e
depart
clinic
children
cancer
hospit
egypt
cairo
egypt
backgroundobject
lymphoma
nhl
consist
complex
group
cancer
aris
mainli
b
lymphocyt
case
occasion
lymphocyt
nhl
usual
develop
lymph
node
nodal
lymphoma
aris
tissu
almost
anywher
bodi
extranod
lymphoma
treatment
lymphoma
nhl
exampl
success
therapi
cancer
children
cure
rate
approxim
unfortun
relaps
nhl
dismal
prognosi
customari
treatment
highli
toxic
chemotherapi
follow
hematopoiet
stem
cell
transplant
hsct
aim
work
analyz
prognost
factor
treatment
outcom
relaps
matur
b
cell
nhl
treat
children
cancer
hospit
accord
lmb
protocol
designmethod
retrospect
studi
includ
patient
age
year
less
initi
diagnos
matur
b
cell
nhl
relaps
follow
initi
chemotherapi
year
period
juli
juli
result
thirti
patient
relaps
mean
age
year
rang
male
femal
patholog
burkitt
lymphoma
burkitt
leukemia
dlbcl
pmlbl
relaps
site
singl
organ
multipl
organ
relaps
patient
stage
iii
iv
un
seventi
percent
patient
receiv
salvag
chemotherapi
best
support
care
follow
relaps
salvag
chemotherapi
ice
os
ef
year
os
ef
respect
conclus
relaps
matur
b
cell
nhl
dismal
outcom
late
relaps
singl
organ
time
relaps
offer
better
chanc
surviv
follow
high
dose
chemotherapi
hematopoiet
stem
cell
transplant
hjort
p
en
h
um
b
ts
tb
olav
trondheim
univers
hospit
children
clinic
trondheim
norway
depart
clinic
molecular
medicin
trondheim
norway
olav
trondheim
univers
hospit
cancer
clinic
trondheim
norway
olav
trondheim
univers
hospit
depart
hematolog
trondheim
norway
backgroundobject
phosphatas
regener
liver
implic
oncogenesi
hematolog
solid
cancer
express
increas
metastat
potenti
invas
associ
poor
prognosi
studi
aim
show
possibl
oncogen
role
classic
hodgkin
lymphoma
chl
designmethod
express
measur
chl
patient
immunohistochemistri
gene
express
analyz
microdissect
malign
cell
knock
chl
cell
line
use
small
molecular
inhibitor
investig
prolifer
migrat
cytokin
product
result
protein
express
patient
sampl
three
differ
gene
express
dataset
significantli
overexpress
compar
normal
control
knockdown
reduc
prolifer
viabil
express
cell
thienopyridon
small
molecul
inhibitor
reduc
prolifer
affect
secret
enhanc
signal
stimul
partial
rescu
prolifer
cell
knockdown
knockdown
reduc
migrat
cell
conclus
overexpress
subset
chl
patient
inhibit
increas
cytokin
product
reduc
migrat
prolifer
viabil
effect
could
mediat
regul
molecul
feedback
loop
mediat
activ
point
role
pathogenesi
hodgkin
lymphoma
could
possibl
new
drug
target
inc
e
r
e
h
k
f
n
eylul
univers
institut
oncolog
pediatr
oncolog
izmir
turkey
eylul
univers
faculti
medicin
radiat
oncolog
izmir
turkey
eylul
univers
faculti
medicin
patholog
izmir
turkey
eylul
univers
faculti
medicin
radiodiagnost
izmir
turkey
eylul
univers
faculti
medicin
nuclear
medicin
izmir
turkey
eylul
univers
faculti
medicin
pediatr
surgeri
izmir
turkey
eylul
univers
faculti
medicin
otorhinolaringolog
izmir
turkey
eylul
univers
institut
oncolog
pediatr
current
address
univers
econom
izmir
turkey
eylul
univers
institut
oncolog
pediatr
current
address
baskent
univers
faculti
medicin
ankara
turkey
backgroundobject
evalu
epidemiolog
clinic
patholog
characterist
treatment
outcom
hodgkin
lymphoma
hl
case
treat
institut
designmethod
patient
review
retrospect
stage
histopatholog
rye
classif
use
diagnost
evalu
method
lymph
node
biopsi
lung
thorax
ct
abdominopelv
usg
ct
advanc
diseas
bone
marrow
aspirationbiopsi
bone
scintigraphi
sinc
use
standard
coppabvd
base
regimen
start
use
gpoh
protocol
low
dose
radiotherapi
administ
patient
cr
chemo
higher
dose
radiotherapi
deliv
patient
residu
diseas
progress
diseas
result
eighti
patient
elig
median
age
major
histolog
subtyp
nodular
sclerosi
mixt
cellular
present
case
stage
distribut
stage
stage
number
involv
lymph
node
region
case
common
nodal
site
involv
cervic
mediastin
bulki
diseas
present
mediastinalperipher
present
children
extranod
diseas
lung
liver
epidur
number
chemotherapi
cours
cours
stage
cours
stage
cours
stage
patient
except
case
stageib
stageiia
stageiib
stageiiisb
stageivb
die
rt
time
come
irradi
median
time
year
ef
rate
os
os
rate
os
rate
found
significantli
differ
diseas
ef
rate
found
differ
also
patient
receiv
gpoh
regimen
year
os
rate
year
os
year
year
ef
year
year
ef
conclus
treatment
result
accept
literatur
similar
os
ef
rate
obtain
coppabvd
base
regimen
find
support
usag
new
safe
treatment
regimen
hl
prognost
factor
could
determin
owe
limit
patient
number
r
khedr
l
cancer
cairo
univers
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
backgroundobject
although
interim
positron
emiss
tomographi
pet
may
inform
therapeut
decis
risk
stratif
diagnosi
allow
earlier
potenti
better
modif
treatment
hl
studi
aim
identifi
prognost
role
ipet
chip
predict
prognosi
hl
center
designmethod
retrospect
singl
center
studi
total
patient
newli
diagnos
hodgkin
lymphoma
enrol
patient
elig
analysi
ipet
chip
score
pet
scan
perform
baselin
two
cycl
chemotherapi
treatment
chang
accord
result
interim
scan
childhood
hodgkin
intern
prognost
score
chip
evalu
log
rank
test
use
compar
ef
chip
result
scan
patient
elig
analysi
ipet
chip
score
patient
score
posit
neg
year
overal
surviv
os
patient
interim
posit
scan
patient
interim
neg
scan
p
surviv
ef
rate
whole
studi
popul
patient
interim
posit
scan
patient
interim
neg
scan
p
ef
patient
chip
patient
chip
patient
chip
patient
chip
limit
number
patient
conclus
prognost
role
valid
use
interim
pet
scan
respons
confirm
strongli
relat
treatment
outcom
present
studi
howev
use
chip
good
inexpens
approach
predict
risk
patient
hl
may
improv
abil
tailor
therapi
risk
factor
known
diagnosi
kozlov
p
l
e
k
n
l
b
gorbacheva
memori
institut
pediatr
hematolog
transplant
first
pavlov
state
medic
univers
st
petersburg
bone
marrow
transplant
russia
backgroundobject
approach
manag
refractori
relaps
lymphoprolif
disord
ld
chang
becom
effect
due
develop
immunotherapi
role
check
point
inhibitor
extens
investig
variou
oncolog
diseas
role
nivolumab
children
ld
elucid
designmethod
sixteen
children
ld
includ
studi
median
age
year
rang
hodgkin
lymphoma
hl
diagnos
children
lymphoma
patient
primari
mediastin
larg
lymphoma
extranod
lymphoma
nasal
type
lymphoma
median
number
previou
chemotherapi
line
rang
refractori
cours
diseas
diagnos
children
relaps
diagnos
nivolumab
administ
mgkg
biweekli
median
cycl
rang
patient
nivolumab
use
monotherapi
children
combin
chemotherapi
bendamustin
hydrochlorid
gemcitabin
result
overal
respons
demonstr
patient
complet
respons
partial
respons
stabil
progress
progress
diagnos
patient
fifteen
children
aliv
median
day
rang
among
children
remain
remiss
sever
clinic
signific
advers
effect
ae
regist
includ
immun
cytopenia
asept
mening
ae
success
cure
nivolumab
discontinu
children
due
ae
conclus
nivolumab
effect
rel
safe
option
children
refractori
relaps
hodgkin
lymphoma
lee
b
tc
univers
hospit
divis
pediatr
depart
pediatr
singapor
singapor
backgroundobject
major
mediastin
mass
children
malign
complex
manag
risk
compress
surround
structur
caus
airway
compromis
vascular
compress
effus
mani
children
manag
intens
care
unit
icu
henc
sought
evalu
local
epidemiolog
malign
mediastin
mass
children
natur
clinic
present
identifi
factor
associ
icu
admiss
patient
need
intens
care
may
identifi
earli
designmethod
retrospect
review
case
record
children
year
age
present
nation
univers
hospit
singapor
malign
mediastin
mass
patient
evalu
studi
collect
data
present
symptom
clinic
sign
radiolog
investig
need
urgent
intervent
correl
factor
admiss
pediatr
icu
result
lymphoma
common
diagnosi
compris
children
patient
neuroblastoma
patient
tumor
patient
acut
lymphoblast
leukemia
overal
patient
admit
icu
factor
significantli
associ
icu
admiss
fever
p
dyspnea
p
stridor
p
pleural
effus
p
pericardi
effus
p
need
pleural
tap
p
need
pericardi
tap
p
factor
reach
statist
signific
associ
chest
pain
lymphadenopathi
night
sweat
loss
appetit
weight
neurolog
symptom
superior
obstruct
radiolog
evid
tracheal
compress
conclus
malign
mediastin
mass
children
institut
rang
leukemia
lymphoma
tumor
neuroblastoma
children
risk
cardiorespiratori
collaps
mani
requir
intens
care
identifi
factor
associ
icu
admiss
aim
earli
identif
intervent
case
l
n
b
g
e
univers
gdansk
depart
hematolog
oncolog
gdansk
poland
univers
wroclaw
depart
pediatr
hematolog
bone
marrow
transplant
wroclaw
poland
backgroundobject
primari
acquir
immunodefici
promot
develop
lymphoma
overtli
immunocompet
patient
diagnos
inflammatori
bowel
diseas
ibd
immunosuppress
treatment
eg
methotrex
thiopurin
necrosi
factor
tnf
increas
risk
lymphoprolif
diseas
ld
viral
infect
includ
latent
viru
ebv
particularli
patient
immunodefici
similar
risk
effect
designmethod
boy
diagnos
juli
diffus
larg
lymphoma
dlbcl
depart
pediatr
hematolog
oncolog
gdansk
first
age
patient
suffer
crohn
diseas
cd
sinc
one
year
old
clinic
cours
cd
time
sever
result
sever
surgeri
includ
excis
intestin
ileostomi
receiv
immunosuppress
drug
azathioprin
steroid
methotrex
past
one
year
lymphoma
diagnos
develop
sever
ebv
infect
dlbcl
localis
bone
spleen
mediastinum
stage
iii
second
age
patient
undefin
immunodefici
suffer
chronic
ebv
infect
develop
dlbcl
localis
abdomen
peripher
lymph
node
stage
iii
result
first
patient
treat
accord
protocol
receiv
cop
induct
sinc
treatment
interrupt
due
excess
neurotox
intrathec
chemotherapi
gastrotox
lack
posit
respons
treatment
six
cycl
introduc
respond
partial
remiss
therefor
radiotherapi
residu
mass
plan
hip
bone
mediastinum
second
patient
treat
accord
protocol
inter
rituximab
remain
complet
remiss
conclus
experi
indic
immunodefici
immunosuppress
treatment
concomit
ebv
infect
risk
factor
develop
lymphoprolif
disord
mahajan
r
v
r
n
v
p
g
j
apollo
hospit
pediatr
oncolog
new
delhi
india
super
sepcial
hospit
pediatr
oncolog
new
delhi
india
ganga
ram
hospit
pediatr
oncolog
new
delhi
india
apollo
hospit
pediatr
oncolog
new
delhi
india
gandhi
cancer
institut
pediatr
oncolog
new
delhi
india
india
institut
medic
pediatr
oncolog
new
delhi
india
cancer
sansthan
medic
pediatr
oncolog
patna
india
india
institut
medic
scienc
pediatr
new
delhi
india
georg
medic
univers
pediatr
lucknow
india
pediatr
oncolog
chennai
india
gandhi
cancer
pediatr
oncolog
new
delhi
india
saran
children
hospit
pediatr
new
delhi
india
india
medic
scienc
radiolog
new
delhi
india
india
institut
medic
scienc
pediatr
oncolog
new
delhi
india
saran
children
hospit
pediatr
new
delhi
india
backgroundobject
vast
improv
seen
hodgkin
lymphoma
hl
outcom
worldwid
larg
attribut
lesson
learnt
collabor
prospect
studi
hitherto
difficult
implement
india
due
lack
formal
fund
health
care
dynam
lead
larg
differ
patient
treatment
first
attempt
studi
prospect
epidemiolog
outcom
hl
children
adolesc
treat
uniformli
per
strategi
designmethod
abvd
chemotherapi
use
fashion
patient
earli
stage
stage
iia
receiv
four
cycl
abvd
advanc
stage
stage
iib
iii
iv
six
cycl
respons
assess
two
cycl
radiat
limit
patient
bulki
diseas
suboptim
respons
two
cycl
event
death
progressionrelaps
secondari
malign
treatment
abandon
result
recruit
commenc
august
conclud
februari
patient
enrol
centr
patient
per
centr
median
patient
median
age
year
male
younger
year
receiv
antituberculosi
treatment
prior
diagnosi
hl
subtyp
mix
cellular
nodular
sclerosi
other
unspecifi
patient
advanc
stage
stage
distribut
ii
iii
iv
b
symptom
bulki
diseas
till
date
event
death
progress
diseaserelaps
abandon
treatment
os
ef
respect
median
follow
month
conclus
studi
demonstr
feasibl
conduct
prospect
multicent
studi
absenc
formal
fund
childhood
cancer
india
provid
valuabl
high
qualiti
epidemiolog
inform
childhood
hl
abandon
could
significantli
reduc
ongo
provid
matur
data
outcom
help
guid
futur
practic
research
jp
meena
ak
ms
r
india
institut
medic
scienc
depart
divis
pediatr
oncolog
new
delhi
india
india
institut
medic
scienc
depart
pediatr
new
delhi
india
backgroundobject
lymphoma
nhl
aggress
malign
children
outcom
improv
past
decad
although
account
childhood
cancer
less
inform
clinic
present
outcom
avail
india
object
studi
clinic
present
outcom
children
year
nhl
centr
designmethod
retrospect
analyz
record
children
diagnos
nhl
centr
august
june
follow
may
result
median
age
time
diagnosi
year
rang
abdomin
distens
abdomin
lump
commonest
present
featur
occur
follow
fever
weight
loss
patient
advanc
stage
stage
iiiiv
diseas
present
primari
present
extranod
nodal
combin
bl
common
subtyp
follow
lymphoma
diffus
larg
lymphoma
dlbcl
anaplast
lymphoma
alcl
three
patient
take
treatment
median
patient
month
month
nineteen
patient
achiev
remiss
four
progress
diseas
surviv
ef
rate
studi
ef
age
group
year
vs
year
vs
log
st
judemurphi
stage
signific
log
ef
significantli
differ
sex
group
diseas
lactat
dehydrogenas
ldh
level
present
featur
conclus
cohort
patient
nhl
show
characterist
similar
report
develop
countri
nhl
occur
younger
age
higher
incid
bl
outcom
patient
year
poor
outcom
nhl
compar
centr
world
megalakaki
hospit
hematolog
piraeu
greec
backgroundobject
hodgkin
lymphoma
adolesc
young
adult
consid
curabl
diseas
wide
recogn
howev
particular
group
patient
pt
present
sever
health
handicap
name
late
effect
survivor
great
import
eg
second
malign
wherea
other
carri
mortal
risk
patient
affect
qualiti
life
paper
present
follow
young
patient
success
treat
hodgkin
lymphoma
designmethod
methodpati
patient
age
year
old
male
femal
histolog
subtyp
classic
hl
nodular
scleros
mix
cellular
nodular
stage
stage
ii
iii
iv
treat
abvd
beacoppesc
mopp
eleven
pt
relaps
receiv
chemotherapi
mini
beam
dhap
autolog
stem
cell
transplant
receiv
radiotherapi
patient
success
treat
remain
year
sinc
last
treatment
extend
median
year
eldest
patient
result
patient
visit
haematolog
depart
least
per
year
follow
eventssitu
record
pt
infertil
andor
sexual
dysfunct
women
men
metabol
disord
cardiovascular
event
thyroid
dysfunct
bone
necrosi
second
primari
malign
respiratori
dysfunct
patient
heavili
treat
present
sever
problem
moreov
pt
ask
report
minor
psycholog
problem
partli
affect
social
behavior
welcom
referr
psycholog
depart
conclus
result
confirm
half
patient
treat
hodgkin
lymphoma
suffer
either
minor
sever
effect
group
doctor
special
nurs
hospit
treat
patient
malign
help
lymphoma
hodgkin
malign
survivor
cope
live
minami
k
kurashiki
central
hospit
okayama
japan
surgeri
kurashiki
central
hospit
okayama
japan
backgroundobject
dumbbel
tumor
tumor
connect
two
region
epidur
intradur
intramedullari
although
neurogen
tumor
known
tend
shape
dumbbel
rare
lymphoma
children
designmethod
report
case
b
lymphoblast
lymphoma
result
case
boy
waist
back
pain
gait
disturb
day
ct
imag
reveal
tumor
surround
vertebr
bodi
tumor
dumbbel
tumor
invad
paravertebr
bodi
spinal
canal
multipl
bone
metastas
neuroblastoma
suspect
prepar
biopsi
start
dexamethason
dex
reduc
edema
inflamm
associ
spinal
cord
compress
could
walk
immedi
day
start
dex
tumor
biopsi
mibg
scintigraphyt
detect
abnorm
accumul
vma
hva
urin
increas
upon
ct
imag
paravertebr
bodi
tumor
shrunk
markedli
metastat
lesion
disappear
discontinu
dex
follow
progress
tumor
tumor
increas
gradual
volum
needl
biopsi
perform
day
first
visit
tumor
biopsi
demonstr
lymphocyt
fine
nuclear
chromatin
diffus
numer
histiocyt
phagocyt
nuclear
dust
tumor
cell
stain
posit
tdt
howev
neg
mpo
tumor
final
diagnos
case
intramedullari
invas
observ
imag
atyp
lymphocyt
found
cerebrospin
fluid
stage
iv
cn
posit
tumor
treat
accord
modifi
protocol
conclus
report
rare
case
present
dumbbel
tumor
consid
differenti
diagnosi
dumbbel
tumor
mf
ml
wa
af
rm
ah
g
r
sa
welfar
teach
baghdad
colleg
iraq
depart
pediatr
baghdad
iraq
depart
cellular
biotechnolog
sapienza
univers
rome
itali
welfar
teach
hospit
depart
baghdad
iraq
univers
depart
experiment
rome
itali
offic
gimema
foundat
rome
itali
backgroundobject
sinc
januari
adapt
protocol
implement
children
welfar
teach
hospit
cwth
baghdad
treatment
children
lymphoma
nhl
first
experi
demonstr
efficaci
feasibl
treatment
iraq
os
ef
respect
adjust
made
attempt
reduc
toxic
report
outcom
second
cohort
children
nhl
treat
compar
result
obtain
previou
studi
designmethod
patient
year
nhl
includ
modif
iraqi
protocol
steroid
fraction
cyclophosphamid
second
cop
critic
patient
doxorubicin
omiss
patient
complet
remiss
cr
cop
result
total
children
regist
male
femal
median
age
year
stage
diseas
stage
iii
stage
iv
bone
marrow
cn
involv
six
patient
die
prior
therapi
refus
treatment
remain
patient
assign
three
therapeut
b
c
one
hundr
obtain
cr
cop
die
treatment
abandon
os
ef
ci
ci
respect
statist
signific
differ
term
os
ef
observ
two
cohort
vs
vs
vs
respect
conclus
iraqi
adapt
protocol
confirm
efficaci
feasibl
treatment
children
cwth
baghdad
howev
mortal
remain
high
requir
protocol
adapt
moschovi
c
n
kapodistrian
univers
athen
depart
pediatr
athen
greec
backgroundobject
mix
cellular
hodgkin
diseas
hd
subtyp
classic
hd
constitut
second
common
type
case
hd
mostli
observ
patient
either
viru
ebv
human
immunodefici
viru
hiv
infect
less
inherit
rate
compar
subtyp
present
two
ident
case
among
sibl
differ
outcom
designmethod
two
sibl
girl
boy
present
mix
cellular
hodgkin
diseas
histolog
subtyp
stage
iii
locat
diseas
biopsi
specimen
neg
ebv
infect
appar
differ
two
case
present
age
girl
diagnos
age
year
old
boy
age
year
old
receiv
chemotherapi
girl
achiev
remiss
chemotherapi
boy
receiv
initi
chemotherapi
due
relaps
diseas
chemotherapi
radiotherapi
ad
succumb
refractori
diseas
result
two
case
sibl
histolog
subtyp
diseas
locat
differ
age
onset
eventu
differ
outcom
girl
receiv
chemotherapi
accord
siop
hd
protocol
till
first
remiss
year
diagnosi
contrast
boy
poor
outcom
conclus
consid
case
ident
anatom
histolog
characterist
also
neg
ebv
infect
conclud
differ
age
onset
subtyp
hd
differ
gender
play
crucial
role
outcom
local
genet
predispos
factor
may
contribut
famili
hd
case
moschovi
kapodistrian
univers
athen
depart
pediatr
athen
greec
backgroundobject
childhood
cancer
survivor
increas
incid
develop
second
cancer
develop
third
cancer
even
uncommon
survivor
popul
case
present
third
metachron
cancer
case
good
outcom
designmethod
boy
year
old
diagnos
diffus
small
cell
non
cleav
non
hodgkin
lymphoma
nasopharynx
receiv
chemotherapi
achiev
remiss
three
year
diagnosi
recurr
lymphoma
primari
site
achiev
second
remiss
chemotherapi
local
radiotherapi
seventeen
year
first
diagnosi
lymphoma
follicular
thyroid
cancer
diagnos
follow
total
thyroidectomi
radiotherapi
radioact
year
later
third
primari
cancer
appear
tongu
complain
persist
ulcer
tongu
squamou
cell
carcinoma
diagnos
surgic
resect
lesion
held
follow
chemotherapi
radiat
therapi
imrt
patient
achiev
remiss
result
patient
surviv
three
metachron
primari
tumor
develop
long
stabl
remiss
lymphoma
thyroid
cancer
also
remiss
squamou
cell
carcinoma
year
conclus
popul
childhood
cancer
survivor
increas
possibl
third
cancer
lead
awar
chemotherapi
radiotherapi
increas
risk
new
primari
cancer
also
genet
predisposit
could
also
interfer
signific
risk
case
mt
nguyen
tt
ttt
thh
hospit
ho
chi
vietnam
depart
hematolog
oncolog
ho
chi
minh
vietnam
hospit
ho
chi
vietnam
depart
patholog
ho
chi
minh
vietnam
hospit
depart
pediatr
oncolog
ho
chi
minh
vietnam
transfus
hematolog
hospit
outpati
depart
ho
chi
minh
vietnam
backgroundobject
associ
viru
ebv
infect
lymphoma
document
numer
report
literatur
context
provid
addit
support
role
ebv
lymphoma
order
strategi
earli
diagnosi
appropri
intervent
patient
designmethod
conduct
cohort
studi
use
registr
databas
children
ebv
infect
children
hospit
primari
secondari
health
center
diagnosi
lymphoma
obtain
registr
databas
hospit
children
cancer
south
vietnam
link
case
ebv
databas
use
uniqu
person
identif
includ
patient
parent
full
name
date
birth
physic
resid
identifi
incid
cancer
exclud
children
previou
lymphoma
diagnos
among
children
ebv
infect
diagnosi
compar
observ
incid
lymphoma
expect
among
children
gener
popul
comput
absolut
lymphoma
risk
rel
risk
standardis
incid
ratio
result
total
children
lymphoma
diagnos
patient
lymphoma
boy
median
age
year
absolut
risk
lymphoma
respect
time
children
expect
diagnos
lymphoma
lymphoma
standardis
incid
ratio
ci
year
ci
year
ci
beyond
year
conclus
find
emphas
consider
insight
associ
ebv
infect
lymphoma
late
consequ
earli
diagnosi
manag
lymphoma
children
risk
improv
patient
surviv
osman
egypt
cancer
institut
pediatr
oncolog
assiut
egypt
egypt
cancer
institut
radiotherapi
assiut
egypt
backgroundobject
hodgkin
lymphoma
hl
highli
curabl
malign
diseas
therapi
children
hl
direct
toward
high
surviv
minim
toxic
optim
qualiti
life
aim
assess
impact
prognost
factor
associ
local
treatment
failur
pediatr
hl
patient
unfavor
criteria
treat
combin
modal
approach
detect
toxic
long
term
complic
patient
designmethod
prospect
studi
carri
januari
januari
median
follow
month
rang
month
newli
diagnos
pediatr
patient
unfavor
hl
stratifi
two
risk
group
intermedi
risk
imr
high
risk
group
hr
patient
treat
cycl
cycl
respect
altern
abvd
doxorubicin
bleomycin
vinblastin
decarbazin
coep
cyclophosphamid
oncovin
etoposid
prednison
chemotherapi
follow
radiat
therapi
ifrt
gy
patient
achiev
complet
respons
gy
achiev
partial
respons
result
patient
imr
patient
hr
treatment
failur
patient
progress
diseas
patient
relaps
patient
die
diseas
palli
care
overal
surviv
os
event
free
surviv
ef
rate
se
respect
factor
affect
os
diseas
bulk
elev
esr
receiv
radiotherapi
p
regard
ef
diseas
stage
radiotherapi
factor
statist
signific
multivari
analysi
reveal
independ
factor
inferior
os
radiotherapi
treatment
gener
well
toler
without
signific
acut
delay
toxic
conclus
radiotherapi
consid
cornerston
treatment
patient
unfavor
criteria
also
intensif
treatment
need
patient
especi
hr
group
achiev
better
result
osman
e
h
egypt
cancer
institut
pediatr
oncolog
assiut
egypt
medicin
patholog
depart
assiut
egypt
egypt
cancer
institut
clinic
patholog
depart
assiut
egypt
backgroundobject
pediatr
lymphoma
known
associ
viru
ebv
infect
frequenc
linkag
vari
countri
well
within
countri
presum
relat
socioeconom
statu
popul
also
vari
within
histolog
subtyp
lymphoma
gender
age
time
diagnosi
studi
aim
examin
preval
ebv
infect
pediatr
patient
lymphoma
pediatr
oncolog
depart
south
egypt
cancer
institut
seci
assiut
univers
designmethod
retrospect
studi
examin
consecut
case
pediatr
lymphoma
presenc
ebv
tumor
cell
pcr
paraffin
block
latent
membran
period
collect
patient
data
age
sex
histolog
sub
type
review
patholog
find
case
confirm
diagnosi
result
hl
diagnos
case
posit
ebv
case
nhl
posit
ebv
posit
case
significantli
relat
age
gender
diagnosi
conclus
preval
ebv
infect
pediatr
patient
lymphoma
pediatr
oncolog
depart
seci
assiut
univers
similar
develop
countri
n
othman
j
k
k
b
l
cancer
center
radiat
oncolog
sulaymaniyah
iraq
cancer
institut
radiat
oncolog
edmonton
canada
backgroundobject
hodgkin
lymphoma
hl
account
childhood
cancer
display
characterist
epidemiolog
clinic
patholog
featur
accord
variou
geograph
area
aim
assess
epidemiolog
aspect
featur
treatment
outcom
overal
event
free
surviv
pediatr
hl
manag
singl
radiotherapi
center
sulaymaniyah
governor
kurdistan
region
iraq
period
march
dec
designmethod
retrospect
review
treatment
chart
patient
fulfil
follow
inclus
criteria
age
year
hl
diagnosi
establish
characterist
histopatholog
find
immunophenotyp
studi
subclassifi
accord
whoclassif
chart
includ
patient
search
demograph
data
histori
detail
examin
find
especi
nodal
region
involv
investig
result
method
establish
diagnosi
treatment
cours
result
thirti
eight
children
adolesc
hlwere
review
age
patient
present
rang
year
median
year
age
diagnosi
major
case
year
male
femal
ratio
cervic
lymphadenopathi
wasth
common
present
nodular
scleros
subtyp
domin
follow
mix
cellular
nodular
lymphocyt
predomin
half
patient
advanceddiseas
ann
arbor
stage
iiiiv
diseas
durat
rang
month
median
time
month
theoveral
surviv
surviv
patient
respect
conclus
region
hl
occur
young
age
group
higher
incid
nodular
scleros
subtyp
advanc
stage
diseas
outcom
hl
treatment
region
satisfactorili
approach
intern
percentag
patel
mc
v
bra
india
institut
medic
new
delhi
depart
medic
oncolog
new
delhi
india
india
institut
medic
new
delhi
depart
patholog
new
delhi
india
india
institut
medic
new
delhi
depart
biostatist
new
delhi
india
backgroundobject
pediatr
lymphoblast
lymphoma
lbl
aggress
lymphoma
howev
intens
protocol
like
lymphoblast
leukemia
produc
good
outcom
lack
clinic
predictor
prognost
lbl
view
lacuna
evalu
outcom
prognost
factor
lbl
treat
center
treat
uniform
protocol
designmethod
studi
conduct
cancer
center
india
institut
medic
scienc
new
delhi
consecut
patient
pediatr
lbl
age
year
jan
till
jan
enrol
ethic
approv
patient
stage
st
jude
murphi
stage
system
patient
treat
like
protocol
event
defin
death
due
caus
relaps
progress
diseas
data
censor
jan
kaplan
meier
method
use
analysi
surviv
result
patient
studi
median
age
year
male
femal
ratio
patient
present
mediastin
diseas
rest
patient
variou
organ
involv
like
lymph
node
bone
liver
spleen
median
month
rang
ef
year
ci
os
multivari
analysi
symptom
durat
day
wbc
serum
albumin
gmdl
predict
inferior
ef
similarli
inferior
os
predict
symptom
durat
day
wbc
serum
albumin
gmdl
conclus
outcom
lower
publish
literatur
trial
set
low
albumin
high
wbc
symptom
durat
less
day
emerg
advers
predictor
ef
os
novel
clinic
predictor
pediatr
lbl
howev
need
valid
prospect
cohort
well
patiroglu
e
ah
erciy
univers
medic
faculti
kayseri
turkey
radiolog
erciy
univers
medic
faculti
kayseri
turkey
backgroundobject
vena
cava
superior
syndrom
vcss
compris
variou
symptom
compress
vena
cava
superior
result
increas
venou
pressur
upper
bodi
may
caus
edema
head
neck
associ
cyanosi
pletor
distend
subcutan
vessel
vcss
rare
childhood
therefor
plan
retrospect
studi
designmethod
retrospect
studi
carri
children
mediastin
tumor
depart
pediatr
erciy
univers
medic
school
januari
decemb
diagnost
procedur
includ
hematolog
investig
chest
radiographi
thorac
comput
tomographi
echocardiographi
lymph
node
mediastin
biopsi
result
five
femal
patient
mediastin
tumor
vcss
mean
age
patient
vcss
year
year
diagnosi
includ
hodgkin
diseas
hd
lymphoma
nhl
acut
lymphoblast
leukemia
neuroblastoma
anaplast
round
cell
sarcoma
one
respect
patient
dyspnea
venou
distent
mediastin
widen
two
patient
nhl
bilater
pleural
effus
patient
receiv
intraven
corticosteroid
mgkg
dexamethason
furthermor
patient
anaplast
round
cell
sarcoma
recevi
emerg
radiotherapi
patient
receiv
chemothepi
follow
pho
clinic
patient
die
vcss
conclus
compress
structur
superior
mediastinum
known
vcss
medic
emerg
requir
urgent
treatment
retrospect
studi
found
common
caus
vcss
hd
differ
literatur
patiroglu
e
c
erciy
univers
medic
faculti
kayseri
turkey
surgeri
erciy
univers
medic
faculti
kayseri
turkey
backgroundobject
tumour
lysi
syndrom
tl
oncolog
emerg
character
metabol
abnorm
includ
hyperuricaemia
hyperphosphataemia
hyperkalaemia
hypocalcaemia
tl
aris
commonli
start
initi
chemotherapeut
treatment
spontan
case
increasingli
document
patient
high
prolif
rate
tumour
burden
burkitt
lymphoma
acut
lymphoblast
leukemia
studi
aim
examin
incid
characterist
outcom
tl
children
hematolog
malign
designmethod
studi
medic
record
patient
leukemia
lymphoma
treat
hospit
januari
decemb
examin
tl
diagnos
accord
procedur
includ
hematolog
biochem
investig
lymph
node
tumor
biop
result
patient
leukemia
acut
lymphoblast
acut
myelooblast
biphenotyp
chronic
myeloid
lymphoma
hodgkin
respect
patient
tl
mean
year
male
lactic
dehidrogenas
ldh
level
sera
patient
tl
iul
mean
uric
acid
level
mean
calcium
level
mgdl
mean
potassium
level
meql
mean
phosphor
level
mgdl
respect
seven
patient
low
intermedi
high
grade
tl
respect
treatment
includ
aggress
hydrat
diuresi
control
hyperuricaemia
allopurinol
prophylaxi
rasburicas
treatment
vigil
monitor
electrolyt
abnorm
one
patient
requir
leukopheresi
patient
also
hemodialysi
due
renal
failur
respect
four
patient
die
tl
conclus
tumor
lysi
syndrom
potenti
lethal
main
principl
manag
identif
patient
initi
prevent
therapi
earli
recognit
metabol
renal
complic
prompt
administr
support
care
includ
hemodialysi
j
ramamoorthi
v
tg
professor
depart
medic
cancer
institut
wia
adyar
chennai
india
professor
depart
medic
cancer
institut
wia
adyar
chennai
india
depart
medic
cancer
institut
wia
adyar
chennai
india
backgroundobject
develop
countri
set
surviv
rate
matur
b
cell
lymphoma
surviv
rate
plagu
higher
toxic
death
rate
poor
toler
chemotherapi
preclud
mainten
chemotherapi
intens
report
incid
grade
toxic
reduc
dosag
chemotherapi
addit
rituximab
expect
improv
surviv
reduc
toxic
death
object
evalu
efficaci
toxic
profil
treatment
schedul
util
addit
rituximab
reduc
dosag
standard
lmb
backbon
chemotherapi
designmethod
prospect
observ
studi
perform
children
year
cd
posit
matur
b
cell
lymphoma
burkitt
lymphoma
diffus
larg
b
cell
lymphoma
inclus
criteria
children
risk
group
b
c
per
lmb
protocol
lmb
protocol
dosag
chemotherapi
reduc
along
singl
dose
rituximab
everi
chemotherapi
cours
includ
prophas
except
mainten
administ
toxic
grade
use
ctcae
version
toxic
profil
treatment
respons
evalu
use
descript
statist
result
seven
children
boy
girl
enrol
januari
octob
median
age
rang
year
children
belong
risk
group
b
median
ldh
iul
respons
rate
prophas
chemotherapi
schedul
could
deliv
day
interv
toxic
profil
grade
none
total
grade
febril
neutropenia
develop
toxic
death
surviv
rate
surviv
relaps
median
month
conclus
administr
rituximab
reduc
dosag
lmb
chemotherapi
protocol
result
improv
surviv
rate
compar
acut
toxic
intens
chemotherapi
could
maintain
without
undu
treatment
delay
le
rio
lopez
castro
l
vasquez
j
geronimo
rebagliati
pediatr
oncolog
lima
peru
rebagliati
medic
oncolog
lima
peru
backgroundobject
lymphoma
bcnhl
adolesc
young
adult
aya
rare
challeng
clinic
entiti
aya
popul
special
interest
due
differ
clinic
present
biolog
outcom
object
compar
surviv
rate
pediatr
adult
regimen
treatment
aya
patient
bcnhl
peru
designmethod
retrospect
studi
patient
age
newli
diagnos
bcnhl
complet
least
three
cycl
chemotherapi
treat
consecut
rebagliati
hospit
histolog
subtyp
clinic
featur
prognost
factor
studi
statist
analys
use
os
surviv
ef
estim
curv
test
signific
level
result
aya
patient
diagnos
bcnhl
includ
six
patient
receiv
pediatr
regimen
withwithout
rituximab
patient
adult
regimen
methotrex
hd
median
age
pediatr
adult
regimen
year
stage
diseas
extranod
diseas
b
symptom
initi
risk
categori
histolog
subtyp
similar
group
relaps
rate
entir
cohort
compar
group
pediatr
vs
adult
among
relaps
case
patient
pediatr
regimen
achiev
second
remiss
autolog
stem
cell
transplant
meanwhil
case
adult
regimen
die
progress
diseas
whole
cohort
ef
os
ef
pediatr
adult
regimen
respect
os
pediatr
group
adult
group
conclus
studi
aya
patient
bcnhl
treat
pediatr
regimen
trend
toward
higher
surviv
rate
adult
regimen
although
signific
reach
find
valid
prospect
multicent
studi
larger
number
patient
ds
sharma
n
medic
colleg
attach
hospit
jaipur
radiotherapi
jaipur
india
jaipur
medic
oncolog
jaipur
india
backgroundobject
earli
beacopp
regimen
basic
escal
emerg
accept
altern
abvd
manag
hodgkin
diseas
hd
term
efficaci
cost
present
studi
modifi
escal
beacopp
regimen
studi
indian
context
modifi
escal
beacopp
regimen
differ
standard
one
higher
doxorubicin
dose
mg
administr
bleomycin
day
addit
day
support
growth
factor
designmethod
april
januari
children
biopsi
proven
hd
clinic
stage
iv
advers
clinic
featur
like
b
symptom
extranod
bulki
mediastin
diseas
select
treatment
modifi
beacopp
regimen
ten
patient
bulki
diseas
receiv
ifrt
dose
gy
result
median
follow
rang
month
median
age
rang
year
male
femal
three
patient
stage
patient
stage
ii
stage
iii
hd
b
symptom
respect
common
subtyp
nodular
sclerosi
seen
mediastin
diseas
follow
mix
cellular
lymphocyt
predomin
lymphocyt
deplet
patient
patient
compliant
prescrib
treatment
grade
iii
anemia
neutropenia
thrombocytopenia
seen
patient
respect
one
patient
develop
locoregion
recurr
anoth
one
develop
distant
relaps
remiss
rate
overal
surviv
one
patient
die
month
due
secondari
aml
conclus
modifi
beacopp
regimen
shown
excel
result
term
prolong
clinic
remiss
accept
morbid
lesser
treatment
cost
durat
desir
patient
well
caregiv
indian
scenario
r
sharma
g
g
h
j
f
univers
school
medicin
depart
pediatr
indianapoli
usa
univers
school
medicin
pediatr
indianapoli
usa
univers
medic
center
pediatr
oncologyhematolog
amsterdam
netherland
antil
univers
school
medicin
hematolog
oncolog
eldoret
kenya
univers
school
medicin
pediatr
eldoret
kenya
children
hospit
pediatr
oncologyhematolog
houston
usa
univers
school
medicin
pediatr
hematolog
oncolog
eldoret
kenya
backgroundobject
hodgkin
lymphoma
hl
common
malign
africa
surviv
children
countri
approach
surviv
larg
unknown
develop
countri
kenya
studi
assess
treatment
outcom
factor
influenc
outcom
cohort
patient
recent
diagnos
hl
one
academ
hospit
kenya
designmethod
retrospect
studi
review
medic
record
patient
diagnos
hl
moi
teach
referr
hospit
eldoret
kenya
data
treatment
outcom
variou
clinic
characterist
collect
patient
receiv
standard
chemotherapi
regimen
abvd
doxorubicin
bleomycin
vinblastin
dacarbazin
cycl
given
day
cycl
result
children
diagnos
hl
studi
period
median
age
year
rang
diagnosi
confirm
core
tissu
biopsi
case
stage
clinic
exam
chest
radiograph
abdomin
ultrasound
complet
patient
frequent
present
advanc
diseas
stage
stage
ii
stage
stage
iv
patient
abandon
treatment
singl
day
biweekli
regimen
month
hl
comparison
abandon
treatment
children
lymphoma
enrol
kenyan
nation
health
insur
fund
distanc
hospit
durat
symptom
prior
diagnosi
month
gender
predict
outcom
overal
patient
event
free
surviv
year
conclus
util
standard
chemotherapi
regimen
lead
surviv
major
patient
hl
kenya
factor
affect
outcom
tumor
type
insur
statu
travel
distanc
predict
hl
outcom
use
abvd
regimen
c
r
thejpal
b
albert
luthuli
central
univers
kwazulu
natal
paediatr
haematolog
durban
south
africa
backgroundobject
children
hodgkin
lymphoma
hl
present
lymph
node
enlarg
system
symptom
present
paraneoplast
syndrom
unusu
site
rare
designmethod
atyp
present
children
hl
manag
inkosi
albert
luthuli
central
hospit
ialch
review
seven
patient
identifi
proptosi
nephrot
syndrom
recurr
pericardi
effus
cerebellar
atrophi
hypertroph
pulmonari
osteoarthropathi
result
patient
african
male
patient
indian
male
eleven
year
month
old
patient
stage
iv
b
nodular
scleros
ns
hl
present
lower
limb
weak
headach
proptosi
nerv
palsi
imag
confirm
intracon
mass
extend
cavern
sinu
eight
year
month
old
patient
stage
ii
mix
cellular
mc
hl
present
facial
pain
proptosi
imag
show
intracrani
extens
diagnosi
confirm
enucl
nine
year
old
patient
stage
iv
mc
hl
present
recurr
pericardi
effus
associ
mediastin
mass
nine
year
old
patient
stage
iv
mc
hl
present
sever
cerebellar
sign
cerebellar
atrophi
imag
nine
year
old
patient
stage
ii
b
mc
hl
ten
year
old
patient
stage
ii
ns
hl
present
nephrot
syndrom
nine
year
old
patient
stage
ii
ns
hl
present
club
finger
joint
pain
month
associ
asymptomat
mediastin
mass
conclus
children
describ
diagnosi
hl
first
consider
atyp
present
paraneoplast
featur
nephrot
syndrom
cerebellar
atrophi
club
resolv
chemotherapi
apart
enucl
patient
proptosi
achiev
remiss
neurolog
deficit
r
g
tokuc
n
e
univers
pediatr
istanbul
turkey
univers
pediatr
istanbul
turkey
univers
pediatr
hematolog
istanbul
turkey
univers
pediatr
endocrinolog
istanbul
turkey
backgroundobject
surviv
rate
hodgkin
lymphoma
hl
increas
result
increas
chemotherapi
radiotherapi
relat
late
one
common
side
effect
side
effect
studi
search
side
effect
pediatr
hodgkin
patient
designmethod
hl
patient
complet
remiss
least
year
elig
prospect
studi
patient
whose
diseas
relaps
complet
remiss
less
year
undergon
bone
marrow
transplant
exclud
thyroid
relat
side
effect
serum
tsh
free
free
thyroglobulin
level
thyroid
gland
ultrasound
assess
gonad
function
serum
fsh
lh
estradiol
girl
testesteron
boy
level
measur
sexual
develop
assess
tanner
stage
ovari
testi
size
note
glucos
metabol
obes
evalu
measur
serum
fast
glucos
insulin
level
homa
bodi
mass
index
bone
metabol
relat
side
effect
serum
ca
p
alp
parameth
detect
data
analyz
comparison
variabl
relat
clinic
featur
treatment
result
patient
hypothroid
thyroid
nodul
detect
patient
patient
serum
fsh
level
normal
patient
increas
homa
index
assess
overweight
obes
accord
bmi
none
patient
abnorm
result
bone
metabol
adren
axi
conclus
studi
popul
hypotiroid
gonad
toxic
insulin
resist
obes
detect
import
follow
patient
prevent
morbid
hl
treatment
although
mani
studi
endocrin
chemotherapi
radiotherapi
hl
patient
detail
random
control
trial
need
especi
glucos
metabol
obes
relat
side
effect
g
e
unal
cabi
n
h
g
g
e
univers
faculti
medicin
depart
pediatr
divis
pediatr
ankara
turkey
univers
faculti
medicin
depart
patholog
ankara
turkey
univers
faculti
medicin
depart
radiolog
ankara
turkey
backgroundobject
develop
countri
epidemiolog
clinic
histopatholog
featur
pediatr
hodgkin
diseas
hd
show
consider
differ
develop
countri
designmethod
chart
children
newli
diagnos
hd
treat
retrospect
analyz
refer
first
period
compar
find
hd
patient
reat
name
second
period
result
first
period
decad
male
predomin
csi
cs
cs
iii
iv
male
predomin
remain
howev
unlik
first
period
yr
initi
present
chang
cs
distribut
note
cs
cs
ii
cs
iv
histopatholog
subtyp
wo
signific
chang
two
period
mc
subtyp
common
decreas
lp
increas
ns
histopatholog
two
group
respect
distribut
histopatholog
subtyp
follow
lp
ns
mc
lp
ns
mc
nlphl
viru
studi
carri
hd
patient
sinc
shown
high
seroposit
patient
second
period
case
addit
serolog
studi
ebv
relat
found
posit
umor
tissu
sampl
patient
conclus
increas
csiii
decreas
csiv
might
due
improv
health
servic
chang
environment
socioeconom
condit
increas
frequenc
ns
histopatholog
may
reflect
characterist
industri
societi
though
high
frequenc
ebv
associ
hd
serolog
immunocytochem
method
suggest
associ
ebv
infect
major
impact
prognosi
children
hd
l
vasquez
b
hospit
pediatr
oncolog
lima
peru
hospit
clinic
oncolog
lima
peru
backgroundobject
hydroa
lymphoprolif
disord
hvlpd
uncommon
viru
ebv
associ
cutan
lymphoma
due
multipl
small
case
seri
report
studi
aim
provid
comprehens
systemat
review
report
case
hvlpd
accord
prisma
guidelin
designmethod
perform
systemat
electron
search
pubmedmedlin
googl
scholar
hand
search
relev
refer
without
languag
restrict
inclus
criteria
involv
newli
diagnos
case
hvlpd
publish
march
accord
world
health
organ
classif
extract
data
includ
age
gender
patient
demograph
present
durat
symptom
system
compromis
patholog
immunohistochemistri
molecular
profil
receiv
therapi
outcom
time
result
total
studi
report
case
hvlpd
includ
analysi
major
case
report
exclus
latin
america
asia
case
male
median
age
year
median
latenc
present
month
rang
initi
clinic
present
report
studi
facial
edema
lesion
sun
exposedunexpos
skin
trunk
andor
extrem
common
featur
rna
eber
neoplast
cell
present
case
gene
clonal
rearrang
detect
case
system
symptom
includ
fever
hepatosplenomegali
lymphadenopathi
describ
case
associ
higher
mortal
clinic
featur
prognosi
vari
pediatr
adult
patient
system
chemotherapi
frequent
describ
treatment
follow
immunomodulatori
agent
death
report
case
conclus
hvlpd
rare
entiti
mainli
affect
children
latin
america
asia
distinct
clinic
featur
research
focu
long
term
studi
give
concret
evid
prognost
factor
standard
treatment
diseas
yilmaz
e
n
p
univers
pediatr
hematologyoncolog
istanbul
turkey
univers
goztep
educ
research
hospit
pediatr
hematologyoncolog
istanbul
turkey
scienc
umraniy
educ
research
hospit
patholog
istanbul
turkey
univers
medic
genet
istanbul
turkey
univers
goztep
educ
research
hospit
pediatr
istanbul
turkey
backgroundobject
lymphadenopathi
abnorm
size
charact
lymph
node
includ
reactiv
malign
condit
assess
lymphadenopathi
children
common
diagnost
problem
field
pediatr
understand
wide
varieti
diseas
condit
may
present
lymphadenopathi
essenti
determin
appropri
workup
individu
patient
cell
develop
numer
adapt
respons
regul
hypoxia
alpha
hypox
stress
consid
polymorph
may
play
role
process
carcinogenesi
increas
earli
stage
cancer
indic
polymorph
significantli
associ
overal
cancer
risk
present
project
aim
investig
whether
gene
polymorphisim
availi
lymph
node
reactiv
hyperplasia
lymphoma
designmethod
twenti
lymphoma
hodgkin
lymphoma
reactiv
hyperplasia
preserv
paraffin
embed
ffpe
investig
polymeras
chain
fragment
length
polymorph
use
assess
polymorph
gene
differ
genotyp
group
compar
result
polymorph
observ
lymphoma
reactiv
hyperplasia
case
particularli
polymorph
seen
hodgkin
lymphoma
reactiv
hyperplasia
case
conclus
reactiv
hyperplasia
lymphoma
differenti
term
earli
diagnosi
treatment
lymph
node
malign
interestingli
polymorph
associ
increas
suscept
reactiv
hyperplasia
studi
light
result
emphas
children
diagnos
reactiv
hyperplasia
follow
close
x
zhang
w
g
hospit
affili
zhengzhou
univers
depart
pediatr
oncolog
surgeri
zhengzhou
china
hospit
affili
zhengzhou
univers
depart
blood
oncolog
zhengzhou
china
hospit
affili
zhengzhou
univers
depart
dermatolog
zhengzhou
china
backgroundobject
present
case
small
intestin
lymphoma
sever
multipl
perfor
treatment
therapeut
effect
designmethod
present
case
studi
report
case
girl
intestin
perfor
patient
present
fever
vomit
abdomin
distent
acut
bowel
obstruct
initi
diagnos
base
abdomin
radiograph
find
reexamin
abdomin
radiograph
reveal
free
air
diaphragm
prompt
suspicion
intestin
perfor
emerg
laparotomi
reveal
ten
discret
perfor
fifteen
ulcer
lesion
small
bowel
start
duodenojejun
junction
terminalileum
closur
perfor
undergon
sever
involv
bowel
resect
result
patholog
result
lesion
show
primari
small
bowel
diffus
larg
b
cell
lymphoma
follow
surgeri
six
cycl
chemotherapi
rituximab
cyclophosphamid
doxorubicin
vincristin
prednison
year
patient
indic
normal
obviou
recurr
metastasi
lymphoma
found
conclus
patient
small
intestin
lymphoma
sever
perfor
achiev
good
therapeut
effect
care
oper
standard
postop
chemotherapi
x
zhang
w
g
hospit
affili
zhengzhou
univers
pediatr
oncolog
surgeri
zhengzhou
china
hospit
affili
zhengzhou
univers
blood
oncolog
zhengzhou
china
hospit
affili
zhengzhou
univers
dermatolog
zhengzhou
china
backgroundobject
present
case
small
intestin
lymphoma
sever
multipl
perfor
treatment
therapeut
effect
designmethod
present
case
studi
report
case
girl
intestin
perfor
patient
present
fever
vomit
abdomin
distent
acut
bowel
obstruct
initi
diagnos
base
abdomin
radiograph
find
reexamin
abdomin
radiograph
reveal
free
air
diaphragm
prompt
suspicion
intestin
perfor
emerg
laparotomi
reveal
ten
discret
perfor
fifteen
ulcer
lesion
small
bowel
start
duodenojejun
junction
terminalileum
closur
perfor
undergon
sever
involv
bowel
resect
result
patholog
result
lesion
show
primari
small
bowel
diffus
larg
b
cell
lymphoma
follow
surgeri
six
cycl
chemotherapi
rituximab
cyclophosphamid
doxorubicin
vincristin
prednison
year
patient
indic
normal
obviou
recurr
metastasi
lymphoma
found
conclus
patient
small
intestin
lymphoma
sever
perfor
could
achiev
good
therapeut
effect
care
oper
standard
postop
chemotherapi
x
zhang
w
g
hospit
affili
zhengzhou
univers
pediatr
oncolog
surgeri
zhengzhou
china
hospit
affili
zhengzhou
univers
blood
oncolog
zhengzhou
china
hospit
affili
zhengzhou
univers
dermatolog
zhengzhou
china
backgroundobject
present
case
small
intestin
lymphoma
sever
multipl
perfor
treatment
therapeut
effect
designmethod
present
case
studi
report
case
girl
intestin
perfor
patient
present
fever
vomit
abdomin
distent
acut
bowel
obstruct
initi
diagnos
base
abdomin
radiograph
find
reexamin
abdomin
radiograph
reveal
free
air
diaphragm
prompt
suspicion
intestin
perfor
emerg
laparotomi
reveal
ten
discret
perfor
fifteen
ulcer
lesion
small
bowel
start
duodenojejun
junction
terminalileum
closur
perfor
undergon
sever
involv
bowel
resect
result
patholog
result
lesion
show
primari
small
bowel
diffus
larg
b
cell
lymphoma
follow
surgeri
six
cycl
chemotherapi
rituximab
cyclophosphamid
doxorubicin
vincristin
prednison
year
patient
indic
normal
obviou
recurr
metastasi
lymphoma
found
conclus
patient
small
intestin
lymphoma
sever
perfor
could
achiev
good
therapeut
effect
care
oper
standard
postop
chemotherapi
z
zhen
j
j
f
j
x
univers
cancer
center
pediatr
oncolog
guangzhou
china
backgroundobject
data
regard
use
rituximab
children
adolesc
burkitt
lymphoma
bl
limit
studi
retrospect
analyz
effect
rituximab
children
adolesc
bl
designmethod
patient
underw
chemotherapi
accord
revis
protocol
rituximab
administ
dose
day
cycl
result
total
patient
includ
stratifi
number
dose
rituximab
patient
group
rituximab
group
dose
rituximab
group
dose
rituximab
respect
surviv
ef
rate
group
group
group
respect
patient
diseas
ef
rate
patient
treat
rituximab
treat
without
rituximab
patient
diseas
relaps
rate
group
group
group
respect
p
conclus
rituximab
highli
effect
children
adolesc
bl
optim
number
dose
patient
bl
j
zhu
z
j
f
j
x
key
laboratori
oncolog
south
collabor
innov
center
cancer
sun
univers
cancer
pediatr
oncolog
guangzhou
china
backgroundobject
burkitt
lymphoma
usual
involv
bone
marrow
bm
surviv
improv
use
intens
chemotherapi
short
puls
central
nerv
system
prophylaxi
present
studi
retrospect
analyz
outcom
chines
pediatr
burkitt
lymphoma
patient
bm
involv
burkitt
leukemia
treat
use
rituximab
designmethod
data
collect
burkitt
lymphoma
patient
younger
year
old
treat
protocol
sun
univers
cancer
center
patient
bm
involv
burkitt
leukemia
avail
analysi
patient
marrow
blast
classifi
burkitt
leukemia
marrow
blast
classifi
bm
involv
burkitt
lymphoma
result
total
case
burkitt
lymphoma
bm
involv
burkitt
leukemia
analys
male
femal
median
age
year
old
rang
ten
case
bm
involv
burkitt
lymphoma
case
burkitt
leukemia
burkitt
leukemia
eight
case
marrow
blast
five
case
marrow
blast
patient
design
high
risk
group
treat
use
rituximab
total
six
cours
administ
patient
rituximab
combin
protocol
given
case
median
time
month
month
total
case
die
two
case
die
tumour
progress
one
abandon
therapi
tumour
lysi
syndrom
reliev
estim
surviv
overal
surviv
rate
respect
conclus
pediatr
burkitt
lymphoma
bm
involv
burktt
leukemia
achiev
better
surviv
treat
protocol
abba
hospit
children
glasgow
paediatr
haematolog
oncolog
royal
hospit
children
glasgow
glasgow
unit
kingdom
backgroundobject
retrospect
analysi
ciclosporin
csa
data
children
age
month
year
median
year
underw
allogen
hematopoiet
stem
cell
transplant
hsct
undertaken
determin
iv
csa
dose
mgkgday
achiev
target
trough
concentr
patient
malign
n
diseas
n
designmethod
total
patient
identifi
studi
period
patient
divid
two
group
underli
malign
diseas
diseas
initi
final
daili
dose
requir
reach
target
trough
concentr
vari
age
weight
diseas
type
studi
ratio
trough
dose
patient
averag
determin
relationship
two
variabl
result
trough
concentr
differ
altern
dose
regimen
calcul
number
percentag
patient
would
achiev
differ
concentr
rang
differ
dosag
regimen
calcul
result
initi
mgkgday
csa
dose
increas
malign
patient
patient
median
final
daili
dose
requir
reach
target
trough
concentr
mgkgday
rang
malign
patient
mgkgday
rang
patient
patient
requir
dose
increas
diseas
younger
lower
weight
requir
greater
increas
dose
time
achiev
target
trough
concentr
longer
patient
compar
malign
patient
day
vs
day
p
conclus
conclus
start
dose
mgkgday
low
achiev
target
trough
concentr
malign
diseas
children
vari
age
weight
consid
altern
dosag
regimen
either
age
year
weight
kg
would
appropri
mm
alam
ha
faisal
specialist
hospit
research
center
depart
section
pediatr
hematologyoncologybmt
jeddah
saudi
arabia
backgroundobject
hematopoiet
stem
cell
transplant
hsct
becom
accept
therapeut
modal
wide
varieti
diseas
increasingli
util
consid
cur
treatment
thalassemia
major
tm
sickl
cell
diseas
scd
designmethod
retrospect
analysi
clinic
laboratori
outcom
data
result
total
patient
includ
tm
remain
scd
mean
age
transplant
year
male
femal
condit
regimen
bucyatg
flubucyatg
italian
protocol
sourc
stem
cell
patient
bone
marrow
mean
stem
cell
dose
cd
x
acut
gvhd
observ
skin
gut
liver
skin
gut
grade
ii
iii
iv
gvhd
observ
patient
respect
chronic
gvhd
notic
patient
skin
involv
median
durat
anc
engraft
rang
median
platelet
engraft
rang
day
patient
remain
patient
delay
platelet
engraft
day
cmv
reactiv
observ
case
major
asymptomat
remain
clinic
manifestationorgan
involv
pneumonia
skin
manifest
os
rate
median
durat
follow
month
conclus
result
pediatr
bmt
program
institut
nearli
compar
report
literatur
far
morbid
mortal
concern
howev
durat
short
outcom
yet
determin
alsaleh
b
v
faisal
specilaist
hospit
research
centr
pediatr
hematolog
oncolog
riyadh
saudi
arabia
faisal
specilaist
hospit
research
centr
pediatr
nurs
riyadh
saudi
arabia
backgroundobject
learn
stem
cell
transplant
sct
could
cur
option
avail
mark
begin
journey
take
batteri
test
patient
indic
sct
clear
thu
clearanc
necessit
effect
approach
nurs
hematologist
oncologist
improv
transplant
outcom
sct
often
offer
cur
option
inherit
blood
disord
nmbd
sever
case
refer
pediatr
hematolog
section
king
faisal
specialist
hospit
research
centr
riyadh
designmethod
hematolog
screen
clearanc
modul
develop
part
institut
perform
improv
initi
reduc
clearanc
time
research
electron
data
captur
redcap
softwar
use
gener
diseas
specif
log
medic
investig
result
total
case
sct
hemoglobinopathi
sickl
cell
diseas
sickl
bone
marrow
failur
fanconi
aplast
dyserythropoiet
kostmann
syndrom
sideroblast
dyskeratosi
congenita
patient
categor
virtual
report
base
hla
type
workup
clearanc
statu
clear
respect
patient
list
weekli
review
clearanc
team
facilit
investig
altern
donor
search
conduct
period
patient
donor
list
clear
patient
transplant
comparison
median
clearanc
time
patient
transplant
first
three
quarter
conduct
reduct
day
observ
conclus
featur
enabl
electron
plan
identif
area
addit
patient
catalogu
effect
altern
donor
search
preliminari
cost
indic
cost
save
usd
analysi
warrant
ss
anak
e
v
k
medipol
univers
pediatr
hematologyoncologybmt
istanbul
turkey
backgroundobject
despit
gener
excel
prognosi
children
hodgkin
lymphoma
hl
approxim
patient
relaps
salvag
therapi
autolog
hsct
follow
chemotherapi
andor
allogen
haematopoiet
sct
may
improv
surviv
designmethod
retrospect
analysi
consecut
pediatr
patient
relapsedrefractori
hl
treat
institut
conduct
evalu
effect
approach
result
girl
boy
median
age
year
year
relapsedrefractori
hl
treat
except
one
pr
patient
cr
sct
beam
busulphan
e
toposid
melphalan
condit
regimen
patient
bendamustin
replac
bcnu
pr
patient
could
achiev
cr
patient
remain
ccr
relaps
one
relaps
patient
treat
use
nivolumab
trial
still
cr
one
year
relaps
patient
sever
chemotherapi
regimen
togeth
bridg
therapi
brentuximab
cours
patient
use
achiev
cr
remain
pr
fmd
haplosct
post
transplant
cyclophosphamid
ric
melphalan
busulphan
fludarabin
conduct
patient
full
donor
chimer
could
achiev
patient
pr
sct
expir
month
progress
diseas
among
patient
median
follow
year
year
cr
one
stabl
diseas
conclus
outcom
patient
chemosensit
relaps
hl
receiv
need
bridg
chemotherapi
seem
accept
chemoresist
patient
result
encourag
approach
must
evalu
larger
patient
group
chakraborti
r
v
n
k
p
shaw
medic
narayana
health
citi
pediatr
blood
marrow
transplant
bangalor
india
backgroundobject
recent
studi
shown
condit
haematopoiet
stem
cell
transplant
hsct
acut
myeloid
leukemia
aml
use
busulfan
along
fludarabin
flu
lieu
cyclophosphamid
cy
lead
signific
decreas
regimen
relat
toxic
transplant
relat
mortal
designmethod
retrospect
analysi
pediatr
patient
aml
undergo
hsct
center
juli
januari
result
twenti
eight
patient
median
age
month
rang
includ
studi
eleven
patient
fludarabin
busulphan
base
myeloabl
condit
use
patient
underw
match
sibl
donor
msd
transplant
underw
haploident
transplant
tcr
deplet
post
transplant
cyclophosphamid
ptci
gvhd
prophylaxi
median
mnc
kg
kg
dose
msd
tcr
deplet
ptci
group
respect
twenti
six
patient
achiev
hematolog
recoveri
neutrophil
platelet
engraft
median
day
respect
grade
mucos
seen
patient
vod
seen
patient
sever
total
death
relaps
sepsi
cumul
incid
non
relaps
mortal
acut
gvhd
grade
year
respect
overal
surviv
diseas
free
surviv
year
respect
conclus
aml
well
toler
condit
regimen
accept
toxic
transplant
outcom
hj
jy
choi
h
hj
h
jm
hy
kt
hy
hs
research
seoul
nation
univers
colleg
medicin
depart
pediatr
seoul
republ
korea
medic
center
children
hospit
divis
pediatr
depart
pediatr
seoul
republ
korea
nation
univers
hwasun
chonnam
nation
univers
medic
school
depart
pediatr
hwasun
republ
korea
yeungnam
univers
depart
pediatr
daegu
republ
korea
backgroundobject
chronic
diseas
cgvhd
common
late
complic
follow
allogen
stem
cell
transplant
standard
therapi
fail
respond
steroid
cgvhd
associ
high
morbid
studi
evalu
efficaci
safeti
imatinib
mesyl
gleevec
mycophenol
mofetil
mmf
treat
scleroticfibrot
type
cgvhd
designmethod
prospect
phase
ii
studi
enrol
patient
scleroticfibrot
type
cgvhd
particip
treat
mmf
dose
maximum
bid
gleevec
initi
dose
maximum
primari
endpoint
overal
complet
partial
respons
rate
scleroticfibrot
cgvhd
gleevec
plu
mmf
year
secondari
endpoint
includ
safeti
qualiti
life
discontinu
steroid
overal
surviv
rate
result
total
patient
enrol
octob
juli
median
age
year
rang
year
five
patient
previous
experienc
acut
gvhd
diagnos
acut
lymphoblast
leukemia
acut
myeloid
leukemia
chronic
granulomat
diseas
neuroblastoma
hemophagocyt
lymphohistiocytosi
patient
nine
patient
achiev
partial
respons
pr
show
stabl
diseas
sd
die
pulmonari
infect
progress
chronic
lung
gvhd
remain
patient
die
primari
diseas
progress
overal
respons
rate
nine
patient
abl
reduc
discontinu
steroid
among
patient
patient
show
improv
lee
cgvhd
symptom
scale
score
assess
qualiti
life
common
advers
event
includ
grade
liver
enzym
creatinin
elev
fever
conclus
although
limit
small
sampl
size
gleevec
plu
mmf
cgvhd
show
promis
result
accept
toxic
dreneva
v
rogachev
nation
research
center
pediatr
oncolog
immunolog
clinic
rehabilit
research
center
patient
remiss
russkoy
pole
moscow
russia
backgroundobject
acut
lymphoblast
leukemia
common
childhood
malign
present
surviv
rate
contain
treatment
success
result
current
method
treatment
includ
radiotherapi
chemotherapi
howev
case
necessari
use
hematopoiet
stem
cell
transplant
hsct
well
initi
diseas
hsct
lead
defici
domain
motor
skill
cognit
function
integr
designmethod
use
integr
test
assess
motor
coordin
visual
percept
integr
cambridg
neuropsycholog
test
autom
batteri
evalu
execut
function
cohort
consist
children
adolesc
surviv
patient
underw
hsct
femal
mean
age
patient
femal
mean
age
result
comparison
two
subgroup
patient
reveal
hsct
recipi
demonstr
significantli
wors
result
function
integr
visual
percept
motor
coordin
work
memori
attent
find
coher
research
indic
defici
execut
function
integr
fine
motor
skill
children
conclus
accord
studi
procedur
hsct
suppos
caus
sever
impair
domain
work
memori
attent
integr
survivor
compar
condit
without
hsct
dj
duran
rodriguez
gonzalez
rm
ayudam
vivir
pro
con
cancer
de
el
salvador
pediatr
oncolog
san
salvador
el
salvador
hospit
civil
de
guadalajara
pediatr
hematolog
oncolog
guadalajara
mexico
backgroundobject
pediatr
depart
civil
hospit
guadalajara
diagnos
averag
new
patient
cancer
per
year
look
forward
improv
outcom
pediatr
cancer
bone
marrow
transplant
unit
bmtu
built
retrospect
studi
aim
describ
characterist
patient
admit
bmtu
designmethod
studi
includ
patient
age
six
month
year
old
admit
bmtu
patient
elig
stem
cell
transplant
present
diagnosi
malign
benign
hematolog
diseas
solid
tumor
inform
abstract
bmtu
censu
also
clinic
chart
review
obtain
demograph
clinic
variabl
descript
statist
analysi
done
use
epiinfo
result
children
receiv
stem
cell
transplant
sct
male
femal
type
sct
allogen
transplant
n
umbil
cord
autolog
mean
age
six
year
major
sct
perform
patient
leukemia
stc
children
benign
hematolog
diseas
repres
acut
graft
versu
host
diseas
gvhd
observ
patient
patient
mortal
sojourn
bmtu
conclus
inform
provid
studi
repres
improv
rescu
therapi
support
care
manag
gvhd
children
cancer
guadalajara
research
regard
follow
patient
seem
next
step
creat
strategi
approach
patient
relaps
finkbein
v
k
g
children
hospit
pediatr
hematologyoncologytranspl
calgari
canada
backgroundobject
epstein
barr
viru
ebv
infect
reactiv
common
occurr
allogen
hematopoiet
stem
cell
transplant
hsct
sought
determin
overal
incid
ebv
reactiv
lymphoprolif
diseas
ptld
children
designmethod
retrospect
chart
review
children
underw
allogen
hsct
alberta
children
hospit
calgari
alberta
januari
januari
result
period
allogen
hsct
patient
perform
malign
condit
overal
incid
ebv
level
overal
incid
ebv
greater
iuml
incid
ptld
use
globulin
atg
condit
significantli
associ
high
ebv
titr
ebv
reactiv
associ
presenc
ebv
posit
donor
neither
recipi
ebv
statu
presenc
mismatch
ebv
statu
donor
recipi
signific
patient
receiv
peripher
blood
stem
cell
pbsc
higher
risk
ebv
reactiv
compar
cord
blood
bone
marrow
use
cord
blood
protect
multivari
analysi
use
atg
presenc
ebv
posit
donor
remain
signific
factor
patient
receiv
treatment
ebv
level
greater
iuml
receiv
rituximab
part
therapi
associ
ebv
reactiv
develop
graft
versu
host
diseas
gvhd
graft
failur
death
conclus
ebv
reactiv
common
children
undergon
allogen
hsct
overal
incid
greater
iuml
statist
associ
use
atg
ebv
posit
donor
use
pbsc
develop
featur
ptld
uncommon
treatment
initi
onset
symptom
g
k
h
v
e
guler
univers
pediatr
hematolog
oncolog
antalya
turkey
univers
medic
park
hospit
pediatr
hematolog
oncolog
istanbul
turkey
backgroundobject
autolog
peripher
blood
stem
cell
transplant
absct
high
dose
chemotherapi
one
treatment
option
aggress
tumor
refractori
relaps
diseas
childhood
malign
designmethod
studi
retrospect
analyz
data
children
receiv
hdt
follow
absct
center
result
patient
male
median
age
transplant
month
month
indic
transplant
includ
neuroblastoma
n
hodgkin
lymphoma
n
ewe
sarcoma
non
hodgkin
lymphoma
other
patient
receiv
treatment
part
primari
tumor
treatment
rest
receiv
hdt
follow
absct
due
refractori
relaps
diseas
diseas
statu
transplant
complet
remiss
good
partial
respons
rest
patient
febril
neutropenia
mucos
diseas
complic
four
patient
die
due
regimen
relat
toxic
patient
relaps
mean
time
month
month
absct
patient
lost
due
progress
diseas
despit
salvag
chemotherapi
rest
still
remiss
four
patient
lost
follow
five
year
ef
os
group
respect
one
patient
develop
secondari
aml
lost
despit
treatment
overal
patient
still
remiss
median
follow
month
month
conclus
conclud
absct
high
dose
chemotherapi
treatment
option
refractori
relaps
solid
tumor
j
hui
k
b
n
j
h
j
children
hoapit
haemotologyoncolog
shanghai
china
backgroundobject
observ
effect
haploid
peripher
blood
pb
combin
umbil
cord
blood
ucb
stem
cell
transplant
treatment
children
sever
aplast
anemia
saa
includ
implant
transplant
relat
complic
overal
surviv
rate
os
explor
prognost
factor
saa
patient
hsct
designmethod
august
januari
case
saa
treat
proport
boy
girl
median
age
year
median
time
interv
diagnosi
transplant
day
median
number
pb
mononuclear
cell
median
cell
pretreat
program
mainli
includ
busulfan
fludarabin
cyclophosphamid
antithymocyt
globulin
csa
mmf
combin
short
cours
mtx
use
prevent
gvhd
result
earli
hematopoiet
megakaryocyt
function
patient
recov
median
time
neutrophil
platelet
day
day
transplant
respect
transplant
str
show
complet
chimer
without
cord
blood
compon
case
degre
agvhd
chronic
gvhd
occur
case
mainli
local
skin
eye
complic
case
secondari
implant
case
invas
fungal
infect
case
cytomegaloviru
infect
case
eb
viru
infect
case
organ
mental
disord
transplant
median
time
month
os
one
case
die
diffus
alveolar
hemorrhag
dah
occur
tenth
month
transplant
conclus
effect
method
treatment
saa
without
sib
unrel
match
donor
umbil
cord
blood
assist
infus
allevi
graft
versu
host
reaction
may
increas
incid
viral
infect
data
significantli
differ
major
haploid
transplant
center
world
p
iamsirirak
children
hospit
pediatr
bangkok
thailand
backgroundobject
thalassemia
common
genet
diseas
thailand
countri
sever
thalassemia
affect
health
qualiti
life
life
expect
includ
beta
thalassemia
major
bb
beta
thalassemiahb
e
diseas
allogen
hematopoiet
stem
cell
transplant
hsct
cur
therapi
diseas
present
match
relat
unrel
donor
effect
use
hsct
sever
thalassemia
howev
patient
lack
suitabl
donor
extend
opportun
hsct
thalassemia
haploident
donor
stem
cell
hsct
studi
object
studi
demonstr
efficaci
earli
complic
patient
sever
thalassemia
reciev
haploident
hsct
institut
designmethod
collect
demograph
transplant
relat
data
patient
thalassemia
underw
haploident
hsct
samitivej
srinakarin
hospit
result
patient
diagnos
thalassemia
underw
transplant
median
age
year
rang
year
condit
regimen
consist
antithymocyt
globulin
fludarabin
iv
busulfan
donor
either
father
mother
peripher
blood
stem
cell
median
cell
kg
rang
infus
neutropenia
engraft
occur
day
rang
day
two
patient
develop
primari
graft
failur
underw
second
haploident
hsct
howev
one
engraft
surviv
median
length
hospit
stay
day
rang
day
infecti
complic
includ
bacteri
sepsi
fungal
sepsi
cmv
reactiv
acut
graft
versu
host
diseas
gvhd
diagnos
patient
grade
four
patient
requir
picu
admiss
three
patient
readmit
within
day
discharg
conclus
demonstr
haploident
hsct
patient
thalassemia
feasibl
may
consid
choic
cur
treatment
hj
im
h
kn
sy
jj
ulsan
colleg
asan
medic
center
pediatr
seoul
republ
korea
backgroundobject
evalu
outcom
haploident
hct
hhct
use
ex
vivo
tcd
graft
condit
ric
contain
tbi
pediatr
patient
acut
leukemia
al
designmethod
patient
al
aml
nr
nine
relaps
previou
allogen
hct
patient
aml
underw
uniform
ric
regimen
consist
cgi
fludarabin
cyclophosphamid
rabbit
atg
patient
receiv
condit
regimen
aml
remain
receiv
higher
tbi
dose
cgi
result
patient
achiev
sustain
neutrophil
engraft
median
day
rang
cumul
incid
acut
gvhd
grade
march
patient
surviv
free
diseas
median
month
rang
trm
year
ef
os
year
patient
respect
among
patient
receiv
relaps
wherea
none
receiv
relaps
among
patient
aml
ef
patient
receiv
first
hhct
cr
better
patient
receiv
hct
activ
diseas
relaps
previou
allogen
hct
vs
p
conclus
ex
vivo
tcd
hhct
use
ric
contain
feasibl
low
trm
outcom
patient
aml
receiv
first
transplant
cr
excel
howev
outcom
poor
suggest
intensifi
condit
regimen
may
reason
furthermor
innov
treatment
strategi
warrant
patient
relaps
refractori
aml
h
c
kai
b
n
j
j
h
children
hoapit
haemotologyoncolog
shanghai
china
backgroundobject
explor
feasibl
prognosi
modifi
umbil
cord
blood
transplant
ucbt
treatment
famili
hemophagocyt
syndrom
fhl
donor
specif
hla
antibodi
dsa
posit
designmethod
summar
clinic
featur
treatment
plan
short
term
patient
dsa
strongli
posit
review
literatur
result
case
review
old
boy
diagnos
fhl
found
gene
mother
mutat
sourc
relaps
month
regimen
treatment
meanwhil
central
nervou
system
involv
intrathec
inject
given
time
chemotherapi
anti
monoclon
antibodi
strengthen
condit
control
transplant
select
found
child
dsa
posit
mainli
exist
b
dqb
mfi
treatment
rituximab
plasma
exchang
reexamin
dsa
significantli
reduc
final
chose
hla
cb
tnc
posit
antiprototyp
antibodi
posit
compar
cb
transplant
scheme
final
improv
precondit
regimen
front
atg
prevent
gvhd
csa
cur
effect
analysi
time
neutrophil
platelet
day
day
transplant
respect
reexamin
gene
mutat
str
show
complet
chimer
degre
agvhd
skin
grade
found
cytomegaloviru
infect
present
literatur
review
home
abroad
point
failur
rate
ucbt
high
mani
complic
transplant
relat
report
ucbt
dsa
posit
conclus
umbil
cord
blood
transplant
fhl
difficult
mani
complic
front
atg
precondit
regimen
advantag
protect
umbil
cord
blood
cell
increas
implant
bk
kim
kt
hj
hy
jy
hy
hs
ss
js
nation
univers
colleg
medicin
pediatr
seoul
republ
korea
nation
univers
colleg
medicin
laboratori
medicin
seoul
republ
korea
univers
sacr
heart
hospit
laboratori
medicin
anyang
republ
korea
backgroundobject
diseas
ptld
one
common
malign
ptld
occur
hematopoiet
stem
cell
transplant
pediatr
patient
rituximab
monoclon
antibodi
use
prophylaxi
treatment
ptld
efficaci
preemptiv
treatment
yet
fulli
elucid
purpos
studi
prove
effect
preemptiv
treatment
rituximab
ebv
relat
ptld
hsct
pediatr
patient
designmethod
analyz
pediatr
patient
undergo
allogen
hsct
seoul
nation
univers
children
hospit
develop
high
ebv
dnaemia
administr
rituximab
preemptiv
patient
copiesml
daili
follow
weekli
ebv
load
copiesml
investig
ebv
titer
whole
blood
rituximab
infus
check
ptld
incid
side
effect
result
underli
diseas
patient
acut
leukemia
aplast
anemia
genet
rare
diseas
median
ebv
titer
rituximab
treatment
copiesml
rang
copiesml
rituximab
infus
median
day
rang
day
ebv
dnaemia
patient
ebv
dnaemia
erad
median
day
rang
day
ptld
occur
patient
patient
sever
side
effect
hsct
relat
mortal
occur
patient
ebv
infect
ptld
acut
graft
versu
host
diseas
hepat
venou
occlus
diseas
patient
still
aliv
without
diseas
median
month
rang
transplant
conclus
preemptiv
therapi
rituximab
effect
safe
treatment
ebv
dnaemia
pediatrt
hsct
preemptiv
therapi
expect
reduc
incid
ptld
hsct
improv
outcom
howev
follow
studi
need
k
kirgizov
e
n
e
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
institut
manag
translat
medicin
moscow
russia
russian
children
research
hospit
bone
marrow
transplant
moscow
russia
backgroundobject
hematopoiet
stem
cell
transplant
hsct
effect
method
treatment
children
adult
broad
spectrum
diseas
experi
hsct
children
malign
diseas
first
year
life
limit
object
studi
repres
featur
hsct
children
first
year
life
designmethod
sixteen
patient
transplant
includ
analysi
age
median
month
male
diagnos
nb
aml
jmml
patient
neuroblastoma
receiv
autolog
hsct
children
hematolog
malign
allogen
hsct
match
unrel
donor
match
relat
donor
patient
receiv
myeloabl
condit
standard
support
care
result
twelv
patient
surviv
four
patient
die
patient
aml
relaps
patient
neuroblastoma
relaps
mortal
median
year
caus
death
regist
toxic
mild
mucos
patient
sever
mucos
patient
mild
enterocol
sever
enterocol
regist
patient
success
treat
complic
resolv
adequ
support
care
sever
gvhd
found
patient
receiv
reveal
patient
receiv
less
intens
mucos
sever
late
effect
reveal
develop
growth
normal
conclus
hsct
patient
first
year
life
effect
safe
method
treatment
malign
disord
includ
solid
tumor
leukemia
toxic
could
control
case
adequ
support
care
nutrit
support
breast
feed
children
first
year
life
could
transplant
intens
myeloabl
condit
regimen
futur
develop
patient
affect
gk
lam
fwt
rkt
mhm
mk
v
ck
wale
chines
univers
hong
kong
depart
paediatr
hong
kong
hong
kong
sar
wale
chines
univers
hong
kong
depart
chemic
patholog
hong
kong
hong
kong
sar
backgroundobject
children
receiv
busulfan
base
condit
regimen
haematopoiet
stem
cell
transplant
hsct
mark
variabl
busulfan
pharmacokinet
studi
aim
review
transplant
relat
toxic
paediatr
hsct
patient
receiv
intraven
busulfan
therapeut
drug
monitor
tdm
tertiari
hospit
hong
kong
designmethod
patient
year
underw
hsct
busulfan
condit
april
decemb
includ
busulfan
pharmacokinet
analys
first
dose
target
area
curv
auc
defin
umol
min
daili
dose
umol
min
everi
hour
dose
clinic
outcom
interest
hepat
diseas
vod
mortal
result
patient
includ
malign
condit
condit
median
age
year
sixteen
patient
mainli
malign
condit
receiv
daili
dose
thirteen
receiv
dose
four
patient
dosag
adjust
proport
base
tdm
result
increas
reduc
vod
occur
patient
receiv
daili
dose
receiv
dose
median
time
vod
diagnosi
day
one
patient
high
auc
umol
min
develop
sever
vod
despit
dose
reduct
die
failur
month
patient
auc
within
target
rang
first
dose
recov
vod
overal
surviv
patient
develop
vod
day
conclus
vod
might
common
children
receiv
daili
dose
busulfan
two
patient
dose
reduc
one
still
develop
sever
vod
die
two
patient
dose
increas
without
sever
vod
repeat
tdm
busulfan
dose
modif
may
guid
decis
adjust
r
martin
k
regensburg
depart
pediatr
hematolog
oncolog
stem
cell
transplant
regensburg
germani
health
strategi
statist
bethesda
usa
pharmaceut
medic
palo
alto
usa
backgroundobject
hepat
diseasesinusoid
obstruct
syndrom
vodso
potenti
complic
hematopoiet
stem
cell
transplant
hsct
vodso
dysfunct
mod
may
associ
mortal
analysi
assess
surviv
report
literatur
pediatr
patient
year
treat
defibrotid
vodso
without
mod
designmethod
systemat
literatur
review
pubm
embas
specif
congress
websit
search
defibrotid
report
publish
juli
studi
type
cohort
case
seri
retrospect
chart
review
random
effect
model
use
pool
efficaci
data
interstudi
heterogen
assess
cochran
percentag
total
variat
across
studi
due
heterogen
evalu
advers
event
ae
summar
result
six
studi
provid
data
pediatr
patient
receiv
defibrotid
mgkgday
overal
estim
surviv
ci
vodso
mod
studi
identifi
pool
estim
surviv
one
studi
identifi
vodso
without
mod
estim
surviv
safeti
result
pool
individu
studi
result
consist
phase
histor
control
trial
vodso
mod
pediatr
patient
control
ae
hypotens
frequent
defibrotid
control
common
hemorrhag
ae
ie
pulmonari
alveolar
gastrointestin
hemorrhag
occur
patient
control
conclus
pool
analysi
pediatr
patient
vodso
treat
defibrotid
mgkgday
estim
surviv
mod
without
mod
safeti
result
gener
consist
known
defibrotid
safeti
profil
analysi
publish
literatur
provid
insight
estim
surviv
pediatr
patient
vodso
treat
defibrotid
mgkgday
support
jazz
pharmaceut
k
mullanfiroz
r
dhirubhai
ambani
hospit
blood
marrow
transplant
mumbai
india
dhirubhai
ambani
hospit
transfus
medicin
mumbai
india
backgroundobject
clinic
outcom
especi
white
cell
platelet
engraft
autolog
stem
cell
transplant
asct
depend
great
extent
viabil
stem
cell
infus
recipi
techniqu
cryopreserv
stem
cell
key
determin
viabil
two
method
use
cryopreserv
viz
control
dump
freezinguncontrol
rate
freez
former
said
gold
standard
view
expertis
infrastructur
requir
control
rate
freez
techniqu
practic
centr
herebi
evalu
efficaci
method
term
engraft
recipi
receiv
frozen
product
designmethod
stem
cell
product
studi
period
year
viabil
stem
cell
deriv
product
cryopreserv
thaw
ie
time
infus
recipi
measur
flow
cytometri
stem
cell
infus
month
rang
month
averag
cryopreserv
pair
test
use
statist
analysi
data
recipi
receiv
ident
support
care
measur
per
clinic
need
result
mean
viabil
post
thaw
viabil
overal
reduct
viabil
p
valu
averag
white
cell
platelet
engraft
recipi
cryopreserv
product
infus
asct
rang
rang
day
respect
conclus
optim
method
cryopreserv
stem
cell
evidenc
signific
loss
viabil
stem
cell
seen
studi
howev
clinic
outcom
engraft
post
asct
almost
ident
report
literatur
henc
dump
freez
accept
option
cryopreserv
especi
develop
countri
infrastructur
control
freez
current
lack
k
mullanfiroz
g
r
dhirubhai
ambani
hospit
blood
marrow
transplant
mumbai
india
dhirubhai
ambani
hospit
transfus
medicin
mumbai
india
backgroundobject
clinic
outcom
especi
white
cell
platelet
engraft
autolog
stem
cell
transplant
asct
depend
great
extent
viabil
stem
cell
infus
recipi
techniqu
cryopreserv
stem
cell
key
determin
viabil
two
method
use
cryopreserv
viz
control
dump
freezinguncontrol
rate
freez
former
said
gold
standard
view
expertis
infrastructur
requir
control
rate
freez
techniqu
practic
centr
herebi
evalu
efficaci
method
term
engraft
recipi
receiv
frozen
product
designmethod
stem
cell
product
studi
period
year
viabil
stem
cell
deriv
product
cryopreserv
thaw
ie
time
infus
recipi
measur
flow
cytometri
stem
cell
infus
month
rang
month
averag
cryopreserv
pair
test
use
statist
analysi
data
recipi
receiv
ident
support
care
measur
per
clinic
need
result
mean
viabil
post
thaw
viabil
overal
reduct
viabil
p
valu
averag
white
cell
platelet
engraft
recipi
cryopreserv
product
infus
asct
rang
rang
day
respect
conclus
optim
method
cryopreserv
stem
cell
evidenc
signific
loss
viabil
stem
cell
seen
studi
howev
clinic
outcom
engraft
post
asct
almost
ident
report
literatur
henc
dump
freez
accept
option
cryopreserv
especi
develop
countri
infrastructur
control
freez
current
lack
ponlakan
n
medicin
ramathibodi
mahidol
univers
depart
pediatr
bangkok
thailand
backgroundobject
hemorrhag
cystiti
hc
common
complic
allogen
hsct
bk
viru
bkv
adenoviru
adv
major
organ
caus
hc
clinic
sever
rang
microscop
hematuria
renal
failur
howev
kinet
bkv
adv
viral
load
patient
allogen
hsct
well
elucid
prospect
bkv
respons
studi
patient
allogen
hsct
withwithout
hc
object
demonstr
kinet
bkv
adv
viral
load
determin
bkv
respons
patient
allogen
hsct
designmethod
prospect
cohort
studi
recruit
patient
underw
allogen
hsct
novemb
novemb
demograph
transplant
relat
data
collect
viral
load
prospect
regularli
measur
start
day
month
transplant
bkv
respons
detect
use
flow
cytometri
techniqu
patient
classifi
group
neg
viral
load
hc
posit
viral
load
hc
posit
viral
load
hc
result
median
age
year
rang
year
underli
diseas
malign
diseas
patient
receiv
haploident
donor
stem
cell
hc
occur
patient
median
onset
day
caus
bkv
adv
mix
mean
maxim
bkv
adv
viral
load
serum
copiesml
copiesml
mean
maxim
bkv
respons
conclus
serum
bkv
adv
viral
load
patient
hc
higher
without
hc
interestingli
patient
bkv
andor
adv
infect
without
hc
produc
higher
viral
specif
respons
patient
hc
data
support
usag
viru
specif
therapi
set
pusalkar
r
v
k
p
k
v
j
dhirubhai
ambani
hospit
depart
laboratori
medicin
mumbai
india
dhirubhai
ambani
hospit
depart
paediatr
oncolog
bmt
mumbai
india
dhirubhai
ambani
hospit
depart
haematolog
bmt
mumbai
india
backgroundobject
detect
donor
chimer
use
detect
earli
graft
loss
diseas
recurr
pcr
fragment
analysi
base
detect
use
short
tandem
repeat
str
marker
help
accur
measur
percentag
donor
cell
aim
present
studi
standard
valid
assay
detect
mix
donor
chimer
follow
bmt
designmethod
standard
assay
carri
use
artifici
chimer
blood
sampl
four
healthi
volunt
differ
grade
donor
cell
popul
valid
assay
done
per
standard
guidelin
total
patient
donor
pair
screen
base
line
str
analysi
hsct
total
sampl
hsct
case
assess
baselin
screen
inform
str
marker
done
pcr
amplif
str
loci
viz
fga
ame
along
gapdh
intern
control
product
subject
capillari
electrophoresi
use
genet
analys
data
analys
use
genemapp
softwar
pcr
fragment
analysi
carri
specif
inform
marker
across
artifici
chimer
sampl
well
sampl
result
chimer
sampl
healthi
volunt
show
accuraci
detect
expect
donor
chimer
valu
result
independ
valid
concord
coeffici
variat
accuraci
estim
donor
statu
could
achiev
level
donor
cell
conclus
chimer
data
standard
sampl
real
patient
sampl
show
excel
correl
compar
independ
laboratori
thu
confirm
valid
diagnost
method
analys
post
transplant
chimer
thu
use
assay
facilit
earli
detect
graft
loss
diseas
recurr
post
transplant
patient
ramzan
r
hospit
dept
pediatr
hematolog
oncolog
bmt
jaipur
india
hospit
obstetr
gynecolog
jaipur
india
hospit
dept
hematopatholog
jaipur
india
backgroundobject
bk
hemorrhag
cystiti
bkhc
potenti
seriou
complic
occur
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
ciprofloxacin
prophylaxi
shown
reduc
incid
sever
bkhc
hsct
match
relat
unrel
donor
designmethod
retrospect
analyz
data
patient
underw
haploident
hsct
vari
indic
august
februari
institut
univers
ciprofloxacin
prophylaxi
start
condit
regimen
till
post
hsct
episod
hemorrhag
cystiti
hc
grade
follow
grade
microscop
hematuria
grade
macroscop
hematuria
grade
macroscop
hematuria
small
blood
clot
grade
massiv
macroscop
hematuria
requir
instrument
urinari
tract
caus
urinari
retent
includ
grade
bkhc
sever
bkhc
result
thirti
six
patient
underw
haploident
hsct
thirti
three
benign
hemoglobinopathi
aplast
anemia
diamond
blackfan
anemia
primari
immunodefici
malign
cell
lymphoma
acut
myeloid
leukemia
total
hc
grade
six
grade
two
four
thirti
six
bkv
reactiv
sever
bkhc
condit
regimen
includ
thiotepa
signific
symptom
hc
bkv
reactiv
mean
day
bkv
reactiv
day
post
hsct
none
patient
bkhc
featur
acut
graft
versu
host
diseas
patient
symptom
hc
initi
treat
leflunamid
one
treat
cidofovir
nephropathi
die
due
sepsi
conclus
ciprofloxacin
prophylaxi
effect
reduc
sever
bkhc
haploident
hsct
condit
regimen
thiotepa
associ
bkv
reactiv
studi
need
confirm
result
rivera
r
navarro
martin
del
al
alvarado
civil
de
guadalajara
juan
menchaca
pediatr
hematolog
oncolog
guadalajara
mexico
backgroundobject
hemorrhag
cystiti
ch
character
micromacroscop
hematuria
variabl
intens
least
day
durat
present
patient
receiv
hematopoiet
cell
transplant
relat
intens
condit
high
dose
cyclophosphamid
thrombocytopenia
secondari
transplant
viral
infect
cmv
polyomaviru
prevent
includ
hyperhydr
mesna
treatment
late
cystiti
support
object
know
incid
hc
transplant
unit
center
analyz
use
therapi
designmethod
systemat
retrospect
review
patient
transplant
unit
hematopoiet
progenitor
hospit
civil
de
guadalajara
juan
menchaca
hc
classifi
grade
microscop
hematuria
grade
macroscop
hematuria
grade
gross
hematuria
clot
grade
andor
urinari
obstruct
renal
failur
bladder
damag
ch
defin
microscop
macroscop
hematuria
dysuria
neg
urin
bacteri
cultur
hemorrhag
condit
result
patient
transplant
patient
develop
ch
averag
durat
day
patient
viral
infect
determin
etiolog
patient
requir
least
differ
treatment
requir
hyperhydr
patient
blood
product
patient
grade
iii
cystiti
patient
die
activ
hc
conclus
incid
hc
unit
within
world
incid
viral
marker
disadvantag
determin
certainli
etiolog
give
specif
treatment
target
prophylaxi
k
roja
rivera
gonzalez
r
mallin
orozco
c
carballido
g
tavar
guadalajara
mexico
backgroundobject
object
report
clinic
case
patient
develop
toxic
epiderm
necrolysi
net
allogen
transplant
good
respons
treatment
clinic
report
femal
pure
aplasia
red
seri
allogen
transplant
ident
famili
presenc
antibodi
compat
histori
ferritin
iron
overload
condit
busulfan
cfm
fludarabin
atg
rituximab
plasmapheresi
infus
progenitor
present
gener
cutan
rash
achiev
day
present
intens
erythema
exanthema
flictena
neck
anterior
thorax
extrem
becom
slough
figur
day
skin
biopsi
figur
spongiosi
document
dermoepiderm
junction
incipi
subderm
vesicl
format
receiv
treatment
surgic
debrid
topic
colloid
silver
methylprednisolon
mg
kg
day
immunoglobulin
g
kg
weekli
mtx
mg
prophylaxi
gvhd
folin
acid
mg
dose
thu
lesion
resolv
toward
day
day
discharg
designmethod
descript
case
report
result
net
manifest
syndrom
follow
develop
erythema
skin
subsequ
prurit
macul
rapidli
evolv
larg
necrot
blister
involv
oral
ocular
genit
mucosa
among
trigger
agent
sulfonamid
tetracyclin
carbamazepin
allopurinol
barbitur
antimalari
agent
chemotherapeut
drug
warfarin
agent
onset
net
usual
acut
may
occur
week
start
therapi
also
first
month
treatment
diagnosi
base
mainli
clinic
sign
histolog
analysi
skin
biopsyprognosi
reserv
although
appropri
therapi
high
mortal
adult
less
children
conclus
relationship
patholog
suggest
mani
author
k
roja
rivera
gonzalez
r
mallin
orozco
c
carballido
g
tavar
guadalajara
mexico
backgroundobject
introduct
object
report
clinic
case
patient
develop
toxic
epiderm
necrolysi
net
allogen
transplant
good
respons
treatment
clinic
report
femal
year
old
diagnos
pure
aplasia
red
seri
underw
allogen
transplant
ident
famili
patient
hla
condit
busulfan
cfm
fludarabin
atg
rituximab
plasmapheresi
day
present
grade
iv
gvhd
begin
intens
gener
erythema
exanthema
flictena
evolv
shini
edemat
skin
cm
flictena
right
upper
limb
knee
area
disloc
skin
detach
figur
day
skin
biopsi
perform
figur
spongiosi
evidenc
dermoepiderm
junction
incipi
format
subderm
vesicl
without
evid
vascul
suggest
gvhd
designmethod
case
report
result
toxic
epiderm
necrolysi
ten
lyell
syndrom
febril
reaction
scarc
occurr
lead
sever
skin
involv
affect
femal
gender
character
complet
loss
epidermi
leav
denud
area
involv
bodi
surfac
appear
describ
adult
conclus
gvhd
allogen
transplant
hematopoiet
stem
cell
may
repres
immun
trigger
often
difficult
differenti
net
clinic
given
cutan
involv
gener
howev
biopsi
help
differenti
diagnosi
howev
condit
evolv
relationship
patholog
suggest
mani
author
kh
ryu
es
ej
yh
ka
hm
jw
sy
woman
univers
colleg
medicin
depart
pediatr
seoul
republ
korea
univers
daegu
school
medicin
depart
pediatr
daegu
republ
korea
woman
univers
colleg
medicin
depart
microbiolog
seoul
republ
korea
univers
colleg
medicin
depart
pediatr
wonju
republ
korea
woman
univers
colleg
medicin
depart
biochemistri
seoul
republ
korea
backgroundobject
administr
mesenchym
stem
cell
msc
procedur
bone
marrow
transplant
bmt
wide
report
promot
bm
engraft
studi
assess
effect
msc
condit
medium
cm
bm
engraft
addit
investig
whether
msc
cm
could
restor
vascular
endotheli
cell
ec
order
enhanc
bm
engraft
designmethod
partial
ablat
mous
bone
marrow
bm
perform
administr
busulfan
cyclophosphamid
condit
regimen
mgkg
bu
day
mgkg
cy
day
balbc
recipi
mice
donor
bm
cell
isol
mice
transplant
via
tail
vein
without
mesenchym
stem
cell
condit
medium
cm
cm
inject
two
day
later
bm
engraft
examin
day
use
h
e
stain
femur
flow
cytometri
analysi
bm
cell
restor
endotheli
cell
ec
examin
measur
ec
circul
flow
cytometri
endomucin
express
proxim
femur
immunohistochemistri
result
cm
improv
bm
engraft
reveal
microscop
observ
h
e
stain
femur
flow
cytometr
mhc
class
haplotyp
condit
regimen
impair
vascular
ec
henc
increas
number
circul
ec
identifi
increas
peripher
ec
treatment
partial
restor
bmt
decreas
cm
treatment
express
endomucin
marker
bm
endotheli
cell
examin
found
endomucin
express
downregul
bmt
group
mice
wherea
cm
treatment
protect
bm
endotheli
cell
conclus
conclus
cm
administr
bmt
enhanc
bm
engraft
part
restor
ec
studi
requir
find
molecul
secret
msc
show
effect
bm
engraft
find
highlight
potenti
therapeut
relev
cm
increas
bmt
efficaci
sen
k
r
k
p
r
v
dhirubhai
ambani
hospit
depart
paediatr
oncolog
bmt
mumbai
india
dhirubhai
ambani
hospit
depart
haematolog
bmt
mumbai
india
dhirubhai
ambani
hospit
depart
laboratori
medicin
mumbai
india
backgroundobject
optimum
mode
storag
non
frozen
stem
cell
product
defin
standardis
transplant
unit
would
store
stem
cell
non
frozen
state
meant
infus
within
hour
howev
viabil
stem
cell
certain
permiss
time
storag
avail
henc
ascertain
viabil
stem
cell
product
store
hour
collect
designmethod
peripher
blood
stem
cell
pbsc
product
taken
studi
sampl
kept
non
frozen
liquid
state
flow
cytometri
use
protocol
use
determin
viabil
sampl
hour
collect
hour
statist
analysi
result
done
use
pair
test
result
mean
volum
sampl
test
ml
ml
mean
wbc
count
averag
viabil
hour
hour
averag
viabil
equat
loss
howev
viabil
drop
hour
hour
drop
conclus
pbsc
integr
optim
maintain
upto
hour
store
liquid
state
use
limit
use
dmso
cryopreserv
assist
decis
make
harvest
pbsc
earli
mobilis
rapid
studi
provid
conclus
evid
accept
viabil
pbsc
store
upto
hour
sen
k
dhirubhai
ambani
hospit
depart
paediatr
oncolog
bmt
mumbai
india
dhirubhai
ambani
hospit
depart
haematolog
bmt
mumbai
india
backgroundobject
primari
graft
failur
remain
one
import
caus
mortal
morbid
case
stem
cell
transplant
report
case
aplast
anaemia
immedi
rescu
haploident
stem
cell
transplant
differ
donor
result
success
engraft
designmethod
old
male
child
diagnos
sever
aplast
anemia
unfortun
match
sibl
donor
henc
haploident
transplant
use
father
stem
cell
undertaken
condit
fludarabin
cyclophosphamid
atg
tbi
post
transplant
cyclophosphamid
use
gvhd
prophylaxi
unfortun
fail
engraft
day
undertook
second
rescu
haploident
transplant
primari
graft
failur
reject
father
stem
cell
decid
use
father
second
time
around
donor
use
mother
stem
cell
though
profoundli
neutropen
wbc
count
decid
give
full
repeat
condit
protocol
surmis
still
activ
immun
system
reject
primari
graft
repeat
condit
use
protocol
start
day
mother
stem
cell
infus
day
result
engraft
success
day
second
transplant
though
transplant
complic
cutan
fungal
infect
cmv
reactiv
child
discharg
home
donor
engraft
conclus
second
haploident
transplant
use
repeat
condit
use
success
case
primari
graft
failur
n
k
sen
dhirubhai
ambani
hospit
depart
paediatr
oncolog
bmt
mumbai
india
dhirubhai
ambani
hospit
depart
haematolog
bmt
mumbai
india
backgroundobject
lack
hla
match
sibl
fulli
match
unrel
donor
impedi
transplant
haploident
transplant
viabl
altern
develop
world
context
especi
relev
indian
subcontin
due
lack
larg
stem
cell
registri
cost
associ
obtain
cell
oversea
registri
designmethod
februari
march
haploident
bone
marrow
transplant
bmt
done
patient
age
rang
month
year
median
yr
male
femal
patient
underw
haploident
bmt
indic
rang
malign
diseas
relaps
aml
cml
benign
diseas
like
thalassemia
major
chronic
granulomat
diseas
aplast
anaemia
donor
parent
immedi
sibl
haploident
recipi
result
die
due
transplant
relat
toxic
child
aplast
anaemia
first
transplant
father
graft
reject
second
success
haploident
bmt
done
mother
donor
receiv
cell
replet
stem
cell
post
transplant
cyclophosphamid
mmf
calcineurin
inhibitor
gvhd
prophylaxi
one
receiv
bone
marrow
stem
cell
transfus
gcsf
stimul
peripher
blood
stem
cell
conclus
median
follow
period
month
data
still
young
howev
overal
surviv
haploident
bone
marrow
transplant
promis
new
option
special
develop
world
lack
appropri
donor
sen
k
r
dhirubhai
ambani
hospit
depart
paediatr
oncolog
bmt
mumbai
india
dhirubhai
ambani
hospit
depart
haematolog
bmt
mumbai
india
dhirubhai
ambani
hospit
depart
laboratori
medicin
mumbai
india
backgroundobject
though
abo
incompat
contraind
bmt
factor
respons
graft
failur
lower
surviv
present
data
abo
incompat
transplant
outcom
designmethod
identifi
transplant
done
abo
incompat
januari
decemb
indic
bmt
malign
like
refractori
aml
relaps
b
benign
haematolog
condit
like
aplast
anaemia
thalassemia
major
among
abo
incompat
bmt
major
incompat
minor
major
bidirect
blood
group
incompat
determin
recipi
antibodi
titr
case
recipi
isoagglutinin
titr
repeat
plasma
exchang
done
till
antibodi
titr
less
ivig
dose
gmkg
also
given
recipi
day
red
cell
deplet
graft
centrifug
also
undertaken
case
major
abo
incompat
result
one
patient
major
abo
incompat
sever
haemolyt
reaction
follow
infus
bone
marrow
stem
cell
transplant
abort
baselin
isoagglutinin
level
repeat
plasma
deplet
patient
done
reduc
isoagglutinin
level
peripher
blood
stem
cell
harvest
donor
red
cell
deplet
centrifug
infus
without
incid
none
case
immedi
delay
haemolyt
reaction
howev
patient
subsequ
die
due
graft
failur
sepsi
conclus
seri
abo
incompat
seem
major
factor
behind
poor
outcom
mortal
limit
seri
possibl
due
aggress
natur
primari
diseas
like
refractori
aml
patient
condit
rather
blood
group
mismatch
per
se
sharma
n
p
sp
medic
paediatr
haematolog
oncolog
bmt
gurgaon
india
backgroundobject
haploident
famili
donor
univers
avail
fast
emerg
altern
donor
choic
children
leukaemia
need
hematopoiet
stem
cell
transplant
hsct
herein
describ
experi
treat
children
leukaemia
haploident
hsct
cyclophosphamid
ptci
designmethod
retrospect
analys
outcom
data
children
acut
leukaemia
acut
lymphoblast
acut
myeloid
mix
phenotyp
acut
underw
haploident
hsct
median
age
month
ten
complet
remiss
cr
prior
hsct
one
partial
remiss
donor
mobil
gcsf
condit
fludarabin
cyclophosphamid
mgkg
total
bodi
irradi
tbi
myeloabl
thiotepa
mgkg
fludarabin
cyclophosphamid
mgkg
tbi
fludarabin
busulfan
mgkg
receiv
ptci
mgkg
day
graft
vs
host
diseas
gvhd
prophylaxi
along
tacrolimu
mycophenol
mofetil
median
million
infus
result
engraft
rate
median
time
neutrophil
engraft
day
platelet
engraft
day
chimer
day
fulli
donor
children
four
children
relaps
die
one
child
posit
leukaemia
therapi
rituximab
remain
patient
cr
acut
gvhd
seen
patient
four
children
develop
chronic
gvhd
aliv
three
children
receiv
condit
relaps
overal
surviv
surviv
median
day
conclus
haploident
hsct
ptci
safe
effect
therapi
children
acut
leukaemia
myeloabl
condit
chronic
gvhd
lead
improv
surviv
n
sidorova
k
e
v
e
marrow
transplat
russian
children
research
hospilt
moscow
russia
backgroundobject
hematopoiet
stem
cell
transplant
match
unrel
donor
mud
hsct
routin
method
oncolog
diseas
children
import
factor
discuss
designmethod
period
perform
mud
hsct
diagnosi
malign
blood
diseas
diseas
gender
distribut
male
femal
age
median
yo
month
yo
stem
cell
sourc
bone
marrow
peripher
blood
stem
cell
pt
receiv
mud
hsct
pt
mud
hsct
differ
system
singl
group
minor
major
mix
age
donor
yo
yo
yo
gender
differ
donorrecipi
malefemal
femalemal
one
sex
result
group
estim
probabl
overal
surviv
os
group
os
overal
incid
graft
versu
host
diseas
agvhd
st
group
increas
donor
age
year
reduc
os
howev
os
donor
year
old
found
differ
transplant
donor
compatibleincompat
abo
gender
differ
donorrecipi
conclus
studi
show
role
genet
match
hla
system
patient
unrel
donor
donor
age
valu
transplant
better
outcom
lower
incid
sever
gvhd
younger
donor
increas
os
signific
increas
os
donor
year
old
n
sidorova
k
e
v
e
russian
children
research
hospit
bone
marrow
transplant
moscow
russia
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
institut
manag
translat
medicin
moscow
russia
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
hematopoiet
stem
cell
transplant
moscow
russia
backgroundobject
hematopoiet
stem
cell
transplant
match
unrel
donor
mud
hsct
routin
method
malign
diseas
children
import
factor
discuss
object
analyz
factor
affect
outcom
hematopoiet
stem
cell
transplant
children
designmethod
perform
mud
hsct
diagnos
malign
blood
diseas
diseas
gender
distribut
male
femal
age
median
yo
month
yo
stem
cell
sourc
bone
marrow
peripher
blood
stem
cell
pt
receiv
mud
hsct
pt
mud
hsct
differ
system
singl
group
minor
major
mix
age
donor
yo
yo
yo
gender
differ
donorrecipi
malefemal
femalemal
one
sex
result
group
estim
probabl
overal
surviv
os
group
os
overal
incid
graft
versu
host
diseas
agvhd
st
group
increas
donor
age
year
reduc
os
howev
os
donor
year
old
differ
transplant
donor
compatibleincompat
abo
well
gender
differ
donorrecipi
conclus
show
transplant
better
outcom
lower
incid
sever
gvhd
younger
donor
increas
os
signific
increas
os
donor
year
old
c
strahlendorf
k
g
children
hospit
divis
hemoncbmt
vancouv
canada
childrenshospit
vancouv
canada
vancouv
canada
backgroundobject
peripher
blood
mononuclear
cell
pbmc
collect
administr
recombin
human
granulocyt
factor
use
autolog
hematopoiet
stem
cell
myeloabl
therapi
mani
instanc
pediatr
cancer
children
abil
time
collect
accur
well
effici
collect
enough
stem
cell
shortest
possibl
time
advantag
new
continu
mononuclear
cell
collect
cmnc
protocol
spectra
optia
apheresi
system
collect
autolog
peripher
blood
stem
cell
pbsc
allow
us
evalu
method
pediatr
designmethod
evalu
stem
cell
collect
use
cmnc
protocol
spectra
optia
children
solid
tumour
mobil
chemotherapi
monitor
peripher
count
prior
collect
final
product
cp
evalu
cell
result
children
weight
rang
kg
mean
solid
tumour
stem
cell
collect
use
cmnc
protocol
apheresi
durat
minut
peripher
count
rang
collect
effici
rang
median
platelet
loss
median
count
product
averag
cellskg
equat
dose
procedur
linear
correl
peripher
count
final
product
dosekg
allow
predict
model
effici
collect
procedur
well
toler
advers
event
engraft
data
yet
avail
conclus
spectra
optia
cmnc
protocol
success
collect
cell
yield
suffici
autolog
transplant
solid
tumour
children
cell
yield
predict
good
excel
collect
effici
pbsc
collect
cmnc
protocol
advantag
predict
final
product
dose
minim
platelet
loss
minim
product
volum
make
stem
cell
collect
children
easier
faster
safe
n
subbotina
v
v
g
blokhin
nation
medic
research
oncolog
center
institut
pediatr
oncolog
hematolog
moscow
russia
backgroundobject
great
problem
resist
cgvhd
treatment
suppos
patient
immun
system
reset
may
benefit
case
designmethod
patient
z
diagnos
juli
age
yo
jmml
treat
cytarabin
epigenet
agent
decemb
diseas
progress
prime
follow
mac
melphalan
treosulfan
unmanipul
haploident
pbsct
mother
perform
earli
posttranspl
period
top
immunosuppress
therapi
cni
mmf
patient
acut
gvhd
also
treat
steroid
inhibitor
multipl
ecp
boy
stay
complet
remiss
full
donor
chimer
attempt
immunosupress
reduct
caus
skin
flare
gvhd
patient
kept
high
dose
tacrolimu
mmf
cours
steroid
till
spring
decid
make
kind
immun
system
reset
april
may
patient
got
two
dose
rituximab
part
prepar
regimen
immun
system
restor
later
may
first
cours
cy
perform
hematolog
recoveri
prime
pbsc
collect
done
june
patient
underw
nma
regimen
cy
day
flu
day
follow
auto
hsct
result
hematolog
recoveri
fast
without
signific
toxic
becom
possibl
declin
dose
tacrolimu
month
pt
becam
patient
remiss
mmf
sign
gvhd
month
conclus
thu
approach
donor
immun
system
restor
consid
new
treatment
option
long
last
aggress
gvhd
c
vya
f
n
v
memori
research
institut
pediatr
bone
marrow
transplant
gurugram
india
backgroundobject
allogen
stem
cell
transplant
servic
children
still
far
behind
india
compar
develop
countri
resourc
constraint
present
experi
variou
benign
malign
paediatr
diseas
designmethod
retrospect
analysi
total
children
male
femal
underw
januari
may
centr
done
mean
age
patient
year
rang
year
indic
hemoglobinopathi
thalassemia
major
tm
sickl
cell
diseas
scd
aplast
fanconi
immunodefici
one
syndrom
syndrom
acut
myeloid
leukaemia
aml
acut
lymphoblast
leukaemia
juvenil
myelomocyt
leukaemia
jmml
myelodysplast
relaps
chronic
myeloid
leukaemia
cml
donor
singl
antigen
match
sourc
stem
cell
peripher
blood
patient
bone
marrow
patient
chose
cyclophosphamid
base
approach
major
haploident
transplant
result
total
patient
patient
aliv
diseas
free
median
day
rang
day
median
time
neutrophil
engraft
day
rang
day
five
patient
reject
one
tm
scd
aml
cml
jmml
acut
graft
versu
host
diseas
gvhd
report
patient
grade
chronic
gvhd
patient
grade
day
mortal
caus
non
relaps
mortal
seven
patient
die
due
relaps
andor
progress
diseas
conclus
result
compar
report
develop
countri
term
complic
outcom
treatment
give
hope
mani
children
need
allogen
stem
cell
transplant
develop
world
wilhelmsson
j
j
falck
l
jh
k
h
institutet
karolinska
univers
hospit
depart
women
children
health
stockholm
sweden
institutet
karolinska
univers
hospit
depart
clintec
stcokholm
sweden
univers
depart
clinic
medicin
aarhu
denmark
cancer
societi
research
center
danish
cancer
societi
research
center
copenhagen
denmark
helsinki
helsinki
univers
depart
univers
helsinki
helsinki
univers
hospit
helsinki
finland
institutet
dept
women
children
health
stockholm
sweden
univers
hospit
skejbi
depart
paediatr
aarhu
denmark
backgroundobject
survivor
childhood
aml
treat
allogen
hematopoiet
stem
cell
transplant
allosct
may
significantli
higher
hospit
rate
gener
popul
survivor
treat
chemotherapi
designmethod
cohort
survivor
childhood
aml
treat
accord
protocol
nordic
countri
identifi
databas
linkag
basic
treatment
nation
hospit
registri
could
perform
aml
survivor
includ
studi
treat
allosct
chemotherapi
survivor
observ
number
hospit
compar
expect
number
popul
hospit
start
year
aml
diagnosi
year
latest
allosct
condit
use
allosct
result
total
allosct
survivor
hospit
observ
expect
ratio
oe
ci
main
caus
hospit
includ
gastrointestin
cardiovascular
pulmonari
endocrin
diseas
urinari
system
compar
gener
popul
oe
significantli
increas
hospit
due
cardiovascular
ci
endocrin
pulmonari
gastrointestin
infecti
diseas
neurolog
urinari
system
condit
proport
hospit
survivor
among
ct
survivor
oe
hospit
compar
gener
popul
howev
ct
survivor
oe
significantli
increas
hospit
due
gastrointestin
disord
conclus
survivor
childhood
aml
treat
allosct
significantli
increas
risk
hospit
compar
gener
popul
childhood
aml
survivor
treat
allosct
higher
burden
hospit
convent
treat
aml
survivor
xie
hospit
qingdao
univers
hematolog
pediatr
qingdao
china
backgroundobject
purif
vitro
critic
autolog
hematopoiet
stem
cell
transplant
ahsct
ultraviolet
uv
histor
consid
agent
cell
sensit
damag
cell
past
decad
uv
diod
led
altern
uv
sourc
recommend
replac
tradit
uv
lamp
due
number
advantag
current
studi
observ
impact
uv
led
murin
leukemia
cell
hematopoiet
stem
cell
hsc
vitro
explor
feasibl
uv
led
vitro
purif
ahsct
designmethod
hsc
mous
isol
immunomagnet
bead
sort
use
biotin
pe
label
antibodi
hsc
cell
irradi
uv
led
variou
dose
incub
variou
time
coloni
format
cell
prolifer
apoptosi
cell
observ
automat
coloni
count
assay
annexin
doubl
stain
respect
result
puriti
hsc
determin
flow
cytometri
uv
led
inhibit
coloni
format
cell
inhibitori
effect
stronger
hsc
among
signific
similarli
uv
led
significantli
inhibit
prolifer
induc
apoptosi
cell
dose
manner
effect
cell
stronger
hsc
signific
conclus
uv
led
select
kill
cell
dose
time
depend
manner
vitro
mechan
includ
inhibit
coloni
format
inhibit
cell
prolifer
induct
apoptosi
yet
littl
effect
hsc
yilmaz
e
akcin
ee
b
c
univers
faculti
medicin
pediatr
hematologyoncolog
istanbul
turkey
univers
faculti
medicin
depart
biotechnolog
istanbul
turkey
univers
faculti
medicin
yeditep
univers
ivf
center
istanbul
turkey
technic
univers
depart
biochemistri
istanbul
turkey
univers
faculti
medicin
depart
gynecolog
obstetr
istanbul
turkey
backgroundobject
complex
mammalian
ovarian
follicl
consist
oocyt
neighbor
follicular
cell
known
cumulu
cell
cc
close
interact
oocyt
cc
known
aim
investig
whether
cc
role
cell
therapi
besid
import
role
oocyt
develop
designmethod
oocyt
harvest
mural
cumulu
granulosa
cell
remov
follicular
fluid
two
hour
sperm
inject
figur
cc
digest
hylorunidas
shortli
seper
occyt
help
scraper
cumulu
cell
digest
hyaluronidas
cultiv
medium
contain
fb
psa
seed
onto
collagen
coat
flask
incub
day
prolifer
cell
character
flow
cytometri
gene
express
analysi
surfac
marker
respect
condit
media
collect
cumulu
cell
filter
unwant
cell
introduc
pancreat
cancer
cell
line
pancrea
cancer
cell
treat
condit
cumulu
media
incub
hypox
normox
environ
three
day
separ
cellular
death
pancreat
cancer
cell
monitor
detect
gene
express
analysi
caspas
depend
pathway
relat
gene
caspas
depend
cell
death
earli
apoptot
marker
investig
flow
cytometri
assay
annexin
v
stain
respect
result
cc
express
cumulu
cell
differ
hypox
condit
figur
pancreat
cancer
cell
gone
apoptosi
cumulu
condit
media
apoptosi
found
much
hypox
condit
caspas
pathway
figur
earli
biomark
apoptosi
figur
increas
hypox
condit
conclus
metabolit
secret
cumulu
cell
caus
apoptosi
pancreat
cancer
cell
could
promis
tool
cancer
treatment
abdelalim
h
n
g
research
spiciatist
clinic
research
depart
hospit
cairo
egypt
backgroundobject
ganglioneuroma
benign
neuroblast
tumor
aris
neural
crest
sympathogonia
adren
medulla
repres
differenti
spectrum
neuroblast
tumor
surgeri
therapi
choic
ganglioneuroma
domin
histolog
ganglioneuroblastoma
especi
biopsi
materi
ganglioneuroma
repres
also
histolog
matur
neuroblastomaganglioneuroblastoma
occur
commonli
chemotherapi
aim
studi
clinicopatholog
featur
outcom
ganglioneuromat
tumor
whether
confirm
ganglioneuroma
underw
matur
ganglioneuroma
treatment
clinicopatholog
characterist
ganglioneuroma
core
biopsi
turn
ganglioneuroblastoma
resect
open
biopsi
materi
designmethod
retrospect
studi
includ
patient
diagnos
children
cancer
hospit
egypt
period
result
patient
patient
patient
extradren
patient
intraspin
extens
surgic
resect
patient
complet
surgic
resect
patient
bone
marrow
biopsi
neg
twenti
four
patient
chang
gnb
excisionbiopsi
adren
one
patient
prove
nodular
patient
intraspin
extens
underw
surgeri
patient
complet
resect
patient
bone
marrow
biopsi
neg
thirti
nine
case
diagnos
neuroblastoma
patient
ganglioneuroblastoma
adren
patient
intraspin
extens
patient
bone
marrow
posit
two
nmyc
amplifi
underw
surgeri
undergo
complet
resect
follow
reveal
ganglioneuromat
patient
aliv
overal
survic
ganglioneuroblastoma
case
pot
therapi
matur
ganglioneroma
case
conclus
ganglioneuroma
benign
tumor
excel
surviv
complet
surgic
resect
nt
differ
incomplet
resect
case
chang
gnb
intermix
matur
ganglioneuroma
separ
group
differen
biolog
surviv
ackermann
b
c
c
f
f
r
r
r
f
j
f
j
hospit
cologn
experiment
pediatr
oncolog
cologn
germani
cologn
translat
genom
cologn
germani
hospit
cologn
pediatr
oncolog
hematolog
cologn
germani
pediatr
oncolog
hematolog
berlin
germani
univers
center
medic
genet
ghent
belgium
cologn
depart
patholog
cologn
germani
pittsburgh
cancer
institut
upci
pharmacolog
chemic
biolog
pittsburgh
usa
depart
medic
oncolog
essen
germani
cancer
research
center
neuroblastoma
genom
heidelberg
germani
backgroundobject
recent
genom
transcriptom
profil
studi
neuroblastoma
shed
light
cancer
gene
mutat
frequenc
structur
genom
rearrang
copi
number
alter
tumor
type
howev
none
abl
convert
data
coher
model
explain
pathogenesi
diverg
subtyp
separ
case
spontan
regress
occur
whose
diseas
progress
designmethod
determin
molecular
basi
favor
advers
diseas
cours
perform
massiv
parallel
sequenc
untreat
neuroblastoma
sequenc
target
sequenc
determin
telomer
mainten
mechan
case
addit
perform
target
sequenc
neuroblastoma
relaps
sampl
result
detect
genom
alter
gene
relat
ra
pathway
patient
presenc
mutat
strongli
associ
dismal
outcom
entir
cohort
well
subgroup
relaps
neuroblastoma
frequenc
mutat
increas
sampl
notic
howev
prognost
effect
pathway
mutat
strictli
depend
occurr
telomer
mainten
mechan
surviv
patient
whose
tumor
telomer
dramat
inferior
addit
pathway
mutat
present
compar
without
alter
contrast
patient
whose
tumor
lack
telomer
mainten
mechan
excel
outcom
spontan
regress
differenti
occur
presenc
absenc
pathway
mutat
conclus
togeth
data
suggest
precis
mechanist
definit
clinic
neuroblastoma
phenotyp
base
presenc
absenc
telomer
mainten
ra
pathway
mutat
provid
start
point
improv
diagnost
therapeut
manag
neuroblastoma
patient
j
akter
h
r
r
institut
clinic
saitama
cancer
center
clinic
oncolog
saitama
japan
backgroundobject
neuroblastoma
nb
common
pediatr
tumor
account
death
children
chromatin
remodel
factoratrx
tumor
suppressor
gene
recurr
somat
mutat
associ
stage
nb
patient
precis
mechan
atrx
mutat
relat
nb
tumorigenesi
aggress
remain
elucid
demonstr
ko
induc
depend
dna
damag
respons
nb
cell
designmethod
atrx
ko
clone
establish
mycn
amplifi
ngp
singl
copi
nb
cell
use
technolog
cell
prolifer
detect
wst
assay
express
analysi
atrx
ko
clone
perform
agil
oligonucleotid
microarray
gene
set
enrich
analysi
gsea
use
analyz
data
inactiv
done
lentivir
mutant
transduct
atm
signal
pathway
studi
analysi
result
herein
sever
atrx
ko
clone
establish
nb
cell
line
interestingli
clone
prolifer
slowli
compar
control
becom
differenti
gsea
analysi
microarray
data
indic
relat
dna
break
repair
dna
damag
respons
neg
cell
cycl
regul
checkpoint
pathway
activ
induc
atrx
ko
cell
vitro
analysi
atrx
loss
result
increas
express
phosphoryl
histon
variant
canon
marker
break
indic
accumul
endogen
dna
damag
atrx
ko
cell
furthermor
accumul
dna
damag
result
activ
pathway
lead
cell
cycl
arrest
moreov
inactiv
rescu
decreas
cell
growth
level
atrx
ko
cell
also
studi
correl
pathway
inactiv
multiom
databas
analysi
conclus
taken
togeth
find
suggest
atrx
play
role
maintain
dna
integr
pathway
inactiv
requir
nb
tumorigenesi
z
anan
p
w
g
children
medic
center
hematolog
oncolog
shanghai
china
backgroundobject
time
treatment
complet
patient
neuroblastoma
still
abnorm
hepat
imag
aim
investig
hepat
surviv
neuroblastoma
stage
designmethod
retrospect
review
clinicl
inform
imag
survivor
neuroblastoma
hepat
involv
treat
june
decemb
shanghai
children
medic
center
divid
children
two
group
accord
hepat
infiltr
treatment
complet
result
identifi
stage
stage
patient
median
age
diagnosi
month
six
children
amplifi
mycn
except
one
children
primari
tumor
remov
without
chemotherapi
remain
children
receiv
median
cycl
chemotherapi
two
children
receiv
radiat
one
children
receiv
autolog
hemopoiet
stem
cell
transport
children
hepat
biopsi
cours
treatment
postop
patholog
confirm
neuroblastoma
metastasi
complet
treatment
hepat
imag
children
abnorm
show
singl
multipl
low
densiti
shadow
six
case
tumor
recurr
locat
imag
abnorm
remain
case
resolv
without
intervent
advers
liver
outcom
detect
fourteen
children
still
normal
hepat
imag
treatment
complet
six
case
local
systemat
relaps
median
period
rang
month
diagnosi
year
year
event
free
surviv
accord
univari
analysi
high
level
lactic
dehydrogenas
time
nomal
valu
age
two
signific
poor
prognost
factor
conclus
onset
neuroblastoma
hepat
involv
young
time
treatment
complet
abnorm
hepat
imag
frequent
poor
prognost
factor
may
resolv
time
without
invent
advers
liver
outcom
detect
z
anan
j
x
p
children
medic
center
hematolog
oncolog
shanghai
china
backgroundobject
investig
surviv
late
effect
secondari
malign
children
high
risk
neuroblastoma
receiv
comprehens
treatment
includ
chemotherapi
autolog
stem
cell
transplant
radiat
designmethod
total
children
high
risk
neuroblastoma
receiv
comprehens
treatment
shanghai
children
medic
center
elig
test
formul
accord
children
oncolog
group
guidelin
approv
parent
late
side
effect
grade
ctcae
hear
loss
relat
platinum
grade
brock
chang
result
median
month
patient
least
one
late
effect
occurr
rate
advers
effect
case
patient
grade
advers
effect
case
children
develop
hear
loss
side
children
develop
dental
abnorm
compris
microdontia
miss
teeth
root
stunt
enamel
hypoplasia
children
scoliosi
children
develop
hypogonad
delay
growth
children
abnorm
respiratori
function
children
abnorm
cardiac
function
develop
renal
damag
children
low
level
cortisol
adrenocorticotroph
hormon
normal
children
normal
function
thyroid
three
patient
second
malign
leukemia
malign
fibroma
liver
tumor
conclus
incid
patient
neuroblastoma
treat
chemotherapi
abmt
irradi
high
includ
hear
loss
dental
abnorm
cardiopulmonari
function
abnorm
musculoskelet
problem
et
al
upmost
import
establish
program
discov
problem
earli
improv
life
qualiti
accept
abstract
publish
offici
public
z
anan
p
x
w
g
children
medic
center
hematolog
oncolog
shanghai
china
backgroundobject
evalu
number
imag
defin
risk
factor
idrf
correl
tumor
resect
therapi
respons
prognost
valu
also
evalu
impact
individu
idrf
tumor
resect
surviv
designmethod
retrospect
review
imag
patient
local
neuroblastoma
enrol
june
decemb
shanghai
children
medic
center
unequivoc
categor
regard
idrf
possibl
patient
idrf
assess
made
diagnosi
neoadjuv
chemotherapi
median
period
rang
month
diagnosi
result
mri
ct
indic
total
idrf
patient
logist
regress
analysi
reveal
highli
signific
neg
correl
number
idrf
possibl
complet
remov
neuroblastoma
multivari
logist
regress
analysi
detect
two
independ
factor
complet
tumor
resect
intraspin
tumor
extens
vessel
involv
accord
univari
analysi
high
number
idrf
intraspin
tumor
extens
signific
poor
prognost
factor
conclus
high
number
idrf
use
predict
surgic
outcom
also
event
free
surviv
accept
abstract
publish
offici
public
applebaum
e
j
h
b
c
chicago
pediatr
chicago
usa
chicago
chemistri
chicago
usa
chicago
medicin
chicago
usa
backgroundobject
epigenet
modif
associ
gene
activ
adult
cancer
signatur
serv
robust
biomark
cancer
outcom
recent
dr
invent
novel
highli
sensit
technolog
allow
character
use
small
quantiti
tumor
dna
hypothes
play
key
role
regul
gene
drive
neuroblastoma
phenotyp
profil
prognost
outcom
neuroblastoma
designmethod
quantifi
use
dna
local
bank
ffpediagnost
neuroblastoma
tumor
fragment
count
call
use
featurecount
normal
also
identifi
gene
differenti
risk
group
gene
ontolog
go
pathway
analysi
differenti
gene
perform
result
profil
tumor
elast
net
regress
model
identifi
gene
abl
distinctli
cluster
tumor
compar
current
neuroblastoma
risk
classif
schema
profil
enabl
accur
predict
outcom
one
patient
diseas
unexpectedli
good
outcom
two
patient
classifi
relaps
addit
identifi
uniqu
differenti
hydroxymethyl
gene
tumor
similar
express
profil
tumor
risk
group
pathway
neuron
differenti
enrich
tumor
wherea
gain
tumor
detect
embryon
mainten
pathway
current
imposs
predict
patient
diseas
surviv
perform
exploratori
analysi
identifi
gene
abl
accur
stratifi
patient
outcom
conclus
profil
differenti
neuroblastoma
risk
group
may
refin
risk
classif
diagnosi
stabil
eas
isol
biomark
suitabl
signatur
translat
clinic
set
r
r
rr
p
r
br
p
n
r
n
r
n
bansal
institut
medic
educ
research
hematologyoncolog
dept
advanc
pediatr
center
chandigarh
india
institut
medic
educ
research
transfus
medicin
chandigarh
india
institut
medic
educ
research
pediatr
advanc
pediatr
center
chandigarh
india
institut
medic
educ
research
radiotherapi
chandigarh
india
institut
medic
educ
research
radiodiagnosi
chandigarh
india
institut
medic
educ
research
nuclear
medicin
chandigarh
india
institut
medic
educ
research
histopatholog
chandigarh
india
institut
medic
educ
research
cytolog
chandigarh
india
institut
medic
educ
research
hematolog
chandigarh
india
backgroundobject
outcom
neuroblastoma
asct
rare
report
develop
countri
designmethod
studi
design
retrospect
chart
review
patient
neuroblastoma
period
set
govern
india
patient
treat
backbon
protocol
surgeri
asct
radiotherapi
measur
reduc
costinfect
ensur
rapid
engraft
includ
transplant
perform
regular
ward
without
hepa
filter
b
echogfrpft
assess
c
cryopreserv
stem
cell
stem
cell
apheresi
perform
consecut
day
e
venou
access
peripher
cannula
except
apheresi
f
antibioticantifungalantivir
prophylaxi
g
result
year
patient
neuroblastoma
diagnos
high
intermedi
low
among
patient
opt
treatment
limit
financ
treat
without
asct
data
patient
receiv
asct
present
month
twelv
underweight
asct
perform
day
start
cojec
condit
regimen
includ
melphalan
oral
parenter
median
stem
cell
collect
cellskg
harvest
product
store
c
day
median
viabil
rang
median
time
neutrophil
engraft
day
rang
relaps
record
patient
median
durat
month
treatment
relat
mortal
observ
patient
mean
durat
aliv
patient
month
rang
overal
month
respect
conclus
administr
treatment
disciplin
innov
asct
success
achiev
cure
select
patient
neuroblastoma
public
hospit
india
c
c
v
sf
km
c
belting
medic
center
ulm
pediatr
adolesc
medicin
ulm
germani
medic
center
ulm
intern
medicin
ii
ulm
germani
medic
center
ulm
intern
medicin
ulm
germani
backgroundobject
overexpress
survivin
crucial
regul
mitot
spindl
checkpoint
addit
antiapoptot
effect
associ
poor
prognosi
neuroblastoma
nb
transcript
inhibitor
survivin
test
clinic
trial
howev
result
disappoint
thu
investig
small
molecul
inhibit
dimer
survivin
protein
compar
efficaci
markedli
decreas
survivin
express
novel
transgen
nb
mous
designmethod
mice
hemizyg
cross
mice
gener
mycn
tg
mice
nb
growth
assess
serial
mri
imag
growth
determin
soft
agar
result
mice
develop
nb
mrna
protein
express
survivin
markedli
decreas
surprisingli
incid
latenc
nb
develop
mycn
tg
mice
differ
nb
mice
growth
tumor
decreas
surviv
mice
increas
immunohistochemistri
nb
show
decreas
prolifer
increas
apoptosi
chang
vascular
differ
copi
number
variat
two
nb
mous
model
discern
determin
whether
dysfunct
cell
describ
mice
hemizyg
could
mask
loss
aggress
nb
cell
hemizyg
nb
mycn
tg
mice
transplant
mycn
mice
differ
tumor
incid
latenc
growth
detect
stark
contrast
abolish
growth
nb
cell
line
conclus
despit
mark
decreas
express
hemizygos
nb
inhibit
transgen
mice
contrast
show
mark
efficaci
vitro
result
support
target
survivin
protein
nb
inhibit
interact
protein
c
tfe
w
b
j
dr
k
de
f
gm
l
km
c
belting
medic
center
ulm
pediatr
adolesc
medicin
ulm
germani
univers
cologn
pediatr
oncolog
hematolog
cologn
germani
medic
center
ulm
patholoy
ulm
germani
mainz
pathophysiolog
mainz
germani
cancer
univers
new
south
wale
children
cancer
institut
australia
sydney
australia
univers
center
medic
genet
cmgg
ghent
belgium
children
hospit
kid
cancer
centr
sydney
australia
backgroundobject
want
know
whether
lactat
dehydrogenas
ldha
import
compon
ldh
tetram
pivot
warburg
effect
associ
patient
surviv
neuroblastoma
nb
therapeut
target
tumor
designmethod
end
express
ldha
mrna
protein
determin
nb
patient
sampl
respect
correl
surviv
risk
factor
ldha
ldhb
knock
human
nb
cell
line
respect
aerob
glycolysi
clonogen
tumorigen
determin
express
ldha
relat
mycn
determin
nb
cell
line
nb
mous
model
result
observ
express
ldha
mrna
protein
significantli
independ
associ
decreas
patient
surviv
predomin
cytoplasm
local
ldha
protein
associ
poor
outcom
amplif
express
mycn
correl
express
ldha
nb
cell
line
mice
respect
knockout
ldha
inhibit
clonogen
tumorigen
tumor
growth
without
abolish
ldh
activ
significantli
decreas
aerob
glycolysi
concomit
deplet
ldha
isoform
ldhb
ablat
clonogen
abrog
ldh
activ
decreas
aerob
glycolysi
isoform
ldhc
express
conclus
conclud
high
express
ldha
independ
associ
outcom
nb
nb
cell
inhibit
deplet
ldha
ldhb
inhibit
appear
unrel
ldh
activ
aerob
glycolysi
thu
investig
inhibitori
mechan
attenu
aerob
glycolysi
warrant
nb
normal
cell
bhat
medic
collegeludhiana
pediatr
ludhiana
india
backgroundobject
due
overlap
clinic
radiolog
featur
differenti
osteomyel
bone
tumor
challeng
present
eleven
month
old
infant
present
fever
left
thigh
swell
initi
manag
outsid
hospit
acut
osteomyel
turn
boni
metastasi
adren
neuroblastoma
designmethod
case
report
result
month
old
infant
came
hospit
complaint
fever
swell
left
thigh
sinc
day
inabl
bear
weight
irrit
sinc
last
day
examin
child
tachycardia
heart
rate
temperatur
sever
pallor
irrit
local
examin
diffus
swell
cm
lower
end
left
femur
tender
touch
overli
red
rais
temperatur
xray
lower
end
femur
show
lytic
lesion
initi
child
manag
case
osteomyel
laboratori
investig
reveal
hemoglobin
gmdl
total
leucocyt
count
neutrophil
predomin
child
alreadi
receiv
day
intraven
antibiot
biopsi
done
reveal
round
cell
tumor
bone
scan
suggest
metastasi
lower
end
left
femur
rib
ct
abdomen
reveal
primari
tumor
left
supraren
gland
bone
marrow
examin
also
reveal
infiltr
round
cell
tumor
patient
diagnos
stage
iv
neuroblastoma
boni
metastasi
conclus
patient
osteomyel
like
symptom
bone
pain
refractori
medic
treatment
thorough
diagnost
undertaken
unusu
neoplasm
haematopoet
malign
consid
differenti
diagnosi
bhatnagar
hospit
children
pediatr
surgeri
india
india
backgroundobject
neuroblastoma
outcom
depend
consist
manag
protocol
base
extens
workup
risk
stratif
metastat
statu
howev
low
middl
incom
countri
suboptim
workup
may
lead
suboptim
manag
adopt
adapt
risk
stratif
treatment
guidelin
recommend
provid
improv
outcom
designmethod
prospect
data
collect
done
year
april
decemb
per
recommend
resourc
set
neuroblastoma
diagnosi
stage
risk
stratif
identifi
base
resourc
set
patient
diagnos
stage
treatment
initi
institut
identifi
set
wherein
neuroblastoma
stage
risk
classif
includ
ct
neck
chest
abdomen
pelvi
intraven
contrast
mri
site
suspect
spinal
involv
site
tumor
extent
well
defin
ct
mibg
scan
adapt
risk
stratif
treatment
assign
done
stage
patient
result
children
diagnos
neuroblastoma
stage
risk
stratifi
per
adapt
risk
stratif
low
risk
group
intermedi
risk
group
belong
high
risk
group
per
guidelin
modifi
therapi
given
risk
group
lead
shorter
cours
treatment
reduct
cumul
dose
reduc
toxic
maintain
surviv
outcom
os
low
risk
group
intermedi
group
high
risk
group
conclus
inspit
limit
resourc
infrastructur
lmic
adapt
recommend
guidelin
allow
risk
assign
children
neuroblastoma
regardless
set
select
feasibl
appropri
treatment
blom
j
van
r
r
j
van
van
e
van
der
g
center
pediatr
oncolog
research
utrecht
netherland
research
experiment
immunohematolog
amsterdam
netherland
medic
center
laboratori
genet
metabol
diseas
amsterdam
netherland
medic
center
oncogenom
amsterdam
netherland
backgroundobject
approxim
neuroblastoma
tumor
diagnost
mibg
imag
lead
imag
interpret
although
norepinephrin
transport
net
protein
express
correl
mibg
avid
biolog
origin
differ
avid
diseas
larg
unclarifi
recent
exist
two
type
neuroblastoma
cell
diverg
gene
express
profil
demonstr
besid
classic
adrenerg
neuroblastoma
cell
undifferenti
mesenchym
cell
exist
lead
intratumor
heterogen
mesenchym
cell
enrich
relaps
tumor
aim
studi
investig
whether
mesenchym
neuroblastoma
cell
show
less
net
express
consequ
less
mibg
uptak
designmethod
use
qpcr
human
neuroblastoma
cell
line
c
gimen
ngp
includ
two
isogen
cell
line
pair
test
net
mrna
express
net
protein
express
determin
cell
line
use
western
blot
adrenerg
cell
line
gener
contain
induc
regul
mesenchym
transform
time
seri
net
mrna
express
measur
induct
use
rt
qpcr
subset
cell
line
mibg
intern
studi
perform
result
net
mrna
express
mesenchym
cell
line
gimen
lowundetermin
comparison
classic
adrenerg
cell
line
mesenchym
cell
line
show
protein
express
induct
regul
mesenchym
transform
result
motil
mesenchym
phenotyp
accompani
decreas
net
express
time
intern
studi
mibg
affirm
find
two
hour
incub
medium
contain
radiolabel
mibg
adrenerg
cell
line
show
high
uptak
could
nearli
fulli
inhibit
desipramin
wherea
mesenchym
cell
line
show
select
uptak
mibg
conclus
mesenchym
differenti
state
neuroblastoma
seem
accompani
absenc
net
express
brik
simon
children
medic
pediatr
hematolog
petach
israel
children
medic
center
pediatr
hematolog
oncolog
petach
tikva
israel
backgroundobject
eight
year
old
patient
metastat
neuroblastoma
develop
hypertens
elev
creatinin
hematuria
four
week
receiv
first
cisplatin
treatment
attribut
first
nephrotox
effect
chemotherapi
simultan
blood
count
show
sign
hemolysi
worsen
thrombocytopenia
peripher
blood
smear
demonstr
schistoct
contribut
diagnos
atyp
hemolyt
urem
syndrom
designmethod
receiv
neg
mutat
normal
level
complement
decid
treat
ecolizumab
complement
inhibitor
dose
kidney
function
test
blood
count
start
recov
slowli
result
complement
level
low
confirm
effect
ecolizumab
treatment
result
ecolizumab
treatment
sign
hemolysi
worsen
kidney
function
note
patient
abl
receiv
necessari
chemotherapi
proceed
autolog
bmt
conclus
abnorm
regul
complement
may
associ
case
hu
treatment
eculizumab
may
appropri
affect
individu
v
brilliantova
e
e
rogachev
nation
research
center
pediatr
oncolog
immunolog
russian
ministri
health
moscow
russia
backgroundobject
actual
problem
patient
neuroblastoma
extens
tumor
pediatr
solid
oncolog
detect
minim
residu
diseas
mrd
popular
method
mrd
monitor
real
time
pcr
base
detect
gene
mrna
express
neuroblastoma
cell
three
specif
marker
recommend
siopen
group
monitor
mrd
patient
neuroblastoma
tyrosinehydroxylas
th
doublecortin
dcx
gene
introduc
calibr
real
time
pcr
system
make
possibl
observ
chang
mrd
intens
treatment
designmethod
group
patient
consist
children
age
year
diagnosi
neuroblastoma
bone
marrow
biopsi
examin
four
time
treatment
start
therapi
second
fourth
block
chemotherapi
conclus
induct
treatment
rna
extract
sampl
standard
way
rever
transcript
reaction
add
pcr
primer
probe
target
gene
housekeep
gene
result
experi
observ
correl
mrd
calcul
number
target
gene
transcript
copi
determin
calibr
number
target
transcript
copi
chang
patient
neuroblastoma
treatment
posit
mrd
statu
initi
observ
patient
patient
mrd
neg
first
time
treatment
long
term
remiss
patient
die
progress
mrd
posit
bone
marrow
patient
die
trm
patient
aliv
two
year
becam
mrd
neg
mrd
posit
bone
marrow
conclus
mrd
detect
neuroblastoma
pcr
includ
calibr
system
suitabl
high
risk
group
patient
help
observ
mrd
chang
treatment
nl
bui
tl
ha
ad
hs
md
nation
children
hospit
pediatr
oncolog
hematolog
center
hanoi
vietnam
nation
children
hospit
surgic
intens
care
unit
hanoi
vietnam
backgroundobject
children
hr
neuroblastoma
poor
outcom
convent
therapi
difficult
perform
develop
countri
high
cost
studi
assess
feasibl
initi
result
protocol
patient
hr
neuroblastoma
vnch
designmethod
patient
male
femal
age
month
year
hr
neuroblastoma
treat
regimen
includ
intens
induct
rapid
cojec
tumor
resect
myeloabl
therapi
bumel
follow
stem
cell
rescu
irradi
mainten
ra
octob
june
patient
diseas
progress
induct
phase
assess
base
bilater
bma
bone
marrow
biopsi
bone
tc
pet
ct
ct
scan
primari
tumor
serum
ldh
level
urin
vmahva
assay
present
updat
result
march
result
patient
aliv
without
progress
diseas
month
diagnosi
one
patient
die
earli
bone
marrow
relaps
pneumocysti
pneumonia
two
patient
bone
marrow
relaps
month
diagnosi
one
continu
treatment
suffer
second
relaps
deceas
month
diagnosi
one
aliv
palli
treatment
patient
receiv
chemotherapi
rapid
cojec
regimen
everi
day
plan
residu
tumor
unabl
remov
one
patient
total
cell
harvest
peripher
blood
patient
bone
marrow
engraft
occur
day
day
anc
plt
complic
sever
infect
cost
cover
govern
insur
conclus
treatment
protocol
feasibl
vnch
children
hr
neuroblastoma
lead
improv
surviv
fb
n
fd
professor
bezmialem
vakif
univers
pediatr
hematolog
oncolog
istanbul
turkey
pediatr
neurolog
fatih
turkey
backgroundobject
retino
asit
ra
agent
use
mainten
treatment
neuroblastoma
case
report
concern
complic
central
nervou
system
cn
secondari
ra
bleed
cranial
nerv
palsi
increas
intracrani
pressur
report
encephalopathi
develop
result
ra
rare
complic
report
present
year
old
neuroblastoma
patient
develop
encephalopathi
secondari
ra
designmethod
yr
old
boy
diagnos
neuroblastoma
origin
right
side
adren
gland
ra
treatment
sinc
month
first
period
ra
treatment
last
without
complain
howev
second
set
boy
could
open
eye
look
around
eyelid
close
day
complet
ra
sleepi
unabl
walk
let
physician
obtain
cn
magnet
reson
imag
result
normal
find
viral
serolog
nse
spot
urin
vma
level
csf
cytopatholog
chemistri
result
reveal
patholog
condit
electroencephalographi
establish
encephalopathi
develop
due
ra
result
boy
use
drug
ra
ra
medic
stop
patient
close
without
treatment
sleepi
patient
reduc
patient
becom
activ
around
day
time
month
time
neurolog
examin
bilater
ptosi
within
physiolog
limit
conclus
ra
treatment
rare
caus
central
nervou
system
patholog
neuroblastoma
metastasi
meningoenceph
rule
risk
factor
respons
ra
administr
patient
gradual
becom
activ
stop
ra
treatment
v
v
b
r
v
di
g
k
j
sophia
children
hospit
depart
pediatr
athen
greec
gaslini
children
hospit
depart
genoa
itali
michallon
de
grenobl
franc
polytechn
la
fe
hospit
pediatr
oncolog
depart
valencia
spain
children
medic
center
depart
israel
universitair
saint
luc
et
oncologi
bruxel
belgium
cancer
research
institut
st
anna
children
hospit
unit
studi
statist
integr
research
project
vienna
austria
laboratoir
de
recherch
translationnel
lyon
cedex
franc
catania
pediatr
hematolog
oncolog
catania
itali
curi
laboratoir
de
et
biologi
de
cancer
pari
franc
children
hospit
depart
paediatr
haematolog
oncolog
oxford
unit
kingdom
valencia
depart
statist
valencia
spain
backgroundobject
differenti
diagnosi
neonat
supraren
mass
rang
benign
adren
haemorrhag
malign
neuroblastoma
adren
carcinoma
optim
manag
clearli
defin
neuroblastoma
age
intrigu
entiti
carri
good
prognosi
case
siopen
intern
societi
paediatr
oncolog
european
neuroblastoma
launch
studi
risk
neuroblastoma
studi
http
wwwclinicaltrialsorg
primari
aim
maintain
ef
initi
approach
infant
small
local
supraren
mass
designmethod
singl
multicent
prospect
studi
infant
day
mass
region
metastat
involv
undertaken
initi
work
includ
urinari
catecholamin
imag
us
andor
mri
migb
scintigraphi
mycn
analysi
sera
infant
monitor
first
year
mass
increas
volum
orand
catecholamin
excret
increas
observ
stop
surgeri
perform
mass
persist
month
excis
mass
recommend
result
cohort
infant
regist
median
age
day
rang
femal
mass
describ
cystic
solid
mix
antenat
diagnosi
made
case
patient
underw
resect
observ
end
observ
period
prove
neuroblastoma
two
surgic
complic
includ
hemorrhag
renal
ischemia
without
fatal
migb
done
patient
receiv
thyroid
protect
despit
protocol
guidelin
ef
respect
os
median
month
fifteen
event
observ
progress
ms
tumor
conclus
observ
approach
infant
local
supraren
mass
discov
antenat
neonat
suspect
neuroblastoma
prove
safe
patient
avoid
surgeri
close
monitor
effect
jeopard
overal
outcom
g
p
v
v
technolog
center
bio
vitro
divis
barcelona
spain
universitario
la
fe
pediatr
oncolog
valencia
spain
polytechn
la
fe
hospit
pediatr
oncolog
valencia
spain
backgroundobject
neuroblastoma
nb
account
least
death
children
although
current
treatment
approach
nb
result
improv
outcom
remain
need
new
approach
stratifi
patient
especi
respond
convent
therapi
relaps
treatment
studi
evalu
potenti
metabolom
profil
improv
current
stratif
system
neuroblastoma
designmethod
plasma
sampl
nb
patient
collect
diagnosi
metabolom
analysi
plasma
sampl
carri
liquid
spectrometri
pattern
recognit
select
discrimin
metabol
featur
group
perform
use
supervis
partial
least
analysi
result
plasma
metabolom
profil
differenti
low
patient
diagnosi
valid
set
model
correctli
predict
patient
patient
result
sensit
specif
addit
plasma
metabolom
profil
identifi
key
differ
diagnosi
high
risk
patient
evid
diseas
immedi
treatment
progress
treatment
model
identifi
valid
set
subject
complet
remiss
end
treatment
subject
progress
treatment
conclus
present
studi
show
metabolom
signatur
abl
provid
use
inform
biomark
discrimin
patient
also
distinguish
patient
activ
diseas
remiss
omic
prospect
valid
could
definit
contribut
refin
stratif
patient
also
monitor
respons
treatment
casey
b
nk
la
sloan
ketter
cancer
center
depart
radiat
oncolog
new
york
citi
usa
sloan
ketter
cancer
center
depart
pediatr
new
york
citi
usa
sloan
ketter
cancer
center
depart
surgeri
new
york
citi
usa
backgroundobject
patient
neuroblastoma
dose
gy
primari
tumor
site
gross
total
resect
gtr
provid
excel
local
control
howev
never
clinic
trial
specif
evalu
optim
dose
radiat
therapi
rt
recent
report
describ
increas
risk
late
effect
treatment
gy
sought
assess
local
control
reduct
dose
primari
site
gy
gy
designmethod
induct
chemotherapi
surgic
resect
patient
age
median
year
enrol
treat
rt
prospect
trial
per
protocol
patient
underw
gtr
follow
gy
hyperfract
rt
fraction
gy
patient
also
receiv
monoclon
antibodi
part
consolid
therapi
result
patient
stage
nb
diseas
complet
remiss
cr
persist
bone
marrow
involv
three
patient
treat
proton
therapi
rest
treat
photon
therapi
median
year
initi
treatment
local
failur
observ
among
entir
cohort
overal
surviv
patient
first
cr
respect
patient
metastat
cr
prior
rt
overal
surviv
conclus
rt
gy
compromis
local
control
patient
gtr
current
cohort
patient
protocol
receiv
gy
given
young
patient
age
increas
incid
late
toxic
seen
improv
surviv
essenti
find
optim
dose
rt
minim
toxic
without
compromis
diseas
outcom
e
cecen
b
fb
n
e
h
f
n
eylul
univers
enstitut
oncolog
depart
pediatr
oncolog
izmir
turkey
univers
school
medicin
depart
pediatr
oncolog
bursa
turkey
univers
school
medicin
depart
pediatr
oncolog
istanbul
turkey
univers
school
medicin
depart
pediatr
oncolog
ankara
turkey
univers
school
medicin
depart
pediatr
oncolog
antalya
turkey
hamidiy
etfal
train
hospit
depart
pediatr
oncolog
istanbul
turkey
univers
school
medicin
depart
pediatr
oncolog
konya
turkey
train
hospit
depart
pediatr
oncolog
izmir
turkey
univers
school
medicin
depart
pediatr
oncolog
ankara
turkey
univers
school
medicin
depart
pediatr
oncolog
ankara
turkey
backgroundobject
neuroblastoma
nb
common
extracrani
solid
tumor
children
wide
metastat
time
diagnosi
half
patient
frequenc
central
nervou
system
cn
metastas
nb
low
studi
aim
investig
statu
cn
metastas
neuroblastoma
turkey
designmethod
undertook
review
cn
involv
due
recurr
diseas
progress
children
stage
neuroblastoma
includ
turkish
pediatr
oncolog
group
neuroblastoma
protocol
june
decemb
result
percent
patient
stage
diseas
group
other
group
nb
patient
underw
transplant
myeloabl
chemotherapi
remain
patient
treat
convent
chemotherapi
eighteen
patient
develop
document
cn
diseas
site
recurr
progress
thirteen
patient
isol
cn
recurr
remain
patient
develop
recurr
concomitantli
site
none
cn
nb
time
diagnosi
median
interv
initi
diagnosi
involv
cn
month
patient
die
despit
sever
rescu
treatment
conclus
cn
recurr
nb
rare
fatal
multicent
studi
suffici
number
patient
ame
improv
novel
therapeut
manag
patient
need
hh
chang
wm
mc
yf
h
hf
kh
dt
taiwan
univers
hospit
pediatr
taipei
taiwan
roc
taiwan
univers
hospit
surgeri
taipei
taiwan
roc
taiwan
univers
colleg
medicin
institut
anatomi
cell
biolog
taipei
taiwan
roc
sinica
institut
cellular
organism
biolog
taipei
taiwan
roc
taiwan
univers
depart
life
scienc
taipei
taiwan
roc
backgroundobject
previou
studi
reveal
activ
protein
nkap
express
correl
differenti
neuroblastoma
nb
predict
favor
prognosi
patient
nb
howev
underli
mechan
nkap
regul
tumorigenesi
nb
unclear
designmethod
oligonucleotid
microarray
experi
agil
system
primari
nb
tumor
conduct
gene
whose
express
similar
correl
nkap
express
microarray
data
select
map
relat
pathway
analysi
vitro
valid
experi
conduct
retinoid
acid
ra
nb
cell
differenti
result
gene
found
similar
gene
express
nkap
microarray
data
gene
posit
gene
neg
correl
nkap
gene
express
seven
pathway
map
relat
nkap
gene
express
gene
valid
result
vitro
studi
quantit
pcr
nb
cell
line
treat
ra
day
mrna
level
parn
along
nkap
increas
cell
increas
signific
day
day
ra
treatment
parallel
control
neuron
differenti
marker
nse
consist
cell
use
lentiviru
infect
protocol
deliv
nkap
cell
nkap
promot
neuron
differenti
increas
express
cell
augment
ra
treat
day
addit
level
cell
return
basal
level
compar
control
day
concomit
increas
activ
caspas
cleav
caspas
conclus
nkap
speed
neuron
differenti
nb
cell
promot
differenti
nb
cell
undergo
apoptosi
chen
yh
eastern
memori
hospit
divis
pediatr
depart
surgeri
new
taipei
citi
taiwan
roc
backgroundobject
neuroblastoma
one
common
extracrani
malign
earli
childhood
prognosi
patient
still
away
satisfi
find
novel
biomark
therapeut
neuroblastoma
import
task
cytoplasm
polyadenyl
element
bind
rna
bind
protein
involv
translat
regul
cytoplasm
polyadenyl
element
cpe
mrna
recent
express
level
found
decreas
sever
cancer
type
howev
report
neuroblastoma
therefor
aim
explor
possibl
role
human
neuroblastoma
cell
designmethod
human
neuroblastoma
cell
use
studi
function
effect
cell
viabil
verifi
mtt
assay
annexinv
pi
stain
molecular
mechan
tumor
suppress
examin
pcr
luciferas
report
assay
mutagenesi
result
western
blot
analysi
found
level
endogen
protein
low
neuroblastoma
cell
ectop
express
significantli
decreas
viabil
cell
cell
panel
analysi
oncogen
level
show
mycn
oncogen
cell
found
associ
protein
mrna
mycn
sequenc
analysi
reveal
cpe
sequenc
region
mrna
mycn
insert
mycn
cpe
sequenc
luciferas
gene
significantli
luciferas
activ
context
express
furthermor
mutat
mycn
cpe
longer
associ
rescu
inhibit
luciferas
activ
conclus
exert
strong
effect
human
neuroblastoma
cell
inhibit
express
mycn
activ
induct
would
potenti
approach
find
novel
therapeut
neuroblastoma
b
chi
bao
v
c
quang
medicin
pharmaci
hcmc
centr
molecular
biomedicin
hochiminh
vietnam
medicin
area
scienc
park
intern
centr
genet
engin
biotechnolog
triest
itali
hospit
children
oncolog
siem
reap
cambodia
children
hospit
surgeri
hochiminh
vietnam
backgroundobject
neuroblastoma
nb
associ
rearrang
htert
molecular
regul
htert
remain
poorli
understood
designmethod
base
nb
cohort
n
public
databas
chip
analysi
luciferas
assay
perform
determin
interact
domain
subunit
swisnf
chromatin
remodel
directli
occupi
within
htert
proxim
promot
region
result
show
occup
retino
acid
ra
induc
differenti
nb
cell
line
demonstr
essenti
recruit
complex
suppress
telomeras
activ
express
upon
retino
differenti
mechan
inhibit
inactiv
domain
sirna
target
silenc
moreov
mutat
htert
promot
enhanc
bound
vitro
luciferas
activ
final
nb
cohort
show
lost
low
express
rel
link
elev
express
tert
emin
featur
aggress
nb
conclus
result
indic
play
tumor
suppress
role
tert
express
recruit
complex
via
modifi
chromatin
access
w
choeyprasert
u
hospit
pediatr
bangkok
thailand
mahidol
univers
pediatr
bangkok
thailand
backgroundobject
neuroblastoma
nbl
poor
outcom
high
rate
recurr
despit
intens
therapi
includ
chemotherapi
surgeri
radiotherapi
autolog
stem
cell
transplant
previou
studi
allogen
stem
cell
transplant
shown
advantag
compar
object
studi
aim
explor
feasibl
outcom
treatment
high
risk
nbl
patient
designmethod
children
diagnos
high
risk
nbl
underw
ramathibodi
hospit
mahidol
univers
retrospect
analyz
result
total
patient
male
femal
underw
haploident
sct
haplo
mrd
enrol
median
age
year
rang
year
transplant
three
patient
recurr
diseas
patient
receiv
treatment
median
dose
mci
rang
mci
condit
regimen
mrd
compris
fludarabin
busulfan
fludarabin
busulfan
globulin
atg
busulfan
melphalan
busulfan
melphalan
atg
compris
busulfan
melphalan
busulfan
melphalan
atg
haplo
group
patient
also
receiv
cyclophosphamid
gvhd
prophylaxi
patient
receiv
median
x
stem
cell
median
month
rang
month
overal
surviv
rate
regardless
donor
type
seven
patient
die
relaps
diseas
bronchiol
obliteran
diseas
encephalopathi
patient
complet
remiss
cr
transplant
tend
lower
relaps
rate
better
df
os
compar
cr
conclus
studi
show
feasibl
favor
outcom
high
risk
nbl
patient
k
yb
choi
l
ji
keon
j
hye
ki
k
hong
medic
sungkyunkwan
univers
school
medicin
pediatr
seoul
republ
korea
nation
univers
hospit
pediatr
cheongju
republ
korea
univers
school
kangbuk
samsung
hospit
pediatr
seoul
republ
korea
backgroundobject
although
prognosi
gener
good
patient
neuroblastoma
consensu
reach
ideal
treatment
regimen
studi
analyz
treatment
outcom
toxic
patient
younger
month
stage
mycn
neuroblastoma
designmethod
retrospect
analyz
patient
younger
month
newli
diagnos
stage
mycn
neuroblastoma
januari
decemb
patient
receiv
cycl
chemotherapi
surgeri
without
local
radiotherapi
follow
cycl
differenti
therapi
acid
chemotherapi
consist
altern
cycl
cedc
cisplatin
etoposid
doxorubicin
cyclophosphamid
ice
ifosfamid
carboplatin
etoposid
regimen
result
common
primari
tumor
site
abdomen
common
metastat
site
lymph
node
follow
bone
liver
skin
bone
marrow
end
induct
therapi
patient
achiev
complet
respons
achiev
good
partial
respons
achiev
partial
respons
show
mix
respons
nine
patient
receiv
local
radiotherapi
median
month
rang
month
none
patient
experienc
relaps
progress
secondari
malign
die
three
year
chemotherapi
complet
none
patient
experienc
grade
late
advers
effect
conclus
patient
younger
month
stage
mycn
neuroblastoma
show
excel
outcom
without
signific
late
advers
effect
treat
altern
cycl
cedc
ice
follow
surgeri
differenti
therapi
l
ding
q
j
medic
huazhong
univers
scienc
technolog
depart
pediatr
wuhan
china
medic
huazhong
univers
scienc
technolog
depart
experiment
medicinecent
wuhan
china
backgroundobject
aurora
kinas
aurka
correl
prognosi
nb
small
molecul
aurka
target
inhibitor
suppress
activ
aurka
research
explor
effect
mechan
nb
studi
advers
effect
process
designmethod
appli
western
blot
stain
cell
cycl
apoptosi
analysi
sirna
transfect
immunofluoresc
immunohistochemistri
explor
effect
nb
treatment
possibl
underli
mechan
result
neuroblastoma
cell
small
molecul
inhibitor
induc
cell
cycl
arrest
cell
senesc
besid
express
significantli
increas
signific
chang
found
express
pten
relat
protein
nb
nude
mice
xenograft
model
see
induc
neuroblastoma
cell
senesc
inhibit
tumor
growth
prolong
lifetim
mice
neuroblastoma
could
significantli
increas
protein
express
aurka
nb
cell
line
morev
immunohistochemistri
tumor
tissu
nb
nude
mice
show
express
total
aurka
treatment
group
also
cell
aurka
small
interf
rna
siaurka
compar
cell
treat
alon
combin
group
exhibit
synergist
effect
nb
treatment
conclus
could
induc
cellular
senesc
nb
cell
signal
pathway
addit
might
increas
express
total
aurka
inhibit
aurka
phosphoryl
howev
combin
treatment
siaurka
transfect
exhibit
synergist
effect
nb
treatment
druy
l
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
research
institut
medic
cell
technolog
laboratori
cytogenet
molecular
molecular
oncolog
group
moscow
yekaterinburg
russia
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
laboratori
molecular
molecular
oncolog
group
moscow
russia
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
laboratori
cytogenet
molecular
genet
moscow
russia
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
depart
clinic
oncolog
moscow
russia
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
institut
translat
medicin
moscow
russia
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
director
moscow
russia
backgroundobject
clinic
heterogen
hallmark
neuroblastoma
depend
inequ
gene
express
profil
differ
multigen
signatur
develop
defin
prognosi
neuroblastoma
patient
designmethod
consensu
gene
express
panel
includ
gene
present
least
intern
classifi
creat
k
de
preter
demonstr
prognost
signific
silico
analysi
current
studi
express
gene
measur
nanostr
primari
relaps
neuroblastoma
sampl
patient
belong
observ
intermedi
risk
group
upon
protocol
criteria
group
prognost
signific
determin
surviv
ef
calcul
median
time
month
result
patient
gain
unfavor
gene
express
perfectli
predict
outcom
ef
compar
favor
express
group
one
toxic
death
advers
event
low
intermedi
risk
group
gain
tym
express
strongli
associ
advers
event
ef
vs
p
unfavor
gene
less
signific
total
cohort
patient
express
ncan
slightli
correl
clinic
risk
group
predict
outcom
contrast
unfavor
signatur
gene
describ
defin
dismal
prognosi
ef
gain
fyn
express
opposit
ensur
advers
event
ef
independ
clinic
risk
group
p
enhanc
express
paic
ahci
mycn
demonstr
poor
prognost
signific
patient
relaps
patient
favor
gene
express
signatur
predict
good
secondari
ef
also
independ
risk
group
conclus
consensu
gene
express
signatur
creat
merg
sever
classifi
provid
robust
clinic
relev
prognost
inform
regardless
convent
risk
group
elhemali
cancer
univers
children
cancer
hospit
egypi
pediatr
oncolog
cairo
egypt
cancer
institut
children
cancer
hospit
egypt
paediatr
oncolog
cairo
egypt
cancer
institut
surgic
oncolog
cairo
egypt
cancer
children
cancer
hospit
egypt
paediatr
oncolog
cairo
egypt
backgroundobject
children
neuroblastoma
poor
outcom
progress
treatment
use
myeloabl
chemotherapi
radiotherapi
plu
purg
abmt
signific
differ
event
free
surviv
ef
compar
convent
chemotherapi
cc
although
overal
surviv
os
significantli
differ
work
aim
find
os
ef
high
risk
neuroblastoma
patient
designmethod
retrospect
studi
nation
cancer
institut
egypt
includ
patient
result
patient
receiv
induct
chemotherapi
cado
cycl
two
die
septic
shock
two
cr
patient
vgpr
pr
nr
year
os
cr
vgpr
pr
group
compar
nr
pd
group
p
patient
need
salvag
ice
die
septic
shock
show
cr
vgpr
pr
patient
progress
diseas
hsct
done
patient
patient
receiv
hsct
show
better
year
overal
surviv
p
median
os
month
median
ef
month
primari
site
mediastinum
better
year
overal
surviv
abdomin
statist
signific
impact
differ
metastat
site
overal
surviv
except
liver
metastasi
show
inferior
year
overal
surviv
compar
without
p
mycn
amplif
show
inferior
year
overal
surviv
compar
mycn
end
treatment
dead
treatment
complic
cr
vgpr
pr
patient
pd
conclus
high
risk
neuroblastoma
still
poor
outcom
insight
done
tandem
transplant
immun
therapi
improv
outcom
j
elhoudzi
n
hospit
moham
pediatr
hematolog
oncolog
marrakesh
morocco
hospit
moham
vi
pediatr
hematolog
oncolog
marrakesh
morocco
backgroundobject
neuroblastoma
nb
occur
rare
age
year
old
inform
scarc
characterist
clinic
cours
age
group
show
clinic
featur
outcom
neuroblastoma
nb
children
age
year
provid
theoret
basi
improv
prognosi
designmethod
retrospect
analysi
perform
clinic
data
previous
untreat
nb
children
clinic
featur
outcom
analyz
sinc
till
result
case
repres
neuroblastoma
center
averag
age
year
male
predomin
adren
locat
frequent
clinic
patient
admit
poor
statu
abdomin
pain
case
abdomin
mass
found
predomin
advanc
stage
patient
metastas
diagnosi
bone
metastas
frequent
follow
bone
marrow
patient
multipl
sitt
mibg
posit
patient
ferritinemia
ldh
elevet
case
catecholamin
case
histolog
one
case
correspond
poorli
differenti
one
differenti
nb
moreov
tumour
consid
undifferenti
seven
case
stage
iv
except
one
stage
iii
nmyc
done
partial
primari
resect
tumor
possibl
one
patient
chemotherapi
done
accord
moroccan
protocol
four
seven
patient
undergo
chemotherapi
requir
palli
treatment
progress
mass
metastas
without
possibl
surgic
cure
death
rate
seri
one
patient
die
first
cours
year
metronom
protocol
patient
still
treatment
conclus
age
neuroblastoma
associ
poor
prognosi
high
dose
chemotherapi
seem
use
henc
need
new
therapeut
approach
age
group
f
erbey
f
g
univers
scholl
medicin
pediatr
hematologyoncolog
bmt
unit
turkey
backgroundobject
recent
year
condit
regimen
given
hematopoiet
stem
cell
transplant
hsct
compar
term
efficaci
toxic
larg
studi
neuroblastoma
case
hand
experi
allogen
hsct
neuroblastoma
increas
reason
aim
share
clinic
experi
autolog
allogen
hsct
neuroblastoma
designmethod
eighteen
neuroblastoma
patient
underw
autolog
case
allogen
case
hsct
may
march
includ
studi
diseas
statu
condit
regimen
complic
recurr
recent
statu
record
surviv
ef
overal
surviv
os
calcul
result
ten
patient
male
patient
girl
mean
age
diagnosi
year
sixteen
case
metastat
diagnosi
ten
case
relaps
refractori
transplant
complet
remiss
case
good
partial
respons
case
partial
respons
case
transplant
sixteen
patient
autolog
transplant
receiv
condit
regimen
carboplatin
etoposid
melphalan
cem
busulfan
melphalan
bumel
two
patient
allogen
transplant
receiv
treosulfan
base
condit
regimen
first
patient
unrel
donor
second
patient
sibl
donor
use
engraft
occur
patient
common
toxic
mucos
esophag
signific
differ
bumel
cem
condit
regimen
toxic
infect
recurr
mortal
ef
os
mean
period
transplant
month
recurr
develop
transplant
seven
patient
six
patient
die
mortal
ef
os
respect
conclus
condit
regimen
found
effect
feasibl
accept
effect
profil
data
need
order
abl
ripen
allogen
transplant
outcom
h
fan
c
q
w
x
g
x
x
children
capit
medic
nation
center
children
health
hematolog
oncolog
center
beij
china
backgroundobject
aim
present
studi
investig
preval
anemia
iron
defici
newli
diagnos
neuroblastoma
patient
designmethod
clinic
characterist
retrospect
collect
newli
diagnos
neuroblastoma
patient
center
dec
jan
iron
defici
defin
accord
nccn
guidelin
anemia
version
result
male
month
old
origin
abdomen
neuroblastoma
bone
marrow
metastasi
patient
accord
inclus
criterion
anemia
observ
patient
significantli
like
occur
patient
tumor
origin
abdomen
bone
marrow
metastasi
p
mean
valu
mch
total
iron
bind
capac
serum
iron
pg
anemia
group
significantli
lower
anemia
group
p
absolut
iron
defici
aid
function
iron
defici
fid
possibl
function
iron
defici
iron
defici
occur
anemia
patient
aid
fid
like
happen
patient
age
month
tumor
origin
abdomen
bone
marrow
metastasi
p
hemoglobin
significantli
higher
aid
fid
group
gl
iron
defici
group
gl
serum
ferritin
lower
aid
fid
group
ngml
iron
defici
group
ngml
p
conclus
neuroblastoma
patient
high
preval
anemia
iron
defici
initi
diagnosi
iron
defici
like
happen
patient
month
old
effect
iron
supplement
differ
type
iron
defici
need
studi
fawzi
n
f
g
cancer
hospit
egypt
nation
cancer
institut
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
clinic
research
cairo
egypt
cancer
hospit
egypt
patholog
cairo
egypt
cancer
hospit
egypt
radiolog
cairo
egypt
cancer
hospit
egypt
nuclear
medicin
cairo
egypt
cancer
hospit
egypt
clinic
patholog
cairo
egypt
cancer
hospit
egypt
surgic
oncolog
cairo
egypt
backgroundobject
bilater
supraren
neuroblastoma
bsn
rare
present
could
occur
side
simultan
metachron
less
common
previous
publish
literatur
show
patient
bsn
favor
biolog
featur
prognosi
studi
aim
evalu
clinic
biolog
featur
outcom
patient
bsn
treat
children
cancer
egypt
cche
designmethod
retrospect
studi
includ
patient
bsn
present
cche
biopsi
primari
tumor
mandatori
confirm
done
avail
time
present
clinic
variabl
includ
age
inss
stage
use
associ
biolog
featur
inpc
mycn
determin
patient
risk
group
result
studi
includ
patient
bsn
cche
patient
neuroblastoma
period
male
femal
less
year
old
year
age
rang
month
year
metachron
diseas
present
ten
patient
amplifi
mycn
amplifi
done
diagnosi
patient
metastat
diseas
stage
stage
stage
patient
stage
fifteen
treat
high
risk
hr
intermedi
risk
ir
low
risk
lr
undetermin
due
inadequ
tissu
biopsi
total
number
death
overal
surviv
hr
ir
patient
respect
surviv
hr
ir
patient
conclus
compar
result
patient
unilater
adren
diseas
similar
stage
risk
patient
bilater
supraren
neuroblastoma
wors
outcom
show
poorer
biolog
featur
advanc
diseas
consequ
poorer
outcom
previous
report
literatur
well
fawzi
h
g
n
cancer
hospit
egypt
nation
cancer
institut
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
surgic
oncolog
cairo
egypt
cancer
hospit
egypt
clinic
research
cairo
egypt
cancer
hospit
egypt
patholog
cairo
egypt
cancer
hospit
egypt
radiolog
cairo
egypt
cancer
hospit
egypt
nuclear
medicin
cairo
egypt
cancer
hospit
egypt
radiotherapi
cairo
egypt
backgroundobject
neuroblastoma
remark
broad
spectrum
clinic
behavior
rang
spontan
regress
inevit
progress
death
surviv
patient
neuroblastoma
nbl
markedli
improv
develop
risk
stratif
system
favor
multimod
tailor
treatment
present
studi
aim
evalu
surviv
outcom
newli
diagnos
pediatr
intermedi
risk
patient
nbl
treat
children
cancer
cche
relat
variou
clinic
patholog
factor
designmethod
studi
includ
patient
year
stage
nbl
stage
diseas
year
favor
histopatholog
featur
infant
year
stage
diseas
stage
diseas
children
year
favor
biolog
infant
stage
unfavor
biolog
featur
patient
receiv
system
chemotherapi
form
etoposid
carboplatin
altern
cyclophosphamid
doxorubicin
vincristin
administ
interv
total
cycl
target
object
respons
completeveri
good
partialparti
respons
end
point
result
studi
includ
patient
male
femal
abdomin
primari
tumor
present
patient
mediastin
mass
mass
neck
among
patient
stage
remain
metastat
diseas
overal
surviv
respect
gender
age
patholog
statist
significantli
differ
either
overal
event
free
surviv
overal
surviv
significantli
differ
surgeri
versu
surgeri
inoper
residu
statist
conclus
high
rate
surviv
current
achiev
patient
intermedi
risk
neuroblastoma
chemotherapi
chemotherapi
surgeri
treatment
reduc
complic
late
effect
among
survivor
highli
recommend
r
vasquez
c
arambu
p
calderon
r
k
quintero
montero
k
braga
c
children
hospit
benjamin
bloom
pediatr
san
salvador
el
salvador
escuela
universitario
pediatr
tegucigalpa
hondura
infantil
manuel
de
jesu
rivera
la
mascota
pediatr
managua
nicaragua
de
oncologia
pediatrica
unop
pediatr
guatemala
citi
guatemala
del
dr
esquivel
pediatr
panama
panama
infantil
dr
robert
reid
cabral
pediatr
santo
domingo
dominican
republ
casa
medicin
paulo
social
medicin
paulo
brazil
jude
children
research
hospit
global
medicin
depart
tennesse
usa
backgroundobject
risk
assign
treatment
major
challeng
success
outcom
children
neuroblastoma
nb
central
america
ca
prospect
studi
aim
implement
protocol
designmethod
ahopca
enrol
patient
year
old
januari
decemb
el
salvador
guatemala
nicaragua
dominican
republ
panama
hondura
use
intern
neuroblastoma
stage
system
inss
age
histopatholog
featur
patient
stratifi
treatment
low
intermedi
group
receiv
chemotherapi
regimen
avail
region
surgeri
radiotherapi
surviv
ef
overal
surviv
os
estim
use
method
test
employ
compar
surviv
curv
statist
analys
alpha
use
result
children
evalu
male
mean
age
diagnosi
year
major
patient
present
advanc
diseas
stage
children
classifi
abandon
observ
patient
overal
ef
os
respect
risk
classif
significantli
correl
outcom
ef
os
estim
low
intermedi
high
risk
group
respect
p
histolog
also
affect
conclus
ahopca
success
implement
region
protocol
neuroblastoma
abl
achiev
high
cure
rate
patient
low
intermedi
risk
addit
capac
build
necessari
optim
diagnosi
risk
assign
better
inform
resourc
alloc
ch
fung
f
ihi
kki
pkh
mari
hospit
divis
paediatr
depart
surgeri
hong
kong
hong
kong
sar
backgroundobject
neuroblastoma
common
pediatr
extracrani
solid
tumor
account
pediatr
mortal
studi
aim
evalu
surviv
outcom
children
neuroblastoma
treat
tertiari
centr
relationship
variou
clinic
patholog
factor
designmethod
retrospect
analysi
patient
diagnos
neuroblastoma
perform
patient
demograph
site
primari
tumor
stage
diseas
present
extent
tumor
excis
presenc
amplif
extract
analyz
overal
surviv
calcul
use
method
compar
surviv
probabl
result
total
patient
identifi
includ
studi
median
age
diagnosi
year
rang
month
year
patient
present
intern
neuroblastoma
stage
system
stage
diseas
overal
surviv
cohort
respect
inss
stage
diseas
amplif
extent
tumor
resect
found
statist
signific
influenc
surviv
stage
diseas
patient
surviv
year
compar
patient
stage
diseas
respect
p
hand
posit
patient
surviv
year
compar
neg
patient
p
extent
resect
complet
resect
tumor
resect
found
posit
influenc
surviv
surviv
vers
patient
subtot
resect
tumor
resect
p
conclus
predomin
advanc
stage
patient
cohort
despit
surviv
outcom
patient
treat
centr
compar
intern
centr
surviv
versu
european
centr
k
georgantzi
e
e
tiensuu
r
univers
dept
women
children
section
pediatr
uppsala
sweden
univers
dept
women
children
section
pediatr
surgeri
uppsala
sweden
univers
dept
medic
scienc
uppsala
sweden
backgroundobject
neuroblastoma
nb
common
extracrani
solid
tumor
childhood
except
diseas
stage
diagnosi
mani
molecular
factor
also
import
stage
tumor
diagnosi
analysi
molecular
profil
base
tumor
sampl
taken
either
fine
needl
biopsi
core
needl
biopsi
open
biopsi
method
use
depend
local
tradit
routin
uppsala
univers
hospit
ultrasound
guid
needl
biopsi
ucnb
use
diagnosi
pediatr
solid
tumor
sinc
aim
investig
ucnb
appropri
method
diagnosi
nb
designmethod
medic
record
patient
nb
underw
pretreat
diagnost
ucnb
uppsala
univers
hospit
review
inform
extract
patient
record
includ
age
diagnosi
gender
tumor
site
inss
stage
molecular
analys
mycn
statu
p
delet
biopsi
complic
bleed
pain
complic
due
anesthesia
result
total
ucnb
perform
patient
three
patient
undergo
biopsi
one
occas
achiev
adequ
materi
diagnosi
molecular
studi
correct
primari
diagnosi
obtain
patient
molecular
studi
tumor
perform
six
percent
drop
hemoglobin
bleed
biopsi
need
analgesia
procedur
neither
infect
tumor
growth
needl
tract
observ
patient
experi
complic
relat
anesthesia
conclus
ucnb
safe
patient
nb
give
adequ
amount
tumor
tissu
obtain
histolog
diagnosi
well
analysi
molecular
profil
nb
k
georgantzi
r
e
tiensuu
l
univers
dept
women
children
section
pediatr
uppsala
sweden
univers
dept
medic
scienc
uppsala
sweden
univers
dept
women
children
section
paediatr
surgeri
uppsala
sweden
univers
dept
medic
scienc
uppsala
sweden
univers
dept
genet
patholog
uppsala
sweden
backgroundobject
chromogranin
cga
synaptophysin
among
known
gener
neuroendocrin
ne
marker
also
use
patholog
work
neuroblastoma
nb
synapt
vesicl
similar
synaptophysin
integr
protein
vesicular
membran
play
import
role
fusion
cytoplasmat
membran
vesicular
monoamin
transport
vmat
vmat
acid
glycoprotein
respons
uptak
storag
catecholamin
vmat
abundantli
express
adren
medulla
vmat
aim
compar
rel
incid
cga
synaptophysin
human
nb
order
identifi
best
immunohistochem
marker
identif
furthermor
investig
possibl
relationship
express
vmat
urinari
catecholamin
excret
respect
patient
designmethod
tumor
sampl
patient
variou
nb
stage
includ
tumor
specimen
obtain
andor
treatment
patient
pretreat
treatment
tumor
tissu
avail
consecut
mm
section
immunostain
marker
concentr
measur
patient
diagnosi
statist
use
test
correl
surviv
differ
catecholamin
result
cga
show
equal
rel
incid
tumour
examin
contradict
synaptophysin
less
frequent
express
rel
incid
vmat
higher
vast
major
specimen
examin
compar
vmat
furthermor
vmat
immunoreact
correl
acid
vma
excret
final
acid
hva
excret
correl
outcom
conclus
use
altern
ne
marker
diagnosi
nb
vmat
may
act
catecholamin
transport
tumour
could
predict
outcom
r
glincher
e
sloan
ketter
cancer
center
pediatr
new
york
usa
backgroundobject
autolog
stem
cell
rescu
ascr
often
util
neuroblastoma
revers
myelosuppress
myeloabl
chemotherapi
hdc
mibg
therapi
ascr
report
associ
acut
toxic
perform
center
use
establish
procedur
includ
fluid
furosemid
vital
paramet
monitor
hour
prefer
perform
ascr
set
designmethod
receiv
approv
irb
retrospect
analyz
record
patient
nb
receiv
ascr
focus
toxic
first
hour
result
ascr
perform
patient
infus
perform
outpati
set
reason
inpati
ascr
includ
neutropen
fever
plan
chemotherapi
pain
manag
seizur
electrolyt
imbal
stem
cell
infus
intract
vomit
hematuria
hypertens
manag
prior
chemotherapi
includ
ifosfamid
carboplatin
etoposid
carboplatin
irinotecan
temozolomid
etoposid
cyclophosphamid
carboplatin
irinotecan
temozolomid
thiotepa
cyclophosphamid
topotecan
vincristin
other
intraven
radiopharmaceut
includ
mibg
therapi
median
cell
number
rang
cellskg
median
dmso
patient
collect
mskcc
patient
collect
elsewher
volum
ml
rang
ml
acut
reaction
duringimmedi
occur
patient
includ
nausea
vomit
fever
hypertens
nine
patient
evalu
follow
day
symptom
fever
nausea
vomit
tachycardia
fourteen
patient
admit
within
hour
neutropen
fever
one
admit
sinu
bradycardia
post
platelet
transfus
conclus
ascr
well
toler
patient
receiv
myeloabl
regimen
nb
consid
inpati
administr
reduc
cost
stress
patient
caregiv
hassan
al
u
el
r
univers
pediatr
zagazig
egypt
univers
pediatr
mansoura
egypt
univers
pediatr
tanta
egypt
backgroundobject
neuroblastoma
common
extracrani
solid
tumor
infanc
embryon
malign
sympathet
nervou
system
aim
studi
epidemiolog
characterist
neuroblastoma
egypt
multicent
studi
four
egyptian
center
designmethod
featur
neuroblastoma
infant
children
retrospect
investig
januari
januari
pediatr
oncolog
unit
mansoura
zagazig
tanta
univers
children
hospit
egypt
result
case
neuroblastoma
omit
studi
due
defect
data
median
age
patient
month
age
year
age
year
time
diagnosi
ratio
supraren
gland
common
primari
tumor
site
major
patient
stage
iv
diseas
favor
patholog
observ
patient
exhibit
unfavor
patholog
estim
surviv
rate
patient
mean
surviv
time
month
rate
mortal
patient
age
year
age
year
patient
favor
patholog
rate
mortal
significantli
lower
compar
patient
unfavor
patholog
addit
age
year
associ
unfavor
patholog
stage
iv
diseas
supraren
primari
tumor
site
conclus
associ
age
present
stage
patholog
support
hypothesi
neuroblastoma
heterogen
diseas
establish
effect
computer
registr
system
neuroblastoma
urgent
requir
north
east
egypt
furthermor
larger
intern
multicent
studi
requir
support
find
present
studi
hirano
k
e
h
univers
school
medicin
pediatr
surgeri
tokyo
japan
univers
school
medicin
gener
medicin
tokyo
japan
backgroundobject
differenti
therapi
convert
neuroblastoma
nb
cell
matur
ganglioma
cell
promis
cur
treatment
current
develop
howev
tremend
clinic
heterogen
nb
therapi
provid
benefit
limit
number
patient
elucid
molecular
mechan
underli
nb
cell
differenti
identifi
appropri
therapeut
target
investig
role
nuclear
receptor
subfamili
group
member
identifi
candid
prognost
factor
differenti
nb
cell
uekusa
et
al
int
j
designmethod
human
nb
cell
line
without
mycn
amplif
use
studi
sirna
transfect
cell
express
vector
transfect
gener
cell
stabli
express
follow
analysi
cell
morpholog
well
express
differenti
marker
prognost
factor
mycn
silenc
use
sirna
determin
direct
effect
express
chromatin
immun
precipit
chip
assay
perform
examin
bind
mycn
protein
regulatori
region
gene
result
clone
stabli
express
show
obviou
neurit
outgrowth
along
differenti
marker
express
tend
higher
cell
without
mycn
amplif
mycn
amplif
addit
mycn
cell
show
increas
express
similar
phenotyp
cell
chip
assay
show
mycn
bind
promot
region
exon
gene
conclus
data
indic
promot
differenti
nb
cell
express
neg
regul
mycn
hiwatari
k
j
tokyo
cell
therapi
transplant
medicin
tokyo
japan
tokyo
pediatr
tokyo
japan
backgroundobject
presenc
alk
aberr
rel
frequent
observ
patient
neuroblastoma
alk
inhibitor
crizotinib
provid
novel
treatment
opportun
malign
associ
alk
transloc
neuroblastoma
cell
harbor
alk
rel
resist
crizotinib
inhibit
alk
remain
therapeut
challeng
neuroblastoma
designmethod
identifi
compound
potenti
inhibit
oncogen
activ
alk
neuroblastoma
implement
high
throughput
chemic
screen
neuroblastoma
cell
line
vari
alk
status
use
curat
librari
compound
evalu
therapeut
effect
crizotinib
combin
treatment
inhibitor
cucurbitacin
neuroblastoma
cell
line
cultur
cell
evalu
effect
drug
prolifer
signal
assess
synergi
result
drug
screen
kinas
inhibitor
cucurbitacin
discriminatori
regard
sensit
cell
line
neuoblastoma
cell
line
harbor
alk
crizotinib
combin
cucurbitacin
enhanc
tumor
respons
show
synergist
cytotox
combin
therapi
cell
line
alk
aberr
alk
cell
line
mycn
amplif
loh
effect
vehicl
crizotinib
alon
cucurbitacin
ialon
analysi
downstream
molecul
mapk
akt
pathway
show
tgw
cell
line
harbor
alk
express
lower
level
perk
pakt
combin
therapi
compar
cell
treat
cucurbitacin
crizotinib
alon
conclus
result
may
provid
indic
combin
alk
inhibitor
may
benefit
th
etrat
neuroblastoma
enhanc
efficaci
reduc
toxic
studi
suggest
combin
alk
inhibitor
could
valuabl
therapeut
optionfor
neuroblastoma
potenti
clinic
applic
hotonu
p
h
great
north
children
newcastl
univers
teach
hospit
nh
foundat
trust
paediatr
surgeri
newcastl
uppon
tyne
unit
kingdom
gener
leed
teach
hospit
nh
trust
paediatr
oncolog
leed
unit
kingdom
great
north
children
newcastl
univers
teach
hospit
nh
foundat
trust
paediatr
oncolog
newcastl
uppon
tyne
unit
kingdom
hey
children
hospit
paediatr
surgeri
liverpool
unit
kingdom
great
north
children
newcastl
univers
teach
hospit
foundat
trust
paediatr
surgeri
newcastl
uppon
tyne
unit
kingdom
backgroundobject
open
surgic
biopsi
tradit
utilis
diagnosi
neuroblastoma
previou
ukcclg
protocol
last
decad
increas
number
centr
uk
abroad
utilis
needl
core
biopsi
ncb
howev
lack
knowledg
current
trend
biopsi
neuroblastoma
uk
designmethod
onlin
survey
conduct
among
surgeon
data
includ
type
biopsi
surgic
vs
needl
core
perform
surgeon
vs
radiologist
ncb
number
core
perfom
addit
outcom
survey
compar
data
obtain
retrospect
audit
current
practic
neuroblastoma
biopsi
uk
centr
data
month
period
obtain
analys
result
sixteen
centr
respond
survey
uk
respons
rate
perform
ncb
imag
guidanc
report
core
usual
obtain
yield
adequ
tissu
gaug
needl
utilis
g
done
radiologist
still
done
paediatr
surgeon
major
perform
oper
theatr
intervent
radiolog
suit
result
audit
show
biopsi
obtain
via
ncb
via
open
surgeri
signific
morbid
case
biopsi
perform
diagnosi
achiev
via
differ
rout
eg
bone
marrow
sampl
conclus
current
survey
reflect
chang
practic
uk
regard
biopsi
neuroblastoma
open
ncb
appear
yield
adequ
tissu
sampl
diagnosi
larger
intern
studi
may
use
provid
guidanc
futur
neuroblastoma
protocol
c
huang
x
x
l
h
h
x
children
capit
medic
univers
nation
center
children
health
beij
key
laboratori
pediatr
hematolog
nation
disciplin
ministri
moe
key
laboratori
major
diseas
hematolog
oncolog
center
beij
china
children
capit
medic
nation
center
children
health
beij
key
laboratori
pediatr
hematolog
nation
disciplin
ministri
moe
key
laboratori
major
diseas
depart
head
neck
surgeri
beij
china
children
capit
medic
nation
center
children
health
beij
key
laboratori
pediatr
hematolog
nation
disciplin
ministri
moe
key
laboratori
major
diseas
depart
ultrasonographi
beij
china
children
capit
medic
nation
center
children
health
beij
key
laboratori
pediatr
hematolog
nation
disciplin
ministri
moe
key
laboratori
major
diseas
depart
patholog
beij
china
children
capit
medic
nation
center
children
health
beij
key
laboratori
pediatr
hematolog
nation
disciplin
ministri
moe
key
laboratori
major
diseas
depart
surgic
oncolog
beij
china
backgroundobject
presenc
distant
metastas
one
power
predictor
outcom
patient
neuroblastoma
summar
clinic
featur
analys
surviv
situat
order
guid
therapi
designmethod
research
analys
medic
record
patient
cervic
lymph
node
metastasi
nb
singl
center
treatment
divid
two
phase
analys
surviv
situat
treatment
effect
phase
follow
time
end
januari
result
total
case
admit
research
neuroblastoma
patient
case
metastas
site
confin
cervic
lymph
node
case
bone
marrow
metastasi
case
bone
metastasi
number
patient
group
total
case
receiv
system
treatment
os
patient
ef
earlier
phase
treatment
ef
os
accord
second
phase
treatment
ef
os
patient
ef
os
conclus
patient
metastat
diseas
limit
cervic
lymph
node
higher
intern
report
probabl
reason
ultrasound
becom
routin
examin
screen
lymph
node
metastasi
center
ef
patient
lower
anoth
foreign
center
haver
report
probabl
reason
proport
patient
center
higher
metastast
diseas
nt
receiv
surgic
radiotherapi
total
center
inc
b
e
e
h
k
n
eylul
univers
institut
oncolog
pediatr
oncolog
izmir
turkey
eylul
univers
faculti
medicin
patholog
izmir
turkey
eylul
univers
institut
oncolog
basic
oncolog
izmir
turkey
eylul
univers
faculti
medicin
radiat
oncolog
izmir
turkey
eylul
univers
faculti
medicin
pediatr
surgeri
izmir
turkey
eylul
univers
faculti
medicin
radiodiagnost
izmir
turkey
eylul
univers
institut
oncolog
pediatr
current
address
univers
econom
izmir
turkey
backgroundobject
evalu
patient
diagnos
stage
neuroblastoma
nb
treat
protocol
center
designmethod
clinic
characterist
treatment
respons
stage
nb
patient
analyz
retrospect
result
stage
nb
patient
elig
analysi
mf
ratio
median
age
diagnosi
mo
primari
site
surren
cervic
paravertebr
mycn
neg
mycn
neg
posit
risk
group
rg
low
rg
intermedi
histolog
intermedi
histolog
tumor
heterogen
patient
intermedi
risk
favour
histolog
group
primari
surgeri
total
resect
done
patient
delay
surgeri
tumor
total
disappear
patient
one
patient
die
progress
diseas
surgeri
one
patient
asymptomat
follow
patient
receiv
chemo
treatment
chang
cyclophosphamid
etoposid
cisplatin
ifosfamid
vincristin
dacarbazin
adriamycin
one
cours
receiv
radiotherapi
rt
one
patient
receiv
rt
liver
extens
liver
metastasi
clinic
symptom
advanc
hepatomegali
respiratori
distress
vena
cava
inferior
syndrom
decreas
urin
output
hypertens
patient
liver
metastasi
rapidli
progress
chemotherapi
rt
given
liver
median
follow
time
yr
patient
diseas
free
patient
progress
chemotherapi
third
month
forth
month
control
chemotherapi
rt
one
die
fifth
month
progress
diseas
despit
chemotherapi
conclus
treatment
outcom
children
stage
neuroblastoma
satisfactori
treatment
respons
symptomat
patient
carboplatin
etoposid
vincristin
base
cours
good
quick
effect
respons
provid
addit
rt
chemotherapi
one
patient
extens
liver
metastasi
pepper
syndrom
respiratori
distress
inc
e
z
h
e
k
n
eylul
univers
institut
oncolog
pediatr
oncolog
izmir
turkey
eylul
univers
institut
oncolog
basic
oncolog
izmir
turkey
eylul
univers
faculti
medicin
pediatr
surgeri
izmir
turkey
univers
faculti
medicin
pediatr
surgeri
izmir
turkey
eylul
univers
faculti
medicin
radiodiagnost
izmir
turkey
eylul
univers
faculti
medicin
radiat
oncolog
izmir
turkey
eylul
univers
faculti
medicin
patholog
izmir
turkey
eylul
univers
faculti
medicin
nuclear
medicin
izmir
turkey
eylul
univers
institut
oncolog
pediatr
current
address
univers
econom
izmir
turkey
backgroundobject
analyz
patient
diagnos
local
neuroblastoma
nb
designmethod
clinic
characterist
treatment
respons
patient
diagnos
local
neuroblastoma
analyz
retrospect
result
median
age
diagnosi
mf
ratio
distrubut
stage
stage
stage
stage
risk
group
lrg
irg
hrg
patient
ipog
protocol
one
patient
follow
year
without
diseas
stage
patient
paravertebr
tumor
primari
total
resect
secondari
surgeri
macroscop
residu
rt
one
event
death
progress
month
primari
relaps
month
lrg
stage
tumor
local
surren
paravertebr
midlin
mycn
two
patient
opsomyoklonu
receiv
patient
rohhad
syndrom
receiv
cyclophosphamid
rituximab
ivig
one
patient
paravertebr
tumor
receiv
chemotherapi
ct
decompress
surgeri
macroscop
residu
complementari
surgeri
diseas
free
cervic
paravertebr
nb
patient
asymptomath
surgeri
follow
without
treatment
lrg
median
follow
time
yr
event
death
patient
rohhad
irg
stage
patient
paravertebr
tumor
diagnos
gnb
primari
surgeri
macroscop
residu
two
cours
ct
tumor
resect
totali
diseas
free
mo
tumor
patient
diseas
treat
primari
surgeri
one
cord
decompress
result
macroscop
residu
patient
induct
respons
crpr
rt
given
primari
tumor
irg
median
follow
time
yr
os
one
event
stage
patient
pepper
syndrom
die
relat
surgeri
hrg
paravertebr
primari
surgeri
induct
respons
crpr
two
patient
refractori
progress
diseas
one
die
progress
die
sct
relat
except
patient
rohhad
syndrom
patient
local
nb
median
follow
time
year
ef
os
respect
conclus
treatment
respons
overal
event
free
surviv
rate
localis
neuroblastoma
accept
consist
literatur
toxic
relat
death
inc
e
z
e
r
h
k
n
eylul
univers
institut
oncolog
pediatr
oncolog
izmir
turkey
eylul
univers
institut
oncolog
basic
oncolog
izmir
turkey
eylul
univers
faculti
medicin
radiat
oncolog
izmir
turkey
eylul
univers
faculti
medicin
patholog
izmir
turkey
eylul
univers
faculti
medicin
pediatr
surgeri
izmir
turkey
eylul
univers
faculti
medicin
medic
biolog
genet
izmir
turkey
eylul
univers
faculti
medicin
radiodiagnost
izmir
turkey
eylul
univers
institut
oncolog
pediatr
current
address
univers
econom
izmir
turkey
backgroundobject
evalu
clinic
characterist
treatment
respons
surviv
rate
infant
neuroblastoma
nb
designmethod
clinic
characterist
treatment
respons
patient
diagnos
neuroblastoma
center
analyz
retrospect
result
forthyf
patient
elig
analysi
mf
ratio
median
age
diagnosi
patient
month
stage
distrubut
stage
stage
stage
stage
stage
except
patient
treat
ipog
protocol
risk
strafic
patient
lrg
irg
hrg
ten
patient
treat
patient
protocol
lrg
five
patient
stage
stage
mycn
neg
amplifi
one
patient
one
patient
die
diseas
progress
year
ef
os
shimada
five
patient
mycn
neg
patient
cours
one
patient
receiv
rt
progress
liver
metastasi
cr
achiev
patient
liver
metastasi
die
relat
surgeri
year
ef
os
shimada
seven
patient
stage
stage
mycn
neg
year
ef
os
hrg
three
patient
stage
mycn
amplifi
patient
one
stage
two
stage
three
patient
progress
diseas
die
year
ef
os
ten
patient
receiv
rt
five
infant
receiv
rt
liver
metastasi
median
follow
time
ef
os
median
event
time
mo
patient
progress
one
nonprimari
relaps
one
refract
diseas
one
surgeri
relat
death
occur
caus
surgeri
relat
mycn
perform
amplifi
patient
ef
os
respect
patient
ef
os
respect
conclus
surviv
rate
infanc
neuroblastoma
patient
succesful
similar
literatur
os
ef
rate
significantli
differ
patient
inc
e
z
r
h
e
k
n
eylul
univers
institut
oncolog
pediatr
oncolog
izmir
turkey
eylul
univers
institut
oncolog
basic
oncolog
izmir
turkey
eylul
univers
faculti
medicin
radiat
oncolog
izmir
turkey
eylul
univers
faculti
medicin
radiodiagnost
izmir
turkey
eylul
univers
faculti
medicin
pediatr
surgeri
izmir
turkey
univers
faculti
medicin
pediatr
surgeri
izmir
turkey
eylul
univers
faculti
medicin
patholog
izmir
turkey
eylul
univers
faculti
medicin
nuclear
medicin
izmir
turkey
eylul
univers
institut
oncolog
pediatr
oncolog
current
address
univers
econom
izmir
turkey
backgroundobject
evalu
patient
diagnos
intermedi
risk
group
neuroblastoma
designmethod
patient
treat
tpog
protocol
one
went
anoth
elig
clinic
characterist
treatment
respons
surviv
rate
analyz
retrospect
result
median
age
diagnosi
mf
ratio
site
surren
paravertebr
midlin
neuroblastoma
nb
ganglioneuroblastoma
gnb
stage
distrubut
patient
metastat
metastasi
region
lymph
node
bone
bone
marrow
subcutan
nodul
lung
del
del
gain
patient
mycn
patient
dna
diploidi
analyz
patient
diploidi
neardiploidi
tetraploidi
shimada
classif
favour
histolog
unfavour
histolog
gnb
histopatholog
diagnosi
evalu
fail
no
primari
total
resect
one
lymph
node
metastasi
liver
metastasi
macroscop
patient
could
evalu
induct
chemotherapi
respons
rate
tumor
regress
ct
delay
surgeri
time
come
yet
cr
achiev
patient
total
resect
primari
surgeri
one
liver
metastasi
progress
rt
given
liver
tumor
resect
total
delay
second
look
surgeri
patient
macroscop
residu
primari
surgeri
cr
achiev
complementari
surgeri
perform
patient
rt
given
primari
tumor
cr
achiev
delay
surgeri
done
patient
without
primari
total
resect
macroscop
residu
rt
given
patient
progress
liver
metastasi
five
patient
receiv
rt
primari
tumor
median
follow
time
yr
year
ef
os
four
event
patient
group
one
progress
liver
metastasi
one
nonprimari
relaps
one
refractori
diseas
one
surgeri
relat
death
conclus
surviv
rate
succesful
treatment
respons
similar
cog
siopen
gpo
japan
pediatr
oncolog
group
result
toxic
accept
level
toxic
relat
death
one
patient
die
relat
surgeri
inc
e
e
n
eylul
univers
institut
oncolog
pediatr
oncolog
izmir
turkey
eylul
univers
faculti
medicin
patholog
izmir
turkey
backgroundobject
residu
tumor
induct
chemotherapi
effect
treatment
prognosi
intermedi
risk
group
neuroblastoma
preliminari
studi
role
residu
tumor
histopatholog
hp
treatment
decis
investig
designmethod
elig
medic
record
analyz
retrospect
hp
classif
tumor
tissu
chang
induct
chemotherapi
regress
patern
rp
matur
patern
mp
regress
matur
patern
rpmp
chang
despit
chemotherapi
rp
defin
intens
fibrozi
calcif
necrosi
without
nb
differenti
schwannian
stroma
ss
format
mp
ganglioneuroblastoma
type
ss
differenti
nb
without
ss
ped
blood
cancer
result
mf
ratio
mo
tumor
localis
surren
paravertebr
midlin
metastat
diseas
stage
distrubut
stage
stage
stage
stage
primari
surgeri
macroscop
residu
induct
respons
crpr
diagnosi
histopatholog
andifferenti
nb
poor
differenti
nb
differenti
nb
evalu
gnb
mki
low
delay
surgeri
result
total
resect
macroscop
residu
patient
total
resect
receiv
rt
hp
report
evalu
rpmp
rp
mp
gnb
ss
mp
without
ss
differenti
nb
subgroup
rpmp
chang
chemo
patient
macroscop
residu
die
relat
surgeri
receiv
rt
primari
tumor
receiv
rt
group
tumor
hp
chang
ct
mp
differenti
nb
without
ss
rp
rt
group
patient
rp
rpmp
mainten
chemotherapi
given
group
patient
macroscop
residu
delay
surgeri
receiv
rt
refractori
diseas
rt
patient
famili
nb
nonprimari
relaps
patient
group
follow
death
conclus
despit
patient
number
short
follow
time
accord
result
preliminari
studi
patient
residu
tumor
induct
chemotherapi
surgeri
patient
wih
hp
follow
receiv
maintan
treatment
differenti
antiangiogen
agent
without
addit
chemotherapi
cours
andor
rt
consid
long
time
side
effect
risk
inou
medic
saitama
medic
univers
pediatr
surgeri
kawago
citi
japan
medic
saitama
medic
univers
medic
research
kawago
citi
japan
backgroundobject
antitumor
therapi
immun
check
point
inhibit
concept
block
tumor
progress
signal
transfer
engag
molecul
surfac
cancer
cell
cell
tumor
microenviron
howev
pediatr
cancer
frequenc
surfac
express
molecul
report
low
evalu
effect
immun
checkpoint
inhibit
mous
neuroblastoma
cell
express
molecul
surfac
follow
analyz
immunolog
reaction
host
mous
lymphat
organ
tumor
microenviron
designmethod
express
molecul
mous
neuroblastoma
cell
surfac
analyz
flowcytometri
inocul
subcutan
host
mous
thigh
administr
antibodi
day
follow
tumor
inocul
treat
group
pb
control
mice
sacrif
day
tumor
size
evalu
cell
inguin
lymph
node
spleen
collect
cell
analyz
use
flowcytometri
result
molecul
especi
express
surfac
howev
tumor
growth
markedli
suppress
antibodi
treat
group
compar
control
remark
differ
immun
cell
popul
inguin
lymph
node
spleen
group
howev
tumor
infiltr
cell
markedli
increas
compar
control
cell
express
mhc
ii
surfac
moreov
cell
express
howev
weakli
express
conclus
treatment
effect
suppress
tumor
growth
neg
cell
increas
tumor
infiltr
cell
activ
immun
cell
cell
neg
slightli
express
molecul
surfac
jin
f
h
l
h
l
x
children
capit
medic
nation
center
children
china
beij
key
laboratori
pediatr
diseas
head
neck
beij
biobank
diseas
children
beij
china
children
capit
medic
nation
center
children
china
beij
key
laboratori
pediatr
diseas
head
neck
surgeri
beij
china
children
capit
medic
nation
center
children
china
depart
surgic
oncolog
beij
china
children
capit
medic
nation
center
children
china
depart
patholog
beij
china
backgroundobject
neuroblastoma
common
pediatr
solid
tumor
neural
crest
origin
rang
tumor
predominantli
poorli
differenti
neuroblast
larg
consist
fulli
differenti
sympathet
neuron
molecular
basi
remain
unclear
chromosom
segreg
protein
report
regul
cell
cycl
although
sever
studi
report
play
differ
role
varieti
cancer
littl
known
role
neuroblastoma
demonstr
function
oncogen
maintain
highli
dedifferenti
stage
aggress
malign
neoplasm
regul
nuclear
factor
erythroid
like
designmethod
neuroblastoma
clinic
specimen
use
investig
correl
express
neuroblastoma
cell
differenti
nb
cell
prolifer
cell
cycl
apoptosi
assess
follow
knockdown
express
transcriptom
profil
conduct
explor
pathway
chang
silenc
affin
purif
mass
spectrometri
util
explor
interactom
protein
nb
cell
result
among
neuroblastoma
clinic
specimen
signific
posit
correl
document
express
neuroblastoma
cell
suffici
inhibit
neuroblastoma
cell
growth
vitro
vivo
silenc
also
sensit
neuroblastoma
cell
retino
acid
promot
cell
differenti
transcriptom
analysi
neuroblastoma
cell
lack
reveal
induct
neuron
differenti
pathway
signal
pathway
repress
oncogen
signal
pathway
affin
purif
mass
spectrometri
found
interact
protein
arginin
methyltransferas
posit
regul
express
neuroblastoma
cell
conclus
overal
find
illumin
novel
molecular
axi
neuroblastoma
cell
differenti
regul
potenti
implic
improv
diagnosi
treatment
diseas
kachanov
v
g
e
v
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
clinic
oncolog
moscow
russia
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
radiolog
moscow
russia
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
nuclear
medicin
moscow
russia
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
cytogenet
moscow
russia
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
patholog
moscow
russia
backgroundobject
aim
studi
analyz
clinic
radiolog
biolog
characterist
neuroblastoma
present
lung
metastas
designmethod
patient
stage
neuroblastoma
period
month
includ
analys
stage
assign
accord
inss
patient
stratifi
treat
accord
german
protocol
compar
analysi
clinic
biolog
characterist
done
patient
without
lung
metastas
overal
os
surviv
ef
assess
use
method
result
patient
stage
neuroblastoma
stratifi
n
n
group
includ
analysi
patient
lung
metastas
median
age
month
rang
common
site
primari
tumor
adren
gland
patient
stratifi
group
group
patient
one
two
side
involv
equal
distribut
multinodular
involv
calcif
note
case
patient
thrombosi
compar
analys
patient
without
lung
metastas
show
statist
signific
differ
term
gender
age
diagnosi
topographi
primari
tumor
mycn
statu
site
metastas
progress
therapi
observ
often
patient
lung
metastas
ef
patient
without
lung
metastas
os
wors
case
lung
metastas
versu
conclus
lung
metastas
rare
patient
dissemin
neuroblastoma
assess
initi
imag
experienc
radiologist
import
correct
differenti
diagnosi
lung
lesion
neuroblastoma
patient
care
implement
treatment
protocol
time
assess
respons
extrem
import
patient
lung
metastas
statist
significantli
wors
prognosi
diseas
kazantsev
p
e
l
b
memori
institut
pediatr
hematolog
transplant
pediatr
oncolog
russia
memori
institut
pediatr
hematolog
transplant
hematolog
russia
memori
institut
pediatr
hematolog
transplant
pediatr
russia
memori
institut
pediatr
hematolog
transplant
transplant
russia
backgroundobject
neuroblastoma
nb
common
extracrani
pediatr
tumor
overal
prognosi
gener
good
result
primari
resistantrelaps
nb
still
dismal
establish
guidelin
patient
therapi
cur
option
case
spite
moder
good
initi
respons
rate
data
target
therapi
abl
improv
result
popul
designmethod
review
consecut
cohort
patient
median
age
rang
year
primari
resist
relaps
nb
receiv
combin
chemotherapi
irinotecan
temozolomid
target
therapi
sirolimu
dasatinib
patient
dissemin
diseas
time
therapi
initi
expos
line
salvag
chemotherapi
achiev
clinic
respons
case
patient
previou
exposur
topoisomeras
inhibitor
total
cours
median
rang
cours
per
patient
perform
respons
routin
evalu
cours
therapi
stop
diseas
progress
fourteen
patient
clinic
respons
receiv
addit
chemotherapi
immun
therapi
alk
inhibitor
result
cr
reach
patient
patient
achiev
pr
patient
becom
clinic
respons
observ
patient
median
ef
month
patient
current
aliv
receiv
addit
therapi
therapi
character
accept
toxic
mostli
hematolog
allow
use
outpati
set
conclus
although
combin
use
cur
major
case
provid
good
respons
rate
median
ef
compar
histor
cohort
london
w
popul
well
toler
factor
determin
respons
best
option
remiss
consolid
still
determin
r
kebudi
bs
f
fb
n
univers
cerrahpasa
medic
faculti
oncolog
institut
pediatr
hematolog
oncolog
istanbul
turkey
univers
cerrahpasa
medic
faculti
pediatr
hematolog
oncolog
istanbul
turkey
sultan
suleyman
train
research
hospit
pediatr
oncolog
istanbul
turkey
alem
univers
school
medicin
pediatr
hematoogi
oncolog
istanbul
turkey
eylul
univers
oncolog
institut
pediatr
oncolog
izmir
turkey
backgroundobject
neuroblastoma
nb
common
extracrani
solid
tumor
childhood
primari
secondari
testicular
involv
extrem
uncommon
neuroblastoma
designmethod
children
neuroblastoma
treat
turkish
pediatr
oncolog
group
tpog
neuroblastoma
studi
testi
involv
either
diagnosi
relaps
retrospect
evalu
review
case
neuroblastoma
testi
involv
literatur
done
result
three
children
nb
document
involv
test
two
diagnosi
one
recurr
within
case
treat
turkish
pediatr
oncolog
group
tpog
neuroblastoma
protocol
advanc
stage
two
infant
third
case
first
recur
central
nervou
system
follow
testi
case
histopatholog
confirm
case
testicular
paratesticular
neuroblastoma
report
children
case
repres
metastas
adren
neuroblastoma
three
case
seri
conclus
conclus
testi
involv
extrem
uncommon
neuroblastoma
neuroblastoma
consid
differenti
diagnosi
testicular
mass
scrotal
ultrasonographi
use
first
diagnost
tool
abdomin
ultrasonographi
shall
done
addit
testi
examin
perform
diagnosi
regularli
boy
diagnos
neuroblastoma
test
may
sanctuari
site
neuroblastoma
metastat
case
leukemia
fs
khan
children
hospit
institut
child
health
lahor
pakistan
paediatr
haematologyoncolog
lahor
pakistan
children
hospit
institut
child
health
lahor
pakistan
paediatr
haematolog
lahor
pakistan
backgroundobject
neuroblastoma
second
commonest
solid
tumor
children
account
childhood
cancer
europ
usa
less
common
develop
countri
like
pakistan
bone
marrow
infiltr
neuroblastoma
occur
advanc
stage
diseas
accur
assess
bone
marrow
infiltr
newli
diagnos
case
immens
signific
object
determin
frequenc
pattern
bone
marrow
infiltr
neuroblastoma
correl
hematolog
paramet
amplif
cytogenet
sophist
test
avail
resourc
limit
set
like
public
sector
hospit
pakistan
designmethod
studi
includ
newli
diagnos
case
neuroblastoma
januari
decemb
depart
paediatr
haemtolog
paediatr
haematologyoncolog
children
hospit
lahor
pakistan
clinicohaematolog
paramet
bone
marrow
biopsi
metastas
analyz
case
chemotherapi
exclud
studi
data
analyz
use
spss
result
anemia
equal
common
case
without
marrow
infiltr
leucopenia
thrombocytopenia
significantli
p
valu
associ
marrow
infiltr
bone
marrow
infiltr
present
case
case
aspir
trephin
biopsi
posit
posit
marrow
aspir
show
focal
infiltr
diffus
infiltr
rosett
seen
case
focal
diffus
infiltr
infiltr
trephin
seen
focal
infiltr
case
diffus
infiltr
focal
diffus
infiltr
anoth
seven
case
fibrosi
present
seven
case
bilater
infiltr
present
trephin
biopsi
conclus
outcom
high
risk
diseas
usual
poor
surviv
less
countri
posit
therebi
necess
earli
detect
advanc
diseas
v
khandelw
r
b
superspeci
hospit
haematooncolog
bmt
delhi
india
superspeci
hospit
transfus
medicin
delhi
india
superspeci
hospit
haematolog
delhi
india
backgroundobject
high
dose
chemotherapi
follow
autolog
hematopoiet
stem
cell
transplant
hsct
recommend
neuroblastoma
relaps
refractori
lymphoma
high
risk
ewe
sarcoma
plerixafor
approv
use
combin
factor
hematopoiet
stem
cell
collect
apheresi
adult
multipl
myeloma
lymphoma
howev
use
efficaci
side
effect
pediatr
patient
report
report
experi
use
plerixafor
stem
cell
collect
autolog
hsct
high
risk
neuroblastoma
children
age
year
year
designmethod
retrospect
observ
analysi
perform
studi
medic
record
pediatr
patient
receiv
plerixafor
part
mobil
regimen
march
march
primari
outcom
stem
cell
yield
secondari
outcom
includ
abil
undergo
autolog
hsct
engraft
statu
result
four
stem
cell
collect
apheresi
mobil
gcsf
plerixafor
perform
pediatr
patient
dose
plerixafor
use
mgkg
bodi
weight
subcutan
sc
inject
major
advers
event
plerixafor
administr
apheresi
collect
report
four
case
high
risk
neuroblastoma
heavili
pre
treat
paediatr
patient
age
year
two
patient
plerixafor
use
elect
day
two
patient
use
yield
stem
cell
gcsf
low
patient
peripher
blood
stem
cell
harvest
plerixafor
inject
provid
adequ
dose
stem
cell
autolog
hsct
median
dose
cellskg
collect
million
engraft
median
time
neutrophil
platelet
engraft
day
day
respect
conclus
plerixafor
combin
safe
potenti
help
mobil
agent
heavili
pre
treat
paediatr
patient
kn
koh
hj
n
h
sh
jw
sy
ys
es
cj
hm
jj
medic
center
children
univers
ulsan
colleg
medicin
pediatr
seoul
republ
korea
medic
univers
ulsan
colleg
medicin
asan
institut
life
scienc
seoul
republ
korea
medic
univers
ulsan
colleg
medicin
laboratori
medicin
seoul
republ
korea
colleg
yonsei
univers
pediatr
wonju
republ
korea
backgroundobject
perform
pilot
studi
evalu
feasibl
efficaci
haploident
hematopoiet
cell
transplant
posttranspl
immunotherapi
use
zoledron
interleukin
il
children
relaps
neuroblastoma
designmethod
patient
relaps
neuroblastoma
chemotherapi
show
least
partial
respons
salvag
treatment
elig
studi
day
prior
patient
receiv
singl
intraven
infus
mcikg
condit
regimen
compris
fludarabin
day
thiotepa
mgkgday
day
melphalan
day
rabbit
globulin
mgkg
day
mgkg
day
graft
underw
deplet
neg
select
zoledron
administ
engraft
year
posttranspl
result
four
patient
two
complet
respons
two
partial
respons
relaps
tandem
chemotherapi
enrol
treatment
condit
engraft
rapid
complet
donor
chimer
achiev
patient
prior
transplant
cell
predomin
among
cell
median
day
posttranspl
cell
predominantli
compris
cell
median
three
patient
receiv
round
zoledron
stimul
expand
cell
number
although
cell
number
decreas
time
transplant
administr
zoledron
transient
revers
declin
administr
three
patient
develop
acut
diseas
gvhd
none
develop
chronic
gvhd
two
patient
remain
without
chronic
gvhd
two
patient
die
due
progress
diseas
conclus
result
suggest
posttranspl
immunotherapi
use
zoledron
feasibl
treatment
possibl
benefit
warrant
investig
sd
kristian
universita
gadjah
mada
dr
sardjito
gener
indonesia
depart
child
health
yogyakarta
indonesia
backgroundobject
factor
determin
cure
rate
children
neuroblastoma
nb
depend
factor
protocol
gener
health
nutrit
state
infect
factor
genet
factor
diagnost
risk
stratif
drug
avail
expertis
pediatr
oncolog
team
final
protocol
protocol
adher
designmethod
retrospect
review
children
year
old
nb
children
ward
dr
sardjito
gener
hospit
yogyakarta
indonesia
data
taken
yogyakarta
pediatr
cancer
registri
ypcr
medic
record
result
patient
nb
diagnos
base
histopatholog
treat
opec
protocol
patient
aliv
end
studi
opec
protocol
along
excel
support
care
gave
promis
result
develop
countri
year
ago
around
overal
surviv
even
high
risk
patient
give
result
low
middl
incom
countri
problem
low
middl
incom
countri
patient
came
stage
iv
diseas
poor
nutrit
state
death
caus
sepsi
indic
infect
rate
therapi
high
patient
came
low
educ
famili
might
implic
high
number
lost
follow
biolog
genet
examin
risk
stratif
also
could
done
conclus
year
experi
patient
main
problem
outsid
protocol
patient
came
late
lack
access
biolog
risk
stratif
poor
support
care
therapi
abandon
also
becam
problem
b
kumar
vd
r
gandhi
post
graduat
institut
medic
scienc
paediatr
surgic
superspeci
lucknow
india
gandhi
post
graduat
institut
medic
scienc
radiodiagnosi
lucknow
india
backgroundobject
neuroblastoma
common
childhood
tumour
characteris
spectrum
clinic
present
divers
prognosi
present
experi
case
advanc
neuroblastoma
stage
iiiiv
inss
manag
limit
resourc
designmethod
patient
advanc
neuroblastoma
stage
iiiiv
juli
june
manag
centr
includ
chemotherapi
offer
patient
radiotherapi
tumour
resect
done
feasibl
final
outcom
categoris
complet
respons
cr
partial
respons
pr
respons
nr
progress
diseas
pd
surviv
analysi
signific
stage
age
done
result
ten
patient
neuroblast
origin
tumour
ganglioneuroma
ganglioneuroblastoma
neuroblastoma
includ
studi
patient
femal
age
rang
month
year
median
age
year
locat
one
mediastin
tumor
rest
abdomin
tumor
pelvi
paraspin
adren
patient
detect
boni
lung
metastasi
time
diagnosi
chemotherapi
given
patient
surgeri
perform
patient
patient
receiv
local
radiotherapi
addit
patient
refer
higher
center
due
partial
respons
diseas
progress
recurr
within
one
year
patient
die
patient
aliv
includ
patient
ganglioneuroma
one
patient
palli
care
multipl
boni
recurr
one
year
rang
month
year
median
year
conclus
age
stage
respons
chemotherapi
major
factor
outcom
patient
year
stage
iii
achiev
cr
except
one
patient
ganglioneuroblastoma
develop
pd
one
patient
stage
iv
show
cr
develop
recurr
within
year
r
ladenstein
u
k
k
j
p
r
w
e
v
c
j
h
anna
kinderkrebsforschung
ev
studi
statist
integr
research
project
vienna
austria
anna
children
hospit
depart
medic
univers
vienna
austria
cancer
research
institut
studi
statist
integr
research
project
vienna
austria
univers
radiotherapi
depart
ghent
belgium
vienna
radiotherapi
depart
vienna
austria
roussi
servic
de
villejuif
austria
georg
hospit
surgic
depart
london
unit
kingdom
descart
necker
assist
publiqu
de
pari
depart
paediatr
surgeri
pari
franc
la
fe
pediatr
oncolog
surgeri
valencia
spain
ormond
street
hospit
paediatr
oncolog
haematolog
london
unit
kingdom
ircc
istituto
nazional
dei
tumori
paediatr
oncolog
haematolog
milan
itali
children
medic
center
israel
paediatr
oncolog
haematolog
petachtikvah
israel
univers
medic
colleg
paediatr
oncolog
haematolog
krakow
poland
paediatr
oncolog
haematolog
oslo
norway
sofia
children
hospit
athen
paediatr
oncolog
haematolog
athen
greec
dublin
paediatr
oncolog
haematolog
dublin
ireland
astrid
lindgren
children
hospit
paediatr
oncolog
haematolog
stockholm
sweden
hospit
aarhu
paediatr
oncolog
haematolog
aarhu
denmark
children
hospit
paediatr
oncolog
haematolog
randwick
australia
roussi
paediatr
oncolog
haematolog
villejuif
franc
colleg
hospit
paediatr
oncolog
haematolog
london
unit
kingdom
backgroundobject
investig
local
relaps
rate
lrr
outcom
neuroblastoma
designmethod
treatment
includ
rapid
cojec
induct
plu
two
tvd
cours
unsatisfactori
metastat
respons
attempt
primari
tumour
gross
resect
hdtsct
bumel
cem
radiotherapi
primari
site
follow
addit
antibodi
analysi
includ
patient
start
treatment
prior
hdtsct
aliv
without
event
day
sct
inform
radiotherapi
cumul
incid
local
relapseprogress
cilrp
either
isol
combin
site
calcul
consid
compet
risk
caus
includ
isol
distant
relapseprogress
rp
rp
unknown
site
death
secondari
malign
without
prior
rp
result
radiotherapi
respons
data
avail
patient
median
year
ef
ef
cilrp
isol
cilr
observ
whilst
combin
local
distant
cir
local
cr
lcr
lcr
cilrp
respect
radiotherapi
given
plan
patient
ef
cilrp
versu
patient
without
radiotherapi
decis
irradi
relat
young
age
larg
radiotherapi
field
base
volum
adjust
stage
age
surgic
result
hdtsct
regimen
remiss
statu
radiotherapi
signific
impact
ef
cilrp
hazard
ratio
conclus
local
radiotherapi
import
better
local
control
rate
european
histor
data
previous
shown
lrr
research
optimis
use
radiotherapi
need
importantli
local
radiotherapi
contribut
improv
outcom
lammen
k
g
univers
hospit
depart
pediatr
stem
cell
transplant
ghent
belgium
univers
cancer
research
insititut
ghent
ghent
belgium
univers
hospit
depart
pharmaci
ghent
belgium
backgroundobject
despit
remark
progress
understand
neuroblastoma
biolog
past
decad
neuroblastoma
remain
devast
diseas
genet
aberr
identifi
tumor
sampl
might
eventu
lead
identif
novel
therapeut
target
detail
analysi
routin
diagnost
array
compar
genom
hybrid
cgh
assay
might
contribut
process
designmethod
routin
diagnost
acgh
perform
describ
kump
c
et
al
associ
gene
express
clinic
genet
paramet
evalu
silico
use
platform
impact
methotrex
apoptosi
cytotox
viabil
neuroblastoma
cell
line
evalu
vitro
triplex
assay
promega
result
routin
acgh
diagnost
neuroblastoma
patient
observ
focal
amplif
encompass
gene
involv
metabol
express
nine
metabol
gene
known
process
found
significantli
higher
stage
diseas
significantli
correl
presenc
mycn
amplif
older
age
dataset
addit
high
express
atic
tym
dhfr
found
associ
overal
surviv
surviv
treatment
neuroblastoma
cell
line
methotrex
wide
use
folat
antagonist
block
metabol
reveal
methotrex
provok
signific
cell
death
apoptosi
cell
line
character
mycn
amplif
conclus
data
point
toward
import
target
metabol
pathway
neuroblastoma
result
provid
ration
base
investig
metabol
neuroblastoma
diseas
current
result
line
previou
report
illustr
associ
express
gene
reduc
folat
carrier
mycn
overexpress
neuroblastoma
lau
td
et
al
oncotarget
k
w
n
b
l
hospit
sick
children
divis
haematologyoncolog
toronto
canada
hospit
sick
children
depart
molecular
univers
center
human
genom
precis
toronto
canada
hospit
sick
children
program
genet
genom
hospit
sick
depart
paediatr
laboratori
hospit
sick
canada
toronto
canada
hospit
sick
children
depart
molecular
univers
center
human
genom
precis
univers
usa
toronto
canada
backgroundobject
alk
commonli
mutat
gene
patient
famili
neuroblastoma
nb
advanc
sequenc
lead
identif
novel
germlin
variant
potenti
role
patient
without
suspect
cancer
predisposit
syndrom
designmethod
patient
newli
diagnos
relaps
malign
includ
nb
patient
enrol
sequenc
germlin
dna
tumor
dna
rna
rare
germlin
substitut
indel
call
use
gatk
popul
allel
frequenc
compar
exac
intern
databas
known
polymorph
dbsnp
variant
pathogen
classifi
molecular
tumor
board
rare
variant
uncertain
signific
vu
support
correspond
somat
data
patient
phenotyp
andor
literatur
function
analys
term
variant
uncertain
signific
limit
evid
pathogen
result
date
analys
complet
nb
patient
patient
histori
retrospect
categor
high
genet
risk
hgr
patient
base
follow
criteria
famili
histori
nb
andor
signific
famili
histori
cancer
patient
nb
anoth
primari
tumor
nb
plu
congenit
anomali
pathogen
variant
known
gene
involv
includ
identifi
hgr
patient
patient
rare
like
pathogen
variant
gene
includ
blm
identifi
patient
notabl
addit
hgr
patient
harbour
gene
includ
conclus
preliminari
result
identifi
frequent
pathway
alter
variant
gene
commonli
associ
nb
predisposit
syndrom
even
absenc
famili
histori
find
may
implic
therapi
eg
parp
inhibitor
genet
counsel
patient
famili
lee
ch
l
w
elizabeth
hospit
children
haematolog
cancer
centr
singapor
singapor
elizabeth
medic
centr
surgeri
centr
children
singapor
singapor
univers
hong
kong
depart
paediatr
adolesc
medicin
hong
kong
hong
kong
sar
backgroundobject
outsid
europ
north
america
littl
known
outcom
children
suffer
neuroblastoma
aim
contribut
experi
southeast
asia
designmethod
retrospect
studi
neuroblastoma
treat
singl
institut
new
case
patient
partial
treat
accept
intens
treatment
surviv
measur
date
autolog
transplant
day
relaps
death
end
diseas
statu
time
transplant
countri
resid
condit
regimen
time
transplant
diagnosi
examin
impact
surviv
result
children
boy
mean
age
year
treat
three
children
diagnos
de
novo
rest
receiv
treatment
elsewher
five
children
consid
local
singapor
malaysia
indonesia
time
transplant
nine
children
good
partial
remiss
complet
remiss
nine
children
condit
rest
addit
six
receiv
therapeut
eight
receiv
total
bodi
irradi
part
condit
nine
children
late
transplant
month
diagnosi
transplant
earli
eleven
children
relaps
die
neuroblastoma
three
children
die
remiss
accid
massiv
gastrointestin
bleed
myelodysplasia
respect
surviv
none
studi
factor
statist
signific
impact
surviv
although
trend
toward
better
surviv
patient
local
compar
countri
vs
conclus
experi
children
neuroblastoma
accept
treatment
despit
prior
suboptim
therapi
aggress
approach
intens
chemotherapi
surgeri
result
survivor
li
f
h
sr
ag
medic
center
koseikan
life
scienc
research
institut
saga
japan
centr
pediatr
oncolog
immunolog
name
dmitri
rogachev
departmart
pediatr
hematolog
oncolog
moscow
russia
cancer
center
research
institut
chiba
japan
cancer
center
research
institut
clinic
oncolog
saitama
japan
himat
foundat
tosu
tosu
japan
backgroundobject
calcineurin
serinethreonin
phosphatas
involv
number
biolog
process
aberrantli
activ
calciumcalcineurinnfat
nuclear
factor
activ
signal
promot
tumor
prolifer
invas
angiogenesi
previous
identifi
mutat
calcineurin
catalyt
subunit
neuroblastoma
nb
tissu
mycn
amplif
addit
found
high
express
significantli
predict
poor
outcom
nb
independ
known
clinic
prognost
factor
designmethod
overexpress
knockdown
conduct
sever
nb
cell
line
investig
function
role
mutant
nb
nb
cell
line
without
mycn
amplif
treat
two
kind
calcineurin
inhibitor
cai
cyclosporin
csa
cell
viabil
prolifer
cell
death
assess
mtt
assay
trypan
blue
exclus
cell
growth
curv
assay
fac
analysi
respect
express
nfat
target
gene
detect
western
blot
analysi
result
overexpress
wildtyp
mutat
promot
cell
growth
knockdown
decreas
cell
growth
nb
cell
activ
transcript
factor
inhibit
activ
result
increas
express
mycn
treatment
calcineurin
inhibitor
suppress
cell
prolifer
induc
apoptot
cell
death
sever
nb
cell
line
express
along
mycn
decreas
mrna
protein
level
respons
cai
conclus
find
demonstr
elev
express
express
constitut
activ
mutant
contribut
aggress
behavior
nb
tumor
calcineurin
inhibitor
strong
activ
vitro
target
result
suggest
inhibit
calcineurin
activ
might
therapeut
potenti
nb
r
liao
j
z
j
f
j
x
yat
univers
cancer
center
pediatr
oncolog
guangzhou
china
yat
univers
cancer
center
patholog
guangzhou
china
backgroundobject
investig
clinic
signific
express
level
neuroblastoma
nb
designmethod
clinic
data
tumor
paraffin
tissu
nb
collect
sun
univers
cancer
center
januari
decemb
express
detect
immunohistochem
technolog
relationship
express
clinic
prognosi
patient
nb
analyz
result
total
one
hundr
patient
nb
low
risk
intermedi
risk
high
risk
nb
respect
patient
posit
low
express
high
express
high
express
posit
relat
risk
stratif
stage
mycn
gene
statu
ef
patient
low
high
express
respect
os
respect
patient
ef
patient
low
high
express
respect
os
respect
patient
ef
patient
low
high
express
respect
os
respect
posit
rate
nb
tumor
tissu
patient
low
express
express
nb
significantli
correl
tumor
size
age
gender
stage
treatment
effici
mycn
gene
statu
risk
stratif
surviv
multivari
analysi
show
posit
mycn
amplif
independ
advers
prognost
factor
os
posit
advanc
stage
independ
advers
prognost
factor
ef
p
conclus
studi
show
may
use
new
prognost
indic
nb
futur
j
z
lu
children
hospit
hematologyoncolog
shanghai
china
children
hospit
surgeri
shanghai
china
backgroundobject
metastasi
neuroblastoma
shown
associ
acquisit
transit
emt
molecular
mechan
uncertain
transform
growth
factor
tgf
beta
involv
develop
progress
emt
tumor
cell
previou
studi
found
tgf
beta
induc
occurr
emt
human
neuroblastoma
cell
line
non
smad
signal
pathway
transcript
factor
gli
key
regul
emt
induc
human
neuroblastoma
cell
also
key
transcript
factor
downstream
hedgehog
signal
pathway
aim
investig
molecular
mechan
tgf
beta
regul
emt
neuroblastoma
designmethod
tgf
beta
induc
emt
phenotyp
vitro
cultur
neuroblastoma
cell
line
studi
molecular
mechan
hedgehoggli
signal
pathway
emt
induc
tgf
beta
neuroblastoma
cell
westernblot
fluoresc
quantit
pcr
sirna
interfer
lentiviru
mediat
gene
overexpress
knockout
result
express
increas
emt
induc
neuroblastoma
cell
express
transcript
factor
induc
increas
significantli
neuroblastoma
cell
interfer
overexpress
classic
smad
pathway
affect
express
emt
gli
induc
studi
show
increas
express
affect
inhibit
classic
hedgehog
pathway
neuroblastoma
cell
line
tgf
beta
regul
express
protein
phosphoryl
akt
conclus
suggest
signal
pathway
togeth
hedgehog
pathway
express
induc
tgf
beta
neuroblastoma
abnorm
activ
pathway
may
involv
increas
gli
express
emt
close
relat
metastasi
neuroblastoma
x
x
l
z
w
q
c
c
x
children
capit
medic
univers
nation
center
children
health
beij
key
laboratori
pediatr
hematolog
nation
disciplin
ministri
moe
key
laboratori
major
diseas
hematolog
oncolog
center
beij
china
keyin
evergreen
institut
medic
research
compani
limit
beij
keyin
technolog
compani
beij
china
backgroundobject
evalu
plasma
dna
cfdna
promis
biomark
neuroblastoma
nb
tumor
burden
designmethod
elig
patient
newli
diagnos
nb
recruit
beij
children
hospit
april
april
addit
septemb
june
patient
stabl
nb
evalu
median
time
month
approxim
ml
peripher
blood
drawn
upon
enrol
plasma
cfdna
level
measur
via
quantit
polymeras
chain
reaction
qpcr
total
cfdna
analysi
perform
use
long
interspers
nuclear
element
bp
fragment
dna
integr
calcul
ratio
bp
fragment
bp
fragment
result
total
nb
patient
median
age
month
compris
group
newli
diagnos
nb
patient
main
primari
tumor
site
retroperiton
adren
region
three
metastat
site
found
patient
stabl
nb
patient
older
month
compris
stabl
nb
patient
enolas
nse
lactat
dehydrogenas
ldh
cfdna
level
dramat
increas
newli
diagnos
nb
patient
significantli
differ
stabl
nb
patient
moreov
concentr
cfdna
much
higher
patient
larger
tumor
analyz
area
receiv
oper
characterist
roc
curv
auc
area
total
cfdna
nse
ldh
level
respect
conclus
sensit
specif
data
clarifi
level
circul
cfdna
plasma
consid
reliabl
biomark
describ
tumor
load
nb
plasma
cfdna
concentr
accur
level
ldh
nse
describ
tumor
burden
children
nb
n
miyagawa
w
f
j
n
h
children
medic
center
divis
hematologyoncolog
japan
children
medic
center
divis
clinic
laboratori
japan
children
medic
center
divis
surgeri
japan
children
medic
center
divis
patholog
japan
backgroundobject
bone
marrow
bm
examin
necessari
risk
stratif
neuroblastoma
nbl
use
immunostain
procedur
use
antibodi
evalu
bm
metastasi
residu
bm
diseas
induct
chemotherapi
designmethod
retrospect
review
clinic
cours
nbl
patient
bm
metastasi
diagnos
institut
januari
decemb
posit
rate
immunostain
procedur
bm
treatment
outcom
site
relaps
evalu
result
twenti
eight
patient
metastas
prove
bm
metastasi
initi
diagnosi
inrg
classif
stratifi
high
risk
hr
group
posit
rate
immunostain
procedur
initi
bm
examin
respect
hr
group
patient
peripher
blood
stem
cell
pbsc
harvest
initi
clearanc
andor
posit
nbl
cell
bm
seventeen
hr
patient
receipt
high
dose
follow
auto
pbsc
rescu
four
patient
receipt
allograft
continu
posit
detect
immunostain
induct
chemotherapi
one
patient
undergo
therapi
earli
death
hr
group
ef
os
cumul
incid
relaps
ci
ci
ci
respect
median
period
month
rang
eight
patient
relaps
primari
site
primari
site
bm
central
nervou
system
interestingli
relaps
nbl
cell
becam
neg
immunostain
procedur
cord
blood
transplant
one
case
although
posit
detect
relaps
tumor
cell
conclus
immunostain
procedur
use
term
sensit
specif
detect
bm
metastasi
residu
diseas
nbl
morini
r
j
font
de
sa
mv
b
g
r
ar
l
gaslini
institut
laboratori
molecular
biolog
genoa
itali
gaslini
institut
stem
cell
laboratori
cell
therapi
center
genoa
itali
ircc
istituto
nazional
dei
tumori
pediatr
oncolog
milan
itali
children
hospit
pediatr
hematolog
oncolog
rome
itali
de
sanitaria
la
fe
clinic
translat
research
cancer
valencia
spain
universitari
la
fe
valencia
spain
institut
cancer
patholog
children
cancer
research
group
leed
unit
kingdom
gaslini
institut
unit
experiment
therapi
oncolog
genoa
itali
institut
pediatr
oncolog
pari
franc
anna
children
hospit
pediatr
oncolog
vienna
austria
gaslini
institut
patholog
unit
genoa
itali
gaslini
institut
pediatr
oncolog
genoa
itali
backgroundobject
respons
hr
neuroblastoma
nb
patient
lack
prognost
molecular
indic
sensitivityresist
circul
exosom
repres
bioprint
tumor
cell
origin
liquid
biopsi
investig
modul
exosom
microrna
express
respons
designmethod
exosom
isol
plasma
sampl
patient
collect
flow
cytometri
use
detect
posit
vesicl
express
measur
rtqpcr
mirna
panel
data
analys
includ
featur
select
pathway
analysi
result
exosom
isol
plasma
sampl
posit
indic
vesicl
specif
secret
tumor
cell
analys
whole
exosom
popul
found
express
fold
chang
p
valu
significantli
modul
respons
chemotherapi
provid
evid
may
serv
biomark
cluster
analysi
demonstr
profil
identifi
two
group
patient
potenti
reflect
differ
chemotherapi
respons
pathway
analysi
result
show
major
differenti
express
predict
regul
drug
efficacyresist
gener
linear
model
identifi
three
clearli
differenti
poor
good
respond
silico
analysi
show
interact
chemotherapeut
employ
cisplatinetoposid
profil
middl
phase
treatment
investig
identifi
earli
predictor
respons
may
allow
time
chang
induct
protocol
conclus
demonstr
plasma
sampl
contain
posit
exosom
releas
tumor
cell
obtain
proof
principl
biomark
indic
susceptibilityresist
specif
drug
result
pave
way
applic
liquid
biopsi
circul
biomark
respons
potenti
develop
nb
target
treatment
moschovi
nm
p
kapodistrian
univers
athen
depart
pediatr
athen
greec
backgroundobject
neuroblastoma
common
extracrani
solid
tumor
infanc
malign
children
month
age
earli
onset
neuroblastoma
suggest
potenti
relationship
age
diagnosi
biolog
tumor
studi
associ
perinat
characterist
high
incid
diagnosi
neuroblastoma
designmethod
children
neuroblastoma
involv
diagnos
month
age
systemat
treatment
requir
paramet
like
resid
gender
birth
weight
gestat
age
analyz
result
age
diagnosi
rang
birth
month
patient
age
less
month
diagnosi
patient
live
urban
center
repres
analyz
age
diagnosi
base
resid
observ
urban
center
ratio
age
diagnosi
month
vs
month
wherea
provinc
ratio
male
patient
consid
resid
percentag
male
increas
urban
center
decreas
provinc
durat
pregnanc
week
gestat
age
week
case
deliveri
schedul
cesarean
section
patient
birth
weight
rang
wherea
birth
weight
patient
conclus
neuroblastoma
among
children
month
old
appear
frequent
first
six
month
life
male
superior
notabl
mainli
urban
center
gestat
age
week
patient
birth
weight
mean
prematur
low
birth
weight
full
term
infant
may
predispos
factor
g
muftakhova
r
k
l
n
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
institut
manag
translat
medicin
moscow
russia
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
institut
radiolog
nuclear
medicin
moscow
russia
backgroundobject
neonat
oncolog
new
scientif
object
modern
paediatr
children
first
year
life
uniqu
popul
increas
risk
cancer
featur
diagnost
treatment
children
age
group
object
analyz
experi
dmitri
rogachev
center
neonat
oncolog
designmethod
three
hundr
eighti
one
patient
admit
dmitri
rogachev
center
analys
patient
boy
median
onset
first
clinic
sign
month
diagnosi
month
case
neuroblastoma
soft
tissu
sarcoma
wilm
tumor
hepatoblastoma
malign
rhabdoid
tumor
modifi
protocol
nb
siopel
cw
use
treatment
case
differ
diseas
use
innov
approach
escal
therapi
depend
diseas
result
complic
case
patient
neuroblastoma
nb
children
stage
obrserv
group
special
attent
paid
patient
syndrom
reduc
intens
chemo
requir
patient
estim
probabl
os
ef
median
month
event
regist
usual
month
old
hepatoblastoma
patient
standard
risk
group
surviv
os
group
median
month
os
rhabdoid
tumor
group
sever
predisposit
mutat
found
p
p
p
predisposit
syndrom
found
children
conclus
cancer
patient
first
year
life
uniqu
situat
requir
individu
multidisciplinari
approach
includ
ration
chemotherapi
surgeri
radiat
cellular
therapi
predisposit
syndrom
import
patient
new
method
diagnost
therapi
allow
improv
result
k
mullanfiroz
dhirubhai
ambani
hospit
blood
marrow
transplant
mumbai
india
backgroundobject
standard
care
treatment
hr
neuroblastoma
nb
includ
remiss
induct
chemotherapi
follow
surgeri
myeloabl
condit
follow
autolog
stem
cell
transplant
asct
follow
radiotherapi
immunotherapi
chimer
antibodi
remain
main
stay
immun
therapi
howev
financi
constraint
unavail
limit
use
develop
countri
overal
surviv
os
report
develop
world
podc
set
os
report
much
less
designmethod
retrospect
analysi
children
underw
asct
tertiari
centr
western
india
conduct
children
defin
hr
base
either
age
diagnosi
andor
statu
andor
stage
andor
histolog
result
nine
children
boy
age
median
month
underw
asct
asct
undertaken
complet
remiss
cr
evidenc
neg
scan
mibg
scan
andor
bone
marrow
biopsi
test
confirm
condit
therapi
use
entir
cohort
averag
stem
cell
dose
averag
white
cell
platelet
engraft
respect
day
children
underw
local
radiotherapi
follow
oral
acid
therapi
month
two
children
relaps
month
asct
median
month
month
os
cohort
without
use
chimer
antibodi
approxim
cost
asct
usd
centr
conclus
develop
countri
asct
justifi
offer
children
achiev
cr
especi
antibodi
unavail
cost
prohibitori
although
studi
follow
short
recommend
care
patient
select
aggress
therapi
popul
os
compar
develop
world
achiev
even
without
immunotherapi
e
k
r
h
h
k
univers
school
medicin
pediatr
surgeri
tokyo
japan
univers
school
medicin
gener
medicin
tokyo
japan
backgroundobject
recent
found
polyethylen
glycol
deriv
origin
extract
filament
bacteria
strongli
suppress
growth
mani
type
tumor
cell
includ
neuroblastoma
nb
howev
exert
antitumor
effect
remain
unclear
present
studi
investig
molecular
mechan
underli
cytotox
nb
cell
designmethod
nb
cell
line
mycn
amplif
without
mycn
amplif
well
normal
fibroblast
cell
use
studi
cell
viabil
addit
analyz
assay
cell
cycl
distribut
determin
use
flow
cytomet
fac
express
cell
protein
analyz
western
blot
result
decreas
viabil
cell
dose
depend
manner
suppress
cell
growth
complet
least
day
contrast
normal
fibroblast
cell
surviv
even
high
concentr
fac
analysi
show
ratio
phase
phase
increas
treatment
wherea
ratio
dead
cell
hardli
chang
western
blot
show
express
cell
protein
increas
treatment
activ
observ
conclus
suppress
cell
viabil
nb
cell
regardless
presenc
absenc
mycn
amplif
induct
manner
elucid
detail
mechan
underli
antitumor
action
examin
effect
respons
cell
sever
kind
stress
sinc
show
limit
effect
normal
fibroblast
cell
strong
potenti
becom
new
drug
n
nishimura
kkm
n
k
n
k
univers
graduat
school
medicin
pediatr
kobe
japan
children
hospit
hematolog
oncolog
kobe
japan
backgroundobject
determin
express
profil
minim
residu
diseas
mrd
marker
bone
marrow
bm
peripher
blood
pb
patient
neuroblastoma
designmethod
total
bm
pb
sampl
clinic
diseas
evalu
obtain
patient
neuroblastoma
treat
kobe
children
hospit
kobe
univers
hospit
januari
januari
mrna
express
mrd
marker
dbh
ddc
th
quantifi
droplet
digit
pcr
ddpcr
express
copi
number
use
evalu
differ
two
group
result
patient
diagnos
neuroblastoma
treat
accord
japan
children
cancer
group
jccg
neuroblastoma
committe
jnbsg
protocol
bm
pb
sampl
obtain
frequent
possibl
entir
cours
treatment
initi
diagnosi
total
copi
number
mrd
marker
significantli
larger
bm
pb
bm
sampl
patient
pb
sampl
patient
complet
induct
therapi
diagnosi
relaps
significantli
larger
bm
relaps
patient
patient
sampl
relaps
patient
sampl
patient
although
statist
signific
also
tend
larger
pb
relaps
patient
patient
sampl
relaps
patient
sampl
patient
conclus
express
mrd
marker
bm
pb
sampl
may
repres
diseas
statu
predict
relaps
neuroblastoma
patient
obu
k
h
k
e
h
h
graduat
school
medicin
kyoto
univers
kyoto
japan
pediatr
graduat
school
medicin
kyoto
univers
kyoto
japan
human
health
graduat
school
medicin
kyoto
univers
kyoto
japan
discoveri
technolog
develop
center
ip
cell
research
applic
kyoto
univers
kyoto
japan
graduat
school
medic
scienc
kyoto
prefectur
univers
medicin
kyoto
japan
backgroundobject
neuroblastoma
nb
common
extracrani
solid
tumor
childhood
thought
aris
neural
crest
nc
immatur
cell
sinc
prognosi
patient
nb
recurrentrefractori
diseas
remain
poor
despit
intens
multimod
therapi
novel
therapeut
intervent
requir
also
known
mcam
cell
adhes
molecul
express
variou
neural
deriv
expect
therapeut
target
immunotherapi
variou
malign
designmethod
express
level
six
nb
cell
line
clinic
sampl
examin
flow
cytometr
immunohistochem
analys
effect
block
rabbit
polyclon
antibodi
shrna
knockdown
evalu
vitro
assay
sphere
form
assay
vivo
subcutan
transplant
immunodefici
mice
result
cell
detect
nb
cell
line
clinic
sampl
polyclon
antibodi
knockdown
significantli
inhibit
vitro
tumor
viabil
polyclon
antibodi
also
suppress
vivo
tumor
format
immunodefici
mice
detail
underli
mechan
investig
conclus
notabl
effect
block
facilit
novel
immunotherapi
nb
v
nh
tm
ar
cc
fa
ac
rm
g
g
lm
em
paulo
univers
medic
school
brazil
pediatr
depart
sao
paulo
brazil
clinic
school
univers
brazil
laboratori
medic
investig
lim
paulo
brazil
cancer
brazil
laboratori
paulo
brazil
univers
brazil
depart
genet
evolutionari
sao
paulo
brazil
sao
paulo
state
univers
brazil
laboratori
botucatu
brazil
paulo
univers
medic
school
brazilhospit
israelita
albert
einstein
hematolog
oncolog
brazil
pediatr
depart
sao
paulo
brazil
hemocentro
de
paulo
divis
molecular
genet
brazil
paulo
brazil
backgroundobject
neuroblastoma
autonom
embryon
tumor
common
cancer
diagnos
first
year
life
sever
key
member
transcript
factor
forkhead
box
fox
foxo
foxk
subfamili
strongli
implic
drug
resist
cancer
variant
associ
carboplatin
plu
doxorubicin
resist
neuroblastoma
investig
designmethod
twelv
neuroblastoma
obtain
children
neuroblastoma
stage
intern
neuroblastoma
stage
system
patient
older
month
mycn
children
expos
platin
deriv
plu
doxorubicin
delay
surgeri
preoper
chemotherapi
assess
cell
cell
treat
carboplatin
plu
doxorubicin
tumor
sampl
neuroblastoma
patient
tumor
blood
sequenc
use
target
resequenc
perform
dna
librari
prepar
kit
illumina
san
diego
ca
usa
accord
manufactur
instruct
sequenc
miseq
sequenc
platform
illumina
san
diego
ca
usa
polymorph
identifi
use
genom
project
consortium
nhlbi
exom
sequenc
project
esp
databas
minor
allel
frequenc
record
databas
clinvar
databas
result
three
somat
variant
describ
previous
neuroblastoma
identifi
patient
variant
c
like
induc
conform
chang
protein
could
consider
repercuss
includ
effect
cellular
event
dna
bind
nuclear
variant
c
chang
threonin
methionin
may
affect
bind
proxim
promot
region
conclus
evid
studi
argu
strongli
variant
reliabl
diagnost
marker
genotox
drug
resist
neuroblastoma
tc
e
ap
z
n
olgun
behalf
turkish
pediatr
oncolog
group
eylul
univers
institut
oncolog
izmir
turkey
backgroundobject
heterogen
cancer
differ
tumor
cell
biolog
behavior
neuroblastoma
treatment
depend
risk
classif
includ
molecular
test
studi
search
heterogen
dna
ploidi
mycn
amplif
delet
gain
metachron
neuroblastoma
sampl
designmethod
case
among
case
turkish
pediatr
oncolog
group
neuroblastoma
databas
multipl
sampl
mycn
amplif
gain
evalu
dna
ploidi
flow
cytometri
fresh
tumor
sampl
statist
analyz
made
use
spss
pair
sampl
test
frequenc
calcul
result
mean
age
case
month
patient
femal
patient
male
patient
low
risk
intermedi
risk
high
risk
group
heterogen
observ
case
mycn
gain
dna
ploidi
conclus
molecular
heterogen
observ
neuroblastoma
among
differ
tumor
sampl
patient
molecular
test
better
analys
tumor
tissu
sampl
obtain
differ
time
case
evalu
risk
classif
possibl
chang
z
b
e
n
olgun
behalf
turkish
pediatr
oncolog
group
eylul
univers
institut
oncolog
depart
basic
oncolog
izmir
turkey
eylul
institut
oncolog
izmir
univers
faculti
medicin
basic
medic
scienc
izmir
turkey
eylul
univers
institut
oncolog
depart
pediatr
oncolog
izmir
turkey
backgroundobject
neuroblastoma
heterogen
molecular
clinic
behavior
still
need
find
new
biomark
treatment
determin
prognosi
aim
studi
determin
whether
express
level
dismutas
protein
identifi
candid
biomark
previou
proteom
studi
import
neuroblastoma
tissu
designmethod
neuroblastoma
case
studi
immunohistochem
express
paraffin
tissu
sampl
protein
express
score
neg
one
two
three
posit
express
delet
gain
evalu
pcr
dna
ploidi
detect
flow
cytometri
tissu
sampl
protein
express
level
correl
molecular
clinic
data
includ
patient
express
delet
gain
dna
ploidi
statist
analysi
perform
use
pearson
correl
analysi
result
age
rang
month
averag
month
case
femal
male
posit
found
del
gain
diploid
express
neg
one
posit
two
posit
three
posit
case
express
found
associ
differenti
posit
express
ganglioneuron
area
neurofil
ganglion
cell
detect
intens
express
show
signific
correl
clinic
data
p
conclus
protein
show
similar
level
express
thought
relat
differenti
moreov
express
show
correl
clinic
data
number
patient
increas
assess
whether
protein
express
import
biomark
result
assess
accord
neuroblastoma
risk
group
clinic
observ
z
n
olgun
eylul
univers
institut
oncolog
depart
basic
oncolog
izmir
turkey
eylul
univers
institut
oncolog
depart
pediatr
oncolog
izmir
turkey
backgroundobject
neuroblastoma
patient
still
neeed
new
therapaut
cisplatin
ii
cddp
main
chemotherapaut
neuroblastoma
treatment
mani
advers
effect
oleuropein
ole
found
oliv
leaf
shown
reduc
cancer
cell
viabil
aim
studi
investig
possibl
apoptot
effect
ole
combin
cddp
good
prognost
poor
prognost
kelli
neuroblastoma
fibroblast
cell
designmethod
psi
cell
cultur
dmem
kelli
cell
culter
rpmi
medium
supplement
fb
penicillinstreptomycin
ole
um
cddp
combin
appli
hour
psi
kelli
cell
dose
determin
cell
viabil
analysi
use
test
apoptot
cell
death
determin
use
assay
cddp
ole
ole
treatment
cell
statist
analysi
perform
use
test
p
valu
consid
statist
signific
result
kelli
neuroblastoma
cell
ole
um
decreas
viabil
show
apoptot
effect
contrast
ole
um
um
combin
induc
apoptosi
cell
kelli
cell
inhibit
cell
viabil
apoptot
effect
ole
um
determin
especi
hour
cell
conclus
studi
show
first
time
ole
cddp
combin
induc
cell
death
neuroblastoma
cell
apoptot
cell
death
mechan
ole
also
caus
apoptosi
healthi
fibroblast
cell
furthermor
induc
cell
death
bad
prognost
kelli
cell
mechan
effect
ole
neuroblastoma
studi
studi
vitro
vivo
p
n
olgun
eylul
univers
institut
ocnolog
izmir
turkey
eylul
univers
depart
experiment
anim
scienc
izmir
turkey
backgroundobject
high
dose
cisplatin
induc
dose
limit
side
effect
neuroblastoma
nb
mesenchym
stem
cell
msc
multipotenti
properti
contemporari
research
area
cellular
therapi
aim
studi
evalu
interfer
msc
cisplatin
nb
nude
mice
anim
model
designmethod
atym
male
nude
mice
inject
subcutan
nb
cell
line
tumor
format
within
day
one
cm
diamet
experiment
group
control
cisplatin
therapi
msc
therapi
cisplatinmsc
therapi
randomli
design
mice
group
anim
intraperiton
inject
cisplatin
intraven
inject
msc
day
anim
sacrifi
tumor
tissu
evalu
necrosi
viabil
apoptosi
evalu
annexin
vpi
flow
cytomet
msc
ratio
within
tumor
evalu
flow
cytomet
tripl
express
statist
evalu
perform
nonparametr
kruscal
walli
mann
whitney
u
test
p
level
result
viabil
tumor
tissu
higher
mc
treat
group
necrosi
tumor
tissu
statist
signific
cisplatin
group
cisplatinmsc
group
compar
control
msc
group
although
cisplatinmsc
group
seem
lower
tumor
necrosi
ratio
cisplatin
group
statisticali
signific
observ
msc
chang
tumor
dimens
decreas
msc
found
control
cisplatin
group
treat
group
tripl
express
conclus
studi
msc
candid
side
effect
prevent
agent
cellular
therapi
found
somehow
interfer
antitumor
effect
cisplatin
nb
decreas
apoptosi
necrosi
although
stop
tumor
diment
decreas
caus
cisplatin
role
side
effect
care
consid
point
view
tumor
therapi
b
n
olgun
eylul
univers
institut
health
depart
translat
oncolog
izmir
turkey
celal
bayar
univers
hasan
ferdi
turgutlu
faculti
depart
softwar
engin
manisa
turkey
eylul
univers
institut
depart
basic
oncolog
izmir
turkey
eylul
univers
institut
depart
pediatr
oncolog
izmir
turkey
backgroundobject
neuroblastoma
common
solid
tumor
among
childhood
cancer
except
skull
fifti
percent
neuroblastoma
case
children
two
year
age
neuroblastoma
type
cancer
nervou
system
origin
brain
carri
messag
whole
bodi
neuroblastoma
divid
three
risk
group
low
moder
high
level
depend
cog
chidren
oncolog
group
risk
group
group
differ
treatment
surviv
rate
studi
aim
improv
decis
support
system
use
machin
learn
algorithm
better
decis
make
ad
differ
variabl
exist
accept
class
designmethod
order
identifi
risk
group
neuroblastoma
patient
dataset
gdc
genom
data
common
featur
set
divid
two
group
base
featur
set
individu
featur
way
differ
featur
set
obtain
combin
base
featur
set
individu
featur
analyz
predict
perform
six
learn
algorithm
naiv
bay
logist
regress
multilay
perceptron
support
vector
machin
algorithm
three
ensembl
method
adaboost
bag
random
forest
consid
result
random
forest
decis
tree
classifi
outperform
learn
algorithm
classif
accuraci
random
forest
algorithm
use
grade
diagnost
categori
featur
set
base
featur
set
use
first
event
featur
set
base
featur
set
yield
highest
predict
perform
algorithm
obtain
better
predict
perform
combin
featur
set
conclus
identif
risk
group
neuroblastoma
great
import
proper
treatment
believ
support
decis
help
clinician
give
better
result
studi
empir
analysi
machin
learn
base
method
present
rel
high
predict
perform
p
v
e
e
h
k
k
n
seeg
eastern
european
e
petrid
kapodistrian
univers
athen
medic
school
dept
epidemiolog
medic
statist
athen
greec
agia
sofia
children
hospit
depart
pediatr
athen
greec
pan
agl
kyriak
children
hospit
depart
pediatr
athen
greec
agia
sofia
children
hospit
pediatr
hematologyoncolog
first
depart
univers
athen
athen
greec
hospit
depart
pediatr
hematolog
oncolog
thessaloniki
greec
univers
ahepa
hospit
pediatr
depart
thessaloniki
greec
crete
depart
pediatr
heraklion
greec
mitera
children
hospit
pediatr
depart
athen
greec
p
kyriak
children
hospit
patholog
laboratori
athen
greec
agia
sofia
children
hospit
patholog
laboratori
athen
greec
joana
daniela
anna
domen
sultan
raluca
mario
maciej
tina
anna
anton
ryzhov
eastern
european
group
eastern
europ
greec
institut
unit
clinic
depart
medicin
stockholm
sweden
backgroundobject
neuroblastoma
tumor
infancyearli
childhood
variabl
clinic
behavior
outcom
aim
explor
whether
socioeconom
indic
associ
neuroblastoma
incid
ir
surviv
european
see
countri
designmethod
incid
rate
air
calcul
correl
hdi
incid
neuroblastoma
case
diagnos
among
children
year
report
registri
see
countri
tempor
trend
assess
use
poisson
regress
joinpoint
analys
curv
multivari
cox
proport
hazard
model
use
assess
effect
age
gender
primari
tumor
site
hdi
urban
overal
surviv
os
result
overal
air
rang
case
diagnos
infanc
ir
reach
ir
posit
associ
hdi
especi
age
year
lower
median
age
diagnosi
correl
higher
air
primari
locat
abdomen
neuroblastoma
slightli
common
male
mf
especi
among
infant
ir
among
infant
decreas
overtim
slovenia
cypru
increas
ukrain
belaru
see
vari
wide
ukrain
poland
age
month
diagnost
period
rural
resid
hr
live
inhigh
medium
hdi
countri
specif
primari
locat
hrabdomen
hrcn
weresignificantli
associ
wors
outcom
conclus
neuroblastoma
incid
vari
significantli
see
lower
infant
low
hdi
countri
possibl
indic
less
incid
surg
infanc
care
examin
avoid
unnecessari
intervent
tumour
could
spontan
regress
surviv
wors
children
rural
area
lower
hdi
countri
may
attribut
potenti
modifi
healthcar
system
perform
characterist
v
e
h
e
p
n
e
petrid
kapodistrian
univers
athen
medic
school
dept
epidemiolog
medic
statist
athen
greec
agia
sofia
children
hospit
depart
pediatr
athen
greec
pan
agl
kyriak
children
hospit
depart
pediatr
athen
greec
agia
sofia
children
hospit
pediatr
hematologyoncolog
first
depart
univers
athen
athen
greec
hospit
depart
pediatr
hematolog
oncolog
thessaloniki
greec
crete
depart
pediatr
heraklion
greec
mitera
children
hospit
pediatr
depart
athen
greec
univers
ahepa
hospit
pediatr
depart
thessaloniki
greec
backgroundobject
clinic
nationwid
registri
childhood
haematolog
malign
solid
tumour
greec
function
sinc
aim
present
characterist
outcom
neuroblastoma
case
designmethod
data
incid
neuroblastoma
case
age
year
extract
analys
use
standard
descript
analys
cox
regress
model
result
total
patient
regist
male
result
rel
high
incid
season
peak
signific
tempor
trend
observ
month
month
median
age
year
mean
age
year
wherea
male
intern
neuroblastoma
risk
group
inrg
stage
local
metastat
mm
evalu
patient
infant
children
month
primari
site
metastat
respect
opsoclonusmyoclonu
present
patient
manag
follow
siopen
protocol
ef
overal
surviv
os
mean
time
month
respect
specif
localis
metastat
month
month
respect
multivari
analysi
deriv
hazard
ratio
hr
month
associ
wors
outcom
ci
ci
stage
stage
ms
ci
hro
conclus
incid
rel
higher
greec
compar
european
countri
us
surviv
compar
develop
countri
vari
significantli
age
stage
clinic
registr
data
import
also
show
recent
financi
crisi
affect
provis
high
qualiti
special
care
childhood
neuroblastoma
greec
p
c
c
k
hospit
pediatr
bangkok
thailand
kaen
univers
pediatr
khon
kaen
thailand
songkla
univers
pediatr
songkla
thailand
kaen
hospit
pediatr
khon
kaen
thailand
hospit
pediatr
bangkok
thailand
chulalongkorn
memori
hospit
pediatr
bangkok
thailand
sirikit
nation
institut
child
health
pediatr
bangkok
thailand
hospit
pediatr
bangkok
thailand
backgroundobject
background
neuroblastoma
common
pediatr
solid
tumor
wide
rang
clinic
present
respons
treatment
despit
use
combin
chemotherapi
surgeri
radiat
patient
respond
poorli
topotecan
wide
use
treat
relaps
pediatr
solid
tumor
includ
neuroblastoma
herein
introduc
topotecan
first
line
therapi
induct
regimen
patient
object
determin
clinic
outcom
identifi
prognost
factor
predict
induct
respons
neuroblastoma
patient
receiv
regimen
thailand
designmethod
method
neuroblastoma
patient
undergon
thaipog
neuroblastoma
protocol
enrol
induct
regimen
consist
cycl
chemotherapi
topotecan
introduc
first
cycl
treatment
clinic
data
laboratori
result
imag
studi
initi
diagnosi
cycl
prior
surgeri
collect
analyz
addit
potenti
prognost
factor
studi
identifi
order
predict
treatment
respons
patient
result
one
hundr
seven
patient
diagnos
neuroblastoma
enrol
studi
major
patient
diagnos
treat
univers
hospit
undergo
induct
regimen
almost
patient
achiev
satisfi
reason
treatment
respons
none
patient
respons
progress
diseas
interestingli
featur
tumor
histolog
shimada
histolog
predict
factor
induct
respons
howev
support
care
seem
signific
impact
induct
respons
common
toxic
febril
neutropenia
toxic
mucos
diarrhea
minim
conclus
induct
regimen
could
provid
satisfi
treatment
respons
minim
toxic
neuroblastoma
patient
thailand
k
phuakpet
n
k
n
j
n
c
g
divis
depart
siriraj
hospit
mahidol
univers
bangkok
thailand
backgroundobject
treatment
neuroblastoma
depend
variou
factor
includ
tumor
stage
mycn
amplif
howev
test
mycn
amplif
avail
center
thailand
includ
institut
treatment
stratif
institut
depend
mainli
stage
shimada
histolog
avoid
patient
shift
higher
risk
group
object
assess
treatment
outcom
surviv
children
neuroblastoma
treat
institut
designmethod
retrospect
chart
review
neuroblastoma
patient
conduct
result
analyz
result
patient
enrol
studi
median
age
diagnosi
year
accord
inss
classif
cog
risk
stratif
without
use
mycn
amplif
major
patient
inss
stage
iv
high
risk
hr
group
patient
receiv
combin
treatment
surgeri
chemotherapi
patient
grade
iii
iv
hematolog
toxic
hr
group
patient
grade
iv
hematolog
toxic
lr
ir
group
vs
overal
surviv
os
whole
group
lr
ir
hr
group
respect
patient
relaps
median
time
year
median
time
year
year
conclus
although
lr
ir
patient
fals
classifi
hr
group
surviv
rate
hr
group
remain
unsatisfi
wherea
lr
ir
group
excel
outcom
moreov
hr
patient
experienc
treatment
toxic
due
intens
treatment
accur
tumor
stratif
method
includ
use
mycn
amplif
identifi
patient
true
risk
group
treatment
reduct
fals
classifi
hr
group
prevent
unnecessari
intens
chemotherapi
result
less
treatment
toxic
without
compromis
treatment
result
b
pongtanakul
c
medicin
siriraj
mahidol
univers
divis
hematolog
depart
pediatr
bangkok
thailand
backgroundobject
neuroblastoma
second
common
solid
tumor
children
variou
tumor
marker
use
diagnosi
diseas
howev
vanillymandel
acid
vma
homovanil
acid
hav
urin
tumor
marker
choic
neuroblastoma
difficult
properli
collect
especi
young
children
evalu
signific
serum
enolas
nse
level
diagnosi
neuroblastoma
designmethod
serum
sampl
nse
analysi
hospit
includ
nse
level
clinic
data
final
diagnosi
record
analyz
correl
nse
level
diagnosi
result
one
hundr
nineti
five
patient
enrol
sixti
seven
patient
diagnos
neuroblastoma
nb
nnb
mean
nse
level
nb
nnb
group
ngml
p
top
three
highest
nse
level
nnb
group
leukemia
ngml
wilm
tumor
ngml
gonad
germ
cell
tumor
ngml
nb
group
mean
nse
stage
ii
iii
iv
iv
ngml
respect
use
nse
level
normal
valu
ngml
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
respect
howev
use
nse
level
ngml
sensit
specif
ppv
npv
combin
nse
level
ngml
patient
present
abdomin
mass
sensit
specif
ppv
npv
respect
conclus
serum
nse
use
tumor
marker
neuroblastoma
howev
serum
nse
rise
mani
childhood
malign
cut
nse
level
ngml
increas
specif
posit
predict
valu
diagnosi
neuroblastoma
especi
advanc
stage
patient
present
abdomin
mass
vr
prasanth
n
r
cs
n
cancer
centr
paediatr
oncolog
trivandrum
india
cancer
centr
patholog
trivandrum
india
backgroundobject
evalu
clinic
profil
treatment
outcom
infant
neuroblastoma
nb
tertiari
cancer
centr
india
designmethod
infant
nb
patient
treat
januari
decemb
retrospect
analys
patient
demograph
inss
stage
treatment
modal
includ
chemotherapi
surgeri
radiat
surviv
calcul
use
method
result
infant
median
age
day
day
f
ratio
asymptomat
abdomin
mass
commonest
present
adren
common
primari
inss
stage
seen
infant
respect
estim
avail
henc
done
part
routin
diagnost
work
infant
receiv
chemotherapi
surgeri
includ
delay
primari
done
infant
infant
receiv
radiat
receiv
radiat
alon
massiv
hepatomegali
median
follow
month
rang
month
infant
recurr
month
diagnosi
infant
diseas
progress
die
year
overal
os
inss
stage
stage
tumour
year
os
three
year
os
stage
respect
stage
infant
year
os
high
lactat
dehydrogenas
signific
univari
analysi
os
conclus
infant
nb
patient
advanc
diseas
diagnosi
even
limit
resourc
avail
low
middl
incom
countri
lmic
year
os
could
achiev
incorpor
biolog
risk
stratifi
tailor
therapi
essenti
lmic
improv
treatment
outcom
infant
nb
v
radhakrishnan
j
p
institut
wia
medic
oncolog
pediatr
oncolog
chennai
india
institut
wia
medic
oncolog
pediatr
oncolog
chennai
india
backgroundobject
manag
neuroblastoma
especi
hr
diseas
difficult
resourc
limit
set
pauciti
literatur
outcom
patient
treat
lmic
present
studi
conduct
analys
clinic
profil
treatment
outcom
patient
neuroblastoma
treat
centr
designmethod
studi
includ
newli
diagnos
patient
neuroblastoma
treat
centr
year
intern
neuroblastoma
stage
system
risk
group
use
classifi
patient
sr
ir
hr
sr
patient
underw
surgeri
ir
patient
receiv
cycl
chemotherapi
feasibl
surgic
resect
primari
hr
patient
receiv
induct
chemotherapi
follow
surgic
resect
primari
autolog
stem
cell
transplant
asct
radiotherapi
primari
mainten
method
use
calcul
overal
surviv
os
result
studi
includ
patient
median
age
male
malnutrit
observ
patient
adren
common
site
patient
follow
mediastinum
sr
observ
patient
ir
hr
patient
protocol
use
patient
asct
could
perform
hr
patient
median
month
median
os
patient
month
os
sr
ir
hr
patient
respect
factor
predict
os
hr
patient
univari
analysi
includ
asct
surgic
resect
primari
radiotherapi
primari
hemoglobin
cycl
chemotherapi
multivari
analysi
chemotherapi
predict
better
os
conclus
outcom
hr
neuroblastoma
lmic
remain
dismal
due
treatment
abandon
lack
access
asct
surgic
expertis
radiotherapi
ramadwar
os
g
n
memori
hospit
annex
patholog
mumbai
india
memori
hospit
molecular
patholog
mumbai
india
memori
hospit
medic
oncolog
mumbai
india
memori
hospit
radiolog
mumbai
india
memori
hospit
surgic
oncolog
mumbai
india
memori
hospit
radiat
oncolog
mumbai
india
backgroundobject
apart
mycn
gene
amplif
mna
aberr
segment
chromosom
aberr
sca
known
advers
prognost
signific
patient
nb
mlpa
techniqu
enabl
test
gain
loss
amplif
multipl
gene
designmethod
studi
perform
patient
nb
mlpa
kit
panel
mrc
holland
amsterdam
use
test
sca
chromosom
includ
test
coffalys
softwar
use
data
analysi
siopen
guidelin
use
nomenclatur
result
age
rang
month
patient
month
old
mlpa
yield
meaning
result
sampl
yield
ambigu
valu
sinc
fall
defin
categori
amplifi
templat
dna
inadequ
sampl
mna
found
patient
number
sca
rang
gain
amplif
common
follow
gain
amplif
inclus
mna
loss
loss
gain
aberr
seen
none
tumour
show
aberr
infantil
nb
sampl
show
mna
rest
show
sca
respect
alk
amplif
seen
two
patient
conclus
go
beyond
amplif
detect
number
sca
emerg
advers
biolog
prognost
factor
patient
nb
short
next
gener
sequenc
platform
found
mlpa
effect
tool
multiplex
gene
test
sca
includ
singl
assay
thu
easier
cost
effect
conform
intern
neuroblastoma
risk
group
inrg
recommend
techniqu
enabl
us
determin
clinic
signific
sca
detect
beyond
current
guidelin
resham
b
f
khan
univers
hospit
paediatr
child
health
karachi
pakistan
indu
children
cancer
hospit
paediatr
oncolog
karachi
pakistan
khan
univers
hospit
aga
khan
univers
hospit
karachi
pakistan
khan
univers
hospit
oncolog
karachi
pakistan
khan
univers
hospit
orthopaed
surgeri
karachi
pakistan
backgroundobject
evalu
prognost
factor
treatment
outcom
paediatr
ewe
sarcoma
ew
two
major
paediatr
oncolog
centr
pakistan
designmethod
patient
year
aga
khan
univers
hospit
indu
children
cancer
hospit
factor
relev
surviv
relaps
analys
result
one
patient
identifi
left
treatment
median
age
analys
male
extrem
commonest
site
bone
ew
tumour
size
transloc
perform
localis
diseas
metastat
lung
common
site
metastasi
major
receiv
receiv
protocol
patient
given
differ
regimen
treat
surgeri
radiat
receiv
surgeri
radiat
median
period
month
improv
overal
surviv
os
localis
diseas
associ
surgeri
tumour
size
clear
surgic
margin
event
occur
relaps
treatment
abandon
die
os
ef
localis
metastat
ew
ci
ci
os
localis
ew
ci
ef
localis
metastat
ew
relaps
treatment
abandon
death
ci
conclus
studi
demonstr
excel
surviv
localis
diseas
fifti
percent
patient
get
treatment
insuffici
resourc
metastasi
present
delay
present
lack
access
medic
care
tumour
size
clear
surgic
margin
correl
well
outcom
statist
signific
due
small
sampl
size
resham
r
f
khan
univers
hospit
paediatr
child
health
karachi
pakistan
indu
children
cancer
hopsit
paediatr
oncolog
karachi
pakistan
khan
univers
hospit
orthopaed
surgeri
karachi
pakistan
khan
univers
hospit
oncolog
karachi
pakistan
backgroundobject
evalu
signific
prognost
factor
treatment
outcom
osteosarcoma
two
major
paediatr
oncolog
centr
pakistan
designmethod
patient
year
aga
khan
univers
hospit
indu
children
cancer
hospit
patient
characterist
treatment
outcom
factor
influenti
surviv
relaps
analys
result
one
identifi
left
treatment
median
age
includ
femal
extrem
commonest
site
metastat
diseas
lung
frequent
site
metastasi
protocol
given
receiv
cisplatinadriamycin
treat
differ
regimen
receiv
chemotherapi
improv
overal
surviv
os
localis
diseas
associ
limb
salvag
clear
surgic
margin
tissu
necrosi
age
year
limb
amput
show
rel
inferior
event
free
surviv
ef
median
follow
month
iqr
month
event
occur
experienc
relaps
treatment
abandon
mortal
os
localis
metastat
osteosarcoma
ci
os
localis
osteosarcoma
ci
ef
localis
osteosarcoma
relaps
event
ci
ef
localis
localis
metastat
diseas
relaps
death
treatment
abandon
event
ci
ci
conclus
limb
salvag
surgeri
good
respons
chemotherapi
favour
prognost
factor
poor
outcom
associ
treatment
abandon
metastat
diseas
present
resham
r
b
khan
univers
hospit
paediatr
child
health
karachi
pakistan
indu
children
cancer
hospit
paediatr
oncolog
karachi
pakistan
khan
univers
hospit
oncolog
karachi
pakistan
khan
univers
hospit
orthopaed
surgeri
karachi
pakistan
backgroundobject
evalu
prognost
factor
outcom
paediatr
rhabdomyosarcoma
two
centr
pakistan
designmethod
patient
year
aga
khan
univers
hospit
indu
children
cancer
hospit
factor
relev
surviv
relaps
analys
result
one
hundr
patient
identifi
left
treatment
data
analys
median
age
five
year
male
paramening
commonest
site
group
iii
stage
stage
stage
embryon
tumour
size
localis
diseas
metastat
lung
commonest
site
treat
major
receiv
receiv
protocol
receiv
radiat
surgeri
wherea
surgeri
radiat
median
period
month
improv
overal
surviv
os
associ
age
year
dose
radiat
local
control
surgeri
radiat
event
occur
relaps
die
progress
diseas
die
treatment
caus
remain
unknown
abandon
treatment
os
localis
metastat
diseas
event
free
surviv
ef
relaps
os
patient
treat
cur
intent
ef
relaps
ef
relaps
death
treatment
abandon
conclus
favour
site
present
effect
local
control
appropri
dose
radiat
correl
well
posit
outcom
diagnos
patient
either
start
abandon
therapi
seriou
concern
set
rongh
r
j
c
k
hospit
children
paediatr
haematolog
oncolog
glasgow
unit
kingdom
hospit
children
paediatr
oncolog
glasgow
unit
kingdom
west
scotland
cancer
centr
clinic
apheresi
glasgow
unit
kingdom
backgroundobject
audit
effect
recommend
chang
peripher
blood
stem
cell
pbsc
collect
protocol
paediatr
neuroblastoma
patient
treatment
current
dictat
siopen
studi
effect
stem
cell
mobilis
current
siopen
protocol
question
follow
comparison
pbsc
stem
cell
yield
ewe
sarcoma
mobilis
regim
designmethod
retrospect
audit
paediatr
patient
neuroblastoma
treat
royal
hospit
children
glasgow
data
collect
sheet
complet
patient
paper
note
document
episod
pbsc
transplant
episod
arrang
categori
accord
variat
mobilis
chemotherapi
plerixafor
rapid
cojec
rapid
cojec
hot
heel
mobilis
chemotherapi
defin
last
myelotrop
medic
given
collect
attempt
rapid
cojec
gcsf
hot
heel
regim
patient
given
day
follow
rapid
cojec
facilit
neutrophil
count
recoveri
prior
apheresi
collect
result
mobilis
still
attempt
follow
rapid
cojec
second
attempt
carri
use
plerixafor
rescu
therapi
plerixafor
effect
mobilis
regim
howev
promis
result
seen
collect
follow
rapid
cojec
delay
allow
neutrophil
count
recoveri
conclus
mobilis
follow
rapid
cojec
abl
produc
highest
total
cell
dose
peripher
cell
count
howev
rate
success
transplant
product
rapid
cojec
gcsf
plerixafor
result
suggest
collect
may
success
use
gcsf
plerixafor
hot
heel
approach
allow
greater
neutrophil
recoveri
increas
number
day
mobilis
collect
whilst
administ
c
rosswog
c
f
b
r
children
hospit
cologn
depart
experiment
pediatr
oncolog
cologn
germani
berlin
depart
pediatr
oncolog
hematolog
berlin
germani
children
hospit
cologn
depart
pediatr
oncolog
hematolog
cologn
germani
integr
oncolog
univers
depart
translat
genom
cologn
germani
backgroundobject
amplif
genom
region
chromosom
occur
sever
cancer
entiti
extrachromosom
doubl
minut
dm
intrachromosom
homogen
stain
region
hsr
amplicon
cover
associ
poor
prognosi
evolutionari
process
lead
amplif
remain
elus
far
designmethod
examin
seven
primari
neuroblastoma
case
three
cell
line
harbor
complex
genom
amplif
pattern
along
multipl
rearrang
chromosom
gain
insight
tumor
evolutionari
process
amplif
rearrang
event
fulli
character
sampl
use
whole
genom
sequenc
multicolor
fish
analys
addit
larg
genom
map
cell
line
gener
use
bionano
optic
map
tumor
sampl
character
sequenc
rearrang
copi
number
integr
model
silico
reconstruct
amplif
pattern
infer
order
event
mechan
behind
result
amplif
region
occur
hsr
dm
involv
occasion
link
mycn
amplif
two
cell
line
harbor
neochromosom
structur
hsr
neochromosom
amplifi
region
compos
highli
fluctuat
copi
number
firestorm
intertwin
numer
rearrang
dm
appear
uniformli
fewer
rearrang
connect
loop
walkabl
manner
result
suggest
initi
catastroph
event
lead
disrupt
one
chromosom
follow
rejoin
separ
fragment
gener
stabl
loop
structur
amplif
breakag
fusion
bridg
cycl
loop
structur
may
linear
acquir
telomer
thu
result
neochromosom
integr
normal
chromosom
hsr
conclus
amplif
region
show
complex
pattern
copi
number
chang
rearrang
highli
variabl
among
patient
cell
line
comprehens
structur
analyz
allow
reconstruct
modul
chronolog
complex
event
saroha
v
h
g
n
n
memor
hospit
pediatr
oncolog
mumbai
india
memor
hospit
pediatr
surgeri
mumbai
india
memor
hospit
patholog
mumbai
india
memor
hospit
nuclear
medicin
mumbai
india
memor
hospit
radiat
oncolog
mumbai
india
memor
hospit
palli
medicin
mumbai
india
backgroundobject
risk
stratifi
treatment
neuroblastoma
shown
optimis
outcom
reduc
toxic
howev
requir
advanc
diagnost
appropri
infrastructur
care
surveil
could
challeng
low
middl
incom
lmic
set
analyz
outcom
patient
neuroblastoma
treat
risk
stratifi
approach
centr
designmethod
children
histolog
proven
low
risk
lr
intermedi
risk
ir
neuroblastoma
treat
januari
decemb
underw
retrospect
review
chart
databas
clinic
demograph
detail
outcom
stage
includ
bilater
bone
marrow
biopsi
petct
mibg
amplif
risk
stratif
accord
intern
neuroblastoma
stage
system
inss
intern
neuroblastoma
risk
group
inrg
lr
patient
treat
observ
surgeri
chemotherapi
situat
ir
patient
surgeri
cycl
chemotherapi
result
children
lr
ir
histolog
neuroblastoma
ganglioneuroma
ganglioneuroblastoma
children
favour
histolog
fh
unfavour
histolog
uh
inpc
classif
stage
per
inrg
categor
children
ms
median
month
patient
lr
year
os
ci
year
ef
ci
ir
year
os
ci
year
ef
ci
year
ef
observ
alon
lr
ci
os
ci
conclus
risk
stratifi
approach
neuroblastoma
feasibl
lmic
set
excel
outcom
low
intermedi
risk
neuroblastoma
centr
treat
neuroblastoma
lmic
need
acquir
basic
minimum
infrastructur
order
optimis
outcom
sattar
r
c
n
g
j
ormond
street
hospit
london
paediatr
oncolog
london
unit
kingdom
ormond
street
hospit
london
specialist
integr
haematolog
malign
diagnost
london
unit
kingdom
ormond
street
hospit
london
paediatr
surgeri
london
unit
kingdom
ormond
street
hospit
london
paediatr
haematolog
london
unit
kingdom
ormond
street
hospit
ucl
great
ormond
street
institut
child
health
paediatr
oncolog
london
unit
kingdom
backgroundobject
identif
neuroblastoma
metastasi
bone
marrow
examin
aspir
trephin
sampl
requisit
stage
use
follow
treatment
respons
detect
relaps
designmethod
analys
consecut
bone
marrow
sampl
patient
neuroblastoma
compris
aspir
trephin
procedur
trephin
taken
sampl
underw
prospect
examin
flow
cytometri
disaggreg
cell
enumer
neg
posit
cell
follow
livedead
gate
compar
result
standard
morpholog
trephin
histopatholog
result
aspir
sampl
show
clear
popul
posit
cell
flow
cytometri
whilst
morpholog
neg
neuroblast
infiltr
two
sampl
taken
diagnosi
whilst
sampl
taken
follow
start
treatment
nineteen
trephin
sampl
similarli
posit
flow
cytometri
whilst
neg
standard
analysi
four
diagnosi
whilst
post
treatment
conclus
flow
cytometri
appear
increas
sensit
compar
aspir
trephin
morpholog
may
addit
quick
cost
effect
tool
detect
minim
residu
diseas
patient
neuroblastoma
w
hospit
chongq
medic
univers
depart
pediatr
surgic
oncolog
chingq
china
backgroundobject
investig
express
protein
tissu
children
neuroblastoma
analyz
relationship
express
clinicopatholog
paramet
sensit
chemotherapeut
agent
designmethod
quantit
pcr
immunohistochem
ihc
stain
perform
detect
express
mrna
protein
neuroblastoma
nb
ganglioneuroblastoma
gnb
ganglioneuroma
gn
immunohistochem
stain
polymeras
chain
reaction
amplif
sequenc
employ
examin
express
mutat
genom
marker
nbgnb
result
rna
level
nbgnb
significantli
higher
gn
vs
p
nbgnb
mrna
express
associ
tumor
stage
risk
stratif
shimada
classif
differenti
size
metastasi
p
noth
age
sex
p
protein
level
consist
mrna
level
strongli
posit
protein
express
stage
iii
iv
tumor
weakli
posit
stage
ii
tumor
neg
gn
ihc
five
genom
marker
agent
examin
includ
excis
repair
topoisomeras
topo
topoisomeras
ii
topo
iia
methyltransferas
mgmt
show
tumor
sampl
highli
sensit
platinum
highli
sensit
irinotecantopotecan
anthracyclineetoposid
cyclophosphamid
respect
highli
sensit
temozolomidecarmustinesemustin
mrna
express
significantli
higher
poorli
sensit
cyclophosphamid
group
highli
sensit
group
vs
p
signific
correl
sensit
platinum
irinotecantopotecan
anthracyclineetoposid
temozolomidecarmustinesemustin
p
conclus
express
associ
tumor
stage
risk
stratif
shimada
classif
differenti
size
metastasi
may
identifi
promot
tumorigenesi
progress
furthermor
express
relat
cyclophosphamid
resist
may
potenti
therapeut
target
nbgnb
v
smith
j
colleg
medicin
texa
children
hospit
pediatr
cancer
center
houston
usa
univers
public
health
lisl
usa
backgroundobject
patient
relapsedrefractori
high
risk
neuroblastoma
hrnbl
die
diseas
despit
numer
salvag
regimin
respons
rate
regimen
known
unknown
total
treatment
effect
surviv
describ
treatment
relaps
refractori
high
risk
neuroblastoma
patient
time
first
relaps
progress
time
death
diseas
consist
stabl
diseas
designmethod
data
electron
medic
record
abstract
patient
hrnbl
treat
texa
children
hospit
surviv
analysi
use
explor
time
death
time
relaps
report
analysi
perform
spss
vs
result
patient
relapsedrefractori
neuroblastoma
record
avail
entir
treatment
cours
identifi
patient
aliv
diseas
stabl
diseas
least
month
phase
therapi
frequent
util
regimen
mean
number
day
time
diagnosi
relaps
day
day
relaps
death
mean
number
progress
andor
relaps
particip
phase
trial
significantli
higher
mean
number
day
relaps
death
phase
trial
vs
signific
differ
time
death
patient
took
break
treatment
defin
day
without
therapi
howev
took
break
report
mean
day
relaps
death
compar
take
break
conclus
patient
particip
phase
trial
greater
number
day
relaps
death
take
break
therapi
appear
impact
time
death
sokolov
e
n
children
clinic
hospit
russian
ministri
health
depart
microsurgeri
moscow
russia
children
clinic
hospit
russian
ministri
health
depart
hematolog
moscow
russia
backgroundobject
greatest
difficulti
surgic
treatment
neuroblastoma
occur
tumor
intim
connect
larg
vessel
intern
organ
success
treatment
categori
patient
thorough
stratif
oncolog
surgic
risk
necessari
designmethod
analysi
result
diagnosi
treatment
neuroblastoma
abdomin
thoracoabdomin
local
children
age
month
implement
five
children
classifi
high
risk
intermedi
risk
detect
three
patient
low
one
receiv
treatment
accord
protocol
preoper
assess
surgic
risk
base
visual
diagnost
method
number
factor
averag
result
injuri
renal
vein
patient
aorta
child
inferior
vena
cava
case
celiac
trunk
patient
sutur
without
subsequ
complic
injuri
sutur
inferior
vena
cava
patient
pariet
thrombu
without
clinic
signific
hemodynam
disturb
observ
postop
thrombosi
left
renal
arteri
caus
blood
flow
disord
requir
nephrectomi
damag
pancrea
child
accompani
long
drainag
subsequ
anastomosi
pancrea
small
intestin
perform
volum
tumor
resect
averag
durat
postop
month
overal
surviv
surviv
rate
continu
growth
tumor
regist
patient
group
conclus
radic
remov
neuroblastoma
accept
absenc
invas
growth
adjac
vessel
intern
organ
otherwis
resect
perform
cytoreduct
elimin
disord
caus
compress
neoplasm
sugawa
h
j
k
h
e
h
k
children
medic
center
hematolog
oncolog
saitama
japan
children
medic
center
pediatr
surgeri
saitama
japan
children
medic
center
radiolog
saitama
japan
children
medic
center
clinic
research
saitama
japan
children
medic
center
patholog
saitama
japan
backgroundobject
recent
ultrasonographi
progress
number
neonat
diagnos
adren
tumormass
without
symptom
increas
mass
neuroblastoma
adren
hemorrhag
optim
strategi
diagnosi
treatment
mass
remain
challeng
clinician
designmethod
medic
record
neonat
without
symptom
diagnos
adren
tumormass
depart
radiolog
saitama
children
medic
center
april
march
review
result
nine
patient
diagnos
antenat
birth
initi
diagnosi
adren
hemorrhag
patient
group
adren
tumor
patient
group
b
group
patient
final
diagnos
adren
hemorrhag
ultrasonographi
urin
vanillylmandel
acid
vma
homovanil
acid
hva
test
regress
final
howev
one
patient
found
grow
neuroblastoma
group
b
complet
surgic
resect
biopsi
observ
perform
patient
respect
among
patient
adren
tumor
patient
final
diagnos
adren
hemorrhag
teratoma
neuroblastoma
respect
among
patient
neuroblastoma
stage
stage
stage
mycn
amplif
detect
tumor
case
patient
aliv
last
conclus
case
use
initi
imag
clinic
inform
urin
vmahva
test
perform
differenti
diagnosi
neuroblastoma
supraren
hemorrhag
high
accuraci
howev
diagnosi
chang
case
ultrasonographi
urin
vmahva
test
import
mass
achiev
regress
surgic
remov
diagnost
treatment
strategi
consid
mass
takatori
h
k
h
cancer
center
research
institut
divis
innov
cancer
therapeut
chiba
japan
cancer
center
research
institut
divis
cancer
genet
chiba
japan
backgroundobject
high
copi
number
amplif
oncogen
involv
develop
variou
type
tumor
neuroblastoma
gene
amplif
mycn
andor
alk
involv
tumorigenesi
although
target
amplifi
genom
region
therapeut
challeng
previous
develop
pi
polyamid
target
mycn
gene
neuroblastoma
studi
confirm
activ
xenograft
mous
model
investig
mode
action
highli
amplifi
mycn
region
also
employ
system
target
mycn
dna
damag
agent
investig
whether
mycn
amplif
potenti
druggabl
target
neuroblastoma
designmethod
sinc
alk
gene
includ
potenti
bind
sequenc
test
growth
inhibit
effect
neuroblastoma
cell
mycn
also
alk
amplif
synthes
autom
peptid
synthes
crispr
target
mycn
gene
design
accord
broad
crispr
design
tool
http
wwwcrisprmitedu
result
system
target
mycn
significantli
increas
number
apoptot
cell
compar
control
crrna
neuroblastoma
cell
induct
apoptosi
observ
mycn
cell
neuroblastoma
cell
significantli
suppress
mycn
gene
express
cell
prolifer
xenograft
mous
model
use
neuroblastoma
cell
administr
mgkg
significantli
inhibit
tumor
growth
without
affect
weight
gain
mice
neuroblastoma
cell
treatment
demonstr
potenc
convent
alk
inhibitor
crizotinib
alectinib
intriguingli
diminish
probe
hybrid
mycn
alk
loci
fish
analys
suggest
reduc
copi
number
gain
amplifi
gene
vitro
vivo
conclus
dna
damag
induct
within
amplifi
region
oncogen
potenti
therapeut
strategi
neuroblastoma
p
techavichit
k
medicin
pediatr
bangkok
thailand
backgroundobject
neuroblastoma
common
extracrani
malign
children
usual
present
high
risk
diseas
poor
treatment
outcom
topotecan
contain
regimen
show
effect
feasibl
treatment
high
risk
neuroblastoma
designmethod
retrospect
studi
depart
pediatr
faculti
medicin
chulalongkorn
univers
bangkok
thailand
result
fourteen
patient
femal
male
median
age
year
diagnos
accord
cog
institut
studi
period
patient
receiv
six
cycl
induct
chemotherapi
consist
initi
two
cycl
topotecancyclophosphamid
subsequ
four
cycl
cisplatin
etoposid
cyclophosphamid
vincristin
doxorubicin
patient
toler
treatment
well
show
least
partial
respons
local
control
surgeri
attempt
patient
six
patient
receiv
consolid
treatment
mcikg
mibg
treatment
follow
busulflexmelphalan
autolog
stem
cell
rescu
rest
eight
patient
underw
four
cycl
ifosfamidecarboplatinetoposid
without
stem
cell
rescu
mainten
treatment
continu
month
acid
patient
median
month
event
free
surviv
group
respect
statist
signific
median
time
progress
group
month
respect
eight
patient
group
die
diseas
conclus
topotecan
contain
chemotherapi
effect
well
toler
high
risk
neuroblastoma
treatment
mibg
treatment
high
dose
chemotherapi
autolog
stem
cell
rescu
prolong
time
progress
signific
surviv
benefit
p
tembhar
k
k
n
g
g
n
pg
memori
centr
hematopatholog
laboratori
mumbai
india
memori
centr
depart
patholog
mumbai
india
memori
centr
depart
medic
oncolog
mumbai
india
memori
centr
depart
surgic
oncolog
mumbai
india
backgroundobject
bone
marrow
bm
metastasi
neuroblastoma
ideal
bilater
costli
pain
procedur
perform
anesthesia
requir
adequ
assess
presenc
circul
tumor
cell
ctc
potenti
similar
prognost
impact
detect
ctc
immunophenotyp
fci
readili
avail
safe
rel
method
henc
studi
aim
determin
util
detect
ctc
fci
predict
neuroblastoma
designmethod
compar
presenc
ctc
fci
morpholog
alon
combin
morpholog
fci
bilater
bm
aspiratebiopsi
presenc
metastasi
children
neuroblastoma
fci
done
includ
result
children
neuroblastoma
age
rang
year
children
show
fci
bm
involv
bilater
unilater
median
level
rang
notabl
children
neg
aspiratebiopsi
morpholog
indic
fci
higher
sensit
morpholog
alon
patient
ctc
detect
patient
median
tumor
level
rang
median
studi
analysi
rang
ctc
detect
child
without
bm
metastasi
specif
sensit
ctc
predict
respect
major
patient
ctc
lower
number
cell
studi
cell
minim
level
burden
tumor
level
conclus
presenc
ctc
sensit
fci
highli
predict
underli
bm
metastasi
neuroblastoma
data
indic
detect
ctc
sensit
fci
avoid
invas
bm
procedur
approxim
children
neuroblastoma
improv
studi
higher
timmerman
l
c
ce
van
der
g
c
research
landstein
laboratori
depart
hematopoiesi
amsterdam
netherland
research
landstein
laboratori
depart
experiment
immunohematolog
amsterdam
netherland
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
backgroundobject
neuroblastoma
nb
second
common
cancer
childhood
show
strong
tendenc
metastas
bone
marrow
bm
settl
bm
tumor
cell
acquir
chemoresist
becom
dormant
hide
trigger
prolifer
like
key
factor
diseas
relaps
unaccept
high
nb
therefor
better
understand
dormanc
control
essenti
improv
nb
therapi
cancer
type
bone
metastat
tumor
cell
creat
microenviron
recruit
affect
mesenchym
stromal
cell
msc
turn
shown
induc
tumor
cell
dormanc
aim
studi
whether
influenc
msc
nich
designmethod
diagnost
bm
aspir
patient
stage
compar
patient
stage
also
examin
bm
sampl
patient
relaps
diseas
msc
count
flow
cytometri
use
classic
phenotyp
get
insight
phenotyp
chang
within
heterogen
msc
popul
also
analyz
distribut
subtyp
character
surfac
marker
result
immunophenotyp
analys
reveal
nb
patient
bm
metastas
higher
frequenc
msc
bm
patient
without
bm
metastas
diagnosi
well
relaps
particular
interest
distinct
msc
subtyp
appear
uniqu
patient
note
cell
express
henc
conclus
togeth
find
suggest
metastas
affect
msc
microenviron
character
msc
subtyp
within
nich
ongo
may
uncov
subset
ultim
increas
understand
could
provid
target
potenti
combin
therapi
act
bm
microenviron
enhanc
nb
tsumura
c
k
h
r
k
center
child
health
develop
children
cancer
center
tokyo
japan
center
child
health
develop
divis
surgeri
tokyo
japan
center
child
health
develop
depart
radiolog
tokyo
japan
center
child
health
develop
divis
endocrinolog
metabol
tokyo
japan
backgroundobject
short
statur
due
growth
hormon
defici
ghd
frequent
recogn
among
child
cancer
survivor
treat
tbi
avoid
radiat
induc
late
effect
regimen
introduc
neuroblastoma
treatment
standard
therapi
sinc
late
retrospect
investig
growth
pattern
survivor
treat
regimen
institut
designmethod
serial
survivor
clinic
data
diagnos
decemb
februari
review
patient
receiv
chemotherapi
surgeri
local
radiat
therapi
regimen
follow
autolog
pbsct
perform
regular
basi
patient
found
late
sequela
treat
accordingli
result
nineteen
survivor
diagnosi
median
age
year
old
median
height
one
basic
diseas
affect
height
loss
median
follow
period
year
survivor
median
age
year
old
last
survivor
survivor
short
statur
median
survivor
ghd
recogn
one
patient
skull
base
tumor
six
patient
requir
replac
therapi
thyroid
dysfunct
five
gonadotropin
dysfunct
one
fanconi
syndrom
sever
renal
failur
conclus
multidisciplinari
treatment
significantli
impact
height
spite
spare
tbi
appar
growth
spurt
recogn
even
care
replac
therapi
short
statur
might
caus
factor
endocrin
level
l
upton
children
women
hospit
foundat
trust
nutrit
dietet
birmingham
unit
kingdom
backgroundobject
import
preserv
growth
nutrit
statu
children
cancer
well
acknowledg
throughout
literatur
practic
achiev
children
diagnos
high
risk
neuroblastoma
nb
present
signific
dietet
challeng
studi
suggest
children
present
underweight
diagnosi
small
et
al
children
typic
follow
multimod
intens
treatment
protocol
treatment
stage
elicit
side
effect
affect
suitabl
effici
nutrit
support
intervent
may
contraind
abil
maintain
child
nutrit
statu
designmethod
aim
develop
dietet
treatment
pathway
track
alongsid
protocol
identifi
treatment
specif
strateg
dietet
intervent
optimis
nutrit
outcom
result
method
treatment
pathway
produc
bwch
oncolog
dietitian
support
specialist
oncolog
anp
collabor
allow
detail
understand
anticip
side
effect
stage
protocol
focu
nutrit
growth
implic
andor
manag
conclus
implic
practic
anticip
pathway
encourag
proactiv
appropri
dietet
intervent
children
follow
aim
improv
qualiti
care
prevent
malnutrit
weight
loss
pathway
includ
identif
timefram
optimis
weight
gain
consider
enter
nutrit
paramet
regimen
feed
formul
pertin
use
parenter
nutrit
also
hope
support
famili
understand
child
nutrit
need
stage
treatment
manag
expect
surround
growth
toler
nutrit
intervent
la
urcuqui
mx
p
le
foundat
vall
del
lili
pediatr
oncolog
cali
colombia
foundat
vall
del
lili
bone
marrow
transplant
unit
cali
colombia
californiapeckham
center
cancer
blood
radi
children
san
univers
california
san
diego
moor
cancer
la
ca
pediatr
oncolog
san
diego
usa
del
vall
cali
popul
base
cancer
patholog
depart
cali
colombia
foundat
centro
imbanaco
de
colombia
vigicanc
childhood
cancer
surveil
system
medic
behalf
vigicanc
work
group
cali
colombia
backgroundobject
countri
neuroblastoma
nb
common
extracrani
solid
tumor
surviv
cali
third
largest
citi
colombia
annual
incid
nb
per
million
children
common
extracrani
solid
tumor
outcom
data
low
countri
scarc
describ
surviv
children
nb
cali
designmethod
vigicanc
establish
support
foundat
child
matter
program
cali
cancer
registri
collect
data
outcom
patient
year
old
new
diagnosi
cancer
treat
pediatr
oncolog
unit
baselin
data
collect
medic
record
hospit
discharg
log
patholog
report
death
certif
nation
public
health
insur
databas
surviv
analys
perform
use
result
identifi
nb
within
children
year
age
regist
median
age
year
rang
male
stage
stage
achiev
complet
respons
patient
underw
autolog
bmt
death
abandon
respect
overal
surviv
surviv
ci
respect
patient
year
age
ci
stage
ci
ci
respect
stage
patient
aliv
stage
patient
higher
patient
insur
compar
public
health
insur
vs
conclus
nb
surviv
cali
lower
countri
found
surviv
dispar
health
insur
type
high
death
abandon
limit
access
autolog
transplant
contribut
surviv
gap
vaddadi
sr
l
h
children
banjara
hill
pediatr
hematolog
oncolog
hyderabad
india
children
banjara
hill
pediatr
hematolog
oncolog
hyderabad
india
children
banjara
hill
pediatr
neurolog
hyderabad
india
children
banjara
hill
pediatr
surgeri
hyderabad
india
backgroundobject
ataxia
syndrom
oma
opsoclonu
myoclonu
ataxia
compon
chang
like
irrit
behavior
problem
children
oma
may
underli
neuroblastoma
howev
incid
oma
neuroblastoma
data
scanti
literatur
outcom
aim
determin
outcom
children
neuroblastoma
oma
associ
oma
outcom
neuroblastoma
designmethod
type
retrospect
observ
studi
rainbow
children
tertiari
care
center
materi
medic
record
children
neuroblastoma
oma
record
children
attend
neurolog
clinic
oma
review
result
total
children
diagnos
oma
neurolog
outpati
underli
neuroblastoma
median
age
month
variou
neurolog
opsoclonu
myoclonu
ataxia
stage
neuroblastoma
stage
one
child
stage
ii
stage
iii
one
stage
iv
diseas
except
remain
underw
upfront
surgic
resect
two
tumor
resolv
neoadjuv
chemotherapi
without
need
surgeri
oma
treat
steroid
acth
rituximab
treatment
neuroblastoma
recurr
year
follow
three
prolong
oma
year
subsequ
recov
rest
recov
month
time
conclus
screen
underli
neuroblastoma
mandatori
children
oma
multidisciplinari
team
approach
neurolog
pediatr
oncolog
pediatr
surgeri
team
result
excel
outcom
verli
g
r
r
f
n
j
r
r
l
van
medic
center
depart
pediatr
oncolog
amsterdam
netherland
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
medic
center
laboratori
genet
metabol
diseas
amsterdam
netherland
medic
center
depart
oncogenom
amsterdam
netherland
backgroundobject
prognosi
neuroblastoma
determin
risk
factor
stage
mycn
amplif
mna
recent
identifi
elev
urinari
independ
risk
factor
poor
clinic
outcom
patient
neuroblastoma
verli
et
al
eur
j
cancer
sought
biolog
explan
correl
elev
urinari
poor
prognosi
led
us
discoveri
regul
level
thu
might
explain
poor
prognosi
designmethod
bioinformat
analys
conduct
use
platform
gene
signatur
correspond
elev
gener
test
cohort
valid
second
cohort
correl
gene
signatur
clinic
outcom
test
intern
cohort
set
compar
gene
signatur
final
effect
catecholamin
biosynthesi
investig
overexpress
mycn
mycn
singl
copi
neuroblastoma
cell
line
western
blot
use
detect
catecholamin
biosynthet
enzym
hplc
use
measur
result
signatur
correspond
urinari
accuraci
high
signatur
associ
poor
clinic
outcom
n
ef
vs
p
signatur
mainli
correl
signatur
r
p
predict
mna
signatur
sensit
respect
overexpress
mycn
caus
downregul
dopamin
subsequ
shift
catecholamin
metabol
toward
conclus
increas
neuroblastoma
caus
biochem
blockag
catecholamin
biosynthesi
forc
catecholamin
metabol
toward
therefor
elev
urinari
highli
sensit
biomark
correl
better
mna
might
improv
futur
patient
neuroblastoma
k
watanab
k
k
k
h
k
j
univers
tokyo
depart
pediatr
tokyo
japan
univers
depart
pediatr
hiroshima
japan
research
institut
child
health
develop
depart
biolog
tokyo
japan
univers
tokyo
hospit
depart
cell
therapi
transplant
medicin
tokyo
japan
school
kyoto
univers
depart
patholog
tumor
biolog
kyoto
japan
institut
medic
univers
tokyo
laboratori
dna
inform
human
genom
centr
tokyo
japan
children
medic
center
depart
hematologyoncolog
saitama
japan
backgroundobject
prognosi
neuroblastoma
nbl
remain
poor
novel
treatment
demand
tumor
metabol
promis
research
field
mani
kind
cancer
nbl
fulli
explor
designmethod
unravel
genet
epigenet
basi
associ
metabol
alter
rna
sequenc
dna
methyl
analysi
perform
nbl
specimen
open
data
target
nbl
also
analyz
extract
phgdh
code
phosphoglycer
dehydrogenas
phgdh
essenti
enzym
serin
biosynthesi
respons
arginin
synthesi
candid
target
conduct
function
analysi
effect
mediat
knock
phgdh
inhibitor
nbl
cell
line
assess
also
analyz
effect
arginin
deplet
recombin
arginin
deiminas
radi
sensit
metabolom
analysi
nbl
cell
line
perform
studi
effect
treatment
result
cohort
high
express
hypermethyl
gene
bodi
region
phgdh
observ
sampl
mycn
amplif
part
sampl
delet
high
express
phgdh
significantli
associ
wors
prognosi
case
delet
express
level
phgdh
posit
correl
inhibit
phgdh
suppress
cell
growth
nbl
cell
high
express
phgdh
administr
radi
enhanc
cytotox
effect
nbl
cell
low
express
phgdh
metabolom
analysi
show
distinct
effect
radi
cell
line
radi
administ
advanc
cell
low
express
phgdh
show
distinct
metabol
reaction
conclus
result
suggest
phgdh
promis
target
nbl
addit
radi
might
chang
tumor
metabol
expand
applic
phgdh
inhibitor
includ
nbl
low
express
phgdh
f
westermann
cancer
research
center
neuroblastoma
genom
heidelberg
germani
backgroundobject
aberr
express
myc
famili
member
predict
poor
clinic
outcom
mani
human
cancer
oncogen
myc
profoundli
alter
metabol
mediat
antioxid
respons
maintain
redox
balanc
designmethod
global
mycn
synthet
lethal
screen
metabol
amino
acid
profil
perform
versu
background
global
proteom
primari
neuroblastoma
analyz
use
mass
spectrometri
compar
global
transcriptom
data
small
molecul
inhibitor
treatment
knockdown
use
valid
function
hit
vivo
relev
test
neuroblastoma
xenograft
model
result
show
mycn
induc
massiv
lipid
peroxid
upon
deplet
cystein
amino
acid
glutathion
biosynthesi
sensit
cell
ferroptosi
oxid
type
cell
death
high
cystein
demand
childhood
neuroblastoma
met
uptak
transsulfur
methionin
cystein
uptak
limit
cystein
usag
protein
synthesi
maintain
expens
glutathion
thu
creat
achil
heel
inhibit
cystein
uptak
transsulfur
strongli
reduc
neuroblastoma
growth
vivo
inact
transsulfur
may
contribut
spontan
tumor
regress
neuroblastoma
conclus
identifi
sever
protein
mechan
crucial
ferroptot
escap
provid
multipl
previous
unknown
site
may
act
therapeut
n
yaman
k
prefectur
amagasaki
gener
medic
center
depart
clinic
laboratori
amagasaki
japan
prefectur
amagasaki
gener
medic
center
depart
pediatr
hematolog
oncolog
amagasaki
japan
prefectur
amagasaki
gener
medic
center
depart
pediatr
amagasaki
japan
backgroundobject
circul
cell
free
dna
cfdna
novel
tumor
specif
biomark
clinic
oncolog
noninvas
analysi
tumor
genom
name
liquid
biopsi
promis
futur
invent
individu
therapi
clinic
signific
serial
cfdna
analysi
especi
tumor
lysi
syndrom
larg
unknown
designmethod
establish
standard
oper
procedur
isol
cfdna
ml
plasma
serial
analyz
mycnnagk
cfdna
quantit
polymeras
chain
reaction
boy
advanc
stage
neuroblastoma
nb
develop
sever
episod
laboratori
tumor
lysi
syndrom
treatment
period
analyz
associ
serum
tumor
marker
level
mycnnagk
cfdna
result
quantifi
mycnnagk
cfdna
ident
tumor
biopsi
specimen
base
cfdna
analysi
allow
us
analyz
mycnnagk
within
hour
found
serial
mycnnagk
alter
significantli
correl
diseas
activ
pearson
correl
coeffici
mycnnagk
alter
serum
tumor
marker
ie
neuron
specif
enolas
lactat
dehydrogenas
statist
signific
p
valu
amount
cfdna
final
normal
follow
complet
high
dose
chemotherapi
conclus
found
base
cfdna
analysi
liquid
biopsi
rapid
inexpens
method
evalu
tumor
dynam
even
tumor
lysi
syndrom
observ
suggest
cfdna
includ
within
reliabl
supplementari
techniqu
might
provid
clinician
addit
data
clonal
evolut
treatment
g
yavuz
e
n
h
univers
faculti
medicin
depart
divis
ankara
turkey
backgroundobject
neuroblastoma
one
common
malign
neoplasm
childhood
tumour
repres
heterogen
group
term
clinic
cours
histolog
appear
rang
benign
slowli
grow
often
asymptomat
ganglioneuroma
malign
highli
aggress
neuroblastoma
case
occur
sporad
rare
case
sever
individu
famili
present
ganglioneuroblastomat
tumour
germlin
mutat
small
proport
neuroblastoma
patient
report
gene
report
case
famili
neuroblastoma
occur
three
sibl
designmethod
boy
diagnos
ganglioneuroblastoma
origin
thorac
abdomin
paravertebr
ganglion
medic
histori
learn
male
sibl
die
neuroblastoma
anoth
hospit
patient
receiv
combin
chemotherapi
shrunk
tumor
mass
taken
gross
total
surgeri
autolog
stem
cell
transplant
follow
stabl
size
thorac
residuel
mass
year
treatment
mother
new
babi
bilater
adren
mass
detect
babi
diagnos
neuroblastoma
chemotherapi
surgeri
free
diseas
result
obtain
peripher
blood
sampl
two
sibl
sent
genet
analysi
gen
mutat
detect
male
sibl
conclus
neuroblastoma
embryon
tumor
origin
neural
crest
cell
one
common
solid
tumor
childhood
recent
constitut
mutat
shown
confer
increas
risk
neuroblastoma
missens
nonsens
polylalanin
repeat
expans
mutat
shown
respons
herit
disord
account
hereditari
neuroblastoma
patient
hereditari
neuroblastoma
differ
sporad
diseas
diagnos
earlier
age
andor
one
primari
tumor
reflect
cancer
predisposit
syndrom
yoshimoto
h
j
n
h
center
global
health
medicin
pediatr
tokyo
japan
backgroundobject
locat
metastasi
neuroblastoma
stage
ms
limit
skin
liver
bone
marrow
therapi
infant
neuroblastoma
vari
observ
chemotherapi
experienc
uniqu
case
featur
stage
ms
atyp
metastasi
skelet
muscl
pancrea
neuroblastoma
character
aberr
designmethod
case
asymptomat
boy
present
abdomin
distens
hepatomegali
multipl
subcutan
nodul
laboratori
find
serum
enolas
nse
urinari
creatinin
cre
adjust
vanillymandel
acid
vma
homovanil
acid
hva
elev
ngml
mg
cre
mg
cre
respect
metaiodobenzylguanidin
mibg
scintigraphi
show
abnorm
uptak
nodul
skelet
muscl
mass
locat
pancrea
addit
left
adren
mass
liver
biopsi
subcutan
nodul
reveal
poorli
differenti
neuroblastoma
mycn
loss
heterozygos
loh
dna
index
result
hepatomegali
level
tumor
marker
improv
without
treatment
howev
undefin
metastasi
stage
ms
presenc
aberr
key
initi
chemotherapi
age
month
conclus
discuss
metastasi
muscl
pancrea
uncommon
neuroblastoma
might
special
suggest
ms
might
allow
metastat
locat
contrast
aberr
ms
patient
consid
associ
poor
prognosi
indic
popul
might
share
differ
clinic
characterist
typic
ms
patient
like
case
optim
intens
chemotherapi
infant
neuroblastoma
heterogen
still
construct
zhang
w
tongren
capit
medic
univers
pediatr
beij
china
backgroundobject
neuroblastoma
nb
one
common
malign
solid
tumor
infant
high
mortal
special
nb
aim
studi
surviv
outcom
nb
children
collect
last
nine
year
pediatr
designmethod
collect
nb
patient
patholog
diagnosi
nb
classifi
categori
base
clinic
biolog
featur
accord
inrgss
nb
patient
follow
march
date
diagnosi
analyz
clinic
data
use
spss
softwar
studi
surviv
outcom
nb
children
relationship
outcom
nb
risk
factor
result
nb
patient
surviv
account
nb
patient
dead
patient
ir
account
last
time
follow
time
nb
patient
month
case
os
nb
patient
ef
nb
patient
medium
surviv
time
nb
patient
month
confid
interv
ci
month
medium
os
nb
patient
hr
group
nb
patient
hr
group
patient
dead
patient
surviv
conclus
relaps
one
risk
factor
nb
prognosi
nb
hr
group
poor
special
recurr
nb
therefor
import
diagnosi
earli
reduc
relaps
rate
improv
surviv
outcom
nb
z
zhang
x
institut
pediatr
hematologyoncolog
beij
china
backgroundobject
evalu
efficaci
safeti
chimer
antigen
receptor
cell
childhood
neuroblastoma
designmethod
juli
march
case
childhood
neuroblastoma
adopt
chimer
antigen
receptor
cell
analyz
clinic
featur
evalu
treatment
effect
observ
advers
effect
result
among
patient
male
femal
median
age
year
month
old
patholog
type
nodular
ganglioneuroblastoma
infus
chimer
antigen
receptor
cell
case
statu
diseas
progress
case
complet
remiss
median
number
chimer
antigen
receptor
cell
kg
infus
case
got
continu
complet
respons
case
get
wors
got
improv
shortli
recurr
month
case
got
recurr
month
respect
advers
effect
mainli
fever
headach
bone
pain
could
toler
conclus
chimer
antigen
receptor
cell
effect
short
time
safe
treatment
neuroblastoma
case
use
one
treatment
children
neuroblastoma
especi
sensit
chemotherapi
clinic
trial
need
confirm
q
zhao
h
z
w
j
z
h
children
capit
medic
univers
nation
center
children
beij
hematolog
oncolog
center
beij
china
children
capit
medic
univers
nation
center
children
beij
patholog
depart
beij
china
backgroundobject
summar
clinic
characterist
therapeut
effect
prognosi
neuroblastoma
nb
patient
designmethod
clinic
inform
therapeut
effect
nb
patient
analyz
retrospect
gene
statu
evalu
fish
patient
treat
protocol
follow
death
result
nb
patient
median
age
month
defin
stage
iv
high
risk
amplif
got
recurr
final
dead
primari
tumor
locat
retroperiton
least
two
site
metastas
tumor
chromosom
abnorm
exist
patient
patient
nse
first
diagnosi
ldh
ul
patient
cycl
chemotherapi
nse
ldh
decreas
patient
got
vgpr
pr
sd
surgeri
given
chemotherapi
cycl
chemotherapi
patient
got
cr
vgpr
pr
patient
got
pd
patient
got
recurr
month
median
mainli
abdomin
bm
liver
lymph
node
central
lung
patient
got
palli
treatment
got
chemotherapi
patient
got
chemo
mibg
radiotherapi
time
diagnosi
first
relaps
month
group
p
overal
surviv
time
month
averag
time
first
recurr
death
month
averag
conclus
nb
often
got
huge
tumor
involv
recurr
took
place
consolid
therapi
indic
induct
chemotherapi
local
control
clinic
monitor
still
need
investig
treatment
recurr
includ
chemotherapi
mibg
radiotherapi
might
effect
prolong
overal
surviv
time
q
zhao
j
medic
univers
cancer
institut
hospit
pediatr
oncolog
tianjin
china
backgroundobject
program
formul
pediatr
oncolog
committe
china
associ
base
program
studi
aim
summar
recent
clinic
statu
applic
treatment
neuroblastoma
multicent
china
designmethod
clinic
data
children
diagnos
treat
neuroblastoma
collect
januari
august
hospit
result
total
case
identifi
patient
give
treatment
ultim
case
includ
studi
case
receiv
regular
treatment
children
group
total
case
underw
radic
surgeri
case
partial
resect
cr
vgpr
rate
surviv
time
month
median
month
surviv
group
cr
vgpr
rate
patient
surviv
patient
die
surviv
time
month
median
month
case
group
cr
vgpr
rate
case
accept
autolog
peripher
blood
stem
cell
transplant
includ
two
sequenti
transplant
case
case
receiv
radiotherapi
final
case
surviv
case
relaps
case
progress
patient
die
surviv
time
rang
month
median
month
signific
differ
p
group
group
regular
irregular
treatment
group
higher
risk
wors
prognosi
p
conclus
result
show
reason
risk
assign
risk
level
close
relat
patient
prognosi
regular
treatment
significantli
improv
surviv
rate
children
indic
current
treatment
program
great
potenti
valu
still
need
clinic
valid
w
zhao
x
r
x
key
laboratori
pediatr
hematolog
disciplin
pediatr
ministri
key
laboratori
major
diseas
medic
univers
hematolog
oncolog
center
beij
china
backgroundobject
summar
cytokin
level
bone
metastasi
neuroblastoma
children
understand
correlatioin
cytokin
bone
metastasi
children
nb
order
seek
effect
treatment
improv
surviv
rate
designmethod
retrospect
research
carri
analyz
medic
record
patient
bone
metastasi
nb
dec
april
hematolog
oncolog
center
beij
children
hospit
capit
medic
univers
diagnosi
stage
treatment
base
stage
iv
nb
patient
bone
metastas
treat
control
group
peripher
blood
cytokin
level
measur
flow
cytometri
level
express
retrospect
analys
relationship
cytokin
gener
clinic
data
analyz
summar
result
children
nb
bone
metastasi
admit
research
express
lower
bone
metastas
group
nonbon
metastas
group
p
valu
express
bone
metastas
higher
nonbon
metastas
p
valu
express
bone
marrow
metastas
lower
marrow
metastas
express
bone
marrow
metastas
higher
marrow
metastas
conclus
studi
peripher
blood
cytokin
level
relat
occurr
develop
nb
indirectli
reflect
bone
metastas
children
nb
determin
level
express
cytokin
may
use
adjunct
assess
bone
metastas
monitor
efficaci
nb
children
bone
metastas
fever
bone
pain
bone
marrow
metastas
associ
level
zhu
children
capit
medic
univers
nation
center
children
health
patholog
depart
beij
china
backgroundobject
analyz
clinic
characterist
prognosi
neuroblastoma
liver
involv
children
designmethod
case
neuroblastoma
liver
involv
children
beij
children
hospit
analyz
retrospect
end
decemb
clinic
characterist
analyz
use
test
cumul
surviv
estim
method
result
median
age
patient
month
male
femal
primari
site
involv
retroperitoneum
mediastinum
other
risk
group
hr
mr
lr
incid
liver
involv
imag
manifest
metastasi
invas
rate
bone
metastasi
bone
marrow
metastasi
adjac
organ
involv
patient
myc
test
myc
amplif
patient
alanin
transaminas
elev
patient
transaminas
elev
diagnosi
among
case
case
receiv
stratifi
therapi
base
risk
group
regularli
one
patient
receiv
liver
radiotherapi
median
cumul
surviv
case
univari
analysi
suggest
signific
differ
patient
month
month
vs
signific
differ
patient
without
myc
amplif
vs
high
risk
group
vs
cumul
surviv
conclus
clinic
featur
liver
metastasi
invas
similar
neuroblastoma
liver
invas
prefer
infiltr
adjac
organ
neither
alt
ggt
could
regard
liver
involv
marker
patient
liver
involv
higher
rate
myc
amplif
myc
amplif
group
associ
signific
wore
outcom
abosoudah
n
al
q
h
faisal
specialist
hospit
research
centr
depart
oncolog
jeddah
saudi
arabia
faisal
specialist
hospit
research
centr
depart
pediatr
hematologyoncolog
riyadh
saudi
arabia
sultan
militari
medic
citi
depart
pediatr
hematolog
oncolog
riyadh
saudi
arabia
abdullah
special
children
hospit
depart
pediatr
hematolog
oncolog
riyadh
saudi
arabia
abdul
aziz
medic
citi
pediatr
hematolog
oncolog
section
jeddah
saudi
arabia
fahd
specialist
hospit
depart
pediatr
hematologyoncolog
sct
dammam
saudi
arabia
jeddah
gener
hospit
pediatr
depart
jeddah
saudi
arabia
backgroundobject
wilm
tumor
wt
region
outcom
data
scarc
therefor
sapho
perform
nationwid
studi
evalu
clinic
outcom
patient
wt
designmethod
inform
patient
age
year
retrospect
review
referr
center
result
six
seven
center
submit
data
case
identifi
case
analyz
median
age
diagnosi
month
femal
unilater
diseas
occur
bilater
patient
present
combin
follow
abdomin
distens
abdomin
pain
hematuria
vascular
thrombosi
half
patient
consid
stage
iii
iv
diagnosi
respect
patient
favor
histopatholog
relaps
incid
observ
major
stage
iii
iv
v
os
stage
stage
ii
iii
iv
v
ef
stage
stage
ii
v
although
differ
os
ef
statist
signific
observ
ef
compar
base
stage
conclus
result
demonstr
overal
surviv
wt
saudi
arabia
similar
report
countri
howev
observ
half
patient
stage
iii
iv
diagnosi
advanc
diseas
diagnosi
explain
delay
present
data
upfront
surgeri
vs
upfront
chemotherapi
collect
definit
analysi
complet
rart
ahmad
india
institut
medic
scienc
pediatr
surgeri
delhi
india
india
institut
medic
scienc
pediatr
surgeri
new
delhi
india
india
institut
medic
scienc
laboratori
oncolog
new
delhi
india
backgroundobject
background
cancer
develop
depend
genet
alter
epigenet
chang
cancer
epigenom
produc
herit
gene
express
pattern
critic
neoplast
initi
progress
sequenc
ng
provid
mean
visual
human
epigenom
alter
cancer
epigenom
wilm
tumor
studi
extens
aim
evalu
global
methyl
pattern
wilm
tumor
identifi
epigenet
profil
designmethod
prospect
studi
util
specimen
follow
upfront
surgic
resect
untreat
case
wilm
tumour
adjoin
normal
renal
tissu
resect
specimen
use
control
cell
sampl
dna
isol
follow
ng
use
pcr
enrich
done
use
standard
protocol
methyl
region
case
compar
control
result
methyl
variabl
posit
mvp
signific
p
x
identifi
wilm
tumor
specimen
among
dmr
differenti
methyl
region
wilm
tumor
sampl
genom
wide
signific
identifi
dmr
hypermethyl
respect
normal
kidney
predict
level
methyl
dna
circul
may
increas
increas
tumor
burden
charlton
et
al
found
mvp
initi
analysi
contrast
current
analysi
demonstr
mvp
techniqu
util
extens
sensit
studi
global
methyl
conclus
studi
defin
global
epigenet
profil
wilm
tumor
patient
india
dmr
hypermethyl
respect
normal
kidney
predict
level
methyl
dna
circul
may
increas
increas
tumor
burden
current
studi
signific
give
broader
spectrum
methyl
pattern
dmr
identifi
would
provid
area
interest
analysi
mf
hh
sa
rm
aa
kj
r
js
sa
ah
af
ar
sa
welfar
teach
medic
baghdad
colleg
medicin
oncolog
unit
baghdad
iraq
welfar
teach
medic
wasit
colleg
medicin
oncolog
unit
baghdad
iraq
welfar
teach
medic
citi
oncolog
unit
baghdad
iraq
colleg
london
great
ormond
street
institut
child
unit
kingdom
development
biolog
cancer
london
unit
kingdom
colleg
london
great
ormond
street
institut
child
unit
kingdom
haematolog
oncolog
london
unit
kingdom
teach
medic
citi
patholog
baghdad
iraq
backgroundobject
wilm
tumor
wt
excel
surviv
rate
develop
countri
similar
outcom
challeng
achiev
countri
iraq
acknowledg
damag
health
care
servic
lack
multidisciplinari
approach
secur
challeng
surviv
jeopard
studi
manag
outcom
wt
patient
hospit
largest
institut
iraq
designmethod
retrospect
analysi
children
treat
wt
period
children
welfar
teach
hospitalmed
citybaghdad
perform
test
use
compar
surviv
time
period
result
determin
wt
patient
biopsi
nephrectomi
radiolog
evid
wt
nephrectomi
biopsi
median
age
diagnosi
month
rang
femal
patient
year
forti
one
treat
accord
cog
siop
adapt
protocol
abdomin
us
ct
abdomenchest
stage
patient
iii
iv
v
delay
referr
month
patient
post
nephrectomi
result
local
recurr
metastasi
median
follow
month
day
year
patient
aliv
die
abandon
treatment
compar
os
subsequ
period
second
period
better
surviv
rate
aliv
die
abandon
vs
first
period
die
abandon
conclus
optim
treatment
registr
wt
challeng
iraq
surviv
seem
improv
last
year
studi
might
reflect
better
health
servic
improv
manag
oncolog
team
collabor
major
institut
would
like
increas
surviv
j
ali
n
k
n
k
b
l
cancer
center
radiat
oncolog
sulaymaniyah
iraq
cancer
hospit
hemotolog
sulaymaniyah
iraq
cancer
institut
radiat
oncolog
edmonton
canada
backgroundobject
wilm
tumor
wt
common
primari
renal
tumor
children
rate
around
among
childhood
cancer
current
treatment
guidelin
includ
nephrectomi
chemotherapi
case
radiotherapi
aim
studi
identifi
mode
clinic
present
stage
distribut
surviv
outcom
wt
patient
institut
designmethod
retrospect
studi
wt
patient
manag
oncolog
complex
northern
iraq
ten
year
januari
januari
comparison
relev
publish
literatur
accomplish
statist
packag
social
scienc
spss
softwar
version
use
surviv
outcom
analyz
method
result
fifti
children
femal
male
analys
median
age
time
diagnosi
year
rang
distribut
stage
follow
stage
stage
ii
stage
iii
stage
iv
stage
v
favor
histolog
identifi
patient
remain
unfavor
histolog
nation
wilm
tumor
studi
strategi
appli
treatment
case
neoadjuv
chemotherapi
administ
receiv
adjuv
chemotherapi
patient
receiv
radiat
postop
overal
surviv
surviv
respect
conclus
countri
obtain
surviv
outcom
show
improv
outcom
comparison
local
result
report
last
decad
still
lower
treatment
outcom
wt
gain
develop
nation
need
effort
improv
oncolog
care
get
better
result
beck
j
medic
johann
univers
mainz
children
hematolog
oncolog
mainz
germani
medic
johann
mainz
depart
urolog
pediatr
urolog
mainz
germani
backgroundobject
renal
cell
carcinoma
rcc
rare
children
adolesc
designmethod
present
unusu
case
two
children
sever
primari
diseas
treat
depart
pediatr
hematolog
oncolog
mainz
univers
medic
center
well
review
literatur
result
patient
boy
histori
tetralog
fallot
sever
development
delay
seizur
disord
present
institut
evalu
precoci
virilis
ultrasound
magnet
reson
imag
mri
reveal
tumor
right
kidney
consid
wilm
tumor
neuroblastoma
patient
underw
nephron
spare
tumor
resect
laparoscop
surgeri
histopatholog
reveal
papillari
rcc
patient
boy
suffer
hereditari
leiomyomatosi
undergo
treatment
mtor
inhibitor
rapamycin
admit
due
urinari
tract
infect
imag
studi
reveal
tumor
left
kidney
multipl
stone
tumor
entir
typic
nephroblastoma
howev
wilm
tumor
could
rule
neoadjuv
chemotherapi
initi
accord
protocol
intern
societi
pediatr
oncolog
siop
reassess
week
treatment
show
chang
tumor
size
patient
subject
open
tumor
resect
histopatholog
report
confirm
papillari
rcc
patient
recov
fulli
diseas
free
month
respect
conclus
rcc
rare
entiti
pediatr
patient
patient
underw
success
surgeri
favor
outcom
bouti
md
f
f
children
hospit
paediatr
urolog
parkvil
australia
hopit
necker
enfant
malad
paediatr
surgeri
pari
franc
hospitali
universitair
de
paediatr
surgeri
franc
hospitali
universitair
de
nant
paediatr
surgeri
nant
franc
hospitali
universitair
de
bordeaux
paediatr
surgeri
bordeaux
franc
paediatr
surgeri
marseil
franc
hospitali
universitair
de
tour
paediatr
surgeri
tour
franc
children
hospit
paediatr
surgeri
parkvil
australia
backgroundobject
determin
siop
criteria
minim
invas
surgeri
mi
wilm
tumour
wt
could
safe
expand
designmethod
conduct
intern
multicentr
review
mi
resect
wt
electron
paper
medic
record
retrospect
assess
demograph
imag
treatment
patholog
oncolog
outcom
data
analys
wt
includ
site
receiv
local
institut
ethic
board
approv
result
fifti
patient
centr
includ
median
age
diagnosi
month
tumour
metastat
diagnosi
three
radiolog
evid
ruptur
patient
underw
percutan
biopsi
prior
treatment
receiv
neoadjuv
chemotherapi
accord
siop
protocol
locat
tumour
upper
pole
lower
pole
interpolar
region
kidney
median
tumour
volum
ml
cross
later
border
spine
three
cross
midlin
convers
median
volum
ml
three
cross
later
border
spine
intraop
ruptur
median
lymph
node
sampl
case
tumour
stage
ii
iii
histolog
report
low
three
intermedi
high
risk
five
three
patient
posit
tumour
margin
median
month
two
local
recurr
stage
intermedi
risk
month
one
metastat
relaps
stage
iii
high
risk
month
conclus
surgeon
experienc
mi
oncolog
surgeri
siop
criteria
safe
expand
tumour
abut
midlin
low
threshold
convers
howev
remain
event
surgic
difficulti
buletov
v
pediatr
oncolog
hematolog
nn
blokhin
head
neck
tumor
children
moscow
russia
russian
nation
research
medic
univers
pediatr
depart
moscow
russia
backgroundobject
tumor
salivari
gland
rare
neoplasm
differ
morpholog
structur
benign
malign
neoplasm
small
larg
salivari
gland
repres
tumor
head
neck
area
patient
salivari
gland
tumor
childhood
adolesc
paper
present
rare
clinic
case
secretori
adenocarcinoma
small
salivari
gland
hard
palat
year
old
patient
aim
current
public
reflect
featur
treatment
respons
therapi
patient
age
group
designmethod
region
seventh
tooth
round
defect
mucou
membran
inflammatori
roller
along
peripheri
found
histolog
analysi
confirm
growth
secretori
adenocarcinoma
small
salivari
gland
accord
immunohistochem
analysi
b
given
histolog
immunohistochem
find
instrument
method
decid
start
special
treatment
accord
follow
scheme
cisplatin
day
doxorubicin
day
result
total
three
cours
neoadjuv
polychemotherapi
conduct
without
appar
dynam
control
analys
decid
start
oper
treatment
tumor
volum
resect
upper
jaw
left
replac
defect
musculocutan
flap
displac
medial
surfac
forearm
base
result
treatment
patient
discharg
observ
satisfactori
condit
period
unev
conclus
secretori
adenocarcinoma
small
salivari
gland
palat
rare
type
tumor
children
pose
difficulti
diagnost
treatment
patient
work
success
case
treatment
adenocarcinoma
small
salivari
gland
palat
present
r
carvalho
p
fn
f
da
silva
mf
se
pa
silvestr
de
v
nascimento
hr
ado
moura
nation
institut
inca
brazil
pediatr
oncolog
surgeri
rio
de
janeiro
brazil
nation
institut
inca
brazil
pediatr
oncolog
surgeri
fellowship
rio
de
janeiro
brazil
nation
institut
inca
brazil
pediatr
research
rio
de
janeiro
brazil
nation
institut
inca
brazil
oncolog
pediatr
rio
de
janeiro
brazil
nation
institut
inca
brazil
patolog
rio
de
janeiro
brazil
nation
institut
inca
brazil
radiolog
intervent
rio
de
janeiro
brazil
nation
institut
inca
brazil
pediatr
surgeri
rio
de
janeiro
brazil
backgroundobject
wilm
tumor
commom
solid
renal
cancer
children
year
old
repres
approxim
cancer
diagnosi
age
group
still
stand
therapeut
challeng
aim
studi
evalu
bilater
wilm
tumor
submit
surgic
procedur
use
siop
intern
societi
pediatr
oncolog
protocol
last
year
brazilian
institut
designmethod
record
patient
treat
bilater
tumor
suspect
radiolog
ultrasound
ct
mr
hospit
last
year
follow
siop
protocol
retrospect
data
collect
compos
age
surgeri
associ
condit
neoadjuv
adjuv
chemotherapi
radiat
therapi
surgic
detail
patholog
result
patient
surviv
result
studi
compos
male
femal
mean
age
year
one
patient
ambigu
genitalia
one
syndrom
one
von
willebrand
diseas
metastasi
detect
lung
patient
three
patient
receiv
radiotherapi
pulmonari
metastasi
posit
surgic
margin
local
recurr
children
submit
neoadjuv
chemotherapi
three
femal
need
adjuv
chemotherapi
nephron
spar
surgeri
nss
perform
four
patient
one
case
occour
tumor
breakdown
patholog
result
show
kidney
unfavor
histolog
favor
histolog
global
surviv
rate
one
patient
still
treatment
chemotherapi
one
chang
citi
one
therapi
possibl
conclus
bilater
willm
tumor
still
big
challeng
pediatr
surgeon
even
larg
cancer
treatment
center
nss
could
consid
select
case
good
outcom
nephron
preserv
aim
take
posit
surgic
margin
risk
nss
side
reli
postop
chemotherapi
care
plan
radiotherapi
avoid
recurr
kwe
chan
hyv
syb
jwc
kh
princ
wale
chines
univers
hong
kong
divis
paediatr
surgeri
paediatr
depart
surgeri
hong
kong
hong
kong
sar
backgroundobject
hong
kong
children
hospit
hkch
establish
late
pediatr
oncolog
servic
central
hkch
hkch
adopt
siop
umbrella
protocol
manag
wilm
tumor
aim
studi
conclud
surgic
experi
manag
wilm
tumor
use
protocol
designmethod
retrospect
studi
conduct
review
patient
wilm
tumor
underw
nephrectomi
accord
protocol
univers
teach
hospit
hong
kong
januari
januari
result
fourteen
boy
eleven
girl
wilm
tumor
underw
nephrectomi
studi
period
mean
age
year
rang
year
four
children
stage
diseas
stage
ii
diseas
stage
iii
diseas
stage
iv
stage
v
diseas
chemotherapi
given
children
stage
iii
diseas
mean
tumour
size
cm
rang
cm
unilater
radic
nephrectomi
perform
children
unilater
diseas
via
transperiton
laparotomi
children
bilater
diseas
underw
surgeri
nss
lymph
node
biopsi
perform
case
posit
lymph
node
involv
intraop
tumour
ruptur
patient
underw
nephrectomi
intraop
complic
includ
small
bowel
injuri
diaphragmat
injuri
major
bleed
requir
transfus
one
patient
urinari
leakag
nss
median
year
local
recurr
two
patient
distant
tumor
recurr
os
ef
conclus
upfront
nephrectomi
safe
perform
ruptur
collabor
siop
futur
believ
ef
improv
c
citak
g
univers
faculti
medicin
pediatr
oncolog
mersin
turkey
univers
faculti
medicin
pediatr
mersin
turkey
backgroundobject
childhood
renal
tumor
account
around
childhood
cancer
major
case
wilm
tumor
studi
aim
evalu
clinic
patholog
featur
renal
tumor
children
designmethod
record
children
renal
tumor
institut
retrospect
analyz
data
collect
compos
demograph
clinic
characterist
includ
gender
age
time
diagnosi
symptom
side
tumor
patholog
evalu
result
total
children
renal
tumor
male
femal
includ
studi
diagnos
mean
age
month
rang
mean
month
common
symptom
lump
mass
area
kidney
abdomin
pain
hematuria
four
patient
diagnos
antenat
period
wilm
tumor
found
children
major
histolog
group
renal
tumor
renal
cell
carcinoma
congenit
mesoblast
nephroma
angiomyolipoma
bilater
tumor
detect
children
one
patient
wilm
tumor
hors
shoe
kidney
surgic
treatment
perform
patient
patient
chemotherapi
radiotherapi
respect
seven
patient
die
conclus
wilm
tumor
common
pediatr
renal
neoplasm
hand
show
consider
number
children
renal
tumor
tumor
includ
renal
cell
carcinoma
congenit
mesoblast
nephroma
angiomyolipoma
w
espin
rm
del
al
ha
civil
de
guadalajara
juan
menchaca
servic
pediatr
hematolog
oncolog
jalisco
mexico
backgroundobject
wilm
tumor
common
kidney
tumor
childhood
overal
surviv
preserv
renal
function
becom
fundament
goal
treatment
normal
valu
glomerular
filtrat
rate
gfr
greater
mlmin
slight
decreas
gfr
mlmin
moder
decreas
gfr
mlmin
sever
decreas
gfr
mlmin
acut
failur
dialysi
mean
gfr
less
mlmin
rate
chronic
renal
failur
wilm
tumor
survivor
objet
assess
gfr
patient
wilm
tumor
end
treatment
designmethod
retrospect
transvers
analyt
cohort
studi
design
patient
diagnos
hospit
wilm
tumor
includ
gfr
measur
modifi
schwartz
method
urin
test
evalu
pre
result
gfr
patient
evalu
ratio
patient
present
stage
stage
ii
stage
iii
stage
iv
stage
v
start
treatment
patient
normal
gfr
slight
decreas
gfr
moder
decreas
gfr
none
show
lower
gfr
treatment
gfr
patient
remain
normal
patient
slight
decreas
gfr
patient
moder
decreas
gfr
two
patient
present
chronic
renal
failur
kidney
transplant
remark
own
horsesho
kidney
urinari
tract
infect
associ
patient
patient
present
proteinuria
nephrot
rang
conclus
detect
import
reduct
gfr
valu
treatment
children
wilm
tumor
patient
proteinuria
treatment
show
decreas
gfr
end
studi
one
patient
requir
end
renal
stage
treatment
w
guan
w
w
l
hospit
affili
shanghai
jiaotong
univers
medic
school
patholog
shanghai
china
backgroundobject
observ
chang
chromosom
ploidi
renal
tumor
children
designmethod
detect
case
renal
tumor
research
diagnos
xinhua
hospit
shanghai
jiaotong
univers
school
medicin
fish
observ
chang
chromosom
ploidi
renal
tumor
children
result
case
renal
tumor
research
patient
age
month
year
averag
age
year
male
femal
histolog
case
nephroblastoma
mix
type
contain
blastem
epitheli
stromal
compon
case
cmn
classic
type
cellular
variant
mix
case
ccsk
classic
patten
case
orit
percentag
trisomi
cell
wt
averag
tetrasomi
cell
averag
percentag
trisomi
cell
cmn
averag
tetrasomi
cell
percentag
trisomi
cell
ccsk
averag
tetrasomi
cell
averag
percentag
trisomi
cell
orti
tetrasomi
cell
averag
meanwhil
percentag
trisomi
cell
case
nonneoplasitc
kiney
tissu
averag
tetrasomi
cell
conclus
percentag
trisomi
cell
cmn
orti
much
higher
tumor
nonneoplasitc
kiney
tissu
meanwhil
percentag
tetrasomi
cell
ccsk
highest
case
trisomi
cmn
orti
tetrasomi
ccsk
seem
cytogenet
alter
characterist
tumor
detect
chromosom
renal
tumor
childhood
may
help
differenti
among
tumor
hein
g
n
oncolog
pediatr
oncolog
univers
children
hospit
saarland
homburg
germani
hospit
saarland
depart
mri
radiolog
homburg
germani
backgroundobject
aggress
fibromatosi
pose
mani
therapeut
dilemma
often
suscept
chemotherapi
often
requir
also
surgic
radiat
approach
tri
affect
cure
designmethod
report
girl
diagnos
aggress
fibromatosi
right
maxilla
age
one
thirteen
yr
age
multipl
local
recurr
requir
surgic
intervent
seven
oper
hemimaxillektomi
consecut
radiotherapi
chemotherapi
tri
four
cycl
vincristin
cyclophosphamid
actinomycin
follow
liposomal
doxorubicin
follow
tamoxifen
diclofenac
follow
vinblastin
methotrex
combin
never
stop
progress
local
recurr
even
extens
oper
local
multifoc
recurr
observ
sorafenib
initi
avail
cutan
bulla
paronchia
pronounc
implement
vinblastin
mgsqm
bodi
surfac
area
valproat
mgkgday
palli
measur
make
life
less
burdensom
patient
famili
result
therapi
adopt
gastrostomi
put
fear
feed
would
becom
difficult
cours
diseas
chemotherapi
given
via
felt
end
option
diseas
nt
come
back
mri
februari
could
depict
site
vital
tumor
gastrostomi
remov
child
eat
suffici
therapi
well
toler
sever
infecti
complic
observ
blood
count
show
mild
lymphopenia
mri
scan
demonstr
show
cours
diseas
conclus
feel
vinblastin
addit
valproat
might
option
treatment
aggress
fibromatosi
pediatr
patient
though
clear
whether
chemotherapi
cycl
surgic
measur
radiotherapi
addit
effect
thu
caus
diseas
remiss
j
huang
z
z
l
z
w
univers
cancer
center
depart
pediatr
oncolog
guangzhou
china
univers
cancer
center
depart
patholog
guangzhou
china
backgroundobject
retrospect
analyz
surviv
outcom
differ
subtyp
fh
wilm
tumor
chines
children
designmethod
octob
may
clinic
data
fh
wilm
tumor
patient
year
old
treat
sun
univers
cancer
center
collect
analyz
tumor
specimen
biopsi
surgeri
collect
chemotherapi
fh
wilm
tumor
divid
stromal
type
epitheli
type
blastem
predomin
type
mix
type
patient
treat
base
protocol
stage
patient
receiv
modifi
protocol
result
total
patient
fh
wilm
tumor
enrol
male
femal
median
age
year
old
rang
month
year
case
stage
case
stage
histopatholog
type
includ
mix
type
epitheli
type
stromal
type
blastem
predomin
type
median
time
month
rang
month
year
case
second
patient
recurr
includ
blastem
predomin
type
mix
type
epitheli
type
stromal
type
recurr
rate
differ
subtyp
blastem
predomin
type
mix
type
epitheli
type
stromal
type
year
surviv
rate
ef
overal
surviv
rate
os
follow
blastem
predomin
type
mix
type
epitheli
type
stromal
type
surviv
analysi
show
blastem
predomin
type
independ
prognost
factor
ef
os
conclus
studi
show
patient
blastem
predomin
type
wilm
tumor
higher
recurr
rate
lower
ef
os
treatment
wilm
tumor
blastem
predomin
type
intensifi
improv
surviv
r
ismail
u
uparkar
e
ross
registrar
pediatr
oncolog
leicest
unit
kingdom
backgroundobject
introduct
recurr
metastasi
central
nervou
system
cn
children
wilm
tumour
wt
rare
account
less
develop
cn
metastasi
commonli
associ
concurr
prior
lung
designmethod
case
report
june
year
old
boy
present
month
histori
worsen
back
pain
sign
spinal
cord
compress
find
confirm
mri
reveal
left
renal
mass
multipl
pulmonari
node
left
para
spinal
extradur
mass
compress
nerv
root
biopsi
mass
confirm
triphas
wt
commenc
drug
neoadjuv
per
week
therapi
partial
respons
pr
local
metastat
site
note
given
week
therapi
post
nation
wt
consensu
prior
attempt
local
control
sept
underw
left
radic
nephrectomi
follow
radiat
whole
abdomen
para
spinal
vertebr
area
receiv
drug
high
risk
adjuv
chemotherapi
week
aug
end
therapi
assess
show
complet
respons
cr
local
site
stabl
diseas
paravertebr
mass
cr
lung
oct
present
short
histori
headach
mri
reveal
cerebellar
tumor
mass
effect
day
succumb
diseas
seizur
activ
follow
cone
brain
result
limit
postmortem
find
consist
metastat
wt
cerebellum
conclus
whenev
clinic
suspicion
cranial
surveil
ad
routin
detect
intracrani
tumor
time
fashion
case
need
separ
prognost
subgroup
understand
biolog
tumor
copp
mj
et
al
med
ped
lowi
sp
et
al
cancer
kebudi
r
et
al
j
neuro
oncol
bouffett
e
et
al
cancer
l
joseph
r
h
n
lg
medic
vellor
depart
paediatr
vellor
india
backgroundobject
overal
event
free
surviv
wilm
tumour
wt
improv
remark
even
low
middl
incom
countri
howev
signific
proport
children
still
die
diseas
complic
look
caus
death
children
wt
regist
depart
cater
larg
low
middl
incom
popul
designmethod
clinic
data
collect
medic
record
children
wt
diagnos
famili
contact
get
addit
inform
requir
result
children
wt
die
boy
girl
median
age
year
rang
month
year
five
year
four
year
diagnosi
metastat
diseas
present
one
child
stage
diseas
stage
ii
stage
v
diseas
child
stage
diseas
local
recurr
die
infect
relaps
treatment
among
five
stage
ii
diseas
three
die
liver
toxic
one
die
respiratori
infect
fifth
patient
relaps
diseas
month
post
treatment
one
except
stage
iii
tumour
die
diseas
three
inoper
tumour
develop
metastat
diseas
post
treatment
patient
die
varicella
infect
stage
iv
tumour
die
progress
diseas
caus
death
bilater
diseas
cardiac
dysfunct
road
traffic
accid
one
progress
inoper
diseas
remain
two
overal
children
die
refractori
relaps
diseas
four
treatment
relat
liver
cardiac
toxic
three
die
infect
one
unrel
caus
conclus
children
wilm
tumour
regist
system
die
progress
primari
diseas
relaps
account
death
w
juan
z
z
l
h
z
g
univers
cancer
center
depart
pediatr
oncolog
guangzhou
china
univers
cancer
center
patholog
depart
guangzhou
china
univers
cancer
center
depart
radiotherapi
guangzhou
china
backgroundobject
analyz
surviv
prognosi
paediatr
primari
ccsk
januari
may
sun
univers
cancer
center
designmethod
primari
treatment
renal
clear
cell
sarcoma
children
januari
may
sun
univers
cancer
center
collect
patient
receiv
combin
treatment
surgerychemotherapyradiotherapi
chemotherapi
regimen
includ
cavc
ctxthpvcr
cavi
result
total
patient
enrol
includ
male
femal
median
age
month
month
case
stage
case
stage
ii
case
stage
iii
patient
underw
direct
radic
nephrectomi
patient
receiv
preoper
neoadjuv
chemotherapi
preoper
biopsi
nephroblastoma
patient
receiv
cours
neoadjuv
chemotherapi
sd
pd
except
one
patient
stage
iii
receiv
radiotherapi
remain
patient
receiv
radiotherapi
median
dose
gy
gy
patient
receiv
adjuv
chemotherapi
case
use
cavc
regimen
case
use
cavi
regimen
median
cours
cycl
patient
achiev
cr
comprehens
treatment
median
durat
month
month
one
case
stage
iii
patient
occur
brain
metastasi
month
first
cr
one
patient
receiv
chemotherapi
cavi
regimen
develop
tubulointerstiti
nephriti
month
discontinu
treatment
ef
rate
os
rate
whole
group
conclus
pediatr
local
ccsk
good
prognosi
comprehens
treatment
reduc
treatment
intens
patient
worth
studi
kaneko
rp
h
cancer
center
research
institut
clinic
oncolog
ina
japan
cancer
center
research
institut
cancer
genom
divis
tokyo
japan
univers
depart
patholog
tokyo
japan
children
medic
center
depart
patholog
yokohama
japan
center
child
health
develop
research
institut
tokyo
japan
colleg
medicin
depart
pediatr
surgeri
nishinomiya
japan
medic
univers
depart
radiolog
koshigaya
japan
univers
school
medicin
depart
pediatr
tokyo
japan
medic
center
research
institut
matern
child
health
depart
pediatr
surgeri
izumi
japan
univers
school
medicin
depart
pediatr
surgeri
tokyo
japan
backgroundobject
overal
surviv
os
rate
patient
wilm
tumor
wt
reach
biomark
predict
favor
unfavor
outcom
need
improv
os
rate
avoid
advers
late
effect
designmethod
analyz
array
cgh
acgh
pattern
mutat
gene
unilater
wt
patient
classifi
accord
acgh
genet
alter
alter
correl
surviv
rf
os
rate
express
microarray
analysi
perform
wt
upregul
gene
specif
chromosom
duplic
wt
downregul
gene
specif
chromosom
arm
lost
wt
determin
correl
overexpress
upregul
gene
downregul
gene
favor
unfavor
os
determin
use
databas
result
patient
alter
tumor
rf
type
acgh
aberr
rf
silent
type
acgh
chang
without
alter
type
patient
classifi
presenc
absenc
loss
rf
better
without
rf
wors
loss
without
rf
wt
examin
gene
chromosom
upregul
tumor
compar
tumor
gene
downregul
tumor
compar
tumor
overexpress
upregul
gene
downregul
gene
correl
better
wors
os
patient
wt
respect
conclus
prognost
signific
chromosom
abnorm
may
causal
relat
upregul
gene
extra
chromosom
downregul
gene
delet
chromosom
arm
region
kohorst
p
c
clinic
depart
pediatr
adolesc
medicinedivis
hematolog
oncolog
rochest
usa
backgroundobject
renal
cancer
account
childhood
tumor
wilm
tumor
common
rare
renal
malign
account
approxim
renal
tumor
date
tumor
uniqu
clinic
present
genet
underpin
patholog
find
imag
characterist
treatment
cours
object
studi
report
incid
clinic
present
treatment
outcom
pediatr
renal
malign
designmethod
retrospect
review
conduct
clinic
featur
pediatr
renal
tumor
period
result
januari
januari
patient
age
year
diagnos
renal
tumor
wilm
tumor
rare
renal
tumor
includ
renal
cell
carcinoma
rcc
mesoblast
nephroma
rhabdoid
tumor
ewe
sarcoma
malign
peripher
nerv
sheath
tumor
unclassifi
renal
tumor
rare
renal
malign
femal
median
age
diagnosi
year
rang
year
clinic
present
variabl
present
asymptomat
symptom
includ
pain
hematuria
palpabl
mass
irrit
diagnosi
metastat
diseas
region
lymph
node
rcc
rhabdoid
initi
manag
includ
front
total
partial
nephrectomi
chemotherapi
radiat
median
follow
time
year
rang
year
patient
develop
recurr
rcc
mesoblast
nephroma
patient
die
diseas
recurr
rcc
remain
aliv
last
follow
conclus
renal
tumor
compris
clinic
signific
percentag
renal
malign
children
tumor
treat
differ
wilm
tumor
therefor
import
distinguish
continu
attent
tumor
necessari
meaning
advanc
treatment
patient
outcom
n
ludwig
l
r
n
e
univers
human
genet
homburg
germani
univers
pediatr
hematolog
oncolog
homburg
germani
univers
chair
clinic
bioinformat
germani
backgroundobject
wilm
tumor
wt
common
childhood
kidney
cancer
treatment
accord
siop
includ
preoper
chemotherapi
without
histolog
confirm
wt
biopsi
diagnost
marker
confirm
wt
diagnosi
highli
warrant
date
limit
knowledg
serum
mirna
profil
patient
wt
two
studi
analyz
serum
level
select
number
mirna
designmethod
studi
analyz
serum
profil
mirna
individu
includ
patient
differ
subtyp
wt
patient
renal
cancer
diseas
treatment
use
microarray
identifi
mirna
differenti
abund
wt
compar
control
use
differ
subtyp
use
anova
result
identifi
mirna
significantli
higher
mirna
significantli
lower
level
serum
wt
patient
compar
control
amongst
other
level
higher
level
lower
serum
patient
wt
compar
patient
renal
tumor
anova
comparison
abund
level
reveal
mirna
signific
differ
wt
subtyp
control
detail
found
mirna
differenti
express
serum
patient
wt
subtyp
differ
blastem
cell
content
includ
higher
lower
express
patient
blastem
subtyp
regressivemix
subtyp
high
residu
blastem
compar
patient
wt
subtyp
conclus
identifi
set
mirna
differenti
express
serum
patient
wt
significantli
differ
patient
renal
malign
diseas
furthermor
mirna
show
also
differenti
express
differ
subtyp
wt
mirna
show
promis
biomark
differenti
wt
patient
control
time
diagnosi
n
merkulov
rogachev
nation
research
center
pediatr
oncolog
immunolog
surgeri
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
oncolog
moscow
russia
backgroundobject
analysi
experi
center
surgic
treatment
patient
congenit
mesoblast
nephroma
cmn
designmethod
research
includ
patient
establish
diagnosi
vmn
receiv
treatment
octob
till
januari
assess
abund
process
tactic
treatment
defin
within
recommend
siop
children
main
method
treatment
surgic
oncotomi
result
total
center
oper
children
tumor
kidney
among
children
younger
month
initi
oper
children
patient
oper
carri
preoper
chemotherapi
median
age
patient
time
detect
tumor
kidney
made
month
month
time
median
age
realiz
oper
made
month
month
children
new
growth
kidney
diagnos
prenat
period
other
patient
tumor
reveal
screen
ultrason
investig
antenat
patient
carri
nephrectomi
radic
oper
execut
observ
intraop
ruptur
tumor
reveal
one
case
median
overse
patient
made
month
common
surviv
summer
surviv
local
recurr
diagnos
patient
two
patient
die
conclus
keyest
treatment
children
smn
radic
oncotomi
violat
whole
capsul
tumor
lead
develop
recurr
diseas
progress
diseas
follow
demand
intensif
chemotherapi
repeat
surgic
intervent
k
nakata
r
v
g
k
intern
cancer
institut
cancer
control
center
osaka
japan
great
ormond
street
institut
child
health
development
biolog
cancer
programm
london
unit
kingdom
societi
pediatr
surgeon
malign
tumor
committe
tokyo
japan
children
cancer
group
renal
tumor
committe
tokyo
japan
birmingham
cancer
research
uk
clinic
trial
unit
birmingham
unit
kingdom
medicin
depart
patholog
doha
qatar
backgroundobject
analysi
found
significantli
higher
annual
incid
childhood
renal
cancer
age
year
england
japan
vs
per
million
respect
enhanc
understand
differ
use
clinic
trial
dataset
enrol
major
patient
countri
year
period
provid
detail
patient
tumour
demograph
designmethod
three
consecut
clinic
trial
dataset
import
uk
one
prospect
observ
studi
japanes
societi
pediatr
surgeon
jsp
registri
use
compar
distribut
patient
sex
age
diagnosi
stage
largest
diamet
histolog
tumour
number
treatment
hospit
uk
japan
overal
surviv
os
surviv
ef
estim
use
method
result
total
patient
uk
japan
wilm
tumour
wt
common
childhood
renal
cancer
countri
uk
japan
japanes
patient
wt
significantli
younger
median
age
diagnosi
compar
uk
vs
proport
metastat
diseas
stage
iv
higher
uk
vs
proport
largest
tumour
diamet
vs
proport
anaplast
tumour
also
higher
uk
japan
vs
hospit
treat
wt
japan
compar
hospit
uk
signific
differ
os
ef
wt
uk
os
ci
vs
ef
vs
respect
conclus
differ
age
distribut
proport
metastat
diseas
tumour
size
anaplast
tumour
uk
japan
wt
patient
cure
countri
e
nazarova
g
e
rogachev
nation
research
center
pediatr
oncolog
immunolog
radiolog
moscow
russia
backgroundobject
wilm
tumor
wt
nephroblastoma
one
common
extracrani
tumor
pediatr
popul
differ
histolog
type
nephroblastoma
impact
stage
treatment
option
outcom
aim
studi
analyz
possibl
correl
imag
dwi
data
differ
histolog
type
wt
designmethod
studi
base
data
pediatr
patient
histopathologicali
verifi
wt
median
age
time
diagnosi
year
year
old
male
femal
ratio
imag
data
obtain
mri
magnet
reson
imag
scanner
appar
diffus
coeffici
adc
valu
tumor
calcul
use
interest
measur
mean
adc
valu
histolog
type
wt
compar
use
regress
analysi
method
result
patient
low
risk
intermedi
high
risk
mean
adc
valu
low
grade
wt
medium
grade
wt
high
grade
wt
intraclass
correl
coeffici
conclus
studi
found
signific
correl
adc
valu
histolog
type
wt
mri
dwi
use
tool
initi
assess
differenti
diagnosi
patient
nephroblastoma
r
nerli
kidney
foundat
divis
pa
urolog
belgaum
india
backgroundobject
approxim
children
wilm
tumor
present
bilater
diseas
treatment
challeng
achiev
high
cure
rate
maintain
adequ
renal
function
report
feasibl
outcom
surgeri
child
bilater
wilm
tumor
treat
institut
designmethod
due
rariti
bwt
nss
less
commonli
use
pediatr
renal
tumor
shown
provid
excel
oncolog
control
time
preserv
renal
function
articl
describ
oper
step
nss
child
bwt
result
year
old
male
child
present
paediatr
urolog
servic
hospit
complaint
distens
abdomen
child
normal
mile
stone
vaccin
per
schedul
child
anem
hb
gm
weigh
kg
serum
creatinin
mg
ultrasonograph
examin
reveal
bilater
renal
mass
comput
tomographi
ct
show
heterogen
enhanc
lobul
mass
cm
upper
pole
right
kidney
solid
mass
cm
upper
mid
polar
mass
left
kidney
conclus
focu
treatment
children
bwt
surviv
preserv
good
long
term
renal
function
surgeri
children
bilater
wilm
tumor
nearli
alway
technic
feasibl
accept
complic
approach
combin
adjuv
therapi
provid
opportun
preserv
renal
function
maintain
high
probabl
cure
consid
strongli
patient
synchron
bilater
wilm
tumor
despit
radiograph
appear
kidney
associ
tumor
k
oshea
r
e
p
manchest
children
hospit
paediatr
surgeri
manchest
unit
kingdom
backgroundobject
congenit
mesoblast
nephroma
cmn
compris
childhood
renal
tumour
consid
benign
howev
certain
subtyp
demonstr
propens
recurr
mortal
cellular
cmn
histolog
cytogenet
ident
congenit
infantil
fibrosarcoma
cif
demonstr
high
frequenc
gene
fusion
present
case
seri
inform
understand
advers
prognost
factor
influenc
clinic
outcom
cmn
cif
designmethod
retrospect
review
case
cmn
cif
institut
data
collect
regard
age
present
oper
intervent
tumour
ruptur
stage
histolog
molecular
genet
recurr
morbid
mortal
outcom
note
relat
molecular
genet
immunohistolog
stain
transloc
result
case
identifi
cmn
cif
patient
cmn
group
primari
nephrectomi
intraop
tumour
ruptur
histolog
identifi
cellular
classic
mix
type
tumour
transloc
identifi
cmn
cmn
group
identifi
recurr
ruptur
cellular
subtyp
none
demonstr
transloc
case
recurr
manag
chemotherapi
resect
one
child
cur
children
die
overal
mortal
median
month
cif
group
case
manag
primari
resect
case
biopsi
prior
resect
demonstr
transloc
mortal
group
median
month
conclus
cmn
whilst
consid
benign
diseas
aggress
associ
mortal
seri
cellular
subtyp
tumour
ruptur
lack
transloc
appear
associ
poor
prognosi
propos
transloc
neg
cmn
may
repres
differ
undescrib
tumour
entiti
advanc
molecular
test
whole
genom
rna
sequenc
requir
investig
ocak
r
b
tm
z
istanbul
medic
faculti
pediatr
hematolog
oncolog
istanbul
turkey
istanbul
medic
faculti
pediatr
urolog
istanbul
turkey
backgroundobject
wilm
tumor
usual
origin
renal
parenchyma
rare
tumor
aris
renal
pelvi
appear
similar
botryoid
sarcoma
due
atyp
localis
extens
diagnosi
stage
difficult
designmethod
boy
admit
pediatr
urolog
depart
dysuria
physic
examin
reveal
abdomin
mass
regular
border
abdomin
usg
mri
show
solid
lobul
mass
fill
right
renal
pelvi
extend
uret
right
side
nefroureterectomi
perform
patholog
examin
consist
wilm
tumor
signific
necrosi
without
anaplasia
ureter
wall
infiltr
day
oper
dysuria
urgenc
develop
repeat
cystoscopi
reveal
necrot
mass
bladder
caviti
free
form
bladder
wall
mass
also
full
ghost
cell
necrosi
thorax
ct
report
normal
togeth
ureter
extens
necrot
bladder
mass
patient
accept
stage
favor
diseas
studi
protocol
start
still
chemotherapi
free
diseas
result
botryoid
wilm
tumor
rare
respons
origin
local
extens
pattern
literatur
case
report
date
differ
classic
wilm
tumor
dysuria
urgenc
hematuria
common
symptom
thought
aris
intralobar
nephrogen
rest
renal
pelvi
despit
atyp
localis
extens
prognosi
report
similar
parenchym
wilm
tumor
conclus
ureter
extens
necrot
mass
baldder
caviti
pose
diffuculti
stage
treatment
case
light
present
evid
literatur
evalu
patient
classic
tumor
think
addit
standart
treatment
need
regular
cystoscop
examin
bladder
involv
discuss
case
r
palasseri
k
j
n
ramaiah
medic
colleg
medic
oncolog
bengaluru
india
diagnost
oncopatholog
gurgaon
india
ramaiah
medic
colleg
radiat
oncolog
bengaluru
india
backgroundobject
multipl
primari
malign
mpm
extrem
rare
pediatr
often
associ
cancer
predisposit
syndrom
treatment
challeng
due
vari
drug
sensit
therapi
relat
advers
effect
report
case
year
old
femal
synchron
wilm
tumor
wt
alveolar
soft
part
sarcoma
asp
designmethod
case
report
result
year
old
femal
stomach
pain
found
abdomin
mass
ct
scan
show
bilater
pulmonari
nodul
larg
left
renal
mass
anoth
mass
within
left
psoa
muscl
behind
renal
mass
renal
mass
biopsi
show
triphas
wt
receiv
chemotherapi
vincristin
doxorubicin
week
follow
left
nephrectomi
remov
psoa
mass
histopatholog
kidney
show
wt
focal
anaplasia
psoa
mass
consist
asp
patient
underw
genet
screen
cancer
predisposit
syndrom
neg
receiv
adjuv
chemotherapi
high
risk
wt
along
lung
abdomen
radiat
radiat
boost
asp
tumor
bed
pulmonari
relaps
wt
month
post
therapi
evid
diseas
nephrectomi
bed
opposit
kidney
psoa
muscl
current
undergo
salvag
chemotherapi
wt
relaps
conclus
mpm
includ
sarcoma
wt
describ
children
fanconi
anemia
mutat
syndrom
mutat
patient
test
neg
mutat
chose
treat
patient
wt
direct
therapi
sinc
asp
poor
sensit
chemotherapi
case
highlight
rariti
mpm
children
limit
understand
cancer
predisposit
syndrom
need
individu
treatment
plan
patient
f
v
p
c
institut
et
doncologi
lyon
franc
translat
research
laboratori
lyon
franc
civil
de
lyon
patholog
lyon
franc
backgroundobject
nephroblastoma
wilm
tumor
wt
heterogen
embryon
tumor
compos
three
main
subtyp
blastema
stroma
epithelium
chemotherapi
accord
siop
classif
wt
blastem
associ
poor
prognosi
hand
surgeri
wt
blastem
without
prognost
impact
immun
microenviron
wt
bare
known
work
aim
character
microenviron
wt
take
account
heterogen
use
transcriptom
approach
designmethod
specif
area
ffpe
sampl
patient
treat
ihop
centr
lyon
franc
accord
protocol
retrospect
select
one
two
french
refer
pathologist
wt
order
analyz
everi
tissu
compon
wt
transcript
involv
tumorigenesi
immun
respons
oncolog
biomark
panel
perform
use
htg
edgeseq
system
result
area
pass
qualiti
control
blastema
epithelium
stroma
mixt
nephrogen
rest
identifi
gene
differenti
express
p
blastem
versu
stromal
area
blastem
versu
epitheli
area
respect
particular
gene
recurr
mutat
wt
strongli
upregul
blastem
area
compar
stroma
epithelium
unsupervis
hierarch
cluster
analysi
use
variant
gene
identifi
group
blastem
sampl
cluster
either
one
group
blastem
sampl
wt
enrich
inflammatori
respons
gene
compar
wt
conclus
gene
express
differ
compon
wt
result
may
help
identifi
new
prognost
factor
therapeut
target
p
e
e
e
h
k
k
n
seeg
eastern
european
e
petrid
kapodistrian
univers
athen
medic
school
dept
epidemiolog
medic
statist
athen
greec
p
kyriak
children
hospit
oncolog
depart
athen
greec
univers
ahepa
hospit
pediatr
depart
thessaloniki
greec
agia
sofia
children
hospit
pediatr
first
depart
pediatr
athen
greec
agia
sofia
children
hospit
depart
pediatr
athen
greec
depart
pediatr
hematolog
oncolog
thessaloniki
greec
crete
depart
pediatr
heraklion
greec
mitera
children
hospit
pediatr
depart
athen
greec
p
kyriak
children
hospit
patholog
laboratori
athen
greec
agia
sofia
children
hospit
patholog
laboratori
athen
greec
joana
daniela
anna
domen
sultan
snezana
zivkov
mario
maciej
tina
anna
anton
ryzhov
eastern
european
group
eastern
europ
greec
institut
clinic
epidemiolog
depart
medicin
stockholm
sweden
backgroundobject
wilm
wt
tumor
larg
obscureetiolog
remark
variabl
surviv
aim
compar
incid
surviv
rate
among
children
year
european
see
countri
relat
human
develop
index
hdi
designmethod
incid
rate
air
calcul
correl
hdi
see
collabor
countri
entail
registri
curv
cox
proport
hazard
analys
use
assess
role
age
gender
urban
hdi
overal
surviv
os
countri
entail
registri
result
median
age
diagnosi
year
steadili
declin
rate
fifth
year
life
transit
slightli
male
slightli
femal
preponder
advanc
age
overal
signific
differ
among
registri
statist
signific
posit
associ
higher
hdi
increas
incid
regress
coeffici
ci
persist
region
variat
shape
overal
remark
gradual
escal
os
result
report
first
time
greec
show
high
total
registr
period
last
five
year
boy
children
age
year
live
rural
area
high
hdi
countri
hrhigh
hrmedium
significantli
higher
death
risk
conclus
variat
incid
describ
first
time
across
see
countri
chang
male
femal
pattern
advanc
age
posit
associ
hdi
impli
plausibl
interplay
environment
genet
factor
diseas
etiolog
likewis
children
resid
area
equal
enjoy
substanti
gain
wt
surviv
point
strong
socioeconom
differenti
despit
recent
therapeut
improv
p
e
e
e
h
p
k
k
n
e
petrid
kapodistrian
univers
athen
medic
school
dept
epidemiolog
medic
statist
athen
greec
p
kyriak
children
hospit
oncolog
depart
athen
greec
pediatr
aristotl
univers
ahepa
hospit
unit
thessaloniki
greec
depart
univers
agia
sofia
children
hospit
pediatr
unit
athen
greec
agia
sofia
children
hospit
depart
pediatr
athen
greec
hospit
depart
pediatr
hematolog
oncolog
thessaloniki
greec
crete
depart
pediatr
heraklion
greec
mitera
children
hospit
pediatr
depart
athen
greec
p
kyriak
children
hospit
patholog
laboratori
athen
greec
agia
sofia
children
hospit
patholog
laboratori
athen
greec
backgroundobject
present
first
time
characterist
outcom
children
suffer
wilm
tumor
wt
deriv
childhood
cancer
registri
entail
also
clinic
data
develop
period
financi
crisi
greec
designmethod
followingintens
collabor
personnel
attend
physician
aim
increas
qualiti
harmon
childhood
cancer
registr
demograph
clinic
data
wt
patient
analyzedaccord
standard
methodolog
result
total
patient
year
regist
median
age
year
year
male
annual
age
standard
incid
rate
surviv
overal
specif
increas
time
major
receiv
protocol
chemotherapi
neither
relaps
rate
death
rate
show
statist
signific
differ
among
boy
respect
compar
girl
respect
one
girl
stv
high
risk
histolog
die
due
refractori
diseas
wherea
death
attribut
toxic
relaps
rate
increas
significantli
anatom
stage
likewis
death
rate
relaps
rate
among
patient
histolog
time
higher
compar
intermedi
riskfavor
histolog
wherea
death
rate
time
higher
signific
differ
regard
relapsedeath
rate
among
differ
age
group
patient
chemotherapi
vs
immedi
surgeri
observ
conclus
data
indic
provis
special
care
childhood
cancer
seem
lag
behind
inde
ef
osin
greec
compar
albeit
somehow
lower
two
larg
cooper
intern
group
nwtsg
higherenrol
rate
clinic
trial
may
facilit
process
develop
clinic
compon
n
rostovtsev
v
e
region
children
hospit
surgeri
chelyabinsk
russia
blokhin
russian
cancer
research
center
institut
pediatr
oncolog
hematolog
moscow
russia
ural
state
medic
univers
pediatr
surgeri
chelyabinsk
russia
region
children
hospit
pediatr
oncolog
haematolog
chelyabinsk
russia
backgroundobject
photodynam
therapi
pdt
use
recent
great
import
wilm
tumor
wt
treatment
advanc
stage
diseas
aim
studi
determin
optim
pdt
regimen
radochlorin
photosensibiliz
intraop
radiat
nephroblastoma
children
designmethod
patient
diagnosi
stage
wt
receiv
pdt
treatment
clinic
median
age
whole
group
year
pdt
perform
intrasurg
tumor
remov
laser
output
w
treatment
laser
power
densiti
differ
dose
light
energi
use
radiat
dose
increas
tumor
deep
infiltr
growth
inject
photosensibiliz
amount
mgkg
exposur
time
depend
tumor
size
chang
min
lightguid
microlen
end
use
tumor
irradi
result
pdt
effect
evalu
perform
accord
follow
criteria
complet
local
tumor
recurr
absenc
visual
accord
ultrasound
examin
palpat
sign
tumor
growth
local
recurr
month
without
effect
tumor
growth
extens
earli
postop
period
accord
ultrasound
measur
pdt
direct
result
evalu
perform
month
period
suffici
tumor
recurr
reveal
tumor
recurr
patient
recurr
reveal
children
recurr
patient
gener
wt
case
repeat
pdt
cours
perform
tumor
extens
patient
recurr
diseas
month
year
examin
period
conclus
studi
show
pdt
high
therapeut
effici
children
wilm
tumor
advanc
stage
howev
children
tumor
recurr
year
r
samujh
n
graduat
institut
medic
educ
chandigarh
pediatr
surgeri
chandigarh
india
backgroundobject
wilm
tumour
wt
commonest
paediatr
renal
tumour
occur
associ
variou
predispos
syndrom
genet
abnorm
clinic
malform
renal
cyst
rare
seen
paediatr
popul
frequenc
rare
neoplast
potenti
designmethod
case
report
result
month
old
infant
present
small
phallu
hypospadia
bilater
undescend
test
laparoscop
orchiopexi
done
age
one
year
androgen
stimul
post
follow
unev
age
year
child
present
painless
hematuria
fever
abdomin
lump
evalu
wilm
tumor
aris
lower
pole
right
kidney
retrospect
evalu
previou
mri
show
small
simpl
renal
cyst
lower
pole
right
kidney
subsequ
patient
develop
tumor
site
patient
manag
modifi
siop
protocol
radic
perform
preoper
chemotherapi
histopatholog
show
triphas
wilm
tumor
predominantli
mesenchym
compon
patient
well
year
follow
conclus
suspect
cortic
renal
cystic
lesion
associ
wilm
tumor
may
regard
tumor
precursor
special
associ
risk
factor
like
genitourinari
malform
patient
follow
frequent
ultrasonographi
imag
atleast
till
age
year
high
index
suspicion
clinic
set
sarin
azad
medic
new
india
pediatr
surgeri
new
delhi
india
backgroundobject
metanephr
adenofibroma
maf
rare
renal
neoplasm
thought
repres
matur
form
wilm
tumor
wt
designmethod
girl
present
abdomin
mass
durat
cect
show
right
renal
mass
peripher
left
pulmonari
metastas
biopsi
gave
differenti
diagnos
mesenchym
variant
wt
cellular
mesoblast
nephroma
consid
stage
iv
wt
receiv
cycl
avd
chemotherapi
post
chemotherapi
cect
show
complet
resolut
lung
nodul
signific
chang
size
renal
mass
underw
right
nephroureterectomi
resect
lymph
node
sampl
final
histopatholog
hpe
report
maf
keep
benign
natur
tumor
mind
postop
chemotherapi
administ
kept
close
two
year
initi
present
present
larg
local
recurr
cect
reveal
hypodens
mass
lesion
right
renal
fossa
abut
right
psoa
inferior
border
liver
gall
bladder
loss
fat
plane
encas
aorta
lung
metastas
pathologist
maintain
maf
review
previou
hpe
slide
trucut
biopsi
recurr
mass
show
featur
wt
chang
administ
cycl
ice
chemotherapi
cect
reveal
mass
reduc
dramat
size
underw
excis
residu
mass
total
necrot
lymph
node
found
administ
flank
radiat
along
boost
local
recurr
site
cycl
ie
result
week
close
surveil
conclus
review
literatur
reveal
renal
tumor
contain
area
maf
wt
receiv
adjuv
therapi
initi
wt
regardless
tumor
histolog
sarin
azad
medic
new
india
pediatr
surgeri
new
delhi
india
backgroundobject
congenit
mesonephr
nephroma
cmn
commonest
renal
tumor
earli
infanc
usual
dealt
surgic
excis
manag
cellular
cmn
especi
adjunct
chemotherapi
standard
yet
designmethod
report
case
antenat
detect
right
renal
mass
polypoid
peripher
cystic
compon
ultrasonographi
gestat
associ
retroperiton
periren
collect
hemorrhag
cect
perform
week
age
reveal
right
renal
mass
solid
cystic
compon
associ
local
collect
underw
right
day
life
elsewher
histopatholog
examin
hpe
reveal
cellular
atyp
mesoblast
nephroma
foci
tumor
show
classic
cmn
featur
definit
diffus
infiltr
renal
sinu
tumor
cell
show
brisk
mitosi
express
vimentin
cyclin
immunoneg
receiv
cycl
actinomycin
chemotherapi
start
day
age
month
chemotherapi
develop
recurr
grew
larger
origin
tumor
come
week
month
age
first
seen
center
explor
reveal
larg
friabl
mass
infiltr
adren
gland
along
fat
gerota
fascia
resect
done
hpe
show
tumor
compos
round
spindl
cell
present
sheet
entrap
adren
gland
clear
eosinophil
cytoplasm
show
brisk
mitosi
cystic
degener
suggest
cellular
cmn
receiv
whole
abdomen
radiat
gy
fraction
view
tumor
ruptur
adjuv
ice
chemotherapi
cycl
third
center
result
last
month
conclus
av
therapi
use
wilm
tumor
ideal
chemotherapi
cellular
cmn
chemotherapi
use
sarcoma
administ
infant
cellular
cmn
schiavetti
c
mg
e
sapienza
pediatr
rome
itali
backgroundobject
wilm
tumor
wt
extrem
rare
adult
diagnosi
usual
unexpect
surgeri
designmethod
retrospect
review
wt
treat
singl
center
select
adult
patient
wt
result
two
patient
adult
refer
pediatr
oncolog
unit
manag
relaps
tumor
case
old
man
refer
pediatr
oncolog
unit
manag
abdomin
relaps
two
month
robot
surgeri
kidney
cancer
eventu
turn
wilm
tumor
patient
treat
preoper
chemotherapi
aggress
surgeri
includ
complet
nephrectomi
remov
metastat
deposit
omentum
pariet
peritoneum
whole
abdomen
radiotherapi
postop
chemotherapi
patient
therapi
aliv
without
diseas
case
old
woman
underw
open
radic
right
nephrectomi
diagnosi
renal
cell
carcinoma
made
six
year
patient
present
lung
nodul
resect
histolog
show
epitheli
nephroblastoma
histolog
revis
primari
renal
tumor
confirm
diagnosi
nephroblastoma
seven
month
new
lung
nodul
detect
lobectomi
perform
patient
refer
pediatr
oncolog
unit
present
well
without
diseas
seven
month
surgeri
chemotherapi
yet
conclus
need
consult
pediatr
oncolog
center
start
postop
treatment
emphas
nephroblastoma
diagnosi
made
urolog
center
adult
wt
may
success
rescu
multimod
therapi
accord
pediatr
guidelin
also
case
relaps
sharma
r
jn
medic
kle
academi
higher
educ
research
jnmc
india
depart
urolog
belagavi
india
kle
kidney
kle
dr
prabhakar
kore
hospit
india
depart
urolog
belagavi
india
biotechnolog
karnatak
india
depart
biotechnolog
microbiolog
dharwad
india
backgroundobject
present
studi
prospect
assess
oncolog
outcom
well
renal
function
outcom
children
unilater
local
wilm
tumor
wt
treat
either
nephron
spare
surgeri
nss
abl
nephrectomi
designmethod
children
present
unilater
wilm
tumor
period
jan
dec
prospect
random
undergo
either
abl
simplerad
nephrectomi
nephron
spare
surgeri
treatment
administ
children
accord
siop
protocol
result
studi
period
thirteen
children
underw
abl
nephrectomi
wherea
remain
underw
nephron
spare
surgeri
opposit
kidney
normal
usg
ct
mean
age
intervent
eight
children
stage
diseas
remain
stage
ii
diseas
mean
period
month
children
aliv
last
event
free
surviv
children
undergo
nss
wherea
children
undergo
abl
nephrectomi
children
aliv
clinic
evid
diseas
last
children
undergo
abl
nephrectomi
significantli
higher
mean
systol
diastol
blood
pressur
well
significantli
higher
mean
valu
serum
creatinin
compar
children
undergo
nss
conclus
children
unilater
wilm
tumor
oncolog
outcom
nephron
spare
surgeri
good
abl
nephrectomi
nss
minim
loss
renal
function
hg
n
h
e
g
univers
medic
faculti
pediatr
oncolog
ankara
turkey
univers
medic
faculti
pediatr
urolog
ankara
turkey
univers
medic
faculti
pediatr
surgeri
ankara
turkey
univers
medic
faculti
patholog
ankara
turkey
univers
medic
faculti
radiolog
ankara
turkey
univers
medic
faculti
radiat
oncolog
ankara
turkey
backgroundobject
recent
success
treatment
approach
reach
earli
stage
wilm
tumor
designmethod
total
wilm
tumor
patient
follow
pediatr
oncolog
ankara
univers
retrospect
evalu
result
male
femal
ratio
age
median
age
year
bilater
wilm
tumor
seen
three
patient
one
patient
bilater
cryptorchid
one
patient
bilater
aniridia
without
kidney
anomali
abdomin
mass
abdomin
pain
hematuria
hypertens
seen
diagnosi
patient
evalu
accord
siop
stage
system
stage
v
doxorubicin
ad
patient
lung
metastas
three
patient
tumor
thrombu
vci
thrombu
found
extend
right
atrium
resorb
chemotherapi
three
case
spontan
ruptur
diagnosi
unilater
patient
underw
radic
nephroureterectomi
total
nephrectomi
unilater
conserv
surgeri
perform
bilater
patient
surgic
stage
sampl
paracav
paraaort
renal
hilu
lymph
node
perform
tissu
specimen
evalu
anaplasia
seen
four
patient
cgi
appli
tumor
site
cgi
appli
lung
metastas
period
year
median
year
six
patient
advanc
clinic
stage
die
due
refractori
diseas
one
die
although
receiv
combin
tyrosin
kinas
inhibitor
refractori
case
carboplatin
paclitaxel
chemotherapi
also
ad
one
case
lost
progress
autolog
transplant
prepar
regimen
surviv
rate
conclus
develop
countri
still
diagnos
wilm
tumor
case
advanc
stage
import
follow
wilm
tumor
experienc
clinic
obtain
success
result
treger
r
g
r
c
r
j
n
k
pritchard
w
great
ormond
street
institut
child
franci
crick
institut
development
biolog
bioinformat
comput
biolog
laboratori
london
unit
kingdom
great
ormond
street
institut
child
health
development
biolog
cancer
london
unit
kingdom
school
hygien
tropic
medicin
clinic
research
faculti
infecti
tropic
diseas
london
unit
kingdom
franci
crick
institut
bioinformat
comput
biolog
laboratori
london
unit
kingdom
great
ormond
street
institut
child
health
development
biolog
depart
paediatr
haematolog
oncolog
london
unit
kingdom
great
ormond
street
institut
child
health
development
biolog
depart
histopatholog
london
unit
kingdom
backgroundobject
diffus
anaplast
wilm
tumour
dawt
rare
subtyp
often
miss
needl
biopsi
somat
mutat
found
approxim
case
associ
poorer
surviv
particularli
advanc
stage
diseas
detect
circul
could
aid
earlier
diagnosi
anaplast
tumour
chemotherapi
commenc
without
histolog
confirm
standard
manag
childhood
renal
tumour
countri
follow
siop
guidelin
designmethod
patient
diagnosi
wt
enrol
import
studi
patient
treat
accord
siop
wt
normal
kidney
tumour
tissu
collect
surgeri
whilst
blood
urin
collect
five
treatment
time
point
assess
statu
frozen
tumour
match
germlin
dna
circul
tumour
dna
ctdna
plasma
serum
urin
patient
dawt
statu
determin
sanger
target
sequenc
droplet
digit
polymeras
chain
reaction
ddpcr
employ
evalu
ctdna
sampl
patient
dawt
variant
result
mutant
detect
ctdna
plasma
serum
patient
detect
variant
volum
urin
one
patient
display
heterogen
tumour
despit
section
display
anaplast
histolog
concentr
ctdna
plasmaserum
taken
vari
significantli
patient
rang
observ
variat
ctdna
throughout
treatment
one
patient
relaps
day
ctdna
level
fell
follow
nephrectomi
conclus
result
first
demonstr
ddpcr
effect
method
detect
mutant
ctdna
children
wt
even
somat
heterogen
low
burden
diseas
h
ueno
h
k
r
c
k
k
n
research
institut
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
univers
school
medicin
depart
patholog
tokyo
japan
center
child
health
develop
depart
patholog
tokyo
japan
center
child
health
develop
divis
surgic
children
cancer
center
tokyo
japan
center
child
health
develop
divis
leukemia
lymphomasolid
children
cancer
center
tokyo
japan
center
child
health
develop
divis
children
cancer
center
tokyo
japan
center
child
health
develop
depart
radiolog
tokyo
japan
center
child
health
develop
divis
stem
cell
transplant
cellular
children
cancer
center
tokyo
japan
backgroundobject
optim
multimod
therapi
base
patholog
subgroup
essenti
improv
outcom
pediatr
renal
tumor
howev
biopsi
tumor
obtain
diagnost
sampl
routin
perform
consid
risk
spillag
tumor
cell
hand
recent
studi
reveal
intern
tandem
duplic
itd
bcor
genet
hallmark
clear
cell
sarcoma
kidney
ccsk
intens
chemotherapi
radiotherapi
indic
show
liquid
biopsi
make
diagnosi
ccsk
identif
cell
free
dna
cfdna
plasma
children
renal
tumor
designmethod
extract
cfdna
plasma
three
children
renal
tumor
treatment
two
case
ccsk
one
stage
stage
ii
one
case
nephroblastoma
perform
pcr
use
primer
detect
cfdna
result
detect
ccsk
case
neg
nephroblastoma
case
well
normal
control
duplic
sequenc
amplifi
cfdna
contain
consensu
sequenc
previous
report
ccsk
conclus
liquid
biopsi
method
could
provid
preoper
diagnosi
ccsk
identif
cfdna
even
though
case
earli
stage
approach
enabl
diagnosi
ccsk
without
risk
tumor
raptur
furthermor
detect
cfdna
might
use
posit
tumor
r
g
r
e
l
brassesco
sao
paulo
fmrp
cell
biolog
preto
brazil
sao
paulo
fmrp
blood
center
preto
brazil
sao
paulo
fmrp
pediatr
preto
brazil
sao
paulo
fmrp
medicin
rehabilit
locomotor
system
preto
brazil
sao
paulo
biolog
preto
brazil
backgroundobject
despit
advanc
multimod
manag
surviv
rate
patient
osteosarcoma
os
present
metastas
diagnosi
remain
dysregul
development
regul
homeobox
hox
associ
tumor
growth
progress
unanim
upregul
hox
gene
found
cancer
canon
express
develop
andor
undifferenti
cell
wherea
downregul
normal
express
differenti
tissu
interestingli
hoxa
hoxd
gene
cluster
respons
develop
bone
tissu
specif
alter
express
result
defect
hind
limb
mice
herein
aim
investig
express
level
pediatr
os
associ
clinic
paramet
designmethod
mrna
level
studi
consecut
primari
os
sampl
compar
normal
bone
primari
osteoblast
cultur
immunohistochem
reaction
perform
os
sampl
antibodi
detect
kit
respect
analyz
ihc
imag
analysi
toolbox
result
mrna
scarc
express
tissu
highli
express
tumor
sampl
fold
chang
highli
posit
immunostain
verifi
tumor
sampl
though
posit
focal
paradox
lower
express
focal
stain
associ
higher
tumor
volum
respect
lower
express
among
sampl
diffus
immunostain
associ
death
p
global
surviv
correl
tumor
relaps
huvo
grade
metastasi
found
conclus
high
level
suggest
dysregul
common
featur
os
might
contribut
tumor
establish
howev
seen
other
express
may
fluctuat
influenc
tumor
prognosi
consid
pleiotrop
natur
identif
target
may
reveal
use
biomark
novel
therapeut
target
mx
castro
la
p
le
foundat
vall
del
lili
pediatr
oncolog
cali
colombia
californiapeckham
center
cancer
blood
radi
children
san
univers
california
san
diego
moor
cancer
la
ca
pediatr
oncolog
cali
colombia
del
vall
cali
popul
base
cancer
patholog
depart
cali
colombia
foundat
centro
imbanaco
de
colombia
vigicanc
childhood
cancer
surveil
system
medic
behalf
vigicanc
work
group
cali
colombia
backgroundobject
low
countri
lmic
osteosarcoma
ewe
sarcoma
e
surviv
dismal
high
frequenc
advanc
diseas
diagnosi
major
contribut
factor
poor
surviv
lmic
howev
literatur
scarc
contribut
factor
lmic
herein
describ
outcom
children
metastat
e
cali
colombia
designmethod
vigicanc
establish
support
foundat
child
matter
program
within
cali
cancer
registri
collect
data
outcom
patient
year
old
new
diagnosi
cancer
treat
pediatr
oncolog
unit
baselin
data
collect
medic
record
hospit
discharg
log
patholog
report
death
certif
nation
public
health
insur
databas
surviv
analys
perform
use
includ
e
analys
method
use
surviv
analys
cox
regress
adjust
hazard
rate
hra
result
identifi
osteosarcoma
ewe
patient
mean
age
sd
year
old
male
public
insur
pi
metastat
e
mo
e
pi
patient
compar
insur
spi
osteosarcoma
ewe
overal
surviv
respect
mo
e
compar
e
treatment
relat
mortal
abandon
respect
mo
e
associ
increas
mortal
pi
hra
ci
conclus
found
role
diseas
extens
prognost
factor
inconsist
patient
popul
similar
data
era
research
need
identifi
contribut
factor
dismal
outcom
lmic
implement
effect
treatment
celkan
g
b
h
e
n
vmm
faculti
medicin
divis
pediatr
hematolog
oncolog
turkey
faculti
medicin
pediatr
turkey
faculti
medicin
patholog
turkey
faculti
medicin
radiolog
turkey
faculti
medicin
orthoped
traumatolog
turkey
backgroundobject
aim
studi
evalu
patient
osteosarcoma
treat
singl
center
see
effect
mifamurtid
treatment
compar
histor
result
designmethod
case
osteosarcoma
record
januari
review
clinic
inform
obtain
clinic
chart
period
patient
osteosarcoma
treat
accord
protocol
neoadjuv
chemotherapi
cisplatin
epirubicin
ifosfamid
time
addit
oper
mifamurtid
usual
use
combin
chemotherapi
chemotherapi
cycl
finish
follow
resect
patient
result
median
age
diagnosi
year
rang
primari
tumor
locat
extrem
leg
right
humeru
axial
skeleton
surgeri
limb
salvag
except
axial
local
amput
done
relaps
good
histopatholog
respons
tumour
necrosi
found
seven
patient
relaps
lung
lung
local
local
patient
treat
mifamurfid
relaps
local
two
patient
isol
lung
recurr
free
diseas
surgic
resect
metastasi
treat
mifamurtid
three
case
lost
diseas
conclus
physician
treat
patient
osteosarcoma
occasion
face
dilemma
deal
local
recurr
diseas
suspicion
mifamurfid
usag
decreas
lung
relaps
increas
local
relaps
analysi
patient
group
import
guid
manag
decis
histor
cohort
os
overal
surviv
new
cohort
surviv
os
respect
although
period
short
addit
mifamurtid
treatment
protocol
improv
os
result
p
echebarria
jm
de
r
r
l
j
health
research
institut
pediatr
oncolog
group
barakaldo
spain
universitario
cruce
pediatr
oncolog
hematolog
barakaldo
spain
universitario
cruce
orthoped
surgeri
traumatolog
barakaldo
spain
backgroundobject
bone
sarcoma
repres
new
pediatr
cancer
case
osteosarcoma
os
ewe
sarcoma
es
common
one
patient
need
multidisciplinari
approach
new
therapi
improv
prognosi
object
descript
characterist
patient
diagnos
bone
sarcoma
pediatr
oncolog
unit
tertiari
hospit
enrol
spanish
protocol
designmethod
retrospect
analysi
clinic
biolog
radiolog
data
pediatr
patient
diagnos
os
es
spss
result
patient
diagnos
bone
sarcoma
januari
januari
patient
os
es
median
age
rang
sex
distribut
boy
girl
os
es
common
locat
femur
pelvi
respect
ten
patient
show
metastasi
moment
diagnosi
patient
os
es
lung
metastas
frequent
fifti
percent
patient
metastasi
die
patient
treat
chemotherapi
conserv
surgeri
radiotherapi
mifarmutid
also
use
case
thirteen
patient
relaps
less
year
diagnosi
os
es
nine
one
relaps
eleven
patient
die
os
es
os
patient
relaps
aliv
one
evid
diseas
year
includ
clinic
trial
lenvatinib
thirteen
patient
es
os
aliv
evid
diseas
conclus
multidisciplinari
approach
conserv
surgeri
improv
qualiti
life
patient
bone
tumor
howev
surviv
rate
still
remain
low
therefor
develop
new
target
person
medicin
introduct
new
drug
need
enhanc
outcom
ergurhan
ilhan
n
bilimleri
univers
ankara
oncolog
hospit
pediatr
hematologyoncolog
ankara
turkey
bilimleri
ankara
oncolog
hospit
pediatr
hematolog
oncolog
ankara
turkey
backgroundobject
febril
neutropenia
fen
one
major
caus
morbid
mortal
patient
cancer
clinic
effect
cefoperazon
sc
demonstr
adult
fen
retrospect
studi
aim
assess
efficaci
sc
empric
monotherapi
fen
pediatr
cancer
patient
designmethod
children
neutropen
fever
hospit
center
lymphoma
solid
tomor
includ
studi
patient
assign
receiv
sc
mgkgday
everi
hour
reevalu
hour
case
persist
fever
aminoglycosid
andor
glycopeptid
ad
treatment
respons
defin
success
without
modif
overal
success
failur
result
episod
fen
patient
median
year
evalu
common
diagnosi
osteosarcom
ewe
sarcoma
iymphoma
rhabdomyosarcoma
absolut
neutrophil
count
durat
neutropenia
day
median
time
therapi
day
episod
develop
induct
therapi
partial
remiss
treatment
relaps
diseas
remmiss
origin
fever
could
detect
fuo
episod
microbiolog
document
infect
mdi
present
episod
infect
clinic
document
cdi
success
rate
without
treatment
modif
failur
rate
overal
success
rate
none
patient
die
infect
sc
monotherapi
fail
episod
mdi
episod
cdi
sc
monotherapi
success
episod
fever
origin
could
detect
conclus
empir
sc
monotherapi
found
effect
fenepisod
fuo
episod
mdi
cdi
may
reguir
modif
f
klot
n
mm
j
h
k
pediatr
depart
comprehens
cancer
center
munich
pediatr
munich
germani
tumour
refer
centr
institut
univers
hospit
univers
switzerland
patholog
basel
switzerland
klinikum
staedtisch
klinikum
radiolog
munich
germani
klinikum
recht
der
isar
der
tu
germani
surgeri
munich
germani
thorac
klinikum
recht
der
isar
der
tu
germani
thorac
surgeri
munich
germani
klinikum
muenchen
klinikum
muenchen
pediatr
surgeri
munich
germani
allgemein
pathologi
und
pathologisch
technisch
patholog
munich
germani
backgroundobject
improv
antitumor
activ
drug
captiv
strategi
amelior
current
treatment
option
trabectedin
bind
minor
groov
dna
induc
break
result
activ
enzym
respons
pathway
combin
olaparib
trabectedin
lead
deregul
dna
damag
repair
machineri
shown
elicit
antitumor
activ
preclin
model
addit
osteosarcoma
cell
brcaness
found
suscept
parp
inhibit
combin
chemotherapi
base
high
frequenc
brcaness
osteosarcoma
hypothes
therapi
olaparib
inhibitor
follow
trabectedin
could
effect
patient
refractori
osteosarcoma
designmethod
patient
refractori
osteosarcoma
treat
olaparib
monotherapi
follow
trabectedin
temozolomid
patient
brcaness
suffer
bulki
diseas
treat
cycl
olaparib
patient
treat
olaparib
addit
trabectedin
patient
brcaness
suffer
refractori
pulmonari
metastas
receiv
cycl
olaparib
follow
combin
trabectedin
temozolomid
respect
olaparib
given
mgd
day
trabectedin
day
temozolomid
given
day
dosag
first
cycl
escal
feasabl
result
therapi
toler
well
toxic
aplasia
grade
iv
nausea
one
patient
patient
show
progress
diseas
conclus
therapi
parp
inhibitor
combin
chemotherapi
feasibl
show
efficaci
limit
cohort
patient
refractori
osteosarcoma
includ
brcaness
posit
tumor
mechan
therapi
failur
includ
elucid
resist
mechan
need
better
understood
employ
synthet
lethal
approach
clinic
applic
consid
adapt
treatment
schedul
ac
j
hospit
specialti
pediatr
oncolog
chihuahua
mexico
hospit
specialti
patholog
chihuahua
mexico
hospit
specialti
neurosurgeri
chihuahua
mexico
hospit
specialti
pediatr
fellow
chihuahua
mexico
backgroundobject
report
rare
case
destruct
telangiectat
osteosarcoma
secondari
aneurysm
bone
cyst
cervic
vertebra
mexican
child
discuss
pathogenesi
diseas
combin
telangiectat
osteosarcoma
aneurysm
bone
cyst
cervic
thorac
spine
rare
primari
bone
neoplasm
report
rariti
diagnost
difficulti
report
kind
countri
designmethod
studi
design
case
report
review
previou
literatur
present
method
plain
ct
scan
mri
indic
expansil
destruct
lesion
involv
bodi
vertebra
caus
spinal
cord
compress
result
oper
tumor
remov
complet
relaps
vertebra
gave
us
patholog
report
receiv
treatment
chemotherapi
reduc
tumor
anoth
surgeri
remov
complet
actual
sign
tumor
recurr
conclus
report
rare
case
destruct
telangiectat
osteosarcoma
secondari
aneurysm
bone
cyst
cervic
thorac
vertebra
child
mexico
full
investig
indic
complet
resect
tumor
chemotherapi
prevent
recurr
need
declar
lifelong
cure
diseas
n
gaspar
fj
bautista
r
b
e
sj
f
gallego
canet
c
p
c
c
q
roussi
cancer
campu
villejuif
franc
ircc
istituto
nazional
dei
tumori
milan
itali
infantil
universitario
jesu
madrid
spain
children
hospit
houston
usa
children
hospit
birmingham
unit
kingdom
de
toulous
de
enfant
toulous
franc
nant
nant
franc
colleg
london
hospit
london
unit
kingdom
pediatrico
bambino
univers
pavia
rome
itali
hospit
vall
dhebron
barcelona
spain
universitario
politecnico
la
fe
hospit
valencia
spain
stuttgart
olgahospit
stuttgart
germani
children
hospit
muenster
pediatr
hematolog
oncolog
muenster
germani
curi
psl
research
oncolog
center
siredo
pari
franc
lyon
franc
ltd
hatfield
unit
kingdom
co
ltd
tokyo
japan
inc
woodcliff
lake
usa
great
north
children
hospit
royal
victoria
infirmari
newcastl
upon
tyne
unit
kingdom
backgroundobject
lenvatinib
multikinas
inhibitor
target
report
emerg
data
phase
lenvatinib
expans
phase
cohort
lenvatinib
etoposid
ifosfamid
relapsedrefractori
osteosarcoma
designmethod
patient
age
year
relaps
osteosarcoma
prior
therapi
receiv
lenvatinib
phase
phase
combin
regimen
start
dose
lenvatinib
ifosfamid
etoposid
day
primari
endpoint
phase
surviv
month
per
recist
phase
recommend
dose
data
cutoff
octob
result
phase
cohort
median
number
cycl
receiv
rang
common
advers
event
teae
diarrhea
hypothyroid
proteinuria
common
grade
teae
back
pain
dyspnea
one
patient
discontinu
due
teae
myelodysplast
syndrom
evalu
patient
achiev
best
overal
rate
bor
partial
respons
pr
stabl
diseas
sd
phase
combin
cohort
patient
receiv
lenvatinib
lenvatinib
chemotherapi
receiv
lenvatinib
lenvatinib
chemotherapi
dlt
lenvatinib
grade
thrombocytopenia
lenvatinib
grade
thrombocytopenia
grade
bleed
patient
grade
oral
dysesthesia
grade
back
pain
grade
muscl
spasm
patient
grade
teae
incid
lenvatinib
lenvatinib
respect
patient
discontinu
due
teae
bor
pr
sd
lenvatinib
auc
clearanc
compar
lenvatinib
combin
conclus
phase
cohort
patient
lenvatinib
achiev
phase
lenvatinib
chemotherapi
manag
safeti
profil
studi
ongo
b
abou
k
ghanem
f
r
h
r
h
univers
beirut
pediatr
beirut
lebanon
univers
beirut
patholog
laboratori
medicin
beirut
lebanon
univers
beirut
surgeri
beirut
lebanon
univers
beirut
medicin
beirut
lebanon
backgroundobject
outcom
pediatr
osteosarcoma
dramat
improv
past
decad
overal
surviv
rate
patient
local
metastat
diseas
respect
designmethod
retrospect
review
clinic
characterist
outcom
patient
treat
singl
institut
lebanon
patient
receiv
uniform
chemotherapi
regimen
consist
cisplatin
doxorubicin
methotrex
ifosfamid
etoposid
ad
adjuv
treatment
regimen
case
metastat
diseas
andor
poor
degre
tumor
necrosi
result
median
month
rang
month
patient
local
diseas
overal
surviv
rate
approxim
respect
metastat
diseas
approxim
common
primari
site
long
bone
around
knee
six
patient
metastat
diseas
lung
three
synchron
multifoc
bone
diseas
lung
metastas
advers
prognost
factor
includ
extrem
site
metastas
poor
degre
necrosi
delay
week
local
control
bivari
analysi
degre
necrosi
prognost
predictor
surviv
diseas
recurr
conclus
treatment
pediatr
osteosarcoma
multidisciplinari
cancer
center
lebanon
result
similar
surviv
develop
countri
delay
local
control
associ
wors
outcom
statist
signific
inferior
outcom
predictor
poor
degre
necrosi
time
local
control
ghisoli
l
j
g
c
oncolog
medic
citi
children
hospit
pediatr
hematolog
oncolog
dalla
usa
inc
medic
director
dalla
usa
univers
medic
oncolog
experiment
research
toledo
usa
inc
director
oper
dalla
usa
bio
scientif
director
dalla
usa
backgroundobject
ew
aggress
tumor
affect
aya
treatment
combin
compress
chemotherapi
surgeri
andor
radiat
prognosi
poorer
patient
metastat
diseas
surviv
within
two
year
diagnosi
fusion
gene
ew
type
variant
case
ew
exon
exon
design
type
lpx
demonstr
preclin
safetyefficaci
strategi
silenc
target
gene
express
designmethod
phase
studi
escal
determin
safeti
mtd
test
lpx
start
mgkg
patient
advanc
ew
type
transloc
intraven
infus
given
twice
week
four
week
follow
escal
schema
requir
kp
adequ
organ
function
cytokin
induct
pre
post
infus
analyz
result
first
cohort
enrol
yo
three
patient
line
therapi
patient
refractori
diseas
patient
receiv
complet
cycl
lpx
twice
week
infus
total
dose
given
promin
relat
toxic
hematolog
patient
develop
neutropenia
anoth
develop
anemia
requir
prbc
transfus
patient
signific
bone
bm
involv
one
patient
receiv
singl
lpx
infus
develop
fatal
rsv
pneumonia
report
toxic
includ
fatigu
headach
evalu
patient
stabl
diseas
month
progress
one
patient
sustain
respons
month
two
patient
aliv
month
last
dose
conclus
preliminari
experi
support
safeti
potenti
efficaci
type
lpx
limit
toxic
increas
correl
higher
lpx
infus
rate
symptom
two
patient
aliv
despit
multipl
previou
progress
gunasekera
p
cancer
sri
lanka
paediatr
oncolog
colombo
sri
lanka
cancer
sri
lanka
paedoatr
oncolog
colombo
sri
lanka
cancer
sri
lanka
clinic
oncolog
colombo
sri
lanka
backgroundobject
three
year
event
free
surviv
ef
patient
osteosarcoma
high
incom
countri
hic
exce
low
incom
countri
lic
like
sri
lanka
sl
much
less
improv
outcom
osteosarcoma
children
main
initi
launch
adapt
standard
high
dose
methotrex
base
chemotherapi
protocol
treat
childhood
osteosarcoma
patient
establish
tumour
board
decid
treatment
adapt
febril
neutropenia
treatment
protocol
aim
studi
describ
impact
initi
outcom
past
year
designmethod
cohort
studi
analys
prospect
collect
data
patient
treat
osteosarcoma
sl
compar
data
extract
clinic
record
period
signific
differ
surviv
analys
use
analysi
varianc
anova
result
period
children
year
less
respect
treat
osteosarcoma
sri
lanka
three
year
ef
p
metastat
diseas
present
treatment
abandon
rate
limb
salvag
surgeri
local
treatment
mean
durat
treatment
delay
week
chemotherapi
week
due
surgeri
conclus
rel
simpl
intervent
like
adapt
standard
treatment
protocol
establish
tumour
board
adapt
infect
control
method
improv
outcom
osteosarcoma
lic
like
sl
sri
lanka
limb
salvag
rate
continu
low
decad
cr
hong
ih
sh
je
hs
sk
hy
ch
hj
kd
hy
hs
nation
univers
colleg
medicin
divis
depart
cancer
research
institut
seoul
republ
korea
nation
univers
colleg
medicin
depart
radiat
oncolog
seoul
republ
korea
nation
univers
colleg
medicin
depart
patholog
seoul
republ
korea
nation
univers
colleg
medicin
depart
radiolog
seoul
republ
korea
nation
univers
colleg
medicin
depart
orthoped
surgeri
seoul
republ
korea
nation
univers
colleg
medicin
divis
pediatr
neurosurgeri
seoul
republ
korea
nation
univers
colleg
medicin
depart
pediatr
surgeri
seoul
republ
korea
nation
univers
colleg
medicin
depart
thorac
cardiovascular
surgeri
seoul
republ
korea
nation
univers
hospit
depart
pediatr
chonbuk
republ
korea
backgroundobject
prognosi
patient
newli
diagnos
ewe
sarcoma
famili
tumor
esft
improv
significantli
last
decad
nonetheless
surviv
still
patient
high
risk
featur
role
high
dose
chemotherapi
autolog
stem
cell
transplant
hdct
asct
high
risk
relaps
esft
need
evalu
designmethod
retrospect
medic
chart
review
done
efst
patient
underw
hdct
asct
septemb
januari
seoul
nation
univers
children
hospit
metastasi
diagnosi
bulki
primari
tumor
axialcentr
primari
site
relaps
diseas
singl
transplant
perform
earlier
period
regimen
mec
melphalan
etoposid
carboplatin
ttc
topotecan
thiotepa
carboplatin
bumel
busulfan
melphalan
tandem
transplant
perform
recent
period
bumel
follow
modifi
mec
result
patient
diagnos
median
age
year
underw
convent
chemotherapi
radiat
andor
surgeri
hdct
asct
complet
respons
partial
respons
overal
surviv
median
year
event
free
surviv
ef
median
year
ef
recipi
singl
transplant
mec
ttc
bumel
respect
ef
recipi
tandem
transplant
seven
patient
relaps
median
month
chemotherapi
die
diseas
aliv
without
diseas
one
patient
develop
acut
myeloid
leukemia
month
aliv
without
diseas
chemotherapi
haploident
stem
cell
transplant
donor
lymphocyt
infus
one
patient
die
transplant
relat
mortal
conclus
hdct
asct
may
promis
treatment
option
high
risk
relaps
esft
refin
may
need
identifi
optim
regimen
hdct
asct
r
ismail
h
u
e
oncolog
leicest
unit
kingdom
royal
infirmari
paediatr
leicest
unit
kingdom
backgroundobject
ewe
sarcoma
mesenchym
cell
tumour
second
commonest
malign
primari
bone
tumour
childhood
tumour
extrem
rare
hand
account
less
affect
metacarp
commonest
around
case
report
literatur
past
affect
finger
thumb
affect
phalanx
proxim
phalanx
patient
receiv
multimod
therapi
aliv
median
month
median
time
symptomatolog
diagnosi
report
month
unusu
site
durat
designmethod
six
year
old
boy
right
hand
present
swell
proxim
phalanx
littl
finger
around
month
initi
regular
surveil
dermatolog
presum
diagnosi
hemangioma
swell
note
later
last
year
warrant
investig
underw
excis
biopsi
histolog
revel
ewe
sarcoma
gene
mutat
underw
stage
work
found
local
diseas
complet
excis
start
adjuv
chemotherapi
per
plan
ray
amput
post
induct
result
patient
mri
reveal
involv
bone
extra
axial
soft
tissu
lesion
pet
scan
reveal
local
metabol
activ
current
still
induct
receiv
cycl
vide
conclus
five
year
surviv
local
ewe
sarcoma
almost
tune
achiev
diagnos
patient
time
manner
institut
multimod
therapi
although
finger
rare
site
ewe
sarcoma
consid
differenti
diagnosi
jerom
j
eur
j
hand
surg
eur
mohan
j
radiol
imag
baccari
j
otsr
gokalp
j
clin
imag
sci
smith
cancer
iukhta
p
e
l
b
chemotherapi
hdct
autolog
hemopoiet
stem
cell
transplant
children
young
adult
ewe
sarcoma
famili
tumor
singl
center
experi
bone
marrow
transplant
depart
pediatr
solid
tumor
russia
backgroundobject
current
treatment
protocol
allow
achiev
surviv
local
esft
patient
surviv
case
still
unsatisfactori
although
consider
bodi
data
consolid
real
effect
optim
indic
option
still
complet
clarifi
therefor
larg
prospect
cohort
analysi
still
necessari
designmethod
whole
cohort
includ
consecut
esft
patient
median
age
rang
year
receiv
hdct
obtain
cr
pr
stabl
diseas
featur
includ
lung
bone
bone
marrow
involv
inadequ
local
control
primari
axial
tumor
larg
lesion
volum
poor
treatment
respons
chemosensit
relaps
patient
sever
risk
factor
dissemin
diseas
patient
also
evalu
accord
prognost
score
rladenstein
et
al
case
hdct
use
relaps
patient
receiv
tandem
hsct
second
regimen
result
median
observ
time
rang
month
overal
os
ef
surviv
accordingli
present
patient
aliv
remain
remiss
therapi
toxic
accept
ctc
gr
tociv
observ
case
one
toxic
death
import
outcom
predictor
inadequ
local
control
chemoresist
case
high
prognost
score
valu
initi
bone
marrow
involv
patient
dissemin
diseas
one
patient
die
within
month
conclus
hdct
may
still
feasibl
option
accept
toxic
chemosensit
patient
inadequ
local
control
primarili
dissemin
case
ineffect
primari
resist
metastat
patient
e
kousteni
coss
cooper
osteo
sarcoma
cancer
klinikum
olgahospit
pediatr
immunolog
stuttgart
germani
backgroundobject
osteosarcoma
os
consid
rare
associ
wide
dissemin
diseas
literatur
limit
case
report
small
seri
sought
evalu
present
treatment
prognosi
os
designmethod
primari
os
coss
registri
os
aris
time
diseas
cours
analyz
treatment
relat
factor
outcom
result
coss
protocol
never
includ
routin
cn
imag
identifi
os
caus
median
os
diagnosiscn
involv
respect
os
locat
extrem
primari
metastas
mostli
pulmonari
initi
patient
receiv
chemotherapi
achiev
complet
surgic
remiss
detect
initi
subsequ
progressionrecurr
notic
symptom
chanc
find
upon
imag
unknown
metastas
limit
cn
combin
site
solitari
multipl
treatment
includ
complet
incomplet
irradi
surgeri
radiotherapi
chemotherapi
patient
achiev
surgic
remiss
cn
involv
site
median
first
month
rang
aliv
yr
die
os
suicid
unknown
year
actuari
number
surgic
remiss
statu
chemotherapi
radiotherapi
correl
prognosi
multivari
analys
conclus
os
aris
time
diseas
cours
largest
report
seri
found
treatment
correl
surviv
expect
overal
outcom
remain
dismal
ja
lee
hm
cancer
center
hospit
depart
pediatr
seoul
republ
korea
cancer
center
hospit
divis
radiolog
scienc
clinic
studi
seoul
republ
korea
univers
wonju
colleg
medicin
depart
pediatr
wonju
republ
korea
backgroundobject
human
mice
repres
power
vivo
model
studi
human
hematopoiesi
interact
human
immun
system
cancer
studi
aim
establish
human
osteosarcoma
model
use
nsg
mice
designmethod
nsg
mice
jackson
laboratori
usa
condit
busulfan
korea
otsuka
pharmaceut
korea
human
umbil
cord
blood
ucb
cell
cellsmic
inject
sinu
seven
week
human
cell
transplant
osteosarcoma
cell
express
luciferas
inject
knee
joint
orthotop
cell
thigh
heterotop
cell
human
nsg
mice
tumor
growth
monitor
size
measur
luminesc
imag
result
bone
marrow
spleen
nsg
mice
analyz
express
week
human
cell
transplant
engraft
rate
week
week
week
bone
marrow
week
week
spleen
respect
express
level
week
bone
marrow
spleen
level
week
week
bone
marrow
growth
tumor
monitor
day
tumor
implant
use
xtreme
imag
brunker
usa
observ
nsg
mice
implant
cell
week
cell
transplant
show
faster
tumor
growth
metastat
tumor
spread
liver
lung
mice
implant
cell
week
conclus
pilot
studi
establish
human
osteosarcoma
mice
model
sophist
modif
necessari
enhanc
human
cell
engraft
detect
earli
tumorigenesi
ja
lee
sk
hm
cancer
center
hospit
depart
pediatr
seoul
republ
korea
univers
hospit
depart
pediatr
incheon
republ
korea
univers
wonju
colleg
medicin
depart
pediatr
wonju
republ
korea
backgroundobject
leukocyt
count
peripher
blood
associ
surviv
adult
patient
cancer
aim
determin
prognost
signific
pediatr
patient
osteosarcoma
designmethod
retrospect
review
medic
record
pediatr
osteosarcoma
patient
treat
korea
cancer
center
hospit
may
march
pretreat
day
first
chemotherapi
leukocyt
count
lymphocyt
neutrophil
monocyt
ratio
lmr
evalu
patient
divid
group
use
median
valu
paramet
surviv
rate
compar
result
median
age
patient
femal
male
year
rang
year
tumor
site
distal
femur
proxim
humeru
proxim
tibia
proxim
fibula
elsewher
median
pretreat
neutrophil
lymphocyt
monocyt
count
rang
rang
rang
respect
pretreat
lmr
rang
median
day
neutrophil
lymphocyt
monocyt
count
rang
rang
rang
respect
day
lmr
rang
patient
follow
median
month
rang
month
overal
os
surviv
ef
rate
respect
patient
higher
pretreat
lymphocyt
count
better
os
vs
ef
vs
howev
day
lymphocyt
count
associ
surviv
surviv
differ
observ
patient
group
accord
pretreat
lmr
patient
higher
fare
better
lower
os
vs
conclus
addit
pretreat
lymphocyt
count
lmr
chemotherapi
prognost
signific
pediatr
osteosarcoma
patient
studi
involv
larger
cohort
necessari
valid
find
n
osifodunrin
j
hospit
children
oncolog
glasgow
unit
kingdom
backgroundobject
anthracyclin
includ
chemotherapi
regimen
describ
current
protocol
use
across
uk
europ
euro
ewe
treatment
ewe
sarcoma
osteosarcoma
although
anthracyclin
chemotherapi
shown
improv
outcom
bone
sarcoma
also
associ
cardiotox
cardiovascular
complic
lead
relat
caus
morbid
mortal
childhood
cancer
survivor
certain
risk
factor
associ
cardiotox
found
includ
higher
cumul
anthracyclin
dose
femal
sex
younger
age
diagnosi
presenc
cardiovascular
diseas
designmethod
retrospect
review
patient
diagnos
ewe
sarcoma
osteosarcoma
undertaken
echocardiogram
perform
treatment
treatment
review
cardiotox
grade
use
common
terminolog
criteria
advers
event
v
result
patient
identifi
patient
osteosarcoma
patient
ewe
sarcoma
patient
die
treatment
femal
male
median
cumul
dose
anthracyclin
median
age
diagnosi
year
patient
eject
fraction
ef
treatment
ctcae
grade
remain
patient
ef
rang
percentag
declin
ef
averag
patient
requir
dose
reduct
anthracyclin
patient
requir
treatment
cardiotox
conclus
small
cohort
patient
treat
anthracyclin
per
euramo
protocol
signific
problem
cardiotox
long
term
follow
howev
necessari
pick
late
toxic
park
jm
hy
sy
jh
hg
hj
bk
pediatr
nation
cancer
center
pediatr
cancer
republ
korea
cancer
center
center
pediatr
cancer
republ
korea
cancer
center
depart
patholog
republ
korea
cancer
center
orthoped
oncolog
clinic
republ
korea
backgroundobject
histolog
respons
chemotherapi
import
prognost
factor
osteosarcoma
thu
tri
develop
effect
neoadjuv
regimen
obtain
better
histoloig
respons
designmethod
patient
treat
osteosarcoma
nation
cancer
center
korea
jan
dec
regist
patient
receiv
two
cours
neoadjuv
chemotherapi
map
regimen
methotrex
cisplatin
p
doxorubicin
mapi
regimen
map
plu
ifosfamid
appli
strategi
mapi
without
lengthen
preoper
period
compar
map
adjuv
chemotherapi
tailor
accord
necrosi
rate
resect
tumor
specimen
necrosi
rate
toxic
assess
two
group
differ
outcom
also
compar
result
total
patient
includ
patient
mapi
group
patient
map
group
interv
first
day
neoadjuv
chemotherapi
surgeri
day
mapi
group
day
map
group
p
good
histolog
respons
necrosi
observ
mapi
group
map
group
multivari
logist
regress
analysi
major
toxic
grade
wors
differ
two
group
probabl
surviv
overal
surviv
mapi
group
p
map
group
p
conclus
studi
suggest
addit
ifosfamid
convent
map
therapi
given
similar
durat
preoper
phase
could
achiev
better
histolog
respons
without
signific
increas
major
toxic
studi
larger
scale
warrant
reach
solid
conclus
c
shin
univers
depart
pediatr
niigata
japan
backgroundobject
surviv
osteosarcoma
os
patient
still
unsatisfactori
mainli
due
uncontrol
refractori
lung
metastas
immunotherapi
may
offer
new
perspect
patient
sever
studi
report
tremend
efficaci
chimer
antigen
receptor
car
engin
cell
malign
howev
target
solid
tumor
car
difficult
lack
suitabl
antigen
variou
mechan
immun
escap
includ
express
immun
checkpoint
molecul
ligand
critic
cancer
evad
host
immun
surviv
aim
develop
novel
car
construct
kill
os
cell
target
ligand
designmethod
test
sever
os
cell
line
express
ligand
construct
sever
car
construct
target
use
extracellular
domain
human
cell
ligand
bind
domain
investig
whether
cell
surfac
express
ligand
upregul
target
cell
result
cell
retrovir
transduc
success
expand
presenc
anti
block
antibodi
ad
earli
phase
expans
cultur
os
cell
line
test
express
moder
amount
also
express
cell
show
potent
cytotox
os
cell
line
mimic
reproduc
ligand
upregul
cell
attack
stimul
os
cell
line
cytokin
supernat
cell
raji
burkitt
lymphoma
cell
treatment
induc
ligand
upregul
os
cell
line
test
cell
express
ligand
increas
therebi
enhanc
cytotox
exert
cell
conclus
may
candid
novel
therapi
os
andor
solid
tumor
secondari
therapi
cancer
evad
first
cell
target
anoth
molecul
p
singh
ps
india
institut
medic
sciec
neurosurgeri
new
delhi
india
india
institut
medic
scienc
neurosurgeri
new
delhi
india
backgroundobject
paediatr
vertebr
haemangioma
vh
exceedingli
rare
benign
highli
vascular
tumour
spine
purpos
studi
evalu
long
term
outcom
year
patient
vertebr
haemangioma
present
myelopathi
treat
surgic
designmethod
seven
patient
mean
age
year
rang
year
femal
male
treat
surgic
may
june
clinicalneurolog
outcom
assess
use
american
spinal
injuri
associ
asia
scale
surgeri
consist
intra
oper
bilater
transpedicular
absolut
alcohol
inject
laminectomi
level
patholog
follow
instrument
fusion
use
pedicl
screw
rod
laminectomi
alcohol
inject
laminectomi
alcohol
bone
cement
inject
corpectomi
instrument
demograph
clinic
radiolog
oper
detail
postop
event
retriev
hospit
record
result
myelopathi
present
patient
asia
score
c
patient
thorac
region
imag
studi
mean
follow
rang
month
month
patient
show
improv
power
asia
score
e
last
follow
conclus
present
studi
largest
seri
paediatr
symptomat
vh
year
follow
surgeri
tailor
accord
need
patient
good
long
term
outcom
star
j
n
b
k
k
l
cancer
center
radiationoncolog
sulaimaniyah
iraq
cancer
center
radiat
oncolog
sulaimaniyah
iraq
cancer
institut
radiat
oncolog
alberta
canada
backgroundobject
ewe
sarcoma
es
rare
malign
neoplasm
tumour
musculoskelet
system
second
common
malign
bone
tumour
children
adolesc
age
group
ideal
manag
es
includ
multimod
approach
neoadjuv
chemotherapi
surgic
resect
andor
radiotherapi
follow
adjuv
chemotherapi
aim
studi
evalu
treatment
outcom
paediatr
es
patient
institut
designmethod
descript
studi
retrospect
chart
review
paediatr
patient
year
old
proven
diagnosi
es
manag
zhianawa
cancer
center
zcc
hiwa
cancer
hospit
hch
spss
softwar
use
data
analysi
result
total
paediatr
es
patient
enrol
studi
patient
receiv
chemotherapi
radiotherapi
underw
tumour
resect
free
surgic
margin
obtain
patient
median
age
diagnosi
year
studi
show
lower
surviv
among
femal
patient
p
valu
also
poor
surviv
patient
tumour
recurr
p
valu
furthermor
signific
differ
diseas
recurr
mean
surviv
time
patient
recurr
ci
month
recurr
ci
month
overal
surviv
os
surviv
conclus
surviv
rate
es
region
much
lower
compar
surviv
develop
countri
spite
use
multimod
treatment
approach
includ
chemotherapi
surgeri
radiotherapi
lack
multidisciplinari
decis
shortag
adequ
oncolog
facil
region
may
partial
attribut
lower
outcom
taniguchi
n
k
k
h
h
univers
hospit
orthopaed
kanazawa
japan
backgroundobject
patient
pediatr
osteosarcoma
postop
leg
length
discrep
clinic
problem
howev
impact
surgeri
leg
length
still
unclear
purpos
studi
evalu
postop
leg
length
discrep
patient
pediatr
osteosarcoma
assess
differ
among
surgic
procedur
designmethod
patient
primari
osteosarcoma
lower
extrem
treat
depart
examin
patient
male
femal
age
year
enrol
locat
tumor
proxim
femur
n
distal
femur
n
proxim
tibia
n
patient
divid
femur
tibia
group
base
tumor
locat
postop
discrep
femur
tibia
length
assess
use
frontal
view
radiograph
untreat
bone
defin
ipsilater
femur
tibia
affect
tumor
differ
untreat
bone
length
discrep
associ
use
frozen
autograft
prosthesi
evalu
statist
analyz
result
averag
period
rang
month
femur
group
averag
femur
length
discrep
rang
cm
tibia
group
averag
tibia
length
discrep
rang
cm
femur
group
averag
untreat
bone
length
discrep
associ
use
frozen
autograft
prosthesi
cm
cm
respect
differ
found
signific
p
tibia
group
averag
untreat
bone
length
discrep
associ
use
frozen
autograft
prosthesi
cm
cm
respect
differ
found
signific
conclus
patient
osteosarcoma
femur
may
experi
sever
postop
leg
length
discrep
averag
approxim
cm
use
prosthesi
distal
femur
caus
shorten
tibial
length
f
yamazaki
n
c
h
cancer
center
research
institut
depart
clinic
genom
tokyo
japan
univers
graduat
school
medicin
tokyo
japan
cancer
center
research
institut
divison
rare
cancer
research
tokyo
japan
cancer
center
central
hospit
depart
pediatr
oncolog
tokyo
japan
cancer
center
central
hospit
depart
musculoskelet
oncolog
tokyo
japan
cancer
center
central
hospit
depart
patholog
tokyo
japan
backgroundobject
homolog
recombin
defici
hrd
mainli
due
inactiv
caus
mani
structur
variat
sv
copi
number
alter
cna
breast
ovarian
cancer
genom
sever
score
system
sv
andor
cna
estim
hrd
develop
score
recogn
use
predict
biomark
recent
specif
signatur
signatur
signatur
analysi
found
correl
hrd
osteosarcoma
os
known
exhibit
except
high
number
sv
cna
thu
assess
genom
alter
os
viewpoint
hrd
designmethod
perform
sequenc
we
analysi
sarcoma
sampl
adolesc
young
adult
aya
patient
includ
oss
analyz
mutat
profil
base
signatur
list
cosmic
databas
use
packag
signatur
estim
furthermor
conduct
snp
array
analysi
addit
oss
pediatr
aya
patient
determin
loss
heterozygos
loh
score
one
score
system
hrd
result
significantli
higher
contribut
signatur
observ
oss
aya
sarcoma
p
loh
score
calcul
we
data
also
higher
oss
vs
p
signatur
contribut
loh
score
correl
os
r
loh
score
calcul
snp
array
data
mostli
high
median
oss
similar
report
breast
ovarian
cancer
tumor
separ
respons
neoadjuv
chemotherapi
includ
platinum
agent
loh
score
significantli
higher
good
respond
least
necrosi
poor
respond
vs
p
conclus
result
suggest
hrd
underli
high
genom
alter
os
hrd
score
may
becom
predict
biomark
os
treatment
h
yonezawa
n
k
k
school
medic
kanazawa
univers
depart
orthopaed
surgeri
kanazawa
japan
backgroundobject
simpl
bone
cyst
sbc
benign
bone
tumor
howev
treatment
sbc
remain
controversi
heal
rate
invas
surgeri
defin
short
hydroxyapatit
ha
pin
pin
length
shorter
half
bone
diamet
purpos
studi
evalu
treatment
sbc
use
short
ha
pin
designmethod
patient
men
women
mean
age
year
age
rang
year
sbc
treat
continu
decompress
insert
ceram
ha
pin
sbc
locat
humeru
femur
patient
minim
fenestr
cyst
wall
curettag
multipl
drill
cyst
wall
perform
follow
insert
ha
pin
mean
period
month
radiograph
defin
two
type
recurr
one
recurr
cyst
contact
pin
central
type
c
type
recurr
cyst
apart
pin
peripher
type
p
type
oper
time
heal
period
risk
factor
recurr
cure
rate
evalu
result
five
case
activ
phase
three
latent
phase
two
patient
recurr
cure
curettag
artifici
bone
graft
final
heal
rate
cannul
use
short
ha
pin
reoper
perform
recurr
cyst
recurr
interv
case
shorter
case
conclus
present
studi
cannul
use
short
ha
pin
sbc
long
bone
found
use
techniqu
associ
low
rate
recurr
j
zhang
j
c
j
q
w
children
medic
center
depart
hematolog
oncolog
shanghai
china
backgroundobject
ewe
sarcoma
famili
tumor
esft
malign
often
occur
children
studi
aim
evalu
efficaci
vcpiev
protocol
pediatr
esft
analyz
possibl
prognost
factor
designmethod
septemb
novemb
total
patient
esft
diagnos
hospit
enrol
protocol
vcpiev
includ
vincristin
cyclophosphamid
etoposid
ifosfamid
adriamycin
dactinomycin
almost
rhabdomyosarcoma
patient
success
follow
method
use
analyz
surviv
result
male
femal
median
age
month
rang
month
ef
estim
respect
patient
lr
mr
group
reach
much
better
result
hr
group
differ
signific
ef
lr
mr
group
hr
group
ef
better
patient
local
diseas
metastat
diseas
primari
diagnosi
differ
also
signific
vs
declin
trend
larger
size
tumor
vs
also
found
ef
differ
signific
vs
one
patient
develop
second
malign
therapi
relat
death
document
conclus
vcpiev
protocol
esft
safe
effici
high
risk
group
metastat
diseas
larger
tumor
size
predict
poor
prognosi
b
zhumadullaev
b
g
k
g
e
center
pediatr
pediatr
surgeri
oncolog
almati
kazakhstan
center
pediatr
pediatr
surgeri
radiolog
almati
kazakhstan
center
pediatr
pediatr
surgeri
patholog
almati
kazakhstan
center
pediatr
pediatr
surgeri
intens
care
almati
kazakhstan
backgroundobject
proport
osteosarcoma
children
age
republ
kazakhstan
endoprosthet
reconstruct
follow
resect
bone
improv
qualiti
life
children
osteosarcoma
perform
sick
children
adolesc
malign
bone
tumor
purpos
studi
show
result
use
endoprosthesi
patient
osteosarcoma
designmethod
retrospect
review
patient
osteosarcoma
treat
scientif
centr
pediatr
pediatr
surgeri
februari
februari
done
boy
girl
median
age
patient
year
metastat
diseas
reveal
patient
proxim
local
tumor
case
patient
distal
local
patient
treat
accord
euramoss
protocol
map
arm
local
surgic
control
method
limb
salvag
treatment
modular
invas
endoprosthesi
hydroxylapatit
coat
use
fixat
perform
limb
function
assess
accord
scale
societi
tumor
score
result
type
perform
limb
salvag
surgeri
endoprosthet
shoulder
joint
patient
knee
joint
case
evalu
limb
function
assess
satisfactori
patient
good
excel
patient
local
relaps
occur
patient
tumor
proxim
metaphysi
humeru
month
therapi
complet
infect
complic
observ
case
month
surgeri
caus
candida
famata
success
antimycot
treatment
reendoprosthet
perform
overal
surviv
median
month
rang
month
conclus
endoprosthet
improv
function
limb
increas
qualiti
life
time
number
infecti
complic
relaps
minim
n
acharfi
benhami
l
amaadour
k
z
benbrahim
fz
n
mella
oncolog
depart
hassan
ii
univers
hospit
fez
morocco
backgroundobject
sarcoma
head
neck
rare
heterogen
malign
tumor
difficulti
manag
requir
intervent
multidisciplinari
team
improv
prognosi
object
studi
report
epidemiolog
clinic
histolog
therapeut
evolutionari
peculiar
designmethod
retrospect
studi
conduct
medic
oncolog
depart
hassan
ii
hospit
univers
fez
includ
patient
head
neck
sarcoma
stretch
januari
decemb
result
case
report
men
woman
mean
age
year
order
evalu
tumor
extens
facial
ct
perform
patient
mri
patient
seat
sarcoma
patient
nasal
caviti
patient
cheek
one
patient
histolog
type
rhabdomyosarcoma
patient
leiomyosarcoma
one
patient
pleomorph
sarcoma
one
patient
myxofibrosarcoma
one
patient
patient
tumor
stage
local
patient
metastat
patient
pulmonari
metastas
evidenc
patient
four
patient
treat
surgic
radiotherapi
perform
adjuv
patient
chemotherapi
administ
patient
includ
neoadjuv
set
metastat
patient
chemotherapi
protocol
use
mai
patient
includ
patient
neoadjuv
situat
patient
metastat
situat
vac
patient
includ
neoadjuv
patient
metastat
patient
median
month
patient
remain
good
control
one
patient
lost
one
patient
die
conclus
sarcoma
head
neck
repres
rel
rare
histolog
divers
group
treatment
essenti
base
combin
surgeri
radiotherapi
chemotherapi
optim
therapeut
result
b
aydin
c
n
b
univers
pediatr
oncolog
ankara
turkey
backgroundobject
treatment
option
children
relapsedrefractori
tumor
limit
number
chemotherapeut
agent
left
first
line
regimen
respons
rate
usual
low
present
outcom
result
paclitaxel
carboplatin
cyclophosphamid
paxcc
salvag
regimen
patient
relapsedrefractori
tumor
designmethod
medic
record
patient
receiv
paxcc
either
alon
altern
vac
vincristin
actinomycin
cyclophosphamid
regimen
cycl
retrospect
review
demograph
characterist
respons
treatment
outcom
result
median
age
year
rang
f
ratio
histopatholog
diagnos
rabdomyosarcoma
ewe
sarcoma
wilm
tumor
osteosarcoma
soft
tissu
sarcoma
yolk
sac
tumor
paxcc
use
second
third
fourth
fifth
line
regimen
patient
tumor
resect
perform
andor
radiotherapi
primari
metastat
site
given
adjuv
treatment
patient
patient
receiv
median
cours
object
respons
rate
patient
best
respons
cr
vgpr
pr
sd
patient
twenti
patient
progress
diseas
median
time
month
overal
surviv
rate
first
year
patient
receiv
fare
better
other
receiv
paxcc
ef
rate
os
rate
ef
rate
patient
rhabdomyosarcoma
ewe
sarcoma
conclus
paxcc
seem
impact
relapsedrefractori
tumor
might
option
salvag
regimen
paclitaxel
might
effect
vac
altern
regimen
beder
p
r
j
institut
child
diseas
depart
pediatr
surgeri
bratislava
slovak
republ
institut
child
diseas
depart
pediatr
hematolog
oncolog
bratislava
slovak
republ
backgroundobject
sarcoma
children
rel
rare
heterogen
group
malign
origin
mesenchym
cell
divid
soft
tissu
sarcoma
st
bone
sarcoma
st
extrascelet
malign
tumor
classifi
rhabdomyosarcoma
rm
soft
tissu
sarcoma
nrst
multipl
histolog
variat
aim
report
present
treatment
strategi
outcom
cohort
soft
tissu
sarcoma
designmethod
retrospect
singl
centr
analysi
patient
treat
st
period
summari
latest
strategi
surgic
treatment
recommend
epssg
european
pediatr
soft
tissu
sarcoma
studi
group
perform
author
collect
patient
review
period
rm
group
consist
femal
median
age
year
diagnosi
result
complet
remiss
achiev
patient
year
overal
surviv
rate
nrst
group
present
femal
median
age
year
diagnosi
show
differ
histolog
find
overal
surviv
rate
complet
remiss
patient
patient
nrst
underw
surgeri
local
control
pulmonari
metastas
confirm
patient
relaps
case
unilater
metastasectomi
patient
bilater
metastasectomi
perform
conclus
outcom
prognosi
st
depend
time
diagnosi
presenc
metastas
tumor
size
extent
resect
sarcoma
particular
nrst
gener
weakli
sensit
radio
chemotherapi
therefor
complet
resect
main
cur
therapi
metastasectomi
indic
patient
pulmonari
metastas
even
recurr
case
slovakia
got
approxim
million
inhabit
pediatr
popul
million
children
limit
number
present
studi
thank
particip
european
studi
group
result
contribut
evalu
patient
uncommon
diagnosi
j
bradley
r
h
c
e
florida
radiat
oncolog
fl
usa
children
specialti
clinic
pediatr
oncolog
fl
usa
backgroundobject
purpos
studi
determin
pattern
failur
clinic
outcom
prognost
factor
pediatr
patient
paramening
alveolar
rhabdomyosarcoma
arm
designmethod
clinic
treatment
plan
record
children
age
year
paramening
arm
treat
definit
adjuv
rt
enrol
institut
prospect
registri
evalu
nodal
region
irradi
diseas
diseas
involv
nodal
level
treat
gy
rbe
involv
node
gy
rbe
sequenti
plan
product
limit
method
assess
local
region
control
surviv
pf
overal
surviv
os
test
use
evalu
prognost
impact
result
patient
median
age
year
rang
identifi
median
year
patient
rang
year
live
patient
rang
patient
group
iii
node
neg
posit
fox
fusion
statu
diseas
infratempor
fossa
common
subsit
intracrani
extens
ice
present
lumbar
punctur
perform
neg
stage
pet
patient
treat
concurr
chemotherapi
proton
rt
median
dose
gy
rbe
rang
rbe
median
week
rang
year
local
control
recurr
region
control
year
pf
os
median
time
failur
year
rang
diseas
ice
associ
inferior
os
respect
variabl
signific
associ
local
control
patient
develop
distant
metastas
first
site
recurr
leptomening
conclus
region
failur
rare
local
recurr
leptomening
progress
ice
suggest
need
intensif
local
cn
therapi
buletov
v
pediatr
oncolog
hematolog
nn
blokhin
head
neck
tumor
children
moscow
russia
backgroundobject
method
endonas
surgeri
es
use
treatment
inflammatori
diseas
remov
benign
neoplasm
nasal
caviti
paranas
sinus
skull
base
adult
patient
pediatr
onoclog
practic
method
common
designmethod
endoscop
transnas
surgeri
perform
patient
age
month
year
malign
tumor
benign
tumor
first
group
common
rhabdomyosarcoma
estheioneuroblastoma
morpholog
verifi
second
group
signific
varieti
morpholog
variant
neoplasm
first
group
biopsi
tumor
remov
includ
previous
biopsi
perform
case
delay
surgeri
perform
second
group
format
remov
result
main
complic
remov
tumor
intraop
liquorrhea
case
requir
plastic
dura
mater
period
rang
year
year
first
group
patient
aliv
lost
observ
die
includ
progress
underli
diseas
caus
toxic
treatment
relaps
aros
patient
aliv
second
group
patient
aliv
relaps
occur
case
patient
oper
observ
period
month
conclus
use
es
complex
treatment
children
malign
tumor
possibl
obtain
histolog
materi
method
local
control
endoscop
transnas
remov
benign
tumor
children
independ
suffici
method
treatment
techniqu
safe
allow
improv
visual
control
wound
low
traumat
shorten
recoveri
time
patient
buletov
r
n
v
n
n
v
pediatr
oncolog
hematolog
nn
blokhin
head
neck
tumor
children
moscow
russia
institut
oncolog
name
nn
blokhin
genet
laboratori
depart
moscow
russia
institut
oncolog
name
nn
blokhin
laboratori
depart
moscow
russia
institut
oncolog
name
nn
blokhin
patolog
depart
moscow
russia
backgroundobject
find
optim
surgic
tactic
medullari
thyroid
carcinoma
children
risk
develop
medullari
cancer
part
syndrom
designmethod
patient
oper
age
year
children
year
age
underw
surgic
treatment
connect
risk
mtc
part
syndrom
detect
mutat
ret
gene
patient
diagnos
oper
mtc
patient
men
type
syndrom
meh
type
famili
mtc
case
sporad
case
diseas
result
patient
metastas
lymph
node
neck
patient
metastas
die
patient
monitor
patient
disappear
observ
total
patient
aliv
one
patient
disappear
observ
four
die
result
progress
diseas
children
prophylact
thyroidectomi
connect
risk
mtc
part
syndrom
detect
mutat
ret
gene
case
mutat
exon
detect
mutat
exon
case
germin
mutat
found
g
exon
exon
case
mutat
exon
reveal
conclus
treatment
mtc
aggress
mutat
ret
gene
detect
risk
develop
men
syndrom
prevent
te
oper
perform
earli
possibl
sw
chou
hh
yl
dt
kh
st
taiwan
univers
children
hospit
pediatr
taipei
citi
taiwan
roc
taiwan
univers
hospit
laboratori
medicin
taipei
citi
taiwan
roc
backgroundobject
taiwan
pediatr
oncolog
group
tpog
initi
two
consecut
protocol
treat
pediatr
patient
rhabdomyosarcoma
sinc
howev
result
analyz
report
yet
aim
studi
investig
treatment
result
two
protocol
hospit
assess
whether
result
compar
studi
designmethod
treatment
pediatr
patient
rhabdomyosarcoma
accord
tpog
protocol
nation
taiwan
univers
hospit
began
patient
treat
tpog
rm
protocol
base
patient
treat
tpog
rm
protocol
adapt
studi
clinic
data
patient
obtain
retrospect
review
medic
record
date
latest
decemb
result
patient
enrol
studi
overal
surviv
os
surviv
rate
respect
os
rate
patient
treat
tpog
rm
tpog
rm
protocol
respect
age
diagnosi
less
ten
year
old
receiv
oper
gross
total
subtot
tumor
resect
identifi
independ
prognost
factor
predict
better
outcom
multivari
analysi
conclus
clinic
outcom
pediatr
patient
rhabdomyosarcoma
taiwan
improv
dramat
incorpor
two
consecut
protocol
tpog
addit
treatment
result
two
protocol
compar
studi
countri
b
coakley
h
l
k
j
c
p
w
anderson
cancer
center
depart
surgic
oncolog
houston
usa
mount
sinai
health
system
depart
divis
pediatr
surgeri
new
york
usa
hospit
lo
angel
depart
pediatr
surgeri
lo
angel
usa
anderson
cancer
center
depart
biostatist
houston
usa
anderson
cancer
center
depart
sarcoma
medic
oncolog
houston
usa
anderson
cancer
center
depart
pediatr
houston
usa
anderson
cancer
center
depart
radiat
oncolog
houston
usa
cleveland
clinic
pediatr
hematolog
oncolog
blood
marrow
transplant
houston
usa
backgroundobject
desmoplast
small
round
cell
tumor
dsrct
rare
sarcoma
primarili
affect
adolesc
young
adult
patient
present
mani
periton
implant
conduct
phase
clinic
trial
util
cytoreduct
surgeri
hypertherm
intraperiton
chemotherapi
cisplatin
patient
dsrct
abdomin
sarcoma
designmethod
prospect
cohort
studi
perform
patient
underw
procedur
cisplatin
patient
enrol
phase
clinic
trial
patient
diseas
complet
cytoreduct
could
achiev
exclud
outcom
record
result
fourteen
patient
dsrct
five
patient
sarcoma
one
patient
repeat
hipec
patient
dsrct
significantli
longer
median
overal
surviv
surgeri
patient
tumor
vs
month
p
overal
surviv
time
diagnosi
dsrct
patient
estim
median
surviv
rf
month
howev
rf
patient
dsrct
significantli
longer
patient
vs
month
p
among
patient
dsrct
without
hepat
portal
metastas
longer
median
rf
tumor
site
vs
month
p
patient
without
hepat
portal
metastasi
periton
diseas
recurr
conclus
complet
cisplatin
effect
select
patient
dsrct
patient
dsrct
hepat
portal
metastasi
poorer
outcom
crocoli
c
c
gm
r
di
md
de
children
hospit
ircc
surgeri
rome
itali
children
hospit
ircc
oncohematolog
rome
itali
children
hospit
ircc
patholog
rome
itali
backgroundobject
inflammatori
myofibroblast
tumor
imt
rare
pediatr
neoplasm
unpredict
biolog
behavior
occur
young
age
complet
resect
treatment
choic
sinc
develop
target
therapi
studi
anaplast
lymphoma
kinas
alk
express
tumor
trigger
alk
gene
rearrang
chromosom
could
potenti
role
diseas
manag
designmethod
data
patient
diagnos
treat
imt
bambino
children
hospit
retrospect
evalu
primari
site
tumor
dimens
surgic
intervent
alk
express
consid
result
eleven
patient
boy
median
age
year
rang
diagnos
imt
januari
decemb
primari
neoplasm
site
lung
omentum
paratesticular
limb
tumor
diamet
cm
patient
cm
patient
evalu
two
patient
alk
express
evalu
patient
result
posit
one
case
oment
imt
patient
underw
tumor
radic
resect
demolit
case
pneumonectomi
omentectomi
orchiectomi
three
patient
underw
adjuv
chemotherapi
methotrex
plu
vinorelbin
case
inhibitor
case
median
follow
month
rang
month
patient
aliv
ten
diseas
free
conclus
data
seri
emphas
role
surgeri
cornerston
treatment
pediatr
imt
role
target
therapi
alk
imt
controversi
investig
howev
unresect
tumor
attempt
reduc
surgic
morbid
biopsi
perform
alk
express
evalu
r
dugo
mf
e
de
garcia
de
ricardo
gutierrez
oncolog
unit
bueno
air
argentina
de
ricardo
gutierrez
patholog
unit
bueno
air
argentina
backgroundobject
rhabdomyosarcoma
rm
frequent
malign
subtyp
soft
tissu
sarcoma
st
prognosi
variabl
accord
age
anatomopatholog
stage
report
clinic
histolog
andor
molecular
characterist
surviv
overal
surviv
infant
younger
year
rm
treat
institut
designmethod
review
medic
record
patient
p
rm
younger
year
admit
hospit
de
ricardo
januari
decemb
result
patient
solid
tumor
admit
st
younger
month
twenti
rm
three
neonat
male
femal
median
age
month
month
median
year
histolog
embryon
botroid
alveolar
no
molecular
analysi
presenc
foxo
rearrang
stage
ii
iii
iv
locat
site
head
neck
limb
prostat
paramening
paratesticular
retroperiton
perin
vagina
thorax
bladder
treatment
initi
complet
resect
neoadjuv
chemotherapi
accord
siop
scheme
local
control
surgeri
alon
radiotherapi
alon
surgeri
radiotherapi
receiv
adjuv
chemotherapi
outcom
evalu
surviv
nine
die
progress
diseas
toxic
sepsi
relaps
local
cn
pulmonari
two
rescu
chemotherapi
surgeri
radiotherapi
remain
diseas
free
year
ten
aliv
median
year
os
ef
conclus
patient
younger
one
year
rm
uncommon
st
popul
head
neck
locat
embryon
subtyp
frecuent
molecular
analisi
help
us
better
cathegor
patient
allow
us
choos
best
treatment
el
nadi
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
backgroundobject
rm
case
aris
mostli
sporad
tumor
small
fraction
associ
herit
genet
syndrom
describ
infant
present
synchron
solid
tumor
wilm
tumor
rhabdomyosarcoma
cure
designmethod
patient
initi
present
surgic
resectd
tongu
swell
patholog
embryon
rhabdomyosarcoma
investig
rm
done
result
initi
ct
chest
lower
cut
show
accident
discoveri
well
defin
solid
mass
seen
rt
supraren
region
natur
pet
ct
show
intens
focal
fdg
uptak
seen
correspond
larg
right
renal
mass
involv
upper
half
right
kidney
sarcoma
start
protocol
base
cog
low
risk
scheduel
biopsi
right
renal
mass
patholog
wilm
tumor
patient
radic
nephrectomi
stage
satg
iii
surgeri
follow
radiotherapi
renal
bed
receiv
right
flank
conform
radiotherapi
patient
continu
protocol
replac
adriamycin
everi
cycl
receiv
altern
cours
vac
vad
radiotherapi
tongu
omit
age
complet
resect
lesion
inspit
margin
confirm
clear
patient
develop
tongu
mass
recurr
biopsi
show
recurr
embryon
rhabdomyosarcoma
receiv
salvag
chemotherapi
form
cycl
cce
local
radiotherapi
tongu
patient
follow
sinc
last
visit
patient
complet
remiss
conclus
infant
show
neg
famili
histori
neg
consanguin
matern
age
year
unremark
pregnanc
genet
analysi
child
show
abnorm
neg
inspit
cancer
infant
repres
less
malign
neoplasm
form
particulari
interest
group
studi
j
elhoudzi
n
hospit
moham
pediatr
hematolog
oncolog
marrakesh
morocco
hospit
moham
vi
pediatr
hematolog
oncolog
marrakesh
morocco
hospit
moham
vi
maxillar
surgeri
depart
marrakesh
morocco
backgroundobject
rhabdomyosarcoma
rm
remain
one
common
pediatr
soft
tissu
sarcoma
pediatr
cancer
also
common
sarcoma
head
neck
pauciti
case
pediatr
popul
make
difficult
diseas
studi
singl
institut
object
review
clinic
present
histolog
stage
treatment
modal
surviv
pediatr
head
neck
rhabdomyosarcoma
designmethod
retrospect
studi
pediatr
hematolog
oncolog
depart
treat
year
primari
head
neck
rm
result
studi
concern
children
rm
median
age
year
major
tumor
paramening
locat
embroy
histolog
primari
surgic
exicis
perform
patient
patient
receiv
chemotherapi
receiv
radiotherapi
overal
surviv
durat
studi
patient
relaps
confirm
histolog
patient
tempor
rm
stabl
evolut
persist
tumor
possibl
complet
surgeri
conclus
pediatr
head
neck
rm
challeng
studi
given
low
incid
evolv
diagnosi
treatment
plan
although
surgeri
consid
critic
treatment
sarcoma
may
feasibl
mani
head
neck
rm
multimod
approach
remain
ultim
treatment
plan
j
elhoudzi
h
e
k
hospit
moham
pediatr
hematolog
oncolog
marrakesh
morocco
hospit
moham
pediatr
surgeri
depart
marrakesh
morocco
backgroundobject
childhood
rhabdomyosarcoma
rm
common
malign
tumor
childhood
account
approxim
case
cancer
among
children
age
year
present
local
diseas
need
multimod
therapi
object
aim
studi
discuss
differ
therapeut
protocol
analyz
differ
prognost
element
term
global
surviv
surviv
designmethod
retrospect
descript
studi
case
rhabdomyosarcoma
rm
collect
pediatr
hematolog
oncolog
depart
moham
vi
medic
center
marrakech
result
rm
repres
admiss
median
age
year
male
predomin
sex
ratio
diagnos
done
tumor
syndrom
pain
especi
head
neck
area
frequent
embryon
form
common
histolog
type
head
neck
locat
common
follow
urogenit
tract
patient
present
advanc
diseas
iii
iv
patient
receiv
chemotherapi
follow
surgeri
radiotherapi
receiv
vac
vad
protocol
protocol
radiotherapi
carri
patient
averag
dose
administ
date
latest
news
patient
die
aliv
complet
remiss
cr
progress
relaps
conclus
difficult
compar
result
other
studi
use
differ
protocol
special
loss
follow
relat
luck
financi
social
support
howev
overal
surviv
rel
good
k
gordon
g
p
h
n
aberdeen
children
hospit
depart
paediatr
haematolog
oncolog
aberdeen
unit
kingdom
royal
infirmari
depart
patholog
aberdeen
unit
kingdom
backgroundobject
paraneoplast
neurolog
syndrom
pn
rare
result
attack
nervou
system
respons
develop
cancer
children
common
pn
opsoclonu
myoclonu
syndrom
limbic
enceph
receptor
enceph
paraneoplast
optic
neuriti
report
adult
patient
lung
cancer
particularli
small
cell
lung
cancer
howev
found
publish
report
phenomenon
occur
children
designmethod
present
case
year
old
boy
develop
unilater
visual
loss
prior
commenc
chemotherapi
alveolar
rhabdomyosarcoma
result
patient
teenag
boy
left
paratesticular
rhabdomyosarcoma
undergon
orchidectomi
prepar
first
chemotherapi
cycl
patient
report
histori
decreas
vision
pain
movement
right
eye
neurolog
examin
routin
observ
otherwis
normal
person
famili
histori
ophthalmolog
neurolog
autoimmun
diseas
examin
reveal
markedli
decreas
visual
acuiti
swollen
optic
disc
right
eye
left
eye
normal
magnet
reson
imag
mri
show
inflamm
right
optic
nerv
consist
optic
neuriti
evid
space
occupi
lesion
metastat
diseas
serum
virolog
screen
autoantibodi
screen
neg
csf
bacteri
virolog
test
neg
malign
cell
identifi
csf
lactat
protein
albumin
igg
normal
pair
serum
csf
oligoclon
band
consist
inflammationinfect
treatment
consist
day
iv
methylprednisolon
immunoglobulin
week
oral
prednisolon
chemotherapi
commenc
per
standard
protocol
good
recoveri
follow
treatment
resolut
optic
disc
oedema
normal
visual
acuiti
affect
eye
conclus
case
highlight
paraneoplast
optic
neuriti
occur
children
occult
underli
tumour
consid
children
present
optic
neuriti
c
hsiao
chang
gung
memori
hospit
medic
educ
kaohsiung
taiwan
roc
chang
gung
memori
hospit
depart
pediatr
hematolog
oncolog
kaohsiung
taiwan
roc
backgroundobject
malign
ectomesenchymoma
rare
potenti
aggress
biphas
tumor
consist
mesenchym
neuroectoderm
element
neoplast
cell
believ
aris
pluripot
embryolog
neural
creast
cell
also
least
one
malign
mesenchym
element
gener
rhabdomyosarcoma
tumor
occur
mostli
children
adolesc
designmethod
two
pediatr
patient
identifi
data
pertain
tumor
size
histolog
immunohistochem
ihc
studi
treatment
outcom
report
result
case
patient
male
infant
present
left
inguin
mass
size
around
x
incident
found
left
inguin
herniorrhaphi
initi
patholog
show
rhabdomyosarcoma
follow
total
tumor
excis
orchiedectomi
ihc
stain
show
posit
synaptophysin
myogenin
desmin
myo
result
consist
malign
ectomesenchymoma
consist
schwann
cell
rhabdomyosarcomat
element
stage
treat
tpog
rm
low
risk
chemotherapi
protocol
vincristin
actinomycin
finish
chemotherapi
pet
scan
mri
show
residu
tumor
patient
year
diagnosi
without
evid
diseas
case
patient
femal
infant
note
mass
x
cm
right
inguin
excis
patholog
show
ganglion
cell
rhabdomyosarcomat
element
result
ihc
stain
case
resect
margin
involv
sarcoma
stage
ii
finish
tpog
rm
low
risk
b
chemotherapi
protocol
cyclophosphamid
vincristin
actinomycin
residu
tumor
found
pet
scan
patient
found
without
recurr
metastat
diseas
month
conclus
report
highlight
inguin
malign
ectomesenchymoma
may
masquerad
inguin
hernia
earli
detail
ihc
stain
requir
establish
accur
diagnosi
chemotherapi
rhabdomyosarcoma
protocol
combin
radiotherapi
could
appli
patient
malign
ectomesenchymoma
w
j
w
huh
texa
md
anderson
cancer
center
pediatr
houston
usa
backgroundobject
develop
leptomening
diseas
lmd
pediatr
patient
nervou
system
cn
base
primari
tumor
uncommon
portend
grim
prognosi
lack
data
literatur
regard
patient
characterist
durat
respons
convent
treatment
method
object
studi
describ
clinic
characterist
treatment
patient
lmd
singl
institut
goal
studi
obtain
data
regard
durat
surviv
respons
toward
develop
novel
therapeut
trial
lmd
designmethod
retrospect
review
medic
record
pediatr
patient
treat
univers
texa
md
anderson
cancer
center
januari
decemb
base
primari
tumor
subsequ
recur
lmd
result
fourteen
evalu
patient
identifi
median
age
initi
diagnosi
year
rang
month
year
patient
male
alveolar
rhabdomyosarcoma
rm
common
histolog
identifi
follow
embryon
rm
headneck
present
primari
tumor
site
patient
includ
one
intracrani
sarcoma
seven
patient
metastasi
initi
diagnosi
one
patient
embryon
rm
note
leptomening
involv
initi
diagnosi
median
time
last
treatment
without
lmd
lmd
recurr
month
rang
month
includ
patient
progress
frontlin
chemotherapi
despit
aggress
multimod
therapi
median
time
death
patient
lmd
diagnosi
month
rang
month
one
patient
current
aliv
diseas
month
follow
lmd
diagnosi
conclus
develop
lmd
convey
extrem
poor
prognosi
current
multimod
therapi
provid
signific
durabl
respons
result
studi
provid
histor
control
durat
surviv
comparison
develop
novel
therapi
lmd
inc
e
b
r
h
h
e
k
n
eylul
univers
institut
oncolog
pediatr
oncolog
izmir
turkey
eylul
univers
faculti
medicin
radiat
oncolog
izmir
turkey
eylul
univers
faculti
medicin
radiodiagnost
izmir
turkey
eylul
univers
faculti
medicin
pediatr
surgeri
izmir
turkey
eylul
univers
faculti
medicin
orthoped
izmir
turkey
eylul
univers
faculti
medicin
patholog
izmir
turkey
eylul
univers
institut
oncolog
pediatr
oncologyy
institut
current
address
izmir
univers
econom
izmir
turkey
backgroundobject
evalu
clinic
featur
treatment
result
children
diagnosi
ewe
sarcoma
famili
tumor
esft
center
designmethod
medic
record
children
esft
treat
analyz
retrospect
clinic
characterist
treatment
surviv
rate
analyz
result
case
elig
analyz
median
age
diagnosi
mf
ratio
tumor
site
extrem
paravertebr
pelvic
extrapulmonari
intrathorac
skull
bone
parapharyng
cheek
abdomin
retroperiton
histopatholog
examin
reveal
ewe
sarcoma
pnet
case
rate
metastat
case
bone
median
time
ef
os
primari
surgeri
perform
case
case
admit
center
oper
anoth
center
differ
chemotherapi
ct
regimen
given
patient
radiotherapi
rt
primari
tumor
site
appli
aliv
without
aliv
lost
case
die
ii
neoadjuvan
chemotherapi
given
primari
chemotherapi
iecess
protocol
case
other
receiv
cycifo
anthracyclin
base
differ
regimen
induct
chemotherapi
respons
iia
surgeri
perform
neoadjuv
ct
case
induct
respons
group
relaps
occur
refractori
diseas
die
secondari
leukemia
occur
one
case
month
die
relat
iib
surgeri
nt
perform
neoadjuv
ct
case
induct
respons
one
case
metastat
ewe
sarcoma
die
earli
lost
among
case
receiv
ct
case
refractori
earli
case
late
relaps
occur
conclus
although
metastat
diseas
rate
esft
group
high
surviv
rate
approach
multiag
chemotherapi
nonmutil
surgeri
radiotherapi
promis
despit
high
dose
alkyl
agentsanthracyclin
contain
regimen
toxic
death
nt
occur
howev
secondari
leukemia
develop
one
case
remark
late
effect
jie
children
hospit
radiolog
depart
bei
jing
china
backgroundobject
observ
investig
clinic
effect
arteri
embol
intervent
phenomenon
kmp
patient
provid
experi
refer
diagnosi
treatment
diseas
designmethod
patient
hemangioma
children
kmp
case
arteriosclerosi
embol
choic
bleomycin
lipiodol
dexamethason
contrast
agent
format
emuls
microspher
bleomycin
mix
microspher
embol
oper
clinic
observ
laboratori
examin
imag
check
treatment
effect
comparison
spss
softwar
use
analyz
preoper
postop
index
result
patient
treat
arteri
embol
cure
improv
averag
platelet
count
fibrinogen
tumor
size
oper
respect
chang
gl
gl
differ
signific
two
case
reach
standard
surgeri
complet
tumor
resect
conclus
arteri
embol
therapi
signific
safe
reproduc
therapeut
effect
hemangioma
coagul
dysfunct
base
experi
oper
suggest
improv
success
rate
treatment
effect
preoper
enhanc
ct
care
evalu
attent
soft
punctur
use
ultrasound
guidanc
appropri
select
embol
materi
technolog
aspect
sclerotherapi
kachanov
n
v
g
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
clinic
oncolog
moscow
russia
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
radiat
therapi
moscow
russia
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
pediatr
surgeri
moscow
russia
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
patholog
moscow
russia
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
radiolog
moscow
russia
backgroundobject
rhabdomyosarcoma
rm
common
soft
tissu
sarcoma
childhood
paramening
pm
site
proven
unfavor
prognost
factor
aim
studi
analyz
result
therapi
pm
rm
children
treat
feder
center
russian
feder
designmethod
prospect
regist
patient
pm
rm
age
group
year
treat
period
includ
diagnosi
confirm
histolog
patient
examin
stratifi
accord
gpoh
cooper
weichteilsarkom
studi
cw
group
guidanc
result
patient
median
age
diagnosi
month
rang
includ
male
femal
ratio
initi
locat
rm
infratempor
pterygoid
palatin
fossa
nasopharynx
middl
ear
paranas
sinus
simultan
spread
tumor
nasopharynx
oropharynx
paranas
sinus
seven
patient
stage
iii
stage
iv
local
control
provid
patient
radiotherapi
radiotherapi
surgeri
median
radiat
dose
gy
rang
median
age
begin
radiotherapi
month
rang
median
time
month
rang
event
observ
patient
earli
death
multipl
organ
failur
patient
experienc
recurr
patient
progress
cycl
chemotherapi
patient
aliv
receiv
palli
treatment
die
overal
surviv
os
surviv
ef
conclus
multidisciplinari
approach
includ
system
chemotherapi
radiat
therapi
select
case
surgic
treatment
improv
prognosi
pm
rm
term
ef
os
karamercan
c
fg
h
univers
medic
school
pediatr
oncolog
hematolog
depart
ankara
turkey
univers
medic
school
depart
patholog
ankara
turkey
univers
medic
school
depart
radiat
oncolog
ankara
turkey
backgroundobject
studi
aim
investig
clinic
epidemiolog
properti
soft
tissu
sarcoma
nrst
center
designmethod
total
patient
nrst
year
depart
pediatr
oncolog
includ
research
result
malefemal
ratio
mean
age
case
found
month
month
common
complaint
painless
swell
diagnos
mean
month
month
first
admiss
common
histopatholog
diagnos
fibrosarcoma
malign
mesenchym
tumor
hemangioperistoma
patient
follow
month
median
month
encount
tumor
locat
head
neck
region
region
lymph
node
involv
local
diseas
rate
found
surgic
margin
clear
patient
wide
excis
neoadjuv
chemotherapi
administ
patient
wherea
patient
receiv
adjuv
chemotherapi
patient
receiv
radiotherapi
dose
cgi
median
cgi
receiv
radiotherapi
primari
site
five
patient
relaps
within
month
median
month
diagnosi
seven
patient
die
frequent
caus
death
progress
neutropen
sepsi
sixteen
patient
remiss
overal
surviv
osef
respect
conclus
nrst
rare
heterogen
group
tumor
children
nrst
rel
insensit
chemotherapi
main
treatment
modal
surgeri
radiotherapi
seri
half
patient
cure
diseas
osef
accept
current
manag
studi
consist
seri
report
n
khanna
b
c
g
b
memori
hospit
radiat
oncolog
mumbai
india
memori
hospit
medic
oncolog
mumbai
india
memori
hospit
surgic
patholog
mumbai
india
memori
hospit
radiolog
mumbai
india
memori
hospit
nuclear
medicin
mumbai
india
backgroundobject
evalu
treatment
respons
prognost
factor
patient
ewe
sarcoma
es
head
neck
region
treat
cur
intent
tata
memori
hospit
tmh
designmethod
januari
decemb
patient
histolog
proven
es
age
group
month
yr
median
yr
retrospect
evalu
prognost
factor
like
age
diagnosi
sex
skelet
origin
primari
site
pnsnon
pn
tumor
size
node
perform
statu
hematolog
biochem
paramet
hemoglobin
total
count
lactat
dehydrogenas
alkalin
phosphatas
albumin
respons
chemotherapi
cth
type
local
treatment
evalu
result
total
male
patient
diseas
mean
tumor
size
patient
receiv
multimod
treatment
form
eft
system
cth
local
treatment
compris
surgeri
sx
radiat
therapi
rth
rth
alon
offer
case
sx
either
feasibl
deem
associ
signific
morbid
median
month
local
control
lc
diseas
free
surviv
df
overal
surviv
os
respect
last
follow
patient
aliv
diseas
free
three
patient
local
relaps
distant
metastas
local
relaps
distant
metastas
three
patient
die
treatment
relat
toxic
analysi
patient
undergo
sxrth
similar
lc
df
os
compar
rth
alon
none
prognost
factor
statist
signific
conclus
multimod
treatment
use
combin
cth
sx
rth
result
optim
diseas
control
accept
toxic
radiotherapi
alon
give
outcom
similar
combin
surgeri
adjuv
radiotherapi
krawczyk
e
b
em
e
e
univers
gdansk
depart
hematolog
oncolog
gdansk
poland
univers
gdansk
depart
patholog
neuropatholog
gdansk
poland
medic
univers
depart
pediatr
bone
marrow
oncolog
hematolog
wroclaw
poland
univers
gdansk
english
divis
pediatr
oncolog
scientif
circl
gdansk
poland
clinic
centr
depart
hematolog
oncolog
gdansk
poland
univers
gdansk
depart
pathomorpholog
gdansk
poland
univers
gdansk
depart
pharmaceut
chemistri
gdansk
poland
backgroundobject
assess
role
tumor
express
factor
hif
glucos
transport
glut
carbon
anhydras
ca
ix
vascular
endotheli
growth
factor
vegf
predict
respons
chemotherapi
nacht
children
advanc
inoper
rhabdomyosarcoma
rm
designmethod
studi
includ
patient
embryon
rm
rme
alveolar
rma
treat
cw
protocol
immunohistochem
express
hypoxia
marker
determin
tumor
tissu
microarray
evalu
stain
intens
percentag
immunoposit
cell
result
patient
rme
respons
nacht
influenc
express
ca
ix
respect
respect
rma
subgroup
small
statist
analys
howev
patient
low
express
analyz
marker
respond
well
nacht
high
tumor
marker
express
rma
rme
tumor
display
high
express
analyz
protein
hypoxia
marker
correl
posit
surprisingli
rme
rma
demonstr
simultan
high
express
marker
patient
high
express
marker
respond
well
nacht
whole
cohort
marker
hypoxia
independ
factor
includ
multivari
logist
regress
model
predict
chemotherapi
odd
ratio
confid
interv
conclus
process
adapt
hypoxia
influenc
childhood
rm
immunohistochem
express
pattern
endogen
marker
hypoxia
tumor
diagnosi
emerg
promis
tool
predict
respons
cht
children
rm
base
differ
frequenc
protein
rme
rma
histolog
may
also
import
larger
group
rma
patient
enrol
prove
hypothesi
lou
l
leader
surgeri
depart
hangzhou
childrenshospit
hangzhou
china
surgeri
depart
hangzhou
childrenshospit
hangzhou
china
backgroundobject
object
assist
determin
differ
type
skin
hemangioma
help
color
doppler
ultrasound
develop
individu
rel
accur
optoelectron
technolog
treatment
plan
designmethod
method
total
patient
hemangioma
collect
age
day
year
old
male
femalesth
scope
hemangioma
infiltr
type
natur
tumor
measur
psv
relat
blood
flow
paramet
measur
ultrasound
imag
featur
variou
type
skin
hemangioma
count
accord
color
doppler
ultrasound
guidanc
patient
divid
two
group
group
subdivid
three
group
group
depth
skin
hemangioma
select
intens
puls
light
ipl
treatment
group
hemangioma
depth
mm
singl
puls
long
puls
width
nm
nd
yag
laser
treatment
group
rapist
mm
depth
blood
flow
veloc
ipl
combin
singl
puls
long
puls
width
nd
yag
treatment
group
b
skin
lesion
children
subject
color
doppler
ultrasonographi
singl
puls
long
puls
width
nm
nd
yag
laser
treatment
select
base
experi
clinician
group
patient
treat
time
efficaci
compar
result
overal
effici
group
treatment
group
group
group
effect
rate
group
b
differ
total
effect
rate
group
group
b
statist
signific
p
conclus
color
doppler
ultrasound
help
determin
type
skin
hemangioma
show
differ
imag
featur
skin
hemangioma
guidanc
color
doppler
ultrasound
reason
choic
optoelectron
technolog
treatment
skin
hemangioma
enhanc
efficaci
reduc
advers
reaction
lu
x
j
x
z
j
j
f
j
univers
cancer
center
pediatr
oncolog
guangzhou
china
children
medic
center
hematolog
oncolog
shanghai
china
children
capit
medic
univers
hematolog
oncolog
center
beij
china
hospit
chongq
medic
univers
surgic
oncolog
chongq
china
backgroundobject
analyz
clinic
characterist
treatment
prognosi
children
adolesc
fibrosarcoma
fs
designmethod
review
medic
record
patient
fs
younger
year
old
treat
four
hospit
includ
sun
univers
cancer
center
sysucc
shanghai
children
medic
center
scmc
beij
children
hospit
capit
medic
univers
bch
cmu
children
hospit
chongq
medic
univers
chcmu
januari
januari
patient
clinic
characterist
treatment
effect
prognost
factor
analyz
result
total
patient
includ
studi
includ
patient
sysucc
patient
scmc
patient
bch
cmu
nine
patient
chcmu
median
age
year
old
year
old
male
femal
common
site
lower
limb
patholog
type
classifi
follow
infantil
fibrosarcoma
n
fs
n
dermatofibrosarcoma
n
scleros
epithelioid
fibrosarcoma
n
patient
treat
surgeri
alon
eighteen
patient
receiv
surgeri
combin
chemotherapi
two
patient
receiv
surgeri
combin
median
time
month
rate
total
patient
local
recurr
among
patient
treat
surgeri
alon
five
patient
receiv
surgeri
combin
chemotherapi
last
time
overal
surviv
rate
surviv
rate
patient
treat
surgeri
alon
combin
chemotherapi
respect
p
recurr
two
patient
receiv
surgeri
combin
conclus
children
adolesc
fs
treat
surgeri
alon
higher
local
recurr
rate
surgeri
combin
chemotherapi
help
reduc
local
recurr
rate
x
children
capit
medic
univers
nation
center
children
health
hematolog
oncolog
center
beij
china
backgroundobject
analys
relationship
toxic
chemotherapi
genom
dna
polymorph
children
rhabdomyosarcoma
rm
designmethod
retrospect
analysi
rm
children
admit
center
januari
decemb
patient
treat
base
vac
vincristin
doxorubicin
cyclophosphamid
vi
vincristin
irinotecan
standard
mr
analysi
clinic
featur
major
organ
function
relationship
toxic
drug
genom
dna
test
result
total
case
median
age
month
month
case
head
neck
case
urogenit
tract
case
limb
case
truncu
case
embryon
type
case
alveolar
case
case
case
case
detect
ga
gg
aa
type
gene
case
ct
case
tt
case
cc
type
gene
ga
type
case
gg
type
case
aa
type
case
ag
type
case
organ
function
primit
normal
case
grade
neutropenia
case
grade
patient
use
irinotecan
case
grade
neutropenia
patient
grade
toxic
drug
genom
dna
nt
statist
differ
conclus
studi
show
relationship
toxic
chemotherapi
genom
dna
polymorph
children
rm
need
studi
verifi
result
md
mathey
l
n
g
w
j
lopez
p
barriga
ab
p
de
juan
p
garrahan
hematolog
oncolog
capit
feder
argentina
de
juan
p
garrahan
patholog
capit
feder
argentina
de
juan
p
garrahan
dermatolog
capit
feder
argentina
de
sor
ludovica
oncolog
la
plata
argentina
backgroundobject
st
infant
heterogen
group
tumor
repres
overal
st
differ
mani
aspect
older
children
respect
histolog
biolog
behavior
prognosi
difficulti
manag
report
clinic
featur
outcom
patient
year
histolog
diagnosi
st
designmethod
retrospect
analyz
infant
st
admit
institut
januari
decemb
result
st
children
repres
total
st
admit
studi
period
common
symptom
tumor
nineteen
patient
present
symptom
neonat
period
time
birth
median
age
diagnosi
month
femalemal
histolog
rhabdomyosarcoma
infantil
fibrosarcoma
if
malign
rhabdoid
tumor
mrt
fibroblasticmyofibroblast
tumor
ewe
sarcoma
no
sarcoma
common
primari
site
trunk
extrem
follow
head
neck
genitourinari
respect
multipl
tumor
size
patient
eleven
patient
metastat
diseas
surgeri
treatment
patient
if
fibroblasticmyofibroblast
tumor
chemotherapi
administ
patient
dosag
accord
age
weight
wait
see
patient
fibroblasticmyofibroblast
tumor
mrt
nt
receiv
treatment
two
patient
receiv
radiotherapi
treatment
median
month
os
ef
respect
os
vs
ef
vs
vs
vs
rhabdomyosarcoma
if
fibrobasticmyofibroblast
tumor
respect
mrt
conclus
st
infant
repres
rare
heterogen
entiti
common
histolog
type
rm
fsi
rm
mrt
show
high
preval
unfavor
featur
may
impact
poor
outcom
fsi
excel
surviv
l
mendez
r
cardena
r
rodriguez
nacion
de
pediatria
pediatr
oncolog
mexico
citi
mexico
backgroundobject
accord
recent
review
case
soft
tissu
sarcoma
committe
children
oncolog
group
anaplasia
suggest
common
previous
report
may
impact
clinic
outcom
nonetheless
high
suspicion
anaplast
characterist
envolv
efficaci
therapi
prognosi
rare
repres
difficulti
consid
among
morpholog
criteria
intern
classif
rhabdomyosarcoma
designmethod
preval
anaplasia
focal
diffus
assess
among
group
eleg
patient
classifi
accord
de
intern
classif
rhabdomyosarcoma
criteria
treat
januari
decemb
evalu
morpholog
featur
histolog
subtyp
determin
clinic
correl
treatment
respons
surviv
result
sampl
patient
nation
institut
pediatr
instituto
nacion
de
diagnosi
rhabdomyosarcoma
anaplasia
analyz
median
age
diagnosi
year
anaplasia
common
patient
tumor
favor
site
embrion
histolog
commonli
seen
patient
stage
clinic
group
lll
diseas
regardless
distribut
focal
diffus
univari
analysi
presenc
anaplasia
signific
neg
impact
surviv
vs
year
surviv
vs
year
p
patient
embryon
rhabdomyosarcoma
effect
clearli
pronounc
children
intermedi
risk
diseas
impact
alveolar
rhabdomyosarcoma
conclus
preval
anaplasia
rhabdomyosarcoma
higher
previous
describ
may
prognost
signific
children
intermedi
risk
embryon
rhabdomyosarcoma
mikeskova
institut
children
diseas
depart
paediatr
haematholog
oncolog
bratislava
slovak
republ
institut
children
diseas
depart
paediatr
surgeri
bratislava
slovak
republ
institut
children
diseas
depart
radiolog
bratislava
slovak
republ
backgroundobject
soft
tissu
sarcoma
st
heterogen
group
tumor
slovak
republ
approxim
new
case
childhood
st
diagnos
per
year
children
treat
accord
epssg
strategi
one
three
slovak
center
pediatr
hematolog
oncolog
st
separ
two
basic
group
rhabdomyosarcoma
rm
nonrm
clinic
present
vari
depend
tumor
type
locat
object
studi
analyz
outcom
patient
st
singl
center
slovakia
designmethod
studi
retrospect
analysi
period
januari
januari
focus
treatment
strategi
accord
epssg
studi
criteria
event
free
ef
overal
surviv
os
cohort
consist
patient
st
group
rm
analyz
patient
age
median
year
group
consist
patient
age
median
year
result
common
histolog
type
embryon
rm
children
initi
children
rm
group
metastat
group
children
metastas
studi
year
ef
rm
resp
cohort
resp
os
conclus
multimod
therapeut
approach
mainstay
treatment
st
case
initi
metastat
diseas
ef
os
rapidli
descend
outcom
patient
smaller
center
crucial
part
intern
collabor
je
montoya
vasquez
c
ugaz
j
e
maradiegu
l
vasquez
nacion
de
enfermedad
lima
lima
peru
edgardo
rebagliati
martin
lima
lima
peru
backgroundobject
sarcoma
non
rhabdomyosarcoma
tumor
repres
pediatr
cancer
countri
receiv
patient
advanc
diseas
previou
studi
field
main
object
know
clinic
featur
group
patient
evalu
overal
surviv
designmethod
retrospect
descript
studi
infant
children
younger
year
sarcoma
non
rhabdomyosarma
diagnos
instituto
nacion
de
enfermedad
inen
januari
decemb
includ
sampl
size
patient
stata
use
statist
analysi
result
total
children
identifi
femal
male
median
age
year
rang
month
year
frequent
diagnosi
synovi
sarcoma
eight
sarcoma
locat
extrem
six
patient
lima
capit
studi
found
overal
surviv
year
five
patient
abandon
treatment
conclus
studi
found
overal
surviv
year
high
percentag
patient
complet
treatment
result
encourag
us
look
caus
treatment
abandon
evalu
surgic
manag
respons
chemotherapi
radiotherapi
use
l
morimoto
x
c
x
ss
j
c
california
berkeley
school
public
health
berkeley
usa
univers
school
public
health
new
usa
southern
california
keck
school
medicin
lo
angel
usa
backgroundobject
background
rhabdomyosarcoma
rm
common
soft
tissu
sarcoma
children
compris
embryon
erm
alveolar
arm
subtyp
posit
associ
observ
acceler
fetal
growth
risk
erm
arm
alter
growth
factor
igf
may
mediat
associ
use
candid
gene
mendelian
random
approach
evalu
role
genet
variat
igf
pediatr
rm
risk
designmethod
method
archiv
newborn
dri
blood
spot
caucasian
rm
case
diagnos
age
year
identifi
california
cancer
registri
genotyp
use
illumina
omniexpress
array
publicli
avail
control
genotyp
gener
array
match
case
base
genet
ancestri
genotyp
imput
base
haplotyp
refer
consortium
panel
gene
igfinsulin
pathway
select
gh
ghr
ghrh
in
insr
associ
rm
assess
use
minp
test
base
upon
permut
assess
role
circul
instrument
variabl
construct
use
genet
variant
result
associ
total
erm
associ
rarer
subtyp
arm
estim
circul
invers
associ
total
rm
risk
result
erm
arm
statist
signific
molar
ratio
unrel
risk
conclus
evid
code
protein
play
key
role
transmit
insulin
growth
factor
signal
intracellular
pathway
associ
rm
risk
caucasian
children
circul
invers
associ
rm
risk
result
paradox
current
hypothes
acceler
fetal
growth
rm
risk
separ
analys
underway
independ
set
rm
case
replic
find
nelson
j
c
h
r
nation
medic
center
center
cancer
blood
disord
district
columbia
usa
gener
hospit
depart
radiat
oncolog
boston
usa
sloan
ketter
cancer
center
depart
radiat
oncolog
new
york
usa
univers
medic
center
divis
pediatr
nashvil
usa
univers
medic
center
depart
radiat
oncolog
nashvil
usa
hopkin
school
medicin
depart
radiat
oncolog
molecular
radiat
scienc
baltimor
usa
backgroundobject
primari
site
impact
treatment
outcom
pediatr
rhabdomyosarcoma
rm
clinic
observ
children
nasal
ala
rm
frequent
local
recurr
region
nodal
failur
compar
favor
head
neck
site
may
indic
need
evalu
current
treatment
paradigm
subset
patient
designmethod
retrospect
identifi
pediatr
patient
rm
nasal
ala
buccalnas
region
nasal
caviti
primari
exclud
treat
septemb
februari
differ
pediatr
cancer
center
within
unit
state
primari
endpoint
local
control
lc
surviv
ff
overal
surviv
os
surviv
analysi
use
gener
surviv
curv
outcom
cox
regress
appli
model
hazard
event
occurr
bootstrap
method
result
median
age
diagnosi
year
major
alveolar
histolog
four
patient
region
nodal
diseas
patient
metastasi
diagnosi
surgeri
either
biopsi
alon
upfront
resect
delay
primari
excis
patient
receiv
intermedi
risk
chemotherapi
radiat
therapi
rt
rang
gy
primari
diseas
site
involv
lymph
node
present
mean
follow
year
twelv
patient
experienc
recurr
median
time
recurr
month
five
year
lc
rate
ff
os
recurr
significantli
associ
nodal
diseas
present
trend
toward
improv
outcom
higher
cyclophosphamid
dose
rt
dose
surgeri
type
appear
influenc
recurr
rate
conclus
experi
pediatr
rm
nasal
alar
region
fare
poorli
current
treatment
algorithm
risk
stratif
treatment
strategi
patient
consid
lb
peruzzo
g
w
j
lopez
ab
p
de
pediatria
juan
p
garrahan
hematolog
oncolog
bueno
air
argentina
de
pediatria
juan
p
garrahan
patholog
bueno
air
argentina
de
pediatria
juan
p
garrahan
dermatolog
bueno
air
argentina
backgroundobject
if
common
soft
tissu
sarcoma
non
rhabdomyosarcoma
children
year
local
aggress
high
curabl
rate
conserv
therapi
report
experi
institut
if
analyz
clinic
featur
respons
treatment
outcom
designmethod
retrospect
descript
studi
patient
histolog
diagnosi
if
treat
institut
januari
decemb
accord
epssgnonrm
protocol
result
median
age
diagnosi
month
malefemal
delay
onset
symptom
diagnosi
day
extrem
common
site
tumor
diamet
patient
if
misdiagnos
vascular
tumor
clinic
imag
find
patient
patient
metastat
diseas
lung
molecular
techniqu
perform
case
fish
andor
posit
patient
initi
surgeri
perform
patient
stage
ir
ir
ii
remain
patient
receiv
chemotherapi
vincristineactinomycin
va
patient
progress
diseas
surgeri
receiv
va
delay
surgeri
could
perform
patient
ir
ii
ir
iii
rate
respons
chemotherapi
good
partial
responseparti
respons
stabl
diseas
common
toxic
hematolog
febril
neutropenia
observ
median
follow
month
patient
except
metastat
one
aliv
overal
surviv
vs
event
free
surviv
seri
respect
conclus
if
often
challeng
problem
due
similar
vascular
tumor
although
fsi
local
aggress
high
rate
overal
surviv
similar
seri
due
good
respons
chemotherapi
va
surgeri
even
involv
margin
atma
rahman
sf
csh
cy
pediatr
hematolog
oncolog
dhaka
bangladesh
dental
colleg
hospit
emerg
dhaka
bangladesh
dermatolog
venereolog
dhaka
bangladesh
backgroundobject
evalu
clinic
characterist
treatment
outcom
children
rhabdomyosarcoma
among
seri
children
bsmmu
hospit
emphasi
age
gender
clinic
present
site
histolog
subtyp
tnm
stage
treatment
modal
surviv
designmethod
retrospect
studi
carri
analyz
medic
record
patient
rhabdomyosarcoma
bsmmu
tumor
registri
medic
record
children
rhabdomyosarcoma
review
period
year
june
may
result
male
femal
f
ratio
age
diagnosi
rang
month
year
case
present
mass
vari
site
primari
site
diseas
head
neck
follow
pelvi
frequent
histolog
subtyp
embryon
rhabdomyosarcoma
follow
alveolar
rhabdomyosarcoma
botryoid
type
spindl
cell
type
unspecifi
time
diagnosi
patient
tnm
stage
next
frequenc
stage
iv
patient
receiv
multimod
therapi
radiotherapi
chemotherapi
surgeri
overal
surviv
rate
stage
iii
stage
iv
signific
relationship
overal
surviv
stage
diseas
conclus
data
regard
clinic
characterist
histolog
stage
rhabdomyosarcoma
bsmmu
hospit
similar
data
worldwid
countri
major
present
advanc
stage
diseas
sensit
multimod
therapi
poor
surviv
rate
correl
advanc
stage
diseas
ramanathan
v
kc
n
n
g
memori
centr
pediatr
oncolog
mumbai
india
memori
centr
patholog
mumbai
india
memori
centr
radiodiagnosi
mumbai
india
memori
centr
surgic
oncolog
mumbai
india
memori
centr
radiat
oncolog
mumbai
india
memori
centr
palli
care
mumbai
india
backgroundobject
factor
influenc
outcom
rhabdomyosarcoma
rm
develop
countri
evolv
clinic
characterist
molecular
profil
prognost
data
outcom
develop
countri
scarc
analysi
pediatr
rm
treat
multimod
regimen
base
chemotherapi
compris
vincrisitin
ifosfamid
etoposid
vie
vincristin
cyclophosphamid
vac
designmethod
retrospect
studi
children
histopatholog
proven
rm
treat
jan
dec
year
patient
receiv
chemotherapi
vie
vac
definit
therapi
form
radiotherapi
surgeri
result
total
patient
diagnos
rm
took
treatment
hospit
amongst
rest
palliat
children
abandon
treatment
patient
refer
outsid
median
age
analyz
cohort
year
boy
girl
ratio
embryon
alveolar
variant
seen
patient
respect
inconclus
patient
molecular
studi
done
patient
show
posit
diseas
patient
posit
patient
low
lr
intermedi
ir
high
risk
hr
tumor
seen
patient
respect
seventeen
patient
progress
relaps
median
time
month
develop
second
cancer
mortal
due
treatment
relat
toxic
note
patient
median
month
os
pf
respect
low
risk
diseas
p
favor
site
p
emerg
good
prognost
variabl
univari
multivari
analysi
fusion
statu
histolog
variant
gender
bear
surviv
conclus
encourag
outcom
low
intermedi
risk
group
ask
decreas
therapi
avoid
toxic
death
lmic
molecular
studi
need
incorpor
frontlin
order
better
risk
stratifi
patient
n
roy
moulik
h
jc
fellow
children
young
peopl
royal
marsden
hospit
sutton
unit
kingdom
marsden
uk
children
young
peopl
unit
sutton
unit
kingdom
backgroundobject
paediatr
sarcoma
involv
peritoneum
patient
either
primari
site
diseas
metastat
involv
diagnosisrelaps
occasion
follow
surgic
tumour
spillag
optimum
manag
potenti
condit
clear
due
scarciti
report
data
retrospect
studi
present
experi
periton
rhabdomyosarcoma
rm
designmethod
electron
medic
record
patient
age
year
regist
unit
juli
june
diagnosi
rm
ascit
periton
involv
presentationrelaps
review
data
mode
present
imag
histopatholog
molecular
marker
treatment
receiv
outcom
record
result
nine
patient
median
age
year
male
femal
embryon
biphas
ascit
present
relaps
primari
seen
except
potenti
periton
involv
heterogen
rang
small
volum
ascit
nodular
deposit
plaqu
cake
strand
peritoneum
two
patient
baselin
ascit
embryon
histolog
abdomin
tumour
document
periton
diseas
initi
treatment
compris
standard
system
chemotherapi
local
therapi
surgeri
radiotherapi
two
patient
diseas
free
year
treatment
rest
relapsedprogress
last
analysi
five
patient
progressiverelaps
diseas
die
median
month
relaps
despit
second
line
chemotherapi
long
term
survivor
one
small
volum
ascit
periton
diseas
baselin
histolog
near
complet
resect
residu
diseas
focuss
radiotherapi
conclus
periton
involv
seen
mostli
patient
primari
abdomin
rm
pattern
periton
involv
heterogen
overal
outcom
periton
diseas
dismal
howev
patient
histolog
undergo
adequ
local
therapi
surviv
long
term
r
shaikh
children
hospit
dana
farber
cancer
center
intervent
radiolog
boston
usa
backgroundobject
desmoid
tumor
highli
aggress
rare
musculoaponeurot
tumor
often
recur
treatment
convent
treatment
includ
surgic
resect
radiat
system
therapi
neoadjuv
radiat
without
chemotherapi
report
mean
local
failur
rate
radiat
alon
surgeri
alon
radiat
plu
surgeri
respect
report
mean
stabl
diseas
rate
cytotox
noncytotox
chemotherapi
respect
cryoablat
use
isol
adjuv
chemotherapyradiotherapi
larg
recalcitr
desmoid
promot
faster
tumor
necrosi
shrinkag
critic
structur
also
help
long
term
control
tumor
progress
present
experi
percutan
cryoablat
desmoid
tumor
object
show
safeti
efficaci
treatment
designmethod
eight
patient
year
mean
yr
ten
symptomat
recurr
resist
progress
desmoid
tumor
post
resect
chemotherapi
underw
percutan
imag
guid
cryoablat
septemb
march
desmoid
anatom
challeng
locat
patient
evalu
interdisciplinari
tumor
confer
refer
cryoablat
percutan
imag
guid
cryoablat
perform
use
argon
helium
gase
singl
stage
session
pre
procedur
follow
clinic
imag
evalu
done
assess
outcom
result
follow
cryoablat
signific
improv
symptom
tumor
size
regress
follow
year
technic
success
tumor
shrinkag
seen
tumor
major
complic
conclus
percutan
cryoablat
local
control
resist
desmoid
safe
effect
modal
consid
primari
adjuv
manag
desmoid
tumor
j
shin
w
jhc
univers
medic
center
radiat
oncolog
chicago
usa
medicin
chicago
proton
center
radiat
oncolog
warrenvil
usa
univers
medic
center
radiat
oncolog
nashvil
usa
backgroundobject
object
studi
assess
efficaci
acut
toxic
proton
beam
radiotherapi
pbt
part
definit
manag
pediatr
patient
diagnos
soft
tissu
sarcoma
designmethod
identifi
pediatr
patient
treat
soft
tissu
sarcoma
endpoint
analyz
acut
toxic
surviv
pf
overal
surviv
os
acut
toxic
assess
accord
ctcae
data
analys
perform
use
spss
estim
use
analyz
os
rate
result
median
month
rhabdomyosarcoma
common
histolog
follow
ewe
sarcoma
patient
underw
primari
surgeri
patient
receiv
chemotherapi
common
proton
radiat
techniqu
use
uniform
scan
remain
patient
receiv
pencil
beam
scan
median
proton
radiat
prescript
cobalt
gray
equival
cgye
cgye
fraction
commonli
report
acut
toxic
grade
dermat
patient
four
patient
grade
dermat
one
patient
experienc
grade
nausea
grade
acut
toxic
includ
pain
patient
weight
loss
fatigu
nausea
patient
patient
aliv
without
local
failur
distant
diseas
last
correspond
os
local
control
rate
pf
rate
respect
conclus
proton
beam
therapi
pediatr
sarcoma
appear
effect
deliv
accept
acut
toxic
set
definit
adjuv
irradi
warrant
suehara
n
univers
orthoped
surgeri
tokyo
japan
cancer
univers
new
south
wale
pediatr
new
south
wale
australia
children
hospit
pediatr
adelaid
australia
children
hospit
pediatr
nagano
japan
ladi
children
hospit
pediatr
crumlin
iran
minnesota
medic
school
depart
minneapoli
mn
usa
inc
none
south
san
usa
univers
medic
oncolog
tokyo
japan
backgroundobject
trk
fusion
involv
gene
occur
broad
rang
malign
larotrectinib
first
select
trk
inhibitor
demonstr
overal
respons
rate
trk
fusion
solid
tumor
children
favor
safeti
profil
drilon
et
al
nejm
laetsch
et
al
lancet
oncolog
press
larotrectinib
provid
worldwid
accord
local
regul
via
expand
access
patient
trk
fusion
cancer
efficaci
safeti
result
pediatr
sarcoma
subset
experi
present
designmethod
pediatr
patient
trk
fusion
sarcoma
unabl
access
larotrectinib
clinic
trial
elig
patient
receiv
larotrectinib
oral
bid
max
continu
diseas
respons
assess
investig
surgeri
local
control
allow
investig
discret
result
feb
six
patient
infantil
fibrosarcoma
sarcoma
no
retroperiton
congenit
sarcoma
age
year
japan
australia
ireland
usa
enrol
four
patient
fusion
involv
fusion
involv
previou
therapi
includ
chemotherapi
surgeri
chemotherapi
surgeri
one
patient
one
patient
grade
nausea
grade
vomit
anoth
grade
increas
liver
transaminas
dose
modif
discontinu
due
advers
event
object
respons
rate
cr
pr
ongo
durat
treatment
rang
month
one
patient
underw
surgeri
neg
margin
surgeri
upon
signific
tumor
reduct
follow
month
treatment
conclus
set
larotrectinib
effect
safe
treatment
pediatr
patient
trk
fusion
sarcoma
prevent
disfigur
surgeri
sugiyama
n
n
c
cancer
center
hospit
depart
pediatr
oncolog
tokyo
japan
cancer
center
hospit
depart
pediatr
surgic
oncolog
tokyo
japan
cancer
center
hospit
depart
musculoskelet
oncolog
rehabilit
tokyo
japan
backgroundobject
prognosi
pediatr
relaps
solid
tumor
remain
poor
necessit
new
treatment
strategi
treat
pediatr
patient
relaps
solid
tumor
use
topotecan
ifosfamid
ti
therapi
topotecan
ifosfamid
everi
day
retrospect
analyz
treatment
outcom
advers
event
clarifi
efficaci
safeti
ti
therapi
designmethod
review
electron
medic
record
patient
receiv
ti
therapi
depart
pediatr
oncolog
nation
cancer
center
hospit
march
decemb
result
twenti
patient
male
femal
median
age
rang
year
receiv
ti
therapi
tumor
histolog
compris
ewe
sarcoma
famili
tumor
patient
rhabdomyosarcoma
patient
osteosarcoma
patient
retinoblastoma
patient
desmoplast
small
round
cell
tumor
patient
median
number
treatment
cours
patient
receiv
addit
therapi
includ
radiotherapi
surgeri
autolog
peripher
stem
cell
transplant
advers
event
ae
mainli
limit
hematolog
toxic
common
ae
includ
nausea
constip
aspart
aminotransferas
ast
increas
alanin
aminotransferas
alt
increas
proteinuria
grade
ae
infrequ
includ
febril
neutropenia
patient
elev
ast
patient
elev
alt
patient
proteinuria
patient
grade
ae
report
except
patient
evalu
lesion
patient
achiev
complet
partial
respons
within
four
cours
median
surviv
day
confid
interv
day
conclus
ti
therapi
effect
relaps
pediatr
solid
tumor
toler
heavili
treat
patient
although
frequent
achiev
complet
respons
particular
span
surviv
could
attain
treatment
thu
ti
therapi
use
relaps
pediatr
solid
tumor
tamura
n
k
children
hospit
depart
hematolog
oncolog
kobe
citi
japan
children
hospit
depart
diagnost
patholog
kobe
citi
japan
backgroundobject
prognosi
patient
metastat
ewe
sarcoma
dismal
therefor
clear
need
novel
therapeut
strategi
immun
checkpoint
inhibitor
becom
emerg
therapeut
strategi
variou
kind
cancer
howev
almost
data
regard
use
drug
ewe
sarcoma
express
may
surrog
marker
respons
immun
checkpoint
inhibitor
investig
express
pattern
ewe
sarcoma
immunohistochemistri
analysi
tumor
sampl
diagnosi
designmethod
immunohistochemistri
analysi
perform
pretherapeut
tumor
biopsi
newli
diagnos
patient
ewe
sarcoma
sarcoma
assess
stain
semiquantit
score
system
neg
weak
intermedi
high
use
result
express
detect
tumor
cell
sampl
ewe
sarcoma
express
detect
weakli
tumor
infiltr
lymphocyt
ewe
sarcoma
sarcoma
sampl
express
ewe
tumor
cell
either
strongli
intermedi
contrast
none
tumor
cell
express
two
patient
express
ewe
sarcoma
present
distant
metastas
contrast
patient
ewe
sarcoma
without
express
tumor
cell
present
distant
metastas
conclus
ewe
sarcoma
tumor
cell
usual
express
express
tumor
infiltr
lymphocyt
predomin
ewe
sarcoma
howev
strongli
express
subset
ewe
sarcoma
tumor
cell
contrast
sarcoma
tumor
cell
express
tugcu
z
ozkan
r
z
istanbul
faculti
medicin
pediatr
istanbul
turkey
istanbul
faculti
medicin
radiolog
istanbul
turkey
istanbul
faculti
medicin
plastic
reconstruct
surgeri
istanbul
turkey
backgroundobject
local
treatment
complex
vascular
anomali
often
difficult
recent
year
report
use
sirolimu
symptomat
case
surgic
local
sclerotherapi
appli
studi
aim
report
treatment
result
ten
patient
underw
sirolimu
treatment
designmethod
ten
patient
girl
treat
sirolimu
januari
februari
cystic
complex
lymphangiomat
malform
six
case
complex
venou
malform
four
case
median
age
diagnosi
year
year
lesion
locat
head
neck
trunck
patient
extrem
patient
case
diagnos
radiolog
clinic
evalu
ultrasonographi
mri
imag
perform
accord
lesion
locat
sirolimu
initi
case
growth
pain
lesion
birth
presenc
loss
function
case
suitabl
local
treatment
therapi
result
evalu
result
sirolimu
use
two
dose
per
day
month
accord
respons
treatment
case
evalu
monthli
clinic
respons
infect
lymphopenia
hyperlipidemia
interv
term
radiolog
respons
clinic
radiolog
complet
near
complet
respons
achiev
case
lymphangioma
howev
two
four
complex
venou
malform
case
minim
decreas
clinic
complaint
lesion
size
stabl
find
seen
case
signific
respons
obtain
sirolimu
well
toler
insignific
side
effect
conclus
sirolimu
found
effect
treatment
vascular
anomali
especi
lymphangioma
howev
determin
efficaci
treatment
venou
malform
good
lymphangioma
studi
larger
sampl
size
warrant
optimum
length
treatment
possibl
side
effect
evalu
longer
term
result
c
ugaz
olivar
j
montoya
j
garcia
l
vasquez
nacion
de
enfermedad
neoplasica
lima
lima
peru
nacion
edgardo
rebagliati
lima
lima
peru
backgroundobject
rhabdomyosarcoma
rm
infant
younger
year
repres
subset
patient
challeng
treatment
studi
report
singl
center
experi
nation
institut
neoplast
diseas
inen
designmethod
collect
retrospect
clinic
outcom
data
children
younger
year
diagnos
rm
result
patient
younger
year
definit
diagnosi
rm
includ
median
age
month
rang
femal
predomin
nineteen
patient
histolog
subtyp
patient
primari
locat
nine
patient
metastat
diseas
onset
median
month
surviv
ef
overal
surviv
os
rate
standard
error
se
standard
error
se
respect
metastat
diseas
signific
prognost
factor
os
ef
conclus
studi
confirm
rm
infant
dismal
prognosi
multicent
studi
encourag
analyz
prognosi
factor
patient
b
vaarwerk
r
w
de
h
r
davila
p
van
den
b
l
h
children
hospitalacadem
medic
centr
depart
paediatr
oncolog
amsterdam
netherland
medic
center
depart
oral
maxillofaci
surgeri
amsterdam
netherland
children
academ
medic
center
depart
paediatr
oncolog
amsterdam
netherland
medic
center
depart
radiolog
amsterdam
netherland
medic
center
depart
radiat
oncolog
amsterdam
netherland
medic
centr
utrecht
depart
radiat
oncolog
utrecht
netherland
medic
center
orbit
depart
ophthalmolog
amsterdam
netherland
netherland
cancer
institut
depart
head
neck
oncolog
surgeri
amsterdam
netherland
medic
center
depart
reconstruct
hand
surgeri
amsterdam
netherland
centr
paediatr
oncolog
solid
tumour
depart
amsterdam
netherland
backgroundobject
surviv
relaps
rhabdomyosarcoma
head
neck
area
hnrm
prior
extern
beam
radiotherapi
ebrt
poor
sinc
option
adequ
local
treatment
often
lack
studi
describ
experi
salvag
amor
patient
relaps
hnrm
prior
ebrt
designmethod
patient
relaps
hnrm
prior
ebrt
salvag
amor
treatment
consid
feasibl
analys
includ
patient
paramening
head
neck
orbit
localis
amor
treatment
consist
abl
surgeri
mould
techniqu
brachytherapi
surgic
reconstruct
result
total
patient
receiv
salvag
amor
treatment
nine
patient
relaps
paramening
pm
rm
two
patient
relaps
head
neck
rm
seven
patient
relaps
orbit
rm
local
control
rate
overal
surviv
confid
interv
patient
pm
rm
patient
rm
patient
orbit
rm
aliv
median
year
one
patient
pm
rm
surviv
year
die
secondari
cancer
six
patient
develop
local
relaps
one
patient
also
develop
distant
metastasi
two
patient
develop
distant
metastas
report
advers
event
surviv
patient
pm
locat
tumour
musculoskelet
deform
growth
hormon
defici
report
advers
event
surviv
patient
orbit
locat
tumour
musculoskelet
deform
caus
orbit
exenter
conclus
salvag
amor
treatment
safe
effect
local
therapi
approach
even
prior
ebrt
sinc
salvag
amor
treatment
sometim
cur
option
patient
relaps
hnrm
encourag
physician
consid
salvag
amor
treatment
patient
relaps
hnrm
prior
ebrt
vela
p
j
l
pm
la
paz
institut
health
research
idipaz
translat
research
pediatr
hematopoiet
transplant
cell
therapi
madrid
spain
paz
univers
hopsit
pediatr
unit
madrid
spain
medic
molecular
genet
la
paz
univers
hopsit
molecular
pediatr
oncolog
unit
madrid
spain
nation
cancer
research
centr
cnio
hematolog
malign
clinic
research
unit
madrid
spain
backgroundobject
metastasi
occur
sarcoma
patient
remain
main
caus
death
propos
novel
immunotherapeut
approach
base
anti
antibodi
bristol
myer
squibb
combin
activ
expand
natur
killer
nkae
cell
therapi
upregul
sarcoma
signal
blockad
may
reduc
tumor
growth
metastat
burden
nkae
cell
shown
cytotox
osteosarcoma
ewe
sarcoma
designmethod
express
differ
sarcoma
cell
line
analyz
flow
cytometri
migrat
invas
capac
toward
test
use
transwel
plate
matrigel
nkae
cell
obtain
cocultur
healthi
donor
peripher
blood
mononuclear
cell
cell
rhabdomyosarcoma
cell
inocul
intraven
immunodefici
nsg
mice
gener
vivo
model
metastat
sarcoma
four
treatment
arm
establish
nkae
vehicl
luminisc
tumor
monitor
subsequ
micrometastasi
identifi
quantifi
immunohistochemistri
fluoresc
situ
hybrid
result
alveolar
rhabdomyosarcoma
cell
line
show
highest
express
concomit
highest
migrat
invas
index
nkae
effici
reduc
vitro
cell
migrat
invas
combin
agent
complet
abrog
vivo
assay
nkae
treatment
enough
complet
prevent
tumor
implant
nontheless
analysi
found
lung
micrometastasi
mice
group
combin
nkae
necessari
complet
elimin
immunohistochem
situ
hybrid
analysi
confirm
result
conclus
vitro
vivo
studi
show
complementari
role
anti
antibodi
nkae
cell
therapi
prevent
rhabdomyosarcoma
cell
migrat
invas
tumor
implant
lung
metastasi
format
preclin
result
constitut
first
evid
efficaci
combin
immunotherapi
prevent
sarcoma
diseas
dissemin
wang
j
l
l
hospit
jilin
univers
depart
pediatr
changchun
china
hospit
jilin
univers
depart
pediatr
oncolog
changchun
china
hospit
jilin
univers
depart
prdiatric
oncolog
changchun
china
hospit
jilin
univers
depatr
pediatr
ultrasound
changchun
china
backgroundobject
report
extern
irradi
combin
brachytherapi
femal
invas
maxillofaci
rhabdomyosarcoma
designmethod
femal
present
depart
complaint
swell
right
face
small
mass
note
right
cheek
open
mouth
restrict
appoxam
intraror
examin
reveal
small
mass
needl
biopsi
tumor
diagnos
spindl
cell
rhabdomyosarcoma
needl
biopsi
mass
enlarg
quickli
three
day
could
saw
huge
tumor
grow
outsid
mouth
gave
first
cycl
chemotherapi
vincristin
ifosfamid
etoposid
even
chemotherapi
tumor
continu
grow
gave
patient
intratumor
inject
carboplatin
first
week
intratumor
inject
mass
mouth
kept
grow
chemotherapi
region
switch
vincristin
topotecan
cyclophosphamid
second
cycl
chemotherapi
mass
mouth
came
patient
receiv
concurr
radiochemotherapi
dose
gross
target
volum
mri
show
mass
still
girl
receiv
brachytherapi
surgeri
girl
receiv
cycl
chemotherapi
eighth
chemotherapi
seriou
bleed
happen
suffac
tumor
mouth
open
mouth
restrict
symptomat
support
treament
patient
receiv
addit
chemotherapi
result
whole
treatment
procoss
took
scan
show
residu
fraction
tumor
inact
hard
girl
open
mouth
freeli
facial
skin
pigment
caus
radiat
therapi
increas
mental
burden
young
girl
conclus
consensu
radiotherapi
children
maxillofaci
rhabdomyosarcoma
although
patient
tumor
well
control
seriou
advers
reaction
associ
radiotherapi
pattern
dosag
radiotherapi
studi
x
x
yanli
hospit
affili
shanghai
jiao
tong
univers
school
medicin
depart
pediatr
hematologyoncolog
shanghai
china
backgroundobject
explor
effect
feasibl
multidisciplinari
treatment
mdt
base
protocol
analyz
prognost
factor
surviv
children
rhabdomyosarcoma
rm
designmethod
medic
record
patient
newli
diagnos
rm
year
old
xinhua
hospit
affil
shanghai
jiao
tong
univers
school
medicin
may
till
april
clinic
data
age
gender
primari
site
histolog
type
fusion
gene
tumor
size
lymph
node
involv
stage
postsurg
group
risk
pattern
treatment
accord
differ
year
retrospect
analyz
result
total
new
case
children
rm
treat
hospit
patient
exclud
analysi
abandon
treatment
diagnosi
henc
patient
complet
data
elig
studi
male
femal
ratio
median
age
diagnosi
month
median
time
month
year
year
respect
univari
analysi
show
patholog
subtyp
postop
clinic
group
treatment
pattern
significantli
associ
overal
surviv
multivari
analysi
show
postsurg
group
recurr
progress
diseas
treatment
pattern
independ
prognost
factor
case
develop
recurr
progress
diseas
median
relaps
progress
time
month
diagnosi
month
number
patient
relaps
progress
diseas
account
rate
signific
differ
conclus
main
caus
high
recurr
progress
diseas
lack
multidisciplinari
treatment
suggest
protocol
mdt
modal
could
effect
improv
prognosi
children
rm
h
yoshida
p
k
minnesota
depart
surgeri
minneapoli
usa
backgroundobject
oncolyt
adenoviru
oad
infect
replic
kill
target
cancer
cell
select
myog
one
muscl
differenti
marker
express
restrict
muscl
system
cell
previou
report
indic
activ
mutant
myog
promot
myogp
mutat
region
approxim
ten
time
compar
parent
without
mutat
therefor
develop
oad
attack
rm
cell
normal
cell
exploit
differ
myog
express
normal
rm
cell
also
develop
anoth
oad
attack
rm
specif
designmethod
two
rm
cell
line
posit
rd
neg
use
follow
experi
three
differ
length
myogp
myodp
myodp
myodp
l
clone
establish
evalu
length
myogp
power
specif
rm
subsequ
evalu
cell
kill
abil
also
made
virus
fulli
compet
oad
result
luciferas
assay
reveal
myogp
mutat
show
highest
activ
closest
wild
type
promot
wt
among
three
length
myogp
next
luciferas
assay
use
myogp
control
adv
show
higher
activ
rd
differ
wt
signific
base
result
made
evalu
kill
abil
need
time
high
viru
titer
cell
line
addit
need
time
high
viru
titer
kill
normal
differenti
muscl
cell
compar
rm
cell
differ
cell
kill
abil
wt
clear
rd
use
conclus
myogp
control
oad
specif
kill
rm
enhanc
specif
develop
viru
fiber
recogn
rm
specif
cell
surfac
antigen
sp
gt
sa
u
tg
w
j
c
pr
ja
hospit
muenster
depart
pediatr
hematolog
oncolog
muenster
germani
colleg
veterinari
medicin
baker
institut
anim
health
ithaca
usa
univers
depart
oncolog
pediatr
washington
usa
hospit
essen
west
german
cancer
pediatr
hematologyoncolog
essen
germani
research
group
pediatr
sarcoma
institut
patholog
germani
hospit
muenster
institut
patholog
muenster
germani
massachusett
medic
school
depart
biochemistri
molecular
pharmacolog
worcest
usa
backgroundobject
chromatin
modif
increasingli
recogn
key
mechan
cancer
ewe
sarcoma
es
driven
shown
mediat
global
gene
specif
epigenet
alter
es
biolog
peptidylarginin
deiminas
padi
enzym
catalyz
definit
structur
remodel
chromatin
call
citrullin
modul
gene
regul
hypercitrullin
occur
follow
padi
overexpress
cancer
discov
novel
gene
target
es
dissect
oncogen
role
potenti
therapeut
target
designmethod
use
differ
vitro
vivo
model
analyz
express
respons
oncogen
driver
studi
effect
downregul
via
shrna
es
cell
line
effect
pharmacolog
reduct
result
found
isoform
specif
overexpress
es
cell
line
confirm
es
patient
cohort
upregul
specif
found
es
clinic
sampl
compar
sarcoma
type
includ
sarcoma
harbor
differ
transloc
express
histon
citrullin
featur
es
patient
knockdown
via
shrna
decreas
express
vitro
vivo
use
probe
disrupt
interact
found
treatment
significantli
reduc
express
es
cell
line
vice
versa
reduct
es
cell
abrog
oncogen
phenotyp
aberr
express
andor
hypercitrullin
target
therapeut
es
significantli
induc
apoptosi
reduc
coloni
format
compar
cell
es
cell
line
vitro
conclus
increas
express
hypercitrullin
follow
hallmark
es
therapeut
abrog
citrullin
cytotox
es
warrant
valid
inhibitor
target
novel
epigenet
regul
es
deepli
understand
pathobiolog
ahmad
childrenhospit
institut
child
health
lahor
paediatr
haematologyoncolog
lahor
pakistan
children
hospit
institut
child
health
lahor
pakistan
paediatr
ophthalmolog
lahor
pakistan
backgroundobject
retinoblastoma
highli
curabl
develop
countri
outcom
still
dismal
pakistan
low
ocular
patient
surviv
rb
one
common
malign
paediatr
oncolog
develop
countri
object
studi
analyz
challeng
rx
abandon
enucl
refus
advanc
stage
face
manag
rb
public
sector
hospit
pakistan
designmethod
retrospect
review
patient
enrol
diagnosi
rb
januari
decemb
depart
paediatr
ophthalmolog
paediatr
oncolog
children
hospit
lahor
pakistan
data
analyz
use
spss
result
total
children
male
year
year
age
bilater
rb
present
unilater
trilater
two
case
optic
nerv
involv
brain
metastasi
neoadjuv
chemotherapi
given
enucl
done
chemotherapi
start
late
case
refus
enucl
default
treatment
cours
initi
therapi
local
therapi
radiotherapi
given
treatment
complet
case
outcom
default
rx
abscond
expir
relaps
put
conclus
retinoblastoma
one
challeng
childhood
cancer
manag
resourc
limit
set
immens
sociocultur
barrier
focu
improv
accept
famili
life
save
procedur
enucl
complianc
treatment
emphas
requir
strong
multidisciplinari
team
manag
intens
psychosoci
support
ap
alcasaba
jp
cl
c
c
j
p
philippin
philippin
gener
hospit
depart
pediatr
manila
philippin
philippin
philippin
gener
hospit
pediatr
manila
philippin
philippin
medic
center
pediatr
davao
philippin
jude
children
research
hospit
global
pediatr
medicin
memphi
usa
backgroundobject
retinoblastoma
program
systemat
develop
pediatr
cancer
unit
pcu
philippin
stage
base
treatment
protocol
implement
unilater
retinoblastoma
includ
upfront
enucl
identif
patholog
high
risk
featur
complet
stage
time
administr
chemotherapi
complianc
key
treatment
compon
measur
qualiti
healthcar
deliveri
report
protocol
adher
pcu
patient
surviv
outcom
designmethod
prospect
data
collect
retrospect
analysi
consecut
unilater
patient
januari
decemb
studi
march
result
total
patient
seen
mean
age
month
f
symptom
diagnosi
interv
month
median
distanc
patient
resid
treatment
center
km
forti
five
patient
underw
upfront
enucl
refus
treatment
chemotherapi
median
time
diagnosi
enucl
day
patholog
high
risk
featur
determin
patient
present
patient
receiv
upfront
enucl
five
patient
incomplet
stage
chemotherapi
start
median
day
enucl
patient
includ
without
high
risk
featur
sixteen
percent
chemotherapi
cycl
delay
studi
aliv
die
infect
refus
abandon
treatment
develop
new
tumor
contralater
eye
abandon
sensit
overal
event
free
surviv
conclus
systemat
evalu
develop
standard
measur
healthcar
deliveri
retinoblastoma
foster
patient
safeti
time
treatment
potenti
may
decreas
abandon
improv
surviv
especi
complex
clinic
scenario
requir
multidisciplinari
care
coordin
decis
make
b
baizakova
r
b
b
center
pediatr
pediatr
surgeri
oncolog
almati
kazakhstan
center
pediatr
pediatr
surgeri
radiolog
almati
kazakhstan
center
pediatr
pediatr
surgeri
patholog
almati
kazakhstan
center
pediatr
pediatr
surgeri
ophthalmolog
almati
kazakhstan
center
pediatr
pediatr
surgeri
intens
care
almati
kazakhstan
center
eye
diseas
pediatr
ophthalmolog
almati
kazakhstan
backgroundobject
retinoblastoma
frequent
intraocular
tumor
children
annual
case
treat
tertiari
cancer
center
kazakhstan
sinc
patient
retinoblastoma
around
countri
focus
one
center
reveal
patient
retinoblastoma
per
year
aim
studi
analyz
result
multidisciplinari
approach
treatment
retinoblastoma
designmethod
case
patient
treat
scientif
center
pediatr
pediatr
surgeri
analyz
data
includ
age
sex
durat
diagnosi
stage
result
therapi
patient
treat
accord
protocol
result
total
patient
eye
enrol
f
ratio
bilater
retinoblastoma
occur
case
averag
age
month
unilater
month
month
bilater
averag
time
onset
first
symptom
hospit
month
classif
accord
icrb
system
primari
enucl
perform
patient
secondari
enucl
includ
one
bilater
enucl
exenter
conduct
patient
histolog
classif
remov
eye
accord
irss
stage
ii
stage
iii
stage
forti
children
complet
treatment
mean
time
month
overal
surviv
rate
thirteen
patient
refus
treatment
differ
stage
therapi
continu
treatment
foreign
clinic
bilater
form
one
complet
reject
fatal
outcom
within
month
conclus
multidisciplinari
approach
focu
specialist
patient
one
center
made
possibl
improv
manag
retinoblastoma
reduc
mortal
limit
capac
local
therapi
main
reason
refus
treatment
cs
cho
j
dong
j
hyoung
k
jin
k
jeong
blind
farb
laboratori
clinic
research
seoul
nation
univers
hospit
seoul
republ
korea
ophthalmolog
seoul
nation
univers
colleg
medicin
seoul
republ
korea
backgroundobject
mani
patient
respond
initi
treatment
chemotherapi
patient
resist
chemotherapi
multidrug
resist
known
one
caus
purpos
studi
establish
carboplatin
resist
retinoblastoma
cell
line
studi
treatment
chemotherapi
retinoblastoma
designmethod
base
human
retinoblastoma
cell
line
establish
stepwis
method
resist
cell
carboplatin
induc
cell
death
valid
use
mtt
assay
dna
fragment
assay
immunocytochemistri
cleav
order
investig
mechan
carboplatin
resist
cell
express
multidrug
resist
gene
growth
curv
cell
cycl
distribut
cell
cycl
protein
express
observ
order
compar
therapeut
effect
carboplatin
intraocular
inject
perform
vivo
xenogen
anim
model
made
parent
resist
cell
result
resist
cell
line
develop
stepwis
increas
concentr
carboplatin
human
retinoblastoma
cell
line
cell
viabil
analysi
dna
fragment
cleav
express
assay
show
resist
carboplatin
increas
resist
cell
compar
parent
cell
addit
resist
cell
increas
express
multidrug
resist
relat
gene
compar
parent
cell
interestingli
growth
rate
resist
cell
slower
parent
cell
cell
cycl
distribut
show
increas
phase
resist
cell
express
level
cyclin
decreas
resist
cell
express
level
increas
confirm
resist
cell
form
vivo
intraocular
tumor
effect
even
intravitr
inject
carboplatin
parent
cell
conclus
studi
suggest
carboplatin
resist
retinoblastoma
cell
line
multidrug
resistanc
use
studi
chemotherapi
retinoblastoma
h
dimara
h
k
j
hospit
sick
children
ophthalmolog
vision
scienc
toronto
canada
texa
medic
branch
prevent
medicin
commun
health
galveston
usa
backgroundobject
explor
natur
type
partnership
within
one
retinoblastoma
world
http
network
designmethod
conduct
egocentr
social
network
analysi
identifi
preval
type
partnership
one
retinoblastoma
world
network
particip
complet
identifi
collabor
retinoblastoma
treatment
center
node
partner
alter
survey
collect
detail
interact
eg
patient
consult
joint
plan
resourc
share
durat
frequenc
natur
partnership
eg
formal
inform
network
map
gener
visual
connect
key
inform
particip
interview
provid
partnership
detail
result
network
member
submit
survey
respons
particip
rate
repres
contin
collect
identifi
alter
treatment
center
organ
outsid
network
north
american
european
node
identifi
alter
mean
respect
middl
eastern
north
african
node
identifi
fewest
mean
partnership
relat
patient
referr
oper
within
singl
geograph
region
four
research
network
identifi
node
act
central
hub
four
twin
network
identifi
dyad
central
hub
connect
node
key
inform
reveal
main
concept
definit
partnership
vari
main
motiv
behind
partnership
improv
patient
outcom
develop
strong
partnership
challeng
partnership
activ
limit
capac
partner
conclus
one
retinoblastoma
network
highli
connect
distinct
pattern
partnership
follow
region
line
except
partnership
activ
centr
retinoblastoma
referr
appear
mitig
local
resourc
capac
constraint
partnership
improv
avail
retinoblastoma
treatment
enhanc
surviv
monitor
evolut
network
time
may
reveal
key
influenc
capac
improv
surviv
h
hattori
n
n
k
k
hospit
organ
nagoya
medic
center
depart
clinic
genet
nagoya
japan
hospit
organ
nagoya
medic
center
depart
pediatr
nagoya
japan
hospit
organ
nagoya
medic
center
depart
ophthalmolog
nagoya
japan
cancer
center
hospit
depart
genet
medicin
servic
tokyo
japan
cancer
center
research
institut
oncogen
research
unitcanc
prevent
unit
utsunomiya
japan
backgroundobject
retinoblastoma
rb
repres
inherit
childhood
cancer
even
unilater
rb
exhibit
mutat
case
compar
bilater
rb
purpos
genet
test
unilater
rb
screen
high
risk
case
relaps
trilater
rb
andor
secondari
cancer
genet
test
clinic
practic
introduc
japan
sinc
health
insur
coverag
initi
designmethod
start
genet
test
rb
practic
principl
parent
whose
child
newli
diagnos
inform
genet
test
result
patient
receiv
genet
counsel
test
fourteen
analysi
complet
apr
pattern
mutat
includ
exon
skip
one
splice
alter
one
nonsens
mutat
germlin
mosaic
suggest
two
patient
inform
parent
whose
child
mutat
import
possibl
risk
secondari
cancer
continu
use
brain
mri
imag
ophthalmoscopi
mutat
posit
patient
frequenc
bilater
case
discontinu
mri
mutat
neg
patient
conclus
genet
test
provid
medic
benefit
enabl
us
higher
risk
patient
close
addit
genet
test
unilater
rb
perform
support
individu
diseas
manag
plan
also
consid
psycholog
impact
affect
famili
observ
need
elucid
impact
mosaic
andor
mutat
upon
relaps
trilater
rb
develop
secondari
cancer
h
hong
j
c
w
zhao
x
q
c
x
children
hospit
capit
medic
univers
nation
center
children
health
hematolog
oncolog
center
beij
china
children
hospit
capit
medic
univers
nation
center
children
health
depart
ophthalmolog
beij
china
children
hospit
capit
medic
univers
nation
center
children
health
depart
ophthalmolog
beij
china
backgroundobject
analyz
alter
blood
urea
nitrogen
bun
serum
creatinin
scr
children
retinoblastoma
rb
chemotherapi
clinic
signific
chemotherapi
effect
provid
refer
improv
safeti
treatment
designmethod
children
retinoblastoma
enrol
studi
treat
cev
carboplatin
etoposid
vincristin
method
combin
local
ophthalm
therapi
enucl
bun
scr
detect
initi
chemotherapi
last
chemotherapi
elig
eye
classifi
accord
intern
intraocular
retinoblastoma
classif
iirc
result
patient
includ
male
femal
mean
treatment
cycl
mean
age
month
case
clinic
diagnos
case
patholog
diagnos
case
extraocular
stage
case
glaucoma
case
intraocular
period
among
intraocular
rb
tumor
occur
unilater
children
bilater
children
bun
mmol
l
chemotherapi
mmol
l
chemotherapi
group
age
month
less
month
bun
chemotherapi
higher
group
chang
statist
differ
bun
valu
group
beyond
highest
refer
valu
initi
chemotherapi
patient
scr
refer
rang
case
bun
refer
valu
conclus
renal
function
rb
children
treatment
normal
percent
patient
bun
refer
rang
percent
scr
refer
rang
suggest
refer
valu
bun
scr
need
adjust
bun
infant
rb
increas
significantli
chemotherapi
met
current
diagnost
criteria
mild
nephrotox
still
earli
renal
damag
need
notic
jin
j
c
w
x
q
c
h
x
children
capit
medic
nation
center
children
health
hematolog
oncolog
center
beij
china
children
capit
medic
nation
center
children
health
depart
ophthalmolog
beij
china
backgroundobject
assess
multidisciplinari
approach
intraocular
retinoblastoma
rb
system
local
chemotherapi
evalu
preserv
eye
eye
sight
safeti
surviv
rate
designmethod
patient
intraocular
rb
eye
treat
beij
children
hospit
least
cours
chemotherapi
decemb
april
retrospect
review
patient
treat
carboplatin
vincristin
etoposid
vec
surviv
probabl
caus
death
toxic
measur
patient
follow
nov
result
male
femal
median
age
month
month
unilater
rb
bilater
rb
patient
eye
patient
advanc
intraoeular
diseas
enucl
time
present
enucl
recommend
eye
chemotherapi
group
group
e
bilater
patient
eye
eye
enucl
chemotherapi
group
group
e
group
c
patient
grade
hematolog
toxic
chemotherapi
case
receiv
pack
rbc
transfus
platelet
transfus
case
children
die
major
caus
death
central
nervou
system
relaps
median
time
month
month
overal
surviv
rate
includ
os
unilater
rb
os
bilater
rb
signific
differ
conclus
vec
chemotherapi
combin
local
therapi
intraocular
rb
safe
effect
intracrani
metastasi
still
major
caus
death
rb
longest
children
group
year
second
tumor
occur
dh
jo
e
jh
yg
jh
nation
univers
hospit
depart
ophthalmolog
seoul
republ
korea
nation
univers
hospit
depart
ophthalmologyfight
blind
farb
clinic
research
institut
seoul
republ
korea
univers
colleg
pharmaci
seongnam
republ
korea
backgroundobject
known
highli
express
retinoblastoma
tumor
previous
report
inhibit
could
treatment
option
retinoblastoma
via
cluster
studi
investig
therapeut
potenti
inhibitor
librari
differ
deriv
michael
acceptor
treatment
retinoblastoma
designmethod
cell
differ
retinoblastoma
cell
line
treat
inhibitor
librari
deriv
screen
cellular
toxic
level
phosphoryl
estim
immunosorb
assay
express
level
target
gene
measur
quantit
polymeras
chain
reaction
upon
treatment
inhibitor
librari
inhibitor
potent
inhibitor
select
aforement
assay
use
mous
orthotop
transplant
model
vivo
therapeut
efficaci
evalu
toxic
inhibitor
normal
retin
tissu
estim
histolog
evalu
termin
deoxynucleotidyl
transferas
dutp
nick
end
label
assay
result
differ
deriv
demonstr
differenti
cellular
toxic
phosphoryl
express
target
gene
potent
inhibitor
effect
inhibit
format
retinoblastoma
tumor
mous
orthotop
transplant
model
despit
therapeut
efficaci
inhibitor
significantli
affect
cellular
viabil
histolog
integr
retina
even
time
therapeut
concentr
conclus
novel
inhibitor
identifi
screen
librari
chemic
demonstr
potent
vitro
vivo
therapeut
efficaci
without
definit
toxic
normal
tissu
expect
inhibitor
util
treatment
retinoblastoma
dh
jo
hb
sj
jh
jh
nation
univers
hospit
depart
ophthalmolog
seoul
republ
korea
nation
univers
colleg
medicin
depart
medicin
seoul
republ
korea
nation
univers
hospit
fight
blind
farb
clinic
research
institut
seoul
republ
korea
toronto
faculti
art
scienc
toronto
canada
backgroundobject
retinoblastoma
common
intraocular
malign
tumor
children
mainli
relat
gene
mutat
lack
function
retinoblastoma
protein
link
uncontrol
growth
tumor
cell
address
function
consequ
gene
mutat
import
figur
mutat
spectrum
among
patient
retinoblastoma
studi
investig
mutat
spectrum
gene
patient
retinoblastoma
data
open
databas
designmethod
ncbi
pubm
databas
articl
identifi
use
search
word
retinoblastoma
mutat
februari
relev
paper
inform
gene
mutat
inform
obtain
regard
mutat
pattern
type
mutat
substitut
consequ
substitut
identifi
manual
verif
result
total
paper
identifi
use
search
word
retinoblastoma
mutat
substitut
chang
one
nucleotid
common
mutat
type
identifi
report
germlin
somat
mutat
also
identifi
transit
cytidin
thymidin
c
mutat
common
substitut
pattern
also
remark
nonsens
mutat
evid
report
germlin
somat
mutat
conclus
studi
success
identifi
mutat
spectrum
gene
patient
retinoblastoma
expect
data
help
us
investig
therapeut
approach
address
consequ
gene
mutat
treatment
retinoblastoma
kashyap
l
mk
b
india
institut
medic
scienc
ocular
patholog
new
delhi
india
india
institut
medic
scienc
ophthalmolog
new
delhi
india
india
institut
medic
scienc
medic
oncolog
new
delhi
india
backgroundobject
deregul
apoptot
pathway
lead
cancer
develop
prolifer
treatment
resist
protein
famili
play
key
role
control
apoptosi
initi
apoptot
pathway
noxa
puma
transcript
target
play
activ
role
apoptosi
aim
studi
evalu
express
puma
noxa
prognost
signific
human
retinoblastoma
rb
designmethod
prospect
analys
primari
enucl
retinoblastoma
specimen
imunohistochem
assess
puma
noxa
express
confirm
western
blot
also
perform
amplifi
gene
cytoplasm
stain
consid
posit
express
correl
clinic
paramet
tumor
differenti
histopatholog
high
risk
factor
like
massiv
choroid
invas
scleral
invas
optic
nerv
invas
etc
result
total
case
poorli
differentiatedretinoblastoma
necrosi
calcif
found
present
case
respect
eye
massiv
choroid
invas
retrolaminar
cut
end
optic
nerv
invas
iri
ciliari
bodi
invas
anterior
chamber
invas
express
puma
observ
case
express
casesand
noxa
posit
case
confirm
western
blot
techniqu
alon
significantli
correl
poor
tumor
differenti
similarli
puma
noxa
correl
tumor
differenti
variou
histopatholog
high
risk
factor
conclus
express
puma
noxa
may
regul
tumor
suppressor
protein
therefor
protein
may
use
futur
therapeut
target
combat
retinoblastoma
futur
investig
pathway
might
help
develop
biomark
manag
retinoblastoma
patient
b
r
kebudi
h
univers
oncolog
institut
cancer
genet
istanbul
turkey
univers
oncolog
institut
pediatr
hematolog
oncolog
istanbul
turkey
univers
istanbul
medic
faculti
ophthalmolog
istanbul
turkey
univers
cerrahpasa
medic
faculti
oncolog
institut
pediatr
hematolog
oncolog
istanbul
turkey
backgroundobject
retinoblastoma
malign
tumor
embryon
neural
retina
observ
young
children
mutat
gene
tumor
suppressor
gene
respons
case
retinoblastoma
howev
genet
chang
may
involv
studi
report
genet
chang
observ
infant
bilater
retinoblastoma
dysmorph
featur
development
delay
designmethod
peripher
blood
patient
parent
investig
small
indel
rearrang
gene
use
next
gener
sequenc
ng
multiplex
probe
amplif
mlpa
analysi
result
three
month
old
babi
boy
diagnos
bilater
retinoblastoma
icrb
right
group
b
left
group
born
second
child
healthi
unrel
parent
famili
histori
unremark
treat
six
cours
chemotherapi
vincristin
carboplatinum
local
ophtalm
treatment
high
broad
forehead
deepli
groov
philtrum
development
delay
thirteen
month
old
present
genet
analysi
reveal
complet
delet
gene
addit
gene
partial
delet
mutat
parent
mutat
child
bilater
retinoblastoma
de
novo
mutat
conclus
case
bilater
retinoblastoma
uniqu
genet
alter
three
gene
delet
may
respons
neurolog
phenotyp
gene
flank
gene
name
also
encod
candid
tumor
suppressor
addit
genet
alter
could
play
role
retinoblastoma
studi
fund
istanbul
univers
research
fund
grant
khan
p
khanum
memori
cancer
hospit
research
center
pediatr
oncolog
lahor
pakistan
backgroundobject
retinoblastoma
rb
one
common
malign
childhood
present
either
bilater
hereditari
form
presenc
gene
unilater
hereditari
review
conduct
determin
stage
diseas
children
present
retinoblastoma
type
local
control
offer
eye
salvag
set
designmethod
retrospect
audit
done
patient
present
shaukat
khanum
memori
cancer
hospit
septemb
septemb
retinoblastoma
receiv
local
therapi
diseas
salvag
well
chemotherapi
result
total
patient
chart
review
bilater
diseas
seen
patient
wherea
unilater
find
receiv
carboplatin
vincristin
etoposid
joe
chemotherapi
diagnosi
median
number
cycl
given
rang
major
patient
diseas
salvag
therapi
preserv
globe
attempt
patient
eleven
patient
treat
laser
therapi
topotecan
use
patient
four
patient
went
get
second
line
ifosphamid
vincristin
doxorubicin
ivad
chemotherapi
along
effort
local
salvag
five
patient
progress
despit
effort
local
salvag
rest
patient
still
observ
conclus
despit
system
chemotherapi
attempt
local
salvag
unsuccess
upfront
enucl
chemotherapi
featur
present
save
patient
prolong
cours
treatment
associ
anxieti
kulkarni
n
k
g
n
memori
hospit
radiodiagnosi
mumbai
india
memori
hospit
surgic
oncolog
mumbai
india
memori
hospit
medic
oncolog
pediatr
mumbai
india
backgroundobject
assess
safeti
efficaci
superselect
ophthalm
arteri
chemoinfus
soac
intraocular
retinoblastoma
designmethod
retrospect
analysi
eye
patient
intraocular
retinoblastoma
receiv
superselect
ophthalm
arteri
chemoinfus
either
melphalan
alon
melphalancarboplatin
melphalan
cycl
repeat
per
tumor
respons
investig
done
pre
post
procedur
cbc
coagul
profil
biochemistri
mri
evalu
anesthesia
electroretinogram
result
treat
eye
patient
separ
session
soac
twenti
eye
receiv
soac
primari
treatment
eye
receiv
soac
secondari
treatment
accord
intern
classif
retinoblastoma
icrb
eye
group
b
diseas
eye
group
c
diseas
eye
group
diseas
eye
group
e
diseas
technic
success
rate
catheter
success
session
mean
session
soac
per
eye
rang
session
per
eye
median
follow
period
month
rang
month
complet
respons
seen
eye
partial
respons
eye
progress
eye
stabl
diseas
eye
globe
surviv
month
month
stabl
upto
month
median
progress
free
surviv
month
major
complic
procedur
note
conclus
superselect
ophthalm
arteri
chemoinfus
intraocular
retinoblastoma
safe
effect
novel
techniqu
achiev
good
tumor
respons
offer
mean
salvag
globe
preserv
use
vision
patient
intraocular
retinoblastoma
offer
primari
well
secondari
treatment
even
advanc
retinoblastoma
persistentrecurr
diseas
system
chemotherapi
effect
k
w
pediatr
jagiellonian
univers
medic
colleg
depart
children
oncolog
hematolog
krakow
poland
backgroundobject
last
decad
magnific
progress
made
diagnosi
treatment
retinoblastoma
rb
lead
improv
surviv
rate
thu
rb
patient
surviv
diseas
live
adulthood
although
second
primari
tumor
extrem
rare
case
rb
patient
may
occur
month
year
primari
malign
diagnos
consid
lead
caus
death
patient
herit
rb
designmethod
report
case
boy
bilater
rb
develop
chronic
myeloid
leukemia
cml
month
treatment
rb
result
boy
diagnos
rbl
eye
age
month
patient
start
vec
chemotherapi
vincristin
etoposid
carboplatin
along
local
treatment
brachytherapi
photocoagul
cryoapplic
eye
partial
respons
observ
thu
enucl
left
eye
perform
two
cycl
vec
given
treatment
finish
patient
start
care
monitor
toward
relaps
side
effect
therapi
month
later
regular
follow
visit
complet
blood
count
reveal
white
blood
cell
count
platelet
count
physic
examin
patient
neither
hepato
splenomegali
lymphadenopathi
bone
marrow
examin
reveal
presenc
bcrabl
transloc
confirm
diagnosi
cml
child
receiv
therapi
hydroksyurea
imatinib
final
underw
stem
cell
transplant
form
unrel
donor
child
well
complet
remiss
leukemia
rb
one
left
eye
regress
stabl
preserv
vision
conclus
screen
second
primari
malign
import
part
pediatr
oncolog
patient
herit
retinoblastoma
screen
second
primari
malign
import
part
pediatr
oncolog
patient
herit
retinoblastoma
k
sah
children
hospit
kathmandu
nepal
backgroundobject
retinoblastoma
malign
tumor
embryon
neural
retina
common
intraocular
tumor
childhood
diseas
earli
childhood
case
diagnos
age
year
median
age
diagnosi
year
bilater
case
diagnos
earlier
median
month
unilater
median
age
month
incid
retinoblastoma
approxim
live
birth
develop
countri
aim
studi
clinic
patholog
featur
treatment
surviv
children
retinoblastoma
eighteen
year
designmethod
retrospect
hospit
base
studi
conduct
march
march
gender
age
clinic
present
patholog
report
treatment
follow
outcom
record
time
diagnosi
result
total
children
retinoblastoma
unilater
bilater
male
femal
ratio
children
came
rural
area
among
children
advanc
diseas
common
present
sign
extra
ocular
proptosi
leukoria
phthisi
bulbi
strabismu
age
present
rang
month
mean
age
month
male
femal
ratio
present
yr
follow
month
major
children
poorli
differenti
retinoblastoma
follow
well
differenti
moder
differenti
optic
nerv
involv
studi
cev
base
protocol
use
treat
enucl
yr
surviv
death
abandon
conclus
despit
sever
resourc
limit
pediatr
oncolog
unit
success
treat
retinoblastoma
success
rate
k
sah
children
hospit
kathmandu
nepal
backgroundobject
retinoblastoma
malign
tumor
embryon
neural
retina
common
intraocular
tumor
childhood
diseas
earli
childhood
case
diagnos
age
year
median
age
diagnosi
year
bilater
case
diagnos
earlier
median
month
unilater
median
age
month
incid
retinoblastoma
approxim
live
birth
develop
countri
aim
studi
clinic
patholog
featur
treatment
surviv
children
retinoblastoma
eighteen
year
designmethod
retrospect
hospit
base
studi
conduct
march
march
gender
age
clinic
present
patholog
report
treatment
follow
outcom
record
time
diagnosi
result
total
children
retinoblastoma
unilater
bilater
male
femal
ratio
children
came
rural
area
among
children
advanc
diseas
common
present
sign
extra
ocular
proptosi
leukoria
phthisi
bulbi
strabismu
age
present
rang
month
mean
age
month
present
yr
follow
month
major
children
poorli
differenti
retinoblastoma
follow
well
differenti
moder
differenti
optic
nerv
involv
studi
cev
base
protocol
use
treat
enucl
yr
surviv
death
abandon
conclus
despit
sever
resourc
limit
nepal
pediatr
oncolog
unit
success
treat
retinoblastoma
success
rate
c
sampor
v
r
j
g
de
pediatria
jp
garrahan
hematolog
oncolog
bueno
air
argentina
de
pediatra
jp
garrahan
bueno
air
argentina
bueno
air
argentina
patholog
servic
bueno
air
argentina
immunolog
servic
bueno
air
argentina
nation
univers
molecular
oncolog
laboratori
bueno
air
argentina
bueno
air
genet
molecular
biolog
bueno
air
argentina
backgroundobject
trilater
retinoblastoma
trb
rare
manifest
hereditari
retinoblastoma
present
intracrani
tumor
pineal
supraparasellar
region
consid
almost
invari
fatal
sinc
intracrani
tumor
seldom
time
resect
quickli
dissemin
current
risk
factor
predict
evolut
final
outcom
patient
aim
studi
evalu
minim
dissemin
md
bone
marrow
bm
cerebrospin
fluid
csf
diagnosi
review
potenti
impact
outcom
trb
patient
designmethod
retrospect
studi
includ
patient
trb
evalu
md
detect
homebox
mrna
crx
andor
immunocitolog
sampl
bm
csf
obtain
diagnosi
relaps
treatment
involv
system
chemotherapi
patient
accord
protocol
patient
moder
dose
chemotherapi
one
one
receiv
treatment
result
three
patient
receiv
high
dose
chemotherapi
two
underw
stem
cell
rescu
patient
receiv
treatment
die
progress
diseas
three
patient
leptomening
relaps
die
one
patient
remain
month
diagnosi
one
patient
tumor
cell
csf
none
bm
involv
one
case
four
present
md
csf
without
concomit
detect
bm
upon
leptomening
relaps
case
md
bm
conclus
presenc
md
csf
without
system
circul
involv
could
indic
forthcom
relaps
posit
tumor
dissemin
csf
conclud
death
patient
result
denot
import
aggress
chemotherapi
direct
csf
compart
ms
sedki
h
h
e
f
w
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
nation
cancer
institut
cairo
univers
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
nation
cancer
institut
cairo
univers
patholog
cairo
egypt
cancer
hospit
egypt
ophtalmolog
cairo
egypt
cancer
hospit
egypt
radiolog
cairo
egypt
cancer
hospit
egypt
cancer
hospit
menoufiah
univers
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
clinic
research
cairo
egypt
backgroundobject
extens
intraocular
unilater
non
germ
line
retinoblastoma
carri
higher
risk
local
recurr
metastasi
despit
upfront
enucl
high
risk
histopatholog
factor
adjuv
chemotherapi
suggest
prevent
treatment
failur
aim
assess
outcom
extens
intraocular
unilater
retinoblastoma
high
risk
histopatholog
featur
patient
receiv
adjuv
chemotherapi
designmethod
retrospect
analyz
newli
diagnos
non
germ
cell
unilater
retinoblastoma
patient
undergo
enucl
put
follow
without
adjuv
chemotherapi
patient
featur
invas
optic
disc
lamina
focal
choroid
independ
high
risk
featur
optic
nerv
posterior
lamina
cribrosa
massiv
choroid
invas
risk
featur
combin
receiv
adjuv
vincristin
etoposid
carboplatin
vec
chemotherapi
result
patient
mf
mean
age
month
underw
enucl
fifti
one
patient
lack
high
risk
featur
kept
follow
one
patient
focal
choroid
show
local
recurr
patient
high
risk
featur
massiv
choroid
invas
optic
nerv
invas
post
lamina
combin
receiv
adjuv
vec
one
focal
choroid
optic
disc
invas
lamina
show
metastasi
ciliari
bodi
invas
ruptur
globe
show
metastasi
die
year
overal
surviv
os
patient
without
high
risk
featur
receiv
adjuv
vec
respect
event
free
surviv
ef
respect
conclus
adjuv
chemotherapi
role
diseas
control
post
enucl
patient
high
risk
featur
prompt
histopatholog
examin
crucial
proper
stratif
sharma
u
j
tsk
n
r
departmemt
pediatr
chandigarh
india
depart
pediatr
chandigarh
india
depart
ophthalmolog
chandigarh
india
intern
technolog
india
bioinformat
bangalor
india
intern
technolog
bangalor
india
center
system
biolog
molecular
yenepoya
deem
mangalor
india
bioinformat
bangalor
india
departmemt
histopatholog
chandigarh
india
depart
immunopatholog
chandigarh
india
backgroundobject
microrna
mirna
increasingli
explor
therapeut
potenti
oncolog
limit
number
mirna
report
earlier
retinoblastoma
typic
util
microarray
polymeras
chain
reaction
pcr
report
mirnom
profil
retinoblastoma
tumor
tissu
use
next
gener
sequenc
ng
designmethod
set
univers
hospit
studi
durat
januari
decemb
tumor
tissu
obtain
patient
unilater
retinoblastoma
group
e
undergo
enucl
normal
retin
tissu
obtain
institut
eye
bank
rna
extract
qualiti
assess
determin
rna
integr
number
rin
use
bioanlayz
quantit
perform
use
fluoromet
librari
sampl
satisfactori
rna
criteria
gener
use
illumina
librari
prepar
kit
sequenc
illumina
miseq
platform
mirna
express
profil
estim
use
miseq
report
differenti
express
mirna
identifi
use
deseq
target
fetch
differenti
express
mirna
use
targetscan
diana
tool
pcr
perform
valid
express
target
gene
result
six
normal
retina
retinoblastoma
tissu
enrol
four
sampl
group
satisfi
recommend
criteria
rin
rna
concentr
sequenc
read
significantli
upregul
mirna
identifi
retinoblastoma
among
three
mirna
report
previous
retinoblastoma
target
analysi
reveal
put
mirna
target
hallmark
pathway
cancer
cell
signal
wnt
apoptosi
tumor
invas
cell
cycl
protein
express
select
target
gene
reveal
downregul
cyclin
e
corrobor
mirna
express
profil
conclus
report
upregul
novel
mirna
retinoblastoma
util
ng
platform
target
analysi
mirna
reveal
particip
oncogen
pathway
mirna
could
explor
therapeut
applic
patient
retinoblastoma
n
shirakawa
c
cancer
center
hospit
pediatr
oncolog
tokyo
japan
cancer
center
hospit
ophthalm
oncolog
tokyo
japan
backgroundobject
patient
advanc
unilater
retinoblastoma
often
requir
initi
enucl
diagnosi
conserv
manag
local
control
system
chemotherapi
aim
preserv
eye
optim
visual
function
retrospect
chart
review
aim
investig
efficaci
combin
system
chemotherapi
andor
local
ophthalm
treatment
unilater
retinoblastoma
use
avoid
enucl
extern
beam
radiat
therapi
ebrt
designmethod
review
electron
medic
record
newli
diagnos
patient
unilater
retinoblastoma
treat
nation
cancer
center
hospit
januari
decemb
defin
event
either
enucl
ebrt
analyz
surviv
ef
among
patient
result
examin
patient
median
age
rang
month
median
period
month
among
patient
receiv
initi
enucl
ebrt
patient
classifi
per
intern
classif
retinoblastoma
icrb
group
b
n
c
n
n
e
n
initi
treat
system
chemotherapi
andor
local
therapi
among
patient
subsequ
requir
enucl
requir
ebrt
ef
ci
ef
icrb
bc
icrb
de
ci
ci
p
respect
one
patient
group
die
central
nervou
system
invas
retinoblastoma
patient
experienc
second
malign
conclus
half
patient
treat
combin
system
chemotherapi
andor
local
ophthalm
treatment
initi
treatment
conserv
manag
safe
feasibl
strategi
unilater
patient
retinoblastoma
avoid
initi
enucl
mk
singh
l
n
j
ophthalm
india
institut
medic
scienc
ocular
patholog
new
delhi
india
millia
islamia
bioscienc
new
delhi
india
ophthalm
india
institut
medic
scienc
ophthalmolog
new
delhi
india
ophthalm
india
institut
medic
scienc
ocular
biochemistri
new
delhi
india
backgroundobject
high
mobil
group
box
form
protein
complex
regul
balanc
tumor
cell
death
surviv
play
role
suppress
promot
tumorigenesi
apoptosi
autophagi
contribut
resist
tumor
variou
therapi
interact
respons
dna
damag
promot
bind
damag
dna
therebi
provid
molecular
platform
subsequ
dna
repair
interact
protein
regul
tumorigenesi
tumor
invas
aim
studi
detect
protein
complex
retinoblastoma
patient
designmethod
immunohistochemistri
use
protein
complex
perform
formalin
fix
retinoblastoma
tissu
done
fresh
primari
enucl
retinoblastoma
sampl
immunoexpress
togeth
consid
protein
complex
call
immunoposit
express
protein
taken
posit
express
immunoneg
protein
taken
neg
express
result
correl
clinicopatholog
paramet
western
blot
perform
fresh
primari
enucl
retinoblastoma
sampl
confirm
immunohistochem
express
result
immunoexpress
protein
complex
found
retinoblastoma
case
immunoexpress
local
nucleu
normal
retina
wherea
cytoplasm
nuclear
express
seen
tumour
cell
transcript
level
complex
express
found
immunoexpress
complex
significantli
correl
poor
tumor
differenti
choroid
invas
optic
nerv
invas
correl
clinic
paramet
conclus
preliminari
data
suggest
protein
complex
may
contribut
tumorigenesi
retinoblastoma
translat
studi
requir
explor
natur
interact
cytoplasm
identifi
induc
progress
retinoblastoma
susanah
sadikin
gener
hospit
pediatr
bandung
indonesia
eye
hospit
pediatr
bandung
indonesia
eye
hospit
pediatr
ophthalmolog
bandung
indonesia
backgroundobject
retinoblastoma
common
intraocular
tumour
children
second
frequent
children
malign
indonesia
case
came
hospit
late
stage
calcif
ultrasound
histopatholog
find
tumour
mass
would
confirm
diagnosi
chemotherapi
delay
requir
histopatholog
result
aim
studi
standard
polici
indonesia
whether
bilater
retinoblastoma
nt
need
histopatholog
result
prior
chemotherapi
designmethod
retrospect
medic
record
children
retinoblastoma
child
health
depart
hasan
sadikin
hospit
cicendo
eye
hospit
bandung
indonesia
result
case
examin
case
exclud
uncomplet
medic
record
first
present
less
year
year
unilater
retinoblastoma
case
bilater
retinoblastoma
case
bilater
retinoblastoma
calcif
present
ultrasound
invas
histopatholog
case
case
calcif
ultrasound
without
invas
histopatholog
case
calcif
without
histopatholog
result
grade
patient
loss
follow
calcif
invas
case
calcif
refus
enucl
case
patient
perform
usg
histopatholog
show
case
calcif
ultrasound
histopatholog
eighti
six
case
unilater
retinoblastoma
perform
ultrasound
histopatholog
show
case
calcif
ultrasound
histopatholog
analysi
show
signific
correl
presenc
calcif
ultrasound
histopatholog
find
conclus
patient
bilater
retinoblastoma
chemotherapi
could
perform
soon
enucl
without
histopatholog
result
susanti
p
eye
hospit
pediatr
bandung
indonesia
sadikin
gener
hospit
pediatr
bandung
indonesia
eye
hospit
pediatr
ophthalmolog
bandung
indonesia
backgroundobject
primari
symptom
white
pupil
could
clinic
challeng
mani
ocular
condit
children
might
mimic
retinoblastoma
either
similar
primari
sign
like
white
pupil
similar
physic
examin
child
present
white
pupil
consid
retinoblastoma
unless
proven
otherwis
less
common
type
present
occur
includ
red
squint
extrud
eye
decreas
visual
acuiti
pain
orbit
cellul
howev
consid
differenti
diagnosi
coat
diseas
congenit
cataract
retinopathi
prematur
toxocariasi
toxoplasmosi
choroid
coloboma
tuberculosi
uveiti
anterior
vitreou
hemorrhag
retin
capillari
hemangioma
medulloepithelioma
intracerebr
tumor
aim
studi
distinguish
diagnosi
white
pupil
children
whether
retinoblastoma
designmethod
retrospect
medic
record
children
work
diagnosi
retinoblastoma
cicendo
eye
hospit
bandung
indonesia
result
case
examin
work
diagnosi
retinoblastoma
case
exclud
uncomplet
medic
record
case
histori
take
physic
examin
imag
techniqu
like
ultrasound
comput
tomographi
scan
magnet
reson
imag
case
retinoblastoma
consist
case
unilater
retinoblastoma
case
bilater
retinoblastoma
thirteen
case
retinoblastoma
although
sign
symptom
mimick
retinoblastoma
consist
boy
girl
case
exud
retin
ablat
case
persist
hyperplast
primari
vitreou
case
coat
diseas
case
group
endogen
endophtalm
retinopathi
prematur
coloboma
glioma
acut
lymphoblast
leukemia
adult
orbit
xantogranuloma
conclus
patient
white
pupil
care
histori
take
includ
famili
histori
physic
examin
perform
imag
techniqu
critic
proper
diagnosi
f
tarrillo
edgardo
rebagliati
martin
pediatr
oncolog
lima
peru
backgroundobject
retinoblastoma
rb
frequent
primari
intraocular
tumor
children
previou
studi
countri
lmic
suggest
delay
present
treatment
abandon
associ
higher
rate
extraocular
spread
metastasi
studi
aim
determin
effect
diagnost
treatment
delay
abandon
children
diagnos
rb
peru
designmethod
retrospect
analyz
data
medic
record
children
diagnos
rb
rebagliati
hospit
clinic
characterist
time
diagnosi
td
defin
length
time
notic
first
symptom
diagnosi
time
treatment
tt
defin
length
time
diagnosi
treatment
abandon
treatment
txab
overal
os
surviv
ef
result
total
children
diagnos
rb
includ
case
unilater
bilater
median
td
week
unilater
bilater
rb
respect
diagnosi
median
tt
week
rang
accord
intern
rb
stage
system
present
least
e
eye
txab
occur
children
os
unilater
bilater
rb
respect
ef
unilater
bilater
rb
respect
td
longer
week
associ
higher
rate
extraocular
diseas
death
rate
tt
longer
week
significantli
higher
patient
extraocular
diseas
multivari
analys
txab
metastasi
hr
independ
factor
wors
os
similarli
txab
extraocular
diseas
independ
factor
wors
ef
median
time
month
conclus
peru
surviv
rate
children
rb
gener
similar
surviv
rate
lmic
delay
diagnosi
txab
rate
high
significantli
affect
outcom
tashvighi
aa
hedayati
h
n
v
fallah
hematolog
oncolog
research
center
shahid
beheshti
univers
medic
scienc
tehran
iran
backgroundobject
children
diagnos
retinoblastoma
earli
stage
life
risk
bilater
tumor
advanc
diseas
aim
studi
evalu
epidemiolog
characterist
clinic
featur
retinoblastoma
infant
less
month
age
mahak
pediatr
cancer
treatment
research
center
mpctrc
iran
designmethod
retrospect
studi
infant
age
month
diagnos
retinoblastoma
mpctrc
may
may
epidemiolog
characterist
analyz
use
spss
softwar
version
surviv
analys
patient
perform
use
test
result
eye
infant
includ
studi
femal
frequenc
bilater
tumor
famili
histori
cancer
found
among
children
retinoblastoma
first
degre
rel
patern
retinoblastoma
consanguin
marriag
defin
parent
mean
age
diagnosi
day
frequent
symptom
leukocoria
almost
eye
intern
classif
retinoblastoma
group
e
enucl
perform
patient
two
patient
eye
enucl
often
use
protocol
system
chemoreduct
vincristin
etoposid
carboplatin
vec
vec
bilater
retinoblastoma
associ
lower
overal
surviv
compar
unilater
vs
overal
surviv
three
year
enucl
free
surviv
rate
bilater
unilater
tumor
one
patient
second
malign
osteosarcoma
age
year
four
patient
die
due
complic
therapi
metastasi
conclus
sinc
challeng
treatment
retinoblastoma
infant
less
month
multicent
studi
nation
registri
retinoblastoma
requir
improv
diagnosi
treatment
diseas
v
thavaraj
council
medic
research
child
health
new
delhi
india
backgroundobject
nation
retinoblastoma
registri
set
india
designmethod
new
case
retinoblastoma
center
india
use
common
core
proforma
along
sop
data
enter
excel
sheet
internalextern
qualiti
control
done
duplic
remov
stata
use
analyz
data
surviv
analysi
done
use
kaplan
meier
curv
result
confirm
case
enrol
registri
jan
march
total
case
patient
remov
diagnosi
entrynon
analyt
median
age
month
boy
girl
enrol
studi
first
sign
notic
leucocoria
famili
histori
retinoblastoma
seen
case
case
retinoblastoma
occur
year
seer
data
year
case
occur
year
seer
data
unilater
retinoblastoma
seen
case
bilater
case
less
year
old
bilater
seen
unilater
trilater
retinoblastoma
convert
uni
bilater
diseas
seer
data
bilater
diseas
iirc
group
show
case
group
e
total
intraocular
eye
extraocular
chantada
stage
data
case
multi
modal
treatment
discuss
median
follow
month
median
surviv
time
reach
overal
diseas
free
surviv
studi
done
respect
age
sex
stage
extra
ocular
statu
risk
patholog
later
type
therapi
conclus
surviv
case
rb
enrol
rb
registri
india
report
ushakova
e
b
v
pediatr
oncolog
hematolog
n
n
blokhin
scienc
medic
research
center
oncolog
head
neck
tumor
moscow
russia
medic
academi
postgradu
educ
pediatr
oncolog
moscow
russia
clinic
experiment
radiolog
n
n
blokhin
scienc
medic
research
center
oncolog
intervent
radiolog
moscow
russia
pediatr
oncolog
hematolog
n
n
blokhin
scienc
medic
research
center
oncolog
scientif
advisori
outpati
moscow
russia
fyodorov
eye
microsurgeri
feder
state
institut
eye
oncolog
moscow
russia
helmholtz
research
institut
eye
diseas
eye
oncolog
moscow
russia
backgroundobject
aim
improv
treatment
result
children
retinoblastoma
rb
select
iac
intravitr
ivic
chemotherapi
designmethod
research
includ
treatment
result
children
eye
retinoblastoma
n
n
blokhin
scienc
medic
research
center
oncolog
patientsey
divid
group
first
group
includ
eye
carri
due
insuffici
effici
earlier
treatment
rb
refractori
form
eye
accord
multicent
protocol
retinoblastoma
c
group
treatment
eye
second
group
includ
eye
local
chemotherapi
first
line
treatment
result
patient
aliv
caus
death
one
case
acut
leukemia
second
metastasi
connect
parent
refus
observ
one
patient
eye
first
group
eye
lost
studi
first
group
eye
retain
salvag
eye
reach
year
year
year
year
year
patient
follow
month
one
patient
lost
studi
group
primari
local
chemotherapi
group
primari
local
chemotherapi
eye
retain
paitient
salvag
eye
reach
year
patient
follow
month
conclus
local
chemotherapi
effect
perspect
method
use
complex
therapi
part
advanc
refractori
rb
form
primari
therapi
identifi
rb
wang
tongren
capit
medic
univers
pediatr
beij
china
backgroundobject
investig
relationship
radiograph
enhanc
enhanc
rb
postop
patholog
prognosi
evalu
diagnost
valu
imag
clinic
guid
valu
patholog
grade
designmethod
preoper
mri
examin
eyelid
perform
record
whether
optic
nerv
thicken
andor
intensifi
postop
optic
nerv
invas
divid
group
invad
optic
disc
invas
septum
plate
infring
posterior
optic
nerv
ethmoid
plate
infring
optic
nerv
stenosi
treatment
accord
patholog
result
treat
accordingli
analysi
correl
radiograph
find
postop
patholog
find
prognosi
result
clinic
data
characterist
male
femal
male
femal
ratio
eye
eye
eye
monocular
eye
ratio
eye
eye
clinic
stage
eye
ac
phase
eye
phase
eye
e
phase
case
extraocular
phase
addit
surgeri
chemotherapi
combin
local
treatment
intramuscular
inject
radiotherapi
comprehens
treatment
imag
characterist
analysi
postop
patholog
grade
grade
case
account
ii
case
case
account
grade
iii
case
account
iv
grade
case
account
cumul
surviv
rate
overal
surviv
rate
cox
regress
surviv
analysi
suggest
degre
optic
nerv
involv
patholog
grade
risk
factor
affect
surviv
time
degre
optic
nerv
invas
differ
imag
differ
surviv
rate
among
group
conclus
degre
tumor
involv
orbit
mri
posit
correl
patholog
grade
n
zia
indu
hospit
depart
pa
hematolog
oncolog
karachi
pakistan
backgroundobject
retinoblastoma
neoplasm
eye
childhood
repres
neoplasm
develop
countri
may
compris
diagnos
paediatr
cancer
hospit
base
retrospect
studi
two
third
diagnos
year
year
age
analyz
clinic
featur
outcom
children
retinoblastoma
highlight
area
improv
requir
designmethod
medic
record
patient
diagnos
retinoblastoma
region
center
retrospect
chart
review
june
juli
irb
approv
result
total
patient
chart
review
male
patient
seen
femal
n
patient
diagnos
age
year
posit
famili
histori
observ
patient
total
number
bilater
diseas
trilater
unilater
diseas
patient
present
upfront
enucl
patient
stage
iv
metastat
diseas
median
age
present
bilater
diseas
unilater
diseas
patient
activ
treatment
palliat
left
treatment
patient
activ
treatment
surviv
conclus
signific
percentag
present
advanc
metastat
diseas
lead
poor
outcom
signific
number
present
enucl
recurr
centr
referr
pead
oncologist
need
awar
among
ophthalmologist
rate
abandon
higher
due
poor
low
literaci
rate
fals
myth
limit
peadiatr
oncolog
treatment
centr
pakistan
also
need
educ
histopathologist
report
retinoblastoma
accord
standard
guidelin
may
miss
intermedi
high
risk
histopatholog
featur
limit
expertis
local
control
modal
due
unabl
salvag
advanc
group
eye
retinoblastoma
aguiar
f
g
r
cm
lima
da
caminada
de
v
c
camargo
cancer
center
molecular
oncolog
sao
paulo
brazil
sao
paulo
genet
sao
paulo
brazil
camargo
cancer
center
pediatr
sao
paulo
brazil
camargo
cancer
center
cipe
sao
paulo
brazil
camargo
cancer
center
patholog
sao
paulo
brazil
oncolog
pediatr
sao
paulo
brazil
oncolog
pediatr
sao
paulo
brazil
backgroundobject
hepatoblastoma
hb
embryon
tumor
liver
histolog
featur
resembl
differ
stage
liver
differenti
identif
molecular
pathway
involv
hb
develop
expand
understand
connect
disrupt
normal
differenti
cancer
designmethod
exom
sequenc
agil
sureselect
target
enrich
analysi
perform
hepatoblastoma
match
non
tumor
liver
tissu
fresh
frozen
tissu
bioinformat
analysi
use
varseq
softwar
golden
helix
inc
bozeman
montana
us
exom
data
identifi
somat
variant
gene
chosen
valid
use
target
sequenc
panel
sureselectxt
target
enrich
system
illumina
sequenc
librari
group
hb
case
result
total
somat
rare
code
mutat
missens
valid
consid
entir
hb
group
somat
analysi
reveal
pathogen
mutat
gene
recurr
missens
mutat
gene
role
mutat
explor
ihq
studi
protein
well
gene
express
analysi
also
use
result
illumina
evalu
methyl
level
gene
conclus
investig
hb
carri
pathogen
genet
mutat
observ
low
frequenc
somat
mutat
result
similar
previou
studi
propos
explan
base
fact
pediatr
tumor
would
origin
precursor
cell
pluripot
characterist
therefor
tumor
may
requir
fewer
mutat
adult
solid
tumor
develop
congenit
hb
case
cohort
discrep
scenario
sinc
rel
high
number
mutat
found
compar
hb
group
knowledg
first
comprehens
genom
character
brazilian
hb
next
step
includ
expand
casuistri
exom
sequenc
tumor
includ
two
case
hb
associ
hirschprung
diseas
g
algazieva
k
b
g
e
u
center
pediatr
pediatr
surgeri
oncolog
almati
kazakhstan
center
pediatr
pediatr
surgeri
surgeri
almati
kazakhstan
center
pediatr
pediatr
surgeri
radilog
almati
kazakhstan
center
pediatr
pediatr
surgeri
patholog
almati
kazakhstan
center
pediatr
pediatr
surgeri
intens
care
almati
kazakhstan
backgroundobject
everi
year
primari
patient
hepatoblastoma
detect
republ
kazakhstan
structur
malign
tumor
childhood
goal
studi
analyz
outcom
hepatoblastoma
treatment
designmethod
retrospect
review
patient
hepatoblastoma
enrol
februari
decemb
done
data
regard
patient
age
sex
stage
treatment
cours
surgic
treatment
outcom
treatment
given
accord
siopel
protocol
result
total
number
patient
averag
age
month
f
ratio
stage
accord
pretext
system
stage
ii
stage
iii
stage
iv
initi
averag
tumor
volum
initi
mean
level
alpha
fetoprotein
ng
ml
treatment
patient
die
neoadjuv
therapi
given
case
includ
combin
adriamycin
cisplatin
cycl
case
monotherapi
cisplatin
receiv
patient
partial
regress
observ
case
progress
chemotherapi
report
patient
case
patient
refus
surgic
treatment
control
volum
tumor
decreas
amount
oper
treatment
patient
hemihepatectomi
left
hemihepatectomi
atyp
liver
resect
extend
left
extend
hemihepatectomi
earli
postop
mortal
occur
patient
adjuv
chemotherapi
perform
patient
overal
surviv
rate
median
month
conclus
neoadjuv
therapi
lead
partial
tumor
regress
patient
turn
improv
result
surgic
treatment
prognosi
howev
risk
fatal
complic
associ
oper
remain
high
l
b
j
l
c
g
ja
f
p
c
armengol
scienc
research
institut
german
tria
pujol
igtp
childhood
liver
oncolog
group
badalona
spain
dinvestigacion
august
pi
sunyer
hospit
univers
barcelona
liver
unit
barcelona
spain
vall
dhebron
patholog
depart
barcelona
spain
hospit
la
paz
patholog
depart
madrid
spain
hospit
la
paz
pediatr
oncolog
depart
madrid
spain
vall
dhebron
pediatr
oncolog
depart
barcelona
spain
vall
dhebron
pediatr
surgeri
depart
barcelona
spain
hospit
la
paz
pediatr
surgeri
depart
madrid
spain
hospit
reina
pediatr
oncolog
depart
spain
institut
oncolog
ico
translat
research
laboratori
bellvitg
spain
hepat
digest
diseas
barcelona
spain
backgroundobject
precis
medicin
decad
establish
model
rare
diseas
childhood
cancer
necessari
tool
assess
new
drug
base
molecular
character
aim
develop
new
model
hepatoblastoma
hb
main
childhood
liver
cancer
base
establish
orthotop
pdx
organoid
cultur
designmethod
pdx
establish
fresh
tumor
piec
hb
patient
graft
liver
nude
mice
organoid
establish
fresh
nt
piec
hb
minc
digest
singl
cell
suspens
seed
matrigel
grown
growth
cultur
media
patholog
molecular
character
perform
examin
slide
studi
gene
sequenc
gene
express
profil
final
use
establish
pdx
tool
test
effect
new
agent
result
orthotop
pdx
organoid
success
establish
case
respect
patholog
examin
pdx
show
immatur
phenotyp
compar
primari
ts
mainli
character
loss
foetal
epitheli
compon
increas
embryon
scu
pattern
gene
mutat
found
primari
ts
also
present
model
organoid
isol
nt
tissu
model
show
gene
express
profil
similar
correspond
primari
ts
contrast
afp
express
preserv
pdx
lost
organoid
final
signific
inhibit
pdx
growth
observ
use
molecular
therapi
conclus
abl
develop
model
almost
hb
could
use
test
innov
therapi
near
futur
acknowledg
studi
support
agaur
chiltern
project
l
r
von
r
berger
von
hauner
children
hospit
pediatr
surgeri
munich
germani
memmingen
surgeri
memmingen
germani
backgroundobject
infantil
hemangioendothelioma
vascular
tumor
liver
tumor
typic
harmless
show
aggress
cours
signific
complic
prognost
marker
identifi
aggress
cours
entir
absent
previous
shown
hedgehog
signal
overexpress
infantil
hemangioma
skin
aggress
cours
hypothes
hedgehog
signal
overactiv
aggress
designmethod
patient
record
specimen
patient
previous
diagnos
surgic
treat
aggress
select
tumor
bank
analyz
quantit
pcr
specimen
perform
investig
express
marker
well
hedgehog
signal
compon
shh
target
gene
comparison
addit
analyz
case
kaposiform
hemangioendothelioma
khe
compar
result
previous
analyz
express
level
aggress
hemangioma
skin
result
case
express
hemangioma
marker
notabl
upregul
hedgehog
signal
compon
shh
well
transcript
factor
target
gene
detect
case
found
posit
correl
express
level
shh
r
p
khe
found
express
well
similar
overexpress
hedgehog
signal
compon
shh
p
respect
hedgehog
signal
similar
express
aggress
hemangioma
skin
p
respect
conclus
studi
demonstr
overexpress
hedgehog
compon
shh
target
gene
aggress
find
help
effort
understand
identifi
aggress
growth
possibl
make
independ
biomark
allow
earli
intervent
chiang
ap
aw
cw
ch
kk
r
ek
ac
ph
jj
univers
hong
kong
paediatr
adolesc
medicin
hong
kong
hong
kong
sar
wale
hospit
paediatr
hong
kong
hong
kong
sar
elizabeth
hospit
paediatr
hong
kong
hong
kong
sar
mun
hospit
paediatr
adolesc
medicin
hong
kong
hong
kong
sar
margaret
hospit
paediatr
adolesc
medicin
hong
kong
hong
kong
sar
wale
hospit
surgeri
hong
kong
hong
kong
sar
univers
hong
kong
surgeri
hong
kong
hong
kong
sar
mari
hospit
radiolog
hong
kong
hong
kong
sar
backgroundobject
review
outcom
consensu
hbhcc
treatment
protocol
paediatr
hepatoblastoma
hb
investig
role
pretext
stage
risk
stratif
designmethod
overal
surviv
os
surviv
ef
predictor
outcom
determin
hb
patient
year
treat
juli
june
retrospect
assign
pretext
stage
siopel
risk
group
perform
result
sixti
patient
enrol
median
age
diagnosi
year
rang
median
time
year
rang
eight
patient
tumour
ruptur
afp
rais
patient
five
lung
metastas
present
twelv
pateint
upfront
surgic
resect
patient
receiv
treatment
chemotherapi
cisplatin
vincristin
requir
altern
agent
surgic
resect
could
perform
patient
whilst
patient
unresect
metastat
diseas
among
underw
upfront
liver
transplant
death
relaps
os
ef
rate
respect
predictor
inferior
outcom
includ
advanc
evan
stage
unresect
bilobar
diseas
tumour
ruptur
low
afp
suboptim
respons
chemotherapi
pretext
stage
perform
patient
retrospect
stage
pretext
ii
iii
iv
patient
belong
standard
risk
sr
high
risk
hr
accord
siopel
risk
criteria
os
ef
rate
significantli
better
sr
hr
patient
vs
vs
p
conclus
although
consensu
hbhcc
protocol
could
achiev
cure
hb
patient
robust
risk
stratif
system
requir
identifi
high
risk
patient
improv
treatment
outcom
cornet
f
f
c
p
v
chu
pediatr
surgeri
pari
franc
chu
anesthesiolog
pari
franc
chu
pediatr
intens
care
unit
pari
franc
besancon
pediatr
oncolog
besancon
franc
de
renn
hopit
sud
pediatr
oncolog
renn
franc
backgroundobject
surgeri
one
cornerston
treatment
hepatoblastoma
partial
hepatectomi
ph
demand
procedur
periop
complic
common
object
studi
assess
periop
complic
ph
hepatoblastoma
designmethod
patient
ph
hepatoblastoma
chemotherapi
accord
siopel
protocol
institut
pediatr
liver
diseas
transplant
center
januari
januari
includ
studi
examin
variabl
patient
characterist
tumour
characterist
periop
complic
impact
chemotherapi
result
patient
underw
ph
hepatoblastoma
hepatoblastoma
hepatoblastoma
pretext
iii
pretext
iiiiv
procedur
undergon
hepat
vascular
exclus
median
durat
minut
rang
minut
major
hepatectomi
perform
eleven
complic
occur
patient
includ
sever
hemorrhag
ruptur
tumour
patient
air
embol
one
case
one
patient
die
due
sever
hemorrhag
air
embol
postop
complic
occur
patient
consist
complic
grade
complic
grade
accord
classif
seven
patient
requir
second
oper
first
day
partial
hepatectomi
one
hemorrhag
biliari
periton
one
diaphragmat
ruptur
five
patient
present
biliari
leakag
manag
drainag
irrevers
acut
liver
failur
observ
rate
complic
higher
compar
periop
complic
result
delay
chemotherapi
impact
year
overal
surviv
conclus
periop
complic
partial
hepatectomi
rel
frequent
result
signific
delay
postop
chemotherapi
impact
year
overal
surviv
report
cornet
l
brull
chu
pediatr
surgeri
pari
franc
research
develop
evri
franc
backgroundobject
made
assumpt
releas
partial
regener
factor
might
help
prolifer
intrahepat
distant
hepatoblastoma
hb
tumor
cell
aim
studi
evalu
impact
partial
hepatectomi
ph
extrahepat
intrahepat
tumor
growth
hb
anim
model
designmethod
took
advantag
panel
hb
xenograft
firstli
hb
fragment
implant
subcutan
athym
nude
mice
partial
hepatectomi
ph
perform
day
implant
control
group
sham
laparotomi
sl
done
tumor
growth
assess
weekli
tumor
volum
reach
second
time
orthotop
model
luminesc
hb
athym
nude
mice
develop
ph
perform
procedur
hb
cell
inject
liver
tumor
growth
evalu
weekli
monitor
serum
alfa
foeto
protein
afp
bioluminesc
result
subcutan
model
median
time
reach
day
sl
group
day
ph
group
differ
statist
signific
orthotop
model
averag
afp
three
week
hb
cell
inject
sl
group
ph
group
bioluminesc
measur
sl
group
ph
group
conclus
result
suggest
increas
tumor
growth
induc
hepatectomi
occur
intrahepat
model
hb
athym
nude
mice
dsouza
lv
k
n
children
hospit
medic
center
hematolog
oncolog
cincinnati
usa
children
hospit
medic
center
pediatr
surgeri
cincinnati
usa
cincinnati
chemistri
cincinnati
usa
backgroundobject
relaps
hepatoblastoma
hbl
upfront
hepatocellular
carcinoma
hcc
notori
chemoresist
tumor
associ
poor
outcom
gankyrin
small
subunit
proteasom
known
oncogen
overexpress
pediatr
liver
cancer
implic
chemoresist
object
work
studi
role
small
molecul
inhibitor
gankyrin
treatment
pediatr
liver
cancer
designmethod
initi
work
done
tissu
cultur
use
human
hbl
mous
hcc
cell
line
cell
treat
alon
combin
cisplatin
doxorubicin
analysi
includ
prolifer
cytotox
assay
western
blot
vivo
work
done
wild
type
mice
treat
differ
dose
assess
toler
toxic
clinic
patholog
radiograph
data
collect
fresh
sampl
pediatr
hbl
histolog
examin
done
stain
gankyrin
determin
presenc
overexpress
result
treatment
cancer
cell
cytotox
lead
reduc
prolifer
rescu
tumor
suppressor
protein
combin
cisplatin
doxorubicin
signific
increas
cytotox
seen
chemotherapi
alon
well
toler
mice
base
gross
examin
serum
analysi
histolog
treatment
alon
combin
chemotherapi
patient
deriv
xenograft
undergo
analysi
pediatr
tumor
sampl
show
gankyrin
heavili
express
especi
patient
minim
necrosi
chemotherapi
relaps
diseas
conclus
gankyrin
inhibit
block
prolifer
cancer
cell
enhanc
cytotox
tradit
chemotherapeut
agent
use
pediatr
liver
cancer
hbl
sampl
gankyrin
overexpress
wide
seen
support
use
target
approach
pediatr
patient
appear
safe
toler
mice
experi
patient
deriv
xenograft
underway
r
dong
hospit
fudan
key
laboratori
neonat
diseas
depart
pediatr
hepatobiliari
surgeri
shanghai
china
hospit
fudan
univers
depart
pediatr
surgeri
shanghai
china
backgroundobject
hepatoblastoma
common
liver
tumor
earli
childhood
recent
circular
rna
circrna
identifi
novel
regul
prognost
marker
sever
cancer
howev
express
profil
clinic
signific
circrna
hepatoblastoma
still
unknown
designmethod
circular
rna
microarray
conduct
identifi
circrna
go
analysi
pathway
analysi
mirna
respons
element
analysi
conduct
predict
potenti
function
dysregul
circrna
hepatoblastoma
mtt
assay
stain
transwel
assay
conduct
detect
effect
circrna
silenc
hepatoblastoma
cell
function
bioinformat
vitro
experi
conduct
investig
mechan
hepatoblastoma
cell
function
result
identifi
differenti
express
circrna
includ
circrna
circrna
hepatoblastoma
sampl
signific
enrich
go
term
circrna
biolog
process
cellular
compon
molecular
function
chromosom
organ
cytoplasm
organ
cyclic
compound
bind
tight
junction
signal
pathway
rank
top
potenti
affect
regulatori
network
significantli
human
hepatoblastoma
specimen
metastat
hepatoblastoma
cell
line
silenc
decreas
hepatoblastoma
cell
viabil
prolifer
invas
vitro
act
spong
regul
hepatoblastoma
cell
function
vitro
conclus
find
indic
circrna
involv
pathogenesi
hepatoblastoma
promis
therapeut
target
prognosi
diagnosi
treatment
hepatoblastoma
j
elhoudzi
e
hospit
moham
pediatr
hematolog
oncolog
marrakesh
morocco
hospit
moham
vi
pediatr
hematolog
oncolog
marrakesh
morocco
hospit
moham
vi
pediatr
surgeri
depart
marrakesh
morocco
backgroundobject
liver
tumor
account
pediatr
solid
tumor
domin
hepatoblastoma
annual
incid
per
million
children
usual
occur
age
year
studi
sought
identifi
clinic
present
histolog
stage
treatment
modal
surviv
pediatr
hepatoblastoma
marrakesh
designmethod
retrospect
studi
includ
case
collect
nine
year
june
pediatr
depart
univers
hospit
moham
vi
marrakesh
result
hepatoblastoma
rare
case
per
year
averag
age
month
abdomin
distens
constant
reason
consult
diagnosi
evid
case
case
need
biopsi
confirm
infant
stage
iv
pretext
chemotherapi
administ
infant
cisplatin
doxorubucin
cur
surgeri
perform
patient
complet
remiss
death
regist
treatment
death
caus
sepsi
week
post
chemotherapi
conclus
manag
hepat
tumor
children
done
special
center
work
done
past
ten
year
led
improv
classif
descript
factor
prognosi
satisfactori
reach
nearli
overal
surviv
difficulti
lie
surgic
techniqu
prevent
liver
function
center
need
develop
support
care
improv
surviv
j
feng
children
hospit
surgic
oncolog
beij
china
backgroundobject
bile
leakag
common
postop
complic
pediatr
patient
receiv
hepatectomi
hepatoblastoma
howev
persist
bile
leakag
uncommon
articl
aim
summar
discuss
treatment
prognosi
rare
condit
designmethod
persist
postop
bile
leakag
occur
three
patient
hepatoblastoma
medic
record
review
summar
result
boy
girl
underw
hepatectomi
hepatoblastoma
median
age
month
receiv
preoper
chemotherapi
bile
leakag
occur
within
week
surgeri
durat
month
month
month
respect
case
complic
sever
bacteri
infect
bile
leakag
cure
case
cholangiojejunostomi
liver
transplant
patient
receiv
chemotherapi
afterward
other
treatment
median
period
month
surviv
without
sign
bile
leakag
tumor
conclus
persist
bile
leakag
may
induc
sever
infect
liver
injuri
intervent
start
time
diagnosi
surgeri
may
recommend
effect
way
treatment
even
without
adjuv
chemotherapi
oper
outcom
bad
mayb
relat
local
infect
immun
c
fiori
f
lc
hospit
pediatr
oncolog
cascavel
brazil
hospit
surgeri
oncolog
cascavel
brazil
backgroundobject
introduct
liver
tumor
rare
childhood
adolesc
tumor
origin
vari
age
object
report
seri
case
childhood
adolesc
hepat
tumor
treat
referr
center
pediatr
cancer
brazil
describ
clinic
find
diagnosi
treatment
clinic
evolut
case
designmethod
retrospect
descript
cross
studi
patient
treat
cancer
hospit
uopeccan
cascavel
parana
result
total
number
patient
n
six
present
diagnosi
benign
tumor
fifteen
malign
hepatoblastoma
n
common
malign
tumor
common
clinic
sign
abdomin
tumor
abdomin
pain
fever
abdomin
ultrasound
first
complementari
exam
perform
patient
afp
elev
seven
case
case
hepatoblastoma
hb
one
patient
hepatocarcinoma
hcc
four
case
treat
exclus
chemotherapi
six
case
exclus
surgeri
benign
eleven
case
chemotherapi
combin
surgic
resect
surviv
rate
malign
tumor
primari
liver
tumor
n
liver
metastas
n
p
conclus
abdomin
tumor
common
clinic
manifest
hepat
tumor
childhood
adolesc
abdomin
ultrasound
main
complementari
examin
initi
investig
hepatoblastoma
common
malign
liver
tumor
afp
increas
case
benign
tumor
exclus
surgic
treatment
chemotherapi
combin
surgic
resect
present
better
result
treatment
primari
liver
tumor
compar
liver
metastas
c
grimaldi
c
e
r
mc
f
pediatrico
bambino
gesu
pediatr
surgeri
transplant
roma
itali
universitair
pari
sud
aphp
bicetr
pediatr
surgeri
le
kremlin
bicetr
franc
backgroundobject
background
even
hcc
rare
children
treatment
option
improv
last
decad
surgeri
mainstay
treatment
primari
target
obtain
complet
resect
howev
resect
compromis
differ
condit
case
lt
may
indic
theoret
advantag
remov
tumor
also
entir
diseas
liver
designmethod
present
hcc
diagnos
bambino
gesu
children
hospit
rome
itali
chu
bicetr
franc
patient
exclud
analysi
receiv
surgeri
tumor
ruptur
one
metastat
diseas
two
patient
current
chemotherapi
receiv
post
mortem
diagnosi
hcc
neonat
hemochromatosi
result
case
chronic
liver
diseas
tyrosinemia
criptogen
cirrhosi
biliari
atresia
pfic
mytocondri
diseas
patient
underw
cadaver
lt
median
time
wait
list
day
none
receiv
chemotherapi
surgeri
except
one
patient
die
unrel
caus
patient
aliv
diseas
free
median
follow
year
year
conclus
seri
patient
receiv
chemotherapi
lt
prove
good
option
treatment
hcc
chronic
liver
diseas
accur
surgic
evalu
experienc
liver
surgeon
mandatori
assess
correct
manag
c
grosset
de
bordeaux
bordeaux
franc
backgroundobject
surgeri
treatment
hepatoblastoma
hb
current
guarante
surviv
patient
howev
import
challeng
remain
diagnos
high
risk
tumor
identifi
relev
target
pathway
offer
new
therapeut
avenu
previous
two
molecular
subclass
hepatoblastoma
tumor
describ
name
subgroup
poorest
prognosi
advanc
tumor
stage
worst
overal
surviv
rate
associ
signatur
discrimin
two
tumor
subgroup
propos
transfer
clinic
routin
designmethod
address
issu
perform
rna
sequenc
tumor
match
normal
liver
sampl
patient
result
transcript
profil
separ
hb
three
distinct
subgroup
name
identifi
concis
signatur
vim
characterist
prolif
tumor
differenti
express
gene
confirm
expand
cohort
immunohistochemistri
also
reveal
signific
overexpress
gene
involv
fanconi
anemia
fa
pathway
subgroup
investig
abil
sever
describ
fa
inhibitor
block
grow
hb
cell
vitro
vivo
demonstr
bortezomib
proteasom
inhibitor
strongli
impair
prolifer
surviv
hb
cell
line
vitro
block
fa
pathway
associ
dna
repair
significantli
imped
hb
growth
vivo
conclus
conclus
highli
prolifer
subtyp
character
gene
fa
pathway
activ
hb
therapeut
arsen
could
includ
bortezomib
treatment
patient
aggress
tumor
j
hu
h
w
center
children
health
beij
children
capit
medic
univers
surgic
oncolog
beij
china
backgroundobject
focal
nodular
hyperplasia
fnh
uncommon
nonmalign
epitheli
liver
tumor
annual
incid
high
case
per
million
children
mostli
lesion
diamet
less
cm
remov
data
experi
surgic
treatment
larg
pediatr
fnh
limit
thu
paper
aim
furtherli
verifi
effect
oper
cm
fnh
lesion
designmethod
studi
evalu
pediatr
patient
patholog
diagnos
fnh
januari
januari
institut
data
collect
age
diagnosi
size
lesion
present
symptom
histori
past
ill
radiograph
find
patholog
find
clinic
outcom
result
total
children
liver
tumor
treat
institut
period
meanwhil
nine
male
thirteen
femal
age
month
old
diagnos
fnh
mean
month
none
histori
malign
treatment
hepat
viru
use
contracept
drug
patient
differ
degre
symptom
includ
abdomin
pain
abdomin
distent
palpabl
mass
nausea
occasion
found
radiolog
examin
diagnost
accuraci
respect
follow
ultrasound
ct
enhanc
scan
mri
complet
resect
solitari
mass
achiev
diamet
cm
largest
one
cm
main
factor
affect
postop
hospit
day
includ
bodi
temperatur
abdomin
drainag
diet
statu
central
fibrovascular
scar
found
case
approxim
consist
preoper
imag
find
month
case
surviv
without
recurr
diseas
progress
conclus
simpl
resect
play
vital
role
treatment
pediatr
liver
fnh
overal
prognosi
favor
jiang
hospit
affili
shanghai
jiaotong
univers
school
medicin
radiotherapi
shanghai
china
backgroundobject
hepatoblastoma
hb
common
malign
embryon
liver
tumor
pediatr
popul
incid
increas
radiat
therapi
may
potenti
option
adjuv
therapi
hb
case
could
manag
surgeri
chemotherapi
experi
knowledg
radiat
therapi
hb
treatment
limit
order
evalu
feasibl
util
radiat
therapi
hb
remedi
conduct
vitro
experi
detect
radiosensit
hb
cell
line
designmethod
prolifer
morpholog
chang
cell
apoptosi
cell
cycl
cell
receiv
gradient
irradi
system
studi
assay
microscopi
annexin
pi
singl
stain
respect
result
prolifer
cell
significantli
inhibit
inhibit
effici
posit
correl
irradi
dose
cell
receiv
higher
irradi
dose
show
higher
percentag
deform
cell
character
plenti
bubbl
cytosol
earli
stage
post
irradi
debri
cytosol
shape
dead
cell
later
stage
cell
apoptosi
enhanc
increment
irradi
dose
percentag
cell
arrest
phase
increas
meanwhil
proport
cell
phase
decreas
rise
dose
gradient
conclus
cell
line
radiosensit
vitro
effici
inhibit
posit
correl
irradi
dose
receiv
indic
potenti
radiat
therapi
treatment
hb
r
kappler
c
von
munich
depart
pediatr
surgeri
munich
germani
paidopatholog
pediatr
tumor
registri
kiel
germani
backgroundobject
hepatoblastoma
hb
common
malign
liver
tumor
childhood
mainli
driven
mutat
either
adenomatosi
polyposi
coli
apc
gene
howev
molecular
mechan
underli
tumor
progress
remain
elus
aim
identifi
gene
caus
metastat
spread
hb
designmethod
genom
dna
isol
unaffect
liver
tissu
primari
tumor
metastasi
three
patient
hb
dna
analyz
whole
exom
sequenc
function
annot
mutat
gene
perform
david
result
found
mean
mutat
rate
heavili
increas
metastas
per
tumor
compar
primari
tumor
per
tumor
report
mutat
rate
literatur
hb
per
tumor
metastas
show
signific
enrich
mutat
gene
involv
coval
chromatin
modif
atrx
canon
wnt
signal
mutat
driver
gene
andapc
well
genom
caretak
gene
atrx
stabl
occur
primari
tumor
metastas
conclus
genet
alter
found
metastas
patient
hb
pinpoint
role
genom
instabl
epigenet
derail
process
tumor
spread
khalid
children
hospit
institut
child
health
pediatr
hematologyoncolog
lahor
pakistan
backgroundobject
primari
pediatr
hepat
malign
account
childhood
solid
tumor
hepatoblastoma
hb
hepatocellular
carcinoma
hcc
common
make
upto
respect
object
studt
analyz
clinic
data
outcom
pediatr
liver
tumor
develop
countri
limit
resourc
designmethod
data
patient
diagnos
hb
hcc
report
januari
decemb
children
hospit
lahor
analyz
retrospect
patient
demograph
extent
tumor
surgic
procedur
perform
complic
treatment
outcom
compil
result
data
forti
nine
patient
malign
liver
tumor
analyz
retrospect
hepatoblastoma
account
major
case
present
month
year
age
case
hcc
year
old
male
predisposit
account
case
patient
present
palpabl
lump
abdomen
alpha
fetoprotein
afp
liver
biopsi
perform
case
stage
done
pretext
syatem
stage
iii
patient
hb
start
treatment
accord
siopel
protocol
case
receiv
standard
risk
chemotherapi
surgic
resect
done
case
unresect
treatment
complet
case
follow
patient
expir
treatment
howev
death
due
post
oper
complic
twelv
patientswer
counsel
regard
palliat
lost
follow
treatment
conclus
certaininti
diagnosi
hb
without
biopst
children
age
month
year
elev
afp
high
moreov
multidisciplinari
approach
involv
combin
chemotherapi
surgeri
better
outcom
pediatr
liver
tumor
n
kitagawa
k
h
f
e
k
children
medic
center
children
cancer
center
yokohama
japan
children
medic
center
depart
surgeri
yokohama
japan
children
medic
center
depart
radiolog
yokohama
japan
children
medic
center
depart
patholog
yokohama
japan
backgroundobject
perform
thorough
lung
metastasecromi
hepatoblastoma
limit
tumor
number
size
set
oper
indic
even
lesion
extirp
use
indocyanin
green
fluoresc
method
icgf
strategi
result
surviv
rate
stage
iv
hepatoblastoma
convent
chemotherapi
aim
studi
confirm
accuraci
preoper
ct
scan
find
designmethod
retrospect
review
ct
find
patholog
find
oper
record
perform
oper
includ
thoracotomi
wedg
resect
tumor
icgf
done
intraven
administr
icg
one
day
oper
fluoresc
detect
detector
within
infrar
ray
radiat
pde
neor
result
two
hundr
nodul
extirp
oper
patient
institut
among
nodul
prove
metastas
patholog
confirm
preoper
ct
size
tumor
less
respect
posit
rate
ct
less
respect
fals
posit
found
nodul
ct
hand
fals
posit
found
intraop
icgf
caus
bleed
granul
sutur
string
atelectasi
minimum
size
tumor
conclus
sensit
preoper
ct
estim
fals
posit
rate
result
small
lesion
ct
find
reliabl
r
kizyma
z
b
b
r
ukrainian
special
pediatr
medic
centr
pediatr
surgeryoncolog
lviv
ukrain
nation
medic
univers
pediatr
lviv
ukrain
nation
medic
univers
pediatr
surgeri
lviv
ukrain
ukrainian
special
pediatr
medic
centr
intens
care
depart
lviv
ukrain
backgroundobject
object
analysi
review
clinic
present
manag
children
hepatoblastoma
factor
influenc
outcom
lviv
region
despit
good
overal
prognosi
patient
tumour
children
develop
countri
present
late
stage
diseas
diagnosi
requir
care
risk
group
stratif
decis
designmethod
retrospect
chart
review
perform
children
hepatoblastoma
receiv
protocol
chemotherapi
institut
diagnosi
confirm
histolog
convent
ct
mri
sonographi
perform
accordingli
initi
diagnosi
preoper
adjuv
treatment
treatment
protocol
base
siopel
recommend
patient
risk
group
identifi
due
pretreat
extent
diseas
pretext
group
guidelin
result
age
rang
diagnosi
month
year
median
month
main
present
symptom
abdomin
mass
median
alpha
fetoprotein
afp
level
time
diagnosi
ngml
pretext
stage
ii
document
patient
iii
patient
four
patient
high
risk
diseas
pretext
iv
metastat
diseas
involv
lung
patient
receiv
neoadjuv
chemotherapi
postop
chemotherapi
surgeri
perform
cycl
chemotherapi
trisectionectomi
hemihepatectomi
perform
base
tumour
initi
extent
chemotherapi
respons
median
month
overal
surviv
patient
conclus
approach
siopel
risk
stratif
neoadjuv
chemotherapi
hepatoblastoma
strict
time
surgeri
decent
strategi
realm
develop
countri
consid
statist
larger
amount
advanc
stage
tumour
present
l
lu
z
children
shanghai
jiao
tong
univers
depart
gener
surgeri
shanghai
china
backgroundobject
hepatoblastoma
hb
common
pediatr
liver
malign
chemotherapi
effect
improv
tumor
resectabl
overal
surviv
howev
patient
metastat
hb
often
fail
respond
standard
treatment
critic
identifi
novel
molecular
marker
metastasi
predict
investig
new
therapeut
stagey
patient
metastat
hb
designmethod
tumor
tissu
metastat
hb
patient
use
identifi
potenti
molecular
marker
regul
dna
methyl
relat
tumor
metastasi
suppress
reconstitut
tumor
cell
line
use
explor
role
metastat
hb
meanwhil
assay
conduct
analyz
transcriptom
altern
result
silenc
reveal
mechan
regul
tumor
metastasi
result
frequent
cpg
methyl
found
metastat
tumor
tissu
hb
normal
liver
primari
tumor
tissu
express
observ
significantli
downregul
metastat
hb
studi
reveal
descent
could
revers
methyltransferas
inhibitor
methyl
two
critic
region
cpg
island
around
transcript
start
site
result
silenc
defici
increas
invas
migrat
abil
tumor
cell
evidenc
analysi
silenc
alter
gene
involv
cell
adhes
cellular
cytoskeleton
knockdown
upregul
protein
level
phosphoryl
level
mlc
indic
potenti
transit
emt
suppressor
mechan
exert
effect
via
inhibit
ra
protein
activ
subsequ
rasraferk
pathway
conclus
studi
indic
methyl
level
promis
biomark
metastat
hb
diagnosi
data
reveal
suppress
emt
process
hb
develop
regul
rasraferk
pathway
suppli
new
therapeut
target
patient
metastat
hb
sy
min
jw
h
kn
hj
jj
dy
jm
sh
dk
medic
center
children
univers
ulsan
colleg
medicin
divis
pediatr
depart
pediatr
seoul
republ
korea
medic
center
children
univers
ulsan
colleg
medicin
depart
pediatr
surgeri
seoul
republ
korea
medic
center
children
univers
ulsan
colleg
medicin
depart
thorac
cardiovascular
surgeri
seoul
republ
korea
backgroundobject
common
metastat
site
hepatoblastoma
lung
patient
hepatoblastoma
lung
metastas
consid
patient
aim
studi
investig
clinic
characterist
treatment
outcom
hepatoblastoma
lung
metastas
designmethod
medic
record
patient
newli
diagnos
hepatoblastoma
asan
medic
center
children
hospit
januari
august
review
retrospect
among
patient
lung
metastas
diagnosi
result
patient
diagnos
lung
metastas
pretext
ii
iii
iv
respect
pretext
affect
surviv
outcom
patient
lung
metastasi
among
patient
lung
metastas
metastas
lung
organ
pulmonari
metastasectomi
done
patient
signific
differ
surviv
outcom
underw
pulmonari
metastasectomi
four
patient
underw
liver
transplant
lt
aliv
without
diseas
overal
surviv
os
rate
patient
without
lung
metastasi
significantli
better
lung
metastasi
vs
p
os
rate
patient
lung
metastasi
diagnos
better
diagnos
modest
signific
vs
p
twenti
patient
complet
radiograph
resolut
pulmonari
metastat
lesion
strong
statist
signific
surviv
outcom
complet
resolut
lung
metastas
p
conclus
patient
pulmonari
metastat
hepatoblastoma
unfavor
prognosi
howev
recent
outcom
improv
probabl
due
effect
chemotherapi
lt
resolut
pulmonari
metastat
lesion
import
prognost
factor
larger
studi
requir
investig
treatment
strategi
improv
outcom
hepatoblastoma
lung
metastasi
f
neumann
l
b
c
b
v
hospit
pediatr
oncolog
depart
franc
kremlin
hospit
pediatr
radiolog
depart
le
kremelin
franc
roussi
cancer
campu
depart
oncolog
children
villejuif
franc
necker
depart
patholog
pari
franc
kremlin
hospit
depart
patholog
le
kremelin
franc
kremlin
hospit
pediatr
surgeri
depart
le
kremelin
franc
backgroundobject
aim
studi
assess
prognost
radiolog
characterist
lung
nodul
children
metastat
hepatoblastoma
hb
designmethod
patient
treat
franc
includ
central
databas
hepatobio
elig
studi
pulmonari
tomographi
scan
central
review
diagnost
inform
number
size
later
evolut
treatment
collect
data
histopatholog
chemotherapi
regimen
record
overal
surviv
os
event
free
surviv
ef
analyz
univari
analysi
result
period
patient
metastat
hb
includ
patient
treat
studi
overal
surviv
os
event
free
surviv
ef
respect
patient
less
nodul
increas
ef
ci
os
ci
vs
ci
ci
patient
nodul
ef
os
respect
patient
nodul
ef
os
vs
ef
ci
os
ci
p
ef
os
respect
patient
bilater
nodul
ef
ci
os
wherea
patient
unilater
lesion
ef
os
conclus
children
metastat
hb
poor
prognosi
variou
present
diseas
seem
exist
among
patient
light
metastat
diseas
better
prognosi
treatment
intens
could
adapt
regard
burden
metastat
diseas
limit
toxiti
long
term
multivari
analysi
must
perform
confirm
result
author
thank
hepatobio
databas
scientif
committe
ohno
k
k
k
center
child
health
develop
divis
depart
surgic
specialti
tokyo
japan
center
child
health
develop
divis
surgic
oncolog
tokyo
japan
center
child
health
develop
children
cancer
center
tokyo
japan
center
child
health
develop
center
organ
transplant
tokyo
japan
center
child
health
develop
depart
patholog
tokyo
japan
backgroundobject
complet
resect
import
tool
cure
hepatoblastoma
hb
pulmonari
metastas
recent
navig
surgeri
use
indocyanin
green
icg
report
use
techniqu
detect
minim
pulmonari
metastat
lesion
perform
icg
navig
surgeri
eight
case
metastat
hb
center
discuss
efficaci
drawback
designmethod
retrospect
analyz
eight
case
six
male
two
femal
hepatoblastoma
underw
metastasectomi
august
decemb
intraven
inject
icg
administ
hour
prior
surgeri
icg
accumul
intraop
detect
infrar
camera
dedic
procedur
age
oper
rang
month
year
old
two
recurr
case
underw
procedur
twice
procedur
perform
right
thoracotomi
three
case
left
one
case
bilater
four
case
lesion
palpabl
nodul
detect
preoper
comput
tomographi
ct
scan
remov
wedg
resect
result
total
lesion
resect
ultim
patholog
proven
metastat
tumor
lesion
viabl
tumor
wherea
lesion
among
resect
lesion
detect
preoper
ct
metastat
tumor
four
metastat
nodul
detect
ct
conclus
icg
navig
could
demonstr
minimum
lesion
undetect
ct
scan
procedur
extrem
sensit
although
fals
posit
rate
also
high
investig
warrant
decreas
number
nodul
avoid
unnecessari
resect
amg
pared
guerra
rebagliati
hospit
paediatr
oncolog
lima
peru
backgroundobject
evalu
impact
latest
surgic
advanc
evolut
treatment
childhood
hepatocarcinoma
hcc
major
center
peru
prognost
signific
designmethod
descript
retrospect
longitudin
studi
patient
hepatocarcinoma
year
center
year
result
case
cancer
liver
hepatocarcinoma
averag
age
year
school
malefemal
hepatomegali
abdomin
mass
weight
loss
immun
hepat
b
vaccin
chronic
activ
hepat
b
receiv
lamiduvudin
one
hcc
tyrosinemia
anoth
secondari
everolimu
alphafetoprotein
averag
debut
ngml
siopel
stadium
pretext
ii
iii
pretext
iv
twelv
metastas
cirrhosi
percutan
biopsi
diagnost
epitheli
hepatocarcinoma
five
debut
resect
tumor
liver
transplant
tyrosinemia
receiv
adjuv
chemotherapi
qt
sorafenib
qt
thalidomid
remiss
one
die
surgeri
hepat
vein
invol
twenti
unresect
debut
receiv
siopel
protocol
siopel
intrarteri
hepat
doxorubicin
receiv
siopel
sorafenib
siopel
thalidomid
treatment
becam
resect
one
pack
ruptur
onset
four
chronic
activ
hepatitisb
cirrhosi
die
one
six
cronic
activ
hepat
b
remiss
patient
aliv
remiss
second
line
chemotherapi
relaps
surviv
patient
remiss
month
conclus
higher
incid
mortal
patient
immun
hepat
b
cirrhosi
pretext
greater
ng
ml
portal
vein
hepat
involv
spontan
ruptur
onset
metastasi
epitheli
histolog
liver
transplant
chemotherapi
white
therapi
favor
good
respons
hcc
togeth
surgic
advanc
updat
multicentr
protocol
v
radhakrishnan
j
p
institut
wia
medic
oncolog
pediatr
oncolog
chennai
india
institut
wia
medic
oncolog
pediatr
oncolog
chennai
india
backgroundobject
hepatoblastoma
rare
paediatr
tumour
aris
liver
present
studi
conduct
ascertain
clinic
profil
surviv
outcom
patient
hepatoblastoma
treat
centr
designmethod
collect
case
record
patient
hepatoblastoma
treat
januari
decemb
analys
baselin
characterist
treatment
detail
outcom
surviv
analys
use
kaplan
meier
method
result
patient
hepatoblastoma
receiv
treatment
centr
studi
period
median
age
patient
month
male
commonest
present
symptom
abdomin
mass
median
alpha
fetoprotein
afp
level
time
diagnosi
ngml
pretext
stage
ii
document
iii
patient
high
risk
diseas
pretext
iv
metastat
diseas
portal
venou
invas
afp
ngml
document
patient
neoadjuv
chemotherapi
nact
given
patient
complet
surgic
resect
possibl
nact
infusion
cisplatin
doxorubicin
plado
given
patient
liver
transplant
done
patient
median
month
overal
surviv
standard
risk
patient
respect
conclus
patient
standard
risk
hepatoblastoma
surviv
outcom
compar
western
countri
howev
outcom
patient
high
risk
inoper
diseas
remain
low
due
financi
constraint
perform
liver
transplant
multimod
treatment
includ
nact
plado
base
regimen
follow
resect
feasibl
strategi
ritz
r
j
von
e
von
hauner
children
hospit
depart
pediatr
surgeri
munich
germani
von
hauner
children
hospit
depart
pediatr
gastroenterolog
hepatolog
munich
germani
backgroundobject
sarcopenia
reflect
decreas
psoa
muscl
surfac
area
pmsa
associ
poor
outcom
children
hepatoblastoma
hb
high
risk
sarcopenia
due
immobl
malnutrit
system
inflamm
henc
hypothes
children
hb
would
smaller
pmsa
healthi
control
pmsa
would
correl
clinic
paramet
designmethod
children
age
year
hb
treat
institut
includ
pilot
studi
ct
mri
imag
retriev
hospit
imag
databas
pmsa
measur
intervertebr
disc
level
z
score
calcul
use
age
gender
specif
refer
valu
larg
cohort
pediatr
trauma
victim
pmsa
z
score
correl
clinic
variabl
outcom
result
total
children
hb
includ
lumbar
level
pmsa
significantli
smaller
hb
subject
compar
healthi
control
mean
sd
mean
sd
p
pmsa
z
score
correl
poorli
weight
z
score
bmi
r
r
pmsa
hb
correl
age
diagnosi
length
hospit
stay
pretext
mutat
gene
signatur
metastasi
afp
level
tumor
typehistolog
focal
conclus
retrospect
pilot
studi
pmsa
significantli
lower
children
hb
compar
healthi
control
although
pmsa
correl
clinic
marker
result
interpret
care
children
sever
sarcopenia
importantli
pmsa
correl
poorli
particip
weight
z
score
bmi
thu
sarcopenia
might
novel
independ
nutrit
biomark
children
liver
cancer
kh
ryu
es
ej
ka
yh
jw
sy
woman
univers
colleg
medicin
depart
pediatr
seoul
republ
korea
univers
daegu
school
medicin
depart
pediatr
daegu
republ
korea
woman
univers
colleg
medicin
depart
microbiolog
seoul
republ
korea
woman
univers
colleg
medicin
depart
biochemistri
seoul
republ
korea
backgroundobject
carcinoma
progress
epitheli
mesenchym
transit
emt
play
crucial
role
earli
step
metastasi
cell
lose
contact
acquir
increas
motil
spread
surround
distant
tissu
epitheli
plastic
becom
hot
issu
hepatocellular
carcinoma
hcc
strong
induc
emt
transform
growth
abl
orchestr
fibrogenesi
carcinogenesi
show
rise
cytokin
level
cirrhosi
late
stage
hcc
thu
intens
interest
target
signal
pathway
therapi
show
whether
human
palatin
mesenchym
stem
cell
regul
emt
phenotyp
human
hepatocellular
carcinoma
cell
line
cell
designmethod
cell
cultur
presenc
concentr
ngml
observ
extent
prolifer
express
emt
marker
cancer
stem
cell
marker
investig
effect
prolifer
gene
express
cell
condit
medium
ad
separ
cell
harvest
prolifer
rate
compar
perform
carboxyfluorescein
succinimidyl
ester
cfse
assay
also
express
epcam
detect
result
cell
rapidli
prolifer
accompani
increas
emt
marker
cancer
stem
cell
marker
upon
stimul
hr
howev
medium
effect
decreas
prolifer
cell
importantli
medium
markedli
suppress
marker
emt
hepatocellular
stem
conclus
find
indic
inhibit
carcinoma
progress
trait
cell
paracrin
effect
via
releas
factor
effect
least
part
due
disturb
signal
j
von
sm
r
p
kk
von
schmid
von
hauner
children
munich
depart
pediatr
hematolog
children
research
center
munich
germani
zentrum
munich
german
research
center
environment
health
research
unit
protein
scienc
munich
germani
von
hauner
children
munich
depart
pediatr
surgeri
munich
germani
freis
numar
regensburg
lehrstuhl
genomorientiert
bioinformatik
freis
germani
ferrara
franc
depart
surgeri
experiment
medicin
ferrara
itali
von
hauner
children
children
research
center
munich
germani
backgroundobject
microrna
import
genet
regul
physiolog
pathophysiolog
process
includ
cancer
initi
progress
hepatoblastoma
common
liver
tumour
childhood
aim
identifi
malign
metastasi
promot
effect
mirna
previous
report
overexpress
metastat
hepatoblastoma
furthermor
intend
evalu
diagnost
prognost
potenti
designmethod
stabl
transient
overexpress
two
liver
tumour
cell
line
use
analys
featur
metastat
tumour
progress
prolifer
growth
migrat
invas
via
mass
spectrometri
base
proteom
screen
investig
effect
proteom
level
explor
underli
biolog
one
predict
target
gene
experiment
valid
via
luciferas
assay
diagnost
prognost
properti
studi
hepatoblastoma
tumour
sampl
result
show
significantli
enhanc
cell
prolifer
growth
migrat
invas
hepatoblastoma
cell
also
identifi
valid
transmembran
adhes
receptor
hyaluronan
direct
function
target
mirna
strong
direct
impact
two
isoform
standard
high
express
correl
aggress
tumour
bear
potenti
predict
reduc
surviv
conclus
identifi
target
regul
number
biolog
featur
import
malign
metastasi
furthermor
demonstr
diagnost
prognost
potenti
promis
novel
therapeut
target
biomark
hepatoblastoma
sekiguchi
k
r
r
n
k
k
k
j
univers
tokyo
depart
pediatr
tokyo
japan
center
child
health
develop
depart
biolog
tokyo
japan
univers
depart
patholog
tumor
biolog
kyoto
japan
center
child
health
develop
children
cancer
center
tokyo
japan
univers
depart
pediatr
surgeri
fukuoka
japan
univers
tokyo
human
genom
institut
medic
scienc
tokyo
japan
children
medic
center
depart
pediatr
surgeri
saitama
japan
children
medic
center
depart
hematologyoncolog
saitama
japan
children
medic
center
depart
patholog
kanagawa
japan
backgroundobject
although
hepatoblastoma
hbl
common
pediatr
liver
tumor
genet
heterogen
defin
clinic
varieti
hbl
yet
clarifi
designmethod
investig
genet
epigenet
divers
hbl
identifi
therapeut
target
perform
target
captur
sequenc
tc
gene
rna
sequenc
dna
methyl
array
analysi
snp
array
analysi
sampl
hbl
sinc
detoxif
enzym
critic
protect
cell
oxid
stress
cytotox
identifi
promis
target
hbl
perform
inhibit
experi
use
sirna
dicoumarol
inhibitor
hbl
cell
line
subsequ
effect
inhibit
cell
prolifer
drug
resist
assess
result
identifi
mutationsdelet
sampl
tc
consensu
cluster
methyl
data
reveal
presenc
three
cluster
distinct
clinic
biolog
featur
found
essenti
biolog
differ
among
subgroup
differenti
stage
base
differenti
methyl
bind
site
master
regul
hepatocyt
differenti
compar
subgroup
identifi
high
express
promot
hypomethyl
key
marker
group
knockdown
inhibit
experi
use
high
express
sirna
dicoumarol
induc
signific
growth
inhibit
addit
also
sensit
cell
drug
cisplatin
doxorubicin
effect
observ
low
express
conclus
comprehens
genet
epigenet
analys
defin
three
distinct
subgroup
hbl
identifi
promis
target
group
result
sirna
knockdown
dicoumarol
inhibit
suggest
effect
suppress
growth
inhibit
chemosensit
aggress
hbl
cell
thu
therapeut
target
poor
prognost
hbl
case
high
express
r
shaikh
children
hospit
dana
farber
cancer
center
intervent
radiolog
boston
usa
backgroundobject
demonstr
safeti
feasibl
imag
guid
intervent
radiolog
therapi
pediatr
liver
tumor
designmethod
present
initi
experi
treat
patient
liver
tumor
intervent
radiolog
follow
transarteri
chemo
embol
tace
primari
hepatocellular
carcinoma
year
old
patient
radiofrequ
ablat
rfa
metastat
gastrointestin
liver
tumor
year
old
patient
transarteri
embol
tae
metastat
gastrointestin
liver
tumor
year
old
patient
microwav
ablat
mw
metastat
renal
cell
carcinoma
year
old
patient
metastat
hepatocellular
carcinoma
year
old
patient
transarteri
embol
cryoablat
enzing
hemangioma
year
old
patient
patient
discuss
multidisciplinari
tumor
confer
prior
techniqu
challeng
util
modal
manag
pediatr
liver
tumor
discuss
result
patient
underw
success
intervent
radiolog
treatment
palliat
bridg
transplant
without
major
complic
conclus
minim
invas
intervent
radiolog
therapi
feasibl
safe
treatment
pediatr
liver
tumor
consid
adjuv
combin
treatment
modal
shinkai
k
n
f
k
h
r
univers
tsukuba
pediatr
surgeri
tsukuba
japan
univers
tsukuba
pediatr
tsukuba
japan
backgroundobject
real
time
fluoresc
imag
use
indocyanin
green
icg
appli
wide
oncolog
surgeri
order
detect
sentinel
lymph
node
metastasi
surgic
margin
metastat
lesion
sever
fluoresc
pattern
hepatocellular
carcinoma
report
investig
fluoresc
pattern
primari
site
periton
metastat
lesion
hepatoblastoma
designmethod
three
hepatoblastoma
patient
analyz
hepatectomi
icg
inject
intraven
hour
surgeri
detect
icg
perform
use
portabl
handi
camera
hamamatsu
photon
japan
endoscop
system
aim
stryker
result
case
girl
pretext
iii
tumor
periton
dissemin
bilater
lung
metastasi
case
boy
petext
tumor
without
distant
metastasi
case
boy
pretext
ii
tumor
without
distant
metastasi
case
treat
neoadjuv
chemotherapi
hepatectomi
case
fals
neg
fluoresc
oment
dissemin
fals
posit
residu
resect
liver
surfac
primari
site
tumor
case
show
floresc
posit
case
floresc
posit
surround
tissu
primari
site
tumor
conclus
icg
navig
surgeri
report
use
detect
lung
metastasi
hepatoblastoma
case
sever
floresc
pattern
primari
site
seen
hepatoblastoma
moreov
fals
posit
fals
neg
confirm
icg
floresc
pattern
hepatoblastoma
need
investig
relationship
floresc
pattern
hepatoblastoma
tumor
biolog
yamada
k
h
h
k
k
univers
school
nation
center
child
health
develop
pediatr
surgeri
tokyo
japan
univers
school
medicin
pediatr
surgeri
tokyo
japan
univers
school
medicin
pediatr
tokyo
japan
backgroundobject
curabl
heaptoblastoma
hb
larg
depend
achiev
radic
surgic
resect
advanc
imag
technolog
contribut
precis
resect
tumor
report
three
patient
age
year
old
underw
liver
transplant
ltx
follow
resect
metastat
hb
util
indocyanin
green
icg
navig
techniqu
designmethod
icg
given
intraven
hour
hour
prior
oper
fluoresc
imag
system
photodynam
eye
hamamatsu
photon
pinpoint
system
novadaq
util
visual
lesion
taken
icg
result
case
femal
underw
ltx
unresect
hb
follow
preoper
chemotherapi
protocol
partial
lung
resect
metastat
hb
perform
icg
navig
two
three
year
ltx
diseas
free
month
normal
valu
afp
case
male
initi
present
ruptur
hb
age
underw
rescu
ltx
follow
multipl
session
chemotherapi
recurr
hb
observ
transplant
liver
peritoneum
year
ltx
underw
second
ltx
icg
navig
help
us
clear
extrahepat
hb
time
second
ltx
recurr
free
year
sinc
case
femal
underw
rescu
ltx
along
chemotherapi
ct
show
recurr
hb
chest
wall
diaphragm
two
year
ltx
thoracoscopi
load
pinpoint
system
util
visual
recurr
tumor
recurr
tumor
well
demarc
near
infrar
mode
resect
patient
tumor
free
year
sinc
metastasectomi
conclus
advanc
icg
imag
technolog
provid
precis
sensit
resect
metastat
hb
lead
cure
even
patient
w
yang
w
children
hospit
oncolog
surgeri
beij
china
backgroundobject
analyz
factor
associ
recurr
hepatoblastoma
children
order
make
develop
treatment
modal
patient
recurr
hepatoblastoma
assess
prognosi
designmethod
total
patient
recurr
hepatoblastoma
review
summar
clinic
stage
patholog
type
alpha
fetoprotein
afp
level
chang
trend
tumor
volum
afp
level
patient
receiv
chemotherapi
decreas
afp
level
surgic
resect
result
group
case
clinic
stage
case
stage
ii
case
stage
case
stage
iv
case
embryon
patholog
type
case
fetal
type
case
mix
type
case
giant
trabecular
type
small
cell
undifferenti
type
case
onset
serum
afp
valu
rang
ngml
preoper
chemotherapi
tumor
volum
decreas
case
afp
level
drop
normal
rang
case
afp
level
one
patient
drop
normal
within
one
month
oper
random
select
case
non
recurr
hepatoblastoma
period
compar
recurr
group
result
show
patient
recurr
clinic
stage
higher
non
recurr
group
recurr
patient
proport
tumor
reduct
extent
afp
decreas
proport
afp
drop
normal
rang
within
one
month
chemotherapi
significantli
lower
patient
without
recurr
signific
differ
two
group
factor
conclus
main
factor
affect
recurr
hepatoblastoma
includ
preoper
stage
tumor
volum
reduct
afp
level
decreas
preoper
chemotherapi
rate
afp
level
decreas
normal
tumor
resect
w
yao
k
k
x
hospit
fudan
univers
pediatr
surgeri
shanghai
china
backgroundobject
investig
feasibl
safeti
modifi
associ
liver
partit
portal
vein
ligat
stage
hepatectomi
alpp
hepatoblastoma
designmethod
boy
present
heterogen
mass
still
involv
couinaud
hepat
segment
vii
viii
iva
small
dissemin
foci
involv
segment
ii
iii
sent
hospit
cycl
chemotherapi
left
hemihepatectomi
segment
viiviii
resect
need
perform
larg
short
hepat
vein
also
need
retain
drain
venou
residu
liver
modifi
alpp
procedur
perform
first
stage
oper
ligat
left
middl
branch
glission
irregular
liver
split
perform
larg
short
hepat
vein
preserv
drain
venou
segment
v
vi
second
stage
oper
perform
remov
left
liver
vii
viii
day
later
day
oper
laparotomi
hepat
duct
jejunum
anastomosi
perform
obstruct
jaundic
result
remnant
liver
volum
first
step
oper
increas
day
oper
futur
liver
remnant
account
liver
total
volum
first
second
step
oper
oper
time
first
second
step
oper
min
min
respect
jaundic
gradual
subsid
liver
function
normal
oper
week
last
oper
liver
function
blood
coagul
function
patient
normal
current
patient
finish
cycl
adjuv
chemotherapi
tumor
recurr
found
year
oper
conclus
although
alpp
complic
procedur
provid
new
treatment
option
hepatoblastoma
patient
residu
liver
insuffici
h
zaidan
al
f
hamad
univers
hospit
paediatr
surgeri
manama
bahrain
hospit
dublin
surgeri
dublin
ireland
hospit
crumlin
surgeri
dublin
ireland
hospit
crumlin
oncolog
dublin
ireland
hospit
dublin
patholog
dublin
ireland
hospit
dublin
oncolog
dublin
ireland
backgroundobject
demonstr
effect
specif
train
liver
surgeri
decis
therapi
adjuv
care
outcom
designmethod
studi
compar
outcom
lr
two
separ
era
group
previous
publish
group
oper
liver
tumour
patient
file
histologyradiolog
record
hipe
clinic
follow
use
group
patient
result
age
present
diagnosi
type
surgeri
morbid
mortal
analyz
descript
statist
surviv
kaplan
meier
log
rank
regress
result
malign
diseas
compris
patient
patient
patient
discuss
mdt
tumour
board
underw
complet
tumour
resect
neg
margin
perform
train
pa
hb
surgeon
patient
receiv
adjuv
chemotherapi
wherea
patient
receiv
adjuv
therapi
six
patient
incomplet
resect
biopsi
underw
attempt
complet
resect
overal
surviv
seriou
morbid
note
patient
conclus
studi
confirm
essenti
benefit
specif
hb
train
mdt
chemotherapi
paediatr
patient
malign
liver
diseas
improv
outcom
minim
morbid
long
term
surviv
seen
group
patient
compar
group
potenti
impact
deliveri
care
jurisdict
roi
also
deliveri
train
paediatr
surgeri
zhang
j
first
hospit
jilin
univers
pediatr
oncolog
changchun
china
backgroundobject
among
institut
hypothes
treatment
combin
oxaliplatinvincristinetopotecan
ovt
pair
radiofrequ
ablat
rfa
twelv
patient
multipl
refractoryrecurr
pulmonari
hepatoblastoma
hb
due
lack
standard
treatment
combin
use
compassion
treatment
designmethod
oxaliplatin
mgkg
patient
month
age
younger
administr
infus
day
vincristin
day
administ
minut
intraven
topotecan
administr
infus
day
treatment
cycl
repeat
everi
week
maximum
six
cycl
rfa
perform
seven
fourteen
day
last
cycl
chemotherapi
multitin
expand
radiofrequ
rf
needl
electrod
use
patient
goal
rfa
session
attempt
treat
metastas
locat
one
lung
singl
session
imposs
second
session
target
lung
week
later
result
total
patient
includ
studi
five
patient
achiev
cr
two
patient
pr
two
patient
pd
three
patient
sd
ef
ci
os
studi
group
ci
toxic
event
handl
satisfactorili
toxic
relat
death
observ
conclus
report
show
ovt
combin
rfa
success
treatment
modal
previous
heavili
treat
refractoryrecurr
pulmonari
metastat
lesion
hepatoblastoma
zhang
l
first
hospit
jilin
univers
pediatr
oncolog
changchun
china
institut
system
univers
connecticut
depart
physiolog
neurobiolog
storr
usa
backgroundobject
hepatoblastoma
hb
common
liver
tumor
children
somat
mutat
gene
encod
compon
preval
sporad
hb
case
interplay
myc
signal
shown
play
critic
role
poorli
differenti
aggress
hb
howev
myc
harbor
caviti
small
molecul
easili
bind
designmethod
work
motiv
report
aurka
express
upregul
transcriptom
genom
analysi
human
hb
addit
neuroblastoma
tumorigenesi
promot
signal
network
propos
central
regulatori
role
hb
effect
ran
aurka
result
result
show
malign
tissu
higher
rna
aurka
express
normal
liver
sampl
rna
aurka
also
upregul
panel
malign
hb
cell
demonstr
ran
key
downstream
compon
signal
aurka
key
downstream
compon
ran
signal
show
inhibit
sirna
significantli
decreas
hb
cell
prolifer
coloni
format
suggest
pathway
may
play
critic
role
hb
develop
also
elucid
translat
inhibit
aurka
hb
overexpress
markedli
decreas
aurka
utr
activ
protein
express
repress
hb
cell
prolifer
coloni
format
contrast
aurka
rescu
suppress
hb
cell
growth
clonal
importantli
decreas
express
correl
poor
outcom
hb
patient
conclus
result
reveal
new
repressor
hb
growth
via
inhibit
oncogen
pathway
l
zhu
l
l
jude
children
research
hospit
pharmaceut
scienc
memphi
usa
children
hospit
patholog
houston
usa
backgroundobject
hepatoblastoma
hb
common
liver
cancer
cancer
children
prognosi
children
metastat
recurr
hb
remain
dismal
past
decad
previou
studi
demonstr
cell
often
hijack
normal
stem
cell
pathway
gain
surviv
growth
advantag
recent
advanc
stem
cell
cultur
provid
mean
rapidli
select
propag
cancer
cell
strong
stem
properti
biolog
analysi
therapeut
test
designmethod
hb
organoid
model
establish
mous
human
tumor
via
stem
cell
cultur
vivo
tumorigen
determin
via
liver
orthotop
transplant
mice
conduc
larg
compar
profil
identifi
gene
commonli
dysregul
metastat
hb
tumor
organoid
compar
counterpart
biolog
function
therapeut
valu
top
candid
gene
determin
via
impact
molecular
manipul
hb
cell
growth
invas
metastasi
drug
respons
vitro
vivo
result
multipl
hb
organoid
model
display
potent
vivo
tumorigen
drive
rapid
invas
metastasi
upon
orthotop
transplant
profil
identifi
small
number
gene
significantli
upregul
aggress
hb
tumor
organoid
among
enzym
catalyz
format
deoxyribonucleotid
ribonucleotid
essenti
dna
replic
repair
analysi
reveal
signific
associ
express
prognosi
hb
patient
make
promis
therapeut
target
high
risk
hb
studi
current
ongo
reveal
effect
biolog
pharmacolog
inhibit
hb
growth
metastasi
vitro
vivo
conclus
approach
repres
uniqu
strategi
model
high
risk
hb
power
research
platform
identif
novel
diseas
mechan
drug
target
e
k
j
e
k
l
r
g
e
j
b
k
j
p
j
w
b
j
w
g
j
j
e
univers
gdansk
dep
oncolog
gdansk
poland
univers
gdansk
dep
hematolog
oncolog
gdansk
poland
specialist
hospit
wroclaw
dep
paediatr
surgeri
wroclaw
poland
child
institut
warsaw
dep
oncolog
surgeri
children
adolesc
warsaw
poland
collegium
medicum
cracow
dep
paediatr
oncolog
hematolog
cracow
poland
medicum
bydgoszcz
dep
hematolog
oncolog
bydgoszcz
poland
specialist
hospit
kielc
dep
paediatr
oncolog
hematolog
kielc
poland
uniwers
bialystok
deppaediatr
oncolog
hematolog
bialystok
poland
medic
univers
dep
paediatr
katowic
poland
children
hospit
lublin
oncolog
children
transplantolog
lublin
poland
univers
wroclaw
dep
children
bone
marrow
oncolog
hematolog
wroclaw
poland
univers
poznan
dep
hematolog
paediatr
transplantolog
poznan
poland
univers
warsaw
dep
hematolog
oncolog
warsaw
poland
univers
lodz
dep
hematolog
diabetolog
lodz
poland
medic
univers
dep
paediatr
children
oncolog
szczecin
poland
hospit
chorzow
dep
children
hematolog
oncolog
chorzow
poland
clinic
hospit
katowic
dep
hematolog
oncolog
katowic
poland
children
memori
health
warsaw
dep
oncolog
warsaw
poland
univers
warsaw
dep
hematolog
oncolog
warsaw
poland
univers
lodz
dep
hematolog
diabetolog
lodz
poland
medic
univers
dep
paediatr
katowic
poland
medic
univers
dep
hematolog
children
oncolog
zabrz
poland
univers
szczecin
dep
paediatr
children
oncolog
szczecin
poland
univers
szczecin
dep
hematooncolog
gastroenterolog
szczecin
poland
bydgoszcz
hematolog
oncolog
bydgoszcz
poland
univers
wroclaw
dep
bone
marrow
children
oncolog
hematolog
wroclaw
poland
backgroundobject
analys
clinic
histolog
featur
ovarian
germ
cell
tumour
gct
children
adolesc
treat
polish
oncolog
centr
accord
protocol
designmethod
analysi
girl
year
age
ovarian
gct
perform
clinic
histolog
data
multicentr
polish
databas
evalu
result
fifti
nine
patient
gct
present
ovarian
locat
primari
tumour
median
age
diagnosi
seven
girl
year
old
patient
tumour
develop
right
ovari
left
one
tumour
reveal
bilater
lower
clinic
stage
found
girl
advanc
stage
metastas
appear
mainli
retroperiton
mediastin
lymph
node
peritoneum
liver
gct
marker
assess
diagnosi
patient
alfafetoprotein
afp
increas
afp
appear
patient
histolog
examin
tumour
perform
case
monomorph
mostli
yolk
sac
tumour
dysgerminoma
teratoma
tumour
mix
nonmutil
surgic
procedur
start
treatment
perform
patient
tumour
radic
resect
without
chemotherapi
use
chemotherapi
perform
second
surgeri
remov
rest
need
girl
recurr
observ
patient
achiev
second
complet
remiss
poor
outcom
seen
one
girl
diagnosi
start
chemotherapi
fifti
eight
survivor
complet
remiss
long
term
side
effect
hear
disturb
nephrotox
note
patient
conclus
ovarian
gct
recognis
mostli
year
age
tumour
diagnos
advanc
stage
prognosi
excel
girl
stage
treat
surgeri
surviv
e
b
k
w
b
r
j
e
univers
gdansk
dep
patholog
neuropatholog
gdansk
poland
univers
gdansk
dep
biolog
genet
gdansk
poland
hospit
gdansk
dep
pathomorpholog
gdansk
poland
health
memori
institut
warsaw
dep
patholog
warsaw
poland
health
memori
institut
warsaw
dep
ocolog
warsaw
poland
univers
cluj
dep
children
oncolog
cluj
romania
univers
gdansk
dep
hematolog
oncolog
gdansk
poland
backgroundobject
germ
cell
tumor
gct
group
neoplasm
differ
level
direct
differenti
gonad
extragonad
local
embryon
cell
migrat
way
sever
signal
pathway
particip
migrat
specif
cell
line
embryogenesi
catenin
tgfb
sonic
hedgehog
shh
pathway
role
shh
signal
gct
analyz
detail
abnorm
activ
signal
observ
mani
type
gastric
lung
breast
pancreat
prostat
also
glioma
medulloblastoma
main
element
pathway
encod
shh
smo
sufu
shh
signal
interact
also
mani
system
designmethod
analysi
express
shh
pathway
relat
gene
pediatr
gct
perform
case
tumor
differ
histolog
categori
matur
teratoma
immatur
teratoma
mix
gct
yolk
sac
tumor
dysgerminomaseminoma
embryon
carcinoma
control
tissu
tissu
section
underw
dna
rna
isol
express
analysi
perform
repeat
qpcr
case
quiagen
kit
hedgehog
signal
pathway
profil
pcr
array
includ
gene
engag
shh
signal
transduct
next
step
analysi
dedic
softwar
geneglob
quiagen
result
result
avail
tumor
signific
differ
express
control
tumor
sampl
observ
concern
key
gene
smo
hhip
overexpress
differ
tumor
signific
differ
express
variou
gct
histolog
categori
also
found
conclus
result
show
shh
relat
protein
involv
gct
biolog
context
level
direct
differenti
work
financ
polish
nation
scienc
centr
grant
head
e
ahmad
childrenhospit
institut
child
health
lahor
paediatr
haematologyoncolog
lahor
pakistan
children
hospit
institut
child
health
lahor
pakistan
paediatr
surgeri
lahor
pakistan
backgroundobject
children
hospit
lahor
bed
tertiari
hospit
bed
paediatr
oncolog
unit
provid
free
cancer
treatment
new
case
year
refer
punjab
across
border
object
present
clinic
histolog
featur
prepubert
testicular
ovarian
tumor
experi
singl
institut
resourc
limit
set
review
designmethod
total
prepubert
children
treat
gonad
tumor
children
hospit
lahor
pakistan
januari
decemb
retrospect
review
histopatholog
find
risk
stratif
clinic
stage
outcom
analyz
treat
use
ukccsg
protocol
jeb
chemotherapi
result
among
primari
ovarian
testicular
tumor
case
femal
less
year
age
tumor
size
cm
high
risk
histopatholog
reveal
yolk
sac
mix
malign
gct
teratoma
jgcto
sertoli
leydig
cell
tumor
rest
unspecifi
stage
ii
stage
iii
stage
iv
surgeri
form
orchidectomi
oosalpingectomi
done
case
mdt
util
case
complet
rx
well
abandon
rx
expir
mainli
due
infect
progress
diseas
advanc
stage
delay
onset
rx
febril
neutropenia
common
event
rx
obstruct
uropathi
recurr
tumor
surgeri
refer
chemotherapi
time
tumor
benign
conclus
prepubert
gonad
tumor
malign
common
histolog
yolk
sac
tumor
follow
dysgerminoma
high
mortal
abandon
reduc
time
diagnosi
effect
multidisciplinari
team
manag
achiev
excel
cure
rate
obtain
develop
countri
hw
chueh
sy
jy
univers
colleg
medicin
depart
laboratori
medicin
busan
republ
korea
univers
colleg
medicin
depart
pediatr
busan
republ
korea
backgroundobject
gonadoblastoma
malign
transform
occur
frequent
femal
turner
syndrom
ts
chromosom
materi
gonadoblastoma
usual
occur
bilater
mostli
patient
late
adolesc
earli
howev
gonadoblastoma
germ
tumor
malign
transform
patient
turner
syndrom
without
materi
report
rare
designmethod
report
girl
diagnos
yolk
sac
tumor
turner
syndrom
without
chromosom
materi
result
case
girl
came
pediatr
depart
evalu
mass
sacral
area
receiv
resect
surgeri
area
biopsi
reveal
benign
teratoma
sacrum
ultrasonographi
serum
afp
level
check
everi
month
regularli
surgeri
studi
visit
show
rise
serum
afp
upto
ngml
newli
found
mass
lesion
size
x
cm
sacral
area
resect
done
biopsi
result
reveal
yolk
sac
tumor
metastat
work
show
evid
mestastasi
sacral
tumor
big
attach
firmli
sacral
area
bladder
rectum
suffer
neurogen
bladder
incontin
surgeri
karyotyp
result
report
surgeri
show
abnorm
femal
chromosom
x
der
x
del
xp
del
xq
x
neg
sri
gene
receiv
cycl
chemotherapi
treatment
current
well
without
sign
relaps
receiv
rehabilit
therapi
bladder
train
hear
conclus
gonadoblastoma
origin
malign
occur
turner
syndrom
without
chromosom
materi
need
evalu
find
whether
germ
cell
tumor
occur
process
gonadoblastoma
occur
incident
md
de
pasqual
p
r
g
f
p
f
f
children
hospit
ircc
oncohematolog
rome
itali
civico
di
cristina
e
itali
pediatr
hematologyoncolog
unit
palermo
itali
children
hospit
ircc
surgeri
rome
itali
children
hospit
ircc
patholog
rome
itali
istituto
g
gaslini
oncolog
genova
itali
padua
pediatr
women
children
health
depart
padova
itali
ircc
istituto
nazional
dei
tumori
di
milano
pediatr
milano
itali
ircc
istituto
nazional
dei
tumori
di
milano
surget
milano
itali
padua
pediatr
surgeri
women
children
health
depart
padova
itali
palermo
pediatr
surgeri
palermo
itali
backgroundobject
due
rariti
diseas
high
cure
rate
newli
diagnos
patient
limit
data
salvag
treatment
children
relapsedresist
germ
cell
tumor
gct
designmethod
prospect
collect
data
regard
patient
enrol
aieop
associazion
italiana
ematologia
oncologia
pediatrica
tcgm
protocol
treatment
gct
analyz
patient
relapsedprogress
malign
gct
chemotherapi
includ
result
patient
male
femal
median
age
month
rang
includ
studi
primari
tumor
site
extragonad
patient
ovari
patient
testi
patient
diagnosi
patient
present
metastat
diseas
patient
local
diseas
patient
non
seminomat
gct
twelv
patient
relaps
progressiveresist
diseas
patient
receiv
chemotherapi
slct
base
combin
carboplatin
etoposid
ifosfamid
patient
surgeri
residu
diseas
slct
also
perform
subsequ
patient
underw
high
dose
chemotherapi
hdct
autolog
hematopoiet
stem
cell
rescu
one
patient
lost
follow
complet
remiss
cr
hdct
median
time
month
relaps
rang
patient
aliv
cr
slct
receiv
hdct
patient
die
due
diseas
progress
three
receiv
hdct
progress
diseas
slct
overal
surviv
surviv
respect
death
conclus
slct
follow
hdct
effect
salvag
treatment
children
relapsedresist
gct
howev
role
hdct
follow
treatment
need
investig
especi
regard
identif
specif
patient
subgroup
benefici
intens
treatment
l
fan
xinhua
hospit
affili
shanghai
jiaotong
univers
school
medicin
depart
pediatr
surgeri
shanghai
china
backgroundobject
studi
aim
review
clinic
characterist
treatment
outcom
children
ovarian
germ
cell
tumor
ogct
designmethod
clinic
data
case
histolog
proven
ovarian
germ
cell
tumor
treat
depart
june
june
retrospect
analyz
result
one
hundr
six
patient
recruit
period
mean
age
year
menstruat
case
right
side
case
left
side
ovarian
tumor
group
common
symptom
pelvic
mass
acut
abdomin
pain
case
ovarian
torsion
patient
underw
emerg
exploratori
surgeri
patient
underw
elect
exploratori
surgeri
patient
underw
unilater
receiv
tumor
dissect
histolog
subtyp
includ
matur
teratoma
immatur
teratoma
dysgerminoma
yolk
sac
tumor
embryon
carcinoma
case
young
granular
cell
tumor
postop
patient
receiv
chemotherapi
accord
patholog
find
time
month
month
one
patient
recurr
diseas
underw
secondari
surgeri
period
girl
admit
puberti
normal
menstruat
normal
fshlh
level
conclus
ovarian
germ
cell
tumor
rare
childhood
girl
abdomin
pain
abdomin
mass
highli
vigil
treatment
fertil
spare
oper
show
good
outcom
dissect
unilater
ovari
attach
affect
adolesc
menstruat
fshlh
level
data
fumino
k
h
h
prefectur
univers
medicin
depart
pediatr
surgeri
kyoto
japan
prefectur
univers
medicin
depart
orthoped
kyoto
japan
prefectur
univers
medicin
depart
pediatr
kyoto
japan
backgroundobject
sacrococcyg
germ
cell
tumor
children
consist
teratoma
malign
standard
surgic
goal
intrapelv
lesion
en
bloc
resect
tumor
coccygectomi
via
approach
sinc
introduc
laparoscopi
abdomin
approach
report
experi
use
approach
en
bloc
resect
paper
designmethod
april
march
three
children
cystic
teratoma
yolk
sac
tumor
underw
laparoscop
approach
laparoscop
procedur
port
use
coagul
shear
result
regard
teratoma
two
infant
altman
ii
iii
underw
surgic
treatment
indic
laparoscopi
tumor
consist
mainli
multilocular
cyst
patient
cardiac
function
toler
pneumoperitoneum
surgic
strategi
teratoma
follow
laparoscop
mobil
pelvic
part
tumor
preserv
intrapelv
structur
hypogastr
nerv
constant
observ
intraabdomen
posterior
approach
purpos
manipul
posterior
sacral
part
perform
lower
limb
retract
upward
keep
supin
posit
postop
cours
patient
satisfactori
good
cosmet
regard
malign
girl
yolk
sac
tumor
larg
intrapelv
mass
intraspir
extens
cycl
neoadjuv
chemotherapi
laparoscop
combin
approach
sacrectomi
perform
time
laparoscop
maneuv
perform
order
tumor
margin
mark
metal
clip
en
bloc
sacretomi
prone
posit
small
tumor
size
sever
adhes
surround
organ
postop
cours
satisfactori
neurolog
deficit
develop
conclus
use
laparoscopi
provid
good
surgic
view
pelvi
allow
minim
manipul
intrapelv
tumor
abdomin
approach
feasibl
safti
procedur
hambraeu
j
l
univers
hospit
pediatr
surgeri
lund
sweden
univers
laboratori
medicin
lund
sweden
univers
clinic
scienc
lund
sweden
backgroundobject
sacrococcyg
teratoma
sct
rare
congenit
tumor
birth
preval
pathogenet
background
remain
unclear
studi
aim
evalu
presenc
genom
alter
gene
express
signatur
sct
designmethod
screen
allel
imbal
analysi
perform
sampl
sacrococcyg
teratoma
gene
express
analyz
rna
sequenc
case
matur
sct
case
immatur
sct
rna
extract
sampl
repres
matur
immatur
neuron
area
teratoma
gener
sampl
global
gene
express
pattern
compar
refer
group
consist
malign
pediatr
tumor
morpholog
differ
area
within
sct
result
analysi
detect
allel
imbal
analyz
sct
sampl
compar
refer
group
sct
uniqu
transcript
profil
divers
set
gene
highli
express
sct
includ
signal
pathway
neuron
synaps
neurotransmitt
egf
molecul
pathway
earli
germ
cell
state
pluripot
also
highli
express
sct
compar
morpholog
differ
area
within
sct
immatur
region
show
high
express
histon
gene
compar
neuron
area
addit
gene
two
transcript
factor
show
high
express
immatur
area
current
evalu
correspond
protein
marker
immatur
sct
compon
conclus
sacrococcyg
teratoma
genet
stabl
tumor
highli
divers
respect
gene
express
sct
share
common
activ
pathway
involv
neuron
develop
endoderm
growth
well
pathway
earli
germ
cell
pluripot
jy
han
children
capit
medic
univers
surgic
oncolog
beij
china
backgroundobject
analyz
treatment
outcom
endoderm
sinu
tumor
est
vagina
children
designmethod
retrospect
review
conduct
medic
record
patholog
materi
patient
est
vagina
treat
beij
children
hospit
ultrasonographi
ct
scan
detect
serum
afp
level
biopsi
perform
treatment
evalu
tumor
statu
diagnos
confirm
patholog
imag
find
patient
treat
bleomycin
etoposid
cisplatin
bep
combin
chemotherapi
without
surgeri
result
patient
median
age
month
rang
identifi
averag
tumor
size
cm
one
patient
iliac
fossa
lymph
node
metastasi
serum
afp
level
markedli
elev
treatment
decreas
dramat
chemotherapi
drop
normal
level
two
three
cycl
chemotherapi
averag
cycl
seven
patient
obtain
complet
remiss
cr
averag
four
cycl
chemotherapi
five
patient
obtain
partial
remiss
pr
whose
serum
afp
turn
normal
level
residu
tumor
nodul
remain
three
receiv
surgeri
postop
patholog
confirm
necrot
tumor
cell
two
patient
refus
surgeri
receiv
cycl
bep
chemotherapi
without
serum
afp
increas
mean
time
patient
month
one
recurr
conclus
bep
chemotherapi
treatment
est
vagina
achiev
excel
result
children
lymph
node
metastasi
may
requir
chemotherapi
children
patient
residu
tumor
nodul
repeat
chemotherapi
recurr
subsequ
surgeri
chemotherapi
find
confirm
good
prognosi
vagin
est
k
x
z
hua
hospit
affili
shanghai
jiao
tong
univers
school
medicin
depart
pediatr
hematologyoncolog
shanghai
china
backgroundobject
pediatr
germ
cell
tumor
good
outcom
multimod
treatment
includ
surgeri
platinum
base
chemotherapi
pediatr
malign
tumor
refractori
recurr
case
need
salvag
therapi
report
two
aim
studi
result
current
treatment
surgeri
jeb
regimen
chemotherapi
extracrani
mgct
chines
children
investig
safeti
efficaci
multimod
salvag
approach
recurr
refractori
mgct
case
center
designmethod
patient
diagnos
extracrani
malign
germ
cell
tumor
enrol
period
anoth
recurr
refractori
case
refer
ad
studi
salvag
approach
treatment
includ
surgeri
jeb
carboplatin
etoposid
bleomycin
regimen
chemotherapi
case
salvag
approach
includ
chemotherapi
radiotherapi
surgeri
tri
recurr
refractori
case
result
evalu
treatment
result
median
month
surviv
overal
surviv
primari
case
respect
recurr
refractori
case
enter
salvag
approach
studi
seventeen
patient
aliv
till
end
surviv
overal
surviv
case
seri
respect
univari
analys
prognost
factor
found
signific
differ
os
patient
treat
without
local
irradi
versu
treat
without
second
surgeri
versu
cox
regress
model
reveal
surgeri
could
consid
individu
factor
contribut
shorter
surviv
conclus
combin
surgic
resect
jeb
chemotherapi
gct
children
good
outcom
demonstr
superior
surviv
outcom
recurr
refractori
case
success
local
control
radiotherapi
surgeri
chemotherapi
l
leung
ihi
phi
kki
pkh
paediatr
univers
hong
kong
depart
queen
mari
hospit
hong
kong
hong
kong
sar
backgroundobject
aim
studi
diseas
spectrum
long
term
surviv
paediatr
testicular
tumour
designmethod
retrospect
review
record
patient
testicular
tumour
patient
demograph
histolog
characterist
surgic
approach
treatment
modal
surviv
ef
surviv
analyz
variabl
evalu
correl
surviv
includ
stage
age
oper
tumour
size
tumour
marker
level
resect
margin
adjuv
therapi
result
identifi
patient
prepubert
adolesc
median
age
month
rang
month
diagnosi
percent
non
seminomat
germ
cell
tumour
yolk
sac
tumour
embryon
carcinoma
mix
embryon
carcinoma
yolk
sac
tumour
matur
teratoma
remain
two
larg
cell
calcifi
sertoli
cell
tumor
testicular
angiomyxoma
respect
ten
patient
diagnos
stage
one
stage
iii
three
two
stage
iv
twelv
patient
underw
radic
inguin
orchidectomi
one
underw
scrotal
orchidectomi
prior
referr
center
resect
margin
clear
patient
four
receiv
adjuv
chemotherapi
none
radiotherapi
median
follow
durat
month
rang
month
overal
surviv
ef
overal
surviv
relaps
occur
patient
median
month
rang
month
univari
multivari
analysi
identifi
posit
predict
factor
ef
overal
surviv
conclus
seri
show
predomin
malign
patholog
prepubert
patient
overal
long
term
surviv
favour
prompt
referr
special
center
vigil
surveil
relaps
recommend
lf
lope
cr
donato
g
eira
sr
v
milon
mt
de
assi
f
albonei
r
ca
cancer
center
children
cancer
hospit
barreto
brazil
de
oncologia
universidad
feder
de
sao
paulo
pediatr
oncolgi
sao
paulo
brazil
cancer
center
children
cancer
center
barreto
brazil
infantil
boldrini
pediatr
oncolgi
campina
brazil
cancer
center
pediatr
oncolgi
sao
paulo
brazil
de
tratamento
fabiana
macedo
de
moraesgacc
pediatr
oncolgi
sao
jose
do
campo
brazil
de
sao
oncolog
sao
paulo
brazil
da
de
brasilia
jose
de
alencar
pediatr
oncolog
brasilia
brazil
erasto
gaertner
pediatr
oncolgi
curitiba
brazil
santa
marcelina
pediatr
oncolgi
sao
paulo
brazil
de
medicina
da
preto
pediatr
oncolgi
ribeirao
preto
brazil
backgroundobject
germ
cell
tumour
childhood
rare
patient
refer
one
nation
protocol
designmethod
method
low
risk
lr
receiv
chemotherapi
protocol
treat
respond
standard
dose
pe
hd
pe
pe
receiv
pei
addit
ifosfamid
result
avail
analysi
pt
exclud
snc
violat
ovarian
testicular
sacrococcyg
mediastin
retroperiton
headneck
vagina
other
parotid
heart
peni
e
pt
e
ii
e
iii
e
iv
histolog
yst
pure
teratoma
mix
tumour
dysgerminoma
immatur
teratoma
embrionari
ca
coriocarcinoma
surviv
analysi
lr
year
overal
surviv
ir
gr
pr
treat
pe
hr
gr
pr
total
hr
pt
treat
e
iii
iv
gonad
extra
gonad
gr
treat
hdpe
pr
treat
hdpeivb
hr
pt
protocol
e
iii
iv
extra
gonad
iv
gonad
gr
receiv
cycl
pei
pr
receiv
cycl
pei
hr
protocol
extra
gonad
iii
iv
gonad
iv
pt
gr
receiv
cycl
pei
pr
pt
conclus
therapi
produc
excel
outcom
patient
gct
ir
challeng
remain
approach
patient
hr
diseas
g
martin
lf
ag
c
r
f
l
cancer
hospit
pediatr
depart
barreto
brazil
pediatr
paulo
brazil
marcelina
pediatr
paulo
brazil
da
de
pediatr
brazil
usp
pediatr
paulo
brazil
infantil
de
domingo
boldrini
pediatr
campina
brazil
backgroundobject
incid
gonad
tumor
increas
puberti
prior
year
age
predominantli
extragonad
studi
describ
germ
celltumor
gct
rare
region
head
neck
vagina
among
other
designmethod
nation
multicentr
protocol
gct
gct
gct
identifi
case
rare
region
result
rare
site
regist
consecut
protocol
gct
tumor
follow
number
patient
patient
respect
seri
show
follow
locat
kidney
dorsal
region
pericardi
sac
midlin
stomach
esophagu
uteru
liver
vagina
head
neck
vagina
gct
account
case
head
neck
other
case
head
neck
tumor
area
face
parotid
rhinopharynx
ephignatu
predominantli
pure
teratoma
immatur
teratoma
histolog
follow
yolk
sac
embryon
carcinoma
less
often
mix
gct
common
histolog
subtyp
vagin
gct
yolk
sac
less
often
mix
gct
vagin
tumor
patient
high
risk
contrast
head
neck
tumor
major
patient
low
risk
overal
surviv
year
vagina
head
neck
rare
primari
site
respect
conclus
rare
locat
tumor
malign
histolog
could
treat
patient
excel
rate
surviv
includ
one
present
vagin
tumor
usual
lead
wors
rate
surviv
relat
site
may
happen
probabl
due
resect
andor
stage
sinc
tumor
high
risk
regard
tumor
present
benign
histolog
could
observ
surviv
rate
relat
exclus
resect
ms
nwe
sg
cmj
sy
women
children
hospit
paediatr
haematologyoncolog
subspecialti
singapor
singapor
backgroundobject
mediastin
germ
cell
tumour
mgct
paediatr
group
rare
often
challeng
manag
describ
experi
singl
paediatr
center
asian
popul
designmethod
data
within
collect
singapor
children
cancer
registri
epidemiolog
aspect
clinic
present
treatment
outcom
review
result
incid
among
gct
year
period
two
patient
exclud
move
centr
median
age
year
year
male
one
associ
multipl
congenit
abnorm
klinefelt
syndrom
found
common
present
cough
week
patient
two
patient
stage
rest
stage
diagnosi
four
signific
rais
afp
afpbhcg
rais
patient
cur
chemotherapi
except
child
multipl
congenit
abnorm
global
retard
six
neoadjuv
chemotherapi
follow
surgeri
upfront
surgeri
perform
complic
residu
tumor
phrenic
nerv
damag
need
second
surgeri
receiv
adjuv
chemotherapi
one
patient
receiv
chemotherapi
alon
relaps
one
year
treatment
salvag
surgeri
myeloabl
chemotherapi
none
receiv
radiotherapi
year
os
df
respect
median
month
month
two
death
second
cancer
two
death
diseas
one
treatment
one
choriocarcinoma
second
cancer
happen
patient
one
leiomyosarcoma
lung
bone
bone
marrow
month
first
malign
surviv
salvag
chemotherapi
two
develop
haematolog
malign
system
mastocytosi
myeloprolif
marrow
mdsaml
month
year
first
diagnosi
respect
conclus
mgct
seen
mainli
adolesc
prognosi
poor
second
haematolog
malign
sw
quah
sh
gb
gener
hospit
paediatr
depart
paediatr
sarawak
malaysia
backgroundobject
paediatr
germ
cell
tumour
gct
account
approxim
childhood
cancer
western
popul
designmethod
retrospect
review
children
extracrani
gct
treat
sarawak
paediatr
oncolog
centr
year
patient
characterist
treatment
modal
outcom
analyz
result
extracrani
gct
compris
total
paediatr
cancer
treat
sarawak
incid
rate
case
per
children
sarawak
major
extracrani
gct
patient
youngest
age
group
year
year
group
anoth
year
group
year
male
femal
ratio
malay
predomin
ethnic
group
affect
follow
iban
chines
gonad
extragonad
tumour
almost
equal
distribut
major
extragonad
tumour
sacrococcyg
follow
retroperiton
thorac
other
children
year
age
common
site
sacrococcyg
region
retroperitoneum
testi
ovari
commonest
site
children
older
year
old
extracrani
gct
sarawak
commonli
present
mass
abdomin
distens
constitut
symptom
pain
obstruct
symptom
diagnos
antenat
matur
teratoma
made
extracrani
gct
rest
yolk
sac
tumour
immatur
teratoma
mix
malign
germ
cell
tumour
dysgerminoma
treat
surgeri
chemotherapi
requir
surgeri
term
outcom
patient
still
aliv
patient
die
lost
follow
conclus
incid
extracrani
gct
sarawak
higher
western
popul
excel
overal
surviv
rate
h
saeed
aur
khanum
memori
cancer
hospit
research
center
pediatr
oncolog
lahor
pakistan
north
children
hospit
pediatr
oncolog
newcastl
upon
tyne
unit
kingdom
ark
children
hospit
wale
pediatr
oncolog
cardiff
unit
kingdom
backgroundobject
residu
mass
present
upto
patient
malign
germ
cell
tumor
mgct
chemotherapi
varieti
site
mani
requir
mutil
surgeri
achiev
complet
resect
incid
viabl
tumor
vari
conduct
studi
review
manag
outcom
residu
mass
mgct
institut
designmethod
retrospect
review
electron
medic
record
pediatr
mgct
patient
residu
mass
end
chemotherapi
studi
period
partial
respons
pr
defin
reduct
size
imag
result
treat
patient
residuum
common
histolog
type
yst
patient
stage
iii
iv
common
locat
retroperiton
pr
seen
stabl
diseas
sd
progress
pd
fifteen
patient
underw
surgic
resect
biopsi
residu
mass
surgic
procedur
hysterectomyoophorectomi
five
patient
remain
biopsi
residu
tumor
identifi
two
patient
patient
achiev
pr
patient
receiv
chemoradi
residu
mass
resect
rest
follow
expectantli
progress
free
surviv
overal
surviv
entir
cohort
respect
year
median
follow
month
analyz
degre
respons
found
statist
signific
differ
os
pf
pr
os
pf
sd
os
pf
p
surviv
slightli
wors
patient
receiv
chemotherapyradi
residu
mass
conclus
residu
mass
frequent
find
end
treatment
mgct
tumor
greater
radiolog
respons
predict
excel
outcom
care
instead
aggress
therapi
may
consid
r
shah
k
j
r
l
blood
marrow
children
center
cancer
blood
children
hospit
lo
angel
depart
keck
school
univers
southern
california
lo
angel
usa
blood
marrow
transplant
children
center
cancer
blood
children
hospit
lo
angel
lo
angel
usa
blood
marrow
children
center
cancer
blood
children
hospit
lo
angel
depart
prevent
medicin
keck
school
univers
southern
california
lo
angel
usa
hospit
lo
angel
depart
radiolog
lo
angel
usa
backgroundobject
standard
surveil
earli
detect
relaps
extracrani
solid
tumor
est
elev
tumor
marker
tm
diagnosi
includ
tm
monitor
serial
radiograph
imag
given
high
sensit
tm
detect
relaps
role
radiograph
imag
debat
patient
est
designmethod
retrospect
chart
review
newli
diagnos
patient
est
elev
tm
result
patient
male
age
rang
year
includ
median
year
hepatoblastoma
hb
hepatocellular
carcinoma
hcc
malign
germ
cell
tumor
gct
median
serum
afp
diagnosi
ngml
ngml
ngml
hb
hcc
gct
respect
median
chorion
gonadotropin
diagnosi
gct
fourteen
patient
experienc
confirm
relaps
patient
tm
elev
preced
radiograph
detect
relaps
one
patient
hcc
tm
never
normal
diseas
progress
detect
radiograph
imag
prior
rise
serum
afp
mean
time
tm
elev
radiograph
detect
relaps
day
total
number
radiograph
imag
studi
perform
chest
comput
tomographi
ct
chest
ct
abdomenpelvi
magnet
reson
imag
radionuclid
bone
total
number
afp
assay
perform
respect
base
medicar
fee
schedul
total
tm
cost
radiograph
imag
cost
thu
omiss
routin
radiograph
surveil
patient
cohort
could
potenti
result
mean
cost
save
conclus
tm
assess
without
radiograph
imag
adequ
diseas
surveil
patient
est
elev
tm
diagnosi
normal
end
primari
treatment
surveil
tm
alon
reduc
radiat
exposur
health
care
cost
l
h
k
univers
school
medicin
depart
pediatr
nagano
japan
univers
graduat
school
medicin
center
advanc
medicin
clinic
research
nagoya
japan
teach
hospit
depart
pediatr
muthanna
iraq
municip
hospit
depart
patholog
nagano
japan
backgroundobject
dedic
cytokinesi
defici
rare
diseas
combin
immunodefici
exemplifi
broad
clinic
featur
primari
immunodefici
diseas
pid
account
autosom
recess
hyper
ige
syndrom
extend
beyond
recurr
infect
includ
atopi
autoimmun
cancer
lymphoprolif
diseas
lpd
complic
pid
difficult
diagnos
designmethod
case
report
iraqi
girl
histori
sever
eczema
sinc
earli
childhood
repeat
chest
infect
autoimmun
enteropathi
rel
retard
growth
present
year
ago
slowli
grow
right
jaw
mass
progress
sever
month
bilater
cervic
axillari
lymphadenopathi
laboratori
evalu
show
immunoglobulin
ig
assay
fold
normal
level
ige
iga
igg
respect
low
igm
addit
eosinophilia
lymphopenia
elev
ldh
bone
marrow
aspir
bma
hypercellular
eosinophilia
iraq
two
biopsi
mass
suggest
one
japan
reveal
spectrum
lpdplasmacyt
hyperplasia
complic
pid
though
viru
neg
situ
hybrid
japan
bma
transfer
japan
use
flinder
technolog
associ
fta
card
result
detect
sequenc
japan
use
dna
patient
treat
conserv
neither
steroid
chemotherapi
start
diet
gradual
jaw
mass
regress
eczema
rel
improv
conclus
although
lymphoma
could
occur
case
assert
care
pathogenet
evalu
advanc
set
crucial
rule
neoplast
process
avoid
expos
patient
unnecessari
riski
therapi
addit
disclosur
mutat
diagnost
entiti
cure
hematopoiet
stem
cell
transplant
acknowledg
appreci
siop
accept
abstract
publish
offici
congress
public
l
k
k
univers
school
medicin
depart
pediatr
nagano
japan
univers
graduat
school
medicin
center
advanc
medicin
clinic
research
nagoya
japan
colleg
sulaymaniyah
pediatr
teach
hospit
depart
pediatr
sulaymaniyah
iraq
municip
hospit
depart
patholog
nagano
japan
backgroundobject
mendelian
suscept
mycobacteri
diseas
msmd
caus
genet
defect
mononuclear
type
pathway
patient
msmd
increas
suscept
system
infect
weakli
virul
nontubercul
mycobacteria
ntm
includ
bacillu
bcg
vaccin
strain
mutat
gene
encod
receptor
identifi
patient
dissemin
salmonella
ntm
infect
dissemin
bcg
infect
follow
inocul
vaccin
set
unrespons
designmethod
case
report
syrian
girl
live
refuge
iraq
receiv
bcg
vaccin
develop
progress
axillari
swell
side
bcg
vaccin
repeat
biopsi
axillari
mass
regimen
given
accord
clinic
base
persist
high
esr
local
set
onoff
differ
systemat
infect
includ
mening
addit
relapsingremit
skin
rash
lymphadenopathi
fever
necessit
intens
care
one
occas
receiv
frequent
cours
doubt
respons
bone
marrow
aspir
bma
iraq
normal
bma
sampl
transfer
japan
use
flinder
technolog
associ
fta
card
result
mutat
detect
perform
sequenc
japan
use
genom
dna
extract
fta
sampl
conclus
diagnosi
msmd
due
defici
possibl
transfer
fta
sampl
genet
evalu
japan
acknowledg
appreci
siop
accept
abstract
publish
offici
congress
public
alkhamisi
z
v
faisal
special
hospit
research
centr
pediatr
surgeri
riyadh
saudi
arabia
faisal
special
hospit
research
centr
pediatr
hematolog
oncolog
riyadh
saudi
arabia
faisal
special
hospit
research
centr
radiat
oncolog
riyadh
saudi
arabia
backgroundobject
wilm
tumor
wt
common
childhood
malign
kidney
may
also
aris
outsid
renal
parenchyma
extraren
wilm
ewt
tumor
rare
often
report
sporad
isol
case
report
literatur
designmethod
present
case
old
girl
ewt
king
faisal
specialist
hospit
research
center
riyadh
result
old
girl
ewt
refer
abdomin
distens
month
histori
abdomin
distens
big
palpabl
mass
abdomen
start
left
flank
cross
midlin
abdomin
ultrasound
reveal
larg
solid
mass
left
side
abdomen
ct
abdomen
perform
reveal
soft
tissu
mass
occupi
left
abdomen
midlin
measur
approxim
x
x
cm
underw
open
biopsi
frozen
section
sent
histopatholog
confirm
diagnosi
wt
evid
anaplasia
stage
stage
iii
start
chemotherapi
ct
abdomen
repeat
week
chemotherapi
show
mild
reduct
tumor
size
laparotomi
tumor
mobil
separ
left
kidney
excis
tumor
safe
margin
done
patient
given
radiotherapi
left
abdomin
flank
conclus
ewt
rare
littl
inform
known
prognosi
respons
therapi
outcom
also
defin
manag
guidelin
establish
entiti
still
earli
manag
patient
thu
far
shown
good
respons
standard
manag
wt
continu
follow
term
respons
therapi
also
long
term
surviv
ash
e
e
e
children
medic
center
israel
rina
zaizov
divis
rosh
haain
israel
faculti
medicin
tel
aviv
univers
tel
aviv
israel
medic
center
dept
diagnost
radiolog
petach
tikva
israel
children
medic
section
pediatr
cardiolog
petach
tikva
israel
children
medic
center
israel
dept
diagnost
radiolog
petach
tikva
israel
medic
center
pediatr
oncolog
unit
afula
israel
medic
center
beilinson
hospit
dept
patholog
petach
tikva
israel
rabin
medic
center
institut
oncolog
petach
tikva
israel
backgroundobject
desmoid
fibromatos
rare
clinic
enigmat
soft
tissu
tumor
high
propens
local
invas
metastat
potenti
surgeri
remain
cornerston
primari
treatment
postop
recurr
common
tend
behav
aggress
primari
tumor
system
option
wide
vari
overal
show
margin
benefit
except
doxorubicin
doxorubicin
proven
clinic
benefit
use
limit
toxic
designmethod
maxim
local
efficaci
doxorubicin
minim
system
toxic
develop
protocol
doxorubicin
deliveri
via
drug
elut
bead
present
result
select
doxorubicin
elut
bead
four
children
recurr
refractori
desmoid
fibromatos
use
cumul
dose
assess
efficaci
tumor
respons
magnet
reson
imag
mri
symptomat
improv
result
tumor
volum
reduc
within
three
twelv
month
treatment
accompani
reduct
complet
elimin
mri
signal
patient
desmoid
fibromatos
symptomat
relief
accomplish
within
three
month
patient
singl
patient
experienc
transient
lower
extrem
paresthesia
grade
resolv
within
two
month
advers
effect
encount
post
treatment
follow
month
conclus
present
first
use
doxorubicin
deliveri
via
drug
elut
bead
patient
desmoid
fibromatos
achiev
control
local
drug
deliveri
achiev
promis
clinic
diseas
respons
quickli
use
fraction
standard
system
dose
encount
signific
toxic
e
ataseven
z
b
b
h
tepecik
research
train
hospit
depart
pediatr
hematolog
oncolog
izmir
turkey
tepecik
research
train
hospit
depart
pediatr
izmir
turkey
tepecik
research
train
hospit
depart
pediatr
gastroenterolog
hepatolog
izmir
turkey
backgroundobject
intestin
ganglioneuromatosi
gastrointestin
system
extrem
rare
often
associ
neurofibromatosi
multipl
endocrin
neoplasia
rare
present
sporad
form
report
patient
diffus
ganglioneuromatosi
diagnos
malign
peripher
nerv
sheath
tumor
mpnst
detect
surgeri
designmethod
boy
appli
attack
month
sever
abdomin
pain
diminish
oral
intak
kg
weight
loss
abdomin
usg
tomographi
reveal
diffus
ileal
wall
thicken
mesenter
lymphadenopathi
hospit
preliminari
diagnosi
inflammatori
bowel
diseas
physic
examin
reveal
diffus
skin
lesion
axillari
freckl
eye
examin
lisch
nodul
detect
famili
histori
learn
father
brownish
macul
skin
diagnos
colonoscopi
reveal
diffus
inflamm
mri
enterographi
perform
reveal
ileal
wall
thicken
diffus
polypoid
lesion
plexiform
neurofibroma
ileum
mesenteri
diffus
nodular
lesion
infiltr
superior
vascular
format
doubl
balloon
entheroscopi
reveal
diffus
polypoid
lesion
cm
segment
ileum
mucos
biopsi
taken
mucosa
reveal
diffus
ganglioneuromatosi
decid
surgeri
patient
sever
abdomin
pain
diminish
oral
intak
uncontrol
diarrhea
attack
surgeri
ileal
segment
polypoid
lesion
nodular
format
mesenteri
resect
resect
ileal
segment
contain
plexiform
neurofibromatosi
without
malign
transform
hand
mesenter
nodular
lesion
contain
mpnst
surgeri
residu
lesion
mesenteri
cevaia
carboplatinum
epirubicin
vincristin
ifosfamid
etoposid
actinomycin
chemotherapi
start
week
treatment
patient
achiev
remiss
month
follow
without
diseas
result
diffus
ganglioneuromatosi
larg
intestin
usual
affect
rare
condit
malign
transform
neurofibroma
occur
patient
mpnst
common
tumor
case
import
age
ganglioneuromatosi
small
intestin
rare
coexist
mpnst
conclus
malign
kept
mind
age
patient
follow
close
term
malign
mv
barcelona
ja
mj
j
mj
r
rey
memori
medic
center
depart
radiotherapi
manila
philippin
r
rey
memori
medic
center
depart
section
pediatr
manila
philippin
backgroundobject
major
consider
give
radiotherapi
children
acut
toxic
standard
treatment
nasopharyng
carcinoma
npca
adult
consist
concurr
chemoradiotherapi
without
adjuv
chemotherapi
howev
rariti
pediatr
patient
npca
make
sequenc
dosag
modal
less
protocol
publish
children
oncolog
group
note
good
overal
paper
aim
show
outcom
pediatr
patient
npca
treat
institut
util
protocol
designmethod
case
report
year
old
filipino
male
present
neck
mass
around
cm
note
year
prior
consult
without
accompani
symptom
five
month
prior
consult
mass
increas
cm
punch
biopsi
reveal
squamou
cell
carcinoma
poorli
differenti
head
neck
ct
scan
show
lobul
right
nasopharyng
mass
extend
right
tempor
lobe
enlarg
level
ii
lymph
node
stage
iva
protocol
adopt
cycl
induct
chemotherapi
ci
x
day
cisplatin
initi
ct
scan
reveal
absenc
mass
lymphadenopathi
patient
given
concurr
chemoradiotherapi
cisplatin
radiotherapi
includ
oppos
later
faciocerv
field
prescrib
fraction
low
anterior
neck
area
anteroposterior
field
prescrib
fraction
result
patient
toler
treatment
week
without
complic
delay
rtog
grade
toxic
skin
saliva
mucou
membran
note
imag
year
post
treatment
reveal
complet
absenc
mass
metastat
cognit
test
reveal
normal
find
conclus
first
report
use
protocol
case
pediatr
nasopharyng
carcinoma
countri
illustr
feasibl
effect
set
h
medic
center
pediatr
unit
rehovot
israel
children
medic
center
israel
pediatr
depart
israel
univers
medic
center
pediatr
depart
israel
medic
center
pediatr
unit
afula
israel
zedek
medic
center
pediatr
gaucher
hematolog
unit
jerusalem
israel
rehabilit
center
children
adolesc
depart
rehabilit
jerusalem
israel
rappaport
children
rambam
health
care
campu
pediatr
depart
haifa
israel
backgroundobject
nasopharyng
carcinoma
npc
rare
childhood
cancer
inform
regard
clinic
characterist
biolog
long
term
follow
childhood
npc
scarc
present
data
late
follow
npc
children
designmethod
retrospect
data
collect
medic
file
electron
data
studi
approv
local
irb
committe
result
children
npc
treat
pediatr
center
israel
thirti
four
patient
male
median
age
diagnosi
year
year
sixti
three
percent
children
jewish
patient
arab
four
patient
diagnos
stage
diseas
patient
diagnos
stage
diseas
none
children
distant
metastas
present
patient
receiv
radiotherapi
averag
dose
gy
gy
children
treat
chemotherapi
accord
regimen
use
year
median
time
year
month
year
long
term
follow
ten
children
event
five
patient
local
child
distant
patient
diseas
recurr
median
time
recurr
month
moth
four
children
develop
secondari
malign
median
time
secondari
malign
diagnosi
month
month
one
child
develop
intracrani
bleed
cavernoma
radiat
field
margin
median
time
first
event
month
month
six
children
die
four
children
succumb
diseas
children
die
secondari
malign
twenti
five
year
overal
surviv
event
free
surviv
respect
conclus
nasopharyng
carcinoma
rare
children
continu
long
term
follow
necessari
order
consid
novel
treatment
approach
highli
curabl
neoplasm
j
paj
h
bishop
aberdeen
children
hospit
depart
paediatr
oncolog
aberdeen
unit
kingdom
royal
infirmari
depart
patholog
aberdeen
unit
kingdom
aberdeen
children
hospit
depart
radiolog
aberdeen
unit
kingdom
backgroundobject
mutat
affect
key
subunit
switchsucros
swisnf
chromatin
remodel
complex
recent
identifi
caus
syndrom
css
omim
rare
autosom
domin
syndrom
heterogen
phenotyp
typic
involv
intellectu
disabl
characterist
facial
featur
aplasiahypoplasia
distal
phalanx
nail
fifth
digit
hirsut
spars
scalp
hair
swisnf
complex
also
function
tumour
suppressor
ts
import
aetiolog
paediatr
malign
rhabdoid
tumour
mrt
mutat
predominantli
involv
subunit
despit
ts
function
swisnf
complex
neoplast
disord
spars
report
amongst
patient
css
mrt
previous
describ
css
designmethod
report
case
year
old
femal
mrt
recent
diagnos
css
due
mutat
whole
exom
sequenc
part
deciph
development
disord
studi
absent
express
tumour
analysi
literatur
search
ovid
medlin
embas
perform
review
exist
evid
risk
mrt
css
result
report
identifi
mrt
css
singl
case
report
hepatoblastoma
schwannomatosi
astrocytoma
css
current
limit
understand
link
swisnf
relat
neurodevelopment
disord
neoplast
diseas
although
caus
protein
css
report
associ
tumour
develop
conclus
css
rare
disord
genet
basi
recent
identifi
multipl
subunit
swisnf
complex
may
affect
heterogen
mutat
disord
report
novel
case
mrt
context
germlin
mutat
research
warrant
whether
germlin
mutat
compon
swisnf
complex
impact
risk
diseas
develop
sever
relat
tumour
mrt
bay
r
univers
oncolog
institut
pediatr
hematolog
oncolog
istanbul
turkey
univers
cerrahpasa
medic
faculti
oncolog
institut
pediatr
hematolog
oncolog
istanbul
turkey
univers
oncolog
institut
surgic
oncolog
istanbul
turkey
backgroundobject
malign
melanoma
mm
compris
malign
children
adolesc
studi
aim
evalu
clinic
aspect
histopatholog
featur
treatment
outcom
mm
patient
designmethod
retrospect
review
result
femal
male
patient
median
age
year
mo
diagnos
istanbul
univers
oncolog
institut
evalu
three
patient
consult
thu
patient
assess
cutan
melanoma
except
one
mucos
conjunctiv
melanoma
frequent
local
lower
extrem
six
upper
extrem
head
neck
abdomen
two
sentinel
lymposcintigraphi
sentinel
node
biopsi
petct
perform
stage
procedur
initi
diagnosi
local
diseas
present
seven
patient
nine
region
lymph
node
metastasi
three
develop
distant
metastasi
bone
lung
median
month
median
breslow
width
tumor
mm
mm
treatment
surgeri
local
diseas
surgeri
adjuv
interferon
patient
region
lymph
node
metastasi
one
patient
region
lymph
node
bone
metastasi
recurr
reciev
vemurafenib
immunotherapi
pembrolizumab
three
month
die
anoth
die
metastat
recurr
patient
conjunctiv
melanoma
distant
metastasi
respond
treatment
temozolamid
mutat
neg
immunotherapi
ipilumumab
initi
palli
radiotherapi
administ
bone
brain
metastasi
median
patient
month
mo
year
overal
surviv
conclus
although
mm
rare
children
prognosi
good
diagnos
earli
clinician
awar
skin
lesion
full
layer
biopsi
obtain
suspici
skin
lesion
patient
congenit
melanocyt
nevu
dysplast
nevu
also
follow
cautious
fb
f
professor
bezmialem
vakif
univers
pediatr
hematolog
oncolog
istanbul
turkey
pediatr
fatih
turkey
pediatr
istanbul
turkey
backgroundobject
thymic
carcinoma
rare
neoplasm
children
identifi
larg
mass
anterior
mediastinum
hypertroph
pulmonari
osteoartropathi
hpo
occur
paraneoplast
syndrom
defin
develop
club
finger
toe
prolif
periost
long
bone
pain
symmetr
arthropathi
intrathorac
neoplasm
like
thymic
carcinoma
major
caus
hpo
yr
old
boy
develop
hpo
diagnos
thymic
carcinoma
present
designmethod
yr
old
boy
one
yr
last
malais
tender
bodi
develop
chang
finger
toe
chest
pain
last
three
month
present
tachypn
tachycard
physic
examin
unremark
club
finger
toe
swell
ankl
chest
mass
lesion
anterior
mediastinum
result
magnet
reson
imag
show
mass
cystic
solid
compon
show
mass
dens
fdg
involv
hypermetabol
state
biyopsi
reveal
primari
lymphoepitelioma
like
carcinoma
thymu
sinc
mass
unresect
clear
margin
cisplatin
etoposid
combin
chemoterapi
initi
symptom
malais
pain
wain
first
cycl
mass
gross
total
resect
four
cycl
conclus
thymic
carcinoma
rare
neoplasm
childhood
howev
paraneoplast
syndrom
like
hpo
alert
physician
suspicion
mediastin
mass
cakmakci
n
b
ergurhan
bilimleri
ankara
oncolog
hospit
pediatr
hematolog
oncolog
ankara
turkey
bilimleri
ankara
oncolog
hospit
surgeri
ankara
turkey
bilimleri
ankara
oncolog
hospit
patholog
ankara
turkey
backgroundobject
solid
pseudopapillari
tumor
pancrea
spt
rare
malign
tumor
exocrin
pancrea
account
pancreat
tumor
mainli
seen
young
women
aim
present
two
case
spt
pancrea
designmethod
case
girl
admit
trauma
histori
firm
mass
right
upper
side
abdomen
carcinoembryon
antigen
cea
level
elev
n
abdomin
ultrasound
usg
comput
tomographi
ct
reveal
larg
mass
pancreat
bodi
tail
x
cm
left
renal
vascular
structur
extend
midlin
stomach
capsular
tumor
total
excis
microscop
tumor
cell
eosinophil
cytoplasm
pseudopapillari
structur
mostli
compos
solid
area
diagnosi
consist
spt
postop
residu
lesion
x
cm
observ
subtot
pancreatectomi
splenectomi
left
hemicolectomi
perform
fin
remiss
month
sinc
diagnosi
result
case
girl
evalu
stomach
pain
last
month
refer
clinic
abdomin
mass
larg
firm
mass
palpat
right
upper
quadrant
protein
afp
human
chorion
gonadotrop
hormon
bhcg
cea
level
normal
ct
abdomen
reveal
larg
mass
x
cm
aris
right
lobe
liver
extend
right
kidney
cystic
solid
area
subtot
resect
pancreat
head
subtot
gastrectomi
cholecystectomi
perform
whippl
procedur
patholog
examin
spt
diagnos
neg
surgic
margin
recurr
observ
conclus
pancreat
spt
rare
tumor
gold
standard
treatment
surgeri
neg
margin
protect
pancreat
tissu
target
much
possibl
chavez
r
r
j
lima
peru
lima
lima
peru
backgroundobject
background
gastric
adenocarcinoma
gac
extrem
rare
type
cancer
children
repres
childhood
cancer
limit
inform
clinic
present
outcom
object
report
two
pediatr
patient
less
year
age
gac
treat
institut
designmethod
case
report
result
case
male
histori
month
weight
loss
dysphagia
anemia
mani
consult
endoscopi
show
suspici
lesion
neoplasia
refer
inen
march
thin
pale
patch
diffus
distribut
pain
epigastrium
mass
endoscopi
conclud
type
iii
stenos
gastric
malign
neoplasm
type
lesion
gastric
bodi
probabl
synchron
ct
scan
describ
thicken
distal
portion
esophagu
gastric
esophag
junction
stomach
partial
extend
adjac
fat
surround
aorta
celiac
trunk
metastat
diseas
anatom
patholog
infiltr
adenocarcinoma
solid
pattern
signet
ring
cell
unresect
tumor
genet
evalu
possibl
neurofibromatosi
legiu
syndrom
receiv
chemotherapi
folfox
regimen
leucovorin
oxaliplatin
cours
die
month
diagnosi
progress
diseas
case
girl
histori
month
character
abdomin
pain
dysphagia
ct
scan
show
thicken
gastric
wall
liver
metastasi
refer
inen
januari
endoscopi
describ
involv
anterior
wall
posterior
greater
curvatur
ulcer
lesion
infiltr
edg
find
relat
bormann
iii
patholog
report
infiltr
tubular
adenocarcinoma
moder
differenti
unresect
lung
metastasi
start
chemotherapi
folfox
scheme
complet
cours
progress
diseas
die
month
diagnosi
conclus
gastric
adenocarcinoma
gac
rare
type
cancer
children
poor
prognosi
h
cheng
children
capit
medic
nation
center
children
health
surgic
oncolog
beij
china
backgroundobject
malign
rhabdoid
tumor
mrt
rare
highli
aggress
tumor
commonli
occur
infanc
young
children
add
curremt
knowledg
diseas
review
mrt
patient
treat
institut
designmethod
retrospect
medic
record
review
conduct
patient
patholog
confirm
mrt
beij
children
hospit
januari
octob
result
patient
diagnos
mrt
median
age
month
includ
case
malign
rhabdoid
tumor
kidney
mrtk
five
case
atyp
teratoid
rhabdoid
tumor
atrt
involv
central
nervou
system
case
extraren
extracrani
rhabdoid
tumor
eert
fifteen
patient
mrtk
five
patient
eert
distant
stage
accord
surveil
epidemiolog
end
result
seer
stage
system
diagnosi
wherea
patient
atrt
local
region
tumor
among
patient
studi
patient
die
patient
surviv
four
patient
lost
among
dead
patient
patient
die
diseas
rapid
progress
tumor
recurr
patient
die
within
month
diagnosi
overal
surviv
rate
three
year
five
year
entir
cohort
respect
patient
male
younger
age
diagnosi
distant
seer
stage
poor
outcom
statist
signific
differ
surviv
note
among
patient
treat
regular
chemotherapi
radiotherapi
conclus
mrt
still
highli
aggress
tumor
children
patient
male
younger
age
metastat
diseas
like
poor
outcom
due
rapid
progress
recurr
tumor
multimod
therapi
combin
surgeri
chemotherapi
radiotherapi
recommend
consolid
radiotherapi
may
benefit
patient
p
chitalkar
cd
saim
cancer
centr
depart
medic
pediatr
oncolog
indor
india
medic
oncolog
indor
india
backgroundobject
langerhan
cell
histiocytosi
lch
present
spectrum
clinic
manifest
singl
bone
lesion
skin
rash
explos
dissemin
diseas
evalu
patholog
dendrit
cell
blood
bone
marrow
proven
lch
caus
myeloid
dendrit
cell
activ
ra
pathway
evid
suggest
cladribin
combin
cytosar
activ
advanc
lch
agent
shown
activ
bortezomib
lenalidomid
howev
evid
lack
safeti
efficaci
proteosom
inhibitor
immunomodul
children
report
case
child
rural
western
madhya
pradesh
india
designmethod
describ
eight
year
old
child
present
advanc
multisystem
lch
loss
follow
achiev
major
respons
induct
result
dk
resid
villag
km
away
develop
nail
chang
itch
rash
age
year
diagnos
lch
treat
induct
phase
vinblastin
prednison
month
lost
year
present
bulg
right
eyebal
vision
loss
decemb
mri
suggest
diffus
expans
bone
soft
tissu
along
wall
right
orbit
caus
axial
proptosi
found
hepat
skin
multisystem
lch
treat
cycl
cladribin
cytosar
day
everi
day
induct
achiev
signific
relief
proptosi
heal
cranial
bone
lesion
follow
maintain
vinblastin
five
day
prednison
six
day
purinethol
per
week
child
remain
major
partial
respons
good
qualiti
life
seventeen
month
treatment
conclus
case
repres
multisystem
involv
langerhan
cell
histiocytosi
advanc
case
cn
involv
cladribin
activ
combin
cf
classen
hematolog
univers
children
hospit
rostock
germani
backgroundobject
lung
carcinoma
extrem
rare
children
adolesc
therapi
prognosi
depend
histolog
subtyp
stage
era
target
therapi
molecular
understand
essenti
designmethod
pediatr
patient
lung
carcinoma
diagnos
univers
children
hospit
rostock
inoper
primari
tumor
metastas
found
howev
treatment
outcom
complet
differ
depend
diseas
subtyp
result
first
patient
caucasian
male
squamou
cell
cell
lung
carcinoma
without
egfr
overexpress
mutat
present
paraplegia
due
spinal
metastas
treatment
follow
adult
protocol
includ
cisplatinumgemcitabin
irradi
docetaxel
transient
respons
patient
experienc
progress
die
month
second
patient
caucasian
male
papillari
lung
adenocarcinoma
present
pain
hematothorax
pulmonari
metastas
biopsi
show
specif
genet
marker
mutat
palli
therapi
initi
cisplatinumpemetrexedbevacizumab
lead
tumor
reduct
gross
tumor
resect
multipl
chemotherapi
patient
prolong
stabl
diseas
good
qualiti
life
year
diagnosi
third
patient
caucasian
male
present
larg
tumor
upper
pulmonari
lobe
numer
scelet
metastas
lymph
node
biopsi
show
nut
carcinoma
polychemotherapi
initi
follow
recent
publish
observ
yet
earli
comment
outcom
none
patient
show
establish
drugabl
molecular
target
first
patient
treat
checkpoint
inhibit
era
conclus
lung
carcinoma
rare
children
adolesc
howev
may
manifest
extend
stage
therapi
follow
recommend
adult
depend
molecular
genet
howev
subtyp
like
nut
carcinoma
rare
adult
consid
requir
specif
treatment
approach
corsia
mjdd
j
n
n
g
mp
p
f
psl
research
univers
translat
research
pediatr
oncolog
pari
franc
psl
research
univers
unit
somat
genom
pari
franc
psl
research
univers
siredo
oncolog
center
innov
research
adolesc
young
adult
cancer
pari
franc
institut
et
doncologi
ihop
lyon
franc
strasbourg
laboratori
ea
progress
tumoral
et
approch
translationnel
et
strasbourg
franc
toulous
hematolog
oncolog
orthoped
surgeri
unit
toulous
franc
depart
patholog
lyon
franc
backgroundobject
rhabdoid
tumor
rt
exhibit
biallel
inactiv
core
member
swisnf
complex
genet
abnorm
rare
rt
present
retain
express
loss
anoth
core
subunit
complex
whether
rt
homogen
entiti
never
deepli
address
far
aim
answer
question
comprehens
analysi
biolog
featur
rt
designmethod
identifi
patient
rhabdoid
tumor
biolog
featur
assess
whole
exom
sequenc
rnaseq
methylom
array
illumina
k
rt
compar
cohort
rt
non
rt
pediatr
cancer
n
sever
cluster
method
appli
determin
biolog
homogen
rt
result
median
age
diagnosi
month
rang
month
famili
histori
cancer
report
tumor
locat
kidney
bladder
soft
tissu
thorax
show
region
metastat
extens
patient
refractori
treatment
relaps
within
year
diagnosi
die
within
year
constitut
dna
avail
patient
germlin
alter
genom
analysi
show
rt
copi
number
variat
apart
chromosom
also
notic
low
mutat
rate
compar
rt
recurr
mutat
cluster
method
use
rnaseq
methylom
profil
across
pediatr
cancer
show
rt
nt
cluster
separ
rt
conclus
rt
equal
aggress
rt
consist
approach
reveal
rt
highli
similar
featur
function
analys
cell
line
ongo
address
extent
redund
loss
rhabdoid
context
elhemali
w
g
cancer
univers
children
cancer
hospit
egypi
pediatr
oncolog
cairo
egypt
univers
children
cancer
hospit
egypt
radiotherapi
cairo
egypt
canser
univers
childrean
canser
hospit
egypt
surgic
oncolog
cairo
egypt
cancer
univers
children
cancer
hospit
egypi
surgic
oncolog
cairo
egypt
cancer
univers
children
cancer
hospit
egypi
radiodiagnosi
cairo
egypt
cancer
hospit
egypt
clinic
research
cairo
egypt
backgroundobject
colorect
carcinoma
crc
common
adult
extrem
rare
children
present
poor
prognosi
surgic
manag
entiti
still
obscur
lack
data
studi
aim
evalu
clinic
characterist
childhood
crc
determin
predictor
poor
outcom
designmethod
studi
retrospect
done
group
case
less
year
age
median
age
year
treat
children
cancer
hospit
egypt
period
patient
unfavor
crc
histopatholog
type
mucin
adenocarcinoma
case
metastat
diseas
present
initi
surgic
resect
complet
case
patient
receiv
adjuv
chemotherapi
four
patient
diagnos
rectal
adenocarcinoma
treat
upfront
patient
inform
includ
age
sex
predispos
factor
posit
famili
histori
clinic
characterist
diagnost
procedur
extent
diseas
treatment
method
histolog
type
outcom
collect
file
patient
approv
result
patient
tumor
progress
relaps
die
tumor
overal
surviv
os
event
free
surviv
ef
case
respect
year
two
case
rectal
case
progress
diseas
die
famili
histori
posit
case
case
predispos
syndrom
adenomat
famili
polyposi
neurofibromatosi
type
one
case
syndrom
conclus
delay
diagnosi
advanc
stage
diseas
importantli
mucin
type
histolog
major
determin
poor
outcom
childhood
colorect
carcinoma
surgeri
remain
mainstay
treatment
pediatr
crc
adult
preoper
radiotherapi
rectal
adenocarcinoma
offer
better
prognosi
chemotherapi
play
role
metastat
diseas
abl
stage
primari
tumor
better
local
control
r
farah
z
w
r
j
j
f
al
x
e
j
j
p
r
jj
g
r
z
yj
sy
c
g
oussama
abla
behalf
asian
middl
eastern
ame
histiocytosi
georg
hospit
univers
medic
center
depart
pediatr
beirut
lebanon
sick
children
divis
depart
pediatr
toronta
canada
friendship
hospit
beij
china
hospit
institut
medic
scienc
mumbai
india
medic
center
karachi
pakistan
medic
center
tel
hashom
tel
aviv
israel
institut
pediatr
beij
china
children
hospit
beij
china
behesho
medic
univers
iran
medic
univers
japan
faisal
cancer
center
kingdom
saudi
arabia
medic
center
israel
medic
scienc
univers
tokyo
tokyo
japan
univers
tokyo
japan
children
medic
center
israel
center
child
health
develop
tokyo
japan
univers
japan
medic
center
seoul
korea
children
hospit
iran
univers
medic
scienc
tehran
iran
abdulaziz
medic
citi
kingdom
saudi
arabia
children
hospit
institut
child
health
lahor
pakistan
women
children
hospit
singapor
jude
children
research
hospit
tennesse
unit
state
america
nation
medic
center
district
columbia
unit
state
america
univers
hospit
germani
indu
cancer
children
hospit
karachi
pakistan
khan
hospit
karachi
pakistan
children
medic
center
shanghai
china
backgroundobject
background
histiocyt
disord
present
wide
rang
clinic
manifest
sever
data
need
physician
look
patient
asia
middl
east
ame
lack
group
expert
region
conven
histiocyt
societi
meet
creat
ame
histio
network
object
assess
challeng
physician
ame
encount
treat
patient
histiocyt
disord
regard
diagnosi
treatment
avail
moleculargenet
test
assess
exist
nation
consensu
guidelin
designmethod
method
questionnair
distribut
question
includ
presenc
nation
registri
patient
support
group
avail
special
diagnost
test
exist
treatment
guidelin
result
particip
ten
countri
respond
nation
histiocytosi
associ
parent
support
group
histiocytosi
registri
special
imag
studi
avail
almost
center
sophist
geneticmolecular
test
hlh
genet
test
lack
mani
institut
center
adopt
intern
lch
hlh
treatment
protocol
difficulti
find
common
histiocytosi
chemotherapi
drug
novel
drug
cladribin
clofarabin
readili
avail
mani
center
great
interest
particip
nation
registri
clinic
trial
geneticmolecular
studi
exchang
inform
resourc
due
heterogen
particip
countri
prioriti
expect
vari
depend
countri
avail
resourc
conclus
lack
nation
histiocytosi
associ
parent
organ
treatment
guidelin
note
particip
diagnost
treatment
challeng
vari
among
differ
countri
due
econom
rather
geograph
reason
establish
intern
train
scholarship
support
physician
countri
limit
resourc
partnership
center
could
first
step
face
challeng
farrag
w
c
u
rwth
aachen
univers
hospit
divis
pediatr
oncolog
stem
cell
transplant
aachen
germani
egypt
cancer
assiut
univers
pediatr
oncolog
depart
assiut
egypt
school
hannov
institut
virolog
hannov
germani
backgroundobject
endem
area
almost
case
nasopharyng
carcinoma
npc
link
infect
viru
ebv
aim
investig
relationship
plasma
iga
antibodi
clinic
paramet
children
adolesc
npc
area
designmethod
data
patient
npc
regist
npc
studi
center
german
societi
pediatr
oncolog
hematolog
gpoh
aachen
univers
hospit
analyz
retrospect
paramet
analyz
includ
patient
age
gender
stage
diseas
statu
level
plasma
iga
time
diagnosi
end
therapi
durat
follow
outcom
result
one
hundr
patient
includ
studi
median
age
diagnosi
year
male
median
durat
follow
year
patient
stage
iv
iii
time
diagnosi
respect
time
analysi
patient
aliv
pretreat
plasma
level
avail
patient
posit
patient
iga
done
patient
posit
patient
median
plasma
level
diagnosi
copiesml
patient
stage
iv
diseas
vs
copiesml
patient
stage
copiesml
patient
relapsediseas
progress
vs
copiesml
other
detect
end
treatment
associ
higher
incid
relaps
p
mortal
p
conclus
level
plasma
diagnosi
children
adolesc
npc
correl
diseas
stage
high
level
plasma
diagnosi
continu
detect
end
treatment
predictor
relaps
poor
outcom
fortunati
j
j
w
g
p
nacion
de
j
p
garrahan
hematolog
oncolog
bueno
air
argentina
nacion
de
j
p
garrahan
radiolog
bueno
air
argentina
nacion
de
j
p
garrahan
orthoped
traumatolog
bueno
air
argentina
nacion
de
j
p
garrahan
surgeri
bueno
air
argentina
nacion
de
j
p
garrahan
patholog
bueno
air
argentina
backgroundobject
df
rare
tumor
intermedi
malign
local
invas
high
rate
local
relaps
lr
surviv
rate
although
surgeri
consid
mainstay
treatment
current
recommend
includ
conserv
approach
stabl
tumor
aim
describ
clinic
featur
outcom
patient
df
designmethod
retrospect
studi
patient
tumor
df
admit
institut
treat
sinc
accord
protocol
result
median
age
diagnosi
year
median
time
diagnosi
day
frequent
symptom
tumor
two
patient
gardner
syndrom
tumor
site
trunk
limb
respect
abdomen
pelvi
head
neck
respect
tumor
multifoc
patient
primari
surgeri
perform
tumor
complet
resect
ir
ir
ii
lr
occur
includ
ir
median
time
recurr
month
low
dose
chemotherapi
ldc
metotrexatevinblastin
given
patient
tumor
least
partial
respons
evid
tumor
tumor
stabl
diseas
tumor
show
progress
diseas
tumor
complet
remiss
initi
surgeri
major
toxic
observ
patient
aliv
except
one
lost
die
due
progress
diseas
eleven
patient
present
sequela
frequent
mobilitylimit
keloid
scar
surviv
overal
surviv
respect
conclus
df
local
aggress
diseas
high
lr
rate
regardless
surgic
margin
excel
surviv
rate
seri
ldc
allow
achiev
stabil
even
remiss
low
toxic
could
decreas
risk
surgic
sequela
gorbunova
blokhin
nation
medic
research
center
oncolog
sergeri
head
neak
moscow
russia
backgroundobject
nasopharyng
cancer
nc
rare
malign
epitheli
tumor
children
diseas
often
regist
boy
year
undifferenti
histolog
variant
nc
predomin
overal
surviv
rate
young
patient
local
stage
dissemin
one
exceed
object
report
result
treatment
nasopharyng
cancer
pediatr
patient
designmethod
studi
includ
patient
period
among
sick
boy
predomin
averag
age
boy
g
girl
g
undifferenti
version
nc
verifi
case
common
stage
nc
detect
patient
among
distant
metastas
detect
studi
antibodi
antigen
viru
carri
patient
chemotherapi
includ
drug
bleomycin
cyclophosphamid
doxorubicin
vinblastin
fluorouracil
cisplatin
dactinomycin
averag
cours
ht
radiat
therapi
sod
gy
nasopharynx
lymph
node
neck
area
distant
metastasi
irradi
background
special
treatment
immunotherapi
perform
result
median
treatment
month
relaps
aros
local
tumor
dissemin
process
therapi
carri
patient
local
dissemin
relaps
nc
live
without
sign
tumor
includ
dissemin
nc
elimin
die
progress
caus
relat
underli
diseas
conclus
carri
research
allow
establish
ration
combin
chemotherapi
radiat
immun
therapi
yang
patient
nc
j
hu
h
x
j
center
children
health
beij
children
capit
medic
univers
surgic
oncolog
beij
china
center
children
health
beij
children
capit
medic
univers
patholog
depart
beij
china
backgroundobject
inflammatori
myofibroblast
tumor
imt
mesenchym
neoplasm
low
incid
paper
aim
studi
clinic
characterist
treatment
abdomin
inflammatori
myofibroblast
tumor
aimt
children
designmethod
studi
evalu
pediatr
patient
diagnos
aimt
januari
januari
review
medic
record
data
result
studi
popul
male
femal
onset
age
rang
month
median
month
case
diffus
abdomin
lesion
remain
tumor
solitari
tumor
occur
urinari
system
includ
bladder
kidney
uret
accompani
symptom
like
hematuria
frequent
urin
pain
urin
tumor
occur
mesenteri
greater
omentum
mesorectum
initi
led
fever
anemia
intussuscept
dysuria
difficulti
defec
tumor
occur
retroperiton
space
repres
obstruct
jaundic
abdomin
enlarg
one
tumor
head
pancrea
also
led
jaundic
two
liver
led
abdomin
distent
fever
case
examin
ultrasound
ct
rich
blood
flow
enhanc
intens
phase
case
underw
resect
open
surgeri
includ
nephrectomi
pancreatoduodenectomi
five
enterectomi
two
children
diffus
abdomin
lesion
respect
underw
oper
cours
postop
chemotherapi
tumor
cell
fusiform
inflammatori
cell
infiltr
final
three
case
lost
infant
die
infect
month
surgeri
case
follow
month
surviv
includ
one
diffus
abdomin
lesion
conclus
imt
occur
abdomin
region
divers
symptom
solitari
lesion
remov
oper
studi
treat
diffus
abdomin
lesion
want
e
v
n
e
kachanov
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
clinic
oncolog
moscow
russia
research
center
oncolog
name
nn
petrov
cancer
biolog
russia
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
patholog
moscow
russia
research
center
pediatr
oncolog
immunolog
name
dmitri
rogachev
cytogenet
moscow
russia
backgroundobject
inflammatori
myofibroblast
tumor
imt
rare
type
neoplasm
pediatr
age
group
intermedi
biolog
behavioralk
gene
rearrang
occur
itm
larg
studi
lovli
cm
activ
gene
detect
patient
tumor
find
serv
basi
implement
crizotinib
group
imt
designmethod
boy
present
histori
chronic
anemia
time
diagnosi
growth
retard
note
well
laboratori
test
show
elev
inflammatori
marker
crp
mgl
pgml
imag
find
demonstr
presenc
larg
stomach
mass
size
cm
v
biopsi
done
histopatholog
reveal
imt
neg
alk
express
immunohistochemistri
ihc
alk
rearrang
fluoresc
situ
hybrid
fish
polymeras
chain
reaction
reveal
unbalanc
express
gene
detect
fusion
tumor
deem
unresect
allow
us
start
treatment
inhibitor
crizotinib
crizotinib
given
dose
mg
twice
daili
oral
result
rapid
respons
detect
first
month
therapi
volum
tumor
decreas
well
inflammatori
marker
mgl
pgml
also
patient
transfus
requir
progress
decreas
bodi
weight
time
diagnosi
kg
increas
weight
month
therapi
kg
inflammatori
marker
reach
normal
valu
month
therapi
signific
side
effect
observ
therapi
patient
treatment
month
conclus
present
patient
imt
dramat
respons
inhibitor
crizotinib
case
demonstr
necess
detail
analys
neg
imt
find
addit
druggabl
target
n
kalkan
b
b
n
c
univers
faculti
medicin
pediatr
oncolog
ankara
turkey
backgroundobject
involv
craniofaci
bone
common
langerhan
cell
histiocytosi
lch
lch
particular
craniofaci
bone
regard
lesion
chemotherapi
commonli
indic
studi
aim
review
institut
experi
children
isol
craniofaci
lch
bone
lesion
designmethod
hospit
chart
children
year
age
diagnos
craniofaci
bone
lch
hospit
review
retrospect
data
demograph
characterist
present
symptom
diagnost
intervent
treatment
approach
event
final
outcom
collect
analyz
result
case
identifi
diagnos
depart
januari
decemb
median
age
year
malefemal
common
symptom
pain
swell
ptosi
plain
commonli
util
imag
modal
follow
computer
tomographi
magnet
reson
imag
primari
site
involv
pariet
frontal
occipit
orbit
mandibular
tempor
bone
surgic
perform
case
patient
receiv
system
chemotherapi
two
requir
radiotherapi
surgic
perform
mostli
cranial
bone
pariet
occipit
frontal
bone
lesion
underw
biopsi
among
case
consid
cn
risk
lesion
one
underw
surgeri
none
receiv
chemotherapi
median
month
patient
lost
regular
one
patient
recurr
lch
tibia
second
remiss
chemotherapi
none
case
experienc
signific
lch
relat
sequela
conclus
local
control
surgic
resect
mostli
suffici
bone
lesion
craniofaci
lch
even
dura
involv
eight
case
lesion
experienc
problem
despit
chemotherapi
concept
lesion
especi
lch
orbit
bone
involv
revisit
z
karaka
r
istanbul
medic
faculti
depart
pediatr
istanbul
turkey
backgroundobject
extraren
rhabdoid
tumor
errt
rare
aggress
tumor
mainli
occur
infant
children
may
manifest
neurolog
symptom
involv
peripher
nerv
herein
report
boy
errt
brachial
plexu
palsi
designmethod
boy
admit
new
onset
immobl
left
arm
physic
examin
consist
brachial
plexu
palsi
axillari
mass
contrast
enhanc
mri
reveal
solid
infiltr
mass
aris
left
axillari
fossa
reach
supraclavicular
fossa
encircl
vascular
neural
bundl
patholog
examin
biopsi
report
ewe
sarcoma
thorax
ct
neg
metastas
altern
cours
ie
vac
schedul
fourth
cours
mri
repeat
due
left
shoulder
pain
swell
progress
residu
mass
document
subtot
resect
mass
perform
patholog
examin
report
malign
rhabdoid
tumor
chang
diagnosi
local
radiotherapi
second
line
chemotherapi
start
still
chemotherapi
partial
regress
mass
result
errt
rare
aggress
soft
tissu
sarcoma
great
diagnost
therapeut
challeng
tumor
usual
locat
region
total
resect
possibl
case
due
local
infiltr
pattern
literatur
similar
patient
two
case
brachial
plexu
involv
errt
report
conclus
small
children
malign
rhabdoid
tumor
place
differenti
diagnosi
soft
tissu
sarcoma
region
correct
diagnosi
schedul
aggress
local
attempt
import
increas
success
treatment
karaman
bayrak
z
istanbul
faculti
medicin
pediatr
hematolog
turkey
istanbul
faculti
medicin
pediatr
turkey
faculti
medicin
radiolog
turkey
backgroundobject
manag
epithelioid
hemangioendothelioma
ehe
consist
surgic
treatment
drug
administr
bevacizumab
without
treatment
aim
present
case
ehe
manag
without
treatment
designmethod
herein
introduc
girl
diagnosi
epithelioid
hemangioendothelioma
establish
incident
immunohistochem
investig
reveal
endotheli
specif
marker
includ
detail
examin
show
multipl
metastat
lesion
brain
lung
regardless
extent
metastat
lesion
without
treatment
prefer
base
patient
asymptomat
clinic
statu
result
third
month
sixth
month
first
year
control
visit
radiolog
examin
indic
stabl
multifoc
epithelioid
hemangioendothelioma
new
metastat
lesion
conclus
physician
awar
without
treatment
render
patient
ehe
asymptomat
clinic
statu
kawasaki
n
h
r
k
h
f
n
r
e
univers
pediatr
yamagata
japan
univers
second
depart
surgeri
yamagata
japan
univers
radiolog
yamagata
japan
univers
patholog
diagnost
yamagata
japan
univers
graduat
school
medicin
patholog
osaka
japan
backgroundobject
congenit
hemangioma
ch
rare
benign
vascular
tumor
prolifer
utero
occur
cutan
diaphragmat
lesion
rare
although
patholog
examin
import
exclud
aggress
tumor
biopsi
diaphragmat
lesion
difficult
abund
blood
flow
designmethod
describ
case
neonat
present
diaphragmat
ch
accompani
massiv
pleural
effus
receiv
biopsi
safe
prior
embol
feeder
vessel
result
newborn
male
admit
local
hospit
due
cyanosi
truncal
ct
scan
reveal
massiv
pleural
effus
larg
tumor
along
right
diaphragm
tumor
extend
liver
epicardium
continu
drainag
plural
effus
requir
enough
breath
thorac
mri
show
slight
hypo
intens
mass
contrast
well
open
chest
biopsi
embol
tumor
feeder
vessel
done
lesion
consist
nodular
lobular
capillari
vessel
neg
diagnosi
ch
made
pleural
effus
subsid
one
month
tumor
show
reduct
size
infant
particular
symptom
conclus
six
neonat
diaphragmat
ch
describ
literatur
case
first
case
diagnos
patholog
biopsi
tumor
feed
vessel
embol
prior
feed
vessel
embol
efficaci
safe
biopsi
accur
diagnosi
r
kebudi
r
b
fy
e
univers
cerrahpasa
medic
faculti
oncolog
institut
pediatr
hematolog
oncolog
istanbul
turkey
univers
oncolog
institut
radiat
oncolog
istanbul
turkey
univers
oncolog
institut
pediatr
hematolog
oncolog
istanbul
turkey
backgroundobject
aim
studi
evalu
demograph
clinic
therapeut
characterist
outcom
childhood
adolesc
nasopharyng
carcinoma
npc
singl
center
designmethod
januari
januari
file
patient
year
npc
treat
istanbul
univers
oncolog
institut
evalu
retrospect
patient
receiv
three
cours
neoadjuv
chemotherapi
regimen
bleomycin
epirubicin
bep
sinc
ep
follow
radiotherapi
given
primari
tumor
metastat
cervic
lymph
node
result
boy
girl
f
median
age
yr
present
mostli
lump
neck
headach
ear
nose
problem
median
month
year
nineti
biopsi
npc
type
iii
tumor
patient
advanc
stage
tumor
distant
metastati
chemotherapi
follow
radiotherapi
gy
primari
tumor
involv
lymph
node
cervic
nodal
region
overal
surviv
os
signific
differ
surviv
patient
receiv
bep
ep
seventeen
patient
die
accidentsuicid
second
primari
cancer
progress
diseas
seven
second
malign
develop
six
patient
late
effect
includ
hypothyroid
neck
fibrosi
xerostomia
boni
hypoplasia
skin
problem
hear
loss
conclus
children
adolesc
advanc
npc
treat
neoadjuv
chemotherapi
radiotherapi
high
locoregion
control
rate
much
higher
surviv
os
vs
os
report
center
reciev
radiotherapi
radiotherapi
adjuv
chemotherapi
neoadjuv
therapi
ep
chemotherapi
seem
effect
bep
survivor
follow
morbid
n
khanna
j
g
b
memori
hospit
radiat
oncolog
mumbai
india
memori
hospit
medic
oncolog
mumbai
india
memori
hospit
surgic
patholog
mumbai
india
memori
hospit
surgic
oncolog
mumbai
india
memori
hospit
diagnost
radiolog
mumbai
india
memori
hospit
nuclear
medicin
mumbai
india
backgroundobject
pleuropulmonari
blastoma
ppb
rare
aggress
neoplasm
childhood
aris
pleuropulmonari
mesenchym
evalu
profil
treatment
respons
outcom
patient
ppb
treat
tata
memori
hospit
tmh
designmethod
patient
histolog
confirm
ppb
retrospect
analyz
result
decemb
march
patient
male
histolog
proven
ppb
age
group
year
median
year
evalu
tmh
treatment
detail
avail
patient
mean
tumor
size
cohort
rang
presenc
pleural
effus
intrathorac
node
observ
patient
respect
present
local
extens
type
iiiii
diseas
cur
intent
treatment
offer
patient
receiv
intens
chemotherapi
six
patient
progress
induct
chemotherapi
henc
undergo
local
treatment
local
treatment
offer
patient
form
surgeri
follow
adjuv
radiotherapi
patient
wherea
patient
receiv
definit
radiotherapi
alon
time
last
follow
patient
aliv
diseas
free
patient
progress
diseas
chemotherapi
receiv
local
treatment
die
diseas
progress
patient
receiv
local
treatment
die
earli
local
relaps
surviv
entir
cohort
respect
choic
local
treatment
impact
outcom
conclus
ppb
associ
dismal
outcom
patient
respond
induct
chemotherapi
receiv
local
treatment
better
surviv
find
warrant
develop
new
aggress
strategi
manag
rare
neoplasm
p
khullar
hospit
research
institut
radiat
oncolog
new
delhi
india
hospit
research
institut
radiat
oncolog
new
delhi
india
backgroundobject
breast
cancer
pabc
defin
breast
cancer
diagnos
pregnanc
within
year
deliveri
pauciti
data
pabc
india
aim
studi
assess
paramet
outcom
pabc
centr
designmethod
screen
breast
cancer
case
regist
januari
decemb
found
case
pabc
result
median
age
year
rang
median
durat
symptom
month
median
tumor
size
cm
american
joint
committe
cancer
stage
distribut
stage
stage
ii
stage
iii
stage
iv
patient
seven
patient
present
inflammatori
breast
cancer
posit
famili
histori
elicit
fifteen
patient
brca
mutat
found
case
patient
diagnos
deliveri
patient
first
trimest
patient
second
trimest
patient
third
trimest
estrogen
receptor
er
progesteron
receptor
pr
posit
human
epiderm
growth
factor
receptor
posit
respect
tripl
neg
found
case
thirti
patient
tumor
patholog
node
posit
median
month
year
relaps
free
surviv
overal
surviv
respect
brain
common
site
system
relaps
conclus
pabc
constitut
breast
cancer
patient
associ
advanc
stage
present
outcom
poor
group
probabl
bad
tumor
biolog
tripl
neg
posit
found
respect
kn
koh
sm
jj
sy
jw
h
hj
hm
jj
medic
center
children
univers
ulsan
colleg
medicin
pediatr
seoul
republ
korea
medic
univers
ulsan
colleg
medicin
patholog
seoul
republ
korea
colleg
yonsei
univers
pediatr
wonju
republ
korea
backgroundobject
mapk
pathway
activ
known
associ
oncogenesi
langerhan
cell
histiocytosi
lch
purpos
studi
investig
frequenc
genet
mutat
correl
clinic
featur
prognosi
korean
patient
lch
designmethod
genom
dna
extract
sampl
patient
patholog
confirm
lch
treat
asan
medic
center
profil
somat
mutat
critic
gene
relat
tumor
develop
perform
use
oncomap
version
massarray
technolog
platform
sequenom
san
diego
ca
result
total
lch
case
evalu
median
age
diagnosi
year
rang
year
ratio
patient
singl
system
diseas
unifoc
bone
diseas
multifoc
bone
diseas
skin
diseas
multisystem
diseas
without
risk
organ
involv
risk
organ
involv
oncomap
assay
reveal
patient
harbor
braf
mutat
mutat
one
patient
braf
mutat
recurr
mutat
includ
n
n
n
mutat
age
diagnosi
presenc
multisystem
involv
differ
accord
genet
mutat
patient
braf
mutat
seem
unifoc
bone
diseas
patient
without
mutat
p
overal
surviv
surviv
rf
rate
patient
respect
rf
differ
accord
genet
mutat
conclus
studi
show
braf
mutat
frequent
demonstr
korean
patient
lch
result
suggest
mutat
profil
associ
organ
involv
predict
sever
diseas
u
kontni
l
b
univers
medic
center
pediatr
oncolog
stem
cell
transplant
aachen
germani
univers
medic
center
patholog
aachen
germani
univers
medic
center
interdisciplinari
center
clinic
research
aachen
germani
backgroundobject
nasopharyng
carcinoma
npc
highli
malign
epitheli
cancer
link
ebv
infect
addit
radiochemotherapi
led
surviv
rate
children
adolesc
npc
cell
sensit
apoptosi
via
tumor
necrosi
apoptosi
induc
ligand
trail
explor
role
trail
pathway
kill
npc
cell
natur
killer
nk
cell
designmethod
cell
differ
npc
cell
line
nasoepitheli
cell
line
use
control
expos
nk
cell
healthi
donor
presenc
absenc
cytotox
measur
calcein
assay
role
differ
kill
pathway
nk
cell
use
respect
inhibitor
regul
death
ligand
checkpoint
modul
rnaseq
flow
cytometri
result
nk
cell
kill
nasoepitheli
cell
kill
predomin
mediat
via
trail
pathway
incub
nk
cell
increas
cytotox
npc
cell
concomit
incub
npc
cell
cocultur
reduc
cytotox
could
overcom
block
axi
conclus
combin
augment
cytotox
nk
cell
npc
cell
vitro
could
strategi
improv
therapi
requir
evalu
vivo
na
f
l
e
l
c
l
materno
infantil
del
instituto
de
seguridad
social
del
estado
de
municipio
pediatr
oncolog
toluca
mexico
de
seguridad
social
al
servicio
de
lo
trabajador
del
estado
pediatr
oncolog
ciudad
de
mexico
nacion
de
pediatr
oncolog
ciudad
de
mexico
mexico
estat
de
dr
lui
gonzalez
f
pediatr
oncolog
campech
mexico
de
especialidad
pediatrica
pediatr
oncolog
tuxtla
gutierrez
mexico
gener
de
mexico
pediatr
oncolog
ciudad
de
mexico
mexico
infantil
teleton
oncologia
pediatr
oncolog
queretaro
mexico
para
el
pediatr
oncolog
tabasco
mexico
para
el
del
instituto
materno
infantil
del
estado
mexico
pediatr
oncolog
toluca
mexico
gener
de
celaya
pediatr
oncolog
celaya
mexico
para
el
poblano
pediatr
oncolog
puebla
mexico
backgroundobject
rare
malign
tumor
make
cancer
pediatr
age
nation
intern
cooper
project
allow
understand
biolog
improv
treatment
result
object
know
clinic
cours
prognosi
mexican
pediatr
patient
rare
malign
tumor
designmethod
design
multicentr
case
seri
includ
patient
rare
malign
tumor
childhood
accord
intern
cancer
classif
children
evalu
characterist
age
gender
main
symptom
durat
histopatholog
diagnosi
stage
mortal
receiv
treatment
surviv
time
descript
statist
perform
surviv
analyz
method
result
patient
evalu
age
month
year
year
time
evolut
symptom
prior
diagnosi
day
year
median
month
frequent
symptom
pain
palpabl
mass
predomin
histolog
type
thyroid
carcinoma
follow
gonad
tumor
pancreat
exocrin
tumor
patient
metastat
diseas
diagnosi
basic
treatment
surgeri
receiv
palli
treatment
patient
die
due
progress
due
toxic
patient
lost
due
abandon
transfer
adult
hospit
overal
surviv
rare
tumor
month
overal
surviv
thyroid
carcinoma
month
conclus
systemat
studi
patient
usual
possibl
difficult
know
real
incid
stage
treat
protocol
design
adult
major
patient
diagnos
advanc
stage
seri
surgeri
cornerston
treatment
age
constitut
organiz
barrier
treatment
patient
countri
p
mahajan
j
u
r
dw
r
colleg
texa
children
cancer
center
hematologyoncolog
texa
usa
colleg
medicin
patholog
houston
usa
colleg
medicin
pediatr
houston
usa
backgroundobject
outcom
children
rare
cancer
lag
behind
cancer
due
lack
clinic
trial
standard
treatment
protocol
diseas
expertis
north
american
pediatr
rare
tumor
registri
establish
texa
children
hospit
advanc
care
children
rare
cancer
designmethod
patient
less
year
age
diagnosi
rare
cancer
incid
per
million
consent
person
via
telephon
clinic
inform
abstract
medic
record
tumor
tissu
blood
saliva
sampl
obtain
patient
saliva
sampl
collect
biolog
parent
result
februari
march
patient
enrol
ten
differ
state
usa
canada
median
age
diagnosi
enrol
patient
year
rang
two
month
year
patient
male
patient
identifi
white
black
asian
american
indian
pacif
island
mix
race
four
declin
patient
hispan
diagnos
includ
thyroid
cancer
germ
cell
tumor
neuroendocrin
tumor
clear
cell
sarcoma
kidney
carcinoma
desmoplast
small
round
cell
tumor
melanoma
sex
cord
stromal
tumor
borderlin
tumor
ovari
mammari
analogu
secretori
cancer
pancreatoblastoma
inflammatori
myofibroblast
tumor
malign
mesenchym
tumor
soft
tissu
sarcoma
synovi
sarcoma
angiomatoid
fibrou
histiocytoma
epithelioid
sarcoma
dermatofibrosarcoma
protuberan
mpnst
liposarcoma
undifferenti
sarcoma
fifti
tumor
sampl
bloodsaliva
sampl
collect
patient
saliva
sampl
collect
parent
conclus
larg
number
children
rare
cancer
enrol
biolog
sampl
collect
inaugur
year
registri
registri
serv
resourc
clinic
basic
scienc
investig
interest
pediatr
rare
cancer
l
mark
p
e
f
dela
c
sloan
ketter
cancer
center
pediatr
new
york
usa
sloan
ketter
cancer
center
sloan
ketter
institut
new
york
usa
univers
medic
center
intern
medicin
new
york
usa
univers
medic
center
irv
cancer
center
core
new
york
usa
univers
cancer
center
system
biolog
new
york
usa
backgroundobject
malign
rhabdoid
tumor
mrt
rare
aggress
pediatr
solid
tumor
character
chromosom
rearrang
inactiv
gene
outcom
remain
poor
despit
multimod
treatment
mrt
among
genom
stabl
cancer
lack
therapeut
target
genet
mutat
use
virtual
infer
enrich
regulon
viper
algorithm
comput
infer
protein
activ
mrt
whole
transcriptom
data
avail
target
databas
identifi
candid
encod
vulner
approach
identifi
markedli
aberr
activ
nuclear
export
protein
mrt
compar
tumor
type
hypothes
mrt
may
depend
high
activ
depend
novel
direct
therapeut
approach
use
inhibitor
selinexor
designmethod
panel
mrt
atyp
teratoidrhabdoid
tumor
atrt
cell
line
use
vitro
studi
two
xenograft
pdx
mous
model
mrt
treat
selinexor
determin
effect
result
mrt
cell
line
demonstr
mark
baselin
activ
median
follow
hour
selinexor
treatment
nm
iqr
nm
mrt
nm
iqr
um
atrt
um
iqr
um
cell
line
correl
infer
activ
cell
line
highest
infer
activ
sensit
selinexor
treatment
selinexor
vitro
led
cell
cycl
arrest
induct
apoptosi
mrt
cell
line
vivo
treatment
two
mrt
pdx
oral
selinexor
day
significantli
inhibit
tumor
growth
model
p
conclus
selinexor
demonstr
efficaci
preclin
model
mrt
result
support
investig
selinexor
phase
ii
studi
children
mrt
c
mcate
j
c
fein
b
c
children
cancer
center
pediatr
houston
usa
nation
medic
center
pediatr
washington
dc
usa
children
medic
center
pediatr
cincinnati
usa
steven
alexandra
cohen
children
medic
center
new
york
pediatr
new
york
usa
children
hospit
pediatr
denver
usa
children
hospit
radiolog
houston
usa
backgroundobject
patient
langerhan
cell
histiocytosi
neurolog
dysfunct
may
fail
standard
therapi
biolog
clinic
parallel
neurodegener
multipl
sclerosi
ms
evalu
role
rituximab
treat
designmethod
chart
patient
treat
rituximab
fail
therapi
review
includ
male
femal
diagnos
age
year
central
nervou
system
risk
bone
lesion
occur
pituitari
involv
diabet
insipidu
di
onset
rang
year
diagnosi
lch
year
diagnosi
di
follow
treatment
failur
regimen
includ
cytarabin
clofarabin
alemtuzumab
ivig
rituximab
gener
given
dose
weekli
week
plan
repeat
dose
month
interv
howev
initi
week
period
complet
dose
frequenc
decreas
patient
develop
worsen
symptom
frequenc
increas
week
interv
four
patient
worsen
symptom
rituximab
weekli
week
repeat
week
interv
current
initi
protocol
patient
receiv
rituximab
time
onset
rituximab
therapi
rang
year
median
year
respons
motor
neuropsycholog
signssymptom
assess
result
six
patient
experienc
clinic
improv
rituximab
therapi
motor
symptom
improv
ataxia
tremor
children
propriocept
deficit
dysarthriadysphasia
five
patient
demonstr
improv
intellectu
behavior
psycholog
symptom
improv
tend
sustain
monthli
infus
rituximab
conclus
rituximab
treatment
result
improv
motor
behavior
intellectu
psycholog
symptom
select
group
patient
respond
therapi
monthli
infus
may
provid
optim
respons
k
nakashima
h
k
h
school
medic
kyushu
univers
depart
pediatr
fukuoka
japan
univers
depart
orthoped
surgeri
fukuoka
japan
school
medic
kyushu
univers
depart
radiolog
fukuoka
japan
school
medic
kyushu
univers
depart
pediatr
surgeri
fukuoka
japan
school
medic
kyushu
univers
depart
patholog
fukuoka
japan
backgroundobject
langerhan
cell
histiocytosi
lch
clonal
diseas
focal
dissemin
lesion
may
compress
surround
tissu
includ
spinal
cord
report
describ
spinal
symptom
first
manifest
pediatr
lch
neurolog
outcom
remain
unclear
designmethod
boy
histori
development
growth
delay
transfer
hospit
studi
leg
weak
admiss
seven
day
onset
paralysi
vital
sign
normal
neurolog
examin
reveal
complet
paralysi
lower
leg
comput
tomographi
ct
reveal
multipl
osteolyt
lesion
region
skull
vertebra
mass
lesion
lung
magnet
reson
imag
mri
whole
spine
show
compress
fractur
imag
epidur
tumor
level
compress
spinal
cord
result
twelv
day
develop
leg
weak
emerg
radiotherapi
start
tumor
biopsi
cours
radiotherapi
paralysi
steadili
amelior
exclud
infect
determin
patholog
diagnosi
lch
chemotherapi
start
appar
improv
complet
paraplegia
observ
total
gy
radiotherapi
subsequ
chemotherapi
leav
neurolog
sequela
year
age
literatur
search
studi
publish
found
children
lch
show
gener
favor
recoveri
neurolog
dysfunct
acut
phase
spinal
symptom
conclus
report
underscor
util
emerg
radiotherapi
neurolog
recoveri
spinal
lch
infant
observ
denot
valu
treatment
term
intact
surviv
preserv
motor
function
physic
growth
arzola
ce
cicero
palomo
colli
sadowinski
le
jf
medina
murillo
castorena
infantil
de
federico
oncolog
citi
mexico
infantil
de
federico
depart
clinic
experiment
patholog
citi
mexico
backgroundobject
langerhan
cell
histiocytosi
lch
rare
case
per
million
children
age
year
diseas
character
prolifer
accumul
clonal
dendrit
cell
extrem
clinic
heterogen
unpredict
cours
object
analyz
clinic
characterist
treatment
outcom
children
lch
designmethod
januari
decemb
newli
diagnos
patient
lch
enrol
retrospect
studi
medic
record
analyz
retrospect
patient
diagnos
patient
treat
hospit
infantil
de
federico
lch
iii
protocol
surviv
determin
use
method
differ
differ
group
compar
use
test
result
includ
patient
evalu
boy
girl
patient
diseas
clinic
group
cg
seven
diseas
cg
patient
diseas
cg
frequent
site
involv
bone
bone
marrow
involv
ocur
three
patient
hepat
enlarg
spleen
enlarg
respons
week
achiev
evalu
patient
patient
relaps
receiv
second
cours
induct
protocol
year
studi
five
children
die
due
progress
diseas
overal
surviv
os
median
period
year
conclus
studi
children
treat
lch
protocol
institut
drug
treatment
relaps
describ
origin
protocol
respons
rate
second
reinduct
effect
diseas
second
initi
treatment
patient
without
respons
week
effect
salvag
therapi
need
taken
account
futur
studi
new
strategi
decreas
incid
relaps
need
amg
pared
guerra
r
c
c
e
rebagliati
hospit
paediatr
oncolog
lima
peru
backgroundobject
liver
sarcoma
infrequ
mesenchym
neoplasm
difficult
diagnos
imag
histolog
object
emphas
earli
differenti
diagnosi
manag
designmethod
descript
studi
longitudin
retrospect
liver
sarcoma
children
year
rebagliati
hospit
year
result
case
hepat
cancer
sarcoma
averag
age
year
femal
sick
time
week
abdomin
pain
palpabl
mass
low
weight
normal
ultrasound
tomographi
larg
cystic
mass
partit
cm
right
hepat
lobe
one
case
pulmonari
metastasi
case
biopsi
undifferenti
embryon
sarcoma
desmin
vimentin
receiv
cyclophosphamidedoxorubicinifosfamideetoposid
first
case
chemotherapi
pre
postsurgeri
remiss
month
relaps
die
surgeri
second
case
stage
iv
receiv
dose
chemotherapi
present
massiv
hepat
hemorrhag
die
case
imag
echo
tomographi
diagnos
hydatid
cyst
receiv
albendazol
day
complic
tumor
ruptur
perform
tamponad
drainag
dissemin
vesicl
liver
patholog
undifferenti
embryon
hepat
sarcoma
desmin
vimentin
post
cours
chemotherapi
radic
surgeri
abscess
tumor
hepatocutan
fistula
receiv
chemoadjuv
case
biopsi
epitheli
hepatoblastoma
cours
cisplatin
tumor
increas
vein
thrombu
review
patholog
hepat
leiomyosarcoma
posit
start
imatinibifosfamidedoxorubicin
radic
surgeri
plu
chemoadjuv
global
surviv
one
undifferenti
embryon
sarcoma
one
leiomyosarcoma
diseas
free
surviv
month
conclus
sarcoma
uncommon
hepat
tumor
clinic
imag
challeng
diagnos
easili
complic
abscess
andor
hemorrhag
due
tumor
ruptur
histolog
diagnosi
difficult
due
morpholog
posit
hepat
tumor
immunohistochemistri
radic
surgeri
plu
chemotherapi
white
therapi
increas
surviv
park
hl
yj
hs
hs
sk
hw
mj
jm
es
jh
yj
ej
pediatr
nation
cancer
center
pediatr
cancer
republ
korea
samsung
sungkyunkwan
univers
school
medicin
depart
pediatr
seoul
republ
korea
univers
dongsan
medic
center
depart
pediatr
daegu
republ
korea
hee
univers
colleg
medicin
depart
pediatr
seoul
republ
korea
univers
univers
ulsan
colleg
medicin
depart
pediatr
ulsan
republ
korea
univers
colleg
medicin
depart
pediatr
busan
republ
korea
univers
colleg
medicin
depart
pediatr
cheonan
republ
korea
univers
colleg
medicin
depart
pediatr
daegu
republ
korea
nation
univers
colleg
medicin
depart
pediatr
jinju
republ
korea
univers
schoool
medicin
depart
pediatr
gwangju
republ
korea
nation
univers
colleg
medicin
depart
pediatr
daejon
republ
korea
cathol
univers
hospit
depart
pediatr
daegu
republ
korea
backgroundobject
oral
propranolol
recent
shown
highli
effect
infantil
hemangioma
ih
current
recommend
treatment
ih
present
prospect
studi
aim
identifi
possibl
therapeut
mechan
propranolol
earli
regress
indic
hematolog
paramet
designmethod
blood
sampl
obtain
babi
median
age
day
rang
day
day
treat
propranolol
medic
center
korea
twelv
differ
serum
cytokin
involv
angiogenesi
vasculogenesi
andor
chronic
inflamm
analyz
andor
month
propranolol
treatment
use
luminex
multiplex
assay
result
seventeen
patient
complet
studi
blood
sampl
month
patient
show
excel
regress
visual
analogu
score
va
maximum
score
seven
patient
lost
withdrew
consent
studi
month
propranolol
treatment
patient
still
studi
patient
larger
size
hemangioma
show
significantli
higher
growth
vascular
endotheli
growth
p
serum
vegf
matrix
show
steadi
decreas
treatment
period
statist
signific
patient
greater
improv
ih
year
show
significantli
less
decreas
year
patient
lower
matrix
show
greater
volum
reduct
year
treatment
conclus
studi
show
first
time
signific
chang
sever
blood
paramet
involv
angiogenesi
serum
indic
ih
regress
propranolol
potenti
use
sign
monitor
vascular
prolifer
n
peter
r
jk
n
graduat
institut
medic
educ
chandigarh
pediatr
surgeri
chandigarh
india
graduat
institut
medic
educ
chandigarh
anesthesia
critic
care
chandigarh
india
backgroundobject
backgroundaim
chest
wall
tumor
cwt
constitut
childhood
cancer
includ
sarcoma
studi
challeng
surgic
approach
event
resect
cwt
children
designmethod
materi
method
retrospect
analysi
patient
oper
chest
wall
malign
septemb
decemb
done
data
present
radiolog
histolog
diagnosi
neoadjuv
therapi
surgeri
immedi
post
oper
event
analyz
result
total
patient
boy
girl
oper
age
rang
year
median
year
five
patient
present
respiratori
distress
chest
pain
two
evalu
fever
two
present
upper
back
swell
preoper
fnac
done
case
ewe
sarcoma
posterior
chest
wall
rabhdomyosarcoma
rm
patient
underw
neoadjuv
chemotherapi
follow
surgic
excis
surgic
none
patient
requir
chest
wall
reconstruct
use
mesh
artifici
support
import
structur
like
brachial
plexu
diaphragm
spinal
canal
close
proxim
resect
margin
two
patient
requir
excis
part
lung
parenchyma
achiev
resect
six
patient
requir
blood
transfus
one
patient
requir
post
oper
ventil
patient
signific
problem
pulmonari
toilet
post
oper
period
biopsi
report
show
neg
margin
patient
one
patient
recurr
month
other
diseas
free
period
month
year
conclus
rib
chest
wall
resect
adequ
margin
import
treatment
cwt
surgic
plan
includ
accur
preoper
radiolog
approach
number
rib
resect
proxim
import
structur
reconstruct
keep
mind
adequ
pulmonari
toilet
pain
relief
ray
c
hospit
sick
children
paediatr
haematolog
oncolog
glasgow
unit
kingdom
backgroundobject
inflammatori
myofibroblast
tumour
imt
rare
mesenchym
malign
peak
incid
within
first
decad
life
complet
excis
fundament
cure
crizotinib
promis
novel
therapi
anaplast
lymphoma
kinas
alk
play
key
role
oncogenesi
alk
mutat
imt
well
describ
literatur
recent
trial
suggest
alk
inhibit
effect
crizotininb
consid
first
line
evid
discontinu
current
lack
designmethod
year
old
girl
present
progress
right
lid
swell
ptosi
downward
displac
globe
necessit
urgent
ophthalmolog
review
mri
ct
reveal
non
metastat
mass
within
right
superior
orbit
biopsi
confirm
imt
wild
type
alk
mutat
result
initi
commenc
prednisolon
long
term
effect
nt
sustain
ibuprofen
start
despit
initi
stabl
diseas
tumour
progress
month
trial
celecoxib
unsuccess
month
crizotinib
commenc
respons
dramat
detect
diseas
mri
post
month
therapi
conclus
patient
suffer
profound
myelosuppress
persist
prolong
neutropaenia
result
requir
signific
dose
reduct
patient
crizotinib
year
diseas
recurr
evid
guid
cessat
therapi
refer
target
alk
crizotinib
pediatr
anaplast
larg
cell
lymphoma
inflammatori
myofibroblast
tumor
children
oncolog
group
studi
yael
p
moss
et
al
http
journal
clinic
oncolog
octob
rhead
e
k
radcliff
oxford
univers
hospit
paediatr
oncolog
oxford
unit
kingdom
radcliff
oxford
univers
hospit
patholog
oxford
unit
kingdom
radcliff
oxford
univers
hospit
paediatr
surgeri
oxford
unit
kingdom
backgroundobject
primari
pancreat
tumour
rare
childhood
adolesc
present
diagnost
therapeut
challeng
clinician
present
singl
institut
experi
tumour
designmethod
year
retrospect
analysi
primari
pancreat
tumour
paediatr
adolesc
patient
carri
januari
march
data
collect
includ
patient
demograph
clinic
present
diagnosi
treatment
outcom
result
six
patient
identifi
primari
pancreat
tumour
femal
age
rang
diagnosi
year
case
histolog
diagnosi
confirm
imag
biopsi
resect
primari
mass
diagnosi
confirm
patient
liver
biopsi
tumour
type
solid
pseudopapillari
neoplasm
n
metastat
pancreat
neuroendocrin
tumour
net
n
tumour
indetermin
type
n
four
patient
underw
complet
surgic
resect
one
patient
metastat
pancreat
net
undergo
dotat
therapi
second
patient
start
cold
octreotid
treatment
multipl
endocrin
neoplasia
type
genet
confirm
patient
net
patient
current
aliv
median
follow
year
month
follow
rang
month
year
month
conclus
pancreat
tumour
extrem
rare
paediatr
adolesc
patient
incid
per
million
year
old
nation
cancer
institut
seer
surveil
epidemiolog
end
result
databas
tumour
account
less
paediatr
death
clinic
symptom
often
present
may
delay
localis
tumour
complet
surgic
resect
optim
treatment
offer
best
outcom
manag
metastat
tumour
depend
histolog
diagnosi
option
metastat
net
provid
prolong
symptom
control
roja
b
p
children
alberta
health
servic
pediatr
oncolog
edmonton
canada
children
univers
alberta
pediatr
oncolog
edmonton
canada
cancer
institut
pediatr
oncolog
edmonton
canada
backgroundobject
esthesioneuroblastoma
esn
tumor
aris
nasal
neuroepithelium
associ
vasopressin
product
syndrom
inappropri
secret
antidiuret
hormon
siadh
cerebr
salt
wast
csw
present
hyponatremia
describ
case
report
adult
aim
report
cohort
children
diagnos
esn
present
hyponatremia
trigger
intraven
fluid
ivf
designmethod
case
seri
pediatr
patient
age
year
esn
hyponatremia
induc
ivf
treat
two
center
result
three
patient
present
high
grade
esn
biopsi
proven
aris
paranas
sinus
intracranialorbit
extens
cervic
lymph
node
patient
bone
metastas
patient
receiv
cisplatin
day
etoposid
day
cycl
hydrat
hour
hour
patient
normal
baselin
sodium
na
develop
sever
hyponatremia
requir
ivf
titrat
normal
salin
salin
strict
fluid
balanc
electrolyt
monitor
patient
hyponatremia
serum
osmol
urin
osmol
specif
graviti
urinari
sodium
na
becam
normal
patient
tumor
resect
patient
patient
male
initi
decompress
intracrani
tumor
extens
satisfactori
recoveri
month
later
day
na
patient
male
receiv
ivf
prior
central
line
insert
present
lethargi
na
requir
salin
case
present
siadh
base
fluid
retent
euvolemia
hyponatremia
patient
femal
day
na
csw
confirm
hypovolemia
hyponatremia
later
complic
proxim
tubulopathi
conclus
esn
present
siadh
salt
wast
result
hyponatremia
unmask
ivf
children
care
electrolyt
monitor
recommend
popul
prospect
studi
requir
confirm
associ
rongh
c
g
r
n
hospit
children
paediatr
oncolog
glasgow
unit
kingdom
hospit
children
paediatr
endocrinolog
glasgow
unit
kingdom
hospit
children
paediatr
ent
depart
glasgow
unit
kingdom
hospit
children
genet
glasgow
unit
kingdom
west
scotland
cancer
centr
clinic
oncologist
glasgow
unit
kingdom
backgroundobject
famili
tumour
suscept
syndrom
associ
mutat
first
describ
syndrom
characteris
autosom
domin
pattern
inherit
associ
rare
tumour
includ
pleuropulmonari
blastoma
cystic
nephroma
pineoblastoma
multinodular
goitr
present
case
minim
invas
follicular
thyroid
carcinoma
girl
dicer
syndrom
designmethod
patient
follow
stabl
renal
cyst
age
year
thyroid
swell
note
clinic
euthyroid
signific
famili
histori
benign
goitr
matern
side
femal
requir
thyroidectomi
post
pregnanc
thyroid
function
test
parathyroid
hormon
thyroid
antibodi
normal
ultrasound
scan
demonstr
larg
vascular
mass
within
left
lobe
thyroid
mri
confirm
mass
local
mass
effect
tracheal
deviat
evid
metastat
diseas
follow
mdt
discuss
perform
molecular
immunohistochem
profil
consist
minim
invas
follicular
carcinoma
excis
complet
discuss
manag
nation
intern
level
excis
complet
total
thyroidectomi
deem
necessari
therapi
also
felt
best
interest
given
young
age
complet
excis
late
advers
effect
associ
use
result
year
post
remain
clinic
well
given
famili
histori
rariti
tumour
genet
test
perform
gene
mutat
identifi
conclus
case
highlight
import
consid
test
presenc
posit
famili
histori
goitr
associ
featur
syndrom
genet
counsel
offer
affect
famili
recognis
need
surveil
chest
abdomin
ultrasound
scan
cranial
mri
although
evid
base
screen
lack
c
h
r
f
rongh
hospit
children
paediatr
oncolog
glasgow
unit
kingdom
hospit
children
paediatr
ent
glasgow
unit
kingdom
west
scotland
cancer
centr
clinic
oncolog
glasgow
unit
kingdom
therapi
institut
clinic
oncolog
florida
usa
backgroundobject
differenti
diagnosi
parotid
swell
children
expans
present
benign
malign
lesion
may
ident
parotid
salivari
gland
tumour
exceedingli
rare
present
two
case
salivari
gland
tumour
discuss
manag
outcom
designmethod
patient
girl
patient
boy
present
histori
parotid
gland
swell
patient
onward
referr
imag
instig
lesion
increas
size
investig
patient
initi
uss
reveal
well
circumscrib
lesion
within
left
parotid
gland
confirm
mri
patient
uss
demonstr
solid
mass
superfici
lobe
parotid
gland
associ
low
vascular
result
patient
underw
left
superfici
parotidectomi
mass
adher
facial
nerv
patholog
consist
low
grade
mucoepidermoid
carcinoma
posit
margin
near
facial
nerv
elect
treat
proton
therapi
given
high
risk
recurr
tumour
difficulti
surgeri
would
involv
ie
sacrif
facial
nerv
year
post
treatment
diseas
recurr
patient
underw
left
parotidectomi
tumour
local
extens
mandibular
branch
facial
nerv
histolog
consist
sialoblastoma
close
excis
margin
acknowledg
signific
risk
associ
radiotherapi
elect
observ
appreci
diseas
recur
surgic
excis
prove
difficult
six
year
post
resect
remain
well
evid
recurr
conclus
parotid
gland
tumour
exceedingli
rare
manag
complex
requir
multi
disciplinari
approach
report
success
outcom
two
patient
remain
diseas
free
three
year
post
therapi
sarod
f
g
n
greater
glasgow
clyde
surgerygener
medicin
glasgow
unit
kingdom
greater
glasgow
clyde
paediatr
oncolog
glasgow
unit
kingdom
greater
glasgow
clyde
paediatr
otorhinolaryngolog
glasgow
unit
kingdom
greater
glasgow
clyde
otorhinolaryngolog
glasgow
unit
kingdom
greater
glasgow
clyde
paediatr
endocrinologist
glasgow
unit
kingdom
greater
glasgow
clyde
clinic
oncolog
glasgow
unit
kingdom
backgroundobject
although
thyroid
cancer
compris
commonest
paediatr
endocrin
malign
absolut
incid
remain
low
consequ
remain
pauciti
evid
surround
optim
treatment
strategi
condit
aim
summaris
experi
manag
paediatr
thyroid
cancer
west
scotland
hope
expand
evid
base
inform
clinician
deal
uncommon
clinic
signific
condit
designmethod
patient
malign
thyroid
diseas
identifi
prospect
databas
thyroid
oper
perform
west
scotland
data
extract
use
retrospect
approach
extract
data
includ
follow
date
gp
referr
first
ent
outpati
review
ultrasound
fine
needl
aspir
surgeri
treatment
perform
result
analysi
identifi
five
relev
patient
averag
age
time
surgeri
year
manag
patient
highli
involv
follow
member
ent
surgeon
endocrinologist
paediatrician
clinic
oncologist
patient
underw
prior
surgeri
two
case
patholog
unequivoc
thyroid
carcinoma
patholog
reveal
three
patient
papillari
carcinoma
remain
two
follicular
carcinoma
averag
time
first
ent
outpati
review
day
surgeri
day
three
patient
underw
therapi
two
cycl
third
cycl
patient
develop
secondari
malign
time
analysi
conclus
analysi
confirm
incid
paediatr
thyroid
cancer
remain
low
west
scotland
experi
patient
manag
use
similar
strategi
adult
patient
condit
due
lack
guidelin
hope
build
upon
data
present
inform
clinic
practic
cap
af
rcp
ja
mj
sr
lg
c
scride
preto
medicin
school
univers
paulo
genet
depart
preto
brazil
de
recherch
en
de
inserm
oncolog
montpelli
franc
preto
medicin
school
univers
centro
pediatr
depart
preto
brazil
infantil
state
univers
campina
unicamp
pediatr
campina
brazil
preto
medicin
school
univers
paulo
pediatr
depart
preto
brazil
backgroundobject
although
childhood
adrenocort
tumor
act
rare
neoplasm
incid
brazil
particularli
higher
current
reliabl
biomark
abl
predict
diagnosi
prognosi
act
children
aim
find
potenti
biomark
act
prognosi
valid
express
found
differenti
express
microrna
profil
conduct
pediatr
act
sampl
designmethod
valid
perform
act
pediatr
tumor
adren
pediatr
sampl
associ
mirna
profil
clinicalbiolog
featur
analyz
test
express
adrenocort
carcinoma
cell
line
use
lentivir
vector
evalu
cell
viabil
gene
express
potenti
target
gene
e
result
overexpress
tumor
sampl
compar
adren
p
higher
level
found
tumor
mutat
patient
classifi
stage
ii
relat
classifi
stage
iv
accord
sandrini
classif
silenc
increas
cell
viabil
compar
control
p
also
increas
mrna
level
e
p
conclus
taken
togeth
data
show
express
profil
may
indic
prognosi
biologicalclin
paramet
pediatr
act
data
suggest
possibl
relationship
mirna
regul
gene
belong
pathway
import
adren
develop
igf
deregul
contribut
process
tumorigenesi
rcp
cap
ja
mj
sr
srr
lg
c
scride
preto
medicin
school
univers
centro
cesmac
brazil
pediatr
depart
preto
brazil
preto
medicin
school
univers
paulo
genet
depart
preto
brazil
infantil
boldrini
state
univers
campina
unicamp
pediatr
campina
brazil
preto
medicin
school
univers
paulo
pediatr
depart
preto
brazil
backgroundobject
mani
effort
done
understand
molecular
biolog
pediatr
adrenocort
tumor
act
rare
neoplasm
incid
higher
brazil
although
mirna
signatur
evalu
differ
cohort
none
reliabl
biomark
assum
act
prognosi
children
preview
data
mirna
valid
show
higher
level
associ
lower
surviv
ef
rate
independ
prognost
factor
p
analyz
tumor
size
advanc
stage
pediatr
patient
aim
investig
role
cell
viabil
designmethod
sinc
cell
present
none
express
induc
express
lentivir
vector
mirna
neg
control
negctrl
select
transduc
cell
puromycin
cell
viabil
assay
conduct
resazurin
salt
cisplatin
um
inhibitor
um
without
drug
treatment
anova
test
perform
use
spss
softwar
result
transduct
increas
express
cell
acquir
differ
grow
profil
compar
negctrl
cell
viabil
assay
confirm
cell
show
signific
higher
viabil
rate
negctrl
mainli
seed
cell
resist
cisplatin
treatment
um
hour
howev
notic
resist
profil
cell
concentr
use
p
hour
um
except
highest
dose
um
conclus
patient
ef
data
higher
viabil
rate
observ
vitro
suggest
overexpress
drive
malign
profil
act
cell
may
associ
igf
signal
assay
must
perform
identifi
road
behind
observ
ms
sedki
h
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
patholog
cairo
egypt
cancer
hospit
egypt
radiolog
cairo
egypt
cancer
hospit
egypt
clinic
research
cairo
egypt
backgroundobject
high
risk
organ
ro
langerhan
cell
histiocytosi
lch
least
surviv
present
outcom
ro
lch
pediatr
singl
centr
designmethod
fifti
ro
lch
patient
treat
retrospect
analyz
line
induct
vinblastin
vbl
prednison
pred
intermedi
dose
methotrex
idmtx
adopt
till
idmtx
omit
afterward
result
year
overal
surviv
os
idmtx
non
idmtx
group
respect
event
free
surviv
ef
respect
week
induct
better
statu
obtain
receiv
mtx
statist
signific
factor
associ
poor
os
ef
cytopenia
hepat
dysfunct
tri
high
risk
organ
combin
singl
induct
factor
associ
diseas
progress
dp
post
induct
cytopenia
hepat
dysfunct
lack
idmtx
diseas
reactiv
rea
season
autumn
winter
lung
diseas
male
gender
idmtx
conclus
idmtx
associ
better
respons
surviv
risk
stratif
highlight
role
tri
hemopoiet
cytopenia
hepat
dysfunct
tri
high
risk
organ
cn
risk
site
lung
associ
doubl
induct
season
autumn
winter
might
carri
viral
agent
reactiv
ms
sedki
h
z
cancer
hospit
egypt
nation
research
centr
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
nation
cancer
institut
cairo
univers
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
nation
cancer
institut
cairo
univers
patholog
cairo
egypt
cancer
hospit
egypt
nation
cancer
institut
cairo
univers
radiolog
cairo
egypt
cancer
hospit
egypt
clinic
research
cairo
egypt
backgroundobject
fail
line
treatment
high
risk
organ
ro
pediatr
langerhan
cell
histiocytosi
lch
highest
mortal
aim
present
outcom
fail
line
ro
lch
show
impact
salvag
aracytin
designmethod
fifti
four
ro
lch
patient
treat
retrospect
analyz
patient
fail
line
due
either
diseas
progress
dp
end
induct
reactiv
rea
achiev
better
statu
receiv
salvag
without
result
thirti
four
patient
fail
line
divid
group
group
dp
group
ii
rea
group
patient
receiv
die
patient
receiv
die
except
one
group
ii
rea
patient
receiv
one
die
patient
receiv
surviv
except
two
overal
surviv
os
patient
show
failur
dp
rea
respect
p
os
dp
patient
versu
none
respect
os
rea
patient
versu
none
respect
conclus
rescu
dp
rolch
relat
regimen
without
moreov
impact
rea
remain
controversi
relat
repetit
line
treatment
w
hospit
chongq
medic
univers
depart
pediatr
surgic
oncolog
chingq
china
backgroundobject
analyz
efficaci
safeti
differ
treatmentsrel
oral
propranolol
vascular
anomali
children
designmethod
confirm
vascular
anomali
includ
children
hospit
chongq
medic
univers
juli
march
divid
three
treatment
group
group
treat
oral
propranolol
group
treat
oral
propranolol
unit
topic
inject
bleomycin
group
treat
oral
propranolol
unit
comprehens
treatment
treatment
group
take
oral
propranolol
initi
dosag
time
twice
one
day
gradual
add
time
twice
one
day
three
day
observ
record
chang
lesion
size
color
textur
associ
symptom
advers
reaction
group
result
among
case
male
femal
median
age
seven
month
eleven
day
old
clinic
respons
complet
remiss
lesion
disappear
good
partial
remiss
lesion
reduc
partial
remiss
lesion
reduc
micro
remiss
lesion
reduc
stabl
diseas
lesion
reduc
less
overal
treatment
effici
lesion
reduc
vascular
anomali
achiev
advers
effectr
abnorm
liver
function
sever
advers
effect
hypotendion
bradycardia
convuls
vomit
case
hemangioma
case
vascularmalform
case
coexist
lesion
overal
treatment
effici
respect
therapeut
effect
differ
treatment
group
variou
overal
treatment
effici
group
total
case
group
total
case
group
total
case
conclus
differ
comprehens
treatmeng
centr
oral
propranolol
effect
safe
treatment
ofvascular
anomali
children
j
kap
gm
lp
da
children
hospit
divis
hematolog
oncolog
belgrad
serbia
children
hospit
surgeri
depart
belgrad
serbia
hospit
clinic
minnesota
cancer
blood
disord
minneapoli
usa
hospit
clinic
minnesota
intern
ppb
registri
minneapoli
usa
st
loui
children
washington
univers
medic
center
lauren
v
ackerman
laboratori
surgic
patholog
mo
usa
nation
medic
center
depart
center
cancer
immunolog
research
washington
dc
usa
backgroundobject
pleuropulmonari
blastoma
ppb
rare
malign
may
occur
sporad
context
pathogen
variant
gene
pathogen
variant
increas
risk
ppb
ovarian
renal
thyroid
brain
tumor
intestin
polyp
lung
cyst
designmethod
report
case
patient
diagnos
type
iii
ppb
result
girl
admit
hospit
dyspnea
radiolog
examin
reveal
left
pneumothorax
pleural
effus
side
necrot
pneumonia
pleural
empyema
suspect
pleural
drainag
ct
scan
reveal
tumor
mass
left
side
contralater
cystic
lesion
soon
percutan
biopsi
develop
superior
vena
cava
syndrom
underw
left
thoracotomi
gross
total
resect
tumor
histopatholog
analysi
treat
institut
show
type
iii
ppb
central
patholog
review
provid
intern
ppb
registri
show
undifferenti
sarcoma
featur
genet
analysi
tumor
reveal
biallel
pathogen
mutat
surgeri
treat
ifosfamid
vincristin
doxorubicin
dactinomycin
complet
primari
treatment
releas
hospit
complet
remiss
four
month
finish
primari
treatment
local
recurr
detect
underw
gross
total
resect
recurr
ppb
histolog
confirm
current
receiv
treatment
ifosfamid
carboplatin
etoposid
radiat
therapi
site
recurr
plan
conclus
contralater
cystic
lesion
age
patient
classic
ppb
despit
histolog
appear
less
classic
test
consid
young
children
undifferenti
malign
thorac
tumor
initi
present
pneumonia
pneumothorax
solid
cystic
mix
lung
lesion
sy
soh
women
children
hospit
haematologyoncolog
singapor
singapor
women
children
hospit
pharmaci
singapor
singapor
women
children
hospit
patholog
laboratori
medicin
singapor
singapor
backgroundobject
role
braf
inhibitor
histiocyt
disord
increasingli
explor
designmethod
report
case
success
vemurafenib
diseas
reactiv
young
infant
refractori
langerhan
cell
histiocytosi
lch
result
infant
present
month
age
lch
risk
organ
involv
show
partial
respons
prednisolon
vinblastin
week
continu
develop
diseas
progress
rash
hepatosplenomegali
fever
malais
cytopenia
fail
respond
salvag
chemotherapi
immunohistochemistri
braf
perform
skin
biopsi
diseas
progress
show
equivoc
stain
sequenc
two
set
primer
reveal
mutat
confirm
presenc
braf
mutat
parent
consent
vemurafenib
start
bid
gradual
increas
bid
week
within
day
parent
report
improv
child
week
longer
need
transfus
hepatosplenomegali
regress
continu
absolut
dose
bid
month
develop
diseas
reactiv
fever
malais
progress
hepatosplenomegali
cytopenia
rash
within
one
week
stop
vemurafenib
vemurafenib
restart
diseas
reactiv
rapid
improv
condit
vemurafenib
continu
dose
bid
despit
child
weight
gain
month
taper
gradual
anoth
month
child
remain
well
month
taper
vemurafenib
conclus
remark
respons
patient
diseas
progress
highlight
promis
role
braf
inhibitor
group
lch
patient
diseas
control
challeng
whose
prognosi
often
poor
current
limit
includ
lack
commerci
avail
pediatr
formul
inadequ
understand
optim
pediatr
dose
therapi
durat
p
sowithayasakul
c
j
p
p
univers
pediatr
bangkok
thailand
mahidol
univers
pediatr
bangkok
thailand
backgroundobject
macrophag
activ
syndrom
ma
life
threaten
complic
sever
autoimmun
diseas
system
lupu
erythematosu
sle
rare
report
associ
hiv
infect
ma
coexist
sle
hiv
never
report
literatur
herein
report
case
sle
coexist
hiv
infect
child
manifest
ma
designmethod
case
report
result
girl
present
fever
week
physic
examin
reveal
bodi
temperatur
puffi
eyelid
splenomegali
complet
blood
count
show
hemoglobin
gdl
wbc
count
anc
count
platelet
count
diagnos
congenit
hiv
infect
good
adher
arv
therapi
viral
load
less
copiesml
count
investig
reveal
hyperferritinemia
ngml
hypofibrinogenemia
mgdl
fast
triglycerid
mgdl
increas
hemophagocyt
activ
bone
marrow
blood
urea
nitrogen
creatinin
mgdl
respect
immunolog
screen
posit
ana
homogen
serum
low
gl
gl
respect
kidney
biopsi
report
compat
lupu
glomerulonephr
diagnos
ma
subsequ
treat
treatment
protocol
consist
ivig
dexamethason
etoposid
respond
treatment
die
multi
organ
failur
day
initi
treatment
conclus
macrophag
activ
syndrom
concomit
system
lupu
erythematosu
hiv
infect
fatal
physician
take
care
children
hiv
infect
awar
condit
particularli
present
prolong
fever
pancytopenia
l
stangler
r
f
k
de
da
santa
casa
de
paulo
depart
collect
health
paulo
brazil
backgroundobject
among
children
cancer
uncommon
mixtur
neoplasm
particular
biolog
clinic
characterist
call
rare
tumor
rt
studi
aim
describ
epidemiolog
rt
head
neck
region
h
n
among
children
adolesc
year
old
paulo
state
sp
brazil
designmethod
descript
studi
includ
case
rt
h
n
retriev
cancer
registri
sp
diagnos
classifi
accord
definit
rarecar
project
descript
statist
use
character
malign
accord
attribut
person
gender
age
group
tumor
type
previou
diagnosi
place
home
state
time
year
diagnosi
result
identifi
tumor
patient
correspond
rt
pediatr
group
gender
equal
distribut
male
femal
case
diagnos
young
children
year
adolesc
year
approxim
case
arriv
hospit
without
diagnosi
percentag
lower
live
outsid
sp
vs
individu
live
sp
p
major
case
live
sp
state
repres
frequenc
rang
mina
gerai
frequent
malign
hodgkin
lymphoma
retinoblastoma
thyroid
nasopharyng
carcinoma
number
case
increas
studi
period
case
manag
hospit
seven
respons
treat
case
conclus
epidemiolog
profil
rare
pediatr
cancer
h
n
paulo
state
brazil
similar
report
literatur
treatment
appear
central
special
center
howev
public
polici
warrant
faster
diagnosi
referr
still
requir
g
e
n
h
hg
ba
z
z
f
univers
medic
faculti
pediatr
oncolog
ankara
turkey
univers
medic
faculti
pediatr
endocrinolog
ankara
turkey
backgroundobject
tumor
bone
gctb
primarili
seen
young
adult
usual
benign
tumor
frequent
recur
local
surgic
resect
designmethod
would
like
present
two
pediatr
patient
success
treat
denosumab
result
girl
present
facial
mass
caus
swell
left
side
famili
histori
reveal
father
brother
diagnos
gctb
patient
treat
intralesionar
steroid
calcitonin
develop
cellul
hospit
broad
spectrum
antibiot
surgic
drainag
curettag
discharg
lost
follow
year
final
admit
left
maxillari
huge
mass
put
subcutan
everi
day
imatinib
mesyl
oral
two
month
later
maxillofaci
surgeon
perform
intralesionar
steroid
weekli
month
everi
month
denosumab
treatment
plan
satisfactori
regress
tumor
start
denosumab
induct
dose
mg
subcutan
weekli
week
follow
mg
subcutaen
per
month
current
year
treatment
patient
requir
iu
day
oral
vitamin
elementari
calcium
supplement
develop
hypocalcemia
tumor
show
shrinkag
reconstruct
surgeri
plan
four
year
old
anoth
femal
patient
diagnos
gcbt
use
imatinib
mesyl
first
patient
clinic
radiolog
progress
denosumab
start
patient
respond
dramat
denosumab
conclus
denosumab
monoclon
antibodi
use
target
therapi
gctb
frequent
seen
adult
experinc
import
pediatrician
v
ra
teixeira
lm
c
al
lr
p
mt
c
p
paulo
univers
medic
school
sao
brazil
albert
einstein
hospit
brazil
pediatr
depart
fmusp
itaci
hematolog
divis
hiae
sao
paulo
brazil
paulo
univers
medic
school
sao
brazil
pediatr
depart
fmusp
itaci
hematolog
divis
hiae
sao
paulo
brazil
backgroundobject
hy
capabl
interf
viru
ebv
replic
inhibit
ribonucleotid
reductas
hy
shown
elimin
ebv
episom
burkitt
lymphoma
suggest
valu
neoplasia
chodosh
j
also
possibl
effect
achiev
dose
attract
complet
resolut
cr
ptmld
hy
child
without
condit
regular
chemotherapi
describ
designmethod
girl
liver
transplant
month
earlier
due
unspecif
hepat
develop
plasmoblast
lymphoma
involv
multipl
supradiaphragmat
nodal
area
tumor
cell
posit
ebv
situ
hybrid
ebvish
pcr
rtpcr
ebv
reveal
copi
treat
per
protocol
includ
cyclophosphamid
cyclo
prednison
pred
rituximab
six
weekli
dose
cr
disappear
viral
load
month
later
aggress
recurr
seen
huge
abdomin
mass
document
bone
marrow
bm
involv
biopsi
reveal
pattern
tumor
posit
ebvish
howev
without
cell
copi
circul
ebv
found
altern
aggress
chemotherapi
etoposid
doxorubicin
vincristin
cyclo
pred
without
rituximab
determin
tumor
lysi
syndrom
provid
partial
respons
biopsi
remain
mass
show
featur
includ
neg
posit
ebvish
decis
ad
hydroxyurea
day
done
consid
child
precari
condit
base
upon
presenc
tumor
ebv
result
cr
achiev
neg
bm
without
sign
tumor
relaps
march
month
ebv
rtpcr
remain
neg
child
experi
sign
graft
reject
immunosuppress
ever
sinc
diagnosi
ptmld
conclus
hydroxyurea
may
use
safe
therapeut
approach
lymphrolif
disord
effici
prevent
tool
viral
replic
potenti
consequ
torchareon
h
n
k
p
p
medicin
pediatr
bangkok
thailand
backgroundobject
nasopharyng
carcinoma
npc
rare
children
rel
common
asian
popul
compar
other
designmethod
retrospect
review
result
seven
patient
male
femal
median
age
year
old
diagnos
npc
hospit
palpabl
mass
without
epistaxi
present
case
one
case
viral
ebv
load
posit
diseas
stage
iii
four
patient
iva
two
patient
ivb
one
patient
histolog
subtyp
consist
three
undifferenti
four
patient
patient
receiv
neoadjuv
chemotherapi
consist
cisplatin
cycl
subsequ
gy
irradi
cycl
adjuv
cisplatin
none
underw
surgic
tumor
remov
median
time
recurr
event
month
median
follow
time
month
four
patient
aliv
diseas
one
aliv
diseas
one
loss
follow
conclus
npc
rare
among
pediatr
malign
predomin
male
adolesc
ebv
neg
neoadjuv
chemotherapi
cisplatin
irradi
revel
good
diseas
respons
outcom
k
v
p
p
z
b
jerbai
wadia
hospit
children
depart
pediatr
mumbai
india
backgroundobject
langerhan
cell
histiocytosi
lch
rare
diseas
limit
data
publish
india
lch
need
system
chemotherapi
designmethod
retrospect
analysi
patient
requir
system
chemotherapi
singl
system
multifoc
bone
ms
multisystem
withwithout
risk
organ
ro
involv
bj
wadia
children
hospit
mumbai
done
period
result
patient
treat
period
present
vari
month
median
month
f
liver
commonli
involv
follow
spleen
hematopoiet
system
skin
lung
node
cn
ear
dental
children
start
lch
iiiiv
refer
standard
protocol
sp
protocol
children
diseas
progress
treat
salvag
protocolsjlsgp
japanes
lch
studi
group
protocol
target
therapi
respons
assess
done
week
children
ssmultifoc
bone
involv
respond
sp
remiss
among
children
ms
respond
diseas
progress
remiss
jlsgp
relaps
year
post
therapi
remiss
sp
present
remiss
children
ms
remiss
diseas
braf
mutat
start
vemurafinib
achiev
start
stratum
expir
due
treatment
toxic
among
progress
opt
worsen
liver
diseas
initi
cours
expir
children
ms
ro
remiss
mortal
studi
mortal
follow
salvag
therapi
studi
comparit
result
better
target
therapi
jlsgp
increas
mortal
studi
probabl
due
extens
diseas
involv
patient
diabet
insipidu
follow
diagnosi
conclus
lch
requir
high
index
suspicion
earli
diagnosi
sinc
center
tertiari
hospit
western
india
mani
patient
advanc
stage
diagnosi
could
one
reason
increas
mortal
ssmf
bone
involv
excel
prognosi
therapi
c
willi
j
hospit
children
paediatr
oncolog
glasgow
unit
kingdom
backgroundobject
small
cell
carcinoma
ovari
hypercalcaem
type
sccoht
extrem
rare
ovarian
tumour
peak
incid
third
decad
one
year
surviv
rate
fifti
percent
five
year
surviv
rate
ten
percent
report
sccoht
characteris
germlin
somat
mutat
share
malign
featur
malign
rhabdoid
tumour
group
designmethod
patient
fourteen
year
old
girl
present
six
week
histori
abdomin
pain
nausea
vomit
examin
demonstr
grossli
distend
abdomen
larg
palpabl
pelvic
mass
initi
blood
reveal
hypercalcaemia
afp
hcg
normal
elev
result
mri
confirm
larg
pelvic
mass
stage
investig
reveal
local
region
spread
lung
metastasi
histolog
tumour
compos
undifferenti
small
round
blue
cell
oval
vesicular
nuclei
numer
mitosi
immunohistochemistri
posit
vimentin
ema
genet
test
reveal
heterozyg
pathogen
variant
mum
also
mutat
hypercalcaemia
manag
iv
fluid
pamidron
manag
discuss
extens
mdt
treat
cisplatin
etoposid
chemotherapi
dramat
initi
symptom
relief
correspond
fall
calcium
level
recurr
symptom
second
cycl
correspond
diseas
progress
alongsid
symptomat
manag
underw
palli
laparotomi
ovarian
mass
resect
omentectomi
later
stage
diseas
make
much
comfort
palli
care
input
patient
pass
away
peac
month
follow
diagnosi
conclus
manag
patient
sccoht
complex
metastat
inevit
fatal
case
implic
mutat
famili
member
must
consid
mother
child
subsequ
bilater
oophorectomi
one
youngest
patient
sccoht
report
literatur
hy
wong
yk
kwe
kh
paediatr
surgeri
paediatr
depart
princ
wale
chines
univers
hong
kong
depart
surgeri
hong
kong
hong
kong
sar
backgroundobject
lipoblastoma
rare
childhood
tumor
origin
embryon
adipos
tissu
aim
review
studi
surgic
outcom
lipoblastoma
chines
pediatr
popul
designmethod
retrospect
studi
surgic
outcom
manag
lipoblastoma
tertiari
center
hong
kong
studi
result
total
case
lipoblastoma
treat
unit
four
boy
two
girl
f
ratio
underw
surgic
resect
patient
present
asymptomat
slow
grow
subcutan
tissu
mass
median
age
present
month
rang
month
median
age
diagnosi
month
rang
month
month
median
tumor
volum
document
imag
locat
trunk
scalp
omentum
cytogenet
studi
perform
recent
case
show
gene
alter
median
month
local
recurr
found
conclus
studi
conclud
experi
surgic
aspect
manag
lipoblastoma
good
long
term
outcom
expect
complet
surgic
excis
high
awar
essenti
time
diagnosi
rare
benign
tumor
wu
hospit
pediatr
surgeri
shanghai
china
backgroundobject
articl
intend
summar
clinic
featur
children
thyroid
carcinoma
treat
xinhua
hospit
affili
shanghai
jiaotong
univers
school
medicin
recent
year
analyz
treatment
method
prognosi
discuss
diagnosi
treatment
experi
designmethod
nineteen
children
thyroid
cancer
year
old
admit
hospit
januari
decemb
review
clinic
characterist
patholog
featur
treatment
method
prognosi
care
analyz
result
patient
youngest
month
largest
patient
treat
surgeri
surgic
method
includ
total
thyroidectomi
case
subtot
thyroidectomi
case
lymph
node
dissect
perform
patient
preoper
ct
postop
scan
confirm
pulmonari
metastas
patient
postop
complic
occur
patient
case
suffer
hypocalcemia
patient
develop
sonar
recov
symptomat
treatment
postop
patholog
result
show
papillari
thyroid
carcinoma
ptc
case
follicular
thyroid
cancer
ftc
patient
receiv
isotop
therapi
total
dose
mci
year
overal
surviv
rate
case
postop
local
recurr
pulmonari
metastasi
two
patient
die
conclus
thyroid
carcinoma
children
ptc
cancer
highli
invas
recurr
rate
thyroid
carcinoma
children
high
overal
prognosi
good
patient
total
thyroidectomi
subtot
resect
combin
cervic
lymph
node
dissect
import
besid
postop
necessari
isotop
therapi
play
import
role
support
treatment
need
perform
strictli
indic
yaman
bajin
b
n
b
n
c
univers
depart
divis
pediatr
oncolog
ankara
turkey
backgroundobject
langerhan
cell
histiocytosi
lch
rare
diseas
usual
affect
bone
singl
systemsingl
site
bone
lesion
usual
manag
surgic
without
intralesion
steroid
inject
chemotherapi
radiotherapi
treatment
option
studi
aim
review
institut
experi
children
singl
systemsingl
site
lch
bone
lesion
designmethod
hospit
chart
children
year
age
diagnos
singl
systemsingl
site
lch
bone
lesion
hospit
review
retrospect
data
demograph
characterist
present
symptom
diagnost
intervent
treatment
approach
event
final
outcom
collect
analyz
result
lch
case
singl
systemsingl
site
bone
lesion
diagnos
januari
decemb
malefemal
median
age
year
initi
present
symptom
swell
pain
patient
frequent
site
involv
skull
patient
trunk
extrem
case
histopatholog
diagnosi
incision
biopsi
excision
patient
follow
without
treatment
incision
biposi
respect
treat
vinblastinprednisolon
chemotherapi
six
patient
receiv
radiotherapi
cgi
sacroiliac
region
vertebra
median
month
case
lost
regular
diseas
relaps
patient
relaps
distant
bone
treat
surgeri
chemotherapi
andor
radiotherapi
complet
remiss
seven
patient
problem
like
tooth
disrupt
arm
numb
vertebra
compress
conclus
local
control
surgic
cur
case
singl
systemsingl
site
lch
bone
lesion
low
dose
radiotherapi
use
select
case
especi
vertebra
involv
aggress
treatment
avoid
prevent
long
term
morbid
x
yuan
hospit
affili
shanghai
jiao
tong
univers
school
medicin
depart
pediatr
hematologyoncolog
shanghai
china
backgroundobject
phenomenon
kmp
rare
patient
hemangioma
rapid
progress
poor
prognosi
recogn
optim
therapeut
schedul
aim
studi
analyz
characterist
massiv
hemangioma
kmp
compar
differ
efficaci
multipl
modal
calcul
cost
treatment
reduc
misdiagnosi
diseas
designmethod
retrospect
collect
archiv
infant
diagnos
hemangioma
april
decemb
xinhua
hospit
case
develop
kmp
treat
combin
therapi
monotherapi
median
time
year
main
observ
index
includ
variat
lump
size
platelet
count
coagul
disord
result
kmp
incid
rate
infant
hemangioma
center
male
femal
ratio
median
age
diagnosi
day
averag
interv
diagnosi
day
onset
kmp
averag
total
cost
treatment
us
us
twenti
infant
receiv
combin
therapi
got
complet
remiss
cr
still
aliv
eleven
case
receiv
monotherapi
among
three
infant
got
cr
three
got
partial
remiss
pr
three
show
respons
includ
one
lost
two
die
final
one
patient
underw
surgeri
due
local
primari
lump
got
cr
oper
anoth
infant
receiv
support
care
abandon
treatment
due
deterior
coagul
disord
conclus
misdiagnosi
delay
diagnosi
two
risk
factor
poor
prognosi
kmp
increas
treatment
cost
studi
combin
therapi
superior
monotherapi
could
greatli
improv
prognosi
kmp
h
zbarouskaya
research
center
pediatr
hematolog
immunolog
childhood
cancer
subregistri
belaru
minsk
reg
belaru
backgroundobject
qualiti
life
survivor
childhood
cancer
social
function
unquestion
import
era
pediatr
oncolog
success
designmethod
use
survey
among
survivor
pediatr
thyroid
cancer
cure
year
belaru
four
domain
physic
health
psycholog
social
relationship
environ
score
transform
scale
present
ad
addit
question
survey
level
educ
employ
marit
statu
children
diseas
thyroid
carcinoma
disabl
major
patient
gomel
brest
region
belaru
median
age
moment
chernobyl
disast
year
median
age
time
ill
year
time
fill
questionnair
year
mf
ratio
result
distribut
respond
level
educ
higher
peopl
secondari
secondari
special
secondari
technic
peopl
basic
class
unemploy
men
women
sixti
five
respond
marri
level
marriag
higher
among
higher
educ
children
particip
child
particip
children
case
children
famili
sixti
peopl
indic
ill
disabl
accord
survey
respond
mean
overal
percept
qualiti
life
qualiti
health
domain
phisic
health
psycholog
social
relationship
environ
conclus
knowledg
factor
affect
qualiti
life
survivor
childhood
thyroid
cancer
extremli
necessari
plan
rehabilit
activ
adequ
social
function
societi
w
zhang
tongren
hospit
pediatr
beij
china
tongren
medic
univers
pediatr
beij
china
backgroundobject
analysi
vascular
endotheli
growth
factor
vegf
express
characterist
tumor
tissu
malign
solid
tumor
case
explor
correl
tumor
type
metastasi
prognosi
designmethod
clinic
data
patient
vegf
gene
express
tumor
tissu
detect
collect
hospit
correl
among
vegf
express
metastasi
differ
tumor
type
prognosi
analyz
applic
statist
result
classif
malign
solid
tumor
neuroblastoma
case
hepatoblastoma
case
wilm
tumor
case
rhabdomyosarcoma
case
primit
neuroectoderm
tumor
case
tumor
case
express
vegf
gene
distant
metastasi
tumor
distant
metastasi
rate
low
express
group
middl
express
group
high
express
group
respect
p
valu
fisher
exact
test
three
group
differ
statist
signific
characterist
vegf
mrna
express
distant
metastasi
case
neuroblastoma
show
case
metastasi
low
express
group
case
metastasi
middl
express
group
case
metastasi
high
express
group
signific
differ
fisher
exact
test
vegf
gene
mrna
express
prognosi
surviv
time
low
express
group
vegf
mrna
month
surviv
time
middl
express
group
month
surviv
time
high
express
group
month
three
group
test
show
signific
differ
conclus
express
level
vegf
gene
mrna
tumor
tissu
close
relat
tumor
distant
metastasi
proport
middl
high
vegf
mrna
express
hepatoblastoma
wilm
tumor
tissu
significantli
higher
neuroblastoma
tissur
v
ahern
j
r
p
c
b
l
j
g
princess
mari
cancer
westmead
hospit
sydney
medic
univers
sydney
radiat
oncolog
westmead
sydney
australia
princess
mari
cancer
westmead
hospit
radiat
oncolog
westmead
sydney
australia
brisban
women
hospit
radiat
oncolog
brisban
australia
luke
radiat
oncolog
network
radiat
oncolog
dublin
ireland
maccallum
cancer
centr
radiat
oncolog
melbourn
australia
hospit
radiat
oncolog
christchurch
new
zealand
hospit
radiat
oncolog
christchurch
new
caledonia
backgroundobject
fewer
radiat
oncologist
anz
manag
children
scatter
vast
geograph
area
time
zone
fortnightli
paediatr
radiat
therapi
rt
videoconfer
began
august
initi
paediatr
radiat
oncolog
special
interest
group
royal
australian
new
zealand
colleg
radiologist
purpos
ensur
children
receiv
high
qualiti
rt
proton
facil
anz
current
aim
current
audit
document
case
discuss
chang
rt
made
consequ
confer
referr
children
specialis
rt
includ
proton
designmethod
minut
videoconfer
held
januari
review
inform
analys
includ
tumour
patholog
present
purpos
time
commenc
rt
review
rt
target
volum
organ
risk
manag
chang
made
whether
recommend
proton
brachytherapi
result
case
present
almost
case
present
purpos
discuss
appropri
use
rt
rt
target
volum
dose
chang
treatment
intent
rt
plan
made
around
case
peer
review
rt
target
volum
perform
case
three
patient
refer
abroad
proton
therapi
result
discuss
videoconfer
two
patient
refer
citi
brachytherapi
conclus
telemedicin
brought
togeth
small
group
paediatr
radiat
oncologist
anz
case
confer
result
rt
manag
chang
import
proport
children
discuss
next
phase
implement
qualiti
assur
checklist
peer
review
rt
treatment
plan
children
treat
radic
intent
prior
start
rt
sa
castaneda
l
lt
se
romero
univers
hospit
drexel
univers
colleg
medicin
depart
radiat
oncolog
philadelphia
usa
miami
depart
radiat
oncolog
miami
usa
abreu
servic
radiotherapi
radiosurgeri
santo
domingo
dominican
republ
santo
domingo
servic
radiotherapi
santo
domingo
dominican
republ
backgroundobject
dominican
republ
dr
robust
model
radiotherapi
insuffici
data
regard
resourc
pediatr
radiotherapi
avail
contrast
haiti
current
work
radiotherapi
servic
sought
elucid
model
pediatr
oncolog
review
pediatr
experi
primari
referr
site
identifi
opportun
global
health
dr
designmethod
two
resid
particip
american
societi
radiat
oncologyassoci
resid
radiat
oncolog
astroarro
global
health
scholar
program
aim
studi
radiotherapi
servic
model
dr
oncoserv
santo
domingo
select
primari
pediatr
radiotherapi
referr
site
explor
global
health
opportun
result
dr
sever
payment
model
healthcar
servic
includ
contribut
regimen
employ
base
subsid
regimen
govern
sponsor
privat
insur
nation
intern
polici
minor
patient
pediatr
patient
treat
referr
cancer
center
modern
radiotherapi
equip
expert
pediatr
staff
hematolog
oncolog
radiotherapi
surgeri
anesthesiolog
pediatr
patient
treat
oncoserv
santo
domingo
august
analyz
patient
includ
male
femal
median
age
year
rang
year
patient
cn
tumor
hematolog
malign
wilm
tumor
eight
headneck
tumor
six
disord
one
gynecolog
malign
radiotherapi
goal
definitiveadjuv
prophylact
palli
patient
treat
use
linac
employ
techniqu
case
techniqu
case
imrt
techniqu
case
interestingli
patient
dr
haiti
patient
nation
similar
demograph
oncolog
characterist
conclus
dr
radiotherapi
infrastructur
offer
modern
techniqu
pediatr
patient
dr
haiti
studi
warrant
character
global
health
model
allow
treat
pediatr
patient
come
haiti
eriksson
gothenburgsahlgrenska
institut
neurosci
physiolog
depart
pharmacolog
gothenburg
sweden
gothenburgsahlgrenska
academi
institut
neurosci
physiolog
univers
gothenburgsahlgrenska
academi
institut
clinic
scienc
depart
pharmacolog
gothenburg
sweden
gothenburgsahlgrenska
academi
institut
clinic
scienc
depart
oncolog
gothenburg
sweden
backgroundobject
brain
tumour
one
common
childhood
cancer
cranial
radiotherapi
one
treatment
lead
perman
brain
damag
late
effect
irradi
includ
perturb
growth
late
puberti
cognit
impair
understand
mechan
chronic
damag
major
import
abl
find
way
help
childhood
cancer
survivor
amyloid
precursor
protein
often
associ
alzheim
diseas
accumul
thalamu
four
month
irradi
develop
brain
interestingli
accumul
occur
astrocyt
aim
project
identifi
genet
alter
astrocyt
cranial
irradi
could
use
better
understand
injuri
mechan
designmethod
male
mice
receiv
singl
dose
gray
brain
postnat
day
four
month
irradi
thalamu
homogen
follow
cell
sort
target
astrocyt
next
gener
sequenc
follow
ingenu
pathway
analysi
use
analys
differenti
gene
express
p
thalam
astrocyt
irradi
result
cranial
irradi
young
mous
brain
increas
number
thalam
astrocyt
compar
control
gene
involv
cognit
immunolog
show
alter
respons
four
month
cranial
irradi
consist
downregul
observ
gene
involv
cell
structur
cell
adhes
cell
motil
interestingli
gene
code
axonem
dynein
express
primari
cilia
also
downregul
conclus
cranial
irradi
young
mous
brain
increas
number
thalam
astrocyt
alter
gene
express
four
month
injuri
induc
basic
import
function
neg
affect
thalam
astrocyt
irradi
increas
astrocyt
thalamu
might
therefor
compensatori
mechan
respons
radiat
huijsken
van
j
b
medic
center
radiat
oncolog
amsterdam
netherland
backgroundobject
ct
scan
quantifi
respiratori
motion
order
optim
safeti
margin
howev
children
adult
respiratori
motion
measur
alway
accur
predict
respiratori
motion
throughout
treatment
cours
suggest
respiratori
motion
could
also
monitor
throughout
treatment
use
ct
cbct
aim
studi
investig
diaphragm
motion
children
constant
radiotherapi
session
designmethod
retrospect
studi
base
cbct
children
year
treat
radiotherapi
variou
childhood
cancer
accord
protocol
set
patient
receiv
cbct
within
one
multipl
fraction
treatment
cours
cbct
diaphragm
dome
posit
manual
detect
cbct
project
imag
correspond
phase
amplitud
quantifi
differ
diaphragm
dome
posit
phase
respiratori
motion
also
express
breath
frequenc
breathsmin
test
possibl
differ
amplitud
frequenc
cbct
pair
p
result
mean
cbct
acquisit
time
interv
rang
min
overal
averag
amplitud
standard
deviat
cbct
respect
fraction
amplitud
larger
first
cbct
second
cbct
absolut
differ
amplitud
cbct
averag
differ
fraction
patient
breath
frequenc
also
significantli
differ
cbct
averag
breathsmin
respect
averag
differ
breathsmin
conclus
diaphragm
motion
children
constant
radiotherapi
session
could
thu
reliabl
predict
singl
cbct
laskar
n
r
g
p
memori
hospit
radiat
oncolog
mumbai
india
memori
hospit
pediatr
oncolog
mumbai
india
memori
hospit
surgic
oncolog
mumbai
india
memori
hospit
patholog
mumbai
india
memori
hospit
radiodiagnosi
mumbai
india
memori
hospit
bio
imag
mumbai
india
memori
hospit
palli
care
mumbai
india
backgroundobject
analyz
outcom
patient
low
intermedi
risk
h
n
rhabdomyosarcoma
treat
ir
iv
chemotherapi
regimen
along
radiotherapi
andor
surgeri
designmethod
medic
record
patient
low
intermedi
risk
h
n
rhabdomyosarcoma
treat
singl
institut
analyz
result
median
age
year
rang
mth
yr
less
yr
commonest
histolog
erm
follow
arm
specifi
pleomorph
spindl
cell
site
diseas
paramening
orbit
site
mean
tumor
size
cm
rang
cm
region
node
posit
major
intermedi
risk
diseas
median
durat
induct
chemotherapi
week
rang
week
local
therapi
form
surgeri
alon
radiotherapi
alon
surgeri
follow
radiotherapi
receiv
patient
respect
median
follow
mth
rang
mth
local
control
lc
diseas
free
surviv
df
overal
surviv
os
yr
respect
patient
low
risk
superior
outcom
compar
intermedi
risk
diseas
lc
vs
df
vs
os
vs
patient
orbit
diseas
superior
df
compar
site
vs
relaps
seen
patient
isol
local
relaps
grade
acut
skin
mucos
toxic
seen
late
toxic
includ
cataract
xerostomia
dental
cari
subcutan
fibrosi
respect
conclus
chemotherapi
along
radiotherapi
andor
surgeri
patient
h
n
rhabdomyosarcoma
result
good
diseas
outcom
accept
toxic
cancer
research
radiotherapi
imag
london
unit
kingdom
marsden
nh
foundat
trust
joint
depart
physic
london
unit
kingdom
marsden
nh
foundat
trust
children
young
peopl
unit
london
unit
kingdom
backgroundobject
upper
abdomin
organ
motion
children
may
overestim
current
appli
plan
target
volum
ptv
comput
tomographi
intern
target
volum
itv
approach
use
adult
radiotherapi
plan
take
organ
motion
rrom
account
less
well
describ
paediatr
cohort
studi
dosimetr
consequ
target
coverag
organ
risk
use
itv
approach
compar
ptv
margin
high
risk
neuroblastoma
investig
designmethod
patient
midlin
target
lateralis
two
dual
arc
volumetr
modul
arc
therapi
plan
x
creat
averag
phase
use
itv
approach
use
motion
inform
ptvitv
itv
ptv
expans
use
standard
ptv
ptvconv
ctv
ptv
expans
chang
ptv
size
number
vertebr
level
irradi
near
prescript
dose
compar
addit
differ
target
coverag
result
ptv
volum
gener
itv
approach
consist
smaller
mean
sd
rang
compar
sd
rang
p
itv
approach
enabl
reduct
vertebr
level
irradi
near
prescript
dose
patient
ptvitv
plan
met
clinic
dose
object
ptv
kidney
ptv
coverag
compromis
midlin
ptvconv
plan
meet
kidney
constraint
ptvconv
mean
compar
conclus
itv
approach
rrom
children
significantli
reduc
absolut
ptv
volum
dosimetr
gain
target
coverag
kidney
dose
midlin
target
reduct
number
vertebr
bodi
irradi
near
prescript
dose
proport
patient
demonst
n
lavan
g
fh
h
cancer
research
radiotherapi
imag
london
unit
kingdom
marsden
nh
foundat
trust
joint
depart
physic
london
unit
kingdom
marsden
nh
foundat
trust
children
young
peopl
unit
london
unit
kingdom
backgroundobject
optim
use
abdomin
rt
proton
therapi
imrt
impt
requir
quantif
intern
motion
common
solid
tumour
requir
upper
abdomin
rt
occur
young
children
major
requir
gener
anaesthesia
ga
commonli
use
intrafract
motion
assess
adult
studi
use
deform
imag
registr
dir
estim
kidney
motion
paediatr
patient
without
ga
designmethod
patient
includ
right
left
kidney
ga
median
age
sd
rang
without
ga
median
age
sd
rang
kidney
contour
phase
singl
clinician
dir
refer
phase
perform
raystat
raysearch
laboratori
ab
stockholm
deform
vector
field
dvf
displac
voxel
within
kidney
quantifi
motion
superior
inferior
si
right
left
rl
anterior
posterior
ap
direct
patient
largest
mean
dvf
displac
rl
ap
si
determin
wors
case
scenario
plan
compar
group
result
median
dvf
displac
mm
patient
ga
right
left
kidney
rl
ap
si
compar
patient
ga
respect
statist
significantli
differ
two
group
p
wilcoxon
sign
rank
test
greater
individu
variat
demonstr
patient
without
ga
maximum
displac
superiorli
compar
ga
conclus
intrafract
kidney
motion
young
anaesthetis
children
small
strategi
reduc
systemat
random
uncertainti
warrant
optim
maximis
normal
tissu
spare
made
possibl
imrt
impt
wide
variat
si
motion
children
ga
support
individu
motion
assess
patient
v
lee
e
j
dlw
zj
k
awm
univers
hong
kong
depart
clinic
oncolog
hong
kong
hong
kong
sar
univers
hong
hospit
clinic
oncolog
center
shenzhen
china
backgroundobject
volumetr
modul
arc
therapi
vmat
deliv
total
bodi
irradi
tbi
pediatr
patient
report
sinc
prolong
anesthesiased
necessit
plan
treatment
report
feasibl
vmat
deliv
tbi
first
pediatr
patient
designmethod
boy
diagnos
acut
lymphoid
leukemia
refer
tbi
autolog
stem
cell
rescu
februari
intraven
sedat
immobil
vacuum
mattress
comput
tomographi
ct
scan
whole
bodi
perform
slice
thick
ct
imag
split
segment
plan
isocent
autosegment
import
includ
lung
heart
brain
kidney
well
plan
target
volum
ptv
perform
eclips
treatment
plan
systemtm
version
manual
adjust
treatment
plan
gener
rapidarctm
softwar
vmat
full
arc
upper
bodi
segment
full
arc
lower
bodi
segment
deliv
overlap
least
neighbor
segment
improv
dose
homogen
twelv
gy
fraction
given
ptv
linear
acceler
result
mean
dose
lung
heart
brain
kidney
gy
respect
percentag
ptv
receiv
prescrib
dose
respect
dmax
total
mu
segment
fraction
mu
time
contour
dose
calcul
optim
qualiti
assur
hour
treatment
well
toler
acut
grade
fatigu
conclus
vmat
highli
feasibl
tbi
patient
expens
long
plan
qualiti
assur
patient
setup
treatment
deliveri
time
f
meniai
f
r
curi
radiat
oncolog
pari
franc
gustav
roussi
radiat
oncolog
pari
franc
curi
depart
physic
pari
franc
backgroundobject
rhabdomyosarcoma
rm
common
soft
tissu
sarcoma
pediatr
popul
case
rm
develop
head
neck
h
n
region
proton
beam
therapi
pbt
may
reduc
toxic
limit
exposur
normal
tissu
radiat
studi
report
toxic
outcom
follow
pbt
pediatr
h
n
rm
designmethod
may
februari
pediatr
patient
local
metastat
embryon
rm
treat
pbt
clincal
dosimetr
data
abstract
medic
record
treatment
plan
system
institut
review
board
approv
patient
reciev
chemotherapi
protontherapi
surgic
resect
base
tumor
site
access
toxic
grade
accord
common
terminolog
criteria
advers
event
version
result
fifti
six
consecut
pediatr
patient
treat
pbt
h
n
rm
median
month
rang
month
median
dose
gy
rel
biolog
effect
rbe
tumor
sub
site
includ
para
mening
orbit
actuari
surviv
ef
overal
surviv
os
local
control
lc
respect
entir
cohort
grade
acut
radiat
dermat
oral
mucos
report
respect
acut
toxic
higher
grade
common
late
toxic
facial
deform
cataract
n
dental
problem
n
chronic
otiti
n
hear
loss
n
growth
hormon
deficit
n
tow
secondari
solid
malign
conclus
studi
report
low
rate
acut
late
toxic
cohort
pediatr
patient
h
n
rm
late
toxic
common
survivor
pediatr
h
n
rm
pbt
appear
safe
repres
effect
radiat
modal
pediatr
h
n
rm
longer
requir
evalu
analys
j
mul
e
c
van
de
mm
van
den
go
maxima
center
pediatr
oncolog
radiat
oncolog
utrecht
netherland
medic
center
utrecht
radiat
oncolog
utrecht
netherland
backgroundobject
current
renal
tumor
protocol
radiotherapi
flank
administ
case
decad
two
oppos
photon
beam
standard
techniqu
flank
irradi
recent
consensu
guidelin
delin
target
volum
develop
tumor
studi
group
guidelin
combin
volumetr
modul
arc
therapi
vmat
enabl
spare
larg
amount
normal
tissu
organ
risk
oar
purpos
studi
analyz
dosimetr
benefit
vmat
versu
designmethod
twenti
consecut
children
renal
tumor
median
year
select
purpos
studi
therapeut
dose
fraction
use
sinc
prescrib
major
patient
delin
organ
kidney
pancrea
intestin
consid
clinic
relev
oar
mean
dose
oar
compar
result
signific
differ
techniqu
ctv
coverag
averag
patient
found
whole
group
reduct
mean
dose
kidney
pancrea
p
intestin
p
observ
vmat
individu
patient
dose
reduct
kidney
pancrea
intestin
respect
obtain
vmat
bodi
volum
outsid
ctv
receiv
prescrib
dose
averag
patient
time
higher
techniqu
p
one
receiv
prescrib
dose
compar
techniqu
conclus
vmat
appli
flank
delin
pediatr
renal
tumor
reduc
normal
tissu
dose
compar
individu
patient
dose
reduct
exceed
observ
prescrib
nagaraja
c
c
ph
b
particl
univers
hospit
essen
essen
germani
german
cancer
center
wtz
essen
germani
german
proton
therapi
center
essen
wpe
essen
germani
westenfeld
str
bochum
germani
backgroundobject
proton
therapi
pt
potenti
reduc
treatment
relat
morbid
children
pelvic
rhabdomyosarcoma
rm
studi
investig
bladder
toxic
clinic
outcom
children
pelvic
rm
treat
pt
designmethod
children
pelvic
rm
median
age
year
rang
year
embryon
ir
group
iii
treat
median
month
rang
month
includ
children
receiv
chemotherapi
accord
cw
protocol
median
pt
dose
rang
advers
event
includ
bladder
toxic
prospect
document
accord
ctcae
within
kiproreg
registri
result
three
children
undergon
cystectomi
pt
one
child
underw
cystectomi
month
pt
due
histolog
proven
progress
diseas
anoth
year
due
recurr
urinari
tract
infect
pt
patient
experienc
grade
cystiti
grade
cystiti
last
contact
children
retain
normal
bladder
function
grade
late
urinari
toxic
median
mean
maximum
dose
receiv
bladder
rang
rang
respect
eighteen
patient
complet
remiss
experienc
local
failur
stabl
diseas
develop
distant
metastasi
overal
surviv
rate
local
progress
caus
death
patient
tumour
size
cm
associ
poor
local
control
wherea
total
dose
result
better
local
control
surgic
resect
pt
appear
add
signific
benefit
conclus
bladder
preserv
use
proton
therapi
associ
favour
toxic
profil
good
clinic
outcom
verif
result
larger
cohort
longer
necessari
n
ozawa
f
f
tsukuba
depart
health
innov
nurs
ibaraki
japan
prefectur
univers
depart
nurs
saitama
japan
backgroundobject
proton
beam
therapi
expect
reduc
late
complic
howev
institut
difficult
aspect
requir
transfer
receiv
support
mother
far
suggest
expect
pressur
mother
characterist
concept
understand
necessari
clarifi
process
decis
make
designmethod
searcher
interview
mother
analyz
ground
theori
approach
result
mother
particip
everi
children
transfer
hospit
deriv
categori
relat
decis
make
increas
fear
radiat
therapi
search
treatment
method
regret
expect
proton
beam
therapi
one
treatment
think
specif
select
x
ray
confid
choic
receiv
proton
beam
therapi
mother
high
degre
increas
fear
radiat
therapi
trace
process
search
treatment
method
regret
even
offer
option
medic
personnel
mother
high
degre
increas
fear
radiat
therapi
even
offer
option
doctor
search
treatment
method
regret
increas
expect
proton
beam
therapi
one
treatment
get
confid
choic
receiv
proton
beam
therapi
mother
low
degre
increas
fear
radiat
therapi
sometim
go
think
specif
select
x
ray
degre
acquir
inform
proton
therapi
propos
other
low
conclus
due
degre
fear
mother
provid
inform
medic
personnel
process
differ
need
provid
psycholog
support
mother
high
fear
expect
provid
inform
beyond
boundari
facil
rao
j
w
j
hopkin
univers
school
medicin
radiat
oncolog
baltimor
usa
backgroundobject
evalu
precis
two
cone
beam
comput
tomographi
protocol
align
bone
pediatr
patient
receiv
radiat
therapi
igrt
abdomen
pelvi
ap
designmethod
imag
qualiti
evalu
cbct
pediatr
patient
treat
igrt
januari
guid
develop
two
significantli
protocol
rotat
kv
ma
total
frame
collim
rotat
kv
ma
total
frame
collim
repres
scan
patient
least
cbct
protocol
regist
separ
bone
landmark
simul
ct
eighteen
ident
blind
random
offset
appli
patient
start
registr
realign
use
rigid
registr
differ
vector
magnitud
differ
appli
offset
final
registr
attempt
calcul
adjust
systemat
error
initi
registr
analyz
evalu
deliv
higher
dose
superior
lower
dose
bone
align
result
compar
registr
bone
landmark
across
patient
differ
vector
magnitud
offset
use
mean
mm
standard
deviat
mm
mm
mm
compar
registr
landmark
across
patient
align
use
mm
mm
result
larger
differ
vector
magnitud
offset
compar
mm
mm
conclus
clinic
treat
pediatr
patient
implement
protocol
mirror
ap
igrt
align
bone
consid
evalu
align
b
rombi
l
f
ag
f
therapi
center
santa
chiara
hospit
trento
itali
bellaria
hospit
bologna
itali
orsola
hospit
radiat
oncolog
depart
bologna
itali
orsola
hospit
depart
bologna
itali
hospit
neuro
radiolog
depart
bologna
itali
backgroundobject
evalu
cystic
dynam
two
pediatr
low
grade
glioma
proton
beam
therapi
pbt
weekli
mri
follow
fu
time
earli
late
toxic
also
report
designmethod
solid
cystic
tumor
compon
drown
weekli
mri
perform
proton
radiat
fu
phase
case
multipl
partial
resect
yo
girl
hypothalam
pylocit
astrocytoma
second
line
chemotherapi
acut
lost
visual
acuiti
due
cystic
tumor
progress
case
yo
boy
progress
mesencephal
pylocit
astrocytoma
previous
treat
chemotherapi
sever
surgeri
cystic
drainag
treat
pbt
gy
gce
result
proton
therapi
mri
mri
patient
perform
nt
shown
cyst
growth
requir
intervent
develop
two
episod
sever
acut
headach
develop
partial
alopecia
cystic
solid
compon
progress
reduc
patient
cyst
part
progress
increas
transient
cyst
growth
pt
signific
volum
reduct
second
fu
month
median
fu
late
side
effect
note
howev
improv
visual
acuiti
conclus
complianc
excel
acut
side
effect
relat
pt
rare
mild
without
treatment
break
evid
earli
late
side
effect
also
note
preliminari
data
confirm
import
evalu
possibl
cystic
dynam
chang
cystic
tumor
pt
ds
sharma
k
medic
colleg
attach
hospit
jaipur
india
radiotharapi
jaipur
india
backgroundobject
evalu
role
radiotherapi
paediatr
patient
singl
tertiari
care
centr
designmethod
present
retrospect
studi
carri
depart
radiotherapi
sm
medic
colleg
jaipur
india
pediatr
patient
less
year
treat
radiotherapi
result
total
pediatr
patient
treat
median
age
rang
year
boy
girl
children
belong
rural
background
common
malign
seen
pediatr
patient
acut
lymphoblast
leukemia
follow
central
nervou
system
cn
tumor
bone
tumor
nasopharyng
tumor
other
common
caus
prescrib
pediatr
radiotherapi
prohylact
follow
cur
palli
common
rt
prescript
gyfract
follow
other
among
children
receiv
cur
rt
complet
respons
partial
respons
stabl
diseas
progress
diseas
among
reciev
palli
rt
symptomat
relief
note
conclus
scarciti
data
regard
rt
paediatr
patient
patient
present
differ
symptomatolog
site
diseas
requir
differ
dose
fraction
h
van
dijk
k
n
c
j
j
b
medic
center
radiat
oncolog
amsterdam
netherland
children
hospitalacadem
medic
princess
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
backgroundobject
combin
hyperthermia
shown
success
treatment
recurr
tumour
adult
cancer
patient
children
chemotherapi
plu
hyperthermia
favor
treatment
strategi
indic
wherea
plu
hyperthermia
yet
investig
object
investig
feasibl
treat
previous
irradi
paediatr
sarcoma
recurr
pelvi
extrem
plu
hyperthermia
designmethod
children
year
diagnos
recurr
sarcoma
amc
previous
irradi
outfield
recurr
locat
pelvi
extrem
pelvic
recurr
larger
cm
without
diagnost
ct
scan
suitabl
treatment
plan
exclud
treatment
plan
combin
radiotherapi
hyperthermia
two
pelvic
recurr
sarcoma
one
sarcoma
foot
one
lower
leg
gener
use
realist
low
dose
treatment
schedul
ie
gy
fraction
plu
weekli
hyperthermia
radiosensit
effect
hyperthermia
quantifi
use
biolog
model
chang
paramet
model
possibl
effect
plu
hyperthermia
estim
calcul
equival
radiotherapi
dose
distribut
result
treatment
plan
show
feasibl
effect
heat
pelvic
locat
extrem
children
evalu
equival
dose
distribut
indic
hypertherm
radiosensit
quantifi
addit
typic
gy
ptv
therebi
realiz
least
effect
biolog
equival
cur
dose
gy
without
substanti
increas
equival
dose
organ
risk
eg
bladder
rectum
conclus
plu
hyperthermia
theoret
feasibl
promis
effect
treatment
recurr
paediatr
sarcoma
pelvic
region
extrem
base
result
plan
investig
clinic
feasibl
bhargava
hospit
r
kanpur
india
institut
pharmaci
pharmaci
kanpur
india
backgroundobject
liver
cancer
diseas
uncontrol
cell
growth
may
invad
adjac
tissu
caus
infiltr
beyond
liver
potent
effect
anticanc
drug
use
liver
cancer
therapi
show
poor
bioavail
desir
site
well
toxic
natur
aim
studi
investig
mannos
modifi
liquid
crystallin
nanoparticl
lcnp
carrier
effici
site
specif
deliveri
potent
anticanc
drug
methotrex
use
hepat
carcinoma
therapi
designmethod
mtx
load
lcnp
prepar
lipid
cast
film
method
sonic
method
nanoparticl
character
shape
size
percent
drug
entrap
stabil
optic
microscopi
cross
polar
light
microscpi
cplm
transmiss
electron
microscopi
tem
diffract
xrd
atom
forc
microscopi
afm
result
stabil
studi
reveal
lcnp
formul
stabl
day
room
temperatur
cell
cytotox
perform
human
hepatoma
cell
line
studi
includ
fluoresc
microscopi
organ
distribut
studi
show
mannos
modifi
lcnp
exhibit
better
accumul
liver
compar
unmodifi
system
result
present
studi
indic
system
stabl
compar
system
conclus
eventu
may
conclud
incorpor
mtx
mannos
modifi
lcnp
increas
resid
time
drug
bodi
alter
pharmacokinet
biodistribut
pattern
drug
primarili
concentr
liver
system
show
excel
cytotox
toward
cancer
cell
present
investig
evid
system
may
use
liver
cancer
liver
diseas
bhargava
v
institut
pharmaci
pharmaci
kanpur
india
hospit
pharmaci
kanpur
india
backgroundobject
cancer
uncontrol
growth
cell
devoid
apoptosi
project
aim
develop
ligand
mediat
tumor
target
via
carrier
system
multiwal
carbon
nanotub
mwcnt
select
mitochondri
target
central
role
apoptosi
multipl
activ
pathway
tumour
growth
depend
energi
avail
mitochondriotrop
shown
rapidli
taken
mitochondria
live
cell
serv
tripl
purpos
mwcnt
choic
deliveri
system
directli
enter
cell
without
pass
larg
inner
volum
distinct
inner
outer
surfac
abil
enter
cell
spontan
mechan
thu
propos
work
envisag
conjug
paclitaxel
load
provid
enhanc
cell
permeat
mitochondri
order
enhanc
mitochondri
avail
paclitaxel
designmethod
raw
mwcnt
procur
purifi
oxid
conjug
carbodimid
method
mwcnt
character
shape
size
scan
sem
transmiss
electron
microscopi
tem
ftir
analysi
diffract
zeta
potenti
determin
stabil
studi
perform
exagger
condit
along
hemolyt
toxic
studi
cell
cytotox
assay
done
use
hela
cell
line
mitochondri
local
determin
clsm
studi
studi
compris
determin
distribut
drug
variou
organ
fluoresc
microscopi
result
cnt
show
high
paclitaxel
load
sustain
releas
excel
biocompat
evid
drug
releas
low
hemolyt
toxic
mtt
assay
hela
cell
line
suggest
potenti
anticanc
activ
develop
system
confoc
microscop
studi
suggest
mitochondri
specif
local
conjug
mwcnt
hela
cell
conclus
thu
conclud
conjug
paclitaxel
load
system
potenti
provid
enhanc
cell
permeat
mitochondri
local
effect
tumour
chemotherapi
bhargava
institut
pharmaci
pharmaci
kanpur
india
backgroundobject
tumor
origin
lung
tissu
bronchi
invad
adjac
tissu
caus
infiltr
beyond
lung
lung
macrophag
express
endocytosi
receptor
might
bind
intern
mannos
termin
dendrim
therefor
hypothes
incorpor
anticanc
drug
mannos
anchor
dendrim
transport
drug
effect
tumor
cell
via
receptor
mediat
endocytosi
project
aim
investig
target
potenti
mannos
conjug
poli
propyl
imin
ppi
dendrim
potent
anticanc
drug
gemcitabin
lung
cancer
cell
dendrim
conjug
enhanc
therapeut
potenti
reduc
advers
effect
anticanc
drug
designmethod
gener
dendrim
synthes
character
ftir
nuclear
magnet
reson
nmr
ppi
dendrim
prepar
conjug
mannos
drug
load
shape
size
character
transmiss
electron
microscopi
tem
drug
load
effici
drug
releas
stabil
studi
studi
constitut
hemolyt
toxic
studi
cell
cytotox
studi
mtt
cytotox
assay
lung
adenocarcinoma
epitheli
cell
line
studi
perform
albino
rat
pharmakokinet
paramet
studi
also
biodistribut
studi
done
access
gemcitabin
level
attain
differ
organ
result
thu
mannosyl
ppi
dendrim
show
high
gemcitabin
load
sustain
releas
excel
biocompat
evid
low
hemolyt
toxic
mtt
assay
suggest
high
cytotox
cancer
cell
line
presenc
ligand
dendrim
molecul
elev
receptor
mediat
bind
intern
develop
ligand
conjug
dendrit
system
target
higher
concentr
gmch
lung
free
drug
conclus
thu
conclud
gmch
load
mannosyl
ppi
dendrit
system
could
higher
potenti
target
anticanc
drug
lung
effect
chemotherapi
lung
tumor
p
b
l
brugier
c
n
roussi
depart
child
adolesc
cancer
villejuif
franc
roussi
drug
develop
depart
villejuif
franc
backgroundobject
mount
evid
support
inclus
adolesc
year
adult
earli
phase
iii
trial
without
requir
prior
specif
paediatr
trial
howev
adult
earli
phase
trial
current
includ
adolesc
hand
classic
arbitrari
upper
age
limit
paediatr
trial
year
old
hinder
appropri
access
trial
young
adult
year
paediatr
diseas
type
designmethod
retrospect
review
phase
iii
trial
open
gustav
roussi
solid
tumourslymphoma
systemat
analysi
protocolsynopsi
three
independ
medic
adolescentyoung
adult
paediatr
oncologist
main
object
describ
current
inclus
adolesc
adult
trial
young
adult
paediatr
trial
result
period
analys
trial
fulfil
inclus
criteria
includ
adolesc
year
paediatr
trial
adult
trial
adult
trial
lower
age
limit
year
concern
trial
open
adolesc
recruit
adolesc
could
includ
trial
trial
open
tumour
type
frequent
found
adolesc
eg
sarcoma
lymphoma
germ
cell
tumour
inclus
young
adult
year
allow
accrual
paediatr
trial
upper
age
limit
year
trial
year
trial
trial
open
cohort
tumour
type
also
found
age
group
conclus
lower
upper
age
limit
futur
paediatr
adult
earli
phase
trial
individu
discuss
taken
paediatr
medic
oncologist
account
current
evid
intern
recommend
denburg
w
j
hospit
sick
children
haematologyoncolog
toronto
canada
univers
health
research
evid
impact
hamilton
canada
hospit
sick
children
child
health
evalu
scienc
toronto
canada
backgroundobject
cost
novel
cancer
drug
continu
rise
put
pressur
health
system
budget
public
polici
approach
fund
paediatr
cancer
medicin
remain
understudi
current
approach
health
technolog
assess
hta
present
varieti
conceptu
methodolog
practic
problem
context
child
health
studi
explor
technic
social
polit
determin
public
fund
decis
paediatr
cancer
drug
canada
designmethod
interview
stratifi
purpos
sampl
stakehold
involv
affect
cancer
drug
fund
decis
children
provinci
ontario
nation
level
canada
ground
theori
method
employ
guid
data
collect
themat
analysi
theme
emerg
inform
develop
conceptu
practic
insight
social
valu
system
dynam
relat
public
policymak
coverag
novel
cancer
drug
children
result
particip
reflect
norm
system
dimens
drug
fund
children
reveal
notabl
differ
relat
child
cancer
drug
priorit
evalu
public
fund
analysi
differ
reveal
number
substant
procedur
shortcom
current
hta
paradigm
respect
child
health
underscor
need
account
distinguish
featur
childhood
cancer
biolog
health
system
sociocultur
term
assess
paediatr
cancer
drug
public
coverag
conclus
studi
furnish
novel
empir
data
social
polit
econom
determin
cancer
drug
fund
children
canada
bring
light
uniqu
rang
social
valu
attach
child
health
technolog
map
health
system
dynam
condit
assess
paediatr
cancer
drug
public
coverag
insight
yield
fundament
knowledg
norm
dimens
hta
children
german
cancer
drug
polici
canada
intern
h
dincaslan
e
n
g
z
g
univers
pediatr
ankara
turkey
univers
pediatr
gastroenterolog
ankara
turkey
univers
patholog
ankara
turkey
backgroundobject
goal
frontlin
chemotherapi
hodgkin
lymphoma
cure
patient
without
need
addit
therapi
abvd
wide
use
regimen
patient
advanc
stage
hodgkin
lymphoma
brentuximab
vedotin
shown
signific
clinic
activ
manag
safeti
profil
patient
relaps
refractori
hodgkin
lymphoma
designmethod
case
report
present
child
advanc
hl
hepat
failur
immunodefici
patient
receiv
brentuximab
vedotin
plu
dose
reduc
avd
therapi
result
boy
refer
hospit
chronic
hepat
failur
cvid
abdominalpelv
comput
tomographi
show
hepatosplenomegali
ascit
multipl
paraaort
conglomer
lymphadenopathi
suggest
lymphoprolif
diseas
lymph
node
biopsi
reveal
classic
mix
cellular
hodgkin
lymphoma
posit
bone
marrow
biopsi
show
hodgkin
diseas
involv
intens
abnorm
focu
fdg
uptak
multipl
enlarg
lymph
node
multipl
focus
bone
bone
marrow
scan
evalu
stage
iv
viral
studi
level
detect
rather
high
copyml
hepat
failur
immunodefici
fear
might
toler
full
cours
standard
chemotherapi
decis
made
start
brentuximab
vedotin
mgkgeveri
week
intraven
rituximab
week
intraven
second
week
brentuximab
combin
dose
reduc
avd
cycl
chemotherapi
repeat
reveal
complet
resolut
increas
fdg
uptak
treatment
continu
withou
toxic
relat
chemotherapi
conclus
brentuximab
vedotin
plu
avd
regimen
well
toler
result
therapi
child
newli
diagnos
advanc
stage
hodgkin
lymphoma
case
first
child
patient
use
brentuximab
vedotin
first
line
therapi
literatur
l
geron
k
k
ca
lg
preto
medic
school
genet
preto
brazil
preto
medic
school
pediatr
preto
brazil
preto
medic
school
pediatr
genet
preto
brazil
backgroundobject
medulloblastoma
mb
common
malign
brain
tumor
childhood
compris
four
major
subgroup
wingless
wnt
sonic
hedgehog
shh
group
group
medulloblastoma
repres
intermedi
prognosi
subgroup
overal
surviv
rate
rang
antagonist
shh
signal
especi
inhibit
pathway
level
smo
sonidegib
clinic
trial
mb
despit
show
pronounc
initi
respons
treatment
smo
inhibitor
human
mice
model
acquir
resist
treatment
relaps
within
short
period
suggest
inhibitor
may
ineffect
administ
monotherapi
display
vari
degre
chromosom
instabl
alter
express
mitot
spindl
checkpoint
gene
like
contribut
phenotyp
interestingli
sever
mitot
spindl
checkpoint
gene
associ
modul
shh
pathway
thu
studi
set
mitot
spindl
screen
conduct
interrog
involv
gene
sonidegib
respons
designmethod
cell
line
daoy
stabli
express
gener
express
confirm
western
blot
perform
crispr
screen
contain
sgrna
target
protein
follow
sonidegib
treatment
result
identifi
synthet
lethal
sonidegib
treatment
silico
analysi
reveal
express
these
three
gene
associ
shh
subgroup
mb
patient
conclus
togeth
observ
suggest
combin
sonidegib
may
potenti
target
mb
treatment
shh
subgroup
sg
cb
k
k
hed
h
e
gz
k
pokrovskaja
ji
n
herold
institutet
depart
stockholm
sweden
institutet
childhood
cancer
research
depart
women
children
health
stockholm
sweden
hospit
heidelberg
depart
infecti
diseas
heidelberg
germani
institutet
chemic
biolog
consortium
sweden
stockholm
sweden
univers
depart
medic
scienc
uppsala
sweden
backgroundobject
three
ten
children
acut
myelogen
leukaemia
aml
die
cancer
even
though
aml
therapi
belong
toxic
chemotherapi
regimen
paediatr
oncolog
cytarabin
deoxycytidin
analogu
build
togeth
anthracyclin
backbon
aml
treatment
clinic
efficaci
correl
propens
aml
blast
produc
retain
activ
metabolit
demonstr
sam
hd
protein
inactiv
hydrolysi
lead
resist
tin
primari
paediatr
aml
blast
anim
model
paediatr
aml
furthermor
express
level
significantli
correl
neg
surviv
paediatr
aml
addit
show
impact
efficaci
induct
therapi
limit
outcom
consolid
cours
contain
combin
inhibitor
bear
potneti
greatli
improv
outcom
children
aml
consolid
chemotherapi
designmethod
sever
librari
small
molecul
screen
assay
identifi
compound
sensitis
cell
cell
efficaci
valid
aml
mous
model
vitro
activ
togeth
cellular
thermal
shift
assay
furthermor
deciph
mode
action
inhibit
activ
alloster
vs
catalyt
result
identifi
two
substanc
expir
patent
extens
safeti
data
exist
adult
children
drug
complet
allevi
resist
primari
aml
sampl
manner
resensitis
anim
model
aml
conclus
advoc
clinic
studi
prospect
test
abil
novel
improv
surviv
combin
consolid
cours
magalha
g
alencastro
veiga
k
silva
k
rodrigu
da
g
ribeiro
de
r
carolin
peixoto
sao
paulo
genet
ribeirao
preto
brazil
sao
paulo
pediatr
ribeirao
preto
brazil
backgroundobject
ependymoma
epn
third
common
childhood
cancer
central
nervou
system
rela
epn
account
approxim
childhood
supratentori
tumor
show
worst
prognosi
among
supratentori
epn
due
low
efficaci
chemotherapi
treatment
option
tumor
limit
sonidegib
hedgehog
hh
pathway
inhibitor
via
smoothen
antagon
phase
ii
studi
pediatr
brain
tumor
howev
role
hh
pathway
epn
still
remain
unclear
aim
studi
evalu
hh
pathway
activ
cell
line
classifi
rela
subgroup
examin
effect
sonidegib
cell
prolifer
apoptosi
cell
line
designmethod
gene
express
evalu
use
taqman
probe
gu
hprt
util
endogen
control
normal
brain
cdna
calibr
protein
express
investig
western
blot
cell
prolifer
assess
resazurin
cell
apoptosi
detect
flow
cytometri
result
overexpress
smo
downregul
sufu
observ
untreat
bxd
cell
line
compar
normal
brain
moreov
protein
express
detect
total
protein
lysat
data
suggest
hh
pathway
signal
activ
bxd
cell
treatment
bxd
cell
line
sonidegib
result
decreas
mrna
express
smo
sufu
well
protein
express
sonidegib
significantli
caus
reduct
cell
prolifer
increas
cell
apoptosi
hour
treatment
conclus
data
show
hh
pathway
activ
bxd
cell
line
sonidegib
exert
antiprolif
proapoptot
effect
cell
find
encourag
futur
investig
better
character
role
hedgehog
signal
epn
rela
subgroup
l
marcu
g
drug
administr
silver
md
usa
drug
administr
offic
cancer
excel
silver
md
usa
drug
administr
depart
oncolog
product
silver
md
usa
backgroundobject
tradit
oncolog
drug
approv
specif
tumor
type
advanc
molecular
profil
biomark
develop
show
multipl
differ
cancer
type
share
genet
signatur
yield
opportun
approach
drug
develop
target
abnorm
across
multipl
cancer
type
includ
rare
pediatr
tumor
tissu
agnost
drug
approv
pathway
may
expedit
approv
cancer
dual
preval
adult
pediatr
designmethod
share
genet
aberr
exist
across
multipl
rare
pediatr
cancer
limit
patient
number
often
preclud
random
trial
larg
effect
respons
rate
respons
durat
may
provid
suffici
evid
efficaci
clinic
benefit
common
rare
molecular
abnorm
pediatr
tumor
leverag
tissu
agnost
approach
facilit
time
develop
approv
certain
target
therapi
result
fda
approv
pembrolizumab
tumor
breakthrough
therapi
design
protein
drug
entrectinib
larotrectinib
illustr
applic
approach
evalu
drug
target
molecular
abnorm
adult
pediatr
cancer
sporad
found
pediatr
cancer
glioma
colorect
cancer
lynch
syndrom
tumor
pathognomon
rare
tumor
infantil
fibrosarcoma
congenit
mesoblast
nephroma
data
submit
support
underli
biolog
biomark
across
tumor
type
pharmacokinet
profil
bridg
data
clinic
meaning
respons
rate
blind
central
review
result
favor
expedit
regulatori
decis
conclus
sinc
evalu
target
therapi
multipl
small
popul
ineffici
often
infeas
tissu
agnost
approach
valuabl
advanc
drug
develop
subset
adult
pediatr
rare
cancer
recent
tissu
agnost
approv
pembrolizumab
tumor
develop
larotrectinib
entrectinib
cancer
demonstr
promis
approach
advanc
treatment
pediatr
cancer
nana
de
ricardo
gutierrez
oncolog
bueno
air
argentina
backgroundobject
antitumor
effect
observ
varieti
malign
via
blockad
immun
checkpoint
express
pediatr
tumor
still
research
pembrolizumab
monoclon
antibodi
use
small
cell
lung
carcinoma
urotheli
carcinoma
hodgkin
lymphoma
hl
head
neck
tumor
report
use
pembrolizumab
pediatr
patient
report
respons
toler
pembrolizumab
pediatr
patient
unknownknown
express
test
designmethod
review
record
patient
treat
pembrolizumab
hospit
de
ricardo
gutierrez
dose
mgkg
hl
mgdose
carcinoma
minut
infus
everi
day
outpati
basi
toxic
control
endocrinolog
laboratori
clinic
control
test
perform
biopsi
sampl
immunohistochemistri
result
three
patient
two
relaps
hl
progress
brentuximab
patient
unresect
squamou
cell
carcinoma
conjunctiva
xeroderma
pigmentosum
age
year
total
infus
one
grade
ii
liver
toxic
requir
temporari
suspens
endocrinolog
toxic
patient
hl
receiv
infus
good
object
respons
dose
current
treatment
patient
carcinoma
receiv
total
infus
pseudoprogress
first
cours
complet
respons
third
infus
necrosi
spontan
tumor
detach
current
treatment
complet
remiss
express
test
perform
last
patient
neg
result
obtain
patient
achiev
complet
clinic
remiss
conclus
effect
objet
respons
achiev
patient
despit
unknownneg
express
treatment
safe
easili
manag
good
toler
good
partial
respons
achiev
patient
hl
known
therapeut
option
patient
irresect
carcinoma
complet
respons
allow
preserv
eye
vision
necessari
continu
test
express
pediatr
tumor
use
antibodi
pediatr
patient
achiev
conclus
nomura
n
j
children
cancer
hematolog
baylor
colleg
medicin
pediatr
houston
usa
institut
biomed
health
nutrit
laboratori
experiment
anim
model
experiment
anim
resourc
bank
ibaraki
japan
univers
pediatr
surgeri
suita
japan
backgroundobject
osteosarcoma
common
bone
cancer
children
adolesc
patient
metastat
diseas
still
extrem
poor
prognosi
report
activ
pathway
close
associ
osteosarcoma
develop
metastat
progress
tegavivint
novel
pathway
inhibitor
reportedli
activ
multipl
type
cancer
cell
studi
investig
antitumor
activ
tegavivint
metastat
osteosarcoma
use
pdx
model
designmethod
antitumor
efficaci
evalu
assay
vitro
use
establish
osteosarcoma
cell
line
cell
thein
vivo
activ
tegavivint
evalu
use
pair
pdx
model
immunodefici
mice
deriv
inher
osteosarcoma
patient
differ
diseas
stage
deriv
biopsi
primari
tumor
deriv
relaps
metastat
lung
lesion
chemotherapi
gene
protein
express
quantifi
qpcr
western
blot
analysi
cell
sort
popul
aldefluor
assay
cell
intraven
inject
nsg
mice
result
vitro
tegavivint
effect
inhibit
cell
surviv
type
cell
subcutan
engraft
tumor
significantli
suppress
tegavivint
express
potenti
marker
cancer
stem
cell
significantli
downregul
tegavivint
furthermor
lung
metastasi
model
use
cell
intraven
inject
nsg
mice
demonstr
tegavivint
markedli
suppress
lung
metastas
final
cell
show
higher
express
higher
sensit
tegavivint
cell
vitro
intraven
inject
model
demonstr
significantli
lung
lesion
group
group
tegavivint
significantli
suppress
deriv
lung
metastas
conclus
preclin
find
demonstr
tegavivint
promis
therapeut
potenti
primari
metastat
osteosarcoma
blockad
axi
c
willi
j
hospit
children
paediatr
oncolog
glasgow
unit
kingdom
backgroundobject
mortal
childhood
cancer
rapidli
declin
recent
trend
steep
especi
amongst
children
solid
tumour
hope
develop
novel
therapi
includ
target
therapi
tt
may
favour
alter
diseas
outcom
object
review
determin
number
children
solid
tumour
treat
tt
trial
document
surviv
outcom
report
side
effect
designmethod
patient
solid
tumour
receiv
tt
last
three
year
identifi
patient
enrol
clinic
trial
exclud
patient
electron
record
use
collat
inform
diagnosi
stage
tt
use
side
effect
profil
diseas
outcom
result
three
patient
treat
tt
trial
identifi
male
femal
diagnosi
includ
metastat
rearrang
renal
cell
carcinoma
treat
sunitinib
relaps
undifferenti
sarcoma
treat
pazopanib
inflammatori
myofibroblast
tumour
imt
treat
crizotinib
age
diagnosi
rang
year
patient
treat
sunitinib
experienc
white
pigment
hair
eye
lash
cycl
treatment
surveil
imag
demonstr
stabl
diseas
patient
treat
pazopanib
therapi
discontinu
cycl
due
radiolog
evid
diseas
progress
current
two
month
treatment
clinic
progress
patient
treat
crizotinib
excel
respons
therapi
within
day
start
treatment
light
profound
myelosuppress
requir
signific
dose
reduct
therapi
year
remain
complet
remiss
conclus
limit
experi
three
patient
two
patient
receiv
tt
posit
outcom
minim
side
effect
profil
research
outcom
side
effect
profil
target
agent
paediatr
oncolog
need
sh
ali
h
r
j
univers
radiotherapi
karachi
pakistan
khan
univers
radiotherapi
nairobi
kenya
backgroundobject
plan
craniospin
irradi
fif
homogen
techniqu
combin
daili
modul
field
junction
minim
possibl
spinal
cord
overdos
techniqu
craniospin
irradi
csi
may
result
dose
inhomogen
within
treatment
volum
usual
requir
weekli
manual
shift
field
junction
minim
possibl
spinal
cord
overdos
nowaday
techniqu
use
feather
dose
inhomogen
caus
multipl
field
start
use
techniqu
acquir
advanc
technolog
machin
recent
year
designmethod
patient
adult
children
treat
craniospin
irradi
retrospect
chosen
analysi
patient
plan
treat
contour
brain
spine
cord
organ
risk
alreadi
done
plan
done
eclips
tm
treatment
plan
system
varian
patient
plan
later
field
posterior
spinal
field
plan
use
fif
techniqu
field
junction
automat
modul
maxim
homogen
within
treatment
fraction
dose
volum
histogram
dvh
use
analysi
result
correspond
plan
without
fif
techniqu
plan
maximum
dose
junction
note
patient
plan
read
evalu
result
plan
inhomogen
improv
fif
techniqu
plan
daili
modul
junction
shift
provid
consist
dose
deliveri
fraction
treatment
across
junction
maximum
dose
calcul
junction
higher
csi
plan
without
fif
compar
fif
techniqu
conclus
paper
henc
prove
fif
techniqu
better
plan
craniospin
irradi
adel
fahmideh
c
g
j
k
c
ce
b
ls
h
institutet
unit
institut
environment
medicin
stockholm
sweden
institutet
neurogenet
depart
molecular
medicin
surgeri
stockholm
sweden
agenc
research
cancer
iarc
section
environ
radiat
lyon
franc
tropic
public
health
institut
depart
epidemiolog
public
health
basel
switzerland
basel
univers
basel
basel
switzerland
cancer
registri
norway
cancer
registri
norway
oslo
norway
children
hospit
zurich
depart
oncolog
zurich
switzerland
danish
cancer
societi
research
centr
unit
survivorship
copenhagen
denmark
centr
oncolog
depart
copenhagen
denmark
bern
swiss
childhood
cancer
institut
social
prevent
medicin
bern
switzerland
bern
children
univers
hospit
bern
bern
switzerland
gothenburg
depart
pediatr
gothenburg
sweden
hospit
herlev
depart
pediatr
copenhagen
denmark
quantifi
stockholm
sweden
backgroundobject
genet
risk
score
gr
use
demonstr
genet
variant
contribut
polygen
architectur
complex
diseas
present
studi
use
gr
investig
addit
impact
known
adult
glioma
suscept
loci
pediatr
brain
tumor
risk
assess
proport
pediatr
brain
tumor
herit
attribut
suscept
loci
designmethod
gener
gr
pediatr
brain
tumor
base
allel
associ
effect
size
deriv
previous
publish
associ
studi
gwa
adult
glioma
turn
base
two
gwa
includ
case
control
also
three
addit
independ
replic
seri
includ
case
control
gr
calcul
base
snp
cefalo
studi
cefalo
studi
brain
tumor
children
adolesc
age
year
conduct
sweden
denmark
norway
switzerland
includ
saliva
dna
case
control
uncondit
logist
regress
model
appli
evalu
whether
standard
gr
associ
risk
pediatr
brain
tumor
adjust
age
sex
countri
measur
varianc
explain
effect
gr
nagelkerk
calcul
result
result
indic
genet
risk
score
adult
brain
tumor
associ
increas
risk
pediatr
brain
tumor
ci
p
varianc
pediatr
brain
tumor
could
explain
effect
genet
risk
score
liabil
scale
conclus
studi
provid
evid
herit
risk
pediatr
brain
tumor
attribut
common
genet
variant
associ
adult
glioma
k
mg
e
ped
hem
onc
riyadh
saudi
arabia
radiat
oncolog
riyadh
saudi
arabia
neurosci
riyadh
saudi
arabia
backgroundobject
cn
tumor
among
young
children
vyc
associ
dismal
prognosi
conduct
studi
observ
surviv
pattern
among
vyc
cn
tumor
tertiari
care
hospit
designmethod
medic
record
patient
diagnos
treat
review
research
databas
maintain
data
prospect
fashion
surviv
pattern
evalu
via
surviv
curv
result
total
patient
includ
median
age
year
primari
diagnost
relat
group
drg
includ
medulloblastoma
follow
atyp
teratoidrhabdoid
tumor
atrt
receiv
type
treatment
refer
hospit
seventeen
got
radiat
therapi
first
line
treatment
regimen
relapseprogress
diseas
rate
local
distant
localdist
relaps
site
mortal
rate
medulloblastoma
highest
follow
atrt
month
five
year
overal
surviv
whole
group
patient
ependymoma
observ
follow
atrt
medulloblstoma
among
aliv
palli
care
evalu
aliv
case
cr
sd
remain
pd
conclus
vyc
cn
tumor
distinct
group
oncolog
patient
poor
prognosi
emphas
novel
therapeut
strategi
biolog
advanc
need
augment
person
care
uniqu
group
patient
alharbi
na
balbaid
abdal
sami
n
fayea
f
w
z
bani
war
e
cancer
king
fahad
medic
citi
kfmc
saudi
arabia
pedatr
oncolog
riyadh
saudi
arabia
cancer
king
fahad
medic
citi
kfmc
saudi
arabia
radait
oncolog
riyadh
saudi
arabia
cancer
king
fahad
medic
citi
kfmc
saudi
arabia
radiat
oncolog
riyadh
saudi
arabia
cancer
king
fahad
medic
citi
kfmc
saudi
arabia
oncolog
riyadh
saudi
arabia
king
fahad
medic
citi
kfmc
saudi
arabia
oncolog
riyadh
saudi
arabia
women
harvard
medic
depart
usa
research
saudi
human
genom
project
king
fahad
medic
citi
kfmc
depart
brigham
women
harvard
medic
riyadh
saudi
arabia
hospit
toronto
pediatr
neuroncolgi
toronto
canada
backgroundobject
kfmc
major
tertiari
care
center
children
brain
tumor
saudi
arabia
aim
studi
analyz
demograph
data
treatment
strategi
clinic
outcom
saudi
children
medulloblastoma
mb
pineablastoma
treat
saudi
arabian
pediatr
hematolog
oncolog
societi
sapho
treatment
studi
protocol
designmethod
retrospect
studi
patient
newli
diagnos
mb
pineablastoma
year
year
treat
kfmc
receiv
multimod
therapi
consist
maxim
surgic
resect
follow
risk
adapt
craniospin
radiat
concurr
oral
adjuv
chemotherapi
consist
cycl
cisplatin
plu
oral
altern
cycl
cyclophosphamid
vincristin
mainten
oral
isotretinoin
given
month
molecular
analysi
done
use
next
gener
target
sequenc
ng
ffpe
tissu
gene
molecular
subgroup
analysi
done
mb
patient
wnt
group
shh
group
group
result
major
patient
male
median
age
diagnosi
month
treat
ar
treat
hr
pineablastoma
patient
treat
high
overal
surviv
os
ar
patient
hr
patient
median
time
start
radiat
day
median
month
pf
entir
studi
patient
os
os
wnt
subgroup
shh
subgroup
group
group
conclus
studi
protocol
result
accept
compar
intern
studi
although
patient
high
risk
featur
oral
toler
conveni
craniospin
radiat
studi
form
baselin
unifi
treatment
protocol
children
brain
tumor
saudi
arabia
r
alyoussef
k
r
n
univers
beirut
pediatr
beirut
lebanon
univers
beirut
surgeri
beirut
lebanon
backgroundobject
outcom
brain
tumor
infant
less
month
well
describ
countri
brain
tumor
age
group
differ
manag
approach
compar
older
children
designmethod
retrospect
analysi
diseas
characterist
treatment
surviv
outcom
done
children
less
month
diagnos
brain
tumor
children
cancer
institut
lebanon
result
sixteen
patient
male
femal
median
age
month
rang
month
identifi
supratentori
infratentori
tumor
present
symptom
includ
increas
head
circumfer
vomit
irrit
seizur
abnorm
eye
movement
hemiparesi
development
delay
decreas
vision
thirteen
patient
underw
surgic
resect
gross
total
subtot
patient
three
patient
undergo
surgic
resect
diagnosi
clear
radiolog
optic
nerv
glioma
histolog
diagnosi
includ
astrocytoma
medulloblastoma
choroid
plexu
carcinoma
chroid
plexu
papiloma
glioblastoma
immatur
teratoma
atyp
teratoid
rhabdoid
tumor
anaplast
ependymoma
twelv
patient
receiv
chemotherapi
one
patient
atrt
receiv
proton
radiotherapi
outsid
countri
none
patient
receiv
radiotherapi
median
month
rang
month
overal
surviv
rate
ci
respect
tumor
progress
occur
patient
glioma
patient
underw
complet
surgic
resect
recurr
conclus
brain
tumor
infant
less
month
well
control
surgic
resect
chemotherapi
avoid
side
effect
convent
radiotherapi
studi
larger
number
patient
need
confirm
find
n
amayiri
n
e
v
hussein
cancer
center
depart
pediatr
amman
jordan
hussein
cancer
center
diagnost
radiolog
amman
jordan
hussein
cancer
center
radiat
oncolog
amman
jordan
hussein
cancer
center
depart
surgeri
amman
jordan
hospit
sick
children
hematolog
oncologyneurooncolog
toronto
canada
hussein
cancer
center
depart
patholog
amman
jordan
backgroundobject
medulloblastoma
compris
four
distinct
molecular
subgroup
wnt
shh
uniqu
clinic
prognost
implic
howev
relationship
rare
report
middl
east
designmethod
assembl
institut
cohort
children
year
diagnos
medulloblastoma
receiv
radiotherapi
khccjordan
subgroup
tumour
use
limit
gene
express
analysi
result
patient
identifi
femal
median
age
patient
patient
treat
standard
risk
sr
high
risk
hr
subgroup
reveal
shh
wnt
median
time
craniotomi
radiotherapi
day
median
durat
radiotherapi
overal
ef
os
statist
signific
sr
hr
absenc
metastasi
surviv
advantag
os
shh
tumor
good
os
respect
metastat
well
os
metastat
dismal
os
unexpectedli
wnt
patient
rel
poor
os
conclus
shh
medulloblastoma
excel
surviv
compar
develop
countri
despit
treatment
delay
strikingli
observ
lower
surviv
wnt
subgroup
suggest
possibl
background
differ
compar
cohort
highlight
import
valid
molecular
stratif
develop
world
suggest
background
genet
differ
may
underli
differ
therapi
respons
e
auwart
c
abdel
el
k
p
farber
cancer
institut
pediatr
boston
usa
farber
cancer
institut
pediatr
oncolog
boston
usa
cancer
hospit
egypt
clinic
research
cairo
egypt
cancer
hospit
egypt
neurosurgeri
cairo
egypt
farber
cancer
institut
radiat
oncolog
boston
usa
cancer
hospit
egypt
radiat
oncolog
cairo
egypt
backgroundobject
pediatr
brain
tumor
affect
mani
children
worldwid
attribut
diagnos
pediatr
cancer
annual
newli
diagnos
pediatr
brain
tumor
case
occur
develop
incom
countri
lmic
pauciti
overal
surviv
studi
examin
surviv
children
lmic
compar
children
hic
designmethod
retrospect
chart
review
conduct
patient
diagnos
medulloblastoma
ependymoma
treat
either
cancer
institut
dfci
boston
children
cancer
hospit
egypt
cche
cairo
egypt
studi
cohort
data
extract
medic
record
cancer
registri
hospit
identifi
case
cche
case
dfci
patient
diagnos
abstract
follow
period
patient
outcom
took
place
evalu
demograph
clinic
factor
overal
surviv
os
use
test
curv
stratifi
tumor
type
overal
surviv
rate
compar
two
cohort
median
follow
six
year
result
os
dfci
medulloblastoma
ependymoma
cche
medulloblastoma
ependymoma
type
treatment
receiv
associ
significantli
improv
os
among
medulloblastoma
patient
age
diagnosi
associ
significantli
improv
os
among
ependymoma
patient
conclus
current
treatment
protocol
still
upward
mortal
medulloblastoma
ependymoma
lmic
number
even
higher
find
highlight
import
collabor
develop
countri
lmic
consolid
therapi
improv
overal
surviv
c
b
aydin
n
b
n
univers
pediatr
oncolog
ankara
turkey
backgroundobject
atyp
teratoid
rhabdoid
tumor
atrt
rare
high
grade
malign
brain
tumor
poor
prognosi
patient
younger
year
age
age
becom
younger
prognosi
get
wors
rariti
experi
regard
chemotherapi
recommend
scarc
designmethod
medic
record
patient
treat
diagnosi
atrt
evalu
retrospect
demograph
featur
present
symptom
treatment
approach
respons
treatment
outcom
result
median
age
girl
boy
month
three
patient
younger
month
age
patient
older
year
age
time
diagnosi
nine
patient
supratentori
infratentori
spinal
primari
tumor
tumor
resect
complet
near
complet
partial
resect
biopsi
patient
patient
median
month
os
patient
older
year
diagnosi
patient
younger
year
die
within
first
year
treatment
seven
patient
receiv
etoposid
cisplatin
os
rate
os
rate
patient
receiv
intens
chemotherapi
first
year
craniospin
radiotherapi
csrt
given
patient
diagnosi
eight
patient
relapsedrefractori
diseas
receiv
second
chemotherapi
addit
rt
surviv
better
patient
addit
radiotherapi
conclus
younger
age
diagnosi
sign
poor
prognosi
intens
chemotherapi
regimen
need
atrt
csrt
part
treatment
also
intens
second
line
chemotherapi
addit
rt
might
impact
surviv
recurr
diseas
e
l
barakat
k
w
j
j
r
e
ver
j
hospit
philadelphia
divis
oncolog
philadelphia
usa
pennsylvania
perelman
school
medicin
philadelphia
usa
north
carolina
chapel
hill
school
nurs
chapel
hill
usa
pittsburgh
school
medicin
pittsburgh
usa
arizona
psycholog
arizona
usa
pennsylvania
school
nurs
philadelphia
usa
backgroundobject
young
adult
survivor
childhood
brain
tumor
ya
impact
childhood
cancer
survivor
caregiv
task
famili
manag
fm
ie
manag
special
need
ya
incorpor
respons
everyday
life
compon
fm
includ
ya
daili
life
caregiv
effort
abil
manag
impact
condit
famili
famili
life
difficulti
abil
work
togeth
known
evid
base
intervent
exist
support
fm
ya
studi
describ
develop
intervent
train
problem
solv
tip
base
bright
idea
support
famili
capac
caregiv
ya
improv
caregiv
ya
qualiti
life
hrqol
designmethod
direct
content
analysi
identifi
fm
challeng
data
interview
matern
caregiv
aya
survivor
interdisciplinari
team
expert
met
biweekli
develop
bright
idea
fm
challeng
creat
inform
video
caregiv
common
fm
challeng
design
engag
websit
address
health
literaci
issu
access
includ
videoconferenc
technolog
live
chat
coach
mix
method
use
evalu
accept
feasibl
prototyp
modul
among
key
stakehold
commun
advisori
board
caregiv
ya
result
tip
organ
seven
modul
base
core
fm
challeng
survivor
survivor
independ
sibl
famili
activ
parent
caregiv
survivor
late
effect
support
advocaci
eight
caregiv
provid
feedback
prototyp
modul
initi
rate
accept
feasibl
high
caregiv
report
tip
understand
inform
relev
experi
coach
interact
strongli
endors
conclus
find
support
initi
accept
feasibl
tip
may
effect
tool
improv
fm
among
caregiv
caregiv
ya
hrqol
baroni
milan
gav
cap
vk
rg
de
paula
ca
lg
preto
medic
school
univers
sao
paulo
genet
preto
brazil
preto
medic
school
univers
sao
paulo
pediatr
preto
brazil
backgroundobject
medulloblastoma
mb
common
type
pediatr
malign
primari
brain
tumor
despit
new
advanc
one
third
mb
patient
die
due
recurr
survivor
suffer
side
effect
search
potenti
target
found
member
mst
kinas
famili
mammalian
steril
twenti
like
belong
hippo
signal
sever
studi
shown
involv
hippo
pathway
carcinogenesi
differ
tumor
type
therefor
aim
studi
analyz
express
mb
sampl
investig
effect
pharmacolog
inhibit
viabil
mb
cell
line
designmethod
analyz
express
sampl
mb
cell
line
mb
human
cerebellum
perform
pharmacolog
inhibit
daoy
cell
line
drug
select
inhibitor
cell
treat
differ
dose
time
perform
resazurin
cell
viabil
kit
clonogen
surviv
analysi
cell
treat
hour
coloni
count
stain
giemsa
apoptosi
assay
annexinpropidium
iodid
posit
cell
count
flow
cytometri
hour
treatment
statist
analysi
perform
spss
statist
result
upregul
tumor
cell
line
compar
cerebellum
observ
viabil
cell
decreas
treatment
clonogen
assay
form
coloni
dose
apoptosi
increas
treatment
conclus
preliminari
data
show
express
higher
mb
sampl
kinas
may
involv
pathway
import
cell
surviv
mb
ja
bermudez
lugo
ramirez
niembro
zapata
san
angel
inn
universidad
pediatr
mexico
citi
mexico
nacion
de
pediatria
pediatr
mexico
mexico
nacion
de
pediatria
pediatr
oncolog
mexico
citi
mexico
nacion
de
pediatria
pediatr
oncolog
mexico
mexico
backgroundobject
cn
neoplasm
second
common
childhood
tumor
repres
childhood
cancer
ependymoma
purpos
studi
describ
clinic
characterist
surviv
pediatr
patient
diagnos
ependymoma
period
mexican
pediatr
oncolog
refer
center
designmethod
retrospect
retrolect
descript
observ
studi
medic
file
pediatr
patient
diagnos
ependymoma
analyz
clinic
characterist
summar
measur
central
frequenc
result
thirti
patient
diagnosi
found
women
men
ratio
averag
age
diagnosi
year
year
frequent
locat
ventricular
region
hemispher
cerebellum
column
mesencephalon
bridg
regard
histolog
classic
anaplast
mixopapillari
common
symptom
nausea
vomit
present
patient
follow
headach
paresi
hydrocephalu
ataxia
neurodevelopment
regress
paralysi
nerv
visual
chang
achiev
complet
surgic
resect
underw
partial
resect
surgeri
perform
surviv
less
patient
lesion
patient
lesion
found
aliv
one
year
diagnosi
conclus
frequent
symptom
time
diagnosi
relat
intracrani
hypertens
found
lower
surviv
popul
compar
report
due
delay
diagnosi
first
contact
physician
carri
action
focus
medic
educ
media
inform
campaign
plan
order
shorten
time
diagnosi
v
bhat
g
h
kc
r
memori
hospit
pediatr
oncolog
mumbai
india
memori
hospit
patholog
mumbai
india
memori
hospit
radiat
oncolog
mumbai
india
memori
hospit
radiodiagnosi
mumbai
india
backgroundobject
patient
high
risk
relaps
medulloblastoma
continu
poor
outcom
compar
averag
risk
diseas
low
middl
incom
countri
lmic
combat
oral
metronom
therapi
shown
benefit
surviv
patient
relaps
embryon
brain
tumor
review
efficaci
feasibl
modifi
combat
high
risk
relaps
medulloblastoma
patient
treat
designmethod
retrospect
evalu
patient
april
decemb
high
risk
medulloblastoma
relaps
medulloblastoma
start
modifi
combat
regimen
complet
convent
therapi
includ
analysi
modifi
combat
modifi
version
sodium
valproat
replac
celecoxib
regimen
consist
low
dose
temozolomid
etoposid
sodium
valproat
acid
administ
cycl
result
thirti
nine
children
median
age
year
median
month
male
femal
ratio
start
modifi
combat
studi
period
start
complet
convent
therapi
start
relaps
molecular
data
avail
children
wnt
shh
group
group
n
progress
free
surviv
pf
start
modifi
combat
ci
ci
upfront
therapi
relaps
medulloblastoma
respect
overal
surviv
ci
ci
upfront
therapi
relaps
medulloblastoma
child
develop
secondari
aml
warrant
discontinu
modifi
combat
therapi
conclus
modifi
combat
regimen
effect
treatment
option
complet
convent
treatment
children
high
risk
medulloblastoma
especi
lmic
option
high
dose
chemotherapi
stem
cell
transplant
routin
avail
futur
studi
base
molecular
subtyp
delin
role
modifi
combat
patient
high
risk
medulloblastoma
biswa
v
p
india
institut
medic
scienc
radiotherapi
oncolog
new
delhi
india
india
institut
medic
scienc
medic
oncolog
new
delhi
india
india
institut
medic
scienc
patholog
new
delhi
india
backgroundobject
paediatr
primari
central
nervou
system
lymphoma
pcnsl
rare
constitut
pcnsl
designmethod
data
pertain
paediatr
patient
pcnsl
attend
institut
abstract
retrospect
chart
review
result
identifi
immunocompet
paediatr
patient
pcnsl
median
age
present
year
rang
year
male
femal
ratio
median
ecog
perform
statu
common
symptom
includ
headach
vomit
seizur
visual
symptom
motor
impair
patient
patient
solitari
patient
multipl
parenchym
lesion
csf
cytolog
show
atyp
cell
patient
none
ocular
involv
system
lymphoma
neg
biopsi
resect
tumour
done
patient
respect
histopatholog
reveal
dlbcl
nhl
patient
patient
underw
induct
chemotherapi
median
cycl
modifi
deang
protocol
iv
mg
vincristin
procarbazin
everi
week
singl
agent
everi
week
patient
chemotherapi
grade
neutropenia
grade
mucos
note
patient
radiotherapi
rt
administ
patient
due
patient
whole
brain
rt
given
patient
craniospin
rt
follow
whole
brain
rt
given
patient
posit
csf
cytolog
subsequ
consolid
chemotherapi
cycl
cytarabin
iv
everi
week
administ
patient
due
patient
median
month
patient
complet
radiolog
remiss
conclus
paediatr
pcnsl
rare
tumour
multimod
manag
methotrex
rituximab
base
cranial
radiotherapi
lead
excel
earli
clinic
outcom
awar
entiti
import
preclud
surgic
resect
highli
chemosensit
radiosensit
tumour
j
j
g
v
braunstein
california
san
francisco
radiat
oncolog
san
francisco
usa
california
san
francisco
radiolog
san
francisco
usa
california
san
francisco
neurolog
neurolog
surgeri
san
francisco
usa
california
san
francisco
radiat
oncolog
neurolog
surgeri
san
francisco
usa
backgroundobject
qualit
radiograph
featur
associ
molecular
subgroup
pediatr
embryon
brain
tumor
may
provid
use
inform
adapt
adjuv
therapi
util
quantit
imag
radiom
function
guid
provid
novel
inform
beyond
physician
conscious
observ
purpos
studi
investig
prognost
util
quantit
magnet
reson
imag
mri
radiom
analysi
primari
pediatr
embryon
brain
tumor
designmethod
pediatr
embryon
brain
tumor
patient
concurr
post
contrast
invers
recoveri
flair
mr
imag
identifi
institut
databas
median
year
radiom
featur
extract
axial
flair
contour
use
matlab
featur
select
analysi
base
qualit
radiograph
featur
prognost
signific
pediatr
embryon
brain
tumor
logist
regress
linear
regress
receiv
oper
characterist
curv
harrel
c
index
somer
index
use
test
relationship
radiom
featur
demograph
variabl
clinic
outcom
result
found
pediatr
embryon
brain
tumor
older
patient
increas
normal
mean
tumor
intens
decreas
tumor
volum
increas
marker
heterogen
flair
rel
younger
patient
identifi
quantit
radiom
featur
delin
medulloblastoma
pineoblastoma
supratentori
primit
neuroectoderm
tumor
includ
size
heterogen
flair
decreas
marker
tumor
heterogen
predict
neuraxi
metastas
trend
toward
signific
flair
tumor
increas
size
flair
decreas
heterogen
flair
diagnosi
like
recur
conclus
quantit
radiom
featur
associ
pediatr
embryon
brain
tumor
patient
age
histolog
neuraxi
metastas
recurr
data
suggest
quantit
mri
radiom
analysi
could
use
risk
stratifi
pediatr
embryon
brain
tumor
patient
l
aj
p
j
b
v
v
universitario
la
fe
pediatr
oncolog
valencia
spain
de
sanitaria
hospit
la
fe
biostatist
valencia
spain
de
sanitaria
hospit
la
fe
genom
valencia
spain
universitario
la
fe
patholog
valencia
spain
backgroundobject
medulloblastoma
mb
common
malign
cn
tumor
children
molecular
mechan
involv
mb
pathogenesi
aggress
still
poorli
understood
microrna
mirna
type
short
rna
recogn
import
regul
cancer
relat
signal
pathway
aim
analyz
mirna
express
profil
liquid
biopsi
correl
mb
specif
signal
pathway
histopatholog
tumor
behavior
designmethod
circul
obtain
mb
patient
express
evalu
use
genechip
mirna
platform
affymetrix
penal
regress
model
elast
net
implement
evalu
associ
mirna
express
profil
clinic
behavior
histopatholog
major
pathway
alter
tumor
result
differenti
express
profil
identifi
wnt
mb
subgroup
notabl
differenti
express
level
identifi
compar
relaps
patient
conclus
liquid
biopsi
mirna
profil
could
repres
promis
tool
earli
detect
relaps
also
improv
mb
classif
valid
signatur
need
larger
patient
cohort
microrna
target
pathway
mb
would
provid
new
potenti
power
candid
therapeut
intervent
f
c
k
j
c
capra
ladi
children
hospit
haematologyoncolog
dublin
ireland
backgroundobject
surviv
young
children
medulloblastoma
mb
primit
neuroectoderm
tumour
pnet
gener
poor
follow
resect
high
dose
chemotherapi
hdc
stem
cell
rescu
scr
provid
treatment
option
negat
signific
radiotherapi
rt
toxic
immatur
develop
brain
document
respons
toxic
treatment
designmethod
retrospect
review
patient
year
diagnos
mbpnet
june
februari
treat
ireland
perform
hdc
compris
sequenti
cycl
thiotepacarboplatin
administ
cycl
induct
combin
chemotherapi
follow
contemporari
protocol
result
evalu
patient
mb
chang
stage
pnet
metastat
boy
four
patient
treat
hdcscr
remain
complet
resect
evid
diseas
receiv
rt
remain
aliv
evid
diseas
ned
partial
remiss
remain
aliv
ned
die
due
diseas
progress
adenoviru
pulmonari
fibrosi
three
patient
receiv
craniospin
rt
progress
diseas
fatal
recurr
x
aliv
ned
nine
receiv
rt
aliv
ned
febril
neutropaenia
follow
episod
induct
consolid
chemotherapi
respect
five
patient
requir
chemotherapi
dose
reduct
surviv
total
group
mbl
pnet
subgroup
respect
overal
surviv
patient
complet
remiss
subgroup
conclus
surgeri
hdcscr
rt
provid
cure
nearli
young
children
mbpnet
ireland
associ
signific
toxic
includ
fatal
outcom
complet
remiss
favour
prognost
variabl
j
chan
b
c
san
francisco
radiat
oncolog
san
francisco
usa
sloan
ketter
cancer
center
radiat
oncolog
new
york
usa
san
francisco
pediatr
san
francisco
usa
san
francisco
patholog
san
francisco
usa
women
hospit
radiat
oncolog
boston
usa
backgroundobject
craniospin
irradi
csi
histor
integr
manag
intracrani
germ
cell
tumor
nggct
howev
improv
system
therapi
concern
late
sequela
csi
motiv
limit
radiat
field
goal
studi
evalu
failur
site
subsequ
salvag
therapi
outcom
designmethod
patient
receiv
treatment
intracrani
nggct
singl
institut
retrospect
review
actuari
estim
surviv
pf
overal
surviv
os
determin
use
method
result
patient
underw
treatment
combin
surgeri
chemotherapi
radiat
therapi
median
age
diagnosi
year
iqr
patient
primari
tumor
pineal
gland
alon
bifoc
tumor
signific
heterogen
initi
radiat
therapi
rt
approach
rang
rt
rt
whole
ventricl
wvrt
whole
brain
wbrt
radiotherapi
csi
median
year
iqr
year
rate
pf
os
respect
recurr
median
time
year
iqr
four
recurr
occur
among
patient
receiv
rt
rt
wvrt
wbrt
csi
respect
among
irradi
patient
none
experienc
recurr
among
patient
recurr
salvag
csi
chemotherapi
median
os
time
salvag
therapi
year
iqr
os
diagnosi
patient
underw
salvag
therapi
year
iqr
conclus
despit
high
rate
recurr
among
cohort
patient
nggct
overal
surviv
appear
preserv
potenti
due
success
salvag
therapi
c
citak
e
g
univers
faculti
medicin
pediatr
oncolog
mersin
turkey
univers
faculti
medicin
depart
opthalmolog
mersin
turkey
state
hospit
depart
opthalmolog
mersin
turkey
univers
faculti
medicin
pediatr
mersin
turkey
univers
faculti
medicin
bioistatist
mersin
turkey
backgroundobject
studi
aim
evalu
central
retin
thick
crt
macular
volum
mv
patient
neurofibromatosi
type
compar
healthi
subject
designmethod
studi
includ
eye
patient
well
eye
healthi
subject
ocular
patholog
control
group
macular
section
obtain
heidelberg
retin
tomographi
hrt
pupillari
dilat
tropicamid
crt
mv
measur
record
analys
normal
data
distribut
test
group
use
test
normal
distribut
paramet
summar
descript
statist
mean
standard
deviat
categor
variabl
express
use
descript
statist
number
percentag
mann
whitney
u
student
use
compar
mean
paramet
patient
control
group
data
analys
perform
use
spss
packag
program
p
consid
signific
result
crt
valu
significantli
increas
patient
group
compar
control
group
addit
mv
decreas
patient
group
compar
control
group
insignific
conclus
present
studi
show
crt
increas
patient
compar
healthi
subject
j
contrera
h
p
univers
school
medicin
radiat
oncolog
st
loui
usa
backgroundobject
neurocognit
dysfunct
known
late
toxic
radiotherapi
pediatr
patient
studi
assess
effect
proton
therapi
pt
volumetr
chang
hippocampu
associ
cognit
function
use
nation
institut
health
toolbox
cognit
batteri
tcb
designmethod
prospect
cohort
studi
conduct
children
age
cn
malign
treat
pt
patient
complet
tcb
test
baselin
schedul
visit
brain
magnet
reson
imag
bmri
complet
schedul
visit
within
day
test
brain
substructur
automat
segment
mprage
mri
use
freesurf
linear
mix
effect
model
use
analyz
effect
age
time
sinc
pt
pt
dose
cn
volum
tcb
metric
result
thirteen
children
median
age
year
rang
bmri
includ
median
follow
time
two
year
rang
total
hippocamp
volum
thv
increas
time
lower
rate
chang
seen
patient
irradi
younger
age
thv
correl
cognit
function
composit
p
fluid
composit
episod
memori
domain
found
decreas
baselin
valu
cours
follow
p
increas
volum
total
hippocampu
receiv
greater
gy
associ
wors
neurocognit
outcom
p
conclus
chang
total
hippocamp
volum
higher
dose
pt
associ
decreas
perform
neurocognit
test
studi
suggest
hippocamp
dose
may
repres
action
treatment
paramet
treatment
pediatr
cn
malign
dahlin
c
u
j
c
r
u
b
univers
radiat
oncolog
sweden
serum
institut
depart
congenit
danish
centr
neonat
screen
copenhagen
denmark
agenc
research
cancer
section
environ
radiat
lyon
franc
cancer
societi
research
center
unit
bioinformat
registri
copenhagen
denmark
institutet
depart
medic
epidemiolog
biostatist
stockholm
sweden
backgroundobject
associ
studi
gwa
identifi
germlin
genet
variant
genet
loci
increas
individu
risk
develop
glioma
adulthood
aim
present
studi
investig
genet
variant
increas
risk
glioma
childhood
designmethod
base
two
recent
gwa
adult
glioma
select
genet
variant
locat
differ
loci
investig
associ
genet
variant
risk
pediatr
glioma
investig
case
control
sweden
denmark
recruit
case
control
genotyp
perform
use
illumina
beadchip
untyp
variant
imput
data
genom
project
refer
result
three
investig
variant
map
locu
associ
pediatr
glioma
risk
odd
also
found
indic
interact
variant
locat
near
three
gene
involv
pathway
conclus
find
line
exist
evid
genet
variant
locu
increas
risk
pediatr
glioma
interact
genet
locat
gene
involv
pathway
warrant
investig
dandapani
j
l
r
children
hospit
paediatr
oncolog
nottingham
unit
kingdom
children
hospit
paediatr
nottingham
unit
kingdom
kinder
ziekenhui
paediatr
oncolog
groningen
netherland
nottingham
children
brain
tumour
research
centr
nottingham
unit
kingdom
backgroundobject
leptomening
diseas
provid
treatment
challeng
due
dissemin
natur
inadequ
penetr
chemotherapi
site
diseas
intra
csf
chemotherapi
use
central
nervou
system
cn
prophylaxi
treatment
leukemia
lymphoma
well
cn
tumour
object
assess
safeti
toler
etoposid
patient
relaps
refractori
cancer
leptomening
diseas
designmethod
patient
treat
nottingham
children
hospit
individualis
basi
patient
receiv
intraventricular
treatment
adjunct
system
treatment
via
indwel
devic
ommaya
reservoir
lumbar
port
patient
ventriculoperiton
shunt
dose
base
age
treatment
schedul
day
treatment
per
week
week
per
cycl
use
treatment
outpati
base
carri
design
area
per
protocol
result
twenti
nine
children
young
peopl
treat
intra
csf
etoposid
sixteen
male
thirteen
femal
twenti
five
patient
receiv
treatment
etoposid
alcohol
free
median
age
year
rang
year
twenti
patient
relaps
cn
tumour
medulloblastoma
ependymoma
primit
neuroectoderm
tumour
pineoblastoma
patient
receiv
intra
csf
treatment
multipl
line
system
therapi
treatment
free
interv
base
clinic
cours
mean
number
cycl
receiv
rang
median
time
progress
day
treatment
gener
well
toler
main
complic
includ
infect
mechan
issu
one
patient
origin
cohort
still
receiv
treatment
conclus
experi
shown
us
etoposid
well
toler
feasibl
patient
leptomening
diseas
efficaci
treatment
remain
fulli
explor
v
daylidit
g
n
cancer
research
centr
pediatr
stem
cell
transplant
moscow
russia
cancer
research
centr
pediatr
haematolog
moscow
russia
backgroundobject
hr
medulloblasoma
character
poor
surviv
group
medulloblastoma
includ
patient
residu
tumor
metastasi
unfavor
histolog
type
anaplast
poor
prognosi
molecular
biolog
amplif
suppos
use
high
dose
thiotepa
may
improv
prognosi
patient
designmethod
treatment
base
tandem
condit
thiotepa
pt
month
mgkg
day
carboplatin
carbo
pt
month
mgkg
day
consolid
stage
follow
autolog
stem
cell
transplant
asct
second
cours
chemotherapi
hdct
given
week
later
provid
blood
count
recov
suffici
without
evid
tumor
progress
result
till
patient
hr
medulloblastoma
got
tandem
hdct
base
tt
carbo
median
age
year
patient
got
ct
rt
induct
regimen
toxic
nt
strongli
increas
second
cours
toxic
mortal
rate
observ
two
patient
die
sepsi
second
cours
one
patient
die
delay
neurolog
toxic
cerebr
necrosi
year
end
treatment
second
cours
hdct
patient
sign
diseas
patient
stabl
diseas
without
sign
progress
date
patient
aliv
one
relaps
treatment
conclus
two
cycl
high
dose
thiotepa
asct
toler
got
overal
surviv
median
month
surviv
median
month
group
patient
dreneva
v
rogachev
nation
research
center
pediatr
oncolog
immunolog
clinic
rehabilit
research
center
patient
remiss
russkoy
pole
moscow
russia
backgroundobject
past
decad
surviv
rate
patient
posterior
fossa
tumor
substanti
increas
nevertheless
patient
often
demonstr
defici
cognit
motor
skill
caus
either
tumor
treatment
frequent
observ
effect
impair
motor
skill
integr
execut
function
due
cerebellum
patholog
involv
aim
trial
determin
potenti
feasibl
execut
function
train
patient
surviv
posterior
fossa
tumor
designmethod
cohort
includ
patient
surviv
posterior
fossa
tumor
femal
male
mean
age
first
phase
trial
patient
complet
assess
use
cambridg
neuropsycholog
test
autom
batteri
integr
test
test
sampl
split
two
subgroup
equal
sex
age
diagnosi
second
phase
trial
one
patient
subgroup
receiv
session
execut
function
train
two
week
subgroup
underw
empti
two
week
intervent
phase
assess
cognit
motor
function
conduct
patient
third
phase
subgroup
chang
first
subgroup
went
empti
two
week
second
one
complet
train
whole
assess
carri
patient
result
result
indic
signific
improv
domain
integr
motor
skill
work
memori
train
condit
compar
control
condit
conclus
trial
reveal
potenti
effect
train
function
integr
spatial
work
memori
attent
cohort
pediatr
posterior
fossa
tumor
survivor
ech
c
children
hospit
hematologyoncolog
boston
usa
children
hospit
program
boston
usa
backgroundobject
pediatr
brain
tumor
second
common
caus
cancer
children
age
year
old
unit
state
like
pediatr
cancer
children
brain
tumor
live
long
enough
experi
impair
hrqol
due
substanti
improv
surviv
rate
children
experi
sever
neurolog
cognit
psychosoci
impair
affect
overal
hrqol
hrqol
well
recogn
neg
impact
cancer
treatment
sequela
persist
throughout
trajectori
care
purpos
literatur
review
describ
hrqol
experi
children
brain
tumor
designmethod
four
electron
databas
search
research
find
use
term
pediatr
brain
tumor
qol
children
brain
tumor
hrqol
studi
publish
februari
januari
english
languag
exclus
criteria
articl
literatur
review
studi
focus
pediatr
cancer
survivor
andor
type
pediatr
cancer
use
formal
guidelin
prefer
report
item
systemat
review
data
extract
includ
studi
synthes
result
articl
met
inclus
criteria
children
brain
tumor
experienc
multipl
impair
hrqol
dimens
due
treatment
variabl
cognit
emot
motor
sensori
dysfunct
predict
lower
hrqol
score
children
infratentori
tumor
report
lower
hrqol
baselin
compar
children
supratentori
tumor
children
brain
tumor
report
higher
score
physic
function
dimens
hrqol
experienc
less
pain
nausea
pain
compar
children
solid
andor
hematolog
malign
higher
intellig
function
predict
higher
hrqol
score
overtim
children
activ
treatment
conclus
futur
research
need
examin
impair
emot
psychosoci
hrqol
domain
focu
pediatr
brain
tumor
higher
risk
lower
hrqol
f
veldhuijzen
van
g
van
univers
medic
center
pediatr
oncologyhematolog
amsterdam
netherland
center
pediatr
oncolog
pediatr
oncologyhematolog
utrecht
netherland
backgroundobject
purpos
phase
iii
trial
investig
safeti
toler
preliminari
efficaci
combin
vegf
inhibitor
bevacizumab
topoisomeras
inhibitor
irinotecan
egfr
inhibitor
erlotinib
children
progress
diffus
intrins
pontin
glioma
dipg
designmethod
biweekli
bevacizumab
mgkg
irinotecan
administ
intraven
concomitantli
daili
oral
erlotinib
two
success
cohort
receiv
increas
dose
erlotinib
follow
schedul
indefinit
diseas
progress
maximum
one
year
toxic
dlt
extens
monitor
bi
weekli
treatment
pf
os
determin
base
clinic
radiolog
respons
clinic
respons
assess
use
predefin
case
report
form
radiolog
respons
assess
use
modifi
rano
criteria
qualiti
life
qol
assess
use
pedsql
questionnair
result
novemb
juli
nine
patient
diseas
progress
initi
radiotherapi
enrol
patient
averag
month
diagnosi
ci
treatment
well
toler
first
dose
cohort
erlotinib
one
patient
experienc
dlt
acut
ctace
grade
iii
diarrhea
result
three
addit
patient
enrol
cohort
addit
dlt
observ
maximum
dose
patient
receiv
median
cycl
rang
median
time
secondari
progress
month
ci
median
os
diagnosi
month
ci
qol
stabl
treatment
conclus
daili
erlotinib
combin
biweekli
bevacizumab
irinotecan
safe
well
toler
children
progress
dipg
subsequ
patient
mtor
inhibitor
everolimu
ad
combin
cohort
three
patient
receiv
escal
dose
everolimu
follow
schedul
n
e
lopez
b
basqu
upvehu
depart
physic
anthropolog
anim
physiolog
leioa
spain
hospit
cruce
depart
pediatr
barakaldo
spain
backgroundobject
pediatr
medulloblastoma
mb
common
malign
tumor
central
nervou
system
pediatr
although
classif
treatment
improv
recent
year
mortal
remain
around
case
new
marker
need
improv
diagnosi
manag
patient
line
microrna
mirna
proven
use
marker
diagnosi
differ
type
cancer
howev
diagnost
signatur
pediatr
md
defin
object
work
defin
signatur
mirna
util
diagnosi
pediatr
mb
systemat
review
literatur
designmethod
systemat
search
made
pubm
march
term
rna
medulloblastoma
mirna
medulloblastoma
exosom
medulloblastoma
extracellular
vesicl
medulloblastoma
secretom
medulloblastoma
inclus
criteria
studi
present
origin
independ
inform
evalu
impact
express
mirna
diagnosi
mb
human
popul
use
pediatr
age
year
patient
control
result
appli
defin
search
criteria
articl
obtain
appli
inclus
criteria
articl
remain
mirna
select
use
signific
result
least
two
studi
among
other
downregul
upregul
tumor
conclus
review
despit
studi
carri
far
mirna
alreadi
identifi
possibl
use
diagnosi
pediatr
mb
new
studi
confirm
result
necessari
e
lopez
hospit
cruce
depart
pediatr
barakaldo
spain
basqu
upvehu
depart
physic
anthropolog
anim
physiolog
leioa
spain
backgroundobject
pediatr
medulloblastoma
mb
common
malign
primari
brain
tumor
children
recent
microrna
mirna
proven
use
marker
differ
type
cancer
diagnost
classif
prognost
signatur
alreadi
exist
howev
although
studi
alreadi
carri
prognost
signatur
defin
pediatr
mb
object
work
determin
signatur
mirna
util
prognosi
pediatr
mb
defin
systemat
review
literatur
designmethod
systemat
search
made
pubm
march
term
rna
medulloblastoma
mirna
medulloblastoma
exosom
medulloblastoma
extracellular
vesicl
medulloblastoma
secretom
medulloblastoma
inclus
criteria
studi
present
origin
independ
inform
evalu
impact
express
mirna
prognosi
mb
human
popul
use
pediatr
age
year
patient
result
defin
search
criteria
articl
obtain
among
studi
met
inclus
criteria
total
signific
mirna
howev
none
mirna
replic
conclus
review
due
limit
number
studi
carri
far
pediatr
mb
possibl
identifi
signatur
mirna
util
prognosi
pediatr
mb
reason
new
studi
need
defin
prognost
signatur
r
gartrel
aa
g
td
ym
p
j
univers
irv
medic
center
depart
pediatr
divis
pediatr
hematologyoncolog
stem
cell
transplant
new
york
usa
eye
john
hopkin
school
medicin
depart
ophthalmolog
baltimor
usa
univers
irv
medic
center
depart
patholog
cell
biolog
new
york
usa
univers
columbia
colleg
new
york
usa
univers
irv
medic
center
depart
medicin
divis
hematologyoncolog
new
york
usa
univers
irv
medic
center
depart
pathlog
cell
biolog
new
york
usa
univers
irv
medic
center
depart
ophthalmolog
divis
ophthalm
plastic
reconstruct
new
york
usa
univers
irv
medic
center
depart
pediatr
new
york
usa
backgroundobject
optic
nerv
glioma
ong
childhood
rare
tumor
variabl
clinic
behavior
avail
data
suggest
pediatr
ong
alter
protein
kinas
pathway
microglia
implic
pathogenesi
molecular
landscap
tumor
immun
microenviron
ong
remain
understudi
designmethod
case
pediatr
ong
biopsi
resect
columbia
univers
irv
medic
center
identifi
medic
record
tumor
dna
sequenc
use
columbia
combin
cancer
panel
sampl
stain
use
quantit
multiplex
immunofluoresc
qmif
multispectr
imag
acquir
use
vectratm
analyz
use
informtm
softwar
r
studio
evalu
densiti
immun
phenotyp
within
tumor
microenviron
result
seven
patient
identifi
two
specimen
insuffici
analysi
target
sequenc
evalu
case
identifi
mutat
braf
fusion
novel
truncat
mutat
histon
methyltransferas
accompani
braf
fusion
clinic
aggress
behavior
case
repres
mutat
character
qmif
find
increas
cytotox
lymphocyt
ctl
infiltr
associ
braf
fusion
compar
mutat
similar
infiltr
microgliamacrophag
braf
fusion
mutat
case
increas
macrophag
infiltr
associ
braf
fusion
conclus
find
distinct
pattern
tumor
immun
cell
infiltr
case
pediatr
ong
differ
molecular
alter
provid
new
insight
variabl
clinic
behavior
challeng
tumor
next
gener
sequenc
show
mutual
exclus
recurr
braf
fusion
mutat
ong
novel
mutat
aggress
ong
qmif
analysi
show
higher
ctl
activ
macrophag
infiltr
associ
braf
fusion
compar
acknowledg
project
receiv
fund
swim
across
america
garvin
gartrel
gevorgian
p
e
l
b
memori
institut
children
hematolog
pavlov
first
saint
petersburg
state
medic
univers
bone
marrow
transplant
depart
pediatr
solid
tumor
st
petersburg
russia
center
roentgenoradiolog
pediatr
cancer
multimod
treatment
research
laboratori
moscow
russia
backgroundobject
central
nervou
system
cn
tumor
second
common
pediatr
malign
overal
surviv
rate
group
tri
assess
effect
chemotherapi
hdct
autolog
hematopoiet
transplant
patient
group
designmethod
pediatr
patient
relaps
medulloblastoma
supratentori
pnet
no
germinoma
pineoblastoma
atyp
teratoid
rhabdoid
tumor
choriocarcinoma
etmr
receiv
singl
tandem
hdct
induct
chemotherapi
radiotherapi
surgic
treatment
moment
hdct
patient
complet
remiss
cr
patient
partial
remiss
pr
patient
stabl
diseas
sd
result
median
month
rang
patient
cr
pr
relaps
month
hdct
patient
current
cr
pr
mainten
therapi
cumul
incid
relaps
year
account
ci
condit
regimen
accept
toxic
complic
grade
observ
case
transplant
relat
mortal
year
ci
overal
surviv
os
patient
group
diseas
free
surviv
df
mb
embryon
cn
tumor
better
surviv
rate
df
respect
compar
germ
cell
tumor
df
df
better
among
patient
compar
children
accordingli
patient
cr
pr
moment
hdct
better
df
rate
patient
sd
respect
conclus
hdct
pediatr
patient
cn
tumor
may
feasibl
option
patient
crpr
induct
chemotherapi
ineffect
salvag
therapi
refractori
patient
g
halliday
u
e
l
u
hospit
sick
children
divis
haematolog
oncolog
toronto
canada
hospit
sick
children
divis
ophthalmolog
toronto
canada
hospit
sick
children
child
health
evalu
scienc
toronto
canada
zedek
hospit
haematolog
oncolog
jerusalem
israel
backgroundobject
preclin
model
suggest
phosphodiesteras
inhibitor
may
slow
prevent
axon
damag
optic
nerv
mice
visual
pathway
glioma
like
elev
camp
sought
evalu
whether
theophyllin
could
stabil
improv
visual
outcom
vision
impair
children
optic
pathway
glioma
opg
suffer
visual
loss
despit
activ
chemotherapi
absenc
radiolog
progress
designmethod
case
seri
opg
patient
moder
sever
visual
impair
experienc
visual
declin
treat
theophyllin
plan
durat
month
initi
theophyllin
dose
calcul
base
ideal
bodi
mass
subsequ
adjust
accord
trough
plasma
concentr
safeti
defin
absenc
grade
toxic
use
nation
cancer
institut
common
toxic
criteria
version
visual
acuiti
assess
monthli
time
interv
result
eleven
patient
median
age
year
rang
treat
theophyllin
hospit
sick
children
toronto
mean
durat
therapi
month
grade
treatment
relat
toxic
identifi
three
patient
discontinu
therapi
prematur
two
suffer
grade
toxic
improv
binocular
vision
seen
three
eleven
patient
three
patient
show
stabil
vision
conclus
theophyllin
given
combin
standard
opg
chemotherapi
well
toler
proport
patient
progress
visual
declin
despit
activ
chemotherapi
theophyllin
enabl
stabil
improv
visual
acuiti
f
hamid
indu
hospit
karachi
paediatr
haematolog
oncolog
depart
karachi
pakistan
backgroundobject
see
impact
dedic
pediatr
servic
resourc
limit
set
comparison
patient
turnov
overal
abandon
two
distinct
period
year
year
introduct
paediatr
brain
tumor
second
common
childhood
cancer
leukemia
lymphoma
common
solid
tumor
children
diseas
outcom
poor
develop
countri
due
variou
challeng
special
lack
train
health
care
provid
neuro
oncolog
lead
advanc
diseas
present
designmethod
materi
method
retrospect
chart
review
studi
conduct
depart
peadiatr
oncolog
indu
hospit
karachi
pakistan
retrospect
data
made
baselin
compar
initi
dedic
servic
via
variabl
includ
age
gender
patient
number
abandon
includ
patient
refer
opinion
left
treatment
lbt
overal
outcom
result
massiv
increas
number
patient
averag
patient
present
per
year
number
increas
overal
major
patient
present
seek
opinion
lbt
number
patient
seek
opinion
fell
percentag
patient
lbt
also
decreas
conclus
start
servic
caus
increas
number
patient
almost
time
similarli
abandon
lost
follow
ratio
also
drastic
reduc
signific
increas
number
patient
receiv
activ
treatment
import
approach
paediatr
neuro
oncolog
also
import
contribut
factor
differ
achiev
dedic
paediatr
expertis
surgeri
need
hour
p
ivanovski
faculti
univers
belgrad
cancer
prevent
research
center
belgrad
serbia
backgroundobject
achiev
world
without
cancer
consequ
without
siop
designmethod
comprehens
read
paper
cancer
epidemiolog
pathogenesi
exclus
use
cortic
neuron
result
literatur
data
neoplasm
origin
termin
differenti
cell
tdc
purkinj
neuron
betz
neuron
alpha
motoneuron
indic
carcinogenesi
occur
cell
mitot
potenti
consequ
mitot
cross
mco
loss
heterozygos
loh
mechan
respons
disabl
tumor
suppressor
gene
known
cancer
far
deriv
cell
possess
mitot
activ
cancer
privileg
cell
larger
bodi
cell
burden
longer
life
mean
mitos
mco
loh
greater
chanc
cancer
develop
syndrom
lf
rare
autosom
domin
hereditari
disord
carrier
cancer
develop
germlin
heterozyg
mutat
mutat
present
bodi
cell
includ
tdc
classic
frequent
lf
malign
sarcoma
cancer
breast
brain
especi
glioblastoma
adrenocort
carcinoma
leukemia
lymphoma
despit
exagger
predisposit
cancer
develop
cancer
origin
tdc
seen
lf
person
far
malign
cell
tumor
lf
homozyg
mutat
loh
present
gener
mco
event
mitos
cell
conclus
chemic
biochem
scientist
must
creat
oral
mco
inhibitor
basic
substanc
salicyl
acid
would
administr
human
throughout
lifetim
form
food
supplement
achiev
final
goal
world
without
cancer
v
kasatkin
v
rogachev
nation
research
center
pediatr
oncolog
immunolog
clinic
research
rehabilit
center
russko
pole
moscow
russia
state
univers
neurobiolog
moscow
russia
backgroundobject
cerebellum
mostli
involv
type
eye
movement
cerebellar
lesion
inevit
provok
oculomotor
impair
patient
differ
age
eye
track
techniqu
wide
use
method
measur
oculomotor
paramet
patient
injuri
designmethod
present
report
show
improv
function
oculomotor
system
children
adolesc
patient
recov
cerebellar
surgeri
chemotherapi
andor
radiotherapi
undergo
cours
neurocognit
rehabilit
patient
ask
perform
two
oculomotor
test
gaze
stabil
test
visual
count
test
rehabilit
eye
movement
record
eye
tracker
acquisit
rate
sampless
result
within
final
session
test
observ
signific
improv
task
perform
gaze
stabil
enhanc
like
decreas
number
intrus
saccad
microsaccad
disrupt
fixat
gaze
object
execut
time
declin
visual
scanpath
got
shorten
visual
count
test
probabl
optim
visual
scan
visual
process
inform
conclus
find
indic
posit
dynam
function
oculomotor
system
patient
follow
cerebellar
tumor
remov
surgeri
subsequ
neurocognit
rehabilit
experiment
data
support
effect
util
eye
track
techniqu
diagnost
tool
field
neurooncolog
g
kaur
k
sloan
ketter
cancer
center
new
york
usa
sloan
ketter
cancer
center
radiolog
new
york
usa
backgroundobject
cerebr
cavernoma
encount
pediatr
patient
central
nervou
system
cn
tumor
may
caus
neurolog
compromis
incid
cavernomat
lesion
brain
mr
pediatr
patient
treat
intraventricular
radioimmunotherapi
unknown
designmethod
patient
treat
institut
clinic
trial
serial
intraventricular
inject
mci
label
monoclon
antibodi
crit
target
tumor
associ
antigen
brain
mr
baselin
period
follow
sever
year
obtain
brain
mr
gradient
echo
imag
imag
use
identifi
cavernomat
lesion
result
patient
identifi
caucasian
african
american
asian
wish
identifi
median
age
time
crit
year
year
median
time
mr
examin
month
time
first
crit
cavernomat
lesion
detect
patient
patient
surviv
year
sinc
crit
patient
prior
extern
beam
radiotherapi
caucasian
african
american
diagnos
metastat
neuroblastoma
medulloblastoma
ependymoma
pineoblastoma
rhabdomyosarcoma
patient
unifoc
cavernoma
frontal
lobe
tempor
lobe
pariet
multipl
supratentori
infratentori
lesion
detect
patient
patient
lesion
involv
brainstem
one
patient
cavernoma
concurr
vascul
neurolog
symptom
remain
patient
asymptomat
conclus
cavernomat
lesion
found
patient
long
term
survivor
treat
crit
extern
beam
radiotherapi
major
lesion
multifoc
supratentori
despit
numer
lesion
patient
remain
without
neurolog
compromis
r
kebudi
b
f
e
univers
cerrahpasa
medic
faculti
oncolog
institut
pediatr
hematolog
oncolog
istanbul
turkey
univers
oncolog
institut
pediatr
hematolog
oncolog
istanbul
turkey
univers
oncolog
institut
radiat
oncolog
istanbul
turkey
backgroundobject
intracrani
germ
cell
tumor
igct
constitut
malign
neoplasm
children
aim
studi
evalu
demograph
characterist
therapi
long
term
outcom
children
igct
singl
institut
designmethod
retrospect
review
result
children
femal
male
median
age
year
yr
diagnos
treat
igct
evalu
three
consult
thu
patient
assess
treat
accord
institut
protocol
patient
year
old
germinoma
reciev
radiotherapi
rt
alon
patient
yr
old
reciev
cours
etoposid
cisplatinum
follow
cranial
radiotherapi
nongerminoma
patient
reciev
cours
bleomycin
etoposid
cisplatinum
follow
rt
twelv
germinoma
nongerminomat
gct
twelv
suprasellar
pineal
suprasellar
pineal
afp
bhcg
evalu
serum
csf
diagnosi
therapi
three
seed
spinal
axi
one
widespead
system
metastasi
four
total
resect
biopsi
clinicallyradiolog
diagnos
shunt
patient
aliv
median
year
year
diagnosi
one
patient
new
germ
cell
tumor
right
testi
year
treatment
patient
also
follow
endocrinolog
clinic
five
patient
recurrenceprogress
median
month
year
event
free
surviv
surviv
respect
conclus
cisplatin
base
chemotherapi
radiotherapi
success
well
toler
children
igct
possibl
earli
clinic
diagnosi
base
mri
tumor
marker
use
modern
neurosurg
techniqu
increas
chanc
cure
give
chanc
reduc
acut
morbid
decreas
late
effect
c
khaiman
p
k
p
pediatr
hematolog
depart
faculti
chulalongkorn
univers
pediatr
bangkok
thailand
genepro
faculti
chulalongkorn
univers
depart
patholog
bangkok
thailand
backgroundobject
intracrani
germ
cell
tumor
igct
consid
rare
highli
curabl
neoplasm
kra
gene
kitra
signal
pathway
play
import
role
pathogenesi
mani
cancer
kra
mutat
report
patient
diagnos
igct
object
describ
clinicopatholog
molecular
featur
kra
mutat
treatment
outcom
children
diagnos
igct
designmethod
retrospect
review
patient
diagnos
igct
depart
pediatr
king
chulalongkorn
memori
hospit
molecular
studi
dna
extract
fix
ffpe
tissu
patient
identifi
mutat
codon
kra
gene
perform
use
pcr
techniqu
coba
test
pyrosequenc
method
result
eighteen
patient
diagnos
igct
male
femal
age
rang
year
median
year
diagnosi
germinoma
igct
patient
elev
marker
reveal
approxim
patient
four
patient
leptomening
involv
patient
underw
surgic
procedur
receiv
adjuv
chemotherapi
radiotherapi
given
patient
craniospin
radiat
csi
given
leptomening
metastasi
median
follow
month
overal
surviv
germinoma
igct
mutat
kra
gene
detect
pyrosequenc
techniqu
one
patient
mutat
locat
codon
frequenc
unit
nucleotid
substitut
caa
cta
amino
acid
substitut
patient
carri
mutant
gene
diagnos
intracrani
germinoma
csf
metastasi
eventu
die
treatment
conclus
studi
reveal
treatment
outcom
igct
thai
children
describ
kra
codon
mutat
metastasi
germinoma
patient
poor
outcom
support
kra
codon
mutat
may
clinic
correl
igct
kimura
c
k
h
h
r
h
k
k
center
child
health
develop
children
cancer
center
tokyo
japan
center
child
health
develop
divis
neurosurgeri
tokyo
japan
center
child
health
develop
depart
radiolog
tokyo
japan
center
child
health
develop
depart
patholog
tokyo
japan
center
child
health
develop
divis
radiat
oncolog
tokyo
japan
backgroundobject
aim
studi
evalu
clinic
featur
prognosi
ependymoma
designmethod
conduct
retrospect
studi
pediatr
patient
ependymoma
treat
center
april
februari
result
fourteen
patient
boy
girl
median
age
diagnosi
year
year
median
period
month
month
locat
tumor
supratentori
n
infratentori
n
spinal
cord
n
six
patient
show
anaplast
patholog
frontlin
treatment
modal
vari
five
patient
dead
time
analysi
surviv
ef
overal
surviv
os
rate
patient
respect
differ
ef
patient
achiev
gross
total
resect
gtr
vs
patient
achiev
gtr
better
os
vs
frontlin
radiat
therapi
associ
better
ef
os
among
patient
achiev
gtr
supratentori
locat
associ
better
os
age
diagnosi
anaplast
patholog
treatment
modal
associ
better
surviv
patient
neurolog
sequela
occur
patient
cranial
nerv
palsi
motor
paralysi
epilepsi
two
patient
endocrinopathi
growth
hormon
gonadotropin
defici
cognit
dysfunct
observ
patient
conclus
children
ependymoma
initi
gtr
associ
better
os
tumor
locat
prognost
factor
patient
neurolog
sequela
common
endocrinopathi
cognit
dysfunct
uncommon
survivor
pediatr
ependymoma
k
kramer
b
n
u
p
j
j
e
j
j
nk
sloan
ketter
pediatr
new
york
usa
ped
new
york
usa
ped
new
york
usa
radiolog
new
york
usa
rad
onc
new
york
usa
neurosurgeri
new
york
usa
surgeri
new
york
usa
ped
new
yrok
usa
backgroundobject
tumor
metastas
central
nervou
system
cn
associ
signific
mortal
intraventricular
monoclon
antibodi
target
tumor
associ
antigen
may
erad
micrometastas
designmethod
test
toxic
dosimetri
intraventricular
monoclon
antibodi
omburtomab
target
patient
cn
diseas
phase
iii
trial
csf
flow
determin
cisternographi
intraventricular
devic
patient
median
age
year
year
receiv
inject
involv
mci
tracer
imag
therapeut
inject
mci
dose
level
mci
increment
phase
patient
expand
cohort
mciinject
pharmacokinet
studi
serial
csf
blood
sampl
hour
dosimetri
base
pharmacokinet
roi
analys
serial
scan
toxic
defin
ctcae
repeat
month
absenc
seriou
advers
event
progress
diseas
tumor
respons
determin
clinic
radiograph
cytolog
criteria
overal
surviv
note
result
inject
well
toler
routin
administ
outpati
set
rare
advers
event
includ
grade
fever
headach
vomit
biochem
elev
ast
alt
inject
grade
alt
elev
dose
level
although
dose
limit
myelosuppress
occur
patient
receiv
craniospin
radiat
mci
therapi
mci
safe
administ
patient
leptomening
neuroblastoma
posit
respons
mean
absorb
csf
dose
cgymci
cgymci
blood
long
term
surviv
note
sever
challeng
pediatr
cn
malign
includ
embryon
tumor
multilay
rosett
recurr
ependymoma
choroid
plexu
carcinoma
metastat
neuroblastoma
conclus
intraventricular
omburtomab
safe
favor
csf
blood
dosimetri
cur
potenti
treatment
cn
cancer
lauhasurayotin
k
p
p
univers
depart
pediatr
bangkok
thailand
univers
depart
patholog
bangkok
thailand
backgroundobject
central
nervou
system
cn
atyp
teratoidrhabdoid
tumor
atrt
rare
clinic
aggress
tumor
often
affect
young
children
standard
treatment
atrt
well
establish
object
studi
characterist
outcom
atra
patient
treat
malign
rhabdoid
tumor
mrt
protocol
surgeri
irradi
designmethod
retrospect
review
patient
diagnos
atrt
depart
result
eight
patient
diagnos
patholog
confirm
atrt
male
femal
age
rang
month
median
month
tumor
six
patient
spinal
metastasi
two
patient
present
symptom
consist
increas
intracrani
pressur
patient
hemiparesi
three
patient
total
tumor
remov
perform
four
partial
remov
three
biopsi
one
patient
adjuv
chemotherapi
consist
ifosfamid
carboplatin
etoposid
altern
vincristin
doxorubicin
cyclophosphamid
total
eight
cycl
given
seven
patient
craniospin
radiat
csi
given
five
patient
gy
tumor
bed
spine
respect
median
follow
month
overal
surviv
surviv
patient
underw
upfront
total
tumor
remov
receiv
csi
immedi
chemotherapi
complet
spinal
metastasi
five
patient
die
diseas
median
surviv
time
month
one
patient
age
six
month
die
one
month
diagnosi
treatment
conclus
treatment
outcom
atrt
unfavor
intens
adjuv
chemotherapi
protocol
major
prognost
factor
surviv
respect
metastat
diseas
csi
e
v
hospit
lima
lima
peru
hospit
lima
lima
peru
backgroundobject
medulloblastoma
embryon
tumor
aggress
behavior
commonli
seen
children
purpos
identifi
epidemiolog
pattern
analyz
prognosi
factor
emphasi
treatment
time
outcom
designmethod
studi
particip
identifi
retrospect
cohort
patient
less
year
old
histolog
confirm
meduloblastoma
diagnos
institut
data
obtain
medic
record
phone
call
time
delay
surgeri
radiat
chemotherapi
categor
day
respect
statist
analysi
perform
multimod
treatment
includ
surgeri
follow
craniospin
irradi
gy
follow
posterior
fossa
boost
gy
result
mean
durat
symptom
day
median
surgeri
therapi
durat
day
patient
receiv
radiat
year
patient
receiv
delay
radiotherapi
day
median
time
month
patient
diseas
overal
surviv
os
rate
diseas
free
surviv
df
respect
patient
diseas
os
df
rate
respect
multivari
analysi
group
risk
independ
prognost
factor
os
along
metastat
diseas
risk
hr
posit
csf
delay
radiat
start
surgeri
day
associ
inferior
os
signific
differ
os
among
delay
chemotherapi
time
surgeri
time
conclus
children
older
year
delay
radiat
start
surgeri
signific
factor
unfavor
prognosi
earli
treatment
addit
quickli
diagnosi
key
manag
medulloblastoma
still
need
achiev
levashov
n
v
g
g
blokhin
nation
medic
research
center
oncolog
pediatr
hematolog
oncolog
institut
moscow
russia
blokhin
nation
medic
research
center
oncolog
experiment
diagnost
treatment
tumor
institut
moscow
russia
burdenko
nation
medic
research
center
neurosurgeri
depart
neuropatholog
moscow
russia
blokhin
nation
medic
research
center
oncolog
depart
patholog
moscow
russia
burdenko
nation
medic
research
center
neurosurgeri
depart
neurosurgeri
moscow
russia
state
univers
medicin
dentistri
moscow
state
univers
medicin
dentistri
moscow
russia
backgroundobject
aim
studi
estim
overal
surviv
os
surviv
ef
accord
risk
stratif
mgmt
protein
express
designmethod
forti
nine
pediatr
patient
de
novo
medulloblastoma
includ
trial
averag
risk
group
arg
present
high
risk
group
hrg
anaplast
lca
histolog
variant
shh
subgroup
mgmt
protein
express
assess
immunohistochem
method
wnt
fish
children
underw
therapi
result
twenti
seven
children
includ
arg
hrg
statu
reveal
patient
lca
variant
molecular
subgroup
assess
patient
wnt
subgroup
determin
case
shh
mgmt
protein
express
reveal
case
os
arg
hrg
p
ef
arg
hrg
p
median
month
event
reveal
arg
hrg
event
present
late
relaps
case
earli
relaps
case
local
relaps
case
dissemin
relaps
case
progress
chemotherapi
case
secondari
tumor
case
treatment
relat
mortal
children
due
septic
complic
patient
complet
respons
ef
wnt
shh
p
ef
group
tumor
sampl
p
conclus
program
therapi
show
good
effect
arg
patient
also
determin
neg
prognost
signific
mgmt
protein
express
yl
liu
yc
cw
ml
sh
tt
js
medic
univers
tmu
hospit
pediatr
taipei
taiwan
roc
medic
univers
research
center
biostatist
taipei
taiwan
roc
medic
univers
hospit
pediatr
taipei
taiwan
roc
medic
univers
shuang
ho
hospit
pediatr
taipei
taiwan
roc
medic
univers
hospit
pediatr
neurosurgeri
taipei
taiwan
roc
medic
univers
colleg
medic
scienc
technolog
taipei
taiwan
roc
backgroundobject
atyp
teratoidrhabdoid
tumor
atrt
rare
highli
aggress
embryon
brain
tumor
young
children
designmethod
perform
nationwid
studi
atrt
code
taiwan
use
taiwan
cancer
registri
databas
nation
death
certif
databas
result
total
case
male
femal
median
age
year
patholog
diagnosi
atrt
regist
site
primari
tumor
includ
supratentori
infratentori
spinal
unspecifi
nervou
system
other
surviv
analysi
infant
atrt
diagnos
age
year
n
die
within
month
diagnosi
case
diagnos
age
year
n
overal
surviv
probabl
year
n
p
case
treat
surgeri
n
die
within
month
case
treat
chemotherapi
without
radiotherapi
n
die
within
year
case
treat
radiotherapi
chemotherapi
n
p
surgic
extent
radiotherapi
field
evalu
dataset
univari
cox
proport
hazard
model
identifi
older
age
year
supratentori
site
use
radiotherapi
chemotherapi
predictor
better
surviv
contrast
gender
treatment
era
effect
surviv
multivari
analysi
patient
specifi
primari
site
data
confirm
impact
age
site
treatment
surviv
conclus
nationwid
data
taiwan
case
atrt
show
older
age
supratentori
site
radiotherapi
predictor
better
surviv
develop
effect
therapi
younger
children
atrt
desper
need
ya
liu
c
linda
univers
children
hospit
pediatricschild
neurolog
loma
linda
usa
linda
univers
children
hospit
pediatricshematolog
oncolog
loma
linda
usa
linda
univers
children
hospit
pediatricschild
neurolog
loma
linda
usa
linda
univers
children
hospit
pediatricsneonatolog
loma
linda
usa
linda
univers
medic
center
pediatr
ophthalmolog
loma
linda
usa
backgroundobject
preval
visual
sequela
children
brain
tumor
receiv
limit
attent
literatur
perform
retrospect
analysi
visual
outcom
may
affect
consid
significantli
improv
surviv
designmethod
review
record
children
primari
brain
tumor
detail
inform
tumor
demograph
eye
relat
diagnos
analyz
result
patient
evalu
ophthalmolog
across
visit
common
tumor
type
includ
glioma
medulloblastoma
ependymoma
tumor
locat
optic
pathway
posterior
fossa
brainstem
total
patient
receiv
chemotherapi
andor
radiat
overal
surviv
median
month
median
time
tumor
diagnosi
initi
ophthalmolog
evalu
month
month
ten
children
present
visual
symptom
tumor
diagnosi
abnorm
ophthalmolog
exam
find
visual
acuiti
impair
amblyopia
papilledema
visual
field
defect
optic
atrophi
keratopathi
requir
tarsorrhaphi
corneal
transplant
presenc
unrecogn
visual
field
defect
high
patient
visual
complaint
strabismu
occur
frequent
patient
posterior
fossa
tumor
radiat
associ
amblyopia
increas
risk
conclus
unrecogn
visual
sequela
promin
children
primari
brain
tumor
ophthalmolog
evalu
help
identifi
complic
treatment
may
improv
qualiti
life
affect
individu
ar
martinez
fria
perez
eg
aguillen
ortiz
le
juarez
c
leal
ge
ana
niembro
zapata
nacion
de
pediatria
pediatr
oncolog
mexico
citi
mexico
medico
nacion
siglo
xxi
pediatr
oncolog
mexico
citi
mexico
infantil
de
mexico
federico
gomez
pediatr
oncolog
mexico
citi
mexico
universitario
dr
eleuterio
pediatr
oncolog
monterrey
mexico
infantil
de
chihuahua
pediatr
oncolog
mexico
citi
mexico
backgroundobject
choroid
plexu
carcinoma
cpc
constitut
less
central
nervou
system
tumor
cpc
usual
diagnos
year
life
even
report
newborn
assum
cpc
congenit
diseas
clinic
present
character
intracrani
hypertens
symptom
prognosi
depend
grade
surgic
resect
radiotherapi
also
increas
overal
surviv
nevertheless
young
age
patient
allow
mode
treatment
chemotherapi
frontlin
manag
report
chemotherapi
increas
surviv
designmethod
made
observ
descript
retrospect
longitudin
multicentr
studi
describ
age
primari
site
treatment
outcom
infant
diagnosi
cpc
result
present
six
case
infant
male
cpc
differ
oncolog
center
median
age
present
month
frequent
site
present
third
ventricl
percentag
surgic
resect
vari
among
current
aliv
month
follow
lanski
perform
conclus
clinic
present
primari
site
observ
seri
one
report
intern
literatur
three
patient
aliv
radiotherapi
administ
patient
current
chemotherapi
play
secondari
role
manag
patient
howev
live
patient
report
case
receiv
protocol
includ
ifosfamid
carboplatin
etoposid
patient
receiv
chemotherapi
dead
treatment
modal
play
import
role
outcom
patient
surgeri
radiotherapi
seem
good
treatment
strategi
avoid
chemotherapi
toxic
group
age
must
regist
cpc
case
global
specif
mexico
order
offer
major
benefit
systemat
treatment
surgeri
radiotherapi
chemotherapi
massimino
f
f
l
l
p
ml
e
e
g
l
l
ircc
istituto
nazional
dei
tumori
pediatr
milano
itali
ircc
istituto
nazional
dei
tumori
statistica
med
biom
e
bioinform
milano
itali
sapienza
scienz
oncologich
e
anatomo
patologich
roma
itali
neurom
patholog
pozzilli
itali
ircc
istituto
neurologico
carlo
besta
neuroradiolog
milano
itali
sanna
laboratorio
di
patholog
depart
como
itali
sapienza
dipartimento
di
scienz
oncologich
e
anatomo
patologich
rome
itali
giannina
gaslini
dipartimento
e
neuroscienz
genova
itali
della
salut
e
della
scienza
pediatr
oncolog
torino
itali
pediatrico
meyer
pediatr
oncolog
firenz
itali
ospedaliera
pediatr
oncolog
padova
itali
oncologico
del
veneto
radiotherapi
padova
itali
centro
di
riferimento
oncologico
radiotherapi
aviano
itali
santobonopausilipon
pediatr
oncolog
napoli
itali
della
salut
e
della
scienza
radiotherapi
torino
itali
pediatrico
bambino
pediatr
oncolog
roma
itali
agostino
gemelli
pediatr
oncolog
roma
itali
ircc
istituto
nazional
dei
tumori
radiotherapi
milano
itali
backgroundobject
aim
patient
radiolog
surveil
ascertain
relaps
appli
therapi
accru
patient
phase
protocol
therapi
standardizedcur
assesstreat
iatrogen
effect
aim
lessen
emot
socioeconom
burden
patient
famili
ideal
need
establish
whether
schedul
radiolog
surveil
give
patient
better
outcom
wait
symptom
sign
appear
designmethod
analyz
prospect
seri
treat
pediatricadolesc
patient
intracrani
ependymoma
compar
patient
recurr
diseas
identifi
schedul
examin
recpt
group
case
patient
show
signssymptom
recurr
diseas
symppt
group
case
median
month
result
signific
differ
emerg
two
group
term
gender
age
tumor
gradesit
shunt
residu
diseas
type
relaps
local
distant
concomit
time
relaps
median
month
rang
possibl
differ
symppt
recpt
group
either
presenc
signssymptom
unfavor
factor
overal
surviv
os
recurr
os
vs
multivari
analysi
adjust
model
confirm
much
conclus
improv
os
symptomat
patient
earli
identif
within
first
year
initi
diagnosi
would
desir
might
achiev
focus
heurist
detect
subgroup
patient
describ
gener
prognost
variabl
also
seek
potenti
biolog
differ
light
patient
sign
symptom
g
michaiel
n
u
h
j
b
jr
ms
ka
g
l
np
na
kk
e
l
children
hospit
section
pediatr
bmt
ab
canada
margaret
hospit
children
pediatr
oncolog
hematolog
perth
australia
hospit
sick
children
divis
hematologyoncolog
canada
hospit
eastern
ontario
divis
hematologyoncolog
canada
columbia
children
hospit
divis
neurolog
oncolog
bc
canada
children
hospit
divis
oncolog
palli
care
ab
canada
health
scienc
centr
pediatr
oncolog
canada
children
murdoch
children
research
institut
solid
brain
tumour
divis
melbourn
australia
children
hospit
hematologyoncolog
bmt
oh
usa
hospit
philadelphia
pediatr
program
pa
usa
hospit
lo
angel
children
center
cancer
blood
diseas
lo
ca
usa
hospit
colorado
pediatr
co
usa
robert
h
luri
children
hospit
chicago
stem
cell
transplant
il
usa
palmer
hospit
children
pediatr
fl
usa
jude
children
research
hospit
depart
oncolog
tn
usa
children
hospit
divis
hematologyoncolog
wa
usa
packard
children
hospit
stanford
pediatr
hematolog
oncolog
ca
usa
hospit
lo
angel
children
center
cancer
blood
diseas
lo
ca
usa
backgroundobject
intracrani
grow
teratoma
syndrom
igt
rare
phenomenon
paradox
germ
cell
tumor
gct
growth
follow
treatment
despit
normal
tumor
marker
sought
evalu
frequenc
clinic
characterist
outcom
igt
patient
australian
institut
designmethod
patient
igt
diagnos
retrospect
evalu
result
gct
diagnos
igt
identifi
patient
igt
occur
gct
immatur
teratoma
germinomasgerminoma
matur
teratoma
secret
tumour
median
age
gct
diagnosi
year
rang
male
gender
pineal
locat
predomin
patient
elev
marker
median
serum
afp
ngml
rang
iul
rang
respect
igt
occur
median
time
month
rang
diagnosi
chemotherapi
radiat
treatment
complet
surgic
resect
attempt
lead
gross
total
resect
patient
resum
gct
chemotherapyradi
surgeri
median
year
rang
patient
aliv
succumb
progress
diseas
malign
transform
gct
conclus
igt
occur
less
patient
gct
commonli
initi
chemotherapi
igt
common
patient
biopsi
gct
surgic
resect
princip
treatment
modal
surviv
outcom
patient
develop
igt
favour
g
michaiel
n
h
l
g
v
alberta
children
hospit
section
pediatr
bmt
ab
canada
laboratori
servic
cellular
therapi
laboratori
ab
canada
children
hospit
depart
pediatr
ab
canada
backgroundobject
use
chemotherapi
hdc
autolog
hematopoiet
stem
cell
transplant
hsct
use
certain
pediatr
patient
brain
tumour
delayspar
radiotherapi
aim
studi
factor
predict
success
stem
cell
collect
scc
correl
stem
cell
dose
infus
hsct
outcom
designmethod
retrospect
chart
review
undertaken
pediatr
patient
brain
tumour
treat
centr
hdchsct
result
patient
identifi
male
median
age
year
time
scc
rang
patient
diagnos
medulloblastoma
atrt
pnet
patient
underw
scc
remain
requir
scc
procedur
peripher
blood
stem
cell
sourc
collect
success
scc
collect
ideal
scc
achiev
patient
respect
use
mobil
chemotherapi
factor
associ
achiev
ideal
collect
gender
age
stem
cell
sourc
peripher
blood
count
signific
higher
infus
associ
faster
neutrophil
engraft
first
cours
hdchsct
platelet
engraft
first
cours
conclus
major
scc
autolog
hsct
success
complet
singl
apheresi
session
mobil
chemotherapi
yield
higher
compar
alon
higher
dose
infus
associ
faster
neutrophil
limit
scale
platelet
recoveri
mizumoto
h
tsukuba
radiat
oncolog
tsukuba
japan
jude
children
research
hospit
radiat
oncolog
memphi
usa
jude
children
research
hospit
biostatist
memphi
usa
backgroundobject
investig
impact
radiat
dose
clinic
factor
final
height
craniospin
irradi
csi
designmethod
pediatr
patient
treat
csi
includ
medulloblastoma
investig
cohort
limit
patient
surviv
year
cohort
includ
male
patent
median
age
csi
year
old
rang
csi
dose
growth
hormon
replac
administ
necessari
refus
result
median
year
rang
height
measur
obtain
clinic
record
median
measur
per
patient
consid
patient
age
year
time
csi
male
femal
patient
respect
follow
median
height
determin
prior
csi
cm
vs
year
age
vs
year
age
vs
cm
year
age
cm
vs
cm
median
height
ile
male
ile
femal
compar
us
popul
median
height
impair
male
vs
femal
vs
year
old
vs
year
old
vs
year
old
multivari
analysi
show
younger
age
higher
csi
dose
femal
significantli
associ
short
statur
conclus
final
height
significantli
lower
us
popul
pediatr
patient
brain
tumor
treat
csi
impair
final
height
expect
patient
expos
csi
age
year
younger
age
higher
csi
dose
signific
risk
factor
height
impair
moschovi
kapodistrian
univers
athen
depart
pediatr
athen
greec
backgroundobject
brain
tumor
common
solid
tumor
childhood
possibl
associ
perinat
characterist
occurr
brain
tumor
children
point
studi
designmethod
children
brain
tumor
diagnos
depart
enrol
studi
paramet
like
gender
birth
weight
gestat
age
analyz
result
medic
record
children
review
age
diagnosi
rang
day
year
mean
age
year
male
patient
mother
age
pregnanc
rang
year
case
mother
age
less
year
durat
pregnanc
rang
week
must
point
case
durat
pregnanc
equal
less
week
addit
patient
first
born
case
deliveri
perform
schedul
caesarean
section
birth
weight
rang
case
birth
weight
less
conclus
brain
tumor
common
male
signific
differ
regard
gestat
age
mother
birth
order
compar
publish
data
gener
popul
greec
notabl
case
durat
pregnanc
less
equal
week
birth
weight
less
thu
indic
children
brain
tumor
possibl
born
prematur
lower
birth
weight
even
full
term
pregnanc
factor
affect
intrauterin
growth
may
predispos
occurr
brain
tumor
hl
j
j
j
oldenburg
medic
campu
univers
oldenburg
depart
pediatr
pediatr
hematolog
oncolog
oldenburg
germani
depart
neuroradiolog
germani
institut
biostatist
clinic
research
muenster
germani
southern
medic
univers
depart
neurosurgeri
guangzhou
china
hospit
uke
depart
neurosurgeri
hamburg
germani
backgroundobject
assess
presurg
hypothalam
involv
pshi
hypothalam
damag
trhd
relev
decis
treatment
rehabilit
strategi
craniopharyngioma
designmethod
surgic
report
craniopharyngioma
patient
recruit
kraniopharyngeom
analyz
data
pshi
avail
base
surgeon
refer
neuroradiologist
local
radiologist
assess
surgic
degre
resect
dor
assess
neurosurgeon
refer
neuroradiologist
local
radiologist
trhd
assess
neurosurgeon
refer
neuroradiologist
local
radiologist
neurosurg
center
size
categor
base
patient
load
result
surgic
assess
pshi
dor
trhd
document
surgic
report
could
compar
assess
respect
paramet
refer
neuroradiologist
differ
regard
dor
trhd
p
detect
surgeon
refer
neuroradiologist
assess
wherea
pshi
assess
similarli
concord
dor
trhd
observ
respect
surgeon
estim
higher
rate
complet
resect
lower
rate
trhd
neuroradiolog
refer
assess
trhd
higher
predict
valu
hypothalam
sequela
surgic
assess
observ
differ
relat
neurosurg
center
size
conclus
observ
differ
surgic
neuroradiolog
estim
risk
factor
craniopharyngioma
support
necess
neuroradiolog
refer
review
assur
standard
qualiti
could
establish
central
neuroradiolog
review
kraniopharyngeom
standard
surgic
report
includ
specif
assess
tumordamag
locat
recommend
k
hl
medic
campu
univers
oldenburg
depart
pediatr
pediatr
hematolog
oncolog
oldenburg
germani
oldenburg
medic
campu
univers
oldenburg
depart
pediatr
pediatr
hematolog
oncolog
oldenburg
germani
kiel
depart
pediatr
oncolog
kiel
germani
backgroundobject
prolactinoma
rare
pituitari
adenoma
secret
prolactin
studi
diagnost
treatment
prognosi
pediatr
prolactinoma
patient
rare
designmethod
analyz
clinic
present
respons
treatment
prognosi
paediatr
prolactinoma
patient
base
patient
record
result
tumor
includ
microadenoma
tumor
volum
median
rang
serum
prolactin
diagnosi
median
ngml
rang
ngml
macroadenoma
volum
median
rang
prolactin
median
ngml
rang
giant
adenoma
volum
median
rang
prolactin
median
ngml
rang
data
patient
avail
dopamin
agonist
treatment
safe
effect
lead
reduct
tumor
size
p
prolactin
level
p
threat
vision
indic
decompress
surgeri
oper
patient
patient
irradi
function
capac
impair
compar
sellar
mass
conclus
pediatr
prolactinoma
diagnosi
base
hyperprolactinemia
imag
dopamin
agonist
treatment
effect
safe
function
capac
measur
qualiti
surviv
impair
indic
optimist
prognosi
surgeri
consid
emerg
situat
threaten
visual
function
present
fast
respons
dopamin
agonist
treatment
sever
side
effect
medic
lack
efficaci
consid
contraind
k
c
de
j
j
hl
oldenburg
medic
campu
univers
oldenburg
depart
pediatr
pediatr
hematolog
oncolog
oldenburg
germani
univers
depart
gastroenterolog
hangzhou
china
southern
medic
univers
depart
neurosurgeri
guangzhou
china
backgroundobject
express
extracellular
matrix
protein
periostin
found
increas
adamantinomat
fibroblast
identifi
novel
marker
fatti
liver
diseas
nafld
half
craniopharyngioma
cp
patient
hypothalam
involv
develop
nafld
hypothes
periostin
concentr
elev
cp
patient
patholog
hepat
paramet
designmethod
analyz
patient
cp
patient
isol
growth
hormon
defici
ghd
patient
low
growth
factor
igf
healthi
control
periostin
concentr
determin
serum
cp
ghd
healthi
control
urin
cp
ghd
healthi
control
salvia
cp
ghd
healthi
control
result
periostin
serum
urin
salvia
concentr
cp
patient
similar
concentr
group
hypothalam
involv
well
hepat
enzym
associ
elev
periostin
concentr
howev
due
low
patient
number
patholog
hepat
paramet
cp
show
increas
hepat
enzym
conclus
drawn
measur
periostin
concentr
serum
interestingli
subgroup
patient
low
level
show
elev
concentr
serum
periostin
compar
group
conclus
periostin
seem
suitabl
marker
nafld
cp
howev
associ
low
level
periostin
part
investig
j
hl
oldenburg
medic
campu
univers
oldenburg
depart
pediatr
pediatr
hematolog
oncolog
oldenburg
germani
hospit
depart
neuroradiolog
germani
institut
biostatist
clinic
research
germani
oldenburg
biolog
psycholog
depart
psycholog
oldenburg
germani
backgroundobject
sever
obes
due
diseas
andor
hypothalam
lesion
hl
frequent
impair
qualiti
life
craniopharyngioma
patient
cp
cp
often
show
eat
restraint
bing
eat
oxytocin
peptid
hormon
produc
hypothalamu
secret
posterior
pituitari
gland
play
major
role
regul
eat
behavior
bodi
composit
designmethod
cp
healthi
control
particip
studi
aim
investig
associ
eat
behavior
disord
hl
osc
oxytocin
saliva
concentr
osc
measur
standard
breakfast
immunoassay
eat
behavior
assess
use
inventori
eat
behavior
weight
problem
inventori
eat
disord
result
cp
anterior
plu
posterior
hl
grade
score
patholog
regard
eat
behavior
eat
disord
associ
obes
cp
lower
hl
grade
healthi
control
eat
behavior
cp
anterior
hl
grade
similar
healthi
control
except
tendenc
high
dietari
restraint
decreas
postprandi
compar
fast
osc
associ
advers
eat
behavior
cp
healthi
control
higher
bmi
sd
cp
conclus
first
studi
show
differ
grade
hl
associ
distinct
pattern
eat
behavior
addit
result
suggest
reduc
postprandi
compar
fast
osc
associ
weight
problem
cp
advers
eat
behavior
eat
disord
cp
healthi
control
n
mushtaq
k
f
khan
univers
hospit
depart
oncolog
karachi
pakistan
khan
univers
hospit
depart
patholog
karachi
pakistan
khan
univers
hospit
depart
karachi
pakistan
backgroundobject
introduct
glioblastoma
multiform
gbm
aggress
malign
primari
brain
tumor
glioblastoma
repres
primari
brain
tumor
pediatr
cn
tumor
maximum
safe
surgic
resect
principl
treatment
follow
focal
radiat
concurr
temozolomid
tmz
mainten
tmz
studi
highlight
clinic
characterist
outcom
children
adolesc
gbm
singl
tertiari
health
care
center
help
better
understand
diseas
impact
design
support
program
designmethod
methodsmateri
descript
crossect
retrospect
studi
includ
patient
year
diagnosi
gbm
januari
aga
khan
univers
hospit
relev
inform
clinic
featur
present
radiolog
find
metastat
workup
histopatholog
manag
outcom
collect
medic
record
approv
erc
result
twenti
case
includ
studi
studi
predomin
femal
patient
major
patient
year
common
present
featur
vomit
hemiparesi
headach
common
site
posterior
fossa
durat
present
ill
month
patient
patient
present
metastat
diseas
famili
histori
cancer
posit
patient
subtot
resect
commonli
perform
chemotherapi
given
radiat
therapi
receiv
patient
fourteen
patient
expir
four
progress
diseas
three
recurr
patient
aliv
residu
diseas
three
patient
lost
follow
conclus
gbm
rare
pediatr
primari
malign
brain
tumor
major
patient
die
despit
get
chemo
radiat
therapi
earli
diagnosi
safe
surgic
resect
strong
rehabilit
program
key
factor
manag
gbm
children
n
mushtaq
k
bm
f
e
sa
v
u
c
u
e
khan
univers
hospit
depart
oncolog
karachi
pakistan
khan
univers
hospit
depart
histopatholog
karachi
pakistan
khan
univers
hospit
depart
radiat
oncolog
karachi
pakistan
khan
univers
hospit
depart
radiolog
karachi
pakistan
khan
univers
hospit
depart
karachi
pakistan
children
cancer
institut
depart
oncolog
karachi
pakistan
hospit
sick
children
depart
toronto
canada
hospit
sick
children
depart
patholog
toronto
canada
hospit
sick
children
depart
toronto
canada
backgroundobject
twin
program
start
june
aga
khan
univers
hospit
indu
children
cancer
institut
karachi
pakistan
hospit
sick
children
toronto
canada
monthli
basi
designmethod
report
descript
analysi
month
improv
manag
pediatr
brain
tumor
pakistan
minut
video
teleconfer
retrospect
review
june
march
result
month
case
discuss
two
center
karachi
low
grade
glioma
medulloblastoma
high
grade
glioma
ependymoma
oligodendroglioma
craniopharyngioma
other
germinoma
pineoblastoma
choroid
plexu
carcinoma
one
hundr
three
sampl
sent
sick
kid
medulloblastoma
molecular
subgroup
immunohistochemistri
four
six
famili
consanguin
brain
tumor
found
constitut
biallel
mismatch
repair
syndrom
cmmrd
famili
diagnos
li
fraumeni
compassion
base
dabrafenib
start
one
patient
braf
immunoposit
optic
glioma
earli
referr
format
multidisciplinari
team
chang
radiat
dose
necess
immedi
scan
second
look
surgeri
chang
due
twin
chang
manag
plan
base
recommend
initi
case
went
current
analysi
recommend
follow
conclus
twin
akuh
sickkid
hospit
improv
manag
children
brain
tumor
time
referr
neurosurgeon
radiat
oncolog
twin
program
help
develop
local
treatment
protocol
well
program
necess
low
middl
incom
set
improv
surviv
outcom
qualiti
care
provid
eventu
allow
us
develop
program
within
countri
provid
local
twin
mv
p
r
r
r
v
shaw
medic
narayana
health
citi
pediatr
blood
marrow
transplant
bangalor
india
backgroundobject
tumor
cn
may
fail
respond
chemotherapi
result
drug
resist
limit
drug
exposur
tumor
tissu
order
overcom
chemotherapi
autolog
stem
cell
transplant
explor
also
appropri
young
children
radiat
avoid
bridg
modal
designmethod
retrospect
analysi
investig
demograph
data
treatment
detail
clinic
outcom
patient
diagnos
high
risk
malign
brain
tumour
institut
treat
march
march
result
children
male
mean
age
month
rang
month
diagnos
malign
brain
tumour
enrol
four
children
age
nine
children
high
risk
medulloblastoma
recurr
medulloblastoma
metastat
pineoblastoma
atyp
teratoid
rhabdoid
tumour
atrt
five
children
receiv
chemotherapi
children
receiv
radiotherapi
eleven
patient
receiv
tandem
transplant
cisplatin
vincristin
cyclophosphamid
base
condit
regimen
four
patient
receiv
tandem
transplant
carboplatin
thiotepa
base
condit
regimen
median
infus
cell
dose
x
kg
x
kg
median
mononuclear
cell
count
x
x
haematolog
recoveri
form
neutrophil
platelet
engraft
happen
median
day
patient
aliv
time
analysi
two
year
progress
free
surviv
transplant
relat
mortal
document
studi
conclus
feasibl
option
high
risk
cn
tumor
along
modal
treatment
produc
durabl
compar
remiss
multimod
standard
treatment
limit
studi
singl
institut
studi
retrospect
analysi
rel
small
sampl
size
n
v
nair
g
k
e
oncolog
princess
norah
oncolog
kamc
radiat
oncolog
jeddah
saudi
arabia
radiat
univers
ottawa
radiat
oncolog
ottawa
canada
oncolog
princess
norah
oncolog
kamc
pediatr
oncolog
jeddah
saudi
arabia
physic
princess
norah
oncolog
kamc
medic
physic
jeddah
saudi
arabia
backgroundobject
vmat
base
irradi
demonstr
abil
dosimetr
spare
organ
risk
comparison
convent
radiat
techniqu
howev
clinic
data
support
still
emerg
studi
present
earli
late
toxic
data
pediatr
medulloblastoma
treat
tertiari
oncolog
center
designmethod
treatment
chart
patient
age
year
treat
vmat
imrt
select
retrospect
review
patient
identifi
patient
diagnosi
medulloblastoma
treat
select
analysi
treatment
toxic
detail
collect
tabul
follow
ctcae
toxic
criteria
result
median
month
mean
overal
surviv
entir
cohort
month
median
os
reach
median
age
year
rang
year
fifteen
high
risk
dose
deliv
gy
deliv
fraction
tumor
boost
dose
gy
fraction
common
acut
toxic
includ
anorexia
mucos
nausea
vomit
neutropenia
common
sever
grade
toxic
neutropenia
febril
neutropenia
anorexia
common
acut
toxic
becam
chronic
headach
alopecia
common
late
toxic
skin
hyperpigment
hypothyroid
endocrinopathi
patient
develop
secondari
malign
period
conclus
earli
data
suggest
high
precis
radiat
techniqu
like
help
reduc
acut
toxic
children
use
multidisciplinari
approach
manag
long
term
toxic
warrant
patient
nakano
k
j
k
k
h
r
j
cancer
center
research
institut
divis
brain
tumor
translat
research
tokyo
japan
nation
hospit
divis
regen
institut
clinic
research
osaka
japan
univers
hospit
depart
patholog
gunma
japan
center
child
health
develop
depart
patholog
tokyo
japan
citi
gener
hospit
depart
pediatr
hematolog
oncolog
osaka
japan
citi
gener
hospit
depart
pediatr
neurosurgeri
osaka
japan
medic
univers
intern
medic
center
depart
saitama
japan
backgroundobject
histopatholog
diagnosi
brain
tumor
sometim
challeng
rariti
divers
facilit
diagnosi
latest
classif
cn
tumour
recommend
integr
diagnosi
base
histopatholog
genet
inform
report
recent
implement
integr
diagnosi
system
pediatr
brain
tumor
jccg
designmethod
patient
regist
jccg
observ
studi
particip
center
sampl
collect
manag
data
center
case
underw
central
patholog
review
set
genet
analysi
use
frozen
sampl
perform
accord
patholog
diagnos
follow
glioma
detect
braf
fusion
analysi
hot
spot
pathogen
variant
pv
braf
pyrosequenc
medulloblastoma
subgroup
express
analysi
use
nanostr
sequenc
copi
number
analysi
supratentori
ependymoma
detect
rela
fusion
posterior
fossa
ependymoma
pfa
pfb
classif
analysi
methyl
statu
three
select
gene
andor
immunohistochemistri
show
diagnost
abnorm
routin
analysi
type
tumor
target
dna
sequenc
rna
sequenc
andor
methyl
analysi
perform
necessari
final
report
gener
integr
histopatholog
molecular
find
sent
local
physician
result
april
march
tumor
underw
central
patholog
review
frozen
sampl
deposit
molecular
analysi
routin
molecular
analysi
braf
fusion
pv
detect
approxim
glioma
target
sequenc
identifi
kit
pv
germinoma
target
fusion
includ
ntrk
fusion
also
detect
sever
glioma
conclus
nationwid
central
diagnosi
system
pediatr
brain
tumor
clinic
set
establish
japan
c
nantavithya
k
k
univers
texa
md
anderson
cancer
center
radiat
oncolog
houston
usa
chulalongkorn
memori
hospit
divis
therapeut
radiat
depart
radiolog
bangkok
thailand
univers
texa
md
anderson
cancer
center
health
servic
research
houston
usa
univers
texa
md
anderson
cancer
center
pediatr
houston
usa
children
cancer
center
pediatr
houston
usa
colleg
medicin
pediatr
houston
usa
backgroundobject
defin
factor
increas
risk
develop
second
primari
tumor
spt
analyz
surviv
outcom
medulloblastoma
patient
designmethod
patient
diagnos
medulloblastoma
registri
classifi
accord
age
year
gender
male
femal
race
white
black
year
diagnosi
adjuv
treatment
radiat
rt
chemotherapi
ct
rt
ct
rt
alon
ct
alon
region
atlant
south
west
histolog
desmoplast
nodular
larg
cell
otherwis
specifi
result
case
case
develop
spt
benign
overal
incid
rate
spt
year
differ
spt
patient
receiv
rt
rtct
year
year
rtct
show
better
overal
surviv
os
compar
rt
alon
year
year
p
multipl
regress
analysi
femal
gender
earlier
year
diagnosi
p
associ
higher
risk
develop
spt
common
spt
includ
brain
nervou
system
thyroid
reticuloendotheli
os
rate
patient
develop
second
malign
benign
tumor
year
year
p
conclus
femal
gender
diagnosi
show
associ
higher
risk
develop
spt
patient
receiv
rt
ct
better
os
without
reduct
spt
compar
rt
alon
k
okada
h
j
j
citi
gener
hospit
depart
pediatr
hematologyoncolog
osaka
japan
proton
center
depart
radiat
oncolog
kobe
japan
citi
gener
hospit
depart
pediatr
neurosurgeri
osaka
japan
univers
hospit
depart
patholog
maebashi
japan
backgroundobject
test
whether
multidrug
chemotherapi
simultan
irradi
abl
reduc
dose
craniospin
irradi
csi
patient
medulloblastoma
mb
designmethod
children
three
year
elig
patient
stage
classifi
mb
other
includ
patient
postop
residu
tumor
classifi
mb
patient
receiv
chemotherapi
consist
cyclophosphamid
etoposid
cisplatin
vincristin
intrathec
methotrex
radiotherapi
start
concomitantli
second
cours
chemotherapi
radiat
dose
gy
primari
site
gy
craniospin
axi
except
patient
year
receiv
gy
csi
patient
receiv
five
cours
chemotherapi
everi
week
patient
receiv
four
cours
chemotherapi
everi
week
five
six
week
last
chemotherapi
start
patient
receiv
chemotherapi
consist
thiotepa
melphalan
thiotepa
continu
infus
melphalan
infus
day
autolog
stem
cell
rescu
result
patient
averag
high
enrol
pf
os
seven
patient
year
old
receiv
gy
csi
although
expect
hematolog
grade
toxic
observ
leukoencephalopathi
death
two
patient
experienc
secondari
cancer
conclus
promis
result
suggest
intens
chemotherapi
simultan
irradi
chemotherapi
might
abl
reduc
dose
csi
gy
regardless
risk
oshiro
j
c
l
medic
center
hospit
radiat
oncolog
tsukuba
japan
jude
children
research
hospit
radiat
oncolog
memphi
usa
jude
children
research
hospit
memphi
usa
jude
children
research
hospit
psycholog
memphi
usa
backgroundobject
investig
tumor
control
rate
pediatr
patient
local
ependymoma
treat
radiat
therapi
rt
use
cm
clinic
target
volum
ctv
margin
surround
tumor
bed
evalu
reduct
dose
brain
cochlea
compar
treatment
use
cm
ctv
margin
designmethod
begin
novemb
pediatr
patient
local
ependymoma
receiv
postop
rt
use
cm
ctv
margin
median
age
year
rang
tumor
locat
infratentori
patient
gross
total
resect
perform
multipl
surgeri
total
prescrib
dose
n
n
base
age
clinic
plan
patient
supratentori
infratentori
tumor
locat
treat
intens
modul
radiotherapi
imrt
proton
therapi
pt
randomli
select
evalu
impact
normal
tissu
dose
reduc
ctv
margin
cm
result
median
month
rang
month
patient
die
experienc
progress
form
local
n
distant
n
combin
local
distant
failur
n
local
control
surviv
overal
surviv
rate
ci
ci
ci
respect
one
case
fatal
secondari
brain
tumor
one
case
fatal
brain
necrosi
observ
mean
brain
ipsilater
contralater
cochlear
dose
reduc
respect
use
cm
ctv
margin
conclus
tumor
control
rate
pattern
failur
use
cm
ctv
margin
compar
observ
pediatr
patient
treat
cm
margin
ctv
margin
cm
substanti
reduc
dose
brain
cochlea
h
ottensmei
pg
r
bo
children
univers
medic
center
wuerzburg
depart
pediatr
hematolog
oncolog
wuerzburg
germani
muenster
biostatistik
clinic
research
muenster
germani
medic
pediatr
hematolog
oncolog
hamburg
germani
backgroundobject
medulloblastoma
mb
ependymoma
ep
requir
multimod
treatment
might
affect
mental
outcom
order
unveil
deficit
use
model
intellig
adapt
pecular
children
year
designmethod
neuropsycholog
examin
perform
children
treat
within
hit
trial
examin
perform
two
five
year
surgeri
male
femal
ratio
follow
test
appli
mental
intellig
colour
progress
matric
integr
kaufman
assess
batteri
children
psychomotor
abil
execut
function
continu
perform
hit
rate
decis
time
particip
daili
life
fmh
scale
order
control
variabl
appli
multivari
analysi
median
age
set
year
time
point
analysi
adjust
exactli
year
use
estim
score
test
result
signific
differ
compar
standard
score
ss
differ
treatment
group
year
furthermor
effect
could
detect
multivari
analysi
main
differ
exist
differ
treatment
patient
receiv
system
chemotherapi
mtxith
choosen
refer
children
relaps
primari
mbm
receiv
system
chemotherapi
craniospin
irradi
csi
perform
significantli
wors
ss
cpm
vmi
ss
fmh
p
posit
effect
regard
psychomotor
abil
could
observ
patient
supratentori
ep
receiv
system
chemotherapi
local
radiotherapi
rt
show
significantli
better
tap
score
p
conclus
mb
patient
receiv
system
chemotherapi
csi
show
signific
wors
perform
test
score
contrast
ep
supratentori
tumor
locat
combin
local
rt
seem
better
preserv
psychomotor
abil
ozyoruk
f
children
hematolog
oncolog
hospit
pediatr
oncolog
ankara
turkey
yildirim
beyazit
train
research
hospit
genet
diagnost
center
ankara
turkey
children
hematolog
oncolog
hospit
patholog
ankara
turkey
yildirim
beyazit
train
research
hospit
neurochirurgi
ankara
turkey
backgroundobject
constitut
mismatch
repair
defici
syndrom
rare
childhood
cancer
predisposit
syndrom
result
biallel
germlin
mutat
mmr
gene
poorli
recognis
clinician
far
designmethod
present
cmmrd
sendrom
due
germlin
msh
mutat
multipl
cancer
famili
member
index
case
femal
present
intracrani
mass
mri
brain
famili
histori
parent
first
degre
cousin
one
sister
diagnos
aggress
brain
tumor
year
age
afterthat
brother
diagnos
childhood
neurofibromatosi
type
medulloblastoma
follow
colorect
cancer
year
age
mother
great
uncl
diagnos
colorect
cancer
age
physic
examin
unremarc
cafe
au
lait
spot
hipod
macul
bodi
resect
cerebellar
mass
histopatholog
reveal
classic
desmoplast
medulloblastoma
genet
test
done
novel
homozyg
singl
bone
insert
mutat
exon
msh
gene
detect
nf
nf
gene
found
neg
blood
sampl
obtain
parent
sibl
result
parent
found
heterozyg
mutat
two
sibl
found
homozyg
two
sibl
heterozyg
one
homozyg
sibl
diagnos
medulloblastoma
desmoplast
nodullar
subtyp
colon
adenocarcinoma
year
age
year
ago
die
progress
diseas
homozyg
sibl
multipl
cafe
au
lait
spot
hipod
macul
bodi
heterozyg
sibl
year
old
age
conclus
intern
collabor
requir
evalu
guidelin
screen
treatment
malign
explor
prevent
strategi
patient
cmmrd
rn
palomar
b
garcia
de
ricardo
gutierrez
oncolog
unit
bueno
air
argentina
fleni
oncolog
unit
bueno
air
argentina
backgroundobject
argentina
cn
tumor
repres
pediatr
neoplasm
medulloblastoma
mb
frequent
malign
tumor
treatment
base
surgeri
radiotherapi
chemotherapi
relaps
diseas
alway
poor
prognosi
evalu
result
treatment
irinotecan
temozolamid
bevacizumab
itb
patient
p
relaps
refractori
medulloblastoma
radiotherapi
chemotherapi
toxic
object
respons
mean
time
progress
designmethod
retrospect
analysi
medic
record
patient
relaps
medulloblastoma
treat
outpati
basi
iv
irinotecan
everi
week
oral
temozolamid
day
everi
week
iv
bevacizumab
mgkgday
everi
week
result
evalu
patient
median
age
diagnosi
yo
chang
stage
complet
resect
surgeri
high
risk
anaplasia
median
time
relaps
month
two
patient
progress
treatment
stage
relaps
treatment
relaps
surgeryradiotherapychemotherapi
radiotherapychemotherapi
total
cycl
perform
median
cycl
toxic
diarrhea
gii
haematolog
toxic
giii
giii
one
patient
show
cholinerg
symptom
irinotecan
infus
evalu
month
mri
complet
respons
cr
partial
respons
pr
stabl
diseas
sd
refractori
diseas
object
respons
mean
time
progress
month
patient
current
aliv
second
relaps
cervic
lymph
node
metastasi
month
initi
relaps
undergo
radiotherapi
cr
autosct
month
sinc
relaps
conclus
itb
treatment
use
safe
well
toler
high
object
respons
achiev
patient
therapeut
option
r
rajagop
kt
az
bustam
ty
la
wa
h
malaya
medic
centr
depart
paediatr
kuala
lumpur
malaysia
malaya
medic
centr
depart
surgeri
kuala
lumpur
malaysia
malaya
medic
centr
depart
patholog
kuala
lumpur
malaysia
malaya
medic
centr
depart
radiat
oncolog
kuala
lumpur
malaysia
backgroundobject
determin
outcom
young
children
year
old
malign
central
nervou
system
cn
tumour
treat
univers
malaya
medic
centr
malaysia
januari
decemb
designmethod
retrospect
review
young
children
malign
cn
tumour
treat
definit
surgeri
intens
induct
follow
myeloabl
chemotherapi
autolog
hematopoiet
stem
cell
rescu
ascr
use
head
start
ii
protocol
result
twenti
patient
identifi
median
year
rang
mean
age
year
rang
male
femal
ratio
thirteen
patient
diagnos
medulloblastoma
five
posterior
fossa
ependymoma
one
left
frontal
lobe
primit
neuroectoderm
tumour
posterior
fossa
atyp
teratoidrhabdoid
tumour
respect
six
patient
dissemin
diseas
present
twelv
patient
complet
induct
myeloabl
chemotherapi
ascr
five
recurr
occur
median
durat
month
ascr
two
respond
subsequ
salvag
radiotherapi
anoth
four
patient
experienc
diseas
progress
median
time
month
follow
diagnosi
induct
phase
five
recurr
ascr
three
patient
progress
diseas
die
median
durat
month
progress
four
toxic
death
occur
induct
surviv
overal
surviv
whole
group
respect
seven
medulloblastoma
survivor
without
radiat
one
patient
ependymoma
palliat
progress
diseas
conclus
strategi
definit
surgeri
intens
induct
follow
myeloabl
chemotherapi
ascr
use
head
start
ii
protocol
young
children
malign
cn
tumour
elimin
need
radiat
seven
survivor
henc
intens
chemotherapi
feasibl
countri
rate
toxic
death
differ
develop
countri
rana
h
hospit
pediatr
hematolog
oncolog
dubai
unit
arab
emir
hospit
depart
pediatr
hematolog
oncolog
dubai
unit
arab
emir
backgroundobject
dubai
hospit
one
three
main
center
treat
childhood
cancer
unit
arab
emir
last
five
year
twenti
seven
children
brain
tumor
present
institut
present
detail
rare
group
tumor
region
designmethod
children
diagnosi
brain
tumor
seen
dubai
hospit
identifi
hospit
electron
record
system
year
result
total
twenti
seven
children
brain
tumor
manag
end
dubai
health
author
age
diagnosi
rang
six
week
eleven
year
median
age
five
year
male
femal
ratio
major
tumor
pilocyt
astrocytoma
major
malign
one
medulloblastoma
brain
stem
tumor
abl
get
genet
four
tumor
specimen
found
braf
mutat
posit
two
pilocyt
astrocytoma
mutat
posit
two
pontin
glioma
one
child
posit
headach
vomit
present
symptom
children
signific
morbid
death
conclus
major
children
brain
tumor
surviv
albeit
sever
sequel
mutat
braf
mutat
one
identifi
pontin
glioma
astrocytoma
respect
need
push
genet
studi
tumor
specimen
abl
offer
target
therapi
henc
improv
surviv
futur
renzi
v
u
e
u
hospit
sick
canada
divis
hematolog
oncolog
toronto
canada
backgroundobject
primari
benign
malign
central
nervou
system
cn
tumor
frequent
solid
tumor
pediatr
age
repres
signific
caus
death
childhood
mortal
popul
extens
studi
object
investig
mortal
larg
cohort
children
diagnos
institut
designmethod
use
intern
databas
identifi
patient
diagnos
benign
malign
cn
tumor
treat
hospit
sick
children
januari
decemb
patient
analyz
accord
differ
variabl
tumor
diagnosi
locat
gender
age
diagnosi
age
death
time
elaps
diagnosi
death
caus
death
statist
descript
result
patient
succumb
diseas
mortal
rate
vari
significantli
accord
tumor
subtyp
rang
low
grade
glioma
lgg
high
grade
glioma
hgg
repres
total
diagnos
hgg
account
total
death
diffus
intrins
pontin
glioma
patient
die
medulloblastoma
embryon
tumor
ependymoma
male
femal
ratio
median
age
death
year
year
mean
time
elaps
diagnosi
death
year
year
n
patient
die
dissemin
diseas
diagnosi
caus
death
progress
primari
diseas
complic
sepsi
periop
death
secondari
malign
gbm
lymphoma
conclus
mortal
remain
signific
burden
children
brain
tumor
less
case
caus
death
unrel
diseas
progress
research
continu
focu
improv
treatment
strategi
patient
whose
prognosi
remain
dismal
ie
high
grade
glioma
r
riccardi
c
g
l
b
univers
sacr
hearth
depart
pediatr
oncolog
rome
itali
univers
sacr
hearth
depart
neuroradiolog
rome
itali
univers
sacr
hearth
depart
ophtalmolog
rome
itali
backgroundobject
accord
current
clinic
guidelin
children
optic
pathway
glioma
opg
deterior
compromis
visual
function
regardless
tumor
volum
chang
consid
criteria
local
andor
system
treatment
aim
studi
retrospect
evalu
chang
visual
function
associ
tumor
progress
low
grade
childhood
opg
designmethod
clinic
visual
function
histori
brain
mri
children
opg
collect
follow
least
year
review
result
least
two
consecut
ophthalmolog
test
confirm
signific
declin
visual
acuiti
line
well
reduct
peripher
visual
field
goldmann
degre
patient
patient
signific
chang
greater
tumor
volum
observ
follow
conclus
present
result
suggest
clinic
signific
visual
declin
found
opg
patient
detect
tumor
progress
challeng
current
guidelin
therapeut
manag
opg
given
high
percentag
visual
impair
absenc
tumor
progress
discoveri
new
molecular
pathway
involv
associ
opg
suggest
decreas
visual
function
without
tumor
volum
increas
occur
emerg
target
therapeut
treatment
ie
inhibitor
lovastatin
antiapoptot
treatment
nerv
growth
factor
test
placebo
control
studi
avoid
aggress
treatment
includ
chemotherapi
radiotherapi
support
fondazion
per
loncologia
pediatrica
rivera
r
navarro
martin
del
al
alvarado
civil
de
guadalajara
juan
menchaca
pediatr
hematolog
oncolog
guadalajara
mexico
backgroundobject
medulloblastoma
mb
frequent
solid
tumor
pediatr
age
incid
close
mexico
incid
case
per
million
children
dissemin
diseas
diagnosi
experi
tumor
progress
recurr
cur
therapi
exist
patient
present
relaps
respons
treatment
designmethod
retrospect
studi
design
identifi
children
treat
mb
relaps
progress
treatment
hospit
civil
de
guadalajara
juan
menchaca
pattern
relaps
treatment
surviv
relaps
analyz
result
forti
three
patient
receiv
treatment
relaps
detect
one
second
neoplasm
two
progress
diseas
despit
treatment
relaps
pattern
one
posterior
fossa
three
extend
leptomening
relaps
relaps
frontal
lobe
median
time
relaps
month
relaps
treatment
consist
combin
surgeri
focal
radiotherapi
rt
chemotherapi
relaps
progress
surviv
month
one
patient
treat
palli
care
one
still
treatment
patient
die
relaps
conclus
relaps
mb
fatal
cours
seri
could
reflect
absenc
target
therapi
molecular
subgroup
classif
new
therapi
urgent
need
rivera
r
navarro
martin
del
al
alvarado
civil
de
guadalajara
juan
menchaca
pediatr
hematologyoncolog
guadalajara
mexico
backgroundobject
medullobastoma
common
malign
brain
tumor
children
incid
highest
incid
year
common
male
treatment
standard
risk
group
includ
maxim
surgic
resect
follow
craniospin
irradi
csi
chemotherapi
vincristin
vcr
platinum
cddp
regimen
approach
result
overal
surviv
os
near
group
highest
risk
group
os
designmethod
transvers
retrospect
studi
includ
patient
age
year
diagnos
medulloblastoma
hospit
civil
de
guadalajara
juan
menchaca
data
collect
includ
date
diagnosi
age
diagnosi
sex
stage
patholog
treatment
recurr
current
statu
result
total
case
enrol
ratio
median
age
diagnosi
year
twelv
patient
infant
risk
classif
high
risk
patient
patient
standard
risk
patient
unclassifi
dead
surgeri
patient
receiv
oncolog
treatment
death
refus
treatment
lost
transfer
metastas
pattern
show
patient
patient
ice
without
temozolamid
use
treatment
regimen
high
risk
patient
cddpvcrcyclophosphamid
standard
risk
infant
methotrex
base
chemotherapi
overal
surviv
death
order
frequenc
due
relaps
infect
progress
diseas
abandon
conclus
frequent
caus
death
relaps
patient
younger
year
group
abandon
mortal
rate
remain
high
relat
high
risk
stage
lack
resourc
molecular
classif
order
give
target
therapi
e
salnikova
e
e
rogachev
nation
research
center
pediatr
oncolog
immunolog
neurooncolog
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
pathoanatom
moscow
russia
burdenko
neurosurg
institut
pathoanatom
moscow
russia
cancer
research
center
dkfz
clinic
cooper
unit
neuropatolog
heidelberg
germani
rogachev
nation
research
center
pediatr
oncolog
immunolog
radiat
therapi
moscow
russia
children
clinic
hospit
oncolog
moscow
russia
region
clinic
hospit
hematolog
khabarovsk
russia
oncolog
center
oncolog
orenburg
russia
center
oncolog
children
depart
bishkek
kyrgyzstanr
rogachev
nation
research
center
pediatr
oncolog
immunolog
clinic
rehabilit
research
center
patient
remiss
russkoy
pole
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
head
neurooncolog
depart
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
gener
director
moscow
russia
backgroundobject
definit
risk
group
patient
medulloblastoma
still
necessari
evalu
treatment
result
patient
primarili
diagnos
medulloblastoma
depend
current
risk
factor
designmethod
retrospect
analyz
data
patient
observ
rogachev
center
june
till
septemb
molecular
genet
test
perform
case
dkfzgermani
diagnos
case
mycmycn
case
hit
treatment
regim
use
patient
case
aliv
patient
case
aliv
shh
case
aliv
risk
group
sr
shh
amplif
amplif
hr
shh
shh
nmyc
vhr
result
pf
withwithout
myc
mycn
amplif
withwithout
loss
gain
withwithout
mutat
withwithout
withwithout
os
pf
conclus
factor
high
risk
myc
loss
absenc
rt
shh
r
vp
statist
significantli
wors
os
valu
obtain
patient
vhr
group
sato
b
j
b
iowa
stead
famili
children
hospit
pediatr
hematolog
oncolog
iowa
citi
usa
iowa
carvar
colleg
medicin
iowa
citi
usa
iowa
biostatist
iowa
citi
usa
iowa
neurosurgeri
iowa
citi
usa
iowa
neurosurgeri
neurosurgeri
usa
backgroundobject
exact
caus
posterior
fossa
syndrom
pf
larg
unknown
unpredict
outcom
make
manag
pf
challeng
studi
object
investig
prognost
factor
pf
children
posterior
fossa
tumor
iowa
designmethod
retrospect
chart
review
march
conduct
medic
record
children
posterior
fossa
tumor
analyz
look
outcom
clinic
variabl
tumor
type
present
surgic
method
pre
post
surgic
mri
imag
patient
evalu
pf
predict
result
chart
review
medulloblastoma
low
grade
glioma
ependymoma
atrt
fifteen
patient
develop
pf
medulloblastoma
low
grade
glioma
atrt
ependymoma
ten
patient
pf
sever
pf
symptom
among
observ
variabl
intraop
split
vermi
prognost
factor
pf
pre
post
oper
mri
patient
avail
damag
bilater
dentat
nuclei
superior
cerebellar
peduncl
detect
significantli
pf
respect
conclus
studi
work
elucid
incid
clinic
outcom
prognost
risk
factor
pf
univers
iowa
patient
posterior
fossa
tumor
symptom
pf
vari
thu
retrospect
chart
review
may
underestim
actual
incid
postop
mri
find
could
use
suspect
pf
may
lead
deliv
earli
intervent
schiavetti
mg
b
c
g
sapienza
pediatr
rome
itali
backgroundobject
estim
rate
major
respons
mr
complet
respons
cr
partial
respons
pr
toxic
surviv
pf
overal
surviv
os
children
relapsedrefractori
brain
tumor
treat
bevacizumab
contain
regimen
singl
center
phase
ii
studi
designmethod
patient
receiv
ii
line
treatment
without
megatherapi
includ
schedul
follow
bevacizumab
bvz
mgkg
iv
irinotecan
iri
iv
everi
week
temozolamid
tmz
po
daili
day
everi
day
tmz
omit
heavili
pretreat
case
result
patient
median
age
diagnosi
month
rang
medulloblastoma
n
low
grade
glioma
n
high
grade
glioma
n
enrol
patient
receiv
bvziri
median
cours
rang
also
receiv
mainten
therapi
bvz
median
cours
rang
tmz
median
cours
rang
ad
patient
stop
myelotox
lack
complianc
month
cr
pr
stabl
diseas
progress
diseas
observ
radiolog
evalu
rate
mr
nine
case
experienc
improv
neurolog
symptom
median
time
progress
month
confid
interv
month
pf
rate
respect
current
os
importantli
case
medulloblastoma
high
grade
glioma
month
respect
treatment
well
toler
good
qualiti
life
conclus
associ
temozolamid
show
encourag
result
relaps
brain
tumor
prospect
clinic
trial
need
evalu
efficaci
extend
set
schiavetti
fr
sapienza
oncolog
scienc
rome
itali
sapienza
pediatr
rome
itali
backgroundobject
retrospect
evalu
prognost
relev
molecular
subgroup
wnt
shh
group
patient
medulloblastoma
treat
singl
institut
addit
prognost
relev
express
assess
cohort
designmethod
patient
median
age
year
treat
chemotherapi
cycl
carboplatin
total
maximum
dose
per
patient
per
cours
etoposid
follow
radiotherapi
chemotherapi
cycl
carboplatin
etoposid
paraffin
embed
ffpe
sampl
analyz
via
ihc
fish
sanger
sequenc
accord
classif
system
result
correl
outcom
surviv
analysi
result
patient
sr
hg
accord
chang
stage
system
complet
treatment
progress
free
surviv
pf
year
diagnosi
sr
hr
overal
surviv
os
sr
hr
accord
molecular
subgroup
os
wnt
shh
classifi
nc
group
wnt
vs
group
p
associ
better
outcom
patient
os
compar
os
p
express
higher
group
compar
shhwntnc
group
p
conclus
surviv
rate
compar
contemporari
studi
use
less
drug
confirm
molecular
subgroup
relev
risk
stratif
independ
prognost
marker
medulloblastoma
n
sirachainan
samart
u
usanarat
montana
ramathibodi
hospit
pediatr
bangkok
thailand
ramathibodi
hospit
surgeri
bangkok
thailand
ramathibodi
hospit
radiolog
bangkok
thailand
backgroundobject
recurr
medulloblastoma
account
patient
medulloblastoma
especi
high
risk
group
treatment
recurr
medulloblastoma
includ
surgeri
chemotherapi
without
hematopoiet
stem
cell
transplant
hsct
advanc
target
therapi
howev
outcom
remain
poor
respons
rate
around
aim
studi
demonstr
outcom
patient
recurr
medulloblastoma
treat
temozolomid
irinotecan
designmethod
studi
enrol
patient
diagnos
recurr
medulloblastoma
document
magnet
reson
imag
mri
studi
patient
previous
receiv
nation
high
risk
medulloblastoma
protocol
diagnosi
document
tumor
progress
neurosurgeri
consult
possibl
chemotherapi
includ
temozolomid
dose
day
irinotecan
dose
day
day
given
cycl
tumor
progress
result
seven
patient
median
age
year
old
enrol
five
male
patient
tumor
recurr
primari
site
leptomenig
involv
overal
surviv
os
os
median
os
month
fever
neutropenia
identifi
one
patient
treatment
relat
death
observ
conclus
outcom
patient
recurr
medulloblastoma
treat
temozolomid
irinotecan
compar
previou
high
dose
chemotherapi
hsct
side
effect
minim
acknowledg
ramathibodi
comprehens
cancer
center
faculti
medicin
ramathibodi
hospit
g
p
univers
silesia
depart
pediatr
haematolog
chemotherapi
katowic
poland
backgroundobject
medulloblastoma
mb
common
malign
brain
tumor
children
although
treatment
result
significantli
improv
patient
group
unsuccess
treatment
outcom
aim
studi
assess
surviv
determin
risk
factor
children
medulloblastoma
treat
center
period
designmethod
clinic
pictur
mb
analyz
take
account
locat
tumor
extent
resect
histopatholog
form
time
surgeri
begin
therapi
respons
initi
treatment
respons
end
treatment
result
institut
children
diagnos
medulloblastoma
age
month
year
old
middl
age
year
dominat
tumor
iv
chamber
resect
total
almost
total
gtr
partial
histopatolog
classic
type
desmoplast
anaplast
patient
control
imag
mr
initi
treatment
patient
complet
respons
obtain
partial
case
progress
chang
observ
end
treatment
cr
diagnos
children
case
progress
diseas
observ
children
die
patient
relaps
recurr
cr
diagnos
children
includ
patient
local
recurr
children
primari
tumor
locat
period
examin
group
os
overal
surviv
ef
event
free
surviv
obtain
patient
conclus
initi
dissemin
form
anaplast
type
mb
signific
risk
factor
treatment
failur
full
assess
factor
therapi
failur
assess
molecular
group
mb
recommend
stepanova
g
state
medic
univers
pediatr
oncolog
voronezh
russia
children
hospit
pediatr
oncolog
voronezh
russia
backgroundobject
atyp
cn
tumor
rare
highli
aggress
neoplasm
occur
mainli
young
children
bad
prognosi
averag
overal
surviv
patient
chemotherapi
month
chemo
radiotherapi
month
morpholog
pictur
combin
classic
rhabdoid
primit
neuroectoderm
mesenchym
compon
vimentin
ema
chromosom
mutat
designmethod
three
children
atyp
tumor
observ
result
case
boy
age
diagnosi
atyp
tumor
third
ventricl
metastasi
spinal
cord
protocol
treatment
receiv
within
year
month
month
metastasi
level
oper
intervent
made
tumour
spinal
cord
remov
verifi
atro
month
later
metastas
found
progress
tumor
process
led
lethal
outcom
case
boy
age
year
month
diagnosi
atyp
teratoid
rhabdom
tumor
pineal
region
stage
complic
syndrom
therapi
protocol
atro
child
stabil
diseas
case
boy
age
month
biopsi
made
tumor
remov
diagnosi
atro
angl
metastasi
brain
stem
spinal
cord
atro
protocol
child
die
age
month
conclus
atyp
mix
tumor
rare
three
patient
male
possibl
assum
chromosom
link
x
chromosom
case
patient
enter
depart
seriou
condit
stabil
diseas
occur
child
radic
remov
tumor
two
patient
tumor
biopsi
subtot
remov
die
continu
tumor
growth
median
surviv
month
research
need
improv
prognosi
hg
n
tacyildiz
h
e
k
g
univers
medic
faculti
pediatr
oncolog
ankara
turkey
univers
medic
faculti
pediatr
neurulog
ankara
turkey
univers
medic
faculti
ophthalmolog
ankara
turkey
backgroundobject
optic
pathway
glioma
opg
common
cn
tumor
seen
neurofibromatosi
type
ratio
repres
childhood
brain
tumor
studi
aim
describ
characterist
manag
patient
opg
designmethod
retrospect
analysi
clinic
imag
data
treatment
histori
children
opg
seen
singl
center
perform
result
period
individu
screen
duse
brainorbit
mri
opg
identifi
patient
median
age
detect
year
sixteen
children
girl
boy
diagnos
opg
among
medianag
patient
without
detectionwa
main
reason
seek
medic
advic
decreas
vision
decreas
vision
proptosi
hemiparesi
moyamoya
diseas
headach
due
hydrocephalu
confus
papillari
stasi
incident
brain
comput
tomographi
scan
head
injuri
au
lait
spot
patient
show
deterior
visual
acuiti
patient
imag
find
one
underw
tumor
resect
wherea
receiv
radiat
treatment
receiv
chemotherapi
five
patient
glioma
treat
averag
cycl
vincristin
carboplatin
plu
mg
oral
imatinib
therapi
one
patient
system
chemotherapi
imatinib
use
optic
glioma
conclus
children
without
requir
therapeut
intervent
wherea
patient
receiv
treatment
opg
childrenwith
frequent
remain
indol
differ
opg
gener
popul
aggress
howev
symptomat
opg
lead
vision
loss
subset
children
h
toledano
n
univers
molecular
biolog
ariel
israel
children
medic
center
israel
pediatr
oncolog
petach
tikva
israel
aviv
univers
sackler
faculti
medicin
tel
aviv
israel
univers
hospit
neurosurgeri
jerusalem
israel
medic
research
beilinson
hospit
krieger
eye
research
laboratori
petah
tikva
israel
zion
medic
center
ophthalmolog
haifa
israel
ruth
bruce
rappaport
faculti
medicin
haifa
israel
backgroundobject
medulloblastoma
mb
common
malign
brain
tumor
children
divid
four
subgroup
wnt
sonic
hedgehog
shh
group
group
subgroup
distinct
demograph
genet
profil
outcom
subgroup
base
treatment
protocol
current
evolv
escal
therapi
high
risk
group
patient
low
risk
wnt
group
patient
wnt
shh
subgroup
biomark
distinguish
group
group
straightforward
microrna
mirna
regul
posttranscript
gene
express
involv
mb
tumorigenesi
howev
rna
mrna
regulatori
network
mb
far
fulli
understood
aim
investig
mirna
express
regul
mb
subgroup
assess
mirna
target
relationship
identifi
mirna
distinguish
group
group
designmethod
aim
integr
transcriptom
mrna
mirna
express
analysi
perform
primari
tumor
sampl
collect
children
mb
use
mirna
sequenc
rna
sequenc
quantit
pcr
result
express
mirna
appear
significantli
differenti
express
de
group
subgroup
fals
discoveri
rate
fdr
includ
mirna
first
time
report
conjunct
mb
analysi
identifi
gene
de
group
subgroup
fdr
among
seven
predict
target
five
de
mirna
exhibit
invers
express
pattern
conclus
studi
identifi
mirna
molecul
may
involv
group
etiolog
gener
distinguish
group
group
particular
addit
understand
involv
mirna
target
mb
may
improv
diagnosi
advanc
develop
target
treatment
mb
j
trelinska
w
k
k
w
univers
lodz
depart
hematolog
diabetolog
lodz
poland
univers
lodz
depart
biostatist
translat
medicin
lodz
poland
univers
lodz
depart
pediatr
central
research
hospit
lodz
poland
children
memori
health
institut
depart
neurolog
epileptolog
pediatr
rehabilit
warsaw
poland
univers
warsaw
depart
child
neurolog
warsaw
poland
backgroundobject
aim
studi
evalu
efficaci
safeti
mtor
inhibitor
everolimu
votubia
novarti
therapi
standard
reduc
dose
regist
clinic
trial
emin
drk
patient
tuber
sclerosi
tsc
subependym
giant
cell
astrocytoma
sega
treat
decemb
march
designmethod
thirteen
patient
sega
age
met
inclus
criteria
treat
everolimu
daili
dose
attain
trough
concentr
ngml
standard
treatment
least
month
mainten
dose
emin
studi
three
time
week
daili
dose
standard
treatment
tumor
volum
evalu
use
magnet
reson
imag
baselin
month
standard
dose
month
mainten
dose
advers
event
ae
therapi
assess
result
signific
reduct
sega
volum
note
month
standard
dose
treatment
median
tumor
volum
versu
baselin
treatment
mainten
dose
result
slight
signific
increas
sega
volum
sega
volum
measur
mainten
therapi
significantli
lower
compar
baselin
volum
median
volum
month
mainten
dose
respect
versu
baselin
ae
grade
note
mainten
therapi
conclus
studi
confirm
efficaci
mtor
inhibitor
everolimu
treatment
sega
patient
tsc
mainten
dose
month
standard
treatment
influenc
efficaci
significantli
reduc
rate
advers
event
fund
nation
scienc
center
grant
number
watanab
r
univers
graduat
school
medicin
pediatr
miyagi
japan
univers
school
medicin
neurosurgeri
yamanashi
japan
medic
univers
intern
medic
center
saitama
japan
univers
school
medicin
neurosurgeri
kanagawa
japan
backgroundobject
balanc
central
standard
pediatr
cancer
treatment
emphas
sinc
announc
core
pediatr
cancer
center
organ
system
difficult
conduct
studi
clarifi
current
state
treatment
pediatr
brain
tumor
designmethod
investig
current
state
pediatr
brain
tumor
hospit
well
nation
level
questionnair
survey
conduct
core
facil
neurosurgeri
across
japan
depart
neurosurgeri
pediatr
member
facil
japan
children
cancer
group
result
hospit
proudli
report
progress
made
interdisciplinari
cooper
neurosurgeon
pediatr
oncologist
well
among
healthcar
profession
improv
medic
care
level
provis
care
howev
attribut
establish
core
pediatr
cancer
center
hospit
intend
continu
treat
new
patient
contrast
approxim
physician
state
medic
care
provid
nation
level
best
possibl
care
survey
data
also
reveal
inabl
provid
emerg
craniotomi
magnet
reson
imag
need
lack
adequ
diagnost
patholog
evalu
skill
neurosurgeon
difficult
without
address
point
possibl
central
medic
care
small
number
facil
furthermor
due
possibl
need
emerg
surgeri
hospit
metropolitan
rural
area
use
system
inadequ
educ
system
low
public
awar
underscor
need
develop
proactiv
approach
conclus
current
situat
favor
gather
treat
pediatr
patient
brain
tumor
core
pediatr
cancer
center
find
show
mani
issu
remain
address
determin
optim
method
chang
treatment
system
lesion
withrow
berrington
de
ms
cjk
ke
ms
nation
cancer
institut
radiat
epidemiolog
branch
rockvil
usa
nation
cancer
institut
surveil
research
program
rockvil
usa
nation
cancer
institut
pediatr
oncolog
branch
bethesda
usa
nation
cancer
institut
immunoepidemiolog
branch
rockvil
usa
backgroundobject
though
rare
brain
central
nervou
system
cn
cancer
lead
caus
us
pediatr
cancer
mortal
use
us
cancer
registri
estim
recent
nation
trend
rate
pediatr
cn
tumor
designmethod
malign
primari
cn
cancer
pilocyt
astrocytoma
borderlin
benign
routin
histor
regist
includ
incid
rate
annual
percent
chang
apc
incid
rate
calcul
age
year
glioma
stratifi
grade
histolog
locat
estim
absolut
chang
number
case
diagnos
due
chang
incid
time
calcul
differ
number
case
estim
base
rate
appli
us
censu
popul
count
result
rate
malign
cn
cancer
combin
chang
confid
interv
ci
statist
signific
chang
sever
howev
glioma
incid
increas
year
embryon
cancer
decreas
year
ci
pilocyt
astrocytoma
rate
increas
year
estim
malign
tumor
pilocyt
astrocytoma
diagnos
us
children
includ
addit
glioma
addit
pilocyt
astrocytoma
fewer
embryon
cn
tumor
would
expect
rate
remain
stabl
conclus
rel
slow
gradual
chang
incid
measur
major
type
pediatr
cn
cancer
like
due
combin
chang
classif
registri
clinic
level
true
cn
cancer
risk
time
yamaoka
j
k
k
univers
school
medicin
pediatr
tokyo
japan
univers
fujigaoka
hospit
pediatr
kanagawa
japan
univers
graduat
school
medicin
pediatr
osaka
japan
citi
gener
hospit
pediatr
hematologyoncolog
osaka
japan
univers
hospit
pediatr
kyoto
japan
children
hospit
hematologyoncolog
nagano
japan
women
children
hospit
hematologyoncolog
osaka
japan
univers
school
medicin
pediatr
tokyo
japan
data
center
hematopoiet
cell
transplant
committe
nationwid
survey
data
manag
nagoya
japan
center
child
health
develop
children
cancer
center
tokyo
japan
backgroundobject
central
nervou
system
germ
cell
tumour
highli
chemosensitv
multimod
manag
still
remain
controversi
search
higher
surviv
rate
minor
morbid
evid
relationship
system
gct
facilit
employ
dose
escal
strategi
treatment
recurr
paper
make
clear
effect
chemotherapi
hdc
recurr
japan
designmethod
retrospect
analysi
patient
nationwid
registri
data
japan
societi
haematopoiet
cell
transplant
result
patient
male
femal
recurr
treat
hdc
elig
analysi
median
age
hdc
year
rang
year
median
time
hdc
month
rang
month
surviv
rf
germinoma
germ
cell
tumour
nggct
overal
surviv
os
respect
rf
patient
achiev
complet
remiss
cr
hdc
achiev
cr
os
cr
respect
especi
nggct
rf
patient
cr
hdc
os
cr
respect
toxic
death
associ
hdc
multivari
analysi
pre
hdc
statu
cr
hazard
ratio
ci
favor
prognost
factor
conclus
larg
cohort
hdc
stem
cell
rescu
recurr
shown
toler
effect
surviv
even
nggct
cr
hdc
prospect
studi
need
confirm
optim
hdc
regimen
patient
c
b
e
b
r
n
yock
gener
hospit
radiat
oncolog
boston
usa
backgroundobject
hear
loss
hl
associ
cochlear
exposur
radiotherapi
rt
cisplatin
chemotherapi
designmethod
children
treat
mgh
medulloblastoma
posterior
fossa
pf
ependymoma
year
audiogram
compris
studi
popul
hl
grade
use
ototox
scale
investig
associ
cochlear
rt
cisplatin
dose
grade
hl
hghl
last
audiogram
cochleaeear
patient
analyz
independ
result
children
ependymoma
medulloblastoma
includ
repres
ear
respect
median
audiogram
year
ear
hghl
prior
rt
exclud
analysi
receiv
chemotherapi
cumul
ear
develop
hghl
higher
proport
among
children
treat
medulloblastoma
ear
versu
ependymoma
ear
medulloblastoma
higher
median
cochlear
dose
gy
versu
gy
p
higher
incid
cisplatin
exposur
ependymoma
versu
p
ear
hghl
like
medulloblastoma
ci
higher
rt
dose
gy
versu
gy
receiv
cisplatin
ci
multivari
model
includ
age
diagnosi
radiat
dose
cisplatin
exposur
variabl
significantli
increas
odd
hghl
stratifi
diagnosi
reveal
similar
except
rare
addit
cisplatin
increas
rate
hghl
among
ear
children
ependymoma
vs
conclus
hghl
occur
frequent
children
treat
medulloblastoma
compar
pf
ependymoma
versu
like
due
higher
rate
exposur
ototox
radiat
therapi
cisplatin
chemotherapi
cisplatin
use
may
increas
hghl
among
children
pf
ependymoma
h
zeng
w
children
hospit
radiolog
depart
shenzhen
china
backgroundobject
describ
case
intracrani
dural
malign
meningioma
initi
show
hemorrhag
spot
skin
decreas
platelet
count
designmethod
clinic
inform
radiolog
data
patholog
data
analyz
result
histori
boy
good
birth
condit
present
enlarg
head
circumfer
greater
neurolog
sign
growth
develop
line
age
infant
hospit
month
ago
site
hemorrhag
spot
limit
hunch
tempor
region
mild
enlarg
liver
biochem
test
character
decreas
platelet
count
platelet
admiss
l
examin
bone
marrow
cytolog
blood
smear
perform
admiss
unclassifi
cell
found
whole
sampl
cell
size
rel
uniform
diamet
irregular
edg
protrus
less
cytoplasm
moder
basophilia
larg
nuclear
chromatin
nucleolar
inconsist
figur
consid
unclear
cell
morpholog
similar
megakaryocyt
one
week
later
hospit
proport
abnorm
cell
immun
group
peripher
blood
leukemia
immunophenotyp
express
among
support
diagnosi
figur
figur
imag
find
mri
fig
multipl
mass
circular
cerebr
mass
cerebr
hernia
cerebellum
broad
basement
connect
dura
mater
figur
show
slightli
lower
signal
enhanc
scan
figur
markedli
enhanc
dural
tail
sign
seen
dwi
figur
suggest
mild
diffus
restrict
mass
effect
obviou
without
brain
edema
conclus
awar
malign
meningioma
young
children
l
l
l
p
j
b
k
zitterbart
memori
cancer
institut
region
centr
appli
molecular
oncolog
brno
czech
republ
hospit
brno
depart
pediatr
oncolog
brno
czech
republ
hospit
brno
depart
patholog
brno
czech
republ
univers
central
european
institut
technolog
brno
czech
republ
backgroundobject
medulloblastoma
mb
compris
distinct
molecular
diseas
consensu
base
epigenet
transcript
method
defin
four
main
subgroup
mb
wnt
shh
group
group
diverg
biolog
clinic
outcom
recent
quantit
proteom
develop
robust
approach
addit
genom
identifi
prognost
marker
drugabl
target
human
cancer
report
proteom
differ
group
group
mb
designmethod
mb
tissu
classifi
use
transcriptom
analysi
set
discriminatori
gene
group
group
mb
shotgun
proteom
method
employ
quantit
profil
fifti
microgram
peptid
per
sampl
label
tmt
label
accord
manufactur
protocol
tmt
label
reagent
set
thermo
fisher
scientif
analyz
use
orbitrap
elit
coupl
ultim
rslcnano
chromatograph
result
list
quantifi
protein
tumor
proteom
obtain
subject
bioinformat
statist
evalu
cluster
differenti
express
protein
reveal
upregul
adhes
protein
actin
cytoskeleton
protein
group
mb
target
interest
among
significantli
upregul
protein
group
mb
netrin
receptor
dcc
chlorid
intracellular
channel
protein
conclus
sum
demonstr
mass
proteom
approach
allow
distinguish
molecular
signatur
link
medulloblastoma
subgroup
studi
support
ministri
health
czech
republ
grant
azv
project
abib
f
f
oncolog
institut
graacc
feder
univers
paulo
pediatr
surgeri
paulo
brazil
univers
paulo
student
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
infecti
diseas
control
paulo
brazil
backgroundobject
infect
enhanc
morbid
mortal
cancer
cathet
withdraw
indic
protocol
antibiot
treatment
recommend
immunocompet
children
cvc
salvag
specif
recommend
given
immunocompromis
patient
benefit
cathet
remov
must
weigh
difficulti
obtain
altern
venou
access
children
object
assess
impact
cathet
mainten
children
cancer
designmethod
singl
institut
studi
implant
year
patient
pediatr
infecti
diseas
control
databas
exclus
criteria
cvc
associ
infect
complic
cvc
relat
infect
sepsi
fungal
infect
polymicrobi
infect
treatment
success
clinic
improv
fever
astenia
andor
neg
blood
cultur
treatment
infect
cure
treatment
failur
posit
blood
cultur
treatment
reincid
infect
agent
clinic
deterior
need
prolong
antibiot
therapi
day
death
result
patient
cvc
infect
implant
port
male
femal
age
cvc
infect
mo
ys
ys
solid
tumor
hematolog
neutropenia
remov
cathaet
mantain
cure
failur
clinic
differ
remov
mantain
group
agent
gram
posit
gram
neg
cure
failur
independ
agent
group
mantain
cathet
neutropenia
interfer
cure
rate
neither
oncolog
diagnosi
age
ys
tend
impact
univari
analysi
death
occur
need
antibiot
day
conclus
cathet
mainten
children
cancer
impact
mortal
studi
greater
sampl
lapid
possibl
risk
factor
cathet
mainten
abib
f
h
mt
oncolog
institut
graacc
feder
univers
paulo
pediatr
surgeri
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
pediatr
oncolog
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
radiolog
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
patholog
paulo
brazil
backgroundobject
surgeri
mileston
liver
tumor
treatment
pretext
guid
risk
group
also
tumor
resect
along
postext
classif
still
consensu
indic
extend
liver
resect
liver
transplant
olt
patient
cetral
liver
postext
iii
iv
vascular
extens
pro
con
although
literatur
show
similar
surviv
rate
aim
studi
describ
seri
compar
approach
designmethod
singl
center
experi
liver
tumor
includ
patient
result
hepatoblastoma
pretext
iii
pretext
iiiiv
hepatocarcinoma
hepat
sarcoma
hemangioendothelioma
mesenchym
hamartoma
inclus
criteria
postext
hepatoblastoma
iiiiv
submit
extend
resect
liver
transplant
patient
includ
one
patient
extens
patient
submit
olt
extend
liver
resect
median
surviv
rate
month
one
patient
die
one
relaps
surgic
procedur
extend
liver
resect
right
trisegmentectomi
left
trisegmentectomi
one
cbp
non
anatom
resect
one
olt
indic
rescu
transplant
left
trisegmentectomi
complic
post
olt
graft
reject
biliari
stenosi
graft
portal
thrombosi
retransplant
bleed
complic
occur
extend
resect
group
differ
surviv
rate
olt
extend
resect
group
conclus
extend
resect
feasibl
safe
provid
similar
surviv
rate
observ
liver
transplant
group
case
treat
refer
center
abib
f
jc
h
mt
oncolog
institut
graacc
feder
univers
paulo
pediatr
surgeri
paulo
brazil
univers
paulo
cardiovascular
surgeri
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
pediatr
oncolog
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
radiolog
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
patholog
paulo
brazil
backgroundobject
hepatoblastoma
common
malign
liver
tumor
childhood
therapeut
manag
import
evolut
advent
neoadjuv
chemotherapi
follow
surgic
resect
liver
transplant
howev
despit
advanc
tumor
vascular
cardiac
extens
still
consid
surgic
challeng
object
present
case
hepat
tumor
vascular
cardiac
extens
discuss
surgic
challeng
simultan
thorac
abdomin
approach
use
cardiopulmonari
bypass
cpb
designmethod
case
report
result
male
patient
abdomin
mass
vomit
imag
initi
biopsi
reveal
hepatoblastoma
tumor
extens
suprahepat
vein
atrium
enter
ventriculum
valv
confirm
echocardiogram
although
high
risk
embol
treatment
made
preoper
chemotherapi
follow
surgic
approach
cardiopulmonari
bypass
cpb
total
circulatori
arrest
profund
hypothermia
make
possibl
cardiac
tumor
resect
follow
partial
hepatectomi
circulatori
return
patient
unev
postop
period
receiv
chemotherapi
present
elev
afp
liver
relaps
conclus
hepatoblastoma
vascular
extens
complex
challeng
surgic
perspect
object
case
report
present
surgic
approach
cardiopulmonari
bypass
cardiac
arrest
profund
hypothermia
case
abib
f
h
mt
oncolog
institut
graacc
feder
univers
paulo
pediatr
surgeri
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
pediatr
oncolog
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
radiolog
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
patholog
paulo
brazil
backgroundobject
wilm
tumor
common
malign
renal
tumor
childhood
knowledg
clinic
characterist
accomplish
adequ
surgic
procedur
import
impact
prognosi
diseas
testicular
paratesticular
metastasi
due
tumor
report
occurr
extrem
rare
case
report
literatur
aim
studi
report
wilm
tumor
testicular
metastasi
designmethod
case
report
result
male
left
wilm
tumor
stage
iii
intermedi
risk
preoper
ruptur
siop
protocol
preoper
chemotherapi
submit
left
nephrectomi
left
partial
colectomi
primari
anastomosi
distal
pancreatectomi
bilater
inguin
herniorrhaphi
month
first
procedur
obstruct
acut
abdomen
reoper
sign
tumor
relaps
adhes
month
develop
testicular
volum
increas
first
treat
orchiti
without
success
day
right
inguin
explor
indic
orchiectomi
due
macroscop
appear
testi
perform
patholog
reveal
wilm
tumor
discuss
ipsilater
spread
caus
spermat
vein
retrograd
transcelom
pathway
kidney
testi
may
owe
patenc
vagin
conduit
howev
hematogen
pathway
may
consid
conclus
although
testicular
tumor
rare
children
solid
scrotal
mass
consid
malign
proven
otherwis
especi
malign
neoplasm
present
outsid
testicl
therefor
recommend
routin
examin
testicl
patient
wilm
tumor
treatment
period
abib
f
c
r
h
mt
oncolog
institut
graacc
feder
univers
paulo
pediatr
surgeri
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
pediatr
oncolog
paulo
brazil
univers
paulo
pediatr
gastroenterolog
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
radiolog
paulo
brazil
oncolog
institut
graacc
feder
univers
paulo
patholog
paulo
brazil
backgroundobject
germ
cell
tumor
gct
occur
variou
site
less
case
primari
liver
gct
literatur
aim
paper
relat
rare
case
entiti
designmethod
case
report
result
ys
femal
present
nausea
weight
loss
kg
jaundic
scleros
cholang
ulcer
rectocol
sinc
ys
old
intern
extern
biliari
drainag
drain
obstruct
jaundic
liver
abscess
treat
antibiot
persist
liver
abscess
imag
despit
antibiot
investig
tumor
neg
colonoscopi
cea
e
afp
ca
imag
guid
biopsi
solid
pattern
carcinoma
liver
necrot
area
suggest
either
liver
adenocarcinoma
cholangiocarcinoma
tumor
consid
unresect
due
previou
histori
resect
evalu
intraop
surgic
find
right
lobe
tumor
blockag
hilum
due
presenc
biliari
drain
risk
hilum
element
injuri
intraop
cholangiographi
perfom
decid
non
anatom
resect
right
hepatectomi
unev
postoperatori
period
extub
day
po
drug
discharg
hospit
po
cholangiographi
po
kehr
drain
withdrawn
afp
level
present
fever
due
bile
leakag
treat
imag
guid
drainag
patholog
reveal
mix
malign
germ
cell
tumor
yolk
sac
embrionari
carcinoma
tumor
site
diagnosi
gct
origin
liver
receiv
chemotherapi
tcg
brazilian
protocol
intermedi
risk
stage
ii
etoposid
e
cisplatin
cycl
x
x
imag
reevalu
cycl
unfortun
die
due
sepsi
conclus
primari
liver
gct
extrem
rare
consid
differenti
diagnosi
liver
biliari
carcinoma
agarwala
v
k
v
india
institut
medic
scienc
pediatr
surgeri
new
delhi
india
india
institut
medic
scienc
medic
brairch
new
delhi
india
india
institut
medic
scienc
brairch
new
delhi
india
india
institut
medic
scienc
brairch
new
delhi
india
india
institut
medic
scienc
radiodiagnosi
new
delhi
india
backgroundobject
evalu
surgic
treatment
outcom
children
ewe
sarcoma
ew
pnet
rib
correl
outcom
presenc
metastat
diseas
treatment
strategi
designmethod
ewpnet
rib
regist
novemb
june
includ
receiv
neoadjuv
chemotherapi
nact
vincristin
doxorubicincisplatinifosphamideetoposid
either
radic
radiotherapi
alon
rrt
surgic
resect
sx
surgeryrt
sxrt
kaplan
meier
surviv
estim
overal
surviv
os
event
free
surviv
ef
event
progressionrecurrencedeath
done
use
statist
program
stata
result
twenti
two
children
rib
involv
age
group
month
mean
enrol
month
age
tumor
size
greater
cm
pleural
effus
metastat
diseas
lung
bone
marrow
receiv
neoadjuv
chemotherapi
nact
ninteen
receiv
local
treatment
form
surgic
resect
sxrt
rrt
one
die
one
discontinu
treatment
nact
patient
undergo
surgeri
achiev
clear
margin
resect
singl
rib
achiev
cr
though
recur
rrt
alon
achiev
cr
pleural
effus
metastat
sxrt
rrt
local
treatment
achiev
cr
recur
overal
achiev
cr
metastat
recur
overal
death
give
os
event
death
progress
recurr
give
ef
conclus
ewpnet
rib
present
larg
tumor
metastat
resect
involv
rib
alon
adequ
give
cr
recurr
rate
os
ef
anand
v
r
v
india
institut
medic
scienc
pediatr
surgeri
new
delhi
india
india
institut
medic
scienc
medic
brairch
new
delhi
india
india
institut
medic
scienc
pediatr
new
delhi
india
india
institut
medic
scienc
radiodiagnosi
new
delhi
india
backgroundobject
evalu
outcom
surgic
manag
children
neuroblastoma
nb
syndrom
oma
designmethod
retrospect
analysi
children
manag
institut
januari
januari
perform
result
eighteen
patient
mean
age
rang
month
equal
gender
preponder
includ
one
patient
metastat
diseas
right
orbit
sphenoid
bone
thirteen
abdomin
tumor
adren
pelvic
five
thorac
locat
mibg
scan
show
uptak
primari
tumor
perform
eleven
receiv
chemotherapi
neoadjuv
nact
adjuv
act
act
receiv
adjuv
radiat
sixteen
underw
surgic
resect
upfront
surgeri
without
nact
medic
intervent
includ
adrenocorticotroph
hormon
immunoglobulin
puls
methylprednisolon
use
addit
death
aliv
diseas
free
complet
remiss
oma
symptom
achiev
two
resect
also
achiev
complet
remiss
tumor
symptom
nact
alon
histolog
resect
specimen
ganglioneuroblastoma
neuroblastoma
ganglioneuroma
identifi
tumor
two
children
residu
neurolog
sequela
slur
speech
gait
instabl
resolv
subsequ
visit
conclus
children
neuroblastoma
syndrom
diseas
case
surgeri
without
chemotherapi
mainstay
treatment
adjuv
treatment
form
adrenocorticotroph
hormon
puls
methylprednisolon
immunoglobulin
aid
resolut
neurolog
symptom
case
achiev
complet
resolut
neurolog
symptom
diseas
free
long
term
surviv
long
term
residu
neurolog
sequela
observ
p
b
f
arthur
child
health
univers
uk
depart
paediatr
surgeri
liverpool
unit
kingdom
hey
children
hospit
nh
foundat
trust
depart
paediatr
surgeri
liverpool
unit
kingdom
hey
children
nh
foundat
trust
depart
oncolog
liverpool
unit
kingdom
backgroundobject
ovarian
neoplasm
children
rare
heterogen
lesion
variabl
biolog
behaviour
outcom
von
allmen
sem
pediatr
surg
designmethod
femal
patient
requir
oper
ovarian
tumour
identifi
singl
center
period
clinic
outcom
report
result
eighti
eight
patient
ovarian
tumour
includ
synchron
metachron
neoplasm
mean
age
diagnosi
year
tumour
equal
distribut
left
right
ovari
bilater
diseas
occur
eighti
six
neoplasm
benign
malign
requir
chemotherapi
radiat
signific
differ
maximum
tumour
diamet
benign
vs
malign
lesion
tumour
marker
studi
bhcg
afp
normal
benign
neoplasm
fifteen
lesion
metastat
present
includ
case
dissemin
periton
gliomatosi
two
case
matur
cystic
teratoma
periton
deposit
surgic
manag
includ
ovari
excis
ovari
spare
tumourectomi
extirp
case
lymphadenectomi
perform
patient
togeth
periton
fluid
cytolog
case
abdomin
ascit
omentectomi
requir
patient
multipl
periton
biopsi
case
biopsi
suspici
organ
bowel
mesenteri
contralater
ovari
patient
recurr
metachron
lesion
occur
case
teratoma
adenocarcinoma
overal
surviv
death
mucin
cystadenocarcinoma
desmoplast
small
round
cell
tumour
ovarian
origin
small
cell
carcinoma
ovari
hypercalcaemia
conclus
data
confirm
excel
surviv
pediatr
ovarian
neoplasm
rare
malign
neoplasm
dismal
prognosi
modern
era
effort
made
preserv
fertil
oper
bakhshi
b
dn
india
institut
medic
scienc
medic
oncolog
new
delhi
india
kolkata
medic
oncolog
kolkata
india
india
institut
medic
scienc
otorhinolaryngolog
new
delhi
india
india
institut
medic
scienc
radiat
oncolog
new
delhi
india
backgroundobject
treatment
head
neck
ewe
sarcoma
famili
tumor
esft
challeng
may
caus
disfigur
morbid
lack
random
data
compar
radiotherapi
versu
surgeri
analyz
local
treatment
modal
impact
overal
surviv
os
event
free
surviv
ef
local
control
rate
lcr
prognost
factor
esft
head
neck
region
treat
uniform
chemotherapi
protocol
designmethod
patient
esft
head
neck
treat
june
novemb
analyz
retrospect
univari
surviv
analysi
perform
graph
compar
multivari
surviv
analysi
conduct
cox
proport
hazard
model
result
patient
includ
analysi
median
age
year
patient
non
metastat
fifti
patient
receiv
local
therapi
receiv
wherea
patient
receiv
radic
radiotherapi
five
year
os
ef
lcr
whole
cohort
respect
five
year
os
ef
lcr
cohort
respect
cohort
patient
comparison
vs
radic
radiotherapi
done
five
year
ef
vs
os
vs
lcr
vs
p
multivari
analysi
non
metastat
group
symptom
durat
two
month
better
year
ef
vs
wbc
l
predict
poor
ef
vs
os
wbc
l
predict
poor
os
vs
conclus
largest
data
head
neck
esft
suggest
surgeri
may
mandatori
site
baselin
wbc
independ
predictor
poor
outcom
perhap
patient
symptom
durat
month
rel
less
aggress
biolog
bhagat
g
l
n
memori
hospit
pediatr
surgic
oncolog
mumbai
india
memori
hospit
radiolog
mumbai
india
memori
hospit
pediatr
oncolog
mumbai
india
memori
hospit
radiat
oncolog
mumbai
india
memori
hospit
patholog
mumbai
india
backgroundobject
lymph
node
ln
sampl
indispens
compon
stage
wilm
tumor
howev
definit
guidelin
sampl
retroperiton
ln
usual
hilar
random
enlarg
ln
sought
also
uncommon
overlook
entir
perform
prospect
studi
systemat
sampl
retroperiton
ln
per
predefin
station
compar
result
retrospect
data
random
ln
sampl
designmethod
children
group
wilm
tumor
enrol
studi
may
januari
lymph
node
sampl
perform
five
station
ipsilater
hilar
suprahilar
infrahilar
region
suprahilar
infrahilar
interaortocav
region
tumor
presenc
ln
metastas
interaortocav
region
neg
ipsilater
ln
consid
skip
metastas
lymph
node
yield
incid
posit
ln
skip
metastas
diseas
relaps
analys
compar
data
consecut
patient
randomli
sampl
ln
oper
centr
januari
novemb
group
b
result
median
number
ln
sampl
rang
group
versu
eight
rang
group
b
overal
incid
ln
metastas
entir
cohort
incid
group
compar
group
b
p
skip
metastas
present
group
presenc
posit
ln
signific
risk
diseas
relaps
entir
cohort
conclus
yield
incid
posit
node
better
systemat
sampl
though
differ
compar
random
sampl
howev
high
incid
skip
metastas
justfi
disciplin
ln
sampl
presenc
ln
metastas
increas
incid
relaps
p
boam
child
health
univers
liverpool
depart
paediatr
surgeri
liverpool
unit
kingdom
backgroundobject
patient
wilm
tumour
inferior
vena
cava
ivc
diseas
typic
manag
neoadjuv
chemotherapi
hope
tumour
thrombu
regress
make
oper
safer
excis
tumour
thrombu
challeng
case
involv
cavotomi
cavectomi
cardiopulmonari
bye
pass
reconstruct
vascular
surgeri
studi
critic
examin
evid
support
refut
whether
major
surgeri
requir
patient
designmethod
english
languag
publish
literatur
search
studi
detail
surgic
manag
patient
wilm
tumour
ivc
diseas
extens
report
cite
full
histopatholog
data
treat
patient
analyz
result
ten
elig
studi
identifi
report
data
patient
ivc
diseas
extens
children
receiv
adjuv
radiotherapi
patient
found
viabl
thrombu
oper
exclud
case
also
receiv
radiotherapi
children
radiotherapi
viabl
tumour
thrombu
conclus
base
current
avail
inform
tumour
thrombectomi
like
necessari
achiev
complet
oncolog
clearanc
patient
advanc
stage
wilm
tumour
radiotherapi
play
vital
role
pre
care
plan
show
tumour
shrinkag
obliter
achiev
obviat
heroic
surgeri
subset
patient
surgeon
led
trial
would
use
address
debat
braungart
pd
p
rj
manchest
children
hospit
depart
paediatr
surgeri
manchest
unit
kingdom
manchest
children
hospit
depart
paediatr
oncolog
manchest
unit
kingdom
manchest
children
hospit
depart
neonatolog
manchest
unit
kingdom
liverpool
divis
child
health
liverpool
unit
kingdom
backgroundobject
paediatr
cardiac
tumour
rare
report
autopsi
rate
uzun
et
al
orphanet
journal
rare
diseas
predominantli
lesion
characteris
benign
histolog
howev
due
mass
effect
often
present
problem
cardiac
outflow
tract
obstruct
heart
failur
arrhythmia
rhabdomyoma
common
histolog
subtyp
tumour
lesion
includ
fibroma
teratoma
haemangioma
myxoma
though
far
less
common
designmethod
report
success
outcom
newborn
larg
cardiac
teratoma
describ
uniqu
present
diagnost
studi
definit
manag
result
babi
girl
deliv
prematur
caesarean
section
due
reduc
fetal
movement
week
gestat
antenat
ultrasound
note
polyhydramnio
fetal
hydrop
pericardi
tumour
associ
pericardi
effus
fig
birth
apgar
poor
min
patient
resuscit
transfer
emerg
region
paediatr
cardiac
surgic
center
imag
birth
deliveri
show
larg
cardiac
tumour
fig
afp
bhcg
normal
complet
resect
tumour
cardiopulmonari
bypass
success
infant
made
excel
recoveri
patholog
show
immatur
pericardi
teratoma
lesion
yolk
sac
element
microfoci
infant
remain
healthi
conclus
cardiac
teratoma
paediatr
age
group
extrem
rare
echocardiographi
comput
tomographi
ct
magnet
reson
imag
mri
heart
main
diagnost
tool
import
preoper
prognosi
favour
follow
complet
surgic
resect
treatment
gener
requir
gross
total
resect
challeng
due
anatom
lesion
locat
case
tumour
recurr
malign
differenti
describ
world
literatur
aftercar
surveil
imag
notabl
echocardiographi
monitor
tumour
marker
mandatori
braungart
rj
p
pd
manchest
children
hospit
depart
paediatr
surgeri
manchest
unit
kingdom
manchest
children
hospit
depart
paediatr
oncolog
manchest
unit
kingdom
liverpool
divis
child
health
liverpool
unit
kingdom
backgroundobject
famili
neuroblastoma
nbl
rare
nbl
contrast
sporad
case
occur
younger
age
often
multifoc
primari
tumour
inherit
pattern
incomplet
autosom
domin
two
frequent
mutat
includ
alk
mutat
lesser
germlin
mutat
designmethod
present
two
sibl
famili
neuroblastoma
discuss
clinic
manag
result
male
present
classic
symptom
nbl
fatigu
bone
pain
weight
loss
biopsi
confirm
poorli
differenti
nbl
mycn
gain
segment
chromosom
abnorm
stage
show
metastat
tumour
thorax
liver
bone
bone
marrow
diseas
commenc
treatment
stage
iv
nbl
complet
respons
metastat
diseas
follow
rapid
cojec
induct
thorac
mass
remain
unchang
requir
gross
total
resect
unilater
ocular
miosi
incident
detect
surgeon
asymptomat
sister
visit
brother
hospit
imag
femal
sibl
show
multifoc
nbl
tumour
left
lung
apex
thorac
paraspin
abdomin
lesion
biopsi
confirm
neuroblastoma
mycn
gain
segment
chromosom
abnorm
asymptomat
femal
commenc
treatment
nbl
patient
refer
clinic
genet
await
whole
genom
sequenc
conclus
case
famili
neuroblastoma
provid
great
opportun
advanc
genet
understand
nbl
screen
asymptomat
children
histori
famili
nbl
propos
effort
detect
two
common
mutat
alk
posit
surveil
sonographi
urinari
catecholamin
age
year
recommend
boss
et
al
cancer
robust
clinic
data
exist
support
practic
famili
nbl
link
genet
polymorph
subtl
anomali
notabl
ocular
miosi
sibl
children
nbl
therefor
requir
care
investig
whole
genom
sequenc
may
aid
insight
famili
overal
herit
nb
braungart
rj
p
pd
manchest
children
hospit
depart
paediatr
surgeri
manchest
unit
kingdom
liverpool
divis
child
health
liverpool
unit
kingdom
backgroundobject
horner
syndrom
hs
ocular
miosi
ptosi
anhidrosi
may
subtl
sign
occult
patholog
otherwis
asymptomat
children
neuroblastoma
nbl
commonest
associ
malign
tumour
despit
knowledg
robust
evid
guid
best
clinic
practic
spars
incid
occult
malign
children
horner
syndrom
remain
larg
unclear
perform
systemat
review
aim
identifi
incid
neuroblastoma
children
hs
unknown
aetiolog
establish
screen
neuroblastoma
routin
perform
patient
popul
designmethod
systemat
review
literatur
pubm
ovidmedlin
databas
result
initi
search
identifi
manuscript
record
screen
duplic
remov
exclus
criteria
paper
address
research
question
english
languag
case
report
reviewcom
six
paper
includ
final
analysi
report
retrospect
studi
without
control
group
studi
includ
patient
unilater
miosi
associ
sign
posit
cocain
test
without
previous
known
diagnosi
studi
includ
total
patient
age
rang
mean
age
overal
incid
lesion
detect
neuroblastoma
diagnos
seven
patient
diagnos
rhabdomyosarcoma
ewe
sarcoma
ganglioneuroma
astrocytoma
juvenil
xanthogranuloma
intraorbit
hemolymphangioma
brain
stem
vascular
malform
conclus
well
recogn
hs
may
first
sign
occult
malign
neuroblastoma
common
one
report
first
systemat
review
studi
comprehens
investig
incid
occult
malign
uniqu
patient
cohort
studi
crucial
show
suspicion
hs
unknown
aetiolog
children
involv
investig
exclud
underli
space
occupi
lesion
strongli
recommend
ctmri
imag
brain
neck
thorax
plu
urinari
catecholamin
prompt
diagnosi
treatment
braungart
pd
p
j
k
de
colvin
k
bf
okoy
h
p
c
k
tm
roger
g
rj
manchest
children
hospit
depart
paediatr
surgeri
manchest
unit
kingdom
liverpool
divis
child
health
liverpool
unit
kingdom
hospit
children
depart
paediatr
surgeri
glasgow
unit
kingdom
ormond
street
hospit
depart
paediatr
surgeri
london
unit
kingdom
belfast
hospit
sick
children
depart
paediatr
surgeri
belfast
unit
kingdom
georg
hospit
depart
paediatr
surgeri
london
unit
kingdom
royal
victoria
infirmari
depart
paediatr
surgeri
newcastl
unit
kingdom
hospit
sick
children
depart
paediatr
surgeri
edinburgh
unit
kingdom
hospit
depart
paediatr
surgeri
cambridg
unit
kingdom
children
hospit
depart
paediatr
surgeri
bristol
unit
kingdom
gener
infirmari
depart
paediatr
surgeri
leed
unit
kingdom
royal
infirmari
depart
paediatr
surgeri
aberdeen
unit
kingdom
backgroundobject
ovarian
tumor
pediatr
age
group
rare
signific
number
children
ovarian
mass
lesion
present
hour
surgic
emerg
surgic
manag
may
involv
specialti
servic
notabl
surgic
oncologist
gener
surgeon
studi
herein
report
mode
clinic
present
may
influenc
oper
classic
open
vs
minim
invas
surgeri
mi
ii
examin
young
femal
present
surgic
emerg
like
undergo
radic
oophorectomi
vs
surgeri
designmethod
nationwid
multicent
voluntari
data
studi
registri
amongst
pediatr
oncolog
center
femal
year
index
diagnosi
ovarian
tumor
exclud
functionalneonat
ovarian
cyst
recruit
data
analyz
result
patient
ovarian
patholog
identifi
mean
age
surgeri
year
iqr
case
underw
classic
open
surgeri
minim
invas
oper
surgeri
initi
mi
convert
open
oper
mi
oper
perform
emerg
procedur
vs
classic
open
procedur
fisher
exact
test
tumor
size
mi
oper
smaller
median
tumor
size
iqr
vs
iqr
classic
open
group
p
surgeri
significantli
common
mi
vs
classic
open
group
p
fisher
exact
test
femal
patient
underw
emerg
resect
less
like
surgeri
conclus
major
femal
patient
report
voluntari
nation
studi
registri
underw
open
classic
surgeri
resect
ovarian
tumor
total
oophorectomi
case
mi
like
receiv
surgeri
small
tumor
size
mi
group
cohort
may
facilit
outcom
braungart
rj
p
j
k
de
colvin
k
bf
okoy
h
p
c
k
tm
roger
g
pd
manchest
children
hospit
depart
paediatr
surgeri
manchest
unit
kingdom
hospit
children
depart
paediatr
surgeri
glasgow
unit
kingdom
ormond
street
hospit
depart
paediatr
surgeri
london
unit
kingdom
belfast
hospit
sick
children
depart
paediatr
surgeri
belfast
unit
kingdom
georg
hospit
depart
paediatr
surgeri
london
unit
kingdom
royal
victoria
infirmari
depart
paediatr
surgeri
newcastl
unit
kingdom
hospit
sick
children
depart
paediatr
surgeri
edinburgh
unit
kingdom
hospit
depart
paediatr
surgeri
cambridg
unit
kingdom
children
hospit
depart
paediatr
surgeri
bristol
unit
kingdom
gener
infirmari
depart
paediatr
surgeri
leed
unit
kingdom
royal
infirmari
depart
paediatr
surgeri
aberdeen
unit
kingdom
liverpool
divis
child
health
liverpool
unit
kingdom
backgroundobject
ovarian
tumor
children
rare
incid
depend
tumor
biolog
patient
age
robust
protocol
guidelin
aid
patient
tumor
excis
distinctli
lack
publish
work
show
metachron
tumor
recurr
occur
patient
nevertheless
surgeon
recommend
patient
requir
tumor
excis
outlook
mani
children
consid
excel
therefor
perform
nationwid
multicent
studi
investig
incid
recurr
ii
metachron
diseas
pediatr
patient
follow
ovarian
tumor
resect
designmethod
nationwid
multicent
voluntari
data
studi
registri
amongst
pediatr
oncolog
center
femal
patient
index
diagnosi
ovarian
tumor
identifi
functionalneonat
ovarian
cyst
exclud
tumor
recurr
defin
tumor
occur
ovari
follow
primari
resect
metachron
diseas
new
tumor
occur
contralater
ovari
primari
oper
result
patient
ovarian
tumor
surgic
oncolog
center
identifi
mean
age
surgeri
patient
present
surgic
emerg
elect
present
unclear
histori
children
found
bilater
tumor
first
primari
oper
common
diagnosi
matur
teratoma
immatur
teratoma
serousmucin
cystadenoma
dysgerminoma
femal
identifi
tumor
recurr
metachron
diseas
major
patient
recurr
metachron
diseas
diagnos
routin
clinic
incident
lesion
imag
follow
road
traffic
accid
due
new
symptom
unclear
mean
time
detect
recurr
andor
metachron
diseas
month
conclus
nationwid
studi
clearli
show
ovarian
tumor
recurr
metachron
diseas
occur
major
patient
recurr
andor
metachron
diseas
detect
routin
clinic
strongli
advoc
femal
pediatr
patient
robust
care
plan
diagnosi
resect
ovarian
tumor
r
chave
ribeiro
sdc
v
lf
pediatr
cancer
hospit
pediatr
surgeri
barreto
brazil
oncolog
institut
feder
univers
paulo
graacc
pediatr
surgeri
paulo
brazil
varga
pediatr
hospit
pediatr
surgeri
paulo
brazil
pediatr
cancer
hospit
pediatr
oncolog
barreto
brazil
backgroundobject
germ
cell
tumour
childhood
rare
diseas
thu
testicular
germ
cell
tumor
rariti
pediatr
popul
adequ
inform
clinic
cours
difficult
aim
studi
present
clinic
histolog
featur
testicular
tumor
multicentr
protocol
designmethod
retrospect
analysi
testicular
tumor
enrol
one
nation
multicentr
protocol
clinic
charact
histopatholog
find
manag
outcom
patient
analyz
result
avail
analysi
patient
hospit
mean
patient
age
diagnosi
month
stage
ii
iii
iv
histolog
yolk
sac
tumor
pure
teratoma
mix
tumour
seminoma
immatur
teratoma
embrionari
carcinoma
mix
teratoma
risk
classif
patient
low
risk
lr
intermedi
risk
ir
high
risk
hr
primari
orchiectomi
done
low
risk
lr
patient
receiv
chemotherapi
patient
ir
receiv
platiran
etoposid
pe
hr
patient
addit
ifosfamid
primari
orchiectomi
done
relaps
occur
stage
ii
iii
iv
respect
surviv
rate
stage
stage
ii
stage
iii
stage
iv
conclus
testicular
tumor
children
rare
data
yolk
sac
tumor
common
tumor
multicentr
experi
import
understand
clinic
result
rare
tumor
multidisciplinari
approach
surgic
radiolog
patholog
oncolog
input
cornerston
manag
order
achiev
excel
outcom
r
chave
ribeiro
v
oliveira
fmp
ceb
pediatr
cancer
hospit
pediatr
surgeri
barreto
brazil
pediatr
cancer
hospit
pediatr
radiolog
barreto
brazil
backgroundobject
minim
invas
surgeri
mi
commonli
use
perform
nephrectomi
nononcolog
reason
mi
approach
renal
tumor
children
becom
new
frontier
studi
howev
literatur
defin
criteria
laparoscopi
nephrectomi
pediatr
renal
tumor
aim
studi
verifi
distanc
tumor
great
vessel
aorta
cava
vein
volum
tumor
good
criteria
nephrectomi
laparoscop
designmethod
retrospect
analysi
renal
tumor
done
year
patient
divid
two
group
open
surgeri
os
laparoscopi
surgeri
ls
two
group
compar
demograph
characterist
two
specif
criteria
distanc
tumor
kidney
great
vessel
aorta
right
side
tumor
vena
cava
left
side
tumor
hilum
tumor
volum
patient
follow
siop
protocol
result
patient
male
femal
mean
age
month
right
side
tumor
side
none
bilater
three
patient
receiv
preoper
chemotherapi
age
lesser
month
ruptur
preoper
averag
tumor
volum
chemotherapi
volum
decreas
ls
group
patient
os
group
mean
age
month
os
ls
tumor
volum
os
group
ls
great
vessel
distanc
cm
os
group
cm
ls
conclus
laparoscop
nephrectomi
feasibl
pediatr
renal
tumor
tumor
volum
could
criteria
laparoscop
surgeri
howev
anoth
criteria
necessari
studi
need
confirm
whether
tumor
distanc
larg
vessel
criterion
laparoscopi
r
chave
ribeiro
v
oliveira
ka
ff
pediatr
cancer
hospit
pediatr
surgeri
barreto
brazil
pediatr
cancer
hospit
depart
nurs
barreto
brazil
backgroundobject
venou
access
essenti
children
treat
malign
diseas
tunnel
central
line
simpl
tool
allow
simultan
achiev
ideal
punctur
site
cathet
exit
reduc
risk
mani
complic
use
central
insert
central
cathet
cicc
techniqu
particularli
use
children
studi
focus
pediatr
oncolog
patient
aim
studi
evalu
initi
experi
cicc
regard
feasibl
cathet
life
complic
reason
remov
children
cancer
designmethod
retrospect
analysi
pediatr
oncolog
patient
underw
tunnel
cicc
line
insert
pediatr
surgeri
team
institut
may
decemb
demograph
featur
primari
diagnosi
cathet
day
reason
remov
complic
review
result
cicc
insert
children
period
median
cathet
life
day
rang
day
total
cathet
day
complic
rate
per
cathet
day
record
line
remov
elect
due
death
remain
reason
cathet
remov
infect
patient
occlus
dislodg
rate
per
cathet
day
respect
compar
solid
tumor
cathet
hematolog
malign
higher
perman
hematolog
solid
tumor
lymphoma
show
highest
median
conclus
tunnel
cicc
line
feasibl
provid
reliabl
access
children
suffer
malign
particularli
hematolog
malign
induct
chemotherapi
infect
rate
higher
although
develop
countri
set
better
care
proper
dress
import
minim
prematur
remov
suspect
infect
educ
parent
nurs
team
guidelin
need
improv
complic
rate
chen
z
children
hospit
affili
capit
medic
univers
neonat
surgeri
beij
china
children
hospit
surgeri
beij
children
hospit
surgeri
beij
china
backgroundobject
studi
clinic
featur
treatment
effect
neuroblastoma
nb
neonat
small
infant
designmethod
clinic
date
neonat
small
infant
age
month
nb
retrospect
analyz
juli
decemb
neonat
surgeri
depart
beij
children
hospit
result
among
case
tumor
detect
prenat
case
postnat
case
tumor
locatedin
adren
gland
case
retroperitoneum
case
posterior
mediastinum
case
pelvic
caviti
case
nse
test
case
measur
valu
nse
higher
normal
rang
case
higher
case
nb
classifi
accord
inss
case
underw
tumorectomi
complet
remov
sita
tumor
resect
one
side
tumorectomi
bilater
tumor
case
underw
tumor
biopsi
case
follow
case
lost
averag
period
month
case
surviv
case
die
caus
death
parent
case
iv
stage
abandon
oper
one
case
iii
stage
underw
tumor
biopsi
one
case
iv
stage
occur
poli
metastasi
postop
surviv
rate
surviv
rate
higher
case
whose
tumor
detect
prenat
nec
postnat
nse
respect
case
case
stage
surviv
conclus
neonat
small
infant
nb
tumor
detect
prenat
ultrasonographi
patient
better
prognosi
diagnos
postnat
tumorectomi
sita
tumor
resect
patient
stage
essenti
treatment
nse
valu
oper
import
prognosi
evalu
ch
chui
ghn
centr
children
pte
ltd
surgic
oncolog
singapor
singapor
backgroundobject
neuroblastoma
involv
thorax
abdomen
concurr
uniqu
surgic
challeng
involv
major
bodi
compart
tumor
usual
extens
review
experi
focus
diseas
pattern
surgic
approach
designmethod
among
patient
neuroblastoma
databas
neuroblastoma
involv
thorax
abdomen
concurr
patient
clinic
chart
review
analys
diseas
pattern
identifi
group
solitari
thoracoabdomin
tumor
group
b
multifoc
tumor
thorax
abdomen
oper
approach
categor
base
rout
surgic
access
mean
year
year
result
patient
averag
age
year
rang
year
male
femal
ratio
studi
receiv
chemotherapi
among
group
patient
stage
ir
stage
hr
surgic
approach
includ
thoracoabdomin
approach
approach
thorac
approach
averag
durat
oper
hour
rang
hour
patient
residu
diseas
rest
achiev
gross
total
resect
postop
complic
includ
chylou
ascit
intestin
obstruct
pneumonia
spinal
cord
infarct
among
group
b
patient
stage
ir
hr
thorac
compon
includ
satellit
paravertebr
tumor
subcarin
tumor
superior
mediastin
tumor
peribronchi
lymphadenopathi
pariet
pleural
tumor
pulmonari
nodul
surgic
approach
includ
thorac
approach
averag
durat
oper
hour
rang
hour
gross
total
resect
achiev
surgeri
postop
complic
includ
chylou
ascit
horner
syndrom
overal
ir
patient
surviv
hr
patient
relaps
die
diseas
periop
mortal
conclus
surgic
resect
thoracoabdomin
neuroblastoma
feasibl
safe
despit
complex
thoracoabdomin
neuroblastoma
compar
treatment
outcom
compar
diseas
crocoli
l
dell
e
v
md
de
c
children
hospit
ircc
surgeri
rome
itali
pausilipon
children
hospit
anesthesiolog
intens
care
unit
napl
itali
children
hospit
ircc
anesthesiolog
rome
itali
children
hospit
ircc
oncohematolog
rome
itali
backgroundobject
disloc
tunnel
central
venou
cathet
cvc
still
major
complic
among
pediatr
patient
especi
affect
cancer
recent
subcutan
anchor
suturless
devic
sasd
introduc
secur
cvc
role
prevent
disloc
still
debat
data
report
among
pediatr
patient
report
far
designmethod
review
use
sasd
tunnel
cvc
pediatr
patient
insert
period
year
two
tertiari
care
center
cvc
insert
accord
institut
insert
bundl
manag
accord
institut
polici
complic
placement
remov
painexit
site
inflamm
rate
disloc
evalu
result
eleven
cvc
peripher
insert
central
catheterspicc
central
insert
central
catheterscicc
femor
insert
central
cathetersficc
insert
hematolog
malign
hematolog
disord
solid
tumor
secur
sasd
patient
age
rang
month
year
median
age
year
median
durat
cvc
month
rang
month
year
complic
occur
sasd
placement
four
patient
experienc
prolong
pain
sasd
placement
patient
experienc
accident
cvc
remov
skin
eros
exit
site
week
one
patient
kink
cvc
determin
wrong
sasd
placement
sasd
remov
perform
split
two
halv
scissor
requir
sedat
local
anesthesia
easi
unev
case
conclus
sasd
effect
prevent
disloc
pediatr
patient
affect
cancer
neglig
complic
insert
mainten
remov
consid
sasd
save
approxim
per
week
cost
tradit
sutureless
devic
avoid
cvc
primari
dislodg
patient
popul
also
consid
p
dalligna
f
de
l
mc
c
p
r
women
children
padua
pediatr
surgeri
padua
itali
diagnostica
per
immagini
e
radiologia
univers
padua
radiolog
padua
itali
patholog
padua
itali
women
children
padua
pediatr
oncolog
padua
itali
hospit
upmc
patholog
pittsburgh
usa
backgroundobject
benign
tumor
liver
rare
diagnostictherapeut
approach
univoc
children
repres
one
third
primari
liver
mass
retrospect
studi
analyz
experi
epidemiolog
diagnosi
therapi
outcom
children
affect
tumor
observ
institut
data
also
confront
singl
institut
seri
designmethod
medic
record
children
infantil
hepat
hemangioma
ihh
mesenhym
hamartoma
mh
hepat
adenoma
ha
focal
nodular
hyperplasia
fnh
nodular
regen
hyperplasia
nrh
lesion
observ
pediatr
surgeri
unit
univers
padua
analyz
result
patient
f
age
year
median
identifi
affect
ihh
fnh
mh
ha
nrh
case
lesion
incident
discov
diagnosi
obtain
imag
case
biopsi
complet
resect
tumor
wait
see
approach
adopt
patient
surgeri
necessari
embol
patient
treat
propranolol
biliari
fistula
surgic
complic
resect
fnh
patient
aliv
diseas
patient
ihh
die
due
phenomenon
malign
transform
conclus
seri
confirm
rariti
tumor
whose
incid
howev
may
underestim
improv
radiolog
techniqu
recent
year
made
possibl
limit
number
unnecessari
biopsi
surgic
resect
consid
number
case
diagnostictherapeut
approach
seri
compar
other
literatur
howev
data
satisfactori
nationalintern
databas
requir
improv
knowledg
guarante
appropri
approach
still
controversi
lesion
k
dong
h
x
l
hospit
fudan
univers
surgeri
shanghai
china
backgroundobject
retrospect
analysi
case
nephroblastoma
combin
vein
tumor
thrombosi
diagnos
treat
depart
last
year
designmethod
pediatr
patient
nephroblastoma
combin
vein
tumor
thrombosi
diagnos
treat
hospit
januari
decemb
includ
retrospect
analysi
cohort
includ
boy
girl
averag
age
year
five
four
case
clinic
phase
respect
three
case
clinic
phase
show
pulmonari
metastasi
show
liver
pulmonari
metastas
accord
nesbitt
type
venou
thrombosi
renal
malign
method
case
classifi
five
case
type
two
case
type
ii
two
case
type
iii
three
case
type
iv
patient
receiv
standard
treatment
regimen
recommend
nation
wilm
tumor
studi
tumor
resect
vein
tumor
thrombu
remov
oper
carri
without
cardiopulmonari
bypass
accord
differ
type
thrombosi
result
children
recov
well
surgeri
patholog
confirm
twelv
patient
favor
histolog
case
preoper
chemotherapi
tumor
cell
seen
thrombu
fibrou
tissu
foam
cell
oper
type
thrombi
adher
vein
wall
type
adher
wall
infiltr
inferior
vena
cava
differ
degre
patient
follow
year
tumor
recurr
found
five
case
residu
tumor
thrombosi
ivc
signific
chang
found
conclus
nephroblastoma
venou
thrombu
complet
resect
tumor
thrombu
may
aggress
pursu
continu
standard
chemotherapi
radiotherapi
surgeri
guarante
good
prognosi
elgendi
medhat
univers
surgic
oncolog
unit
tanta
egypt
univers
pediatr
surgeri
depart
tanta
egypt
sham
univers
pediatr
surgeri
depart
cairo
egypt
univers
pediatr
surgeri
depart
alexandria
egypt
backgroundobject
investig
current
manag
wilm
tumor
wt
egyptian
pediatr
surgic
associ
epsa
consult
order
assess
practic
pattern
designmethod
approv
epsa
execut
board
questionnair
distribut
individu
consult
attend
gener
assembl
epsa
annual
congress
result
consult
respons
receiv
respons
rate
involv
wt
manag
diagnosi
palpabl
abdomin
mass
indic
respond
common
present
symptom
concern
imag
request
ct
report
total
never
request
preoper
tumor
biopsi
practic
surgeri
respond
perform
approxim
case
annual
regard
time
surgeri
upfront
resect
frequent
report
transvers
transperiton
incis
commonest
use
surgeri
respond
never
encount
intraop
complic
wherea
differ
complic
mainli
tumor
ruptur
total
perform
lymph
node
sampl
tumor
resect
nephron
spare
surgeri
nss
adopt
mainli
bilater
tumor
none
respond
report
use
minim
invas
surgeri
mi
manag
prefer
perform
due
lack
properli
select
case
follow
overal
surgeon
ask
visit
everi
month
first
year
postop
ct
common
imag
request
follow
conclus
upfront
nephrectomi
commonest
procedur
wt
current
practic
epsa
consult
wherea
consensu
mi
manag
surgic
guidelin
nss
still
incomplet
need
tabul
base
result
survey
nation
wide
retrospect
analysi
warrant
establish
uniform
protocol
intern
refer
adopt
egypt
fahi
jt
hospit
sick
children
divis
gener
thorac
surgeri
toronto
canada
hospit
sick
children
divis
haematologyoncolog
toronto
canada
backgroundobject
pediatr
patient
retroperiton
malign
particular
neuroblastoma
wilm
tumor
retroperiton
sarcoma
usual
undergo
surgic
resect
primari
mass
associ
lymph
node
postop
chylou
ascit
potenti
complic
retroperiton
lymphadenectomi
purpos
studi
examin
therapi
durat
postop
chylou
ascit
patient
well
review
impact
complic
adjuv
therapi
designmethod
patient
underw
retroperiton
resect
neuroblastoma
wilm
tumor
sarcoma
hospit
sick
children
review
demograph
diseas
treatment
detail
well
extent
durat
treatment
chylou
ascit
review
impact
addit
therapi
delay
alter
plan
adjuv
therapi
document
result
retroperiton
resect
patient
evid
moder
mark
ascit
postop
imag
week
case
includ
neuroblastoma
retroperiton
rhabdomyosarcoma
wilm
tumor
patient
ascit
resolv
week
either
without
intervent
formuladiet
restrict
oral
intak
parenter
nutrit
three
patient
requir
multipl
paracentes
three
patient
requir
placement
denver
shunt
four
six
patient
requir
paracentes
denver
shunt
chylou
ascit
signific
impact
subsequ
adjuv
therapi
lead
delay
bone
marrow
transplant
median
week
alter
previou
chemotherapi
plan
chang
plan
agent
andor
time
conclus
patient
undergo
resect
retroperiton
malign
postop
chylou
ascit
occur
low
frequenc
signific
impact
adjuv
therapi
care
taken
intraop
minim
risk
lymphat
leak
prompt
definit
manag
special
enter
parenter
diet
shunt
consid
promptli
minim
delay
adjuv
therapi
h
gabra
l
k
p
g
gabriela
jgc
javier
g
giovanna
f
florent
c
calogero
md
g
girolamo
p
great
north
children
newcastl
univers
teach
hospit
paediatr
surgeri
newcastl
uppon
tyne
unit
kingdom
pari
sorbonn
pari
cite
depart
pediatr
surgeri
pari
franc
centr
de
recherch
st
antoin
sorbonn
pediatr
surgeri
pari
franc
ormond
street
hospit
pediatr
surgeri
london
unit
kingdom
italiano
pediatr
surgeri
bueno
air
argentina
universitario
vall
dhebron
servicio
de
barcelona
spain
universitario
la
fe
unidad
de
valencia
spain
buzzi
children
hospit
pediatr
surgeri
milan
itali
universitair
pari
assist
publiqu
de
pari
xi
pediatr
surgeri
pari
franc
royal
children
hospit
paediatr
surgeri
melbourn
australia
women
children
univers
padu
pediatr
surgeri
padua
itali
children
hospit
pediatr
surgeri
urolog
nant
franc
univers
hospit
pediatr
surgeri
germani
children
hospit
pediatr
surgeri
urolog
nant
franc
nord
servic
de
chirurgi
franc
surgeri
istituto
giannina
genova
dinogmi
univers
genoa
pediatr
surgeri
unit
genoa
itali
hey
children
hospit
nh
foundat
univers
liverpool
paediatr
surgeri
liverpool
unit
kingdom
backgroundobject
surgeri
import
part
treatment
neuroblast
usual
challeng
tumour
standard
oper
approach
open
surgeri
case
mainli
adren
locat
minim
invas
surgeri
mi
consid
feasibl
indic
morbid
effici
remain
undetermin
due
small
number
report
seri
aim
studi
report
indic
morbid
ef
os
larg
cohort
patient
intern
expert
centr
designmethod
studi
protocol
approv
siopen
surgic
group
newcastl
ethic
committe
data
collect
regard
patient
demograph
tumour
featur
imag
oper
complic
follow
analys
result
total
patient
centr
countri
inss
stage
stage
stage
stage
stage
iv
inrgss
stage
ms
idrf
present
major
tumour
adren
compar
retroperiton
pelvic
thorac
mean
oper
time
minut
rang
total
almost
total
macroscop
resect
achiev
respect
incomplet
resect
record
biopsi
convers
open
surgeri
median
hospit
stay
day
complic
record
intrapost
oper
day
mortal
median
follow
month
rang
overal
mortal
conclus
largest
report
intern
seri
mi
neuroblast
tumour
presenc
idrf
contraind
mi
convers
open
surgeri
overal
complic
rate
low
reflect
overal
expertis
centr
base
studi
siopen
surgic
group
current
work
identifi
standard
guidelin
mi
neuroblast
tumour
h
halepota
l
h
indu
hospit
pediatr
surgeri
karachi
pakistan
aga
khan
hospit
pediatr
surgeri
karachi
pakistan
backgroundobject
role
surgeon
diagnos
definit
manag
manag
complic
children
cancer
patient
cancer
emerg
major
caus
morbid
mortal
develop
countri
treat
appropri
time
manner
childhood
cancer
curabl
howev
low
resourc
set
mortal
rate
mani
pediatr
cancer
approach
mani
factor
contribut
poor
childhood
cancer
outcom
set
purpos
studi
review
children
requir
surgic
intervent
either
diagnost
purpos
definit
treatment
support
treatment
cours
manag
designmethod
retrospect
review
medic
record
children
admit
indu
hospit
karachi
septemb
august
primari
diagnosi
cancer
requir
surgic
intervent
conduct
children
year
age
includ
demograph
type
locat
tumour
surgic
note
histopatholog
find
radiolog
find
presenc
absenc
metastasi
treatment
protocol
outcom
detail
review
data
analyz
use
result
total
children
requir
surgic
intervent
period
includ
surgic
resect
solid
tumour
diagnost
biopsi
porta
cath
insert
intestin
divers
tube
thoracostomi
commonest
solid
tumour
oper
malign
germ
cell
tumour
follow
renal
tumour
soft
tissu
sarcoma
neuroblastoma
other
conclus
close
collabor
pediatr
oncolog
surgic
servic
essenti
provid
optim
care
children
cancer
role
surgeon
restrict
tumour
excis
alon
diagnost
support
intervent
requir
contribut
greatli
overal
care
outcom
childhood
cancer
patient
hotonu
r
q
h
great
north
children
newcastl
univers
hospit
nh
foundat
trust
paediatr
surgeri
newcastl
upon
tyne
unit
kingdom
backgroundobject
high
risk
neuroblastoma
hrnb
tradit
associ
higher
relaps
rate
risk
group
studi
aim
examin
surgic
outcom
patient
high
risk
neuroblastoma
sinc
incept
european
high
risk
neuroblastoma
trial
centr
designmethod
retrospect
studi
includ
data
inclus
criteria
patient
consid
high
risk
intern
neuroblastoma
risk
group
stage
system
inrgss
two
patient
group
identifi
resect
resect
achiev
base
assess
imag
outcom
measur
surgic
complic
relaps
local
distant
event
free
overal
surviv
predictor
variabl
mycn
amplif
statu
presenc
residu
tumour
imag
statist
analysi
x
p
consid
signific
surviv
plot
use
estim
surviv
test
use
comparison
result
thirti
three
patient
identifi
male
femal
median
age
mycn
major
inrgss
stage
resect
achiev
compar
resect
signific
complic
occur
patient
follow
rang
month
overal
surviv
signific
differ
surviv
resect
vs
resect
group
relaps
occur
patient
distant
metastas
local
correl
degre
resect
overal
relaps
rate
surviv
radiolog
detect
tumour
imag
statist
signific
factor
relaps
mycn
amplif
statu
conclus
surgeri
hrnb
associ
signific
morbid
overal
mortal
howev
observ
effect
degre
resect
presenc
radiolog
detect
tumour
recurr
overal
surviv
patient
trial
hotonu
k
n
l
p
q
h
great
north
children
newcastl
univers
teach
hospit
nh
foundat
trust
paediatr
surgeri
newcastl
uppon
tyne
unit
kingdom
great
north
children
newcastl
univers
teach
hospit
nh
foundat
trust
histopatholog
newcastl
uppon
tyne
unit
kingdom
northern
genet
newcastl
univers
teach
hospit
nh
foundat
trust
cytogenet
newcastl
uppon
tyne
unit
kingdom
great
north
children
newcastl
univers
teach
hospit
nh
foundat
trust
radiolog
newcastl
uppon
tyne
unit
kingdom
hey
children
nh
foundat
trust
paediatr
surgeri
liverpool
unit
kingdom
great
north
children
newcastl
univers
teach
hospit
nh
foundat
trust
paediatr
oncolog
newcastl
uppon
tyne
unit
kingdom
great
north
children
newcastl
univers
teach
hospit
paediatr
surgeri
newcastl
uppon
tyne
unit
kingdom
backgroundobject
needl
core
biopsi
ncb
increasingli
utilis
diagnosi
biolog
stage
neuroblastoma
proven
safe
reliabl
howev
lack
consensu
regard
gaug
core
needl
use
adequ
minim
number
core
requir
yield
adequ
tissu
histolog
cytogenet
aim
develop
uk
guidelin
neuroblastoma
core
needl
biopsi
includ
needl
gaug
number
core
requir
yield
adequ
biopsi
designmethod
retrospect
audit
core
biopsi
receiv
histopatholog
cytogenet
laboratori
newcastl
univers
hospit
period
data
includ
needl
gaug
number
core
receiv
per
biopsi
total
length
core
final
outcom
regard
adequaci
biopsi
diagnosi
neuroblastoma
result
total
number
core
per
biopsi
receiv
core
perform
use
g
needl
overal
adequaci
mean
number
length
ncb
yield
adequ
diagnosi
core
rang
mm
rang
mm
respect
appear
total
length
ncb
reliabl
indic
adequaci
number
core
impress
total
core
length
mm
seem
length
choic
conclus
studi
reflect
current
practic
uk
neuroblastoma
specialist
centr
ncb
approach
choic
highlight
minim
total
length
core
import
factor
minim
number
core
need
nationalintern
standard
guidelin
neuroblastoma
propos
size
needl
aim
core
minim
total
core
length
ilari
g
e
g
g
salesi
children
hospit
paediatr
surgeri
ancona
itali
backgroundobject
children
diagnosi
treatment
intraves
tumor
sometim
difficult
mostli
perimeat
pneumobladd
new
techniqu
util
bladder
surgeri
never
use
diagnosi
treatment
intraves
tumor
paediatr
age
studi
evalu
result
regard
use
pneumobladd
tecniqu
diagnosi
treatment
intraves
tumor
uncertain
behavior
children
designmethod
decemb
decemb
perform
pneumobladd
techniqu
manag
bladder
tumor
male
patient
month
year
respect
procedur
start
cystoscop
examin
bladder
midlin
small
skin
incis
first
mm
trocar
suprapub
introduc
bladder
two
mm
later
trocar
introduc
anterolater
wall
bladder
cystoscop
vesicoscop
vision
bladder
insuffl
carbondioxid
mmhg
pressur
result
one
case
biopsi
primari
tumor
perform
two
case
possibl
total
remov
papilloma
close
connect
ureter
meatu
postop
pain
control
intraven
inject
paracetamolo
patient
group
mean
hospit
stay
day
convers
surgic
complic
observ
conclus
pneumobladd
seem
feasibl
safe
techniqu
diagnosi
treatment
intraves
tumor
children
moreov
pneumobladd
could
altern
procedur
transurethr
endoscop
techniqu
practic
addit
research
studi
evalu
new
approach
anyway
necessari
ilari
g
e
f
g
g
salesi
children
hospit
paediatr
surgeri
ancona
itali
backgroundobject
gastrointestin
stromal
tumour
gist
neoplasm
mesenchym
smooth
muscl
incid
childhood
case
per
million
per
year
tumor
mesenchym
origin
express
membran
protein
kit
mutat
factor
pdgfra
consid
gist
purpos
studi
defin
characterist
gist
patient
recruit
italian
studi
trep
designmethod
patient
enrol
studi
less
year
old
diagnosi
stage
workup
includ
follow
investig
digest
endoscopi
magnet
reson
imag
case
comput
tomographi
sampl
tumour
tissu
also
stain
antibodi
kit
pdgfraa
result
nine
patient
male
femal
gist
enrol
studi
tumour
locat
stomach
patient
ileum
patient
patient
underw
spare
surgeri
one
patient
gastric
gist
requir
afterward
radic
gastrectomi
local
recurr
three
patient
submit
partial
gastric
resect
underw
follow
chemotherapi
hepathicperiton
metastas
two
respond
medic
therapi
one
patient
multipl
resect
hepath
metastas
respond
cours
chemotherapi
submit
liver
transplant
month
diseas
free
patient
aliv
conclus
date
concord
intern
guidelin
regard
treatment
gist
childhood
howev
import
rememb
children
affect
gist
probabl
surviv
therefor
spare
surgeri
consid
even
case
multifoc
diseas
local
nodal
metastas
final
liver
transplant
could
option
manag
children
affect
metastat
gastrointestin
stromal
tumor
respond
chemotherapi
jan
c
terwisscha
van
c
van
de
g
center
pediatr
oncolog
pediatr
surgeri
utrecht
netherland
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
backgroundobject
previou
studi
describ
complic
neuroblastoma
surgeri
sinc
surgic
care
neuroblastoma
nbl
netherland
central
princess
center
pediatr
oncolog
increas
number
perform
procedur
studi
evalu
central
care
improv
surgic
complic
mortal
designmethod
prospect
observ
cohort
studi
conduct
includ
children
treat
nbl
period
princess
center
surgeri
relat
complic
mortal
document
outcom
compar
result
previou
studi
cohort
surgic
treatment
nbl
netherland
perform
five
differ
center
result
children
treat
accord
protocol
three
surgeon
perform
primari
tumor
resect
nbl
children
inss
stage
iii
found
stage
iii
stage
iv
percent
tumor
situat
abdomen
idrf
present
time
surgeri
total
complic
rate
vs
cohort
major
complic
rate
vs
major
hemorrhag
rate
vs
loss
kidney
occur
children
vs
complic
occur
children
vs
concern
complic
vs
complic
vs
postop
picu
support
due
complic
necessari
vs
secondari
surgeri
vs
surgeri
relat
mortal
occur
vs
conclus
sinc
start
central
surgic
care
neuroblastoma
netherland
complic
rate
clearli
improv
postop
complic
rate
also
improv
find
demonstr
possibl
benefit
central
complex
surgeri
b
jindal
k
bk
k
b
institut
postgradu
medic
educ
research
jipmer
depart
pediatr
surgeri
pondicherri
india
institut
postgradu
medic
educ
research
jipmer
depart
medic
oncolog
pondicherri
india
institut
postgradu
medic
educ
research
jipmer
depart
radiolog
pondicherri
india
institut
postgradu
medic
educ
research
jipmer
depart
patholog
pondicherri
india
backgroundobject
renal
tumor
account
childhood
cancer
wilm
tumor
wt
common
pediatr
renal
tumor
renal
tumor
wt
also
call
pediatr
renal
tumor
nwrt
infrequ
account
less
childhood
alway
pose
diagnost
therapeut
challeng
heterogen
poor
understand
patholog
behavior
designmethod
retrospect
review
record
infant
children
treat
pediatr
renal
tumor
analyz
relat
clinic
present
diagnosi
patholog
behavior
outcom
result
case
pediatr
renal
tumor
common
tumor
includ
mesoblast
nephroma
follow
clear
cell
sarcoma
cystic
nephroma
transloc
renal
cell
carcinoma
trcc
primari
primit
tumor
pnet
kidney
case
cystic
partial
differenti
neuroblastoma
cpdn
bilater
wt
usual
present
abdomin
mass
hematuria
patient
undergon
upfront
surgeri
except
three
patient
receiv
chemotherapi
diseas
relaps
seen
one
patient
pnet
refus
treatment
lost
follow
children
follow
recurr
conclus
pediatr
nwrt
compris
less
renal
mass
studi
consid
present
unusu
age
year
approach
upfront
surgeryneoadjuv
chemotherapi
follow
surgeri
depend
age
present
imag
overal
outcom
gener
good
depend
upon
histolog
stage
nwrt
renal
pnet
malign
rhabdoid
tumor
kidney
poor
prognosi
j
karpelowski
f
g
f
sydney
children
cancer
research
depart
paediatr
surgeri
sydney
australia
sydney
children
cancer
research
unit
sydney
australia
hospit
westmead
paediatr
oncolog
sydney
australia
cancer
institut
paediatr
oncolog
sydney
australia
cancer
institut
neuroblastoma
project
leader
sydney
australia
backgroundobject
liquid
biopsi
approach
solid
paediatr
malign
lag
mainli
due
rariti
cancer
overal
low
mutat
burden
lack
recurr
oncogen
point
mutat
mycn
oncogen
amplif
drive
develop
neuroblastoma
routin
assay
therapi
stratif
suggest
use
circul
mycn
dna
copi
number
liquid
biopsi
test
neuroblastoma
man
designmethod
use
ddpcr
develop
mycn
copi
number
variat
assay
evalu
limit
detect
cell
line
test
cell
line
man
tumour
tumour
match
plasma
sampl
patient
deriv
man
xenograft
mice
pdx
plasma
sampl
one
patient
metastat
man
result
circul
mycn
dna
copi
number
evalu
specif
mycn
copi
number
gain
amplif
found
man
sampl
limit
detect
detect
mycn
amplif
cell
per
cell
normal
diploid
background
mycn
gain
cell
per
cell
normal
diploid
background
pdx
plasma
sampl
posit
mycn
amplif
level
pdx
tumour
test
patient
plasma
sampl
abl
detect
mycn
amplif
copi
per
haploid
genom
conclus
result
show
sensit
mycn
copi
number
determin
highli
depend
normal
diploid
background
measur
plasma
mycn
copi
number
simpl
reproduc
assay
may
repres
reason
sensit
specif
tool
proof
principl
mycn
copi
number
base
liquid
biopsi
test
seem
promis
method
accur
assess
man
although
larger
set
patient
need
examin
confirm
result
k
khanna
v
india
institut
medic
scienc
pediatr
surgeri
new
delhi
india
backgroundobject
studi
patient
sacrococcyg
teratoma
sct
long
term
outcom
term
urolog
bowel
cosmet
gait
disturb
designmethod
prospect
studi
conduct
solid
tumor
clinic
depart
includ
case
sct
oper
till
june
data
pertain
clinic
detail
altman
type
treatment
histolog
term
urolog
bowel
cosmet
gait
disturb
analys
result
patient
report
evalu
mean
age
present
follow
period
femal
malign
benign
common
present
complaint
mass
constip
urinari
retent
pain
local
recurr
altman
type
present
patient
benign
diseas
undergon
upfront
surgic
resect
malign
diseas
undergon
surgeri
neoadjuv
chemotherapi
upfront
surgeri
follow
adjuv
chemotherapi
peb
regimen
averag
tumor
size
histopatholog
withwithout
chemotherapi
reveal
matur
teratoma
immatur
teratoma
yolk
sac
tumor
mix
patholog
viabl
tumor
seventeen
patient
month
age
malign
diseas
compar
hazard
urolog
andor
bowel
problem
cosmet
issu
gait
relat
problem
howev
good
qualiti
life
qli
score
higher
incid
bladder
dysfunct
significantli
associ
patient
malign
diseas
rectal
involv
howev
signific
associ
observ
age
sex
altman
type
number
surgeri
conclus
oper
patient
sct
long
term
urolog
bowel
cosmet
gait
problem
howev
mild
affect
qualiti
life
kremer
j
j
r
van
h
r
van
der
e
van
pediatr
surgeri
maastricht
netherland
vu
medic
centr
amsterdam
pediatr
surgeri
amsterdam
netherland
groningen
pediatr
surgeri
groningen
netherland
maxima
centrum
utrecht
pediatr
surgeri
utrecht
netherland
mc
rotterdam
pediatr
surgeri
rotterdam
netherland
kinderziekenhui
utrecht
pediatr
surgeri
utrecht
netherland
backgroundobject
gross
genet
caus
sacrococcyg
teratoma
sct
unknown
howev
might
associ
abnorm
assess
incid
associ
abnorm
larg
nation
cohort
neonat
sct
aim
identifi
predict
risk
factor
designmethod
medic
record
review
consecut
neonat
sct
treat
six
pediatr
surgic
center
netherland
potenti
risk
factor
associ
abnorm
analyz
includ
sex
gestat
age
result
patient
least
one
associ
abnorm
diagnos
hydronephrosi
common
hip
dysplasia
multipl
abnorm
document
prematur
altman
type
iv
sct
associ
increas
risk
associ
abnorm
associ
increas
hydronephrosi
hip
dysplasia
found
patient
type
iv
altman
sct
fourfold
risk
suffer
hydronephrosi
compar
altman
type
sct
addit
logist
regress
analysi
perform
distinguish
potenti
acquir
abnorm
owe
tumor
extens
surgic
treatment
true
congenit
malform
eg
esophag
atresia
renal
agenesi
fallot
tetralog
congenit
hyperthyreosi
omphalocel
altman
type
tumor
histolog
relat
occurr
congenit
malform
patient
sctwhile
prematur
associ
higher
risk
occurr
true
congenit
malform
conclus
sacrococcyg
teratoma
associ
abnorm
children
other
relat
prematur
occur
sporad
incid
congenit
abnorm
slightli
higher
compar
gener
european
popul
contrast
clinic
obviou
anomali
hip
dysplasia
hydronephrosi
might
latent
present
subtl
clinic
present
therefor
suggest
patient
certainli
altman
type
iv
sct
b
kumar
vd
n
mk
sk
gandhi
post
graduat
institut
medic
scienc
paediatr
surgic
superspeci
lucknow
india
backgroundobject
complic
well
known
morbid
treatment
patient
malign
associ
prolong
hospit
stay
even
mortal
aim
studi
present
problem
morbid
associ
manag
retroperitonealren
tumour
children
designmethod
includ
patient
oper
complet
partial
excis
juli
juli
retroperiton
mass
complet
record
minimum
month
complic
morbid
assess
correl
sizestagetypesit
tumour
age
patient
result
total
patient
includ
studi
germ
cell
tumour
yolk
sac
tumour
immatur
matur
teratoma
wilm
tumour
clear
cell
sarcoma
rhabdoid
tumour
kidney
neuroblastoma
primit
neuroectoderm
tumour
rhabdomyosarcoma
patient
diagnosi
pseudotumour
patient
femal
age
rang
month
year
median
age
year
partial
excisionbiopsi
done
patient
almost
complet
excis
perform
rest
patient
nephrectomi
done
patient
problem
encount
patient
includ
excess
bleed
excis
part
adjac
organ
hypothermia
respiratori
problem
immunosupress
wound
infect
adhes
bowel
obstruct
patient
requir
adhesiolysi
stoma
one
patient
patient
die
lost
period
rang
month
conclus
surgic
morbid
depend
size
site
tumour
age
patient
high
incid
adhes
bowel
obstruct
morbid
encount
excess
dissect
rel
larg
size
tumour
age
k
li
hospit
fudan
univers
depart
pediatr
surgeri
shanghai
china
backgroundobject
total
thyroidectomi
doubt
standard
procedur
patient
bilater
thyroid
carcinoma
pediatr
howev
lesion
confin
unilater
thyroid
gland
lobectomi
radic
total
thyroidectomi
still
controversi
pediatr
designmethod
case
pediatr
thyroid
carcinoma
confirm
patholog
retrospect
analyz
hospit
case
unilater
lesion
receiv
lobectomi
other
underw
total
thyroidectomi
recurr
complic
compar
group
also
case
primari
total
thyroidectomi
case
supplementari
resect
residu
gland
complic
compar
result
differ
group
lobectomi
total
thyroidectomi
size
extens
stage
cervic
lymph
node
metastas
distant
metastas
tabl
incid
postop
hypocalcemia
calcium
supplement
recurr
laryng
nerv
damag
recurr
rate
mortal
except
length
stay
hospit
shorter
group
lobectomi
tabl
patient
supplementari
resect
like
present
symptom
postop
hypocalcemia
hypokalemia
difficult
identifi
parathyroid
gland
oper
compar
patient
primari
total
thyroidectomi
tabl
conclus
thyroid
carcinoma
pediatr
inclin
multifoc
even
singl
focu
volum
larg
total
thyroidectomi
bring
much
complic
contrast
morbid
increas
stage
resect
endocrin
hormon
supplement
satisfi
need
growth
develop
mj
li
dx
jh
c
q
children
zhejiang
univers
school
medicin
depart
pediatr
surgeri
hangzhou
china
children
zhejiang
univers
school
medicin
depart
radiolog
hangzhou
china
backgroundobject
present
experi
neoadjuv
region
intraarteri
chemotherapi
combin
system
chemotherapi
treatment
advanc
pelvic
malign
tumor
children
designmethod
patient
male
femal
advanc
pelvic
malign
tumor
receiv
neoadjuv
altern
chemotherapi
system
chemotherapi
median
age
diagnosi
patient
year
rang
year
locat
histopatholog
type
tumor
bladder
prostat
case
rhabdomyosarcoma
inflammatori
myofibroblast
tumor
pelvic
retroperitoneum
case
endoderm
sinu
tumor
rhabdomyosarcoma
ovarian
tumor
case
endoderm
sinu
tumor
vagin
tumor
case
rhabdomyosarcoma
endoderm
sinu
tumor
three
patient
lung
metastasi
admiss
select
arteri
arteri
infus
chemotherapi
bilater
intern
iliac
arteri
infus
drug
cisplatin
pirarubicin
vindesin
intraven
chemotherapi
consist
vindesin
ifosfamid
etoposid
administ
week
arteri
chemotherapi
altern
arteri
intraven
chemotherapi
repeat
interv
cours
oper
oper
patient
underw
chemotherapi
radiotherapi
result
common
side
effect
grade
bone
marrow
suppress
mild
nausea
vomit
cardiotox
nephrotox
hepat
dysfunct
observ
neoadjuv
therapi
tumor
significantli
reduc
preoper
treatment
four
patient
vagin
tumor
nt
need
surgeri
due
tumor
necrosi
fall
twenti
patient
receiv
surgeri
patient
receiv
radiotherapi
surgeri
durat
rang
year
median
year
surviv
rate
overal
surviv
rate
conclus
neoadjuv
altern
arteri
intraven
chemotherapi
safe
effect
treatment
advanc
malign
pelvic
tumor
children
zj
yt
jhi
r
v
sm
se
jcm
ahp
loh
univers
flinder
univers
school
medicin
melbourn
australia
women
children
hospit
depart
paediatr
surgeri
singapor
singapor
hospit
children
centr
singapor
singapor
univers
singapor
yong
loo
lin
school
medicin
singapor
singapor
women
children
hospit
depart
paediatr
medicin
singapor
singapor
nu
medic
school
centr
quantit
medicin
singapor
singapor
women
children
hospit
depart
paediatr
subspecialti
haematolog
oncolog
servic
singapor
singapor
backgroundobject
learn
effici
safe
accur
placement
central
venou
access
devic
cvad
essenti
paediatr
surgic
oncolog
train
commonest
technic
error
subclavian
vein
scv
cannul
relat
incorrect
visual
anatom
structur
wrong
needl
trajectori
improv
mental
visual
venou
anatomi
surround
structur
design
taught
paediatr
surgic
traine
novel
method
scv
cannul
use
coracoid
process
halst
ligament
boni
landmark
compar
train
outcom
scv
cannul
taught
use
classic
surfac
approach
designmethod
prospect
record
patient
surgeon
oper
detail
hickman
line
insert
perform
year
two
equal
period
traine
taught
approach
respect
studi
cvad
placement
supervis
first
blind
percutan
scv
cannul
compar
procedur
durat
number
cannul
attempt
oper
complic
period
result
total
case
includ
studi
traine
perform
procedur
first
second
period
respect
patient
period
differ
gender
cancer
type
cvad
devic
prior
cvad
chemotherapi
infect
statu
second
boni
landmark
period
patient
younger
vs
year
mean
procedur
durat
shorter
vs
minut
p
left
scv
use
often
p
mean
attempt
scv
cannul
incid
oper
complic
differ
significantli
studi
period
respect
conclus
new
pedagogi
traine
could
perform
procedur
faster
despit
oper
younger
patient
without
impact
complic
rate
cannul
attempt
boni
landmark
may
better
approxim
scv
posit
across
rang
bodi
size
habitus
thu
improv
consist
scv
cannul
cvad
placement
children
lukashenko
g
n
cancer
institut
minim
invas
endoscop
intervent
radiolog
kiev
ukrain
cancer
institut
depart
tumor
abdomin
organ
retroperiton
space
kiev
ukrain
cancer
institut
depart
pediatr
oncolog
kiev
ukrain
backgroundobject
pancreat
tumor
children
uncommon
knowledg
present
accru
princip
institut
case
seri
limit
experi
togeth
broad
histolog
heterogen
made
difficult
identifi
possibl
prognost
factor
develop
treatment
protocol
aim
present
paper
perfect
treatment
pancreat
tumor
children
designmethod
retrospect
review
medic
record
patholog
report
children
underw
surgeri
nation
cancer
institut
mention
period
patient
age
younger
underw
surgic
treatment
pancreat
tumor
result
radic
surgic
resect
achiev
patient
case
distal
pancreat
resect
perform
accordingli
local
tumor
pancreat
bodi
tail
pancreatoduodenectomi
pd
perform
case
approach
use
patient
enucl
tumor
pancreat
tail
case
spleen
preserv
distal
pancreatectomi
case
postop
mortal
postop
complic
occur
patient
treat
conserv
median
consist
month
rang
month
patient
postop
pancreat
exocrin
endocrin
insuffici
present
day
patient
aliv
conclus
pancreat
tumor
children
favor
outcom
compar
adult
surgic
treatment
promin
method
pancreat
tumor
children
pancreat
resect
pancreat
tumor
children
perform
surgic
center
n
matinyan
l
blokhin
russian
cancer
research
pediatr
oncolog
hematolog
institut
anesthesiolog
moscow
russia
backgroundobject
pediatr
oncolog
lung
frequent
target
metastasi
diagnost
therapeut
surgeri
requir
guarante
optim
condit
surgeri
collaps
oper
lung
requir
thu
one
lung
ventil
olv
perform
novel
devic
olv
bronchial
blocker
bb
cohen
arndt
allow
achiev
lung
collaps
avoid
traumatis
trachea
complic
experi
use
bb
present
aim
studi
improv
effici
safeti
lung
ventil
thorac
surgic
oncolog
children
designmethod
septemb
march
surgeri
patient
yo
perform
olv
achiev
mantain
use
bb
bb
introduc
lumen
video
endobronchi
tube
place
bronchu
continu
video
control
instal
arndt
bb
conduct
endoscop
control
case
right
case
left
main
bronchu
block
time
bb
instal
lung
collaps
score
hemodynam
frequenc
postop
complic
sore
throat
aphonia
evalu
result
mean
time
intub
bb
instal
case
possibl
achiev
lung
collaps
ensur
collaps
right
lung
present
difficulti
due
anatom
physiolog
featur
higher
embranch
right
upper
lobe
bronchu
case
use
bb
prefer
design
provid
stabil
respect
carina
make
less
like
displac
surgeri
surgeri
left
lung
use
cohen
bb
prefer
conclus
bb
thorac
surgeri
pediatr
oncolog
promis
techniqu
achiev
effect
collaps
lung
side
oper
minim
traumatis
fewer
complic
postop
rapid
rehabilit
anesthesia
l
matthyssen
claey
van
de
k
van
w
w
univers
hospit
dept
gastrointestin
paediatr
surgeri
ghent
belgium
univers
dept
gastrointestin
paediatr
surgeri
ghent
belgium
backgroundobject
cytoreduct
surgeri
cr
hypertherm
intraperiton
chemotherapi
h
ipec
increasingli
use
treatment
sever
tumour
adult
patient
clinic
evid
use
h
ipec
children
remain
rare
aim
investig
evid
literatur
surviv
benefit
circumst
cr
h
ipec
may
benefici
children
designmethod
systemat
review
literatur
accord
prisma
guidelin
three
differ
set
keyword
enter
pubm
embas
web
scienc
duplic
remov
remain
abstract
screen
elig
articl
possibl
contain
data
h
child
age
year
assess
two
independ
research
articl
meet
inclus
criteria
contain
individu
patient
data
select
result
seventeen
origin
articl
identifi
describ
children
underw
cr
h
ipec
nine
case
report
case
seri
five
retrospect
observ
studi
two
articl
base
upon
retrospect
survey
one
trial
qualit
assess
surviv
gain
h
ipec
imposs
methodolog
limit
littl
data
transpar
indic
postop
treatment
h
vari
everi
articl
combin
inform
appear
everi
patient
uniqu
treatment
trajectori
lack
standardis
prevent
analysi
sinc
comparison
possibl
pure
observ
h
ipec
possibl
effect
surviv
mesothelioma
sarcoma
carcinoma
germ
cell
tumour
effect
remain
unclear
conclus
heterogen
patient
describ
literatur
prevent
valid
analysi
possibl
surviv
gain
h
ipec
children
summaris
articl
h
ipec
children
robust
evid
lack
intern
databas
children
undergo
cr
h
ipec
may
improv
data
qualiti
transpar
center
performng
h
ipec
children
consid
work
togeth
studi
potenti
standardis
procedur
v
montano
e
sile
l
ircc
granda
ospedal
maggior
policlinico
pediatr
surgeri
milan
itali
degli
studi
di
padova
pediatr
surgeri
padova
itali
servet
univeris
hospit
pediatr
surgeri
zaragoza
spain
univers
central
hospit
section
pediatr
surgeri
helsinki
finland
children
univeristi
aphp
depart
pediatr
surgeri
urolog
pari
franc
hospit
le
pediatr
radiolog
pari
franc
bicetr
assist
publiqu
hospit
de
pari
pediatr
surgeri
depart
hopitaux
universitair
pari
sud
pari
franc
backgroundobject
biopsi
wide
use
adult
recent
introduc
evalu
paediatr
tumour
develop
intervent
radiolog
techniqu
especi
ultrasonographi
chang
approach
surgeon
world
biopsi
focus
diagnost
util
biopsi
versu
surgic
biopsi
aim
review
determin
accord
present
literatur
diagnost
accuraci
safeti
biopsi
paediatr
patient
designmethod
conduct
systemat
review
articl
publish
search
term
paediatr
oncolog
biopsi
intervent
radiolog
manual
screen
refer
paper
also
perform
report
less
patient
patient
older
year
studi
concern
lymphomasleukemia
retinoblastoma
cerebr
musculoskelet
tumour
exclud
analys
dichotom
continu
variabl
appropri
statist
method
result
paper
analys
includ
review
paper
retrospect
patholog
biopsi
paper
neuroblastoma
thyroid
nodul
tumour
mean
number
patient
includ
studi
result
variabl
regard
possibl
retriev
suffici
tissu
histolog
classif
paper
assess
adequ
tissu
diagnosi
other
insuffici
guid
biopsi
compar
open
advantag
sampl
variou
part
tumour
complic
overal
consid
less
techniqu
minim
bleed
final
multicentr
studi
report
needl
core
biopsi
better
option
patient
candid
biopsi
conclus
biopsi
valuabl
clinic
tool
diagnosi
paediatr
neoplast
lesion
provid
visual
needl
tip
target
area
lower
complic
rate
compar
surgeri
real
efficaci
adequaci
sampl
howev
need
assess
n
amin
j
b
memori
centr
critic
care
pain
mumbai
india
memori
centr
depart
pediatr
surgic
oncolog
mumbai
india
backgroundobject
neuroblastoma
commonest
extracrani
tumor
childhood
aris
neural
crest
sympathet
nervou
system
encas
major
vessel
like
aorta
ivc
henc
surgeri
last
long
durat
may
associ
blood
loss
fluid
shift
aim
studi
identifi
factor
predict
morbid
children
undergo
neuroblastoma
surgeri
designmethod
periop
outcom
data
prospect
collect
children
underw
neuroblastoma
surgeri
jan
dec
morbid
defin
icu
stay
readmiss
resurgeri
mechan
ventil
need
respiratori
cardiovascular
intervent
periop
period
result
one
hundr
patient
male
femal
median
age
year
underw
surgeri
abdomin
thorac
cervic
neuroblastoma
preoper
hypertens
seen
patient
median
durat
surgeri
hour
hour
intraop
hypotens
occur
patient
need
vasopressor
periop
period
associ
preoper
hypertens
need
vasopressor
median
blood
loss
patient
loss
blood
volum
median
intraop
fluid
administ
mlkghr
postop
ventil
requir
patient
one
patient
acut
renal
failur
need
dialysi
period
readmit
respiratori
distress
median
icu
stay
hour
iqr
hour
hospit
stay
day
iqr
day
patient
morbid
fluid
mlkghr
ci
surgic
durat
hour
ci
predict
morbid
icu
hospit
mortal
respect
conclus
studi
morbid
follow
neuroblastoma
surgeri
unrel
age
stage
site
diseas
strongli
relat
durat
surgeri
intraop
fluid
volum
oue
k
r
colleg
medicin
pediatr
surgeri
nishinomiya
japan
children
hospit
pediatr
surgeri
shizuoka
japan
univers
pediatr
surgeri
fukuoka
japan
center
child
health
developmemt
center
clinic
research
develop
tokyo
japan
univers
pediatr
surgeri
tokyo
japan
backgroundobject
treatment
intens
stage
iii
stage
ii
wilm
tumor
wt
variou
factor
includ
tumor
spillag
unresect
lymph
node
metastasi
respons
stage
iii
diseas
present
studi
aim
determin
clinic
factor
associ
featur
stage
iii
wt
establish
new
treatment
strategi
designmethod
among
patient
wt
enrol
japan
wilm
tumor
studi
jwit
stage
iii
diseas
treatment
protocol
essenti
nation
wilm
tumor
studi
nwt
local
hospit
survey
collect
detail
clinic
find
relat
stage
iii
diseas
data
regard
patient
obtain
result
nine
patient
massiv
tumor
underw
chemotherapi
biopsi
perform
reduct
tumor
size
achiev
case
nephrectomi
final
perform
patient
underw
primari
nephrectomi
reason
stage
iii
diseas
lymph
node
metastasi
tumor
spillag
tumor
extensionincomplet
resect
patient
one
factor
tumor
spillag
significantli
correl
tumor
size
vascular
compress
contralater
extens
patient
treat
regimen
patient
receiv
abdomin
radiat
therapi
tumor
recur
three
patient
local
metastasi
two
patient
die
rate
overal
surviv
respect
conclus
prognosi
stage
iii
wt
good
therefor
dose
chemotherapi
radiotherapi
reduc
avoid
late
effect
high
rate
tumor
spillag
primari
resect
suggest
surgic
risk
classif
system
establish
avoid
aggress
tumor
resect
pachl
b
gs
children
hospit
paediatr
surgeri
urolog
birmingham
unit
kingdom
children
hospit
paediatr
oncolog
birmingham
unit
kingdom
backgroundobject
congenit
mesoblast
nephroma
cmn
rare
diseas
seen
commonli
children
less
month
age
treatment
surgic
first
instanc
chemotherapi
thought
role
manag
straightforward
diseas
recent
literatur
suggest
mortal
rate
recurrentmetastat
diseas
designmethod
retrospect
case
note
review
prospect
collect
data
patient
demograph
histopatholog
treatment
outcom
follow
review
result
nine
patient
includ
male
femal
age
present
median
rang
month
follow
median
rang
month
cmn
cellular
classic
mix
remain
patient
underw
primari
surgic
resect
patient
open
procedur
laparoscop
recurr
group
local
pulmonari
cellular
one
mix
two
local
recurr
one
posit
microscop
margin
requir
chemotherapi
surgeri
posit
macroscop
margin
recurr
diseas
unresect
subsequ
disappear
radiolog
follow
extend
cours
chemotherapi
patient
pulmonari
recurr
complet
initi
resect
neg
margin
two
patient
cellular
posit
microscop
margin
receiv
chemotherapi
exhibit
recurr
diseas
patient
pulmonari
recurr
unfortun
die
respiratori
failur
secondari
lung
irradi
diseas
free
patient
diseas
free
aliv
well
sequela
latest
follow
conclus
surgeri
remain
mainstay
manag
chemo
radiotherapi
reserv
unresect
tumour
adjuv
manag
recurr
diseas
microscop
posit
resect
margin
indic
institut
chemotherapi
sile
e
v
l
pio
servet
univers
hospit
depart
pediatr
surgeri
zaragoza
spain
great
ormond
street
institut
child
health
pediatr
surgeri
london
unit
kingdom
ircc
ca
granda
ospedal
maggior
policlinico
depart
pediatr
surgeri
milan
itali
helsinki
univers
central
children
hospit
section
pediatr
surgeri
helsinki
finland
children
univers
aphp
depart
pediatr
surgeri
urolog
pari
franc
depart
pediatr
radiolog
le
franc
descart
necker
assist
de
pari
depart
pediatr
surgeri
pari
franc
universitair
pari
assist
publiqu
de
pari
pediatr
surgeri
depart
le
franc
backgroundobject
aim
studi
compar
outcom
open
ultrasound
us
guid
approach
placement
central
venou
cathet
cvc
pediatr
oncolog
designmethod
use
defin
search
strategi
systemat
review
perform
follow
cochran
handbook
systemat
review
intervent
prefer
report
item
systemat
review
prisma
inclus
criteria
defin
data
collect
includ
factor
relat
patient
cvc
placement
techniqu
complic
maneuv
compar
appropri
statist
method
conduct
use
revman
result
systemat
review
abstract
screen
articl
analyz
paper
infant
met
inclus
criteria
random
studi
one
prospect
articl
infant
report
cvc
placement
ultrasound
percutan
guid
approach
articl
patient
report
open
placement
cvc
fit
inclus
criteria
success
failur
definit
specifi
report
studi
compar
cvc
placement
us
guid
percutan
approach
procedur
versu
open
approach
procedur
occurr
complic
inmedi
delay
forest
plot
show
preval
immedi
complic
us
guid
procedur
compar
open
procedur
delay
complic
preval
immedi
p
conclus
show
potenti
reduc
delay
complic
ultrasound
use
cvc
placement
howev
random
control
trial
need
identifi
risk
factor
prevent
immedi
delay
complic
approach
l
pio
valteau
j
h
necker
pediatr
surgeri
pari
franc
necker
pediatr
surgeri
pari
franc
gustav
roussi
depart
child
adolesc
cancer
villejuif
franc
curi
depart
pediatr
oncolog
pari
franc
curi
imag
depart
pari
franc
necker
depart
neurosurgeri
pari
franc
backgroundobject
prognosi
dumbbel
neuroblastoma
nb
mainli
link
sequel
induc
tumor
neurosurg
approach
primari
chemotherapi
first
treatment
symptomat
case
diagnosi
still
debat
surgic
manag
residu
tumor
especi
intraspin
compon
time
type
surgic
resect
aim
studi
report
singl
center
experi
dumbbel
neuroblastoma
function
oncolog
designmethod
nb
extens
spinal
canal
treat
team
last
year
analyz
regard
time
type
surgeri
complic
function
oncolog
result
children
collect
metastast
local
upfront
surgeri
perform
patient
neoadjuv
chemotherapi
combin
neurosurgicalextraspin
procedur
perform
case
neurosurgeri
first
oper
patient
thorac
surgeri
abdomin
surgeri
extraspin
compon
first
procedur
patient
respect
three
postop
complic
occur
two
transitori
sciatic
paralysi
one
intestin
occlus
requir
surgic
intervent
function
sequel
observ
patient
scoliosi
treat
corset
steppag
paraplegia
neurogen
bladder
twenti
nine
patient
complet
remiss
two
patient
local
recurr
two
patient
metastat
diagnosi
deceas
metastat
relaps
median
year
year
year
conclus
extens
combin
surgic
strategi
provid
good
result
term
surviv
adequ
multidisciplinari
orthoped
neurosurgeon
urologist
mandatori
manag
properli
function
sequel
link
tumor
andor
surgic
resect
l
pio
p
c
v
necker
pari
sorbonn
pari
pediatr
surgeri
depart
peri
franc
curi
depart
adolesc
young
adult
oncolog
pari
franc
depart
paediatr
adolesc
oncolog
villejuif
franc
children
hospit
urolog
depart
melbourn
australia
backgroundobject
present
preliminari
result
laparoscop
ral
total
partial
nephrectomi
renal
malign
tumour
designmethod
total
nephrectomi
transperiton
approach
use
tumour
extract
insid
plastic
bag
without
morcel
pfannenstiel
incis
partial
nephrectomi
perform
use
retroperiton
approach
renal
arteri
clamp
renorrhaphi
done
techniqu
patient
wilm
treat
accord
result
eight
children
underw
ral
nephrectomi
mean
age
year
total
nephrectomi
wilm
tumour
done
case
one
convert
due
renal
vein
injuri
one
renal
vein
tumour
thrombu
misdiagnos
preoper
imag
could
treat
robot
convert
stage
ii
iii
lymph
node
involv
histolog
show
regress
type
diffus
anaplasia
three
patient
partial
nephrectomi
increas
size
one
nodul
bilater
nephroblastomatosi
onset
right
tumour
left
nephrectomi
wilm
tumour
ten
year
liver
transplant
hepatoblatoma
warm
ischemia
time
minut
patholog
wilm
case
stage
standard
histolog
tubulopapillari
renal
cell
carcinoma
tumour
complet
remov
case
ruptur
occur
postop
cours
unev
patient
discharg
day
day
recurr
complic
occur
month
conclus
ral
total
partial
nephrectomi
renal
tumour
children
feasibl
safe
highli
select
children
pohl
j
von
von
hauner
children
depart
pediatr
surgeri
munich
germani
backgroundobject
lymphat
leakag
extens
retroperiton
surgeri
known
complic
patient
abdomin
neuroblastoma
nb
variou
public
adult
patient
definit
treatment
option
clear
definit
regard
frequenc
treatment
pediatr
patient
designmethod
evalu
chart
patient
advanc
nb
inss
stage
receiv
surgeri
depart
age
extend
surgeri
durat
drainag
occur
treatment
option
result
occur
patient
local
advanc
metastas
nb
defin
durat
abdominal
drainag
day
laboratori
test
ascit
chylomicron
posit
none
patient
need
surgic
intervent
closur
treatment
option
includ
watch
wait
total
parenter
nutrit
somatostatin
applic
applic
arista
local
hemostypticum
patient
extend
surgeri
significantli
associ
p
vs
p
signific
associ
mycn
statu
furthermor
none
treatment
option
show
clear
advantag
regard
durat
conclus
frequent
complic
extens
retroperiton
resect
wacht
wait
seem
reliabl
therapeut
option
treatment
h
qin
h
children
capit
medic
nation
center
children
health
surgic
oncolog
depart
beij
china
backgroundobject
investig
safeti
feasibl
complic
pancrea
head
resect
dpphr
surgic
treatment
pediatr
benign
malign
pancreat
head
tumor
designmethod
patient
benign
malign
pancreat
head
tumor
underw
tumor
resect
patient
retrospect
divid
group
dpphr
group
local
enucl
group
convent
pancreatoduodenectomi
pd
group
periop
factor
postop
complic
compar
group
result
statist
signific
found
oper
time
dpphr
pd
group
p
statist
differ
found
incid
postop
pancreat
fistula
complic
group
p
incid
complic
markedli
lower
dpphr
local
enucl
group
pd
group
p
longer
drainag
time
prolong
use
somatostatin
hospit
stay
observ
dpphr
group
statist
signific
compar
pd
group
p
conclus
dpphr
may
safe
procedur
treat
pediatr
patient
benign
malign
pancreat
head
tumor
incid
digest
complic
significantli
lower
dpphr
howev
periop
manag
might
challeng
surgeon
qureshi
g
l
n
memori
hospit
pedaitr
surgic
oncolog
mumbai
india
memori
hospit
radiolog
mumbai
india
memori
hospit
pedaitr
medic
oncolog
mumbai
india
memori
hospit
radiat
oncolog
mumbai
india
memori
hospit
patholog
mumbai
india
backgroundobject
avail
robust
compel
data
upfront
delay
surgeri
invari
lead
dilemma
select
initi
treatment
imag
criteria
associ
risk
ruptur
incomplet
resect
provid
object
assess
custom
time
surgeri
designmethod
eighti
children
unilater
renal
tumour
enrol
studi
januari
decemb
radiolog
featur
perinephr
spread
adjac
organ
infiltr
tumour
cross
midlin
intravascular
thrombu
extens
adenopathi
util
decid
initi
treatment
approach
upfront
nephrectomi
perform
absenc
featur
delay
surgeri
biopsi
chemotherapi
absenc
result
upfront
nephrectomi
perform
eighteen
delay
surgeri
complic
attribut
biopsi
patient
upfront
surgeri
group
predominantli
stage
diseas
one
tumour
ruptur
histolog
diagnosi
wilm
tumour
eleven
tumour
five
benign
tumour
two
delay
surgeri
group
histolog
diagnosi
wilm
tumour
tumour
five
follow
chemotherapi
stage
diseas
one
patient
upfront
group
delay
group
wilm
tumour
receiv
doxorubicin
radiotherapi
stage
diseas
addit
five
stage
blastem
predomin
histolog
also
receiv
doxorubicin
overal
surviv
median
month
entir
cohort
overal
surviv
upfront
surgeri
group
delay
surgeri
group
conclus
custom
approach
base
radiolog
criteria
facilit
identif
wilm
tumour
histolog
children
appropri
initi
chemotherapi
aid
tumour
identif
patholog
rybakova
p
state
budgetari
institut
nation
medic
research
center
oncolog
nn
blokhin
ministri
health
russia
children
oncolog
moscow
russia
backgroundobject
develop
ration
surgeri
solid
pseudopapillari
tumor
spt
pancrea
implement
endosurgeri
designmethod
children
spt
oper
sinc
analyz
clinic
data
oper
option
result
treatment
result
patient
girl
age
year
median
local
tumor
pancrea
tail
bodi
head
size
sm
sm
children
underw
laparoscop
distal
pancreatectomi
pancreatoduoden
resect
gastropancreatoduoden
resect
central
resect
pancrea
distal
subtot
resect
uncin
process
pancrea
resect
resect
duoden
wall
time
oper
min
bleed
median
complic
occur
patient
case
pancreat
pancreat
fistula
bleed
pancreat
branch
splenic
arteri
whippl
oper
bleed
wound
surfac
pleurisi
pneumonia
reoper
complic
observ
period
patient
month
year
patient
aliv
without
evid
diseas
recurr
conclus
main
method
treatment
surgeri
howev
moder
risk
complic
tumor
local
great
attent
paid
prevent
postop
pancreat
promis
method
endosurgeri
provid
earli
rehabilit
cosmet
effect
rybakova
p
state
budgetari
institut
nation
medic
research
center
oncolog
nn
blokhin
ministri
health
russia
children
oncolog
moscow
russia
backgroundobject
defin
possibl
endosurgeri
diagnosi
tumor
thorac
abdomin
local
children
designmethod
institut
diagnost
purpos
carri
oper
children
laparoscop
thoracoscop
biopsi
except
diagnost
biopsi
execut
thoracoscop
resect
lung
children
purpos
diagnost
progress
diseas
confirm
metastat
defeat
inflammatori
process
age
patient
vari
month
year
ratio
floor
approxim
equal
boy
girl
children
one
year
children
result
durat
thoracoscop
laparoscop
biopsi
made
minut
minut
averag
minut
blood
loss
diagnost
oper
averag
ml
intraop
complic
case
postop
endosurgeri
oper
patient
special
treatment
carri
repeat
oper
alreadi
radic
volum
written
continu
treatment
resid
profil
establish
averag
time
begin
special
treatment
made
day
conclus
advantag
use
endosurgeri
children
oncolog
earli
term
begin
special
treatment
small
injuri
minimum
blood
loss
low
number
postop
complic
earli
activ
patient
reduct
term
stay
hospit
good
cosmet
effect
perform
endosurgeri
oper
children
malign
tumor
possibl
age
sever
week
thu
oncolog
principl
perform
surgeri
nt
broken
also
age
child
nt
limit
factor
perform
endosurgeri
oper
rykov
blokhin
medic
research
center
oncolog
ministri
health
russian
feder
institut
pediatr
oncolog
moscow
russia
backgroundobject
review
experi
peripher
insert
central
cathet
pediatr
cancer
patient
designmethod
analysi
includ
patient
month
year
mean
age
year
varieti
cancer
diseas
peripher
insert
central
cathet
place
set
carri
use
ultrasound
guidanc
patient
extern
anatom
landmark
use
intraop
fluoroscopi
result
maxim
durat
line
year
lowest
month
averag
month
among
technic
difficulti
placement
frequent
migrat
distal
end
cathet
intern
jugular
vein
blood
patient
one
case
unabl
catheter
patient
vein
among
common
complic
oper
mark
peripher
insert
central
cathet
clot
occlus
case
symptomat
thrombosi
observ
case
blood
stream
infect
report
remov
peripher
insert
central
cathet
relat
complic
perform
patient
later
implant
venou
port
conclus
peripher
insert
central
cathet
recommend
use
treatment
children
cancer
train
nurs
staff
minim
risk
complic
p
salim
b
child
health
univers
liverpool
uk
depart
paediatr
surgeri
liverpool
unit
kingdom
hey
children
hospit
nh
foundat
trust
depart
paediatr
surgeri
liverpool
unit
kingdom
hey
children
hospit
nh
foundat
trust
depart
oncolog
liverpool
unit
kingdom
backgroundobject
numer
factor
identifi
carri
prognost
valu
neuroblastoma
mani
incorpor
risk
stratif
diseas
investig
associ
anatom
site
neuroblastoma
molecular
biolog
outcom
designmethod
one
hundr
twenti
four
patient
neuroblastoma
studi
year
period
tumour
locat
confirm
ct
mri
imag
data
molecular
biolog
obtain
test
becam
avail
fisher
exact
test
test
use
statist
surviv
analys
result
eighteen
patient
thorax
tumour
tnbl
adren
gland
lesion
anbl
abdomin
paravertebr
chain
neoplasm
pvnbl
anbl
case
significantli
poor
outcom
vs
anatom
group
os
anbl
site
favour
stage
iv
widespread
metastat
diseas
signific
associ
found
tumour
origin
age
diagnosi
mycn
avail
patient
amplif
note
anbl
associ
lower
os
vs
mycn
anbl
vast
major
tnbl
pvnbl
amplifi
carri
better
prognosi
os
dna
copi
data
avail
case
anbl
diploidli
reduc
os
vs
hyperdiploid
anbl
thorax
tumour
tnbl
abdomin
paravertebr
chain
lesion
pvnbl
found
hyperdiploid
better
prognosi
os
hyperdiploid
tnbl
pvnbl
respect
segment
chromosom
alter
gain
delet
detect
patient
prognost
signific
tnbl
pvnbl
conclus
thorac
neuroblastoma
tumour
better
outcom
adren
tumour
may
due
factor
diseas
mycn
oncogen
favour
molecular
biolog
k
sampat
b
v
p
liverpool
institut
integr
biolog
liverpool
unit
kingdom
hey
children
hospit
depart
paediatr
surgeri
liverpool
unit
kingdom
hey
children
hospit
depart
oncolog
liverpool
unit
kingdom
liverpool
institut
child
health
liverpool
unit
kingdom
backgroundobject
describ
util
chick
embryo
new
experiment
model
studi
tumour
biolog
neuroblastoma
nbl
develop
model
observ
neuroblastoma
metastas
live
system
present
preliminari
observ
cancer
drug
agent
screen
chick
designmethod
neuroblastoma
tumour
develop
fluoresc
label
tumour
cell
place
membran
chick
embryo
potenti
novel
agent
cyclin
kinas
cdk
nfkb
inhibitor
identifi
lab
group
genet
profil
metastat
neuroblastoma
tumour
drug
introduc
chick
embryo
abl
observ
real
time
effect
drug
develop
cancer
chick
surviv
weight
use
indic
drug
toxic
tumour
harvest
drug
efficaci
quantifi
use
immunohistochemistri
techniqu
volumetr
whole
tumour
imag
multiphoton
light
sheet
microscopi
allow
analysi
entir
nbl
tumour
without
section
result
embryo
treat
cdk
inhibitor
p
palbociclib
p
show
signific
reduct
prolifer
cell
within
tumour
demonstr
potent
efficaci
neuroblastoma
vivo
vs
control
advanc
microscopi
protocol
visualis
whole
tumour
show
dynam
imag
nbl
tumour
organis
vascularis
tumour
imag
current
permit
unpreced
platform
obtain
novel
measur
beyond
convent
histopatholog
analysi
conclus
chick
embryo
versatil
experiment
model
studi
biolog
neuroblastoma
treatment
use
model
select
screen
target
new
chemotherapi
agent
neuroblastoma
alongsid
convent
tumorigenesi
assay
novel
use
microscopi
imag
allow
detail
observ
drug
effect
nbl
tumour
microenviron
well
cell
invas
metastasi
j
c
l
n
sarnacki
caen
pediatr
surgeri
caen
franc
enfant
malad
pediatr
surgeri
pari
franc
dijon
center
genet
dijon
franc
dijon
digest
surgic
oncolog
dijon
franc
backgroundobject
currarino
syndrom
initi
describ
triad
sacrum
hindgut
anomali
presacr
mass
studi
consid
optim
manag
presacr
mass
currarino
syndrom
designmethod
studi
consid
optim
manag
presacr
mass
currarino
syndrom
analys
two
new
malign
case
one
child
one
adult
review
current
publish
literatur
regard
current
clinic
imag
histolog
genet
data
cs
patient
malign
presacr
mass
result
among
currarino
syndrom
patient
case
malign
presacr
mass
report
date
variou
histolog
type
two
case
assess
gene
mutat
two
addit
case
report
malign
could
directli
link
currarino
syndrom
sinc
occur
presacr
mass
childhood
adulthood
identifi
mutat
within
gene
although
rare
event
malign
transform
presacr
mass
currarino
syndrom
may
occur
adulthood
also
infanc
conclus
two
messag
first
systemat
remov
presacr
mass
currarino
syndrom
mandatori
spinal
cord
mri
particularli
procedur
anorect
spinal
malform
perform
second
investig
possibl
currarino
syndrom
patient
present
presacr
mass
thu
propos
genet
test
mutat
even
featur
currarino
syndrom
present
absenc
famili
histori
sen
n
b
n
india
institut
medic
scienc
depart
ocular
dr
rajendra
prasad
centr
ophthalm
scienc
new
delhi
india
india
institut
medic
scienc
depart
dr
rajendra
prasad
centr
ophthalm
scienc
new
delhi
india
india
institut
medic
scienc
depart
biochemistri
new
delhi
india
india
institut
medic
scienc
ocular
oncolog
dr
rajendra
prasad
centr
ophthalm
new
delhi
india
india
institut
medic
scienc
ophthalmoplasti
dr
rajendra
prasad
centr
ophthalm
scienc
new
delhi
india
india
institut
medic
ansari
nagar
depart
ocular
dr
rajendra
prasad
centr
ophthalm
scienc
new
delhi
india
backgroundobject
retinoblastoma
common
primari
intraocular
childhoodmalign
earlier
studi
suggest
associ
hpv
sporad
retinoblastoma
indic
viru
may
role
develop
tumor
mark
variat
hpv
posit
retinoblastoma
reportedworldwid
present
studi
aim
detect
presenc
hpv
retinoblastoma
north
indian
popul
designmethod
hpv
genom
detect
multiplex
pcr
use
primer
ocular
malign
tumor
follow
genotyp
use
linear
array
revers
hybrid
result
retinoblastoma
case
recruit
unilater
bilater
mean
age
year
month
year
poorli
differenti
pd
well
differenti
optic
nerv
choroid
invas
seen
case
retinoblastoma
case
neg
hpv
multiplex
pcr
well
revers
hybrid
conclus
hpv
genom
absent
retinoblastoma
case
therefor
hpv
may
associ
pathogenesi
tumor
north
india
w
hospit
chongq
medic
univers
depart
pediatr
surgic
oncolog
chingq
china
backgroundobject
analyz
clinic
featur
outcom
correl
prognost
factor
pediatr
synovi
sarcoma
designmethod
januari
novemb
newli
diagnos
children
synovi
sarcoma
children
hospit
chongq
medic
univers
shanghai
children
medic
center
sun
univers
cancer
center
beij
children
hospit
enrol
studi
clinic
featur
surgeri
chemotherapi
radiotherapi
protocol
prognost
factor
retrospect
analyz
result
tumor
resect
first
patient
remain
patient
biopsi
first
three
tumor
resect
cycl
neoadjuv
chemotherapi
patient
receiv
chemotherapi
postoper
median
cycl
five
time
radiotherapi
receiv
ten
patient
postoper
total
dose
eight
patient
gave
treatment
biopsi
direct
surgeri
cycl
chemotherapi
postoper
fulfil
comprehens
treatment
plan
patient
achiev
complet
respons
stabl
diseas
progress
diseas
end
treatment
tumor
metastat
local
relaps
occur
patient
month
month
except
case
give
treatment
median
period
month
month
estim
year
surviv
patient
complet
excit
tumor
initi
surgeri
significantli
better
surviv
signific
prognost
factor
found
includ
age
sex
primari
site
extrem
axial
size
cm
cm
ir
group
distant
metastasi
univari
analysi
conclus
pediatr
synovi
sarcoma
aris
commonli
extrem
comprehens
treatment
advoc
pediatr
synovi
sarcoma
also
tend
late
local
recurr
metastasi
complet
excit
tumor
initi
surgeri
show
effect
prognosi
effect
treatment
need
found
improv
outcom
k
sharma
v
v
india
institut
medic
scienc
pediatr
surgeri
new
delhi
india
india
institut
medic
scienc
radiodiagnosi
new
delhi
india
india
institut
medic
scienc
medic
brairch
new
delhi
india
backgroundobject
satellit
lesion
known
occur
patient
hepatoblastoma
hb
miss
initi
radiolog
evalu
segment
harbour
satellit
lesion
may
retain
hepat
resect
lead
recurr
aim
evalu
role
diffus
weight
mri
fresh
case
hepatoblastoma
hb
detect
satellit
lesion
compar
multiphas
ct
cect
scan
designmethod
cect
scan
perform
initi
chemotherapi
newli
enrol
case
hepatoblastoma
result
interpret
two
separ
radiologist
compar
detect
satellit
lesion
pretext
group
risk
categor
done
accord
siopel
result
ten
fresh
case
hb
age
rang
median
includ
rang
ngml
pretext
group
ii
iii
standard
risk
high
risk
tumor
patient
addit
satellit
lesion
detect
one
patient
cect
diagnos
larg
unifoc
tumor
involv
segment
pretext
iii
hr
addit
satellit
lesion
detect
upgrad
patient
pretext
hr
anoth
patient
cect
detect
larg
lesion
segment
satellit
segment
pretext
iii
hr
addit
satellit
lesion
detect
segment
upgrad
patient
pretext
hr
conclus
compar
multiphas
ct
scan
detect
addit
satellit
lesion
case
detect
addit
satellit
lesion
could
lead
upgrad
pretext
group
chang
extent
hepatectomi
requir
patient
hb
two
upgstag
patient
studi
would
requir
total
hepatectomi
liver
transplant
therefor
investig
choic
decid
local
extent
hb
case
c
signorelli
c
j
j
c
children
hospitalunsw
sydney
kid
cancer
centr
sydney
australia
hospit
westmeadkid
research
instituteunivers
sydney
depart
paediatr
surgerychildren
cancer
research
unit
sydney
australia
southampton
faculti
health
scienc
southampton
unit
kingdom
backgroundobject
surgeri
children
especi
stress
patient
parent
aim
understand
patient
parent
experi
need
long
term
impact
surgeri
pediatr
cancer
designmethod
stage
conduct
systemat
review
paediatr
patient
parent
psychosoci
experi
need
surgic
period
condit
studi
conduct
interview
childhood
cancer
survivor
parent
survivor
year
evalu
experi
need
across
surgic
trajectori
result
stage
review
yield
elig
studi
repres
children
undergo
surgeri
parent
children
commonli
display
advers
psychologicalbehaviour
chang
eg
eat
disturb
parent
mainli
report
psycholog
distress
patient
need
relat
primarili
medicalhealthcar
servic
parent
typic
high
inform
need
patient
prior
hospitalizationssurgeri
report
wors
experi
suggest
experi
may
wors
patient
chronic
condit
studi
elig
review
evalu
experi
children
undergo
surgeri
childhood
cancer
prompt
interview
studi
popul
stage
interview
particip
survivor
mean
surgeri
age
parent
child
surgeri
mean
age
overal
satisfi
surgic
experi
yet
particip
rate
surgeri
highli
distress
survivor
recal
fear
pain
procedur
experienc
immobl
persist
behaviour
disturb
parent
report
stress
last
psycholog
distress
factor
improv
particip
experi
includ
clear
consist
commun
hospit
staff
live
near
hospit
children
parent
support
conclus
surgeri
childhood
appear
last
impact
famili
survivor
parent
describ
vivid
memori
advers
effect
understand
famili
surgic
experi
need
critic
improv
standard
care
offer
reduc
periop
stressor
r
souzaki
j
k
univers
pediatr
surgeri
fukuoka
japan
univers
pediatr
fukuoka
japan
univers
anatom
patholog
fukuoka
japan
backgroundobject
detect
liver
tumor
identif
bile
duct
liver
surgeri
use
indocyanin
green
icg
recent
develop
howev
use
icg
navig
surgeri
hb
fulli
clarifi
herein
report
experi
surgic
navig
use
icg
hb
patient
designmethod
five
hb
patient
liver
tumor
lung
metastat
tumor
intraop
examin
use
infrar
fluoresc
imag
scope
administr
icg
preoper
result
navig
surgeri
use
icg
perform
primari
liver
tumor
case
extend
right
hepatectomi
perform
patient
liver
transplant
patient
primari
tumor
exhibit
intens
fluoresc
fluoresc
detect
residu
liver
tumor
prove
complet
resect
patholog
examin
icg
navig
primari
liver
tumor
use
detect
residu
tumor
surround
ivc
invas
diaphragm
five
navig
surgeri
use
icg
perform
metastat
lung
tumor
two
case
case
perform
bilater
lung
partial
resect
left
upper
lobectomi
recurr
tumor
one
case
metastat
lung
lesion
detect
preoper
ct
exhibit
intens
fluoresc
one
lesion
detect
ct
exhibit
weak
fluoresc
lesion
except
one
lesion
detect
ct
patholog
proven
made
hb
cell
one
lesion
detect
ct
show
tumor
cell
icg
navig
metastat
lung
tumor
use
detect
tumor
confirm
tumor
free
resect
stump
conclus
navig
surgeri
use
icg
patient
hb
use
identifi
tumor
confirm
complet
resect
j
stenman
k
f
j
g
pj
k
univers
hospit
depart
pediatr
surgeri
pediatr
urolog
stockholm
sweden
ormond
street
hospit
depart
specialist
neonat
paediatr
surgeri
london
unit
kingdom
univers
hospit
depart
pediatr
radiolog
stockholm
sweden
backgroundobject
neuroblastoma
surgeri
rare
radic
defin
microscop
clear
resect
margin
complet
resect
determin
surgeon
estim
amout
residu
tumor
tissu
evalu
photograph
imag
iopi
object
document
extent
surgic
resect
amount
residu
tumor
designmethod
photographi
patient
taken
surgeri
inrg
stage
neuroblastoma
karolinska
univers
hospit
great
ormond
street
hospit
retrospect
analyz
photograph
imag
taken
end
resect
analyz
score
respect
imag
qualiti
correl
oper
report
extent
risk
factor
idrf
adequ
display
analysi
perform
surgeon
well
aquaint
field
oper
surgeon
specif
case
result
imag
qualiti
good
adequ
regard
resolut
sharp
lightn
orient
case
case
anatom
region
idrf
clearli
display
correl
photograph
imag
oper
report
complet
partial
absent
case
case
avail
imag
cover
idrf
case
poor
imag
qualiti
made
judgement
residu
diseas
imposs
conclus
systemat
perform
iopi
supplement
standard
surgic
case
report
form
provid
mean
object
document
surgic
resect
allow
retrospect
valid
central
review
qualiti
surgeri
neuroblastoma
prospect
studi
establish
imag
criteria
evalu
iopi
relat
radiograph
imag
initi
talypov
n
e
n
n
rogachev
nation
research
center
pediatr
oncolog
immunolog
pediatr
oncolog
surgeri
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
pediatr
oncolog
moscow
russia
backgroundobject
minim
invas
surgic
mi
intervent
often
displac
open
oper
children
surgic
hospit
also
contribut
wide
spread
video
endoscop
surgeri
pediatr
oncolog
purpos
biopsi
remov
solid
tumor
designmethod
depart
pediatr
surgeri
februari
decemb
minim
invas
oper
aim
remov
solid
tumor
thorac
abdomin
local
perform
laparoscop
surgeri
perform
thoracoscop
laparoscopi
children
retroperiton
neurogen
tumor
benign
tumor
adren
hemorrhag
kidney
tumor
case
remov
solid
tumor
carri
thoracoscop
children
neurogen
tumor
lung
tumor
bronchogen
cyst
esophag
cyst
thymu
tumor
other
minimum
age
month
maximum
year
sex
ratio
boy
girl
approxim
oper
perform
access
bipolar
coagul
use
mobil
tumor
case
vessel
diamet
mm
coagul
vessel
bigger
diamet
clip
clip
isol
tumor
immers
endoscop
contain
extract
expand
hole
one
troacar
result
durat
oper
rang
minut
hour
depend
locat
size
tumor
involv
surround
organ
vessel
convers
larg
tumor
volum
bleed
adhes
process
found
patholog
lesion
lung
intraop
complic
bleed
local
relaps
requir
open
oper
conclus
mi
pediatr
oncolog
justifi
due
less
traumat
promot
faster
recoveri
patient
postop
period
earlier
continu
chemotherapi
underli
oncolog
diseas
h
uchida
k
center
child
health
develop
organ
transplant
center
tokyo
japan
center
child
health
develop
divis
radiolog
tokyo
japan
center
child
health
develop
divis
patholog
tokyo
japan
center
child
health
develop
children
cancer
center
tokyo
japan
backgroundobject
excel
outcom
extrem
procedur
liver
resect
lr
advanc
hepatoblastoma
hb
achiev
recent
report
howev
liver
transplant
lt
remain
surgic
treatment
patient
unresect
hb
aim
studi
evalu
retrospect
data
case
advanc
hb
necessit
surgic
intervent
analyz
prognost
factor
recurr
compar
lr
lt
patient
designmethod
retrospect
review
children
pretext
iiiiiiv
tumor
requir
consider
lt
august
octob
result
stage
time
diagnosi
pretext
iiiiiiv
patient
preoper
stage
neoadjuv
chemotherapi
iiiiiiv
patient
among
patient
complet
resect
primari
tumor
achiev
lt
patient
lr
patient
two
patient
underw
rescu
lt
due
recurr
remain
lobe
liver
signific
decreas
rate
low
tumor
shrinkag
rate
vascular
invas
patholog
find
relat
risk
tumor
recurr
lr
patient
risk
significantli
higher
recurr
rate
without
overal
surviv
surviv
surviv
ef
rate
higher
lt
patient
respect
lr
patient
respect
signific
differ
ef
p
conclus
although
strengthen
preoper
assess
advanc
imag
tool
may
aid
process
regard
solid
strategi
patient
advanc
hb
poor
respons
chemotherapi
definit
priorit
primari
lt
given
possibl
vascular
invas
microscop
residu
tumor
c
van
de
ven
jg
l
h
j
k
l
km
j
pd
j
mp
von
center
pediatr
oncolog
solid
tumor
unit
utrecht
netherland
children
hospit
michael
e
debakey
depart
baylor
colleg
medicin
houston
usa
hospit
gent
pediatr
surgeri
gent
belgium
newcastl
upon
tyne
hospit
pediatr
surgeri
newcastl
upon
tyne
unit
kingdom
armand
trousseau
pediatr
surgeri
pari
franc
univers
hospit
pediatr
surgeri
stockholm
sweden
univers
hospit
pediatr
surgeri
oslo
norway
hospit
gasthuisberg
oncolog
surgeri
leuven
belgium
hospit
necker
pediatr
surgeri
pari
franc
ormond
street
hospit
children
pediatr
surgeri
london
unit
kingdom
g
gaslini
institut
pediatr
surgeri
genova
itali
hospit
la
fe
pediatr
surgeri
valencia
spain
hey
children
hospit
pediatr
surgeri
liverpool
unit
kingdom
children
hospit
pediatr
surgeri
germani
sloan
ketter
cancer
center
pediatr
surgeri
new
york
usa
univers
munich
pediatr
surgeri
munich
germani
backgroundobject
treatment
neuroblastoma
consist
multidisciplinari
approach
induct
chemotherapi
surgic
resect
chemotherapi
radiat
therapi
complet
biolog
therapi
surgic
resect
tumor
often
demand
procedur
tumor
tendenc
encas
vital
vessel
risk
loss
vital
organ
abl
compar
surgic
procedur
multicent
studi
import
regist
surgic
procedur
standard
extens
manner
addit
standard
descript
help
surgic
radiat
plan
designmethod
propos
intern
crf
result
intens
discuss
differ
intern
work
group
combin
exist
surgic
case
report
form
crf
siopen
cog
gpoh
introduc
list
possibl
complic
result
first
part
describ
natur
approach
result
procedur
well
descript
anatom
involv
tumor
second
part
extens
describ
natur
vascular
involv
specif
vessel
includ
degre
resect
damag
organ
involv
resect
macroscop
tumor
residu
record
item
concord
preoper
risk
factor
addit
detail
intraop
complic
record
well
postop
complic
use
classif
form
directli
fill
surgeon
resolv
challeng
link
high
variat
anatom
locat
conclus
first
intern
crf
standard
neuroblastoma
surgeri
improv
collect
surgic
data
facilit
comparison
across
border
crf
also
aim
use
neuroblastoma
l
vierboom
c
sv
j
children
health
depart
paediatr
surgeri
urolog
auckland
new
zealand
children
hospit
westmead
depart
paediatr
surgeri
westmead
australia
backgroundobject
usg
percutan
insert
tunnel
central
venou
access
devic
cvad
shown
safe
effect
adult
howev
concern
safeti
techniqu
small
children
studi
analys
safeti
usg
percutan
cvad
insert
paediatr
popul
weigh
ten
kilogram
less
designmethod
surgic
insert
cvad
children
weigh
ten
kilogram
less
januari
decemb
children
hospit
westmead
retrospect
review
open
usg
percutan
techniqu
compar
intraop
complic
primari
outcom
variabl
secondari
outcom
measur
includ
convers
open
techniqu
complic
oper
time
cathet
longev
result
case
identifi
open
usg
percutan
age
rang
month
weight
kilogram
cvad
rang
size
eleven
usg
percutan
case
requir
convers
open
signific
differ
intraop
complic
rate
open
usg
percutan
group
p
signific
differ
overal
complic
oper
time
cathet
longev
mechan
blockag
significantli
higher
open
group
usg
percutan
group
vs
conclus
usg
percutan
cvad
insert
safe
children
weigh
ten
kilogram
less
open
cathet
insert
may
associ
higher
rate
cathet
blockag
small
children
h
wang
h
x
j
children
hospit
surgic
oncolog
beij
china
backgroundobject
surgeri
accept
optim
treatment
bilater
wilm
tumor
experi
need
accumul
sinc
limit
case
data
particularli
complic
diseas
designmethod
retrospect
review
conduct
case
enrol
beij
children
hospit
synchron
bilater
wilm
tumor
oct
oct
patient
demograph
imag
studi
surgic
techniqu
chemotherapi
patholog
report
review
result
fifti
three
patient
identifi
nine
patient
receiv
upfront
surgeri
three
patient
receiv
bilater
procedur
one
surgeri
total
procedur
case
procedur
nephrectomi
underw
initi
period
succeed
later
period
max
diamet
tumor
kidney
resect
success
procedur
largest
tumor
measur
procedur
underw
without
temporari
vascular
occlus
interrupt
vascular
occlus
renal
pedicl
carri
minut
procedur
oper
relat
erythrocyt
transfus
renal
vessel
thrombogenesi
multifoc
diseas
challeng
plasti
salvag
kidney
conduct
polyest
biolog
patch
patholog
review
favor
case
upon
siop
stage
one
case
stage
lung
metastasi
other
stage
postop
complic
includ
one
case
intestin
obstruct
one
case
renal
failur
complic
includ
tumor
recurr
patient
local
site
patient
implant
nodul
peritoneum
diffus
retroperiton
lymphonodu
seven
patient
report
death
follow
conclus
procedur
feasibl
bilater
wilm
tumor
multifoc
diseas
challeng
surgeri
complic
minim
renal
function
surviv
excel
warmann
c
j
j
children
hospit
pediatr
surgeri
pediatr
urolog
germani
hospit
diagnost
intervent
radiolog
germani
hospit
neurosurgeri
germani
backgroundobject
success
solid
tumor
surgeri
children
regularli
hamper
infiltr
essenti
organ
structur
regularli
imag
data
suggest
conflict
complet
tumor
resect
preserv
organ
integr
andor
function
involv
central
peripher
nerv
often
seem
make
resect
tumor
imposs
designmethod
retrospect
analyz
data
data
children
solid
tumor
relevantli
involv
essenti
neuron
structur
children
underw
surgeri
simultan
perform
pediatr
surgeon
neurosurgeon
analys
perform
regard
surgic
oncolog
outcom
result
diagnos
children
neurofibromatosi
type
neuroblastoma
ewe
sarcoma
desmoid
tumor
site
tumor
thorac
pelvi
abdominalretroperiton
leg
neck
ellbow
three
patient
ewe
sarcoma
desmoid
tumor
tumor
relaps
median
age
surgeri
year
rang
year
macroscop
complet
resect
achiev
patient
remain
case
subtot
tumor
resect
perform
patient
tumor
limb
amput
plan
outsid
institut
howev
simultan
interdisciplinari
surgeri
procedur
could
success
perform
affect
patient
children
nerv
replac
perform
en
bloc
resect
tumor
neuron
structur
postop
complic
occur
three
instanc
transient
foot
flexor
paresi
transient
sensori
motor
deficit
patient
aliv
median
month
conclus
simultan
interdisciplinari
surgeri
combin
neurosurg
techniqu
success
approach
realiz
local
control
tumor
affect
neuron
structur
although
approach
mainli
relev
select
cohort
patient
contain
import
implic
achiev
complet
tumor
resect
certain
condit
solid
tumor
h
wei
q
w
cheng
beij
childrenshospit
bei
jing
china
children
hospit
pediatr
surgeri
oncolog
baod
china
children
hospit
pediatr
surgeri
oncolog
beij
china
backgroundobject
sinusoid
obstruct
syndrom
liver
so
also
known
diseas
vod
commonli
describ
complic
chemotherapi
children
wilm
tumor
observ
suggest
like
caus
hso
outcom
complic
remain
disput
designmethod
present
case
children
wilm
tumor
develop
so
receiv
chemotherapi
consist
vincristin
clinic
featur
summar
result
case
stage
ii
wilm
tumor
right
side
receiv
chemotherapi
dactinomycin
vincristin
develop
so
hepatomegali
pain
weight
gain
palpabl
ascit
liver
dysfunct
bilirubin
abnorm
activ
partial
thromboplastin
time
aptt
prolong
serum
level
elev
boy
girl
diffus
hepatomegali
inhomogen
liver
parenchyma
unclear
thinner
hepat
vein
hydrothoraxascit
splenomegali
observ
doppler
sonographi
patient
underw
liver
biopsi
treatment
basic
symptomat
support
fluid
restrict
defibrotid
involv
treatment
complet
resolut
clinic
sign
amelior
lab
abnorm
follow
within
sever
month
prognosi
good
patient
conclus
children
wilm
tumor
right
side
receiv
chemotherapi
consist
given
greater
awar
so
present
minim
sign
hepatomegali
sudden
weight
gain
liver
dysfunct
coagul
dysfunct
patient
complic
resolv
unev
dk
yadav
dk
india
institut
medic
new
delhi
pediatr
surgeri
new
delhi
india
backgroundobject
evalu
clinic
present
outcom
renal
tumour
children
designmethod
patient
regist
paediatr
surgeri
tumour
clinic
jan
jan
diagnos
tumour
studi
prospect
clinic
present
outcom
result
case
renal
tumor
tumor
case
congenit
mesoblast
nephroma
cmn
present
lump
f
mean
age
present
month
well
follow
period
fup
month
patient
cystic
nephroma
cn
present
lump
mean
age
present
month
well
fup
patient
clear
cell
sarcoma
kidney
ccsk
present
lump
male
mean
age
present
month
one
patient
well
anoth
die
multipl
site
recurr
fup
month
patient
intra
renal
neuroblastoma
nb
present
lump
die
adjuv
chemotherapi
patient
renal
peripher
neuroectoderm
tumor
pnet
present
lump
yr
age
receiv
adjuv
chemotherapi
well
fup
month
patient
transloc
renal
cell
carcinoma
rcc
present
hematuria
lump
f
mean
age
present
month
one
patient
transloc
rcc
develop
local
recurr
lung
metastasi
metastasectomi
done
well
fup
month
second
patient
transloc
rcc
develop
local
recurr
vertebr
metastasi
bl
multipl
lung
metastasi
advis
palli
therapi
third
well
nine
patient
treat
nephrectomi
alon
four
patient
requir
chemotherapi
includ
chemotherapi
ccsk
nb
adjuv
chemotherapi
pnet
conclus
though
clinic
present
tumour
like
wilm
tumour
outcom
vari
depend
histopatholog
b
yalcin
b
c
n
c
univers
faculti
medicin
pediatr
oncolog
ankara
turkey
univers
faculti
medicin
pediatr
surgeri
ankara
turkey
univers
faculti
medicin
patholog
ankara
turkey
backgroundobject
owe
high
success
rate
salvag
recurr
surveil
strategi
orchiectomi
adapt
manag
stage
testicular
nonseminomat
germ
cell
tumor
nsgct
studi
aim
review
institut
experi
stage
testicular
nsgct
teratoma
manag
surveil
surgeri
designmethod
retrospect
review
file
boy
diagnos
local
testicular
nsgct
hospit
data
demograph
characterist
clinicopatholog
find
serum
tumor
marker
event
manag
approach
final
outcom
record
analyz
result
case
testicular
nsgct
identifi
malign
nsgct
median
age
month
teratoma
median
age
month
histopatholog
diagnos
yolk
sac
tumor
yst
matur
teratoma
mt
immatur
teratoma
mix
gct
embryon
carcinoma
ec
age
yst
month
mix
gct
alpha
afp
level
elev
yst
ecmix
gct
level
elev
ecmix
gct
postop
patient
clinic
radiolog
surveil
clinic
laboratori
radiolog
control
median
month
case
experienc
recurr
yst
afp
elev
month
yst
afp
elev
pulmonari
metastasi
month
mix
gct
elev
retroperiton
metastasi
month
ec
mediastin
metastasi
month
recurr
treat
bep
chemotherapi
bleomycinetoposidecisplatin
complet
remiss
surviv
median
month
case
lost
aliv
diseas
free
conclus
surveil
orchiectomi
reliabl
strategi
compliant
stage
testicular
nsgct
case
recurr
detect
earli
treat
success
b
yalcin
b
yagci
b
b
c
univers
faculti
medicin
pediatr
oncolog
ankara
turkey
univers
faculti
medicin
pediatr
surgeri
ankara
turkey
univers
faculti
medicin
patholog
ankara
turkey
univers
faculti
medicin
radiolog
ankara
turkey
backgroundobject
solid
pseudopapillari
neoplasm
pancrea
spnp
mostli
seen
young
women
second
third
decad
life
quit
uncommon
children
complet
surgic
resect
cur
nearli
patient
aim
review
institut
experi
spnp
children
designmethod
hospit
chart
children
year
age
diagnos
spnp
hospit
review
retrospect
data
demograph
characterist
present
symptom
diagnost
intervent
physic
examin
find
radiolog
data
extent
diseas
diagnost
manag
strategi
final
outcom
collect
analyz
result
nineteen
case
diagnos
spnp
hospit
femalemal
median
age
year
rang
common
symptom
abdomin
pain
physic
examin
normal
case
three
case
diagnos
incident
common
tumor
local
head
pancrea
median
tumor
diamet
cm
histopatholog
diagnosi
confirm
case
fine
needl
aspir
biopsi
one
patient
abdomin
dissemin
diseas
other
local
diseas
surgic
intervent
enucl
distal
pancreatectomi
total
resect
patient
patient
follow
surgeri
follow
diagnosi
one
patient
receiv
adjuv
chemotherapi
radiotherapi
overal
one
patient
die
one
lost
month
event
median
month
conclus
children
spnp
demonstr
differ
clinic
featur
compar
adult
complet
resect
cur
patient
unresect
recurr
tumor
cisplatin
base
chemotherapi
might
consid
children
optim
surgic
strategi
spnp
still
debat
instead
radic
resect
limit
pancreat
resect
like
enucl
neg
surgic
margin
attempt
preserv
much
pancreat
tissu
spleen
possibl
abdelrahman
h
al
h
cancer
hospit
egypt
pharmaceut
servic
scienc
cairo
egypt
cancer
hospit
egypt
clinic
research
cairo
egypt
cairo
univers
depart
pharmacolog
toxicolog
cairo
egypt
cancer
hospit
egypt
depart
pediatr
oncolog
stem
cell
transplant
cairo
egypt
backgroundobject
risk
cisplatin
nephrotox
increas
increas
cumul
dose
bolu
dosag
associ
nephrotox
drug
advers
event
earli
detect
manag
improv
patient
care
object
identifi
incid
cisplatin
nephrotox
within
paediatr
well
associ
risk
factor
also
identifi
sensit
test
earli
toxic
detect
possibl
use
earli
therapi
cycl
exposur
predictor
late
nephrotox
designmethod
observ
prospect
studi
patient
schedul
receiv
standard
protocol
run
patient
score
nephrotox
event
glomerular
filtrat
rate
renal
salt
wast
throughout
chemotherapi
cours
use
nation
cancer
institut
common
terminolog
criteria
advers
event
event
sever
correl
patient
demograph
cisplatin
dosag
associ
nephrotox
drug
diseas
risk
use
logist
regress
analys
v
use
test
strength
associ
late
nephrotox
rel
earlier
cycl
toxic
also
differ
nephrotox
event
rel
overal
patient
exposur
result
patient
develop
grade
event
grade
grade
femal
gender
rapid
cisplatin
dose
rate
nephrotox
drug
signific
predictor
higher
toxic
grade
upon
univari
logist
regress
odd
ratio
confid
interv
ci
upon
multivari
logist
regress
aminoglycosid
therapi
signific
predictor
higher
nephrotox
score
odd
ci
v
earli
cisplatin
toxic
v
chemotherapi
toxic
late
toxic
renal
event
sever
overal
patient
exposur
sodium
potassium
phosphoru
magnesium
creatinin
conclus
sever
nephrotox
observ
children
receiv
cisplatin
serum
potassium
sodium
phosphoru
sensit
toxic
detector
nephrotox
chemotherapi
indic
late
nephrotox
combin
femal
gender
rapid
cisplatin
dose
rate
nephrotox
drug
increas
nephrotox
sever
aminoglycosid
withwithout
factor
increas
nephrotox
risk
h
k
n
f
v
faisal
specilaist
hospit
research
centr
pediatr
hematolog
oncolog
riyadh
saudi
arabia
faisal
specilaist
hospit
research
centr
pediatr
nurs
riyadh
saudi
arabia
faisal
specilaist
hospit
research
centr
data
warehous
busi
intellig
depart
riyadh
saudi
arabia
backgroundobject
late
afternoon
discharg
often
associ
admiss
bottleneck
aris
discharg
administr
encourag
clinician
adapt
discharg
noon
dbn
practic
king
faisal
specialist
hospit
research
centr
kfsh
rc
riyadh
oper
trigger
dbn
rate
set
pediatr
hematolog
oncolog
pho
depart
nation
referr
center
malign
case
includ
limit
hematopoiet
stem
cell
transplant
hsct
care
averag
new
case
transplant
per
year
designmethod
weekli
interdisciplinari
round
entitl
discharg
plan
meet
dpm
introduc
earli
retrospect
analysi
compar
dbn
rate
averag
length
stay
alo
outpati
util
rate
patient
perform
result
interdisciplinari
presenc
attend
physician
pharmacist
social
worker
case
manag
clinic
nurs
coordin
nutritionist
charg
nurs
clinic
research
specialist
research
data
manag
staff
result
earli
identif
medic
issu
op
care
evalu
earli
start
increas
dbn
rate
decreas
alo
vs
observ
period
intervent
patient
known
risk
within
day
add
patient
flow
decreas
day
rate
vs
increas
case
vs
case
outpati
util
observ
elimin
hickman
line
relat
conclus
experi
interdisciplinari
discharg
plan
process
enabl
system
effect
commun
priorit
practic
award
annual
perform
award
institut
qualiti
manag
divis
detail
analysi
understand
effect
dpm
patient
outcom
hospit
metric
term
underway
e
alexand
j
n
children
hospit
dietet
melbourn
australia
backgroundobject
import
role
nutrit
support
paediatr
patient
undergo
haematopoiet
stem
cell
transplant
hsct
well
recognis
howev
intern
evid
demonstr
inconsist
way
nutrit
need
address
acut
time
feed
algorithm
children
adolesc
hsct
develop
dietitian
royal
children
hospit
rch
melbourn
input
oncolog
immunolog
gastroenterolog
clinic
nutrit
team
algorithm
develop
help
clinician
make
consist
decis
around
appropri
use
enter
nutrit
en
parenter
nutrit
pn
acut
hsct
phase
purpos
current
project
evalu
algorithm
assess
effect
outcom
determin
barrier
use
designmethod
standard
nutrit
practic
hsct
rch
patient
nasogastr
tube
ngt
place
around
day
commenc
enter
nutrit
support
use
peptid
base
formula
project
standard
nutrit
practic
follow
implement
hsct
feed
algorithm
guid
recommend
en
pn
use
base
clinic
symptom
result
data
collect
children
adolesc
underw
allogen
hsct
month
period
data
present
number
children
within
differ
diagnost
group
anthropometr
measur
use
en
pn
complianc
nutrit
feed
algorithm
barrier
use
conclus
feed
algorithm
children
adolesc
undergo
hsct
implement
evalu
although
algorithm
aid
consist
decis
make
nutrit
support
patient
group
barrier
identifi
patient
lead
inadequ
use
en
andor
inappropri
use
pn
futur
focu
direct
address
barrier
j
l
l
l
u
athal
univers
pediatr
oncolog
hamilton
canada
children
hospit
eastern
ontario
cheo
pediatr
oncolog
ottawa
canada
hospit
sick
children
pediatr
oncolog
toronto
canada
centr
southeastern
ontario
kingston
gener
hospit
pediatr
oncolog
kingston
canada
children
hospit
london
health
scienc
pediatr
oncolog
london
canada
universityhamilton
health
scienc
pediatr
oncolog
hamilton
canada
univers
depart
health
research
evid
impact
hamilton
canada
backgroundobject
prospect
observ
cohort
studi
import
evalu
morbid
children
cancer
studi
provid
level
evid
random
control
trial
avoid
disadvantag
associ
retrospect
studi
name
limit
insight
tempor
sequenc
poor
qualiti
miss
data
howev
conduct
prospect
cohort
studi
challeng
examin
obstacl
encount
initi
conduct
prospect
analyt
cohort
studi
evalu
central
venou
line
dysfunct
impact
outcom
children
cancer
designmethod
studi
aim
enrol
children
year
new
diagnos
cancer
pediatr
oncolog
center
ontario
studi
protocol
gener
review
collabor
site
investig
statistician
variabl
data
collect
manag
procedur
timelin
establish
prior
commenc
result
initi
challeng
secur
fund
studi
support
establish
despit
difficulti
encount
result
delay
studi
timelin
anticip
patient
enrol
period
extend
year
enrol
requir
sampl
size
studi
commenc
obstacl
includ
variabl
institut
ethic
requir
approv
delay
contract
barrier
patient
enrol
logist
challeng
conduct
studi
includ
staff
turnov
manag
larg
volum
data
challeng
address
collabor
monthli
teleconfer
respond
adapt
issu
strateg
engag
research
staff
studi
site
ultim
elig
particip
contribut
data
studi
conclus
adequ
plan
time
resourc
must
allot
execut
prospect
observ
cohort
studi
central
joint
ethic
approv
across
region
nation
center
may
expedit
studi
initi
studi
conduct
support
care
studi
alongsid
larg
therapeut
trial
may
facilit
data
collect
bakhshi
r
g
india
institut
medic
scienc
medic
oncolog
new
delhi
india
council
medic
research
nutrit
delhi
india
backgroundobject
believ
micronutri
may
affect
variou
cellular
process
defici
may
advers
impact
outcom
data
pertain
lack
view
lacuna
evalu
impact
baselin
vitamin
folic
acid
selenium
copper
zinc
iron
os
ef
complet
remiss
cr
acut
lymphoblast
leukemia
designmethod
prospect
observ
studi
conduct
octob
de
novo
patient
serum
folic
acid
measur
boil
competit
immunoassay
vitamin
solid
phase
competit
chemiluminsc
enzym
immunoassay
copper
zinc
selenium
mass
spectrometri
iron
ferrozin
method
without
deprotein
ef
os
measur
method
comparison
outcom
made
patient
defici
vs
normal
valu
anoth
comparison
made
divid
patient
base
median
valu
micronutri
result
total
patient
werer
enrol
median
age
year
rang
patient
defici
serum
folic
acid
vitamin
zinc
selenium
copper
iron
respect
statist
signific
differ
defici
vs
normal
median
vs
median
baselin
micronutri
valueswith
respect
os
ef
cr
trend
toward
better
ef
patient
normal
serum
copper
serum
iron
compar
patient
divid
basi
median
valu
trend
toward
wors
ef
patient
whose
vitamin
median
conclus
largest
studi
evalu
impact
micronutri
outcom
data
suggest
baselin
serum
folic
acid
vitamin
zinc
selenium
copper
iron
impact
os
ef
cr
perhap
micronuti
supplement
warrant
patient
undergo
chemotherapi
sb
k
p
bansal
institut
medic
educ
research
hematologyoncolog
dept
advanc
pediatr
center
chandigarh
india
institut
medic
educ
research
medic
microbiolog
chandigarh
india
backgroundobject
aim
studi
baselin
colon
gut
organ
mdro
surveil
stool
cultur
children
hematolog
malign
correl
bacteria
isol
blood
cultur
episod
febril
neutropenia
cours
treatment
designmethod
design
studi
set
first
second
stool
cultur
collect
diagnosi
start
chemotherapi
respect
patient
follow
episod
febril
neutropenia
posit
blood
cultur
obtain
treatment
compar
stool
cultur
isol
concord
concord
defin
similar
speci
sensit
pattern
result
eighti
patient
enrol
mean
age
year
diagnosi
aml
number
mdro
first
second
stool
cultur
respect
includ
escherichia
coli
enterococcu
faecium
klebsiella
pneumonia
among
other
patient
die
sepsi
pneumonia
bleed
patient
mdro
first
stool
cultur
die
within
day
start
treatment
isol
patient
first
stool
cultur
die
within
day
posit
blood
cultur
obtain
patient
mdro
identifi
mere
one
patient
concord
escherichia
coli
first
stool
cultur
blood
cultur
increas
mortal
among
patient
colon
mdro
observ
compar
colon
howev
concord
mdro
stool
cultur
isol
subsequ
blood
cultur
conclus
isol
mdro
stool
surveil
cultur
signific
risk
factor
mortal
children
hematolog
malign
bauter
l
g
l
b
de
univers
hospit
pediatr
oncolog
stem
cell
transplant
ghent
belgium
univers
hospit
pharmaci
ghent
belgium
backgroundobject
infect
remain
import
caus
morbid
mortal
children
acut
myeloid
leukemia
aml
recent
year
ciprofloxacin
prophylaxi
introduc
hospit
reduc
risk
infecti
complic
recent
report
howev
describ
breakthrough
viridan
group
streptococci
vg
bacteremia
children
aml
receiv
fluoroquinolon
fq
prophylaxi
aim
studi
investig
impact
bloodstream
infect
term
preval
type
isol
speci
pediatr
aml
popul
receiv
fq
prophylaxi
designmethod
retrospect
studi
pediatr
patient
hospit
period
treat
accord
subsequ
intern
aml
protocol
pharmaceut
laboratori
record
analyz
determin
use
fq
ciprofloxacin
identifi
posit
hemocultur
hc
statist
analysi
perform
chi
squar
test
result
studi
includ
patient
de
novo
relaps
aml
repres
episod
hospit
fq
prophylaxi
administ
episod
hc
posit
episod
episod
fq
prophylaxi
use
look
speci
isol
episod
mix
speci
identifi
patient
receiv
prophylaxi
episod
fq
reveal
vg
mix
speci
p
conclus
use
fq
prophylaxi
associ
significantli
higher
number
vg
posit
hc
prompt
us
stop
fq
prophylaxi
pediatr
patient
larger
retrospect
studi
valid
find
current
ongo
beck
j
h
j
medic
center
johann
gutenberg
univers
mainz
children
pediatr
oncolog
hemostaseolog
mainz
germani
medic
center
johann
gutenberg
univers
mainz
children
pediatr
surgeri
mainz
germani
medic
center
johann
univers
mainz
institut
clinic
chemistri
laboratori
medicin
mainz
germani
backgroundobject
central
venou
access
devic
cvad
provid
import
benefit
manag
oncolog
pediatr
patient
howev
cathet
respons
sever
complic
particular
thrombot
event
context
aim
analyz
patient
receiv
cvad
depart
pediatr
hematolog
oncolog
univers
hospit
mainz
period
year
focus
cvad
relat
complic
designmethod
pediatr
oncolog
patient
cvad
retrospect
includ
studi
data
demograph
well
intraop
postop
complic
extract
result
total
patient
analyz
patient
cvad
implant
right
bodi
side
cephal
vein
jugular
vein
subclavian
vein
six
patient
sever
thrombot
complic
identifi
involv
patient
cvad
implant
right
side
patient
thrombosi
upper
extrem
found
suffer
sever
pulmonari
embol
pe
diagnos
first
day
treatment
patient
pe
tunnel
cvad
implant
patient
least
one
mutat
plasminogen
gene
polymorphismand
analyz
patient
least
one
mutat
methylen
tetrahydrofol
reductas
mthfr
could
detect
thrombot
event
could
treat
success
patient
surviv
could
continu
chemotherapi
patient
methotrex
compon
treatment
protocol
conclus
cohort
thrombot
event
rare
analyz
patient
mutat
mthfr
could
found
besid
genet
evalu
advanc
measur
homocystein
could
possibl
support
specifi
risk
chemotherapi
borker
p
cancer
somaiya
india
depart
paediatr
oncolog
mumbai
india
backgroundobject
ptz
recommend
empir
treatment
febril
neutropenia
fn
patient
receiv
chemotherapi
evalu
efficaci
ptz
treatment
fn
unit
designmethod
retrospect
studi
patient
admit
fn
neutropen
infect
septemb
februari
patient
receiv
ptz
mgkgdose
hourli
first
line
antibiot
therapi
second
line
antibiot
start
patient
respond
hour
cultur
dictat
coverag
gram
posit
organ
anti
fungal
therapi
administ
per
guidelin
antibiot
continu
till
hour
defervesc
recoveri
neutropenia
document
infect
document
neg
blood
cultur
whichev
later
result
episod
fn
patient
age
rang
year
mean
age
year
male
femal
ratio
mean
lowest
anc
rang
fourteen
patient
hematolymphoid
malign
patient
solid
tumour
episod
high
risk
neutropenia
respons
first
line
antibiot
seen
episod
clinic
document
infect
cdi
present
episod
respons
first
line
antibiot
seen
case
cdi
microbiolog
document
infect
mdi
present
episod
nine
mdi
due
gram
neg
organ
candida
none
mdi
respond
first
line
antibiot
primari
anti
fungal
prophylaxi
use
episod
episod
presumpt
fungal
infect
proven
fungal
infect
mortal
conclus
respons
ptz
first
line
antibiot
poor
major
patient
high
risk
neutropenia
need
second
line
antibiot
e
g
h
univers
faculti
medicin
depart
pediatr
sakarya
turkey
baysal
univers
faculti
medicin
depart
physiolog
bolu
turkey
univers
faculti
medicin
depart
peatholog
sakarya
turkey
univers
faculti
medicin
depart
microbiolog
sakarya
turkey
univers
faculti
medicin
depart
biochemistri
sakarya
turkey
univers
faculti
medicin
depart
pharmacolog
sakarya
turkey
univers
faculti
medicin
depart
pediatr
hematolog
oncolog
sakarya
turkey
backgroundobject
methotrex
mtx
effici
anticanc
immun
suppress
drug
hepatotox
one
major
side
effect
mtx
limit
use
studi
investig
hepatoprotect
effect
silibinin
role
oxid
stress
marker
cytokin
high
dose
methotrex
induc
hepatotox
rat
designmethod
rat
randomli
divid
five
group
mtx
mgkg
intraperiton
administ
first
day
group
except
control
silibinin
inject
five
day
group
dose
mgkgday
respect
sixth
day
blood
liver
sampl
obtain
rat
sacrif
serum
total
antioxid
capac
total
oxid
statu
total
thiol
nativ
thiol
alanin
aminotransferas
alt
aspart
transaminas
ast
bilirubin
albumin
level
measur
oxid
stress
index
disulphid
level
calcul
paramet
addit
histopatholog
evalu
liver
tissu
peform
result
mtx
reduc
total
antioxid
capac
howev
effect
total
oxid
capac
oxid
stress
index
mtx
increas
disulphidetot
thiol
ratio
reduc
total
thiol
nativ
thiol
level
nativetot
thiol
ratio
induc
oxid
stress
hand
silibinin
reduc
disulphid
level
mtx
reduc
alt
albumin
level
howev
affect
ast
bilirubin
level
level
chang
administr
mtx
andor
silibinin
histopatholog
examin
reveal
mtx
increas
hepat
damag
mgkgdose
silibinin
prevent
inflammatori
cell
infiltr
particular
conclus
silibinin
mgkgday
reduc
hepat
damag
mtx
induc
hepatotox
rat
howev
effect
reflect
biochem
marker
protect
effect
silibinin
made
antioxid
properti
cytokin
fb
l
uslu
professor
bezmialem
vakif
univers
pediatr
hematolog
oncolog
istanbul
turkey
univers
medic
faculti
nuclear
medicin
istanbul
turkey
patholog
istanbul
turkey
backgroundobject
retino
asid
ra
type
vitamin
use
convert
malign
neuroblast
benign
matur
cell
neuroblastoma
report
state
vitamin
causs
hypercalcemia
metastasi
like
boni
chang
scan
report
better
mibg
diagnosi
lesion
neuroblastoma
yr
old
neuroblastoma
case
ra
treatment
report
due
fals
posit
scan
designmethod
yr
old
boy
diagnos
neuroblastoma
origin
right
side
adren
gland
distant
metastasi
free
tumor
gro
total
resect
mass
lesion
start
ra
mainten
therapi
magnet
reson
imag
mri
obtain
everi
month
result
last
mri
mm
metastat
lesion
right
femor
proxim
diaphysi
detect
complain
physic
examin
unremark
blood
chemistri
includ
neuron
specif
enolas
urin
vanilmandel
acid
within
normal
limit
dotat
petmri
obtain
order
rule
boni
metastasi
howev
lesion
dota
posit
confirm
metastasi
biopsi
carri
patholog
within
normal
tissu
limit
conclus
ra
treatment
might
caus
metastasi
like
chang
bone
dotat
petmri
report
superior
detect
primari
relaps
lesion
howev
report
show
dotat
pet
scan
might
fals
posit
great
caution
undertaken
particularli
ra
treatment
castro
w
g
c
de
cartagena
pediatr
depart
cartagena
colombia
bla
de
lezo
oncohematolog
depart
cartagena
colombia
de
cartagena
microbiolog
depart
cartagena
colombia
bla
de
lezo
pediatr
intens
care
unit
cartagena
colombia
rafael
epidemiolog
cartagena
colombia
backgroundobject
febril
neutropenia
fn
frequent
complic
pediatr
oncolog
therapeut
approach
challeng
oncolog
unit
low
countri
intens
chemotherapi
increas
risk
fn
patient
fn
infect
present
bacteremia
mortal
associ
fn
event
near
high
countri
determin
impact
mortal
new
risk
classif
strategi
pediatr
patient
fn
designmethod
compar
studi
three
cohort
first
cohort
retrospect
intern
manag
protocol
patient
fn
appli
protein
procalcitonin
lactat
determin
establish
risk
classif
sepsi
second
cohort
prospect
new
risk
classif
appli
measur
biomark
admiss
hour
gener
earli
interventionist
manag
patient
third
cohort
new
risk
classif
maintain
modif
ad
use
antimicrobi
therapi
result
analyz
fn
event
cohort
treat
intern
guidelin
cohort
treat
protocol
differ
sex
distribut
median
age
year
diagnosi
acut
lymphoblast
leukemia
acut
myeloid
leukemia
other
tumor
neutrophil
count
posit
blood
cultiv
patient
cohort
classifi
high
risk
mortal
conclus
implement
protocol
institut
decreas
mortal
patient
fn
consecut
year
adequ
risk
classif
offer
difer
treatment
strategi
get
better
final
result
risk
classif
strategi
import
oncolog
center
w
chan
p
g
sy
mari
hospit
paediatr
adolesc
medicin
hong
kong
hong
kong
sar
backgroundobject
tuberculosi
tb
import
infect
hong
kong
hk
hk
list
list
world
health
organ
intermedi
burden
tb
amongst
western
pacif
region
area
everi
year
notifi
case
tb
hk
everi
person
hk
develop
diseas
year
rate
time
higher
western
develop
countri
like
unit
state
us
unit
kingdom
uk
myelosuppress
effect
acut
myeloid
leukaemia
aml
subsequ
cytotox
chemotherapi
predispos
patient
develop
tb
infect
designmethod
herebi
report
old
girl
acut
myeloid
leukaemia
aml
institut
receiv
induct
chemotherapi
accord
protocol
develop
right
calcan
osteomyel
due
atyp
mycobacteria
cours
induct
chemotherapi
literatur
review
person
commun
collabor
within
nopho
group
experi
similar
complic
result
urgent
surgic
debrid
perform
patient
intraop
confirm
diagnosi
right
calcan
osteomyel
extens
form
subcutan
abscess
drainag
done
follow
chemotherapi
clarithromycin
levofloxacin
amikin
ethambutol
good
clinic
respons
note
conclus
high
index
suspicion
tuberculosi
infect
requir
aml
patient
develop
prolong
neutropenia
neutropen
fever
immunosuppres
chemotherapi
espeic
endem
area
hong
kong
h
chau
van
h
tran
phan
phan
l
nguyen
h
nguyen
k
central
hospit
pediatr
center
hue
vietnam
children
care
leagu
asian
children
care
leagu
tokyo
japan
backgroundobject
hue
central
hospit
hch
play
key
role
treat
acut
lymphoblast
leukemia
central
zone
vietnam
cover
geograph
wide
area
surviv
rate
low
abandon
rate
aim
studi
determin
outcom
newli
diagnos
children
treat
hch
june
decemb
report
experi
reduc
abandon
designmethod
retrospect
review
children
admit
june
decemb
diagnosi
confirm
morpholog
fab
criteria
cytochemistri
patient
classifi
standard
risk
sr
high
risk
hr
accord
nci
criteria
use
modifi
protocol
social
support
provid
patientsfamili
result
total
children
analyz
mean
age
year
rang
month
year
male
femal
ratio
sr
hr
patient
respect
overal
complet
remiss
cr
rate
day
induct
sr
hr
induct
death
sr
hr
patient
account
relaps
occur
isol
bm
isol
cn
combin
bm
cn
isol
testi
overal
surviv
os
year
sr
hr
surviv
ef
year
sr
hr
abandon
case
conclus
less
toxic
modifi
protocol
surviv
rate
improv
treatment
relat
mortal
minim
though
high
relaps
rate
still
issu
abandon
reduc
success
holist
strategi
financi
support
manag
famili
group
provid
educ
earli
patient
miss
appoint
free
accommod
near
hospit
patientsfamili
curri
j
e
u
hospit
southampton
depart
paediatr
oncolog
southampton
unit
kingdom
hospit
sick
children
divis
haematolog
oncolog
toronto
canada
margaret
cancer
center
depart
radiat
medicin
toronto
canada
backgroundobject
corticosteroid
remain
util
medic
support
care
children
brain
tumour
standard
dose
regimen
exist
dexamethason
use
caus
signific
side
effect
especi
given
high
dose
lengthi
time
period
hypothes
low
dose
dexamethason
ldd
regimen
would
usual
dose
udd
regimen
symptom
control
children
undergo
cranial
radiat
brain
tumour
designmethod
rct
aim
prospect
evalu
effect
ldd
versu
udd
treat
radiat
induc
vomit
headach
studi
fail
accru
adequ
subsequ
survey
distribut
institut
endeavor
discov
factor
hamper
recruit
respond
specifi
local
dexamethason
prescrib
practic
result
studi
open
decemb
may
propos
subject
recruit
children
randomis
receiv
dexamethason
develop
symptom
either
arm
canadian
institut
enrol
patient
factor
identifi
barrier
enrol
includ
trial
administr
work
patient
inelig
due
prior
steroid
administr
short
recruit
window
time
taken
site
trial
open
particip
institut
local
standard
dexamethason
prescrib
wide
variat
dexamethason
dose
prescrib
children
radiat
induc
symptom
highlight
rang
twice
daili
conclus
prospect
trial
prove
ldd
suffici
therapi
radiat
induc
symptom
regrett
fail
accru
notabl
patient
develop
symptom
headach
andor
vomit
cranial
radiat
prophylact
antagonist
larg
discrep
persist
dexamethason
prescrib
regimen
remain
determin
optim
minim
dose
dexamethason
paediatr
patient
especi
vulner
side
effect
kt
r
dci
whn
women
children
hospit
paediatr
haematologyoncolog
singapor
singapor
women
children
hospit
neurosurg
servic
singapor
singapor
women
children
hospit
paediatr
infecti
diseas
servic
singapor
singapor
backgroundobject
patient
haematolog
malign
ifi
cn
high
mortal
rate
report
three
children
acut
lymphoblast
leukaemia
lymphoma
ifi
cn
success
salvag
multidisciplinari
manag
designmethod
retrospect
studi
children
haematolog
malign
ifi
cn
treat
institut
januari
decemb
result
six
year
old
boy
philadelphia
chromosom
posit
b
acut
lymphoblast
leukaemia
present
paranas
sinus
induct
therapi
antral
wash
resect
necrot
tissu
perform
rhizopu
speci
identifi
antifung
therapi
ambisom
voriconazol
repeat
debrid
done
temporari
chemotherapi
interrupt
develop
intracrani
extens
infarct
left
anterior
middl
cerebr
arteri
caus
hemiparesi
underw
craniotomi
resect
affect
brain
leukaemia
therapi
restart
antifung
therapi
continu
year
although
minim
residu
diseas
mrd
remiss
initi
leukaemia
relaps
mainten
present
plan
stem
cell
transplant
second
remiss
without
fungal
recurr
case
ten
year
old
girl
cell
develop
intracrani
haemorrhag
induct
chemotherapi
secondari
cn
aspergillu
infect
treat
craniotomi
evacu
occas
prolong
antifung
therapi
despit
treatment
interrupt
complet
chemotherapi
remain
remiss
present
month
treatment
persist
right
hemiparesi
express
aphasia
nine
year
old
boy
lymphoblast
lymphoma
induct
chemotherapi
develop
dissemin
aspergillu
infect
lung
brain
spinal
cord
requir
drainag
spinal
intradur
abscess
prolong
antifung
therapi
ambisom
voriconazol
remain
complet
remiss
month
initi
diagnosi
persist
monoparesi
conclus
three
case
highlight
aggress
combin
medic
neurosurg
manag
outcom
cn
ifi
improv
although
neurolog
morbid
kt
aa
r
women
children
hospit
paediatr
haematologyoncolog
singapor
singapor
children
hospit
paediatr
haematologyoncolog
yangon
myanmar
burma
backgroundobject
children
cancer
known
increas
risk
blood
stream
infect
due
immunosuppress
indwel
central
venou
cathet
guidelin
care
febril
neutropen
episod
well
studi
littl
evid
avail
direct
care
febril
neutropen
patient
without
central
venou
cathet
object
perform
retrospect
review
febril
episod
neutropen
paediatr
patient
cancer
determin
patient
signific
infect
bacteraemia
could
influenc
decis
regard
empir
antibiot
therapi
designmethod
singl
institut
retrospect
review
episod
fever
temperatur
absolut
neutrophil
count
paediatr
oncolog
patient
admit
kk
women
children
hospit
one
year
result
total
episod
fever
patient
identifi
major
patient
diagnosi
acut
leukaemia
patient
admit
monitor
intraven
antibiot
empir
treatment
ceftrixon
administ
patient
patient
central
venou
cathet
bacteraemia
found
five
sternotrophomona
maltophilia
campylobact
jejuni
staphylococcu
con
acinetobact
baumannii
two
one
con
bacteraemia
requir
port
remov
hypotens
requir
normal
salin
bolu
seen
two
patient
one
bacteraemia
sternotrophomona
posit
blood
cultur
death
due
sepsi
conclus
studi
highlight
even
non
neutropaen
paediatr
oncolog
patient
central
line
risk
bacteri
sepsi
decis
treat
empir
intraven
antibiot
base
clinic
suspicion
clinician
reli
neutrophil
count
alon
make
antibiot
initi
decis
u
demirsoy
f
univers
medic
school
depart
pediatr
oncolog
koca
turkey
backgroundobject
poor
nutrit
consequ
pediatr
malign
frequent
wit
worldwid
neg
effect
treatment
success
medic
treatment
provid
hardwork
prevent
undernutrit
pediatr
cancer
patient
parent
view
issu
well
identifi
herein
present
nutrit
knowledg
patient
cancer
parent
designmethod
studi
conduct
koca
univers
medic
school
pediatr
oncolog
clinic
novemb
march
patient
age
year
receiv
receiv
cancer
treatment
parent
includ
studi
two
differ
questionnair
nutrit
belief
design
investig
patient
fulfil
studi
criteria
ask
complet
questionnair
question
patient
question
parent
outpati
clinic
result
total
volunt
parent
particip
major
patient
median
age
year
patient
hodgkin
diseas
lymphoma
cn
tumor
twelv
patient
receiv
cancer
treatment
studi
patient
thought
nutrit
problem
cancer
treatment
parenter
nutrit
pn
patient
advis
use
oral
nutrit
supplement
on
patient
advis
group
refus
dislik
featur
on
bad
tast
nauseou
effect
three
parent
educ
parent
graduat
primari
school
parent
state
use
on
parent
patient
use
on
believ
vari
posit
effect
group
pn
prefer
method
need
conclus
turkish
children
cancer
parent
gener
favor
oral
nutrit
supplement
also
prone
choos
pn
oral
intak
possibl
fatima
rc
pediatr
oncolog
lahor
pakistan
medic
centr
oncolog
lahor
pakistan
backgroundobject
anthracyclin
ie
doxorubicin
daunorubicin
mainstay
treatment
signific
impact
outcom
mani
pediatr
chemotherapi
protocol
studi
aim
find
risk
factor
anthracyclin
induc
cardiac
dysfunct
pediatr
patient
studi
conduct
children
hospit
shaukat
khanum
hospit
lahor
multipl
logist
regress
model
appli
assess
risk
factor
develop
cardiac
dysfunct
designmethod
pediatr
oncolog
patient
avail
final
analysi
children
male
mean
age
month
n
common
primari
diagnosi
follow
lymphoma
n
aml
n
daunorubicin
alon
combin
doxorubicin
use
n
patient
cumul
dose
mg
use
n
children
children
receiv
radiat
therapi
per
protocol
sepsi
observ
case
result
post
anthracyclin
children
cardiac
dysfunct
within
month
isol
diastol
dysfunct
develop
dysfunct
within
year
pericardi
effus
expir
signific
cardiac
dysfunct
cumul
dose
p
aor
radiat
therapi
p
aor
sepsi
p
aor
found
independ
risk
factor
associ
anthracyclin
induc
cardiac
dysfunct
univari
level
use
daunorubicin
alon
combin
therapi
p
conclus
conclus
anthracyclin
induc
cardiac
dysfunct
mostli
relat
cumul
dose
use
daunorubicin
alon
combin
doxorubicin
mode
deliveri
radiat
therapi
sepsi
regular
long
term
cardiologist
key
point
earli
diagnosi
therapi
long
term
surviv
fatima
rc
pediatr
oncolog
lahor
pakistan
backgroundobject
cancer
patient
often
suffer
malnutrit
rais
risk
infect
immunocompromis
mark
reduct
qualiti
life
qol
health
outcom
malnutrit
also
enhanc
incid
postop
complic
delay
wound
heal
wound
dehisc
morbid
mortal
investig
malnutrit
among
cancer
patient
assess
nutrit
statu
patient
receiv
chemotherapi
designmethod
studi
conduct
sir
ganga
ram
hospit
lahor
simpl
screen
tool
short
screen
sheet
malnutrit
use
nutrit
assess
patient
receiv
chemotherapi
done
assess
bmi
mid
upper
arm
circumfer
muac
tricep
thick
tst
serum
albumin
total
lymphocyt
count
nitrogen
balanc
intak
macronutri
also
analys
result
accord
full
nutrit
assess
patient
found
malnourish
short
screen
sheet
identifi
patient
malnourish
receiv
chemotherapi
ssm
specif
sensit
patient
exhibit
neg
nitrogen
balanc
conclus
nutrit
neglect
area
clinic
care
earli
nutrit
support
counsel
essenti
order
improv
patient
qualiti
life
qol
mass
media
involv
adequ
attent
given
nutrit
issu
aris
diagnost
therapeut
procedur
c
fiori
r
c
hospit
pediatr
oncolog
cascavel
brazil
backgroundobject
introduct
infect
hai
patient
malign
oncolog
hematolog
diseas
import
caus
morbid
mortal
period
bloodstream
infect
empir
antibiot
therapi
use
immedi
accord
preval
microorgan
affect
age
group
specif
characterist
accord
protocol
scientif
studi
worldwid
object
analyz
epidemiolog
profil
hospit
acquir
bloodstream
infect
children
age
year
age
cancer
hospit
januari
decemb
designmethod
studi
perform
model
retrospect
analysi
blood
cultur
report
activ
surveil
method
coordin
hospit
infect
control
commiss
result
episod
infect
contribut
morbid
period
site
studi
prolong
hospit
time
ic
main
hospit
infect
ih
report
ccih
predomin
age
group
children
age
year
isol
infecti
agent
describ
ic
classifi
fungu
frequent
pathogen
coagulas
neg
staphylococcu
group
follow
pseudomona
aeruginosa
candida
spp
oncolog
diseas
present
absolut
report
ic
acut
lymphocyt
leukemia
follow
neuroblastoma
acut
myeloid
leukemia
conclus
result
studi
allow
us
know
preval
pathogen
hospit
may
help
program
prevent
infect
specif
group
number
microorgan
higher
year
empir
antibiot
therapi
antibiot
use
preval
blood
cultur
growth
candida
spp
increas
prevent
candidemia
c
fiori
l
c
hospit
pediatr
oncolog
cascavel
brazil
backgroundobject
introduct
hospit
infect
ih
pediatr
patient
oncolog
diseas
import
caus
morbid
mortal
consid
relev
public
health
problem
result
high
rate
complic
health
prolong
hospit
period
direct
increas
cost
care
favor
select
dissemin
multiresist
microorgan
adolesc
oncolog
diseas
initi
antimicrobi
treatment
empir
knowledg
microbiolog
profil
fundament
effect
type
treatment
object
analyz
microbiolog
profil
bloodstream
infect
ic
adolesc
year
old
hospit
west
januari
decemb
designmethod
studi
accomplish
retrospect
analysi
blood
cultur
report
activ
surveil
method
coordin
hospit
infect
control
commiss
result
ic
major
hospit
infect
ih
report
predomin
age
group
adolesc
age
year
isol
infecti
agent
describ
ic
compuls
neg
fungi
frequent
pathogen
staphylococcu
epidermidi
follow
pseudomona
aeruginosa
candida
albican
year
present
ic
absolut
notif
age
group
avail
year
sampl
conclus
result
studi
allow
us
know
preval
pathogen
hospit
origin
affect
portabl
infecti
diseas
may
lead
auxiliari
prevent
program
specif
group
number
microorgan
higher
exercis
well
empir
antibiot
use
antibiot
good
coverag
preval
blood
cultur
growth
candida
albican
alert
prevent
candidemia
v
forster
j
h
r
f
van
hospit
sick
children
genet
genom
biolog
toronto
canada
sunderland
faculti
health
scienc
wellb
sunderland
unit
kingdom
univers
northern
institut
cancer
research
newcastl
upon
tyne
unit
kingdom
backgroundobject
advers
neurolog
event
common
treatment
pediatr
acut
lymphoblast
leukemia
includ
seizur
stroke
like
syndrom
leukoencephalopathi
addit
chronic
neurotox
emerg
worri
late
effect
treatment
survivor
experienc
decreas
execut
function
process
speed
memori
function
survivor
also
increas
risk
experienc
learn
difficulti
social
withdraw
issu
inattent
hyperact
disord
methotrex
chemotherapi
agent
mainstay
pediatr
leukemia
treatment
regimen
global
wide
implic
caus
neurolog
side
effect
hypothes
methotrex
disrupt
dna
methyl
via
effect
methionin
key
methyl
compon
previous
describ
regul
gene
involv
myelin
designmethod
use
neural
cell
line
glial
cell
deriv
ipsc
treat
methotrex
assay
chang
dna
methyl
consequenti
effect
gene
express
use
methyl
array
rnaseq
respect
gene
correspond
methyl
express
chang
taken
forward
confirm
express
qpcr
assess
protein
level
result
identifi
methyl
express
chang
gene
involv
neurodevelopment
pathway
neurolog
disord
particular
interest
demethyl
consequenti
increas
gene
express
vital
compon
insulin
signal
pathway
highli
express
neural
tissu
implic
regul
cognit
perform
also
detect
alter
methyl
within
gene
encod
major
protein
compon
myelin
identifi
increas
methyl
methotrex
treatment
oligodendrocyt
result
correspond
reduct
transcript
level
protein
conclus
work
provid
insight
biolog
mechan
behind
neurolog
side
effect
first
time
implic
alter
myelin
potenti
caus
factor
neurotox
ac
r
hospit
specialti
pediatr
oncolog
chihuahua
mexico
hospit
specialti
pediatr
neurolog
chihuahua
mexico
hospit
specialti
pediatr
fellow
chihuahua
mexico
backgroundobject
posterior
revers
encephalopathi
syndrom
pre
condit
caracther
headach
alter
mental
function
seizur
visual
alter
magnet
reson
imagin
show
cerebr
edema
predominantli
white
matter
posterior
distribut
multipl
clinic
condit
act
trigger
retrospect
analysi
present
case
children
undergon
chemotherapi
children
hospit
special
mexico
designmethod
identifi
patient
radiolog
clinic
featur
consist
pre
year
januari
januari
children
hospit
special
mexico
acut
lymphoblast
leukemia
receiv
chemotherapi
present
patolog
rewiew
previu
literatur
present
magnet
reson
imag
ct
scan
result
femal
year
old
remiss
induct
chemotherapi
femal
year
old
consolid
chemotherapi
pre
hypertens
headach
seizur
alter
mental
function
visual
alter
patient
develop
epilepsi
remain
chronic
anticonvulsuv
therapi
conclus
pre
increasingli
recogn
complic
pediatr
tratment
report
chemotherapi
case
children
children
hospit
mexico
year
prompt
diagnost
appropi
therapi
rapid
control
seizur
key
avoid
sequela
c
gardner
r
teach
hospit
trust
children
haematolog
oncolog
unit
leed
unit
kingdom
backgroundobject
febril
neutropenia
one
common
potenti
life
threaten
side
effect
chemotherapi
treatment
advanc
nurs
practition
anp
role
ideal
suit
support
structur
care
adher
agre
guidelin
project
undertaken
order
creat
pathway
proforma
guid
multidisciplinari
team
provid
effici
safe
care
patient
ensur
adher
local
treatment
guidelin
prompt
initi
appropri
step
escal
antimicrobi
treatment
aim
introduc
pathway
proforma
guid
treatment
febril
neutropen
patient
within
local
guidelin
tool
would
support
decis
make
identif
risk
factor
admiss
commenc
febril
neutropen
episod
subsequ
daili
basi
durat
hour
designmethod
comprehens
proforma
introduc
ensur
data
collect
first
assess
complet
antibiot
treatment
febril
neutropaenia
audit
cycl
establish
year
ongo
review
modif
multidisciplinari
agreement
final
tool
reach
result
audit
cycl
demonstr
aspect
document
difficult
follow
complet
subject
guidelin
audit
result
show
complet
complianc
period
audit
follow
cycl
audit
multidisciplinari
review
complet
rate
improv
clinic
experi
suggest
audit
complianc
local
guidelin
show
posit
result
conclus
use
structur
treatment
pathway
improv
qualiti
care
implement
go
audit
pathway
appropri
role
anp
tool
guid
decis
make
manag
febril
neutropenia
improv
effect
antimicrobi
treatment
reduc
treatment
initi
time
hospit
reduc
use
antibiot
patient
help
address
current
issu
antimicrobi
resist
stewardship
k
ghanem
h
n
r
r
n
univers
beirut
pediatr
beirut
lebanon
univers
beirut
faculti
medicin
beirut
lebanon
backgroundobject
fever
neutropenia
episod
common
complic
cancer
therapi
children
may
life
threaten
initi
empir
broad
spectrum
antibiot
within
minut
present
shown
decreas
morbid
mortal
associ
infect
requir
length
treatment
safeti
discharg
criteria
admiss
fever
neutropenia
children
document
infect
extens
evalu
designmethod
retrospect
review
admiss
febril
neutropenia
episod
children
treat
cancer
children
cancer
institut
lebanon
develop
new
fever
sign
infect
risk
readmiss
within
hour
discharg
review
result
total
febril
neutropenia
admiss
identifi
patient
readmit
within
hour
discharg
due
febril
neutropenia
none
readmit
patient
signific
morbiditymort
readmiss
admiss
patient
discharg
anc
admiss
patient
discharg
daili
iv
antibiot
administ
outpati
clinic
fifti
discharg
episod
fever
within
hour
discharg
admiss
receiv
inpati
care
hour
conclus
data
show
risk
infect
readmiss
children
cancer
hospit
febril
neutropenia
discharg
anc
low
suggest
patient
discharg
discontinu
antibiot
prior
full
neutrophil
recoveri
safe
xn
goh
gci
women
children
hospit
pharmaci
singapor
singapor
univers
singapor
pharmaci
singapor
singapor
backgroundobject
symptom
may
use
supplement
report
howev
use
symptom
assess
scale
paediatr
oncolog
patient
still
routin
henc
studi
aim
describ
preval
symptom
children
age
year
undergo
chemotherapi
local
paediatr
hospit
evalu
feasibl
use
symptom
assess
scale
special
popul
designmethod
studi
prospect
longitudin
studi
includ
children
age
year
admit
chemotherapi
paediatr
oncolog
ward
kk
women
children
hospit
kkwch
elig
patient
age
year
administ
memori
symptom
assess
scale
children
msa
older
patient
age
year
given
msa
scale
descript
statist
frequenc
distribut
pearson
test
use
summar
demograph
characterist
describ
item
msa
assess
differ
sever
symptom
report
healthcar
profess
patient
respect
result
total
patient
recruit
april
februari
patient
survey
use
msa
patient
survey
use
msa
lack
appetit
common
msa
msa
respect
symptom
report
major
patient
encount
littl
difficulti
took
averag
sd
minut
complet
msa
msa
respect
conclus
studi
demonstr
children
undergo
chemotherapi
children
hospit
singapor
report
experienc
symptom
cancer
chemotherapi
implement
msa
msa
feasibl
local
set
would
allow
optim
control
symptom
paediatr
oncolog
patient
kg
gopakumar
kk
n
r
cs
vr
cancer
centr
pediatr
oncolog
trivandrum
india
cancer
centr
cancer
epidemiolog
biostatist
trivandrum
india
backgroundobject
limit
data
low
middl
incom
countri
regard
manag
outcom
tumor
lysi
syndrom
tl
children
leukemialymphoma
designmethod
clinic
biochem
characterist
children
intermedi
high
risk
develop
tl
retrospect
studi
three
year
period
depart
pediatr
oncolog
region
cancer
centr
south
india
result
medic
record
review
identifi
children
acut
leukemialymphoma
intermedi
risk
high
risk
develop
tl
tl
develop
case
nineti
children
alon
children
subsequ
progress
develop
clinic
tl
patient
clinic
tl
acut
kidney
injuri
aki
one
patient
develop
seizur
signific
reduct
blood
urea
potassium
uric
acid
observ
p
period
hyper
hydrat
alon
hemodialysi
requir
children
one
aki
present
rasburicas
use
children
high
risk
diseas
mean
dose
rasburicas
use
set
mgkg
low
dose
serum
uric
acid
level
decreas
less
mgdl
within
hour
administr
n
case
two
children
expir
cours
tl
manag
multivari
analysi
identifi
hyperuricemia
associ
signific
risk
develop
tl
aki
conclus
data
underscor
import
aggress
hydrat
judici
use
rasburicas
manag
tl
set
grime
r
texa
health
scienc
center
san
antonio
pediatr
san
antonio
usa
backgroundobject
glucocorticoid
critic
treatment
childhood
acut
lymphoblast
leukemia
howev
contribut
numer
advers
effect
includ
sever
hyperglycemia
affect
treatment
induct
hyperglycemia
sih
associ
lower
overal
surviv
childhood
increas
infecti
complic
particularli
age
year
high
risk
diseas
addit
predispos
factor
includ
ethnic
therefor
aim
evalu
associ
sih
hispan
ethnic
childhood
across
larg
popul
designmethod
evalu
patient
age
treat
cancer
center
data
collect
includ
cancer
diagnosi
age
gender
raceethn
serum
glucos
valu
sih
defin
serum
glucos
mgdl
therapi
result
overal
pediatr
patient
met
criteria
sih
patient
hispan
among
hispan
sih
seen
rr
less
frequent
patient
thu
hispan
ethnic
appear
confer
elev
rel
risk
sih
rel
ethnic
rr
addit
stratifi
age
older
patient
age
year
also
experi
greater
sih
compar
younger
children
rr
effect
amplifi
older
age
hispan
ethnic
combin
rr
gender
also
appear
play
role
femal
childhood
patient
slightli
greater
risk
develop
sih
rel
male
rr
conclus
result
suggest
hispan
ancestri
age
year
femal
gender
confer
increas
risk
sih
childhood
sih
known
independ
risk
factor
decreas
surviv
childhood
aggress
identif
manag
sih
may
therefor
improv
surviv
outcom
hispan
children
thu
current
develop
clinic
trial
assess
sih
manag
impact
patient
outcom
h
guo
medic
univers
pediatr
hematologyoncolog
guangzhou
china
backgroundobject
recent
year
argu
mthfr
gene
polymorph
use
predict
advers
reaction
index
methotrex
hdmtx
chemotherapi
children
acut
lymphoblast
leukemia
lymphoma
studi
intend
studi
predict
indic
mucosa
renal
toxic
high
dose
methotrex
children
lymphoma
designmethod
mthfr
gene
c
c
detect
case
fluoresc
situ
hybrid
dna
sequenc
among
renogram
also
done
case
creatinin
clearanc
ccr
calcul
hour
urin
patient
coordin
time
dosag
mtx
adjust
accord
result
gene
test
chang
mtx
concentr
liver
kidney
function
oral
mucosa
state
observ
methotrex
chemotherapi
correl
three
detect
method
side
effect
mtx
analyz
result
difficult
oper
ccr
difficulti
collect
urin
n
children
factor
affect
accuraci
correl
clinic
side
effect
low
renogram
accur
ccr
high
complianc
genet
test
howev
poor
accuraci
guid
clinic
dose
adjust
radioact
mutat
loci
could
predict
activ
mtfhr
enzym
better
guid
dosag
adjust
mtx
conclus
combin
detect
gene
loci
mutat
effect
conveni
method
predict
toxic
methotrex
need
clinic
verif
whether
determin
urinari
metabolit
replac
gene
detect
f
guru
v
j
kashmir
institut
medic
scienc
paediatr
medic
oncolog
srinagar
india
backgroundobject
febril
neutropenia
fn
commonest
medic
oncolog
emerg
clinic
medicin
studi
depict
clinic
profil
microbiolog
yield
antibiot
sensit
pattern
fn
cancer
patient
receiv
chemotherapi
designmethod
studi
conduct
depart
medic
oncolog
institut
medic
scienc
kashmir
decemb
decemb
patient
recruit
consecut
hematolog
malign
receiv
chemotherapi
present
fn
manag
per
idsa
guidelin
evalu
respect
underli
statu
primari
diseas
microbi
isol
antibiot
sensit
pattern
eventu
outcom
treatment
result
diseas
profil
febril
neutropen
patient
depict
tabl
major
patient
fn
episod
acut
lymphoblast
leukemia
overal
cultur
posit
cultur
isol
shown
tabl
b
common
organ
isol
staphylococcu
aureu
escherichia
coli
acinetobact
pseudomona
stenotrophomona
maltophilia
patient
would
treat
per
idsa
guidelin
would
modifi
basi
cultur
sensit
yield
gram
neg
organ
sensit
imipenem
wherea
sensit
pattern
antibiot
order
decreas
sensit
tazoactum
meropenem
cefipim
amikacin
teicoplanin
respect
tabl
acut
lymphoblast
leukemia
acut
myeloid
leukemia
non
hodgkin
lymphoma
ewe
sarcoma
hodgkin
diseas
tabl
b
staphylococcu
aureu
escherichia
coli
acinetobact
pseudomona
stenotrophomona
maltophilia
conclus
hematolog
malign
high
risk
develop
fn
fn
untreat
almost
alway
fatal
prompt
recognit
subtl
sign
symptom
fn
prompt
institut
appropri
treatment
lead
satisfactori
outcom
fn
therapi
tailor
appropri
antibiot
accord
bacteri
cultur
result
v
guru
v
j
p
institut
medic
oncolog
pediatr
oncolog
chennai
india
backgroundobject
varicella
infect
children
acut
lymphoblast
leukemia
associ
signific
morbid
mortal
immunis
varicella
infect
mandatori
per
nation
immun
program
india
therefor
major
children
unimmun
increas
risk
infect
designmethod
patient
previou
histori
varicella
infect
immun
given
singl
dose
live
attenu
varicella
vaccin
hospit
prior
start
mainten
phase
treatment
present
studi
retrospect
analys
case
record
patient
receiv
varicella
vaccin
year
result
studi
includ
patient
median
age
year
patient
male
median
durat
last
dose
chemotherapi
administr
varicella
vaccin
day
rang
day
patient
develop
vaccin
induc
varicella
among
requir
hospit
median
time
develop
vaccin
induc
varicella
day
rang
day
median
durat
hospit
stay
day
rang
day
percent
patient
system
symptom
present
commonest
fever
rash
median
durat
fever
day
rang
patient
develop
febril
neutropenia
mainten
chemotherapi
withheld
symptomat
patient
median
durat
day
rang
day
breakthrough
varicella
infect
vaccin
seen
patient
mortal
due
vaccin
induc
varicella
conclus
varicella
immun
safe
efficaci
children
consid
countri
varicella
immun
routin
practic
vaccin
induc
varicella
commonli
seen
howev
introduct
varicella
immun
hospit
prevent
mortal
due
varicella
infect
yy
sm
yh
jp
cj
jw
han
univers
colleg
medicin
depart
pediatr
seoul
republ
korea
cancer
center
depart
pediatr
seoul
republ
korea
backgroundobject
hepat
diseas
vod
seriou
system
endotheli
diseas
pose
risk
transplant
relat
morbid
mortal
defibrotid
use
treatment
vod
investig
purpos
prophylaxi
use
defibrotid
prophylaxi
limit
due
high
cost
evalu
prevent
efficaci
low
dose
defibrotid
vod
designmethod
total
patient
patient
prophylaxi
histor
control
underw
autolog
hematopoiet
stem
cell
transplant
depart
pediatr
yonsei
cancer
center
seoul
korea
march
juli
review
retrospect
low
dose
defibrotid
mgkgday
hsct
deliv
patient
incid
vod
case
control
group
evalu
result
common
diagnosi
cohort
brain
tumor
age
diagnosi
treatment
procedur
differ
case
control
group
total
group
develop
vod
control
group
wherea
develop
vod
prophylaxi
group
second
hsct
group
prophylaxi
group
develop
vod
develop
non
prophylaxi
group
vod
sever
sever
control
group
prophylaxi
group
set
second
hsct
total
mortal
control
group
wherea
death
prophylaxi
group
conclus
thu
studi
suggest
low
dose
defibrotid
prophylaxi
work
effect
prevent
hepat
vod
also
r
hayashi
k
k
univers
school
medicin
pediatr
st
loui
usa
univers
school
medicin
program
audiolog
commun
scienc
st
loui
usa
loui
children
hospit
audiolog
st
loui
usa
cancer
washington
univers
school
medicin
surgeri
st
loui
usa
backgroundobject
use
hematopoiet
stem
cell
transplant
hsct
increas
varieti
diseas
ototox
procedur
extens
studi
designmethod
retrospect
chart
review
examin
patient
receiv
hsct
st
loui
children
hospit
januari
april
data
extract
includ
therapi
hsct
subsequ
transplant
cours
evalu
patient
complet
medic
record
interpret
audiogram
ototox
analyz
percent
chang
baselin
use
test
differ
proport
siop
grade
prior
hsct
compar
patient
without
ototox
use
ordin
test
trend
jonckheer
test
logist
regress
fisher
exact
test
identifi
associ
ototox
patient
characterist
result
one
hundr
forti
seven
patient
evalu
ototox
observ
patient
higher
siop
grade
prior
hsct
significantli
associ
higher
risk
ototox
p
prior
cisplatin
p
carboplatin
radiat
also
associ
ototox
hsct
diagnosi
solid
tumor
brain
tumor
p
autolog
transplant
p
also
identifi
patient
higher
risk
event
significantli
associ
ototox
conclus
ototox
affect
signific
percentag
patient
undergo
hsct
care
monitor
need
identifi
patient
impact
procedur
e
hernandez
broncano
j
r
nacion
de
enfermedad
neoplasica
oncologia
pediatrica
lima
peru
backgroundobject
acut
lymphoblast
leukemia
common
diagnosi
pediatr
cancer
instituto
nacion
de
enfermedad
mortal
induct
high
incom
countri
nevertheless
number
higher
develop
countri
aim
determin
clinic
characterist
morbid
mortal
induct
treatment
also
caus
factor
associ
surviv
designmethod
retrospect
descript
studi
januari
decemb
patient
less
year
age
diagnos
includ
patient
evalu
common
caus
mortal
morbid
induct
infect
chemotherapi
toxic
surviv
analysi
perform
use
method
result
includ
patient
median
age
year
rang
year
mf
ratio
median
time
follow
month
patient
relaps
patient
abandon
treatment
die
induct
common
caus
septic
shock
intraparenchym
hemorrhag
patient
least
febril
episod
found
posit
blood
cultur
bacteri
fungal
infect
febril
episod
overal
os
surviv
regard
risk
signific
differ
os
number
febril
episod
conclus
instituto
nacion
de
enfermedad
high
mortal
induct
treatment
compar
develop
countri
caus
death
differ
febril
episod
present
patient
high
percentag
posit
blood
cultur
hino
n
r
k
n
univers
depart
graduat
school
medicin
chiba
japan
univers
depart
infecti
medic
mycolog
research
center
chiba
japan
univers
divis
clinic
medic
mycolog
research
center
chiba
japan
backgroundobject
echinocandin
resist
candida
increas
unit
state
identif
pathogen
fungi
suscept
difficult
pediatr
patient
clarifi
necess
bacteriolog
analysi
treatment
pediatr
fungal
infect
retrospect
analyz
clinic
cours
suscept
bacteriolog
confirm
fungal
infect
treat
institut
designmethod
pediatr
oncolog
patient
januari
decemb
analyz
serum
level
analyz
use
test
wako
drug
suscept
test
perform
use
fungu
dp
eiken
kit
studi
approv
ethic
review
board
facil
result
pseudalleshceria
boydii
isol
boy
suffer
otiti
media
stem
cell
transplant
aspergillu
terreu
repeatedli
isol
ear
discharg
patient
otiti
externa
neutropenia
accord
suscept
test
result
patient
safe
receiv
stem
cell
transplant
voriconazol
combin
micafungin
mcfg
yeast
detect
patient
bloodstream
infect
candida
speci
patient
candida
colon
administ
antifung
prophylaxi
although
titer
clinic
manifest
splenic
abscess
worsen
treat
ctropicali
infect
mcfg
suscept
test
result
c
parapsilosi
high
minimum
inhibitori
concentr
mic
mcfg
girl
diagnosi
treat
candidemia
c
parapsilosi
liposom
amphotericin
b
although
c
glabrata
known
sensit
mcfg
c
glabrata
girl
diagnosi
aml
high
mic
mcfg
mutat
obtain
c
glabrata
conclus
identif
pathogen
fungi
drug
suscept
test
result
import
treat
pediatr
oncolog
patient
cglabrata
resist
echinocandin
reveal
may
increas
pediatr
cancer
patient
hussaini
aga
khan
univers
hospit
karachi
cancer
care
karachi
pakistan
backgroundobject
nutrit
deplet
major
problem
among
pediatr
oncolog
patient
develop
world
associ
treatment
relat
toxic
mortal
studi
found
children
malign
die
due
effect
undernourish
rather
malign
earli
identif
thorough
assess
manag
help
prevent
complic
purpos
studi
estim
preval
malnutrit
present
time
diagnosi
designmethod
sampl
size
pediatr
patient
newli
diagnos
within
last
year
octob
till
decemb
taken
estim
nutrit
statu
patient
time
diagnosi
day
induct
week
post
induct
height
weight
bmi
height
age
weight
age
bmi
age
percentil
patient
collect
analysi
done
use
growth
chart
height
weight
bmi
percentil
note
patient
written
consent
taken
patient
particip
studi
result
overal
analysi
data
show
patient
children
found
height
weight
bmi
percentil
indic
alreadi
undernourish
time
diagnosi
furthermor
children
found
height
weight
bmi
percentil
less
clinic
signific
find
addit
find
patient
signific
weight
loss
day
induct
till
week
post
induct
therapi
conclus
need
adequ
nutrit
assess
throughout
therapi
great
signific
therefor
proper
growth
monitor
time
report
manag
requir
prevent
child
develop
complic
studi
plan
holist
strategi
integr
nutrit
therapi
part
cancer
therapi
hyslop
h
n
r
ga
l
hospit
sick
children
program
child
health
evalu
scienc
toronto
canada
hospit
sick
children
divis
haematologyoncolog
toronto
canada
gener
hospit
depart
medicin
toronto
canada
hospit
sick
children
depart
program
child
health
evalu
scienc
toronto
canada
hosptial
sick
children
divis
program
child
health
evalu
scienc
toronto
canada
backgroundobject
symptom
screen
pediatr
tool
sspedi
valid
symptom
screen
tool
children
receiv
cancer
treatment
assess
degre
bother
symptom
object
describ
proport
bothersom
symptom
use
sspedi
document
medic
record
associ
intervent
designmethod
elig
respond
inpati
year
age
receiv
cancer
treatment
expect
hospit
clinic
three
day
later
children
symptom
bother
use
sspedi
evalu
symptom
document
intervent
medic
record
proxim
sspedi
administr
result
children
includ
median
age
rang
year
symptom
measur
symptom
report
use
sspedi
sever
bothersom
document
medic
record
less
time
infrequ
document
sever
bothersom
symptom
problem
think
rememb
thing
chang
bodi
face
look
chang
tast
tingli
numb
hand
feet
intervent
provis
sever
bothersom
symptom
occur
less
time
symptom
infrequ
treat
symptom
think
rememb
thing
chang
bodi
face
look
tingli
numb
hand
feet
chang
tast
diarrhea
feel
tire
even
intervent
provid
often
prescrib
specif
symptom
conclus
document
symptom
provis
intervent
address
gener
infrequ
sever
symptom
almost
never
document
treat
includ
problem
cognit
bodi
imag
chang
tast
peripher
neuropathi
futur
effort
incorpor
symptom
screen
routin
care
facilit
symptom
manag
improv
access
clinic
practic
guidelin
iguchi
j
univers
pediatr
sapporo
japan
backgroundobject
high
cure
rate
childhood
hematolog
malign
achiev
intens
chemotherapi
studi
investig
reconstitut
immun
system
incid
infect
chemotherapi
patient
hematolog
malign
designmethod
review
medic
record
patient
children
median
year
treat
januari
march
depart
pediatr
hokkaido
univers
hospit
analyz
cell
count
serum
immunoglobulin
g
igg
level
incid
infect
year
chemotherapi
administ
patient
whose
cell
count
exclud
patient
receiv
stem
cell
transplant
result
durat
posit
cell
count
chemotherapi
month
patient
acut
lymphoblast
leukemia
month
patient
acut
myelogen
leukemia
aml
month
patient
lymphoma
nhl
month
patient
hodgkin
lymphoma
hl
month
patient
langerhan
cell
histiocytosi
lch
durat
igg
chemotherapi
month
month
aml
month
nhl
month
hl
month
lch
signific
higher
incid
infect
period
month
chemotherapi
period
month
month
month
respect
conclus
studi
cell
count
igg
level
recov
month
chemotherapi
patient
achiev
low
incid
infect
educ
medic
patient
recoveri
cell
count
igg
level
howev
found
higher
incid
infect
period
month
chemotherapi
period
thu
addit
medic
infect
might
need
patient
period
johnston
r
hospit
eastern
ontario
divis
paediatr
hematologyoncolog
ottawa
canada
sick
children
divis
hematologyoncolog
toronto
canada
children
hospit
divis
hematologyoncolog
calgari
canada
children
hospit
divis
hematologyoncolog
vancouv
canada
justin
hospit
divis
hematologyoncolog
montreal
canada
backgroundobject
melatonin
natur
health
product
use
sleep
disturb
preliminari
studi
adult
advanc
cancer
mg
daili
melatonin
approxim
mgkg
associ
reduct
anorexia
weight
loss
symptom
also
impact
pediatr
oncolog
patient
howev
high
dose
melatonin
studi
pediatr
popul
designmethod
multicentr
singl
arm
phase
dose
escal
studi
util
design
primari
object
determin
safeti
toler
escal
dose
melatonin
pediatr
oncolog
patient
relaps
solid
tumor
secondari
object
determin
cumul
effect
cours
high
dose
melatonin
establish
pharmacokinet
melatonin
establish
cytokin
associ
melatonin
determin
melatonin
improv
weight
gain
melatonin
given
week
dose
level
mgkg
maximum
mg
mgkg
maximum
mg
mgkg
maximum
mg
result
melatonin
well
toler
dose
level
signific
advers
event
grade
toxic
bone
marrow
suppress
attribut
concomit
chemotherapi
occur
dose
level
weight
gain
occur
patient
mean
increas
kg
rang
rang
patient
lose
weight
one
dose
level
one
level
pk
data
show
mean
cmax
ngml
elimin
min
dose
level
cmax
ngml
elimin
min
dose
level
cmax
ngml
elimin
min
dose
level
conclus
melatonin
well
toler
dose
mgkg
maximum
mg
pediatr
popul
studi
provid
background
studi
high
dose
melatonin
pediatr
oncolog
patient
hopanc
h
n
kantar
univers
school
medicin
tulay
akta
oncolog
hospit
izmir
turkey
univers
school
medicin
pediatr
oncolog
izmir
turkey
backgroundobject
nutrit
one
major
concern
treatment
children
cancer
clinic
malnutrit
becom
evid
current
intens
treatment
studi
analyz
current
nutrit
approach
children
designmethod
period
patient
cancer
femal
male
mean
age
year
evalu
term
nutrit
within
hour
admiss
oncolog
clinic
use
strongkid
sk
screen
malnutrit
anthropometr
measur
done
use
height
weight
upper
circumfer
umac
daili
intak
energi
protein
record
nutrit
intervent
given
either
enter
oral
supplement
tube
feed
parenter
way
treatment
period
result
diagnosi
patient
bone
soft
tissu
sarcoma
cn
tumor
leukemia
lymphoma
neuroblastoma
tumor
hospit
admiss
patient
weight
percentil
less
height
percentil
less
percent
patient
weight
loss
time
evalu
bmi
less
patient
wherea
umac
accord
strongkid
screen
patient
medium
risk
high
risk
interestingli
found
patient
lower
energi
intak
less
recommend
lower
protein
intak
part
nutrit
intervent
patient
given
oral
supplement
feed
total
parenter
nutrit
conclus
malnutrit
either
admiss
common
problem
could
affect
cancer
treatment
children
oncolog
clinic
screen
use
scale
anthropometr
measur
evalu
data
nutrit
intervent
need
major
patient
document
studi
p
kanvind
z
k
n
b
jerbai
wadia
hospit
children
pediatr
mumbai
india
backgroundobject
patient
acut
leukemia
al
immunocompromis
high
risk
reactiv
latent
infect
like
tuberculosi
tb
aim
studi
clinic
characterist
patient
diagnos
tb
al
impact
treatment
leukemia
designmethod
retrospect
analysi
al
patient
diagnos
tb
bj
wadia
children
hospit
mumbai
done
characterist
relat
al
site
tb
infect
mode
diagnosi
sensit
pattern
respons
antitubercular
treatment
result
total
patient
al
also
diagnos
tb
acut
lymphoblast
leukemia
diagnos
mainten
induct
present
persist
fever
nonrespons
antibiot
antifung
induct
neutropen
site
involv
isol
lung
patient
pleural
effus
mediastin
lymphadenopathi
persist
patch
chest
radiogram
mediastin
lymphadenoapthi
lung
plu
abdomin
miliari
shadow
ileoceac
thicken
ocular
involv
patient
median
time
diagnosi
tb
post
symptom
appear
week
drug
sensit
pattern
proven
sensit
line
drug
patient
multidrug
resist
mdr
extens
drug
resist
xdr
patient
diagnosi
basi
reschedul
chemotherapi
due
delay
diagnosi
tb
requir
patient
complet
cure
seen
patient
patient
xdr
tb
intens
phase
continu
phase
earli
stoppag
chemotherapi
requir
xdr
tb
patient
due
poor
clinic
condit
wherea
other
requir
alter
chemotherapi
post
diagnosi
tb
hepatotox
seen
conclus
tb
requir
high
index
suspicion
earli
diagnosi
studi
tb
caus
signific
delay
alter
chemotherapi
addit
toxic
p
kanvind
z
k
n
b
jerbai
wadia
hospit
children
pediatr
mumbai
india
backgroundobject
bloodstream
infect
bsi
pediatr
cancer
patient
lead
caus
morbid
mortal
treatment
aim
studi
preval
bsi
antibiot
sensit
pattern
outcom
pediatr
cancer
patient
designmethod
data
cultur
sent
pediatr
cancer
unit
bj
wadia
children
hospit
june
januari
analyz
microbiolog
profil
sensit
pattern
clinic
featur
outcom
result
total
blood
cultur
sampl
sent
suspect
bloodstream
infect
cultur
posit
isol
central
venou
line
cultur
proven
bsi
isol
patient
hematolymphoid
malign
cultur
posit
gram
neg
bacilli
gnb
gram
posit
cocci
gpc
candida
speci
among
gnb
organ
isol
pseudomona
kleibseilla
pneumonia
escherichia
coli
citrobact
non
ferment
gnb
among
gpc
staphylococcu
isol
beta
haemolyt
streptococci
among
gnb
resist
gener
cephalosporin
extend
spectrum
beta
lactamas
esbl
produc
resist
carbapenem
cr
sensit
colistin
among
staphylococci
methicillin
sensit
mssa
resist
mrsa
rest
con
underli
morbid
condit
like
down
syndrom
granzym
defici
present
patient
patient
cultur
proven
bsi
sever
neutropenia
sepsi
lead
organ
dysfunct
seen
secondari
hlh
gnb
infect
mortal
cultur
proven
bsi
due
carbapenem
resist
kleibseilla
ecoli
pseudomona
mrsa
conclus
increas
incid
antibiot
resist
complic
among
gnb
need
hour
implement
infect
control
follow
strict
antibiot
polici
regular
surveil
chang
microbiolog
profil
j
kapelushnik
g
beck
ah
h
medic
ben
gurion
univers
pediatr
oncolog
hematolog
beersheva
israel
gurion
univers
negev
physic
beer
sheva
israel
shamoon
colleg
engin
physic
beer
sheva
israel
gurion
univers
negev
immunolog
genet
beer
sheva
israel
backgroundobject
pediatr
hematologyoncolog
set
rapid
identif
infecti
etiolog
highli
import
current
method
mainli
base
microbi
cultur
time
consum
main
object
studi
evalu
potenti
mid
infrar
spectroscop
method
rapid
reliabl
identif
bacteri
viral
infect
base
peripher
blood
sampl
fourier
transform
infrar
ftir
found
use
monitor
effect
antibiot
treatment
cancer
patient
bacteri
infect
use
distinguish
bacteri
viral
etiolog
base
analysi
blood
compon
designmethod
evalu
event
pediatr
hematolog
oncolog
admiss
white
blood
cell
plasma
isol
peripher
blood
sampl
patient
confirm
viral
bacteri
infect
spectroscopi
diagnost
marker
ie
rnadna
ratio
ratio
use
monitor
biochem
chang
wbc
plasma
treatment
obtain
spectra
analyz
multivari
analysi
principl
compon
analysi
follow
linear
discrimin
analysi
time
span
one
hour
collect
blood
sampl
confirm
result
use
develop
refin
algorithm
predict
etiolog
result
employ
ftir
featur
extract
fisher
linear
discrimin
analysi
order
identifi
infecti
type
sensit
accuraci
infect
type
diagnosi
achiev
conclus
present
studi
suggest
ftir
spectroscopi
wbc
potenti
feasibl
effici
tool
diagnosi
infect
etiolog
type
pediatr
hematologyoncolog
set
plan
empow
algorithm
addit
futur
event
develop
system
could
process
drop
enabl
rapid
safe
reliabl
test
result
clinic
decis
make
special
popul
patient
z
karaka
r
istanbul
medic
faculti
depart
pediatr
istanbul
turkey
istanbul
medic
faculti
depart
virolog
istanbul
turkey
backgroundobject
bk
viru
bkv
dna
viru
belong
polyomaviru
famili
primari
infect
occur
childhood
viral
latenc
may
persist
urogenit
tract
epithelium
bkv
reactiv
typic
caus
nephropathi
kidney
hematopoiet
stem
cell
transplant
rare
seen
immuncompromis
patient
associ
system
complic
like
enceph
pneumonia
pneumon
treatment
strategi
controversi
present
children
bkv
infect
secondari
solid
hematolog
malign
relat
immunosuppress
state
designmethod
descript
case
report
result
patient
girl
boy
whose
diagnos
neuroblastoma
acut
myeloid
leukemia
burkitt
lymphoma
respect
patient
develop
hematuria
chemotherapi
cours
high
bkv
titer
detect
urin
blood
hematuria
acut
renal
failur
first
case
develop
right
heart
failur
pneumon
treat
ciprofloxacin
intraven
immunoglobulin
cours
sidofovir
synchron
hemodiafiltr
addit
support
therapi
despit
mild
clinic
recoveri
die
acut
pulmonari
hemorrhag
second
case
enceph
bk
viremia
treat
ciprofloxacin
intraven
immunoglobulin
clinic
condit
improv
bkv
titer
becam
neg
year
follow
case
underli
cirrhosi
cours
chemotherapi
bkv
nephropathi
treat
ciprofloxacin
intraven
immunoglobulin
clinic
condit
improv
support
therapi
bk
viru
titer
becam
neg
remiss
burkitt
lymphoma
stabl
sign
chronic
liver
failur
conclus
bkv
infect
consid
differenti
diagnosi
opportunist
infect
immunosuppress
pediatr
cancer
patient
presenc
renal
involv
treatment
strategi
limit
due
lack
effect
treatment
fatal
consequ
futur
research
risk
factor
bkv
infect
target
therapi
essenti
karim
cy
aa
h
mj
b
sheikh
mujib
medic
univers
paediatr
haematolog
oncolog
dhaka
bangladesh
h
sikder
women
medic
colleg
commun
medicin
dhaka
bangladesh
institut
cancer
research
hospit
paediatr
oncolog
dhaka
bangladesh
militari
savar
administr
dhaka
bangladesh
centr
immunis
research
surveil
children
hospit
sydney
australia
institut
cancer
research
hospit
cancer
epidemiolog
dhaka
bangladesh
centr
immunis
research
surveil
ncir
children
hospit
sydney
australia
backgroundobject
cryptosporidium
major
caus
moder
sever
diarrhoea
worldwid
children
malign
increas
risk
seriou
complic
caus
intestin
parasit
cryptosporidium
burden
cryptosporidium
infect
children
malign
remain
understudi
set
due
lack
afford
test
aim
present
studi
estim
proport
cryptosporidium
infect
among
pediatr
oncolog
patient
diarrhea
tertiari
teach
hospit
dhaka
bangladesh
designmethod
cross
section
studi
carri
march
februari
among
children
malign
depart
pediatr
hematolog
oncolog
bangabandhu
sheikh
mujib
medic
univers
bsmmu
dhaka
bangladesh
seventi
stool
sampl
collect
consecut
patient
develop
diarrhea
hospit
investig
presenc
cryptosporidium
antigen
elisa
microbiolog
laboratori
bsmmu
result
seventi
diarrheal
episod
record
patient
age
median
month
among
hematolog
malign
remain
solid
tumor
cryptosporidium
antigen
detect
stool
sampl
children
stool
frequenc
timesday
two
third
children
pass
low
volum
stool
half
case
stool
wateri
consist
diarrhea
common
induct
phase
chemotherapi
children
diarrhea
profoundli
neutropen
sever
lymphopen
cryptosporidium
posit
case
age
month
prolong
diarrhoea
malnourish
induct
phase
chemotherapi
conclus
data
pilot
studi
suggest
cryptosporidium
caus
diarrhea
pediatr
oncolog
patient
futur
larg
scale
prospect
studi
need
quantifi
burden
cryptosporidium
infect
pediatr
oncolog
patient
khan
ms
indu
hospit
pediatr
hematolog
oncolog
karachi
pakistan
indu
hsopit
pediatr
hematolog
oncolog
karachi
pakistan
indu
hospit
statist
karachi
pakistan
backgroundobject
febril
neutropenia
fn
oncolog
emerg
signific
caus
morbid
mortal
low
countri
earli
recognit
prompt
antibiot
administr
base
risk
stratif
good
support
care
hallmark
better
outcom
aim
determin
outcom
associ
demograph
clinic
laboratori
data
intermedi
risk
pediatr
febril
neutropenia
patient
treat
piperacillin
tazobactam
amikacin
tertiari
care
hospit
pakistan
designmethod
intermedi
risk
fn
irfn
patient
less
year
age
admit
pediatr
oncolog
ward
indu
hospit
may
juli
enrol
outcom
analyz
use
spss
relaps
patient
low
fn
exclud
outcom
defin
success
discharg
complet
antibiot
failur
antibiot
chang
antifung
ad
need
intens
care
due
hemodynam
instabl
death
result
total
episod
occur
event
document
acut
leukemia
induct
consolid
major
chemotherapi
phase
occurr
blood
cultur
posit
success
rate
failur
major
reason
failur
chang
antibiot
due
persist
fever
hr
death
occur
due
probabl
fungal
infect
multivari
analysi
four
independ
risk
factor
found
signific
absolut
neutrohil
count
anc
present
aor
ci
p
protein
crp
aor
ci
respiratori
rate
rr
aor
ci
heart
rate
hr
aor
ci
conclus
approach
treat
irfn
prove
optim
strategi
low
high
risk
need
investig
base
hr
rr
anc
crp
score
model
formul
refin
current
manag
khan
gz
khanum
memori
cancer
hospit
research
center
pediatr
oncolog
lahor
pakistan
backgroundobject
cancer
common
import
caus
pediatr
morbid
mortal
develop
world
improv
treatment
regimen
surviv
rate
higher
howev
chemotherapeut
regimen
also
lead
complic
requir
transfer
intens
care
unit
icu
report
experi
reason
critic
ill
pediatr
oncolog
patient
need
icu
transfer
outcom
designmethod
retrospect
cohort
studi
conduct
decemb
june
irb
approv
pediatr
oncolog
patient
medic
record
icu
admiss
review
data
regard
demograph
diagnosi
diseas
stage
pediatr
risk
mortal
prism
iii
score
therapeut
intervent
result
total
patient
medic
record
icu
admiss
review
boy
girl
median
age
year
rang
leukemia
matur
lymphoma
common
diagnosi
seen
follow
wilm
tumor
mean
score
among
survivor
lower
seen
p
overal
patient
die
mortal
rate
patient
prism
iii
icu
admiss
compar
patient
score
conclus
mortal
rate
pediatr
oncolog
patient
admit
icu
develop
countri
higher
seen
develop
countri
mostli
children
haematolog
malign
refer
icu
mortal
rate
significantli
relat
high
score
admiss
icu
khatoon
df
k
indu
hospit
network
infect
control
karachi
pakistan
backgroundobject
pediatr
cancer
patient
higher
risk
life
threaten
hospit
acquir
infect
hai
due
intens
treatment
enterobacteriacea
cre
type
germ
difficult
treat
manag
due
resist
multipl
antibiot
includ
carbapenem
cre
infect
spread
direct
contact
bodili
fluid
infect
person
well
contact
touch
contamin
surfac
misus
broad
spectrum
antibiot
cre
resist
infect
continu
spread
becom
global
health
issu
hospit
set
limit
surviv
rate
amongst
alreadi
immunocompromis
children
due
multidrug
resist
estim
half
children
becom
infect
cre
die
designmethod
period
six
month
septemb
februari
data
collect
microbiolog
depart
indu
hospit
posit
blood
cultur
sensit
test
result
collect
basi
drug
sensit
result
categor
enterobacteriacea
cre
categor
type
organ
patient
cre
organ
count
multipl
admiss
exclud
sampl
two
differ
cre
organ
found
patient
result
sampl
posit
blood
cultur
sampl
cre
posit
half
cre
sampl
e
coli
cre
sampl
remain
sampl
divid
klebsiella
speci
sampl
enterobact
speci
sampl
patient
cre
organ
mortal
occur
patient
conclus
cre
infect
difficult
treat
case
end
mortal
thu
treat
immunocompromis
children
dire
need
strict
hospit
polici
regard
antibiot
stewardship
infect
control
increas
surviv
k
kishimoto
r
h
k
children
hospit
hematolog
oncolog
kobe
japan
hokuyu
hospit
hematologyoncolog
children
adolesc
sapporo
japan
backgroundobject
object
studi
determin
whether
paranas
sinus
diagnosi
affect
develop
infecti
complic
children
adolesc
cancer
receiv
chemotherapi
designmethod
total
consecut
patient
age
year
hematolog
malign
solid
tumor
receiv
chemotherapi
sapporo
hokuyu
hospit
enrol
retrospect
cohort
studi
chemotherapi
part
condit
regimen
stem
cell
transplant
exclud
analysi
paranas
sinus
defin
presenc
fluid
level
mucos
swell
total
opac
sinu
ct
examin
invas
fungal
diseas
ifd
defin
accord
european
organ
research
treatment
cancercancerinvas
fungal
infect
cooper
group
nation
institut
allergi
infecti
diseas
mycos
studi
group
consensu
result
paranas
sinus
observ
patient
diagnosi
cancer
signific
differ
age
sex
diseas
distribut
patient
paranas
sinus
diagnosi
sinus
group
without
group
cumul
incid
ifd
year
treatment
initi
significantli
higher
sinus
group
group
vs
signific
differ
cumul
incid
bacteremia
septic
shock
two
group
bacteremia
sinus
group
group
septic
shock
sinus
group
group
multivari
analysi
show
paranas
sinus
diagnosi
significantli
associ
increas
risk
ifd
odd
ratio
confid
interv
conclus
found
significantli
higher
incid
ifd
sinus
group
paranas
sinus
diagnosi
recogn
addit
potenti
risk
factor
ifd
p
komvilaisak
p
p
hospit
depart
faculti
khon
kaen
khon
kaen
khon
kaen
thailand
backgroundobject
infect
relat
mortal
childhood
hematolog
malign
could
lead
wors
outcom
treatment
complic
relat
infect
fulmin
bacteri
infect
aeromona
speci
report
patient
acut
lymphoblast
leukemia
designmethod
studi
review
report
three
case
hematolog
malign
fulmin
bacteri
infect
result
among
three
case
case
diagnos
high
risk
acut
lymphoblast
leukemia
case
diagnos
high
risk
acut
monoblast
leukemia
amol
case
start
induct
therapi
consist
vincristin
doxorubicin
prednisolon
two
week
post
therapi
develop
febril
neutropenia
progress
bilater
leg
pain
tender
swell
puls
present
unfortun
leg
becam
discolor
extens
thigh
bloodstream
apart
empir
antibiot
surgic
treatment
includ
knee
amput
aka
left
leg
one
case
initi
fasciotomi
subsequ
bilater
aka
anoth
case
former
case
pass
away
septicemia
latter
case
still
aliv
hemocultur
demonstr
aeromona
hydrophila
aeromona
veronii
sobria
patholog
result
show
extens
muscular
tissu
necrosi
thrombu
vascular
seen
third
case
amol
develop
febril
neutropenia
present
hypotens
right
thigh
pain
swell
consolid
phase
computer
tomographi
angiogram
perform
demonstr
myositi
deep
intramuscular
posterior
compart
right
knee
evid
arteri
occlus
final
underw
aka
right
leg
aliv
muscl
cultur
reveal
plesiomona
shigelloid
hemocultur
reveal
staphylococcu
coagulas
neg
might
contamin
two
surviv
case
also
develop
rhabdomyolysi
post
amput
resolv
conclus
fulmin
aeromona
plesiomona
speci
infect
immunocompromis
patient
hematolog
malign
lead
seriou
complic
disabl
death
earli
detect
empir
antibiot
emerg
surgic
manag
necessari
proper
treatment
order
safe
condit
p
komvilaisak
p
hospit
depart
faculti
khon
kaen
univers
khon
kaen
thailand
backgroundobject
aggress
chemotherapi
improv
outcom
cancer
treatment
preval
invas
fungal
infect
ifi
children
cancer
increas
object
describ
ifi
includ
clinic
manifest
risk
factor
treatment
outcom
pediatr
patient
cancer
designmethod
retrospect
descript
studi
pediatr
patient
year
age
cancer
diagnos
ifi
januari
septemb
result
diagnos
ifi
patient
regard
proven
probabl
possibl
among
two
yeast
infect
candida
tropicali
mold
infect
aspergillu
mucor
underli
diseas
aml
lymphoma
osteosarcoma
factor
contribut
ifi
includ
prolong
antibiot
use
absolut
neutrophil
count
cellsml
absolut
lymphocyt
count
steroid
use
total
parenter
nutrit
central
line
cathet
placement
site
ifi
common
lung
follow
sinus
nasal
caviti
spleen
kidney
patient
ifi
empir
treat
antifung
medic
improv
death
patient
loss
death
organ
sepsi
conclus
ifi
pediatr
patient
cancer
might
result
wors
outcom
cancer
due
increas
mortal
rate
delay
chemotherapi
patient
greater
risk
ifi
appropri
investig
treat
promptli
lead
better
outcom
z
mm
c
k
kulkarni
health
centr
divis
pediatr
hematolog
depart
pediatr
halifax
canada
univers
perinat
epidemiolog
research
depart
pediatr
obstetr
gynaecolog
halifax
canada
backgroundobject
tissu
plasminogen
activ
tpa
commonli
use
treat
central
venou
cathet
cvc
dysfunct
cathet
dysfunct
often
associ
thrombosi
link
poorer
surviv
outcom
adult
recent
pediatr
cancer
patient
object
therefor
examin
associ
tpa
administr
episod
cvc
dysfunct
surviv
pediatr
cancer
patient
designmethod
present
studi
retrospect
cohort
studi
pediatr
oncolog
patient
canadian
maritim
provinc
nova
scotia
princ
edward
island
new
brunswick
pediatr
oncolog
patient
maritim
treat
iwk
health
centr
data
current
studi
came
iwk
pharmaci
databas
pediatr
oncolog
databas
patient
chart
well
cancer
young
peopl
canada
registri
demograph
diagnosi
date
death
date
last
visit
tpa
use
cvc
dysfunct
collect
associ
tpa
surviv
examin
use
cox
proport
hazard
regress
adjust
sex
age
diagnosi
result
patient
receiv
tpa
patient
receiv
one
dose
tpa
receiv
two
receiv
dose
patient
receiv
dose
tpa
poorer
surviv
hr
ci
adjust
model
patient
receiv
one
hr
ci
two
dose
tpa
hr
ci
like
die
patient
never
receiv
tpa
conclus
demonstr
significantli
poorer
surviv
pediatr
cancer
patient
receiv
one
dose
tpa
futur
studi
corrobor
find
popul
examin
role
potenti
confound
determin
role
tpa
prognost
model
cancer
surviv
k
kulkarni
health
centr
divis
pediatr
hematolog
depart
pediatr
halifax
canada
health
centr
divis
pediatr
depart
pediatr
halifax
canada
backgroundobject
due
pauciti
avail
data
present
studi
design
assess
toxic
dexrazoxan
base
treatment
delay
designmethod
ethic
approv
retrospect
cohort
studi
complet
use
chart
databas
inform
children
treat
anthracyclin
sinc
patient
receiv
cumul
anthracyclin
dose
year
old
receiv
dexrazoxan
group
compar
children
receiv
dexrazoxan
toxic
defin
chemotherapi
delay
day
decreas
absolut
neutrophil
count
anc
decreas
platelet
viralbacteri
episod
adjust
incid
rate
ratio
irr
outcom
obtain
use
count
model
result
patient
toxic
data
avail
treat
untreat
mean
age
year
averag
cumul
anthracyclin
dose
treat
group
untreat
group
differ
gender
distribut
seen
total
number
delay
chemotherapi
cycl
treat
group
significantli
higher
p
adjust
irr
total
number
episod
decreas
absolut
neutrophil
count
anc
decreas
platelet
viralbacteri
infect
p
ii
number
delay
due
anc
significantli
higher
treat
group
versu
untreat
group
respect
studi
group
ci
odd
least
platelet
event
conclus
patient
receiv
dexrazoxan
significantli
increas
risk
delay
therapi
due
myelosuppress
infect
thrombocytopenia
sinc
treatment
delay
may
associ
relaps
risk
versu
benefit
dexrazoxan
cardioprotect
agent
children
cancer
examin
k
kulkarni
health
centr
divis
pediatr
hematolog
depart
pediatr
halifax
canada
health
centr
divis
pediatr
depart
pediatr
halifax
canada
backgroundobject
efficaci
dexrazoxan
cardioprotect
agent
children
treat
anthracyclin
well
establish
present
studi
design
assess
efficaci
dexrazoxan
designmethod
ethic
approv
retrospect
cohort
studi
complet
use
chart
databas
inform
children
treat
anthracyclin
sinc
patient
receiv
cumul
anthracyclin
dose
yo
receiv
dexrazoxan
group
compar
children
receiv
dexrazoxan
lack
efficaci
defin
deviat
identifi
cardiac
paramet
echocardiogram
echo
associ
anthracyclin
toxic
includ
eject
fraction
ef
shorten
fraction
fs
left
ventricular
intern
diamet
lvidd
lvid
left
ventricular
posterior
wall
thick
lvpwd
lv
mass
statist
number
cardiac
paramet
reduc
singl
valu
individu
outcom
largest
neg
rel
differ
baselin
consid
correspond
cumul
anthracyclin
dose
cad
adjust
age
sex
diagnosi
ef
fs
valu
except
lvpwd
due
low
number
observ
less
valu
plot
cad
multipl
regress
model
perform
result
patient
efficaci
data
avail
treat
untreat
mean
age
year
averag
cad
treat
group
untreat
group
differ
gender
distribut
seen
signific
differ
cardiac
paramet
treat
untreat
patient
conclus
period
children
receiv
dexrazoxan
show
signific
deviat
baselin
echo
data
studi
identifi
children
risk
signific
cardiotox
would
help
determin
may
benefit
dexrazoxan
kumar
r
depart
medic
oncolog
new
delhi
india
depart
laboratori
oncolog
new
delhi
india
depart
microbiolog
new
delhi
india
depart
biostatist
new
delhi
india
backgroundobject
despit
common
practic
stop
antibiot
low
risk
pediatr
febril
neutropenia
patient
adequ
respond
antibiot
robust
evid
lack
conduct
random
control
pilot
studi
determin
earli
discontinu
antimicrobi
low
risk
febril
neutropenia
effect
continu
therapi
till
recoveri
count
designmethod
pediatr
cancer
patient
low
risk
febril
neutropenia
present
outpati
depart
start
empir
intraven
iv
antibiot
afebril
period
hr
patient
random
stoppag
antibiot
oral
antibiot
arm
intervent
consid
success
patient
remain
afebril
till
recoveri
absolut
neutrophil
count
anc
failur
defin
fever
result
total
patient
screen
patient
fulfil
inclus
criteria
random
patient
patient
b
aselin
paramet
like
age
sex
diseas
type
maximum
grade
fever
interv
fever
onset
present
absolut
neutrophil
count
anc
absolut
monocyt
count
amc
equal
balanc
two
arm
end
studi
patient
experienc
failur
intervent
arm
demonstr
success
rate
vs
respect
patient
fail
respond
optim
iv
antibiot
none
sign
system
instabl
time
failur
one
requir
inpati
care
conclus
low
risk
febril
neutropenia
patient
manag
outpati
basi
initi
intraven
cours
empir
antibiot
till
child
get
afebril
least
appear
adequ
antibiot
may
stop
provid
adequ
close
ensur
base
earli
data
larger
random
control
trial
recruit
activ
centr
lalani
khan
univers
hospit
oncolog
karachi
pakistan
backgroundobject
clabsi
central
line
associ
blood
stream
infect
one
infect
result
longer
hospit
stay
increas
cost
treatment
increas
risk
death
oncolog
patient
especi
chemotherapi
expect
get
neutropen
receiv
therapi
make
prone
infect
studi
also
report
seriou
life
threaten
condit
pertin
clabsi
therefor
keep
check
routin
health
alli
handl
central
line
help
improv
statist
clabsi
pediatr
oncolog
patient
designmethod
bundl
checklist
fill
daili
observ
health
alli
handl
line
variou
purpos
clinic
nurs
coordin
respons
sign
checklist
everi
month
analysi
bundl
made
lack
factor
identifi
reemphas
variou
session
month
plan
nurs
doctor
hand
hygien
central
line
handl
blood
sampl
central
line
done
emphas
correct
practic
handl
central
line
result
qualiti
improv
initi
result
decreas
rate
clabsi
moreov
session
taken
hand
hygien
central
line
handl
brought
deeper
sens
respons
health
alli
handl
central
line
sinc
bundl
produc
greater
effect
clabsi
therefor
checklist
still
continu
improv
practic
central
line
handl
conclus
perk
reduc
clabsi
improv
patient
outcom
also
reduc
mortal
seriou
life
threaten
condit
ie
sepsi
reduc
clabsi
also
improv
satisfact
physician
nurs
patient
famili
lastli
also
provid
financi
benefit
line
save
longer
period
time
complet
therapi
f
li
w
h
tongren
capit
medic
univers
pediatr
beij
china
backgroundobject
infect
fatal
complic
cancer
patient
sometim
prone
distinguish
tumor
progress
compar
diagnost
valu
procalcitonin
pct
protein
crp
lactat
dehydrogenas
ldh
pediatr
malign
solid
tumor
concurr
infect
tumor
progress
designmethod
one
hundr
children
enrol
divid
infect
group
case
control
group
case
group
divid
stabl
group
progress
group
intergroup
comparison
made
term
serum
pct
crp
ldh
children
result
pct
crp
ldh
level
infect
group
significantli
higher
control
group
p
control
group
pct
crp
ldh
level
progress
group
significantli
higher
stabl
group
p
signific
differ
term
pct
crp
infect
group
p
ldh
highest
correl
tumor
progress
pct
lowest
ldh
crp
pct
conclus
pct
highest
valu
diagnos
infect
less
suscept
tumor
progress
crp
ldh
obviou
advantag
judg
tumor
progress
p
liberman
ac
camargo
cancer
center
audiolog
sao
paulo
brazil
backgroundobject
ototox
potenti
advers
effect
chemotherapi
platin
drug
cisplatin
carboplatin
children
hear
loss
hl
affect
frequenc
khz
compromis
speech
percept
aim
studi
investig
whether
genet
variant
previous
implic
ototox
associ
hl
overal
hl
khz
pediatr
oncolog
patient
treat
cisplatin
carboplatin
designmethod
patient
given
cisplatin
carboplatin
pediatr
cancer
least
year
prior
start
studi
enrol
patient
underw
comprehens
audiolog
evalu
genotyp
detect
presenc
g
g
polymorph
result
hear
loss
identifi
patient
includ
treat
cisplatin
treat
carboplatin
hl
associ
higher
mean
dose
cisplatin
p
carboplatin
p
g
variant
heterozyg
homozyg
detect
patient
associ
variant
allel
hl
involv
frequenc
khz
identifi
p
vs
associ
hl
observ
gene
variant
conclus
g
variant
may
increas
risk
hl
pediatr
oncolog
patient
treat
cisplatin
carboplatin
chemotherapi
l
linder
cf
r
utah
colleg
nurs
salt
lake
citi
usa
utah
depart
dermatolog
salt
lake
citi
usa
intern
corpor
univers
utah
real
world
data
servic
depart
salt
lake
citi
usa
children
hospit
nurs
seattl
usa
bridg
children
hospit
pediatr
tacoma
usa
backgroundobject
optim
oral
medic
adher
challeng
adolesc
young
adult
aya
cancer
mhealth
resourc
includ
remind
app
propos
strategi
support
adher
pilot
studi
evalu
oral
medic
adher
among
aya
trial
medic
remind
app
designmethod
aya
median
year
rang
year
receiv
least
one
prescrib
schedul
oral
medic
relat
cancer
treatment
particip
longitudin
singl
group
interrupt
time
seri
studi
baselin
oral
medic
adher
monitor
use
electron
monitor
cap
four
week
particip
use
medic
remind
app
oral
medic
adher
monitor
week
pair
compar
adher
intervent
multilevel
uncondit
growth
curv
model
assess
adher
trajectori
account
individu
variat
visual
graphic
analysi
techniqu
appli
individu
profil
plot
weekli
adher
evalu
trend
identifi
adher
phenotyp
patient
subgroup
similar
adher
pattern
result
adher
differ
intervent
period
compar
baselin
howev
varianc
adher
narrow
highli
adher
aya
four
adher
phenotyp
identifi
high
adher
intervent
period
high
adher
low
adher
intervent
period
low
adher
improv
adher
intervent
period
low
adher
period
conclus
although
overal
averag
adher
unchang
app
use
varianc
adher
narrow
highli
adher
particip
addit
altern
intervent
need
aya
persist
poor
adher
formal
assess
adher
pattern
may
guid
intervent
promot
adher
fund
oncolog
nurs
societi
foundat
huntsman
cancer
institut
gamma
rho
chapter
sigma
theta
tau
intern
univers
utah
colleg
nurs
nation
institut
nurs
research
nation
cancer
institut
nation
center
advanc
translat
scienc
ln
b
b
g
w
c
j
liu
institut
health
nation
institut
nurs
research
bethesda
usa
healthcar
research
develop
lausann
switzerland
backgroundobject
cancer
relat
fatigu
crf
particularli
preval
debilit
condit
multifactori
etiolog
persist
even
survivorship
treatment
approv
crf
due
insuffici
understand
underli
mechan
sustain
inflamm
believ
play
key
role
crf
previous
observ
signific
correl
chang
express
eight
gene
eg
worsen
fatigu
symptom
men
also
observ
cellium
safe
botan
extract
inhibit
inflamm
normal
level
human
alopecia
model
object
investig
effect
oral
cellium
fatigu
mous
model
designmethod
two
success
experi
cellium
placebo
conduct
oral
celliumplacebo
provid
mice
follow
irradi
voluntari
wheel
run
activ
measur
distanc
speed
serv
surrog
object
measur
behavior
mice
result
averag
cumul
run
distanc
greater
return
initi
run
distanc
day
earlier
differ
bodyweight
averag
speed
improv
compar
advers
event
relat
product
use
observ
conclus
oral
cellium
effect
fatigu
mice
possibl
relat
effect
base
safeti
efficaci
observ
model
investig
effect
cellium
cancer
patient
receiv
treatment
includ
pediatr
patient
cancer
survivor
warrant
liu
h
x
f
c
x
z
children
hospit
pharmaci
shenzhen
china
children
hospit
hematolog
oncolog
shenzhen
china
backgroundobject
determin
incid
convent
vancomycin
dose
regimen
per
dose
everi
hour
achiev
target
trough
concentr
chines
pediatr
hematolog
oncolog
patient
designmethod
retrospect
chart
review
vancomycin
use
pediatr
patient
hospit
hematolog
oncolog
depart
within
institut
jan
dec
patient
includ
year
age
receiv
vancomycin
persist
febril
neutropenia
vancomycin
concentr
done
immunoassay
result
cours
vancomycin
therapi
elig
review
trough
concentr
drawn
trough
monitor
rate
vancomycin
peak
concentr
drawn
peak
monitor
rate
amongst
trough
level
hsct
patient
hematolog
malign
vancomycin
cours
dose
initi
base
chines
product
monograph
recomend
pediatr
dose
per
dose
everi
hour
accord
idsa
literatur
recommend
target
steadi
state
trough
level
initi
level
achiev
target
rang
level
subtherapeut
level
supratherapeut
fell
accept
level
dosag
adjust
follow
subtherapeut
level
none
patient
develop
advers
reaction
relat
vancomycin
conclus
singl
center
experi
chines
pediatr
hematolog
oncolog
patient
vancomycin
dose
everi
hour
unlik
achiev
target
trough
concentr
possibl
due
alter
pharmacokinet
febril
neutropenia
approach
individu
vancomycin
therapi
titrat
target
trough
concentr
consid
instead
investig
help
defin
appropri
initi
vancomycin
dose
target
trough
concentr
popul
na
r
para
el
instituto
materno
infantil
del
estado
de
pediatr
oncolog
toluca
mexico
backgroundobject
nausea
vomit
cinv
one
advers
effect
caus
discomfort
patient
cancer
abandon
treatment
caus
adolesc
cisplatin
highli
emet
chemotherapi
fosaprepit
blocker
shown
use
treatment
adult
cnvi
object
assess
efficaci
safeti
fosaprepit
adolesc
girl
treat
cisplatin
designmethod
object
assess
efficaci
safeti
fosaprepit
adolesc
girl
treat
cisplatin
design
open
clinic
trial
includ
adolesc
girl
type
cancer
receiv
cisplatin
day
receiv
randomli
treatment
without
fosaprepit
mg
iv
hour
start
chemotherapi
plu
ondansetron
dexamethason
convent
dose
evalu
nausea
vomit
accord
scale
number
cours
chemotherapi
age
level
nausea
vomit
less
scale
day
consid
effect
local
system
advers
reaction
document
result
cours
chemotherapi
administ
fosaprepit
patient
femal
gender
diagnos
ovarian
germin
tumor
receiv
cisplatin
etoposid
bleomycin
control
effect
record
cours
chemotherapi
vs
p
local
system
advers
effect
record
conclus
fosaprepit
effect
drug
adult
patient
appear
safe
effect
treatment
option
cinv
adolesc
cancer
receiv
cisplatin
contribut
improv
qualiti
life
doubleblind
studi
larger
sampl
requir
confirm
find
na
c
materno
infantil
del
instituto
de
seguridad
social
del
estado
de
municipio
pediatr
oncolog
toluca
mexico
backgroundobject
sepsi
caus
death
children
cancer
febril
neutropenia
biomark
avail
environ
modifi
oncolog
treatment
steroid
level
procalcitonin
pct
ng
dl
biomark
modifi
neutropenia
use
object
know
util
procalcitonin
earli
predictor
septic
shock
children
cancer
febril
neutropenia
designmethod
design
studi
evalu
patient
febril
neutropenia
cancer
evalu
clinic
paraclin
variabl
pct
protein
ldh
microbiolog
age
gender
type
cancer
fever
time
antibiot
adminsitr
interv
sensit
specif
posit
predict
valu
neg
predict
valu
estim
bivari
analysi
perform
evalu
weight
variabl
outcom
patient
result
includ
patient
event
febril
neutropenia
mean
age
year
acut
lymphoblast
leukemia
patient
septic
shock
procalcitonin
greater
bivari
analysi
show
ci
p
sensit
specif
patient
present
system
inflammatori
respons
syndrom
sir
level
procalcitonin
obtain
ci
p
sensit
specif
vpn
procalcitonin
sir
patient
septic
shock
sever
neutropenia
frequent
isol
germ
escherichia
coli
conclus
discuss
procalcitonin
consid
use
biomark
time
detect
septic
shock
patient
cancer
febril
neutropenia
howev
organiz
factor
delay
request
care
start
interv
first
prolong
antibiot
dose
factor
must
modifi
tandem
detect
sepsi
biomark
sf
maarbjerg
le
b
h
univers
hospit
depart
paediatr
adolesc
medicin
aarhu
n
denmark
univers
depart
pharmaceut
bioscienc
uppsala
sweden
univers
depart
pharmaceut
biosciens
uppsala
sweden
diabet
center
copenhagen
clinic
research
copenhagen
denmark
backgroundobject
piptaz
frequent
prescrib
first
line
empir
therapi
children
fever
standard
guidelin
recommend
bolu
administr
everi
hour
best
predictor
antibacteri
efficaci
time
unbound
stay
pathogen
minim
inhibitori
concentr
mic
data
piptaz
pharmacokinet
optim
dose
children
fever
remain
limit
object
investig
pharmacodynam
pd
follow
piptaz
bolu
administr
designmethod
prospect
observ
studi
conduct
april
januari
children
age
month
year
requir
empir
due
fever
includ
accord
standard
guidelin
piptaz
bolu
administ
everi
hour
particip
contribut
blood
sampl
popul
pharmacokinet
poppk
perform
main
outcom
mic
mic
mgl
repres
threshold
valu
pathogen
optim
pd
target
defin
mic
x
mic
result
obtain
children
separ
fever
children
weight
kg
children
kg
preliminari
poppk
analysi
show
mic
pd
target
median
mic
mic
mgl
mic
mgl
categoris
weight
group
children
kg
display
lower
median
mic
mgl
mic
mgl
conclus
data
reveal
pd
target
children
fever
order
improv
piptaz
dose
regimen
investig
hypothes
benefit
continu
infus
next
studi
acknowledg
author
sincer
thank
danish
childhood
cancer
foundat
found
studi
studi
nurs
kamilla
karen
great
assist
collect
madney
h
r
l
n
k
pedeatr
oncolog
cche
lectur
pediatr
oncolog
cancer
institut
cairo
univers
pediatr
oncolog
cairo
egypt
pedeatr
oncolog
cche
nation
cancer
institut
cairo
univers
pediatr
oncolog
cairo
egypt
cancer
hospit
cche
clinic
microbiolog
cairo
egypt
cancer
hospit
cche
clinic
pharmacolog
cairo
egypt
cancer
hospit
cche
research
cairo
egypt
backgroundobject
breakthrough
candidaemia
report
major
clinic
issu
especi
patient
hematolog
malign
antifung
prophylaxi
studi
aim
identifi
clinic
microbiolog
characterist
outcom
breakthrough
candidemia
pediatr
cancer
patient
antifung
prophylaxi
designmethod
june
june
retrospect
review
medic
record
patient
candidaemia
children
cancer
hospit
egypt
cche
breakthrough
candidaemia
defin
candidaemia
develop
administr
agent
candida
spp
identifi
use
vitek
system
result
episod
candidaemia
identifi
breakthrpough
candidemia
c
parapsilosi
case
c
guilliermondii
case
c
tropicali
case
c
albican
case
c
lipolytica
case
c
krusei
case
c
ciferrii
case
use
prophylaxi
breakthrough
case
micafungin
case
voriconazol
case
fluconazol
case
c
parapsilosi
breakthrough
isol
receiv
micafungin
prophylaxi
case
suscept
micafungin
except
one
case
resist
breakthrough
candida
sensit
except
isol
one
case
candida
albican
candida
parapsilosi
candida
krusi
breakthrough
candidemia
show
resist
pattern
fluconazol
case
krusi
lipolytica
c
parapsilosi
resist
pattern
amphotericin
b
case
c
albican
c
krusi
ctropicali
resist
pattern
micafungin
case
c
albican
c
parapsilosi
overal
mortal
rate
patient
attribut
mortal
rate
patient
conclus
breakthrough
candida
major
clinic
issu
high
risk
hematolog
pediatr
cancer
patient
high
mortal
rate
clinician
pay
attent
breakthrough
candida
even
patient
antifung
prophylaxi
serum
bd
glucaln
may
help
earli
detect
sy
mak
ws
pl
mari
hospit
pediatr
adolesc
medicin
hong
kong
hong
kong
sar
backgroundobject
nutrit
statu
children
cancer
import
prognost
factor
clinic
growth
chart
assess
commenc
pediatr
oncolog
unit
sinc
intervent
given
accord
patient
percentil
object
studi
review
nutrit
statu
children
cancer
improv
exist
nutrit
intervent
designmethod
prospect
studi
nutrit
statu
manag
activ
oncolog
case
diagnos
januari
june
age
gender
bodi
weight
bodi
height
bodi
mass
index
nutrit
intervent
initi
diagnosi
post
treatment
record
data
categor
analyz
result
patient
review
patient
leukemia
lymphoma
brain
tumour
account
major
activ
oncolog
case
nutrit
advic
given
nurs
patient
upon
diagnosi
major
patient
growth
curv
equal
percentil
patient
underweight
initi
almost
half
patient
experienc
drop
growth
percentil
third
month
treatment
dietician
consult
offer
patient
patient
receiv
milk
supplement
two
patient
requir
ryle
tube
feed
around
one
third
patient
receiv
total
parent
nutrit
five
patient
three
head
neck
tumour
receiv
extra
oromotor
train
occup
speech
therapist
patient
abl
maintain
improv
growth
curv
month
conclus
nutrit
assess
need
done
regularli
determin
deterior
nutrit
statu
patient
head
neck
tumour
usual
high
risk
malnutrit
priorit
throughout
treatment
nutrit
support
major
part
support
care
prevent
revers
malnutrit
increas
children
cancer
g
manirakiza
c
e
l
healthinshuti
mu
buzima
butaro
cancer
centr
excel
butaro
rwanda
health
butaro
district
hospit
butaro
rwanda
cancer
institut
paediatr
hematologyoncolog
boston
usa
backgroundobject
outcom
acut
lymphoblast
leukaemia
low
incom
countri
poor
patient
success
treat
mani
failur
due
recurr
diseas
mortal
complic
therapi
also
increas
hunger
et
al
propos
regimen
graduat
intens
centr
capac
manag
toxic
particularli
neutropen
fever
nf
built
time
without
excess
death
butaro
cancer
center
excel
transit
lowest
intens
regimen
intens
regimen
hunger
incorpor
delay
intensif
phase
centr
rwandan
district
hospit
limit
antibiot
microbiolog
laboratori
intens
care
unit
studi
includ
patient
treat
hunger
regimen
bccoe
octob
octob
object
captur
incid
nf
diagnosi
end
delay
intensif
phase
describ
manag
outcom
designmethod
retrospect
cohort
studi
design
use
data
extract
manual
chart
review
result
seventeen
patient
commenc
treatment
studi
period
patient
median
one
episod
nf
rang
half
episod
occur
delay
intensif
phase
median
time
antibiot
hour
identifi
sourc
infect
includ
malaria
pyoderma
pneumonia
enterocol
median
three
agent
use
per
epsisod
common
ceftriaxon
ceftazidim
one
patient
requir
oxygen
therapi
episod
nf
resolv
patient
death
conclus
studi
suggest
nf
may
less
limit
factor
treatment
set
suppos
patient
treat
success
use
empir
antibiot
therapi
without
microbiolog
capac
deliv
critic
care
c
mark
c
univers
aberdeen
institut
medic
scienc
aberdeen
unit
kingdom
aberdeen
institut
medic
scienc
aberdeen
unit
kingdom
backgroundobject
children
young
peopl
cancer
diagnosi
risk
invas
fungal
diseas
risk
fungal
blood
stream
infect
increas
vascular
access
devic
present
demonstr
util
human
skin
explant
model
studi
first
instanc
invas
candidiasi
presenc
vascular
access
devic
designmethod
human
skin
obtain
ethic
consent
adult
donor
ship
tissu
solut
ltd
viabil
skin
maintain
incub
dulbecco
modifi
eagl
medium
venou
cathet
insert
section
skin
section
inocul
x
cell
section
without
cathet
situ
present
compar
addit
select
section
present
control
day
incub
invas
skin
candida
speci
assess
light
microscopi
scan
electron
microscopi
sem
interact
explor
use
combin
rna
extract
quantit
polymeras
chain
reaction
qpcr
proteom
biofilm
format
viabil
fungal
cell
determin
use
xtt
assay
sonic
plate
respect
result
sem
light
microscopi
imag
demonstr
cluster
candida
cell
around
cathet
devic
presenc
viabl
candida
coloni
surfac
cathet
skin
tissu
analysi
qpcr
dataproteom
reveal
decreas
express
antimicrobi
peptid
name
human
psoriasin
venou
cathet
present
candida
infect
candida
cell
confirm
metabol
activ
xtt
test
present
cathet
remov
tissu
incub
period
conclus
skin
explant
model
prove
use
highli
translat
mean
studi
invas
candidiasi
presenc
venou
access
devic
mcdaniel
park
comprehens
cancer
center
pediatr
hematologyoncolog
williamsvil
usa
park
comprehens
cancer
center
pediatr
hematologyoncolog
buffalo
usa
backgroundobject
mani
patient
famili
seek
holist
approach
enhanc
treatment
use
support
care
therapi
march
roswel
park
comprehens
cancer
center
depart
pediatr
hematologyoncolog
introduc
complimentari
modal
along
standard
medic
care
patient
enhanc
treatment
experi
integr
evid
base
complimentari
therapi
benefit
patient
without
risk
side
effect
addit
drug
designmethod
assess
attitud
educ
medic
team
safeti
effect
integr
medicin
first
step
achiev
success
program
integr
medicin
program
director
provid
staff
educ
safeti
effect
modal
offer
local
associ
pediatr
hematolog
oncolog
nurs
chapter
support
outsid
lectur
attend
treatment
offer
encourag
staff
particip
survey
feedback
result
fifti
four
percent
survey
tri
form
complementari
therapi
prior
introduct
seventi
three
percent
team
survey
opt
tri
acupunctur
acupressur
andor
aromatherapi
one
hundr
percent
use
multipl
time
one
hundr
percent
survey
state
benefit
treatment
one
state
slight
discomfort
acupunctur
needl
survey
would
refer
support
educ
patient
complimentari
therapi
pain
nausea
relax
andor
anxieti
conclus
team
comfort
level
establish
patient
identifi
discuss
patient
primari
oncologist
initi
prior
treatment
defin
treatment
goal
ensur
patient
safeti
inform
consent
obtain
along
assent
eight
year
staff
understand
support
extrem
import
help
educ
patient
famili
use
complimentari
modal
enhanc
care
safe
effect
manner
jp
meena
j
r
ak
kr
sk
sn
l
india
institut
medic
scienc
deptt
divis
pediatr
oncolog
new
delhi
india
india
institut
medic
scienc
deptt
microbiolog
new
delhi
india
india
institut
medic
scienc
deptt
divis
pediatr
pulmonolog
new
delhi
india
india
institut
medic
scienc
deptt
biostatist
new
delhi
india
india
institut
medic
scienc
deptt
microbiolog
new
delhi
india
backgroundobject
febril
neutropenia
fn
common
complic
pediatr
oncolog
respiratori
virus
rv
common
caus
febril
infect
healthi
children
role
causat
fn
well
studi
designmethod
children
cancer
fn
acut
respiratori
infect
ari
consid
case
febril
neutropen
patient
without
ari
consid
control
throat
swab
sampl
obtain
patient
detect
pathogen
use
polymeras
chain
reaction
result
total
episod
fn
case
episod
fn
control
enrol
baselin
characteris
similar
case
control
among
case
respiratori
viral
infect
rvi
without
rvi
preval
rvi
seen
case
control
p
sole
viru
seen
mix
virus
virus
patient
case
mix
virus
seen
case
vs
rhinoviru
respiratori
syncyti
viru
frequent
detect
respiratori
virus
median
total
durat
fever
day
patient
rvi
day
patient
without
rvi
median
durat
neutropenia
median
durat
antibiot
day
patient
rvi
compar
patient
without
rvi
day
vs
day
day
vs
day
delay
chemotherapi
detect
patient
rvi
group
group
three
mortal
rvi
group
none
group
conclus
high
preval
respiratori
viral
infect
suggest
signific
role
viral
infect
children
present
febril
neutropenia
associ
increas
morbid
mortal
delay
chemotherapi
studi
viral
load
determin
warrant
mishra
india
institut
medic
scienc
medic
oncolog
new
delhi
india
backgroundobject
malnutrit
children
cancer
multifactori
diseas
toxic
relat
treatment
contribut
children
also
higher
risk
infect
toxic
determin
preval
malnutrit
children
present
malign
assess
factor
relat
designmethod
descript
studi
includ
pediatr
patient
year
cancer
regist
center
juli
inform
regard
demograph
anthropometri
type
malign
collect
patient
undernourish
defin
muac
age
sd
year
patient
year
year
age
defin
undernourish
weight
age
bmi
age
respect
patient
classifi
other
classifi
adequ
nourish
result
includ
children
cancer
hematolog
solid
pediatr
tumor
children
age
year
form
major
cohort
male
femal
whole
cohort
undernourish
children
constitut
adequ
nourish
patient
undernourish
constitut
patient
hematolog
pediatr
solid
malign
respect
regard
statu
major
children
belong
rural
commun
differ
undernourish
compar
gender
place
resid
conclus
malnutrit
common
pediatr
patient
malign
present
place
resid
urbanrur
gender
relat
malnutrit
patient
present
monteiro
garrido
v
e
souto
nacion
de
infect
control
section
rio
de
janeiro
brazil
nacion
de
paediatr
oncolog
depart
rio
de
janeiro
brazil
nacion
de
microbiolog
laboratori
depart
rio
de
janeiro
brazil
backgroundobject
bloodstream
infect
bsi
increas
risk
death
cancer
treatment
clinic
outcom
patient
cancer
complic
bsi
seem
influenc
type
neoplasm
howev
data
children
cancer
scarc
aim
studi
compar
epidemiolog
microbiolog
characterist
bsi
episod
children
haematolog
malign
solid
organ
neoplasm
designmethod
cohort
perform
octob
novemb
inclus
patient
age
year
younger
cancer
bsi
assist
referr
hospit
cancer
care
rio
de
janeiro
brazil
case
detect
surveil
data
collect
throughout
day
day
date
bsi
diagnosi
result
episod
bsi
detect
among
children
solid
tumor
haematolog
neoplasm
overal
mortal
respect
without
statist
differ
group
indic
intens
care
unit
admiss
common
children
solid
tumor
vs
bsi
associ
central
line
common
sourc
infect
bsi
associ
frequent
children
haematolog
diseas
vs
p
wherea
bsi
associ
vs
p
vs
zero
p
common
patient
solid
tumor
frequenc
polymicrobi
infect
vs
bsi
caus
bacilli
vs
significantli
greater
among
children
haematolog
neoplasm
conclus
data
bsi
children
cancer
brazil
guid
prevent
treatment
approach
popul
accord
type
cancer
studi
larger
sampl
size
healthcar
center
desir
better
understand
find
k
mullanfiroz
p
n
dhirubhai
ambani
hospit
blood
marrow
transplant
mumbai
india
dhirubhai
ambani
hospit
pediatr
mumbai
india
dhirubhai
ambani
hospit
pediatr
infecti
diseas
mumbai
india
backgroundobject
pulmonari
complic
stem
cell
transplant
asct
set
common
pulmonari
complic
nipc
asct
children
herebi
report
case
probabl
carmustin
induc
nipc
child
designmethod
boy
case
refractori
stage
iv
b
hodgkin
lymphoma
alreadi
receiv
cycl
abvd
adriamycin
bleomycin
vincristin
dacarbazin
chemotherapi
underw
salvag
chemotherapi
follow
asct
institut
attain
complet
remiss
evidenc
normal
pet
scan
prior
beam
condit
b
carmustin
iv
day
e
etoposid
iv
day
day
cytarabin
iv
hourli
day
melphalan
iv
day
day
post
asct
complain
dri
cough
fatigu
chest
examin
given
symptomat
treatment
kept
day
present
dyspnea
hypoxemia
oxygen
satur
room
start
supplement
oxygen
ct
chest
demonstart
centrilobular
ground
glass
opac
bilater
lung
field
suggest
interstiti
pneumonia
probabl
etiolog
radiologist
pulmonologist
bmt
physician
infecti
diseas
specialist
conclud
view
hypoxemia
histori
carmustin
administr
recent
past
carmustin
induc
lung
injuri
probabl
caus
pulmonari
complic
promptli
start
steroid
within
hour
hypoxemia
resolv
result
nipc
due
carmustin
report
adult
children
nipc
must
consid
concurr
radiolog
clinic
find
conclus
nipc
must
consid
cough
dyspnea
hypoxemia
occur
children
especi
receiv
carmustin
without
cyclophospamid
bleomycin
total
bodi
irradi
mediastin
radiat
carmustin
induc
lung
injuri
revers
earli
administr
steroid
result
good
outcom
k
mullanfiroz
dhirubhai
ambani
hospit
depart
paediatr
oncolog
bmt
mumbai
india
dhirubhai
ambani
hospit
depart
paediatr
mumbai
india
dhirubhai
ambani
hospit
depart
haematolog
bmt
mumbai
india
backgroundobject
invas
fungal
infect
ifi
need
prompt
identif
fungu
aggress
treatment
along
revers
neutropenia
immunosuppress
describ
case
mucormycosi
granulocyt
infus
aggres
antifung
therapi
led
success
outcom
designmethod
year
old
child
acut
lymphoblast
leukaemia
present
week
induct
multipl
tender
blackish
discolour
skin
lesion
central
ulcer
bodi
parent
report
presenc
damp
wall
resid
initi
afebril
cbc
hb
g
tlc
neutrophil
platelet
count
empir
start
parenter
antibiot
along
therapi
liposom
voriconazol
skin
biopsi
reveal
bud
yeast
hypha
identifi
mucor
clinic
deterior
caspofungin
ad
dexamethason
taper
stop
start
growth
factor
granulocyt
infus
given
daili
absolut
neutrophil
count
anc
day
day
hospitalis
start
restless
anxieti
disorient
hallucin
urinari
bowel
incontin
mri
brain
normal
worsen
cn
symptom
voriconazol
induc
advers
reaction
suspect
withdrawn
posaconazol
start
gradual
start
improv
regain
bowel
bladder
contin
later
hallucin
restless
reappear
henc
posaconazol
stop
caspofungin
continu
develop
induc
hypersensit
posaconazol
time
toler
well
result
current
patient
well
skin
lesion
heal
complet
conclus
combin
reduc
immunosuppress
rapidli
increas
neutrophil
count
use
treat
sever
ifi
use
granulocyt
infus
combin
effect
antifung
therapi
use
await
count
recoveri
l
c
sr
children
hospit
paediatr
oncologyhematolog
bmt
vancouv
canada
children
hospit
paediatr
vancouv
canada
backgroundobject
invas
fungal
infect
ifi
import
caus
mortal
morbid
children
treat
malign
high
incid
ifi
report
patient
treat
aml
relaps
children
underw
hematopoiet
stem
cell
transplant
prolong
neutropenia
intens
chemotherapi
leav
vulner
infect
evid
incid
rate
worldwid
rise
addit
appear
larg
variabl
incid
ifi
report
literatur
could
due
sever
factor
includ
era
treatment
definit
ifi
treatment
deliv
use
prophylaxi
primari
aim
studi
investig
effect
geographi
rate
ifi
designmethod
perform
systemat
review
identifi
publish
literatur
incid
fungal
infect
proven
probabl
paediatr
oncolog
patient
patient
underw
bone
marrow
transplant
result
search
ovid
medlin
embas
central
lilac
conduct
grey
literatur
search
combin
control
vocabulari
term
keyword
fungal
infect
cancer
bone
marrow
transplant
paediatr
popul
limit
public
date
languag
identifi
studi
titl
abstract
studi
screen
independ
two
author
studi
exclud
remain
studi
process
review
two
author
final
inclus
final
analysi
systemat
review
present
siop
meet
includ
heat
map
world
incid
rate
found
includ
literatur
conclus
much
literatur
ifi
paediatr
oncolog
first
review
worldwid
look
incid
rate
import
review
studi
ifi
paediatr
oncolog
p
obeng
v
l
g
c
sc
b
l
r
anoky
teach
hospit
child
paediatr
oncolog
unit
kumasi
ghana
backgroundobject
caretak
may
face
number
barrier
compli
referr
advic
barrier
financi
geograph
cultur
complex
aspect
referr
care
often
caretak
accept
complianc
referr
recommend
determin
factor
perceiv
need
referr
diseas
sever
caretak
commun
experi
impress
referr
facil
qualiti
cost
time
resourc
object
studi
determin
caretak
barrier
complianc
referr
order
improv
diagnosi
treatment
outcom
guidelin
integr
manag
childhood
ill
imci
designmethod
studi
cross
section
conduct
paediatr
oncolog
unit
pou
komfo
anoky
teach
hospit
kath
ghana
octob
decemb
pou
receiv
referr
per
month
seven
caretak
recruit
weekli
period
week
sampl
size
use
studi
data
time
arriv
referr
facil
barrier
complianc
referr
obtain
inform
consent
ethic
approv
sought
commenc
studi
result
barrier
complianc
referr
caretak
perspect
lack
financi
resourc
time
wast
referr
facil
seek
altern
treatment
experi
impress
referr
facil
lack
knowledg
diseas
sever
conclus
lack
financi
resourc
time
wast
seek
altern
treatment
experi
impress
lack
knowledg
diseas
sever
barrier
complianc
referr
studi
barrier
complianc
referr
inform
outcom
improv
intervent
g
olbara
h
f
j
g
teach
referr
hospit
child
health
pediatr
eldoret
kenya
univers
medic
center
pediatr
amsterdam
netherland
school
medicin
haemato
indianapoli
usa
maxima
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
backgroundobject
surviv
childhood
cancer
countri
approxim
wherea
countri
less
limit
access
set
may
contribut
poor
surviv
rate
studi
evalu
influenc
statu
childhood
cancer
treatment
kenyan
academ
hospit
designmethod
retrospect
medic
record
studi
children
diagnos
malign
includ
data
treatment
outcom
statu
diagnosi
abstract
patient
chart
result
patient
abandon
treatment
die
progress
relaps
diseas
result
surviv
major
patient
diagnosi
main
caus
treatment
failur
among
patient
without
diagnosi
abandon
treatment
occur
less
often
among
patient
diagnosi
surviv
estim
significantli
higher
patient
diagnosi
compar
without
patient
without
diagnosi
enrol
treatment
among
patient
later
enrol
frequenc
progress
relaps
diseas
death
significantli
lower
p
respect
surviv
estim
significantli
higher
p
compar
never
enrol
conclus
childhood
cancer
surviv
kenyan
academ
hospit
main
reason
treatment
failur
abandon
cancer
treatment
children
without
signific
lower
chanc
surviv
childhood
cancer
treatment
outcom
could
amelior
strategi
prevent
abandon
treatment
improv
access
olgun
g
k
r
ea
n
eylul
univers
faculti
medicin
otorhynolaryngolog
izmir
turkey
eylul
univers
institut
oncolog
pediatr
oncolog
izmir
turkey
eylul
univers
faculti
medicin
radiat
oncolog
izmir
turkey
eylul
univers
institut
oncolog
pediatr
current
address
univers
econom
izmir
turkey
backgroundobject
evalu
hear
impair
children
head
neck
cancer
receiv
platinum
compound
designmethod
medic
record
children
diagnosi
cancer
treat
evalu
retrospect
headneck
cancer
receiv
chemotheraphi
characterist
patient
detail
chemotherapi
headneck
radiotherapi
audiolog
record
analyz
audiolog
test
includ
pure
tone
audiometri
transient
emiss
auditori
brainstem
respons
ototox
grade
accord
brock
hear
loss
criteria
result
patient
headneck
cancer
receiv
platinum
baselin
audiolog
assess
avail
patient
diagnosi
cn
tumor
retinoblastoma
nasopharynx
carcinoma
hodgkin
lymphoma
intracrani
germ
cell
tumor
neuroblastoma
rhabdomyosarcoma
fibrohistiocyt
sarcoma
larynx
carcinoma
f
ratio
patient
patient
cisplatincarboplatin
patient
group
group
patient
receiv
cisplatin
divid
dose
schema
group
carboplatin
administ
singl
dose
schema
high
frequenc
hear
loss
detect
patient
accord
brock
grade
system
patient
grade
patient
grade
patient
grade
two
patient
grade
ototox
brock
grade
ototox
incid
diagnosi
age
found
significantli
differ
patient
without
ototox
ototox
differ
boy
girl
ototox
found
significantli
higher
patient
receiv
cumul
dose
also
found
significantli
higher
patient
receiv
platinum
headneck
radiotherapi
patient
receiv
cisplatin
schema
incid
ototox
nt
differ
cumul
carboplatin
dose
nt
differ
patient
without
ototox
ototox
occur
two
patient
ototox
occur
patient
receiv
headneck
radiotherapi
conclus
higher
cumul
dose
cisplatin
perform
headneck
radiotherapi
increas
risk
ototox
audiolog
necessari
earli
manag
improv
qualiti
life
palomo
colli
av
guevara
le
jf
gaytan
ce
cicero
murillo
infantil
de
federico
gomez
oncolog
mexico
citi
mexico
backgroundobject
nausea
vomit
dread
distress
side
effect
cancer
patient
undergo
chemotherapi
treatment
side
effect
signific
impact
patient
qualiti
life
interfer
abil
receiv
intens
chemotherapi
regimen
designmethod
retrospect
cohort
studi
pediatr
oncolog
patient
less
year
age
receiv
chemotherapi
data
abstract
includ
follow
age
gender
type
cancer
emetogen
risk
level
prescrib
prophylact
antiemet
regimen
incid
breakthrough
emesi
emetogen
risk
classifi
base
publish
guidelin
low
moder
high
emetogen
chemotherapi
clinic
effect
assess
base
breakthrough
emesi
result
total
patient
includ
studi
high
emetogen
chemotherapi
administ
moder
emetogen
chemotherapi
administ
patient
receiv
appropri
antiemet
prophylaxi
patient
experienc
breakthrough
emesi
breakthrough
emesi
occur
patient
receiv
high
emetogen
chemotherapi
versu
patient
receiv
moder
emetogen
chemotherapi
use
inadequ
antiemet
regimen
found
patient
breakthrough
emesi
thu
inadequ
prophylaxi
result
risk
breakthrough
emesi
risk
higher
patient
receiv
high
emetogen
chemotherapi
versu
receiv
moder
emetogen
chemotherapi
versu
nausea
vomit
affect
intak
food
recreat
activ
children
evalu
seven
day
chemotherapi
conclus
standard
antiemet
prophylaxi
base
emetogen
level
could
reduc
breakthrough
emesi
improv
qualiti
life
pediatr
oncolog
patient
inadequ
antiemet
prophylaxi
associ
high
risk
breakthrough
emesi
patel
r
r
v
cancer
institut
depart
pediatr
blood
marrow
transplant
chennai
india
cancer
institut
depart
pediatr
intens
critic
care
chennai
india
backgroundobject
trend
mortal
due
neutropen
sepsi
import
qualiti
indic
develop
countri
alarm
increas
incid
multidrug
resist
bacteri
infect
designmethod
perform
retrospect
analysi
children
admit
pediatr
intens
care
unit
picu
neutropen
sepsi
januari
decemb
neutropenia
defin
absolut
neutrophil
count
less
sepsi
defin
per
surviv
sepsi
campaign
guidelin
data
analyz
annual
subset
analysi
done
two
group
group
neutropenia
post
chemotherapi
malign
group
neutropenia
post
hematopoiet
stem
cell
transplant
result
total
patient
admit
picu
nineti
nine
admit
neutropen
sepsi
group
includ
children
group
includ
children
overal
surviv
mortal
rate
respect
mortal
rate
increas
aggress
antibiot
stewardship
intervent
decreas
rate
multidrug
resist
organ
sepsi
institut
mortal
rate
decreas
subset
analysi
found
mortal
rate
significantli
differ
post
chemotherapi
post
hsct
cohort
respect
children
cultur
posit
carbapenam
resist
klebsiella
pneumonia
common
isol
mortal
higher
cultur
posit
sepsi
compar
cultur
neg
conclus
data
provid
evid
need
institut
measur
ration
use
antibiot
team
effort
pediatr
intens
care
unit
surviv
rate
among
post
chemotherapi
post
hsct
group
achiev
trend
qualiti
indic
watch
dilig
platschek
c
b
hk
sport
univers
cologn
institut
movement
neurosci
cologn
germani
cologn
children
hospit
cologn
germani
backgroundobject
fatigu
crf
common
symptom
pediatr
cancer
limit
patient
activ
affect
qualiti
life
crf
multidimension
effect
viciou
cycl
decreas
capac
inact
lack
recoveri
helpless
still
uncertain
potenti
physic
activ
prior
diseas
context
crf
designmethod
fifteen
pediatr
patient
differ
type
cancer
femal
mean
age
year
pedsql
multidimension
fatigu
scale
questionnair
complet
cancer
therapi
standard
treatment
pediatr
patient
adjuv
chemotherapi
accord
nation
protocol
daili
activ
level
diseas
retrospect
interrog
hour
divis
activ
time
sleep
sit
lie
awak
bed
begin
treatment
physic
activ
treatment
queri
questionnair
type
durat
activ
summar
hour
activ
per
month
pearson
correl
use
analyz
data
result
mean
time
start
cancer
therapi
crf
questionnair
day
mean
activ
level
diseas
hour
per
day
patient
higher
activ
level
diseas
show
signific
higher
crf
score
cancer
therapi
r
p
higher
score
indic
lower
crf
mean
time
physic
activ
treatment
hour
per
month
patient
higher
activ
level
diseas
also
show
signific
higher
crf
score
r
p
conclus
physic
activ
potenti
reduc
crf
cancer
treatment
pediatr
cancer
patient
improv
qualiti
life
exercis
repres
effect
therapeut
intervent
prepar
children
success
complet
treatment
reduc
acut
side
effect
like
crf
find
emphas
import
physic
activ
lessen
side
effect
cancer
therapi
platschek
b
hk
sport
univers
cologn
institut
movement
neurosci
cologn
germani
cologn
children
hospit
cologn
germani
backgroundobject
physic
activ
posit
influenc
physic
mental
psychosoci
level
prevent
viciou
cycl
lack
exercis
decreas
capac
counteract
side
effect
howev
begin
cancer
therapi
chang
everday
life
accept
view
posit
impact
exercis
import
much
activ
behavior
affect
designmethod
fifteen
pediatr
patient
differ
type
cancer
femal
mean
age
year
activ
behavior
diseas
queri
daili
activ
level
diseas
retrospect
interrog
hour
divis
activ
time
sleep
sit
lie
awak
bed
begin
treatment
daili
activ
level
diseas
interrog
hour
divis
exercis
treatment
queri
questionnair
type
durat
exercis
summar
hoursmonth
pearson
correl
use
analyz
data
result
mean
activ
level
decreas
hoursday
diseas
hoursday
diseas
p
mean
exercis
decreas
hoursmonth
diseas
hoursmonth
diseas
p
patient
higher
activ
level
diseas
patient
higher
exercis
diseas
show
signific
higher
activ
level
diseas
r
p
r
p
conclus
activ
behavior
seem
significantli
reduc
begin
cancer
therapi
patient
activ
diseas
also
appear
activ
cancer
therapi
exercis
therapi
implement
acut
care
increas
activ
level
prevent
cancer
relat
side
effect
prasad
g
g
r
b
memori
hospit
paediatr
oncolog
mumbai
india
enterpris
clinic
densitometri
mumbai
india
tilak
municip
medic
colleg
gener
hospit
paediatr
mumbai
india
memori
hospit
biostatist
mumbai
india
backgroundobject
half
children
malign
countri
lmic
malnourish
lead
poor
treatment
toler
higher
toxic
lower
surviv
earli
nutrit
intervent
may
obviat
effect
rutf
establish
medic
nutrit
therapi
howev
efficaci
data
children
malign
lack
designmethod
sever
moder
malnourish
sammam
children
cancer
age
year
underw
stratifi
random
receiv
either
rutf
standard
nutrit
therapi
snt
week
dietari
intak
nutrit
statu
weight
height
bodi
mass
index
age
bodi
composit
use
dual
energi
absorptiometri
dexa
scan
health
relat
qualiti
life
hrqol
health
util
treatment
toler
compar
baselin
clinic
monitor
done
weekli
week
monthli
month
result
children
arm
enrol
evalu
median
age
f
children
compar
greater
week
baselin
weight
vs
like
achiev
normal
nutrit
statu
week
month
respect
rutf
enabl
increas
protein
energi
consumpt
increas
hrqol
score
week
children
less
treatment
delay
intervent
period
vs
p
vs
p
well
fewer
episod
febril
neutropenia
vs
shorter
admiss
period
per
episod
vs
conclus
rutf
effect
well
toler
nutrit
intervent
sammam
children
malign
improv
nutrit
statu
qualiti
life
reduc
toxic
chemotherapi
compar
snt
benefit
maintain
time
rutf
immens
potenti
improv
treatment
outcom
supplement
strongli
consid
intens
phase
treatment
vr
prasanth
r
cs
n
kg
cancer
centr
paediatr
oncolog
trivandrum
india
backgroundobject
studi
aim
evalu
loss
protect
anti
hb
titr
seroconvers
hepat
b
hb
immun
intens
phase
chemotherapi
among
paediatr
acut
lymphoblast
leukaemia
patient
neg
hb
serolog
diagnosi
designmethod
paediatr
patient
year
treat
feb
jan
categor
base
anti
hb
titr
present
group
protect
anti
hb
titr
miuml
given
doubl
dose
hepat
b
vaccin
group
ii
titr
miuml
given
hepatit
b
immunoglobulin
hbig
prior
start
chemotherapi
follow
three
doubl
dose
hb
vaccin
month
first
dose
month
hbig
result
fulli
immun
belong
group
group
ii
among
group
patient
retain
protect
titr
end
induct
begin
reinduct
start
mainten
chemotherapi
respect
group
ii
children
attain
protect
titr
evalu
prior
dose
hb
vaccin
week
third
dose
vaccin
subgroup
analysi
group
show
children
initi
anti
hb
titr
iul
retain
protect
titr
better
compar
titr
iul
one
becam
hb
posit
develop
hepat
conclus
recombin
hb
vaccin
doubl
dose
offer
protect
titr
fulli
immun
children
initi
titr
iul
l
intens
phase
chemotherapi
ideal
vaccin
schedul
antihb
remain
establish
lmic
set
due
financi
constraint
although
studi
patient
attain
protect
titr
vaccin
strategi
v
radhakrishnan
j
p
institut
wia
medic
oncolog
pediatr
oncolog
chennai
india
backgroundobject
rasburicas
recombin
urat
oxidas
enzym
approv
use
tumor
lysi
syndrom
tl
act
reduc
serum
uric
acid
level
use
rasburicas
recommend
dose
day
expens
known
whether
extend
schedul
clinic
benefici
compar
singl
fix
dose
mg
aim
present
studi
evalu
efficaci
singl
dose
rasburicas
mg
prevent
manag
tl
designmethod
rasburicas
avail
singl
use
mg
vial
institut
singl
dose
rasburicas
mg
irrespect
bodyweight
use
adult
children
dose
mgkg
maximum
mg
use
sinc
prevent
manag
tl
subsequ
dose
given
base
biochem
respons
clinic
condit
retrospect
analys
case
record
patient
receiv
rasburicas
januari
januari
result
studi
includ
patient
hematolog
malign
receiv
rasburicas
children
account
patient
male
compris
rasburicas
use
prophylact
patient
laboratori
tl
patient
clinic
tl
patient
singl
fix
dose
rasburicas
prevent
laboratoryclin
tl
prophylact
group
prevent
clinic
tl
laboratori
tl
group
none
patient
prophylact
laboratori
tl
group
develop
clinic
tl
howev
major
patient
clinic
tl
requir
one
dose
rasburicas
conclus
singl
dose
mg
vial
rasburicas
effici
prevent
manag
laboratori
tl
econom
viabl
resourc
constrain
set
v
radhakrishnan
k
j
p
institut
wia
medic
oncolog
pediatr
oncolog
chennai
india
backgroundobject
resist
mdr
bacteria
associ
increas
morbid
mortal
children
acut
leukemia
present
studi
conduct
assess
preval
mdr
bacteria
stool
cultur
patient
acut
leukemia
present
hospit
result
correl
blood
cultur
patient
develop
septicemia
designmethod
studi
involv
analysi
case
record
patient
newli
diagnos
acut
leukemia
less
year
age
treat
centr
januari
decemb
stool
cultur
sent
within
hour
hospit
admiss
blood
cultur
sent
clinic
indic
mdr
defin
resist
least
antibiot
follow
antimicrobi
group
cephalosporin
inhibitor
carbapenem
fluoroquinolon
aminoglycosid
result
analysi
includ
patient
acut
leukemia
among
patient
posit
stool
cultur
patient
posit
mdr
bacteria
blood
cultur
posit
mdr
patient
posit
stool
cultur
mdr
patient
neg
stool
cultur
concord
stool
blood
cultur
similar
organ
death
stool
cultur
posit
patient
death
stool
cultur
neg
patient
conclus
studi
show
high
preval
mdr
bacteria
newli
diagnos
children
acut
leukemia
colonis
mdr
bacteria
stool
associ
increas
posit
blood
cultur
mortal
ragab
h
e
sham
univers
pediatr
cairo
egypt
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
radiolog
depart
cairo
egypt
backgroundobject
posterior
revers
encephalopathi
syndrom
pre
diagnosi
character
spectrum
symptom
includ
alter
mental
statu
headach
seizur
visual
impair
aim
studi
risk
factor
clinic
radiolog
pattern
pre
pediatr
cancer
patient
outcom
designmethod
retrospect
studi
includ
pediatr
cancer
patient
develop
pre
cours
treatment
children
cancer
hospit
egypt
januari
june
clinic
radiolog
data
studi
patient
collect
review
mri
find
revis
special
neuroradiologist
defin
differ
kind
pre
medic
record
review
find
underli
medic
condit
patient
includ
studi
result
among
patient
pre
less
year
age
femal
male
ratio
leukemia
lymphoma
wee
commonest
diagnosi
forti
patient
receiv
chemotherapi
immunosuppress
last
day
hypertens
present
patient
time
pre
regard
mri
find
patient
either
occipit
affect
affect
area
like
frontal
involv
seen
patient
tempor
lobe
cerebellum
basal
ganglia
thalamu
unilater
pre
present
patient
atyp
find
patient
advanc
pre
present
complet
clinic
resolut
complet
radiolog
resolut
week
evalu
conclus
although
clinic
radiolog
revers
expect
small
number
patient
may
develop
persist
neurolog
sequela
even
death
may
occur
advanc
atyp
site
wors
prognosi
j
ramamoorthi
v
tg
professor
depart
medic
cancer
institut
adyar
chennai
india
professor
depart
medic
cancer
institut
adyar
chennai
india
depart
medic
cancer
institut
adyar
chennai
india
backgroundobject
high
risk
febril
neutropen
fn
episod
children
acut
lymphoblast
leukemia
treat
antibiot
till
count
recoveri
cr
irrespect
fever
statu
prolong
hospit
stay
escal
treatment
expenditur
necessari
evil
recommend
target
antibiot
administr
children
risk
recurr
febril
neutropenia
rfn
curtail
problem
object
estim
incid
risk
factor
rfn
children
designmethod
fn
episod
januari
june
children
diagnos
year
analyz
retrospect
world
health
organ
definit
util
classifi
nutrit
statu
definit
rfn
febril
episod
develop
hour
within
day
afebril
period
cr
absolut
neutrophil
count
absolut
monocyt
count
peripher
blood
result
episod
rfn
time
occurr
evid
clinic
microbiolog
document
infect
comdi
episod
absenc
cr
risk
factor
associ
develop
rfn
remission
statu
marrow
nrsm
ci
profound
neutropenia
pn
ci
comdi
ci
underweight
ci
multivari
analysi
reveal
signific
associ
rfn
nrsm
pn
underweight
statu
fn
episod
defervesc
cr
hour
rfn
develop
rfn
episod
associ
comdi
underweight
stunt
pn
univari
analysi
underweight
pn
multivari
analysi
conclus
underweight
statu
pn
nrsm
predispos
children
develop
rfn
antibiot
need
continu
count
recoveri
underweight
children
pn
episod
irrespect
defervesc
statu
j
ramamoorthi
v
tg
professor
depart
medic
cancer
institut
wia
adyar
chennai
india
professor
depart
medic
cancer
institut
wia
adyar
chennai
india
depart
medic
cancer
institut
wia
adyar
chennai
india
backgroundobject
resist
inhibitor
carbapenem
report
gram
neg
bacteri
gnb
isol
respect
lifelin
left
manag
multidrug
resist
mdr
gnb
isol
colistimeth
sodium
cs
perform
audit
estim
frequenc
indic
impact
outcom
febril
neutropenia
episod
fne
cs
administr
designmethod
fne
children
period
januari
juli
centr
audit
retrospect
mdr
defin
intermedi
resist
one
agent
atleast
differ
class
antibiot
result
fne
cs
administ
episod
fne
secondari
treatment
acut
myeloid
leukemia
episod
acut
lymphoblast
leukemia
episod
lymphoma
episod
other
episod
durat
neutropenia
febril
neutropenia
day
day
respect
median
day
fne
absolut
neutrophil
count
time
cs
initi
cs
therapi
initi
follow
clinic
sepsi
episod
microbiolog
document
infect
mdi
episod
previou
mdi
mdr
isol
episod
clinic
document
infect
episod
sever
sepsi
episod
mdr
gnb
isol
episod
mdi
escherichia
episod
klebsiella
episod
pseudomona
aeruginosa
episod
initi
cs
deferevesc
achiev
fne
interv
day
defervesc
achiev
episod
result
death
conclus
cs
administ
fne
commonli
children
clinic
sepsi
mdi
cs
initi
necessari
evil
pediatr
oncolog
practic
clinic
risk
stratif
robust
biomark
antibiot
escal
respons
assess
need
avoid
inappropri
util
j
ramamoorthi
v
tg
professor
depart
medic
cancer
institut
wia
adyar
chennai
india
resid
depart
medic
cancer
institut
wia
adyar
chennai
india
professor
depart
medic
cancer
institut
wia
adyar
chennai
india
depart
medic
cancer
institut
wia
adyar
chennai
india
backgroundobject
germlin
polymorph
gene
involv
thiopurin
metabol
influenc
respons
rate
toxic
profil
follow
exposur
preval
nudt
polymorph
nudtp
children
east
asian
ancestri
report
risk
stratifi
test
strategi
expect
reduc
expens
incur
test
nudtp
object
studi
identifi
paramet
clp
could
predict
exist
nudtp
designmethod
twenti
consecut
children
total
leukocyt
count
tlc
seventh
day
thiopurin
exposur
sdtpe
consolid
phase
treatment
enrol
prospect
detail
treatment
interrupt
tlc
febril
neutropenia
episod
fne
collect
receiv
oper
curv
roc
util
deriv
point
sensit
specif
clp
nudtp
evalu
use
allel
specif
real
time
pcr
result
median
age
cohort
year
median
tlc
sdtpe
grade
leukopenia
seen
children
respect
median
durat
leukopenia
dol
day
children
requir
day
recov
tlc
homozyg
heterozyg
nudtp
observ
cohort
respect
nudtp
could
predict
sensit
specif
whenev
tlc
sdtpe
nudtp
could
predict
sensit
specif
respect
whenev
durat
leucopenia
day
children
homozyg
nudtp
day
leucopenia
tlc
sdtpe
children
nudtp
treatment
interrupt
day
fne
child
succumb
fne
conclus
tlc
sdtpe
dol
day
could
util
threshold
screen
nudtp
prospect
evalu
larger
sampl
size
need
valid
point
sr
rassekh
b
k
b
f
r
g
bc
cj
british
columbia
divis
pediatr
hematologyoncologybmt
vancouv
canada
columbia
children
hospit
audiolog
speech
patholog
vancouv
canada
british
columbia
experiment
medicin
vancouv
canada
univers
divis
experiment
medicin
montreal
canada
british
columbia
faculti
pharmaceut
scienc
vancouv
canada
columbia
children
hospit
divis
pediatr
ent
vancouv
canada
alberta
depart
medicin
edmonton
canada
columbia
children
hospit
research
institut
pharmaceut
outcom
programm
vancouv
canada
sick
children
depart
divis
pediatr
nephrolog
toronto
canada
british
columbia
depart
divis
translat
therapeut
vancouv
canada
backgroundobject
cisplatin
highli
effect
chemotherapeut
agent
use
treatment
varieti
childhood
cancer
howev
use
limit
signific
toxic
specif
hear
loss
nephrotox
conduct
multipl
pharmacogenet
studi
ototox
cio
discov
multipl
gene
associ
toxic
valid
find
prospect
cohort
recruit
pharmacogenom
studi
designmethod
abl
team
establish
valid
predict
marker
late
effect
cancer
treatment
includ
cisplatin
induc
toxic
observ
studi
enrol
particip
receiv
cisplatin
treatment
one
canadian
institut
first
second
cycl
cisplatin
therapi
subject
elig
particular
analysi
end
therapi
audiogram
could
grade
use
siop
boston
scale
audiogram
central
review
one
expert
audiologist
pharmacogenom
analys
perform
use
panel
previous
identifi
candid
gene
includ
result
particip
enrol
abl
studi
current
post
therapi
audiogram
upload
incomplet
audiolog
assess
allow
grade
per
siop
boston
scale
die
prior
end
therapi
audiolog
therefor
particip
met
inclus
criteria
ototox
assess
detect
ototox
grade
toxic
observ
includ
grade
ototox
grade
grade
grade
baselin
characterist
analysi
pharmacogenom
result
pend
conclus
ototox
common
children
treat
cisplatin
children
evid
toxic
risk
factor
hear
loss
includ
genet
predictor
analys
present
meet
rhead
j
v
keyn
univers
hospit
paediatr
milton
keyn
unit
kingdom
backgroundobject
febril
neutropenia
fn
emerg
oncolog
patient
requir
rapid
assess
treatment
accord
nice
guidelin
children
malign
fever
assess
receiv
parent
antibiot
within
minut
arriv
hospit
paediatr
oncolog
share
care
unit
poscu
aim
investig
patient
suspect
fn
given
antibiot
within
recommend
door
needl
dtn
time
compar
nation
designmethod
retrospect
audit
conduct
review
medic
note
oncolog
patient
admiss
suspect
fn
septemb
decemb
includ
result
audit
present
depart
produc
fn
pathway
poster
admiss
unit
ward
implement
chang
process
repeat
may
august
januari
june
result
initi
audit
includ
admiss
suspect
fn
admiss
receiv
antibiot
within
minut
first
includ
admiss
admiss
receiv
antibiot
within
minut
second
includ
admiss
receiv
antibiot
within
minut
present
initi
audit
result
along
implement
admiss
pathway
poster
percentag
patient
receiv
antibiot
within
minut
increas
first
second
respect
conclus
nation
audit
publish
herd
et
al
overal
dtn
fn
found
staff
educ
fn
implement
admiss
pathway
rais
awar
posit
outcom
dtn
time
highlight
need
continu
educ
awar
staff
parent
next
step
introduc
inform
leaflet
includ
clock
visual
tool
encourag
time
present
j
rivera
c
r
g
l
infantil
teleton
de
pediatr
emerg
queretaro
mexico
infantil
teleton
de
nurs
queretaro
mexico
jude
children
research
hospit
depart
pediatr
global
medicin
memphi
usa
infantil
teleton
de
pediatr
intens
care
unit
queretaro
mexico
infantil
teleton
de
pediatr
oncolog
queretaro
mexico
backgroundobject
introduct
earli
warn
score
use
clinic
paramet
gener
score
allow
identifi
patient
risk
clinic
deterior
object
evalu
use
pew
pediatr
earli
warn
score
score
marker
earli
clinic
deterior
pediatr
oncolog
patient
requir
evalu
intens
care
team
designmethod
event
review
correspond
patient
diagnosi
cancer
requir
evalu
pediatr
intens
care
unit
picu
team
decemb
octob
pew
score
assign
retrospect
manner
one
event
hour
evalu
picu
team
score
greater
classifi
critic
base
vital
sign
event
classifi
base
intervent
picu
consult
medic
respons
team
activ
code
team
activ
result
evalu
picu
team
patient
critic
pew
picu
evalu
rang
hour
event
moment
event
event
patient
transfer
picu
critic
pew
event
remain
event
requir
transfer
picu
patient
requir
intervent
improv
critic
condit
conclus
use
earli
warn
score
use
identifi
clinic
deterior
earli
result
suggest
earli
warn
score
would
allow
object
identif
patient
risk
deterior
b
g
witwatersrand
paediatr
oncolog
chri
hani
baragwanath
academ
hospit
johannesburg
south
africa
backgroundobject
tuberculosi
tb
report
children
undergo
chemotherapi
object
studi
describ
incid
latent
children
cancer
ii
compar
tuberculin
skin
test
tst
interferon
gamma
releas
assay
diagnos
latent
iii
describ
characterist
outcom
children
cancer
designmethod
prospect
cohort
studi
conduct
tertiari
center
south
africa
april
march
newli
diagnos
children
cancer
enrol
screen
latent
tst
test
suspect
chemotherapi
sputum
sent
cultur
result
total
patient
enrol
latent
document
patient
assay
yield
neg
result
patient
diagnos
chemotherapi
incid
per
child
year
develop
chemotherapi
higher
number
corticosteroid
cours
per
child
year
compar
develop
tb
per
child
year
p
children
develop
septic
episod
associ
profound
neutropenia
vs
p
profound
lymphopenia
vs
p
profound
monocytopenia
vs
p
children
develop
tb
septic
episod
prolong
neutropenia
vs
p
prolong
lymphopenia
vs
p
prolong
monocytopenia
vs
p
death
conclus
incid
latent
children
cancer
low
tst
test
limit
valu
diagnos
immunocompromis
patient
risk
factor
develop
activ
patient
hematolog
malign
use
numer
cours
corticosteroid
profound
prolong
neutropenia
lymphopenia
monocytopenia
mortal
patient
tb
cancer
due
complex
factor
b
g
witwatersrand
paediatr
oncolog
chri
hani
baragwanath
academ
hospit
johannesburg
south
africa
backgroundobject
role
respiratori
virus
rv
infect
pathogen
patient
febril
neutropenia
fn
extens
character
aim
document
incid
children
hematolog
malign
solid
tumour
assess
whether
differ
group
ii
identifi
common
rv
occur
children
fn
iii
document
incid
children
die
designmethod
children
diagnos
cancer
paediatr
oncolog
unit
tertiari
center
south
africa
enrol
prospect
cohort
studi
suspect
septic
episod
sse
defin
accord
standard
definit
fn
sse
blood
investig
nasopharyng
aspir
done
variou
paramet
record
result
patient
hematolog
malign
solid
tumour
total
sse
occur
number
sse
associ
rv
hematolog
malign
solid
tumour
number
sse
hematolog
malign
vs
overal
incid
per
child
year
sse
hematolog
malign
vs
solid
tumour
p
human
rhinoviru
hrv
identifi
occur
twelv
children
die
due
sepsi
eighteen
rv
isol
deceas
patient
human
coronaviru
hrv
conclus
sse
common
among
children
hematolog
malign
compar
solid
tumour
common
rv
identifi
hrv
lower
patient
die
bacteri
fungal
addit
identifi
rv
presenc
clinic
signific
relationship
outcom
remain
uncertain
rykov
v
blokhin
medic
research
center
oncolog
ministri
health
russian
feder
institut
pediatr
oncolog
moscow
russia
children
clinic
hospit
anesthesiolog
nizhni
novgorod
russia
gorbacheva
institut
pediatr
hematolog
transplant
oncolog
russia
rogachev
feder
research
center
pediatr
oncolog
immunolog
anaesthesiolog
moscow
russia
backgroundobject
review
first
russian
feder
experi
picc
pediatr
cancer
patient
designmethod
analysi
includ
patient
month
year
mean
age
year
varieti
cancer
diseas
picc
establish
set
carri
use
ultrasound
navig
patient
use
extern
anatom
landmark
intraop
fluoroscopi
result
maximum
durat
oper
year
lowest
month
averag
month
among
technic
difficulti
instal
frequent
migrat
distal
end
cathet
intern
jugular
vein
blood
flow
patient
case
unabl
catheter
patient
vein
among
common
complic
oper
mark
picc
thrombosi
case
venou
thrombosi
observ
case
bloodstream
infect
report
remov
picc
relat
complic
perform
patient
later
implant
venou
port
conclus
picc
recommend
use
treatment
children
cancer
train
nurs
staff
minim
risk
complic
n
ca
c
e
medico
imbanaco
pediatr
oncolog
unit
cali
colombia
del
vall
school
medicin
cali
colombia
medico
imbanaco
pediatr
infectolog
cali
colombia
del
vall
pediatr
infectolog
cali
colombia
backgroundobject
febril
neutropenia
urgenc
high
mortal
rate
untreat
etiolog
complic
febril
child
chemotherapi
well
known
set
countri
herein
describ
outcom
febril
episod
children
treat
pediatr
oncolog
unit
cali
colombia
designmethod
includ
febril
episod
children
chemotherapi
third
level
privat
pediatr
oncolog
unit
baselin
data
episod
collect
medic
record
laboratori
patholog
report
defin
sever
infect
child
requir
inpati
treatment
microbiolog
isol
local
infect
elev
inflammatori
biomark
set
suspect
infect
descript
statist
result
identifi
event
patient
febril
episod
patient
half
patient
year
old
f
ratio
born
cali
acut
lymphoblast
leukemia
mainten
episod
need
inpati
treatment
sever
infect
microbiolog
isol
frequent
bacteria
follow
viral
adenoviru
cytomegaloviru
influenza
parainfluenza
coxsacki
amebiasi
nineteen
foci
without
isol
organ
pneumonia
upper
respiratori
infecion
gastrointestin
skin
cholecyst
four
episod
requir
picu
aliv
twenti
episod
inpati
infect
episod
tumor
origin
conclus
sever
infect
occur
febril
patient
seem
particularli
relev
mantain
current
intens
chemotherapi
patient
becom
immunosuppress
alway
neutropen
inform
increas
awar
pediatr
emerg
physician
usual
provid
first
clinic
care
patient
k
h
h
n
n
k
schroeder
medic
centr
oncolog
mwanza
tanzania
univers
global
health
durham
usa
univers
medic
center
pediatr
oncolog
global
health
durham
usa
backgroundobject
set
pediatr
cancer
often
goe
unrecogn
creat
barrier
improv
childhood
cancer
surviv
rate
tanzania
fewer
children
cancer
present
treatment
increas
commun
awar
pediatr
cancer
lead
improv
referr
reduc
diagnost
delay
studi
evalu
implement
impact
pediatr
cancer
commun
awar
campaign
tanzania
designmethod
key
stakehold
agre
campaign
educ
content
target
print
radio
media
develop
evalu
commun
focu
group
four
commun
randomli
select
lake
zone
region
tanzania
plan
intervent
includ
urban
rural
commun
survey
conduct
via
random
sampl
assess
individu
knowledg
pediatr
cancer
caus
symptom
treatment
survey
also
evalu
exposur
perceiv
accept
compon
multimedia
campaign
result
signific
differ
respond
age
sex
intervent
group
averag
age
year
femal
post
intervent
knowledg
score
increas
p
increas
improv
among
rural
compar
urban
commun
vs
radio
program
greatest
reach
report
exposur
media
exposur
correl
increas
knowledg
score
pearson
correl
coeffici
conclus
target
multimedia
campaign
effect
increas
pediatr
cancer
knowledg
set
potenti
greater
impact
rural
commun
futur
studi
need
evalu
impact
awar
campaign
outcom
e
schwartz
k
v
de
b
l
n
van
den
r
w
b
r
van
g
univers
medic
center
pediatr
amsterdam
netherland
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
univers
medic
center
epidemiolog
biostatist
amsterdam
netherland
univers
medic
center
pediatr
oncolog
leiden
netherland
univers
medic
center
pediatr
oncolog
nijmegen
netherland
medic
center
pediatr
oncolog
amsterdam
netherland
medic
center
groningen
pediatr
oncolog
groningen
netherland
medic
center
children
hospit
pediatr
oncolog
utrecht
netherland
univers
medic
center
pediatr
oncolog
rotterdam
netherland
backgroundobject
despit
use
antibiot
prophylaxi
bacteri
infect
remain
lead
caus
morbid
children
acut
myeloid
leukemia
aml
object
studi
evalu
cumul
incid
blood
stream
infect
bsi
treatment
accord
last
three
consecut
protocol
dutch
childhood
oncolog
group
dcog
determin
common
bacteri
pathogen
determin
risk
factor
designmethod
retrospect
chart
review
perform
patient
dcog
treatment
protocol
diagnos
de
novo
aml
apl
syndrom
exclud
patient
receiv
prophylaxi
onward
patient
also
receiv
prophylact
fluoroquinolon
bsi
defin
posit
blood
cultur
confirm
hospit
microbiologist
cumul
incid
bsi
determin
use
compet
risk
analysi
death
switch
anoth
protocol
stem
cell
transplant
compet
event
age
sex
bmi
white
blood
cell
count
wbc
diagnosi
cytogenet
treatment
protocol
evalu
risk
factor
result
median
age
year
rang
male
cumul
incid
bsi
common
pathogen
staphylococcu
epidermidi
streptococcu
miti
staphylococci
show
lower
bsi
incid
hazard
ratio
hr
respect
wbc
associ
lower
risk
infect
hr
risk
factor
statist
signific
conclus
recent
dcog
protocol
associ
highest
incid
bsi
probabl
result
high
intens
protocol
furthermor
use
prophylact
antibiot
coverag
may
result
rel
higher
incid
bsi
high
incid
stress
urg
improv
support
care
measur
seetharam
p
kg
cancer
centr
pediatr
oncolog
thiruvananthapuram
india
backgroundobject
syndrom
inappropri
anti
diuret
hormon
secret
siadh
advers
effect
vincristin
vcr
literatur
suggest
asian
predispos
develop
siadh
follow
vcr
administr
howev
data
regard
occurr
siadh
pediatr
oncolog
limit
aim
studi
analyz
incid
clinic
pictur
risk
factor
manag
outcom
siadh
pediatr
patient
induct
chemotherapi
acut
lymphoblast
leukemia
treat
tertiari
cancer
centr
india
designmethod
one
hundr
sixti
six
pediatr
patient
age
upto
year
newli
diagnos
treat
accord
institut
chemotherapi
protocol
modifi
bfm
protocol
januari
decemb
tertiari
cancer
care
centr
south
india
includ
result
incid
siadh
mean
sodium
level
seventi
two
percent
episod
associ
administr
dose
vincristin
preced
week
one
patient
present
seizur
patient
manag
fluid
restrict
two
patient
requir
sodium
correct
hyperton
salin
margin
signific
correl
note
girl
year
age
p
valu
conclus
report
higher
incid
siadh
indian
children
induct
chemotherapi
regular
monitor
sodium
level
induct
chemotherapi
would
help
avert
neurolog
symptom
secondari
siadh
k
sen
dhirubhai
ambani
hospit
depart
paediatr
mumbai
india
dhirubhai
ambani
hospit
depart
paediatr
oncolog
bmt
mumbai
india
dhirubhai
ambani
hospit
depart
haematolog
bmt
mumbai
india
backgroundobject
voriconazol
commonli
use
antifung
agent
use
paediatr
oncolog
patient
prophylaxi
treatment
fungal
infect
report
one
post
transplant
patient
present
acut
bone
pain
tibia
designmethod
year
old
boy
relaps
b
cell
success
match
sibl
donor
transplant
post
transplant
patient
given
presumpt
therapi
liposom
amphotericin
galactomannan
screen
posit
later
antifung
therapi
switch
voriconazol
discharg
voriconazol
level
monitor
kept
therapeut
level
day
patient
present
sever
leg
pain
difficulti
walk
neurolog
find
x
ray
leg
normal
suspect
relaps
bone
marrow
aspir
biopsi
done
show
evid
diseas
recurr
mrd
neg
donor
chimer
pain
increas
sever
extent
child
stop
walk
mri
scan
done
show
periost
thicken
suggest
mild
periost
tibia
differenti
diagnosi
leukem
infiltr
osteomyel
drug
induc
periost
consid
rule
relaps
bone
marrow
examin
inflammatori
marker
neg
deduc
drug
induc
periost
like
caus
symptom
discontinu
voriconazol
led
complet
resolut
pain
within
hour
result
one
year
post
transplant
patient
continu
remiss
pain
free
conclus
pain
periost
rare
complic
long
term
voriconazol
therapi
recent
report
literatur
fluorosi
promot
bone
format
osteoblast
stimul
propos
mechan
voriconazol
induc
periost
increas
awar
rare
condit
lead
earli
correct
diagnosi
r
seth
j
pediatr
delhi
india
cardiolog
new
delhi
india
pediatr
new
delhi
india
backgroundobject
myocard
complic
children
leukemia
due
cardiotox
chemotherapi
also
due
sepsi
due
viral
bacteri
infect
often
fatal
intraven
globulin
found
use
children
myocard
report
result
seri
patient
present
leukemia
septic
shock
myocard
treat
intraven
globulin
designmethod
children
leukemia
undergo
chemotherapi
present
septic
shock
myocard
includ
children
treat
antibiot
diuret
intraven
inotrop
myocard
defin
eject
fraction
without
elev
blood
troponin
level
intraven
gamma
globulin
ivig
given
gmkg
result
five
children
present
combin
leukemia
acut
lymphoblast
leukemia
acut
myeloid
leukemia
juvenil
myelomonocyt
leukemia
complic
sepsi
myocardi
dysfunct
respond
support
care
treat
ivig
start
within
hour
diagnosi
age
rang
year
undergo
chemotherapi
present
featur
sepsi
develop
shock
two
evid
viral
infect
varicella
ebv
four
patient
improv
improv
left
ventricular
function
normal
discharg
enalapril
ace
inhibit
carvedilol
beta
blocker
continu
follow
one
patient
declin
therapi
initi
care
conclus
ivig
found
mycoplasma
chlamydia
etc
activ
herpesviru
varicella
zoster
parvoviru
adenoviru
may
also
scaveng
effect
toxin
inflammatori
mediat
mortal
leukemia
septic
shock
high
ivig
could
potenti
treatment
myocard
demonstr
w
hospit
chongq
medic
univers
depart
pediatr
surgic
oncolog
chingq
china
backgroundobject
studi
effect
shenmai
inject
protect
bone
marrow
reduc
toxic
side
effect
chemotherapi
designmethod
children
malign
solid
tumor
includ
neuroblastoma
lymphoma
hepatoblastoma
rhabdomyosarcoma
synovi
sarcoma
primit
neuroectoderm
tumor
osteosarcoma
immatur
malign
teratoma
yolk
sac
tumor
randomli
divid
control
group
three
dose
gradient
experiment
group
control
group
receiv
standard
chemotherapi
addit
standard
chemotherapi
three
experiment
group
treat
correspond
dose
gradient
shenmai
inject
four
cours
treatment
differ
blood
liver
kidney
function
side
effect
chemotherapi
efficaci
qualiti
life
evalu
experiment
group
control
group
result
signific
differ
three
experiment
group
control
group
white
blood
cell
neutrophil
hemoglobin
platelet
p
signific
differ
liver
function
renal
function
three
experiment
group
control
group
p
signific
differ
cardiac
marker
electrocardiogram
three
experiment
group
control
group
p
signific
differ
nausea
vomit
chemotherapi
side
effect
three
test
group
control
group
p
experiment
group
experiment
group
significantli
differ
control
group
cur
effect
signific
differ
experiment
group
control
group
signific
differ
life
qualiti
three
experiment
group
control
group
respect
conclus
shenmai
inject
help
recov
bodi
chemotherapi
improv
qualiti
life
make
children
abl
toler
complet
chemotherapi
improv
prognosi
children
malign
solid
tumor
sr
siddaiahgari
children
banjara
hill
pediatr
hematolog
oncolog
hyderabad
india
backgroundobject
fungal
infect
becom
lead
caus
mortal
morbid
children
leukemia
present
induct
period
low
leucocyt
platelet
count
aspergillu
common
among
discuss
fungal
infect
occur
rare
site
designmethod
observ
studi
data
children
immuno
defici
primari
acquir
treat
rainbow
children
hospit
develop
fungal
infect
non
sinu
non
pulmonari
site
collect
result
five
case
identifi
four
acut
leukemia
one
chediak
higashi
syndrom
site
infect
eye
one
case
cannula
site
case
foot
one
case
forearm
one
case
fungu
identifi
includ
aspergillu
case
rhizopu
two
case
exserohilum
rostratum
one
case
four
case
recov
aggress
antifung
local
debrid
one
case
requir
limb
amput
conclus
strong
clinic
suspicion
activ
intervent
need
treat
infect
infect
may
occur
rare
fungi
common
fungal
infect
occur
rare
site
g
singh
g
calgari
pediatr
oncolog
calgari
canada
care
manitoba
pediatr
hematolog
oncolog
winnipeg
canada
calgari
pediatr
hematolog
oncolog
stem
cell
transplant
calgari
canada
backgroundobject
evalu
efficaci
safeti
oral
appetit
stimul
improv
nutrit
statu
children
undergo
treatment
cancer
hematopoiet
stem
cell
transplant
hsct
designmethod
comprehens
search
medlin
embas
cinahl
databas
perform
identifi
prospect
retrospect
random
control
studi
rct
evalu
efficaci
oral
appetit
stimul
children
cancer
undergo
chemotherapi
hsct
two
author
independ
identifi
elig
studi
abstract
data
primari
outcom
chang
weight
result
citat
screen
studi
retrospect
prospect
random
control
trial
conduct
patient
includ
review
megestrol
acet
use
studi
cyproheptadin
studi
rct
includ
review
low
risk
bia
show
signific
weight
gain
mean
differ
weight
gain
ci
use
studi
suffer
high
risk
bia
report
differ
outcom
two
studi
report
primari
outcom
interest
show
signific
weight
gain
p
p
cyproheptadin
p
p
cyproheptadin
associ
signific
increas
appetit
two
studi
p
p
low
cortisol
level
demonstr
studi
use
one
studi
report
grade
adren
suppress
heterogen
among
includ
studi
preclud
data
synthesi
conclus
meaning
valid
conclus
efficaci
oral
appetit
stimul
pediatr
oncolog
patient
could
drawn
avail
literatur
studi
need
determin
effect
oral
appetit
stimul
cohort
patient
adren
suppress
associ
must
consid
use
clinic
trial
g
w
slayton
florida
environment
global
health
gainesvil
usa
florida
divis
hematolog
oncolog
gainesvil
usa
backgroundobject
poor
medic
complianc
mainten
therapi
associ
inferior
outcom
children
acut
lymphoblast
leukemia
howev
medic
nonadher
occur
pediatr
patient
medic
error
common
occur
case
address
pilot
healthstep
mobil
health
platform
display
synchron
care
plan
instruct
remind
abil
complet
activ
allow
provid
view
adher
data
aim
determin
usabl
healthstep
via
data
designmethod
pilot
enrol
pediatr
patient
receiv
mainten
therapi
uf
health
gainesvil
florida
administ
three
survey
one
enrol
inquir
demograph
care
manag
two
survey
gaug
app
usag
benefit
challeng
measur
app
usag
use
data
defin
consist
user
complet
care
plan
activ
time
use
either
test
compar
differ
consist
versu
inconsist
app
user
result
among
ten
subject
enrol
thu
far
four
subject
consist
use
app
signific
differ
exist
compar
demograph
smartphon
use
abil
consist
versu
inconsist
app
user
baselin
survey
subject
report
symptom
manag
medic
administr
coordin
care
plan
chang
greatest
challeng
promin
issu
report
confus
remind
conclus
address
issu
remind
amend
studi
protocol
ensur
subject
receiv
test
remind
offic
show
subject
make
remind
appear
perman
base
survey
data
popul
could
benefit
symptom
track
thu
healthstep
version
add
individu
symptom
track
gamif
increas
app
usag
j
slone
j
r
n
j
colleg
medicinetexa
children
hospit
pediatr
houston
usa
illinoi
colleg
medicin
pediatr
peoria
usa
children
hospit
pediatr
littl
rock
usa
reuter
product
manag
london
unit
kingdom
univers
charlott
maxek
johannesburg
academ
hospit
johannesburg
south
africa
backgroundobject
high
mortal
rate
children
cancer
countri
lmic
due
part
lack
resourc
includ
treatment
guidelin
educ
opportun
promot
optim
treatment
pediatr
cancer
lmic
siop
podc
work
group
publish
guidelin
pediatr
blood
cancer
pbc
mani
health
care
provid
lmic
access
medic
journal
like
pbc
treat
pediatr
malign
limit
special
train
siop
podc
educ
train
work
group
launch
new
websit
http
wwwcancerpointecom
octob
support
clinician
lmic
designmethod
juli
assist
siop
podc
leadership
permiss
pbc
eight
guidelin
post
http
wwwcancerpointecom
burkitt
lymphoma
kaposi
sarcoma
medulloblastoma
neuroblastoma
nutrit
support
retinoblastoma
support
care
wilm
tumor
googl
analyt
util
monitor
websit
traffic
paramet
analyz
includ
user
new
user
page
view
countri
origin
though
mechan
differenti
autom
softwar
task
bot
individu
user
access
site
result
octob
april
http
wwwcancerpointecom
visitor
countri
page
view
sinc
post
siop
podc
adapt
treatment
guidelin
juli
http
wwwcancerpointecom
user
new
user
countri
adapt
treatment
protocol
page
guidelin
host
visit
time
period
conclus
host
siop
podc
guidelin
http
wwwcancerpointecom
improv
access
guidelin
healthcar
provid
typic
may
access
medic
journal
cancer
treatment
protocol
open
sourc
platform
increas
social
media
presenc
http
wwwcancerpointecom
could
essenti
tool
rapidli
dissemin
resourc
health
care
provid
lmic
otherwis
would
awar
access
resourc
sosothikul
n
p
univers
depart
pediatr
bangkok
thailand
backgroundobject
incid
venou
thrombot
event
pediatr
patient
hospit
admiss
per
year
syndrom
pt
one
potenti
complic
deep
vein
thrombosi
dvt
compar
accuraci
differ
score
modifi
villalta
score
detect
pt
childhood
cancerhematolog
diseas
previous
diagnos
dvt
designmethod
retrospect
studi
childhood
cancer
hematolog
diseas
pt
diagnos
dvt
king
chulalongkorn
memori
hospit
thailand
result
total
patient
diagnos
dvt
includ
incid
rate
venou
thrombot
event
hospit
admiss
per
year
sixti
patient
patient
total
patient
primari
diagnos
childhood
cancer
hematolog
diseas
respect
median
age
year
common
risk
factor
venou
thrombot
event
thrombosi
compar
patient
diagnos
pt
score
patient
modifi
villalta
score
age
rang
median
year
eight
patient
patient
patient
diagnos
pt
primari
diagnos
childhood
cancer
hematolog
diseas
respect
modifi
villalta
score
group
mild
sever
identifi
score
score
mean
score
group
rang
mean
identifi
score
score
score
score
mean
group
higher
modifi
villalta
group
conclus
score
better
modifi
villalta
score
detect
pt
observ
monitor
pt
childhood
cancer
survivor
diagnos
dvt
essenti
also
benefici
hematolog
diseas
c
soto
c
colleg
hospit
london
children
hospit
london
unit
kingdom
leicest
social
scienc
appli
healthcar
improv
research
sapphir
group
leicest
unit
kingdom
cambridg
cambridg
centr
health
servic
research
cambridg
unit
kingdom
backgroundobject
associ
bloodstream
infect
clabsi
form
healthcar
associ
infect
hcai
potenti
devast
consequ
patient
although
clinic
outcom
clabsi
challeng
profession
child
care
develop
clabsi
investig
designmethod
interview
conduct
profession
experi
care
children
develop
clabsi
interview
digit
record
transcrib
verbatim
data
analysi
base
constant
compar
method
result
although
clabsi
familiar
occurr
healthcar
profession
hcp
studi
still
traumat
event
report
experi
children
signific
clabsi
becom
unwel
dramat
children
memori
children
die
result
clabsi
made
hcp
fear
subsequ
child
care
would
also
die
despit
optim
treatment
describ
signific
emot
turmoil
associ
make
clinic
decis
child
care
felt
sever
clabsi
compar
case
sepsi
wide
appreci
colleagu
often
struggl
explain
peer
unwel
child
believ
contribut
delay
access
extern
support
admiss
picu
surgic
remov
central
line
conclus
clabsi
emot
traumat
event
hcp
leav
signific
residu
emot
impact
case
hcp
describ
face
particular
challeng
commun
sever
clabsi
colleagu
risk
delay
child
care
wider
educ
sever
impact
clabsi
amongst
alli
specialti
coupl
structur
protocol
commun
sever
clabsi
would
valuabl
improv
speed
access
potenti
intervent
c
soto
c
colleg
hospit
children
hospit
london
unit
kingdom
leicest
social
scienc
appli
healthcar
improv
research
sapphir
group
leicest
unit
kingdom
cambridg
cambridg
centr
health
servic
research
cambridg
unit
kingdom
backgroundobject
access
devic
cvad
use
children
complex
medic
condit
deliv
treatment
associ
bloodstream
infect
clabsi
although
rare
result
prolong
hospit
admiss
intens
care
admiss
even
death
children
facilit
live
home
famili
manag
risk
develop
clabsi
impact
live
risk
emot
mental
health
children
home
famili
requir
explor
designmethod
part
larger
studi
explor
care
invas
devic
commun
interview
conduct
parent
children
profession
interview
digit
record
transcrib
verbatim
data
analysi
base
constant
compar
method
result
four
famili
person
experi
clabsi
awar
children
experienc
clabsi
clabsi
unpredict
children
could
deterior
rapidli
famili
awar
children
die
parent
irrespect
familiar
experienc
unrel
fear
child
would
develop
infect
die
famili
describ
state
constant
vigil
continu
monitor
child
sign
infect
expedit
treatment
result
signific
emot
burden
top
emot
workload
inher
care
children
complex
medic
condit
parent
experi
clabsi
recount
vivid
traumat
memori
child
ill
hospit
admiss
infect
disrupt
famili
life
parent
work
school
hobbi
famili
celebr
conclus
clabsi
disrupt
live
children
famili
threat
clabsi
caus
signific
emot
distress
famili
addit
exist
burden
profession
awar
emot
burden
counsel
famili
risk
clabsi
work
famili
manag
fear
children
famili
experi
clabsi
may
benefit
addit
psycholog
support
stanzelova
j
c
ladi
children
crumlin
oncolog
dublin
ireland
school
medicin
medic
scienc
medic
school
dublin
ireland
ladi
children
crumlin
haematolog
dublin
ireland
backgroundobject
febril
neutropenia
fn
defin
singl
temperatur
two
temperatur
least
hour
apart
within
hour
presenc
neutrophil
count
signific
risk
overwhelm
sepsi
time
cover
broad
spectrum
intraven
antibiot
paramount
benchmark
minut
establish
marker
qualiti
care
oncolog
centr
want
determin
length
time
present
administr
antibiot
tta
popul
designmethod
retrospect
audit
medic
record
patient
present
unit
fn
juli
decemb
collect
inform
includ
tta
clinic
symptom
present
length
admiss
treatment
identifi
pathogen
data
analys
excel
spreadsheet
result
episod
fn
children
identifi
tta
less
minut
major
treat
within
hour
eighti
percent
present
fever
symptom
nineti
percent
children
well
upon
present
paediatr
earli
warn
score
pew
twenti
percent
peripher
central
blood
cultur
posit
commonli
identifi
organ
coagulas
neg
staphylococci
seventeen
percent
receiv
antibiot
lock
infect
broviac
line
oncolog
patient
event
per
person
versu
gener
shorter
stay
vs
day
icu
admiss
death
conclus
tta
benchmark
case
show
signific
room
improv
creat
proforma
facilit
earli
identif
treatment
fn
pdsa
cycl
educ
nurs
doctor
parent
implement
proforma
hope
decreas
tta
plan
juli
decemb
c
k
el
n
h
n
ft
p
w
j
medic
center
center
pediatr
adolesc
medicin
depart
pediatr
hematologyoncologyhemostaseolog
mainz
germani
hospit
cologn
depart
intern
center
integr
oncolog
bonn
bonn
germani
sport
univers
institut
cardiovascular
research
sport
medicin
german
cancer
research
center
depart
molecular
cellular
sport
cologn
depart
physic
prevent
research
cancer
heidelberg
germani
sport
univers
institut
cardiovascular
research
sport
medicin
depart
molecular
cellular
sport
cologn
germani
backgroundobject
phase
angl
pha
deriv
bioelectr
imped
paramet
nutrit
statu
healthi
children
adult
well
sick
person
due
multifactori
reason
tumor
cachexia
malnutrit
low
calori
intak
nutrit
statu
often
alter
pediatr
cancer
patient
pha
marker
cellular
health
patient
cancer
low
pha
indic
complic
risk
inferior
prognosi
designmethod
studi
pha
assess
children
adolesc
intens
cancer
treatment
prior
start
new
chemotherapi
cours
time
point
isometr
leg
muscl
strength
measur
handheld
dynamomet
result
intens
cancer
treatment
patient
age
year
includ
seventeen
patient
suffer
solid
tumor
leukemia
central
nervou
system
tumor
eleven
patient
male
compar
age
sex
match
normal
valu
pha
significantli
reduc
present
sampl
pediatr
cancer
patient
vs
pha
show
moder
statist
signific
correl
leg
muscl
strength
pearson
concern
bodi
mass
index
statist
differ
compar
patient
age
sex
match
normal
valu
conclus
even
though
bodi
mass
index
patient
differ
normal
valu
reduc
pha
indic
malnutrit
present
popul
pha
relat
muscl
strength
studi
investig
whether
exercis
train
might
improv
bodi
composit
result
higher
pha
bioelectr
imped
tool
techniqu
evalu
chang
bodi
composit
nutrit
statu
children
adolesc
suffer
cancer
j
styczynski
k
j
f
l
r
z
z
w
j
e
n
univers
hospit
collegium
medicum
umk
depart
pediatr
hematolog
oncolog
bydgoszcz
poland
univers
depart
pediatr
oncolog
transplantolog
poznan
poland
univers
depart
pediatr
hematolog
oncolog
wroclaw
poland
depart
oncolog
warszawa
poland
univers
depart
pediatr
hematolog
oncolog
warszawa
poland
univers
depart
pediatr
oncolog
diabetolog
lodz
poland
univers
depart
pediatr
hematolog
oncolog
szczecin
poland
hospit
collegium
medicum
uj
depart
pediatr
hematolog
oncolog
krakow
poland
univers
depart
pediatr
hematolog
oncolog
zabrz
poland
univers
depart
pediatr
hematolog
oncolog
bialystok
poland
center
depart
pediatr
hematolog
oncolog
chorzow
poland
uwm
depart
pediatr
hematolog
oncolog
olsztyn
poland
hospit
ujk
depart
pediatr
hematolog
oncolog
kielc
poland
univers
depart
divis
hematolog
oncolog
katowic
poland
hospit
ur
depart
pediatr
rzeszow
poland
univers
depart
pediatr
hematolog
oncolog
lublin
poland
univers
depart
pediatr
hematolog
oncolog
gdansk
poland
backgroundobject
decad
ago
mortal
irm
exceed
allogen
hematopoiet
cell
transplant
autolog
hsct
children
anticanc
chemotherapi
object
studi
analysi
incid
outcom
infect
children
treat
malign
pho
pediatr
undergo
hsct
period
consecut
year
center
designmethod
total
number
patient
malign
patient
hsct
includ
result
bacteri
infect
pho
patient
incid
bacteri
infect
lower
vs
p
surviv
better
vs
p
rate
mdr
bacteria
higher
hsct
set
vs
g
vs
bacteria
patient
lower
incid
vs
lower
irm
invas
fungal
diseas
ifd
pho
patient
ifd
incid
lower
vs
p
surviv
ifd
better
vs
p
patient
lower
incid
vs
lower
irm
patient
introduct
nation
antifung
prophylaxi
program
hsct
acut
leukemia
patient
decreas
incid
ifd
hsct
aml
patient
viral
infect
pho
patient
incid
viral
infect
lower
patient
vs
p
compar
patient
vs
surviv
viral
infect
reach
pho
conclus
incid
infect
patient
high
compar
pho
patient
outcom
infect
pho
hsct
patient
larg
improv
comparison
histor
intern
data
v
subramani
b
anil
r
institut
medic
educ
research
depart
pediatr
chandigarh
india
institut
medic
educ
depart
pediatr
chandigarh
india
institut
medic
educ
research
pediatr
hematolog
oncolog
depart
pediatr
chandigarh
india
institut
medic
educ
research
pediatr
hematolog
oncolog
depart
pediatr
chandigarh
india
backgroundobject
undernutrit
un
advers
impact
children
treatment
malign
global
standard
tool
evalu
nutrit
statu
child
evalu
patient
complet
anthropometr
clinic
biochem
assess
designmethod
children
newli
diagnos
malign
classifi
inadequ
nourish
one
follow
paramet
height
age
percentil
weight
height
percentil
bodi
mass
index
bmi
percentil
age
gender
tricep
skinfold
thick
tsf
percentil
age
gender
mid
upper
arm
circumfer
muac
percentil
age
gender
serum
albumin
clinic
evid
un
result
nineti
children
boy
girl
mean
age
month
evalu
six
diagnosi
girl
boy
sixti
percent
children
haematolog
malign
solid
tumour
twenti
three
percent
weight
age
score
children
height
age
score
twenti
percent
children
bmi
age
score
sever
deplet
evid
children
muac
centil
age
tsf
centil
age
percent
children
serum
albumin
level
diagnosi
conclus
children
need
detail
evalu
nutrit
statu
time
diagnosi
cancer
gold
standard
assess
nutrit
statu
children
need
hour
necess
nutrit
rehabilit
patient
vital
get
child
inadequ
nourish
state
order
reduc
associ
morbid
mortal
sugiyama
j
univers
graduat
school
medicin
depart
pediatr
sapporo
japan
backgroundobject
although
glaucoma
report
children
frequenc
paediatr
patient
acut
leukaemia
malign
lymphoma
remain
unclear
typic
patient
administ
substanti
amount
corticosteroid
induct
therapi
requir
consider
hydrat
may
predispos
increas
intraocular
pressur
designmethod
enrol
patient
acut
leukaemia
malign
lymphoma
receiv
chemotherapi
includ
corticosteroid
institut
januari
februari
intraocular
pressur
measur
ophthalmologist
within
day
initi
corticosteroid
patient
requir
medic
includ
eye
drop
diuret
agent
intraocular
pressur
measur
repeat
induct
therapi
evalu
frequenc
glaucoma
paediatr
patient
acut
leukaemia
malign
lymphoma
result
studi
period
patient
seven
male
eight
femal
median
age
rang
year
haematolog
malign
receiv
induct
therapi
month
intraocular
pressur
nine
patient
five
male
four
femal
median
age
rang
year
receiv
eye
drop
mmhg
four
need
diuret
agent
one
patient
underw
trabeculotomi
interv
chemotherapi
intraocular
pressur
two
patient
increas
administr
dexamethason
administr
prednisolon
notabl
two
nine
patient
demonstr
symptom
includ
headach
photophobia
conclus
studi
half
patient
haematolog
malign
receiv
corticosteroid
glaucoma
symptom
paediatr
patient
acut
leukaemia
malign
lymphoma
perform
well
measur
intraocular
pressur
induct
therapi
ce
g
tokuc
n
f
e
univers
pediatri
istanbul
turkey
univers
pediatr
istanbul
turkey
univers
pediatr
cardiolog
istanbul
turkey
backgroundobject
one
commonli
use
chemotherapeut
agent
childhood
malign
anthracyclin
increas
surviv
rate
pediatr
cancer
requri
research
side
effect
drug
one
import
side
effect
chemotherapeut
cardiotox
studi
aim
investig
chronic
cardiotox
due
anthracyclin
variou
method
designmethod
children
follow
least
month
treatment
protocol
contain
anthracyclin
includ
studi
electrocardiograph
echocardiograph
examin
perform
follow
detail
system
physic
examin
children
patient
control
group
serum
troponin
level
studi
elisa
result
analyz
use
window
result
electrocardiographi
reveal
two
incomplet
right
bundl
branch
block
one
degre
av
block
three
sinu
tachycardia
two
patient
systol
diastol
blood
pressur
patient
receiv
high
dose
anthracyclin
significantli
higher
physic
examin
qtc
distanc
electrocardiographi
sgnificantli
longer
ef
ef
e
lower
mpi
ivr
ivc
valu
significantli
higher
echocardiographi
convent
echocardiograph
method
number
patient
diagnos
cardiotox
tissu
doppler
echocardiograph
method
also
use
number
patient
develop
cardiotox
troponin
valu
significantli
higher
patient
group
receiv
anthracyclin
treatment
control
group
signific
relationship
mediastin
radiotherapi
age
gender
cardiotox
conclus
echocardiographi
well
tissu
doppler
echocardiographi
found
use
evalu
subclin
cardiotox
children
treat
anthracyclin
along
larg
number
studi
role
troponin
assess
cardiotox
studi
need
totadri
ej
r
k
graduat
institut
medic
educ
research
pediatr
hematolog
oncolog
depart
pediatr
chandigarh
india
univers
medic
center
divis
hematologyoncologystem
cell
depart
pediatr
new
york
usa
children
hospit
patholog
medicin
hamilton
canada
de
paulo
depart
paulo
brazil
backgroundobject
standard
nutrit
clinic
practic
worldwid
despit
nutrit
modifi
risk
factor
outcom
cancer
initi
step
standard
nutrit
practic
pediatr
oncolog
sought
valid
nutrit
algorithm
specif
applic
low
countri
set
designmethod
fifti
children
cancer
enrol
randomis
intervent
studi
weight
length
arm
circumfer
muac
measur
diagnosi
patient
assign
randomli
two
group
studi
group
administ
nutrit
care
per
algorithm
control
group
receiv
institut
standard
care
weight
monitor
regularli
muac
repeat
month
children
classifi
base
weight
height
age
bodi
mass
index
normal
z
wast
z
sever
wast
z
algorithm
direct
nutrit
care
base
upon
nutrit
statu
patient
avail
resourc
institut
result
nineteen
four
two
three
one
normal
wast
sever
wast
control
studi
group
muac
patient
group
signific
increas
muac
cm
cm
p
weight
kg
kg
three
month
studi
group
signific
chang
observ
control
group
significantli
higher
proport
patient
improv
muac
studi
group
compar
control
group
p
conclus
applic
nutrit
algorithm
design
use
lmic
result
signific
improv
muac
weight
compar
convent
approach
next
step
includ
applic
set
r
tuna
ozkan
z
istanbul
medic
faculti
depart
pediatr
istanbul
turkey
istanbul
medic
faculti
depart
pediatr
neurolog
istanbul
turkey
backgroundobject
cisplatin
platinum
analog
potenti
sensori
neuropathi
accumul
neuron
dorsal
root
ganglion
perman
sensori
neuropathi
seen
approxim
patient
motor
neuropathi
associ
cisplatin
rare
designmethod
descript
case
report
result
girl
present
month
histori
epistaxi
rhinoscopi
examin
reveal
irregular
surfac
lesion
extend
coana
nasal
caviti
right
side
nasopharynx
biopsi
confirm
squamou
nasopharynx
carcinoma
ebv
dna
titer
neg
neccessari
evalu
start
chemotherapi
diagnos
nasopharynx
carcinoma
classif
stage
ivb
cours
cisplatin
epirubicin
receiv
irmt
prescrib
dose
fraction
control
imag
show
primari
lesion
metastas
regress
two
new
millimetr
nodul
found
right
lung
local
tumor
board
favour
chemotherapi
continu
cours
cisplatin
epirubicin
cumul
dose
respect
develop
febril
neutropenia
sever
sepsi
lymphedema
neck
region
vocal
cord
paralys
imag
studi
reveal
find
favor
neck
lymphedema
due
radiat
fibrosi
treat
steroid
respiratori
distress
progress
therefor
underw
tracheostomi
transfer
pediatr
intens
care
unit
postop
could
abl
wean
ventilat
physic
examin
reveal
depress
deep
tendon
reflex
reduc
muscl
strength
extrem
kraniospin
mri
cerebrospin
fluid
examin
normal
emg
reveal
sever
sensorimotor
polyneuropathi
support
therapi
ongo
conclus
cisplatin
neurotox
report
cumul
dose
clinic
pictur
mostli
involv
sensori
neuropathi
motor
symptom
rare
patient
receiv
cisplatin
treatment
care
necessari
term
neurotox
usman
q
b
khan
univers
hospit
oncolog
karachi
pakistan
khan
univers
hospit
pediatr
intens
care
unit
karachi
pakistan
backgroundobject
outcom
pediatr
oncolog
patient
improv
current
treatment
protocol
howev
aggress
therapi
protocol
caus
immunosuppress
lead
system
infect
sepsi
remain
lead
caus
death
patient
especi
develop
countri
like
pakistan
studi
aim
find
outcom
pediatr
oncolog
patient
sepsi
admit
pediatr
intens
care
unit
picu
tertiari
care
hospit
karachi
assess
factor
associ
mortal
patient
designmethod
retrospect
review
medic
record
children
month
year
admit
picu
januari
decemb
underli
oncolog
diagnosi
fulfil
criteria
sepsi
sever
sepsi
septic
shock
done
data
collect
structur
proforma
analyz
use
spss
result
present
mean
standard
deviat
frequenc
percentag
appropri
statist
test
appli
see
factor
associ
mortal
result
patient
patient
includ
studi
male
forti
two
median
age
month
oncolog
diagnosi
includ
forti
five
leukemia
twelv
lymphoma
three
solid
tumor
brain
tumor
forti
two
patient
induct
phase
chemotherapi
ten
consolidationintensif
phase
eleven
mainten
phase
thirti
nine
twenti
four
patient
admit
ward
emerg
room
respect
median
requir
shift
patient
picu
septic
shock
present
twenti
two
patient
median
prism
iii
score
eleven
twenti
six
patient
enterobacteriacea
blood
cultur
thirti
three
patient
surviv
renal
failur
hepat
dysfunct
septic
shock
mechan
ventil
associ
mortal
conclus
children
induct
phase
chemotherapi
mostli
admit
picu
due
sepsi
mechan
ventil
septic
shock
organ
dysfunct
associ
mortal
patient
k
v
p
p
j
b
jerbai
wadia
hospit
children
depart
pediatr
mumbai
india
jerbai
wadia
hospit
children
depart
pediatr
cardiolog
mumbai
india
backgroundobject
peripher
insert
central
cathet
picc
popular
mean
long
term
intraven
access
oncolog
patient
picc
associ
complic
like
breakageleakag
phlebiti
cathet
relat
infect
thrombosi
embol
fractur
embol
rare
potenti
seriou
complic
designmethod
present
unusu
fractur
picc
line
embol
right
ventricl
rv
right
pulmonari
arteri
rpa
result
year
old
boy
diagnos
left
femur
ewe
sarcoma
picc
bard
groshong
size
insert
via
right
median
cubit
vein
chemotherapi
posit
cathet
confirm
chest
radiograph
child
receiv
cycl
chemotherapi
pre
oper
cycl
post
oper
via
picc
line
picc
line
situ
day
radiotherapi
child
refer
anoth
hospit
found
picc
line
occlus
attempt
made
remov
result
fractur
picc
line
incomplet
remov
child
refer
back
hospit
child
asymptomat
present
chest
radiograph
echocardiogram
done
show
embol
picc
line
fragment
rv
rpa
embolis
picc
line
part
retriev
percutan
tran
cathet
snare
assist
retriev
child
toler
procedur
well
conclus
cathet
fractur
rare
complic
mainli
occur
near
entranc
site
remov
factor
lead
cathet
fatigu
durat
chemotheraupt
agent
weekli
dress
blockag
patient
picc
fractur
occur
day
longer
report
interv
andor
due
attempt
remov
anoth
center
emphasis
import
special
train
nurs
staff
picc
fractur
embol
potenti
life
threaten
situat
remov
either
tran
cathet
retriev
open
cardiac
surgeri
latter
caus
consider
morbid
henc
adequ
care
precaut
must
taken
prevent
complic
g
varrasso
de
e
c
v
sapienza
univers
rome
pediatr
rome
itali
backgroundobject
nausea
vomit
cinv
frequent
distress
side
effect
childhood
cancer
treatment
evalu
efficaci
associ
prevent
cinv
children
receiv
moder
mec
highli
emetogen
chemotherapi
hec
designmethod
consecut
patient
solid
tumor
enrol
antiemet
schedul
follow
palonosetron
mcgkg
iv
minut
chemotherapi
day
chemotherapi
durat
less
day
everi
day
chemotherapi
last
day
mec
cours
dexamethason
mgkg
daili
associ
palonosetron
one
day
chemotherapi
hec
cours
dexamethason
given
dosag
mgkg
daili
chemotherapi
mgkg
day
chemotherapi
complet
respons
cr
defin
vomit
rescu
therapi
complet
control
cc
cr
mild
nausea
result
patient
f
median
age
yr
rang
prospect
enrol
total
cours
mec
hec
deliv
mec
cours
cr
obtain
acut
phase
delay
phase
cc
observ
acut
delay
phase
respect
hec
cours
cr
cc
rate
acut
delay
phase
respect
conclus
data
show
high
antiemet
efficaci
associ
children
receiv
mec
hec
k
viani
neto
c
g
bouchabki
b
stachissini
p
de
instituto
da
hospit
da
faculdad
de
universidad
de
paulo
nutrit
paulo
brazil
da
hospit
da
faculdad
de
universidad
de
paulo
nutrit
paulo
brazil
backgroundobject
pediatr
critic
patient
cancer
high
nutrit
risk
may
exacerb
morbimort
goal
studi
evalu
whether
nutrit
statu
declin
first
week
pediatr
intens
care
unit
picu
worsen
mortal
length
stay
compar
group
critic
patient
designmethod
retrospect
longitudin
studi
chart
patient
nutrit
assess
contempl
first
week
picu
review
z
score
base
weight
height
classifi
world
health
organ
growth
chart
arm
circumfer
muac
frisancho
percentil
rank
test
use
comparison
spearman
rank
correl
receiv
oper
characterist
roc
curv
construct
evalu
impact
chang
muac
overal
surviv
result
patient
control
compar
length
stay
death
rate
day
overal
surviv
group
diverg
nutrit
statu
admiss
picu
classifi
weight
height
muac
oncolog
patient
present
less
malnutrit
versu
versu
respect
patient
cancer
also
older
critic
patient
median
versu
month
muac
significantli
reduc
first
week
picu
median
cm
roc
curv
area
ci
patient
ci
control
chang
muac
nt
correl
length
stay
patient
control
conclus
despit
signific
decreas
first
week
muac
alter
nt
correl
overal
mortal
unlik
control
length
stay
nonetheless
initi
deterior
nutrit
statu
reinforc
import
nutrit
care
phase
walli
p
js
botswanaprincess
marina
hospit
pediatr
gaboron
botswana
colleg
medicin
texa
children
hospit
tx
usa
colleg
medicin
texa
children
hospit
tx
usa
children
cancer
hematolog
centr
global
pediatr
excellec
tx
usa
children
cancer
hematolog
center
global
pediatr
excel
tx
usa
backgroundobject
malnutrit
common
set
impact
malnutrit
pediatr
cancer
outcom
unclear
studi
perform
pediatr
cancer
program
botswana
investig
preval
malnutrit
newli
diagnos
pediatr
cancer
patient
risk
factor
associ
malnutrit
impact
surviv
designmethod
retrospect
cohort
studi
perform
via
botswana
pediatr
oncolog
databas
bpod
evalu
cohort
patient
year
diagnos
cancer
weight
height
weight
height
use
categor
nutrit
statu
evalu
relat
demograph
diseas
characterist
outcom
result
total
patient
includ
meet
criteria
malnutrit
median
age
year
standard
deviat
std
year
male
malnourish
patient
lower
mean
albumin
level
diagnosi
gl
std
vs
gl
std
normal
rang
gl
risk
malnutrit
children
cancer
increas
posit
human
immunodefici
viru
hiv
statu
odd
ratio
confid
interv
ci
decreas
famili
privat
medic
aid
ci
p
differ
risk
malnutrit
base
age
gender
resid
cancer
diagnosi
univari
analysi
increas
risk
earli
mortal
month
two
surviv
base
nutrit
statu
initi
diagnosi
conclus
half
patient
cohort
present
malnutrit
hiv
statu
increas
risk
privat
medic
aid
protect
cohort
malnutrit
impact
surviv
either
three
month
two
year
prospect
studi
expand
r
asperen
jpj
van
van
e
c
fv
j
js
mf
j
mm
van
den
j
children
hospitalunivers
medic
center
utrecht
depart
pediatr
intens
care
utrecht
netherland
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
essen
depart
pediatr
intens
care
essen
germani
universitair
femm
hospic
civil
de
lyon
pediatr
intens
care
unit
lyon
franc
univers
hospit
depart
pediatr
intens
care
ghent
belgium
depart
pediatr
adolesc
medicin
copenhagen
denmark
depart
pediatr
kiel
germani
children
hospit
depart
gener
care
medicin
germani
ormond
street
hospit
children
nh
great
ormond
street
depart
critic
care
bioethic
london
unit
kingdom
backgroundobject
outcom
children
diagnos
cancer
improv
dramat
past
year
howev
although
pediatr
cancer
patient
requir
least
one
intens
care
admiss
throughout
diseas
cours
picu
outcom
resourc
util
popul
rigor
studi
specif
group
designmethod
use
systemat
strategi
search
medlin
embas
cinahl
databas
articl
describ
picu
mortal
pediatr
cancer
patient
admit
picu
two
investig
independ
appli
elig
criteria
assess
data
qualiti
extract
data
pool
picu
mortal
estim
use
model
examin
mortal
trend
time
use
model
result
identifi
manuscript
studi
includ
cover
picu
admiss
major
retrospect
natur
overal
pool
weight
mortal
confid
interv
ci
mortal
decreas
slightli
time
patient
exclud
use
mechan
ventil
odd
ratio
ci
p
inotrop
support
ci
p
continu
renal
replac
therapi
ci
p
significantli
associ
picu
mortal
conclus
picu
mortal
rate
pediatr
cancer
patient
far
higher
compar
current
mortal
rate
gener
picu
popul
picu
mortal
remain
rel
unchang
past
decad
slight
decreas
seen
patient
exclud
compar
unfavor
improv
mortal
seen
adult
cancer
admit
icu
improv
led
paradigm
unlimit
aggress
icu
manag
without
limit
resuscit
statu
trial
ej
yang
km
yt
nation
univers
children
hospit
pediatr
republ
korea
backgroundobject
hypomagnesemia
common
find
children
malign
variou
caus
chemotherapi
immunosuppress
antifung
agent
oral
magnesium
supplement
recommend
exclud
patient
diarrhea
diseas
hematopoiet
stem
cell
transplant
hsct
amilorid
diuret
report
reduc
potassium
patient
receiv
amphotericin
b
purpos
studi
evalu
effect
amilorid
pediatr
patient
malign
reduc
need
magnesium
supplement
designmethod
studi
retrospect
identifi
depart
pediatr
pusan
nation
univers
children
hospit
june
may
magnesium
supplement
oral
intraven
rout
maintain
serum
magnesium
level
meql
serum
magnesium
potassium
creatinin
averag
daili
magnesium
supplement
measur
one
week
preced
amilorid
one
two
week
result
patient
mean
age
year
receiv
concomit
amilorid
magnesium
supplement
two
patient
treat
cisplatin
hepatoblastoma
eight
patient
receiv
tacrolimu
hsct
patient
control
group
four
patient
hepatoblastoma
patient
underw
hsct
compar
week
period
total
magnesium
supplement
decreas
mgday
week
mgday
week
serum
magnesium
level
increas
mgdl
week
mgdl
week
serum
potassium
level
increas
mgdl
week
significantli
chang
week
mean
hospit
day
hypomagnesemia
day
compar
day
control
group
conclus
amilorid
safe
effect
reduct
magnesium
supplement
children
malign
addit
amilorid
consid
therapeut
option
decreas
potassium
patient
treat
chemotherapi
hsct
mm
zapata
tarr
le
l
velasco
r
om
francisco
pg
jose
va
martha
rl
ar
nacion
de
pediatria
oncolog
mexico
citi
mexico
infantil
de
mexico
federico
gomez
oncolog
mexico
citi
mexico
nacion
de
oncolog
mexico
citi
mexico
nacion
de
infectolog
mexico
citi
mexico
juarez
de
mexico
oncolog
mexico
citi
mexico
de
mexico
citi
mexico
infantil
de
mexico
federico
econom
research
mexico
citi
mexico
infantil
de
mexico
federico
gomez
infectolog
mexico
citi
mexico
backgroundobject
febril
neutropenia
main
problem
children
cancer
differ
strategi
ambulatori
treatment
realiti
difficult
implement
strategi
medic
resist
patient
social
problem
first
clinic
trial
econom
view
done
citi
designmethod
measur
safeti
effect
two
strategi
antibiot
treatment
oral
ambulatori
versu
intraven
hospit
febril
neutropenia
fn
children
studi
done
three
hospit
oncolog
depart
design
clinic
trial
multicentr
hypothesi
inferior
random
balanc
block
juli
octob
includ
children
yer
old
low
risk
febril
neutropenia
bivari
analysi
microscost
done
direct
indirect
result
event
nf
regist
ambulatori
group
ga
cefixima
oral
hospitalari
group
gh
cefepima
intraven
gh
secur
advers
event
vs
ga
ga
succes
outcom
median
cost
gh
around
american
dollar
vs
american
dollar
ga
p
comparison
indirect
cost
similar
conclus
observ
inferior
ga
gh
high
econom
save
advers
event
realiti
import
overoccup
hospit
extrem
ambulatori
treatment
cefixim
safe
affect
intraven
one
econom
perspect
health
domin
strategi
follow
step
gener
strategi
medic
commun
w
allenidekania
h
universita
indonesia
pediatrict
nurs
depok
indonesia
backgroundobject
import
assess
need
palli
care
children
advanc
cancer
purpos
articl
test
pediatr
palli
screen
scale
papa
scale
instrument
practic
oncolog
child
care
well
identifi
proper
palli
servic
designmethod
quantit
design
use
descript
analysi
approach
appli
pilot
pediatr
palli
screen
scale
papa
scale
instrument
contain
five
domain
diseas
daili
activ
medic
expect
burden
psycholog
symptom
pressur
patient
choic
parent
health
team
life
expect
estim
test
children
cancer
hospitalis
cancer
children
ward
one
top
referr
hospit
jakarta
instrument
translat
indonesian
languag
follow
back
translat
achiev
similar
origin
instrument
interrat
reliabl
test
three
research
equal
r
valid
test
r
domain
cronbach
result
respond
boy
age
year
old
medic
diagnosi
proport
vs
solid
tumor
vs
children
suffer
anemia
leukositosi
trombocitopenia
base
screen
identifi
children
need
palli
care
children
need
earli
palli
care
children
need
delay
palli
care
conclus
papa
scale
instrument
well
recommend
serv
childcar
assess
format
cancer
measur
score
palli
care
need
children
nurs
healthcar
profession
enhanc
role
compet
identifi
need
children
palli
care
improv
qualiti
nurs
care
bravo
r
philippin
medic
center
depart
famili
commun
section
hospic
palli
medicin
davao
citi
philippin
backgroundobject
patient
diagnos
cancer
especi
advanc
case
often
accompani
sever
pain
observ
pediatr
age
differ
adult
patient
pain
assess
difficult
henc
symptom
often
treat
inadequ
lead
poor
qualiti
life
goal
studi
describ
pain
assess
manag
admit
pediatr
patient
malign
solid
tumor
southern
philippin
medic
children
cancer
blood
diseas
unit
ccbdu
davao
citi
designmethod
studi
review
total
medic
chart
admit
patient
children
cancer
blood
diseas
unit
southern
philippin
medic
center
year
januari
decemb
chart
review
initi
pain
assess
medic
manag
pain
nurs
assess
intervent
studi
design
util
studi
result
review
medic
chart
show
evid
complet
consist
record
initi
pain
assess
time
admiss
identif
provoc
allevi
factor
descript
qualiti
radiat
pain
sever
time
patient
receiv
opioid
primari
pain
medic
lack
detail
complet
pain
evalu
nurs
pain
assess
intervent
likewis
record
upon
admiss
primari
vital
step
effect
pain
manag
assess
pain
therefor
regularli
done
pediatr
patient
cancer
manag
pain
definit
unlik
happen
conclus
find
suggest
defici
routin
evalu
record
manag
monitor
pediatr
patient
malign
solid
tumor
lm
bustamant
tuchez
g
p
p
nacion
de
oncologia
pediatrica
palli
care
guatemala
guatemala
nacion
de
oncologia
pediatrica
medicina
integr
guatemala
guatemala
nacion
de
oncologia
pediatrica
oncolog
guatemala
guatemala
jude
research
hospit
oncolog
memphi
usa
child
matter
program
grant
mentor
california
usa
backgroundobject
ethic
dilemma
commonli
occur
around
life
threaten
ill
sourc
distress
famili
medic
provid
unidad
nacion
de
oncologia
pediatrica
unop
larg
pediatr
cancer
center
treat
new
patient
per
year
multidisciplinari
palli
care
team
review
patient
ethic
issu
provid
consult
support
designmethod
retrospect
chart
review
perform
patient
evalu
data
extract
multidisciplinari
team
meet
note
common
ethic
theme
identifi
review
pediatr
palli
physician
result
x
case
review
patient
ethic
dilemma
identifi
case
note
involv
decis
withdraw
withhold
treatment
intens
care
patient
discuss
cerebr
death
refractori
shock
cancer
treatment
decis
relat
chang
direct
therapi
typic
treatment
intens
involv
treatment
refus
mostli
declin
mutil
surgeri
ethic
dilemma
relat
belief
ingrain
mayan
cultur
principl
justic
patient
autonomi
central
discuss
patient
treatment
abandon
found
causal
relationship
religi
belief
cultur
well
poverti
treatment
modif
decis
pregnant
adolesc
patient
substanc
abus
patient
refus
blood
transfus
religi
reason
noteworthi
conclus
ethic
dilemma
common
pediatr
oncolog
patient
care
involv
bioethic
train
profession
multidisciplinari
care
team
help
patient
famili
care
provid
maintain
align
sound
bioethic
principl
make
cultur
sensit
difficult
decis
patient
care
cho
j
univers
hospit
pediatr
sapporo
japan
backgroundobject
children
cancer
experi
much
pain
medic
procedur
mani
japanes
medic
profession
howev
concern
children
stress
involv
procedur
pain
japanes
deem
virtu
endur
pain
lidocain
prilocain
emla
numb
cream
receiv
approv
japan
pain
procedur
needl
analyz
use
numb
medic
point
view
patient
relief
medic
profession
effort
designmethod
emla
cream
introduc
patient
cancer
age
year
hospit
april
present
april
staff
train
began
collect
data
right
procedur
regard
patient
recept
emla
cream
use
type
procedur
patient
anxieti
procedur
pain
reduct
efficaci
side
effect
also
survey
patient
caregiv
medic
staff
impress
numb
medic
result
april
march
pain
procedur
perform
venipunctur
subcutan
inject
intramuscular
inject
bone
marrow
aspir
lumber
punctur
picc
line
insert
patient
male
femal
whose
age
mean
patient
request
emla
cream
regardless
procedur
procedur
patient
felt
allevi
pain
seriou
side
effect
observ
accord
survey
patient
caregiv
satisfi
numb
medic
medic
staff
remark
effort
requir
appli
numb
medic
even
comment
wast
time
delay
procedur
nervous
procedur
success
conclus
even
japan
numb
medic
reduc
patient
pain
anxieti
increas
caregiv
satisfact
staff
troubl
resolv
get
use
procedur
advantag
numb
soon
surpass
inconveni
h
dhingra
apollo
hospit
pediatr
hematolog
oncolog
delhi
india
backgroundobject
abandon
defin
failur
either
begin
continu
plan
cours
miss
treatment
sustain
time
period
extent
impact
abil
cure
definit
control
diseas
continu
one
import
reason
treatment
failur
low
countri
center
multiprong
effort
made
limit
aim
studi
determin
magnitud
predictor
abandon
childhood
cancer
center
cater
patient
belong
vari
educ
background
designmethod
use
establish
databas
retrospect
analysi
conduct
children
age
year
jan
june
abandon
rate
risk
factor
abstract
databas
correl
diagnosi
distanc
financi
constraint
parent
educ
statu
factor
evalu
result
total
children
diagnos
malign
current
undergo
treatment
patient
refus
treatment
diagnosi
abandon
point
cours
among
abandon
patient
suffer
leukemialymphoma
solid
tumor
brain
tumor
multivari
analysi
financi
constraint
aor
ci
parent
educ
statu
aor
ci
associ
higher
risk
abandon
possibl
risk
factor
like
gender
distanc
treat
hospit
diagnosi
predict
outcom
cancer
length
treatment
protocol
also
analyz
howev
statist
signific
conclus
herebi
report
abandon
rate
tertiari
care
center
appear
much
lower
previou
report
india
financi
constraint
educ
statu
major
predictor
continu
effort
made
reduc
abandon
even
j
du
plessi
free
state
paediatr
child
health
bloemfontein
south
africa
free
state
paediatr
child
health
bloemfontein
south
africa
cape
town
palli
care
cape
town
south
africa
backgroundobject
palli
support
care
need
children
cancer
famili
uniqu
requir
special
attent
develop
appropri
servic
sensit
need
famili
base
observ
evid
becom
recogn
introduct
develop
improv
support
palli
care
servic
children
cancer
famili
question
regard
experi
suggest
improv
designmethod
exploratori
qualit
studi
use
ground
theori
approach
sixteen
famili
member
children
cancer
treat
universita
academ
hospit
bloemfontein
south
africa
interview
regard
children
standard
oncolog
supportivepalli
care
respons
studi
repeat
theme
identifi
result
number
area
need
identifi
errat
psychosoci
support
minim
financi
support
poor
parent
access
basic
need
food
provis
prevent
error
procedur
lack
sibl
support
staff
also
alway
suffici
equip
attend
palli
care
patient
conclus
support
palli
care
children
cancer
need
improv
famili
member
valuabl
resourc
interview
identifi
number
theme
valuabl
consid
expans
supportivepalli
servic
intens
studi
creat
awar
make
small
afford
chang
qualiti
care
children
famili
receiv
improv
c
edan
ml
jj
l
ms
c
f
c
gustav
roussi
villejuif
franc
la
brise
equip
ressourc
de
soin
palliatif
bretagn
franc
espoir
child
matter
program
pari
franc
necker
uf
douleur
palli
pari
franc
trechvil
paediatr
oncolog
abidjan
ivori
coastr
hospit
paediatr
oncolog
rabat
morocco
institut
curi
pari
franc
backgroundobject
drive
pediatr
palli
care
ppc
train
programm
africa
within
cur
approach
possibl
abstract
report
experi
within
child
matter
program
initi
sanofi
espoir
fondat
designmethod
rich
countri
program
move
embed
palli
care
time
diagnosi
advanc
cancer
seem
reason
transfer
knowledg
africa
major
cancer
advanc
minor
children
access
cure
integr
ppc
cur
approach
therefor
main
goal
multidisciplinari
traine
oncolog
pilot
unit
pu
african
countri
particip
three
train
session
dakar
abidjan
rabat
provid
basic
knowledg
pediatr
palli
care
special
attent
pain
session
project
improv
practic
produc
team
revis
realist
adjust
current
conduct
situ
evalu
phase
train
result
strike
preliminari
result
far
half
visit
unit
start
gait
half
realli
implement
train
concept
illustr
barrier
situat
natur
rather
cognit
one
lead
differenti
way
implement
pain
ppc
principl
pu
differ
although
african
howev
question
benefici
framework
sure
malefici
concern
ethic
question
legitimaci
action
ignor
regurlarli
appreci
omiss
lead
ineffici
counterproduct
action
even
gener
mistrust
conclus
train
continu
adapt
offer
preliminari
result
two
differ
pedagog
format
train
practic
train
propos
depend
local
achiev
order
improv
actual
qualliti
care
eilertsen
ae
u
norwegian
univers
technolog
depart
public
health
trondheim
norway
univers
colleg
depart
care
palli
research
centr
stockholm
sweden
univers
school
health
societi
stockholm
sweden
backgroundobject
sibl
face
mani
challeng
aim
paper
explor
bereav
sibl
memori
experi
brother
sister
ill
death
designmethod
nationwid
swedish
studi
bereav
sibl
particip
respond
two
question
sibl
posit
neg
memori
experi
ill
death
data
analyz
use
systemat
text
condens
result
bereav
sibl
respons
categor
four
differ
theme
endur
vs
vulner
famili
cohes
vs
famili
conflict
growth
vs
stagnat
profession
support
vs
lack
profession
support
endur
express
influenc
ill
sibl
willpow
good
mood
stamina
healthi
sibl
wherea
vulner
express
feel
empti
loneli
famili
cohes
express
bond
strengthen
famili
member
wherea
famili
conflict
often
led
sibl
feel
invis
unacknowledg
third
theme
sibl
express
feel
grew
individu
process
brother
sister
ill
death
wherea
other
experienc
stagnat
physic
mental
distress
bore
throughout
time
often
feel
forgotten
last
theme
sibl
perceiv
support
physician
staff
hospit
warm
kind
honest
sibl
neg
experi
conclus
studi
show
bereav
sibl
posit
memori
experi
even
though
death
sibl
distress
situat
signific
posit
buffer
effect
bereav
sibl
endur
person
growth
famili
cohes
social
support
note
knowledg
acquir
listen
voic
bereav
sibl
valuabl
show
healthcar
profession
import
support
sibl
children
cancer
throughout
cancer
trajectori
afterward
bereav
l
hrdlickova
k
hospit
motol
depart
pediatr
hematolog
oncolog
pragu
czech
republ
univers
faculti
medicin
pragu
czech
republ
hospit
motol
pediatr
palli
care
team
pragu
czech
republ
palli
care
center
palli
care
pragu
czech
republ
univers
faculti
medicin
pragu
czech
republ
backgroundobject
deliv
bad
news
one
biggest
challeng
physician
pediatr
oncolog
guidelin
seriou
commun
pediatr
oncolog
still
remain
unmet
need
aim
systemat
review
identifi
factor
influenc
seriou
commun
children
adolesc
diagnos
cancer
perspect
patient
famili
care
provid
physician
designmethod
qualit
quantit
paper
produc
sinc
english
french
czech
languag
includ
report
primari
data
children
adolesc
cancer
year
age
famili
member
children
cancer
care
provid
physician
paper
evalu
commun
crucial
time
point
initi
diagnosi
relaps
end
cur
treatment
impend
death
includ
themat
analysi
method
use
combin
analyz
result
result
literatur
search
result
total
citat
remov
duplic
paper
meet
elig
criteria
full
text
articl
remain
total
factor
influenc
deliv
seriou
news
identifi
factor
perspect
parent
perspect
sibl
patient
respect
factor
perspect
physician
six
group
factor
creat
themat
analysi
set
physician
approach
inform
exchang
parent
aspect
ill
relat
factor
age
mental
develop
physician
empathi
parent
protect
role
amount
inform
given
identifi
import
factor
need
taken
account
deliv
bad
news
pediatr
oncolog
conclus
commun
seriou
news
pediatr
oncolog
complex
task
influenc
mani
factor
knowledg
factor
serv
foundat
standard
guidanc
effect
commun
pediatr
cancer
patient
famili
kim
j
univers
depart
social
welfar
seoul
republ
korea
nation
univers
hospit
depart
medic
social
work
seoul
republ
korea
utah
colleg
social
work
salt
lake
citi
usa
backgroundobject
despit
increas
surviv
rate
childhood
cancer
mani
parent
face
death
child
cancer
mother
primari
caregiv
often
experi
signific
life
challeng
adjust
world
without
child
studi
explor
understudi
live
mother
lose
child
cancer
korea
designmethod
seven
session
photovoic
conduct
five
mother
year
old
whose
child
die
cancer
age
elaps
time
sinc
death
rang
month
first
session
includ
orient
discuss
regard
select
theme
futur
session
session
particip
ask
bring
sever
photo
reflect
theme
share
stori
relat
photo
seventh
session
share
photo
commun
stakehold
result
five
theme
select
particip
subthem
emerg
research
themat
analysi
group
discuss
one
day
child
want
child
show
love
child
b
memori
child
proud
child
rememb
happi
moment
child
still
live
heart
c
dream
child
healthi
futur
realiz
mani
dream
becom
adult
help
other
child
enjoy
ordinari
life
gave
strength
children
mother
support
group
hope
meet
child
heaven
e
life
child
would
want
help
energet
mom
forget
healthi
happi
famili
conclus
find
show
mother
lost
child
cancer
need
bereav
care
promot
studi
help
pediatr
oncolog
provid
develop
bereav
intervent
address
parent
grief
improv
qualiti
life
ms
kim
ch
yj
ig
hy
nation
univers
hospit
depart
pediatr
seoul
republ
korea
cancer
center
hospic
palli
care
branch
goyang
republ
korea
backgroundobject
although
pediatr
palli
care
ppc
develop
worldwid
increas
number
children
seriou
ill
concept
pediatr
palli
care
still
unfamiliar
asia
report
pediatr
cancer
patient
referr
pattern
new
ppc
team
children
hospit
korea
designmethod
examin
ppc
databas
perform
descript
statist
analysi
patient
referr
depart
result
april
march
patient
refer
ppc
team
depart
ten
patient
seen
consult
team
refus
palli
care
referr
anoth
hospit
immedi
death
consult
patient
eight
patient
age
year
age
year
older
patient
live
distant
region
hospit
patient
male
diagnos
includ
solid
tumor
primari
cn
leukemialymphoma
signific
number
patient
refer
pediatr
ward
outpati
clinic
intens
care
unit
respect
lastli
patient
die
observ
period
die
inpati
set
die
home
die
hospic
facil
one
die
emerg
depart
time
death
patient
receiv
cardiopulmonari
resuscit
cpr
accord
care
plan
patient
receiv
cpr
median
age
death
year
conclus
report
palli
care
referr
pattern
pediatr
cancer
patient
korean
children
hospit
improv
qualiti
life
children
cancer
palli
care
need
identifi
appropri
servic
provid
na
f
b
l
c
l
n
g
materno
infantil
del
instituto
de
seguridad
social
del
estado
de
municipio
pediatr
oncolog
toluca
mexico
de
seguridad
social
al
servicio
de
trabajador
del
estado
pediatr
oncolog
ciudad
de
mexico
civil
dr
juan
n
menchaca
pediatr
oncolog
guadalajara
mexico
nacion
de
pediatria
pediatr
oncolog
ciudad
de
mexico
materno
infantil
del
estado
de
pediatr
oncolog
toluca
mexico
infantil
teleton
de
oncologia
pediatr
oncolog
queretaro
mexico
para
el
de
saltillo
pediatr
oncolog
saltillo
mexico
para
el
de
morelia
pediatr
oncolog
morelia
mexico
backgroundobject
introduct
mexico
right
palli
care
pc
establish
pediatr
oncolog
unit
ou
provid
staff
object
report
pc
provid
pediatr
patient
cancer
differ
ou
unit
mexico
designmethod
report
seri
case
patient
receiv
pc
ou
unit
evalu
characterist
oncolog
diagnosi
reason
admiss
durat
type
specif
pc
provid
chemotherapi
radiotherapi
surgeri
nonspecif
analgesia
nutrit
support
reason
place
death
result
includ
patient
adolesc
male
gender
parent
basic
educ
resid
urban
environ
profess
cathol
religion
soft
tissu
metastat
bone
sarcoma
diagnosi
therapeut
failur
scheme
metronom
chemotherapi
use
pc
pain
control
achiev
nutrit
support
thanatolog
pc
durat
month
left
cp
death
happen
home
conclus
pc
countri
emerg
field
must
appli
accord
intern
standard
grant
digniti
process
die
patient
main
limit
poor
infrastructur
human
econom
resourc
ignor
benefit
patient
famili
environ
therefor
health
system
manna
n
praya
palli
care
east
medinipur
india
backgroundobject
develop
countri
state
west
bengal
india
huge
burden
cancer
patient
advanc
stage
come
rural
area
awar
regard
use
palli
care
rather
poor
goal
give
pain
free
good
qualiti
life
advanc
stage
cancer
patient
object
studi
identifi
main
difficulti
achiev
goal
rural
villag
set
india
designmethod
advanc
cancer
patient
need
palli
care
variou
villag
rural
india
select
studi
symptom
manag
rural
surround
evalu
ngo
guidanc
senior
palli
care
specialist
work
area
attempt
made
identifi
main
obstacl
get
proper
palli
care
rural
set
result
pain
fatigu
main
symptom
effect
patient
patient
pain
symptom
control
grossli
inadequ
due
lack
properli
train
manpow
rural
india
howev
regular
homecar
visit
group
social
worker
immens
help
last
month
life
ngo
team
well
guid
palli
care
specialist
conclus
wide
gap
train
manpow
fill
rural
area
india
dedic
group
rural
area
need
encourag
proper
train
difficult
symptom
manag
local
along
necessari
social
psycholog
support
patient
manna
n
praya
palli
care
east
medinipur
india
backgroundobject
due
financi
incap
absenc
manpow
poor
famili
often
fail
carri
advanc
cancer
patient
nodal
centr
pilot
studi
explor
whether
commun
mobil
phone
lessen
burden
identifi
tri
solv
extent
possibl
main
difficulti
give
palli
care
termin
cancer
patient
area
designmethod
initi
plan
gener
regard
manag
advanc
cancer
patient
nodal
centr
district
head
quarter
subsequ
everi
two
week
train
social
worker
attach
nodal
centr
follow
give
necessari
advic
emot
support
patient
famili
regist
mobil
phone
number
patient
famili
also
encourag
commun
team
phone
case
fresh
complain
urgenc
result
sinc
initi
cancer
patient
contact
mobil
phone
everi
two
week
enquir
difficulti
situat
train
social
worker
could
give
necessari
advic
phone
regard
manag
physic
symptom
moreov
patient
famili
realli
overwhelm
emot
support
offer
team
phone
cancer
patient
attend
nodal
centr
expert
advic
palli
care
specialist
conclus
novel
approach
help
provid
regular
physic
emot
support
patient
famili
significantli
reduc
financi
manpow
problem
carri
patient
nodal
unit
improv
qualiti
life
patient
continu
guidanc
team
member
take
help
new
strategi
better
commun
uninterrupt
care
k
montgomeri
j
c
e
j
wisconsin
health
american
famili
children
hospit
madison
usa
hospit
colorado
center
cancer
blood
disord
aurora
usa
hospit
lo
angel
children
center
cancer
blood
diseas
lo
angel
usa
children
hospit
medic
center
cancer
blood
diseas
institut
cincinnati
usa
backgroundobject
children
advanc
cancer
may
experi
poorli
control
symptom
outcom
use
research
pediatr
oncolog
howev
literatur
primarili
retrospect
chart
review
emerg
field
patient
allow
better
understand
child
experi
electron
devic
ideal
way
collect
data
real
time
purpos
studi
evalu
feasibl
prospect
electron
data
collect
describ
symptom
frequenc
sever
level
distress
children
advanc
cancer
use
patient
parent
proxi
designmethod
prospect
cohort
design
includ
pediatr
oncolog
institut
across
unit
state
elig
includ
age
year
diagnosi
advanc
cancer
histori
progress
recurr
diseas
decis
pursu
therapi
diseas
treatment
inform
well
modifi
version
memori
symptom
assess
scale
use
measur
symptom
frequenc
sever
level
distress
measur
collect
electron
everi
week
data
analyz
use
descript
statist
univari
logist
regress
analysi
result
dyad
patient
caregiv
particip
median
age
year
children
parent
respect
primari
diagnos
child
particip
includ
leukemialymphoma
solid
tumor
brain
tumor
frequent
report
symptom
pain
lack
energi
nausea
presenc
diseas
p
recent
diseas
progress
receiv
cancer
therapi
signific
factor
presenc
pain
high
intens
cancer
therapi
signific
factor
pain
frequenc
pain
level
distress
conclus
electron
data
collect
feasibl
initi
result
confirm
pain
remain
signific
symptom
worsen
intens
treatment
children
advanc
cancer
mulyowa
n
cancer
institut
pediatr
oncolog
kampala
uganda
backgroundobject
excess
long
wait
time
outpati
clinic
africa
constant
challeng
patient
health
provid
facil
prolong
wait
time
associ
poor
adher
treatment
miss
appoint
failur
delay
initi
necessari
treatment
time
patient
spend
servic
point
attend
health
provid
overal
total
time
patient
spend
health
facil
arriv
time
departur
time
major
factor
toward
percept
patient
toward
care
receiv
designmethod
observ
studi
data
collect
conduct
outpati
period
week
simpl
random
sampl
use
select
respond
outpati
clinic
set
result
averag
patient
wait
time
two
week
period
major
respond
wait
clinic
minut
receiv
servic
sought
longest
averag
patient
wait
minut
doctor
offic
servic
sought
uci
chemotherapi
lab
radiolog
whilst
respond
felt
time
spent
clinic
accept
mani
suggest
improv
avail
staff
station
help
reduc
patient
wait
time
clinic
conclus
identifi
area
delay
actual
mean
wait
time
clinic
first
step
iimplement
need
chang
intern
process
practic
clinic
major
patient
spend
hour
facil
serv
patient
felt
overal
time
spent
facil
accept
suggest
improv
avail
health
worker
station
reduc
patient
wait
time
thu
enhanc
servic
deliveri
clinic
nafratilova
nurs
depart
faculti
nurs
universita
indonesia
depok
indonesia
backgroundobject
bereav
parent
palli
care
affect
qualiti
life
children
famili
research
aim
explor
parent
experi
care
children
cancer
palli
condit
designmethod
research
appli
descript
qualit
phenomenolog
design
data
collect
conduct
interview
involv
ten
parent
particip
data
analysi
use
colaizzi
method
result
eight
theme
identifi
care
love
continu
fight
feel
chang
life
caregiv
child
care
children
easi
tri
normal
parent
seek
help
parent
took
care
children
love
make
comfort
use
love
care
child
stand
child
care
orient
child
parent
shown
tri
tough
keep
fight
care
child
feel
worri
uncertainti
sad
fear
fatigu
ignor
feel
isol
feel
happi
calm
touch
describ
parent
parent
felt
neg
chang
chang
daili
activ
limit
activ
found
difficulti
care
commun
child
financi
problem
limit
time
less
support
famili
jealousi
sibl
parent
also
give
best
child
tri
treat
child
normal
children
conclus
parent
care
child
love
even
though
feel
mix
feel
difficulti
chang
life
palli
care
need
comprehens
support
play
role
primari
care
giver
child
care
love
nurs
health
care
profession
involv
expect
abl
cooper
provid
palli
care
comprehens
continu
children
parent
v
paintsil
b
l
c
anoky
teach
hospit
child
health
kumasi
ghana
backgroundobject
care
children
life
threaten
diseas
difficult
also
could
compound
insuffici
train
compet
symptom
manag
commun
skill
staff
member
affect
qualiti
care
deliv
patient
object
studi
determin
servic
deliv
patient
life
threaten
diseas
could
improv
educ
healthcar
provid
designmethod
twenti
five
doctor
nurs
select
subspecialti
ward
child
health
director
komfo
anoky
teach
hospit
kumasi
personnel
select
taken
day
workshop
palli
care
educ
commun
skill
pain
assess
method
manag
symptom
control
psycholog
support
ethic
consider
palli
care
among
other
personnel
divid
group
group
paediatr
ward
help
integr
palli
care
servic
ward
result
healthcar
personnel
cancer
ward
part
workshop
attest
improv
knowledg
palli
care
issu
workshop
abl
grade
pain
correctli
give
analges
appropri
reliev
pain
symptom
control
patient
becam
better
healthcar
worker
becam
better
psychosoci
support
differ
ward
select
focal
person
support
patient
need
palli
care
led
improv
care
patient
life
threaten
diseas
one
healthcar
worker
develop
interest
palli
care
later
took
fellowship
programm
afterward
conclus
low
middl
incom
countri
set
formal
paediatr
palli
care
programm
inform
educ
healthcar
personnel
lead
improv
palli
care
deliveri
children
personnel
educ
also
train
member
ward
deliv
palli
care
c
prieto
nuestro
hijo
research
develop
santiago
chile
backgroundobject
object
project
give
theoret
practic
tool
physician
nurs
multidisciplinari
oncolog
team
parent
order
favor
implement
palli
care
pain
relief
program
children
cancer
improv
qualiti
life
decreas
socioeconom
burden
famili
la
countri
goal
program
implement
four
la
countri
bolivia
colombia
paraguay
contribut
creation
public
polici
direct
issu
order
profession
oncolog
unit
countri
invit
particip
program
train
palli
care
children
cancer
chile
everi
unit
formul
palli
care
pain
relief
local
program
includ
collabor
sector
popul
state
privat
civil
societi
designmethod
project
involv
stage
year
human
capit
educ
chile
profession
medic
center
except
hospit
del
la
paz
bolivia
educ
profession
countri
multidisciplinari
team
sensibil
civil
societi
technic
assist
administr
money
collect
among
other
project
also
includ
monitor
evalu
achiev
difficulti
result
stage
creat
follow
product
formul
palli
care
formul
local
palli
care
program
implement
palli
care
program
oncolog
unit
conclus
collabor
action
consid
order
improv
manag
palli
care
childhood
cancer
among
latin
american
la
countri
collabor
action
public
health
servic
civil
societi
riva
p
f
g
p
nacion
de
palli
integr
medicin
guatem
guatemala
nacion
de
pediatr
oncolog
guatemala
guatemala
nacion
de
palli
integr
medicin
guatemala
guatemala
jude
research
hospit
depart
global
pediatr
medicin
memphi
usa
spoir
child
matter
program
grand
mentor
lo
angel
usa
backgroundobject
deliveri
palli
care
high
incom
countri
histor
provid
two
model
diagon
model
provid
progress
attent
diseas
worsen
dichotomi
model
distinguish
care
either
cur
palli
unidad
nacion
de
oncologia
pediatrica
unop
largest
pediatr
cancer
center
guatemala
mani
children
present
advanc
diseas
diagnosi
healthcar
resourc
limit
stratifi
model
palli
care
provis
help
alloc
resourc
needi
sanofi
espoir
foundat
child
matter
program
help
train
nurs
physician
deliv
care
designmethod
year
medicina
integr
multidisciplinari
team
mimdt
develop
palli
care
servic
evolv
collabor
pediatr
oncolog
care
deliveri
model
patient
model
group
patient
three
level
base
chanc
surviv
poor
prognosi
chanc
surviv
intermedi
prognosi
good
prognosi
result
new
cancer
diagnos
per
year
approxim
poor
prognosi
depend
upon
function
statu
children
receiv
either
possibl
life
prolong
treatment
symptom
manag
symptomat
relief
end
life
patient
intermedi
prognosi
receiv
palli
consult
symptom
intent
cancer
manag
base
diseas
respons
patient
good
prognosi
diagnosi
receiv
treatment
cur
intent
mimdt
consult
difficult
symptom
conclus
stratifi
model
palli
care
provis
help
priorit
scarc
resourc
improv
qualiti
life
children
cancer
stage
diseas
trajectori
patient
benefit
servic
mimdt
care
degre
involv
determin
initi
categor
level
good
collabor
regular
commun
mimdt
oncolog
team
crucial
success
ks
sharma
p
koirala
memori
cancer
pediatr
oncolog
palli
care
bharatpur
nepal
p
koirala
memori
cancer
hospit
palli
care
bharatpur
nepal
backgroundobject
around
new
pediatr
malign
year
estim
around
regist
hospit
base
cancer
registri
base
b
p
koirala
memori
cancer
hospit
bpkmch
nearli
half
diagnos
children
cancer
admit
treatment
around
complet
recommend
cours
usual
land
cancer
hospit
advanc
incur
state
comfort
care
toward
end
life
new
initi
taken
bpkmch
start
palli
unit
pediatr
want
know
impact
pediatr
palli
care
initi
bpkmch
frequenc
admiss
diagnosi
common
present
symptom
admiss
outcom
pediatr
palli
care
march
februari
designmethod
retrospect
singl
center
case
seri
children
pediatr
palli
care
unit
studi
durat
record
patient
admiss
discharg
record
collect
analyz
age
major
admit
symptom
outcom
result
children
admit
respect
children
age
year
year
year
among
patient
sarcoma
group
tumor
commonest
diagnosi
hematolog
malign
brain
tumor
remain
second
third
commonest
diagnosi
among
children
present
pain
wound
care
short
breath
support
care
gastrointestin
symptom
end
life
care
problem
children
expir
hospic
child
brought
back
home
end
life
discharg
make
comfort
symptom
manag
conclus
pediatr
palli
care
initi
increas
admiss
pain
common
symptom
seek
admiss
pain
manag
guidelin
help
manag
major
children
discharg
better
qualiti
life
szepetowski
traine
pediatr
oncolog
hematolog
depart
marseil
franc
backgroundobject
countri
overal
surviv
childhood
cancer
exce
patient
die
cancer
develop
pediatr
palli
oncolog
ppo
need
allow
best
level
care
qualiti
life
qol
support
patient
report
outcom
pro
measur
studi
aim
prospect
describ
pro
children
cancer
chanc
cure
designmethod
prospect
multicentr
survey
studi
children
malign
symptom
assess
questionnair
inspir
sspedi
open
question
qualiti
life
assess
pedql
gener
version
characterist
patient
diseas
treatment
report
well
factor
physic
activ
educ
result
patient
studi
decemb
februari
cn
tumor
acut
leukemia
solid
tumor
median
time
diagnosi
month
median
number
treatment
line
includ
clinic
trial
educ
interrupt
patient
patient
report
physic
activ
median
symptom
score
median
number
symptom
fatigu
chang
appetit
frequent
symptom
mean
qol
score
point
moder
qol
factor
associ
poorer
qol
cn
tumor
intervent
special
pediatr
palli
care
team
interrupt
educ
particip
clinic
trial
progress
diseas
adjust
confus
factor
qol
associ
global
symptom
score
conclus
first
french
studi
explor
pro
advanc
pediatr
malign
result
suggest
activ
report
better
treatment
symptom
enhanc
qualiti
life
ppo
k
v
p
p
b
jerbai
wadia
hospit
children
depart
pediatr
mumbai
india
backgroundobject
metronom
chemotherapi
use
low
dose
chemotherapi
drug
target
tumor
cell
directli
indirectli
microenviron
designmethod
present
children
metronom
therapi
start
palliat
significantli
improv
qualiti
life
result
year
old
mch
case
earli
thymic
lymphoblast
leukemia
morpholog
remiss
parent
opt
palliat
put
oral
etoposid
day
dexamethason
day
per
month
weekli
vincristin
cyclophospamid
tripl
intrathec
treatment
month
well
follow
year
old
mch
case
relaps
second
time
parent
opt
palliat
put
oral
etoposid
day
dexamethason
day
per
month
weekli
vincristin
cyclophospamid
tripl
treatment
month
well
follow
year
old
fch
down
opt
palliat
upfront
start
oral
methotrex
oral
prednisolon
treatment
month
well
follow
year
old
fch
phladelphia
chromosom
posit
pre
b
earli
cn
relaps
parent
opt
palliat
put
oral
etoposid
day
dexamethason
day
per
month
weekli
vincristin
cyclophospamid
tripl
palli
cranial
radiotherapi
treatment
month
well
follow
year
old
mch
earli
combin
medullari
cn
relaps
parent
opt
palliat
put
oral
etoposid
day
dexamethason
day
per
month
weekli
vincristin
cyclophospamid
tripl
palli
cranial
radiotherapi
expir
month
therapi
year
old
mch
diagnos
stage
neuroblastoma
metastasi
brain
parent
opt
palliat
decreas
discomfort
given
cycl
ojec
palli
cranial
radiotherapi
oral
acid
day
month
etoposid
day
month
treatment
month
last
follow
well
follow
conclus
present
case
report
children
palliat
metronom
chemotherapi
use
success
significantli
improv
qualiti
life
prolong
surviv
ware
children
hospit
melbourn
children
cancer
centr
parent
advisori
group
melbourn
australia
backgroundobject
understand
key
step
help
famili
build
resili
reach
accept
termin
ill
aftermath
vital
role
palli
care
profession
play
assist
hinder
journey
recoveri
designmethod
oral
present
draw
stori
exampl
three
year
termin
neuroblastoma
cancer
journey
son
die
age
year
two
month
result
reflect
cancer
journey
son
marmaduk
particular
final
three
month
life
palli
care
simon
ware
address
key
step
believ
allow
navig
relentless
stress
chang
paediatr
oncolog
yet
emerg
loss
degre
accept
gratitud
draw
parallel
key
step
observ
success
strategi
within
palli
care
team
conclus
comfort
relief
palli
care
provid
paediatr
patient
abil
free
famili
focu
care
celebr
child
life
impact
qualiti
life
patient
potenti
allow
famili
member
approach
emerg
eventu
trauma
grief
loss
stronger
resili
shape
mani
key
step
help
carer
navig
chang
termin
ill
step
palli
care
profession
employ
engag
success
patient
famili
n
yotani
center
child
health
develop
palli
medicin
tokyo
japan
univers
medic
school
palli
medicin
kobe
japan
backgroundobject
clarifi
avail
util
specialist
palli
care
servic
among
children
condit
japan
designmethod
questionnair
administ
assess
avail
specialist
palli
care
servic
among
children
condit
certifi
region
cancer
center
adult
palli
care
team
certifi
children
cancer
center
pediatr
palli
care
team
medic
institut
certifi
palli
care
unit
survey
result
fifteen
percent
adult
palli
care
team
experi
provid
palli
care
children
hematolog
cancer
experi
cancer
pediatr
palli
care
team
experi
provid
palli
care
children
cancer
contrast
adult
palli
care
team
pediatr
palli
care
team
experi
provid
care
popul
estim
children
cancer
japan
use
palli
care
team
eight
children
use
palli
care
unit
solid
tumor
estim
children
cancer
die
japan
use
palli
care
unit
conclus
estim
children
cancer
japan
use
palli
care
team
estim
children
cancer
die
japan
use
palli
care
unit
aldiss
la
b
f
surrey
school
health
scienc
guildford
unit
kingdom
colleg
london
hospit
nh
foundat
trust
divis
oncolog
london
unit
kingdom
york
centr
review
dissemin
york
unit
kingdom
teach
hospit
nh
trust
depart
paediatr
haematolog
oncolog
leed
unit
kingdom
ormond
street
hospit
children
nh
foundat
trust
centr
outcom
experi
research
children
ill
disabl
london
unit
kingdom
backgroundobject
research
agenda
frequent
set
healthcar
profession
research
young
peopl
cancer
age
uniqu
physic
psycholog
social
respons
diagnos
distinct
outcom
aim
engag
young
peopl
carer
profession
systemat
method
identifi
prioritis
research
question
relat
cancer
young
peopl
designmethod
follow
jame
lind
allianc
process
multidisciplinari
steer
group
establish
includ
young
peopl
potenti
research
question
gather
via
onlin
survey
young
peopl
carer
profession
submit
question
check
ensur
unansw
interim
prioritis
undertaken
via
second
survey
identifi
highest
prioriti
question
final
consensu
meet
held
reach
agreement
top
research
prioriti
result
eight
hundr
fifti
five
potenti
question
gather
respond
refin
uniqu
question
seven
alreadi
answer
ongo
studi
therefor
remov
one
hundr
seventi
four
respond
complet
interim
onlin
survey
prioritis
research
question
prioritis
question
debat
workshop
attend
young
peopl
carer
profession
broad
rang
role
top
research
prioriti
psycholog
support
packag
improv
psycholog
social
function
mental
health
treatment
top
question
reflect
breadth
young
peopl
experi
recognis
cancer
alway
curabl
young
peopl
support
wide
network
famili
friend
futur
research
focu
drug
trial
also
deliveri
holist
care
conclus
top
research
prioriti
identifi
use
rigor
approach
involv
stakehold
typic
involv
set
research
agenda
inform
fund
futur
research
barrera
k
j
w
sick
children
psycholog
toronto
canada
women
children
psycholog
vancouv
canada
sick
children
haematologyoncolog
toronto
canada
sick
children
social
worker
toronto
canada
backgroundobject
pediatr
cancer
diagnosi
neg
impact
whole
famili
psychosoci
assess
tool
pat
develop
screen
psychosoci
risk
newli
diagnos
children
cancer
famili
studi
evalu
whether
provid
psychosoci
risk
inform
pat
summari
profil
patient
treat
team
improv
qualiti
life
qol
patient
caregiv
sibl
designmethod
famili
randomli
alloc
intervent
eg
pat
summari
profil
provid
patient
treat
team
control
group
cg
summari
provid
two
pediatr
cancer
centr
parent
n
mean
age
year
children
newli
diagnos
cancer
patient
n
mean
age
sibl
n
mean
age
particip
week
post
diagnosi
parent
complet
pat
caregiv
qualiti
life
cancer
cqolc
qol
pediatr
qualiti
life
inventori
patient
sibl
children
measur
pedsql
measur
complet
month
later
result
patient
total
pedsql
score
accept
level
sibl
report
pedsql
score
accept
level
caregiv
report
total
cqolc
score
accept
level
patient
sibl
report
score
accept
level
caregiv
report
score
accept
level
score
eg
significantli
differ
score
cg
patient
sibl
caregiv
ps
conclus
test
benefit
psychosoci
screen
patient
famili
critic
determin
screen
valid
clinic
implement
whether
treat
team
util
screen
inform
guid
servic
need
investig
acknowledg
canadian
cancer
societi
fund
research
barrera
j
w
k
sick
children
psycholog
toronto
canada
children
women
hospit
psycholog
vancouv
canada
sick
children
haematologyoncolog
toronto
canada
sick
children
social
worker
toronto
canada
backgroundobject
diagnosi
pediatr
cancer
treatment
impact
mental
health
affect
child
famili
psychosoci
assess
tool
pat
screen
psychosoci
risk
newli
diagnos
children
cancer
famili
studi
evalu
whether
provid
psychosoci
risk
inform
pat
summari
profil
patient
treat
team
improv
mental
health
outcom
patient
parent
sibl
designmethod
randomli
alloc
famili
intervent
eg
pat
profil
provid
treat
team
control
group
cg
summari
provid
two
canadian
pediatr
cancer
centr
parent
n
year
children
newli
diagnos
cancer
patient
n
year
sibl
n
year
particip
week
post
diagnosi
parent
patient
sibl
complet
measur
anxieti
depress
hospit
anxieti
depress
scale
pediatr
index
emot
distress
parent
complet
pat
measur
complet
month
later
result
patient
sibl
parent
clinic
rang
anxieti
depress
score
respect
patient
sibl
caregiv
score
clinic
rang
anxieti
depress
score
score
eg
significantli
differ
cg
p
conclus
share
psychosoci
risk
result
treat
team
result
improv
mental
health
outcom
import
investig
degre
psychosoci
screen
result
impact
provis
psychosoci
servic
whether
addit
screen
mental
health
need
improv
outcom
acknowledg
canadian
cancer
societi
fund
research
bilgrami
p
j
v
p
u
jude
india
childcar
centr
develop
mumbai
india
jude
india
childcar
centr
develop
mumbai
india
jude
india
childcar
centr
counsell
mumbai
india
jude
india
childcar
centr
educ
mumbai
india
jude
india
childcar
centr
infect
control
mumbai
india
tata
memori
hospit
paediatr
medic
offic
mumbai
india
jude
india
childcar
centr
chief
execut
offic
mumbai
india
backgroundobject
sjicc
establish
provid
free
accommod
holist
support
needi
famili
travel
children
treatment
metropolitan
hospit
studi
aim
assess
impact
educ
counsel
infect
control
programm
designmethod
interview
famili
children
year
formal
school
twice
june
structur
questionnair
pertain
accommod
hygien
nutrit
fresh
admiss
stay
stay
month
returne
time
first
interview
form
phase
studi
follow
third
interview
home
visit
phase
result
educ
parent
markedli
impact
behaviour
percent
parent
primari
educ
show
signific
improv
parent
higher
educ
understood
share
learn
commun
signific
increas
comprehend
prevent
infect
understand
import
good
nutrit
hygien
famili
follow
recommend
diet
continu
filterboil
water
home
succeed
maintain
similar
cleanli
home
object
children
educ
programm
ensur
return
school
treatment
children
return
home
children
school
immedi
return
home
join
next
academ
year
distanc
school
relaps
diseas
medic
advic
person
reason
prevent
rest
famili
counsel
percent
perceiv
benefit
allevi
anxieti
better
understand
treatment
receiv
exit
counsel
found
help
cope
return
home
conclus
sjicc
ensur
understand
proper
care
child
inculc
posit
attitud
famili
better
outcom
byrjalsen
u
k
k
depart
clinic
genet
depart
paediatr
adolesc
medicin
copenhagen
denmark
depart
paediatr
adolesc
medicin
copenhagen
denmark
depart
clinic
genet
copenhagen
denmark
copenhagen
depart
anthropolog
copenhagen
denmark
backgroundobject
examin
parent
perspect
particip
whole
genom
sequenc
wg
research
week
follow
cancer
diagnosi
designmethod
embed
part
project
stage
sequenc
tumor
germlin
dna
implic
nation
guidelin
qualit
parent
perspect
studi
conduct
physician
anthropologist
document
pragmat
social
ethic
dilemma
face
famili
decid
particip
pediatr
wg
research
follow
genet
counsel
systemat
debrief
held
anthropologist
physician
anthropologist
subsequ
carri
parent
interview
parent
patient
interview
transcrib
verbatim
debrief
interview
read
themat
analyz
anthropologist
physician
separ
follow
meet
consensu
key
theme
result
parent
approach
day
diagnosi
major
report
earli
approach
accept
although
one
famili
state
earli
particip
stage
explain
term
altruism
desir
learn
child
develop
cancer
parent
request
full
feedback
genom
find
although
describ
torn
want
receiv
cancer
diseas
predisposit
find
worri
would
becom
small
minor
want
littl
inform
return
possibl
parent
openli
disagre
amount
inform
want
report
back
follow
famili
deliber
reach
consensu
precondit
particip
stage
conclus
parent
newli
diagnos
childhood
cancer
patient
articul
numer
dilemma
aris
particip
wg
research
enrol
diagnosi
feasibl
howev
flexibl
research
essenti
notwithstand
high
particip
rate
tendenc
choos
full
disclosur
caution
regard
parent
view
particip
wg
research
warrant
studi
famili
receiv
wg
find
necessari
lt
carlsen
danish
cancer
societi
patient
support
commun
activ
denmark
child
cancer
foundat
child
cancer
foundat
copenhagen
denmark
univers
depart
sociolog
social
work
aalborg
denmark
backgroundobject
latest
decad
research
indic
sibl
childhood
cancer
patient
risk
experienc
social
challeng
qualit
studi
aim
gener
knowledg
challeng
need
express
sibl
childhood
cancer
patient
difficult
time
sibl
treatment
studi
also
includ
perspect
parent
child
diagnos
cancer
perspect
sibl
situat
designmethod
studi
philosoph
inform
phenomenolog
refer
framework
ground
theori
approach
use
fulfil
aim
thesi
gener
induct
new
knowledg
social
consequ
childhood
cancer
data
gather
conduct
interview
observ
studi
includ
childhood
cancer
patient
year
childhood
cancer
survivor
year
sibl
childhood
cancer
patient
year
parent
childhood
cancer
patient
collect
differ
famili
survivor
parent
also
ask
give
children
person
detail
includ
diseas
histori
written
document
respect
result
qualit
data
reveal
four
pattern
interact
parent
sibl
receiv
help
without
ask
receiv
help
ask
strain
ask
help
parent
meet
need
ask
help
parent
recogn
surplu
meet
need
pattern
indic
varieti
child
experi
exhibit
differ
strategi
cope
handl
given
situat
absenc
attent
parent
conclus
studi
reveal
four
dynam
pattern
cope
sibl
childhood
cancer
patient
relat
parent
pattern
help
social
healthcar
profession
anticip
consequ
sibl
lt
carlsen
danish
cancer
societi
patient
support
commun
activ
denmark
child
cancer
foundat
child
cancer
foundat
copenhagen
denmark
univers
depart
sociolog
social
aalborg
aalborg
denmark
backgroundobject
last
year
increas
surviv
rate
seen
danish
childhood
cancer
patient
well
intensifi
treatment
protocol
result
increas
number
childhood
cancer
patient
live
side
effect
children
young
adult
live
late
effect
childhood
cancer
purpos
qualit
studi
reduc
impact
childhood
cancer
everyday
life
famili
diagnos
child
designmethod
studi
philosoph
inform
phenomenolog
refer
framework
ground
theori
approach
use
fulfil
aim
thesi
gener
induct
new
knowledg
social
consequ
childhood
cancer
data
gather
conduct
interview
observ
studi
includ
childhood
cancer
patient
year
childhood
cancer
survivor
year
parent
childhood
cancer
patient
subject
provid
person
detail
includ
diseas
histori
written
document
result
qualit
data
reveal
academ
social
challeng
experienc
patient
childhood
cancer
challeng
attribut
side
effect
absenc
school
caus
hospit
patient
childhood
cancer
also
experienc
defici
understand
situat
classmat
contribut
experienc
challeng
children
cancer
often
report
feel
matur
classmat
studi
indic
individu
school
way
handl
situat
affect
way
child
cancer
experi
academ
social
challeng
conclus
studi
reveal
academ
social
challeng
patient
childhood
cancer
patient
overal
data
elabor
import
profession
school
well
engag
parent
group
classmat
caruso
brown
upstat
medic
univers
pediatr
new
hartford
usa
backgroundobject
parent
famili
children
cancer
increasingli
turn
social
media
connect
famili
face
similar
challeng
multidirect
interact
sourc
psychosoci
support
frequent
sourc
medic
inform
well
interact
potenti
meaning
chang
dynam
power
control
trust
famili
pediatr
oncologist
designmethod
survey
pediatr
oncolog
profession
regard
experi
social
media
key
inform
interview
conduct
subset
particip
n
agre
discuss
experi
depth
interview
transcrib
iter
code
distinct
ethic
question
rais
result
encount
famili
discuss
inform
acquir
social
media
particularli
challeng
famili
pose
question
outsid
provid
scope
practic
medic
literatur
offer
definit
answer
also
potenti
domin
encount
pediatrician
intend
use
address
issu
ethic
question
identifi
includ
situat
whose
prioriti
clinic
encount
ought
take
preced
ever
cede
famili
onlin
sourc
ethic
pediatr
oncologist
comment
reliabl
secondhand
inform
expect
evalu
onlin
sourc
verifi
claim
role
pediatr
oncologist
ultim
interact
confidenti
owe
one
patient
conflict
anoth
patient
right
accur
inform
pediatr
oncologist
proceed
conclus
possibl
navig
type
encount
way
maintain
respect
build
trust
requir
open
part
pediatr
oncologist
acknowledg
cultur
chang
inevit
g
r
chan
children
centr
co
limit
oper
singapor
singapor
children
centr
co
limit
nurs
singapor
singapor
children
centr
co
limit
board
singapor
singapor
backgroundobject
children
treatment
cancer
often
abl
attend
school
arc
children
centr
arc
set
provid
safe
environ
children
socialis
learn
develop
fun
educ
activ
time
parent
given
respit
rest
recuper
first
commun
care
centr
singapor
designmethod
arc
open
august
chariti
fund
referr
arc
doctor
patient
sibl
transport
fro
centr
financi
abl
pay
nomin
attend
fee
provid
educ
accord
level
particip
creativ
muscl
strengthen
activ
like
zumba
counsel
servic
also
avail
patient
famili
result
sinc
august
children
sibl
refer
hospit
diagnos
includ
brain
tumour
leukaemia
neuroblastoma
other
help
prepar
transit
normal
school
arc
activ
help
children
confid
less
withdrawn
children
foreign
countri
often
isol
better
adjust
learn
english
sibl
program
help
bridg
gap
sick
child
healthi
sibl
parent
also
benefit
form
inform
support
group
conclus
given
chanc
children
strength
resili
deal
ill
develop
best
children
like
learn
share
comfort
forgiv
learn
respons
help
look
littl
one
well
howev
need
boundari
healthi
love
environ
develop
arc
aim
provid
arc
sinc
extend
program
includ
termin
ill
children
children
ill
w
chan
mari
hospit
paediatr
adolesc
medicin
hong
kong
hong
kong
sar
backgroundobject
improv
medic
oncolog
prolong
surviv
childhood
cancer
patient
morbid
qualiti
life
qol
becom
increasingli
import
issu
address
major
qol
studi
gener
western
develop
countri
local
data
lack
studi
provid
comprehens
systemat
review
literatur
studi
local
qol
take
account
potenti
cultur
differ
valid
designmethod
literatur
review
perform
use
pubm
ovid
medlin
cochran
librari
googl
scholar
use
defin
keyword
qol
cancer
malign
neoplasm
cancer
survivor
child
adolesc
paediatr
hk
search
limit
public
written
english
chines
full
text
avail
publish
past
year
sinc
januari
result
cancer
treatment
great
impact
physic
psychosoci
well
overal
qol
hk
chines
childhood
cancer
survivor
femal
older
age
longer
surviv
time
specif
cancer
diagnos
associ
poorer
physic
mental
adapt
qualiti
life
neg
correl
psycholog
distress
integr
train
program
effect
promot
physic
activ
level
qualiti
life
conclus
first
literatur
review
local
public
concern
qol
morbid
childhood
cancer
survivor
hk
demonstr
compat
conclus
intern
studi
cancer
treatment
long
term
effect
overal
qol
hk
chines
childhood
cancer
survivor
qualit
quantit
research
warrant
better
understand
situat
local
context
earli
recognit
vulner
diseas
group
earli
identif
intervent
psychosoci
risk
factor
patient
caretak
would
improv
qualiti
life
hk
paediatr
oncolog
patient
long
term
ok
chung
hong
kong
school
nurs
hong
kong
china
backgroundobject
fatigu
common
physic
concern
report
childhood
cancer
survivor
previou
studi
indic
survivor
report
feel
fatigu
fatigu
distress
children
may
exacerb
unpleas
symptom
nausea
dyspnoea
pain
substanti
impair
qualiti
life
vital
therefor
healthcar
profession
develop
evalu
appropri
intervent
help
reduc
fatigu
among
popul
group
first
howev
avail
valid
reliabl
instrument
accur
document
level
fatigu
among
childhood
cancer
survivor
crucial
appropri
intervent
appropri
plan
evalu
studi
aim
test
psychometr
properti
chines
version
fatigu
scale
children
designmethod
fatigu
scale
children
first
translat
english
tradit
chines
studi
conduct
two
hundr
children
surviv
blood
cancer
attend
medic
outpati
clinic
public
hospit
hong
kong
invit
particip
particip
ask
respond
chines
version
fatigu
scale
children
center
epidemiolog
studi
depress
scale
children
pediatr
qualiti
life
inventori
intern
consist
content
valid
construct
valid
reliabl
chines
version
fatigu
scale
children
assess
exploratori
confirmatori
factor
analys
conduct
test
construct
valid
result
scale
demonstr
adequ
intern
consist
good
content
valid
appropri
converg
discrimin
valid
exploratori
confirmatori
factor
analys
ad
evid
construct
valid
scale
conclus
result
suggest
scale
use
assess
tool
assess
fatigu
hong
kong
chines
children
surviv
blood
cancer
e
culmina
philippin
children
medic
quezon
philippin
gener
pediatr
quezon
citi
philippin
backgroundobject
studi
aim
determin
compar
anxieti
children
acut
lymphoblast
leukemia
well
sibl
base
child
draw
hospit
manual
identifi
factor
associ
level
anxieti
designmethod
prospect
studi
done
outpati
clinic
privat
clinic
specialist
tertiari
pediatr
hospit
studi
includ
children
five
eleven
year
old
diagnos
acut
lymphoblast
leukemia
well
sibl
result
total
forti
dyad
particip
includ
studi
patient
present
higher
anxieti
score
sibl
howev
statist
signific
weak
direct
correl
overal
anxieti
score
patient
sibl
p
insuffici
evid
demonstr
associ
select
clinic
factor
anxieti
score
linear
regress
model
show
variat
anxieti
score
conclus
direct
correl
overal
anxieti
score
patient
sibl
posit
associ
larger
famili
size
child
respons
sibl
ill
larger
famili
like
healthier
environ
studi
show
low
averag
anxieti
level
among
particip
may
relat
qualiti
care
support
given
institut
inher
resili
famili
l
darci
faculti
worklif
welfar
sweden
backgroundobject
young
children
increasingli
surviv
cancer
experi
live
cancer
crucial
provid
evid
base
care
experi
everyday
life
cancer
elicit
interview
shortli
diagnosi
six
month
later
qualit
analys
result
describ
child
live
cancer
three
year
period
child
apart
strive
live
everyday
life
strong
sens
loneli
isol
feel
left
feel
differ
persist
throughout
studi
emerg
issu
survivorship
child
social
need
reveal
need
address
young
children
learn
live
everyday
life
cancer
effect
treatment
designmethod
present
paper
aim
describ
action
taken
child
life
specialist
depart
paediatr
hospit
west
sweden
base
result
result
child
life
specialist
cl
play
integr
role
oncolog
team
guidelin
work
practis
develop
meet
child
social
need
cl
present
visit
made
preschoolschool
togeth
consult
oncolog
nurs
maintain
contact
preschoolschool
personnel
time
brochur
meet
cl
spread
inform
child
social
need
surround
municip
cl
team
sweden
conclus
result
studi
young
children
cancer
need
implement
evalu
clinic
care
tradit
studi
within
nurs
dissemin
implement
nurs
staff
present
studi
show
disciplin
involv
dissemin
implement
nurs
studi
child
child
need
guid
point
l
dyrgaard
h
g
univers
hospit
pediatr
hematolog
oncolog
depart
copenhagen
denmark
backgroundobject
children
cancer
often
discharg
hospit
shortli
diagnos
treatment
requir
parent
child
train
observ
symptom
handl
necessari
care
task
home
eg
administr
medicin
central
line
care
nasogastr
tube
feed
inadequ
knowledg
train
may
affect
patient
secur
sens
secur
overal
qualiti
treatment
aim
studi
support
parent
gain
necessari
knowledg
train
care
child
home
designmethod
develop
systemat
program
ensur
parent
gain
necessari
knowledg
skill
provid
care
task
children
age
diagnos
parent
invit
particip
shortli
first
discharg
hospit
famili
receiv
visit
nurs
famili
home
video
call
live
km
hospit
program
evalu
questionnair
measur
eg
usabl
sens
secur
parent
complet
home
visit
result
june
februari
famili
receiv
visit
famili
declin
particip
famili
return
questionnair
parent
report
highli
usabl
usabl
prior
visit
famili
report
secur
home
visit
number
increas
famili
report
question
adequ
answer
follow
visit
parent
would
like
second
visit
conclus
visit
enhanc
parent
knowledg
train
improv
sens
secur
first
discharg
hospit
j
elhoudzi
hospit
moham
pediatr
hematolog
oncolog
marrakesh
morocco
backgroundobject
child
cancer
worst
experi
parent
could
live
addit
take
care
child
diseas
also
face
fatigu
anxieti
insomnia
manag
hospit
travel
econom
problem
burden
heavi
bear
chronic
stress
lead
burnout
object
evalu
impact
child
cancer
physic
emot
mental
social
behavior
parent
designmethod
parent
children
follow
month
center
interview
month
result
person
question
patient
live
outsid
marrakech
parent
illiter
without
insur
low
incom
alreadi
receiv
medic
educ
warn
sign
emerg
care
alreadi
hospit
mother
felt
husband
support
conflict
husband
move
marrakesh
stop
profession
activ
parent
feel
qualiti
life
disturb
sleep
problem
eat
disord
anxieti
disord
follow
psychologist
would
like
reason
anxieti
fear
death
sick
child
case
econom
problem
live
far
form
center
accord
zarit
score
burden
mild
moder
case
moder
sever
sever
accord
parent
qualiti
life
improv
facilit
access
care
financi
resourc
help
conclus
parent
often
suppos
support
children
forgot
emotionnel
famili
problem
elli
c
children
hospit
kid
cancer
centr
sydney
australia
new
south
wale
school
women
children
unsw
medicin
sydney
australia
univers
sydney
school
psycholog
sydney
australia
feder
univers
psychophysiolog
clinic
psycholog
depart
russia
backgroundobject
sleep
qualiti
robust
predictor
parent
qualiti
life
child
cancer
treatment
howev
care
child
cancer
may
neg
impact
sleep
qualiti
due
rang
complex
psycholog
physic
environment
factor
experi
famili
countri
russia
larg
underrepres
intern
literatur
therefor
studi
aim
determin
preval
russian
parent
psycholog
distress
well
predictor
parent
sleep
stay
paediatr
oncolog
ward
designmethod
recruit
parent
children
complet
chemotherapi
parent
healthi
children
attend
period
health
examin
children
region
hospit
russia
parent
complet
survey
assess
demographicclin
outcom
sleep
st
mari
sleep
qualiti
questionnair
psycholog
distress
dass
examin
differ
demograph
sleep
psycholog
outcom
conduct
multipl
linear
regress
identifi
predictor
parent
sleep
result
compar
control
parent
childhood
cancer
patient
significantli
male
children
p
work
less
hour
paid
employ
p
also
report
significantli
lower
sleep
durat
increas
awaken
p
wors
sleep
qualiti
p
significantli
higher
score
dass
depress
p
anxieti
p
stress
p
signific
predictor
sleep
durat
parent
cancer
patient
includ
overal
health
age
amount
sleep
attain
previou
week
conclus
russian
parent
sleep
paediatr
oncolog
ward
experi
poor
sleep
high
rate
psycholog
distress
may
reflect
challeng
current
oncolog
care
system
russia
includ
limit
access
psychosoci
support
futur
research
clinic
intervent
target
modifi
factor
associ
sleep
distress
may
improv
parent
qualiti
life
abil
care
unwel
child
fatima
ssa
rc
pediatr
onlcolog
lahor
pakistan
medic
centr
medic
centr
lahor
pakistan
backgroundobject
year
almost
children
diagnos
cancer
pakistan
major
children
underprivileg
henc
cancer
becom
lead
caus
death
diagnosi
treatment
childhood
cancer
continu
emot
distress
parent
particularli
mother
aim
identifi
sever
depress
emot
distress
stress
mental
fatigu
among
parent
children
diagnos
cancer
designmethod
cross
section
studi
conduct
shaukat
khanum
hospit
lahor
march
april
exclus
inclus
criteria
made
one
hundr
fifti
particip
enrol
studi
socio
demograph
characterist
evalu
use
beck
depress
inventori
socio
demograph
form
sever
depress
estim
use
hamilton
variou
variabl
analys
includ
parent
age
level
educ
socioeconom
statu
famili
gender
number
children
result
particip
exhibit
sever
rang
depress
show
moder
depress
particip
show
mild
rang
depress
invers
co
relat
found
educ
statu
occup
statu
paid
unpaid
marit
statu
socioeconom
famili
statu
depress
mother
found
depress
father
conclus
conclud
major
mother
suffer
psychosoci
symptom
particularli
depress
mainli
associ
factor
need
incorpor
parent
especi
mother
diagnosi
treatment
process
come
effect
parent
depress
health
outcom
children
diagnos
cancer
c
k
di
e
l
de
c
lo
g
hospit
policlinico
depart
pediatr
hematolog
oncolog
catania
itali
catania
depart
pediatr
hematolog
depart
clinic
experiment
catania
itali
onlu
lad
onlu
catania
itali
backgroundobject
cure
cancer
take
care
child
famili
golden
standard
paediatr
cancer
treatment
heal
process
goe
far
beyond
hospit
center
total
admiss
cure
children
eastern
sicili
grow
number
patient
challeng
commun
local
institut
resourc
creat
environ
sensibl
child
treatment
development
need
time
diagnosi
throughout
survivorship
designmethod
wonderlad
project
follow
cure
care
approach
cancer
treatment
compos
structur
function
part
structur
one
consist
edif
squar
meter
facil
design
team
architect
dedic
intern
architectur
competit
function
part
consist
seri
activ
guid
support
psycholog
team
art
creativ
tool
use
stimul
child
inner
vital
counterbal
anguish
experi
cancer
result
mani
organ
believ
project
offer
initi
econom
support
year
ministri
labor
social
polici
offer
remain
found
necessari
complet
construct
municip
catania
grant
right
use
ground
squar
meter
erect
build
facil
design
offer
space
perform
daytim
activ
night
recept
six
famili
project
follow
principl
assur
young
patient
impair
immun
system
healthi
environ
open
ceremoni
novemb
conclus
conceiv
clinic
experi
design
upon
child
famili
need
wonderlad
fill
gap
transit
space
hospit
care
life
result
coordin
effort
privat
initi
public
institut
converg
toward
singl
purpos
fernandez
nn
foundat
inc
child
life
program
depart
quezon
citi
philippin
backgroundobject
gabay
magulang
parent
guid
collabor
kyth
foundat
inc
select
medic
student
provid
support
empow
parent
children
newli
diagnos
cancer
guid
parent
would
better
abl
understand
care
children
program
aim
develop
empow
core
parent
leader
take
lead
educ
support
parent
designmethod
focu
group
discuss
fgd
conduct
parent
children
cancer
better
understand
need
best
support
inform
gather
draft
guid
written
medic
student
forward
first
kyth
staff
pediatr
hematologist
oncologist
edit
four
pediatr
hematologist
oncologist
edit
booklet
publish
initi
fgd
select
group
core
parent
invit
parent
leader
four
train
session
use
guid
conduct
kyth
train
parent
leader
led
learn
session
parent
newli
diagnos
children
result
two
program
run
everi
year
four
month
program
monthli
learn
session
conduct
four
month
parent
leader
use
gabay
magulang
four
session
kyth
staff
present
provid
support
need
pediatr
oncolog
fellow
consult
hand
either
discuss
specif
topic
provid
answer
question
aris
conclus
empow
parent
activ
partner
advoc
holist
heal
children
undergo
treatment
cancer
essenti
gabay
magulang
program
publish
parent
guid
train
parent
leader
lead
learn
session
provid
parent
opportun
better
understand
children
ill
treatment
answer
question
session
pediatr
oncolog
fellow
consult
graetz
k
j
jude
children
research
hospit
hematologyoncolog
memphi
usa
farber
cancer
institut
psycholog
boston
usa
farber
cancer
institut
psychiatri
boston
usa
farber
cancer
institut
oncolog
boston
usa
backgroundobject
adolesc
young
adult
aya
experi
cancer
midst
emerg
ident
life
goal
investig
aya
prioriti
cancer
treatment
balanc
psychosoci
concern
therapi
potenti
late
effect
designmethod
survey
aya
cancer
patient
respons
rate
age
treat
cancer
institut
boston
massachusett
oncologist
patient
approach
within
week
diagnosi
ask
rate
import
aspect
cancer
treatment
cancer
outcom
life
treatment
patient
complet
relev
question
attribut
respons
option
extrem
somewhat
littl
import
import
rate
extrem
import
use
indic
strong
prioriti
result
patient
frequent
prioriti
cure
good
peopl
care
support
peopl
around
also
priorit
famili
return
schoolwork
maintain
relationship
friend
feel
normal
still
import
mani
patient
fewer
priorit
minim
long
term
acut
side
effect
fertil
older
aya
like
priorit
cure
romant
relationship
p
around
support
patient
poorer
prognos
chanc
cure
report
oncologist
less
like
priorit
school
work
treatment
less
like
priorit
cure
compar
patient
favor
prognos
conclus
nearli
aya
cancer
patient
priorit
best
chanc
cure
maintain
relationship
sens
normalci
prioriti
may
influenc
decis
make
medic
aspect
treatment
provid
help
support
aya
patient
recogn
acknowledg
prioriti
diagnosi
e
gudmundsdottir
institutet
depart
women
children
health
stochholm
sweden
backgroundobject
assess
evid
advers
reaction
parent
children
diagnos
cancer
focus
map
analyz
level
distress
term
vital
exhaust
theoret
could
relationship
level
traumat
stress
symptom
tss
level
studi
examin
possibl
associ
level
tss
level
symptom
purpos
possibl
earli
screen
suffici
intervent
prevent
designmethod
particip
swedish
iceland
parent
cc
patient
diagnos
year
refer
group
compris
parent
children
without
known
chronic
lethal
diseas
parent
vital
exhaust
assess
use
maastricht
questionnair
traumat
stress
symptom
assess
use
impact
event
result
comparison
parent
clinic
cg
group
ncg
reveal
significantli
p
higher
mean
level
score
cg
compar
group
regard
higher
suggest
clinic
score
result
demonstr
number
parent
higher
score
cg
significantli
higher
group
ncg
p
analysi
mq
total
score
clinic
group
demonstr
strong
relationship
tss
p
analysi
subscal
indic
correl
mq
total
score
symptom
intrus
p
avoid
p
symptom
hyperarous
p
conclus
result
studi
reveal
distress
symptom
term
vital
exhaust
still
significantli
higher
clinic
group
year
child
cancer
diagnosi
compar
ncg
result
may
therefor
add
understand
complex
divers
childhood
parent
burden
time
need
attent
care
guseva
g
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
ministri
russia
rehabilit
center
russko
pole
social
psycholog
rehabilit
moscow
russia
state
univers
mv
lomonosov
sociolog
famili
demographi
moscow
russia
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
ministri
russia
deputi
director
moscow
russia
backgroundobject
famili
stress
associ
vital
danger
stigmat
diseas
child
signific
impact
aspect
famili
life
understand
mechan
overcom
stress
consequ
import
organ
psycholog
social
assist
famili
goal
studi
reproduct
behavior
special
featur
context
famili
stress
pediatr
oncolog
designmethod
data
questionnair
mother
age
averag
cancer
child
remiss
analyz
compar
russian
state
statist
agenc
demograph
research
rang
relev
sociolog
psycholog
theori
attract
analyz
result
investig
statist
process
carri
use
chi
squar
test
pairwis
comparison
bonferroni
correct
appli
result
reproduct
attitud
averag
desir
number
children
vs
averag
expect
vs
respect
birth
rate
vs
respect
cohort
consider
higher
popul
serv
indic
signific
chang
system
valu
need
famili
howev
stress
consider
impact
common
reproduct
health
condit
report
worsen
common
health
violat
reproduct
function
secondari
infertil
common
reproduct
health
condit
worst
group
mother
brain
tumor
bt
children
behavior
mechan
overcom
famili
stress
reveal
conclus
emot
determin
need
care
sick
child
form
context
life
threaten
circumst
actual
need
parent
respons
mother
father
lead
deep
emot
famili
bind
famili
activ
famili
educ
holiday
etc
thu
help
overcom
famili
stress
form
posit
motiv
childbear
increas
need
children
j
cy
p
k
j
sl
wm
han
l
j
women
children
hospit
psycholog
depart
singapor
singapor
women
children
hospit
nutrit
dietet
depart
singapor
singapor
women
children
hospit
occup
therapi
servic
singapor
singapor
women
children
hospit
physiotherapi
depart
singapor
singapor
women
children
hospit
speech
languag
therapi
servic
singapor
singapor
women
children
hospit
child
art
music
therapi
programm
singapor
singapor
women
children
hospit
alli
health
specialti
singapor
singapor
women
children
hospit
haematolog
oncolog
servic
singapor
singapor
backgroundobject
children
undergo
cancer
treatment
risk
malnutrit
weight
loss
associ
increas
fever
episod
poorer
surviv
rate
brinksma
loeffen
al
less
physic
activ
decreas
strength
balanc
cardiovascular
health
compar
peer
gilliam
evalu
introduct
pilot
earli
intervent
program
involv
nutrit
intervent
function
rehabilit
session
designmethod
children
year
rang
diagnos
cancer
kk
women
children
hospit
singapor
march
februari
involv
weight
record
diagnosi
month
function
statu
assess
use
weefim
function
independ
measur
children
baselin
intervent
descript
analysi
pair
test
anova
employ
evalu
chang
among
cancer
type
statist
signific
defin
p
result
cancer
type
includ
blood
cancer
solid
tumour
brain
tumour
group
seen
nutrit
intervent
month
rehabilit
need
nutrit
intervent
median
weight
cohort
improv
iqr
kg
iqr
kg
although
reach
statist
signific
translat
mean
percentag
weight
chang
month
associ
percentag
weight
chang
month
cancer
type
score
weefim
particip
increas
baselin
diagnos
brain
tumour
demonstr
signific
improv
diagnosi
mean
mean
conclus
pilot
earli
intervent
programm
schedul
dietitian
review
show
promis
reduc
neg
impact
cancer
treatment
nutrit
statu
earli
function
rehabilit
demonstr
effect
particularli
children
brain
tumour
reduc
function
impact
cancer
hardi
nation
health
system
oncolog
dc
usa
backgroundobject
annual
psychosoci
screen
survivor
childhood
cancer
standard
care
pediatr
oncolog
howev
institut
suffici
resourc
provid
psychosoci
assess
data
util
screen
questionnair
context
limit
examin
strength
difficulti
questionnair
sdq
predictor
clinic
decis
provid
psycholog
consult
refer
outpati
psychotherapi
survivorship
clinic
visit
designmethod
survivor
childhood
cancer
parent
complet
sdq
prior
survivorship
clinic
visit
sdq
publicli
avail
measur
avail
languag
assess
emot
symptom
conduct
problem
hyperact
peer
problem
prosoci
behavior
total
difficulti
psychologist
review
score
decid
whether
meet
patient
chart
review
conduct
determin
patient
refer
outpati
psychotherapi
result
particip
includ
survivor
age
year
particip
identifi
total
difficulti
borderlin
abnorm
rang
base
establish
cutoff
particip
seen
psycholog
consult
refer
outpati
psychotherapi
receiv
oper
characterist
roc
analys
show
sdq
total
difficulti
score
fair
discrimin
particip
refer
outpati
psychotherapi
total
difficulti
cutoff
lower
establish
cutoff
best
discrimin
need
psychotherapi
referr
particip
total
difficulti
score
least
refer
psychotherapi
psychotherapi
referr
deem
unnecessari
particip
score
conclus
sdq
discrimin
survivor
need
referr
outpati
psychotherapi
though
lower
normal
cutoff
may
need
identifi
patient
need
treatment
screen
patient
sdq
help
physician
identifi
survivor
refer
formal
psychosoci
evalu
treatment
e
harju
k
g
lucern
health
scienc
health
polici
lucern
switzerland
backgroundobject
cancer
diagnosi
exert
profound
psycholog
impact
patient
even
long
therapi
end
heighten
distress
associ
poorer
surviv
cancer
patient
wors
qualiti
life
patient
survivor
consist
evid
promot
psycholog
distress
screen
emot
thermomet
et
valid
screen
tool
sensit
detect
psycholog
distress
cancer
patient
reason
length
use
acut
time
constrain
clinic
set
consist
five
dimens
distress
anxieti
depress
anger
determin
et
integr
screen
practic
systemat
review
undertaken
designmethod
pubm
medlin
psychinfo
cinahl
embas
scopu
systemat
search
studi
use
et
cancer
patient
survivor
result
search
found
public
screen
full
text
inclus
final
studi
includ
review
studi
conduct
europ
screen
distress
use
et
recommend
combin
valid
screen
measur
femal
mean
age
studi
year
patient
survivor
five
studi
valid
et
distress
measur
conclud
et
good
criterion
valid
use
accept
clinician
patient
neg
impact
clinic
throughput
time
conclus
despit
et
valid
feasibl
tool
distress
screen
deliv
prompt
accur
result
distress
screen
et
scarc
recommend
util
et
part
structur
program
earli
distress
screen
cancer
care
applic
younger
popul
still
need
evalu
r
hawk
f
j
art
nyc
weav
artist
new
york
usa
cohain
foundat
artwork
nj
usa
univers
medic
center
depart
pediatr
new
york
usa
backgroundobject
children
cancer
face
mani
challeng
impact
growth
emot
cognit
develop
qualiti
life
art
medicin
program
introduc
varieti
pediatr
medic
set
promot
adjust
ill
hospit
experi
pediatr
cancer
patient
limit
designmethod
saori
holist
japanes
weav
method
base
freestyl
weav
highli
adapt
loom
compat
physic
disabl
hypothes
introduct
saori
weav
intervent
pediatr
oncolog
outpati
clinic
set
would
well
receiv
patient
sibl
result
saori
weav
program
initi
weekli
basi
march
supervis
consist
teach
artist
former
pediatr
oncolog
nurs
particip
patient
sibl
age
year
well
parent
caregiv
mani
particip
multipl
encount
log
encount
maintain
total
encount
document
month
found
particip
report
manifest
improv
realm
physic
comfort
relax
sibl
insight
parent
pride
formal
assess
qol
standard
instrument
pursu
initi
phase
activ
tool
art
intervent
difficult
administ
may
interfer
process
illustr
case
studi
present
introduc
activ
conclus
form
art
intervent
pediatr
oncolog
set
saori
weav
broad
access
provid
subject
evid
enhanc
qol
among
particip
larger
studi
requir
applic
qol
instrument
quantifi
outcom
novel
intervent
ky
ho
llk
whc
univers
hong
kong
school
nurs
hong
kong
hong
kong
sar
backgroundobject
solid
tumor
account
approxim
pediatr
cancer
common
type
solid
tumor
children
includ
brain
tumor
neuroblastoma
rhabdomyosarcoma
wilm
tumor
osteosarcoma
compar
treatment
type
childhood
malign
solid
tumor
often
extens
damag
childhood
survivor
solid
tumor
thu
requir
face
sever
sequela
turn
may
creat
substanti
burden
psycholog
health
survivorship
period
nevertheless
evid
psycholog
children
surviv
solid
tumor
remain
rel
scant
especi
hong
kong
chines
context
studi
aim
address
gap
exist
literatur
explor
impact
cancer
treatment
psycholog
hong
kong
chines
children
surviv
solid
tumor
designmethod
studi
design
employ
subject
recruit
conduct
pediatr
oncolog
outpati
clinic
public
acut
care
hospit
hong
kong
total
childhood
survivor
solid
tumor
age
recruit
purpos
comparison
anoth
similar
age
group
children
surviv
blood
cancer
recruit
outpati
clinic
obtain
parent
consent
childhood
survivor
assess
depress
symptom
qualiti
life
use
instrument
result
childhood
survivor
solid
tumor
report
greater
number
depress
symptom
p
lower
level
p
qualiti
life
p
surviv
blood
cancer
independ
sampl
conclus
studi
bridg
gap
exist
literatur
demonstr
impact
cancer
treatment
psycholog
children
surviv
solid
tumor
appropri
intervent
therefor
develop
implement
thu
optim
psycholog
qualiti
life
long
run
l
hurajova
organ
parent
patient
trnava
slovak
republ
backgroundobject
bone
marrow
transplant
bmt
stem
cell
transplant
sct
long
last
demand
treatment
usual
make
patient
accompani
parent
stay
month
hospit
case
stay
one
room
without
possibl
meet
wider
group
peopl
use
social
isol
might
neg
consequ
patient
parent
health
condit
hand
lower
level
isol
might
assist
undergo
treatment
better
bit
easier
designmethod
commun
parent
whose
children
underw
bmt
sct
decid
lower
isol
level
use
technolog
prepar
start
work
project
call
digitalis
steril
box
first
phase
project
interact
comput
instal
six
steril
box
bmt
unit
sever
applic
provid
entertain
educ
social
functionsfeatur
patient
parent
manag
design
room
call
live
room
within
hospit
bmt
unit
locat
live
room
utilis
mainli
parent
accompani
children
oncolog
treatment
orand
bmtsct
process
organis
event
massag
psychotherapi
cultur
contribut
deal
system
set
within
project
digitalis
steril
box
function
consequ
might
patient
parent
stay
hospit
treatment
result
feedback
patient
parent
use
system
present
new
propos
phase
ii
introduc
conclus
soften
social
isol
patient
undergo
bmtsct
parent
lower
technolog
appli
bw
indraswari
mn
g
public
health
universita
gadjah
mada
dr
sardjito
indonesia
pediatr
depart
yogyakarta
indonesia
univers
medic
netherland
pediatr
hematolog
oncolog
amsterdam
netherland
backgroundobject
surviv
childhood
cancer
patient
increas
last
decad
measur
hrqol
health
relat
qualiti
life
certain
time
treatment
process
recogn
acut
dysfunct
relat
diseas
treatment
characterist
cancer
type
phase
intens
durat
treatment
associ
patient
qualiti
life
studi
aim
identifi
hrqol
childhood
cancer
patient
designmethod
studi
conduct
among
type
pediatr
cancer
dr
sardjito
hospit
indonesia
june
april
hrqol
data
obtain
patient
guardian
use
gener
core
scale
cancer
modul
parent
indonesian
version
result
one
hundr
forti
patient
age
year
guardian
includ
studi
cronbach
alpha
studi
interclass
correl
coeffici
hematolog
malign
group
show
higher
hrqol
malign
almost
sub
scale
patient
guardian
report
patient
guardian
short
treatment
durat
group
report
lower
score
long
treatment
durat
group
total
score
gener
vs
cancer
modul
vs
subscal
impair
significantli
physic
school
anxieti
procedur
subscal
short
treatment
compar
long
treatment
durat
conclus
maneuv
reduc
procedur
anxieti
nausea
import
improv
qualiti
life
pediatr
cancer
psycholog
support
parent
help
search
good
cope
strategi
deal
childhood
cancer
especi
begin
cancer
treatment
r
inou
univers
school
medicin
isehara
japan
backgroundobject
cancer
control
act
enact
japan
core
hospit
pediatr
cancer
treatment
subsequ
establish
fifteen
locat
across
nation
core
hospit
provid
place
survivor
childhood
cancer
famili
interact
ensur
peer
support
avail
designmethod
therefor
purpos
teach
peer
support
skill
member
childhood
cancer
famili
group
implement
train
workshop
core
hospit
pediatr
cancer
treatment
sinc
date
train
workshop
held
nine
time
attend
approxim
peopl
content
workshop
consist
medic
knowledg
childhood
cancer
counsel
seminar
result
major
particip
childhood
cancer
survivor
famili
follow
health
profession
healthcar
volunt
nurs
student
common
reason
particip
interest
concern
well
improv
counsel
skill
effect
workshop
found
particip
establish
cancer
famili
group
peer
counselor
becam
less
distress
conclus
believ
activ
patient
experienc
childhood
cancer
play
larg
role
futur
moreov
believ
activ
contribut
healthcar
improv
peer
counsel
skill
g
jankov
n
f
mg
depart
human
scienc
educ
milano
itali
brianza
foundat
children
mother
mbbm
depart
pediatr
monza
itali
depart
medicin
surgeri
monza
itali
backgroundobject
rate
surviv
acut
lymphoblast
leukaemia
increas
year
thu
literatur
interest
psycholog
effect
treatment
progress
increas
parent
distress
influenc
parent
percept
behaviour
emot
problem
survivor
children
nevertheless
unclear
whether
parent
emot
distress
affect
child
emot
behaviour
aim
studi
investig
whether
parent
emot
affect
emot
disposit
survivor
children
designmethod
cohort
italian
childhood
survivor
parent
ask
complet
respect
children
adult
italian
version
posit
neg
schedul
pana
result
regress
model
show
mother
pana
posit
affect
scale
pa
statist
signific
effect
p
pa
survivor
children
instead
father
pana
scale
effect
p
two
result
control
children
age
children
gender
respect
mother
father
pana
neg
affect
scale
na
final
parent
pa
na
significantli
affect
neg
affect
scale
surviv
children
conclus
order
enhanc
posit
emot
disposit
survivor
children
studi
suggest
set
psycholog
intervent
focus
mother
posit
emot
jarfelt
queen
silvia
children
hospit
pediatr
oncolog
gothenburg
sweden
univers
hospit
depart
obstetr
gynecolog
gothenburg
sweden
backgroundobject
increas
group
childhood
cancer
survivor
abil
becom
parent
valu
one
import
issu
today
first
gener
childhood
cancer
survivor
reach
age
peopl
establish
famili
decid
children
studi
investig
question
fertil
inform
lack
inform
fertil
influenc
adult
survivor
designmethod
cohort
studi
survivor
childhood
cancer
year
age
identifi
childhood
cancer
registri
west
region
sweden
perform
elig
patient
treat
cancer
median
age
identifi
ten
women
eight
men
particip
studi
interview
follow
guid
fill
questionnair
mood
had
sens
coher
soc
result
interview
analys
themat
method
theme
long
wind
road
seen
master
theme
affect
three
underli
subthem
label
follow
pictur
fertil
experi
fertil
emot
fertil
women
score
significantli
higher
depress
men
vs
women
mean
anxieti
individu
level
six
women
two
men
score
indic
need
clinic
intervent
conclus
unnecessari
gap
inform
lack
support
question
fertil
even
former
childhood
cancer
survivor
reach
adulthood
may
influenc
psycholog
wellb
l
jensen
univers
hospit
depart
pediatr
aarhu
denmark
backgroundobject
cancer
adolesc
affect
patient
whole
famili
parent
import
resourc
young
patient
need
support
knowledg
fulfil
role
support
young
patient
even
give
parent
increas
understand
pattern
respons
young
patient
opportun
support
adolesc
get
opportun
meet
other
similar
situat
exchang
experi
designmethod
particip
young
peopl
age
parent
three
special
nurs
knowledg
adolesc
challeng
parent
experi
caus
cancer
attend
group
divid
two
part
adolesc
particip
network
activ
one
nurs
adolesc
opportun
get
know
talk
import
parent
group
receiv
inform
nurs
adolesc
impact
young
peopl
cancer
parent
exchang
experi
spar
nurs
facilit
even
evalu
questionnair
parent
subsequ
oral
evalu
adolesc
result
three
even
total
adolesc
parent
questionnair
complet
document
high
level
satisfact
parent
parent
found
valuabl
attend
parent
gain
use
knowledg
parent
happi
share
experi
parent
young
peopl
particip
even
experi
break
diseas
gain
friendship
young
patient
keep
touch
afterward
conclus
studi
indic
even
valuabl
interact
understand
adolesc
cancer
parent
l
katz
k
k
b
l
washington
psycholog
seattl
usa
univers
pediatr
nashvil
usa
univers
psycholog
nashvil
usa
backgroundobject
child
diagnos
cancer
parent
experi
host
new
stressor
associ
parent
ill
child
parent
stress
treatment
may
affect
wellb
parent
children
may
also
affect
famili
relationship
sibl
relationship
import
sourc
social
instrument
support
yet
littl
known
affect
cancer
examin
whether
parent
strain
longitudin
predict
elev
sibl
conflict
across
first
year
treatment
hypothes
parent
stress
may
one
way
cancer
experi
affect
sibl
relationship
designmethod
famili
recruit
two
us
children
hospit
diagnosi
children
cancer
year
old
caregiv
report
parent
stress
sibl
conflict
parent
stress
measur
assess
stressor
specif
parent
ill
child
ie
commun
role
strain
subscal
form
two
score
frequenc
difficulti
model
sem
examin
relat
parent
stress
sibl
conflict
model
test
whether
parent
stress
predict
sibl
conflict
subsequ
time
point
control
previou
conflict
level
potenti
bidirect
influenc
result
higher
parent
stress
frequenc
predict
higher
sibl
conflict
higher
parent
stress
frequenc
predict
higher
sibl
conflict
neither
revers
pattern
sibl
conflict
predict
later
parent
stress
bidirect
pattern
support
pattern
result
observ
model
examin
parent
stress
difficulti
conclus
parent
stress
may
contribut
sibl
conflict
time
prevent
problem
sibl
relationship
interven
parent
help
manag
caregiv
stress
treatment
may
optim
n
kelli
c
n
hope
support
care
medicin
duart
usa
hope
popul
scienc
duart
usa
backgroundobject
among
survivor
childhood
cancer
neuropsycholog
assess
use
evalu
work
memori
deficit
advers
cognit
late
effect
howev
neuropsycholog
evalu
costli
time
consum
increasingli
parent
report
child
function
use
altern
method
screen
neurocognit
late
effect
particular
behavior
rate
inventori
execut
function
brief
part
screen
neurocognit
batteri
compil
behavior
scienc
committe
children
oncolog
group
use
childhood
cancer
survivor
object
studi
examin
concord
child
perform
object
test
work
memori
child
work
memori
brief
designmethod
particip
dyad
complet
assess
children
least
month
post
cancer
treatment
complet
mean
age
test
year
mean
age
diagnosi
year
major
treat
leukemia
child
perform
assess
use
work
memori
index
parent
report
assess
brief
work
memori
scale
hierarch
regress
analys
predict
parent
report
depend
variabl
use
child
perform
score
independ
variabl
control
child
age
result
child
perform
work
memori
index
neg
associ
work
memori
brief
p
control
age
lower
child
perform
higher
dysfunct
report
parent
exploratori
analys
suggest
child
perform
digit
span
highli
associ
parent
report
work
memori
perform
letter
number
sequenc
conclus
analys
found
good
concord
parent
report
actual
perform
child
work
memori
skill
ad
support
util
parent
report
screen
tool
children
cancer
result
replic
larger
sampl
size
r
kiddl
cancer
foundat
nation
support
offic
auckland
new
zealand
backgroundobject
child
cancer
foundat
nz
employ
famili
support
coordin
support
children
famili
basi
throughout
new
zealand
proactiv
approach
support
point
differ
sector
also
awar
parent
benefit
peer
support
year
pilot
programm
mother
retreat
held
two
retreat
one
north
island
one
south
island
durat
resort
style
venu
object
retreat
empow
women
talk
journey
connect
parent
partak
activ
build
resili
wellb
designmethod
weekend
combin
relax
therapi
led
extern
facilit
accompani
one
famili
support
coordin
explor
issu
parent
face
provid
varieti
cope
mechan
attende
parent
select
accord
criteria
set
famili
support
team
detail
therapeut
programm
seven
activ
put
togeth
cost
associ
attend
retreat
cover
child
cancer
foundat
result
feedback
confidenti
survey
cover
detail
retreat
venu
plan
programm
content
question
ask
averag
recipi
spent
minut
give
feedback
survey
result
show
women
valu
opportun
get
away
would
recommend
activ
famili
interest
physic
activ
varieti
option
suit
person
relax
style
allow
engag
particip
outsid
formal
programm
put
togeth
conclus
programm
extend
nation
next
year
adjust
meet
recommend
made
pilot
group
r
kiddl
cancer
foundat
nation
support
offic
auckland
new
zealand
backgroundobject
child
cancer
foundat
nz
reli
network
volunt
group
make
social
connect
famili
around
new
zealand
famili
indic
interest
connect
famili
social
occas
smaller
gather
commun
current
branch
group
volunt
littl
oversight
event
hold
effect
reach
event
declin
volunt
hour
wish
volunt
impact
particip
committe
embark
project
transit
tradit
branch
model
less
formal
impact
connect
group
model
designmethod
project
transit
team
establish
includ
major
facet
organis
famili
support
fundrais
branch
represent
region
repres
nation
board
project
team
discuss
core
purpos
group
composit
oper
issu
financi
account
commun
tool
support
mechan
discuss
paper
written
agre
propos
chang
present
member
repres
forum
major
branch
sent
repres
extern
facilit
use
world
model
discuss
six
major
topic
forum
attende
particip
feedback
workshop
concept
allow
particip
consensu
find
six
area
result
forum
conclud
chang
need
agre
propos
chang
adapt
feedback
workshop
felt
empow
abil
support
famili
commun
clariti
commit
conclus
chang
implement
next
six
month
includ
rewrit
constitut
time
adopt
annual
gener
meet
novemb
l
korhonen
f
j
falck
n
h
lm
finnish
cancer
registri
finnish
cancer
registri
helsinki
finland
helsinki
helsinki
univers
hospit
children
hospit
helsinki
finland
cancer
societi
research
center
survivorship
unit
copenhagen
denmark
institutet
unit
institut
environment
medicin
stockholm
sweden
backgroundobject
childhood
cancer
survivor
report
particularli
vulner
late
psychiatr
morbid
riski
health
behavior
suicid
accid
violenc
caus
death
regard
extrem
manifest
riski
health
behavior
studi
risk
suicid
riski
health
behavior
relat
death
alcohol
drug
accid
violenc
independ
outcom
among
childhood
cancer
survivor
denmark
finland
sweden
designmethod
linkag
nation
cancer
popul
caus
death
regist
investig
caus
death
patient
diagnos
cancer
age
year
januari
decemb
compar
popul
control
end
decemb
denmark
sweden
decemb
finland
rate
ratio
rr
estim
use
poisson
regress
model
adjust
countri
diagnost
period
result
overal
risk
die
riski
health
behavior
increas
among
cancer
patient
riski
health
behavior
death
compar
control
rr
ci
risk
die
riski
health
behavior
highest
among
patient
central
nervou
system
tumor
rr
femal
patient
rr
patient
diagnos
year
age
rr
overal
risk
suicid
increas
among
cancer
survivor
suicid
compar
control
rr
ci
cancer
survivor
risk
die
riski
health
behavior
suicid
differ
countri
respect
compar
control
correspond
countri
conclus
found
childhood
cancer
survivor
like
die
due
riski
health
behavior
result
impli
emphasi
care
place
psychosoci
screen
support
childhood
cancer
survivor
js
lai
j
univers
medic
social
scienc
chicago
usa
robert
h
luri
children
hospit
chicago
stem
cell
transplant
chicago
usa
backgroundobject
use
outcom
pro
understand
qualiti
life
children
brain
tumor
bt
recogn
yet
littl
known
pro
chang
overtim
relat
clinic
outcom
bt
use
measur
anxieti
depress
symptom
mobil
upper
extrem
function
fatigu
peer
relationship
cognit
outcom
inform
system
promi
studi
aim
fill
gap
explor
relationship
surviv
promi
measur
designmethod
data
particip
bt
age
parent
patient
age
use
averag
age
patient
male
parent
male
respect
patient
attend
school
receiv
individu
educ
program
surgeri
receiv
chemotherapi
receiv
radiat
tumor
year
sinc
last
treatment
particip
complet
promi
measur
version
bt
age
parent
patient
age
complet
promi
measur
patient
die
period
promi
measur
score
use
linear
mix
model
use
evalu
score
time
cox
proport
hazard
model
use
evalu
whether
promi
measur
significantli
predict
surviv
result
linear
mix
model
result
indic
worsen
cognit
anxieti
p
month
surviv
analysi
indic
patient
report
better
mobil
upper
extrem
function
better
surviv
none
proxi
measur
signific
longer
time
sinc
diagnosi
higher
perform
rate
also
predict
surviv
conclus
studi
provid
preliminari
evid
use
pro
predict
clinic
outcom
studi
surviv
small
number
death
result
consid
exploratori
futur
studi
need
confirm
conclus
kwk
lam
hcw
univers
hong
kong
school
nurs
hong
kong
hong
kong
sar
backgroundobject
declin
level
physic
activ
children
cancer
warren
global
attent
grow
evid
support
benefit
exercis
sinc
cancer
diagnosi
amelior
fatigu
depress
symptom
thu
improv
qualiti
life
nevertheless
literatur
review
show
previou
exercis
intervent
unlik
chang
behaviour
studi
aim
examin
effect
integr
experienti
train
program
coach
nurs
student
reduc
fatigu
depress
symptom
enhanc
qualiti
life
children
undergo
cancer
treatment
hong
kong
designmethod
random
control
trial
repeat
design
conduct
total
children
cancer
receiv
treatment
randomli
alloc
experiment
control
group
intervent
experiment
group
consist
home
visit
nurs
student
coach
period
control
group
receiv
amount
time
attent
way
specif
effect
outcom
variabl
data
particip
level
fatigu
physic
activ
depress
symptom
qualiti
life
collect
time
recruit
month
start
intervent
questionnair
result
particip
experiment
group
report
statist
lower
level
fatigu
depress
symptom
higher
level
physic
activ
qualiti
life
control
group
statist
signific
mean
differ
fatigu
depress
symptom
physic
activ
level
qualiti
life
found
among
particip
experiment
group
baselin
month
start
intervent
conclus
integr
experienti
train
program
coach
nurs
student
effect
reduc
fatigu
depress
symptom
promot
physic
activ
qualiti
life
children
cancer
l
mader
k
j
k
g
cancer
societi
research
center
childhood
cancer
copenhagen
denmark
lucern
depart
health
scienc
health
polici
lucern
switzerland
children
hospit
basel
divis
hematologyoncolog
basel
switzerland
hospit
hospit
children
adolesc
divis
hematologyoncolog
aarau
switzerland
children
hospit
mcmaster
univers
divis
hematologyoncolog
hamilton
canada
backgroundobject
intens
experi
childhood
cancer
may
tremend
stressor
parent
relationship
aim
compar
relationship
statu
parent
childhood
cancer
survivor
control
parent
ii
identifi
characterist
associ
marri
iii
evalu
qualiti
parent
relationship
designmethod
sent
questionnair
parent
childhood
cancer
survivor
age
year
diagnosi
year
studi
control
parent
deriv
random
sampl
swiss
gener
popul
child
age
year
standard
age
sex
migrat
background
accord
parent
survivor
use
logist
regress
identifi
factor
associ
marriag
appli
multilevel
model
approach
account
famili
cluster
qualiti
partner
relationship
evalu
use
attach
scale
adult
assess
dimens
scale
scale
result
sampl
includ
parent
mother
mean
year
survivor
control
parent
compar
control
parent
parent
survivor
often
partner
relationship
vs
marri
vs
p
associ
marriag
characterist
identifi
parent
survivor
describ
partner
relationship
secur
scale
vs
indic
higher
depend
scale
vs
control
parent
among
parent
survivor
differ
mother
father
observ
scale
scale
p
conclus
parent
child
cancer
advers
affect
parent
relationship
statu
cancer
experi
rather
appear
strengthen
secur
depend
within
partner
relationship
suggest
parent
manag
child
diseas
team
mf
marcusso
manha
rn
g
cd
univers
sao
paulo
depart
clinic
oncolog
paulo
brazil
backgroundobject
sexual
import
issu
face
cancer
patient
rare
discuss
adolesc
young
adult
aya
patient
health
care
provid
view
challeng
face
patient
testicular
cancer
tc
sought
determin
differ
sexual
problem
report
scale
designmethod
identifi
consecut
brazilian
aya
patient
diagnos
tc
base
measur
includ
screen
program
patient
respons
item
sexual
problem
includ
sexual
problem
distress
thermomet
dt
satisfi
sex
life
function
assess
cancer
look
specif
need
eight
specif
item
includ
cancer
assess
young
qualit
descript
comparison
interrog
result
total
patient
averag
age
histolog
seminoma
surgeri
orchiectomi
chemotherapi
bleomycinetoposidecisplatin
assess
three
patient
report
sexual
problem
use
dt
endors
sex
life
cayat
explor
anoth
opportun
indic
specif
concern
adequ
confid
sex
satisfi
abil
biolog
children
satisfi
abil
ejacul
satisfi
abil
achiev
orgasm
bother
concern
conclus
low
proport
patient
report
sexual
problem
use
gener
briefest
measur
seem
patient
use
dt
report
sexual
problem
even
suitabl
indic
specif
need
comprehens
measur
howev
high
proport
patient
report
need
specif
inquir
sexual
function
given
preliminari
find
rapid
identif
key
indic
follow
focus
assess
guid
treatment
decis
appropri
k
maslak
c
r
f
g
la
l
lo
p
v
e
f
g
di
hospit
policlinico
depart
pediatr
hematolog
oncolog
catania
itali
catania
depart
medic
surgic
scienc
advanc
technolog
gf
ingrassia
catania
itali
hospit
policlinico
section
depart
gener
surgeri
medic
specialti
catania
itali
catania
depart
pediatr
hematolog
depart
clinic
experiment
medicin
catania
itali
backgroundobject
cancer
intrud
children
life
everyday
equilibrium
destroy
suddenli
find
total
new
world
adult
make
import
decis
children
undergo
diagnost
therapeut
treatment
experi
increas
level
anxieti
repeat
invas
procedur
adapt
discomfort
bone
marrow
aspir
lumbar
punctur
remain
one
vivid
memori
even
year
treatment
finish
profession
agre
children
must
receiv
development
appropri
preparatori
inform
invas
procedur
along
adequ
psycholog
support
literatur
describ
differ
support
modal
eg
pharmacolog
behaviour
sed
etc
howev
report
possibl
ask
children
prefer
medic
support
designmethod
day
procedur
child
offer
choos
type
medic
support
among
gener
anesthesia
ga
consciou
sedat
cs
noth
child
receiv
also
psycholog
support
ie
given
psychologist
procedur
ad
hoc
assess
tool
prepar
order
measur
child
discomfort
procedur
also
caregiv
adequaci
measur
base
evalu
form
fill
everi
procedur
attend
psychologist
result
monitor
consecut
invas
procedur
children
found
choic
type
medic
support
differ
variou
age
group
age
group
show
significantli
higher
distress
level
other
distress
level
diminish
succeed
procedur
caregiv
behaviour
influenc
children
experi
conclus
offer
children
opportun
choos
medic
support
invas
procedur
effect
modal
return
activ
control
way
truli
strengthen
children
capac
face
invas
procedur
limit
emot
traumat
content
masumoto
e
k
h
univers
graduat
school
medicin
medic
educ
mie
japan
univers
hakod
media
architectur
hokkaido
japan
citi
univers
graduat
school
medicin
medic
qualiti
safeti
scienc
osaka
japan
univers
pediatr
mie
japan
center
child
health
develop
children
cancer
center
tokyo
japan
medic
school
pediatr
tokyo
japan
backgroundobject
late
effect
follow
treatment
well
sequela
diseas
process
emerg
health
problem
childhood
cancer
survivor
ccss
solv
problem
improv
motiv
consult
physician
patient
educ
studi
develop
two
digit
tool
start
line
fun
quest
educ
ccss
late
effect
health
care
activ
japan
children
cancer
group
conduct
studi
assess
effect
limit
educ
use
tool
ccss
designmethod
ccss
mie
univers
hospit
year
old
recruit
june
may
given
instruct
game
oper
request
play
game
devic
comput
laptop
comput
next
one
month
home
awar
knowledg
late
effect
health
promot
evalu
end
learn
baselin
assess
result
survivor
met
elig
criteria
studi
median
age
baselin
year
rang
year
male
slightli
promin
femal
play
game
score
awar
knowledg
late
effect
health
promot
becam
significantli
higher
baselin
howev
adolesc
young
adult
survivor
score
becam
significantli
lower
similarli
knowledg
late
effect
health
promot
children
also
becam
significantli
lower
conclus
result
suggest
digit
tool
develop
ccss
may
effect
learn
knowledg
late
effect
health
increas
motiv
health
manag
maintain
learn
achiev
repeat
may
recommend
miwa
stluke
intern
hospit
tokyo
japan
backgroundobject
studi
aim
evalu
psycholog
current
statu
sibl
adolesc
young
adult
aya
aya
cancer
patient
japan
designmethod
conduct
nationwid
survey
aya
cancer
survivor
parent
sibl
healthi
aya
control
group
distribut
questionnair
aya
survivor
via
doctor
institut
patient
advocaci
group
june
novemb
two
hundr
healthi
aya
regist
research
compani
recruit
questionnair
analyz
result
sibl
compar
healthi
aya
result
total
respond
mean
age
survey
among
particip
forti
two
percent
male
patient
diagnos
leukemia
brain
tumor
osteosarcoma
malign
lymphoma
breast
cancer
other
sibl
show
lower
healthi
aya
one
categori
posttraumat
growth
higher
score
healthi
aya
categori
chang
percept
self
feel
gratitud
life
common
troubl
sibl
age
year
old
studi
futur
futur
famili
sibl
age
year
old
common
troubl
late
effect
complic
patient
also
troubl
futur
famili
work
conclus
sibl
aya
cancer
patient
troubl
lower
healthi
aya
could
experi
posttraumat
growth
struggl
need
support
improv
molcho
l
univers
ireland
galway
children
studi
galway
ireland
colleg
cork
ireland
sociolog
cork
ireland
univers
institut
health
societi
newcastl
upon
tyne
unit
kingdom
backgroundobject
childhood
cancer
survivor
known
suffer
long
term
effect
addit
differ
support
care
need
paper
present
find
support
care
need
childhood
cancer
survivor
first
ever
nation
survey
survivor
ireland
designmethod
data
survivor
year
age
diagnos
cancer
extract
nation
cancer
registri
ireland
elig
survivor
sent
questionnair
assess
support
care
need
mental
health
qualiti
life
data
analyz
identifi
current
health
problem
health
care
need
support
care
need
within
context
irish
health
system
result
overal
survivor
met
elig
criteria
complet
questionnair
respons
rate
age
survivor
rang
mean
sd
preval
medic
problem
problem
vision
dental
problem
mental
health
issu
depress
anxieti
stress
commonli
report
survivor
respect
common
support
care
need
psycholog
uncertainti
futur
need
help
feel
control
need
help
anxieti
physic
lack
energi
health
system
relat
access
counsel
inform
thing
gender
social
class
differ
demonstr
conclus
previou
research
highlight
need
concern
childhood
cancer
survivor
first
time
map
ireland
one
studi
use
nation
survey
assess
health
need
larg
cohort
survivor
ireland
provid
import
inform
prefer
care
survivor
studi
fund
irish
cancer
societi
nageswara
rao
k
clinic
divis
pediatr
hematologyoncolog
rochest
usa
clinic
depart
nurs
rochest
usa
backgroundobject
cancer
diagnosi
treatment
often
long
process
involv
multipl
clinic
visit
procedur
treatment
manag
side
effect
studi
object
identifi
situat
may
make
children
scare
nervou
clinic
visit
activitiesmeasur
may
help
allevi
fearanxieti
designmethod
survey
children
age
year
diagnos
cancer
undergo
radiationchemotherapi
institut
parent
result
femal
male
patient
survey
median
age
year
rang
year
diagnos
includ
leukemialymphoma
brain
tumor
top
two
situat
children
report
feel
scare
nervou
oftenalwaysa
lot
needl
access
procedur
without
sedat
vast
major
report
neverrarelynot
feel
scare
nervou
meet
doctor
receiv
iv
medicationsinfus
come
clinic
almost
half
report
less
scarednerv
oftenalwaysa
lot
receiv
candi
toy
play
therapistsmus
therapi
watch
televis
play
electron
gameslisten
music
readreceiv
book
differ
note
younger
year
older
year
age
group
report
fearnerv
around
variou
clinic
situat
children
younger
age
group
report
less
scarednerv
older
age
group
readreceiv
book
receiv
toy
play
therapistsmus
therapi
watch
televis
parent
agreedstrongli
agre
interact
game
reward
system
help
children
overcom
fear
nervous
differ
note
parent
child
report
variou
clinic
situat
activitiesmeasur
may
make
children
less
nervousscar
conclus
activ
reward
system
may
help
eas
fearanxieti
associ
clinic
visit
pediatr
oncolog
patient
especi
younger
children
r
children
medicla
center
israel
hematolog
oncolog
petach
tikva
israel
aviv
univers
school
educ
sagol
school
neurosceinc
tel
aviv
israel
backgroundobject
cope
childhood
cancer
difficult
academ
studi
support
use
mind
practic
way
activ
cope
challeng
situat
incorpor
techniqu
medit
may
contribut
better
manag
ill
pathway
thu
achiev
emot
function
allevi
symptom
cope
ill
purpos
offer
program
incorpor
mind
goal
enrich
exist
treatment
option
children
cancer
parent
designmethod
program
consist
six
meet
held
profession
special
mind
social
worker
nurs
two
group
children
parent
held
separ
parallel
meet
attend
three
ten
particip
find
base
observ
unstructur
interview
result
children
group
meet
enabl
open
discuss
share
neg
well
posit
aspect
ill
treatment
feel
pain
loneli
relat
diseas
treatment
well
love
meaning
relationship
forg
close
environ
rais
parent
group
calm
seren
succeed
bring
open
rais
complex
emot
issu
parent
found
practic
offer
refug
everyday
physic
emot
difficulti
conclus
benefit
mind
practic
evid
group
access
train
sick
children
parent
may
improv
symptom
manag
qualiti
life
subject
enhanc
relationship
access
servic
within
structur
framework
expand
rang
exist
therapeut
tool
avail
staff
offer
patient
hisher
famili
mind
care
approach
provid
answer
emot
need
often
unansw
time
distress
crisi
ss
ng
c
cancer
foundat
social
work
singapor
singapor
backgroundobject
diagnosi
childhood
cancer
treatment
place
multipl
psychosoci
challeng
children
famili
whilst
literatur
show
provis
psychosoci
servic
mitig
impact
childhood
cancer
famili
anchor
framework
use
guid
psychosoci
assess
intervent
recognis
divers
challeng
need
client
differ
phase
ill
trajectori
children
cancer
foundat
singapor
ccf
develop
comprehens
integr
system
care
model
offer
continuum
care
extend
servic
beyond
acut
set
client
home
commun
treatment
poor
outcom
cure
longer
possibl
ccf
home
team
provid
holist
care
toward
physic
emot
mental
social
spiritu
children
famili
palli
bereav
support
famili
resili
capac
cope
complex
need
may
exhibit
higher
level
distress
requir
specialis
intervent
support
ccf
integr
system
care
model
help
social
worker
conceptualis
differ
level
target
intervent
match
accord
intens
client
need
end
life
bereav
integr
system
care
model
may
serv
refer
case
manag
servic
develop
agenc
help
profession
provid
psychosoci
support
children
health
issu
famili
designmethod
na
result
na
conclus
na
nishio
center
juntendo
hospit
japan
univers
anesthegiolog
tokyo
japan
univers
graduat
school
medicin
plliativ
medicin
tokyo
japan
backgroundobject
childhood
cancer
survivor
cc
develop
pediatr
cancer
complet
treatment
year
age
aim
clarifi
awar
anguish
regard
physic
survivor
reach
adolesc
young
adulthood
aya
accord
receiv
bone
marrow
transplant
studi
also
aim
examin
method
support
css
psycholog
suffer
designmethod
present
studi
includ
cc
age
year
diagnos
receiv
treatment
year
age
least
year
pass
sinc
complet
treatment
conduct
subject
interview
result
subject
sampl
consist
individu
male
femal
transplant
group
ttg
individu
male
femal
diseas
treat
includ
hematolog
malign
transplant
group
hematolog
malign
malign
lymphoma
rhabdomyosarcoma
brain
tumor
group
base
interview
found
follow
code
regard
sexual
fertil
physic
cc
code
extract
sexual
includ
hormon
supplement
drug
hesit
romant
relationship
becom
intim
fertil
includ
implic
inabl
children
ttg
effect
treatment
fertil
seen
transplant
group
conclus
cc
ttg
receiv
explan
possibl
loss
fertil
due
treatment
cc
ttg
sacrific
fertil
exchang
cur
treatment
therefor
implic
inabl
children
said
cc
ttg
tri
sublim
scar
physic
believ
opportun
meet
fellow
cc
serv
support
cc
oscanoa
gutierrez
rebagliati
martin
lima
lima
peru
backgroundobject
cancer
diseas
high
incid
among
childrenadolesc
patient
need
caregiv
treatment
aim
evalu
emot
burden
qualiti
life
qol
caregiv
chemotherapi
relat
data
presenc
scale
depress
designmethod
studi
caregiv
emot
burden
caregiv
burden
scale
qol
data
collect
result
result
show
caregiv
mother
total
score
emot
burden
compromis
score
emot
aspect
vital
pain
signific
correl
emot
burden
mental
health
vital
conclus
caregiv
present
emot
burden
compromis
aspect
qol
need
intervent
promot
social
emot
wellb
reduc
emot
burden
improv
qualiti
life
qol
consequ
deliv
better
care
patient
chemotherapi
c
phillip
j
ts
unives
school
nurs
indianapoli
usa
univers
school
nurs
indianapoli
usa
univers
depart
biostatist
indianapoli
usa
backgroundobject
adolesc
young
adult
cancer
aya
experi
poor
sens
cancer
treatment
resili
posit
health
outcom
known
enhanc
peopl
face
advers
resili
ill
model
rim
theoret
model
guid
intervent
research
aya
explain
predictor
factor
enhanc
hinder
resili
exploratori
confirmatori
analys
indic
rim
risk
protect
factor
explain
high
level
varianc
resili
unknown
resili
influenc
studi
purpos
examin
relationship
five
rim
predictor
variabl
spiritu
perspect
courag
cope
mean
distress
defens
cope
determin
resili
mediat
rim
variabl
designmethod
data
two
studi
aya
age
use
mediat
model
use
path
model
mplu
use
result
four
rim
predictor
variabl
indic
signific
influenc
increas
level
spiritu
hope
led
greater
path
respect
increas
level
distress
defens
cope
result
wors
path
coeffici
resili
signific
mediat
four
rim
factor
spiritu
defens
cope
courag
cope
hope
play
signific
role
explain
varianc
resili
ill
index
increas
result
lower
resili
lower
conclus
spiritu
hope
distress
defens
cope
significantli
influenc
resili
signific
mediat
four
variabl
spiritu
hope
courag
cope
defens
cope
find
suggest
aya
enhanc
target
rim
factor
futur
intervent
h
queen
children
hospit
oncologypalli
care
birmingham
unit
kingdom
backgroundobject
aim
systemat
review
live
experi
young
peopl
cancer
base
patient
experi
identifi
factor
could
incorpor
adolesc
cancer
care
pathway
specif
focu
need
adolesc
designmethod
modifi
qualit
systemat
review
descript
qualit
research
methodolog
use
two
critic
apprais
tool
studi
met
inclusionexclus
criteria
result
result
themat
analysi
use
systemat
organis
find
four
theme
social
function
school
resili
loss
normal
educ
commun
result
show
persist
lower
score
reduc
cope
strategi
maintain
physic
emot
social
resili
reduc
qualiti
life
loss
normal
social
function
compar
healthi
peer
conclus
physic
emot
psycholog
social
resili
greatli
reduc
result
sens
loss
control
normal
lead
social
isol
chang
sens
self
percept
inabl
maintain
basic
need
activ
daili
live
deficit
literatur
highlight
need
qualit
studi
actual
live
experi
adolesc
order
achiev
social
interact
social
accept
emot
social
resili
compar
healthi
peer
group
research
assist
health
care
profession
provid
comprehens
approach
care
lead
reintegr
post
treatment
place
ill
health
go
parallel
care
plan
outset
treatment
throughout
care
long
term
follow
robust
care
pathway
n
rensen
l
h
g
r
van
univers
medic
center
pediatr
amsterdam
netherland
center
pediatr
oncolog
utrecht
netherland
medic
center
psychosoci
depart
amsterdam
netherland
medic
center
pediatr
amsterdam
netherland
univers
medic
center
ophthalmolog
amsterdam
netherland
backgroundobject
parent
children
cancer
risk
impair
qualiti
life
qol
import
determin
qol
sleep
howev
preval
parent
sleep
problem
associ
risk
factor
larg
unknown
studi
therefor
aim
explor
sleep
influenc
distress
child
characterist
sleep
designmethod
parent
children
cancer
complet
questionnair
sleep
medic
outcom
studi
sleep
scale
distress
distress
thermomet
parent
sleep
score
compar
popul
valu
healthi
adult
calcul
sd
popul
mean
consid
clinic
relev
risk
factor
impair
sleep
assess
multipl
linear
regress
model
stratifi
gender
child
clinic
variabl
test
predictor
well
parent
sociodemograph
variabl
distress
thermomet
score
signific
set
p
final
model
result
parent
n
mother
children
diagnosi
brain
tumor
solid
tumor
retinoblastoma
particip
mean
time
sinc
diagnosi
year
compar
popul
parent
report
clinic
relev
overal
sleep
problem
mother
versu
father
p
risk
factor
sleep
problem
parent
higher
distress
sleep
difficulti
addit
mother
child
retinoblastoma
risk
impair
sleep
risk
factor
explain
varianc
father
sleep
problem
mother
sleep
conclus
even
year
child
cancer
diagnosi
parent
experi
impair
sleep
particularli
risk
parent
higher
level
distress
target
distress
sleep
problem
may
inform
futur
intervent
aim
improv
parent
qol
e
robertson
r
c
p
n
g
r
f
children
hospit
kid
cancer
centr
randwick
australia
sydney
school
women
children
health
randwick
australia
sydney
univers
school
nurs
midwiferi
penrith
australia
wale
clinic
school
unsw
sydney
randwick
australia
hunter
children
hospit
oncolog
newcastl
australia
backgroundobject
process
enrol
child
cancer
earli
phase
trial
complex
examin
perspect
healthcar
profession
hcp
regard
obtain
inform
consent
earli
phase
trial
famili
children
cancer
designmethod
collect
data
hcp
work
paediatr
cancer
centr
across
australianew
zealand
questionnair
address
perceiv
benefit
earli
phase
trial
barrier
obtain
consent
inform
provis
also
examin
hcp
percept
parent
comprehens
prefer
inform
factor
influenc
result
hcp
averag
year
year
experi
paediatr
oncolog
hcp
receiv
formal
train
consent
earli
phase
trial
howev
will
attend
train
hcp
report
inform
famili
earli
phase
trial
without
attempt
influenc
decis
contradict
mani
also
report
slightli
direct
recommend
trial
hcp
main
obstacl
obtain
consent
includ
percept
parent
eager
tri
anyth
feel
respons
maintain
parent
hope
averag
hcp
perceiv
parent
understood
concept
dose
escal
likelihood
therapeut
benefit
hcp
report
usual
share
parent
treat
team
parent
decis
hcp
believ
children
involv
earli
phase
trial
discuss
year
median
decis
enrol
year
median
conclus
earli
phase
trial
import
part
improv
paediatr
cancer
therapi
studi
report
hcp
may
experi
difficulti
conduct
earli
phase
trial
consult
obtain
valid
inform
consent
studi
highlight
need
formal
train
hcp
addit
patient
educ
tool
e
robertson
c
r
j
children
hospit
kid
cancer
centr
randwick
australia
sydney
school
women
children
health
randwick
australia
backgroundobject
famili
often
find
decis
enrol
clinic
trial
difficult
develop
delta
onlin
support
famili
decid
particip
paediatr
oncolog
clinic
trial
delta
aim
improv
clinic
trial
knowledg
decis
satisfact
designmethod
guid
develop
delta
conduct
interview
parent
mean
age
child
whose
child
diagnos
cancer
past
follow
develop
delta
conduct
includ
interview
healthcar
profession
parent
result
interview
parent
describ
feel
overwhelm
inform
yet
still
enough
time
highlight
potenti
discrep
inform
provis
comprehens
parent
access
addit
inform
help
make
decis
includ
onlin
parent
prefer
involv
decis
process
often
felt
nt
choic
parent
emphasis
benefit
base
interview
develop
delta
websit
particip
report
content
easi
read
show
particip
read
line
complet
suggest
engag
content
particip
report
minor
navig
difficulti
particip
found
decis
exercis
use
suggest
need
make
instruct
obviou
overal
particip
report
delta
high
accept
good
usabl
conclus
famili
requir
clearer
inform
provid
multipl
modal
guidanc
engag
emot
support
throughout
decis
process
interview
find
contribut
develop
delta
innov
tool
provid
access
balanc
inform
famili
provid
posit
feedback
request
chang
implement
current
conduct
pilot
delta
earli
pilot
data
suggest
delta
significantli
improv
parent
clinic
trial
knowledg
h
saeed
r
muhammad
jave
khanum
memori
cancer
hospit
research
center
pediatr
oncolog
lahor
pakistan
backgroundobject
knowledg
attitud
practic
kap
cancer
key
factor
success
cancer
treatment
approach
cancer
treatment
determin
local
belief
practic
kap
caregiv
pediatr
cancer
patient
studi
pakistan
thu
conduct
qualit
review
kap
caregiv
pediatr
cancer
patient
designmethod
studi
done
tertiari
care
cancer
hospit
pakistan
shaukat
khanum
hospit
februari
august
uniqu
questionnair
design
accord
local
cultur
religi
belief
practic
sampl
done
opportunist
interview
conduct
urdu
languag
interview
last
minut
interview
tool
content
analyz
discuss
author
identifi
relev
categori
result
caregiv
interview
caregiv
newli
diagnos
patient
parent
caregiv
ask
cancer
repli
danger
diseas
know
remain
consid
worsen
wound
infect
lump
form
diseas
ask
caus
cancer
major
know
eight
consid
ill
fate
destini
god
major
caregiv
consid
cancer
curabl
consid
cancer
contagi
express
fear
rest
famili
state
expect
patient
normal
futur
major
caregiv
use
spiritu
healer
either
prior
treatment
none
awar
screen
cancer
conclus
studi
identifi
mutlipl
caregiv
stressor
erron
belief
regard
food
restrict
etiolog
cancer
find
help
target
specif
issu
counsel
educ
caregiv
serv
pilot
studi
design
intervent
studi
kap
region
c
salaverria
castillo
r
vasquez
cg
children
hospit
benjamin
bloom
pediatr
san
salvador
el
salvador
children
hospit
benjamin
bloom
psycholog
san
salvador
el
salvador
tennesse
usa
backgroundobject
el
salvador
establish
nation
law
comprehens
protect
children
known
lepina
law
integr
protect
children
adolesc
lepina
includ
stipul
medic
team
instruct
must
follow
child
requir
treatment
condit
potenti
statejudici
enforc
polici
analysi
illustr
consider
frontlin
provid
implement
nation
legal
intervent
provis
health
right
countri
implic
childhood
cancer
control
designmethod
data
process
outcom
lepina
implement
prospect
captur
electron
patient
track
system
record
hospit
benjamin
bloom
hbb
nation
pediatr
referr
hospit
retrospect
analyz
polici
triangl
framework
util
consid
central
polici
actor
relationship
polici
context
content
process
result
lepina
law
operation
new
nation
council
children
adolesc
conna
psychosoci
team
member
central
connect
legal
state
provid
commun
lepina
could
appli
facilit
treatment
complet
children
curabl
cancer
children
diagnos
cancer
start
june
lepina
becam
integr
routin
counsel
abandon
prevent
subset
children
curabl
cancer
identifi
treatment
abandon
requir
counsel
potenti
applic
lepina
law
patient
requir
escal
engag
involv
legal
author
complet
treatment
success
median
month
patient
still
abandon
treatment
howev
abandon
reduc
last
seven
year
conclus
divers
actor
affect
effect
polici
implement
nation
law
may
appli
facilit
time
treatment
complet
cancer
addit
work
warrant
character
implic
implement
need
legal
intervent
nm
sari
n
l
hematolog
oncolog
child
health
depart
dr
hasan
sadikin
hospitalfaculti
medicin
universita
padjadjaran
bandung
indonesia
backgroundobject
pediatr
cancer
treatment
especi
limit
incom
countri
face
mani
obstacl
increas
number
patient
accompani
acceler
pediatr
oncolog
diagnost
nevertheless
support
care
facil
thu
result
high
rate
interrupt
abandon
treatment
respect
hospit
commun
concern
pediatr
cancer
bolt
fast
last
year
character
establish
cancer
chariti
hous
cch
object
studi
describ
understand
impact
cch
abandon
treatment
acut
lymphoblast
leukemia
patient
designmethod
mix
method
cross
section
studi
dr
hasan
sadikin
hospit
bandung
west
java
indonesia
data
collect
observ
depth
interview
use
structur
interview
guid
complet
staff
cch
parent
pediatr
oncolog
resid
data
parent
classifi
interrupt
abandon
treatment
group
demograph
patient
data
extract
bandung
onlin
cancer
registri
qualit
data
analysi
satur
method
chi
squre
test
quantit
data
result
four
cch
locat
dr
hasan
sadikin
hospit
name
rumah
kita
rumah
cinta
rumah
harapan
rumah
teduh
bed
capac
initi
parent
support
group
establish
chariti
foundat
support
almost
oper
expens
incident
program
obtain
donat
use
social
media
gain
activ
cch
includ
provid
home
stay
meal
home
school
transport
drug
donat
field
trip
preval
abandon
treatment
time
higher
patient
nt
use
cch
statist
insignific
rp
ci
conclus
role
chariti
hous
pediatr
cancer
manag
promis
decreas
abandon
treatment
sata
childhood
cancer
foundat
oper
lusaka
zambia
backgroundobject
african
set
extens
display
emot
encourag
get
life
event
counsel
avail
one
expect
mourn
period
move
life
per
usual
keep
line
confer
theme
need
find
new
solut
deal
trauma
childhood
cancer
bring
entir
famili
seek
fresh
way
introducingtransform
psychosoci
care
avail
achiev
better
result
round
main
object
abstract
share
find
long
last
solut
better
qualiti
life
parent
survivor
andor
bereav
parent
sibl
designmethod
parent
cancer
riddl
child
exhibit
variou
neg
emot
add
emot
fatigu
result
hypertens
pressur
hospit
domest
respons
addit
strain
financi
expect
mother
die
hypertens
nurs
child
suffer
cancer
relationship
experi
sever
strain
time
absenc
partner
lead
infidel
other
end
exchang
sex
money
pregnanc
singl
mother
marri
men
case
point
case
divorc
rise
sibl
depriv
famili
time
result
feel
neglect
due
attent
sick
sibl
sibl
educ
may
affect
neg
variou
neg
emot
may
also
play
havoc
sibl
result
resourc
stretch
famili
way
life
adjust
necess
consid
conclus
peopl
involv
journey
go
variou
emot
support
mani
way
commun
intervent
employ
sector
approach
engag
variou
stakehold
quest
mitig
childhood
cancer
relat
blood
disord
n
schneider
b
colleg
medicinetexa
children
hospit
pediatr
houston
usa
univers
medic
center
psychiatri
new
york
usa
colleg
medicin
emerg
medicin
houston
usa
backgroundobject
cancer
care
improv
understand
children
cancer
risk
psycholog
distress
american
academi
pediatr
highlight
import
address
concern
studi
aim
identifi
cultur
languag
factor
may
influenc
whether
psycholog
involv
patient
famili
care
preliminari
literatur
research
suggest
vast
major
refer
psycholog
english
speak
designmethod
medic
record
pediatr
patient
die
cancer
complic
consecut
examin
via
retrospect
chart
review
patient
demograph
inform
collect
along
inform
whether
medic
team
request
psycholog
consult
detail
consult
subsequ
intervent
collect
result
chart
review
patient
rang
age
month
year
data
indic
speak
famili
refer
psycholog
nearli
half
rate
famili
ie
patient
compar
patient
appear
statist
signific
differ
refer
group
asid
famili
primari
languag
wide
rang
patient
refer
day
death
conclus
result
indic
though
comprehens
care
children
wide
recogn
import
clear
dispar
servic
offer
famili
speak
languag
english
research
conduct
understand
referr
barrier
miss
opportun
util
pediatr
psycholog
particularli
hospit
unit
state
continu
diversifi
final
offer
provid
educ
identifi
common
psycholog
concern
particularli
hail
differ
cultur
background
may
particularli
valuabl
close
identifi
referr
gap
poster
make
recommend
train
ds
sharma
n
medic
colleg
attach
hospit
jaipur
radiotherapi
jaipur
india
jaipur
medic
oncolog
jaipur
india
backgroundobject
cancer
treatment
one
paediatr
medicin
biggest
success
stori
chemotherapi
radiat
therapi
last
damag
child
develop
bodi
incumb
upon
oncologist
conceiv
paediatr
malign
diseas
begin
diagnosi
end
treatment
protocol
end
instead
initi
trajectori
surviv
implic
qualiti
life
designmethod
emot
need
deepli
frustrat
children
due
long
hospit
strong
parent
bond
jeopard
normal
develop
autonomi
independ
friend
pain
test
anxieti
anguish
hour
loneli
without
tender
critic
suspens
normal
life
shift
emerg
surviv
complic
attain
satisfi
sexual
ident
disrupt
basic
psychosexu
matur
process
result
adolesc
sexual
complex
even
seriou
advers
event
like
cancer
affect
individu
sexual
dimens
young
survivor
significantli
differ
specif
domain
less
feminin
sexual
ident
restrict
submiss
imag
sexual
lower
confid
masturb
less
experi
intercours
effect
better
understood
put
perspect
mani
chang
challeng
young
cancer
survivor
face
cope
differ
emot
affect
relat
cultur
existenti
domain
cultur
issu
sexual
polit
asian
societi
myth
children
young
interest
sexual
presumpt
issu
surviv
overshadow
sexual
provid
barrier
open
commun
sexual
conclus
sexual
function
fertil
longer
regard
oncologist
frivol
irrelev
issu
privileg
relationship
oncologist
patient
permit
assist
children
journey
cancer
manag
mn
sitaresmi
bw
public
health
universita
gadjah
mada
dr
sardjito
hospit
paediatr
depart
yogyakarta
indonesia
backgroundobject
qualiti
life
hrqol
adolesc
cancer
may
affect
diseas
treatment
aim
studi
assess
profil
hrqol
adolesc
cancer
assess
influenc
demograph
medic
characterist
hrqol
score
designmethod
method
conduct
cross
section
studi
hrqol
dr
sardjito
gener
hospit
yogyakarta
indonesia
june
novemb
adolesc
cancer
patient
year
old
guardian
variou
phase
treatment
recruit
hrqol
assess
use
pedsql
gener
modul
cancer
modul
indonesian
valid
version
result
adolesc
guardian
recruit
intern
valid
scale
good
cronbach
alpha
coeffici
rang
well
intern
correl
report
icc
patient
guardian
report
low
score
school
function
subscal
compar
boy
femal
adolesc
patient
report
lower
score
emot
function
subscal
vs
p
late
adolesc
report
lower
score
earli
adolesc
especi
total
score
scale
emot
subscal
worri
subscal
guardian
malign
patient
report
lower
score
hematolog
malign
patient
physic
function
vs
p
social
function
vs
p
function
vs
p
conclus
late
adolesc
problem
gener
cancer
scale
psychosoci
support
provid
famili
peer
group
facilit
cope
diseas
treatment
school
substitut
offer
adolesc
treatment
stepanova
g
n
state
medic
univers
pediatr
oncolog
voronezh
russia
children
hospit
pediatr
oncolog
voronezh
russia
state
medic
univers
pediatr
voronezh
russia
backgroundobject
present
time
problem
organ
manag
profession
abil
work
team
come
current
interest
fore
research
psychosoci
aspect
medic
team
oncologicalhematolog
medic
care
carri
purpos
evalu
psycholog
paramet
medic
team
readi
stabl
profession
activ
designmethod
psycholog
featur
medic
team
children
oncohematolog
depart
voronezh
region
hospit
period
studi
sixteen
physician
examin
women
men
age
year
experi
joint
work
year
women
age
year
experi
year
analysi
psycholog
paramet
format
medic
team
standard
use
well
test
group
role
assess
control
effici
work
quantit
indic
determin
sum
score
paramet
result
accord
standard
map
psycholog
paramet
collect
direct
activ
studi
organiz
uniti
psycholog
uniti
aid
research
shown
team
well
develop
kind
psycholog
uniti
intellectu
emot
strong
will
assess
manag
effect
team
group
role
test
conduct
use
questionnair
specif
section
conclus
accord
research
doctor
children
oncohematolog
depart
repres
form
collect
singl
strategi
character
high
level
activ
psycholog
uniti
organ
depart
expedi
distribut
role
perform
member
collect
complement
reveal
correl
role
collect
promot
effect
profession
activ
stern
j
south
florida
child
famili
studi
tampa
usa
commonwealth
univers
psycholog
richmond
usa
backgroundobject
obes
rate
pediatr
cancer
survivor
pc
alarmingli
high
result
random
control
pilot
trial
aim
improv
healthi
lifestyl
found
posit
effect
parent
pc
bmi
dietari
intak
physic
activ
intervent
particip
retent
concern
studi
explor
potenti
factor
associ
particip
retent
context
pilot
find
designmethod
total
parent
elig
pc
random
either
intervent
enhanc
usual
care
euc
session
addit
provid
baselin
data
particip
either
condit
post
assess
contact
group
assess
conduct
baselin
result
averag
pc
year
old
year
lymphoma
mean
baselin
child
bmi
ile
baselin
differ
pc
bmi
ile
diagnosi
significantli
higher
among
contact
group
parent
complet
either
euc
overal
parent
attend
least
session
gener
speak
lower
annual
incom
associ
fewer
complet
session
sever
factor
associ
complet
assess
famili
older
parent
older
pc
femal
pc
like
continu
particip
assess
p
howev
time
relat
assess
complet
higher
child
baselin
bmi
ile
also
relat
lower
assess
complet
mean
child
bmi
ile
among
parent
complet
baselin
assess
among
parent
complet
baselin
post
assess
among
parent
complet
three
assess
conclus
result
suggest
pc
gender
age
bmi
diagnosi
key
factor
consid
design
behavior
intervent
pc
famili
implic
intervent
strategi
measur
consider
discuss
l
steur
n
van
van
der
n
c
van
den
w
g
r
van
univers
medic
center
depart
pediatr
oncolog
amsterdam
netherland
center
pediatr
oncolog
utrecht
netherland
children
hospit
academ
medic
center
psychosoci
depart
amsterdam
netherland
medic
center
sophia
children
hospit
depart
pediatr
rotterdam
netherland
children
hospit
radboud
univers
medic
center
depart
pediatr
oncolog
nijmegen
netherland
children
hospit
academ
medic
center
depart
pediatr
oncolog
amsterdam
netherland
medic
center
groningen
depart
pediatr
oncolog
groningen
netherland
childhood
oncolog
group
pediatr
oncolog
hagu
netherland
backgroundobject
sleep
problem
common
childhood
cancer
glucocorticoid
treatment
seem
risk
factor
current
evid
limit
small
sampl
size
heterogen
treatment
group
addit
studi
combin
object
subject
assess
although
provid
valuabl
complementari
inform
studi
evalu
effect
dexamethason
treatment
object
subject
sleep
homogen
cohort
children
acut
lymphoblast
leukemia
designmethod
sleep
studi
nation
prospect
studi
sleep
children
treat
accord
dutch
childhood
oncolog
group
treatment
guidelin
one
year
children
treat
cyclic
dexamethason
dex
assess
twice
measur
consist
object
sleep
assess
acceleromet
actigraph
subject
sleep
assess
children
sleep
habit
questionnair
cshq
cshq
calcul
base
dutch
norm
score
differ
evalu
use
multilevel
analysi
effect
sleep
problem
comorbid
age
sex
pain
evalu
result
cshq
score
avail
patient
actigraphi
mean
age
year
girl
preval
sleep
problem
versu
norm
mean
cshq
significantli
higher
compar
ci
signific
differ
object
sleep
outcom
conclus
preval
sleep
problem
high
mainten
treatment
cyclic
dexamethason
sleep
problem
significantli
higher
actigraph
outcom
similar
result
suggest
dex
treatment
higher
sleep
problem
burden
perceiv
parent
stress
import
support
famili
cope
dex
effect
futur
studi
includ
sleep
determin
burden
experienc
patient
c
strahlendorf
children
hospit
divis
hemoncbmt
vancouv
canada
backgroundobject
pediatrician
recogn
import
social
emot
development
domain
care
treatment
patient
studi
evok
humanist
approach
facilit
narr
qualit
methodolog
explor
theme
spiritu
hope
core
enabl
resili
adolesc
undergo
cancer
therapi
diagnosi
cancer
frame
mean
life
treatment
cancer
result
loss
hair
bodi
part
also
digniti
adolesc
cling
midst
treat
cancer
consequ
experi
uncertainti
loss
designmethod
qualit
studi
explor
narr
adolesc
face
cancer
find
mean
live
factor
facilit
resili
cope
treatment
fear
death
interpret
descript
use
analys
data
result
thirteen
adolesc
patient
interview
even
though
buffet
ill
express
live
hope
get
better
although
mani
dimens
contribut
resili
studi
focus
primarili
domain
hope
spiritu
five
domain
identifi
highlight
intern
strength
extern
support
play
import
role
resili
youth
realiti
adolesc
stage
life
child
evolv
cognit
moral
self
evolv
consid
theme
emerg
redefin
relationship
parent
friend
threaten
social
network
arrest
normal
develop
spiritu
optim
conclus
patient
share
insight
live
ill
suffer
clinician
learn
studi
help
us
better
understand
adolesc
ill
take
away
health
care
provid
holist
respond
f
fb
univers
faculti
health
depart
physiotherapi
rehabilit
turkey
medipol
univers
faculti
health
depart
physiotherapi
rehabilit
turkey
univers
faculti
depart
child
oncolog
turkey
backgroundobject
pilot
studi
focus
nintendo
wii
train
children
brain
tumor
paper
describ
virtual
realiti
exercgam
oncolog
rehabilit
function
aim
studi
investig
effect
virtual
realiti
exergam
function
children
brain
tumor
designmethod
children
nintendo
wii
train
week
x
daysweek
x
minutessess
trane
includ
differ
game
soccer
head
ski
jump
penguin
slide
ski
slalom
balanc
bubbl
pre
post
measur
collect
outcom
measur
dempgraph
characterist
physic
clinic
measur
evalu
function
game
score
record
descript
correl
statist
use
result
five
girl
boy
children
nintendo
wii
train
mean
age
year
height
meter
wieght
kg
number
chemotherapi
cure
number
radiotherapi
session
surgeon
age
year
number
nintendo
wii
train
session
found
statistici
signific
relationship
number
nintendo
wii
session
age
height
surgeri
age
score
game
improv
hundr
percent
conclus
children
report
nintendo
wii
train
complianc
consist
posit
respons
motiv
feasibl
question
therefor
nintendo
wii
train
may
effect
rehabilit
strategi
worth
explor
larger
trial
implic
nintendo
wii
train
context
motiv
theori
discuss
goal
virtual
exergam
rehabilit
provid
support
return
normal
life
possibl
l
teo
lingen
women
children
hospit
psycholog
servic
singapor
singapor
backgroundobject
children
diagnos
cancer
singapor
year
enorm
impact
famili
experi
child
survivor
parent
well
document
western
literatur
much
less
well
understood
within
asian
context
studi
sought
explor
experi
singaporean
parent
child
cancer
survivor
studi
part
larger
project
explor
impact
childhood
cancer
singapor
designmethod
parent
survivor
invit
particip
focu
group
discuss
local
childhood
cancer
chariti
time
sinc
diagnosi
rang
year
parent
four
mother
one
father
two
survivor
male
consent
particip
identifi
ethnic
either
singaporean
chines
singaporean
malay
result
discuss
transcrib
verbatim
code
analys
use
themat
analysi
result
two
major
theme
emerg
parent
financi
strain
emot
impact
contain
two
manag
uncertainti
trauma
loss
two
major
theme
identifi
parent
child
discuss
import
hope
educ
concern
conclus
studi
found
common
cope
experi
western
singaporean
cultur
add
knowledg
regard
financi
strain
educ
concern
within
singaporean
context
highlight
need
practic
emot
support
parent
survivor
thompson
nation
health
system
center
cancer
blood
disord
washington
dc
usa
backgroundobject
nonadher
treatment
recommend
common
problem
among
adolesc
young
adult
cancer
frustrat
provid
understand
potenti
consequ
miss
medic
procedur
appoint
challeng
exacerb
patient
reach
age
legal
adulthood
age
us
gain
respons
care
make
treatment
decis
may
neg
affect
health
designmethod
case
studi
present
illustr
clinic
legal
ethic
challeng
young
adult
treat
pediatr
facil
nonadher
treatment
recommend
ur
hispan
male
histori
acut
myeloid
leukemia
sp
haploident
bone
marrow
transplant
although
remiss
requir
ongo
monitor
treatment
signific
graft
versu
host
diseas
infect
ur
symptom
exacerb
nonadher
medic
treatment
recommend
ongo
substanc
use
failur
show
direct
uniqu
perspect
offer
examin
case
dynam
clinic
team
concern
includ
patient
physic
emot
fear
ur
stop
treatment
altogeth
transit
adult
provid
person
emot
invest
patient
legal
concern
center
potenti
risk
hospit
patient
unlik
follow
transit
lack
could
implic
ethic
issu
regard
permiss
recommend
transit
also
discuss
result
number
attempt
intervent
patient
ongo
support
medic
team
consult
hospit
resourc
ur
transit
adult
facil
conclus
young
adult
patient
pediatr
facil
present
numer
uniqu
challeng
especi
nonadher
treatment
recommend
multidisciplinari
care
input
critic
evalu
cours
action
appropri
team
hospit
patient
tremolada
l
g
mc
g
padua
depart
development
social
depart
child
woman
oncolog
hematolog
divis
padua
itali
padua
depart
development
social
psycholog
padua
itali
univers
faculti
educ
itali
padua
depart
child
woman
oncolog
hematolog
divis
padua
itali
backgroundobject
parent
appear
risk
stress
symptomatolog
ptss
tremolada
et
al
acut
phase
leukemia
treatment
predict
risk
factor
ptss
younger
age
femal
gender
rodriguez
et
al
boman
et
al
lower
econom
condit
jurberg
et
al
difficult
past
life
stress
episod
cloitr
al
emot
cope
barrera
et
al
tremolada
et
al
partner
support
unavail
sloper
object
studi
screen
ptss
sever
identifi
possibl
predictor
ptss
parent
designmethod
seven
italian
parent
gave
consent
studi
mostli
mother
mean
age
year
sd
children
mean
age
year
sd
mostli
diagnosi
acut
lymphoblast
leukemia
follow
acut
myeloid
leukemia
parent
interview
one
week
diagnosi
commun
tremolada
et
al
fill
ladder
life
questionnair
day
ptss
checklist
result
parent
show
larg
mark
sever
ptss
symptom
follow
moder
sever
symptom
absenc
evid
symptomatolog
symptom
confirm
model
good
fit
index
df
rmsea
show
parent
direct
effect
ptss
intrus
effect
p
ptss
somat
effect
p
coupl
connected
predict
ptss
avoid
effect
p
futur
life
percept
influenc
intrus
symptom
effect
p
conclus
ptss
prevent
screen
risk
factor
identif
could
allow
set
specif
psycholog
intervent
parent
help
parent
activ
g
tseytlin
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
ministri
russia
social
psycholog
rehabilit
moscow
russia
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
ministri
russia
director
moscow
russia
rogachev
nation
medic
research
center
pediatr
oncolog
immunolog
ministri
russia
deputi
director
moscow
russia
center
qualiti
life
coordin
scientif
program
oncolog
saint
petersburg
russia
center
qualiti
life
chief
saint
petersburg
russia
backgroundobject
goal
rehabilit
pediatr
oncolog
improv
qualiti
life
qol
survivor
parent
therefor
import
carri
monitor
qol
cancer
children
parent
purpos
assess
qol
children
brain
tumor
bt
parent
treatment
designmethod
bt
survivor
yo
yo
boy
parent
yo
mother
studi
mean
time
treatment
tat
month
children
fill
pediatr
qualiti
life
inventori
pedsql
parent
rand
result
qol
bt
survivor
significantli
lower
healthi
children
p
import
find
investig
qol
bt
survivor
goe
increas
tat
wherea
survivor
qol
posit
correl
tat
accord
parent
evalu
qol
children
lower
report
children
scale
pedsql
except
emot
function
parent
bt
survivor
tend
exagger
physic
social
underestim
emot
problem
children
import
intervent
would
focu
establish
emot
contact
dyad
import
find
investig
qol
parent
bt
survivor
significantli
lower
parent
survivor
find
show
major
distress
case
bt
requir
earli
intervent
support
conclus
qol
monitor
import
support
children
bt
parent
process
treatment
b
vaarwerk
p
h
children
hospitalacadem
medic
centr
depart
paediatr
oncolog
amsterdam
netherland
children
hospitalacadem
medic
centr
paediatr
psychosoci
depart
amsterdam
netherland
centr
paediatr
oncolog
solid
tumour
depart
utrecht
netherland
centr
paediatr
oncolog
psychosoci
research
utrecht
netherland
backgroundobject
patient
treat
ewe
sarcoma
es
rhabdomyosarcoma
rm
subject
extens
surveil
complet
therapi
aim
surveil
monitor
treatment
relat
advers
effect
detect
relaps
earli
phase
improv
prognosi
relaps
clinic
valu
surveil
imag
detect
relaps
current
assess
sever
studi
experi
parent
surveil
receiv
less
attent
therefor
assess
view
experi
parent
children
treat
es
rm
examin
surveil
designmethod
qualit
studi
conduct
focu
group
fg
parent
children
treat
es
rm
dutch
paediatr
oncolog
centr
invit
via
parent
childhood
cancer
societi
children
year
complet
therapi
addit
conduct
telephon
interview
parent
particip
fg
meet
person
organiz
reason
fg
meet
interview
transcrib
verbatim
induct
themat
approach
use
analys
data
carri
three
author
result
twelv
parent
patient
treat
es
rm
share
view
examin
surveil
parent
well
awar
recommend
imag
describ
treatment
protocol
identifi
theme
examin
cover
stressanxieti
influenc
time
sinc
schedul
imag
age
child
search
hopesupport
found
routin
imag
strict
arrang
visit
discuss
result
eg
interact
childpartn
interact
sibl
conclus
studi
provid
import
insight
experi
parent
surveil
could
contribut
improv
parent
support
period
generaliz
result
assess
compar
studi
countri
weidman
r
j
hospit
sick
children
hematologyoncolog
toronto
canada
margaret
cancer
centr
uhn
librari
inform
servic
toronto
canada
margaret
cancer
center
depart
support
care
toronto
canada
backgroundobject
one
third
new
cancer
diagnos
pediatr
hospit
occur
adolesc
young
adult
aya
age
year
set
uniqu
psychosoci
need
aya
cancer
ayawc
may
consist
identifi
adequ
address
possibl
impact
qualiti
life
sequela
embark
multiphas
project
approach
improv
care
deliveri
qualiti
life
ayawc
center
designmethod
first
qualiti
improv
project
conduct
identifi
need
ayawc
ayawc
age
year
interview
ask
experi
lack
current
system
second
environment
scan
conduct
aya
cancer
program
global
exist
social
media
applic
ayawc
third
scope
review
four
electron
databas
current
underway
use
arksey
omalley
framework
understand
util
impact
health
relat
social
media
use
ayawc
fourth
patient
need
understood
social
media
tool
develop
evalu
result
need
assess
reveal
unanim
desir
connect
ayawc
patient
request
onlin
resourc
social
network
environment
scan
uncov
mani
support
program
ayawc
major
within
adult
hospit
target
older
aya
opportun
ayawc
peer
support
pediatr
cancer
center
canada
lack
two
peer
support
social
media
applic
exist
ayawc
one
inaccess
canada
social
media
use
among
popul
nearli
univers
mani
benefit
howev
area
inadequ
understood
defici
inform
preliminari
scope
review
result
demonstr
relev
articl
formal
result
pend
conclus
institut
may
specif
need
local
popul
invest
program
import
understand
patient
need
systemat
approach
tool
develop
implement
k
westmoreland
van
der
p
p
n
b
project
malawi
cancer
program
lilongw
malawi
north
carolina
pediatr
chapel
hill
usa
north
carolina
intern
medicin
palli
care
chapel
hill
usa
north
carolina
school
medicin
chapel
hill
usa
colleg
medicin
children
foundat
malawi
cancer
program
lilongw
malawi
cancer
program
lilongw
malawi
children
hospit
pediatr
hematolog
oncolog
houston
usa
univers
popul
health
scienc
durham
usa
project
malawi
cancer
program
director
lilongw
malawi
colleg
medicin
medic
oncolog
blantyr
malawi
north
carolina
medic
oncolog
infecti
diseas
chapel
hill
usa
backgroundobject
outcom
measur
inform
system
pediatr
questionnair
translat
valid
malawi
describ
qualiti
life
hrqol
pediatr
lymphoma
patient
baselin
treatment
designmethod
questionnair
administ
patient
lilongw
particip
report
hrqol
domain
mobil
anxieti
depress
fatigu
peer
relationship
pain
interfer
answer
question
item
per
domain
use
likert
scale
pain
intens
question
score
domain
transform
mean
standard
deviat
base
promi
refer
sampl
result
questionnair
administ
diagnosi
activ
chemotherapi
treatment
median
day
sinc
diagnosi
iqr
median
age
year
iqr
male
diagnosi
children
report
poor
hrqol
improv
treatment
low
level
mobil
median
iqr
improv
averag
median
iqr
p
high
anxieti
median
iqr
improv
averag
median
iqr
p
high
depress
symptom
median
iqr
improv
averag
median
p
high
fatigu
median
iqr
improv
averag
median
iqr
p
averag
satisfact
peer
relationship
median
remain
stabl
median
iqr
high
pain
interfer
median
improv
averag
median
iqr
p
highest
score
pain
intens
given
patient
diagnosi
subsequ
treatment
conclus
hrqol
pediatr
lymphoma
patient
diagnosi
malawi
poor
across
variou
domain
improv
treatment
valid
method
assess
hrqol
time
among
children
cancer
essenti
set
comprehens
understand
effect
cancer
treatment
children
live
l
wiener
zadeh
h
k
c
ka
noronha
ferraz
de
arruda
cancer
center
cancer
nation
institut
health
pediatr
oncolog
branch
bethesda
usa
children
adolesc
young
adult
aya
cancer
program
irvin
usa
farber
cancer
institut
adolesc
young
adult
aya
cancer
program
boston
usa
children
medic
center
adolesc
young
adult
oncolog
program
fort
worth
usa
nation
medic
center
center
translat
sciencechildren
research
institut
dc
usa
cancer
center
support
care
medicin
tampa
usa
institut
mental
nation
institut
health
offic
director
bethesda
usa
backgroundobject
discuss
eol
care
challeng
adolesc
young
adult
aya
live
cancer
mani
help
document
exist
facilit
eol
convers
adult
resourc
exist
aid
aya
commun
prefer
care
live
want
rememb
death
research
complet
nation
cancer
institut
nih
led
develop
advanc
care
plan
acp
guid
voic
vmc
object
studi
determin
perceiv
help
vmc
whether
revis
need
whether
engag
acp
use
vmc
associ
reduc
anxieti
andor
improv
commun
acp
famili
designmethod
aya
age
nci
definit
aya
complet
baselin
assess
anxieti
commun
particip
review
vmc
rate
help
stress
chang
need
page
complet
page
document
assess
anxieti
commun
repeat
month
later
result
nineti
aya
particip
baselin
follow
percent
previous
discuss
wishesprefer
eol
care
famili
baselin
share
wrote
vmc
initi
convers
baselin
discuss
written
vmc
among
convers
specif
barrier
identifi
report
vmc
question
somewhat
helpfulhelpfulveri
help
sever
chang
suggest
includ
remembr
social
media
gener
anxieti
anxieti
around
end
life
plan
decreas
significantli
p
baselin
follow
conclus
introduc
development
appropri
acp
guid
facilit
eol
discuss
aya
famili
member
data
suggest
discuss
lead
reduc
gener
anxieti
anxieti
specif
eol
plan
h
wiman
j
h
g
l
von
univers
women
children
health
uppsala
sweden
backgroundobject
subgroup
adolesc
young
adult
diagnos
cancer
adolesc
report
elev
level
anxieti
depress
symptom
unmet
need
psycholog
support
psycholog
treatment
tailor
popul
lack
studi
examin
feasibl
guid
programm
youngcan
primarili
target
symptom
anxieti
depress
among
young
person
diagnos
cancer
adolesc
designmethod
studi
uncontrol
feasibl
trial
design
potenti
particip
age
year
diagnos
cancer
adolesc
identifi
via
swedish
childhood
cancer
registri
particip
receiv
youngcan
programm
base
primarili
cognit
behaviour
therapi
particip
individu
assign
modul
target
depress
symptom
worri
anxieti
bodi
dissatisfact
stress
interact
peer
support
psychoeduc
function
also
avail
result
total
potenti
particip
identifi
six
particip
alloc
programm
result
overal
particip
rate
addit
studi
experienc
high
level
attrit
conclus
due
low
recruit
high
attrit
possibl
deem
intervent
andor
studi
procedur
feasibl
potenti
reason
may
young
person
live
experi
cancer
adolesc
involv
develop
intervent
andor
studi
procedur
gender
issu
consid
appropri
recruit
procedur
utilis
yamada
r
k
k
effect
research
foundat
depart
clinic
studi
hiroshima
japan
arkansa
medic
scienc
depart
biostatist
littl
arkansa
usa
effect
research
foundat
depart
clinic
studi
nagasaki
japan
jude
children
hospit
depart
epidemiolog
cancer
tennesse
usa
backgroundobject
object
studi
examin
effect
atom
bomb
radiat
demograph
variabl
subject
neurocognit
function
use
japanes
version
neurocognit
questionnair
ncq
among
survivor
expos
atom
bomb
year
old
younger
ncq
measur
subject
neurocognit
function
develop
investig
effect
therapi
includ
radiotherapi
childhood
cancer
survivor
studi
use
ncq
asian
report
designmethod
ncq
administ
part
adult
health
studi
radiat
effect
research
foundat
examin
radiat
effect
atom
bomb
exploratori
factor
analysi
conduct
ncq
item
particip
mean
age
year
old
complet
question
effect
radiat
dose
demograph
variabl
identifi
ncq
factor
examin
among
survivor
expos
atom
bomb
age
year
control
use
linear
mix
model
result
four
factor
repres
item
identifi
label
metacognit
emot
regul
motivationorgan
process
speed
linear
deterior
age
observ
factor
p
lower
educ
suggest
associ
problem
metacognit
process
speed
women
show
deterior
motivationorgan
process
speed
p
signific
deterior
effect
radiat
shown
motivationorgan
adjust
demograph
factor
size
effect
small
conclus
japanes
version
ncq
sensit
demograph
variabl
known
impact
report
subject
cognit
function
exposur
environment
radiat
associ
motivationorgan
problem
though
object
cognit
function
requir
confirm
valid
ncq
gm
afungchwi
r
baptist
hospit
pediatr
oncolog
kumbo
cameroon
children
hospit
pediatr
oncolog
leed
unit
kingdom
backgroundobject
cameroon
baptist
convent
health
servic
oper
childhood
cancer
center
three
rural
hospit
cameroon
baselin
standard
siop
podc
nurs
group
recommend
formal
nurs
orient
programm
theori
skill
train
aim
project
establish
pediatr
oncolog
nurs
induct
programm
meet
standard
designmethod
programm
develop
follow
need
analysi
undertaken
local
nurs
team
consist
two
theori
base
workshop
follow
month
observ
clinic
skill
acquisit
led
expert
nurs
leed
children
hospit
local
lead
nurs
first
workshop
cover
cancer
treatment
support
care
profession
issu
second
workshop
cover
outcom
treatment
survivorship
palli
care
profession
issu
core
compet
develop
specif
compet
chemotherapi
administr
check
list
develop
valid
compet
peer
evalu
moder
lead
pediatr
oncolog
nurs
result
fifteen
nurs
current
train
first
workshop
held
novemb
averag
rate
workshop
structur
content
particip
likert
scale
grade
assign
submiss
april
includ
case
studi
child
commonli
seen
cancer
present
cancer
treatment
polici
nurs
procedur
second
workshop
held
may
grade
assign
submiss
octob
includ
case
studi
elev
speech
nurs
advocaci
research
propos
nurs
care
relat
topic
conclus
siop
podc
baselin
standard
recommend
formal
orient
programm
pediatr
oncolog
nurs
twin
partnership
facilit
develop
train
programm
nurs
low
middl
incom
countri
respond
local
need
carlsson
medicin
univers
univers
health
care
research
center
sweden
univers
faculti
scienc
depart
health
nurs
karlstad
sweden
backgroundobject
concept
fear
defin
unpleas
often
strong
emot
caus
expect
danger
reason
believ
fear
cope
fear
vari
cours
treatment
aim
present
studi
describ
longitudin
perspect
fear
relat
base
children
perspect
well
describ
strategi
children
use
experienc
fear
designmethod
studi
longitudin
descript
qualit
design
three
girl
boy
initi
age
interview
three
time
treatment
period
approxim
two
month
diagnosi
one
year
end
long
treatment
total
interview
conduct
data
analyz
use
qualit
analysi
method
result
children
describ
fear
subject
needl
relat
feed
tube
remov
adhes
tape
take
tablet
well
fear
relat
bodili
chang
caus
existenti
fear
frequent
mention
end
treatment
children
want
particip
care
use
cognit
strategi
think
right
way
emot
strategi
cri
loud
kick
fear
chang
time
fear
subject
needl
remain
half
children
less
intens
end
treatment
strategi
develop
becam
sophist
treatment
period
conclus
fear
chang
throughout
cours
treatment
strategi
use
reason
believ
need
support
also
vari
topic
futur
research
anwar
ali
r
b
indu
hospit
pediatr
oncolgi
nurs
educ
karachi
pakistan
backgroundobject
mentor
play
import
role
learn
career
develop
mentor
process
engag
often
elder
experienc
mentor
younger
mente
complex
dynam
relationship
knowledg
transfer
base
predefin
goal
matovu
jk
et
al
sinc
pakistan
scarc
human
resourc
import
senior
pass
year
experi
upcom
gener
indu
children
cancer
hospit
karachi
taken
initi
establish
mentorship
distant
site
partner
organ
child
matter
grant
designmethod
extens
literatur
review
use
word
mentorship
distant
nurs
pediatr
oncolog
effect
suggest
effect
distant
mentorship
pediatr
oncolog
nurs
conduct
mentor
provid
use
multipl
mode
via
face
face
teach
site
visit
provid
resourc
materi
structur
observership
program
skype
session
whatsapp
group
email
partner
organ
child
matter
grant
effect
shall
evalu
qualit
ask
nurs
assess
progress
quantit
approach
clinic
indic
result
nurs
literatur
suggest
integr
connect
leadership
mentor
profession
career
progress
distant
mentorship
proven
great
modal
base
need
commun
goal
expect
plan
time
method
adequ
connect
project
result
evalu
improv
clinic
object
indic
current
visit
partner
organ
conduct
baselin
assess
provid
materi
tool
direct
progress
project
complet
progress
compar
baselin
assess
conclus
develop
mentorship
program
appreci
improv
knowledg
transfer
career
advanc
research
mentorship
program
exist
within
defin
framework
use
measur
outcom
evalu
effect
includ
achiev
goal
public
career
growth
develop
mente
mentor
continu
cycl
lawrenc
lehana
formal
mentorship
relationship
within
area
variou
medic
disciplin
recommend
convey
skill
effect
benefit
mentor
relationship
gain
barbosa
g
israelita
albert
einstein
pediatr
paulo
brazil
backgroundobject
peripher
intraven
therapi
consid
one
common
procedur
develop
pediatr
therapi
treatment
prolong
chemotherapi
drug
wear
progress
child
venou
system
peculiar
characterist
either
biolog
emot
cognit
sens
peripher
insert
central
cathet
picc
stand
safe
intraven
devic
increasingli
use
oncolog
remain
patient
along
propos
treatment
accord
protocol
use
object
describ
use
picc
pediatr
oncolog
patient
one
year
privat
hospit
paulo
designmethod
descript
retrospect
studi
pediatr
patient
diseas
pediatr
privat
hospit
paulo
use
picc
treatment
januari
april
result
analysi
data
result
show
month
handl
children
oncolog
picc
chemotherapi
treatment
infect
rate
year
median
year
male
predomin
diagnosi
acut
lymphocyt
leukemia
preval
follow
lymphoma
patient
follow
treatment
remov
cathet
due
injuri
skin
devic
dress
preval
protocol
use
therapeut
scheme
conclus
picc
pediatr
oncolog
safe
option
central
access
chemotherapi
treatment
primarili
allow
blood
product
transfus
blood
collect
associ
low
rate
infect
complic
lower
cost
procedur
preserv
avoid
scar
reduc
stress
punctur
c
bartholdson
b
p
institutet
depart
women
children
health
stockholm
sweden
medic
center
depart
medic
human
amsterdam
netherland
antil
univers
depart
clinic
scienc
lund
sweden
backgroundobject
intent
nophonobo
work
group
ethic
wge
offer
clinic
ethic
support
nordic
pediatr
oncolog
wge
offer
healthcar
profession
hcp
cours
facilit
ethic
case
reflect
ecr
session
cours
ecr
implement
aim
present
describ
result
swedish
pediatr
oncolog
includ
ethic
issu
rais
traine
evalu
qualiti
ecr
designmethod
nineteen
hcp
physician
nurs
social
worker
repres
six
pediatr
oncolog
centr
sweden
particip
train
traine
invit
hcp
centr
identifi
dilemma
clinic
case
particip
ecr
session
traine
complet
questionnair
open
end
question
case
dilemma
furthermor
ecr
rate
scale
regard
benefit
group
perform
overal
qualiti
data
analys
content
analysi
descript
statist
result
ecr
perform
two
main
categori
repres
common
pattern
ethic
case
rais
identifi
child
social
situat
includ
differ
exampl
social
vulner
childfamili
conflict
parent
includ
conflict
concern
treatment
level
cultur
practic
benefit
ecr
group
rate
high
also
facilit
perform
rel
high
benefit
group
perform
overal
qualiti
conclus
pediatr
oncolog
includ
complex
medic
ethic
issu
current
case
social
complex
emerg
core
contribut
factor
moral
dilemma
medic
aspect
main
issu
case
rather
need
reflect
comprehens
holist
view
situat
order
decid
best
ethic
action
h
blundel
c
j
j
hospit
southampton
paediatr
oncolog
southampton
unit
kingdom
backgroundobject
deliveri
system
anticanc
therapi
sact
children
young
peopl
cyp
cancer
complex
greater
potenti
error
adult
challeng
includ
dose
calcul
wide
rang
weight
chang
unlicens
use
children
complex
protocol
wide
spectrum
diseas
type
therefor
imper
treatment
assess
accur
ensur
detect
patient
variabl
meet
requir
relev
chemotherapi
nurs
staff
respons
administ
sact
requir
confirm
assess
perform
satisfactori
standard
aim
creat
implement
chemotherapi
checklist
ensur
safe
administr
chemotherapi
suitabl
chemotherapi
reduc
error
paediatr
cancer
unit
univers
hospit
southampton
one
design
cyp
primari
treatment
centr
unit
kingdom
designmethod
chemotherapi
checklist
design
sact
nurs
within
unit
includ
verif
requir
appropri
support
care
prescrib
awar
drug
interact
protocol
confirm
separ
checklist
implement
standard
high
dose
chemotherapi
unit
staff
receiv
educ
complet
checklist
deem
mandatori
checklist
fulli
complet
chemotherapi
could
administ
patient
result
sinc
checklist
implement
chemotherapi
administ
without
complet
checklist
reduct
medic
error
nurs
report
empow
rais
queri
checklist
incomplet
discrep
requir
conclus
implement
full
complianc
use
checklist
administr
chemotherapi
result
safer
effici
process
reduc
prescrib
error
nurs
staff
feel
confid
challeng
doctor
result
intervent
ak
brar
n
r
graduat
institut
medic
educ
pediatr
surgeri
chandigarh
india
backgroundobject
present
experi
surgic
manag
pediatr
solid
tumor
tertiari
care
center
develop
countri
designmethod
patient
pediatr
solid
tumor
underw
surgeri
januari
march
includ
studi
retrospect
analysi
includ
present
neoadjuv
adjuv
therapi
along
outlin
surgic
manag
periop
mortal
morbid
result
boy
girl
age
day
year
geograph
distribut
includ
patient
adjoin
state
forti
two
patient
abdomin
solid
tumor
commonest
wilm
tumor
wt
account
case
tumor
predominantli
includ
neuroblastoma
ganglioneuroma
hepatoblastoma
teratoma
germ
cell
tumor
extra
abdomin
group
includ
chest
wall
ewe
cwt
sacrococcyg
teratoma
amongst
other
patient
underw
neoadjuv
chemotherapi
per
standard
protocol
surgic
excis
oper
time
rang
minut
minut
periop
blood
transfus
given
patient
three
patient
one
cwt
wt
neuroblastoma
requir
post
oper
ventil
hospit
stay
rang
day
relaps
within
year
seen
patient
neuroblastoma
myofibroblast
tumor
malign
nerv
sheath
tumor
cwt
remain
well
immedi
mortal
seri
conclus
wt
commonest
tumor
seri
periop
manag
need
adequ
plan
term
protocolis
approach
surgic
expertis
surgic
nurs
care
post
oper
critic
care
support
may
requir
extens
resect
pediatr
solid
tumor
manag
well
multidisciplinari
set
reason
good
outcom
c
castor
h
k
kristensson
unives
health
scienc
lund
sweden
univers
hospit
rigshospitalet
paediatr
adolesc
copenhagen
denmark
backgroundobject
famili
often
prefer
home
care
hospit
care
servic
ill
children
increas
worldwid
limit
knowledg
famili
need
cur
palli
home
care
aim
studi
elucid
famili
member
live
experi
sick
child
receiv
home
care
healthcar
servic
designmethod
descript
qualit
design
chosen
twelv
famili
includ
sick
children
receiv
home
care
mother
father
sibl
south
sweden
interview
decemb
januari
transcrib
interview
analyz
use
hermeneut
phenomenolog
approach
result
famili
member
live
experi
describ
three
essenti
theme
strengthen
famili
life
relat
home
care
induc
freedom
luxuri
strain
period
life
support
famili
everyday
life
usual
social
activ
relat
maintain
time
energi
save
receiv
home
care
promot
health
relat
famili
member
burden
ill
decreas
child
sign
ill
allevi
whole
famili
increas
child
receiv
care
home
provid
peac
respit
famili
member
psychosoci
recoveri
third
theme
creat
allianc
relat
import
creat
trust
allianc
commun
particip
care
trust
allianc
creat
parent
felt
overwhelm
respons
famili
member
becam
anxiou
conclus
find
suggest
care
famili
home
use
complement
hospit
care
given
close
attent
famili
member
need
posit
effect
home
care
might
jeopard
expect
success
share
studi
fund
swedish
childhood
cancer
foundat
swedish
research
council
health
work
life
welfar
lion
research
foundat
jona
foundat
c
castor
kristensson
k
h
univers
depart
health
faculti
medicin
lund
sweden
univers
hospit
rigshospitalet
paediatr
adolesc
copenhagen
denmark
backgroundobject
home
care
servic
highli
complex
health
care
servic
organ
variou
model
support
famili
everyday
life
advoc
nation
intern
despit
access
util
may
still
limit
aim
studi
determin
characterist
children
referr
children
home
care
servic
sweden
assess
accept
designmethod
descript
studi
report
data
march
march
data
referr
collect
retrospect
review
medic
journal
children
year
age
refer
home
care
servic
data
accept
term
satisfact
safeti
prefer
care
collect
evalu
form
complet
parent
home
care
servic
visit
descript
compar
statist
use
analyz
data
result
preliminari
result
show
referr
lead
home
care
sick
children
differ
age
wide
rang
diagnos
condit
refer
home
care
servic
children
cancer
compos
largest
group
administr
intraven
drug
often
antibiot
account
care
task
ten
percent
children
die
studi
period
refer
palli
care
durat
home
care
servic
vari
highli
median
rang
day
trend
toward
uneven
distribut
care
throughout
counti
parent
show
high
rate
satisfact
safeti
express
prefer
home
care
servic
home
care
servic
visit
conclus
children
age
suffer
cancer
provid
counti
base
home
care
servic
variou
healthcar
need
stage
ill
includ
high
accept
care
though
usag
may
unequ
distribut
chamberlain
h
hospit
southampton
piam
brown
ward
southampton
unit
kingdom
backgroundobject
univers
hospit
southampton
one
paediatr
oncolog
primari
treatment
centr
ptc
unit
kingdom
unit
fortun
dedic
theatr
space
satellit
anaesthet
perform
twice
weekli
elect
lumbar
punctur
bone
marrow
list
particip
safe
situat
awar
everyon
project
key
area
perceiv
vulner
list
identifi
staff
chang
creat
variabl
practic
perform
check
baselin
staff
survey
identifi
improv
could
made
term
consist
check
object
reduc
avoid
error
harm
children
undergo
procedur
gener
anaesthet
within
ward
environ
designmethod
nurs
staff
within
day
unit
creat
implement
safeti
checklist
specif
paediatr
oncolog
patient
undergo
lumbar
punctur
bone
marrow
use
within
ward
environ
result
consist
check
patient
undergo
procedur
gener
anaesthet
within
ward
environ
error
patient
undergo
gener
anaesthet
satellit
theatr
environ
conclus
introduct
new
checklist
enabl
us
tighten
process
check
reduc
variat
therefor
improv
patient
safeti
within
ptc
oncolog
set
new
checklist
embed
clinic
practic
met
increas
staff
satisfact
ongo
improv
cycl
measur
modifi
checklist
requir
ym
dt
ec
cancer
foundat
roctaiwan
board
director
taipei
taiwan
roc
cancer
foundat
roctaiwan
manag
taipei
taiwan
roc
backgroundobject
intern
nurs
studi
impact
childhood
cancer
famili
conduct
health
insur
coverag
health
care
children
taiwan
find
nurs
studi
reveal
need
coordin
concert
effort
help
famili
financi
assist
need
found
famili
financi
assist
also
found
cover
health
care
deliveri
system
respond
challeng
childhood
cancer
object
paper
reexamin
current
health
care
deliveri
system
qualiti
health
care
children
cancer
taiwan
designmethod
histor
review
approach
adopt
studi
data
sourc
includ
file
document
annual
report
childhood
cancer
foundat
ccf
publish
research
paper
result
establish
ccf
coordin
concert
care
team
train
profession
gradual
organ
standard
treatment
protocol
test
implement
medic
center
hospit
around
island
sinc
financi
assist
famili
increas
limit
chemotherapi
drug
includ
full
treatment
regimen
especi
nation
health
insur
introduc
surviv
rate
children
cancer
risen
year
famili
financi
assist
expand
includ
child
normal
need
conclus
meet
world
mission
child
die
cancer
new
effort
cancer
cure
care
regimen
incessantli
exert
implement
thu
impact
financi
burden
famili
child
cancer
remain
account
care
profession
govern
entir
societi
continu
challeng
mh
chen
lh
wy
yl
kp
yc
chi
univers
scienc
technolog
nurs
hualien
taiwan
roc
taiwan
univers
nurs
taipei
taiwan
roc
taiwan
univers
psycholog
taipei
taiwan
roc
univers
mathemat
taipei
taiwan
roc
backgroundobject
studi
purpos
explor
famili
parent
treatment
decis
make
qualiti
life
child
diagnos
cancer
hospit
designmethod
institut
review
board
hospit
approv
studi
procedur
research
design
use
depth
interview
focu
group
discuss
approach
parent
children
diagnos
cancer
hospit
use
particip
observ
studi
approach
data
collect
theme
uncov
interview
data
set
rigor
method
data
analysi
record
data
process
record
interview
particip
observ
data
analysi
author
parent
result
cancer
treatment
decis
made
parent
hospit
children
treat
cancer
mainli
includ
choos
appropri
hospit
treatment
process
fourth
theme
qualiti
life
physiolog
sleep
disturb
due
treatment
children
prone
feel
tire
catch
cold
psycholog
concern
side
effect
treatment
children
b
children
emot
chang
invas
treatment
feel
guilti
children
famili
neglect
feel
difficult
reconcil
demand
work
care
sick
children
chang
everyday
live
diet
mainli
compos
food
time
isol
home
environ
live
one
tribe
use
support
system
mutual
support
among
husband
wive
sibl
paramed
staff
conclus
expect
find
studi
could
provid
famili
member
paramed
staff
posit
forc
support
heal
children
j
chidnog
medicin
ramathibodi
mahidol
univers
pediatr
oncolog
bone
marrow
transplant
ward
thailand
backgroundobject
sepsi
major
caus
mortal
commonli
found
oncolog
patient
clinic
sign
sever
sepsi
call
system
inflamm
respons
syndrom
sir
sir
defin
routin
vital
sign
record
designmethod
develop
chart
record
vital
sign
patient
admit
ward
differ
record
form
patient
age
year
measur
includ
systol
bp
heart
rate
temperatur
respiratori
rate
consciou
valu
measur
grade
score
score
sum
total
score
total
score
recogn
low
risk
record
vital
sign
routin
total
score
mean
moder
risk
repeat
vital
sign
hour
total
score
score
item
mean
high
risk
notifi
physician
assess
patient
appropri
treatment
record
vital
sign
everi
minut
result
patient
admit
oncolog
ward
staff
gave
patient
score
time
score
low
risk
time
moder
risk
time
high
risk
time
seventi
eight
patient
low
moder
risk
discharg
home
plan
two
patient
high
risk
transfer
intermedi
ward
close
observ
discharg
home
safeti
later
twenti
nurs
staff
ask
evalu
satisfact
record
earli
warn
score
use
questionnair
mean
score
satisfact
conclus
conclus
earli
warn
score
effect
tool
recogn
children
earli
sign
sepsi
c
dansereau
farber
boston
children
cancer
blood
disord
center
hematologyoncolog
boston
usa
backgroundobject
evolut
engin
cellular
therapi
chimer
antigen
receptor
car
cell
therapi
provid
clinician
abil
creat
patient
specif
treatment
offer
hope
cure
diseas
previous
thought
life
threaten
fatal
therapi
complex
clinic
develop
way
deliv
patient
safe
effici
provid
novel
therapi
nurs
led
program
develop
designmethod
program
compris
repres
step
complex
process
apheresi
collect
cell
transfer
cell
manufactur
facil
coordin
inpati
admiss
condit
chemotherapi
infus
genet
engin
product
arrang
requir
follow
visit
nurs
leader
respons
orchestr
sequenti
step
prepar
deliveri
autolog
cellular
therapi
team
meet
weekli
review
patient
treatment
well
upcom
patient
new
referr
creat
schedul
patient
review
oper
clinic
issu
identifi
model
provid
central
point
contact
nurs
leader
physician
nurs
staff
ancillari
staff
well
patient
famili
initi
program
team
small
composit
use
continu
qualiti
improv
model
addit
member
ad
address
new
clinic
oper
need
result
program
initi
develop
treat
singl
diseas
indic
novel
engin
cell
therapi
success
expand
infrastructur
model
treat
diseas
led
nurs
leader
use
systemat
approach
conclus
creat
infrastructur
treatment
base
diseas
agnost
offer
institut
abil
nimbl
effici
expediti
get
ground
break
novel
therapi
patient
v
de
la
maza
p
jp
p
e
de
chile
calvo
mackenna
hospit
faculti
medicin
santiago
chile
makenna
hospit
oncolog
santiago
chile
de
lo
and
faculti
medicin
santiago
chile
de
chile
faculti
medicin
santiago
chile
la
cond
santiago
chile
exequiel
gonzalez
oncolog
santiago
chile
backgroundobject
parent
children
cancer
must
receiv
inform
relat
child
diseas
aim
studi
determineth
effect
structur
educ
program
parent
children
cancer
level
knowledg
occurr
advers
event
designmethod
experiment
prospect
studi
parent
children
recent
diagnos
cancer
two
children
hospit
santiago
chile
one
center
parent
receiv
educ
intervent
experiment
group
parent
receiv
intervent
control
group
knowledg
level
child
diseas
evalu
day
occurr
advers
event
one
year
result
total
parent
enrol
june
group
day
group
knowledg
level
howev
day
number
correct
answer
increas
experiment
group
p
regard
advers
event
number
infect
central
venou
catheterwa
significantli
lower
experiment
group
vs
differ
number
emerg
room
visit
number
episod
consult
fever
without
neutropenia
relat
chemotherapi
significantli
lower
experiment
group
p
conclus
result
suggest
educ
program
nurs
parent
children
cancer
increas
knowledg
level
diseas
might
lower
occurr
advers
event
patient
due
result
studi
implement
educ
program
consid
chilean
public
hospit
along
distribut
book
page
creat
local
pediatr
oncolog
specialist
call
let
walk
togeth
orient
parent
children
cancer
prepar
parent
optim
care
children
j
deeg
prins
maxima
centrum
pediatr
oncolog
utrecht
netherland
backgroundobject
prins
maxima
centr
pediatr
oncolog
pmc
initi
central
care
made
uniqu
collabor
health
care
profession
research
parent
children
cancer
first
unit
open
octob
insid
wilhelmina
children
hospit
utrecht
netherland
unit
start
clinic
bed
small
nurs
staff
open
first
unit
begin
year
journey
toward
new
independ
pediatr
oncolog
hospit
netherland
reach
adequ
quantiti
nurs
suffici
pediatr
oncolog
knowledg
challeng
overcom
designmethod
netherland
yet
offici
certifi
nurs
educ
program
contain
whole
spectrum
pediatr
oncolog
cooper
univers
medic
center
umc
utrecht
academi
prins
maxima
academi
develop
one
year
program
lead
certifi
pediatr
oncolog
diploma
keep
learn
vibe
high
level
workfloor
theme
week
develop
sever
program
quick
learn
session
bedsid
teach
multidisciplinari
present
result
year
time
prins
maxima
centr
pediatr
oncolog
increas
health
care
worker
expect
end
increas
till
total
nurs
finish
pediatr
oncolog
specializim
nurs
finish
pediatr
specializim
theme
week
templat
develop
allow
recognis
workfloor
learn
method
theme
week
success
integr
nurs
motiv
optim
learn
posit
conclus
prins
maxima
centr
offici
pediatr
oncolog
program
creat
one
third
nurs
staff
success
finish
program
develop
theme
week
nurs
educ
continu
workfloor
process
motiv
dedic
team
n
demir
h
yildirim
n
e
katip
celebi
univers
nurs
izmir
turkey
univers
pediatr
oncolog
izmir
turkey
backgroundobject
aim
studi
determin
view
life
prioriti
children
undergon
cancer
treatment
parent
designmethod
studi
conduct
pediatr
oncolog
outpati
clinic
studi
includ
children
age
year
follow
aforement
period
treat
cancer
parent
form
question
opinion
use
children
parent
ask
question
life
prioriti
eight
area
request
rate
prioriti
rang
extrem
import
extrem
unimport
number
percentag
use
analysi
result
mean
age
children
children
male
father
mother
state
heard
sperm
egg
freez
method
children
futur
parent
said
inform
futur
diagnosi
made
eleven
boy
underw
sperm
freez
process
mother
father
thought
children
high
risk
children
futur
due
treatment
children
parent
life
prioriti
first
four
place
healthi
go
school
job
start
famili
child
last
life
prioriti
mother
children
father
conclus
studi
result
indic
approxim
half
male
children
cancer
underw
sperm
freez
process
clinic
induct
ovum
girl
recommend
famili
practic
time
diagnosi
life
prioriti
children
rank
last
mother
children
n
demir
e
n
univers
pediatr
oncolog
clinic
izmir
turkey
katip
celebi
univers
nurs
faculti
izmir
turkey
backgroundobject
aim
studi
investig
qualiti
life
healthi
life
style
behavior
adolesc
undergon
cancer
treatment
designmethod
descript
relat
studi
consist
adolesc
cancer
age
year
follow
pediatr
oncolog
polyclin
univers
hospit
whose
activ
cancer
treatment
complet
least
month
ago
studi
sampl
compris
adolesc
health
behavior
adolesc
measur
adolesc
lifestyl
questionnair
alq
qualiti
life
measur
higher
score
obtain
scale
better
healthi
lifestyl
behavior
perceiv
qualiti
life
result
mean
age
adolesc
particip
studi
particip
adolesc
n
femal
complet
cours
treatment
least
month
ago
adolesc
hodgkin
lymphoma
ewe
sarcoma
alq
mean
score
mean
score
subscal
follow
health
respons
physic
activ
nutrit
posit
health
interperson
relat
stress
spiritu
field
lowest
mean
score
obtain
school
famili
subscal
qualiti
life
scale
gender
affect
alq
score
determin
qualiti
life
scale
score
increas
mean
score
posit
health
spiritu
health
subscal
increas
conclus
adolesc
life
style
qualiti
life
level
moder
obtain
lowest
score
physic
activ
school
subscal
j
gattuso
lm
b
k
j
b
k
jude
children
research
hospit
nurs
research
memphi
usa
jude
children
research
hospit
oncolog
memphi
usa
backgroundobject
genom
sequenc
incorpor
clinic
care
patient
cancer
littl
known
parent
children
cancer
consent
sequenc
understand
weigh
risk
benefit
uncertainti
inher
test
qualit
inquiri
part
larger
studi
somat
germlin
sequenc
cohort
prospect
identifi
pediatr
oncolog
patient
treat
st
jude
children
research
hospit
aim
identifi
reason
particip
given
parent
risk
benefit
expect
hope
learn
particip
designmethod
ground
theori
methodolog
guid
aspect
research
conveni
sampl
parent
patient
total
sampl
children
adolesc
cancer
agre
interview
enrol
genom
sequenc
studi
interview
train
interview
interview
complet
person
record
transcrib
interview
guid
use
constant
compar
method
use
data
analysi
code
gener
analysi
complet
jointli
studi
team
member
result
altruism
common
reason
particip
frequent
report
benefit
particip
benefit
includ
gain
knowledg
child
cancer
determin
cancer
hereditari
indic
risk
famili
member
contribut
research
frequent
hope
expect
particip
determin
cancer
hereditari
follow
desir
proactiv
begin
treatment
surveil
earli
possibl
need
parent
recal
risk
possibl
receiv
posit
result
implic
concern
insur
discrimin
howev
mani
perceiv
risk
child
conclus
understand
factor
parent
consid
consent
genom
sequenc
assist
nurs
provid
compassion
inform
care
bs
gau
hy
taiwan
univers
school
colleg
medicin
taipei
taiwan
roc
cancer
foundat
roc
nurs
care
section
taipei
taiwan
roc
backgroundobject
children
cancer
right
educ
learn
howev
diagnosi
treatment
cancer
affect
children
learn
statu
find
previou
studi
indic
stabl
health
statu
avail
resourc
access
care
parent
major
concern
school
arrang
children
level
school
nurs
involv
cancer
child
school
reentri
significantli
affect
learn
adjust
child
current
studi
aim
explor
liaison
care
issu
children
cancer
designmethod
design
conduct
one
thousand
newli
cancer
diagnos
children
enrol
alreadi
attend
kindergarten
even
high
school
questionnair
survey
telephon
appli
collect
data
semant
analysi
explor
school
issu
state
result
chang
learn
statu
includ
dropout
homeschool
account
differ
boy
girl
logist
regress
analysi
indic
neuroblastoma
like
diseas
affect
state
learn
children
solid
tumor
increas
risk
compar
leukemia
ci
children
live
southern
part
taiwan
obvious
fewer
opportun
school
leav
home
school
children
north
metropolitan
area
ci
promot
home
educ
admiss
system
weak
student
empow
children
regain
peer
ident
campu
prepar
parent
increas
resili
reduc
sens
conflict
report
parent
children
conclus
provid
good
qualiti
liaison
care
hospit
school
home
health
profession
need
take
effort
integr
resourc
includ
bedsid
teacher
home
educ
individu
educ
program
support
children
coexist
learn
cancer
r
glincher
c
sloan
ketter
cancer
center
pediatr
new
york
usa
backgroundobject
neuroblastoma
patient
requir
aggress
high
dose
chemotherapi
radiat
therapi
relaps
andor
refractori
diseas
patient
may
requir
autolog
stem
cell
rescu
ascr
ensur
marrow
recoveri
treatment
due
profound
pancytopenia
decondit
patient
excel
nurs
care
essenti
designmethod
past
year
patient
receiv
autolog
stem
cell
outpati
memori
sloan
ketter
cancer
center
mskcc
advanc
practic
nurs
apn
role
manag
complex
patient
standard
care
includ
complet
blood
count
basic
metabol
panel
upon
arriv
follow
prbc
platelet
transfus
clinic
indic
patient
receiv
normal
salin
bolu
mlkg
acetaminophen
diphenhydramin
ondansetron
prior
ascr
stem
cell
administ
attend
physician
via
intraven
push
patient
close
monitor
acut
reaction
bedsid
regist
nurs
rn
follow
ascr
hyper
hydrat
administ
clinic
via
home
infus
pump
hour
furosemid
administ
minut
post
ascr
urinalysi
obtain
everi
void
check
hemoglobinuria
electrolyt
obtain
diuret
patient
observ
four
hour
post
infus
discharg
home
hydrat
clinic
stabl
patient
return
follow
follow
day
full
assess
nurs
practition
result
patient
receiv
ascr
outpati
year
mskcc
common
acut
reaction
nausea
vomit
fever
acut
reaction
well
manag
clinic
team
includ
rn
np
clinic
attend
patient
develop
neutropen
fever
care
outpati
admiss
occur
conclus
ascr
safe
administ
outpati
set
high
qualiti
nurs
care
outpati
administr
ascr
increas
qualiti
life
patient
improv
overal
satisfact
also
elimin
unnecessari
hospit
day
decreas
financi
burden
r
glincher
sloan
ketter
cancer
center
pediatr
new
york
usa
backgroundobject
case
report
present
four
year
old
femal
histori
neuroblastoma
enrol
clinic
trial
memori
sloan
ketter
cancer
center
present
routin
evalu
mediport
previous
access
flush
one
month
prior
arriv
schedul
visit
mediport
access
per
institut
guidelin
use
steril
techniqu
without
complic
blood
return
obtain
five
millilit
normal
salin
flush
swell
tender
erythema
note
blood
return
still
unabl
obtain
due
lack
blood
return
central
venou
cathet
alteplas
instil
blood
return
still
present
peripher
iv
place
chest
obtain
assess
placement
designmethod
central
line
includ
mediport
use
patient
cancer
administr
chemotherapi
bloodwork
placement
must
confirm
radiograph
imag
upon
insert
subsequ
placement
confirm
use
blood
return
blood
return
crucial
prior
instil
solut
medic
line
case
highlight
necess
evalu
unabl
obtain
blood
return
result
chest
show
cathet
port
migrat
hub
locat
entir
within
right
heart
cross
right
atrium
right
ventricl
patient
made
npo
intervent
radiolog
consult
use
ultrasound
guidanc
intervent
radiolog
abl
success
retriev
fractur
cathet
heart
place
new
right
chest
wall
mediport
conclus
due
nurs
vigil
advocaci
central
venou
cathet
use
instil
contrast
schedul
multidisciplinari
team
work
togeth
close
maximum
benefit
patient
case
report
highlight
necess
alway
obtain
blood
return
whenev
use
central
line
import
imag
confirm
line
placement
blood
return
abl
obtain
h
hansson
k
univers
hospit
rigshospitalet
depart
paediatr
adolesc
medicineresearch
unit
women
children
health
copenhagen
denmark
lund
univers
depart
health
lund
sweden
univers
depart
art
cultur
scienc
lund
sweden
backgroundobject
develop
evalu
home
care
hbhc
intervent
outreach
servic
children
cancer
control
trial
denmark
hbhc
success
implement
routin
care
immedi
trial
extern
fund
end
five
year
conduct
present
studi
explor
health
care
profession
made
sens
hbhc
sustain
challeng
gradual
discontinu
aim
identifi
import
factor
process
may
enabl
hinder
sustain
hbhc
designmethod
conduct
narr
analysi
data
collect
individu
focu
group
interview
health
care
profession
clinic
staff
manag
work
differ
unit
depart
also
use
greenhalgh
framework
sustain
analys
data
mean
healthcar
profession
explain
drive
hold
hbhc
back
result
two
share
narr
theme
emerg
meaning
children
famili
enabl
factor
lack
resourc
nurs
staf
hinder
factor
continu
hbhc
differ
term
health
care
profession
made
sens
decis
cancel
home
visit
despit
meaning
children
famili
meant
clinic
staff
manag
conflict
understand
prioriti
respons
relat
continu
hbhc
accord
valu
posit
conclus
sustain
discontinu
hbhc
embodi
conflict
psychosoci
benefit
children
famili
role
resourc
may
use
anticip
challeng
illustr
import
share
process
among
health
care
profession
support
effort
sustain
intervent
long
term
h
hashimoto
h
h
univers
graduat
school
institut
biomed
scienc
tokushima
japan
backgroundobject
parent
children
hematolog
oncolog
diseas
requir
divers
inform
use
decis
make
daili
life
care
although
method
obtain
inform
becom
diversifi
conveni
larg
amount
inform
might
caus
parent
anxieti
confus
studi
examin
parent
use
internet
inform
seek
designmethod
conduct
questionnair
survey
parent
children
hematolog
oncolog
diseas
outpati
depart
analyz
data
obtain
parent
respons
rate
result
thirteen
parent
sought
inform
internet
report
inform
easi
understand
frequent
use
sourc
websit
japanes
nation
special
institut
parent
access
nine
parent
want
talk
health
profession
inform
obtain
internet
although
actual
consult
profession
eight
parent
need
health
profession
advic
seek
inform
internet
base
result
fisher
exact
probabl
test
signific
differ
parent
understand
satisfact
inform
health
profession
found
particip
use
internet
conclus
parent
requir
advic
health
profession
inform
internet
howev
parent
unabl
consult
profession
besid
verifi
need
parent
give
advic
use
internet
health
profession
must
care
consid
whether
parent
ask
question
inform
collect
internet
n
f
children
medic
affili
shanghai
jiaotong
univers
pediatr
hematolog
oncolog
shanghai
china
children
medic
affili
shanghai
jiaotong
univers
nurs
shanghai
china
backgroundobject
common
neg
experi
procedur
pain
well
manag
pediatr
cancer
depart
big
gap
best
evid
clinic
practic
aim
project
implement
best
avail
guidelin
manag
procedur
pain
nurs
practic
pediatr
cancer
depart
designmethod
plan
studi
act
qi
framework
use
intervent
process
includ
four
step
identifi
current
deviat
best
practic
assess
barrier
support
revis
relat
procedur
rule
design
implement
protocol
adopt
protocol
monitor
chang
pain
intens
process
measur
invas
procedur
patientfamili
educ
satisfact
procedur
pain
manag
profession
train
knowledg
procedur
pain
manag
assess
intervent
result
result
implement
audit
show
increas
complianc
rate
prepar
procedur
util
lidocain
procedur
attent
distract
procedur
famili
educ
averag
procedur
pain
pediatr
patient
cancer
also
decreas
p
percentag
moder
higher
procedur
pain
face
va
decreas
p
conclus
effect
way
continu
improv
care
integr
daili
work
perform
feedback
immedi
posit
outcom
new
practic
promot
complianc
care
staff
patientfamili
parent
inspir
work
cooper
healthcar
profession
manag
procedur
pain
h
children
medic
affili
shanghai
jiaotong
univers
pediatr
hematolog
oncolog
shanghai
china
backgroundobject
nurs
play
essenti
role
monitor
report
qualiti
healthcar
hospit
diseas
acuiti
treatment
complex
difficult
situat
pediatr
patient
cancer
alway
keep
pediatr
hematolog
oncolog
nurs
environ
high
intens
howev
report
nurs
report
qualiti
care
nurs
practic
environ
chines
pediatr
hematolog
oncolog
nurs
studi
explor
current
statu
nurs
report
qualiti
care
nurs
practic
environ
chines
pediatr
hematolog
oncolog
nurs
establish
relationship
designmethod
studi
design
investig
pediatr
hematolog
oncolog
nurs
member
institut
chines
associ
pediatr
nurs
group
questionnair
demograph
data
qualiti
care
question
practic
environ
scale
use
result
percentag
nurs
consid
excel
qualiti
care
unit
patient
abl
manag
care
discharg
qualiti
care
hospit
deterior
past
year
respect
score
nurs
practic
environ
lowest
score
staf
resourc
adequaci
qualiti
care
dimens
nurs
practic
environ
significantli
correl
r
rang
p
conclus
qualiti
care
pediatr
hematolog
oncolog
accept
patient
famili
averag
pediatr
hematolog
oncolog
nurs
consid
staf
resourc
adequaci
dissatisfi
signific
relationship
qualiti
care
nurs
practic
environ
hirata
n
f
luke
intern
univers
graduat
school
nurs
scienc
tokyo
japan
colleg
health
scienc
faculti
makuhari
human
care
chiba
japan
children
medic
center
cancer
center
kanagawa
japan
colleg
nurs
school
nurs
nagano
japan
children
hospit
depart
nurs
chiba
japan
backgroundobject
japanes
societi
pediatr
oncolog
nurs
studi
group
publish
revis
edit
nurs
care
guidelin
children
cancer
famili
order
improv
qualiti
life
children
cancer
current
review
revis
studi
aim
examin
challeng
difficulti
encount
nurs
engag
pediatr
oncolog
nurs
team
consid
educ
support
nurs
designmethod
sent
questionnair
nurs
pediatr
oncolog
nurs
experi
hospit
nationwid
return
five
expert
pediatr
oncolog
nurs
qualit
analyz
descript
data
regard
challeng
difficulti
team
approach
result
result
code
data
regard
nurs
role
team
code
categori
extract
five
categori
nurs
express
concern
team
function
properli
burden
nurs
larg
mani
profession
burden
specif
nurs
larg
inform
share
good
enough
nurs
recogn
role
team
regard
difficulti
toward
team
approach
code
categori
extract
eight
categori
team
meet
held
difficulti
adjust
time
meet
nurs
particip
meet
doctor
led
inform
share
difficult
cn
intervent
complic
case
insuffici
continu
team
approach
done
collabor
system
conclus
import
nurs
close
besid
children
hour
recogn
import
role
fulfil
role
coordin
team
believ
educ
nurs
could
play
role
help
overcom
challeng
difficulti
team
approach
j
holt
r
memori
hospit
john
hopkin
health
system
radiat
oncolog
washington
dc
usa
hopkin
health
system
depart
child
depart
radiat
oncolog
baltimor
usa
hopkin
health
system
depart
radiat
oncolog
baltimor
usa
backgroundobject
radiat
therapi
rt
essenti
treatment
modal
mani
pediatr
cancer
treatment
must
precis
deliv
execut
reli
heavili
patient
abil
remain
still
set
deliveri
treatment
length
vari
fifteen
minut
hour
depend
type
treatment
area
bodi
treat
mani
factor
impact
child
abil
compli
behavior
requir
rt
purpos
analysi
understand
treatment
factor
impact
pediatr
cooper
rt
better
predict
patient
safe
treat
without
intervent
designmethod
retrospect
data
patient
collect
via
electron
medic
record
two
collabor
radiat
oncolog
depart
august
august
patient
age
year
younger
underw
rt
data
collect
categori
thought
impact
child
behavior
cooper
rt
correl
medic
record
report
healthcar
provid
result
six
categori
demonstr
statist
signific
p
influenc
behavior
cooper
rt
age
categori
specif
age
odd
ratio
confid
interv
ci
histori
previou
sedat
imag
studi
p
parent
belief
need
medic
success
treatment
p
durat
treatment
time
prefer
languag
p
undergo
total
bodi
irradi
ci
conclus
pediatr
behavior
complianc
rt
complic
three
domain
compris
common
variabl
contribut
patient
conform
rt
demograph
histor
preced
futur
research
focu
best
practic
identifi
children
need
addit
behavior
train
pharmacolog
intervent
order
prevent
unnecessari
anxieti
emot
trauma
rt
py
hsu
fr
taiwan
univers
children
hospit
nurs
taipei
taiwan
roc
backgroundobject
treatment
modal
frequent
accompani
side
effect
potenti
neg
impact
physic
activ
psychosoci
evid
exercis
physic
activ
program
reduc
fatigu
enhanc
psychosoci
health
pediatr
popul
purpos
studi
develop
program
children
cancer
evalu
effect
behavior
respons
treatment
designmethod
set
studi
pediatr
oncolog
ward
taiwan
may
decemb
first
appli
instrument
base
literatur
review
data
collect
start
immedi
cancer
treatment
time
physic
activ
qualiti
sleep
monitor
record
hospit
work
method
design
program
children
reward
card
children
earn
point
everi
exercis
children
make
children
particip
activ
least
minut
physic
activ
walk
kid
percept
set
develop
environ
design
kid
gift
hous
motiv
stimul
children
result
complet
rate
physic
activ
least
minut
physic
activ
per
day
day
per
week
qualiti
sleep
increas
point
point
implement
program
particip
addit
benefit
satisfact
score
caregiv
program
increas
point
program
conclus
base
result
found
program
help
reduc
child
neg
psycholog
respons
side
effect
cancer
treatment
minim
fatigu
enhanc
qualiti
sleep
pediatr
patient
undergo
cancer
treatment
cancer
lm
hu
cy
taiwan
univers
hospit
nurs
taipei
taiwan
roc
backgroundobject
children
pediatr
hematolog
oncolog
disord
almost
everyon
devic
implant
care
essenti
knowledg
skill
nurs
pediatr
hematolog
oncolog
unit
old
angl
needl
practic
model
use
unit
howev
due
frequent
practic
demonstr
part
becam
fall
worn
order
ensur
everi
nurs
skill
care
reduc
children
fear
angl
needl
punctur
innov
model
design
designmethod
pre
post
design
conduct
order
effect
clinic
teach
new
model
use
puppet
chest
implant
bottl
red
dye
substitut
blood
sixteen
nurs
appli
new
model
practic
skill
children
receiv
new
model
demonstr
result
likert
scale
use
measur
nurs
overal
satisfact
new
model
signific
improv
satisfact
point
old
model
new
one
easi
oper
replac
suppli
report
nurs
puppet
soft
textur
love
appear
also
let
children
becom
familiar
care
procedur
importantli
new
model
reliev
level
anxieti
fear
needl
punctur
among
children
significantli
conclus
new
model
demonstr
three
benefit
clinic
nurs
practic
time
effect
econom
benefit
child
friendli
base
experi
found
new
direct
function
develop
new
model
provid
better
nurs
educ
childhood
cancer
care
keep
work
hope
share
short
futur
c
huynh
p
l
j
jl
bacless
radiat
oncolog
caen
franc
backgroundobject
particl
therapi
ie
protontherapi
highli
sophist
radiotherapeut
modal
aim
mainli
limit
acut
long
term
children
avail
select
advanc
center
worldwid
request
specif
workflow
detail
hereinaft
designmethod
treatment
implement
divid
step
follow
ongo
physician
guidelin
provid
children
famili
specif
inform
written
video
document
patient
gener
seen
basi
treatment
prepar
includ
content
devic
visit
deport
treatment
sitedistract
hypnot
approach
use
manag
unusu
increas
treatment
time
pediatr
anesthesia
also
easili
avail
joint
medic
para
medic
therapi
patient
special
requir
eg
come
abroad
arrang
accommod
children
famili
result
group
open
shortli
proton
archadecyclhad
program
estim
third
patient
treat
children
radiat
must
deliv
maxim
accuraci
reproduct
impos
anticip
patient
care
pathway
dedic
team
parent
support
conclus
protontherapi
increasingli
popular
radiotherapeut
modal
requir
specif
patientmanag
team
train
qualiti
assur
program
far
futur
may
explor
new
concept
light
ion
use
highli
radioresist
case
carbon
ion
l
jacqu
g
n
columbia
children
hospit
oncologyhematologybmt
vancouv
canada
backgroundobject
bc
children
hospit
oncologyhematologybmt
outpati
clinic
see
approxim
patient
visit
per
year
build
new
acut
care
tower
outpati
clinic
expand
room
provid
opportun
implement
provid
patient
care
deliveri
model
wherein
patient
could
assign
room
durat
visit
healthcar
provid
hcp
would
move
room
room
see
patient
rather
patient
move
provid
anticip
outcom
model
improv
patient
experi
reduc
appoint
time
without
compromis
workflow
effici
hcp
designmethod
research
model
conduct
way
literatur
review
benchmark
site
visit
meet
stakehold
held
understand
workflow
develop
oper
plan
earli
implement
carri
prior
move
involv
three
trial
use
pdsa
plandostudyact
cycl
evalu
strategi
assess
qualiti
effici
follow
implement
daili
huddl
involv
hcp
carri
obtain
feedback
challeng
improv
opportun
observ
time
studi
experi
survey
repeat
evalu
effect
model
result
model
success
implement
open
day
new
outpati
clinic
continu
opportun
improv
increas
hcp
satisfact
effici
improv
patient
satisfact
observ
time
studi
demonstr
decreas
length
stay
conclus
model
reflect
approach
provid
famili
privat
space
improv
time
spent
provid
reduc
appoint
time
earli
implement
pdsa
cycl
staff
engag
confirm
propos
process
would
realiz
goal
improv
workflow
effici
initi
chang
manag
tangibl
way
ensur
staff
complianc
commit
new
care
deliveri
model
joshi
memori
hospit
nurs
administr
mumbai
india
backgroundobject
pediatr
nurs
special
care
children
face
mani
challeng
work
problem
common
nurs
explor
help
manag
take
decis
proactiv
ensur
qualiti
output
identifi
variou
challeng
face
nurs
find
person
profession
challeng
identifi
potenti
stress
nurs
risk
designmethod
survey
nurs
work
pediatr
oncolog
depart
sampl
conveni
sampl
sampl
techniqqu
structur
interview
percentag
result
find
yr
yr
experi
nurs
year
year
less
year
experi
onco
year
yearsspeci
oncolog
train
special
train
pediatr
pediatr
choic
interest
rotat
pediatr
nurs
learn
theori
practic
attend
programm
spend
hour
hectic
travel
home
work
place
back
nurs
feel
heavi
workload
alway
answer
time
felt
never
difficulti
complet
nurs
respons
said
alway
sometim
said
never
felt
shortag
nurs
attend
equip
risk
unsaf
electr
physic
psycholog
distress
medic
error
felt
risk
potenti
occup
hazard
almost
express
fear
handl
medic
gadget
felt
uncomfort
commun
superior
express
increas
demand
servic
parent
non
nurs
felt
busi
comput
cleric
work
express
busi
manag
attend
job
conclus
suggest
qualiti
induct
programm
improv
nurs
patient
ratio
recognit
reward
appreci
stress
manag
programm
person
develop
programm
regular
health
checkup
conclus
nurs
pediatr
setup
face
mani
challeng
need
empow
oncolog
nurs
overcom
challeng
b
karayat
sp
gurgaon
paediatr
haematolog
oncolog
bone
marrow
transplant
gurgaon
india
backgroundobject
recent
advanc
haematopoiet
stem
cell
transplant
hsct
techniqu
made
possibl
even
parent
becom
donor
emerg
boon
child
acknowledg
donor
percept
experi
concern
take
backseat
entir
process
key
focu
cure
child
report
perspect
experi
parent
haploident
donor
children
designmethod
questionnair
prepar
compris
question
address
concern
comprehens
overal
experi
cover
peritranspl
period
famili
haploident
donor
donor
interview
telephon
respons
note
analys
donor
deceas
patient
interview
result
sixteen
children
underw
haploident
hsct
centr
acut
refractori
solid
stem
cell
donor
male
femal
ratio
mean
age
year
donor
avail
respond
offer
becom
donor
child
felt
anxiou
felt
proud
understood
procedur
gcsf
administr
report
day
peripher
blood
stem
cell
harvest
donor
report
anxieti
signific
pain
discomfort
harvest
one
donor
tingl
numb
wherea
one
shiver
post
cathet
remov
difficulti
report
two
donor
took
post
harvest
medic
month
other
took
week
donor
proud
donor
report
experi
satisfactori
conclus
famili
donor
face
moral
respons
exceed
expect
vital
address
physic
psycholog
concern
allevi
fear
facilit
experi
make
worthi
person
sens
achiev
j
kashiwas
c
c
n
h
k
univers
graduat
school
health
scienc
maebashi
japan
medic
univers
faculti
health
medic
care
hidaka
japan
univers
health
welfar
faculti
health
care
takasaki
japan
univers
faculti
nurs
takasaki
japan
backgroundobject
oral
medic
administr
one
import
treatment
children
chronic
diseas
includ
cancer
inappropri
administr
miss
dose
overdos
report
improv
oral
medic
manag
need
aim
studi
explor
trend
research
japan
oral
medic
manag
children
requir
oral
medic
designmethod
research
articl
publish
past
year
search
via
key
word
child
oral
medic
manag
use
electron
databas
japan
centra
revuo
medicina
web
ver
descript
statist
calcul
number
research
design
subject
target
diseas
data
content
research
qualit
induct
analyz
result
articl
retriev
articl
meet
studi
object
analyz
approxim
half
relat
children
chronic
diseas
one
articl
clearli
state
childhood
cancer
patient
target
studi
qualit
induct
analysi
found
eight
categori
delin
research
content
percept
children
chronic
diseas
toward
take
oral
medic
manag
condit
process
regard
child
take
medic
mother
behavior
support
child
requir
oral
medic
administr
percept
mother
child
requir
oral
medic
administr
support
manag
nurs
involv
oral
medic
administr
investig
children
take
oral
medic
initi
util
inform
technolog
support
take
medic
percept
nurs
medic
manag
children
psychiatr
disord
conclus
studi
examin
oral
medic
manag
regard
childhood
cancer
patient
research
need
topic
especi
area
childhood
cancer
effect
side
effect
strongli
influenc
child
condit
b
khan
r
indu
hospit
pediatr
oncolog
nurs
educ
servic
karachi
pakistan
indu
hospit
pediatr
oncolog
nurs
educ
karachi
pakistan
backgroundobject
nurs
backbon
healthcar
organ
provid
care
patient
frontlin
mani
organ
seek
enhanc
qualiti
patient
care
improv
nurs
knowledg
compet
nurs
duti
continu
educ
inord
remain
awar
updat
medic
advanc
new
research
continu
educ
train
increas
pediatr
oncolog
nurs
clinic
skill
knowledg
formal
pediatr
oncolog
orient
program
new
nurs
requir
siop
podc
baselin
standard
pediatr
oncolog
nurs
care
lmic
essenti
thu
indu
hospit
pediatr
complex
nurs
educ
servic
karachi
pakistan
initi
variou
continu
nurs
educ
cne
session
certif
eg
safe
handl
administr
chemotherapi
basic
pediatr
oncolog
nurs
medic
certif
basic
infect
prevent
control
resuscit
skill
iv
cannul
cavd
care
handl
supplementari
potassium
administr
inord
attain
primari
goal
provid
qualiti
care
improv
patient
qualiti
life
designmethod
evid
base
literatur
suggest
strategi
enhanc
profession
skill
knowledg
nurs
hospit
develop
countri
around
world
observ
comprehens
plan
made
accord
domest
resourc
circumst
annual
monthli
calendar
formul
result
due
differ
certif
cne
session
nurs
improv
nurs
knowledg
compet
increas
enhanc
nurs
skill
knowledg
signific
decreas
patient
mortal
morbid
shall
observ
eg
sepsi
extravas
mucos
chemotherapi
toxic
medic
error
incid
unsuccess
code
blue
attempt
conclus
nurs
educ
essenti
way
enhanc
nurs
profession
skill
knowledg
effect
cnescertif
cours
reflect
qualiti
patient
care
cne
anticip
increas
level
compet
confid
among
pediatr
oncolog
nurs
provid
qualiti
care
meet
base
line
standard
siop
podc
baselin
standard
pediatr
oncolog
nurs
care
lmic
khatoon
df
k
indu
hospit
network
infect
control
karachi
pakistan
backgroundobject
educ
essenti
prevent
infect
pakistan
infect
control
pediatr
oncolog
set
challeng
lead
unnecessari
morbid
mortal
infect
prevent
nurs
associ
ipna
receiv
fund
sanofi
espoir
foundat
creat
educ
materi
reduc
issu
children
cancer
designmethod
indu
hospit
karachi
six
infect
control
nurs
two
doctor
three
depart
member
particip
project
team
work
find
appropri
content
relat
infect
control
pediatr
oncolog
patient
materi
compil
video
health
worker
video
book
patient
famili
head
infect
control
depart
nurs
provid
urdu
translat
pediatr
oncologist
verifi
final
draft
result
five
healthcar
profession
educ
video
line
care
hand
hygien
pneumonia
prevent
urinari
tract
infect
prevent
asept
cannula
insert
made
free
video
distribut
social
media
hospit
target
health
worker
patient
famili
provid
video
cancer
care
detail
book
urdu
infect
control
practic
approxim
book
per
month
continu
distribut
amongst
patient
famili
across
eight
hospit
lahor
islamabad
multan
karachi
conclus
video
book
well
receiv
patient
famili
educ
video
healthcar
profession
encourag
hospit
treat
pediatr
oncolog
patient
karachi
across
pakistan
becom
involv
infect
control
educ
awar
infect
control
practic
key
reduc
unnecessari
suffer
death
lmic
aim
improv
patient
care
surviv
rate
reduc
burden
infect
pakistani
hospit
caregiv
immunocompromis
children
ys
kim
hj
jj
kn
jy
medic
center
children
hospit
pediatr
seoul
republ
korea
nurs
univers
ulsan
seoul
republ
korea
backgroundobject
caregiv
knowledg
perform
regard
care
children
cancer
essenti
issu
thu
studi
conduct
investig
pediatr
cancer
caregiv
knowledg
perform
safeti
manag
antineoplast
agent
designmethod
studi
perform
pediatr
cancer
caregiv
use
questionnair
novemb
asan
medic
center
measur
develop
research
base
american
societi
pharmacist
guidelin
handl
hazard
drug
safe
manag
chemotherapi
home
establish
oncolog
nurs
societi
previou
studi
compos
question
knowledg
perform
safeti
manag
antineoplast
agent
result
averag
score
knowledg
safeti
manag
caregiv
pediatr
cancer
awar
metabolit
antineoplast
agent
higher
lowest
incorrect
answer
use
alcohol
gel
expos
antineoplast
agent
skin
averag
score
anticip
perform
highest
score
item
use
hand
check
without
glove
antineoplast
agent
leak
inject
lowest
score
item
flush
two
time
water
hour
antineoplast
agent
administr
signific
correl
pediatr
cancer
caregiv
knowledg
perform
safeti
manag
r
p
conclus
studi
show
level
knowledg
perform
pediatr
cancer
caregiv
regard
safe
handl
antineoplast
agent
exceed
averag
level
major
area
impli
variou
repeat
educ
safe
handl
antineoplast
agent
improv
knowledg
perform
studi
suggest
repeat
research
standard
tool
warrant
kobayashi
k
k
j
k
univers
tokyo
depart
famili
nurs
tokyo
japan
univers
tokyo
hospit
depart
pediatr
tokyo
japan
univers
tokyo
hospit
depart
nurs
tokyo
japan
children
medic
center
depart
hematologyoncolog
saitama
japan
metropolitan
children
medic
center
depart
hematologyoncolog
tokyo
japan
backgroundobject
parent
life
especi
work
condit
would
impact
children
situat
diagnosi
cancer
hospit
intens
multidisciplinari
treatment
sever
month
year
chang
work
condit
would
lead
lower
parent
qualiti
life
hrqol
understand
parent
belief
would
benefici
support
parent
aim
studi
describ
hrqol
parent
hospit
children
cancer
term
chang
work
condit
owe
children
cancer
clarifi
relationship
hrqol
belief
relat
chang
work
condit
designmethod
studi
employ
septemb
march
three
hospit
japan
hrqol
evalu
use
standard
version
chang
work
condit
assess
term
chang
employ
statu
work
hour
andor
work
content
belief
evalu
use
origin
item
mean
score
summari
score
compar
four
group
classifi
term
chang
work
condit
quitleav
arrang
continu
housew
linear
mix
model
analysi
perform
calcul
coeffici
summari
score
belief
result
data
mother
father
analyz
arrang
group
lowest
mean
physic
pc
mental
compon
summari
score
mc
wherea
quitleav
group
lowest
rolesoci
compon
summari
score
rc
belief
priorit
work
care
child
necessari
item
score
mc
posit
correl
conclus
chang
work
condit
may
lower
hrqol
parent
hospit
children
cancer
belief
also
relat
parent
hrqol
improv
parent
hrqol
healthcar
profession
assess
parent
belief
necessari
encourag
parent
maintain
work
condit
le
f
children
medic
affili
shanghai
jiaotong
univers
pediatr
hematolog
oncolog
shanghai
china
backgroundobject
pediatr
patient
cancer
undergo
repeat
invas
pain
medic
procedur
lumber
punctur
bone
biopsi
pain
highli
distress
one
environ
total
anesthesia
avail
patient
receiv
lumber
punctur
bone
biopsi
studi
evalu
effect
combin
pharmacolog
intervent
program
first
time
lumber
punctur
bone
biopsi
childhood
cancer
patient
designmethod
clinic
control
trial
pediatr
cancer
patient
age
year
receiv
lumber
punctur
bone
biopsi
first
time
outpati
clinic
enrol
patient
control
group
receiv
routin
care
patient
undergo
lumber
punctur
bone
biopsi
provid
combin
pharmacolog
intervent
program
includ
applic
topic
anesthet
prepar
use
children
comic
book
audio
lumber
punctur
bone
biopsi
procedur
pain
fear
complianc
collect
group
result
averag
pain
treatment
group
control
group
statist
signific
differ
p
percentag
procedur
fear
treatment
group
control
group
statist
signific
differ
p
differ
complianc
two
group
conclus
combin
pharmacolog
intervent
program
effect
decreas
procedur
pain
fear
first
time
lumber
punctur
bone
biopsi
childhood
cancer
patient
libura
k
warmia
mazuri
medic
train
simul
centr
olsztyn
poland
rydygi
collegium
nicolau
copernicu
univers
paediatr
hematooncolog
oncolog
laboratori
commun
medcin
bydgoszcz
poland
backgroundobject
work
paediatr
oncolog
depart
demonstr
relat
substanti
level
emot
burden
member
oncolog
care
team
nurs
spend
particularli
high
amount
time
interact
directli
patient
make
suscept
stress
purpos
pilot
studi
identifi
primari
sourc
emot
burden
paediatr
oncolog
nurs
poland
designmethod
questionnair
base
literatur
review
distribut
among
paediatr
oncolog
nurs
work
univers
hospit
bydgoszcz
nurs
return
compet
questionnair
preliminari
find
serv
basi
larger
studi
result
one
particip
studi
indic
work
paediatr
oncolog
depart
sourc
work
satisfact
remain
respond
chose
rather
definit
answer
particip
evalu
work
specialti
emot
burdensom
comparison
hospit
depart
negoti
famili
life
work
major
problem
contrari
expect
major
sourc
stress
emot
relat
state
patient
parent
rel
low
wage
major
also
point
challeng
behaviour
parent
burden
well
complic
interprofession
relat
relat
nurs
also
point
sourc
dissatisfact
interestingli
lenght
shift
indic
problem
conclus
main
sourc
work
relat
burden
paediatr
oncolog
nurs
emot
relat
interact
patient
famili
may
signal
shortcom
train
therm
compet
skill
necessari
prevent
futur
burnout
anoth
major
problemat
area
renumer
wider
problem
nation
context
poland
train
futur
health
profession
team
work
commun
skill
also
crucial
yy
lim
women
children
hospit
paediatr
haematolog
oncolog
singapor
singapor
backgroundobject
chemotherapi
induc
peripher
neuropathi
cipn
complic
affect
childhood
cancer
patient
research
address
need
ensur
consist
screen
cipn
primari
aim
studi
determin
reliabl
nurs
physiotherapist
perform
cipn
assess
use
pediatr
total
neuropathi
score
secondari
aim
establish
relationship
cumul
dose
vincristin
score
designmethod
cohort
studi
use
physiolog
measur
outcom
measur
target
particip
age
year
studi
estim
intraclass
correl
coeffici
icc
nurs
physiotherapist
conduct
assess
cipn
use
particip
nonparametr
spearman
correl
test
use
estim
correl
cumul
dose
vincristin
score
result
preliminari
find
particip
investig
observ
worsen
cipn
score
particip
induct
chemotherapi
vincristin
administ
weekli
particip
experienc
mild
sever
weak
lower
extrem
result
higher
risk
fall
phase
progress
recoveri
overtim
promin
may
suggest
correl
cumul
dose
vincristin
worsen
cipn
score
howev
result
still
infanc
recruit
particip
reach
target
continu
necessari
suffici
power
data
analysi
conclus
earli
detect
cipn
lead
earli
intervent
support
care
minimis
progress
symptom
prevent
patient
harm
allevi
undesir
symptom
associ
cipn
thu
imper
adopt
valid
reliabl
nurs
assess
tool
earli
detect
cipn
reduc
risk
potenti
improv
clinic
outcom
qualiti
life
paediatr
oncolog
patient
yy
lim
women
children
hospit
paediatr
haematolog
oncolog
singapor
singapor
backgroundobject
complex
divers
haematopoiet
stem
cell
transplant
hsct
patient
necessit
nurs
quickli
integr
knowledg
along
advanc
set
clinic
skill
ensur
provis
safe
effect
care
formerli
train
program
new
hsct
nurs
train
job
experienc
nurs
result
practic
variat
furthermor
nurs
felt
inadequ
prepar
practic
complex
clinic
environ
designmethod
paediatr
hsct
nurs
cours
design
provid
nurs
fundament
knowledg
skill
deliv
high
standard
nurs
care
hsct
patient
cours
content
outlin
adopt
oncolog
nurs
certif
corpor
parallel
need
analysi
conduct
among
hsct
nurs
cours
compris
didact
class
deliv
multidisciplinari
team
case
discuss
experienti
learn
clinic
attach
experienc
nurs
translat
theoret
knowledg
clinic
practic
nurs
assess
pre
multipl
choic
question
mcq
skill
assess
case
present
result
nurs
abl
achiev
least
post
cours
mcq
attempt
score
significantli
higher
percentag
repeat
mcq
follow
cours
core
compet
skill
stem
cell
infus
patient
educ
assess
compet
checklist
direct
observ
skill
transfer
nurs
practic
set
post
cours
evalu
shown
increas
rate
confid
level
particip
conclus
hsct
highli
challeng
area
constantli
evolv
nurs
continu
challeng
bridg
advanc
technolog
complex
care
regimen
involv
coordin
interdisciplinari
care
activ
beyond
structur
cours
curriculum
futur
hsct
nurs
educ
amelior
benefit
interprofession
educ
reflect
recent
evid
shape
success
collabor
teamwork
hsct
care
fr
lin
py
taiwan
univers
children
hospit
nurs
taipei
taiwan
roc
backgroundobject
palli
care
pediatr
cancer
patient
famili
includ
relief
symptom
improv
qualiti
life
stage
diseas
care
effect
provid
interdisciplinari
team
purpos
studi
develop
interdisciplinari
care
model
establish
palli
care
end
life
care
children
adolesc
cancer
designmethod
set
studi
pediatr
oncolog
ward
taiwan
novemb
juli
use
satisfact
care
end
life
measur
medic
member
satisfact
instrument
base
literatur
review
work
method
symptom
manag
schedul
educ
symptom
control
care
end
life
patient
fatigu
pain
constip
dyspnea
develop
interdisciplinari
care
model
implement
case
analysi
end
life
patient
redesign
new
counsel
mechan
design
implement
child
life
specialist
requir
set
collect
toy
social
worker
result
studi
three
aspect
satisfact
score
recognit
problem
medic
team
increas
point
point
interdisciplinari
care
increas
point
point
implement
increas
point
point
addit
benefit
rate
coverag
end
life
children
adolesc
cancer
increas
conclus
found
children
adolesc
die
cancer
experienc
substanti
suffer
last
month
life
base
result
establish
interdisciplinari
care
model
effect
healthcar
qualiti
palli
care
improv
k
liu
j
x
x
univers
school
nurs
guangzhou
china
memori
hospit
nurs
depart
guangzhou
china
memori
hospit
pediatr
oncolog
depart
guangzhou
china
backgroundobject
children
malign
tumor
experi
multipl
distress
interrel
symptom
chemotherapi
especi
induct
period
identifi
symptom
interrel
guid
symptom
manag
pediatr
oncolog
depart
purpos
studi
explor
symptom
characterist
symptom
cluster
children
malign
tumor
induct
chemotherapi
period
designmethod
design
survey
conduct
among
children
malign
tumor
induct
chemotherapi
period
use
chines
version
memori
symptom
assess
exploratori
factor
analysi
use
identifi
symptom
cluster
result
averag
age
children
year
boy
common
symptom
children
malign
tumor
induct
period
lack
energi
nervou
lack
appetit
nausea
irrit
vomit
seven
cluster
identifi
data
use
exploratori
factor
analysi
upper
gastrointestin
symptom
cluster
irrit
mood
symptom
cluster
depress
mood
cluster
imag
impair
symptom
cluster
nervou
system
symptom
cluster
skin
mucosa
symptom
cluster
ingest
excret
symptom
cluster
conclus
children
experienc
multipl
symptom
underw
varieti
symptom
cluster
induct
chemotherapi
period
order
allevi
overal
symptom
cluster
distress
health
care
profession
pay
attent
common
symptom
bother
children
induct
chemotherapi
find
control
key
symptom
symptom
cluster
liu
c
n
ps
jiaotong
univers
school
nurs
shanghai
china
univers
school
nurs
shanghai
china
children
medic
center
affili
shanghai
jiaotong
univers
school
medicin
nurs
depart
shanghai
china
nation
health
system
depart
nurs
research
qualiti
center
translat
scienc
washingtondc
usa
georg
washington
univers
school
medicin
washingtondc
usa
backgroundobject
children
cancer
experi
unpleas
symptom
weaken
bodi
health
due
diseas
treatment
purpos
studi
identifi
group
patient
experi
similar
level
symptom
function
use
latent
profil
analysi
lpa
examin
predictor
profil
membership
children
cancer
china
designmethod
children
health
outcom
data
collect
use
chines
version
promi
pediatr
short
form
depress
symptom
anger
anxieti
fatigu
pain
interfer
peer
relationship
physic
physic
extrem
children
adolesc
cancer
age
recruit
three
hospit
china
lpa
use
identifi
character
group
patient
report
similar
level
symptom
suffer
bodi
function
multinomi
logist
regress
use
test
relationship
latent
profil
membership
individu
characterist
result
analysi
includ
patient
treatment
survivorship
half
diagnos
leukemia
children
health
problem
three
health
outcom
profil
identifi
current
receiv
cancer
treatment
hospit
past
seven
day
like
member
profil
highest
level
symptom
suffer
weaken
bodi
function
age
gender
guardian
educ
level
tumor
type
durat
ill
health
problem
associ
profil
membership
conclus
lpa
use
cluster
methodolog
identifi
latent
profil
health
statu
observ
symptom
function
pediatr
oncolog
made
possibl
predict
patient
risk
develop
sever
symptom
weaken
function
allow
clinician
parent
patient
better
anticip
prevent
multipl
symptom
occur
cancer
treatment
c
llano
mc
de
recerca
sant
joan
de
research
foundat
sjd
clinic
trial
unit
barcelona
spain
backgroundobject
immunotherapi
becom
standard
care
neuroblastoma
implement
novel
therapi
signific
toxic
associ
challeng
profession
also
parent
main
object
move
current
dinutuximab
base
treatment
memori
sloan
ketter
cancer
center
mskcc
naxitamab
outpati
administr
main
three
object
achiev
empow
patient
parent
prepar
second
train
profession
procedur
circuit
final
custom
new
protocol
avoid
risk
patient
care
designmethod
train
consist
eight
day
cours
mskcc
local
nurs
staff
learn
healthcar
model
develop
local
program
supervis
hospit
sant
joan
de
mskcc
nurs
staff
result
newli
develop
protocol
patient
treat
includ
nurs
visit
patient
parent
prior
first
infus
focu
techniqu
recommend
deal
expect
toxic
skill
medic
nurs
staff
capabl
face
administr
specif
monitor
strategi
enrol
support
care
profession
includ
child
life
psychologist
anesthesiologist
increas
patient
infus
specif
monitor
registri
elabor
report
whole
experi
profession
patient
parent
weekli
multidisciplinari
staff
meet
set
discuss
singl
patient
treatment
need
conclus
adopt
mskcc
treatment
site
requir
analysi
medic
procedur
whole
manag
patient
importantli
european
legisl
framework
restrict
role
establish
mskcc
nurs
requir
local
adapt
increas
patient
famili
center
support
care
improv
significantli
intens
psycholog
experi
associ
naxitamab
treatment
h
lu
children
medic
affili
shanghai
jiaotong
univers
pediatr
hematolog
oncolog
shanghai
china
backgroundobject
number
pediatr
patient
cancer
countri
expand
rapidli
particularli
china
howev
measur
qualiti
impact
care
provid
essenti
improv
nurs
care
remain
lack
studi
develop
qualiti
indic
system
pediatr
hematolog
oncolog
nurs
china
designmethod
base
donabedian
theori
literatur
review
interview
delphi
method
analyt
hierarchi
process
method
adopt
determin
nurs
qualiti
indic
system
indic
weight
support
chines
associ
nurs
group
result
three
round
expert
advisori
effect
respons
rate
cr
coeffici
w
coeffici
p
valu
indic
system
consist
first
level
indic
indic
indic
analyt
hierarchi
process
use
establish
weight
conclus
construct
indic
system
pediatr
hematolog
oncolog
nurs
scientif
practic
uniqu
specialti
could
facilit
sustain
develop
pediatr
hematolog
oncolog
p
mahon
school
nurs
vancouv
canada
backgroundobject
paediatr
haematologyoncolog
unit
phou
highli
pace
stress
environ
difficult
area
work
thu
unit
present
issu
come
recruit
retain
nurs
littl
research
address
environ
phou
contribut
nurs
desir
stay
leav
environ
designmethod
conduct
project
critic
ethnograph
approach
use
critic
ethnographi
ce
see
construct
power
knowledg
interconnect
make
mutual
contribut
knowledg
hardcastl
et
al
adher
research
belief
critic
ethnographi
base
critic
social
theori
cst
ethnographi
ce
one
evolutionari
path
ethnographi
carspecken
stage
ce
follow
interview
conduct
sampl
repres
approxim
nurs
staff
result
develop
long
term
relationship
children
famili
part
team
sourc
satisfact
abil
learn
opportun
teach
famili
satisfi
aspect
job
thu
impli
staff
famili
unusu
relationship
comparison
hospit
environ
staff
tend
maintain
power
diagnosi
treatment
main
frustrat
describ
pertain
administr
involv
everyday
work
phou
conclus
relationship
team
member
children
famili
satisfi
nurs
howev
difficult
situat
aris
nurs
find
difficult
deal
might
suggest
nurs
work
children
cancer
unwritten
rule
expect
toler
bad
behavior
famili
understand
level
stress
warrant
investig
abil
learn
evolv
field
import
staff
administr
involv
decis
surround
everi
day
work
phou
could
caus
attrit
b
mandrel
l
e
r
r
e
c
j
l
k
jude
children
research
hospit
divis
nurs
research
memphi
usa
jude
children
research
hospit
oncolog
memphi
usa
backgroundobject
littl
known
parent
understand
knowledg
consent
process
genom
sequenc
child
somat
germlin
sampl
object
studi
aim
evalu
chang
parent
genet
knowledg
complet
consent
process
designmethod
design
longitudin
studi
parent
consent
clinic
genom
sequenc
child
cancer
method
parent
interest
clinic
genom
sequenc
child
cancer
particip
consent
process
prior
studi
introductori
visit
siv
parent
complet
genet
knowledg
test
siv
conduct
train
studi
nurs
provid
genet
educ
studi
summari
approxim
week
later
parent
return
inform
consent
convers
icc
conduct
train
studi
nurs
complet
icc
parent
complet
genet
knowledg
test
result
result
parent
particip
siv
icc
comparison
answer
provid
two
genet
knowledg
test
reveal
parent
genet
knowledg
significantli
improv
question
ask
two
question
without
chang
answer
correctli
major
particip
despit
signific
improv
correct
respons
parent
answer
question
differ
germlin
somat
test
correctli
conclus
conclus
parent
consent
clinic
genom
sequenc
child
demonstr
improv
knowledg
follow
consent
process
howev
concept
germlin
somat
mutat
remain
difficult
comprehend
mannaert
g
l
f
van
l
n
gent
pediatr
gent
belgium
hoeck
consult
human
resourc
consult
gent
belgium
backgroundobject
job
evalu
pediatr
ward
pho
univers
hospit
ghent
nurs
express
frustrat
colleagu
lack
certain
skill
without
appreci
suffici
talent
convers
three
major
qualiti
defin
plan
organis
well
chaotic
situat
work
quickli
effici
commun
nurs
need
patient
decid
organ
workshop
order
defin
skill
evalu
colleagu
respect
skill
abl
giverec
feedback
construct
manner
designmethod
workshop
talent
scout
spread
three
session
organis
nurs
close
collabor
consult
first
skill
ideal
nurs
decid
group
convers
small
group
discuss
way
skill
individu
team
could
best
use
develop
give
construct
feedback
irrit
aris
caus
individu
weak
final
nurs
attribut
skill
hesh
thought
signific
colleagu
result
nurs
receiv
diagram
skill
perceiv
colleagu
use
start
point
futur
job
evalu
workshop
central
studi
group
drew
decis
tree
hung
ward
charter
decis
tree
decid
upon
way
react
irrit
behaviour
conclus
individu
diagram
skill
decis
tree
make
frustrat
subject
discuss
mean
start
posit
group
dynam
skill
weak
focuss
upon
possibl
initi
necessari
n
mari
nurs
fct
nigeria
backgroundobject
cancer
one
major
caus
death
children
adolesc
account
death
children
year
nigeria
nurs
care
patient
often
receiv
adequ
attent
report
highlight
challeng
nurs
care
children
low
resourc
set
aim
rais
awar
influenc
advocaci
action
designmethod
retrospect
review
children
treat
cancer
inpati
children
ward
period
novemb
novemb
period
total
children
admit
ward
nurs
care
patient
review
designmethod
retrospect
review
children
treat
cancer
inpati
children
ward
period
novemb
novemb
period
total
children
admit
ward
nurs
care
patient
review
result
children
cancer
account
admiss
ward
addit
nurs
workload
patient
sever
import
challeng
limit
encount
requir
attent
effort
nurs
staff
includ
financi
burden
parent
inabl
cope
cost
psycholog
issu
involv
parent
patient
aggress
anxieti
depress
withdraw
difficulti
commun
diseas
cours
treatment
complic
treatment
challeng
significantli
increas
nurs
burden
patient
often
part
patient
treatment
plan
conclus
import
includ
identifi
challeng
counsel
treatment
plan
children
cancer
particularli
low
resourc
set
burden
nurs
care
enorm
develop
implement
care
multidisciplinari
care
plan
help
address
challeng
n
mashiko
k
r
prefectur
colleg
health
scienc
school
nurs
maebashi
japan
children
hospit
nurs
shizuoka
japan
univers
graduat
school
nurs
nurs
sagamihara
japan
cancer
center
hospit
nurs
japan
medic
univers
school
nurs
adult
nurs
shimotsuk
japan
cancer
center
hospit
east
nurs
kashiwa
japan
hyogo
colleg
nurs
art
scienc
clinic
nurs
hyogo
japan
citi
gener
hospit
nurs
osaka
japan
backgroundobject
studi
explor
context
peer
support
address
studi
adolesc
young
adult
aya
cancer
patient
order
gain
insight
support
util
clinic
practic
improv
qualiti
life
qol
patient
designmethod
first
literatur
search
japan
medic
abstract
societi
databas
perform
use
term
peer
support
cancer
neoplasm
obtain
overview
research
peer
support
japan
literatur
search
pubm
databas
perform
use
term
order
survey
research
countri
research
found
consist
studi
object
exclud
base
titl
articl
abstract
thirteen
articl
japan
countri
extract
base
context
peer
support
aya
cancer
patient
address
result
articl
peer
support
aya
cancer
patient
includ
analysi
analyz
similar
descript
context
peer
support
address
articl
found
includ
theme
peer
support
psychosoci
need
peer
support
strategi
facilit
support
improv
qol
devis
way
effect
implement
peer
support
aya
cancer
patient
conclus
aya
cancer
patient
need
connect
support
peer
howev
medic
personnel
implement
peer
support
direct
care
find
suggest
act
effect
provid
set
conduc
peer
support
use
support
strateg
clinic
practic
may
use
facilit
care
intend
improv
qol
h
megumi
nurs
nagoya
univers
graduat
school
medicin
nagoya
japan
backgroundobject
children
cancer
experi
death
close
companion
struggl
diseas
howev
almost
domest
intern
protocol
assess
grief
care
children
famili
continu
treatment
experienc
death
friend
thu
seem
necessari
investig
experi
parent
children
cancer
examin
method
support
children
cancer
provid
nurs
support
parent
establish
partnership
parent
designmethod
studi
design
qualit
induct
studi
data
collect
method
interview
inclus
criteria
parent
child
cancer
continu
receiv
ambulatori
treatment
complet
cours
treatment
lost
friend
receiv
inpati
care
hospit
period
past
year
result
subject
studi
two
mother
fill
sorrow
child
friend
death
associ
death
surviv
child
brought
person
anxieti
children
either
higher
grade
elementari
junior
high
school
mother
hesit
inform
child
loss
friend
possibl
desir
child
forget
understand
futil
tri
conceal
death
howev
subject
give
due
consider
child
physic
mental
health
plan
time
disclosur
loss
children
disclosur
subject
unabl
evalu
whether
decis
made
correct
children
initi
lack
reaction
disclosur
conclus
necessari
intervent
focu
understand
confus
attitud
support
decis
k
miyagishima
k
k
univers
school
medicin
faculti
nurs
hamamatsu
japan
christoph
univers
school
nurs
hamamatsu
japan
univers
school
medicin
depart
pediatr
hamamatsu
japan
children
hospit
nurs
depart
shizuoka
japan
backgroundobject
studi
aim
elucid
process
adolesc
young
adult
childhood
cancer
survivor
develop
independ
compat
health
manag
social
life
support
designmethod
interview
childhood
cancer
survivor
age
year
perform
analys
use
modifi
ground
theori
approach
result
concept
eight
six
categori
gener
health
manag
childhood
cancer
survivor
overcam
diseas
reli
parent
make
decis
help
includ
complet
accept
diseas
endur
pain
treatment
gain
help
attend
healthcar
visit
parent
develop
treatment
progress
manag
physic
condithin
base
judgment
includ
physic
condit
manag
awar
diseas
consult
obtain
imform
pass
parent
diseas
awar
fade
along
recoveri
physic
condit
howev
also
concern
ongo
effect
cancer
social
live
childhood
cancer
survivor
influenc
health
manag
experienc
school
life
coordin
mental
conflict
includ
adjust
balanc
school
activ
treatment
gain
cooper
teacher
friend
explain
diseas
care
worri
differ
everyon
els
activ
everyon
found
way
live
motiv
perform
activ
live
select
life
path
base
diseas
experi
work
motiv
conscious
make
live
conclus
find
suggest
necess
support
childhood
cancer
survivor
make
cancer
therapi
compat
school
life
live
independ
order
consciou
health
manag
influenc
childhood
cancer
l
morrissey
nw
tm
children
hospit
inpati
hematologyoncolog
nurs
walpol
usa
children
hospit
hematolog
oncolog
unit
yangon
myanmar
burma
children
hospit
hematologyoncolog
unit
yangon
children
hospit
myanmar
burma
backgroundobject
extravas
seriou
complic
pediatr
oncolog
patient
receiv
chemotherapi
via
peripher
intraven
cathet
leakag
vesic
chemotherapi
venou
pathway
caus
injuri
rang
blister
necrosi
surround
skin
tissu
lead
patient
harm
includ
pain
infect
loss
limb
function
children
receiv
cancer
treatment
low
resourc
set
central
venou
access
devic
cvad
avail
especi
vulner
extravas
risk
designmethod
hematologyoncolog
unit
hou
yangon
children
hospit
ych
target
extravas
prevent
qualiti
initi
initi
compon
program
includ
creation
standard
guidelin
chemotherapi
administr
educ
staff
monthli
data
collect
program
led
hou
ward
sister
extravas
rate
calcul
monthli
divid
number
extravas
number
dose
vesic
chemotherapi
multipli
one
thousand
number
day
extravas
new
qualiti
measur
ad
result
sinc
june
monthli
averag
vesic
chemotherapi
dose
administ
increas
concurr
extravas
rate
date
decreas
compar
rate
januari
april
hou
ward
gone
day
count
extravas
conclus
although
number
patient
receiv
chemotherapi
ych
increas
hou
ward
success
decreas
extravas
rate
month
period
develop
standard
guidelin
design
leader
educ
ongo
surveil
proven
success
strategi
reduc
extravas
pediatr
oncolog
program
low
resourc
set
cvad
avail
mulyowa
cancer
institut
pediatr
oncolog
kampala
uganda
backgroundobject
although
major
childhood
cancer
curabl
yet
true
low
resourc
countri
uganda
cancer
care
done
uganda
cancer
institut
jan
dec
new
cancer
case
regist
among
children
mortal
rate
annual
everi
children
diagnos
cancer
surviv
past
one
year
cancer
diagnosi
review
factor
contribut
poor
outcom
potenti
solut
object
designmethod
experi
result
major
children
present
advanc
diseas
cancer
diagnosi
treatment
intent
usual
palli
famili
involv
decis
regard
palli
chemotherapi
end
life
high
pediatr
compar
adult
oncolog
concept
qualiti
life
patient
advanc
cancer
well
perceiv
among
caretak
nurs
play
integr
role
identifi
symptom
provid
care
coordin
patient
time
also
ensur
clear
commun
patient
caretak
nurs
role
patient
admit
spend
time
ward
nurs
nurs
play
big
role
identifi
symptom
provid
care
coordin
implement
doctor
written
order
also
identifi
die
patient
nurs
also
play
big
role
continu
cancel
start
doctor
play
role
reassur
patient
especi
adolesc
also
reassur
famili
conclus
palli
care
train
clinician
healthcar
provid
essenti
also
educ
initi
patient
famili
regard
type
cancer
childpati
treatment
modal
emphas
oncolog
nurs
play
key
role
multidisciplinari
team
approach
paediatr
patient
end
life
care
murata
k
j
j
k
k
univers
tokyo
depart
famili
nurs
tokyo
japan
univers
tokyo
hospit
depart
pediatr
tokyo
japan
univers
tokyo
hospit
depart
nurs
tokyo
japan
children
medic
center
depart
hematologyoncolog
saitama
japan
metropolitan
children
medic
center
depart
hematologyoncolog
tokyo
japan
backgroundobject
fatigu
common
particularli
problemat
symptom
among
children
cancer
undergo
treatment
hospit
previou
studi
report
good
famili
function
reduc
problem
relat
cancer
treatment
howev
studi
evalu
famili
function
reduc
fatigu
among
children
cancer
aim
studi
clarifi
relationship
fatigu
famili
function
among
children
cancer
undergo
treatment
hospit
designmethod
studi
includ
children
cancer
treat
hospit
famili
septemb
march
data
collect
questionnair
medic
record
actigraph
pedsql
multidimension
fatigu
scale
famili
adapt
cohes
evalu
scale
kwansei
gakuin
faceskg
use
evalu
fatigu
famili
function
respect
spearman
rank
correl
coeffici
total
score
subscal
score
faceskg
cohes
adapt
score
calcul
result
fifteen
children
cancer
famili
complet
questionnair
mean
patient
age
year
old
common
diagnosi
acut
lymphoblast
leukemia
n
common
type
cohes
enmesh
n
common
type
adapt
flexibl
n
correl
coeffici
faceskg
cohes
total
score
p
faceskg
cohes
cognit
fatigu
score
p
faceskg
adapt
score
sleeprest
fatigu
score
p
indic
moder
effect
size
conclus
high
famili
cohes
may
reduc
fatigu
among
children
cancer
undergo
treatment
hospit
nurs
may
need
support
patient
enhanc
emot
bond
famili
nagata
gakuin
univers
nurs
yokohama
japan
citi
univers
medicin
yokohama
japan
rehabilitarion
colleg
physic
therapi
nagaoka
japan
backgroundobject
cancer
rehabilit
medic
care
procedur
aim
improv
vital
function
qol
patient
cancer
social
rehabilit
approach
condit
patient
cancer
facilit
return
normal
life
studi
aim
clarifi
statu
provid
support
daili
activ
social
rehabilit
hospit
maintain
improv
abil
patient
childhood
cancer
return
normal
life
discharg
designmethod
interview
seven
nurs
engag
social
rehabilit
basic
daili
activ
independ
lifestyl
social
particip
children
undergo
cancer
treatment
record
interview
transcrib
interview
data
extract
inform
regard
support
activ
daili
live
mention
context
social
rehabilit
children
undergo
cancer
treatment
conduct
qualit
induct
analysi
studi
approv
research
ethic
committe
result
support
activ
report
nurs
divid
eight
categori
support
reestablish
daili
life
rhythm
provis
environ
daili
play
studi
coordin
teacher
volunt
special
support
school
class
enabl
continu
learn
plan
host
season
event
recreat
activ
train
activ
prevent
infect
cvc
nutrit
oral
healthcar
base
immun
state
dietari
educ
cook
meal
session
situat
safeti
educ
conclus
studi
show
support
establish
daili
rhythm
play
learn
daili
activ
order
minim
impact
prolong
hospit
daili
life
nutrit
health
educ
prepar
immunodefici
result
treatment
import
provid
support
activ
daili
live
part
social
rehabilit
children
undergo
cancer
treatment
studi
support
jsp
kakenhi
grant
number
nagayoshi
jikei
univers
school
nurs
tokyo
japan
citi
univers
school
nurs
kanagawa
japan
backgroundobject
infant
retinoblastoma
rb
complet
treatment
late
infanc
attend
kindergarten
studi
aim
clarifi
development
characterist
rb
infant
late
infanc
understand
parent
stress
experienc
mother
explor
progress
treatment
designmethod
prospect
studi
use
strength
difficulti
questionnair
sdq
parent
stress
index
psi
conduct
interv
japanes
mother
rb
infant
longitudin
statist
analys
perform
use
spss
ibm
result
subject
includ
infant
unilater
rb
bilater
rb
singl
eye
enucl
infant
median
age
month
development
quotient
time
age
diagnosi
month
treatment
period
month
infant
enter
kindergarten
signific
differ
psi
sdq
score
observ
time
point
mother
show
score
psi
mood
posit
corel
sdq
conduct
problem
time
p
problemsworri
scoreswer
significantli
higher
norm
mean
p
six
infant
time
four
time
show
high
need
score
sdq
prosoci
score
time
neg
corel
problemsworri
p
total
difficulti
corel
child
domain
total
p
hang
around
parent
p
depress
p
conclus
although
rb
infant
underdevelop
mother
frequent
saw
problem
infant
behavior
social
skill
join
kindergarten
felt
stress
parent
role
may
exacerb
mental
depress
suggest
need
advic
support
tailor
differ
development
stage
acknowledg
studi
fund
partial
scientif
research
nagoya
w
c
k
h
children
hospit
nurs
depart
miyagi
japan
univers
graduat
school
medicin
depart
child
health
nurs
miyagi
japan
children
hospit
depart
hematolog
oncolog
miyagi
japan
backgroundobject
part
famili
support
miyagi
children
hospit
certifi
nurs
specialist
cn
visit
oncolog
unit
everi
two
week
consult
famili
member
hospit
pediatr
patient
aim
studi
retrospect
elucid
famili
member
told
cn
concern
sibl
use
medic
record
designmethod
use
medic
record
juli
juli
narr
person
record
unit
concern
sibl
extract
content
analyz
result
narr
categor
categori
subcategori
categori
follow
chang
lifestyl
sibl
mental
burden
sibl
provis
inform
sibl
social
interact
patient
sibl
make
time
sibl
parent
spend
togeth
awar
growth
sibl
subcategori
follow
worri
chang
lifestyl
adjust
plan
minim
chang
life
worri
creat
mental
burden
revel
physic
behavior
problem
difficulti
find
word
take
feel
consider
degre
understand
diseas
hesit
concern
method
explan
confus
sibl
ask
diseas
patient
surround
peopl
hope
statu
social
interact
visit
sleepov
visit
patient
sibl
difficulti
care
patient
sibl
visit
sleepov
visit
consider
creat
memori
event
long
vacat
consider
period
make
time
sibl
parent
spend
togeth
conclus
result
reveal
parent
worri
feel
hesit
concern
chang
lifestyl
accompani
burden
sibl
need
support
relat
sibl
cn
need
listen
give
advic
parent
concern
worri
hesit
relat
sibl
also
creat
system
directli
provid
support
sibl
nakamura
univers
depart
oral
health
kobe
japan
univers
graduat
school
depart
oral
health
care
doctor
cours
oral
health
scienc
tokushima
japan
univers
graduat
school
depart
oral
health
care
institut
biomed
tokushima
japan
prefectur
kobe
children
hospit
depart
pediatr
dentistri
kobe
japan
prefectur
kobe
children
hospit
depart
hematolog
oncolog
kobe
japan
backgroundobject
poor
oral
hygien
patient
undergo
chemotherapi
often
caus
signific
increas
morbid
howev
parent
child
cancer
may
requir
charg
oral
health
manag
instead
children
conduct
prospect
observ
studi
clarifi
relationship
parent
particip
comprehens
educ
program
oral
health
manag
oral
advers
event
pediatr
cancer
patient
designmethod
april
decemb
patient
age
childhood
cancer
kobe
children
hospit
enrol
studi
undergo
chemotherapi
particip
provid
comprehens
educ
program
oral
health
manag
degre
activ
particip
oral
health
manag
assess
month
enrol
studi
score
structur
questionnair
obtain
particip
categor
activ
particip
particip
oral
complic
stomat
xerostomia
gingiv
dental
cari
retriev
medic
record
comparison
categor
variabl
perform
use
fisher
exact
test
studi
approv
local
institut
ethic
committe
written
inform
consent
obtain
patient
andor
parent
result
preschool
period
yr
incid
gingiv
dental
cari
notabl
increas
particip
group
compar
activ
particip
group
p
wherea
signific
school
age
period
yr
conclus
even
help
patient
oral
health
care
prevent
oral
complic
hospit
parent
particip
level
oral
health
manag
may
associ
oral
advers
event
pediatr
cancer
patient
result
indic
parent
may
play
import
role
oral
health
manag
children
undergo
chemotherapi
ntt
nhan
k
l
children
hospit
nurs
depart
hanoi
vietnam
central
hospit
nurs
depart
hue
vietnam
citi
hospit
nurs
depart
ho
chi
minh
citi
vietnam
pharmaceut
educ
san
texa
usa
benioff
children
hospit
nurs
depart
san
california
usa
children
care
leagu
accl
board
tokyo
japan
san
francisco
depart
famili
health
nurs
global
cancer
program
san
california
usa
backgroundobject
new
case
childhood
cancer
vietnam
significantli
increas
result
effort
aim
toward
earli
screen
referr
pediatr
cancer
center
vietnam
order
optim
care
improv
outcom
patient
essenti
support
emerg
specialti
pediatr
oncolog
nurs
within
vietnam
nurs
countri
l
mic
often
challeng
educ
lack
mentor
scope
profession
practic
limit
resourc
therefor
effort
promot
profession
activ
develop
specialti
pediatr
oncolog
nurs
vietnam
vital
designmethod
commun
via
email
confer
call
visit
vietnam
nurs
leadership
twin
partner
gener
sever
ongo
project
educ
program
mutual
establish
mission
statement
program
object
found
baselin
nurs
standard
focus
effort
develop
opportun
foster
educationtrain
promot
collabor
facilit
network
result
last
year
vietnames
nurs
attend
approxim
fifti
educ
offer
includ
web
conferenc
didact
lectur
skill
train
present
intern
local
pediatr
oncolog
nurs
first
vietnam
pediatr
oncolog
nurs
confer
held
august
program
involv
nurs
session
joint
program
physician
parent
addit
revis
patientpar
educ
handbook
develop
wallet
size
emerg
card
patientspar
exampl
current
collabor
nation
nurs
project
awar
baselin
nurs
standard
led
initi
practic
chang
monthli
confer
call
nurs
leader
key
hospit
support
ongo
collabor
conclus
effort
establish
profession
collabor
environ
nation
led
emerg
compet
commit
empow
nurs
workforc
pediatr
oncolog
nurs
specialti
continu
develop
vietnam
opportun
potenti
activ
includ
establish
pediatr
oncolog
nurs
organ
nilsson
p
af
health
care
scienc
univers
gothenburg
gothenburg
sweden
psychiatri
sahlgrenska
univers
hospit
gothenburg
sweden
learn
commun
univers
gothenburg
gothenburg
sweden
backgroundobject
age
definit
adolesc
young
adult
aya
studi
year
aya
cancer
often
lack
fora
approach
thought
death
die
healthcar
profession
alway
abl
support
aim
investig
need
aya
cancer
peopl
close
relat
support
cope
death
designmethod
questionnair
investig
need
support
distribut
member
organ
ung
cancer
young
cancer
result
total
member
particip
men
undergo
cancer
treatment
complet
cancer
treatment
close
relat
person
cancer
among
close
relat
person
die
cancer
result
indic
think
death
everi
day
report
need
support
averag
rang
need
much
need
rank
order
person
offer
support
partner
psychologist
parent
three
common
context
talk
death
home
social
media
meet
organ
conclus
diagnos
cancer
live
close
relat
person
cancer
often
pronounc
need
come
term
cope
death
opportun
talk
death
improv
manag
neg
stress
anxieti
face
death
project
address
need
cope
death
develop
platform
context
support
noda
h
u
k
k
k
nurs
colleg
nurs
fukuoka
japan
school
medic
kyushu
univers
depart
pediatr
fukuoka
japan
backgroundobject
occup
exposur
hazard
drug
hd
previous
investig
guidelin
hd
exposur
establish
howev
statu
hd
exposur
attend
famili
member
pediatr
cancer
patient
remain
unknown
designmethod
analyz
cyclophosphamid
exposur
environ
urin
attend
famili
member
administ
hd
pediatr
cancer
patient
result
cyclophosphamid
cpm
detect
urin
infant
adolesc
patient
famili
respect
p
hd
exposur
infant
patient
famili
significantli
greater
adolesc
patient
famili
addit
cpm
detect
hot
water
use
bath
infant
underwear
sheet
use
adolesc
exposur
bodi
fluid
excret
infant
adolesc
patient
conclus
treatment
childhood
cancer
measur
prevent
hd
exposur
appli
accord
patient
age
order
minim
health
risk
medic
personnel
also
patient
famili
member
children
presenc
patient
nurs
recommend
educ
patient
famili
member
regard
prevent
hd
exposur
pediatr
medic
center
acknowledg
would
like
express
sincer
gratitud
patient
famili
ward
staff
cooper
research
ns
noviani
indah
sari
h
nation
cancer
centr
pediatr
nurs
dki
jakarta
indonesia
universita
indonesia
pediatr
nurs
depart
depok
indonesia
backgroundobject
constip
one
problem
often
complain
becom
sourc
physic
psycholog
distress
affect
qualiti
life
cancer
children
handl
properli
constip
assess
scale
ca
one
instrument
constip
assess
pediatr
cancer
valid
english
version
howev
indonesia
urg
use
instrument
indonesian
version
purpos
studi
test
valid
reliabl
constip
assess
scale
indonesian
version
pediatr
cancer
popul
identifi
scope
constip
problem
designmethod
ca
instrument
translat
indonesian
languag
follow
back
translat
get
simililar
origin
instrument
ca
indonesian
version
test
children
year
old
cancer
undergo
chemoterapi
receiv
opioid
pain
therapi
analysi
use
valid
reliabl
singl
test
result
ca
instrument
good
valid
r
good
reliabl
chronbach
alfa
ca
screen
result
major
cancer
patient
mild
constip
complaint
chang
bowel
pattern
hard
stool
difficult
bowel
movement
conclus
ca
pediatr
instrument
valid
reliabl
tool
screen
constip
issu
indonesian
pediatr
cancer
j
ogawa
k
univers
colleag
nurs
nutrit
chiba
japan
children
hospit
outpati
ward
chiba
japan
univers
medic
center
pediatr
ward
chiba
japan
univers
hospit
pediatr
ward
chiba
japan
children
hospit
hematolog
oncolog
ward
chiba
japan
children
hospit
intens
care
unit
chiba
japan
backgroundobject
guidelin
prevent
occup
exposur
anticanc
drug
publish
japan
howev
insuffici
cover
pediatr
oncolog
area
research
nurs
think
occup
exposur
focus
buttock
skin
care
children
designmethod
mail
questionnair
regard
prevent
occup
exposur
nurs
work
childhood
cancer
treatment
facil
nurs
hospit
result
got
nurs
respond
includ
nurs
report
hospit
rule
occup
exposur
addit
nurs
learn
prevent
measur
exposur
anticanc
drug
facil
ward
nurs
learn
outsid
hospit
found
nurs
took
prevent
measur
dispos
child
excreta
nurs
educ
famili
caregiv
prevent
exposur
nurs
chang
children
diaper
chemotherapi
everi
hour
chang
everi
hour
left
chang
diaper
famili
nurs
clean
children
time
urin
almost
use
wipe
nurs
wash
hot
water
case
defec
wash
hot
water
ninteen
nurs
appli
ointment
protect
buttock
skin
exposur
prevent
manner
use
medicin
azulen
zinc
oxid
ointment
vaselin
also
shed
skin
cream
conclus
clear
prevent
exposur
anticanc
drug
pediatr
oncolog
ward
suffici
hospit
made
rule
studi
meet
urgent
need
develop
evidenc
base
guidelin
special
childhood
cancer
treatment
h
ojiro
medic
univers
facul
school
medicin
nara
japan
medic
univers
hospit
children
medic
center
nara
japan
backgroundobject
studi
shed
light
upon
parent
concern
emot
regard
peer
among
children
receiv
treatment
pediatr
cancer
children
pediatr
cancer
experi
extend
hospit
familiar
treatment
may
give
advic
peer
play
studi
defin
peer
support
support
receiv
fellow
child
cancer
patient
designmethod
use
qualit
induct
method
conduct
interview
mother
children
formal
diagnos
pediatr
cancer
respons
categor
accord
krippendorff
content
analysi
methodolog
studi
conduct
receiv
approv
nara
medic
univers
ethic
review
board
result
mother
year
age
mean
children
year
age
mean
upon
admiss
diagnos
leukemia
brain
tumor
bone
tumor
analys
yield
theme
parent
consid
peer
support
among
children
receiv
treatment
pediatr
cancer
encourag
see
child
posit
attitud
encourag
see
child
fun
hospit
school
encourag
see
child
fun
children
relief
see
child
cope
way
uniqu
children
concern
treatment
might
interfer
social
concern
peer
parent
express
relief
peer
support
children
receiv
fellow
child
cancer
patient
posit
effect
encourag
treatment
howev
also
express
concern
children
time
social
social
might
neg
influenc
children
conclus
parent
felt
mix
relief
anxieti
peer
among
children
receiv
treatment
pediatr
cancer
must
address
provid
nurs
care
child
cancer
patient
olsson
student
sahlgrenska
universityhospit
sweden
backgroundobject
purpos
studi
explor
psycholog
wellb
adolesc
young
adult
aya
cancer
survivor
designmethod
studi
specif
questionnair
develop
result
focu
group
interview
method
use
question
develop
includ
expert
valid
profession
former
aya
cancer
patient
year
old
area
questionnair
qualiti
life
psycholog
wellb
bodi
imag
sex
fertil
educ
work
leisur
questionnair
sent
aya
cancer
survivor
match
control
sweden
cooper
four
region
cancer
center
studi
focu
variabl
psycholog
wellb
remain
result
analyz
elsewher
result
aya
cancer
survivor
report
higher
incid
depress
control
analysi
femal
aya
survivor
higher
incid
depress
control
p
differ
incid
depress
male
aya
survivor
control
addit
femal
aya
cancer
survivor
report
stress
higher
degre
p
difficulti
fall
asleep
compar
femal
control
furthermor
femal
aya
cancer
survivor
express
need
psycholog
counsel
treatment
higher
frequenc
male
p
conclus
result
studi
show
femal
aya
cancer
survivor
report
lower
mental
wellb
control
observ
indic
opportun
improv
qualiti
life
young
cancer
survivor
screen
depress
take
adequ
psycholog
medic
measur
overal
health
care
profession
need
address
need
psychosoci
counsel
aftermath
cancer
treatment
aya
cancer
survivor
especi
femal
aya
cancer
survivor
p
pergert
c
k
af
institutet
women
children
health
stockholm
sweden
univers
medicin
health
scienc
sweden
backgroundobject
ethic
climat
healthcar
profession
percept
organ
atmospher
influenc
behaviour
attitud
posit
correl
demonstr
ethic
climat
nurs
job
satisfact
ultim
qualiti
patient
care
evalu
ethic
climat
valid
instrument
appropri
set
question
need
aim
studi
describ
process
translat
cultur
adapt
hospit
ethic
climat
survey
develop
swedish
version
relev
paediatr
oncolog
designmethod
procedur
translat
cultur
adapt
swedish
version
follow
scientif
structur
guidelin
three
focu
group
interview
three
cognit
interview
perform
healthcar
profession
furthermor
descript
data
use
previou
studi
healthcar
profession
use
modifi
swedish
hec
result
swedish
consist
item
item
item
ad
develop
version
relev
paediatr
exampl
one
item
ad
concern
parent
wish
relev
paediatr
set
linguist
adjust
made
retain
intend
mean
origin
item
word
respect
use
two
differ
mean
replac
one
particip
concern
respect
patient
wish
impli
alway
compli
conclus
process
develop
swedish
minor
adjust
need
achiev
good
function
level
trustworthi
howev
item
need
ad
achiev
version
relev
paediatr
oncolog
also
better
captur
ethic
climat
perri
k
nation
health
system
hematolog
oncolog
care
unit
dc
usa
nation
health
system
clinic
resourc
manag
dc
usa
inc
oncolog
educ
usa
backgroundobject
famili
children
adolesc
young
adult
aya
new
oncolog
diagnosi
must
absorb
knowledg
skill
need
care
child
home
period
emerg
hospit
intens
medic
intervent
effect
nurs
led
teach
discharg
plan
begun
diagnosi
prepar
famili
safe
care
child
follow
discharg
sourc
satisfact
object
perform
improv
pi
initi
increas
famili
nurs
satisfact
new
diagnosi
educ
discharg
designmethod
use
standard
pi
techniqu
famili
nurs
stakehold
satisfact
current
process
assess
work
establish
best
practic
literatur
review
road
home
design
implement
novel
comprehens
program
includ
visual
interact
display
requir
educ
base
children
oncolog
group
famili
hospit
specif
discharg
materi
standard
teach
tool
document
nurs
caregiv
discharg
tool
kit
stakehold
input
guid
improv
strategi
throughout
phase
implement
result
sustain
increas
famili
nurs
satisfact
result
phase
project
implement
road
home
program
establish
famili
newli
diagnos
oncolog
patient
meet
goal
increas
famili
nurs
satisfact
discharg
educ
conclus
road
home
program
met
aim
develop
interact
patient
educ
method
better
engag
nurs
clinic
team
member
parent
patient
new
diagnosi
cancer
educ
process
improv
commun
nurs
resourc
discharg
tool
incorpor
within
rth
program
proven
impact
sustain
improv
nurs
famili
satisfact
discharg
educ
process
acknowledg
author
would
like
thank
member
hocu
educ
committe
dr
viraj
mane
technic
design
consult
also
acknowledg
phoenix
children
hospit
journey
board
inspir
r
punjwani
anwer
indu
hospit
pead
complex
karachi
pakistan
backgroundobject
countri
like
pakistan
high
cancer
burden
surviv
often
due
late
diagnosi
inaccess
care
recogn
nurs
frontlin
clinician
vital
success
pediatr
oncolog
program
siop
podc
nurs
work
group
defin
essenti
element
pediatr
oncolog
nurs
care
countri
baselin
standard
improv
care
designmethod
project
indu
cancer
hospit
karachi
initi
support
sanofi
espoir
foundat
child
matter
grant
improv
pediatr
oncolog
five
center
across
pakistan
achiev
siop
podc
baselin
nurs
standard
one
object
nurs
strategi
includ
train
mentorship
educ
materi
develop
human
resourc
improv
onsit
evalu
visit
result
although
two
center
experienc
administr
challeng
slow
progress
one
year
nurs
improv
accord
baselin
standard
three
center
includ
safe
staf
pediatr
oncolog
nursepati
ratio
train
nurs
rotat
unit
orient
oncolog
nurs
train
basic
pediatr
oncolog
nurs
continu
educ
identifi
train
one
nurs
unit
pediatr
oncolog
nurs
trainer
educ
materi
distant
ongo
mentorship
provid
multidisciplinari
teamwork
nurs
believ
better
voic
patient
care
consid
part
team
resourc
safe
care
one
unit
biosafeti
cabinet
advocaci
pharmacist
prepar
chemotherapi
ppe
hand
sanit
dispens
handwash
facil
avail
three
unit
five
practic
develop
polici
share
across
unit
conclus
result
initi
survey
across
pakistan
show
multipl
gap
baselin
nurs
standard
year
chang
encourag
sever
standard
achiev
continu
effort
address
rest
plan
next
year
n
radhakrishnan
n
c
n
v
b
j
special
pediatr
hospit
pg
teach
institut
depart
pediatr
hematolog
oncolog
noida
india
backgroundobject
even
pediatr
cancer
care
continu
improv
global
gap
surviv
report
low
middl
incom
countri
lmic
lack
train
treatment
provid
major
reason
purpos
studi
explor
challeng
face
nurs
provid
childhood
cancer
care
resourc
constrain
center
india
designmethod
qualit
research
difficulti
face
nurs
care
first
month
april
march
set
pediatr
depart
done
data
collect
interview
nurs
monthli
meet
confidenti
nurs
maintain
session
result
studi
period
center
cater
outpati
inpati
new
oncolog
patient
procedur
admiss
treat
team
consist
consult
dedic
nurs
challeng
face
classifi
manpow
skill
motiv
poor
nurs
patient
ratio
lack
dedic
dietician
psychologist
social
worker
increas
burden
nurs
compens
focus
rest
problem
skill
develop
major
thrust
area
new
nurs
receiv
induct
pediatr
oncolog
care
standard
oper
procedur
algorithm
approach
common
emerg
situat
adapt
treatment
schedul
etc
develop
social
network
group
help
faster
remedi
problem
motiv
nurs
toward
oncolog
improv
constant
discuss
handl
success
failur
posit
reinforc
consid
make
workplac
happi
effort
team
build
conclus
nurs
closest
famili
backbon
patient
care
situat
empow
nurs
care
provid
help
us
establish
care
best
possibl
manner
dedic
pediatr
oncolog
nurs
sustain
solut
improv
cancer
care
lmic
riva
nacion
de
pali
integr
medicin
guatem
guatemala
backgroundobject
valid
import
collabor
work
doctor
nurs
care
strategi
designmethod
survey
present
nurs
staff
train
nation
pediatr
oncolog
unit
guatemala
know
percept
integr
process
collabor
work
palli
doctor
result
palli
care
train
program
nation
pediatr
oncolog
unit
guatemala
support
child
matter
began
train
nurs
palli
pediatrician
countri
support
work
subsequ
pediatrician
train
palli
care
current
proceed
evalu
integr
binomi
collabor
work
survey
evalu
nurs
percept
regard
particip
doctor
give
prepar
plan
patient
famili
care
result
survey
show
knowledg
palli
care
tend
fundament
support
develop
care
plan
patient
well
evalu
provid
adequ
manag
symptom
well
correct
calcul
use
opioid
nurs
turn
benefici
sometim
take
initi
suggest
use
provid
adequ
calcul
indic
conclus
share
knowledg
leadership
adequ
relationship
integr
nurs
medic
work
result
adequ
palli
care
strategi
nurs
empow
decis
make
discuss
case
enrich
contribut
best
care
patient
countri
nurs
staff
receiv
fair
valu
collabor
work
sadaruddin
indu
hospit
nurs
karachi
pakistan
backgroundobject
background
introduct
pediatr
oncolog
patient
vulner
sudden
clinic
declin
due
toxic
intens
natur
therapi
multipl
modal
treatment
support
care
help
treat
primari
diseas
may
also
alter
bodi
respons
time
react
respond
establish
fact
patient
exhibit
certain
clinic
featur
sign
deterior
identifi
sign
healthcar
facil
use
tool
like
warn
sign
ew
help
healthcar
team
earli
recognit
time
implement
care
reduc
morbid
mortal
standard
pew
ew
specif
pediatr
oncolog
patient
henc
need
special
effect
qualiti
measur
help
conduct
risk
assess
pediatr
oncolog
popul
uk
oncolog
triag
tool
one
earli
warn
assess
tool
specif
recogn
potenti
clinic
sign
pediatr
oncolog
patient
object
aim
paper
examin
uk
oncolog
triag
tool
oncolog
earli
warn
score
oew
assess
role
tool
prevent
pediatr
oncolog
mortal
clinic
deterior
among
children
young
adult
designmethod
sever
paper
review
use
multipl
databas
understand
applic
tool
three
articl
shortlist
cover
essenti
knowledg
detail
implement
effect
result
paper
conclud
oew
serv
bedsid
instrument
may
help
trigger
time
respons
case
clinic
deterior
numer
valu
base
assess
indic
may
help
gener
time
respons
result
improv
clinic
outcom
reduc
incid
cardiopulmonari
resuscit
septic
shock
time
manag
emerg
conclus
overal
paper
attempt
understand
concept
oew
potenti
use
pediatr
oncolog
center
reduc
sudden
collaps
thu
earli
treatment
improv
surviv
sato
k
n
j
r
k
univers
tokyo
depart
famili
nurs
tokyo
japan
cancer
associ
japan
children
cancer
associ
japan
tokyo
japan
univers
school
medicin
depart
neurosurgeri
tokyo
japan
univers
school
medicin
depart
neurosurgeri
kanagawa
japan
treatment
center
hiroshima
univers
hospit
depart
clinic
oncolog
program
hiroshima
japan
univers
tokyo
depart
neurosurgeri
tokyo
japan
neurosurgeri
clinic
sawamura
neurosurgeri
clinic
hokkaido
japan
univers
school
medicin
depart
neurosurgeri
fukuoka
japan
cancer
center
hospit
depart
neurosurgeri
tokyo
japan
hospit
social
welfar
corpor
depart
neurosurgeri
kyoto
japan
medic
univers
intern
medic
center
depart
saitama
japan
prefectur
central
hospit
pediatr
medic
center
ehim
japan
backgroundobject
childhood
cancer
survivor
experi
employ
difficulti
studi
aim
describ
pediatr
survivor
employ
statu
designmethod
observ
studi
conduct
questionnair
distribut
pediatr
survivor
age
year
older
attend
physician
institut
japan
compar
categori
histori
particip
employ
use
nation
censu
inform
factor
relat
delay
employ
earli
employ
termin
examin
use
analys
result
exclud
student
homemak
survivor
median
age
year
year
sinc
diagnosi
product
age
unemploy
never
employ
survivor
employ
occur
later
rel
gener
popul
particularli
lower
educ
level
number
survivor
whose
first
job
termin
within
first
year
higher
rel
gener
popul
particularli
male
survivor
survivor
survivor
describ
work
pattern
irregular
job
type
specialist
profession
reason
earli
termin
unsuit
job
thought
work
wish
serv
commun
lack
confid
conclus
result
show
high
unemploy
rate
multipl
factor
cancer
survivor
educ
welfar
system
identifi
individu
method
social
particip
group
sato
n
univers
faculti
health
scienc
sapporo
japan
univers
hosptal
dept
nurs
chiba
japan
backgroundobject
parent
often
refrain
disclos
name
diseas
children
cancer
howev
necessari
improv
children
abil
cope
diseas
therefor
examin
children
imag
cancer
designmethod
anonym
questionnair
survey
conduct
junior
high
student
questionnair
compris
item
characterist
respond
conscious
regard
cancer
data
analyz
use
spss
analysi
includ
test
result
obtain
effect
respons
student
boy
girl
one
student
mention
gender
student
first
grader
second
grader
third
grader
regard
conscious
cancer
student
report
scari
diseas
consid
immin
diseas
believ
one
could
live
substanti
life
even
contract
diseas
student
believ
childhood
cancer
requir
hospit
though
diseas
could
cure
howev
respond
knew
childhood
cancer
reason
expect
inform
cancer
could
opposit
diseas
want
tell
without
cover
oneself
thought
get
treatment
signific
differ
observ
desir
inform
cancer
term
school
year
person
inform
receiv
conclus
junior
high
student
found
neg
imag
cancer
therefor
medic
personnel
need
provid
appropri
knowledg
cancer
consid
development
stage
understand
level
child
n
shen
c
j
children
medic
center
nurs
depart
shanghai
china
hospit
affili
shanghai
jiaotong
univers
medic
school
depart
hematolog
shanghai
china
univers
school
nurs
school
nurs
shanghai
china
children
medic
center
depart
translat
medicin
institut
shanghai
china
children
medic
center
depart
hematolog
shanghai
china
backgroundobject
children
leukemia
experi
multipl
concurr
interrel
symptom
may
influenc
child
function
statu
qualiti
life
complex
symptom
cluster
popul
although
clinic
import
remain
poorli
understood
manag
identifi
subgroup
children
base
symptom
pattern
provid
valuabl
guidanc
pediatr
cancer
care
designmethod
design
children
leukemia
age
explor
prospect
data
collect
use
demograph
questionnair
chines
version
pediatr
patient
report
outcom
measur
inform
version
includ
five
symptom
domain
depress
anger
anxieti
fatigu
pain
interfer
three
function
domain
peer
relationship
physic
physic
extrem
latent
profil
analysi
lpa
conduct
classifi
homogen
subpopul
respect
symptom
measur
function
impair
compar
across
class
design
result
children
particip
result
lpa
indic
data
best
fit
model
posterior
assign
probabl
profil
given
profil
estim
mean
symptom
score
defin
profil
profil
profil
mild
symptom
group
less
sever
symptom
group
sever
symptom
group
respect
mean
standard
score
three
function
measur
significantli
vari
profil
p
p
analysi
found
children
sever
symptom
group
averag
wors
physic
function
profil
p
children
mild
symptom
group
averag
better
peer
relationship
sever
symptom
group
p
convers
conclus
children
leukemia
undergo
multipl
symptom
empir
reveal
heterogen
popul
three
distinct
profil
children
identifi
respect
pattern
symptom
trend
function
impair
aggrav
children
identifi
experienc
higher
symptom
sever
l
shipway
f
ormond
street
hospit
children
nh
foundat
trust
haematologyoncolog
london
unit
kingdom
backgroundobject
background
nausea
vomit
two
distress
symptom
encount
children
cancer
receiv
chemotherapi
whilst
collect
well
document
nausea
receiv
much
less
attent
nausea
assess
manag
need
assess
effect
intervent
manag
nausea
remain
three
key
prioriti
clinic
practic
object
explor
subject
experi
nausea
children
relat
commun
nausea
strategi
use
manag
symptom
designmethod
phenomenolog
studi
use
creativ
participatori
method
gain
insight
experi
nausea
children
also
sought
find
percept
use
nausea
assess
scale
individu
case
report
themat
data
analysi
built
pictur
experi
nausea
result
conveni
sampl
seven
children
age
haematologicaloncolog
malign
recruit
studi
four
theme
emerg
data
nt
feel
describ
physic
emot
social
impact
nausea
thing
lot
captur
strategi
children
found
help
go
sick
describ
children
look
help
wish
told
highlight
children
inform
need
children
adopt
number
approach
manag
distress
symptom
parent
import
sourc
support
comfort
facilit
commun
child
healthcar
profession
children
report
nausea
scale
would
help
commun
nausea
highlight
inform
need
around
identifi
manag
nausea
conclus
studi
provid
insight
nausea
manag
assess
scale
facilit
commun
howev
research
establish
clinic
util
nausea
scale
explor
strategi
nausea
manag
still
need
l
steendam
e
e
l
g
v
van
de
gent
pediatr
hemato
oncolog
gent
belgium
backgroundobject
everi
year
averag
children
pho
ward
receiv
central
venou
cathet
cvc
long
term
intraven
medic
chemotherapi
coagul
factor
total
parent
nutrit
cvc
ideal
remain
place
intens
therapi
finish
sometim
cathet
relat
problem
requir
earli
remov
replac
sinc
use
cathet
passport
electron
patient
file
record
essenti
data
type
number
lumen
insert
date
remov
date
enabl
registr
cathet
relat
problem
designmethod
retrospect
analysi
perform
cathet
passport
patient
cathet
place
period
determin
incid
cathet
relat
problem
focu
reason
cathet
remov
date
insert
remov
cathet
reason
remov
presenc
infect
occlus
problem
attempt
collect
result
analysi
becam
obviou
essenti
data
miss
incomplet
note
passport
cvc
report
remov
cvc
remov
without
report
reason
reason
remov
given
end
intens
treatment
infect
occlus
accident
remov
ruptur
main
reason
underreport
attribut
electron
patient
file
includ
cathet
passport
time
consum
conclus
result
survey
indic
previou
cathet
passport
poorli
structur
consequ
input
necessari
data
time
consum
nurs
time
pressur
report
cathet
relat
problem
essenti
inform
incomplet
cathet
passport
adapt
logic
structur
predetermin
answer
easi
check
hope
enabl
get
complet
data
futur
sunakozawa
cp
sm
gs
kfm
sca
jlv
lpm
sm
da
hc
fmusp
hematopoiet
stem
cell
transplant
center
paulo
brazil
backgroundobject
given
scarciti
paramet
make
possibl
know
nurs
workload
hematopoiet
stem
cell
transplant
center
hsctc
develop
nurs
activ
product
time
team
essenti
identifi
interventionsact
perform
nurs
staff
first
step
toward
effici
human
resourc
plan
purpos
research
identifi
nurs
activ
perform
hsctc
nurs
team
tertiari
pediatr
hospit
paulo
brazil
classifi
intervent
accord
nurs
intervent
classif
designmethod
consult
medic
record
patient
diagnos
leukemia
hospit
june
june
submit
allogen
stem
cell
transplant
activ
identifi
compar
map
valid
instrument
pediatr
intens
care
unit
picu
activ
includ
previou
instrument
map
insert
accord
similar
definit
intervent
activ
suggest
nic
result
activ
survey
medic
record
identifi
intervent
distribut
class
six
domain
conclus
brazil
hematopoiet
stem
cell
transplant
field
despit
larg
number
complex
nurs
activ
condit
stage
day
infus
may
contribut
substanti
workload
increas
affect
qualiti
care
patient
safeti
still
formal
system
nurs
workload
measur
instrument
construct
interventionsact
allow
futur
studi
correl
time
spent
execut
intervent
thu
propos
paramet
dimens
nurs
staff
hsctc
sunakozawa
khc
cp
gs
jlv
da
hc
fmusp
hematopoiet
stem
cell
transplant
center
paulo
brazil
backgroundobject
patient
undergo
hematopoiet
stem
cell
transplant
hsct
highli
complex
contribut
substanti
nurs
workload
increas
affect
qualiti
care
patient
safeti
also
high
nutrit
risk
may
exacerb
morbimort
studi
goal
identifi
whether
nutrit
statu
children
cancer
affect
demand
nurs
care
pediatr
hsct
unit
designmethod
retrospect
longitudin
studi
chart
patient
cancer
allogen
hsct
review
day
hsct
order
repres
condit
regimen
post
cell
infus
neutrophil
recoveri
patient
classifi
accord
valid
instrument
classif
hospit
pediatr
patient
ichpp
malnutrit
defin
arm
circumfer
muac
percentil
frisancho
tabl
rank
test
use
comparison
spearman
rank
correl
result
patient
median
age
year
femal
frequent
diagnosi
acut
lymphoblast
leukemia
follow
acut
myeloid
leukemia
transplant
haploident
donor
cord
blood
ichpp
median
score
went
establish
time
point
p
patient
consid
intens
muac
significantli
decreas
cm
cm
chang
muac
nt
correl
ichpp
score
malnourish
patient
higher
score
hsct
conclus
despit
deterior
nutrit
statu
nt
correl
nurs
workload
except
patient
malnourish
hsct
increas
ichpp
score
might
due
known
associ
malnutrit
increas
risk
infect
toxic
could
explor
larg
multicentr
studi
n
takenouchi
f
children
medic
center
cancer
center
kanagawa
japan
colleg
health
scienc
faculti
makuhari
human
care
chiba
japan
luke
intern
univers
graduat
school
nurs
scienc
tokyo
japan
children
hospit
nurs
chiba
japan
colleg
nurs
school
nurs
nagano
japan
backgroundobject
japanes
societi
pediatr
oncolog
nurs
studi
group
develop
nurs
care
guidelin
children
cancer
past
research
found
care
item
guidelin
valu
import
howev
nurs
felt
difficulti
provid
care
aim
studi
know
factor
reason
difficulti
nurs
take
care
children
cancer
consid
support
nurs
designmethod
sent
origin
questionnair
facil
nationwid
ask
one
children
cancer
nurs
year
experi
answer
five
profession
pediatr
oncolog
nurs
content
analysi
free
descript
think
nurs
care
difficult
challeng
descript
data
code
result
code
categori
code
found
nurs
feel
difficulti
home
care
termin
stage
end
life
care
support
explain
diseas
treatment
build
trust
relationship
care
recurr
reliev
procedur
pain
symptom
manag
care
stem
cell
transplant
result
categor
code
found
featur
factor
children
condit
understand
famili
intent
lack
nurs
skill
knowledg
experi
collabor
doctor
medic
staff
environment
factor
work
system
conclus
result
pediatr
oncolog
nurs
japan
need
knowledg
skill
deal
complic
situat
also
need
commun
skill
build
trust
relationship
patient
famili
continu
time
diagnosi
result
suggest
addit
educ
system
requir
support
nurs
problem
environ
system
surround
children
cancer
famili
clarifi
nurs
could
provid
higher
qualiti
care
j
taylor
b
w
c
c
j
ward
glasgow
unit
kingdom
backgroundobject
children
young
peopl
mainten
chemotherapi
acut
lymphoblast
leukaemia
tradit
attend
hospit
clinic
weekli
medic
review
manag
chemotherapi
significantli
impact
qualiti
life
child
famili
children
miss
school
parent
take
time
work
attend
hospit
work
collabor
primari
care
educ
project
aim
develop
improv
method
deliv
care
reduc
hospit
attend
enrich
qualiti
life
children
young
peopl
designmethod
advanc
nurs
practition
anp
telephon
clinic
introduc
pilot
aim
extend
servic
patient
mainten
chemotherapi
hospit
attend
reduc
weekli
monthli
visit
patient
attend
review
receiv
monthli
chemotherapi
suppli
visit
patient
manag
home
anp
commun
nurs
patient
blood
count
taken
home
school
outreach
nurs
normalis
procedur
reduc
impact
school
blood
count
check
anp
chemotherapi
prescrib
haematolog
consult
anp
confirm
chemotherapi
dose
follow
arrang
phone
text
parent
young
person
result
twelv
patient
mainten
chemotherapi
manag
anp
telephon
clinic
reduc
hospit
attend
improv
qualiti
life
patient
famili
servic
evalu
patient
famili
survey
show
high
level
satisfact
children
young
peopl
report
servic
improv
attend
school
parent
report
minimis
disrupt
work
famili
life
conclus
work
collabor
chang
tradit
outpati
care
deliv
patient
approach
care
commun
challeng
extend
servic
patient
mainten
chemotherapi
ternald
univers
queen
silvia
children
hospit
depart
pediatr
oncolog
gothenburg
sweden
backgroundobject
child
diagnos
treat
cancer
inform
given
child
famili
great
import
inform
provid
differ
healthcar
profession
oral
written
need
repeat
updat
time
mobil
applic
children
cancer
famili
improv
flow
inform
make
easili
access
current
develop
ensur
inform
line
children
famili
need
survey
assess
demand
develop
designmethod
questionnair
hand
patient
famili
pediatr
oncolog
close
ward
daycar
unit
region
hospit
questionnair
focus
identifi
type
inform
patient
famili
would
like
access
mobil
applic
four
parent
randomli
select
interview
result
children
famili
report
great
enthusiasm
appreci
opportun
access
inform
mobil
applic
three
theme
emerg
patient
specif
inform
includ
test
result
appoint
book
treatment
protocol
b
commun
platform
chat
messag
function
direct
contact
clinic
staff
home
c
care
routin
ward
home
base
care
contact
inform
conclus
idea
mobil
applic
mean
improv
flow
inform
make
effici
welcom
appreci
parent
children
includ
studi
mobil
applic
includ
specif
area
inform
mean
real
time
commun
meet
need
patient
famili
tomlinson
e
e
b
l
sick
children
child
health
evalu
scienc
toronto
canada
parent
advoc
children
cancer
ontario
parent
advoc
children
cancer
toronto
canada
backgroundobject
symptom
screen
pediatr
tool
sspedi
valid
symptom
screen
children
age
year
receiv
cancer
treatment
object
develop
new
symptom
screen
tool
children
receiv
cancer
treatment
year
old
base
sspedi
designmethod
respond
children
age
year
receiv
cancer
treatment
use
cognit
interview
iter
design
develop
three
phase
made
decis
base
upon
respond
understand
phase
consid
complet
least
respond
show
correct
interpret
featur
within
last
group
children
interview
first
determin
questionnair
structur
respect
recal
period
concept
bother
respons
option
format
test
understand
yesterday
today
understand
bother
evalu
three
differ
likert
scale
measur
degre
bother
second
examin
word
symptom
sspedi
item
third
evalu
entir
instrument
eas
complet
second
interview
rate
understand
compon
result
among
enrol
particip
mean
age
rang
year
develop
questionnair
structur
respond
recal
period
today
likert
scale
structur
particip
understood
concept
bother
determin
symptom
word
respond
among
sspedi
item
five
requir
modif
achiev
satisfactori
understand
ten
symptom
evalu
entireti
respond
continu
modif
result
last
children
understand
item
none
thought
hard
complet
conclus
develop
symptom
screen
tool
children
age
year
receiv
cancer
treatment
understand
easi
complet
futur
work
evalu
psychometr
properti
develop
electron
version
instrument
ky
triana
z
universita
indonesia
pediatr
nurs
depart
pediatr
nurs
depart
depok
indonesia
backgroundobject
nausea
vomit
cinv
one
disturb
frighten
symptom
among
patient
cancer
experienc
receiv
chemotherapi
condit
caus
children
risk
physic
psychosoci
problem
risk
experienc
physic
psychosoci
problem
instanc
anorexia
electrolyt
imbal
dehydr
weight
loss
malnutrit
poor
function
statu
anxieti
chemotherapi
program
may
impact
subsequ
treatment
program
qualiti
life
degrad
purpos
literatur
review
describ
mechan
delay
cinv
pediatr
patient
epidemiolog
etiolog
possibl
assess
strategi
delay
cinv
manag
pediatr
patient
designmethod
method
use
articl
literatur
review
summar
techniqu
result
delay
cinv
common
cinv
symptom
experienc
pediatr
patient
affect
use
moder
sever
emetogen
chemotherapeut
agent
therefor
effect
manag
delay
cinv
requir
start
identif
chemotherapi
agent
use
educ
parent
side
effect
cinv
assess
nausea
vomit
children
follow
appli
guidelin
antiemet
combin
therapi
adapt
age
child
develop
dietari
regul
distract
activ
cope
strategi
acupressur
social
support
psychosoci
strategi
conclus
nurs
import
role
care
giver
educ
perform
delay
cinv
manag
pediatr
patient
optim
child
growth
prevent
stress
children
empow
parent
yl
h
jl
tsai
jen
cathol
univers
hospitalchildhood
cancer
rocnat
taiwan
universityfu
jen
cathol
univers
depart
nursingresearch
statist
sectordepart
nursingdepart
nurs
new
taipeitaipei
taiwan
roc
cancer
roc
research
statist
sector
taipei
taiwan
roc
gung
univers
nation
taiwan
univers
school
nurs
school
nurs
taipei
taiwan
roc
backgroundobject
outcom
childhood
cancer
treatment
improv
greatli
three
decad
less
dropout
refus
treatment
chanc
cure
object
current
studi
understand
situat
chang
treatment
refus
children
cancer
taiwan
designmethod
retrospect
design
adopt
studi
databas
taiwan
pediatr
oncolog
group
tpog
found
childhood
cancer
foundat
republ
taiwan
two
cohort
defin
year
nation
health
insur
implement
cohort
cohort
analysi
logist
regress
use
analyz
data
result
number
recommend
treatment
refus
significantli
decreas
cohort
vs
p
differ
sex
age
diagnosi
type
cancer
locat
famili
resid
two
cohort
children
age
signific
high
risk
reject
recommend
treatment
age
greater
children
leukemia
high
risk
reject
recommend
treatment
cohort
p
howev
children
retinoblastoma
soft
tissu
tumor
signific
high
risk
reject
recommend
treatment
control
leukemia
cohort
famili
resid
central
southern
area
taiwan
signific
risk
reject
recommend
treatment
cohort
conclus
reason
age
diagnosi
diagnos
retinoblastoma
soft
tissu
cancer
live
central
southern
area
taiwan
tend
reject
recommend
treatment
need
studi
result
provid
health
care
provid
direct
improv
qualiti
care
jl
tsai
yl
gung
univers
nation
taiwan
univers
school
nurs
school
nurs
citi
taipei
taiwan
roc
jen
cathol
univers
hospitalchildhood
cancer
rocnat
taiwan
universityfu
jen
cathol
univers
depart
nursingresearch
statist
sectordepart
nursingdepart
nurs
new
taipei
taipei
taiwan
roc
backgroundobject
effect
matern
smoke
childhood
cancer
primarili
focus
role
caus
also
report
patern
smoke
posit
associ
offspr
cancer
howev
result
still
inconsist
relationship
patern
smoke
behavior
risk
childhood
cancer
thoroughli
studi
aim
investig
parent
smoke
behavior
relat
factor
among
famili
cancer
child
taiwan
designmethod
conduct
survey
method
taiwan
incid
childhood
cancer
around
per
year
studi
includ
cancer
children
enrol
last
two
year
questionnair
design
data
collect
newli
diagnos
descript
test
use
analyz
data
result
famili
smoke
behavior
home
frequent
place
smoke
outdoor
differ
regard
factor
parent
smoke
behavior
level
educ
parent
patern
ethnic
ethnic
mother
significantli
relat
smoke
behavior
mother
indigen
peopl
taiwan
famili
annual
incom
less
us
dollar
significantli
associ
parent
smoke
p
conclus
order
provid
environ
cancer
children
health
care
provid
may
focu
famili
lower
annual
incom
ethnic
mother
give
educ
attent
n
e
van
p
v
van
de
veld
centr
nurs
ghent
univers
depart
public
faculti
medicin
health
scienc
ghent
belgium
leuven
institut
famili
sexual
studi
leuven
belgium
utrecht
div
juliu
centrum
utrecht
netherland
hospit
ghent
pediatr
hemato
oncolog
ghent
belgium
backgroundobject
adolesc
young
adult
aya
survivor
childhood
cancer
often
experi
consequ
aris
ill
treatment
understand
mean
cancer
experi
surviv
phase
improv
develop
psychosoci
care
aya
survivor
designmethod
collabor
univers
hospit
ghent
univers
hospit
leuven
univers
leuven
univers
centr
nurs
midwiferi
ghent
belgium
set
qualit
research
interview
taken
aya
survivor
age
year
result
even
mani
year
complet
treatment
cancer
experi
remain
deepli
ingrain
live
aya
survivor
deploy
specif
cope
strategi
help
aya
survivor
deal
psychosoci
consequ
cancer
experi
view
ultim
lead
normal
life
abil
assum
directorship
life
appear
drive
forc
behind
exist
action
aya
survivor
conclus
health
care
profession
could
optim
psychosoci
care
provid
aya
survivor
take
experi
point
departur
individu
support
brought
line
way
aya
survivor
integr
cancer
experi
everyday
live
modul
healthcar
profession
develop
aim
promot
insight
specif
experi
need
aya
survivor
n
e
v
van
de
veld
q
hospit
ghent
cancer
centr
ghent
belgium
hospit
ghent
pediatr
hemato
oncolog
ghent
belgium
hospit
ghent
hematolog
ghent
belgium
centr
nurs
ghent
univers
depart
public
faculti
medicin
health
scienc
ghent
belgium
backgroundobject
care
give
parent
adolesc
young
adult
aya
cancer
involv
cancer
trajectori
child
emot
practic
offer
parent
adequ
psychosoci
care
insight
experi
need
expect
crucial
designmethod
qualit
research
base
principl
ground
theori
conduct
univers
hospit
ghent
thirti
interview
taken
parent
aya
age
year
differ
time
cancer
trajectori
start
time
diagnosi
year
end
treatment
result
parent
take
differ
role
care
aya
act
affection
manag
take
simultan
role
repres
advoc
love
parent
aya
moreov
parent
feel
constantli
challeng
find
balanc
relat
aya
relat
partner
possibl
children
relat
network
famili
friend
colleagu
etc
major
parent
experi
lack
parent
experi
import
need
involv
cancer
trajectori
care
aya
want
suffici
use
inform
understand
uniqu
situat
challeng
face
conclus
parent
offer
aya
uncondit
care
face
certain
insecur
fear
adequ
psychosoci
care
parent
requir
acknowledg
differ
role
take
support
child
base
find
research
booklet
develop
parent
aya
booklet
describ
experi
parent
use
illustr
quot
interview
parent
worksheet
implement
offer
parent
tool
express
feel
thought
commun
aya
peopl
surround
van
den
bossch
c
g
e
univers
hospit
paediatr
haematologyoncolog
ghent
belgium
backgroundobject
increas
surviv
patient
childhood
cancer
cc
confront
us
late
long
term
effect
llte
lifelong
fu
advis
improv
qualiti
life
cc
survivor
prevent
ill
death
late
effect
designmethod
nurs
consult
recruit
assist
paediatr
oncologist
improv
long
term
ltfu
program
cc
survivor
hospit
first
long
term
survivor
lt
fu
sever
reason
high
risk
llte
survivor
diagnos
hodgkin
lymphoma
diagnos
bone
brain
tumour
diagnos
current
minimum
year
old
invit
consult
share
oral
written
survivorship
passport
inform
oncolog
histori
appropri
ltfu
secondli
lt
least
year
old
fu
readi
transit
adult
servic
receiv
addit
nurs
consult
focus
qualiti
life
result
invit
lt
fu
seen
consult
survivor
process
transit
receiv
nurs
contribut
transfer
adult
servic
prepar
survivorship
passport
took
hour
consult
hour
nurs
contact
afterward
case
concern
employ
insur
health
care
psychosoci
matter
high
risk
survivor
refer
interdisciplinari
partner
identifi
within
hospit
survivor
low
risk
llte
refer
region
specialistsgener
practition
conclus
still
need
improv
ltfu
program
nurs
consult
play
import
role
achiev
goal
transit
paediatr
adult
health
care
set
sever
nurs
contact
focus
ltfu
health
promot
social
orient
f
wambu
nairobi
hospit
oper
theatr
nairobi
kenya
backgroundobject
social
account
profession
educ
foreground
especi
sinc
public
lancet
commiss
challeng
relev
health
profession
educ
address
current
health
challeng
practic
gap
nurs
educ
concern
impact
clinic
compet
nurs
thu
health
outcom
patient
de
swardt
et
al
studi
address
practic
gap
compet
assess
phenomenon
key
stakehold
viewpoint
zannini
et
al
studi
explor
stakehold
lectur
charg
nurs
clinic
preceptor
work
collabor
achiev
state
clinic
outcom
diploma
nurs
curriculum
designmethod
qualit
studi
use
structur
interview
focu
group
discuss
purpos
sampl
stakehold
includ
year
student
nurs
charg
nurs
preceptor
nurs
lectur
transcrib
data
analys
theme
result
four
theme
emerg
nurs
student
perceiv
clinic
educ
offer
student
advocaci
peer
reciproc
opportun
learn
found
dispar
preceptor
signifi
role
overload
identif
teachabl
moment
opportun
build
relationship
nurs
lectur
identifi
issu
relat
ownership
clinic
learn
complex
clinic
learn
environ
dispar
charg
nurs
report
clinic
educ
function
ward
cultur
moder
offer
opportun
leadership
educ
partner
collabor
dynam
tool
assess
limit
theme
emerg
question
explor
use
compet
assess
tool
stakehold
experienc
limit
tool
measur
student
achiev
skill
knowledg
learn
outcom
clinic
educ
conclus
stakehold
suggest
insight
idea
improv
clinic
educ
suggest
train
clinic
instructor
would
help
institut
bridg
exist
gap
strateg
reorgan
current
clinic
educ
model
hospit
b
zhang
children
medic
affili
shanghai
jiaotong
univers
pediatr
hematolog
oncolog
shanghai
china
backgroundobject
exercis
program
pediatr
oncolog
feasibl
safe
howev
scarc
data
avail
regard
effect
exercis
program
bodi
composit
explor
prospect
studi
design
evalu
effect
inpati
therapeut
exercis
program
designmethod
hsct
children
januari
march
enrol
intervent
group
hsct
children
januari
decemb
compar
intervent
group
term
age
gender
diagnosi
match
addit
routin
care
children
intervent
group
underw
aerob
exercis
resist
exercis
cycl
ergomet
time
per
week
bodi
composit
includ
height
bodi
mass
bmi
fm
ffm
group
test
transplant
differ
two
group
compar
use
varianc
analysi
repeat
measur
result
main
effect
bodi
mass
standard
bodi
mass
fat
mass
statist
signific
p
time
effect
bodi
mass
standard
bodi
mass
bmi
bodi
muscl
statist
signific
p
interact
effect
intervent
time
bodi
mass
p
conclus
exercis
therapi
show
signific
posit
effect
bodi
mass
fm
inpati
children
hsct
slow
fm
accumul
children
hsct
instruct
aerob
exercis
resist
exercis
moder
low
intens
f
zhou
h
children
medic
affili
shanghai
jiaotong
univers
pediatr
hematolog
oncolog
shanghai
china
backgroundobject
cancer
surviv
rate
pediatr
patient
cancer
significantli
improv
pediatr
cancer
survivor
sustain
protect
infect
emphas
first
explor
studi
necess
feasibl
multidisciplinari
cooper
vaccin
manag
pediatr
cancer
survivor
china
designmethod
children
group
old
chemotherapi
complet
year
elig
set
multidisciplinari
cooper
team
vaccin
consult
clinic
tertiari
pediatr
cancer
center
everi
child
receiv
individu
design
protocol
vaccin
evalu
humor
immun
specif
antibodi
qualifi
child
transfer
commun
health
servic
center
got
vaccin
accord
vaccin
protocol
children
return
vaccin
consult
clinic
got
evalu
specif
antibodi
necessari
readjust
vaccin
protocol
result
total
elig
patient
visit
vaccin
consult
clinic
tertiari
pediatr
cancer
center
patient
receiv
hepat
b
vaccin
chemotherapi
protect
antibodi
hepat
b
found
case
patient
receiv
mmr
chemotherapi
protect
antibodi
level
measl
mump
rubella
found
case
case
case
respect
patient
start
booster
vaccin
case
report
mild
side
effect
includ
red
pain
inject
site
slight
fever
parent
case
demonstr
satisfact
multidisciplinari
cooper
vaccin
manag
conclus
consider
number
pediatr
cancer
survivor
lose
immun
chemotherapi
multidisciplinari
cooper
vaccin
servic
benefici
term
integr
coordin
resourc
differ
healthcar
institut
studi
provid
support
feasibl
vaccin
manag
pediatr
cancer
survivor
especi
countri
area
coirini
g
g
j
p
de
j
vilela
pediatr
oncolog
rosario
argentina
infantil
municip
pediatr
argentina
dr
humberto
j
notti
pediatr
oncolog
mendoza
argentina
italiano
de
san
justo
pediatr
bueno
air
argentina
italiano
bueno
air
clinic
oncolog
bueno
air
argentina
italiano
bueno
air
pediatr
bueno
air
argentina
backgroundobject
accord
nation
registri
roha
new
pediatr
osteosarcoma
os
case
per
year
argentina
aim
studi
evalu
real
world
evid
use
mifamurtid
argentina
designmethod
retrospect
analys
pediatr
patient
osteosarcoma
without
clinic
detect
metastat
diseas
local
relaps
os
complet
remiss
receiv
mifamurtid
june
januari
result
analys
boy
girl
os
median
age
year
old
medium
month
frequent
local
distal
femur
proxim
tibia
eight
patient
obtain
necrosi
patient
receiv
differ
combin
chemotherapi
base
platinum
doxorubicin
ifosfamid
high
dose
methotrex
carboplatin
etoposid
docetaxel
gemcitabin
five
hundr
dose
mifarmutida
given
median
time
mifamurtid
initi
day
patient
day
local
osteosarcoma
patient
advers
event
chemotherapymifamurtid
pt
chill
patient
fever
patient
nausea
patient
myalgia
patient
palpit
patient
hypokalemia
patient
one
grade
leucopenia
patient
patient
grade
anemia
patient
grade
thrombocytopenia
patient
patient
grade
ten
patient
receiv
acetaminophen
premed
ten
patient
local
osteosarcoma
current
diseas
free
still
mifarmutid
treatment
four
patient
die
due
progress
diseas
conclus
mifamurtid
therapi
safe
access
well
toler
pediatr
patient
osteosarcoma
chill
fever
major
side
effect
longer
need
confirm
efficaci
n
p
j
cm
l
j
u
pg
f
hg
eyrich
depart
immunolog
germani
pediatr
neurooncolog
heidelberg
germani
children
hospit
pediatr
hematologyoncolog
wurzburg
germani
depart
neuropatholog
germani
medic
center
depart
neurosurgeri
germani
medic
center
children
hospit
germani
medic
center
depart
neurosurgeri
germani
depart
neurosurgeri
berlin
germani
bonn
institut
brain
tumor
refer
center
bonn
germani
center
children
hospit
augsburg
germani
medic
center
children
hospit
hamburg
eppendorf
germani
institut
scienc
depart
immunolog
rehovot
israel
backgroundobject
pediatr
brain
tumor
regard
immunolog
poorli
recogn
cancer
rank
among
malign
lowest
mutat
load
howev
must
correl
poor
immunogen
peptid
bound
tumor
cell
mhc
ligandom
peptid
repres
attract
target
immunotherapi
designmethod
model
diseas
extrem
low
mutat
load
investig
atrt
whether
suitabl
target
immunotherapi
could
identifi
ligandom
versu
peptid
result
upfront
determin
ihc
first
set
atrt
cell
within
tumor
express
tumor
cell
respect
indic
atrt
immunolog
cold
deciph
atrt
ligandom
analyz
central
review
sampl
use
subsequ
bioinformat
valid
peptid
could
identifi
peptid
patient
rang
specif
peptid
per
patient
total
peptid
could
found
peptid
exclus
one
tumor
demonstr
high
individu
ligandom
repres
exampl
ligandom
peptid
prove
immunogen
assay
among
peptid
also
overexpress
lymphoma
brain
tumor
whole
exom
sequenc
far
analyz
atrt
reveal
median
rang
mutat
dispers
entir
genom
silico
predict
show
neoantigen
peptid
similar
bind
affin
compar
ligandom
counterpart
thu
question
superior
neoantigen
versu
peptid
conclus
ligandom
peptid
identifi
vast
major
atrt
silico
vitro
analys
qualifi
suitabl
candid
person
cancer
vaccin
n
lehmann
c
k
el
f
l
r
j
univers
medic
center
johann
gutenberg
univers
mainz
section
pediatr
oncolog
mainz
germani
medic
center
johann
gutenberg
univers
mainz
institut
patholog
mainz
germani
cancer
research
germani
divis
cellular
molecular
patholog
heidelberg
germani
backgroundobject
papillari
renal
cell
carcinoma
rcc
rare
occur
children
inform
tumor
biolog
therapi
limit
far
treatment
choic
pediatr
papillari
rcc
complet
surgic
resect
without
adjuv
therapi
rcc
consid
immunogen
tumor
inform
avail
pediatr
entiti
tumor
cell
recogn
elimin
convent
nonconvent
cell
invari
natur
killer
cell
inkt
cell
cell
unlik
convent
cell
antigen
recognit
independ
hla
haplotyp
inkt
cell
offer
new
option
cancer
immunotherapi
cell
recogn
lipid
via
molecul
far
natur
lipid
larg
unknown
use
synthet
model
antigen
aim
analysi
infiltr
nonconvent
convent
cell
identif
endogen
lipid
ligand
designmethod
first
isol
tumor
infiltr
lymphocyt
til
two
pediatr
papillari
rcc
percol
densiti
centrifug
analyz
til
via
flow
cytometri
infiltr
immun
cell
confirm
immunohistochemistri
furthermor
fraction
tumor
lipid
test
fraction
abil
induc
prolifer
inkt
cell
subset
cell
character
fraction
mass
spectrometri
ongo
result
sampl
detect
infiltr
nonconvent
convent
cell
accord
first
analysi
found
lipid
fraction
abil
induc
prolifer
inkt
cell
conclus
project
expect
provid
new
insight
therapeut
util
nonconvent
cell
therapi
help
get
new
inform
biolog
pediatr
papillari
rcc
ben
mostafa
e
b
stephan
nant
crcina
inserm
danger
de
nant
nant
franc
de
nant
servic
de
chirurgi
nant
franc
de
nant
servic
nant
franc
backgroundobject
immunotherapi
target
emerg
promis
intervent
patient
neuroblastoma
howev
third
patient
experi
immunotherapi
failur
one
reason
tumor
microenviron
potenti
inhibit
optim
respons
context
elucid
potenti
mechan
respons
merit
consider
cell
cytotox
adcc
induc
nk
cell
contribut
antibodi
therapeut
efficaci
addit
addit
synergist
treatment
efficaci
may
achiev
target
immun
cell
howev
tumor
cell
escap
adcc
express
immun
checkpoint
inhibitor
evid
immunomodulatori
effect
induc
modul
immunotherapi
potenc
designmethod
evalu
respons
use
antibodi
syngen
model
mice
treat
combin
monoclon
antibodi
compar
control
next
studi
immun
modul
induc
potenc
evidenc
vivo
end
studi
immun
cell
infiltr
composit
immun
checkpoint
inhibitor
express
tumor
treatment
group
flow
cytometri
result
treatment
antibodi
outperform
treatment
either
antibodi
use
monotherapi
effect
correl
increas
percentag
nk
cell
macrophag
neutrophil
tumor
compar
control
yet
treatment
induc
dose
depend
checkpoint
inhibitor
tumor
cell
conclus
treat
mice
macrophag
neutrophil
could
contribut
nk
cell
potent
therapeut
efficaci
howev
antibodi
enhanc
lytic
activ
could
counteract
checkpoint
inhibitor
better
understand
cellular
molecular
chang
follow
necessari
understand
resist
mechan
immunotherapi
patient
neuroblastoma
b
chi
bao
diem
children
hospit
oncolog
genet
hochiminh
vietnam
medicin
pharmaci
center
molecular
biomedicin
hochiminh
vietnam
hospit
children
oncolog
krong
siem
reap
cambodia
friend
hospit
children
oncolog
luang
prabang
lao
pdr
hospit
surgeri
oncolog
hochiminh
vietnam
backgroundobject
common
genet
contributor
neuroblastoma
nb
amplif
mycn
gene
order
effect
integr
mycn
genet
test
clinic
practic
strategi
tailor
promot
area
popul
investig
designmethod
prospect
studi
involv
nb
patient
parent
guardian
three
independ
center
vietnam
cambodia
lao
level
knowledg
genet
test
patient
attitud
toward
test
evalu
use
standard
questionnair
result
greater
number
nb
patient
parent
guardian
report
posit
attitud
toward
potenti
outcom
benefit
genet
test
vs
p
particip
heard
genet
test
mycn
alk
howev
lao
cambodia
cohort
multivari
analysi
reveal
high
level
genet
knowledg
associ
posit
attitud
respons
regard
potenti
medic
benefit
test
p
neg
attitud
toward
compromis
healthcar
life
insur
p
associ
observ
amongst
vietnames
subject
major
particip
thought
like
believ
genet
test
nb
would
use
interest
genet
test
genet
counsel
conclus
studi
first
demonstr
interest
genet
test
counsel
among
patient
nb
find
demonstr
new
approach
genet
counselor
support
patient
clarifi
gap
misconcept
knowledg
nb
particular
countri
chicard
n
e
g
n
p
f
j
h
f
g
curi
siric
rtop
recherch
translationel
en
oncologi
translat
research
research
psl
research
univers
pari
franc
curi
de
somatiqu
pari
franc
curi
institut
curi
genom
excel
icgex
research
center
pari
franc
curi
de
biologi
de
servic
danatomi
pathologiqu
pari
franc
curi
depart
pediatr
hospit
group
pari
franc
curi
inserm
laboratoir
de
et
biologi
de
research
psl
research
univers
pari
franc
backgroundobject
pediatr
cancer
gener
character
recurr
genet
alter
genet
heterogen
clonal
evolut
play
role
tumor
progress
liquid
biopsi
enabl
monitor
genet
alter
sequenti
sampl
base
analysi
dna
cfdna
designmethod
subsequ
enrol
patient
pediatr
cancer
neuroblastoma
rhabdomyosarcoma
ewe
sarcoma
cn
tumor
cancer
aim
studi
clonal
evolut
base
sequenti
cfdna
analysi
prospect
trial
ngskid
http
wwwclinicaltrialsgov
identifi
median
follow
month
rang
month
tumor
relaps
we
perform
tumor
germlin
dna
well
cfdna
extract
plasma
diagnosi
treatment
follow
sequenti
cfdna
sampl
per
patient
cfdna
analysi
perform
use
modifi
procedur
ng
cfdna
subject
we
follow
modifi
librari
construct
captur
approach
account
small
ctdna
molecul
result
diagnosi
mean
tumor
snv
common
primari
tumor
correspond
cfdna
observ
rang
mean
snv
specif
primari
cfdna
respect
indic
spatial
heterogen
wherea
cfdna
sampl
obtain
patient
without
evid
diseas
reveal
tumor
snv
interestingli
cfdna
sampl
obtain
relaps
harbor
addit
new
snv
mean
rang
case
target
gene
mapk
deep
sequenc
captur
techniqu
panel
encompass
identifi
snv
appli
sequenti
cfdna
sampl
enabl
develop
model
clonal
evolut
conclus
cfdna
we
prove
extrem
power
tool
studi
spatial
tempor
heterogen
pediatr
high
risk
cancer
provid
proof
import
clonal
evolut
cancer
progress
c
derpoort
k
j
g
univers
hospit
pediatr
stem
cell
transplant
ghent
belgium
univers
hospit
pharmaci
ghent
belgium
univers
hospit
clinic
microbiolog
immunolog
ghent
belgium
univers
cancer
research
institut
ghent
ghent
belgium
backgroundobject
proport
childhood
cancer
attribut
germlin
genet
factor
like
underestim
identif
predispos
aberr
significantli
influenc
clinic
decis
make
impact
earli
diagnosi
contribut
better
understand
cancer
develop
recent
perform
whole
genom
sequenc
germlin
dna
famili
children
affect
burkitt
lymphoma
bl
interestingli
mutat
sever
regul
hippo
signal
identifi
valid
find
address
impact
aberr
hippo
signal
context
bl
designmethod
impact
verteporfin
treatment
select
inhibitor
protein
evalu
bl
cell
line
dsmz
use
multipl
concentr
untreat
cell
control
apoptosi
cytotox
viabil
assess
differ
time
point
use
triplex
assay
promega
result
order
unravel
relev
hippo
signal
pathway
bl
aim
block
transcript
program
inhibit
nuclear
effector
decreas
viabil
verteporfin
treatment
measur
investig
bl
cell
line
valu
rang
complet
cell
death
observ
concentr
conclus
importantli
result
illustr
potenti
role
hippo
signal
dysregul
cancer
develop
genet
predisposit
preliminari
function
experi
clearli
show
import
effect
verteporfin
viabil
bl
cell
line
howev
effect
verteporfin
treatment
gene
express
transcript
target
need
evalu
addit
preclin
data
efficaci
toxic
without
chemotherapeuticnovel
agent
context
bl
treatment
gener
gl
tl
share
senior
author
g
n
f
l
p
n
n
c
j
h
c
f
doz
jm
curi
univers
pari
descart
siredo
research
adolesc
young
adult
oncolog
pari
franc
hospit
clinic
pharmacolog
pari
franc
hospit
pediatr
otolaryngolog
pari
franc
pari
descart
ea
pari
franc
roussi
pediatr
adolesc
oncolog
villejuif
franc
pediatr
nanci
franc
institut
pediatr
lyon
franc
pediatr
unit
strasbourg
franc
pediatr
hematolog
bordeaux
franc
univers
trousseau
hospit
depart
pediatr
hematolog
oncolog
pari
franc
oscar
lambret
pediatr
oncolog
adolesc
young
adult
unit
lill
franc
univers
hospit
pediatr
toulous
franc
timon
children
hospit
pediatr
oncolog
depart
marseil
franc
hospit
depart
clinic
pharmacolog
pari
franc
backgroundobject
platinum
wide
use
treatment
sever
childhood
malign
howev
ototox
one
notabl
advers
effect
especi
children
sever
studi
suggest
genet
may
predict
occurr
common
polymorph
associ
platinum
induc
ototox
select
literatur
investig
pediatr
popul
treat
agent
designmethod
retrospect
multicent
studi
patient
treat
cisplatin
andor
carboplatin
screen
patient
audiogram
brock
criteria
avail
includ
select
polymorph
previous
associ
cisplatin
ototox
minor
allel
frequenc
delet
sod
xpc
investig
result
one
hundr
six
children
match
elig
criteria
analyz
patient
develop
moder
sever
ototox
brock
grade
probabl
hear
loss
increas
significantli
patient
carri
null
genotyp
p
aa
genotyp
p
cc
genotyp
p
also
show
associ
cumul
dose
carboplatin
cisplatin
brock
grade
p
conclus
delet
ercc
may
constitut
potenti
predictor
platinum
induc
ototox
eissa
el
cancer
pediatr
oncolog
cairo
egypt
cancer
institut
pediatr
oncolog
cairo
egypt
backgroundobject
noonan
syndrom
ns
commonest
rasopathi
autosom
domin
trait
character
short
statur
craniofaci
dysmorph
congenit
heart
defect
suscept
cancer
research
suggest
relationship
underli
genotyp
appar
phenotyp
aim
review
examin
ns
variat
spectrum
malign
designmethod
review
previous
publish
literatur
conduct
pubm
databas
articl
chosen
review
character
ns
avail
english
peer
review
result
nineti
three
articl
met
inclus
criteria
ns
describ
commonest
inherit
overlap
group
disord
collect
known
rasopathi
includ
castello
leopard
legiu
almost
articl
heterozyg
mutat
kra
nra
braf
cbl
other
identifi
lead
etiolog
ns
develop
abnorm
activ
signal
pathway
also
incrimin
oncogenesi
forti
seven
articl
describ
abnorm
myelopoiesi
juvenil
leukemia
jmml
commonest
malign
cn
tumor
next
common
solid
tumor
neuroblastoma
chondroma
rhabdomyosarcoma
limit
case
report
clinic
featur
ns
describ
articl
anoth
detail
genotyp
variat
variabl
describ
mani
author
exampl
germ
line
cbl
mutat
character
increas
risk
neurolog
disord
jmml
lower
risk
cardiac
defect
growth
retard
cryptorchid
nra
posit
ns
report
associ
hyperpigment
genet
distinct
subtyp
ns
patient
nfn
harbor
neurofibromin
mutat
also
describ
conclus
avail
research
suggest
relationship
underli
genotyp
variabl
express
phenotyp
mutat
pathway
drive
oncogenesi
identifi
util
molecular
diagnost
everi
patient
mutat
potenti
therapeut
target
p
ekert
zcc
prism
omic
zcc
preclini
drug
test
e
k
g
children
research
institut
children
cancer
institut
cancer
research
parkvil
australia
institut
kinghorn
centr
clinic
genom
sydney
australia
cancer
institut
peronalis
medicin
sydney
australia
wale
hospit
hereditari
cancer
clinic
sydney
australia
children
hospit
kid
cancer
centr
sydney
australia
backgroundobject
identif
somat
germlin
variant
paediatr
cancer
pathway
accur
diagnosi
target
treatment
select
zero
childhood
cancer
zcc
prism
trial
aim
assess
feasibl
precis
medicin
platform
identifi
target
therapeut
agent
paediatr
malign
expect
surviv
report
pilot
feasibl
studi
target
initi
experi
prism
trial
open
octob
designmethod
combin
whole
genom
sequenc
wg
deep
sequenc
panel
cancer
associ
gene
whole
transcriptom
rnaseq
togeth
vitro
drug
screen
xenograft
pdx
drug
efficaci
test
follow
assess
recommend
made
nation
multidisciplinari
tumour
board
result
patient
recruit
target
prism
patient
cn
tumour
sarcoma
haematolog
cancer
neuroblastoma
rare
tumour
type
curat
case
complet
molecular
platform
identifi
report
somat
snv
fusion
cnv
patient
includ
germlin
cancer
predisposit
variant
fusion
oncogen
variant
indic
specif
target
treatment
develop
matur
analyt
pipelin
interrog
full
rang
variant
mutat
signatur
identifi
paediatr
cancer
highest
yield
report
variant
deriv
combin
wg
rnaseq
xenograft
model
establish
divers
tumour
type
vitro
screen
possibl
overal
patient
receiv
personalis
medicin
recommend
conclus
establish
matur
analyt
pipelin
interrog
full
rang
variant
mutat
signatur
identifi
paediatr
cancer
zcc
prism
studi
combin
comprehens
genom
analysi
tumour
unbias
vitro
vivo
drug
screen
gener
treatment
recommend
children
adolesc
cancer
p
gargallo
p
mj
l
j
p
j
font
de
j
v
oncolog
valencia
spain
roussi
oncolog
pari
franc
fe
genom
valencia
spain
fe
pediatr
oncolog
valencia
spain
fe
patholog
valencia
spain
fe
genet
valencia
spain
fe
pharmaci
valencia
spain
fe
oncolog
group
valencia
spain
fe
oncolog
valencia
spain
backgroundobject
studi
pediatr
solid
tumor
relapseprogress
precis
medicin
multidisciplinari
board
designmethod
tumor
sampl
patient
prospect
collect
studi
use
cancer
hotspot
panel
embed
paraffin
tissu
patient
cancer
comprehens
panel
fresh
sampl
case
rnaseq
cgh
array
also
perform
patient
respect
genom
immunohistochem
clinic
data
analyz
multidisciplinari
person
medicin
committe
therapeut
recommend
result
frequent
tumor
studi
neuroblastoma
patholog
mutat
cancer
relat
gene
detect
case
mutat
detect
case
patholog
alk
mutat
found
patient
patient
present
atm
mutat
cancer
relat
pathway
frequent
affect
case
mapk
pathway
individu
therapeut
recommend
propos
case
case
clinic
recommend
base
inmunohistochim
studi
exclus
conclus
possibl
transfer
genom
result
laboratori
clinic
practic
pediatr
oncolog
patient
benefit
new
therapeut
strategi
nevertheless
necessari
facilit
access
new
drug
pediatr
age
cgh
array
provid
complementari
inform
interest
hawkin
l
b
b
chicago
pediatr
chicago
usa
washington
hematolog
ongolog
seattl
usa
cancer
institut
pediatr
oncolog
boston
usa
southern
california
prevent
medicin
monrovia
usa
southwestern
depart
clinic
scienc
dalla
usa
chicago
center
research
informat
chicago
usa
backgroundobject
increas
number
children
cancer
avail
studi
form
intern
consortia
neuroblastoma
pediatr
rhabdomyosarcoma
germ
cell
tumor
work
pool
larg
amount
patient
data
develop
consensu
standard
data
dictionari
facilit
data
harmon
prospect
collect
interoper
data
expand
pediatr
cancer
data
common
ad
data
ad
addit
diseas
type
link
addit
extern
data
sourc
designmethod
work
diseas
consortia
creat
consensu
data
dictionari
base
standard
refer
data
databas
nih
ev
sever
intern
meet
accompani
plan
phone
call
requir
consortia
achiev
consensu
data
element
formal
consensu
data
dictionari
establish
diseas
group
cover
small
base
set
data
element
data
prior
trial
transform
instanti
cohort
discoveri
tool
result
cohort
discoveri
tool
germ
cell
tumor
neuroblastoma
pediatr
rhabdomyosarcoma
design
allow
anyon
determin
cohort
count
set
patient
base
baselin
data
element
furthermor
patient
cohort
link
extern
data
sourc
frozen
tissu
biopatholog
center
well
analyz
data
target
databas
onlin
system
request
neuroblastoma
data
place
facilit
review
project
data
fulfil
addit
visual
data
manipul
tool
develop
conclus
built
world
first
common
neuroblastoma
rhabdomyosarcoma
germ
cell
tumor
allow
search
common
data
element
connect
extern
data
sourc
furthermor
clinic
data
common
link
via
uniqu
identifi
avail
genom
data
final
standard
data
dictionari
develop
effort
inform
gener
futur
case
report
form
data
collect
r
kebudi
kap
r
ak
b
e
da
ca
univers
cerrahpasa
medic
faculti
oncolog
institut
pediatr
hematolog
oncolog
istanbul
turkey
pleuropulmonari
registri
ovarian
testicular
stromal
tumor
children
hospit
clinic
minnesota
cancer
blood
disord
program
minneapoli
usa
center
cancer
blood
diseas
children
hospit
lo
keck
school
univers
southern
california
divis
oncolog
blood
marrow
transplant
lo
angel
usa
istanbul
school
medicin
patholog
istanbul
turkey
hospit
lo
angel
depart
patholog
laboratori
lo
angel
usa
univers
oncolog
institut
radiat
oncolog
istanbul
turkey
cancer
immunolog
research
children
nation
medic
center
depart
patholog
washington
dc
usa
clinic
divis
pediatr
depart
pediatr
adolesc
medicin
minnesota
usa
backgroundobject
pathogen
germlin
variant
caus
hereditari
cancer
predisposit
syndrom
increas
risk
variou
benign
malign
condit
rare
sarcoma
genitourinari
tract
associ
herein
present
two
children
germlin
ovarian
sarcoma
designmethod
retrospect
review
next
gener
sequenc
ng
result
patient
old
femal
present
abdomin
pain
imag
identifi
left
adnex
mass
complic
ovarian
torsion
preoper
ruptur
underw
left
oophorectomi
second
resect
residu
abdomin
tumor
metastat
evalu
neg
figo
stage
iiic
patholog
reveal
ovarian
sarcoma
cartilagin
rhabdomyoblast
differenti
receiv
vincristin
actinomycin
cyclophosphamid
year
whole
abdomen
proton
beam
radiotherapi
ng
identifi
monoallel
somat
mutat
germlin
loss
function
mutat
identifi
father
sister
found
mutat
well
patient
old
femal
present
acut
onset
abdomin
pain
imag
demonstr
right
adnex
mass
complic
ovarian
torsion
underw
right
intraop
stage
figo
stage
metastat
evalu
neg
patholog
reveal
sarcoma
heterolog
mesenchym
differenti
undifferenti
small
round
blue
cell
spindl
cell
larg
cell
differenti
receiv
ifosfamid
combin
doxorubicin
ng
demonstr
biallel
somat
mutat
frameshift
mutat
missens
mutat
target
mutat
analysi
confirm
pathogen
germlin
variant
gene
parent
test
progress
patient
remiss
follow
complet
therapi
conclus
ovarian
sarcoma
may
associ
germlin
mutat
identif
pathogen
mutat
import
surveil
implic
individu
famili
b
r
kebudi
h
oncolog
institut
depart
cancer
genet
istanbul
turkey
univers
cerrahpasa
medic
faculti
oncolog
institut
pediatr
hematolog
oncolog
istanbul
turkey
univers
istanbul
medic
faculti
depart
ophtalmolog
istanbul
turkey
backgroundobject
retinoblastoma
rb
common
malign
intraocular
tumor
childhood
retinoblastoma
known
aris
due
two
genet
event
involv
allel
occur
two
form
hereditari
mutat
allel
requir
tumor
initi
gene
show
high
degre
mutat
heterogen
retinoblastoma
crucial
identifi
distinguish
gene
mutat
predict
accur
risk
sibl
offspr
famili
histori
retinoblastoma
cancer
gene
may
also
inactiv
promot
methyl
studi
aim
investig
role
promot
methyl
retinoblastoma
oncogenesi
designmethod
sixti
patient
retinoblastoma
famili
histori
retinoblastoma
cancer
mutat
includ
larg
delet
insert
small
indel
mutat
fifti
two
healthi
control
match
age
gender
recruit
studi
methyl
statu
determin
zymo
research
one
step
qmethyl
kit
use
appli
biosystem
real
time
pcr
system
mann
whitney
u
test
use
compar
methyl
level
group
patient
healthi
control
result
mean
level
methyl
patient
retinoblastoma
healthi
control
respect
signific
differ
detect
two
group
accord
methyl
statu
statist
p
promot
methyl
level
gene
similar
group
patient
healthi
control
conclus
result
suggest
promot
methyl
gene
patient
gene
mutat
may
involv
etiolog
retinoblastoma
gene
involv
retinoblastoma
oncogenesi
studi
fund
istanbul
univers
research
fund
grant
keino
w
n
f
n
h
children
medic
center
childhood
cancer
center
yokohama
japan
univers
school
medicin
hospit
depart
pediatr
kawasaki
japan
backgroundobject
multimod
therapeut
approach
includ
chemotherapi
necessari
pediatr
bone
soft
tissu
tumor
howev
rariti
diseas
difficult
develop
new
chemotherapi
patient
fail
respond
standard
chemotherapi
exploit
new
therapi
preclin
evalu
sorafenib
everolimu
eribulin
perform
droplet
embed
cultur
drug
sensit
test
designmethod
patient
bone
soft
tissu
tumor
primari
tumor
lung
metastat
tumor
surgic
resect
kanagawa
children
medic
center
tumor
tissu
test
sensit
drug
test
drug
concentr
decid
base
clinic
achiev
serum
concentr
drug
exposur
time
test
drug
studi
approv
institut
ethic
board
guardian
inform
consent
obtain
result
success
done
tumor
four
sampl
os
fibrosarcoma
malign
myoepithelioma
malign
rhabdoid
tumor
malign
perivascular
epithelioid
cell
tumor
pecoma
respect
growth
inhibit
achiev
sorafenib
sampl
ugml
sampl
everolimu
ngml
sampl
eribulin
ugml
respect
consid
result
sorafenib
administ
patient
os
malign
myoepithelioma
partial
respons
stabl
diseas
obtain
conclus
sorafenib
everolimu
eribulin
show
good
activ
bone
soft
tissu
tumor
sorafenib
also
show
clinic
efficaci
use
tool
preclin
drug
evalu
necessari
develop
background
clinic
trial
especi
recurr
rare
tumor
r
labib
e
cancer
research
cairo
egypt
cancer
pediatr
oncolog
cairo
egypt
cancer
clinic
patholog
cairo
egypt
backgroundobject
rhabdomyosarcoma
rm
small
round
blue
cell
tumor
repres
childhood
malign
standard
treatment
rm
compos
cyclophosphamid
actinomycin
vincristin
vac
differ
drug
transport
eg
drug
metabol
enzym
play
role
drug
activ
metabol
develop
chemotherapeut
agent
lead
failur
treatment
designmethod
cohort
pediatr
rm
patient
treat
cyclophosphamid
base
first
line
treatment
genotyp
restrict
fragment
polymorph
rflp
taqman
assay
analyz
associ
genotyp
respons
treatment
surviv
outcom
rm
result
frequenc
respect
frequenc
success
detect
carrier
least
one
mutant
allel
significantli
longer
surviv
conclus
result
demonstr
genotyp
may
predict
ef
pediatr
rm
patient
use
better
stratifi
risk
prior
treatment
jw
lee
b
jh
jg
hh
kw
wy
h
hl
medic
sungkyunkwan
univers
school
medicin
depart
pediatr
seoul
republ
korea
medic
center
samsung
genom
institut
seoul
republ
korea
nation
univers
colleg
medicin
depart
pediatr
gwangju
republ
korea
samsung
sungkyunkwan
univers
school
medicin
depart
pediatr
seoul
republ
korea
backgroundobject
relapsedrefractori
pediatr
cancer
show
poor
prognosi
howev
genom
pattern
remain
unknown
investig
genet
mechan
tumor
relaps
therapi
resist
character
genom
alter
diagnost
relaps
lesion
patient
relapsedrefractori
pediatr
solid
tumor
designmethod
relapsedrefractori
pediatr
cancer
patient
sampl
diagnosi
relaps
includ
studi
target
sequenc
panel
cover
exon
cancer
gene
use
character
pair
diagnost
relaps
sampl
result
nineteen
patient
variou
diagnos
includ
rhabdomyosarcoma
neuroblastoma
enrol
studi
mean
coverag
sampl
sd
among
gene
singl
nucleotid
variat
snv
indel
copi
number
alter
one
structur
variat
detect
point
six
percent
snv
primari
tumor
also
found
recurr
lesion
snv
recurr
tumor
newli
occur
among
snvsindel
detect
recurr
lesion
low
variant
allel
fraction
vaf
patient
classifi
three
categori
base
mutat
pattern
cancer
treatment
patient
whose
relaps
tumor
fewer
mutat
diagnost
sampl
longer
surviv
achiev
complet
remiss
relaps
contrastingli
patient
whose
genet
profil
concord
mutat
without
chang
worst
outcom
conclus
character
genom
chang
recurr
pediatr
solid
tumor
find
could
help
understand
biolog
relaps
childhood
cancer
develop
person
treatment
base
genet
profil
f
li
x
r
z
l
children
hospit
shandong
univers
depart
hematolog
oncolog
jinan
china
backgroundobject
irinotecan
trametinib
two
drug
util
treat
acut
leukaemia
cancer
chlidren
studi
aim
evalu
interact
ddi
irinotecan
trametinib
designmethod
determin
inhibitori
effect
trametinib
activ
ugt
inhibit
type
kinet
determin
inhibit
trametinib
toward
vivo
extrapol
iviv
perform
use
follow
equat
auciauc
vivoki
result
ugt
play
key
role
metabol
elimin
irinotecan
um
trametinib
inhibit
activ
furthermor
inhibit
trametinib
toward
demonstr
plot
drawn
determin
inhibit
kinet
type
trametinib
toward
intersect
point
locat
verticl
axi
show
competit
inhibit
trametinib
toward
second
plot
furtherli
drawn
use
slope
line
plot
versu
concentr
trametinib
fit
equat
use
equat
inhibit
kinet
paramet
ki
um
base
vivo
extrapol
iviv
equat
evalu
standard
ki
threshold
valu
induc
vivo
inhibit
calcul
um
conclus
studi
demonstr
inhibit
trametinib
activ
indic
potenti
interact
v
lm
ra
tm
ar
fa
rl
ac
em
pl
u
al
cs
nh
paulo
univers
medic
school
sao
brazil
albert
einstein
hospit
brazil
pediatr
depart
fmusp
itaci
hematolog
divis
hiae
sao
paulo
brazil
paulo
univers
medic
school
sao
brazil
pediatr
depart
fmusp
itaci
sao
paulo
brazil
cancer
brazil
laboratori
paulo
brazil
sao
paulo
state
univers
brazil
laboratori
botucatu
brazil
univers
brazil
depart
genet
evolutionari
biolog
paulo
brazil
paulo
univers
medic
school
sao
brazil
hemocentro
de
brazil
divis
molecular
genet
sao
paulo
brazil
backgroundobject
play
role
cancer
control
also
associ
respons
patient
chemotherapi
andor
adopt
immunotherapi
role
particularli
import
due
cytotox
effect
upon
tumor
cell
primarili
refractoryrecurr
cancer
patient
absolut
number
well
ratio
retrospect
follow
throughout
manag
period
unrespons
pu
compar
period
diseas
complet
remiss
accord
indic
identifi
possibl
relationship
designmethod
children
enrol
acut
leukemia
hodgkin
peripher
neuroectoderm
diffus
pontin
wilm
lymphoprolif
either
unrespons
follow
diagnosi
andor
least
one
document
episod
recurrenceprogress
episod
survivor
without
evid
activ
diseas
sequenti
count
measur
flow
cytometri
done
throughout
phase
treatment
comparison
done
pu
pu
versu
pu
versu
pu
versu
confid
interv
ci
result
individu
analysi
obtain
instanc
pu
signific
differ
seen
median
pu
versu
particularli
versu
p
specif
comparison
median
pu
also
strongli
favor
last
group
p
signific
differ
seen
regard
median
versu
despit
predomin
group
conclus
cell
number
correl
longer
period
absent
progress
diseas
sustain
complet
respons
may
repres
result
potent
cytotox
activ
f
postema
c
j
l
c
de
c
n
van
p
van
den
w
j
l
r
h
children
academ
medic
center
depart
pediatr
oncolog
amsterdam
netherland
medic
center
utrecht
depart
genet
utrecht
netherland
medic
center
depart
clinic
genet
amsterdam
netherland
children
radboud
univers
medic
center
depart
pediatr
oncolog
nijmegen
netherland
univers
medic
center
groningen
depart
genet
groningen
netherland
medic
center
clinic
research
unit
amsterdam
netherland
univers
medic
center
depart
clinic
genet
amsterdam
netherland
center
pediatr
oncolog
depart
pediatr
oncolog
utrecht
netherland
oxford
nuffield
depart
obstetr
gynaecolog
oxford
unit
kingdom
univers
medic
center
depart
human
genet
nijmegen
netherland
univers
medic
center
depart
pediatr
oncolog
amsterdam
netherland
children
erasmu
medic
center
depart
pediatr
oncolog
rotterdam
netherland
univers
medic
center
groningen
depart
pediatr
oncolog
groningen
netherland
medic
center
depart
clinic
genet
rotterdam
netherland
medic
center
depart
pediatr
amsterdam
netherland
backgroundobject
children
cancer
tumor
predisposit
syndrom
tp
identif
tp
child
cancer
clinic
relev
half
tpss
recogn
prior
treatment
cancer
increas
effect
decreas
cost
develop
screen
instrument
ensur
evalu
tp
children
cancer
children
like
tp
refer
clinic
geneticist
full
genet
counsel
designmethod
tup
studi
prospect
observ
studi
includ
children
netherland
newli
diagnos
cancer
screen
instrument
consist
score
form
pictur
digit
assess
two
independ
clinic
geneticist
tp
suspect
least
one
clinic
geneticist
posit
assess
patient
invit
full
genet
consult
primari
outcom
measur
sensit
instrument
result
interim
analysi
first
patient
show
posit
assess
rate
singl
posit
doubl
posit
reason
posit
assess
mainli
base
type
cancer
famili
histori
pictur
although
pictur
seemingli
decis
factor
fourteen
children
refer
part
neg
control
group
patient
evalu
full
genet
consult
thu
far
genet
test
carri
patient
two
patient
tp
diagnos
two
patient
germlin
mutat
signific
found
conclus
preliminari
result
indic
screen
instrument
tool
care
children
cancer
ensur
evalu
tp
number
still
small
determin
sensit
instrument
b
rivera
ak
j
w
univers
oncolog
montreal
canada
univers
health
centr
cancer
research
program
montreal
canada
univers
anatomi
montreal
canada
colleg
london
medicin
londr
unit
kingdom
univers
health
centr
patholog
montreal
canada
gener
hospit
radiolog
montreal
canada
gener
hospit
dermatolog
oncolog
montreal
canada
calgari
depart
oncolog
calgari
canada
minnessota
minneapoli
usa
univers
health
centr
pediatr
patholog
montreal
canada
univers
oncolog
human
genet
medic
genet
montreal
canada
backgroundobject
key
featur
childhood
cancer
suscept
syndrom
sever
tumor
congenit
abnorm
accompani
tumor
develop
recent
advanc
indic
import
proport
childhood
malign
due
germlin
mosaic
mutat
use
high
sensit
sequenc
techniqu
resolv
diagnosi
conundrum
designmethod
we
digit
droplet
pcr
ddpcr
use
studi
patient
suspect
cancer
predisposit
condit
germlin
mutat
previous
found
candid
gene
result
pleuropulmonari
blastoma
ppb
choroid
plexu
papilloma
cpp
child
investig
fluidigm
array
sequenc
mlpa
rule
presenc
germlin
mutat
two
somat
hit
identifi
ppb
sampl
ddpcr
assay
rule
mosaic
cpp
exom
sequenc
perform
blood
child
focus
cancer
suscept
gene
identifi
like
pathogen
mutat
caus
diseas
thu
natur
cpp
remain
elus
adult
male
attend
clinic
diagnosi
mosaic
form
gorlin
syndrom
born
eyelid
close
iri
coloboma
present
facial
asymmetri
age
molecular
screen
blood
normal
fibroblast
affect
area
rule
presenc
germlin
mosaic
mutat
we
perform
blood
tumor
reveal
presenc
smo
mutat
five
tumor
absent
blood
ddpcr
sever
normal
tumor
tissu
confirm
mosaic
statu
mutat
suggest
milder
cours
pediatr
condit
known
curri
jone
syndrom
accur
diagnosi
condit
conclus
multipl
tumor
alway
denot
underli
cancer
suscept
condit
molecular
studi
requir
order
adjust
clinic
manag
accordingli
russo
f
n
b
k
el
l
n
h
n
c
j
medic
center
mainz
depart
pediatr
hematologyoncologyhemostaseolog
mainz
germani
backgroundobject
fanconi
anemia
fa
common
form
inherit
bone
marrow
failur
development
disord
predisposit
leukemia
solid
tumor
fa
caus
mutat
gene
regul
dna
repair
fanconi
anemia
complement
group
better
known
tumor
suppressor
mutat
gene
associ
adult
onset
cancer
risk
particularli
breast
ovarian
cancer
childhood
cancer
predisposit
syndrom
fa
caus
inactiv
gene
instead
bone
marrow
failur
patient
suffer
highli
aggress
embryon
tumor
earli
childhood
gener
medulloblastoma
nephroblastoma
designmethod
identifi
famili
gene
affect
famili
consanguin
famili
includ
children
develop
nephroblastoma
median
age
month
one
child
die
due
diseas
immedi
diagnosi
one
secondari
glioblastoma
age
year
one
affect
brother
still
aliv
follow
failur
due
sever
toxic
cancer
treatment
nephroblastoma
affect
children
reveal
short
statur
microcephali
axillari
freckl
famili
grandmoth
die
metastat
breast
cancer
age
year
daughter
suffer
medulloblastoma
age
year
still
aliv
mother
one
son
diagnos
nephroblastoma
age
month
result
molecular
analysi
prove
compound
heterozygos
mutat
allel
appear
associ
brain
tumor
respect
nephroblastoma
molecular
analysi
reveal
polymorph
associ
sever
cancer
type
includ
breast
ovarian
cancer
conclus
identif
gene
affect
particular
interest
childhood
cancer
predisposit
syndrom
treatment
option
due
mutat
allel
overt
treatment
toxic
consid
choos
suitabl
therapi
eg
parp
inhibitor
r
shirai
k
c
k
k
center
child
health
develop
pediatr
hematolog
oncolog
research
tokyo
japan
citi
univers
graduat
school
medicin
pediatr
kanagawa
japan
center
child
health
develop
children
cancer
center
tokyo
japan
research
institut
child
health
develop
human
genet
tokyo
japan
children
hospit
hematolog
oncolog
shizuoka
japan
center
child
health
develop
patholog
tokyo
japan
school
kyoto
univers
patholog
tumor
biolog
kyoto
japan
backgroundobject
atyp
teratoidrhabdoid
tumor
atrt
malign
rhabdoid
tumor
mrt
common
genom
featur
mutat
andor
delet
gene
chromosom
previou
studi
show
certain
fraction
rhabdoid
tumor
harbor
germlin
mutat
account
case
designmethod
blood
tumor
sampl
case
sporad
rhabdoid
tumor
includ
cn
tumor
n
extracrani
tumor
n
combin
cn
extracrani
tumor
analyz
detect
potenti
alter
gene
use
sanger
sequenc
droplet
digit
pcr
result
alter
identifi
case
intens
genom
analys
demonstr
alter
aros
germlin
eight
patient
includ
case
low
frequenc
alter
consid
mosaic
case
germlin
variant
cn
tumor
case
n
microdelet
n
missens
variant
n
mrt
case
n
missens
variant
n
combin
case
n
microdelet
n
missens
variant
n
median
age
diagnosi
case
germlin
variant
month
rang
month
case
without
germlin
variant
month
rang
month
conclus
confirm
alter
genet
hallmark
atrt
mrt
preval
germlin
alter
higher
previou
report
approxim
half
case
rhabdoid
tumor
associ
germlin
predisposit
found
age
genet
counsel
surveil
famili
member
essenti
rhabdoid
tumor
singh
p
institut
medic
educ
research
paediatr
chandigarh
india
backgroundobject
chimer
gene
fusion
product
drive
variat
behind
chronic
myeloid
leukaemia
certain
form
acut
lymphoblast
leukaemia
current
studi
vitro
induct
fusion
gene
silenc
use
tool
henc
potenti
translat
clinic
cure
addit
studi
bring
light
issu
face
applic
tool
chimer
gene
designmethod
crispr
guid
rna
sgrna
design
use
multipl
onlin
platform
deskgen
chopchop
crispr
plasmid
gener
clone
sgrna
blank
crispr
plasmid
addgen
label
green
fluoresc
protein
gfp
sequenc
perform
verifi
success
clone
result
plasmid
transfect
cell
line
use
lipid
method
select
cell
separ
use
cell
sort
fac
downstream
gene
quantif
phosphoryl
crkl
pcrkl
phosphoryl
perform
use
flowcytometri
result
singl
sgrna
activ
point
target
activ
deskgen
select
transcript
sgrna
procur
form
oligonucleotid
ligat
clone
crispr
plasmid
sequenc
confirm
success
insert
sgrna
design
site
plasmid
transfect
show
effici
pcrkl
level
indic
low
activ
crispr
plasmid
conclus
result
highlight
target
chimer
fusion
gene
result
rel
lower
target
activ
due
fact
chimera
dna
level
inconsist
sequenc
breakpoint
occur
intron
region
henc
sgrna
ca
nt
bind
chimer
form
howev
issu
circumv
either
design
multipl
sgrna
target
chimer
gene
rna
transcript
level
use
modifi
format
crispr
b
thoma
dnb
medic
pediatr
kim
cancer
centr
thiruvananthapuram
india
backgroundobject
biallel
germlin
mutat
explain
approxim
constitut
mismatch
repair
defici
cmmrd
syndrom
case
autosom
recess
disord
associ
high
risk
childhood
cancer
cmmrd
character
highli
penetr
childhood
brain
tumor
hematolog
malign
gastrointestin
cancer
rare
malign
designmethod
would
like
present
case
two
sibl
affect
malign
absolut
histori
cancer
famili
elder
sibl
diagnos
treat
glioblastoma
multiform
younger
sibl
diagnos
acut
lymphoblast
lymphoma
parent
third
degre
cousin
coupl
offer
genet
counsel
decid
go
genet
test
genet
test
done
medgenom
lab
bangalor
india
medgenom
famili
genet
diseas
studi
project
result
exom
sequenc
younger
sibl
detect
homozyg
splice
site
variat
intron
gene
depth
affect
invari
gt
donor
splice
site
silico
predict
variant
found
damag
variant
predict
alter
donor
site
splice
silico
predict
tool
human
gene
splice
finder
observ
variant
previous
report
one
case
studi
clinic
phenotyp
lynch
syndrom
gene
member
mismatch
repair
mmr
gene
mutat
gene
associ
hereditari
nonpolyposi
colorect
cancer
hnpcc
segreg
analysi
observ
variant
gene
detect
homozyg
state
elder
sibl
heterozyg
state
unaffect
parent
thu
homozyg
variant
segreg
affect
individu
famili
conclus
first
time
variant
associ
cmmrd
identifi
indian
famili
trich
g
l
j
hospit
lo
angelesunivers
southern
california
patholog
lo
angel
usa
hospit
lo
angelesunivers
southern
california
pediatr
lo
angel
usa
backgroundobject
sequenc
panel
specif
pediatr
cancer
heretofor
creat
sought
creat
panel
capabl
assess
import
cancer
gene
mutat
copi
number
amplif
gene
fusion
one
assay
could
perform
routin
ffpe
tissu
frozen
section
white
blood
cell
bone
marrow
use
littl
extract
rna
dna
goal
incorpor
reason
frequent
known
genet
alter
report
pediatr
cancer
type
includ
diagnost
prognost
featur
well
action
target
featur
target
therapeut
identifi
designmethod
result
panel
offer
children
hospit
lo
angel
ldt
oncokid
capclia
accredit
center
person
medicin
also
avail
thermo
fisher
oncomin
childhood
cancer
research
assay
consist
gene
includ
hotspot
gene
full
length
code
sequenc
gene
gene
amplif
parent
fusion
gene
partner
variant
potenti
detect
assay
develop
ion
torrent
platform
oncomin
nci
match
program
use
ampliseq
target
amplif
technolog
result
first
six
month
use
chla
patient
least
one
variant
strong
clinic
signific
addit
patient
potenti
germlin
mutat
half
test
inherit
pathogen
variant
least
two
case
novel
gene
fusion
lead
clinic
unsuspect
target
therapi
option
one
case
undiagnos
soft
tissu
sarcoma
novel
ntrk
fusion
led
success
use
ntrk
inhibitor
larotrectinib
conclus
experi
pediatr
cancer
focus
gene
panel
significantli
improv
diagnost
accuraci
led
target
therapeut
altern
would
otherwis
miss
k
van
der
tuin
l
de
ej
se
mjm
van
fj
mc
wd
h
univers
medic
centr
clinic
genet
leiden
netherland
univers
human
genet
montreal
canada
univers
medic
centr
clinic
genet
nijmegen
netherland
univers
medic
centr
pediatr
leiden
netherland
spectrum
twent
endocrinolog
ensched
netherland
jonscher
clinic
hospit
pediatr
poznan
poland
univers
medic
centr
patholog
leiden
netherland
maxima
center
pediatr
oncolog
genet
utrecht
netherland
univers
medic
center
medic
genet
utrecht
netherland
backgroundobject
syndrom
rare
autosom
domin
inherit
disord
predispos
varieti
cancer
noncancer
tumor
mostli
includ
differenti
thyroid
carcinoma
dtc
dtc
hypothes
aris
secondari
increas
preval
lesion
ie
thyroid
hyperplast
nodul
limit
data
avail
acquir
genet
variant
induc
malign
transform
designmethod
perform
somat
mutat
analysi
extens
somat
dna
variant
gene
fusion
ten
patient
syndrom
young
onset
dtc
result
median
age
dtc
diagnosi
year
patient
develop
recurr
metastat
diseas
median
year
thyroid
specimen
show
diffus
nodular
hyperplasia
least
one
focu
suspect
dtc
without
infiltr
growth
extens
vascular
invas
lymph
node
metastasi
distinct
somat
rnase
iiib
domain
variant
identifi
benign
nodul
test
patient
tumor
suggest
multipl
distinct
tumor
furthermor
dtc
lack
well
known
oncogen
driver
dna
variant
gene
rearrang
conclus
basi
clinic
histolog
molecular
data
consid
dtc
form
subgroup
tumor
may
aris
one
mani
benign
polyclon
nodul
right
left
total
thyroidectomi
may
often
requir
radioiodin
treatment
may
unnecessari
given
patient
age
low
propens
metastas
wu
z
hospit
pediatr
surgeri
shanghai
china
backgroundobject
neuroblastoma
subset
neuroblastoma
associ
advanc
stage
diseas
unfavor
biolog
featur
poor
outcom
even
though
pathogen
mycn
neuroblastoma
clear
molecular
pathogen
mechan
remain
unclear
effect
therapeut
approach
neuroblastoma
due
undrugg
properti
mycn
end
profil
mycn
interactom
proteom
illustr
potenti
molecular
signal
pathway
interact
protein
mycn
could
altern
develop
drug
target
mycn
designmethod
mycn
amplifi
cell
pcr
clone
retrovir
vector
stabl
express
construct
cell
line
flag
interactor
precipit
resin
follow
subject
mass
spectrometri
analysi
protein
identif
result
strategi
total
identifi
potenti
interact
protein
mycn
includ
sever
known
interactor
ie
max
aurka
addit
plenti
protein
report
interactor
mycn
thu
far
bioinformat
analysi
reveal
seveal
cancer
relev
signal
pathway
significantli
mycn
interactor
includ
mismatch
repair
dna
replic
also
metabol
pathway
glycolyt
enzym
valid
bona
fide
interact
protein
mycn
target
specif
small
molecular
inhibitor
could
significantli
inhibt
mycn
amplifi
neuroblastoma
cell
line
mycn
nonamplifi
cell
conclus
data
provid
valuabl
inform
discoveri
interact
protein
mycn
neuroblastoma
interactor
could
develop
altern
approach
interupt
mycn
signal
pathway
highlight
indirect
target
mycn
studi
z
wu
k
hospit
pediatr
surgeri
shanghai
china
backgroundobject
neuroblastoma
heterogen
embryon
malign
low
frequenc
genom
mutat
made
genom
character
neuroblastoma
less
success
adult
tumor
gene
actual
shown
drive
diseas
molecular
level
thu
far
quantit
proteom
provid
althern
direct
approach
avail
identifi
diregul
signal
pathway
protein
drive
neuroblastoma
designmethod
neuroblastoma
tissu
evaul
pathologist
protein
extract
digest
trypsin
follow
tmt
label
enabl
quantit
analysi
result
peptid
analyz
coupl
mass
spectrometri
protein
identif
quantif
achiev
maxquant
result
strategi
quantit
profil
neuroblastoma
tissu
sampl
cell
line
primari
data
analysi
show
approxim
protein
identifi
sampl
around
protein
identifi
quantifi
across
sampl
supervis
analysi
neuroblastoma
ganglioneuroblastoma
ganglioneuroma
reveal
differ
signal
pathway
overrepres
three
group
particularli
sever
cancer
relev
signal
pathway
ie
splicesom
dna
replic
mismatch
repair
significantli
enrich
neuroblastoma
group
ganglioneuroblastoma
ganglioneuroma
group
unsupervis
analysi
could
clearli
separ
sampl
four
subgroup
either
use
protein
top
standard
deviat
protein
top
signific
p
valu
interestingli
tow
subgroup
clearli
correl
clinic
paramet
overal
surviv
rate
age
diagnosi
supervis
cluster
analysi
sampl
without
chemotherapi
highlight
sever
chemotherapi
relat
protein
includ
known
drug
resist
relev
protein
ie
also
unknown
potenti
drug
sensit
correl
protein
ctcf
conclus
straightforward
proteom
analysi
provid
altern
strategi
molecular
character
neuroblastoma
primari
find
potenti
develop
new
diagnost
therapeut
option
neuroblastoma
patient
yoshida
k
si
r
k
h
n
k
research
institut
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
citi
univers
depart
graduat
school
medicin
yokohama
japan
research
institut
child
health
develop
depart
biolog
tokyo
japan
center
child
health
develop
children
cancer
center
tokyo
japan
metropolitan
children
medic
center
hematolog
tumor
intern
medicin
tokyo
japan
medic
dental
univers
depart
pediatr
tokyo
japan
children
medic
center
depart
hematologyoncolog
saitama
japan
univers
pediatr
tokyo
japan
marianna
univers
school
medicin
depart
pediatr
kawasaki
japan
univers
hospit
depart
pediatr
chiba
japan
luke
intern
hospit
pediatr
depart
tokyo
japan
prefectur
univers
medicin
depart
pediatr
kyoto
japan
backgroundobject
secondari
malign
neoplasm
smn
one
import
late
complic
treatment
pediatr
malign
recent
higher
preval
germlin
mutat
gene
children
develop
cancer
compar
popul
report
investig
frequenc
genet
mutat
gene
children
suffer
smn
treatment
childhood
cancer
designmethod
germlin
sampl
obtain
patient
develop
smn
childhood
cancer
whole
exom
sequenc
we
perform
detect
germlin
mutat
autosom
domin
ad
gene
detect
code
variant
classifi
five
categori
pathogen
probabl
pathogen
uncertain
signific
probabl
benign
benign
base
common
databas
function
predict
algorithm
call
we
data
control
cohort
without
known
cancer
histori
also
analyz
result
median
age
diagnos
primari
secondari
cancer
year
respect
primari
diseas
hematolog
malign
case
whose
smn
hematolog
malign
n
solid
tumor
n
solid
tumor
case
whose
smn
hematolog
malign
n
solid
tumor
n
mutat
deem
pathogen
probabl
pathogen
ad
categori
identifi
case
develop
smn
preval
significantli
high
compar
control
case
case
p
mutat
gene
ad
categori
observ
smn
cohort
n
n
n
n
conclus
germlin
cancer
predisposit
affect
suscept
smn
case
pediatr
cancer
recognit
potenti
cancer
predisposit
may
chang
treatment
strategi
indic
radiat
alkyl
agent
b
q
b
b
jm
jc
bhatia
univers
medic
center
radiolog
nashvil
usa
univers
medic
center
oncolog
nashvil
usa
univers
medic
center
neurosurgeri
nashvil
usa
backgroundobject
purpos
studi
evalu
treatment
effect
spinal
cord
sc
children
use
diffus
tensor
imag
dti
perform
quantifi
dti
indic
mean
diffus
md
axial
diffus
ad
radial
diffus
rd
fraction
anisotropi
fa
control
patient
oncolog
patient
designmethod
retrospect
analysi
perform
dti
acquir
part
clinic
mri
sc
protocol
pediatr
popul
vanderbilt
children
hospit
diffus
weight
imag
direct
slice
nomin
acquir
philip
achieva
sc
dti
acquisit
includ
axial
slice
placement
vari
patient
volum
interest
voi
manual
select
axial
slice
includ
entir
cord
exclud
csf
slice
identifi
belong
one
four
sc
level
cervic
upper
thorac
thoracolumbar
conu
mean
dti
index
calcul
across
voxel
within
voi
result
singl
md
ad
rd
fa
valu
level
valu
compar
patient
receiv
oncolog
treatment
includ
radiat
chemotherapi
student
perform
patient
cancer
healthi
control
everi
sc
level
dti
metric
result
pediatr
patient
pp
receiv
combin
chemotherapi
andor
radiat
compar
control
patient
hc
statist
signific
differ
dti
indic
pp
hc
cervic
thorac
thoracolumbar
sc
p
howev
conu
hc
higher
md
ad
pp
respect
conclus
dti
sc
provid
object
biomark
analysi
oncolog
treatment
children
primarili
radiat
spine
studi
look
review
radiat
treatment
base
dose
determin
dose
depend
chang
dti
indic
inc
fc
mb
b
k
h
n
eylul
univers
institut
oncolog
pediatr
oncolog
izmir
turkey
eylul
univers
faculti
medicin
radiodiagnost
izmir
turkey
eylul
univers
faculti
medicin
pediatr
izmir
turkey
eylul
univers
institut
oncolog
pediatr
current
adress
izmir
univers
econom
faculti
medicin
izmir
turkey
eylul
univers
faculti
medicin
pediatr
neurolog
izmir
turkey
backgroundobject
neurofibromatosi
common
autosom
domin
neurocutan
disord
affect
central
nervou
system
cn
diagnost
criteria
dc
determin
gutmann
et
al
mani
criteria
describ
clinic
examin
nowaday
magnet
reson
imag
mri
avail
radiodiagnost
method
reveal
distinct
hyperintens
foci
term
unidentifi
bright
object
ubo
studi
aim
determin
incid
diagnost
criterion
incid
characterist
ubo
patient
designmethod
medic
report
patient
anal
retrospect
clinic
laboratori
characterist
diagnost
criteria
cn
mri
find
patient
evalu
retrospect
locat
size
number
ubo
examin
ubo
locat
classifi
basal
ganglia
thalamu
brain
stem
corpu
callosum
cerebrum
also
anal
patient
presumpt
diagnosi
result
definit
diagnosi
probabl
median
age
diagnosi
mf
percent
patient
two
patient
dc
remain
frequenc
dc
plexiform
optic
lisch
bone
cranial
mri
perform
mri
reveal
ubo
patient
median
age
ubo
detect
age
group
ubo
detect
ubo
locat
basal
ganglia
thalamu
brain
stem
cerebellum
corpu
callosum
cerebrum
patient
ubo
detect
multipl
locat
median
diamet
malign
tumor
occur
patient
soft
tissu
sarcoma
probabl
spot
one
nt
meet
dc
howev
mri
reveal
ubo
age
conclus
three
quarter
patient
ubo
ubo
detect
patient
follow
presumpt
diagnosi
highli
probabl
conclud
ubo
could
propos
addit
dc
r
shaikh
children
hospit
dana
farber
cancer
center
intervent
radiolog
boston
usa
backgroundobject
use
intervent
techniqu
treat
adult
oncolog
patient
well
establish
translat
techniqu
pediatr
realm
continu
evolv
intervent
approach
provid
valuabl
altern
diseas
treatment
symptom
manag
pioneer
use
intervent
techniqu
treat
palliat
oncolog
diseas
pediatr
patient
overdu
evalu
pediatr
patient
underw
differ
intervent
procedur
cancer
treatment
palliat
institut
designmethod
pediatr
patient
solid
tumor
underw
intervent
procedur
eg
cryoablat
radiofrequ
ablat
microwav
ablat
sclerotherapi
transarteri
embol
institut
enrol
registri
medic
record
imag
studi
review
patient
diseas
demograph
intervent
procedur
perform
outcom
document
clinic
radiolog
chang
evalu
compar
pre
procedur
post
procedur
result
pt
yr
underw
intervent
oncolog
procedur
differ
indic
outcom
intervent
individu
evalu
procedur
level
clinic
radiolog
outcom
measur
conclus
experi
demonstr
intervent
procedur
feasibl
provid
safe
minim
invas
treatment
palli
option
manag
pediatr
solid
tumor
consid
earli
adjuv
manag
tumor
e
ternovaya
g
rogachev
nation
research
center
pediatr
oncolog
immunolog
nuclear
medicin
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
clinic
oncolog
moscow
russia
backgroundobject
neuroblastoma
nb
one
common
extracrani
solid
tumor
children
almost
nb
present
metastas
initi
diagnosi
pulmonari
metastas
rare
presenc
pulmonari
metastas
requir
differenti
diagnosi
inflammatori
nodal
lung
mass
correct
stage
object
identif
radiolog
find
typic
featur
incid
rate
pulmonari
metastas
paediatr
patient
nb
comparison
plain
radiographi
comput
tomographi
data
designmethod
retrospect
studi
consist
patient
inss
stage
iv
nb
treat
dmitri
rogachev
nation
research
center
pediatr
hematolog
oncolog
immunolog
imag
data
plain
radiographi
comput
tomographi
analyz
patient
undergon
ct
contrast
enhanc
perform
slice
brightspe
ge
comput
tomograph
result
patient
inss
stage
iv
neuroblastoma
diagnos
lung
metastas
diagnosi
bilater
distribut
multifoc
lesion
smallest
size
nodul
measur
largest
measur
cohort
patient
middl
larg
calibr
lesion
predomin
patient
differ
degre
pleural
involv
show
involv
mediastin
lymphat
calcif
lesion
patient
tumor
thrombosi
primari
site
larg
vessel
nodal
lung
lesion
visibl
plain
radiographi
initi
diagnosi
conclus
diagnost
criteria
specif
pulmonari
metastas
nb
formul
foci
medium
larg
calibr
round
shape
even
edg
homogen
structur
presenc
tumor
thrombosi
larg
blood
vessel
absenc
calcif
halo
sign
even
enhanc
contrast
agent
administr
absenc
cavit
imag
obtain
data
help
differenti
diagnosi
chest
ct
consid
part
initi
diagnost
process
e
ternovaya
g
rogachev
nation
research
center
pediatr
oncolog
immunolog
nuclear
medicin
moscow
russia
backgroundobject
chronic
pulmonari
diseas
cgvhd
remain
major
complic
patient
surviv
allogen
stem
cell
transplant
bronchiol
obliteran
bo
consid
one
manifest
cgvhd
bo
lead
anoth
rare
potentiali
lethal
complic
cgvhd
diagnos
earli
thorac
syndrom
tal
diagnost
criteria
bo
well
defin
base
function
test
hard
obtain
pediatr
patient
imag
data
lung
biopsi
object
establish
diagnost
criteria
specif
bo
studi
tal
possibl
complic
designmethod
retrospect
survey
pediatr
patient
age
year
old
receiv
radiolog
clinic
find
consist
pulmonari
cgvhd
median
time
onset
pulmonari
complic
day
interv
day
patient
undergon
chest
comput
tomographi
scan
clinic
data
review
none
patient
iatrogen
tal
could
occur
due
transbronchi
lung
biopsi
mechan
ventil
result
ct
find
bo
mosaic
perfus
patchi
peribronchi
consolid
air
trap
diffus
ground
glass
opac
demonstr
air
collect
patient
syndrom
asymptomat
show
clinic
symptom
ct
find
consist
pneumothorax
combin
pneumomediastinum
pneumothorax
patient
follow
chest
ct
exam
conclus
air
recogn
bo
relat
complic
clinic
manifest
spontan
air
vari
radiolog
find
alon
asymptomat
patient
sever
respiratori
insuffici
chest
ct
modal
choic
initi
follow
diagnost
tal
post
transplant
pediatr
patient
suspect
bo
proven
pulmonari
cgvhd
acut
onset
dyspnea
andor
chest
pain
g
achempim
j
l
child
cancer
programm
accra
ghana
san
francisco
nurs
depart
san
francisco
usa
bu
teach
hospit
depart
child
health
accra
ghana
backgroundobject
uk
aid
fund
world
child
cancer
implement
childhood
cancer
twin
programm
april
accra
kumasi
ghana
one
project
object
increas
publicprofession
awar
childhood
cancer
key
project
activ
includ
ralliesawar
walk
radio
tv
talk
show
poster
bumper
sticker
brand
calendar
distribut
public
educ
church
school
conduct
asid
social
media
campaign
commun
awar
survey
conduct
assess
programm
contribut
toward
public
awar
rais
accra
designmethod
assum
childhood
cancer
awar
base
local
programm
activ
anticip
increas
least
ci
power
total
particip
propos
base
clincal
onlin
sampl
calcul
commun
sampl
simpl
random
purpos
systemat
sampl
oral
individu
interview
perform
week
greater
accra
region
data
analysi
use
microsoft
excel
descript
statist
respond
comment
note
result
respond
age
year
mean
age
interview
though
formal
educ
rest
complet
basic
high
although
respond
heard
childhood
cancer
said
incur
uncertain
experienc
childhood
cancer
awar
inform
channel
includ
social
free
text
comment
question
document
categor
theme
conclus
gener
cancer
awar
studi
accra
respond
none
mention
childhood
cancer
rel
small
budget
site
signific
impact
rais
childhood
cancer
awar
promot
earli
detect
advocaci
commun
support
magnitud
effect
awar
creation
model
programm
support
media
collabor
rais
sustain
childhood
cancer
awar
lmic
alsaleh
bin
v
faisal
specilaist
hospit
research
centr
pediatr
hematolog
oncolog
riyadh
saudi
arabia
backgroundobject
hematolog
servic
known
provid
prompt
consult
hematolog
oncolog
day
week
hour
day
throughout
institut
inpati
outpati
servic
pediatr
hematolog
oncolog
pho
depart
provid
similar
consult
pediatr
patient
king
faisal
specialist
hospit
research
centr
kfsh
rc
riyadh
designmethod
onlin
consult
captur
system
cc
use
redcap
vanderbilt
univers
data
manag
modul
built
serv
gateway
hematolog
consult
primari
care
physician
access
consult
servic
real
time
enabl
follow
track
endors
process
result
total
consult
record
cc
provid
patient
consult
januari
march
consult
servic
request
variou
hospit
area
half
inpati
ward
consult
emerg
room
intens
care
unit
outpati
unit
surgic
unit
clearanc
major
consult
hematolog
complic
relat
cancer
solid
tumor
histiocytosi
observ
consult
hematolog
symptom
observ
bleed
consult
account
bone
marrow
consult
account
reason
observ
consult
conclus
experi
virtual
system
facilit
data
uniqu
pediatr
hematolog
consult
servic
enabl
us
catalogu
practic
identifi
area
led
consolid
consult
servic
center
prove
effect
teach
fellow
data
analysi
underway
explor
premis
nation
hematolog
modul
allow
medic
care
access
everi
corner
kingdom
j
g
j
p
n
p
p
r
r
b
p
r
v
l
j
j
cancer
institut
paediatr
oncolog
kampala
uganda
backgroundobject
paediatr
tumour
board
ptb
key
element
paediatr
oncolog
provid
platform
time
multidisciplinari
care
graduatecontinu
medic
educ
cme
upon
establish
dedic
pediatr
oncolog
depart
uganda
cancer
institut
uci
hypothes
ptb
critic
set
infrastructur
limit
designmethod
last
four
year
deliber
invest
creat
improv
ptb
describ
key
consider
creation
evolut
impact
program
result
critic
specialti
includ
radiotherapi
paediatr
surgeri
patholog
hardli
access
uci
untim
uncoordin
address
challeng
assembl
weekli
ptb
two
paediatrician
paediatr
surgeon
pathologist
radiat
oncologist
discuss
diagnost
challeng
plan
tumour
resect
radiotherapi
initi
discuss
guid
medic
note
evolv
project
case
summari
radiolog
patholog
imag
increas
caseload
ptb
split
solid
tumour
ptb
sinc
establish
east
africa
pediatr
hematolog
oncolog
fellowship
uci
ptb
becam
invalu
educ
platform
discuss
emphas
approach
rather
improvis
accredit
ptb
cme
attract
commit
specialist
subspecialti
engag
research
qualiti
improv
initi
ptb
typic
attend
ptb
grew
five
member
fifti
conclus
ptb
key
platform
rapid
growth
pediatr
cancer
care
uci
support
first
pediatr
oncolog
fellowship
program
region
highli
organ
research
recommend
nascent
pediatr
cancer
program
develop
countri
prioritis
establish
growth
ptb
borja
mj
axxi
oncolog
hematolog
pediatr
quito
ecuador
metropolitano
patholog
servic
quito
ecuador
backgroundobject
determin
preval
abdomin
tumor
children
attend
pediatr
hospit
quito
ecuador
patholog
area
compar
result
anoth
seri
outsid
countri
intern
statist
estim
pediatr
tumor
solid
malign
tumor
locat
abdomen
order
frequenc
tumor
occur
abdomen
neuroblastoma
nephroblastoma
wilm
tumor
hepatoblastoma
germ
cell
tumor
countri
approxim
news
case
year
children
year
old
registr
studi
designmethod
perform
studi
retrospect
analityc
compar
pediatr
patient
diagnost
abdomin
tumor
histopatholog
sampl
definit
diagnost
januari
decemb
equatorian
children
hospit
quito
capit
countri
result
abdomin
tumor
detect
year
old
main
age
frequent
tumor
year
old
gender
distribut
show
predomin
man
case
versu
woman
classif
tumor
type
common
wilm
tumor
case
germ
cell
tumor
hepatoblastoma
case
lymphoma
neuroblastoma
other
malign
pancrea
tumor
angiosarcoma
patient
present
abdomin
pain
palpabl
abdomin
mass
diagnost
conclus
observ
wilm
tumor
frequent
neuroblastoma
compar
statistyc
usa
abdomin
malign
tumor
note
children
year
old
male
common
patient
recommend
creat
nation
program
statist
studi
children
cancer
countri
serv
health
autor
take
correct
decis
develop
program
field
brown
rm
r
j
hospit
southampton
paediatr
oncolog
southampton
unit
kingdom
colleg
london
hospit
nh
foundat
trust
cancer
clinic
trial
unit
london
unit
kingdom
nottingham
paediatr
cancer
biolog
nottingham
unit
kingdom
colleg
london
hospit
nh
foundat
trust
london
sarcoma
servic
london
unit
kingdom
backgroundobject
multidisciplinari
team
meet
mdtm
provid
regular
forum
cancer
team
discuss
patient
care
uk
recent
rise
number
nation
advisori
panel
nap
children
young
peopl
cancer
cyp
panel
distinct
local
mdtm
involv
nation
expert
particular
cancer
type
advic
may
sought
panel
individu
patient
aim
studi
explor
opinion
healthcar
profession
regard
cyp
mdtm
nap
designmethod
healthcar
profession
involv
cyp
cancer
care
invit
complet
onlin
survey
children
cancer
leukaemia
group
cclg
teenag
young
adult
cancer
tyac
membership
list
result
fifti
respons
receiv
repres
uk
princip
treatment
centr
compris
doctor
nurs
rang
profess
within
mdt
patientfamili
awar
discuss
mdtm
report
particip
fifti
percent
felt
consult
respons
inform
patient
mdt
decis
felt
combin
profession
could
respons
major
felt
patient
famili
view
alway
inform
mdtm
view
present
someon
met
respond
agre
patientsfamili
attend
mdt
would
impract
approxim
half
respond
access
nap
patient
last
month
inform
patient
process
common
reason
refer
nap
present
expert
opinion
famili
conclus
care
commun
fundament
effect
mdtm
nap
view
polar
best
achiev
therefor
evalu
warrant
c
citak
e
b
g
univers
faculti
medicin
pediatr
oncolog
mersin
turkey
univers
faculti
medicin
pediatr
oncolog
adana
turkey
health
adana
citi
hospit
pediatr
oncolog
adana
turkey
backgroundobject
studi
evalu
frequenc
euthyroid
sick
syndrom
ess
among
patient
childhood
cancer
associ
stage
diseas
nutrit
paramet
cytokin
level
designmethod
eighti
newli
diagnos
children
includ
studi
ess
diagnos
two
differ
way
group
lower
limit
within
normal
low
limit
tsh
normal
rang
group
level
group
moreov
perform
higher
normal
limit
result
three
children
subclin
hypothyroid
children
subclin
hyperthyroid
patient
ess
identifi
group
group
group
level
significantli
differ
ess
ess
group
p
group
level
significantli
differ
ess
ess
group
p
consid
gender
age
stage
diseas
bmi
patient
statist
signific
differ
subject
without
ess
group
p
group
group
significantli
neg
correl
found
neg
correl
level
group
correl
tsh
level
conclus
ess
may
seen
childhood
cancer
thyroid
function
test
perform
routin
cancer
diagnos
mo
cunha
f
ferreira
da
nacion
de
cancer
hci
brasil
pediatr
oncolog
rio
de
janeiro
brazil
backgroundobject
treatment
childhood
cancer
associ
complic
due
ill
treatment
requir
urgent
emerg
medic
care
possibl
offer
servic
hour
day
day
week
patient
cancer
fundament
improv
cure
rate
aim
studi
describ
reason
emerg
depart
visit
factor
associ
hospit
admiss
designmethod
conduct
retrospect
cohort
analysi
databas
visit
pediatr
patient
cancer
cancer
pediatr
emerg
depart
within
one
year
data
collect
age
gender
tumor
diagnosi
oncolog
statu
number
visit
per
patient
reason
emerg
consult
outcom
result
visit
pediatr
patient
cancer
studi
period
patient
solid
tumor
patient
hematolog
malign
median
age
year
rang
year
three
common
type
primari
diagnosi
intern
classif
childhood
cancer
central
nervou
system
tumor
group
iii
lymphoma
group
ii
wilm
tumor
group
vi
account
visit
common
caus
emerg
visit
due
fever
neutropenia
seventi
percent
patient
discharg
home
patient
admit
hospit
mortal
rate
emerg
low
one
patient
die
due
termin
diseas
conclus
knowledg
common
reason
emerg
visit
pediatr
patient
cancer
import
treatment
plan
improv
outcom
dolendo
k
cl
fd
mc
c
c
c
philippin
medic
center
depart
pediatr
children
cancer
institut
davao
citi
philippin
mindanao
medic
center
depart
pediatr
cagayan
de
oro
citi
philippin
region
medic
center
depart
pediatr
tagum
citi
philippin
philippin
medic
center
depart
pediatr
gener
santo
citi
philippin
citi
medic
center
depart
pediatr
butuan
citi
philippin
vina
gener
inc
depart
pediatr
valencia
citi
philippin
jude
children
research
hospit
global
pediatr
medicin
depart
memphi
usa
manchest
academ
unit
paediatr
adolesc
oncolog
manchest
unit
kingdom
backgroundobject
limit
access
specialist
care
emphas
need
mitig
burden
care
larg
public
tertiari
center
studi
aim
describ
develop
mindanao
pediatr
cancer
care
network
mpccn
share
care
facil
southern
philippin
medic
center
spmc
hub
referr
center
mindanao
philippin
designmethod
retrospect
review
share
care
facil
chosen
strateg
locat
deliv
acut
care
awar
campaign
prompt
referr
follow
mpccn
team
pediatrician
nurs
support
staff
train
spmc
referr
done
phone
call
text
messag
email
onlin
confer
data
collect
includ
clinic
profil
referr
pattern
patient
outcom
decemb
analyz
use
chi
squar
descript
statist
result
six
share
care
facil
tagum
gener
santo
zamboanga
cagayan
de
oro
butuan
valencia
develop
differ
time
point
sinc
januari
decemb
five
share
care
facil
saw
patient
treat
spmc
share
care
manag
facil
major
hematolog
malign
particularli
retinoblastoma
osteosarcoma
germ
cell
tumor
common
among
patient
solid
tumor
outcom
patient
manag
share
care
facil
show
aliv
expir
abandon
refus
data
transfer
facil
studi
period
significantli
greater
number
patient
seen
hematolog
malign
onsit
set
compar
solid
tumor
share
care
p
valu
term
outcom
percentag
patient
aliv
significantli
greater
share
care
compar
onsit
care
vs
p
valu
conclus
optim
commun
train
team
care
pediatr
oncolog
patient
enhanc
share
care
facil
despit
limit
resourc
e
v
l
g
dran
dafn
flexer
foundat
presid
bueno
air
argentina
dafn
flexer
foundat
depart
investig
bueno
air
argentina
dafn
flexer
foundat
psychosoci
depart
bueno
air
argentina
school
univers
bueno
air
pharmacolog
depart
bueno
air
argentina
dafn
flexer
strategi
depart
bueno
air
argentina
council
scientif
technolog
investig
conicet
investig
depart
bueno
air
argentina
backgroundobject
barrier
adequ
childhood
cancer
treatment
usual
develop
countri
determin
poor
surviv
qol
natali
dafn
flexer
foundat
fndf
provid
assist
children
cancer
argentina
aim
studi
describ
incid
determin
barrier
medic
btm
among
famili
assist
fndf
along
period
designmethod
retrospect
quantit
analysi
record
consecut
children
cancer
diagnosi
yo
assist
fndf
primari
outcom
possibl
btm
possibl
undergo
step
obtain
medic
outcom
compar
among
patient
differ
type
medic
cytostat
vs
support
treatment
center
public
vs
privat
diagnos
leukemia
vs
lymphomaoth
solid
tumor
health
coverag
public
vs
job
vs
privat
coverag
fisher
exact
test
use
result
five
hundr
nineti
seven
patient
assist
period
face
btm
boy
argentinean
total
step
taken
obtain
medic
mean
number
per
patient
involv
medic
support
cytostat
coadjuv
barrier
due
institut
delay
lack
pharmaci
stock
lack
countrydrug
bank
famili
delay
unauthor
medicin
proport
patient
face
btm
higher
among
patient
cover
job
insur
public
health
p
privat
coverag
proport
patient
underw
step
get
medic
higher
among
patient
cover
job
privat
insur
public
coverag
outcom
vari
diagnosi
type
treatment
center
type
medic
conclus
substanti
number
famili
experi
barrier
cytostat
support
medicin
cancer
argentina
mostli
relat
institut
delay
ineffici
job
privat
coverag
f
erdmann
l
g
jf
j
agenc
research
cancer
section
environ
radiat
lyon
franc
cancer
societi
research
center
childhood
cancer
research
group
copenhagen
denmark
institutet
unit
institut
environment
medicin
stockholm
sweden
cancer
societi
research
center
lifestyl
gene
copenhagen
denmark
backgroundobject
despit
substanti
advanc
surviv
childhood
cancer
past
decad
children
benefit
equal
improv
condit
children
evid
suggest
factor
act
prior
birth
may
influenc
diseas
trajectori
includ
childhood
cancer
outcom
uniqu
cohort
swedish
danish
children
investig
relationship
birth
characterist
surviv
childhood
cancer
designmethod
children
born
denmark
sweden
diagnos
primari
cancer
age
year
follow
year
diagnosi
multipl
cox
proport
hazard
model
estim
hazard
ratio
hr
confid
interv
ci
use
assess
impact
birthweight
gestat
age
number
sibl
parent
age
mode
deliveri
birth
order
overal
surviv
result
poorer
surviv
observ
children
low
birthweight
g
compar
children
birthweight
g
hr
adjust
gestat
age
ci
analys
birthweight
gestat
age
point
toward
associ
surviv
slight
tendenc
inferior
surviv
found
children
deliv
caesarean
section
analys
specif
cancer
type
show
children
acut
lymphoblast
leukaemia
higher
hr
associ
low
birth
weight
hr
ci
wors
surviv
children
born
small
gestat
age
hr
ci
cn
tumour
associ
observ
associ
parent
age
inconsist
cancer
type
conclus
overal
birth
characterist
appear
strongli
affect
surviv
childhood
cancer
sinc
low
birth
weight
gener
associ
increas
mortal
infanc
rel
surviv
calcul
addit
analys
n
faruqui
r
j
r
h
r
sydney
school
public
health
sydney
australia
georg
institut
global
health
offic
chief
scientist
sydney
australia
ngo
capac
build
delhi
india
super
special
hospit
paediatr
oncolog
delhi
india
ngo
palli
care
servic
delhi
india
apollo
hospit
institut
cancer
delhi
india
india
institut
medic
institut
rotari
cancer
hospit
medic
oncolog
delhi
india
indo
american
cancer
hospit
medic
oncolog
hyderabad
india
institut
oncolog
medic
oncolog
hyderabad
india
children
hospit
pediatr
hyderabad
india
india
institut
medic
scienc
pediatr
oncolog
delhi
india
sydney
faculti
medicin
sydney
australia
backgroundobject
childhood
cancer
surviv
rate
india
estim
primari
reason
behind
poor
outcom
challeng
access
care
individu
health
system
level
qualit
studi
investig
barrier
access
care
symptom
onset
begin
treatment
caregiv
healthcar
profession
perspect
designmethod
studi
conduct
tertiari
cancer
centr
across
delhi
hyderabad
caregiv
children
year
oncologist
senior
resid
nurs
social
worker
dietician
psychologist
radiologist
interview
purpos
sampl
satur
use
ensur
adequ
represent
gender
age
cancer
type
geograph
locat
socioeconom
statu
interview
audio
record
obtain
inform
consent
themat
content
analysi
conduct
organis
use
nvivo
softwar
result
caregiv
healthcar
profession
recruit
caregiv
especi
distant
geograph
area
divers
errat
referr
pathway
partli
due
influenc
famili
friend
andor
stakehold
lack
specialist
doctor
pauciti
diagnost
facil
ruralregion
area
long
travel
time
healthcar
profession
interview
report
similar
complex
patient
journey
well
lack
adequ
infrastructur
patient
load
tertiari
hospit
inadequ
support
govern
barrier
financi
constraint
recur
theme
amongst
famili
unabl
support
daili
expens
throughout
journey
comparison
privat
hospit
caregiv
public
hospit
describ
greater
sever
barrier
long
wait
time
disorganis
administr
support
overal
difficulti
patient
navig
barrier
highlight
healthcar
profession
differ
health
disciplin
conclus
variou
barrier
childhood
cancer
treatment
india
start
symptom
onset
exacerb
treatment
begin
studi
help
inform
policymak
variou
system
level
barrier
prevent
appropri
access
care
c
fiori
hospit
pediatr
oncolog
cascavel
brazil
backgroundobject
introduct
brazil
cancer
children
adolesc
consid
public
health
problem
due
high
mortal
rate
high
financi
cost
rare
diseas
repres
caus
death
rang
year
hand
cure
rate
reach
diagnos
earli
cancer
hospit
cascavel
uopeccan
partnership
ronald
mcdonald
institut
earli
diagnosi
cancer
children
adolesc
program
train
profession
health
pediatr
municip
object
train
profession
health
pediatrician
contribut
earli
identif
cancer
children
adolesc
reduc
time
onset
sign
symptom
diagnosi
special
center
provid
increas
probabl
cure
designmethod
health
profession
train
april
decemb
receiv
basic
inform
children
cancer
adolesc
epidemiolog
sign
symptom
suspicion
care
children
adolesc
cancer
result
profession
doctor
nurs
technician
nurs
assist
commun
health
agent
upper
level
profession
conclus
preliminari
analysi
data
allow
us
observ
children
adolesc
cancer
present
advanc
diseas
diagnosi
observ
chang
stage
diagnosi
patient
come
local
diseas
possibl
chang
may
relat
train
activ
program
develop
brazil
sinc
one
goal
campaign
encourag
educ
prevent
action
becom
known
peopl
symptom
sign
diseas
shorten
time
suspicion
cancer
earli
diagnosi
treatment
certainli
contribut
increas
expect
cure
develop
countri
p
freccero
l
la
v
aa
j
child
cancer
programm
london
unit
kingdom
ghana
medic
school
depart
child
health
accra
ghana
philippin
medic
centr
depart
pediatr
davao
philippin
anoky
teach
hospit
depart
child
health
kumasi
ghana
children
hospit
unit
yangon
myanmar
burma
sheikh
mujib
medic
univers
paediatr
haematolog
oncolog
dhaka
bangladesh
backgroundobject
world
child
cancer
wcc
work
partnership
paediatr
oncolog
programm
incom
countri
lmic
support
improv
servic
children
cancer
central
success
develop
effect
network
situat
match
popul
centr
literatur
develop
network
lmic
current
exist
designmethod
model
develop
learn
year
uk
govern
dfid
fund
programm
ghana
bangladesh
lesson
share
programm
myanmar
philippin
workshop
held
focuss
lesson
learn
practition
repres
network
differ
stage
develop
identifi
key
element
step
necessari
build
network
result
success
network
must
strong
hub
hospit
centr
requir
doctor
train
experi
paediatr
oncolog
commit
team
dedic
bed
space
provis
train
patient
data
record
essenti
medicin
avail
health
partnership
develop
centr
benefici
support
would
ideal
avail
patient
famili
centr
requir
dedic
leader
basic
team
ward
space
oncolog
patient
close
relationship
hub
centr
servic
replic
hub
well
resourc
allow
major
challeng
includ
obtain
support
hospit
administr
govern
polici
financ
develop
collabor
work
good
commun
emphasis
use
treatment
protocol
develop
referr
system
share
learn
principl
sustain
requir
avail
train
within
system
fund
conclus
model
share
enabl
other
lmic
access
inform
inform
system
develop
whilst
exhaust
requir
research
repres
import
first
step
includ
lesson
learn
practition
experi
e
gold
children
cancer
blood
disord
center
global
health
initi
boston
usa
backgroundobject
sinc
global
health
initi
ghi
children
hospit
dfbc
establish
partnership
pediatr
oncolog
hospit
countri
lmic
program
enter
sixth
year
oper
ghi
sought
formal
analyz
lesson
learn
determin
factor
facilit
hinder
impact
partnership
dfbc
perspect
second
phase
studi
interview
intern
ghi
partner
reflect
integr
experi
designmethod
conduct
interview
dfbc
physician
nurs
psychosoci
administr
leadership
structur
interview
guid
use
explor
experi
insight
data
transcrib
manual
code
excel
tabul
identifi
themat
element
effect
global
health
program
irb
approv
obtain
result
theme
emerg
around
strateg
programmat
facilit
challeng
facilit
includ
need
assess
countri
partner
site
continu
work
impact
measur
challeng
center
oper
limit
lmic
eg
staff
turnov
commun
gap
stakehold
engag
respond
report
product
partnership
ghi
staff
formal
alloc
dedic
time
effort
work
concentr
period
time
specif
intern
partner
conclus
find
studi
may
assist
ghi
global
health
program
inform
strateg
decis
futur
partnership
maxim
resourc
product
collabor
programmat
implic
may
includ
around
requir
start
partnership
next
step
includ
complet
second
phase
studi
develop
onlin
publicli
avail
inquiri
form
captur
inform
potenti
new
partner
assess
e
gonzalez
cs
cruz
e
rs
gonzalez
rivera
nacion
de
pediatria
oncolog
mexico
citi
mexico
infantil
teleton
de
oncologia
oncolog
queretaro
mexico
infantil
de
mexico
oncolog
ciudad
de
mexico
mexico
para
el
poblano
oncolog
puebla
mexico
region
president
juarez
oncolog
oaxaca
mexico
medico
nacion
de
noviembr
oncolog
ciudad
de
mexico
mexico
civil
de
guadalajara
oncolog
guadalajara
mexico
backgroundobject
mexico
cancer
second
caus
death
popul
year
old
consid
main
factor
determin
gener
way
prognosi
patient
histolog
tumor
stage
time
diagnosi
object
determin
risk
factor
patient
delay
medic
delay
system
delay
designmethod
observ
descript
prospect
multicent
studi
conduct
survey
appli
medic
variabl
particip
center
offer
pediatr
oncolog
servic
particip
total
patient
result
follow
result
obtain
femal
male
socioeconom
level
low
medium
high
patient
delay
day
day
number
doctor
visit
less
first
action
give
treatment
request
imag
studi
laboratori
refer
anoth
center
hospit
request
biopsi
medic
delay
present
case
median
day
doctor
visit
suspect
cancer
gener
physician
pediatrician
prescrib
antibiot
nsaid
prescrib
patient
accord
parent
thought
symptom
would
resolv
problem
econom
resourc
problem
miss
work
perceiv
mistak
diagnosi
first
doctor
consult
time
diagnosi
present
metastasi
leukemia
lymphoma
solid
tumor
conclus
delay
diagnost
patient
final
diagnos
cancer
oncolog
hospit
mexico
result
may
influenc
health
polit
r
h
n
v
ganga
ram
hospit
pediatr
oncolog
bmt
unit
new
delhi
india
backgroundobject
present
symptom
childhood
cancer
usual
pediatrician
usual
first
point
contact
children
health
system
designmethod
onlin
survey
conduct
august
questionnair
sent
pediatrician
india
repons
pediatr
oncologist
exclud
result
elig
respons
govern
institut
teach
institut
townsvillag
train
pediatr
subspeci
around
year
pediatr
practic
encount
pediatr
cancer
respons
childhood
cancer
curabl
identifi
commonest
malign
leukemia
howev
predict
rate
surviv
rate
hodgkin
lymphoma
wilm
tumour
underestim
around
appropri
respond
fever
abdomin
mass
bicytopenia
leukocoria
bone
pain
could
manifest
malign
alarmingli
presum
minimum
age
develop
cancer
year
felt
steroid
use
treat
leukemia
howev
promptli
respond
bone
marrow
evalu
mandatori
prior
initi
steroid
itp
steroid
mask
underli
malign
incorrectli
respond
leukemia
patient
need
bone
marrow
transplant
cure
erron
respond
one
cord
blood
cure
thalassemia
leukemia
futur
incorrectli
respond
blood
transfus
chang
bone
marrow
find
leukemia
respond
inform
nearbi
pediatr
oncolog
centr
referr
conclus
pediatrician
awar
present
featur
curabl
natur
childhood
cancer
howev
awar
regard
age
onset
natur
treatment
limit
util
one
cord
stem
cell
highli
lack
pediatr
oncologist
ensur
pediatrician
made
awar
aspect
k
handayani
e
b
e
g
ageng
serang
district
hospit
paediatr
yogyakarta
indonesia
univers
medic
centr
paediatr
amsterdam
netherland
antil
gadjah
mada
paediatr
yogyakarta
indonesia
backgroundobject
improv
qualiti
care
outreach
program
challeng
teleconferenc
increasingli
use
consid
breakthrough
medic
educ
evalu
adher
childhood
teleconfer
indonesia
netherland
designmethod
teleconfer
held
april
march
indonesian
academ
hospit
evalu
use
standard
form
adher
diagnost
treatment
advic
explor
medic
record
result
teleconfer
difficult
case
children
discuss
dutch
pediatr
oncologist
indonesian
resid
dutch
oncologist
advic
diagnost
adjust
case
common
diagnost
advic
laboratori
test
imag
physic
examin
diagnost
advic
adher
children
common
reason
applic
set
disagr
dutch
advic
ct
scan
order
patient
die
dutch
oncologist
advic
treatment
adjust
case
common
treatment
advic
chang
protocol
nutrit
prevent
tumor
lysi
syndrom
treatment
advic
adher
children
common
reason
poor
condit
child
applic
set
patient
die
disagr
dutch
advic
children
die
teleconfer
held
children
aliv
children
abandon
complet
still
treatment
conclus
teleconferenc
knowledg
high
low
countri
share
improv
patient
care
local
applic
advic
requir
activ
particip
pediatr
oncologist
partner
site
essenti
therefor
recommend
k
hua
hospit
affili
shanghai
jiao
tong
univers
school
medicin
depart
pediatr
hematologyoncolog
shanghai
china
institut
health
scienc
depart
nurs
shanghai
china
backgroundobject
vast
territori
china
bring
imbalanc
distribut
medic
resourc
eastern
costal
western
inland
area
children
malign
remot
area
minor
nation
predominantli
inhabit
alway
poorli
treat
dedic
twin
plan
make
utmost
exist
medic
resourc
help
patient
newli
diagnos
childhood
adolesc
cancer
designmethod
twin
plan
implement
supervis
station
pediatr
oncologist
work
kashgar
prefectur
locat
western
border
china
popul
million
malign
favor
prognosi
involv
less
complic
treatment
modal
would
treat
local
critic
diagnosi
perform
aid
twin
partner
tertiari
pediatr
cancer
center
shanghai
intens
treatment
phase
elabor
surgeri
also
accomplish
shanghai
patient
came
back
subsequ
treatment
twin
plan
fund
medic
aid
project
result
period
children
adolesc
enrol
median
month
aliv
among
patient
stick
plan
estim
probabl
surviv
psu
accord
survey
conduct
previous
psu
leukemia
solid
tumor
region
respect
lower
rate
hematolog
toxic
sever
infect
chemotherapi
regimen
observ
among
patient
predomin
uygur
khalkha
ethnic
group
kashgar
prefectur
compar
han
nation
counterpart
conclus
owe
twin
plan
outcom
malign
significantli
improv
compar
histor
data
collabor
mode
prove
effici
econom
china
educ
commun
research
treatment
refin
need
provid
equal
care
patient
throughout
countri
l
hessissen
c
c
h
moham
v
rabat
pediatr
oncolog
rabat
morocco
assist
publiqu
de
marseil
aphm
pediatr
oncolog
marseil
franc
roussi
institut
pediatr
oncolog
villejuif
franc
tennesse
health
scienc
center
health
scienc
center
tennesse
usa
jude
children
research
hospit
depart
global
pediatr
medicin
tennesse
usa
espoir
foundat
medic
depart
pari
franc
pari
sud
hospit
pediatr
surgeri
villejuif
franc
rochd
univers
hospit
hematolog
pediatr
oncolog
casablanca
morocco
backgroundobject
sinc
year
thefrench
african
group
pediatr
oncolog
gfaop
createdfifteenpediatr
oncolog
unit
countri
produc
skill
physician
gfaop
next
challeng
gfaop
receiv
financi
intellectu
support
sanofi
espoir
foundat
child
matter
program
establishedth
african
school
pediatr
oncolog
pediatr
oncolog
train
diploma
custom
african
physician
one
year
intens
train
program
accredit
univers
rabat
univers
pari
sud
present
experi
model
countri
face
similar
challeng
designmethod
committe
multidisciplinari
expert
morocco
franc
usa
final
curriculum
pattern
french
model
teach
multidisciplinari
train
candid
per
year
candid
must
commit
serv
parent
institut
one
year
train
includ
didact
lectur
expert
record
onlin
deliveri
practicum
research
project
evalu
involv
candid
evalu
feedback
effect
qualiti
train
result
first
cohort
began
octob
modul
becam
avail
third
cohort
octob
total
candid
recruit
three
cohort
first
two
cohort
traine
respect
achiev
success
rate
whilethird
cohort
traine
remain
session
candid
french
african
countri
success
candid
return
countri
three
new
pediatr
oncolog
unit
establish
niger
central
african
republ
gabon
avail
http
wwwegfaoporg
user
current
regist
fifti
fulli
train
particip
respond
program
evalu
survey
valuabl
feedback
conclus
model
feasibl
implement
countri
challeng
sustain
due
high
time
commit
trainer
b
jone
j
j
c
health
queensland
depart
paediatr
surgeri
south
brisban
australia
queensland
depart
paediatr
child
health
brisban
australia
council
queensland
australian
childhood
cancer
registri
fortitud
valley
australia
univers
menzi
health
institut
gold
coast
australia
children
hospit
depart
paediatr
surgeri
adelaid
australia
adelaid
disciplin
surgeri
adelaid
australia
research
institut
children
cancer
research
unit
sydney
australia
sydney
divis
child
adolesc
health
sydney
australia
backgroundobject
describ
incid
surviv
rhabdomyosarcoma
australia
use
nation
data
australian
childhood
cancer
registri
accr
investig
second
primari
malign
spm
children
treat
rhabdomyosarcoma
designmethod
children
year
diagnos
rhabdomyosarcoma
inclus
identifi
accr
demograph
tumour
characterist
incid
mortal
treatment
data
extract
cs
ef
surviv
year
diagnosi
estim
use
cohort
method
adjust
excess
mortal
hazard
ratio
hr
calcul
use
multivari
flexibl
parametr
surviv
model
cumul
incid
standardis
incid
ratio
sir
mortal
relat
spm
estim
rel
gener
popul
result
children
diagnos
rhabdomyosarcoma
studi
period
incid
rate
chang
significantli
studi
period
estim
per
million
children
per
year
cs
year
respect
ef
cs
improv
studi
period
diagnos
older
age
diagnosi
year
associ
poorer
surviv
compar
younger
age
group
hr
use
baselin
year
patient
achiev
remiss
relaps
subsequ
cs
cumul
incid
spm
year
overal
sir
spm
follow
rhabdomyosarcoma
girl
like
boy
diagnos
spm
breast
cancer
account
excess
femal
risk
common
spm
thyroid
cancer
leukaemia
osteosarcoma
mortal
within
year
spm
diagnosi
conclus
cs
rhabdomyosarcoma
improv
time
australia
survivor
face
greatli
increas
risk
spm
girl
disproportion
affect
b
jone
j
j
c
health
queensland
depart
paediatr
surgeri
south
brisban
australia
queensland
depart
paediatr
child
health
brisban
australia
council
queensland
australian
childhood
cancer
registri
fortitud
valley
australia
univers
menzi
health
institut
gold
coast
australia
children
hospit
depart
paediatr
surgeri
adelaid
australia
adelaid
disciplin
surgeri
adelaid
australia
research
institut
children
cancer
research
unit
sydney
australia
sydney
divis
child
adolesc
health
sydney
australia
backgroundobject
describ
incid
outcom
includ
second
primari
malign
spm
childhood
neuroblastoma
ganglioneuroblastoma
australia
use
nation
data
australian
childhood
cancer
registri
accr
designmethod
children
year
diagnos
neuroblastoma
ganglioneuroblastoma
inclus
identifi
accr
demograph
tumour
characterist
incid
mortal
treatment
data
extract
cs
ef
surviv
year
diagnosi
estim
use
cohort
method
adjust
excess
mortal
hazard
ratio
hr
calcul
use
multivari
flexibl
parametr
surviv
model
cumul
incid
standardis
incid
ratio
sir
mortal
relat
spm
estim
rel
gener
popul
result
total
children
diagnos
neuroblastoma
ganglioneuroblastoma
studi
period
incid
rate
per
million
children
per
year
incid
rate
increas
estim
proport
patient
diseas
diagnosi
increas
p
surviv
year
respect
mortal
risk
due
neuroblastoma
ganglioneuroblastoma
halv
hr
p
ef
patient
achiev
full
remiss
relaps
subsequ
cs
thirteen
patient
diagnos
spm
cumul
incid
year
give
aer
per
sir
leukaemia
common
spm
patient
spm
die
within
year
spm
diagnosi
conclus
diagnosi
neuroblastoma
ganglioneuroblastoma
surviv
substanti
improv
time
australia
relaps
portend
poor
prognosi
spm
uncommon
carri
better
prognosi
relaps
primari
tumour
p
kaushik
k
v
k
n
p
tilak
municip
gener
hospit
divis
pediatr
pediatr
mumbai
india
backgroundobject
sleep
disturb
common
occurr
pediatr
popul
studi
report
preval
sleep
problem
children
cancer
emot
physic
distress
children
treat
cancer
predispos
sleep
disturb
object
studi
preval
sleep
disord
children
undergo
therapi
cancer
assess
domain
sleep
disoredr
affect
cohort
designmethod
studi
descript
studi
conduct
tertiari
care
centr
period
day
children
cancer
age
year
attend
outpati
depart
inpati
care
includ
detail
patient
demograph
sleep
habit
collect
accord
proforma
sleep
habit
assess
use
bear
screen
tool
childhood
sleep
habit
questionnair
chsq
variou
sleep
domain
includ
bedtim
resist
sleep
anxieti
night
awaken
parasomnia
sleep
disord
breath
daytim
sleepi
data
henc
obtain
analys
sampl
size
calcul
rel
precis
result
total
children
includ
studi
patient
leukem
constitut
accord
bear
screen
tool
common
domain
affect
regular
sleep
chsq
score
cut
score
children
make
preval
common
domain
affect
bedtim
resist
follow
daytim
sleepi
parasomnia
least
affect
sleep
disord
breath
preschool
children
higher
mean
chsq
score
compar
older
children
mean
chsq
score
children
intens
maintain
complet
phase
therapi
respect
howev
age
gender
place
resid
treatment
phase
chemotherapi
fail
show
statist
signific
impact
sleep
cohort
conclus
preval
sleep
disord
necessit
address
issu
children
cancer
kovalenko
e
k
region
children
hospit
pediatr
oncolog
hematolog
chelyabinsk
russia
backgroundobject
interv
onset
first
symptom
cancer
start
treatment
suspect
one
import
factor
surviv
improv
aim
studi
investig
diagnost
timeli
variou
group
cancer
children
determin
influenc
earli
mortal
rate
designmethod
data
patient
last
year
chelyabinsk
region
cancer
registri
analyz
determin
interv
first
onset
symptom
cancer
time
point
cancer
diagnosi
diagnost
interv
di
earli
mortal
determin
death
first
year
diagnosi
fisher
exact
test
use
statist
analys
relationship
di
earli
mortal
result
median
di
patient
day
signific
deviat
di
determin
studi
period
minim
di
day
leukemia
subgroup
longest
di
cn
tumor
day
lymphoma
subgroup
di
day
solid
tumor
day
one
year
mortal
rate
mr
patient
studi
use
day
determin
group
appropri
prolong
di
patient
appropri
di
mr
group
prolong
di
mr
patient
leukemia
mr
lymphoma
solid
tumor
respect
differ
statist
insignific
subgroup
conclus
find
show
possibl
relationship
diagnost
timeli
earli
mortal
children
cancer
reduc
diagnost
interv
improv
prognosi
cancer
children
mt
kutluk
univers
faculti
medicin
oncolog
hospit
depart
pediatr
oncolog
ankara
turkey
backgroundobject
surviv
rate
childhood
cancer
improv
significantli
recent
year
howev
cost
treatment
critic
issu
cancer
care
especi
low
countri
cost
diagnosi
treatment
children
pediatr
cancer
investig
designmethod
patient
leukemia
nhl
hodgkin
diseas
medulloblastoma
osteosarcoma
patient
includ
patient
younger
year
age
pediatr
cancer
case
sequenti
diagnos
leukemia
lymphoma
medulloblastoma
osteosarcoma
includ
direct
cost
ambulatori
inpati
care
reimburs
social
secur
system
start
diagnosi
decemb
analyz
iinclud
cost
examin
imag
laboratori
oper
patholog
medicin
medic
suppli
hospit
accommod
servic
cost
inpati
outpati
care
result
total
cost
usd
patient
includ
outpati
inpati
cost
averag
cost
per
patient
distribut
cost
usd
differ
group
patient
oper
servic
medicin
laboratori
examin
examin
patholog
suppli
imag
hospit
fee
total
cost
per
patient
usd
defin
period
leukemia
lymphoma
hodgkin
diseas
medulloblastoma
osteosarcoma
patient
overal
surviv
rate
leukemia
nhl
hodgkin
diseas
medulloblastoma
osteosarcoma
patient
conclus
cost
care
pediatr
cancer
invest
purpos
need
plan
purpos
averag
cost
per
patient
found
reason
countri
detail
econom
analysi
need
overcom
problem
face
pediatr
cancer
control
f
l
b
f
j
j
libe
nairobikenyatta
nation
hospit
patholog
nairobi
kenya
nation
hospit
pediatr
oncolog
unit
nairobi
kenya
nation
hospit
pharmaci
nairobi
kenya
hospit
illinoi
osf
healthcar
pharmaci
peoria
kenya
hospit
illinoi
osfhealthcareorg
pediatr
peoria
usa
illinoi
colleg
medicin
peoria
pediatr
peoria
usa
backgroundobject
previou
research
estim
surviv
os
children
diagnos
wilm
tumor
wt
four
collabor
kenyan
hospit
dismal
surviv
diseas
os
us
due
treatment
abandon
mortal
twin
partnership
countri
lmic
countri
demonstr
improv
qualiti
care
patient
outcom
lmic
need
assess
conduct
pediatr
oncolog
referr
center
kenya
reveal
train
hospit
staff
famili
crucial
requir
twin
partnership
us
institut
improv
pediatr
cancer
outcom
aim
evalu
impact
educ
wt
provid
knowledg
comfort
level
care
patient
wt
designmethod
pilot
us
institut
survey
complet
nurs
resid
day
present
nairobi
kenya
survey
request
month
later
assess
retent
knowledg
result
us
intervent
done
regular
nurs
complet
survey
increas
knowledg
seen
nurs
less
year
experi
p
experienc
nurs
comfort
level
care
patient
unchang
nairobi
nurs
complet
survey
knowledg
comfort
level
significantli
increas
p
seven
resid
complet
although
knowledg
comfort
level
increas
differ
statist
signific
due
small
sampl
size
respons
number
small
assess
retent
conclus
intervent
effect
increas
knowledg
comfort
level
amongst
kenyan
provid
assess
retent
impact
patient
outcom
collect
b
mallon
r
l
r
lukamba
ff
ben
g
nyemb
rakotomahefa
ff
mk
c
gustav
roussi
pediatri
villejuif
franc
yalgado
ouedraogo
depart
de
pediatri
ouagadoug
burkina
faso
de
treichvil
pediatri
abidjan
ivori
coastr
universitair
de
lubumbashi
pediatri
lubumbashi
congo
denfant
de
tuni
servic
de
infantil
c
tuni
tunisia
et
enfant
fondat
chantal
biya
oncologi
yaound
cameroon
universitair
joseph
ravoahangi
andrianavalona
oncologi
antananarivo
madagascar
le
dantec
doncologi
dakar
seneg
universitair
de
kinshasa
cliniqu
universitair
de
kinshasa
kinshasa
congo
sylvanu
olympio
pediatri
lome
togo
gabriel
pediatri
bamako
mali
gustav
roussi
pediatri
villejuif
franc
backgroundobject
incid
childhood
cancer
unknown
africa
gfaop
found
medic
associ
whose
vision
african
children
cancer
must
treat
effect
africa
african
team
time
gfaop
enabl
open
hospit
unit
special
pediatr
oncolog
countri
africa
outset
gfaop
research
program
aim
improv
knowledg
pediatr
cancer
particip
centr
especi
type
cancer
share
high
chanc
remiss
treat
earli
enough
wilm
tumour
wt
retinoblastoma
burkitt
hodgkin
lymphoma
acut
lymphoblast
leukemia
januari
support
child
matter
program
sanofi
espoir
foundat
gfaop
set
hospit
base
regist
sever
aim
collect
data
particip
unit
cancer
type
treatment
outcom
demographi
statu
data
turn
help
identifi
materi
human
resourc
staff
train
need
local
gfaop
provid
data
encourag
consider
pediatr
cancer
nation
intern
cancer
plan
particip
countri
designmethod
januari
decemb
case
childhood
cancer
regist
cancer
unit
data
collect
progress
perform
train
research
assist
use
onlin
redcap
platform
result
median
age
year
year
malefemal
sex
ratio
frequent
diagnosi
wt
burkitt
lymphoma
retinoblastoma
diagnosi
could
achiev
patient
reason
includ
dropout
initi
workup
econom
reason
child
death
diagnosi
imposs
perform
adequ
biopsi
center
conclus
time
applic
learn
research
skill
regist
indispens
work
tool
help
group
evalu
progress
k
matsumoto
k
r
k
center
child
health
develop
children
cancer
center
tokyo
japan
center
child
health
develop
depart
inform
technolog
manag
tokyo
japan
medic
univers
intern
medic
center
depart
saitama
japan
center
child
health
develop
clinic
epidemiolog
research
center
pediatr
cancer
tokyo
japan
medic
dental
univers
graduat
school
depart
health
polici
informat
tokyo
japan
backgroundobject
japan
exist
hospit
care
childhood
cancer
aris
patient
yearli
aim
integr
ministri
health
labour
welfar
elect
core
pediatr
cancer
hospit
seven
region
block
aim
studi
describ
outcom
accord
hospit
surgic
volum
pediatr
patient
underw
brain
tumor
resect
surgeri
japan
designmethod
retrospect
review
pediatr
patient
underw
brain
tumor
resect
surgeri
less
year
old
use
japanes
diagnosi
procedur
combin
inpati
databas
april
march
exclud
patient
biopsi
stay
hospit
longer
day
oper
result
identifi
pediatr
patient
underw
brain
tumor
resect
hospit
hospit
provid
one
surgeri
studi
period
mean
age
patient
year
crude
mortal
rate
cmr
cmr
hospit
lower
surgic
volum
case
year
respect
significantli
higher
higher
surgic
volum
center
case
year
respect
trend
surgic
associ
also
observ
analysi
patient
age
younger
respect
surgic
volum
center
conclus
present
studi
impli
relationship
pediatr
resect
surgeri
brain
tumor
although
outcom
analysi
kind
surgeri
complex
due
heterogen
need
construct
sophist
network
system
pediatr
brain
tumor
japan
patient
refer
prompt
surgic
treatment
larg
center
much
experi
childhood
brain
tumor
mohapatra
india
institut
medic
sci
medic
oncologyhematolo
bhu
india
india
institut
medic
sci
patholog
lab
medicin
bhu
india
backgroundobject
therapeut
intervent
challeng
pediatr
oncolog
patient
develop
countri
primarili
due
limit
financi
resourc
poor
complianc
lack
social
support
system
designmethod
retrospect
descript
studi
children
year
cancer
treat
center
east
india
juli
march
treatment
abandon
defin
failur
start
complet
cur
cancer
therapi
children
stage
solid
tumor
high
risk
leukemialymphoma
time
therapi
consid
advanc
stage
diseas
result
children
leukemialymphoma
rest
solid
tumor
median
age
children
interquartil
rang
iqr
year
male
femal
ratio
median
follow
durat
interquartil
rang
iqr
month
seventi
six
children
high
riskadvanc
stage
diseas
treatment
abandon
observ
children
total
children
die
treatment
treatment
relatedfebril
neutropenia
death
rest
death
attribut
progress
diseas
conclus
higher
rate
treatment
abandon
delay
seek
treatment
risk
factor
poor
surviv
develop
countri
advanc
reduc
treatment
relat
mortal
pediatr
oncolog
patient
middl
low
incom
countri
provis
financi
social
support
made
feasibl
childhood
cancer
patient
may
potenti
curabl
appropri
treatment
mojica
cruz
mier
region
de
alta
especilidad
de
ixtapaluca
pediatr
ixtapaluca
mexico
region
de
alta
especilidad
de
ixtapaluca
pediatr
oncolog
ixtapaluca
mexico
backgroundobject
introduct
childhood
cancer
grow
health
problem
current
second
caus
mortal
children
year
age
multipl
factor
involv
prognosi
diseas
social
cultur
econom
among
other
object
analys
epidemiolog
characterist
patient
part
pediatr
oncolog
clinic
hospit
region
de
alta
especialidad
de
ixtapaluca
conform
june
decemb
designmethod
method
observ
descript
retrospect
studi
patient
year
age
hospit
region
de
alta
especialidad
de
ixtapaluca
diagnos
cancer
june
decemb
base
characterist
popul
age
gender
place
origin
econom
level
definit
diagnosi
current
statu
diseas
result
total
case
includ
femal
averag
age
year
state
mexico
frequent
diagnosi
acut
leukemia
aml
second
place
snc
tumor
current
patient
treatment
referenc
institut
complet
treatment
abandon
treatment
lost
death
surveil
conclus
recent
young
hospit
great
challeng
ahead
us
time
cancer
refer
center
mexico
surviv
rate
promis
moreira
j
c
jude
children
research
hospit
global
pediatr
medicin
memphi
usa
backgroundobject
nation
strategi
address
human
resourc
health
hrh
crucial
effect
care
deliveri
assess
perceiv
import
hrh
nation
pediatr
cancer
care
sought
systemat
review
inclus
nation
cancer
control
plan
nccp
designmethod
public
avail
nccp
nation
health
noncommunic
diseas
plan
collat
st
jude
nation
polici
corebank
plan
avail
decemb
analyz
document
english
french
spanish
german
initi
screen
plan
includ
workforc
element
systemat
analysi
util
six
compon
world
health
organ
hrh
action
framework
perform
plan
result
plan
analyz
countri
territori
document
countri
mention
workforc
element
pediatr
cancer
care
includ
lower
upper
countri
plan
analyz
hrh
action
framework
describ
current
state
hrh
countri
specifi
current
number
pediatr
oncologist
nation
plan
recogn
need
hrh
mention
scale
plan
includ
measur
target
assign
specifi
budget
hrh
element
workforc
train
cancer
manag
includ
across
plan
target
teach
medic
school
continu
medic
educ
specialist
nurs
train
element
action
framework
variabl
includ
partnership
leadership
polici
hr
manag
financ
conclus
nccp
consist
consid
workforc
need
care
children
cancer
addit
plan
lack
clear
strategi
address
need
hrh
defin
strategi
train
retain
equip
integr
increas
workforc
need
children
cancer
consid
essenti
compon
nation
programm
polici
b
g
calibasi
c
e
bb
b
h
e
h
n
olgun
eylul
univers
institut
depart
basic
oncolog
izmir
turkey
eylul
univers
institut
health
depart
translat
oncolog
izmir
turkey
univers
school
depart
paediatr
oncolog
mersin
turkey
eylul
univers
faculti
depart
paediatr
oncolog
izmir
turkey
univers
faculti
depart
paediatr
oncolog
bursa
turkey
numun
train
research
hospit
depart
paediatr
oncolog
adana
turkey
univers
depart
paediatr
oncolog
sakarya
turkey
tepecik
train
research
hospit
depart
paediatr
oncolog
izmir
turkey
aduedutr
adnan
mender
univers
turkey
eylul
univers
institut
depart
prevent
oncolog
izmir
turkey
eylul
univers
institut
oncolog
izmir
turkey
backgroundobject
childhood
cancer
treatment
protocol
standard
regimen
administ
toxic
observ
aim
studi
abl
distinguish
patient
give
good
respons
give
provid
person
treatment
person
designmethod
context
pharmacogenomicsgenet
childhood
cancer
cohort
turkish
paediadr
oncolog
group
turkpedpgx
initi
nationwid
prospect
observ
cohort
studi
main
outcom
measur
toxic
therapeut
respons
throughout
five
year
result
march
april
patient
includ
studi
leukemia
myeloprolif
diseas
myelodysplast
diseas
lymphoma
reticuloendotheli
neoplasm
cn
miscellan
intracrani
intraspin
neoplasm
neuroblastoma
peripher
nervou
cell
tumor
malign
bone
tumor
renal
tumor
retinoblastoma
hepat
tumor
soft
tissu
extraoss
sarcoma
germ
cell
tumor
malign
epitheli
neoplasm
unspecifi
malign
neoplasm
observ
cohort
studi
patient
aliv
toxic
relaps
conclus
drug
metabol
enzym
polymorph
import
determin
phenotyp
treatment
pharmacogenom
may
predict
toxic
risk
treatment
respons
pediatr
cancer
patient
context
popul
base
cohort
studi
one
import
point
defin
variat
use
clinic
acknowledg
studi
conduct
financi
support
tpog
deu
dokuz
eylul
univers
instut
oncolog
ravn
graba
j
falck
hoffmann
f
c
cancer
societi
research
center
lifestyl
gene
copenhagen
denmark
cancer
societi
research
center
rigshospitalet
univers
hospit
lifestyl
gene
depart
gynecolog
copenhagen
denmark
cancer
societi
research
center
childhood
cancer
research
group
copenhagen
denmark
cancer
societi
research
center
statist
pharmacoepidemiolog
copenhagen
denmark
backgroundobject
surveil
childhood
cancer
incid
inform
etiolog
research
health
polici
nationwid
cancer
registri
contain
virtual
complet
data
date
back
seven
decad
designmethod
incid
childhood
cancer
case
year
identifi
danish
cancer
registri
use
calcul
incid
rate
asr
annual
percentag
chang
apc
separ
earli
period
recent
period
case
classifi
accord
birch
marsden
intern
classif
childhood
cancer
result
case
childhood
cancer
earli
period
asr
cancer
per
children
increas
incid
male
apc
ci
femal
apc
ci
recent
period
asr
per
children
increas
incid
male
apc
ci
femal
apc
ci
apc
central
nervou
system
tumor
apc
ci
ci
gonad
neoplasm
apc
ci
ci
increas
period
wherea
apc
sympathet
nervou
system
tumor
apc
ci
retinoblastoma
apc
ci
renal
tumor
apc
ci
increas
earli
period
leukemia
apc
ci
lymphoma
apc
ci
sarcoma
apc
ci
malign
epitheli
tumor
apc
ci
unspecifi
neoplasm
apc
ci
increas
incid
observ
recent
period
conclus
incid
childhood
cancer
denmark
increas
sinc
pronounc
increas
onward
remain
unclear
whether
observ
tempor
trend
might
also
reflect
improv
diagnosi
sole
relat
chang
exposur
p
j
j
k
van
den
r
medic
centr
wilhelmina
children
hospit
pediatr
intens
care
unit
utrecht
netherland
medic
centr
wilhelmina
children
hospit
depart
pediatr
nephrolog
utrecht
netherland
medic
sophia
children
rotterdam
intens
care
depart
paediatr
surgeri
rotterdam
netherland
medic
centr
beatrix
children
hospit
pediatr
intens
care
groningen
netherland
medic
centr
amsterdam
pediatr
intens
care
amsterdam
netherland
medic
centrum
radboud
pediatr
intens
care
nijmegen
netherland
medic
sophia
children
rotterdam
depart
pediatr
nephrolog
rotterdam
netherland
center
pediatr
utrecht
pediatr
oncolog
utrecht
netherland
backgroundobject
acut
kidney
injuri
aki
one
seriou
complic
sinc
introduct
intensifi
treatment
protocol
advanc
support
therapi
pediatr
cancer
hematopoiet
stem
cell
transplant
hsct
patient
continu
renal
replac
therapi
crrt
becom
wide
use
renal
support
modal
use
critic
ill
children
purpos
studi
assess
epidemiolog
outcom
pediatr
cancer
hsct
patient
receiv
crrt
pediatr
intens
care
unit
picu
designmethod
nationwid
retrospect
studi
pediatr
cancer
hsct
patient
receiv
crrt
picu
januari
juli
netherland
primari
outcom
mortal
result
total
patient
cancer
admit
picu
receiv
crrt
far
higher
gener
picu
popul
major
patient
leukemialymphoma
solid
tumor
underli
cancer
diagnosi
fluid
overload
due
renal
failur
primari
picu
admiss
reason
interestingli
increas
bodi
weight
rather
main
criteria
serum
creatinin
oliguria
best
predictor
earli
detect
develop
aki
picu
mortal
three
month
multivari
adjust
fluid
overload
odd
ratio
ci
need
vasoact
support
odd
ratio
ci
independ
predictor
mortal
conclus
continu
renal
replac
therapi
critic
ill
pediatr
cancer
hsct
patient
associ
high
mortal
fluid
overload
especi
begin
crrt
need
vasoact
support
independ
risk
factor
mortal
serum
creatinin
oliguria
seem
sensit
marker
time
detect
aki
popul
r
c
de
k
n
p
roger
p
cancer
cancer
control
research
vancouv
canada
british
columbia
pharmaceut
scienc
vancouv
canada
addict
mental
health
institut
mental
health
polici
research
toronto
canada
gener
hospit
research
institut
toronto
health
econom
technolog
assess
collabor
toronto
canada
clinic
evalu
scienc
analyt
servic
toronto
canada
children
hospit
hematologyoncologybmt
vancouv
canada
hospit
hematologyoncolog
toronto
canada
oncolog
group
ontario
medic
director
toronto
canada
toronto
depart
medicin
faculti
pharmaci
toronto
canada
backgroundobject
effici
use
health
care
resourc
fundament
care
studi
estim
childhood
cancer
resourc
util
phase
care
within
comprehens
health
care
system
compar
util
two
canadian
provinc
designmethod
patient
age
year
diagnos
cancer
identifi
british
columbia
bc
ontario
cancer
registri
health
care
util
estim
patient
initi
treatment
continu
care
final
die
phase
use
link
clinic
administr
health
care
databas
phase
length
day
day
other
document
resourc
includ
inpati
surgeri
emerg
outpati
physician
servic
diagnost
test
procedur
prescript
drug
home
care
servic
result
cohort
number
number
patient
leukemia
cn
tumour
bc
lymphoma
cancer
surviv
year
util
physician
servic
patient
diagnost
test
patient
similar
provinc
across
phase
care
phase
continu
care
inpati
hospit
gener
rank
third
resourc
rel
util
resourc
vari
provinc
phase
care
compar
bc
patient
ontario
patient
document
inpati
hospit
phase
initi
phase
home
care
phase
diagnosi
phase
emerg
visit
continu
care
phase
contrast
bc
patient
document
surgeri
initi
continu
care
phase
emerg
visit
initi
final
phase
radiat
therapi
initi
phase
chemotherapi
final
phase
conclus
differ
resourc
util
pattern
compar
health
care
deliveri
system
may
point
opportun
provid
effici
care
rykov
blokhin
medic
research
center
oncolog
ministri
health
russian
feder
institut
pediatr
oncolog
moscow
russia
backgroundobject
present
reliabl
statist
data
morbid
mortal
mortal
etc
character
state
medic
care
children
oncolog
diseas
russian
feder
purpos
elimin
exist
defect
electron
regist
children
oncolog
diseas
develop
introduc
clinic
practic
allow
obtain
reliabl
statist
data
designmethod
clinic
practic
pilot
medic
organ
oncolog
depart
chemotherapi
tumor
arkhangelsk
region
children
clinic
hospit
name
pg
vyzhletsov
children
oncolog
depart
radiotherapi
complex
method
treatment
russian
scientif
center
roentgenolog
electron
databas
children
oncolog
diseas
result
month
inform
patient
solid
tumor
hemoblastos
treat
date
enter
electron
databas
conclus
electron
regist
independ
develop
mani
possibl
integr
exampl
system
support
make
medic
decis
base
protocol
treatment
medic
organ
abl
regist
patient
diagnosi
date
initi
visit
doctor
verif
diagnosi
data
analysi
treatment
receiv
criteria
assess
qualiti
treatment
plan
inform
avail
bed
number
patient
medic
organ
abil
request
receiv
consult
medic
organ
third
level
patient
receiv
access
treatment
plan
includ
schedul
medic
rout
capabl
introduct
electron
databas
medic
organ
provid
medic
care
children
cancer
allow
obtain
analyz
reliabl
statist
data
monitor
qualiti
medic
care
rout
patient
reduc
cost
budget
fund
improv
surviv
patient
rykov
blokhin
medic
research
center
oncolog
ministri
health
russian
feder
institut
pediatr
oncolog
moscow
russia
backgroundobject
russian
feder
patient
identifi
stage
iii
iv
explain
absenc
specif
symptom
low
train
pediatrician
pediatr
oncolog
designmethod
questionnair
design
sent
region
russian
feder
complet
pediatrician
initi
treatment
patient
questionnair
contain
follow
question
subfebril
fever
day
without
establish
caus
weight
losslethargi
fast
fatigu
congenit
malform
syndrom
oncolog
diseas
famili
macrogematuria
pain
syndrom
leucocoria
enlarg
lymph
node
symptom
increas
intracrani
pressur
headach
vomit
visual
impair
elev
serum
level
elev
serum
chorion
gonadotropin
levelincreas
serum
lactat
dehydrogenas
levelincreas
serum
alkalin
phosphatas
elev
serum
level
aspart
aminotransferas
elev
serum
level
alanin
aminotransferas
anem
syndromeleukocytosi
palpabl
tumor
format
suspici
tumor
accord
instrument
method
examin
ultrasound
two
answer
ye
paragraph
one
ye
answer
paragraph
recommend
send
patient
consult
pediatr
oncologist
one
ye
answer
paragraph
recommend
dynam
observ
result
detect
malign
neoplasm
period
increas
compar
figur
note
year
earlier
conclus
sinc
malign
tumor
children
fairli
rare
diseas
specif
symptom
questionnair
allow
increas
oncolog
alert
pediatrician
rykov
blockhin
medic
research
center
oncolog
ministri
health
russian
feder
institut
pediatr
oncolog
moscow
russia
backgroundobject
plan
organ
medic
care
children
cancer
well
analysi
effect
medic
care
base
analysi
statist
indic
designmethod
oper
report
execut
author
sphere
health
protect
subject
russian
feder
part
central
feder
district
analyz
result
number
children
peopl
year
number
child
oncolog
depart
number
children
oncolog
bed
number
day
berth
employ
year
number
doctor
provid
medic
care
children
cancer
certif
pediatr
oncologist
subject
depart
pediatr
oncolog
absent
children
oncolog
bed
number
primari
patient
malign
neoplasm
number
deceas
patient
includ
identifi
incid
malign
tumor
per
age
group
mortal
rate
per
thousand
age
group
year
mortal
rate
averag
time
taken
establish
diagnosi
elaps
sinc
diagnosi
verifi
start
treatment
unknown
sinc
report
contain
precis
inform
conclus
oper
report
contain
indic
match
incid
rate
significantli
lower
countri
high
statist
reliabl
percentag
patient
identifi
activ
remain
extrem
low
order
elimin
defect
necessari
introduc
singl
databas
children
oncolog
diseas
russian
feder
rykov
blokhin
medic
research
center
oncolog
ministri
health
russian
feder
institut
pediatr
oncolog
moscow
russia
backgroundobject
present
reliabl
statist
data
morbid
mortal
mortal
etc
character
state
medic
care
children
oncolog
diseas
russian
feder
due
lack
singl
electron
databas
patient
designmethod
clinic
practic
two
pilot
medic
organ
electron
databas
children
oncolog
diseas
introduc
allow
keep
record
patient
diagnosi
key
date
data
analyz
treatment
receiv
earlier
criteria
assess
qualiti
make
treatment
plan
obtain
inform
avail
bed
number
patient
variou
medic
organ
conduct
medic
consult
involv
specialist
medic
organ
third
level
patient
legal
repres
patient
access
privat
cabinet
reflect
treatment
plan
includ
schedul
take
medicin
well
rout
possibl
provid
result
month
inform
enter
electron
databas
patient
receiv
treatment
present
conclus
electron
databas
allow
obtain
reliabl
statist
data
monitor
qualiti
medic
care
rout
patient
reduc
cost
budget
fund
improv
surviv
patient
b
sevinir
c
univers
medic
faculti
pediatr
oncolog
bursa
turkey
backgroundobject
evid
certain
congenit
abnorm
associ
increas
risk
develop
cancer
aim
studi
defin
relationship
congenit
anomali
childhood
malign
designmethod
evalu
patient
diagnos
lymphoma
solid
tumor
year
pediatr
oncolog
depart
uludag
univers
hospit
control
group
consist
children
without
chronic
diseas
congenit
anomali
defin
accord
intern
classif
diseas
version
chapter
result
total
number
patient
lymphoma
solid
tumor
healthi
children
similar
age
gender
distrubit
analyz
common
cancer
type
lymphoma
central
nervou
system
cn
tumor
neuroblastoma
soft
tissu
sarcoma
bone
sarcoma
germ
cell
tumor
renal
tumor
patient
control
group
abort
stillbirth
ratio
respect
p
cancer
histori
rel
patient
group
control
group
p
consanguin
marriag
ratio
respect
minor
congenit
anomali
ratio
patient
cancer
control
group
p
highest
abnorm
frequenc
observ
children
cn
tumor
p
common
anomali
eye
ear
face
neck
anomali
lowest
abnorm
ratio
observ
children
lymphoma
conclus
congenit
abnorm
children
cancer
fold
compar
healhti
popul
studi
minor
anomali
commonli
found
patient
cn
tumor
sarcoma
studi
necessari
gene
involv
cancer
develop
congenit
anomali
n
shrivastava
f
l
h
h
chan
school
public
health
health
polici
manag
boston
usa
nacion
de
pediatr
oncolog
guatemala
citi
guatemala
state
medic
univers
public
health
tbilisi
georgia
vivir
financ
account
guatemala
citi
guatemala
farberboston
children
cancer
blood
disord
center
pediatr
oncolog
boston
usa
backgroundobject
need
pediatr
oncolog
servic
exist
countri
lmic
planner
limit
access
free
resourc
develop
comprehens
financi
plan
establish
servic
lack
inform
may
neg
impact
plan
construct
equip
procur
oper
imped
effici
resourc
alloc
financi
sustain
qualit
studi
aim
explor
barrier
effect
financi
plan
examin
past
experi
planner
designmethod
lean
six
sigma
principl
use
methodolog
framework
literatur
review
perform
within
journal
web
databas
assess
exist
financi
plan
resourc
avail
key
inform
interview
use
structur
interview
guid
conduct
stakehold
hospit
intern
organ
univers
tbilisi
georgia
guatemala
citi
guatemala
boston
usa
budget
financi
report
provid
hospit
administr
review
investig
observ
note
interview
transcrib
analyz
use
nvivo
recurr
theme
irb
exempt
obtain
result
recur
theme
organ
six
categori
follow
ishikawa
diagram
structur
peopl
environ
equip
method
materi
interviewe
highlight
environment
factor
imped
budget
includ
insuffici
reimburs
treatment
fluctuat
currenc
exchang
rate
data
also
reveal
lack
financi
manag
train
account
barrier
systemat
transpar
financi
plan
key
inform
note
challeng
specif
pediatr
oncolog
includ
lack
nation
cancer
registri
prevent
accur
incid
estim
subsequ
bed
staf
calcul
conclus
pauciti
financi
plan
resourc
lead
challeng
feasibl
sustain
pediatr
cancer
care
lmic
develop
financi
plan
tool
may
improv
abil
hospit
lmic
budget
effect
procur
steadi
financ
promot
transpar
account
ultim
establish
sustain
facil
children
cancer
r
arora
r
w
v
g
r
j
r
h
p
super
special
saket
medic
oncolog
new
delhi
india
new
delhi
qualiti
research
impact
new
delhi
india
univers
institut
econom
growth
new
delhi
india
india
institut
medic
scienc
institut
rotari
cancer
hospit
new
delhi
india
institut
medic
oncolog
pediatr
oncolog
chennai
india
apollo
hospit
pediatr
hematolog
oncolog
bmt
new
delhi
india
memori
hospit
pediatr
oncolog
mumbai
india
medic
centr
pediatr
hematolog
oncolog
kolkata
india
jerbai
wadia
hospit
children
pediatr
hematolog
oncolog
mumbai
india
child
health
hospit
pediatr
chennai
india
medic
colleg
hospit
pediatr
hematolog
oncolog
mumbai
india
india
institut
medic
scienc
depart
pediatr
new
delhi
india
mahavir
medic
colleg
safdarjung
hospit
pediatr
new
delhi
india
gupta
cancer
centr
research
institut
haematolog
paediatr
oncolog
kolkata
india
ramachandra
medic
colleg
research
institut
depart
pediatr
chennai
india
special
cancer
hospit
pediatr
hematolog
oncolog
chennai
india
cancer
institut
medic
oncolog
mumbai
india
backgroundobject
diagnosi
cancer
child
place
consider
econom
burden
famili
health
expenditur
catastroph
countri
like
india
gdp
spend
health
treatment
financ
usual
oop
object
studi
describ
oop
expenditur
incur
famili
children
cancer
treat
india
prior
cancer
direct
treatment
designmethod
prospect
cost
ill
studi
famili
household
perspect
conduct
centr
citi
india
famili
demograph
data
collect
follow
oop
expenditur
incur
prior
start
treatment
throughout
child
treatment
social
worker
contact
parent
regular
interv
record
expenditur
cancer
direct
treatment
completiondeathprogressionrelapseabandonmenttransf
data
describ
descript
univariatemultivari
analysi
use
logist
regress
done
detect
factor
associ
result
children
male
median
age
year
cancer
enrol
public
charit
trust
privat
sector
hospit
uninsur
famili
monthli
incom
mean
oop
expenditur
per
capita
incom
india
oop
expenditur
onset
symptom
start
treatment
medic
laboratori
test
medicin
hospit
bed
cost
travel
food
lodg
oop
expenditur
cancer
direct
treatment
medic
hospit
bed
cost
support
care
drug
laboratori
test
food
travel
lodg
insur
type
treatment
facil
found
significantli
associ
oop
expenditur
multivari
analysi
conclus
famili
children
cancer
incur
signific
oop
expenditur
prior
treatment
expenditur
vari
significantli
insur
type
treatment
facil
k
l
p
j
skeen
children
hospit
starship
blood
cancer
centr
auckland
new
zealand
hospit
children
haematolog
oncolog
centr
christchurch
new
zealand
backgroundobject
new
zealand
rel
small
popul
necessit
centralis
child
cancer
servic
sinc
cancer
treatment
provid
two
specialist
centr
locat
auckland
christchurch
share
care
centr
produc
updat
surviv
estim
assess
whether
nation
child
cancer
network
nccn
meet
overarch
object
ensur
children
receiv
high
qualiti
care
regardless
live
designmethod
new
zealand
children
cancer
registri
provid
demograph
diagnost
data
children
age
year
diagnos
rel
surviv
estim
calcul
accord
age
sex
prioritis
ethnic
resid
depriv
index
result
overal
child
cancer
surviv
ci
increas
period
compar
outcom
accord
sex
age
group
evid
surviv
children
resid
depriv
area
compar
surviv
least
depriv
accord
ethnic
surviv
maori
ci
pacif
peopl
ci
other
ci
surviv
children
resid
auckland
christchurch
children
travel
outsid
region
cancer
treatment
specialist
centr
differ
surviv
children
refer
auckland
christchurch
conclus
surviv
comparison
indic
new
zealand
provid
equit
cancer
care
nccn
develop
nation
guidelin
harmonis
treatment
across
countri
allow
children
receiv
much
treatment
close
home
possibl
without
impact
surviv
futur
initi
ensur
equiti
access
psychosoci
alli
health
servic
avail
cultur
appropri
patient
famili
support
j
g
e
l
spector
minnesota
pediatr
minneapoli
usa
de
da
santa
casa
paulo
collect
health
sao
paulo
brazil
backgroundobject
hepatoblastoma
largest
averag
annual
percent
chang
aapc
childhood
cancer
year
age
unit
state
nearli
three
decad
determin
true
elsewher
examin
data
cancer
incid
five
contin
system
intern
agenc
cancer
research
http
designmethod
rate
cancer
frequent
diagnos
age
extract
registri
avail
overcom
small
number
individu
registri
numer
denomin
aggreg
within
region
correspond
unit
nation
geoschem
averag
annual
percent
chang
aapc
calcul
use
poisson
regress
model
count
log
popul
offset
robust
standard
error
use
model
correct
overdispers
region
cancer
wald
confid
interv
ci
report
within
region
rank
cancer
aapc
result
hepatoblastoma
hb
cancer
fastest
rise
incid
region
includ
subsaharan
africa
aapc
carribean
central
america
south
america
north
america
northern
europ
western
europ
southern
europ
eastern
europ
east
asia
oceania
southeast
asia
hb
second
fastest
rise
cancer
ependym
tumor
north
africa
western
asia
incid
rose
hb
rank
top
aapc
south
asia
hb
incid
fall
studi
period
conclus
year
period
iarc
databas
cancer
registri
hepatoblastoma
cancer
rapidli
rise
incid
children
year
age
area
world
nearli
worldwid
rapid
rise
hb
incid
impli
exogen
caus
invit
explan
clj
teo
gs
tc
women
children
hospit
paediatr
haematologyoncolog
servic
singapor
singapor
univers
hospit
divis
paediatr
haematolog
oncolog
singapor
singapor
backgroundobject
singapor
childhood
cancer
registri
sccr
establish
aim
studi
epidemiolog
childhood
cancer
within
asian
popul
sccr
systemat
collect
inform
malign
cancer
benign
brain
tumour
children
adolesc
diagnos
treat
singapor
sinc
cancer
case
regist
sccr
notifi
kk
women
children
hospit
nation
univers
hospit
studi
aim
describ
epidemiolog
characterist
childhood
cancer
patient
regist
sccr
period
year
designmethod
sccr
databas
review
local
resid
singapor
citizen
perman
resid
age
year
diagnos
cancer
cancer
classifi
accord
intern
classif
childhood
cancer
iccc
result
total
case
regist
sccr
annual
number
new
case
rang
averag
case
per
year
male
femal
ratio
common
childhood
cancer
leukaemia
central
nervou
system
tumour
lymphoma
follow
germ
cell
tumour
sympathet
nervou
system
tumour
age
group
stratif
year
year
year
year
major
case
chines
follow
malay
indian
ethnic
ethnic
distribut
pattern
similar
nation
popul
conclus
sccr
provid
epidemiolog
clinic
inform
childhood
cancer
offer
basi
variou
research
diseas
singapor
studi
variabl
observ
across
differ
group
cancer
type
age
group
gender
studi
warrant
understand
differ
effect
treatment
plan
improv
outcom
vora
v
n
g
n
g
cs
memori
centr
pediatr
medic
oncolog
mumbai
india
memori
centr
radiat
oncolog
mumbai
india
memori
centr
orthoped
surgic
oncolog
mumbai
india
memori
centr
nation
cancer
grid
mumbai
india
backgroundobject
lack
access
evid
base
multidisciplinari
expertis
caus
suboptim
outcom
pediatr
cancer
low
middl
incom
countri
lmic
unlik
well
recogn
financi
psychosoci
barrier
imbalanc
gener
oncologist
patient
ratio
million
india
million
usa
exacerb
pediatr
oncolog
tmc
ncg
navya
onlin
navya
multidisciplinari
expert
opinion
servic
hour
turnaround
base
clinic
informat
system
valid
clinic
trial
sabc
asco
designmethod
prospect
impact
analysi
use
reach
navya
children
age
three
year
onlin
servic
onlin
opinion
form
medic
report
pediatr
patient
analyz
adult
data
dataset
globocan
data
use
compar
result
patient
analyz
receiv
evid
base
treatment
recommend
navya
pediatr
patient
compar
global
indian
estim
globocan
pediatr
patient
seven
countri
compar
adult
countri
preval
solid
tumour
malign
globocan
india
estim
revers
navya
cohort
demand
pediatr
onlin
expert
opinion
measur
size
pediatr
cohort
growth
rate
compar
initi
baselin
exceed
adult
cohort
growth
rate
conclus
high
percentag
pediatr
solid
tumor
cohort
compar
standard
treatment
protocol
illustr
impact
need
rapid
onlin
access
expertis
uncommon
cancer
requir
complex
multidisciplinari
treatment
opinion
increas
demand
pediatr
expertis
seen
doubl
pediatr
cohort
navya
highli
util
patient
receiv
evid
base
treatment
scale
access
improv
outcom
pediatr
cancer
worldwid
k
wachter
l
th
chan
school
public
health
global
health
popul
boston
usa
th
chan
school
public
health
health
polici
manag
boston
usa
infantil
de
pediatr
oncolog
mexico
health
children
cancer
blood
disord
center
pediatr
oncolog
boston
usa
backgroundobject
limit
data
exist
approach
strategi
leadership
pediatr
oncolog
unit
countri
understand
leadership
trait
element
essenti
strong
hospit
govern
systemat
strateg
plan
effici
resourc
alloc
ultim
improv
patient
outcom
develop
qualit
studi
explor
leadership
profil
examin
process
prioriti
assess
strategi
formul
obtain
staff
recommend
hospit
infantil
de
hito
mexico
children
cancer
blood
disord
center
dfbc
boston
usa
designmethod
conduct
interview
senior
clinic
administr
leader
hito
dfbc
review
strateg
plan
materi
complet
systemat
literatur
review
facilit
group
discuss
exercis
data
record
transcrib
manual
code
excel
irb
approv
obtain
result
four
theme
emerg
around
train
leadership
style
organiz
cultur
respond
learn
manag
skill
decis
hito
driven
strateg
prioriti
includ
obtain
excel
surviv
rate
financi
sustain
posit
workplac
environ
dfbc
workforc
develop
research
partner
engag
respond
emphas
import
leader
cultiv
organiz
cultur
dfbc
respond
express
loyalti
motiv
pride
mission
strong
teach
environ
hito
priorit
effort
defin
cultur
institut
express
appreci
cultur
cite
staff
burnout
moral
focu
area
conclus
pediatr
oncolog
leader
may
differ
train
background
prioriti
share
commit
establish
strong
workforc
organiz
cultur
strengthen
staff
engag
promot
systemat
plan
understand
cultur
leadership
appli
align
prioriti
may
prepar
organ
effect
address
chang
maxim
resourc
improv
cancer
care
deliveri
l
wagner
kentucki
pediatr
lexington
usa
tennesse
health
scienc
center
colleg
nurs
memphi
usa
backgroundobject
adolesc
young
adult
aya
patient
cancer
unit
state
us
treat
commun
oncolog
center
rather
academ
institut
limit
abil
track
outcom
real
world
environ
previou
studi
suggest
race
often
associ
outcom
age
group
object
investig
demograph
featur
outcom
larg
group
aya
patient
treat
commun
oncolog
center
identifi
potenti
racial
dispar
patient
cancer
designmethod
identifi
racial
dispar
commun
oncolog
outcom
analyz
anonym
medic
record
guardian
research
network
http
wwwguardianresearchorg
us
clinic
trial
consortium
hospit
result
data
patient
age
year
treat
select
patient
median
age
diagnosi
year
cancer
femal
caucasian
black
race
diagnos
includ
breast
cancer
lymphoma
gynecolog
cancer
headneck
cancer
colorect
cancer
leukemia
sarcoma
overal
surviv
patient
surviv
black
patient
white
p
within
diseas
group
signific
differ
observ
race
seven
tumor
type
estim
rang
leukemia
p
breast
cancer
multivari
cox
analysi
control
cancer
type
confirm
rel
risk
confid
interv
p
black
patient
versu
white
race
p
men
versu
women
p
conclus
larg
survey
aya
patient
index
cancer
treat
commun
oncolog
center
us
identifi
surviv
gap
race
gender
exist
even
countri
larg
heath
care
expenditur
f
arreguin
e
b
p
f
l
medico
nacion
de
noviembr
issst
pediatr
oncolog
depart
mexico
mexico
medico
nacion
de
noviembr
issst
rehabilit
depart
mexico
mexico
medico
nacion
de
noviembr
issst
pediatr
depart
mexico
mexico
medico
nacion
de
noviembr
issst
psychiatri
depart
mexico
mexico
backgroundobject
although
pediatr
cancer
occur
less
annual
incid
cancer
around
world
remain
common
caus
mortal
age
group
last
year
surviv
rate
diseas
improv
around
world
still
challeng
middl
low
incom
countri
current
everi
children
surviv
cancer
advers
healthrel
qualiti
life
outcom
sequela
issst
institut
secur
social
servic
state
worker
third
level
institut
mexico
take
care
mexico
total
popul
medic
nation
center
de
noviembr
main
refer
hospit
issst
oncolog
patient
overal
surviv
around
creat
first
survivorship
pediatr
cancer
clinic
mexico
designmethod
implement
risk
base
model
base
childhood
cancer
survivor
studi
adjust
need
implement
program
phase
situat
diagnosi
intervent
educ
transit
result
reclut
cancer
survivor
phase
femal
predomin
adolesc
frequent
group
around
survivor
sequela
common
late
effect
endocrin
pituitari
dysfunct
metabol
musculoesquelet
ovarian
dysfunct
detect
social
psycholog
impair
lack
inform
system
patient
cancer
treatment
conclus
real
challeng
oncologist
creat
surveil
clinic
need
improv
data
basi
patient
treatment
complet
inform
result
start
phase
work
time
cancer
patient
order
inform
complet
get
cure
c
audina
children
oncolog
foundat
yoai
survivor
jakarta
indonesia
backgroundobject
name
cindi
audina
born
septemb
diagnos
type
cancer
acut
lymphoblast
leukemia
lymphadenopathi
year
old
octob
finish
treatment
januari
year
old
activ
cancer
buster
commun
cbc
sinc
cbc
survivor
commun
umbrella
indonesia
children
oncolog
foundat
yoai
cbc
activ
mainli
conduct
survivor
cancer
camp
roadshow
throughout
indonesia
support
patient
children
cancer
hospit
visit
child
cancer
easi
life
mani
myth
diseas
appear
commun
cancer
threat
cure
indonesia
movi
cancer
sell
sad
cancer
patient
eventu
die
thu
made
cancer
fighter
broke
spirit
cancer
survivor
cure
would
like
give
support
reviv
hope
childhood
cancer
curabl
cancer
survivor
live
normal
child
gener
designmethod
instal
hope
cancer
patient
spread
miracl
still
exist
wrote
success
stori
battl
cancer
book
titl
nama
tengahku
mukjizat
middl
name
miracl
result
book
launch
juli
lot
patient
parent
get
inspir
success
stori
becom
posit
eiger
protocol
medic
also
get
support
famili
surround
conclus
book
make
peopl
awar
childhood
cancer
curabl
end
book
help
reach
ultim
goal
improv
recoveri
rate
childhood
cancer
patient
indonesia
balcerek
e
h
berlin
paediatr
haematolog
stem
cell
transplant
berlin
germani
koch
institut
psychic
health
berlin
germani
backgroundobject
health
survey
ambul
health
care
util
childhood
cancer
survivor
offspr
compar
children
gener
popul
designmethod
total
childhood
cancer
survivor
receiv
questionnair
everi
known
biolog
child
two
survey
period
investig
health
care
util
question
frequenc
kind
ambul
medic
servic
chosen
bivari
multivari
match
pair
analys
correl
util
anxieti
diagnosi
parent
pain
preterm
birth
child
social
indic
conduct
comparison
gener
popul
data
children
adolesc
age
year
use
data
avail
kigg
baselin
studi
health
children
adolesc
germani
conduct
robert
koch
institut
result
overal
contact
survivor
complet
questionnair
children
health
childhood
cancer
survivor
offspr
show
similar
attend
ambul
primari
health
care
compar
gener
popul
pediatrician
vs
howev
major
specialist
physician
visit
significantli
often
eg
dermatologist
vs
childhood
cancer
survivor
offspr
compar
children
gener
popul
logist
regress
show
parent
diagnosi
solid
tumor
anxieti
children
health
significantli
influenc
health
care
util
conclus
improv
childhood
cancer
survivor
includ
topic
offspr
seem
necessari
offspr
pediatrician
implement
counsel
provid
inform
consid
special
famili
anamnesi
brown
k
p
r
k
l
w
k
g
r
colleg
medicin
pediatr
tx
usa
hutchinson
cancer
research
center
clinic
research
divis
wa
usa
hospit
st
loui
audiolog
st
mo
usa
univers
chicago
pediatr
il
usa
anderson
cancer
center
radiat
physic
tx
usa
jude
children
research
hospit
epidemiolog
cancer
control
tn
usa
univers
medicin
nc
usa
univers
st
loui
pediatr
hematologyoncolog
st
mo
usa
backgroundobject
cisplatin
carboplatin
cranial
radiotherapi
crt
gy
associ
ototox
howev
inform
magnitud
risk
latenc
associ
treatment
combin
limit
designmethod
presenc
absenc
hear
impair
requir
hear
aid
deaf
report
year
childhood
cancer
survivor
mean
year
standard
preval
ratio
pr
hazard
ratio
hr
correspond
confid
interv
ci
estim
year
year
hear
impair
respect
result
among
survivor
preval
hear
impair
ci
year
cumul
incid
ci
cisplatin
exposur
associ
impair
even
dose
pr
ci
higher
dose
remain
associ
impair
eg
hr
ci
contrast
impair
associ
carboplatin
dose
pr
ci
dose
associ
impair
eg
hr
ci
hear
impair
strongli
associ
exposur
gy
combin
platinum
pr
ci
gy
cisplatin
gy
carboplatin
compar
dose
crt
cisplatin
carboplatin
alon
impair
occur
ci
survivor
treat
gy
cisplatin
ci
gy
carboplatin
year
conclus
hear
impair
survivor
childhood
cancer
evolv
decad
follow
treatment
although
incid
greatest
survivor
expos
multipl
ototox
therapi
survivor
treat
platinum
therapi
even
low
dose
high
likelihood
profound
ototox
lt
carlsen
cancer
societi
patient
support
commun
activ
copenhagen
denmark
univers
depart
sociolog
social
work
aalborg
denmark
backgroundobject
object
last
year
increas
surviv
rate
seen
childhood
cancer
patient
percent
cure
nordic
countri
result
increas
number
adult
live
late
effect
childhood
cancer
purpos
qualit
studi
gener
new
knowledg
influenc
late
effect
childhood
cancer
survivor
social
life
studi
includ
patient
perspect
base
uniqu
knowledg
provid
young
adult
childhood
cancer
survivor
physic
mental
social
late
effect
designmethod
design
qualit
studi
base
phenomenolog
methodolog
analysi
strategi
inspir
ground
theori
total
subject
age
particip
part
studi
includ
interview
three
focu
group
interview
observ
group
childhood
cancer
survivor
empir
basi
besid
attend
interview
particip
ask
provid
person
detail
includ
diseas
histori
result
differ
type
late
effect
may
amplifi
affect
may
lead
new
mental
social
late
effect
major
consequ
daili
life
therefor
import
focu
total
sum
late
effect
complic
understand
overal
daili
consequ
life
late
effect
studi
explor
survivor
childhood
cancer
perceiv
social
consequ
late
effect
recogn
henc
late
effect
neg
influenc
four
aspect
survivor
social
life
educ
job
econom
opportun
particip
social
life
establish
famili
relationship
sibl
parent
conclus
studi
impli
survivor
childhood
cancer
late
effect
influenc
qualiti
social
life
four
aspect
social
life
lt
carlsen
danish
cancer
societi
patient
support
commun
activ
denmark
univers
depart
sociolog
social
work
aalborg
denmark
backgroundobject
last
year
increas
surviv
rate
seen
childhood
cancer
patient
percent
cure
nordic
countri
result
increas
number
adult
live
late
effect
childhood
cancer
purpos
qualit
studi
gener
new
knowledg
influenc
late
effect
childhood
cancer
survivor
social
life
studi
includ
patient
perspect
base
uniqu
knowledg
provid
young
adult
childhood
cancer
survivor
physic
mental
social
late
effect
designmethod
qualit
studi
base
phenomenolog
methodolog
analysi
strategi
inspir
ground
theori
total
subject
age
particip
part
studi
includ
interview
three
focu
group
interview
observ
group
childhood
cancer
survivor
empir
basi
besid
attend
interview
particip
ask
provid
person
detail
includ
diseas
histori
result
survivor
share
surviv
character
mani
posit
fantast
success
victori
howev
experi
shadow
side
life
late
effect
explain
simultan
happi
grief
delight
surviv
feel
grief
lost
opportun
chang
life
situat
comfort
secur
familiar
everyday
life
chang
childhood
cancer
patient
lose
opportun
live
normal
childhood
either
period
perman
survivor
describ
loss
conclus
studi
illustr
simultan
thank
grief
adult
survivor
childhood
cancer
cc
cheng
kaohsiung
normal
univers
special
educ
kaohsiung
taiwan
roc
backgroundobject
children
diagnos
langerhan
cell
histiocytosi
lch
taiwan
given
rariti
childhood
lch
lack
school
reentri
protocol
prepar
childhood
cancer
survivor
return
school
taiwan
school
profession
fare
encount
student
lch
disadvantag
famili
first
time
studi
aim
explor
lesson
learn
school
personnel
experi
work
among
parent
keep
middl
school
student
lch
school
designmethod
qualit
studi
research
conduct
interview
five
middl
school
profession
struggl
keep
weiheng
pseudonym
school
weiheng
diagnos
lch
grade
age
left
school
medic
treatment
return
middl
school
grade
age
profession
interview
weiheng
homeroom
teacher
resourc
room
teacher
counselor
social
worker
administr
overse
school
counsel
special
educ
servic
result
particip
agre
work
weiheng
father
past
school
year
arduou
learn
curv
took
differ
stage
adapt
profession
gain
knowledg
seemingli
dysfunct
famili
adjust
expect
accord
chang
understand
could
term
profession
respons
stage
start
teacher
take
charg
seek
addit
profession
support
insight
final
settl
share
bottom
line
conclus
differ
among
profession
ideolog
conflict
perspect
initi
rock
eventu
facilit
implement
school
reentri
project
student
lch
share
goal
keep
weiheng
school
profession
gradual
start
appreci
father
perspect
chang
expect
weiheng
led
effect
collabor
child
e
p
f
md
c
j
j
j
l
houston
depart
psycholog
tx
usa
colleg
medicin
depart
pediatr
tx
usa
univers
texa
md
anderson
cancer
center
depart
radiat
oncolog
tx
usa
clinic
depart
radiat
oncolog
mn
usa
children
hospit
cancer
hematolog
center
tx
usa
children
hospit
psycholog
servic
tx
usa
colleg
medicin
depart
medicin
tx
usa
backgroundobject
proton
beam
radiotherapi
pbrt
reduc
exposur
healthi
tissu
radiat
may
minim
late
effect
patient
pediatr
brain
tumor
studi
compar
social
cognit
academ
outcom
children
treat
pbrt
versu
photon
radiotherapi
xrt
designmethod
survivor
year
year
complet
cognit
process
speed
work
memori
languag
attent
execut
function
memori
academ
read
write
math
fluenci
test
parent
complet
questionnair
assess
survivor
social
function
result
xrt
pbrt
group
differ
demographicclin
variabl
male
year
infratentori
tumor
craniospin
rt
median
rt
dose
gy
except
pbrt
year
xrt
year
interv
pbrt
year
xrt
year
p
tumor
type
includ
glioma
pnetmedulloblastoma
ependymoma
germ
cell
pbrt
group
perform
within
normal
limit
cognit
measur
xrt
group
perform
measur
work
memori
languag
execut
function
memori
group
perform
measur
process
speed
motor
dexter
ancova
test
control
group
differ
interv
survivor
treat
pbrt
outperform
treat
xrt
cognit
p
academ
task
p
except
attent
p
pbrt
group
also
rate
better
social
function
p
conclus
find
suggest
pbrt
may
provid
meaning
benefit
xrt
social
cognit
academ
outcom
pediatr
brain
tumor
survivor
doisaki
r
h
n
r
k
red
cross
nagoya
first
hospit
depart
hematolog
children
medic
center
nagoya
japan
red
cross
nagoya
first
hospit
depart
children
medic
center
nagoya
japan
red
cross
nagoya
first
hospit
depart
obstetr
gynecolog
nagoya
japan
red
cross
nagoya
first
hospit
depart
breast
endocrin
surgeri
nagoya
japan
red
cross
nagoya
first
hospit
depart
urolog
nagoya
japan
backgroundobject
patient
receiv
hematopoiet
stem
cell
transplant
hsct
childhood
often
physic
psycholog
social
problem
due
complic
hsct
ltfu
program
may
play
import
role
support
howev
well
establish
japan
designmethod
april
march
total
hsct
perform
patient
median
age
year
rang
institut
start
ltfu
program
sinc
april
evalu
follow
physic
condit
use
common
terminolog
criteria
advers
event
version
endocrinopathi
central
nervou
system
complic
cardiopulmonari
dysfunct
gastrointestin
hepat
sequela
renal
dysfunct
iron
overload
secondari
malign
march
patient
male
femal
visit
program
underli
diseas
hematolog
malign
patient
solid
tumor
median
age
initi
visit
ltfu
time
hsct
year
rang
year
rang
respect
patient
underw
allogen
hsct
condit
regimen
includ
gy
total
bodi
irradi
tbi
patient
result
ten
patient
develop
moder
sever
chronic
diseas
program
grade
event
identifi
patient
given
gy
tbi
secondari
malign
papillari
thyroid
cancer
renal
cell
carcinoma
iron
overload
pulmonari
dysfunct
cardiac
disord
primari
amenorrhea
patient
secondari
malign
diagnos
earli
stage
success
treat
total
resect
tumor
conclus
found
sever
complic
includ
secondari
malign
ltfu
program
program
use
detect
latent
problem
manag
complic
hsct
dreneva
v
rogachev
nation
research
center
pediatr
oncolog
immunolog
clinic
rehabilit
research
center
patient
remiss
russkoy
pole
moscow
russia
backgroundobject
posterior
fossa
tumor
pft
acut
lymphoblast
leukemia
frequent
observ
type
childhood
malign
current
method
treatment
provid
notabl
increment
patient
surviv
rate
time
initi
diagnosi
combin
treatment
effect
impair
execut
function
includ
work
memori
sustain
attent
inhibit
shift
furthermor
age
diagnosi
treatment
also
matter
designmethod
perform
estim
work
memori
state
use
subtest
visual
work
memori
cambridg
neuropsycholog
test
autom
batteri
sampl
includ
three
group
patient
surviv
pft
femal
mean
age
patient
femal
mean
age
healthi
control
femal
mean
age
use
manova
defin
effect
age
diagnosi
visual
work
memori
state
three
group
result
find
demonstr
signific
differ
work
memori
measur
three
group
particip
patient
pft
worst
result
survivor
shown
better
one
even
though
wors
healthi
children
furthermor
reveal
age
dynam
perform
work
memori
task
age
amount
element
process
work
memori
increas
wherea
contrast
amount
mistak
decreas
conclus
children
adolesc
surviv
oncolog
diseas
show
defici
work
memori
process
contrast
healthi
children
notabl
children
brain
tumor
less
success
task
patient
surviv
blood
malign
moreov
studi
indic
execut
control
volum
work
memori
substanti
increas
age
edgar
j
n
b
hospit
sick
children
haematolog
oncolog
edinburgh
unit
kingdom
west
scotland
cancer
centr
oncolog
glasgow
unit
kingdom
backgroundobject
scottish
govern
recommend
teenag
young
adult
tya
treat
cancer
receiv
treatment
summari
ts
holist
need
assess
hna
aid
commun
educ
identifi
area
concern
object
studi
determin
feasibl
implement
ts
hna
scottish
tya
cancer
treatment
ii
share
ts
health
profession
improv
commun
engag
designmethod
scottish
tya
year
complet
cancer
treatment
april
identifi
weekli
nation
tya
multidisciplinari
team
tya
mdt
meet
treatment
summari
hna
complet
distribut
patient
health
profession
result
elig
patient
recruit
respons
rate
male
median
rang
age
year
among
reloc
relaps
lead
consult
deem
process
relev
respond
cancer
diagnos
germ
cell
tumour
lymphoma
bone
tumour
repres
carcinoma
melanoma
cn
tumour
conclus
treatment
summari
holist
need
assess
complet
almost
two
third
tya
identifi
cancer
treatment
recruit
failur
due
larg
consult
disengag
base
incid
data
current
pathway
allow
identif
almost
half
patient
end
treatment
complet
tshna
labour
intens
adequ
time
train
must
provid
share
treatment
summari
improv
commun
engag
primari
care
provid
clear
pathway
referr
patient
hospit
problem
aris
edgar
j
n
b
hospit
sick
children
haematolog
oncolog
edinburgh
unit
kingdom
west
scotland
cancer
centr
oncolog
glasgow
unit
kingdom
backgroundobject
psychosoci
issu
common
amongst
teenag
young
adult
tya
cancer
treatment
tya
report
feel
unsupport
aim
studi
determin
burden
need
amongst
tya
cancer
treatment
evalu
whether
need
met
designmethod
scottish
tya
year
complet
cancer
treatment
april
identifi
treatment
summari
ts
holist
need
assess
hna
complet
distribut
ts
patient
health
profession
qualit
analysi
identifi
concern
result
elig
tya
recruit
respons
rate
male
median
rang
age
year
germ
cell
tumour
lymphoma
bone
tumour
ts
data
avail
raw
hna
data
patient
tya
report
concern
report
concern
report
concern
report
concern
report
concern
report
concern
gener
appear
physic
fit
emot
issu
numer
one
third
tya
refer
psycholog
support
benefit
third
sector
support
programm
conclus
almost
tya
report
least
one
concern
cancer
treatment
patient
report
five
concern
report
concern
support
servic
larg
provid
third
sector
place
mani
patient
evalu
health
need
assess
explor
relationship
diagnos
identif
gap
servic
requir
inform
futur
develop
esbenshad
dl
l
kc
gt
kr
jp
w
kk
univers
medic
center
pediatr
hematolog
oncolog
nashvil
usa
jude
children
research
hospit
depart
epidemiolog
cancer
control
memphi
usa
cancer
center
medicin
durham
usa
minnesota
pediatr
minneapoli
usa
hutchinson
cancer
research
center
clinic
research
divis
seattl
usa
texa
md
anderson
cancer
center
radiat
oncolog
houston
usa
backgroundobject
uniform
system
comorbid
classif
childhood
cancer
survivor
essenti
enumer
determin
impact
diseas
burden
health
outcom
permit
comparison
across
popul
aim
character
burden
diseas
adult
childhood
cancer
survivor
sibl
use
cumul
ill
rate
scale
geriatr
determin
associ
diseas
burden
incid
mortal
designmethod
baselin
questionnair
complet
ccss
particip
male
mean
standard
deviat
age
age
diagnosi
year
sibl
male
age
year
use
determin
score
summar
diseas
burden
across
item
score
sever
problem
use
character
morbid
among
elderli
individu
without
cancer
survivor
adult
cancer
among
childhood
cancer
survivor
score
outcom
analyz
total
number
categori
score
total
score
total
scorenumb
categori
score
sever
index
number
grade
number
grade
categori
score
compar
survivorss
statist
associ
diseas
burden
incid
mortal
model
cox
proport
hazard
regress
adjust
age
sex
result
survivor
higher
mean
score
metric
sibl
p
total
number
categori
vs
total
score
vs
sever
index
vs
number
grade
vs
number
grade
vs
condit
risk
mortal
increas
ci
point
increas
total
score
ci
point
increas
sever
index
ci
grade
condit
conclus
survivor
greater
burden
diseas
character
higher
summari
score
sibl
score
predict
incid
mortal
l
frederiksen
l
h
l
n
h
jf
f
cancer
societi
research
center
childhood
cancer
research
group
copenhagen
denmark
environment
karolinska
institutet
unit
epidemiolog
stockholm
sweden
cancer
registri
finnish
cancer
registri
helsinki
finland
helsinki
depart
pediatr
helsinki
finland
univers
hospit
depart
pediatr
aarhu
denmark
faculti
health
depart
clinic
medicin
aarhu
denmark
backgroundobject
substanti
improv
childhood
cancer
surviv
result
steadili
increas
popul
childhood
cancer
survivor
wherea
larg
number
studi
investig
somat
late
effect
less
known
concern
socioeconom
condit
survivor
childhood
cancer
systemat
review
aim
evalu
summar
evid
socioeconom
condit
survivor
childhood
cancer
identifi
survivor
particular
risk
advers
socioeconom
outcom
designmethod
systemat
review
conduct
accord
prisma
guidelin
extens
literatur
search
articl
publish
januari
novemb
conduct
search
medlin
embas
psycinfo
articl
identifi
met
inclus
criteria
select
articl
qualiti
apprais
find
summar
narr
synthesi
result
survivor
childhood
cancer
increas
risk
advers
socioeconom
outcom
regard
educ
achiev
incom
uptak
social
secur
benefit
comparison
gener
popul
sibl
comparison
group
find
repeat
grade
employ
statu
occup
posit
inconsist
across
studi
includ
survivor
type
childhood
cancer
notabl
survivor
central
nervou
system
tumor
survivor
treat
cranial
radiotherapi
diagnos
younger
age
independ
cancer
type
particular
risk
advers
socioeconom
outcom
conclus
vulner
group
childhood
cancer
survivor
face
signific
socioeconom
difficulti
later
life
cours
better
understand
underli
mechan
observ
socioeconom
difficulti
childhood
cancer
survivor
high
import
given
increas
popul
childhood
cancer
survivor
target
intervent
support
strategi
address
somat
psychiatr
aspect
late
effect
also
socioeconom
difficulti
high
import
reduc
social
inequ
ensur
high
qualiti
life
childhood
cancer
hosoya
k
k
k
r
luke
intern
hospit
pediatr
tokyo
japan
prefectur
central
hospit
pediatr
ehim
japan
school
nurs
st
luke
intern
univers
child
health
nurs
tokyo
japan
center
grobal
health
medicin
pediatr
tokyo
japan
backgroundobject
previou
report
japan
qualiti
life
childhood
cancer
survivor
ccss
may
underestim
investig
questionnair
thu
made
oper
comprehens
clinic
survey
system
adolesc
young
adult
survivor
childhood
cancer
designmethod
method
underw
medic
examin
ophthalmolog
oral
surgeri
head
mri
heart
ultrasonographi
thyroid
ultrasonographi
cognit
function
test
prevent
healthcar
center
hospit
particip
studi
group
year
age
older
remiss
year
end
treatment
year
diagnosi
control
group
sibl
year
age
older
result
characterist
studi
group
age
consult
year
median
year
age
onset
year
period
end
treatment
year
transplant
control
group
f
age
year
result
unit
lipidosi
studi
group
control
group
fatti
liver
pulmonari
dysfunct
decreas
testicular
size
glaucoma
doubt
cataract
decreas
saliv
lack
tooth
other
hydrocephalu
bladder
cancer
conclus
comprehens
clinic
survey
use
two
peopl
survey
help
diagnosi
diseas
symptom
fatti
liver
lipidosi
frequent
sibl
necessari
educ
take
care
health
male
infertil
may
frequent
previous
report
ic
huang
l
l
ch
k
jude
children
research
hospit
epidemiolog
cancer
control
memphi
usa
state
univers
psycholog
stillwat
usa
jude
children
research
hospit
oncolog
memphi
usa
backgroundobject
financi
strain
famili
children
complet
anticanc
therapi
aim
investig
effect
cognit
behavior
problem
pediatr
survivor
famili
financi
strain
parent
emot
distress
focus
parent
employ
incom
downturn
potenti
mechan
designmethod
pediatr
survivor
mean
year
time
sinc
year
assess
year
survivor
complet
standard
direct
test
cognit
function
includ
execut
function
process
behavior
outcom
report
parent
use
behavior
assess
system
children
includ
extern
intern
problem
adapt
skill
domain
parent
employ
econom
challeng
due
child
health
condit
ie
need
addit
incom
cover
medic
cost
famili
financi
strain
emot
distress
use
brief
symptom
path
analys
test
associ
cognit
andor
behavior
problem
famili
financi
strain
parent
emot
distress
influenc
incom
shortag
result
among
parent
miss
work
incom
shortag
famili
financi
strain
due
child
health
condit
risk
increas
survivor
impair
execut
function
odd
ratio
p
process
p
adapt
skill
p
extern
p
intern
p
behavior
problem
parent
miss
work
higher
risk
incom
shortag
famili
financi
strain
p
incom
shortag
associ
famili
financi
strain
p
problem
execut
function
process
adapt
skill
extern
behavior
significantli
influenc
famili
financ
parent
incom
shortag
p
parent
emot
distress
influenc
survivor
cognitivebehavior
function
parent
incom
shortag
conclus
vocat
support
parent
may
reduc
economicfinanci
burden
famili
pediatr
cancer
survivor
develop
cognit
behavior
problem
ic
huang
l
n
j
k
j
w
dk
l
jude
children
research
hospit
epidemiolog
cancer
control
memphi
usa
tennesse
pharmaci
memphi
usa
jude
children
research
hospit
oncolog
memphi
usa
jude
children
research
hospit
psycholog
memphi
usa
healthcar
atlanta
aflac
cancer
blood
disord
center
atlanta
usa
jude
children
research
hospit
pharmaceut
scienc
memphi
usa
jude
children
research
hospit
biostatist
memphi
usa
jude
children
research
hospit
pediatr
medicin
memphi
usa
backgroundobject
increas
attent
place
use
control
medic
marijuana
pain
manag
potenti
altern
opioid
howev
topic
understudi
cancer
survivor
particularli
among
chronic
pain
investig
pattern
determin
opioid
marijuana
use
among
adult
survivor
childhood
cancer
experienc
chronic
pain
designmethod
adult
survivor
childhood
cancer
particip
sjlife
complet
clinic
evalu
survey
across
two
time
point
mean
year
survey
contain
medic
outcom
studi
bodili
pain
scale
sever
pain
determin
score
opioid
use
marijuana
use
logist
regress
identifi
determin
cancer
treatment
sociodemograph
psycholog
opioid
andor
marijuana
use
result
mean
rang
age
time
diagnosi
among
survivor
year
year
respect
among
survivor
chronic
severeescal
pain
time
report
use
opioid
marijuana
respect
chronic
severeescal
pain
vs
decreas
severeno
pain
time
associ
opioid
odd
ratio
ci
marijuana
use
ci
caucasian
chronic
severeescal
anxieti
lack
health
insur
increas
likelihood
opioid
use
compar
raceethn
decreas
severeno
anxieti
insur
coverag
or
p
lack
health
insur
high
schoolsom
colleg
educ
singledivorc
marit
statu
increas
likelihood
marijuana
use
compar
insur
coverag
collegegradu
educ
marri
statu
or
p
conclus
chronic
severeescal
pain
introduc
opioid
marijuana
use
later
cancer
survivorship
futur
research
focu
effect
potenti
health
impact
opioid
marijuana
among
childhood
cancer
survivor
ishida
h
h
h
k
c
h
r
j
h
j
prefectur
central
hospit
pediatr
medic
center
matsuyama
japan
medic
school
depart
pediatr
tokyo
japan
univers
school
medicin
depart
human
health
scienc
kyoto
japan
univers
school
medicin
depart
pediatr
kurum
japan
univers
hospit
depart
pediatr
hiroshima
japan
univers
graduat
school
depart
pediatr
mie
japan
cancer
center
divis
niigata
japan
children
hospit
divis
hematolog
shizuoka
japan
center
child
health
develop
children
cancer
tokyo
japan
univers
school
medicin
depart
pediatr
child
health
tokyo
japan
univers
school
medicin
depart
pediatr
sendai
japan
hokuyu
hospit
depart
pediatr
sapporo
japan
women
children
hospit
depart
hematologyoncolog
osaka
japan
kyushu
cancer
center
depart
pediatr
fukuoka
japan
children
medic
center
divis
medicin
yokohama
japan
luke
intern
hospit
depart
pediatr
tokyo
japan
institut
radiolog
nation
institut
quantum
radiolog
scienc
technolog
center
radiat
protect
knowledg
chiba
japan
center
neurolog
nation
institut
mental
health
depart
drug
depend
research
tokyo
japan
center
child
health
develop
epidemiolog
clinic
research
center
children
cancer
tokyo
japan
univers
school
medicin
depart
pediatr
surgeri
tokyo
japan
backgroundobject
multidisciplinari
therapi
increas
risk
subsequ
late
effect
detail
analys
secondari
cancer
childhood
cancer
survivor
ccss
limit
asian
countri
studi
aim
evalu
specif
clinic
characterist
secondari
cancer
ccss
use
data
previou
nationwid
survey
japan
designmethod
retrospect
cohort
studi
compris
ccss
diagnos
across
japanes
hospit
conduct
secondari
analys
estim
incid
secondari
cancer
accord
primari
malign
elucid
associ
primari
secondari
cancer
also
explor
risk
factor
develop
secondari
cancer
independ
primari
malign
result
cumul
incid
secondari
cancer
year
vari
among
primari
cancer
hematolog
malign
ci
retinoblastoma
ci
pediatr
solid
tumor
ci
brain
tumor
ci
bonesoft
tissu
sarcoma
ci
other
ci
close
associ
primari
secondari
cancer
diagnos
found
risk
factor
secondari
cancer
develop
depend
primari
cancer
multivari
cox
regress
analysi
show
signific
risk
factor
secondari
cancer
surgeri
hr
ci
allogen
stem
cell
transplant
sct
hr
ci
retinoblastoma
autolog
sct
hr
ci
radiat
hr
ci
conclus
cumul
incid
secondari
cancer
vari
among
primari
cancer
osteosarcoma
retinoblastoma
highest
risk
secondari
cancer
primari
cancer
close
associ
secondari
cancer
autologousallogen
sct
common
risk
factor
secondari
cancer
among
ccss
j
ji
j
univers
depart
medicin
sweden
backgroundobject
number
childbirth
among
cancer
survivor
continu
increas
still
larg
unknown
whether
children
cancer
survivor
might
experi
advers
health
outcom
process
grow
designmethod
identifi
individu
diagnos
cancer
swedish
cancer
registar
link
swedish
medic
birth
regist
identifi
offspr
born
children
whose
parent
without
diagnosi
cancer
match
studi
popul
accord
date
birth
gender
result
link
swedish
hospit
discharg
regist
found
hospit
rate
higher
offspr
femal
cancer
survivor
higher
offspr
male
cancer
survivor
compar
match
control
risk
hospit
stronger
parent
diagnos
childhood
cancer
wherea
risk
much
weaker
parent
diagnos
cancer
age
besid
increas
risk
hospit
due
neoplasm
childhood
significantli
increas
risk
found
hospit
due
infecti
parasit
diseas
diseas
blood
blood
form
organ
certain
disord
involv
immun
mechan
diseas
circulatori
system
diseas
due
pregnanc
childbirth
puerperium
conclus
studi
suggest
children
cancer
survivor
might
experi
moder
increas
rate
hospit
call
clinic
attent
kagramanov
r
c
n
p
sick
children
child
health
evalu
scienc
toronto
canada
health
scienc
centr
institut
clinic
evalu
scienc
toronto
canada
sick
children
haematologyoncolog
toronto
canada
michael
hospit
gener
surgeri
toronto
canada
backgroundobject
survivor
aya
cancer
risk
develop
advers
health
outcom
requir
healthcar
explor
predictor
ltfu
care
receiv
cohort
survivor
impact
care
adher
recommend
surveil
designmethod
conduct
retrospect
cohort
studi
use
administr
health
databas
ontario
canada
survivor
identifi
impact
cohort
provinci
databas
patient
age
year
diagnosi
one
six
common
cancer
defin
four
model
ltfu
care
special
survivor
clinic
avail
treat
paediatr
cancer
centr
oncolog
clinic
primari
care
physician
pcp
regular
care
assess
adher
children
oncolog
group
surveil
guidelin
cardiac
diseas
breast
cancer
poisson
regress
model
examin
attend
rate
logist
regress
model
assess
guidelin
adher
result
cohort
consist
survivor
treat
adult
centr
treat
paediatr
centr
median
year
ci
highest
level
care
access
survivor
clinic
oncolog
clinic
pcp
regular
care
risk
receiv
regular
care
highest
male
increas
per
year
among
elig
special
survivor
clinic
greater
attend
observ
femal
live
closer
clinic
attend
decreas
year
femal
survivor
risk
breast
cancer
time
ci
like
receiv
annual
mammogram
follow
special
survivor
clinic
special
clinic
attend
impact
echocardiographi
adher
conclus
aya
survivor
attend
special
clinic
almost
receiv
regular
care
identifi
access
care
model
maxim
surveil
adher
must
key
research
focu
khanna
p
ds
h
pc
toronto
institut
medic
scienc
toronto
canada
hospit
sick
children
child
health
evalu
scienc
program
toronto
canada
clinic
evalu
scienc
ice
central
toronto
canada
hospit
sick
children
haematologyoncolog
toronto
canada
toronto
institut
health
manag
evalu
toronto
canada
toronto
depart
medicin
toronto
canada
health
network
divis
peter
munk
cardiac
centr
toronto
canada
colleg
hospit
divis
cardiolog
toronto
canada
backgroundobject
childhood
cancer
survivor
cc
elev
risk
variou
cardiovascular
diseas
cvd
howev
studi
focus
primarili
congest
heart
failur
chf
cancer
cardiac
morbid
includ
chf
arrhythmia
valv
abnorm
pericardi
diseas
coronari
arteri
diseas
cad
conduct
retrospect
cohort
studi
determin
incid
predictor
categori
cvd
survivor
designmethod
use
provinci
pediatr
cancer
registri
assembl
cohort
survivor
diagnos
age
year
treat
ontario
pediatr
cancer
center
patient
match
age
sex
geograph
region
popul
control
link
health
administr
databas
outcom
calcul
incid
cvd
cardiac
death
evalu
diagnost
treatment
risk
factor
use
surviv
analysi
account
compet
risk
death
adult
cancer
event
result
age
year
cumul
incid
cvd
cc
confid
interv
ci
compar
ci
control
survivor
increas
risk
chf
hazard
ratio
hr
ci
arrhythmia
hr
ci
valv
diseas
hr
ci
pericardi
diseas
hr
ci
cad
hr
ci
cardiac
death
hr
ci
anthracyclin
dose
hr
ci
age
year
cancer
diagnosi
hr
ci
childhood
relaps
hr
ci
diabet
hr
ci
predict
increas
risk
cvd
survivor
conclus
cc
elev
risk
multipl
type
cvd
absolut
risk
year
age
low
significantli
increas
rel
gener
popul
care
cc
assess
manag
overal
cvd
risk
rather
limit
sole
chf
khattachan
k
p
hematologyoncolog
pediatr
bangkok
thailand
backgroundobject
anemia
common
complic
cancer
therapi
childhood
cancer
survivor
receiv
red
blood
cell
rbc
transfus
may
increas
risk
vital
organ
iron
deposit
caus
seriou
effect
howev
studi
iron
overload
statu
still
limit
childhood
cancer
survivor
object
studi
elucid
preval
risk
factor
transfus
relat
iron
overload
childhood
cancer
survivor
king
chulalongkorn
memori
hospit
designmethod
cross
section
descript
studi
perform
cancer
survivor
age
year
old
diagnosi
time
histori
transfus
cancer
treatment
serum
ferritin
collect
outpati
visit
januari
juli
primari
diagnosi
treatment
cumul
amount
rbc
transfus
collect
serum
ferritin
measur
good
health
condit
repeat
case
serum
ferritin
higher
microgramlit
result
survivor
male
femal
median
age
year
rang
year
recruit
studi
median
episod
rbc
transfus
rang
episod
adjust
cumul
rbc
volumebodi
weight
mlkg
rang
mlkg
time
sinc
last
transfus
month
rang
month
survivor
serum
ferritin
level
mcgl
diseas
high
serum
ferritin
group
solid
tumor
five
hematolog
malign
eleven
post
bone
marrow
transplant
ten
survivor
conclus
signific
correl
transfus
serum
ferritin
compound
number
transfus
adjust
cumul
rbc
volumebodi
weight
mlkg
time
sinc
last
transfus
month
keyword
children
cancer
survivor
iron
overload
serum
ferritin
blood
transfus
studi
support
ratchadapiseksompotch
fund
j
kim
utah
colleg
social
work
salt
lake
citi
usa
univers
depart
social
welfar
seoul
republ
korea
nation
univers
hospit
depart
rehabilit
medicin
seoul
republ
korea
hospit
social
servic
team
seoul
republ
korea
backgroundobject
child
journey
cancer
progress
parent
often
experi
role
chang
make
like
spous
experi
increas
conflict
within
relationship
although
research
conflict
spous
effect
parent
child
limit
research
conflict
creat
develop
evolv
studi
explor
chang
marit
relationship
report
mother
children
cancer
korea
designmethod
interview
conduct
korean
mother
children
diagnos
cancer
within
last
five
year
age
mean
age
particip
year
sd
work
homemak
children
cancer
mean
age
year
sd
boy
girl
mean
age
cancer
diagnosi
year
sd
diagnos
includ
leukemia
malign
lymphoma
brain
tumor
neuroblastoma
osteosarcoma
transcrib
interview
analyz
use
themat
analysi
result
mother
perceiv
relationship
spous
significantli
affect
child
ill
tri
find
way
resolv
conflict
two
major
theme
emerg
mother
interview
conflict
escal
physic
emot
distant
financi
challeng
feel
resent
experienc
lack
understand
reliabl
repercuss
conflict
explos
focu
child
effort
commun
better
husband
effort
conclus
find
demonstr
need
intervent
help
parent
child
cancer
manag
emot
burden
result
marit
conflict
intervent
ultim
promot
relationship
well
psychosoci
child
cancer
r
kleinerman
bs
dh
jm
lm
nation
cancer
institut
divis
cancer
epidemiolog
genet
rockvil
usa
sloan
ketter
cancer
center
ocular
oncolog
new
york
usa
england
medic
center
ophthalm
epidemiolog
genet
servic
boston
usa
backgroundobject
retinoblastoma
rb
one
curabl
childhood
cancer
diagnos
earli
howev
survivor
hereditari
rb
germlin
mutat
strikingli
increas
risk
subsequ
malign
neoplasm
major
caus
mortal
designmethod
among
survivor
retinoblastoma
diagnos
two
major
us
treatment
center
follow
compar
mortal
cohort
expect
us
gener
popul
use
standard
mortal
ratio
smr
absolut
excess
risk
aer
also
estim
cumul
mortal
result
death
cohort
occur
survivor
hereditari
rb
death
confid
attribut
subsequ
malign
neoplasm
aer
smr
death
due
subsequ
malign
neoplasm
highest
year
follow
hereditari
rb
diagnosi
declin
year
follow
diagnosi
contrast
aer
due
subsequ
malign
neoplasm
increas
time
versu
death
per
year
respect
death
due
bone
cancer
soft
tissu
sarcoma
nasal
caviti
cancer
common
survivor
rb
observ
slightli
increas
risk
death
compar
gener
popul
overal
specif
subsequ
malign
neoplasm
smr
caus
similar
gener
popul
survivor
rb
year
rb
diagnosi
cumul
mortal
subsequ
malign
neoplasm
survivor
hereditari
rb
respect
conclus
survivor
hereditari
rb
remain
risk
death
subsequ
malign
neoplasm
especi
sarcoma
year
diagnosi
result
highlight
need
develop
clinic
manag
guidelin
retinoblastoma
survivor
j
kruseova
l
e
g
v
j
j
hospit
motol
depart
paediatr
haematolog
faculti
charl
czech
pragu
czech
republ
hospit
motol
depart
faculti
charl
czech
republ
pragu
czech
republ
bonn
depart
paediatr
haematolog
oncolog
bonn
germani
hospit
motol
bioinformat
faculti
charl
czech
republ
pragu
czech
republ
research
institut
boyn
research
drogheda
ireland
backgroundobject
childhood
cancer
survivor
heterogen
attitud
health
relat
qualiti
life
hrqol
develop
guidelin
much
discuss
centr
frequenc
investig
knowledg
incident
find
need
treatment
may
caus
unnecessari
anxieti
possibl
affect
hrqol
studi
seek
determin
benign
ultrasound
find
influenc
survivor
self
perceiv
health
designmethod
part
pancarelif
studi
survivor
pragu
ltfu
clinic
complet
hrqol
questionnair
current
studi
includ
survivor
ask
particip
regular
visit
abdomin
ultrasound
compar
hrqol
result
ultrasound
find
age
gender
educ
smoke
alcohol
bmi
survivor
least
one
benign
ultrasound
find
remain
abdomin
ultrasound
find
ultrasound
find
includ
liver
focal
nodular
hyperplasia
hemangioma
steatosi
cyst
kidney
angiomyolipoma
cyst
gall
bladder
cholelithiasi
polyp
observ
data
analys
use
linear
model
control
age
possibl
confound
analysi
perform
use
r
statist
packag
result
differ
hrqol
patient
benign
median
iqr
normal
median
iqr
ultrasound
find
power
conclus
confirm
benign
ultrasound
find
affect
hrqol
conclud
guidelin
develop
medic
test
benign
result
may
gener
poorer
qualiti
life
project
receiv
fund
europeanunion
seventh
framework
programm
research
technolog
develop
demonstr
grant
agreement
studi
receiv
fund
ministri
educ
youth
sport
czech
republ
j
kruseova
j
e
v
j
hospit
motol
depart
paediatr
haematolog
charl
school
medicin
pragu
czech
republ
hospit
motol
depart
paediatr
charl
school
medicin
pragu
czech
republ
hospit
motol
depart
charl
school
medicin
pragu
czech
republ
hospit
motol
depart
charl
school
medicin
pragu
czech
republ
hospit
motol
bioinformat
charl
school
medicin
pragu
czech
republ
germani
depart
paediatr
oncolog
germani
backgroundobject
patient
treat
chemotherapi
known
risk
hear
loss
cisplatin
cranial
irradi
may
also
impact
neurocognit
function
evalu
effect
cisplatin
hear
chang
karnovski
index
educ
cn
survivor
designmethod
part
pancarelif
studi
survivor
hear
neurolog
examin
treatment
studi
group
cisplatin
radiotherapi
median
age
dg
median
follow
control
group
radiotherapi
age
dg
fup
control
group
ii
oper
age
dg
fup
extract
indic
hear
impair
karnovski
index
incid
epilepsi
educ
correl
made
five
year
end
treatment
data
analys
use
linear
model
interact
result
hear
impair
studi
group
vs
control
group
vs
control
group
ii
educ
studi
group
vs
control
group
p
vs
control
group
ii
p
studi
group
observ
effect
age
diagnosi
educ
p
karnovski
index
studi
group
vs
control
group
vs
control
group
ii
p
control
group
vs
ii
p
factor
statist
signific
conclus
chemotherapi
greater
detriment
effect
hear
also
educ
achiev
howev
karnovski
index
lower
radiotherapi
patient
probabl
due
longer
number
side
effect
radiotherapi
increas
time
better
understand
result
want
look
mri
find
initi
tumour
size
localis
possibl
influenc
project
receiv
fund
european
union
seventh
framework
programm
research
technolog
develop
demonstr
grant
agreement
ministri
educ
youth
sport
czech
republ
yh
gill
j
mo
univers
medic
korea
depart
pediatr
seoul
republ
korea
backgroundobject
continu
educ
need
qualiti
life
childhood
cancer
survivor
korean
govern
establish
administr
financi
support
hospit
school
sinc
review
current
statu
hospit
school
system
children
cancer
look
futur
direct
designmethod
studi
review
offici
data
ministri
educ
well
internet
homepag
hospit
school
korea
result
hospit
school
nationwid
number
student
current
enrol
class
onlin
class
class
oper
teacher
well
volunt
one
two
classroom
class
schedul
individu
hospit
school
tailor
medic
condit
student
student
difficulti
class
internet
interact
class
video
demand
vod
class
perform
hospit
home
region
agenc
oper
class
approv
attend
origin
school
elementari
student
must
attend
hour
lesson
day
lesson
minut
day
system
hospit
school
case
junior
high
school
student
hour
lesson
lesson
minut
day
system
requir
student
hospit
school
take
assess
test
origin
school
promot
grade
conclus
seem
desir
combin
class
class
children
cancer
advanc
class
content
hospit
school
alter
manag
academ
perform
would
consid
ck
loh
f
mohd
n
abu
mb
faleh
bb
abdul
sc
h
kebangsaan
malaysia
medic
centr
depar
paediatr
kuala
lumpur
malaysia
kebangsaan
malaysia
medic
centr
depart
radiolog
kuala
lumpur
malaysia
backgroundobject
background
anthracyclin
commonli
use
treatment
childhood
cancer
risk
myocardi
damag
echocardiographi
current
method
choic
screen
cardiomyopathi
cardiac
mri
cmr
sensit
measur
ventricl
function
high
detect
case
subclin
cardiomyopathi
object
sought
compar
two
dimension
echocardiographi
cmr
screen
subclin
anthracyclin
cardiomyopathi
designmethod
conduct
studi
childhood
cancer
survivor
receiv
treatment
tertiari
referr
centr
kuala
lumpur
survivor
receiv
anthracyclin
treatment
least
two
year
subject
cmr
echocardiographi
done
two
week
apart
assess
cardiac
function
subclin
anthracyclin
cardiomyopathi
defin
left
ventricular
eject
fraction
lvef
clinic
asymptomat
result
eight
femal
fifteen
male
survivor
ratio
malay
ethnic
compris
chines
indian
one
other
median
age
first
exposur
anthracyclin
iqr
year
old
median
durat
time
exposur
iqr
year
standard
risk
acut
lymphoblast
leukaemia
high
risk
relaps
acut
myeloid
leukaemia
lymphoma
preval
subclin
cardiomyopathi
detect
cmr
compar
echocardiographi
median
lvef
significantli
lower
survivor
subclin
cardiomyopathi
detect
cmr
lvef
compar
p
normal
cardiac
function
signific
differ
lvef
two
group
use
echocardiographi
conclus
conclud
cmr
high
detect
rate
subclin
anthracyclin
cardiomyopathi
among
childhood
cancer
survivor
centr
previous
undiagnos
v
munikoti
ks
p
sv
mk
n
senior
resid
pediatr
hematolog
oncolog
unit
advanc
pediatr
post
graduat
institut
medic
educ
research
chandigarh
india
graduat
institut
medic
educ
research
pediatr
chandigarh
india
graduat
institut
medic
educ
research
radiodiagnosi
chandigarh
india
graduat
institut
medic
educ
research
cardiolog
chandigarh
india
backgroundobject
indic
estim
livermyocardi
iron
concentr
licmic
weight
magnet
reson
imag
mri
cancer
survivor
describ
designmethod
studi
perform
children
treat
patient
month
therapi
complet
receiv
red
cell
transfus
enrol
patient
relaps
diseas
hematopoiet
transplant
exclud
mri
serum
ferritin
perform
result
patient
treat
screen
patient
includ
aml
mpal
enrol
diagnosi
enrol
year
respect
median
number
unit
transfus
iqr
mean
ferritin
rang
patient
lic
elev
patient
eighteen
patient
mild
mgg
moder
mgg
elev
lic
mic
elev
patient
patient
serum
ferritin
elev
lic
lic
correl
ferritin
p
mic
correl
either
ferritin
lic
number
unit
transfus
correl
ferritin
lic
durat
sinc
last
transfus
neg
influenc
serum
ferritin
lic
serum
ferritin
predict
elev
lic
sensitivityspecif
respect
transfus
predict
elev
lic
sensitivityspecif
respect
conclus
preval
elev
lic
mic
respect
patient
sever
elev
licmic
screen
serum
ferritin
suggest
patient
receiv
transfus
serum
ferritin
mri
use
estim
lic
mri
may
avoid
patient
serum
ferritin
patient
elev
lic
nagayoshi
k
k
jikei
univers
school
nurs
tokyo
japan
univers
depart
teacher
educ
yamanashi
japan
educ
special
health
care
need
societi
secretariat
tokyo
japan
metropolitan
shikamoto
gakuen
elementari
school
tokyo
japan
jo
gakuin
univers
faculti
health
welfar
hukuoka
japan
backgroundobject
children
underw
cancer
treatment
childhood
face
mani
difficulti
psychosoci
develop
return
school
designmethod
purpos
studi
understand
difficulti
face
children
recov
cancer
cope
support
develop
leav
hospit
qualit
descript
analysi
perform
interview
japanes
survivor
childhood
cancer
result
identifi
difficulti
absente
classroom
decreas
physic
fit
chemotherapi
constraint
school
activ
decreas
strength
motor
dysfunct
inabl
join
group
activ
decreas
strength
difficulti
join
companion
year
lost
confid
physic
condit
commun
friend
uncomfort
interact
friend
age
hesit
concern
ill
shown
teacher
friend
awar
differ
reduc
academ
abil
due
absenc
studi
difficulti
catch
studi
disadvantag
educ
advanc
caus
prolong
absenc
due
hospit
difficulti
continu
attend
school
late
effect
treatment
chronic
decondit
adulthood
caus
low
mood
feel
frustrat
physic
stress
constraint
work
problem
relat
school
life
work
nine
categori
extract
cope
action
conclus
studi
found
childhood
cancer
survivor
forc
differ
activ
school
life
friend
physic
weak
problem
feel
uncomfort
commun
friend
teacher
experi
hospit
relationship
sick
children
friend
age
person
built
also
adulthood
experi
cope
difficulti
acknowledg
studi
fund
part
scientif
research
nasedkina
e
v
rogachev
nation
research
center
pediatr
oncolog
immunolog
clinic
rehabilit
research
center
patient
remiss
russkoy
pole
moscow
russia
institut
molecular
biolog
russian
academi
scienc
laboratori
biolog
microchip
moscow
russia
backgroundobject
intens
chemotherapi
often
result
develop
sever
complic
affect
differ
tissu
organ
one
complic
metabol
syndrom
met
includ
obes
insulin
resist
arteri
hypertens
impair
fat
metabol
genet
determin
met
children
anticanc
treatment
investig
sinc
knowledg
may
import
individu
therapi
designmethod
children
male
averag
age
year
treat
hematolog
malign
studi
glucos
insulin
blood
level
bodi
mass
index
bmi
blood
pressur
analyz
estim
insulin
resist
ir
homeostasi
model
assess
insulin
resist
use
ir
found
patient
obes
patient
met
diagnos
patient
dna
isol
leukocyt
peripher
blood
total
snp
enzym
gene
system
gene
immun
respons
gene
genotyp
sequenc
perform
patient
use
inherit
diseas
panel
roch
probe
select
result
genotyp
allel
frequenc
differ
group
patient
compar
found
allel
c
allel
g
frequent
patient
ir
compar
normal
group
correspondingli
also
polymorph
variant
associ
met
pediatr
patient
allel
less
frequent
patient
bmi
percentil
compar
patient
suggest
protect
effect
conclus
thu
polymorph
gene
gene
consid
genet
marker
may
influenc
risk
develop
met
children
hematolog
malign
undergo
anticanc
therapi
larger
pharmacogenet
studi
exom
sequenc
import
identifi
novel
genet
marker
predispos
late
effect
anticanc
therapi
neu
n
k
el
f
b
h
w
j
medic
center
mainz
depart
pediatr
hematologyoncologyhemostaseolog
mainz
germani
medic
center
mainz
depart
neuroradiolog
mainz
germani
medic
center
mainz
depart
radiat
oncolog
radiat
therapi
mainz
germani
medic
center
mainz
divis
pediatr
depart
neurosurgeri
mainz
germani
backgroundobject
due
sensit
neuroimag
techniqu
cerebrovascular
complic
cerebr
microble
cmb
cerebr
cavern
malform
ccm
increasingli
recogn
consider
late
effect
treatment
pediatr
brain
tumor
aim
studi
analyz
cmb
cohort
patient
cranial
irradi
therapi
medulloblastoma
pediatr
brain
tumor
use
magnet
reson
imag
swi
designmethod
forti
former
patient
pediatr
brain
tumor
enrol
prospect
studi
examin
cranial
mri
includ
swi
sequenc
cmb
clinic
symptom
disabl
evalu
assess
detail
radiat
therapi
medic
record
research
furthermor
detail
analysi
dose
distribut
cmb
distribut
perform
patient
cmb
irradi
encephalon
identifi
contour
manual
histogram
gener
individu
calcul
median
dose
cmb
volum
whole
encephalon
result
examin
individu
mean
age
mean
time
affect
cmb
thirteen
patient
present
clinic
symptom
individu
cmb
sever
disabl
patient
without
cmb
p
longer
time
higher
craniospin
irradi
dose
correl
higher
total
lesion
count
p
individu
whole
brain
radiotherapi
plu
boost
present
significantli
higher
cmb
count
compar
focal
irradi
p
mean
significantli
higher
mean
p
indic
distinct
tendenc
toward
higher
irradi
dose
cmb
volum
compar
encephal
volum
conclus
cerebrovascular
sequela
occur
frequent
treatment
pediatr
brain
tumor
studi
remark
part
pediatr
brain
tumor
patient
present
cmb
sign
vascular
damag
caus
clinic
symptom
may
correspond
neurocognit
declin
studi
need
standard
mri
protocol
improv
qualiti
nishimura
j
r
luke
intern
hospit
depart
pediatr
tokyo
japan
prefectur
central
hospit
depart
pediatr
ehim
japan
hospit
depart
pediatr
tokyo
japan
backgroundobject
proport
childhood
cancer
survivor
cc
increas
gener
popul
improv
treatment
outcom
childhood
cancer
adolesc
young
adult
aya
survivor
receiv
standard
medic
screen
examin
develop
comprehens
clinic
survey
system
institut
male
cc
analyz
order
studi
sexual
function
designmethod
cc
underw
medic
examin
prevent
healthcar
center
adult
hospit
sinc
eighteen
male
survivor
age
year
old
older
examin
studi
evalu
sexual
hormon
testicular
volum
tanner
development
stage
age
first
ejacul
result
median
age
diagnosi
primari
cancer
enrol
studi
year
old
rang
year
old
rang
respect
primari
cancer
follow
acut
lymphoblast
leukemia
neuroblastoma
brain
tumor
other
two
case
classifi
stage
tanner
development
stage
six
case
small
testicular
volum
ml
either
right
left
side
median
age
first
ejacul
year
old
rang
time
analysi
case
could
ejacul
case
small
testicular
volum
case
show
testosteron
valu
less
ngml
case
ngml
conclus
although
male
survivor
ejacul
show
abnorm
tanner
development
stage
testicular
volum
testosteron
level
spermatogenesi
sperm
fertil
abil
male
cc
may
requir
comprehens
assess
sexual
function
fn
norsker
c
l
l
lm
hk
k
h
h
jf
danish
cancer
societi
danish
cancer
societi
research
depart
copenhagen
denmark
univers
hospit
depart
pediatr
copenhagen
denmark
cancer
societi
danish
cancer
societi
research
center
copenhagen
denmark
cancer
registri
iceland
cancer
registri
reykjavik
iceland
cancer
registri
institut
statist
epidemiolog
cancer
research
helsinki
finland
univers
hospit
divis
paediatr
oncolog
haematolog
lund
sweden
univers
hospit
iceland
divis
pediatr
oncolog
reykjavik
iceland
helsinki
hospit
children
adolesc
helsinki
finland
univers
depart
pediatr
aarhu
denmark
univers
skejbi
depart
pediatr
aarhu
denmark
backgroundobject
rariti
neuroblastoma
poor
surviv
inform
late
effect
neuroblastoma
survivor
spars
comprehens
review
risk
neuroblastoma
survivor
hospit
somat
diseas
designmethod
identifi
survivor
neuroblastoma
nordic
cancer
registri
date
back
identifi
late
effect
nation
hospit
registri
cover
period
treatment
inform
avail
clinic
registri
almost
survivor
rate
hospit
survivor
randomli
select
popul
comparison
somat
diseas
use
calcul
standard
hospit
rate
ratio
shrr
absolut
excess
risk
aer
result
survivor
first
hospit
contact
yield
shrr
ci
correspond
aer
ci
per
highest
rel
risk
diseas
blood
organ
shrr
ci
endocrin
diseas
circulatori
system
diseas
diseas
nervou
system
approxim
excess
new
hospit
survivor
diseas
nervou
system
urinari
system
endocrin
system
bone
soft
tissu
rel
risk
aer
highest
survivor
receiv
intens
treatment
conclus
survivor
neuroblastoma
highli
increas
risk
somat
late
effect
main
diseas
group
compar
background
level
increas
risk
seen
treatment
group
pronounc
survivor
intens
treat
result
use
counsel
survivor
contribut
improv
health
care
plan
clinic
oskarsson
ak
r
l
l
f
h
jf
institutet
depart
women
children
health
stockholm
sweden
cancer
societi
research
centr
survivorship
unit
copenhagen
denmark
univers
depart
women
children
health
uppsala
sweden
institutet
clinic
epidemiolog
unit
stockholm
sweden
colleg
london
depart
epidemiolog
public
health
london
unit
kingdom
univers
clinic
epidemiolog
faculti
medicin
health
sweden
univers
hospit
depart
pediatr
turku
finland
cancer
registri
statist
research
helsinki
finland
cancer
registri
statist
research
reykjavik
iceland
iceland
faculti
medicin
reykjavik
iceland
cancer
registri
statist
research
oslo
norway
oslo
faculti
medicin
oslo
norway
univers
hospit
divis
pediatr
oncolog
haematolog
lund
sweden
univers
depart
clinic
scienc
lund
sweden
univers
hospit
depart
pediatr
aarhu
denmark
backgroundobject
children
adolesc
undergo
treatment
cancer
expos
multipl
factor
impact
develop
peak
bone
mass
bone
qualiti
aim
studi
examin
risk
cumul
incid
osteoporot
fractur
childhood
cancer
survivor
identifi
subgroup
higher
risk
designmethod
nation
cancer
registri
denmark
finland
iceland
sweden
identifi
patient
diagnos
cancer
year
age
start
registr
compar
survivor
cohort
popul
comparison
subject
select
nation
popul
registri
data
deriv
nation
hospit
registri
estim
standard
hospit
rate
ratio
shrr
mean
cumul
count
mcc
hospit
admiss
osteoporot
fractur
identifi
subgroup
risk
use
cox
regress
model
gener
hazard
ratio
hr
osteoporot
fractur
death
new
cancer
treat
compet
risk
result
estim
shrr
first
osteoporot
fractur
ci
mcc
recurr
osteoporot
fractur
differ
survivor
comparison
group
shrr
isol
hip
fractur
adjust
hr
osteoporot
fractur
first
event
cancer
diagnos
year
survivor
cn
tumor
survivor
year
cancer
diagnosi
survivor
cn
tumor
also
higher
risk
experienc
second
fractur
hr
hr
respect
conclus
childhood
cancer
survivor
higher
risk
hospit
osteoporot
fractur
burden
recurr
fractur
higher
subgroup
risk
surveil
bone
health
measur
increas
bone
strength
prevent
fractur
encourag
park
hj
jm
bk
jy
sk
yh
yj
hs
ja
yj
hw
jk
mj
sk
hs
jo
kd
hj
hy
cancer
center
center
pediatr
cancer
goyang
republ
korea
univers
colleg
medicin
pediatr
daegu
republ
korea
nation
univers
school
medicin
depart
pediatr
daegu
republ
korea
univers
univers
ulsan
colleg
medicin
depart
pediatr
ulsan
republ
korea
univers
colleg
medicin
depart
pediatr
seoul
republ
korea
univers
dongsan
medic
center
depart
pediatr
daegu
republ
korea
cancer
center
hospit
depart
pediatr
seoul
republ
korea
nation
univers
colleg
medicin
depart
pediatr
daejon
republ
korea
univers
colleg
medicin
depart
pediatr
busan
republ
korea
univers
busan
paik
hospit
depart
pediatr
busan
republ
korea
univers
colleg
medicin
depart
pediatr
cheonan
republ
korea
univers
colleg
medicin
depart
pediatr
incheon
republ
korea
nation
univers
bundang
hospit
depart
pediatr
seongnam
republ
korea
fatima
hospit
depart
pediatr
daegu
republ
korea
nation
univers
medic
school
depart
pediatr
jeonju
republ
korea
research
seoul
nation
univers
colleg
medicin
depart
pediatr
seoul
republ
korea
backgroundobject
rapidli
grow
number
survivor
knowledg
possibl
influenc
childhood
cancer
survivor
school
life
increasingli
import
issu
therefor
investig
school
perform
childhood
cancer
survivor
focus
child
function
designmethod
studi
children
institut
korea
questionnair
use
studi
result
approxim
survivor
describ
satisfi
school
environ
return
school
children
report
differ
term
peer
relat
children
treat
brain
tumor
report
troubl
make
friend
compar
children
tumor
vs
bulli
report
survivor
survivor
return
primari
school
report
higher
incid
bulli
compar
survivor
return
middl
high
school
percentag
children
miss
class
day
month
higher
survivor
brain
tumor
tumor
approxim
children
report
learn
difficulti
return
school
patient
report
lower
overal
mark
averag
patient
return
high
school
show
highest
rate
repeat
grade
lowest
rate
achiev
high
academ
mark
school
mark
korean
languag
english
physic
educ
wors
children
brain
tumor
children
tumor
conclus
find
suggest
educ
support
return
school
crucial
high
school
student
cancer
difficulti
academ
perform
younger
children
particular
concern
need
patient
brain
tumor
time
intervent
assist
school
life
learn
problem
n
phillip
c
l
k
k
jude
children
research
hospit
epidemiolog
cancer
control
memphi
usa
jude
children
research
hospit
oncolog
memphi
usa
backgroundobject
survivor
childhood
acut
lymphoblast
leukemia
risk
exercis
intoler
neurocognit
deficit
exercis
capac
associ
cognit
perform
intervent
improv
exercis
capac
associ
improv
cognit
perform
popul
thu
aim
analysi
determin
exercis
intoler
associ
neurocognit
impair
survivor
designmethod
submaxim
predict
heart
rate
cardiopulmonari
exercis
test
neurocognit
perform
compar
survivor
femal
mean
rang
age
diagnosi
year
age
evalu
year
control
femal
age
evalu
year
within
survivor
multivari
model
test
associ
peak
oxygen
uptak
neurocognit
domain
adjust
sex
age
diagnosi
cranial
radiat
anthracyclin
exposur
tobacco
smoke
statu
result
survivor
wors
peak
oxygen
uptak
vs
milliliterskilogramminut
mlkgmin
p
perform
verbal
intellig
vs
verbal
fluenci
vs
work
memori
vs
motor
speed
vs
vs
visual
speed
vs
memori
span
vs
read
vs
math
vs
measur
p
control
adjust
model
metabol
equival
increas
exercis
toler
associ
increas
standard
deviat
perform
verbal
intellig
verbal
fluenci
p
work
memori
domin
motor
speed
p
motor
speed
p
speed
p
memori
span
p
read
academ
p
math
academ
p
survivor
conclus
studi
demonstr
fit
level
significantli
lower
survivor
childhood
peer
clear
associ
fit
level
neurocognit
outcom
intellig
execut
function
process
speed
memori
academ
perform
j
pierzynski
n
kr
dk
mm
ic
jude
children
research
hospit
epidemiolog
cancer
control
memphi
usa
jude
children
research
hospit
depart
oncolog
memphi
usa
jude
children
research
hospit
biostatist
memphi
usa
backgroundobject
background
limit
studi
evalu
health
qualiti
life
form
qualiti
life
measur
consid
societ
prefer
childhood
cancer
survivor
aim
compar
health
util
score
adult
survivor
childhood
cancer
gener
popul
identifi
risk
factor
decreas
health
util
among
survivor
designmethod
method
studi
particip
includ
sjlife
studi
survivor
detail
treatment
exposur
abstract
medic
record
chronic
condit
evalu
comprehens
medic
examin
complet
health
survey
health
util
estim
use
compar
norm
data
us
medic
expenditur
panel
survey
treatment
exposur
includ
chemotherapi
corticosteroid
platinum
anthracyclin
alkyl
agent
vincristin
radiotherapi
brain
chest
abdomen
pelvi
invas
surgeri
symptom
preval
measur
domain
sensat
abnorm
movement
problem
cardiac
pulmonari
problem
pain
memori
anxieti
depress
survivor
health
util
compar
norm
data
use
multipl
linear
regress
perform
test
effect
treatment
chronic
condit
symptom
preval
health
util
among
survivor
result
result
survivor
mean
age
survey
year
mean
time
diagnosi
year
health
util
score
survivor
lower
norm
cohen
effect
size
indic
meaning
differ
survivor
hodgkin
lymphoma
central
nervou
system
malign
sarcoma
wors
health
util
leukemia
survivor
p
multivari
analys
indic
femal
p
health
insur
p
peripher
neuropathi
p
skelet
disord
p
diabet
p
associ
lower
health
util
symptom
domain
associ
lower
health
util
p
conclus
adult
survivor
childhood
cancer
experi
wors
health
util
popul
norm
relat
chronic
symptom
condit
j
pierzynski
jl
b
kr
cb
mm
j
ic
jude
children
research
hospit
epidemiolog
cancer
control
memphi
usa
hospit
philadelphia
divis
gener
pediatr
philadelphia
usa
jude
children
research
hospit
depart
pediatr
medicin
memphi
usa
jude
children
research
hospit
oncolog
memphi
usa
backgroundobject
backgroundobject
outcom
pro
measur
valid
use
pediatr
cancer
survivor
care
aim
test
content
valid
four
pediatr
measur
outcom
measur
inform
system
promi
among
survivor
pediatr
cancer
caregiv
designmethod
designmethod
live
experi
four
domain
fatigu
stress
posit
affect
pain
interfer
elicit
interview
among
survivor
year
therapi
year
sinc
diagnosi
year
age
primari
caregiv
transcrib
interview
code
meaning
concept
two
research
correl
coeffici
calcul
base
wordsphras
use
survivor
caregiv
respect
posit
correl
coeffici
indic
usag
survivor
caregiv
neg
coeffici
otherwis
linear
semant
analysi
multidimension
scale
conduct
test
meaning
concept
spatial
cluster
base
frequenc
wordsphras
use
survivor
caregiv
result
result
fatigu
stress
posit
affect
pain
domain
common
concept
report
survivor
need
sleep
day
felt
worri
felt
happi
hurt
lot
respect
top
wordsphras
use
caregiv
felt
tire
felt
distress
felt
happi
hurt
lot
respect
overal
wordsphras
associ
fatigu
pain
stress
posit
affect
use
children
across
domain
caregiv
use
wordsphras
object
content
eg
pain
bad
take
medicin
contrast
survivor
use
subject
content
eg
scare
spatial
analysi
suggest
clear
separ
meaning
concept
elicit
survivor
caregiv
conclus
conclus
import
differ
pro
theme
identifi
among
survivor
caregiv
four
domain
find
help
improv
content
valid
promi
measur
pediatr
cancer
survivor
prasad
h
g
g
p
memori
hospit
paediatr
oncolog
mumbai
india
memori
hospit
clinic
psycholog
mumbai
india
hospit
paediatr
oncolog
mumbai
india
backgroundobject
survivor
childhood
cancer
cc
need
lifelong
detect
late
effect
treatment
mani
known
develop
adulthood
adher
known
drop
time
especi
adolesc
young
adult
aya
cc
access
special
clinic
expenditur
low
awar
societ
attitud
barrier
survivorship
care
set
attempt
prospect
identifi
reason
delay
clinic
attend
aya
cc
designmethod
aya
cc
attend
late
effect
clinic
past
one
year
default
one
year
schedul
visit
interview
reason
delay
clinic
demograph
inform
extract
prospect
maintain
databas
result
cc
regist
default
schedul
default
attend
past
year
aya
median
age
median
durat
femal
grade
late
effect
reason
default
includ
absenc
symptom
lack
time
due
schoolworkfamili
long
distanc
expens
travelstay
expens
hospit
social
issu
medic
issu
elsewher
amongst
femal
male
come
sinc
spous
unawar
cancer
histori
reason
return
medic
concern
routin
respons
track
call
conclus
aya
cc
often
unawar
import
regular
medic
possibl
young
age
diagnosi
current
transit
independ
live
although
hospit
abl
defray
medic
expens
financi
concern
hamper
cc
social
logist
medic
reason
educ
cc
parent
treatment
well
repeatedli
subsequ
visit
import
absenc
central
health
system
platform
social
media
messag
servic
peer
support
group
help
constantli
updat
contact
inform
track
default
c
pediatr
san
jose
costa
rica
costarricens
seguro
social
oncolog
san
jose
costa
rica
costarricens
seguro
social
pediatr
alajuela
costa
rica
backgroundobject
describ
clinic
characterist
evolut
patient
underw
splenectomi
costa
rica
nation
children
hospit
designmethod
chart
review
studi
year
period
includ
children
underw
splenectomi
costa
rica
nation
children
hospit
hundr
seven
children
age
year
old
review
obtain
clinic
present
characterist
indic
splenectomi
evolut
year
period
follow
complic
mortal
also
antibiot
prophylaxi
immun
schedul
analyz
base
intern
recommend
result
total
patient
includ
result
show
mean
age
splenectomi
perform
year
patient
splenectomi
due
hemoglobinophati
mainli
sepsi
hemorrhag
found
complic
postsplenectomi
overal
mortal
conclus
splenectomi
altern
treatment
patient
medic
traumat
diseas
overal
procedur
patient
countri
satisfactori
outcom
vaccin
antibiot
prophylaxi
recommend
follow
case
p
p
c
mainz
medic
dept
insitut
epidemiolog
medic
informat
mainz
germani
mainz
medic
dept
german
childhood
cancer
registri
insitut
biostatist
epidemiolog
medic
informat
mainz
germani
backgroundobject
due
effort
improv
cancer
therapi
children
cancer
surviv
least
five
year
late
effect
cancer
cancer
therapi
particularli
second
primari
neoplasm
spn
becom
preval
designmethod
base
data
german
childhood
cancer
registri
gccr
patient
first
neoplasm
age
surviv
least
month
first
diagnos
januari
decemb
analyz
occurr
second
primari
neoplasm
cumul
incid
estim
use
hazard
ratio
use
fine
gray
regress
subgroup
base
period
standard
incid
ratio
sir
compar
gener
german
popul
calcul
analyz
influenc
radiotherapi
risk
develop
spn
nest
initi
result
among
childhood
cancer
survivor
spn
case
observ
cumul
incid
maximum
year
interv
ci
hazard
ratio
hr
show
higher
risk
develop
spn
femal
patient
patient
system
first
neoplasm
standard
incid
ratio
sir
compar
gener
german
popul
period
femal
male
therapi
data
subgroup
patient
analyz
patient
receiv
radiotherapi
mean
prescrib
dose
gray
conclus
keep
rise
rise
age
patient
radiat
therapi
chemotherapi
sex
age
exposur
show
statist
signific
influenc
spn
risk
investig
aim
identifi
individu
biolog
risk
factor
might
determin
risk
secondari
cancer
survivor
childhood
malign
r
seth
n
j
pediatr
delhi
india
pediatr
new
delhi
india
backgroundobject
childhood
cancer
survivor
studi
report
major
survivor
receiv
medic
care
report
care
focus
prior
cancer
report
survivor
focus
care
includ
advic
risk
reduct
consid
screen
test
concept
area
focu
develop
countri
aim
prepar
determin
util
treatment
complet
card
atcc
childhood
cancer
survivor
designmethod
bilingu
atcc
card
given
pediatr
cancer
survivor
detail
treatment
chemotherapi
radiationsurgeryoth
risk
factor
stage
diseas
note
possibl
late
effect
modal
follow
assess
determin
card
messag
emphasis
child
well
fit
go
school
growth
need
monitor
vaccin
must
resum
follow
need
result
children
receiv
atcc
card
major
come
regular
follow
month
follow
go
school
got
vaccin
growth
monitor
done
late
effect
monitor
via
atcc
card
growth
retard
found
behaviour
problem
common
acut
leukemia
survivor
cardiotox
present
retinoblastoma
survivor
late
effect
relat
chemotherapi
radiat
enucl
conclus
atcc
use
adapt
centr
india
also
need
sensit
cancer
survivor
famili
health
profession
toward
exist
natur
late
effect
atcc
give
comprehens
summari
cancer
treatment
receiv
childhood
late
effect
may
occur
monitor
card
medic
document
must
extrem
valu
readili
avail
refer
patient
care
giver
r
seth
g
r
n
p
p
j
pediatr
delhi
india
gandhi
cancer
institut
research
centr
oncolog
new
delhi
india
hospit
saket
pediatr
oncolog
new
delhi
india
pediatr
lucknow
india
hospit
pediatr
oncolog
new
delhi
india
kalawati
hospit
pediatr
new
delhi
india
trivandrum
pediatr
oncolog
trivandrum
india
kolkata
pediatr
oncolog
kolkata
india
pediatr
oncolog
chennai
india
backgroundobject
advanc
treatment
childhood
cancer
result
grow
popul
childhood
cancer
survivor
prioriti
area
pediatr
oncolog
commun
care
childhood
cancer
survivor
monitor
late
effect
hitherto
neglect
area
india
limit
data
preval
late
effect
besid
registri
childhood
cancer
survivor
exist
india
propos
establish
multicentr
registri
children
complet
cancer
treatment
phase
determin
spectrum
late
effect
childhood
cancer
survivor
formul
recommendationsguidelin
long
term
follow
indian
childhood
cancer
survivor
phase
designmethod
children
complet
treatment
enrol
phase
studi
registri
demograph
treatment
detail
cumul
dose
chemotherapyradi
record
follow
plan
month
phoneteleconsultationphys
evalu
document
remissionrelaps
end
two
year
survivor
elig
phase
wherein
spectrum
late
effect
evalu
result
report
data
phase
registri
nine
centr
across
india
particip
centr
recruit
six
hundr
patient
enrol
median
age
year
rang
year
major
male
commonest
malign
acut
leukemia
follow
lymphoma
retinoblastoma
major
belong
middl
strata
modifi
kuppuswami
scale
period
follow
rang
month
median
month
major
follow
relaps
seen
phase
ii
report
late
effect
conclus
studi
provid
use
epidemiolog
data
childhood
cancer
survivor
long
term
follow
demonstr
profil
late
effect
occur
childhood
cancer
survivor
culmin
form
recommendationsguidelin
long
term
follow
children
india
c
signorelli
c
k
j
b
e
k
wh
r
children
hospitalunsw
sydney
kid
cancer
centr
sydney
australia
sydney
children
hospit
kid
cancer
centr
randwick
australia
road
doctorswellac
lifestyl
well
cancer
bondi
sydney
australia
wale
hospitalunsw
sydney
depart
medic
oncologyn
centr
cancer
survivorship
sydney
australia
hospit
sick
children
depart
hematologyoncolog
edinburgh
unit
kingdom
backgroundobject
mani
childhood
cancer
survivor
disengag
long
term
ltfu
care
despit
increas
import
surveil
second
malign
late
effect
age
assess
ltfu
barrier
pilot
target
intervent
call
designmethod
australian
new
zealand
survivor
parent
survivor
complet
survey
option
interview
ltfu
barrier
use
survey
result
design
current
pilot
disengag
survivor
ie
access
care
result
total
particip
complet
survey
survivor
mean
age
mean
time
sinc
diagnosi
parent
child
mean
age
mean
time
sinc
diagnosi
survivor
disengag
ltfu
report
significantli
greater
dissatisfact
care
receiv
outsid
tertiari
cancer
center
compar
engag
survivor
p
disengag
survivor
endors
barrier
attend
ltfu
includ
cost
p
distanc
clinic
p
unawar
ltfu
p
decreas
clinic
attend
significantli
like
older
survivor
report
higher
total
number
barrier
ltfu
p
design
address
barrier
ehealth
intervent
disengag
survivor
improv
date
pilot
survivor
male
mean
age
year
endors
benefici
remain
littl
bit
burdensom
half
disengag
survivor
late
effect
second
malign
earli
data
show
improv
survivor
conclus
data
uniqu
first
identifi
barrier
use
data
develop
target
intervent
appear
accept
survivor
may
potenti
promot
proport
survivor
pilot
sampl
highlight
critic
need
engag
survivor
appropri
c
ak
singh
p
survivor
group
new
delhi
india
backgroundobject
childhood
cancer
survivor
face
late
lt
side
effect
employ
insur
issu
often
lack
consist
lt
care
present
develop
countri
like
india
survivorship
servic
underdevelop
area
kidscan
survivor
group
kck
strive
improv
servic
avail
survivor
order
address
system
servic
knowledg
gap
experienc
survivor
kck
develop
innov
survivor
passport
program
educ
survivor
late
effect
help
proper
document
need
regular
designmethod
step
educ
brainstorm
stakehold
meet
survivor
parent
reproduct
medicin
specialist
paediatr
oncologist
held
dec
new
delhi
step
survivor
treatment
document
collat
soft
hard
copi
project
servic
option
describ
survivor
step
exist
methodspractic
inform
dissemin
survivor
discuss
step
global
indian
practic
center
review
provid
inform
discuss
decid
survivor
passport
step
subsequ
conduct
survivor
passport
clinic
workshop
time
delhi
kolkata
ahmedabad
focus
issu
childhood
cancer
result
develop
survivor
passport
treatment
complet
card
survivor
monitor
studi
includ
inform
demographi
treatment
summari
exposur
plan
follow
well
socio
econom
psycholog
issu
survivor
attend
clinic
passport
issu
nt
known
lt
side
effect
agre
regular
follow
workshop
conclus
purpos
start
made
develop
passport
address
need
ctya
survivor
india
plan
provid
full
fledg
servic
model
passport
onlin
kck
member
survivor
tahir
childhood
cancer
foundat
cancer
buster
commun
survivor
jakarta
indonesia
backgroundobject
cbc
biggest
childhood
cancer
survivor
commun
indonesia
establish
umbrella
yayasan
onkolog
anak
indonesia
yoai
everi
year
cbc
support
yoai
endeavor
develop
new
program
promot
encourag
patient
year
decid
take
new
approach
celebr
intern
childhood
cancer
day
littl
artisan
project
past
experi
childhood
cancer
patient
understand
well
key
essenti
one
abl
undergo
intens
oner
medic
treatment
howev
consid
condit
patient
certainli
easi
alway
maintain
happi
littl
artisan
project
initi
improv
preserv
content
patient
creativ
product
designmethod
engag
renown
art
commun
jakarta
call
ruangrupa
hold
workshop
program
offer
variou
art
craft
activ
patient
got
choos
one
activ
found
interest
repres
ruangrupa
assist
member
cbc
taught
help
patient
work
complet
work
result
patient
particip
workshop
includ
children
teenag
excit
enthusiast
realiz
abil
produc
artwork
like
children
also
delight
abl
meet
share
new
experi
patient
survivor
mani
patient
satisfi
even
request
anoth
similar
event
held
conclus
order
motiv
patient
found
effici
meaning
encourag
engag
activ
prove
product
abil
also
conclud
patient
happi
realiz
differ
children
tan
c
k
women
children
hospit
paediatr
subspecialti
haematologyoncolog
servic
singapor
singapor
backgroundobject
kkh
one
two
main
children
cancer
centr
singapor
see
new
diagnos
year
survivorship
programm
start
philanthrop
fund
children
cancer
foundat
ccf
paediatr
cancer
survivorship
programm
establish
team
consist
paediatr
oncologist
nurs
coordin
clinic
psychologist
data
manag
aim
report
describ
earli
experi
seen
pilot
cohort
designmethod
survivor
identifi
singapor
childhood
cancer
registri
captur
epidemiolog
treatment
outcom
paediatr
oncolog
patient
seen
public
hospit
sinc
patient
defin
aliv
complet
remiss
year
diagnosi
pilot
cohort
seen
clinic
includ
patient
age
year
cumul
treatment
detail
signific
medic
issu
enter
passport
care
tm
portal
internet
base
tool
develop
baylor
colleg
medicin
cog
gener
individualis
treatment
summari
care
plan
result
survivor
kkh
lost
follow
march
clinic
seen
survivor
case
leukaemia
cn
tumour
leukaemia
survivor
rang
year
chronic
health
problem
spectrum
late
effect
experienc
rang
asymptomat
low
oestradiol
level
osteopaenia
sever
organ
dysfunct
includ
respiratori
fibrosi
cataract
leukaemia
patient
complet
least
secondari
school
educ
see
fair
number
default
clinic
conclus
earli
result
show
mani
survivor
chronic
health
condit
util
electron
tool
standard
practic
survivor
educ
import
increas
attend
clinic
primari
prevent
earli
intervent
help
survivor
maximis
qualiti
life
p
trehan
r
n
graduat
institut
medic
educ
depart
chandigarh
india
hematolog
oncolog
depart
post
graduat
institut
medic
educ
chandigarh
india
hematolog
oncolog
post
graduat
institut
medic
educ
depart
pediatr
chandigarh
india
graduat
institut
medic
educ
pediatr
hematolog
oncolog
pediatr
chandigarh
india
graduat
institut
medic
educ
depart
radiolog
chandigarh
india
backgroundobject
childhood
cancer
survivor
cc
modifi
long
term
complic
alter
bodi
composit
physic
activ
nutrit
statu
prevent
long
term
effect
analyz
cc
designmethod
thirti
adolesc
young
adult
treat
acut
lymphoblast
leukemia
therapi
year
age
match
control
evalu
bodi
composit
assess
anthropometri
dexa
scan
physic
activ
gaug
per
cdc
criteria
nutrit
intak
calcul
food
frequenc
questionnair
result
thirti
patient
diagnos
boy
girl
evalu
year
therapi
diagnosi
normal
weight
underweight
stunt
mean
bmi
evalu
underweight
normal
bmi
overweight
obes
mean
bmi
increas
significantli
p
case
control
similar
bmi
p
three
fourth
survivor
adequ
carbohydr
protein
intak
fat
intak
satisfactori
calcium
intak
suffici
case
nutrit
similar
cc
control
seventeen
cc
osteopenia
osteoporosi
case
bmd
abnorm
inadequ
calcium
intak
physic
activ
better
control
p
cc
moderatevigor
vigor
activ
compar
control
moderatevigor
vigor
activ
diet
associ
bmi
physic
inact
associ
bmi
fat
masslean
mass
signific
p
conclus
cc
control
note
defici
nutrit
especi
calcium
physic
activ
significantli
less
cc
bone
miner
densiti
low
survivor
find
indic
need
target
intervent
cc
healthi
futur
high
preval
low
bmd
need
research
j
van
atteveld
k
w
l
van
den
c
center
pediatr
oncolog
pediatr
late
effect
utrecht
netherland
jude
children
research
hospit
epidemiologycanc
pediatr
medicin
memphi
usa
jude
children
research
hospit
epidemiologycanc
cancer
control
survivorship
program
memphi
usa
jude
children
research
hospit
pediatr
st
jude
graduat
school
biomed
scienc
memphi
usa
jude
children
research
hospit
diagnost
oncolog
memphi
usa
jude
children
research
hospit
epidemiologycanc
comprehens
cancer
cancer
control
survivorship
program
memphi
usa
center
pediatr
oncolog
late
effect
utrecht
netherland
jude
children
research
hospit
epidemiologycanc
control
memphi
usa
backgroundobject
although
low
bone
miner
densiti
bmd
preval
among
adult
survivor
childhood
cancer
guidanc
surveil
low
bmd
among
survivor
dual
absorptiometri
dxa
limit
therefor
aim
develop
valid
predict
model
base
patient
treatment
characterist
identifi
adult
survivor
requir
screen
dxa
designmethod
caucasian
survivor
median
attain
age
rang
year
enrol
st
jude
lifetim
cohort
sjlife
develop
survivor
valid
previous
treat
erasmu
medic
center
netherland
median
age
rang
year
evalu
dxa
determin
lumbar
spine
bmdl
total
bodi
bmdtb
bmd
low
bmd
defin
bmdl
andor
bmdtb
backward
multivari
logist
regress
use
build
predict
model
perform
assess
use
receiv
oper
characterist
curv
diagnost
valu
calcul
differ
probabl
formula
plowbmd
xn
xn
use
predict
individu
probabl
low
bmd
coeffici
predictor
xn
result
low
bmd
preval
among
sjlife
dutch
particip
model
includ
male
sex
height
weight
age
cancer
diagnosi
current
smoke
cranial
irradi
signific
predictor
area
curv
sjlife
dutch
cohort
sensit
specif
accuraci
optim
probabl
correspond
posit
neg
predict
valu
point
survivor
predict
low
bmd
conclus
valid
model
includ
sex
age
diagnosi
height
weight
smoke
statu
prior
exposur
cranial
radiat
correctli
identifi
bmd
statu
nearli
caucasian
adult
survivor
age
year
clinic
applic
warrant
onlin
calcul
al
van
der
kooi
r
c
van
den
j
h
r
mc
sophia
children
hospit
obstetr
gynecolog
rotterdam
netherland
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
nation
servic
scotland
inform
servic
divis
edinburgh
unit
kingdom
nation
servic
scotland
inform
servic
divis
edri
edinburgh
unit
kingdom
hospit
sick
children
depart
oncolog
haematolog
edinburgh
unit
kingdom
edinburgh
mrc
centr
reproduct
health
edinburgh
unit
kingdom
backgroundobject
advanc
cancer
manag
result
improv
surviv
rate
howev
treatment
may
advers
affect
reproduct
outcom
among
femal
survivor
cancer
fsc
examin
risk
advers
pregnanc
perinat
outcom
compar
gener
popul
designmethod
pregnanc
perinat
complic
identifi
linkag
scottish
cancer
registri
hospit
discharg
record
base
commun
health
index
chi
databas
identifi
fsc
age
nullipar
cancer
diagnosi
first
subsequ
pregnanc
three
control
match
age
year
cancer
diagnosi
depriv
quintil
select
chi
rel
risk
interv
perinat
risk
calcul
use
regress
result
total
singleton
first
birth
fsc
compar
singleton
birth
control
women
fsc
like
give
birth
week
gestat
rr
risk
deliv
low
birthweight
offspr
rr
decreas
risk
deliv
offspr
small
gestat
age
rr
childhood
cancer
survivor
cc
diagnos
age
year
three
time
like
undergo
elect
caesarean
section
rr
increas
risk
postpartum
haemorrhag
pph
rr
mark
chang
period
diagnosi
risk
normal
recent
diagnosi
risk
congenit
abnorm
increas
rr
conclus
fsc
risk
prematur
deliveri
small
gestat
age
congenit
abnorm
cc
increas
risk
pph
elect
caesarean
section
heighten
alert
care
manag
fsc
appropri
mark
normal
mode
deliveri
recent
decad
vuotto
k
c
f
n
k
r
w
k
l
g
colleg
mount
saint
vincent
depart
psycholog
new
york
usa
jude
children
research
hospit
depart
epidemiolog
cancer
control
memphi
usa
jude
children
research
hospit
depart
biostatist
memphi
usa
children
cancer
texa
children
hospit
depart
pediatr
houston
usa
univers
texa
southwestern
medic
school
depart
pediatr
dalla
usa
children
hospit
depart
neurolog
boston
usa
univers
texa
anderson
cancer
center
depart
radiat
physic
houston
usa
hutchinson
cancer
research
center
divis
public
health
scienc
seattl
usa
univers
medic
center
divis
medic
depart
medicin
commun
famili
medicin
durham
usa
backgroundobject
survivor
childhood
cancer
receiv
central
nervou
system
cn
therapi
risk
neurolog
sequela
may
advers
impact
psycholog
function
independ
adulthood
designmethod
particip
includ
survivor
childhood
cancer
treat
cranial
radiat
intrathec
methotrex
cytarabin
leukemia
cn
tumor
mean
standard
deviat
age
year
time
sinc
diagnosi
year
neurolog
condit
includ
stroke
seizur
sensori
deficit
focal
neurolog
dysfunct
sever
headach
emot
distress
symptom
measur
includ
anxieti
depress
suicid
ideat
si
function
independ
assess
use
latent
class
analysi
six
indic
independ
live
assist
routin
need
assist
person
care
need
abil
attend
workschool
driver
licens
marit
statu
multivari
regress
model
adjust
age
sex
race
pain
health
statu
estim
rel
risk
rr
odd
ratio
associ
neurolog
morbid
emot
distress
function
independ
result
preval
neurolog
condit
stroke
seizur
sensori
deficit
focal
neurolog
dysfunct
sever
headach
multivari
model
risk
emot
distress
associ
focal
neurolog
dysfunct
anxieti
confid
interv
ci
depress
sensori
deficit
anxieti
depress
si
sever
headach
anxieti
depress
si
stroke
seizur
focal
neurolog
deficit
associ
decreas
likelihood
function
independ
conclus
childhood
cancer
survivor
develop
neurolog
morbid
emot
distress
symptom
includ
suicid
ideat
failur
attain
independ
adulthood
c
willi
j
hospit
children
paediatr
oncolog
glasgow
unit
kingdom
backgroundobject
infantil
tumour
rare
tumour
biolog
infant
differ
older
children
therefor
respons
treatment
surviv
outcom
may
also
differ
object
review
determin
number
infant
diagnos
tumour
benign
malign
exclud
haematolog
diagnosi
year
period
surviv
outcom
five
year
interv
compar
designmethod
retrospect
patient
record
review
infant
year
age
tumour
diagnosi
fifteen
year
period
jan
perform
use
electron
patient
record
databas
patient
identifi
boy
girl
data
collat
includ
benign
solid
cn
group
diagnosi
age
diagnosi
follow
time
period
surviv
outcom
relaps
rate
overal
surviv
comparison
made
result
mean
age
diagnosi
day
day
seventi
four
patient
solid
tumour
fifti
four
malign
eighteen
cn
tumour
fifteen
patient
neuroblastoma
account
malign
solid
tumour
overal
relaps
rate
infant
relaps
rate
highest
patient
neuroblastoma
relaps
patient
surviv
overal
mortal
rate
patient
solid
tumour
benign
malign
patient
cn
tumour
surviv
rate
patient
benign
malign
follow
period
rang
day
year
conclus
solid
tumour
common
cn
tumour
infant
neuroblastoma
commonest
tumour
infant
associ
highest
relaps
rate
last
decad
improv
overal
surviv
infant
diagnos
tumour
report
h
ani
l
r
p
palli
care
psycho
oncolog
depart
new
delhi
india
qualiti
care
research
impact
depart
new
delhi
india
palli
care
new
delhi
india
palli
care
depart
new
delhi
india
backgroundobject
address
servic
gap
primari
treat
center
aris
patient
overload
holidaysweekend
cankid
pediatr
palli
care
center
delhi
provid
children
cancer
inpati
admiss
ambulatori
care
iv
antibiot
cankid
social
support
servic
gener
offer
object
servic
run
stop
social
support
clinic
provid
holist
care
strengthen
palli
care
outpati
inpati
servic
designmethod
pilot
phase
clinic
supplement
ambulatori
care
servic
addit
access
pain
symptom
wound
manag
psycholog
nutrit
counsel
physiotherapi
educ
financi
support
patient
navig
along
care
giver
educ
train
profession
team
clinic
oper
seven
day
week
clinic
provid
servic
provid
train
patient
navig
referr
standard
oper
procedur
patient
data
manag
result
total
patient
receiv
episod
care
patient
receiv
palliat
symptom
indic
inpati
admiss
end
life
care
new
inpati
admiss
clinic
patient
came
iv
ambulatori
care
receiv
social
support
servic
includ
pain
symptom
manag
psycholog
nutrit
hematolog
support
physiotherapi
medic
assist
investig
educ
scholarship
patient
care
train
session
attend
caregiv
particip
extrem
satisfi
satisfi
servic
provid
conclus
well
run
social
support
clinic
togeth
multi
disciplinari
team
includ
palli
care
physician
nurs
psychologist
nutritionist
physiotherapist
patient
navig
pediatr
palli
care
center
provid
enhanc
holist
care
better
understand
accept
palli
care
also
provid
platform
time
parent
educ
care
child
treatment
home
hospit
set
cecil
lc
j
dy
dm
cancer
registri
network
research
assist
kigali
rwanda
de
treichevil
servic
doncologi
pediatriqu
abidjan
ivori
coastr
de
brazzavil
cancerologi
medical
brfazzavil
congo
de
ouagadoug
ouagadoug
burkina
faso
cancer
registri
network
consultantproject
manag
monpelli
franc
african
cancer
registri
network
oxford
unit
kingdom
backgroundobject
inform
occurr
surviv
cancer
popul
level
obtain
cancer
registri
studi
cancer
children
africa
even
difficult
adult
rel
rariti
cancer
occur
age
fact
registri
sub
saharan
africa
cover
limit
usual
urban
popul
partnership
child
matter
programm
sanofi
foundat
african
cancer
registri
network
pilot
project
enhanc
childhood
cancer
registr
contin
designmethod
first
year
registri
two
countri
cote
divoir
republ
congo
expand
scope
becom
nation
registri
paediatr
cancer
new
registri
nation
paediatr
registri
burkina
faso
establish
staff
registri
train
record
stage
diagnosi
childhood
cancer
use
tier
classif
toronto
consensu
principl
special
code
manual
develop
two
long
stand
anglophon
registri
harar
kampala
also
train
stage
cancer
patient
regist
carri
centr
estim
surviv
result
childhood
cancer
profil
differ
centr
kaposi
sarcoma
remain
common
childhood
tumour
east
africa
burkitt
lymphoma
common
uganda
cote
divoir
common
solid
tumour
west
africa
retinoblastoma
wilm
tumour
common
east
africa
surviv
rather
poor
less
half
case
aliv
year
diagnosi
role
stage
determin
poor
outcom
investig
conclus
registr
childhood
cancer
feasibl
africa
proper
train
support
provid
valuabl
data
incid
stage
surviv
jm
choe
jm
associ
children
leukemia
cancer
health
support
bureau
seoul
republ
korea
backgroundobject
kaclc
would
like
present
case
base
emerg
trend
survivorship
care
program
year
cci
confer
childhood
cancer
increas
childhood
cancer
experienc
becom
vital
issu
childhood
cancer
center
activ
focus
build
intern
strength
past
nowaday
put
weight
take
individu
need
beyond
overcom
individu
treatment
experi
recent
experienc
wish
share
return
experi
public
valu
designmethod
network
teenag
young
adult
childhood
cancer
experi
age
korea
support
kaclc
network
hold
monthli
meet
recruit
new
member
yearli
vision
support
healthi
social
childhood
cancer
experienc
set
detail
direct
proceed
activ
establish
speak
experi
contribut
societi
result
carri
variabl
activ
volunt
social
rehabilit
childhood
cancer
experienc
peopl
children
cancer
intern
extern
mentor
public
campaign
improv
awar
childhood
cancer
end
took
report
meet
korea
japan
make
known
public
activ
childhood
cancer
experi
network
korea
share
result
directli
involv
network
conclus
activ
member
establish
ident
childhood
cancer
experienc
learn
accept
individu
experi
sound
way
build
empathi
fellowship
one
anoth
furthermor
social
particip
activ
laid
foundat
growth
independ
member
societi
p
close
espoir
foundat
child
grant
mentor
california
usa
children
research
hospit
depart
pediatr
global
medicin
memphi
usa
espoir
foundat
medic
director
pari
franc
backgroundobject
background
lmic
commonli
lower
cure
rate
pediatr
cancer
due
limit
govern
fund
healthcar
infrastructur
access
specialti
care
rural
area
thu
need
build
capac
effect
manag
pain
symptom
children
may
succumb
cancer
provid
cultur
appropri
support
famili
throughout
treatment
compel
designmethod
method
child
matter
grant
initi
support
improv
pediatr
cancer
program
lmic
provid
competit
fund
grant
countri
sinc
grant
includ
option
develop
palli
care
train
model
care
deliveri
expert
mentor
provid
support
leadership
train
countri
region
andor
institut
encourag
develop
cultur
train
care
model
includ
core
palli
medicin
knowledg
psychosoci
spiritu
care
skill
develop
result
result
lmic
pediatr
oncolog
grant
recipi
demonstr
signific
interest
develop
palli
medicin
capac
parallel
improv
pediatr
cancer
care
total
pediatr
train
profession
includ
eight
thailand
two
bangladesh
four
guatemala
one
nicaragua
hondura
haiti
panama
dominican
republ
physiciannurs
team
fifteen
francophon
countri
africa
travel
center
outsid
countri
palli
medicin
train
addit
document
impact
includ
establish
nation
treatment
guidelin
pediatr
relat
palli
care
develop
new
palli
care
unit
team
pediatr
cancer
center
new
medic
school
compet
numer
nurs
train
cours
enhanc
avail
use
oral
morphin
pediatr
cancer
patient
end
life
languag
public
profession
parent
produc
local
nation
intern
collabor
expand
conclus
philanthrop
support
develop
pediatr
oncolog
palli
care
lmic
demonstr
accept
benefici
impact
figueredo
j
de
ciencia
universidad
nacion
de
san
lorenzo
paraguay
jude
children
research
hospit
depart
global
pediatr
medicin
depart
infecti
diseas
memphi
usa
tennesse
health
scienc
colleg
medicin
depart
pediatr
memphi
usa
espoir
foundat
child
matter
program
pari
franc
backgroundobject
paraguay
lower
countri
million
peopl
mortal
rate
live
birth
cancer
caus
death
children
age
year
popul
live
nation
poverti
line
access
healthcar
health
system
fragment
almost
nil
coordin
health
servic
act
isol
without
articul
pediatr
cancer
center
locat
close
capit
pediatr
cancer
network
implement
paraguay
childhood
cancer
care
network
renaci
auspic
sanofi
espoir
foundat
child
matter
programm
goal
network
decentr
care
children
cancer
establish
sustain
region
pediatr
satellit
clinic
earli
cancer
detect
referr
treatment
social
assist
pediatr
patient
cancer
designmethod
retrospect
descript
studi
transvers
section
use
registri
patient
childhood
cancer
januari
decemb
result
number
patient
evalu
year
satellit
clinic
increas
begin
project
year
total
number
consult
increas
satellit
clinic
respons
attend
total
number
patient
evalu
satellit
clinic
patient
refer
central
hospit
suspect
oncolog
diseas
confirm
patient
conclus
renaci
network
improv
access
medic
care
pediatr
patient
suspect
hematolog
oncolog
diseas
establish
system
referr
satellit
clinic
clinic
allow
medic
social
support
child
famili
closer
home
entir
treatment
period
e
grynszpancholc
dafn
flexer
presid
bueno
air
argentina
dafn
flexer
psycholog
bueno
air
argentina
backgroundobject
dafn
flexer
fndf
provid
direct
servici
thousand
famili
per
month
come
citi
receiv
treatment
emot
support
servici
enough
biggest
hospit
argentina
avail
provid
whole
famili
fndf
locat
close
main
hospit
locat
interior
countri
bereav
parent
group
start
sinc
fndf
record
pathway
famili
affect
childhood
cancer
designmethod
propos
famili
includ
meet
group
hour
long
everi
day
particip
parent
variou
stage
bereav
group
particip
coordin
psychologist
questionnair
fill
start
end
group
period
particip
result
meet
start
famili
particip
sinc
differ
group
mainli
mother
sibl
group
start
last
year
grandpar
meet
coupl
group
also
requir
start
whatsapp
psycholog
support
interior
countri
group
experienc
mother
abl
support
mother
particip
extern
congress
meet
frequent
requir
institut
receiv
orient
profession
conclus
servic
need
famili
lost
bereav
group
avail
focus
lost
childhood
cancer
treatment
desir
affect
knowledg
frequent
issu
rais
meet
use
inform
new
technolog
use
next
challeng
need
explor
knowledg
experi
record
base
lead
chang
law
promot
avail
servic
hospit
kamgar
societi
support
children
suffer
cancer
public
intern
relat
depart
tehran
iran
backgroundobject
mahak
organ
establish
goal
serv
human
combat
pediatr
cancer
nation
intern
medic
care
research
support
servic
depend
exclus
public
support
past
year
mahak
agenda
consist
geograph
physic
expans
improv
qualiti
quantiti
servic
human
resourc
develop
might
best
sum
two
word
sustain
develop
designmethod
mahak
assess
need
develop
plan
attract
support
public
order
address
concern
children
famili
improv
qualiti
live
order
reach
point
provid
integr
servic
across
iran
develop
infrastructur
accord
intern
standard
expans
digit
commun
implement
joint
research
project
focus
childhood
cancer
mahak
main
strateg
plan
result
accord
strateg
plan
devis
reach
goal
deliv
integr
servic
across
countri
mahak
undertaken
variou
method
hold
intern
congress
role
support
servic
multidisciplinari
treatment
childhood
cancer
novemb
presenc
head
intern
societi
pediatr
oncolog
siop
along
differ
nation
intern
speaker
explor
innov
best
practic
childhood
cancer
care
line
outcom
congress
mahak
plan
strateg
project
meet
goal
end
sinc
mention
strateg
plan
launch
mahak
deliv
comprehens
report
outcom
implement
program
conclus
mahak
believ
goal
strateg
plan
met
close
collabor
cci
member
along
alik
organ
across
globe
sa
kim
korea
feder
childhood
cancer
parent
organ
famili
children
cancer
bureau
seoul
republ
korea
backgroundobject
cci
confer
theme
engag
mobil
stakehold
organiz
growth
sustain
impact
societi
prejudic
peopl
experienc
leukemia
childhood
cancer
treatment
experienc
fought
diseas
studi
although
treatment
finish
social
prejudic
hamper
school
employ
love
designmethod
campaign
nation
pilgrimag
peopl
treat
leukem
childhood
cancer
famili
march
jeju
southernmost
island
northernmost
mt
baekdu
korea
everi
year
held
time
week
octob
angel
day
year
set
theme
dress
color
design
walk
around
chant
slogan
even
gather
hotel
discuss
identifi
issu
experienc
person
psycholog
state
sibl
difficulti
caregiv
took
care
consid
solut
issu
also
subject
follow
year
result
campaign
chang
us
societi
mani
way
particip
open
close
mind
start
get
readi
go
societi
someon
fell
love
got
licens
came
courag
challeng
dream
broadcast
media
local
commun
also
interest
movement
societi
chang
pediatr
ward
establish
place
childhood
cancer
hospit
mou
nation
public
corpor
conduct
survey
social
welfar
servic
group
conclus
bring
awar
public
readi
anyth
healthi
bodi
mind
give
hope
courag
injur
experienc
famili
keep
develop
campaign
k
kimura
cancer
associ
japan
niigata
branch
murakami
japan
backgroundobject
ccaj
niigata
branch
one
region
chapter
children
cancer
associ
japan
provid
support
children
famili
place
niigata
cancer
center
hospit
core
base
activ
howev
activ
becam
inact
due
fixat
support
member
repeat
discuss
way
revit
organ
designmethod
member
experi
treatment
childhood
cancer
discuss
requir
support
hospit
creat
action
plan
specif
implement
tea
parti
month
parent
stay
hospit
order
exercis
peer
support
staff
took
care
children
parent
could
easili
particip
tea
parti
result
abl
provid
parent
pleasant
time
relax
commun
parti
contribut
increas
parent
took
posit
attitud
medic
treatment
children
fact
abl
refresh
parent
mind
listen
concern
given
satisfact
confid
support
particip
tea
parti
also
could
improv
enhanc
skill
encourag
parent
children
suffer
cancer
conclus
stagnat
activ
start
member
immobil
neg
prospect
atmospher
afraid
failur
import
thing
produc
activ
plan
support
member
feel
accomplish
support
parent
hospit
children
need
japan
bring
heavi
burden
parent
case
caus
famili
breakdown
hospit
children
famili
expect
support
role
meet
expect
requir
toward
step
activ
continu
care
identifi
need
patient
n
le
cv
nt
kim
w
cancer
famili
group
central
vietnam
hue
hue
vietnam
central
hospit
pediatr
center
hue
vietnam
children
care
leagu
founder
tokyo
japan
backgroundobject
provid
support
care
children
famili
affect
cancer
vital
overcom
diseas
inspir
encourag
support
global
organ
cci
medic
institut
hue
central
hospit
ngo
accl
childhood
cancer
famili
group
central
vietnam
ccfgcv
first
famili
group
vietnam
establish
first
free
accommod
patientsfamili
open
designmethod
sinc
establish
famili
group
patientsfamili
treat
hue
central
hospit
regist
varieti
activ
carri
effect
evalu
collect
data
abandon
death
accommod
usag
sponsor
result
hospit
support
initi
famili
group
monthli
meet
collabor
medic
staff
provid
educ
parent
educ
knowledg
consciou
level
parent
keep
hygien
avoid
infect
deal
fever
higher
core
member
train
experienc
program
direct
correl
success
higher
surviv
rate
lower
abandon
rate
delay
treatment
loss
statist
usag
accommod
place
cook
stay
without
cost
show
satisfactori
level
specif
result
safe
nutriti
food
lead
patient
die
food
infect
medic
student
volunt
group
provid
compassion
care
patient
ward
activ
number
local
sponsor
increas
conclus
famili
group
play
import
role
help
patientsfamili
treatment
collabor
stakehold
lead
improv
surviv
abandon
rate
activ
famili
group
convinc
mani
local
donor
support
children
continu
effort
strengthen
organiz
capac
way
promot
model
region
vietnam
bring
benefit
enhanc
qualiti
life
children
famili
p
indonesian
anyo
foundat
yai
jakarta
indonesia
backgroundobject
indonesian
anyo
foundat
yai
ngo
childhood
cancer
play
activ
role
educ
peopl
earli
detect
childhood
cancer
provid
shelter
hous
children
cancer
indonesian
nation
health
insur
jkn
sinc
encourag
peopl
see
medic
treatment
primari
health
care
govern
bear
medic
treatment
cost
therefor
addit
educ
variou
commun
childhood
cancer
yai
also
activ
educ
medic
personnel
primari
health
care
designmethod
strateg
measur
earli
detect
childhood
cancer
patient
immedi
refer
hospit
treatment
number
pediatr
oncologist
indonesia
still
limit
indonesia
vast
countri
provinc
island
popul
million
peopl
big
challeng
yai
provid
educ
childhood
cancer
provinc
primari
health
care
facil
result
collabor
local
health
author
step
step
copi
guidebook
earli
detect
childhood
cancer
process
distribut
primari
health
care
facil
throughout
indonesia
yai
also
facilit
grant
opthalmoscop
distribut
primari
health
care
save
children
five
age
retinoblastoma
enabl
earli
detect
save
live
eye
also
vision
retinoblastoma
patient
indonesia
seek
medic
treatment
hospit
condit
advanc
make
lose
eye
use
prosthesi
conclus
hope
primari
health
care
obtain
data
suspect
children
cancer
includ
retinoblastoma
hope
effort
also
save
state
expenditur
public
health
sinc
cost
cancer
treatment
expens
especi
case
advanc
condit
r
martinez
v
doctor
pediatr
oncolog
depart
san
pedro
sula
hondura
center
pediatr
center
monza
itali
pediatr
medicin
st
jude
children
research
hospit
memphi
usa
director
foundat
pari
franc
backgroundobject
pediatr
servic
pho
mario
riva
hospit
one
two
center
care
children
cancer
hondura
center
hospit
place
outpati
clinic
receiv
new
case
pediatr
cancer
everi
year
plu
hematolog
diseas
palli
care
pc
provid
hospit
limit
delay
applic
chemotherapi
damag
cure
rate
project
reorgan
implement
support
child
matter
program
sanofi
espoir
foundat
improv
effici
care
deliveri
provid
pc
ambulatori
support
designmethod
element
industri
engin
incorpor
simplifi
organ
monitor
activ
detect
bottleneck
creat
new
workflow
relev
hospit
staff
train
audit
time
gain
conduct
hospic
open
offer
addit
place
palli
patient
entir
team
focus
find
solut
pc
outsid
hospit
whenev
possibl
result
wait
time
outpati
clinic
fell
hour
new
patient
seen
hour
referr
hospic
receiv
children
releas
day
bed
delay
administr
chemotherapi
fell
day
conclus
countri
lot
children
cancer
care
limit
resourc
improv
effici
care
vital
context
avail
outpati
pc
servic
allow
reduc
cost
improv
qualiti
life
systemat
reassess
human
materi
resourc
crucial
masumoto
k
univers
graduat
school
medicin
medic
educ
mie
japan
cancer
associ
japan
tokai
branch
aichi
japan
childhood
cancer
survivor
network
japan
fukuoka
japan
npo
secretariat
director
fukuoka
japan
tomorrow
childhood
cancer
survivor
tokyo
japan
backgroundobject
proport
improv
surviv
rate
number
childhood
cancer
survivor
increas
rapidli
everlastingli
need
support
survivor
becom
ever
import
necess
encourag
survivor
take
initi
peer
activ
foster
spirit
among
survivor
becom
also
issu
designmethod
childhood
cancer
associ
japan
ccaj
organ
childhood
cancer
survivor
ccss
meet
fellow
tomorrow
first
formal
ccss
group
establish
sinc
mani
group
establish
ccss
group
across
japan
ccaj
also
sponsor
leader
meet
leader
cc
group
shareddiscuss
activ
problem
discuss
leader
meet
consensu
reach
organ
nation
forumgroup
involv
survivor
group
individu
japan
result
nation
cc
forumgroup
form
survivor
enhanc
bond
survivor
region
cc
group
meet
held
biannual
consist
three
session
lectur
lead
pediatr
oncologist
discuss
issu
survivor
life
flow
inform
convivi
dinner
mani
issu
discuss
eg
follow
school
employ
marriag
pregnanc
activ
plan
organ
wholli
survivor
includ
rais
fund
cover
expens
ccaj
remain
strong
support
role
strictli
advisori
conclus
enabl
cc
japan
interact
directli
collect
power
enabl
particip
access
better
wider
inform
well
varieti
peer
experi
besid
primari
object
met
posit
outcom
exampl
rais
fund
survivor
bring
good
opportun
enlighten
societi
larg
includ
busi
sector
fact
concern
childhood
cancer
mozzilli
e
f
f
director
presid
paulo
brazil
creativ
sao
paulo
brazil
para
pacient
director
physician
paulo
brazil
para
pacient
director
nurs
paulo
brazil
nurs
paulo
brazil
director
vp
paulo
brazil
backgroundobject
treatment
cancer
caus
children
adolesc
constantli
expos
stressor
use
inform
design
gamif
educ
diseas
treatment
outsid
origin
context
enabl
young
patient
learn
intern
knowledg
children
adolesc
year
old
differ
phase
treatment
cancer
hospit
invit
beaba
camp
project
run
august
designmethod
interdisciplinar
combin
knowledg
physician
nurs
psychologist
nutritionist
social
worker
educ
profession
commun
hospit
safeti
importantli
patient
inform
design
present
cancer
treatment
inform
way
foster
effici
effect
understand
children
adolesc
gamif
appli
game
mechan
increas
engag
arous
user
curios
reward
result
creation
product
customiz
lanyard
badg
one
symbol
import
inform
mission
perform
hand
hygien
medic
administr
even
medit
task
set
camp
program
also
great
import
cancer
treatment
lanyard
use
spontan
particip
earn
badg
complet
mission
addit
immedi
bonu
stimulu
complet
mission
larger
goal
fill
lanyard
conclus
interdisciplinar
essenti
success
project
like
ad
technic
inform
graphic
design
appeal
children
adolesc
gamif
effect
tool
engag
support
outcom
relat
health
camp
program
held
august
includ
result
patient
behavior
respect
hospit
particip
project
present
siop
select
jc
mutabazi
n
children
cancer
relief
execut
director
kigali
rwanda
children
cancer
relief
research
kigali
rwanda
backgroundobject
new
pediatr
cancer
case
diagnos
yearli
worldwid
health
care
provid
mainli
nurs
health
center
hc
level
children
first
opportun
correctli
recogn
respond
earli
sign
symptom
childhood
cancer
appropri
refer
district
hospit
studi
show
nurs
receiv
train
pediatr
cancer
insuffici
knowledg
warn
sign
symptom
pediatr
cancer
usual
lead
improp
diagnosi
delay
diagnosi
henc
loss
mani
live
children
effort
sinc
concentr
train
primari
healthcar
provid
recogn
earli
sign
symptom
childhood
cancer
designmethod
program
consist
train
select
region
rwanda
first
step
train
trainer
workshop
volunt
medic
student
doctor
train
train
nurs
commun
health
worker
two
day
workshop
organ
subsequ
provinc
bring
togeth
least
one
nurs
select
health
center
train
nurs
go
back
materi
train
colleagu
follow
everi
three
month
survey
assess
much
retain
learn
knowledg
impact
made
result
program
conduct
health
center
around
healthcar
provid
train
poster
brochur
flyer
distribut
accord
report
train
number
referr
health
center
increas
post
train
show
accur
nurs
state
differenti
diagnos
conclus
childhood
cancer
curabl
detect
treat
earli
need
build
partnership
privat
public
sector
address
challeng
earli
detect
late
present
hospit
program
train
primari
healthcar
provid
show
good
impact
nikal
sk
f
c
v
p
indian
cancer
societi
cancer
survivorship
mumbai
india
cancer
societi
cancer
survivorship
mumbai
india
canc
societi
director
gener
mumbai
india
backgroundobject
ugam
childhood
cancer
survivor
support
group
establish
umbrella
indian
cancer
societi
ic
vision
ensur
everi
childhood
cancer
survivor
find
way
celebr
life
win
battl
cancer
empower
young
survivor
help
children
cancer
undergo
treatment
creat
social
awar
societi
ugam
mission
current
studi
explor
ugam
variou
cultur
activ
creat
social
awar
help
young
survivor
develop
person
increas
designmethod
ugam
conduct
variou
cultur
program
either
cancer
awar
activ
ic
invit
social
group
interact
bond
societi
cultur
activ
ugam
would
includ
variou
perform
art
like
danc
theatr
etc
ugam
member
regularli
particip
event
interview
analyz
studi
desir
impact
result
ugam
organizedparticip
event
creat
awar
cancer
curabl
childhood
cancer
total
member
particip
event
observ
particip
cultur
event
enabl
young
survivor
develop
creativ
administr
abil
gave
chanc
develop
social
skill
well
creat
sens
togeth
group
event
also
gave
chanc
work
part
activ
let
connect
societi
larg
indirectli
also
help
spread
messag
childhood
cancer
curabl
conclus
encourag
young
survivor
childhood
cancer
particip
cultur
event
perform
art
activ
could
help
creat
posit
impact
shape
overal
person
nuchprayoon
well
foundat
secretari
gener
bangkok
thailand
chulalongkorn
memori
hospit
nurs
bangkok
thailand
univers
hospit
nurs
pathumthani
thailand
backgroundobject
thailand
upper
middl
incom
countri
southeast
asia
univers
health
care
includ
pediatr
cancer
treatment
mani
children
cancer
curabl
less
fortun
children
limit
hope
cure
palli
care
pc
prefer
option
children
wish
well
foundat
establish
mission
provid
palli
care
servic
famili
cancer
children
home
designmethod
pc
servic
start
counsel
parent
famili
home
famili
choos
palli
care
individu
care
plan
establish
enhanc
qualiti
life
children
ask
wish
effort
made
wish
fulfil
children
invit
attend
cancer
camp
palli
care
includ
pain
symptom
manag
provid
home
continu
commun
phone
parent
visit
palli
care
clinic
morphin
medic
home
visit
made
need
children
within
radiu
famili
support
death
bereav
result
children
cancer
provid
home
palli
care
pc
averag
age
sd
year
children
pc
cohort
brain
tumor
follow
recurr
solid
tumor
relaps
leukemia
lymphoma
total
time
median
surviv
month
children
live
year
patient
die
die
home
local
hospit
cancer
center
famili
satisfi
conclus
palli
care
offer
earli
strateg
approach
emphas
qualiti
live
children
follow
provis
pc
home
palli
care
expand
includ
children
network
cancer
treatment
center
k
purwanto
onkolog
anak
indonesia
public
relat
jakarta
indonesia
backgroundobject
case
childhood
cancer
often
found
advanc
stage
due
lack
inform
knowledg
earli
sympton
cancer
know
caus
cancer
provid
basic
understand
earli
detect
childhood
cancer
digit
era
technolog
play
import
role
build
awar
everi
aspect
live
creat
easi
way
provid
inform
health
almost
everyon
need
internet
support
provid
avail
access
mobil
phone
ibm
indonesia
grant
mobil
applic
call
temankank
friend
cancer
yoai
digit
platform
design
provid
access
inform
cancer
need
detail
knowledg
use
patient
survivor
parent
medic
practition
volunt
citizen
social
commun
interconnect
get
depth
inform
cancer
object
enhanc
public
awar
childhood
cancer
indonesian
peopl
quickli
individu
designmethod
applic
content
variou
featur
inform
simptom
type
cancer
prevent
treatment
hospit
inform
chatroom
read
tip
doctor
inspir
survivor
stori
latest
news
relat
cancer
result
six
month
applic
releas
applic
download
peopl
survey
peopl
variou
background
use
featur
doctor
chat
room
inform
success
stori
survivor
user
view
featur
avail
conclus
initi
use
increas
awar
cancer
take
prevent
action
form
solid
inform
cancer
support
around
urban
well
rural
area
indonesia
user
enthusiast
support
will
provid
use
input
develop
applic
futur
qazi
hospit
medic
centr
paediatr
surgeri
lahor
pakistan
backgroundobject
pakistan
percent
popul
year
healthcar
servic
public
sector
sever
human
resourc
financi
constraint
limit
number
paediatr
surgeon
work
mostli
big
citi
offer
wide
spectrum
subspeci
servic
includ
surgic
oncolog
countri
wide
survey
conduct
palpat
current
statu
practic
percept
paediatr
surgic
oncolog
designmethod
questionnair
design
includ
question
determin
hospit
setup
avail
paediatr
oncolog
servic
person
practic
individu
surgeon
diseas
pattern
questionnair
sent
use
survey
monkey
complet
respons
receiv
respons
chart
analys
result
respons
chart
geograph
map
pakistan
cover
entir
countri
respond
work
larg
teach
hospit
bed
one
third
respond
work
children
facil
major
onsit
pathologist
radiolog
servic
onsit
sixti
percent
paediatr
oncolog
servic
avail
hospit
alreadi
establish
tumour
board
surgeon
manag
attend
regularli
percent
respond
experi
one
solid
tumour
per
week
commonest
tumour
wilm
tumour
similarli
frequenc
solid
tumour
surgeri
vari
less
one
per
month
solid
tumour
per
month
respond
major
surgeon
despit
year
consult
continu
perform
routin
oper
like
herniotomi
along
major
solid
tumour
surgeri
frequenc
rang
herniotomi
per
year
conclus
although
practic
paediatr
surgic
oncolog
pakistan
compar
modern
world
howev
survey
demonstr
countri
wide
organ
servic
establish
minim
effort
n
radhakrishnan
j
p
special
pediatr
hospit
pg
teach
institut
depart
pediatr
hematolog
oncolog
noida
india
special
pediatr
hospit
pg
teach
institut
depart
patholog
noida
india
special
pediatr
hospit
pg
teach
institut
depart
transfus
medicin
noida
india
special
pediatr
hospit
pg
teach
institut
depart
pediatr
medicin
noida
india
special
pediatr
hospit
pg
teach
institut
depart
pediatr
surgeri
noida
india
backgroundobject
pediatr
cancer
import
caus
death
develop
countri
access
basic
medic
care
improv
exist
facil
govern
sector
overburden
due
lack
adequ
manpow
facil
describ
challeng
face
solut
emerg
establish
pediatr
servic
govern
sector
india
designmethod
exploratori
qualit
studi
challeng
face
start
depart
exist
servic
solut
emerg
end
month
april
march
done
data
record
prospect
follow
head
clinic
laboratori
servic
manpow
skillspaceequip
patient
relat
attitud
accept
concern
treatment
relat
skill
develop
team
build
collabor
logist
government
support
result
studi
period
depart
cater
outpati
inpati
new
oncolog
patient
procedur
admiss
clinic
laboratori
servic
manpow
equip
initi
major
hurdl
face
skill
develop
exist
staff
employe
volunt
collabor
help
us
overcom
extent
program
rais
awar
regard
curabl
childhood
cancer
reinforc
survivor
normal
child
life
provid
learn
play
activ
help
reduc
abandon
improv
accept
diseas
expens
incur
famili
till
government
aid
arriv
continu
major
concern
advanc
money
hospit
administr
involv
donor
help
partial
allevi
concern
posit
attitud
includ
doctor
nurs
technician
support
staff
vital
establish
servic
conclus
establish
servic
cancer
care
center
none
exist
challeng
support
administr
persever
team
crucial
develop
solut
improv
childhood
cancer
care
region
h
b
rathor
p
medic
project
support
servic
program
new
delhi
india
sight
superspeci
eye
hyderabad
ophthalmolog
hyderabad
india
shroff
chariti
eye
delhi
ophthalmolog
delhi
india
apollo
new
delhi
pediatr
oncolog
hematolog
delhi
india
backgroundobject
retinoblastoma
preval
worldwid
india
bear
burden
pediatr
eye
cancer
surviv
rate
percent
report
india
lower
compar
develop
countri
fight
rb
india
partnership
stakehold
awar
advocaci
program
cankid
social
support
organis
fightrbindia
aim
provid
best
standard
care
improv
hospit
manpow
capac
achiev
surviv
ocular
salvag
prosthesi
coverag
limit
abandon
designmethod
standard
questionnair
develop
map
facil
rb
across
countri
primari
intervent
includ
awar
campaign
amongst
parent
doctor
financ
continu
medic
educ
cme
advocaci
centr
best
standard
care
secondari
intervent
includ
financ
drug
diagnost
support
equip
provis
like
ret
cam
ttt
cryosol
provid
social
worker
nurs
improv
complianc
tertiari
intervent
provid
support
surgic
enucl
prosthet
rehabilit
initi
launch
target
vision
plan
author
lead
intern
renown
ocular
oncologist
mandat
shift
outcom
improv
standard
care
period
time
result
thirti
eight
partner
centr
doctor
identifi
collabor
awar
materi
includ
bruckner
modul
helplin
number
video
distribut
centr
region
ophthalmolog
institut
rb
awar
week
may
year
six
stakehold
meet
five
cme
parent
support
group
forum
fund
conduct
research
protocol
microsit
review
secondari
tertiari
intervent
support
case
respect
till
conclus
stakehold
engag
program
target
improv
outcom
rb
support
group
anchor
multidisciplinari
effort
aim
bring
chang
seto
univers
intern
research
institut
disast
scienc
sendai
japan
kyoto
citi
nurs
kyoto
japan
backgroundobject
intern
childhood
cancer
day
everi
year
peopl
express
love
children
cancer
famili
world
peopl
know
day
sn
sympath
signific
day
come
love
children
cancer
famili
howev
love
express
word
action
would
convey
order
improv
situat
held
activ
visual
love
campaign
iccd
designmethod
creat
camera
frame
love
children
cancer
use
camera
effect
platform
provid
facebook
frame
publish
facebook
use
facebook
user
februari
announc
campaign
facebook
post
announc
peopl
find
explan
campaign
url
camera
frame
hash
tag
follow
iccd
childhoodcanc
children
famili
click
hashtag
obvious
see
feel
love
campaign
particip
result
februari
peopl
world
use
camera
effect
post
pictur
took
selfi
frame
other
post
pictur
beauti
view
messag
final
end
februari
peopl
particip
campaign
conclus
order
visual
love
children
cancer
famili
held
iccd
campaign
frame
mention
alreadi
near
futur
cooper
survivor
childhood
cancer
expand
rang
campaign
around
world
c
sharma
p
survivor
group
new
delhi
india
parent
group
new
delhi
india
backgroundobject
patient
navig
pn
vital
help
facilit
care
particularli
relev
indian
context
high
illiteraci
poverti
overburden
healthcar
infrastructur
shortag
train
individu
parent
childhood
cancer
survivor
may
lost
child
cancer
encourag
join
cankid
parent
support
group
ck
psg
train
empow
becom
pn
major
lesser
privileg
background
never
work
outsid
home
high
school
designmethod
end
treatment
will
parent
join
cankid
ck
psg
six
month
train
impart
requir
knowledg
skill
commun
provid
effect
emot
support
also
get
travel
allow
train
period
complet
becom
pn
get
stipend
three
year
becom
employe
hold
hand
famili
undergo
treatment
facilit
emot
support
direct
care
financi
facilit
bereav
support
outing
celebr
etc
conduct
parent
forum
bridg
gap
treat
team
parent
result
psg
start
two
member
today
member
across
india
last
five
year
psg
navig
famili
help
facilit
testsmed
tune
done
waiver
million
rupe
usd
provid
counsel
time
famili
conduct
ward
visit
interact
patient
famili
group
conduct
parent
support
forum
therebi
foster
famili
engag
participatori
approach
treat
team
conclus
har
untap
resourc
parent
skill
pn
cankid
deliv
holist
care
children
cancer
famili
also
empow
parent
give
sourc
incom
p
sripornsawan
k
n
r
p
songkla
univers
pediatr
hat
songkla
thailand
hospit
pediatr
suratthane
thailand
yai
hospit
pediatr
hat
yai
thailand
nakorn
srithammarat
hospit
pediatr
nakorn
srithammarat
thailand
southern
california
palli
medicin
lo
angel
usa
children
research
hospit
memphi
usa
backgroundobject
background
cure
rate
childhood
cancer
develop
world
around
children
develop
countri
year
newli
diagnos
pediatr
cancer
treat
hospit
mani
famili
could
access
healthcar
servic
could
afford
cost
live
transport
tertiari
center
diagnosi
often
delay
lack
awar
childhood
cancer
treatment
abandon
often
caus
socioeconom
problem
object
share
experi
build
childhood
cancer
network
resourc
limit
set
designmethod
method
southern
childhood
cancer
network
establish
child
matter
program
sponsor
sanofi
espoir
foundat
collabor
union
intern
cancer
control
uicc
thai
nation
health
secur
offic
nhso
holist
care
model
compris
medic
treatment
psychosoci
socioeconom
support
palli
care
result
result
temporari
build
bed
arrang
children
could
afford
place
stay
treatment
improv
treatment
adher
decreas
financi
burden
famili
usd
night
network
includ
hospit
health
care
personnel
pediatrician
train
nurs
local
hospit
abl
give
chemotherapi
result
decreas
admiss
visit
averag
patientsyear
annual
meet
educ
workshop
held
discuss
treatment
strategi
problem
clinic
practic
guidelin
safe
chemotherapi
administr
develop
distribut
patient
visit
local
hospit
chemotherapi
averag
time
per
patient
travel
time
decreas
min
min
per
visit
travel
cost
decreas
averag
usd
usd
per
visit
conclus
network
program
could
decreas
travel
cost
time
therefor
improv
treatment
adher
qualiti
life
children
cancer
southern
thailand
acknowledg
work
support
fund
sanofi
espoir
foundat
nhso
j
sullivan
b
soosay
royal
children
hospit
oncolog
melbourn
australia
children
hospit
oncolog
vientian
lao
pdr
backgroundobject
lao
pdr
countri
care
paediatr
oncolog
patient
commenc
children
hospit
ch
vientian
report
exist
date
care
patient
object
describ
new
twin
program
australia
lao
pdr
report
current
state
paediatr
oncolog
ch
designmethod
exist
agreement
univers
melbourn
health
scienc
lao
enabl
twin
relationship
royal
children
hospit
melbourn
ch
retrospect
data
analysi
perform
dataset
creat
qualit
data
obtain
use
focus
ethnographi
field
note
analys
use
induct
qualit
content
analysi
approv
lao
ethic
committe
obtain
result
children
diagnos
cancer
occur
haematolog
malign
acut
lymphoblast
leukaemia
leukaemia
patient
diagnos
use
morpholog
solid
tumour
histopatholog
diagnosi
major
retinoblastoma
abandon
rate
overal
mortal
rate
two
paediatr
oncologist
work
sinc
chemotherapi
donat
koica
agenc
korea
twin
relationship
australia
began
direct
clinic
support
local
continu
support
provid
teleconfer
rch
preliminari
result
qualit
analysi
includ
lack
structur
care
difficult
engag
surgic
procedur
difficult
access
blood
product
poor
chemotherapi
safeti
improv
intervent
includ
clinic
support
use
standardis
treatment
regimen
educ
support
care
conclus
number
cancer
diagnos
lao
increas
improv
demonstr
human
resourc
support
care
howev
treatment
afford
abandon
remain
challeng
enhanc
diagnost
method
improv
document
data
registri
need
b
soosay
sullivan
j
children
hospit
oncolog
vientian
lao
pdr
royal
children
hospit
oncolog
melbourn
lao
pdr
royal
children
hospit
oncolog
melbourn
australia
backgroundobject
children
hospit
ch
vientian
facil
abl
treat
childhood
cancer
lao
pdr
support
korean
donor
number
cancer
patient
increas
yearli
induct
mortal
rate
treatment
qualiti
benchmark
cancer
care
report
outcom
patient
trend
induct
death
reflect
readi
facil
provid
care
childhood
leukaemia
designmethod
retrospect
review
clinic
data
collect
databas
ch
result
children
diagnos
cancer
amongst
patient
receiv
treatment
includ
relaps
complet
remiss
maximum
month
rate
abandon
total
mortal
rate
death
induct
death
death
present
treatment
death
one
relaps
treatment
relaps
treatment
death
occur
induct
infect
haemorrhag
mean
overal
induct
mortal
rate
new
diagnos
death
induct
patient
receiv
induct
averag
induct
mortal
rate
period
new
diagnos
relaps
patient
induct
first
use
patient
howev
induct
death
rate
death
conclus
patient
number
complex
increas
howev
induct
death
rate
lowest
sever
factor
contribut
better
human
resourc
train
chang
workflow
improv
support
care
reliabl
access
medic
howev
challeng
remain
need
safer
use
chemotherapi
enhanc
diagnost
equip
adapt
diseas
protocol
better
approach
abandon
van
schoor
j
de
l
h
van
faculti
psycholog
educ
scienc
depart
experiment
clinic
health
psycholog
ghent
belgium
cathol
de
louvain
depart
clinic
psycholog
belgium
backgroundobject
childhood
cancer
present
mani
challeng
life
child
diagnos
cancer
parent
sibl
moreov
also
place
consider
demand
famili
daili
life
aim
current
studi
gain
better
understand
sibl
daili
experi
live
famili
one
child
diagnos
cancer
designmethod
ten
sibl
children
blood
cancer
interview
interview
data
analyz
use
interpret
phenomenolog
analysi
result
analysi
data
reveal
two
theme
overal
sibl
studi
experienc
continu
mani
aspect
famili
life
still
experienc
famili
import
sourc
support
informationcommun
warm
love
safe
harbor
famili
member
aim
protect
howev
time
sibl
also
refer
challeng
confront
due
cancer
diagnosi
express
thing
felt
unmistak
differ
specif
mani
felt
famili
whole
rip
apart
greater
focu
diagnos
child
chang
respons
famili
member
conclus
studi
inform
parent
clinician
pediatr
cancer
experi
sibl
perspect
one
often
overlook
sibl
express
need
attent
feel
relat
cancer
well
feel
experi
van
schoor
j
de
l
h
van
faculti
psycholog
educ
scienc
depart
experiment
clinic
health
psycholog
ghent
belgium
cathol
de
louvain
depart
clinic
psycholog
belgium
backgroundobject
childhood
cancer
present
mani
challeng
life
child
cancer
hisher
famili
among
studi
investig
risk
protect
factor
individu
adjust
face
pediatr
cancer
diagnosi
social
support
emerg
import
construct
howev
littl
current
known
famili
member
support
particular
context
designmethod
twelv
interview
mother
father
sibl
perform
multi
famili
member
interview
analysi
use
methodolog
framework
analyz
individu
interview
allow
detail
systemat
analysi
share
famili
experi
result
analysi
data
reveal
three
theme
togeth
matter
famili
identifi
need
physic
togeth
famili
diagnos
child
find
support
talk
theme
articul
eager
famili
talk
ill
impact
experienc
relief
howev
talk
emot
sometim
also
experienc
hard
famili
member
prefer
share
experi
work
togeth
team
famili
describ
work
togeth
team
order
get
everyth
organ
conclus
studi
broaden
understand
interperson
process
famili
support
give
face
pediatr
cancer
meet
famili
famili
invit
whole
order
best
captur
famili
level
construct
also
clinician
sensit
differ
need
regard
cancer
relat
famili
commun
make
subject
discuss
within
famili
k
van
zijl
c
organis
paediatr
support
south
africa
opssa
psychosoci
support
servic
pretoria
south
africa
johannesburg
educ
psycholog
johannesburg
south
africa
johannesburg
nurs
johannesburg
south
africa
backgroundobject
children
haematolog
oncolog
diagnosi
face
plethora
stressor
difficulti
relat
ill
treatment
extend
period
time
advers
initi
experi
stress
trauma
children
may
lead
aggress
behaviour
children
therefor
need
support
deal
aggress
overcom
advers
relat
ill
object
studi
explor
describ
play
utilis
address
aggress
children
haematolog
oncolog
diagnosi
order
facilit
resili
designmethod
qualit
explor
descript
contextu
research
design
utilis
multipl
case
studi
utilis
gener
empir
data
result
utilis
play
assist
particip
commun
express
live
experi
ill
treatment
well
live
experi
led
exhibit
aggress
content
analysi
done
transcrib
content
play
therapi
session
order
identifi
main
theme
live
experi
particip
main
theme
feel
extradit
identifi
feel
depersonalis
feel
disempow
live
experi
launch
assault
resili
play
therapi
utilis
address
live
experi
particip
order
empow
facilit
resili
conclus
live
experi
children
deal
ill
treatment
neg
impact
resili
play
process
implement
play
session
facilit
particip
experi
core
element
resili
mean
awar
express
reformul
emot
percept
live
experi
relat
ill
treatment
n
faruqui
b
c
r
r
sydney
school
public
health
sydney
australia
sydney
faculti
medicin
sydney
australia
univers
school
public
health
global
health
boston
usa
ngo
medic
project
delhi
india
research
independ
research
delhi
india
super
special
hospit
paediatr
oncolog
delhi
india
georg
institut
global
health
offic
chief
scientist
sydney
australia
backgroundobject
limit
access
essenti
medicin
em
treat
chronic
diseas
major
challeng
particularli
countri
although
india
largest
manufactur
gener
medicin
avail
afford
price
guarante
assess
avail
price
em
treat
childhood
cancer
delhi
india
designmethod
use
modifi
health
action
intern
methodolog
collect
data
avail
price
em
specif
dosag
em
studi
control
data
collect
pharmaci
survey
anchor
hospit
public
privat
treat
childhood
cancer
random
sampl
retail
pharmaci
locat
near
survey
anchor
median
price
ratio
mpr
calcul
compar
consum
price
intern
refer
price
irp
result
averag
survey
anchor
area
hospit
plu
retail
pharmaci
em
avail
least
one
dosag
form
avail
em
control
em
respect
inject
inject
unavail
mean
avail
facil
type
em
retail
pharmaci
public
privat
mpr
except
inject
line
target
consum
pay
time
irp
estim
chemotherapi
cost
base
consum
price
treat
child
leukaemia
inr
usd
hodgkin
diseas
inr
usd
india
incom
respect
conclus
em
found
survey
anchor
area
howev
mean
avail
less
control
medicin
meet
target
avail
across
facil
local
context
cost
chemotherapi
medicin
appear
afford
howev
greater
burden
cost
may
lie
elsewher
